PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bi, YM; Stuelten, CH; Kilts, T; Wadhwa, S; Iozzo, RV; Robey, PG; Chen, XD; Young, MF				Bi, YM; Stuelten, CH; Kilts, T; Wadhwa, S; Iozzo, RV; Robey, PG; Chen, XD; Young, MF			Extracellular matrix proteoglycans control the fate of bone marrow stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; OSTEOPOROSIS-LIKE PHENOTYPE; TGF-BETA; STEM-CELLS; IN-VITRO; TARGETED DISRUPTION; NEGATIVE REGULATION; DEFICIENT MICE; DECORIN; EXPRESSION	Extracellular matrix glycoproteins and proteoglycans bind a variety of growth factors and cytokines thereby regulating matrix assembly as well as bone formation. However, little is known about the mechanisms by which extracellular matrix molecules modulate osteogenic stem cells and bone formation. Using mice deficient in two members of the small leucine-rich proteoglycans, biglycan and decorin, we uncovered a role for these two extracellular matrix proteoglycans in modulating bone formation from bone marrow stromal cells. Our studies showed that the absence of the critical transforming growth factor-beta (TGF-beta)-binding proteoglycans, biglycan and decorin, prevents TGF-beta from proper sequestration within the extracellular matrix. The excess TGF-beta directly binds to its receptors on bone marrow stromal cells and overactivates its signaling transduction pathway. Overall, the predominant effect of the increased TGF-beta signaling in bgn/dcn-deficient bone marrow stromal cells is a "switch in fate" from growth to apoptosis, leading to decreased numbers of osteoprogenitor cells and subsequently reduced bone formation. Thus, biglycan and decorin appear to be essential for maintaining an appropriate number of mature osteoblasts by modulating the proliferation and survival of bone marrow stromal cells. These findings underscore the importance of the micro-environment in controlling the fate of adult stem cells and reveal a novel cellular and molecular basis for the physiological and pathological control of bone mass.	NIDCR, Craniofacial & Skeletal Dis Branch, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Anat, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Cell Biol, Philadelphia, PA 19107 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University; Jefferson University; Jefferson University	Chen, XD (corresponding author), Univ Arkansas, Coll Med, 4301 W Markam Str,Slot 587, Little Rock, AR 72205 USA.	xdchen@uams.edu; myoung@dir.nidcr.nih.gov	Robey, Pamela Gehron/H-1429-2011; Iozzo, Renato/AAS-1980-2020	Robey, Pamela Gehron/0000-0002-5316-5576; Iozzo, Renato/0000-0002-5908-5112; Chen, Xiao-Dong/0000-0003-1602-806X; Young, Marian F/0000-0003-0929-8854; Stuelten, Christina/0000-0002-2850-5399	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000379, ZIADE000380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000379, Z01DE000380] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Ameye L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0848com; ANDRES JL, 1992, J BIOL CHEM, V267, P5927; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chen XD, 2004, FASEB J, V18, P948, DOI 10.1096/fj.03-0899com; Chen XD, 2002, J BONE MINER RES, V17, P331, DOI 10.1359/jbmr.2002.17.2.331; Comalada M, 2003, J IMMUNOL, V170, P4450, DOI 10.4049/jimmunol.170.9.4450; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; FRIEDENS.AJ, 1966, J EMBRYOL EXP MORPH, V16, P381; Ghosh-Choudhury Nandini, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P345; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; Goldberg M, 2002, J DENT RES, V81, P520, DOI 10.1177/154405910208100804; Hagedorn L, 2000, DEV BIOL, V228, P57, DOI 10.1006/dbio.2000.9936; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARRIS SE, 1994, J BONE MINER RES, V9, P855; HAUSSER H, 1994, FEBS LETT, V353, P243, DOI 10.1016/0014-5793(94)01044-7; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hoffmann A, 2001, CRIT REV EUKAR GENE, V11, P23; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; IOZZO RV, 1994, MATRIX BIOL, V14, P203, DOI 10.1016/0945-053X(94)90183-X; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; Kostenuik PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE1133; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; Kuznetsov S, 1996, CALCIFIED TISSUE INT, V59, P265, DOI 10.1007/s002239900121; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; Lynch MP, 1998, J CELL BIOCHEM, V68, P31; Mabie PC, 1999, J NEUROSCI, V19, P7077, DOI 10.1523/JNEUROSCI.19-16-07077.1999; Markmann A, 2000, MATRIX BIOL, V19, P631, DOI 10.1016/S0945-053X(00)00097-4; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; Miyazono K, 2000, J CELL SCI, V113, P1101; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Nili N, 2003, AM J PATHOL, V163, P869, DOI 10.1016/S0002-9440(10)63447-5; Noble Nancy A., 1992, Progress in Growth Factor Research, V4, P369, DOI 10.1016/0955-2235(92)90017-C; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OWEN M, 1988, J CELL SCI, P63; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Schaefer L, 2002, AM J PATHOL, V160, P1181, DOI 10.1016/S0002-9440(10)64937-1; Schonherr E, 2000, Dev Immunol, V7, P89, DOI 10.1155/2000/31748; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Tufvesson E, 2002, FEBS LETT, V530, P124, DOI 10.1016/S0014-5793(02)03439-7; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052	67	204	217	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30481	30489		10.1074/jbc.M500573200	http://dx.doi.org/10.1074/jbc.M500573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15964849	hybrid			2022-12-25	WOS:000231362500061
J	Hu, WH; Pendergast, JS; Mo, XM; Brambilla, R; Bracchi-Ricard, V; Li, F; Walters, WM; Blits, B; He, L; Schaal, SM; Bethea, JR				Hu, WH; Pendergast, JS; Mo, XM; Brambilla, R; Bracchi-Ricard, V; Li, F; Walters, WM; Blits, B; He, L; Schaal, SM; Bethea, JR			NIBP, a novel NIK and IKK beta-binding protein that enhances NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-KB; TRANSACTIVATION DOMAIN; SIGNALING PATHWAYS; GENE-EXPRESSION; CELL-SURVIVAL; KINASE-ALPHA; PC12 CELLS; RECEPTOR; APOPTOSIS; COMPLEX	The transcription factor NF-kappa B plays an important role in both physiological and pathological events in the central nervous system. Nevertheless, the mechanisms of NF-kappa B-mediated regulation of gene expression, and the signaling molecules participating in the NF-kappa B pathway in the central nervous system are, to date, poorly understood. To identify such molecules, we conducted a yeast two-hybrid screen of a human brain cDNA library using NIK as bait. As a result, we identified a novel NIK and IKK beta binding protein designated NIBP that is mainly expressed in brain, muscle, heart, and kidney. Interestingly, low levels of expression were detected in immune tissues such as spleen, thymus, and peripheral blood leukocytes, where NF-kappa B is known to modulate immune function. We demonstrated by immunohistochemistry that NIBP expression in the brain is localized to neurons. NIBP physically interacts with NIK, IKK beta, but not IKK alpha or IKK gamma. NIBP overexpression potentiates tumor necrosis factor alpha- induced NF-kappa B activation through increased phosphorylation of the IKK complex and its downstream IkB alpha and p65 substrates. Finally, knockdown of NIBP expression by small interfering RNA reduces tumor necrosis factor-gamma- induced NF-kappa B activation, prevents nerve growth factor-induced neuronal differentiation, and decreases Bcl-xL gene expression in PC12 cells. Our data demonstrate that NIBP, by interacting with NIK and IKK beta, is a new enhancer of the cytokine-induced NF-kappa B signaling pathway. Because of its neuronal expression, we propose that NIBP may be a potential target for modulating the NF-kappa B signaling cascade in neuronal pathologies dependent upon abnormal activation of this pathway.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Univ Miami, Miller Sch Med, Dept Neurol Sci, Miami Project Cure Paralysis, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Program Neurosci, Miami, FL 33136 USA; Sichuan Univ, W China Hosp, Hematol Lab, Chengdu 610041, Peoples R China	Virginia Commonwealth University; University of Miami; University of Miami; Sichuan University	Hu, WH (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Sanger Hall,Rm 12-002,1101 E Marshall St, Richmond, VA 23298 USA.	whu@vcu.edu			NINDS NIH HHS [NS37130, R01 NS037130] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037130] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bales KR, 2000, NEUROBIOL AGING, V21, P427, DOI 10.1016/S0197-4580(00)00143-3; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bui NT, 2002, J NEUROCHEM, V81, P594, DOI 10.1046/j.1471-4159.2002.00841.x; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Foehr ED, 2000, J BIOL CHEM, V275, P34021, DOI 10.1074/jbc.C000507200; Foehr ED, 2000, J NEUROSCI, V20, P7556; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hu WH, 2004, J BIOL CHEM, V279, P35975, DOI 10.1074/jbc.M405699200; Hu WH, 2002, J NEUROCHEM, V81, P36, DOI 10.1046/j.1471-4159.2002.00788.x; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Mattson MP, 2003, NAT NEUROSCI, V6, P105, DOI 10.1038/nn0203-105; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Paddison Patrick J, 2004, Methods Mol Biol, V265, P85; Patke A, 2004, CURR OPIN IMMUNOL, V16, P251, DOI 10.1016/j.coi.2004.01.007; Perkins ND, 2003, ONCOGENE, V22, P7553, DOI 10.1038/sj.onc.1207139; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; Rostasy K, 2000, J NEUROVIROL, V6, P537, DOI 10.3109/13550280009091954; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Soond SM, 2003, MOL CELL BIOL, V23, P8334, DOI 10.1128/mcb.23.22.8334-8344.2003; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866	54	92	106	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29233	29241		10.1074/jbc.M501670200	http://dx.doi.org/10.1074/jbc.M501670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15951441	hybrid, Green Accepted			2022-12-25	WOS:000231021300052
J	Starcevic, D; Dalal, S; Jaeger, J; Sweasy, JB				Starcevic, D; Dalal, S; Jaeger, J; Sweasy, JB			The hydrophobic hinge region of rat DNA polymerase beta is critical for substrate binding pocket geometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; CATALYTIC MECHANISM; KINETIC-ANALYSIS; FIDELITY; CELLS; REPLICATION; SPECIFICITY; INVOLVEMENT; COMPLEXES; RESIDUES	The hydrophobic hinge of DNA polymerase beta facilitates closing and stabilization of the enzyme once the nucleotide substrate has bound. Alteration of the hydrophobic nature of the hinge by the introduction of a hydrophilic glutamine residue in place of isoleucine 260 results in an inaccurate polymerase. The kinetic basis of infidelity is lack of discrimination during the binding of substrate. The I260Q polymerase beta variant has lower affinity than wild type enzyme for the correct substrate and much higher affinity for the incorrect substrate. Our results demonstrate that the hinge is important for formation of the substrate binding pocket. Our results are also consistent with the interpretation that DNA polymerase beta discriminates the correct from incorrect substrate during the binding step.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Program Microbiol, New Haven, CT 06520 USA; Wadsworth Ctr, Ctr Med Sci, Albany, NY 12201 USA	Yale University; Yale University; Yale University; Wadsworth Center	Sweasy, JB (corresponding author), Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA.	joann.sweasy@yale.edu			NATIONAL CANCER INSTITUTE [R01CA080830] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA080830, CA80830] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arndt JW, 2001, BIOCHEMISTRY-US, V40, P5368, DOI 10.1021/bi002176j; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Horton JK, 2002, DNA REPAIR, V1, P317, DOI 10.1016/S1568-7864(02)00008-3; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Jonason AS, 2001, CHROMOSOMA, V110, P402, DOI 10.1007/s004120100165; Kosa JL, 1999, J BIOL CHEM, V274, P35866, DOI 10.1074/jbc.274.50.35866; Krahn JM, 2004, STRUCTURE, V12, P1823, DOI 10.1016/j.str.2004.08.001; Kraynov VS, 1997, BIOCHEM J, V323, P103, DOI 10.1042/bj3230103; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Li SX, 1999, BIOCHEMISTRY-US, V38, P4800, DOI 10.1021/bi9827058; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Ochs K, 1999, CANCER RES, V59, P1544; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Raffoul JJ, 2004, J BIOL CHEM, V279, P18425, DOI 10.1074/jbc.M313983200; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Shah AM, 2003, BIOCHEMISTRY-US, V42, P10709, DOI 10.1021/bi034885d; Showalter AK, 2002, BIOCHEMISTRY-US, V41, P10571, DOI 10.1021/bi026021i; Starcevic D, 2005, BIOCHEMISTRY-US, V44, P3775, DOI 10.1021/bi047956x; Starcevic D, 2004, CELL CYCLE, V3, P998; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; Washington SL, 1997, P NATL ACAD SCI USA, V94, P1321, DOI 10.1073/pnas.94.4.1321; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; Wilson TM, 1996, MUTAT RES-DNA REPAIR, V362, P237, DOI 10.1016/0921-8777(95)00053-4	30	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28388	28393		10.1074/jbc.M502178200	http://dx.doi.org/10.1074/jbc.M502178200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15901725	hybrid			2022-12-25	WOS:000230857300027
J	Auger, R; Motta, I; Benihoud, K; Ojcius, DM; Kanellopoulos, JM				Auger, R; Motta, I; Benihoud, K; Ojcius, DM; Kanellopoulos, JM			A role for mitogen-activated protein kinase(Erk1/2) activation and non-selective pore formation in P2X7 receptor-mediated thymocyte death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVATION; NF-KAPPA-B; P2X(7) RECEPTOR; CELL-DEATH; EXTRACELLULAR ATP; NUCLEOTIDE RECEPTOR; PROTEASOME ACTIVATION; PURINERGIC RECEPTORS; MACROPHAGE CULTURES; CYTOKINE PRODUCTION	Extracellular ATP (ATPe) binds to P2X7 receptors (P2X7R) expressed on the surface of cells of hematopoietic lineage, including murine thymocytes. Activation of P2X7R by ATPe results in the opening of cation-specific channels, and prolonged ATPe exposure leads to the formation of non-selective pores enabling transmembrane passage of solutes up to 900 Da. In the presence of ATPe, P2X7R-mediated thymocyte death is due primarily to necrosis/lysis and not apoptosis, as measured by the release of lactate dehydrogenase indicative of a loss of plasma membrane integrity. The present study is focused on the identification of P2X7R signaling mediators in ATP-induced thymocyte necrosis/lysis. Thus, extracellular signal-regulated protein kinase 1/2 (Erk1/2) phosphorylation was found to be required for cell lysis, and both events were independent of ATP-induced calcium influx. P2X7R-dependent thymocyte death involved the chronological activation of Src family tyrosine kinase(s), phosphatidylinositol 3-kinase, the mitogen-activated protein (MAP) kinase(Erk1/2) module, and the proteasome. Although independent of this signaling cascade, non-selective pore formation may modulate ATP-mediated thymocyte death. These results therefore suggest a role for both activation of MAP kinase(Erk1/2) and non-selective pore opening in P2X7R-induced thymocyte death.	Univ Paris 11, Inst Biochim & Biophys Mol & Celllaire, Lab Activat Cellulaire & Transduct Signaux, CNRS UMR 8619, F-91405 Orsay, France; Univ California, Sch Nat Sci, Merced, CA 95344 USA	UDICE-French Research Universities; Universite Paris Saclay; University of California System; University of California Merced	Kanellopoulos, JM (corresponding author), Univ Paris 11, Inst Biochim & Biophys Mol & Celllaire, Lab Activat Cellulaire & Transduct Signaux, CNRS UMR 8619, Batiment 430, F-91405 Orsay, France.	jean.kanellopoulos@ibbmc.u-psud.fr	, BENIHOUD/O-4334-2019; Ojcius, David/ABE-6557-2020	Ojcius, David/0000-0003-1461-4495				Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Amstrup J, 2003, BIOCHEM J, V374, P51, DOI 10.1042/BJ20030585; ANDERSON SJ, 1994, ADV IMMUNOL, V56, P151, DOI 10.1016/S0065-2776(08)60451-4; Apasov SG, 1997, J IMMUNOL, V158, P5095; Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014-2999(99)00350-7; Bradford MD, 2002, BIOCHEM J, V366, P745, DOI 10.1042/BJ20020358; Budagian V, 2003, J BIOL CHEM, V278, P1549, DOI 10.1074/jbc.M206383200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Chiozzi P, 1996, BIOCHEM BIOPH RES CO, V218, P176, DOI 10.1006/bbrc.1996.0031; Chvatchko Y, 1996, IMMUNITY, V5, P275, DOI 10.1016/S1074-7613(00)80322-2; Colomar A, 2003, J BIOL CHEM, V278, P30732, DOI 10.1074/jbc.M304534200; Coutinho-Silva R, 2003, IMMUNITY, V19, P403, DOI 10.1016/S1074-7613(03)00235-8; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Cui HL, 1997, P NATL ACAD SCI USA, V94, P7515, DOI 10.1073/pnas.94.14.7515; Dallaporta B, 2000, CELL DEATH DIFFER, V7, P368, DOI 10.1038/sj.cdd.4400661; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Donnelly-Roberts DL, 2004, J PHARMACOL EXP THER, V308, P1053, DOI 10.1124/jpet.103.059600; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Etore F, 1998, BIOCHEM PHARMACOL, V55, P1465, DOI 10.1016/S0006-2952(97)00649-7; Falzoni S, 2000, MOL BIOL CELL, V11, P3169, DOI 10.1091/mbc.11.9.3169; Faria RX, 2005, AM J PHYSIOL-CELL PH, V288, pC260, DOI 10.1152/ajpcell.00215.2004; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Ferrari D, 2000, FASEB J, V14, P2466, DOI 10.1096/fj.00-0031com; Freedman BD, 1999, EUR J IMMUNOL, V29, P1635, DOI 10.1002/(SICI)1521-4141(199905)29:05<1635::AID-IMMU1635>3.3.CO;2-2; Gendron FP, 2003, AM J PHYSIOL-CELL PH, V284, pC571, DOI 10.1152/ajpcell.00286.2002; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Gu B, 1998, BLOOD, V92, P946; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Hirsch T, 1998, J IMMUNOL, V161, P35; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Jacques-Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Koshiba M, 1997, P NATL ACAD SCI USA, V94, P831, DOI 10.1073/pnas.94.3.831; Kusner DJ, 2000, J IMMUNOL, V164, P379, DOI 10.4049/jimmunol.164.1.379; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Le Feuvre RA, 2002, J BIOL CHEM, V277, P3210, DOI 10.1074/jbc.M104388200; Le Stunff H, 2004, J BIOL CHEM, V279, P16918, DOI 10.1074/jbc.M313064200; Linford NJ, 2001, J PHARMACOL EXP THER, V299, P67; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mariathasan S, 2001, J IMMUNOL, V167, P4966, DOI 10.4049/jimmunol.167.9.4966; Michel AD, 1999, N-S ARCH PHARMACOL, V359, P102, DOI 10.1007/PL00005328; Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Pfeiffer ZA, 2004, J LEUKOCYTE BIOL, V75, P1173, DOI 10.1189/jlb.1203648; Ralevic V, 1998, PHARMACOL REV, V50, P413; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sperandio S, 2004, CELL DEATH DIFFER, V11, P1066, DOI 10.1038/sj.cdd.4401465; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Suzuki T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Verhoef PA, 2003, J IMMUNOL, V170, P5728, DOI 10.4049/jimmunol.170.11.5728; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Werlen G, 2000, NATURE, V406, P422, DOI 10.1038/35019094; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	63	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28142	28151		10.1074/jbc.M501290200	http://dx.doi.org/10.1074/jbc.M501290200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15937334	Green Published, hybrid			2022-12-25	WOS:000230678600078
J	Yuan, Q; Carle, A; Gao, C; Sivanesan, D; Aly, KA; Hoppner, C; Krall, L; Domke, N; Baron, C				Yuan, Q; Carle, A; Gao, C; Sivanesan, D; Aly, KA; Hoppner, C; Krall, L; Domke, N; Baron, C			Identification of the VirB4-VirB8-VirB5-VirB2 pilus assembly sequence of type IV secretion systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM-TUMEFACIENS VIRB; ESSENTIAL VIRULENCE PROTEIN; T-PILUS; BRUCELLA-SUIS; DNA TRANSFER; ATPASE; PLASMID; BINDING; CONJUGATION; MUTATIONS	Type IV secretion systems mediate the translocation of virulence factors ( proteins and/or DNA) from Gramnegative bacteria into eukaryotic cells. A complex of 11 conserved proteins ( VirB1-VirB11) spans the inner and the outer membrane and assembles extracellular T-pili in Agrobacterium tumefaciens. Here we report a sequence of protein interactions required for the formation of complexes between VirB2 and VirB5, which precedes their incorporation into pili. The NTPase Walker A active site of the inner membrane protein VirB4 is required for virulence, but an active site VirB4 variant stabilized VirB3 and VirB8 and enabled T-pilus formation. Analysis of VirB protein complexes extracted from the membranes with mild detergent revealed that VirB2-VirB5 complex formation depended on VirB4, which identified a novel T-pilus assembly step. Bicistron expression demonstrated direct interaction of VirB4 with VirB8, and analyses with purified proteins showed that VirB5 bound to VirB8 and VirB10. VirB4 therefore localizes at the basis of a trans-envelope interaction sequence, and by stabilization of VirB8 it mediates the incorporation of VirB5 and VirB2 into extracellular pili.	McMaster Univ, Dept Biol, Hamilton, ON LS8 4K1, Canada; Univ Munich, Dept Biol 1, Bereich Mikrobiol, D-80638 Munich, Germany	McMaster University; University of Munich	Baron, C (corresponding author), McMaster Univ, Dept Biol, 1280 Main St W, Hamilton, ON LS8 4K1, Canada.	baronc@mcmaster.ca	Baron, Christian/A-5705-2008	Aly, Khaled/0000-0001-7022-1173				Atmakuri K, 2004, MOL MICROBIOL, V54, P1199, DOI 10.1111/j.1365-2958.2004.04345.x; Balsiger S, 2004, J BACTERIOL, V186, P6824, DOI 10.1128/JB.186.20.6824-6829.2004; BERGER BR, 1994, J BACTERIOL, V176, P3646, DOI 10.1128/JB.176.12.3646-3660.1994; Bhandari P, 1997, J BACTERIOL, V179, P4403, DOI 10.1128/jb.179.13.4403-4406.1997; Bohne J, 1998, P NATL ACAD SCI USA, V95, P7057, DOI 10.1073/pnas.95.12.7057; Cascales E, 2004, P NATL ACAD SCI USA, V101, P17228, DOI 10.1073/pnas.0405843101; Cascales E, 2004, SCIENCE, V304, P1170, DOI 10.1126/science.1095211; Cascales E, 2003, NAT REV MICROBIOL, V1, P137, DOI 10.1038/nrmicro753; Celli J, 2004, CURR OPIN MICROBIOL, V7, P93, DOI 10.1016/j.mib.2003.11.001; Dang TA, 1999, MOL MICROBIOL, V32, P1239, DOI 10.1046/j.1365-2958.1999.01436.x; Dang TAT, 1997, J BACTERIOL, V179, P453, DOI 10.1128/jb.179.2.453-462.1997; Das A, 2000, J BACTERIOL, V182, P758, DOI 10.1128/JB.182.3.758-763.2000; Ding ZY, 2003, TRENDS MICROBIOL, V11, P527, DOI 10.1016/j.tim.2003.09.004; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; Eisenbrandt R, 1999, J BIOL CHEM, V274, P22548, DOI 10.1074/jbc.274.32.22548; FULLNER KJ, 1994, MOL GEN GENET, V245, P704, DOI 10.1007/BF00297277; Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586; Habib SJ, 2005, J BIOL CHEM, V280, P6434, DOI 10.1074/jbc.M411510200; Hapfelmeier S, 2000, J BACTERIOL, V182, P4505, DOI 10.1128/JB.182.16.4505-4511.2000; Harlow E., 1988, ANTIBODIES LAB MANUA; Hoppner C, 2004, J BACTERIOL, V186, P1415, DOI 10.1128/JB.186.5.1415-1422.2004; Jakubowski SJ, 2004, J MOL BIOL, V341, P961, DOI 10.1016/j.jmb.2004.06.052; Jakubowski SJ, 2003, J BACTERIOL, V185, P2867, DOI 10.1128/JB.185.9.2867-2878.2003; JONES AL, 1994, J BACTERIOL, V176, P5255, DOI 10.1128/JB.176.17.5255-5261.1994; Krall L, 2002, P NATL ACAD SCI USA, V99, P11405, DOI 10.1073/pnas.172390699; Kromayer M, 1996, J MOL BIOL, V262, P413, DOI 10.1006/jmbi.1996.0525; KULDAU GA, 1990, MOL GEN GENET, V221, P256, DOI 10.1007/BF00261729; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai EM, 2000, TRENDS MICROBIOL, V8, P361, DOI 10.1016/S0966-842X(00)01802-3; Llosa M, 2004, MOL MICROBIOL, V53, P1, DOI 10.1111/j.1365-2958.2004.04168.x; Lutzmann M, 2002, EMBO J, V21, P387, DOI 10.1093/emboj/21.3.387; Maniatis T., 1982, MOL CLONING LAB MANU; Middleton R, 2005, P NATL ACAD SCI USA, V102, P1685, DOI 10.1073/pnas.0409399102; O'Callaghan D, 1999, MOL MICROBIOL, V33, P1210, DOI 10.1046/j.1365-2958.1999.01569.x; Rabel C, 2003, J BACTERIOL, V185, P1045, DOI 10.1128/JB.185.3.1045-1058.2003; Rouot B, 2003, INFECT IMMUN, V71, P1075, DOI 10.1128/IAI.71.3.1075-1082.2003; Sagulenko E, 2001, J BACTERIOL, V183, P5813, DOI 10.1128/JB.183.20.5813-5825.2001; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmidt-Eisenlohr H, 1999, J BACTERIOL, V181, P7485, DOI 10.1128/JB.181.24.7485-7492.1999; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; Shamaei-Tousi A, 2004, J BACTERIOL, V186, P4796, DOI 10.1128/JB.186.14.4796-4801.2004; SHIRASU K, 1994, MOL MICROBIOL, V11, P581, DOI 10.1111/j.1365-2958.1994.tb00338.x; Stahl LE, 1998, J BACTERIOL, V180, P3933, DOI 10.1128/JB.180.15.3933-3939.1998; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Terradot L, 2005, P NATL ACAD SCI USA, V102, P4596, DOI 10.1073/pnas.0408927102; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Ward DV, 2002, P NATL ACAD SCI USA, V99, P11493, DOI 10.1073/pnas.172390299; Watarai M, 2002, MICROBIOL-SGM, V148, P1439, DOI 10.1099/00221287-148-5-1439; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yeo HJ, 2003, P NATL ACAD SCI USA, V100, P15947, DOI 10.1073/pnas.2535211100; Yeo HJ, 2004, J BACTERIOL, V186, P1919, DOI 10.1128/JB.186.7.1919-1926.2004; Yeo HJ, 2000, MOL CELL, V6, P1461, DOI 10.1016/S1097-2765(00)00142-8	52	86	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26349	26359		10.1074/jbc.M502347200	http://dx.doi.org/10.1074/jbc.M502347200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901731	hybrid			2022-12-25	WOS:000230386800051
J	Cappai, R; Leck, SL; Tew, DJ; Williamson, NA; Smith, DP; Galatis, D; Sharples, RA; Curtain, CC; Ali, FE; Cherny, RA; Culvenor, JG; Bottomley, SP; Masters, CL; Barnham, KJ; Hill, AF				Cappai, R; Leck, SL; Tew, DJ; Williamson, NA; Smith, DP; Galatis, D; Sharples, RA; Curtain, CC; Ali, FE; Cherny, RA; Culvenor, JG; Bottomley, SP; Masters, CL; Barnham, KJ; Hill, AF			Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway	FASEB JOURNAL			English	Article						protein aggregation; Parkinson's disease; amyloid; circular dichroism	PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; SECONDARY STRUCTURE; A-BETA; PATHOGENESIS; MUTATIONS; FIBRILLIZATION; STABILIZATION; DEGRADATION; COMPONENT	Dopamine (DA) and alpha-synuclein (alpha-SN) are two key molecules associated with Parkinson's disease (PD). We have identified a novel action of DA in the initial phase of alpha-SN aggregation and demonstrate that DA induces alpha-SN to form soluble, SDS-resistant oligomers. The DA: alpha-SN oligomeric species are not amyloidogenic as they do not react with thioflavin T and lack the typical amyloid fibril structures as visualized with electron microscopy. Circular dichroism studies indicate that in the presence of lipid membranes DA interacts with alpha-SN, causing an alteration to the structure of the protein. Furthermore, DA inhibited the formation of iron-induced alpha-SN amyloidogenic aggregates, suggesting that DA acts as a dominant modulator of alpha-SN aggregation. These observations support the paradigm emerging for other neurodegenerative diseases that the toxic species is represented by a soluble oligomer and not the insoluble fibril.	Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3168, Australia	University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; Monash University; Monash University	Cappai, R (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	r.cappai@unimelb.edu.au	Hill, Andrew F./AAH-2854-2020; Williamson, Nicholas A/O-9812-2016; Hill, Andrew F./GZL-4124-2022; Cappai, Roberto/B-3347-2010; Hill, Andrew F/B-4527-2009	Williamson, Nicholas A/0000-0002-2173-3452; Hill, Andrew F./0000-0001-5581-2354; Cappai, Roberto/0000-0002-9505-8496; Hill, Andrew F/0000-0001-5581-2354; Smith, David/0000-0001-5177-8574				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Barnham KJ, 2004, FASEB J, V18, P1427, DOI 10.1096/fj.04-1890fje; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chandra S, 2004, P NATL ACAD SCI USA, V101, P14966, DOI 10.1073/pnas.0406283101; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; GERARD C, 1994, POLYHEDRON, V13, P591, DOI 10.1016/s0277-5387(00)84736-1; Golts N, 2002, J BIOL CHEM, V277, P16116, DOI 10.1074/jbc.M107866200; Gotz ME, 2004, ANN NY ACAD SCI, V1012, P193, DOI 10.1196/annals.1306.017; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; Hoyer WG, 2004, J MOL BIOL, V340, P127, DOI 10.1016/j.jmb.2004.04.051; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Norris EH, 2005, J BIOL CHEM, V280, P21212, DOI 10.1074/jbc.M412621200; Perez RG, 2004, J NEUROCHEM, V89, P1318, DOI 10.1111/j.1471-4159.2004.02423.x; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Recchia A, 2004, FASEB J, V18, P617, DOI 10.1096/fj.03-0338rev; Reixach N, 2004, P NATL ACAD SCI USA, V101, P2817, DOI 10.1073/pnas.0400062101; Rekas A, 2004, J MOL BIOL, V340, P1167, DOI 10.1016/j.jmb.2004.05.054; Sidhu A, 2004, FASEB J, V18, P637, DOI 10.1096/fj.03-1112rev; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	40	213	219	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1377	+		10.1096/fj.04-3437fje	http://dx.doi.org/10.1096/fj.04-3437fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946991				2022-12-25	WOS:000230207800023
J	Penz, S; Reininger, AJ; Brandl, R; Goyal, P; Rabie, T; Bernlochner, I; Rother, E; Goetz, C; Engelmann, B; Smethurst, PA; Ouwehand, WH; Farndale, R; Nieswandt, B; Siess, W				Penz, S; Reininger, AJ; Brandl, R; Goyal, P; Rabie, T; Bernlochner, I; Rother, E; Goetz, C; Engelmann, B; Smethurst, PA; Ouwehand, WH; Farndale, R; Nieswandt, B; Siess, W			Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI	FASEB JOURNAL			English	Article						atherosclerotic plaques; ischemic stroke; thrombogenicity; arterial thrombus	FACTOR PATHWAY INHIBITOR; TISSUE-FACTOR; COLLAGEN; THROMBOGENICITY; DEPOSITION; AGGREGATION; RECEPTORS; ADHESION; DOMAINS; ANTIGEN	Lipid-rich atherosclerotic plaques are vulnerable, and their rupture can cause the formation of a platelet-and fibrin-rich thrombus leading to myocardial infarction and ischemic stroke. Although the role of plaque-based tissue factor as stimulator of blood coagulation has been recognized, it is not known whether plaques can cause thrombus formation through direct activation of platelets. We isolated lipid-rich atheromatous plaques from 60 patients with carotid stenosis and identified morphologically diverse collagen type I- and type III- positive structures in the plaques that directly stimulated adhesion, dense granule secretion, and aggregation of platelets in buffer, plasma, and blood. This material also elicited platelet-monocyte aggregation and platelet-dependent blood coagulation. Plaques exposed to flowing blood at arterial wall shear rate induced platelets to adhere to and spread on the collagenous structures, triggering subsequent thrombus formation. Plaque-induced platelet thrombus formation was observed in fully anticoagulated blood (i.e., in the absence of tissue factor-mediated coagulation). Mice platelets lacking glycoprotein VI ( GPVI) were unable to adhere to atheromatous plaque or form thrombi. Human platelet thrombus formation onto plaques in flowing blood was completely blocked by GPVI inhibition with the antibody 10B12 but not affected by integrin alpha(2)beta(1) inhibition with 6F1 mAb. Moreover, the initial platelet response, shape change, induced by plaque was blocked by GPVI inhibition but not with alpha(2)beta(1) antagonists (6F1 mAb or GFOGER-GPP peptide). Pretreatment of plaques with collagenase or anti-collagen type I and anti-collagen type III antibodies abolished plaque-induced platelet activation. Our results indicate that morphologically diverse collagen type I- and collagen type III- containing structures in lipid-rich atherosclerotic plaques stimulate thrombus formation by activating platelet GPVI. This platelet collagen receptor, essential for plaque-induced thrombus formation, presents a promising new anti-thrombotic target for the prevention of ischemic cardiovascular diseases.	Univ Munich, Inst Prevent Cardiovasc Dis, Munich, Germany; Univ Munich, Dept Transfus Med & Hemostaseol, Munich, Germany; Klinikum Munich Schwabing, Dept Vasc Surg, Munich, Germany; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany; Univ Munich, Inst Clin Chem, Munich, Germany; Univ Cambridge, Dept Hematol, Cambridge, England	University of Munich; University of Munich; University of Wurzburg; University of Munich; University of Cambridge	Siess, W (corresponding author), Univ Munich, Klinikum Innenstadt, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, Pettenkoferstr 9, D-80336 Munich, Germany.	wsiess@med.uni-muenchen.de	Rabie, Tamer/C-7886-2013; Siess, Wolfgang/A-6430-2009; Goyal, Pankaj/C-3567-2012	Siess, Wolfgang/0000-0003-0698-6416; Rabie, Tamer/0000-0001-9060-8797				Abi-Younes S, 2000, CIRC RES, V86, P131, DOI 10.1161/01.RES.86.2.131; Ardissino D, 1997, LANCET, V349, P769, DOI 10.1016/S0140-6736(96)11189-2; Badimon JJ, 1999, CIRCULATION, V99, P1780, DOI 10.1161/01.CIR.99.14.1780; BADIMON L, 1987, J LAB CLIN MED, V110, P706; Barnes MJ, 1999, EXP GERONTOL, V34, P513, DOI 10.1016/S0531-5565(99)00038-8; Brandl R, 1997, CIRCULATION, V96, P3360; Cauwenberghs N, 2001, BLOOD, V98, P652, DOI 10.1182/blood.V98.3.652; CAZENAVE JP, 1993, CENTRIFUGATION TECHN; Chen J, 2001, ATHEROSCLEROSIS, V159, P289, DOI 10.1016/S0021-9150(01)00509-3; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; COLLER BS, 1989, BLOOD, V74, P182; Corti R, 2002, AM J MED, V113, P668, DOI 10.1016/S0002-9343(02)01344-X; De Meyer GRY, 1999, ARTERIOSCL THROM VAS, V19, P2524, DOI 10.1161/01.ATV.19.10.2524; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; Haseruck N, 2004, BLOOD, V103, P2585, DOI 10.1182/blood-2003-04-1127; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Kato K, 2003, BLOOD, V102, P1701, DOI 10.1182/blood-2003-03-0717; Katsuda Shogo, 2003, J Atheroscler Thromb, V10, P267; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Komorowicz E, 2002, THROMB HAEMOSTASIS, V88, P827, DOI 10.1055/s-0037-1613310; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Massberg S, 2003, FASEB J, V17, P397, DOI 10.1096/f.03-0464.fje; Merten M, 2001, CIRCULATION, V103, P2032; Moons AHM, 2002, CARDIOVASC RES, V53, P313, DOI 10.1016/S0008-6363(01)00452-7; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Rother E, 2003, CIRCULATION, V108, P741, DOI 10.1161/01.CIR.0000083715.37658.C4; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Siljander PRM, 2004, J BIOL CHEM, V279, P47763, DOI 10.1074/jbc.M404685200; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; Smethurst PA, 2004, BLOOD, V103, P903, DOI 10.1182/blood-2003-01-0308; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131; Westrick RJ, 2001, CIRCULATION, V103, P3044, DOI 10.1161/hc2501.092492; Zillmann A, 2001, BIOCHEM BIOPH RES CO, V281, P603, DOI 10.1006/bbrc.2001.4399	42	119	127	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					898	909		10.1096/fj.04-2748com	http://dx.doi.org/10.1096/fj.04-2748com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923400				2022-12-25	WOS:000230207800037
J	Hardy, KM; Hoffman, EA; Gonzalez, P; McKay, BS; Stamer, WD				Hardy, KM; Hoffman, EA; Gonzalez, P; McKay, BS; Stamer, WD			Extracellular trafficking of myocilin in human trabecular meshwork cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LATROTOXIN RECEPTOR; MULTIVESICULAR BODY; EXOSOMES; OLFACTOMEDIN; EXPRESSION; LOCALIZATION; GENE; IDENTIFICATION; VESICLES; CULTURE	Myocilin ( MYOC) is a protein with a broad expression pattern, but unknown function. MYOC associates with intracellular structures that are consistent with secretory vesicles, however, in most cell types studied, MYOC is limited to the intracellular compartment. In the trabecular meshwork, MYOC associates with intracellular vesicles, but is also found in the extracellular space. The purpose of the present study was to better understand the mechanism of extracellular transport of MYOC in trabecular meshwork cells. Using a biochemical approach, we found that MYOC localizes intracellularly to both the cytosolic and particulate fractions. When intracellular membranes were separated over a linear sucrose gradient, MYOC equilibrated in a fraction less dense than traditional secretory vesicles and lysosomes. In pulse-labeling experiments that followed nascent MYOC over time, the characteristic doublet observed for MYOC by SDS-PAGE did not change, even in the presence of brefeldin A; indicating that MYOC is not glycosylated and is not released via a traditional secretory mechanism. When conditioned media from human trabecular meshwork cells were examined, both native and recombinant MYOC associated with an extracellular membrane population having biochemical characteristics of exosomes, and containing the major histocompatibility complex class II antigen, HLA-DR. The association of MYOC with exosome-like membranes appeared to be specific, on the extracellular face, and reversible. Taken together, data suggest that MYOC appears in the extracellular space of trabecular meshwork cells by an unconventional mechanism, likely associated with exosome-like vesicles.	Univ Arizona, Dept Ophthalmol, Tucson, AZ 85711 USA; Univ Arizona, Dept Cell Biol, Tucson, AZ 85711 USA; Univ Arizona, Dept Pharmacol, Tucson, AZ 85711 USA; Duke Univ, Dept Ophthalmol, Durham, NC 27705 USA	University of Arizona; University of Arizona; University of Arizona; Duke University	Stamer, WD (corresponding author), Univ Arizona, Dept Ophthalmol, 655 N Alvernon Way,Suite 108, Tucson, AZ 85711 USA.	dstamer@eyes.arizona.edu	McKay, Brian/E-5602-2012	McKay, Brian/0000-0002-2893-3959	NEI NIH HHS [EY12797] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012797] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adam MF, 1997, HUM MOL GENET, V6, P2091, DOI 10.1093/hmg/6.12.2091; ALLAIN F, 1995, J IMMUNOL METHODS, V178, P113, DOI 10.1016/0022-1759(94)00249-V; Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200; BAL RS, 1993, BIOCHEMISTRY-US, V32, P1047, DOI 10.1021/bi00055a008; BILL A, 1975, MECH ROUTES AQUEOUS; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; Caballero M, 2001, BIOCHEM BIOPH RES CO, V282, P662, DOI 10.1006/bbrc.2001.4624; Clayton A, 2001, J IMMUNOL METHODS, V247, P163, DOI 10.1016/S0022-1759(00)00321-5; DANIELSON PE, 1994, J NEUROSCI RES, V38, P468, DOI 10.1002/jnr.490380413; Denzer K, 2000, J CELL SCI, V113, P3365; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Fevrier B, 2004, CURR OPIN CELL BIOL, V16, P415, DOI 10.1016/j.ceb.2004.06.003; Filla MS, 2002, INVEST OPHTH VIS SCI, V43, P151; Fingert JH, 1998, GENOME RES, V8, P377, DOI 10.1101/gr.8.4.377; GRANT WM, 1963, ARCH OPHTHALMOL-CHIC, V69, P783; Huang W, 2000, Ophthalmic Genet, V21, P155, DOI 10.1076/1381-6810(200009)21:3;1-Z;FT155; JOHNSTONE MA, 1973, AM J OPHTHALMOL, V75, P365, DOI 10.1016/0002-9394(73)91145-8; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Karavanich CA, 1998, MOL BIOL EVOL, V15, P718, DOI 10.1093/oxfordjournals.molbev.a025975; Kondo D, 2000, J AM SOC NEPHROL, V11, P803, DOI 10.1681/ASN.V115803; Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Lutjen-Drecoll E, 1999, PROG RETIN EYE RES, V18, P91, DOI 10.1016/S1350-9462(98)00011-1; LYNCH MG, 1987, OPHTHALMOLOGY, V94, P851; Mertts M, 1999, LAB INVEST, V79, P1237; Nagano T, 1998, MOL BRAIN RES, V53, P13, DOI 10.1016/S0169-328X(97)00271-4; Nguyen TD, 1998, J BIOL CHEM, V273, P6341, DOI 10.1074/jbc.273.11.6341; Ohlmann A, 2003, GLIA, V43, P128, DOI 10.1002/glia.10233; Ortego J, 1997, FEBS LETT, V413, P349, DOI 10.1016/S0014-5793(97)00934-4; Polansky JR, 1997, OPHTHALMOLOGICA, V211, P126, DOI 10.1159/000310780; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; Rao PV, 2000, EXP EYE RES, V71, P637, DOI 10.1006/exer.2000.0920; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; ROHEN J, 1983, OPHTHALMOLOGY, V95, P673; SNYDER DA, 1991, BIOCHEMISTRY-US, V30, P9143, DOI 10.1021/bi00102a004; SNYDER RW, 1993, EXP EYE RES, V57, P461, DOI 10.1006/exer.1993.1148; Sohn S, 2002, INVEST OPHTH VIS SCI, V43, P3680; STAMER WD, 1995, CURR EYE RES, V14, P611, DOI 10.3109/02713689508998409; Stamer WD, 1998, INVEST OPHTH VIS SCI, V39, P1804; Stamer WD, 2001, INVEST OPHTH VIS SCI, V42, P1803; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Tamm ER, 1999, INVEST OPHTH VIS SCI, V40, P2577; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; TRIPATHI BJ, 1990, EXP EYE RES, V51, P269, DOI 10.1016/0014-4835(90)90023-N; Ueda J, 2000, J HISTOCHEM CYTOCHEM, V48, P1321, DOI 10.1177/002215540004801003; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Van Niel G, 2003, GUT, V52, P1690, DOI 10.1136/gut.52.12.1690; Wentz-Hunter K, 2002, J CELL PHYSIOL, V190, P46, DOI 10.1002/jcp.10032; Wiederholt M, 1998, Curr Opin Ophthalmol, V9, P46, DOI 10.1097/00055735-199804000-00009; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Zimmerman CC, 1999, MOL VIS, V5; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	57	80	85	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28917	28926		10.1074/jbc.M504803200	http://dx.doi.org/10.1074/jbc.M504803200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15944158	hybrid			2022-12-25	WOS:000231021300012
J	Rivera, A; Maxwell, SA				Rivera, A; Maxwell, SA			The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; P53-DEPENDENT APOPTOSIS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; NUCLEAR FACTOR; T-CELLS; P53 TRANSACTIVATION; FUNCTIONAL DOMAIN; CYCLOSPORINE-A; MESSENGER-RNA	Proline oxidase is a p53-induced redox gene that can generate reactive oxygen species (ROS) and mediate apoptosis in tumor cells. We report that proline oxidase is a downstream effector in p53-mediated activation of the calcium/calmodulin-dependent phosphatase calcineurin in lung, renal, colon, and ovarian carcinoma cells. The activation of calcineurin by p53 and proline oxidase was detected by activation of the nuclear factor of activated T cells ( NFAT), an established indicator of activated calcineurin. Both proline oxidase- and p53-induced activation of NFAT were sensitive to the calcineurin inhibitors cyclosporin A and FK- 506, to scavengers of ROS, and to inhibitors of calcium mobilization. A proline oxidase antisense vector suppressed the ability of p53 to up- regulate proline oxidase, activate calcineurin, and induce apoptosis. Moreover, two renal carcinoma-derived mutant p53 proteins were deficient in inducing proline oxidase expression and in activating calcineurin. Inhibitors of calcineurin and calcium mobilization abolished proline oxidase- mediated apoptosis and reduced p53-induced apoptosis. Treatment of colon and ovarian carcinoma cells with the anticancer genotoxic agent etoposide up-regulated both p53 and proline oxidase, activated calcineurin, and induced apoptosis. The etoposide-mediated activation of calcineurin and induction of apoptosis was markedly suppressed by FK- 506 calcineurin inhibitor. We propose that proline oxidase mediates apoptosis through the generation of proline-dependent ROS, which then mobilize calcium and activate calcineurin. The activation of calcineurin-regulated transcription factor pathways by proline oxidase might affect gene expression events important to p53 regulation of cell growth and apoptosis.	Texas A&M Univ, Dept Pathol & Lab Med, Hlth Sci Ctr, College Stn, TX 77836 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Maxwell, SA (corresponding author), Texas A&M Univ, Dept Pathol & Lab Med, Hlth Sci Ctr, 208 Reynolds Med Bldg, College Stn, TX 77836 USA.	s-maxwell@tamu.edu						Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Baek SM, 2003, J LAB CLIN MED, V142, P178, DOI 10.1016/S0022-2143(03)00111-2; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Beck WT, 2001, BIOCHEM SOC T, V29, P702, DOI 10.1042/0300-5127:0290702; Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y; Caetano MS, 2002, FASEB J, V16, P1940, DOI 10.1096/fj.02-0282fje; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cimino F, 1997, CURR TOP CELL REGUL, V35, P123, DOI 10.1016/S0070-2137(97)80005-2; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; Cummings MC, 1996, BBA-MOL BASIS DIS, V1315, P100, DOI 10.1016/0925-4439(95)00104-2; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; Donald SP, 2001, CANCER RES, V61, P1810; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Erin N, 2003, NEUROSCIENCE, V117, P541, DOI 10.1016/S0306-4522(02)00933-8; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Groenendyk J, 2004, MOL CELLS, V17, P383; Gualberto A, 1998, J BIOL CHEM, V273, P7088, DOI 10.1074/jbc.273.12.7088; Haddad JJ, 2002, CELL SIGNAL, V14, P879, DOI 10.1016/S0898-6568(02)00053-0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Huang CS, 2000, J BIOL CHEM, V275, P9143, DOI 10.1074/jbc.275.13.9143; Huang CS, 2001, CANCER RES, V61, P8051; Ikura M, 2002, BIOESSAYS, V24, P625, DOI 10.1002/bies.10105; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KOWALOFF EM, 1976, METABOLISM, V25, P1087, DOI 10.1016/0026-0495(76)90016-0; KRAUSZ Y, 1980, J CLIN INVEST, V66, P603, DOI 10.1172/JCI109893; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Liou JS, 2000, J BIOL CHEM, V275, P39001, DOI 10.1074/jbc.M007154200; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; LIU Y, 2005, IN PRESS CARCINOGENE; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; SCHMID P, 1991, DEVELOPMENT, V113, P857; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; TISHLER RB, 1993, CANCER RES, V53, P2212; Torres M, 2003, FRONT BIOSCI, V8, pD369, DOI 10.2741/999; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	64	133	139	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29346	29354		10.1074/jbc.M504852200	http://dx.doi.org/10.1074/jbc.M504852200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15914462	hybrid			2022-12-25	WOS:000231021300066
J	Yan, QF; Li, XM; Faye, R; Guan, MX				Yan, QF; Li, XM; Faye, R; Guan, MX			Mutations in MTO2 related to tRNA modification impair mitochondrial gene expression and protein synthesis in the presence of a paromomycin resistance mutation in mitochondrial 15 S rRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							16S RIBOSOMAL-RNA; YEAST SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; C1494T MUTATION; DECODING REGION; DEAFNESS; BINDING; BIOSYNTHESIS; 5-METHYLAMINOMETHYL-2-THIOURIDINE; MAINTENANCE	Nuclear gene(s) have been shown to modulate the phenotypic expression of mitochondrial DNA mutations. We report here the identification and characterization of the yeast nuclear gene MTO2 encoding an evolutionarily conserved protein involved in mitochondrial tRNA modification. Interestingly, mto2 null mutants expressed a respiratory-deficient phenotype when coexisting with the C1409G mutation of mitochondrial 15 S rRNA at the very conservative site for human deafness-associated 12 S rRNA A1491G and C1409T mutations. Furthermore, the overall rate of mitochondrial translation was markedly reduced in a yeast mto2 strain in the wild type mitochondrial background, whereas mitochondrial protein synthesis was almost abolished in a yeast mto2 strain carrying the C1409G allele. The other interesting feature of mto2 mutants is the defective expression of mitochondrial genes, especially CYTB and COX1, but only when coexisting with the C1409G allele. These data strongly indicate that a product of MTO2 functionally interacts with the decoding region of 15 S rRNA, particularly at the site of the C1409G or A1491G mutation. In addition, we showed that yeast and human Mto2p localize in mitochondria. The isolated human MTO2 cDNA can partially restore the respiratory-deficient phenotype of yeast mto2 cells carrying the C1409G mutation. These functional conservations imply that human MTO2 may act as a modifier gene, modulating the phenotypic expression of the deafness-associated A1491G or C1409T mutation in mitochondrial 12 S rRNA.	Childrens Hosp, Ctr Med, Div & Program Human Genet, Cincinnati, OH 45229 USA; Childrens Hosp, Ctr Med, Ctr Hearing & Deafness Res, Cincinnati, OH 45229 USA; Ctr Univ Orsay, Inst Curie, Biol Sect, F-91405 Orsay, France; Wenzhou Med Coll, Sch Life Sci, Zhejiang Prov Key Lab Med Genet, Wenzhou 325003, Zhejiang, Peoples R China; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Wenzhou Medical University; University System of Ohio; University of Cincinnati	Guan, MX (corresponding author), Childrens Hosp, Ctr Med, Div & Program Human Genet, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	min-xin.guan@cchmc.org	yan, qing/GZN-2287-2022	Guan, Min-Xin/0000-0001-5067-6736	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005230, R03DC004958, R01DC007696] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC007696, R03 DC004958-02, R01DC05230, R01 DC005230, R01 DC005230-04, R03 DC004958, R01 DC007696-01A2, R01 DC005230-03] Funding Source: Medline; NINDS NIH HHS [R01NS44015, R01 NS044015] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BJORK GR, 1996, ESCHERICHIA COLI SAL, P861; Bregeon D, 2001, GENE DEV, V15, P2295, DOI 10.1101/gad.207701; Cabedo H, 1999, EMBO J, V18, P7063, DOI 10.1093/emboj/18.24.7063; CHEN XJ, 1993, NUCLEIC ACIDS RES, V21, P3473, DOI 10.1093/nar/21.15.3473; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; Colby G, 1998, J BIOL CHEM, V273, P27945, DOI 10.1074/jbc.273.43.27945; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; DESTASIO EA, 1990, J MOL BIOL, V212, P127, DOI 10.1016/0022-2836(90)90309-A; ELSEVIERS D, 1984, NUCLEIC ACIDS RES, V12, P3521, DOI 10.1093/nar/12.8.3521; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Green SM, 1996, MICROBIOL-UK, V142, P3219, DOI 10.1099/13500872-142-11-3219; GREGORY ST, 1995, NUCLEIC ACIDS RES, V23, P4234, DOI 10.1093/nar/23.21.4234; Guan MX, 2001, HUM MOL GENET, V10, P573, DOI 10.1093/hmg/10.6.573; Guan MX, 2000, HUM MOL GENET, V9, P1787, DOI 10.1093/hmg/9.12.1787; Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963; Guan MX, 1997, MOL GEN GENET, V255, P525, DOI 10.1007/s004380050525; Guan MX, 2004, ANN NY ACAD SCI, V1011, P259, DOI 10.1196/annals.1293.025; Hagervall TG, 1998, J MOL BIOL, V284, P33, DOI 10.1006/jmbi.1998.2162; Hamasaki K, 1997, BIOCHEMISTRY-US, V36, P12323, DOI 10.1021/bi970962r; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; Islas-Osuna MA, 2002, J BIOL CHEM, V277, P37987, DOI 10.1074/jbc.M206132200; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Kruger MK, 1998, J MOL BIOL, V284, P609, DOI 10.1006/jmbi.1998.2197; LI M, 1982, J BIOL CHEM, V257, P5921; Li XM, 2002, MOL CELL BIOL, V22, P7701, DOI 10.1128/MCB.22.21.7701-7711.2002; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Nakai Y, 2004, J BIOL CHEM, V279, P12363, DOI 10.1074/jbc.M312448200; NEEFS JM, 1991, NUCLEIC ACIDS RES, V19, P1987, DOI 10.1093/nar/19.suppl.1987; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; Qiu JZ, 1998, NUCLEIC ACIDS RES, V26, P3077, DOI 10.1093/nar/26.13.3077; Rodeheffer MS, 2003, J BIOL CHEM, V278, P18695, DOI 10.1074/jbc.M301399200; ROTHESTEIN RJ, 1993, METHOD ENZYMOL, V101, P202; Sherman F., 1983, METHODS YEAST GENETI; SULLIVAN MA, 1985, J BACTERIOL, V161, P368, DOI 10.1128/JB.161.1.368-376.1985; Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656; Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; WEISSBRUMMER B, 1989, MOL GEN GENET, V217, P362, DOI 10.1007/BF02464905; Yan QF, 2004, BBA-GENE STRUCT EXPR, V1676, P119, DOI 10.1016/j.bbaexp.2003.11.010; Yarian C, 2000, BIOCHEMISTRY-US, V39, P13390, DOI 10.1021/bi001302g; Yarian C, 2002, J BIOL CHEM, V277, P16391, DOI 10.1074/jbc.M200253200; Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794; Zhao H, 2005, NUCLEIC ACIDS RES, V33, P1132, DOI 10.1093/nar/gki262; Zhao H, 2004, AM J HUM GENET, V74, P139, DOI 10.1086/381133; ZIMMERMANN RA, 1990, RIBOSOME, P331; ZWIEB C, 1986, MOL GEN GENET, V203, P256, DOI 10.1007/BF00333963	53	40	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29151	29157		10.1074/jbc.M504247200	http://dx.doi.org/10.1074/jbc.M504247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15944150	Green Accepted, hybrid			2022-12-25	WOS:000231021300042
J	Bandyopadhyay, S; Pai, SK; Watabe, M; Gross, SC; Hirota, S; Hosobe, S; Tsukada, T; Miura, K; Saito, K; Markwell, SJ; Wang, Y; Huggenvik, J; Pauza, ME; Iiizumi, M; Watabe, K				Bandyopadhyay, S; Pai, SK; Watabe, M; Gross, SC; Hirota, S; Hosobe, S; Tsukada, T; Miura, K; Saito, K; Markwell, SJ; Wang, Y; Huggenvik, J; Pauza, ME; Iiizumi, M; Watabe, K			FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis	ONCOGENE			English	Article						PTEN; PI3-K; FAS; siRNA; apoptosis	FATTY-ACID SYNTHASE; TUMOR-SUPPRESSOR GENE; BREAST-CARCINOMA; PROGRESSION; PATHWAY; ACTIVATION; PREDICTOR; OA-519; CELLS; OVEREXPRESSION	Fatty acid synthase (FAS), a key enzyme of the fatty acid biosynthetic pathway, has been shown to be overexpressed in various types of human cancer and is, therefore, considered to be an attractive target for anticancer therapy. However, the exact mechanism of overexpression of the FAS gene in tumor cells is not well understood. In this report, we demonstrate that the expression of the tumor suppressor gene PTEN has a significant inverse correlation with FAS expression in the case of prostate cancer in the clinical setting, and inhibition of the PTEN gene leads to the overexpression of FAS in vitro. We also found that the combination of the expression status of these two genes is a better prognostic marker than either gene alone. Furthermore, our results indicate that the specific inhibition of FAS gene by siRNA leads to apoptosis of prostate tumor cells, and inhibition of PI 3-kinase pathway synergizes with FAS siRNA to enhance tumor cell death. These results provide a strong rationale for exploring the therapeutic use of an inhibitor of the PTEN signaling pathway in conjunction with the FAS siRNA to inhibit prostate tumor growth.	So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, Springfield, IL 62702 USA; Akita Red Cross Hosp, Aichi, Japan; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University; Akita Red Cross Hospital; Southern Illinois University System; Southern Illinois University	Watabe, K (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, 801 N Rutledge St, Springfield, IL 62702 USA.	kwatabe@siumed.edu			NCI NIH HHS [5R01CA89438] Funding Source: Medline; PHS HHS [1R15V50079473] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Clegg DJ, 2002, DIABETES, V51, P3196, DOI 10.2337/diabetes.51.11.3196; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; De Schrijver E, 2003, CANCER RES, V63, P3799; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Innocenzi D, 2003, J CUTAN PATHOL, V30, P23, DOI 10.1034/j.1600-0560.2003.300104.x; JOCHEN AL, 1995, BBA-LIPID LIPID MET, V1259, P65, DOI 10.1016/0005-2760(95)00147-5; Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.can-03-3645; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kusakabe T, 2002, HISTOPATHOLOGY, V40, P71, DOI 10.1046/j.1365-2559.2002.01289.x; Li JN, 2001, CANCER RES, V61, P1493; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MALVOISIN E, 1990, BIOCHIM BIOPHYS ACTA, V1042, P359, DOI 10.1016/0005-2760(90)90165-T; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Pflug BR, 2003, PROSTATE, V57, P245, DOI 10.1002/pros.10297; Piyathilake CJ, 2000, HUM PATHOL, V31, P1068, DOI 10.1053/hupa.2000.9842; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Rashid A, 1997, AM J PATHOL, V150, P201; Sebastiani V, 2004, GYNECOL ONCOL, V92, P101, DOI 10.1016/j.ygyno.2003.10.027; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Su HS, 2000, J NUTR, V130, p315S, DOI 10.1093/jn/130.2.315S; Suzuki H, 1998, CANCER RES, V58, P204; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Takahashi KA, 2004, ENDOCRINOLOGY, V145, P184, DOI 10.1210/en.2003-0337; Van de Sande T, 2002, CANCER RES, V62, P642; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Woessmann Willi, 2003, Rev Clin Exp Hematol, V7, P270; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600	33	95	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5389	5395		10.1038/sj.onc.1208555	http://dx.doi.org/10.1038/sj.onc.1208555			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15897909				2022-12-25	WOS:000231158500013
J	Bundschu, K; Knobeloch, KP; Ullrich, M; Schinke, T; Amling, M; Engelhardt, CM; Renne, T; Walter, U; Schuh, K				Bundschu, K; Knobeloch, KP; Ullrich, M; Schinke, T; Amling, M; Engelhardt, CM; Renne, T; Walter, U; Schuh, K			Gene disruption of Spred-2 causes dwarfism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-3; VASODILATOR-STIMULATED PHOSPHOPROTEIN; CHONDROCYTE PROLIFERATION; FIBROBLAST; SPROUTY; ACTIVATION; MOUSE; MUTATION; FGFR3; DIFFERENTIATION	The impact of the fibroblast growth factor receptor 3 ( FGFR3)-mediated signaling pathway on bone growth has been demonstrated by various genetic approaches. Overexpression of fibroblast growth factors ( FGFs), several gain-of-function mutations in the FGFR3, and constitutive activation of mitogen-activated protein kinase ( MAPK) kinase ( MEK1) in chondrocytes have been shown to cause dwarfism in mice by activation of the MAPK signaling pathway. To investigate the previously reported inhibitory role of Spred in the FGFR3/MAPK pathway, we generated mice with a trapped Spred-2 gene. Here we show that lack of functional Spred-2 protein in mice caused a dwarf phenotype, similar to achondroplasia, the most common form of human dwarfism. Spred-2(-/-) mice showed reduced growth and body weight, they had a shorter tibia length, and showed narrower growth plates as compared with wild-type mice. We detected promoter activity and protein expression of Spred-2 in chondrocytes, suggesting an important function of Spred- 2 in chondrocytes and bone development. Stimulation of chondrocytes with different FGF concentrations showed earlier and augmented ERK phosphorylation in Spred-2(-/-) chondrocytes in comparison to Spred-2(+/+) chondrocytes. Our observations suggest a model in which loss of Spred- 2 inhibits bone growth by inhibiting chondrocyte differentiation through up-regulation of the MAPK signaling pathway.	Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Univ Frauenklin, D-97080 Wurzburg, Germany; Forschungsinst Mol Pharmakol, D-12207 Berlin, Germany; Expt Unfallchirurg, D-20246 Hamburg, Germany	University of Wurzburg	Schuh, K (corresponding author), Inst Klin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	kai.schuh@klin-biochem.uni-wuerzburg.de	Walter, ulrich/W-2478-2017	Walter, ulrich/0000-0001-6784-2307; Renne, Thomas/0000-0003-4594-5975				Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; Callebaut I, 1998, FEBS LETT, V441, P181, DOI 10.1016/S0014-5793(98)01541-5; Chen L, 2001, HUM MOL GENET, V10, P457, DOI 10.1093/hmg/10.5.457; Choi DY, 2001, J BIOL CHEM, V276, P5116, DOI 10.1074/jbc.M002959200; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; DeMille MMC, 1996, GENE, V183, P103, DOI 10.1016/S0378-1119(96)00506-9; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Eigenthaler M, 2003, AM J PHYSIOL-HEART C, V285, pH2471, DOI 10.1152/ajpheart.00362.2003; Engelhardt CM, 2004, HISTOCHEM CELL BIOL, V122, P527, DOI 10.1007/s00418-004-0725-6; Garofalo S, 1999, J BONE MINER RES, V14, P1909, DOI 10.1359/jbmr.1999.14.11.1909; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Hashimoto S, 2002, MECH DEVELOP, V119, pS303, DOI 10.1016/S0925-4773(03)00132-1; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Inoue H, 2005, J EXP MED, V201, P73, DOI 10.1084/jem.20040616; Iwata T, 2000, HUM MOL GENET, V9, P1603, DOI 10.1093/hmg/9.11.1603; Iwata T, 2001, HUM MOL GENET, V10, P1255, DOI 10.1093/hmg/10.12.1255; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Koike M, 2003, J BONE MINER RES, V18, P2043, DOI 10.1359/jbmr.2003.18.11.2043; Kong M, 2002, J BIOL CHEM, V277, P15962, DOI 10.1074/jbc.M102777200; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; Menzies AS, 2004, J NEUROSCI, V24, P8029, DOI 10.1523/JNEUROSCI.1057-04.2004; Minowada G, 1999, DEVELOPMENT, V126, P4465; Miyoshi K, 2004, ONCOGENE, V23, P5567, DOI 10.1038/sj.onc.1207759; Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Naski M C, 1998, Front Biosci, V3, pd781; Nobuhisa I, 2004, J EXP MED, V199, P737, DOI 10.1084/jem.20030830; Nonami A, 2004, J BIOL CHEM, V279, P52543, DOI 10.1074/jbc.M405189200; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Segev O, 2000, HUM MOL GENET, V9, P249, DOI 10.1093/hmg/9.2.249; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wang YC, 1999, P NATL ACAD SCI USA, V96, P4455, DOI 10.1073/pnas.96.8.4455; Weksler NB, 1999, BIOCHEM J, V342, P677, DOI 10.1042/0264-6021:3420677; Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971; Zimmermann J, 2004, J BIOMOL NMR, V29, P435, DOI 10.1023/B:JNMR.0000032526.17586.8c	60	43	43	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28572	28580		10.1074/jbc.M503640200	http://dx.doi.org/10.1074/jbc.M503640200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15946934	hybrid			2022-12-25	WOS:000230857300048
J	Okegawa, Y; Tsuyama, M; Kobayashi, Y; Shikanai, T				Okegawa, Y; Tsuyama, M; Kobayashi, Y; Shikanai, T			The pgr1 mutation in the Rieske subunit of the cytochrome b(6)f complex does not affect PGR5-dependent cyclic electron transport around photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEUS-ENCODED FACTOR; OXYGENIC PHOTOSYNTHESIS; DEHYDROGENASE COMPLEX; NADH-DEHYDROGENASE; CHLOROPLAST NDHB; ARABIDOPSIS; GENE; FLOW; FERREDOXIN; ANTIMYCIN	Although photosystem I ( PSI) cyclic electron transport is essential for plants, our knowledge of the route taken by electrons is very limited. To assess whether ferredoxin (Fd) donates electrons directly to plastoquinone (PQ) or via a Q-cycle in the cytochrome (cyt) b(6)f complex in PSI cyclic electron transport, we characterized the activity of PSI cyclic electron transport in an Arabidopsis mutant, pgr1 (proton gradient regulation). In pgr1, Q-cycle activity was hypersensitive to acidification of the thylakoid lumen because of an amino acid alteration in the Rieske subunit of the cyt b6f complex, resulting in a conditional defect in Q-cycle activity. In vitro assays using ruptured chloroplasts did not show any difference in the activity of PGR5-dependent PQ reduction by Fd, which functions in PSI cyclic electron transport in vivo. In contrast to the pgr5 defect, the pgr1 defect did not show any synergistic effect on the quantum yield of photosystem II in crr2-2, a mutant in which NDH (NAD(P) H dehydrogenase) activity was impaired. Furthermore, the simultaneous determination of the quantum yields of both photosystems indicated that the ratio of linear and PSI cyclic electron transport was not significantly affected in pgr1. All the results indicated that the pgr1 mutation did not affect PGR5-dependent PQ reduction by Fd. The phenotypic differences between pgr1 and pgr5 indicate that maintenance of the proper balance of linear and PSI cyclic electron transport is essential for preventing over-reduction of the stroma.	Kyushu Univ, Grad Sch Agr, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Shikanai, T (corresponding author), Kyushu Univ, Grad Sch Agr, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	shikanai@agr.kyushu-u.ac.jp	Shikanai, Toshiharu/AAK-9112-2020	Okegawa, Yuki/0000-0001-7712-021X				ARNON DI, 1955, BIOCHIM BIOPHYS ACTA, V16, P607, DOI 10.1016/0006-3002(55)90295-X; BENDALL DS, 1995, BBA-BIOENERGETICS, V1229, P23, DOI 10.1016/0005-2728(94)00195-B; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; CARRILLO N, 1981, J BIOL CHEM, V256, P1058; Cramer WA, 2004, BIOCHEMISTRY-US, V43, P5921, DOI 10.1021/bi049444o; de Vitry C, 2004, BIOCHEMISTRY-US, V43, P3956, DOI 10.1021/bi036093p; Endo T, 1998, PLANT CELL PHYSIOL, V39, P1226, DOI 10.1093/oxfordjournals.pcp.a029324; Hashimoto M, 2003, PLANT J, V36, P541, DOI 10.1046/j.1365-313X.2003.01900.x; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; Jahns P, 2002, FEBS LETT, V519, P99, DOI 10.1016/S0014-5793(02)02719-9; Joet T, 2001, PLANT PHYSIOL, V125, P1919, DOI 10.1104/pp.125.4.1919; Kotera E, 2005, NATURE, V433, P326, DOI 10.1038/nature03229; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; MI HL, 1995, PLANT CELL PHYSIOL, V36, P661; MIYAKE C, 1994, PLANT CELL PHYSIOL, V35, P539, DOI 10.1093/oxfordjournals.pcp.a078628; MOSS DA, 1984, BIOCHIM BIOPHYS ACTA, V767, P389, DOI 10.1016/0005-2728(84)90036-7; Munekaga Y, 2004, NATURE, V429, P579, DOI 10.1038/nature02598; Munekage Y, 2002, CELL, V110, P361, DOI 10.1016/S0092-8674(02)00867-X; Munekage Y, 2001, PLANT J, V28, P351, DOI 10.1046/j.1365-313X.2001.01178.x; OGAWA T, 1991, P NATL ACAD SCI USA, V88, P4275, DOI 10.1073/pnas.88.10.4275; Shikanai T, 2003, PLANT CELL, V15, P1333, DOI 10.1105/tpc.011817; Shikanai T, 1998, P NATL ACAD SCI USA, V95, P9705, DOI 10.1073/pnas.95.16.9705; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; TAGAWA K, 1963, P NATL ACAD SCI USA, V49, P567, DOI 10.1073/pnas.49.4.567; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Yamazaki H, 2004, PLANT J, V38, P152, DOI 10.1111/j.1365-313X.2004.02035.x; Zhang HM, 2004, BIOCHEMISTRY-US, V43, P16329, DOI 10.1021/bi048363p; Zhang HM, 2001, J BIOL CHEM, V276, P38159	28	19	19	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28332	28336		10.1074/jbc.M505703200	http://dx.doi.org/10.1074/jbc.M505703200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15951430	hybrid			2022-12-25	WOS:000230857300020
J	Rodriguez-Antona, C; Axelson, M; Otter, C; Rane, A; Ingelman-Sundberg, M				Rodriguez-Antona, C; Axelson, M; Otter, C; Rane, A; Ingelman-Sundberg, M			A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER-MICROSOMES; YEAST-CELLS; MONOOXYGENASE ACTIVITIES; N-DEMETHYLATION; FETAL LIVERS; EXPRESSION; METABOLISM; ENZYMES; IDENTIFICATION; STEREOSELECTIVITY	The cytochrome P450 3A7 (CYP3A7) is the most abundant CYP in human liver during fetal development and first months of postnatal age, playing an important role in the metabolism of endogenous hormones, drugs, differentiation factors, and potentially toxic and teratogenic substrates. Here we describe and characterize a novel enzyme, CYP3A7.1L, encompassing the CYP3A7.1 protein with the last four carboxyl-terminal amino acids replaced by a unique sequence of 36 amino acids, generated by splicing of CYP3A7 with CYP3AP1 RNA. The corresponding CYP3A7-3AP1 mRNA had a significant expression in liver, kidney, and gastrointestinal tract, and its presence was found to be tissue-specific and dependent on the developmental stage. Heterologous expression in yeast revealed that CYP3A7.1L was a functional enzyme with a specific activity similar to that of CYP3A7.1 and, in some conditions, a different hydroxylation specificity than CYP3A7.1 using dehydroepiandrosterone as a substrate. CYP3A7.1L was found to be polymorphic due to a mutation at position -6 of the first splicing site of CYP3AP1 (CYP3A7_39256T3A), which abrogates the pseudogene splicing. This polymorphism had pronounced interethnic differences and was in linkage disequilibrium with other functional polymorphisms described in the CYP3A locus: CYP3A7*2 and CYP3A5*1. Therefore, the resulting CYP3A haplotypes express different sets of enzymes within the population. In conclusion, a novel mechanism, consisting of the splicing of the pseudogene CYP3AP1 to CYP3A7, causes the formation of the novel CYP3A7.1L having a different tissue distribution and functional properties than the parent CYP3A7 enzyme, with possible developmental, physiological, and toxicological consequences.	Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-17177 Stockholm, Sweden; Karolinska Univ Hosp, Dept Clin Chem, S-171776 Stockholm, Sweden; AstraZeneca Res & Dev, Mol Biol, S-43183 Molndal, Sweden; Huddinge Univ Hosp, Karolinska Inst, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; AstraZeneca; Karolinska Institutet	Rodriguez-Antona, C (corresponding author), Karolinska Inst, Inst Environm Med, Div Mol Toxicol, Nobels Vag 13, S-17177 Stockholm, Sweden.	Cristina.Rodriguez-Antona@imm.ki.se	Ingelman-Sundberg, Magnus/ABD-9302-2021; Rodriguez-Antona, Cristina/E-1073-2011; Rane, Anders/L-2675-2013	Rodriguez-Antona, Cristina/0000-0001-8750-7338; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060548] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-R01 GM60548] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelson M, 2000, HEPATOLOGY, V31, P1305, DOI 10.1053/jhep.2000.7877; BELLAMINE A, 1994, EUR J BIOCHEM, V225, P1005, DOI 10.1111/j.1432-1033.1994.1005b.x; Bernal ML, 1999, PHARMACOGENETICS, V9, P657, DOI 10.1097/00008571-199910000-00013; Bertz RJ, 1997, CLIN PHARMACOKINET, V32, P210, DOI 10.2165/00003088-199732030-00004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burk O, 2002, J BIOL CHEM, V277, P24280, DOI 10.1074/jbc.M202345200; Bylund J, 2000, J BIOL CHEM, V275, P21844, DOI 10.1074/jbc.M001712200; CHANG TKH, 1993, BIOCHEM J, V291, P429, DOI 10.1042/bj2910429; Domanski TL, 2001, MOL PHARMACOL, V59, P386, DOI 10.1124/mol.59.2.386; ERNSTER L, 1962, J CELL BIOL, V15, P541, DOI 10.1083/jcb.15.3.541; Finta C, 2002, J BIOL CHEM, V277, P5882, DOI 10.1074/jbc.M109175200; Finta C, 2000, GENE, V260, P13, DOI 10.1016/S0378-1119(00)00470-4; Floyd MD, 2003, PHARMACOGENETICS, V13, P595, DOI 10.1097/00008571-200310000-00003; Foster DJR, 1999, BRIT J CLIN PHARMACO, V47, P403, DOI 10.1046/j.1365-2125.1999.00921.x; Gellner K, 2001, PHARMACOGENETICS, V11, P111, DOI 10.1097/00008571-200103000-00002; JOHANSSON I, 1991, EUR J CLIN PHARMACOL, V40, P553; KRYNETSKI EY, 1995, PHARMACOGENETICS, V5, P103, DOI 10.1097/00008571-199504000-00007; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Lacroix D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/j.1432-1033.1997.00625.x; Ladona MG, 2000, LIFE SCI, V68, P431, DOI 10.1016/S0024-3205(00)00952-8; Lee AJ, 2003, CANCER RES, V63, P6532; Marill J, 2002, BIOCHEM PHARMACOL, V63, P933, DOI 10.1016/S0006-2952(01)00925-X; Matsunaga T, 2000, DRUG METAB DISPOS, V28, P1291; Miller KKM, 2004, DRUG METAB DISPOS, V32, P305, DOI 10.1124/dmd.32.3.305; Nebert DW, 1997, AM J HUM GENET, V60, P265; Ohmori S, 1998, BBA-GEN SUBJECTS, V1380, P297, DOI 10.1016/S0304-4165(97)00156-6; PELLINEN P, 1994, EUR J PHARM-ENVIRON, V270, P35, DOI 10.1016/0926-6917(94)90078-7; Rodriguez-Antona C, 2005, CLIN PHARMACOL THER, V77, P259, DOI 10.1016/j.clpt.2004.11.003; Shimada T, 1996, DRUG METAB DISPOS, V24, P515; Stevens JC, 2003, J PHARMACOL EXP THER, V307, P573, DOI 10.1124/jpet.103.054841; Thompson EE, 2004, AM J HUM GENET, V75, P1059, DOI 10.1086/426406; TRUAN G, 1993, GENE, V125, P49, DOI 10.1016/0378-1119(93)90744-N; URBAN P, 1990, BIOCHIMIE, V72, P463, DOI 10.1016/0300-9084(90)90070-W; Westlind A, 1999, BIOCHEM BIOPH RES CO, V259, P201, DOI 10.1006/bbrc.1999.0752; Westlind A, 2001, BIOCHEM BIOPH RES CO, V281, P1349, DOI 10.1006/bbrc.2001.4505; Westlind-Johnsson A, 2003, DRUG METAB DISPOS, V31, P755, DOI 10.1124/dmd.31.6.755; Williams ET, 2004, MOL PHYLOGENET EVOL, V33, P300, DOI 10.1016/j.ympev.2004.05.013; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	38	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28324	28331		10.1074/jbc.M502309200	http://dx.doi.org/10.1074/jbc.M502309200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15937338	hybrid			2022-12-25	WOS:000230857300019
J	Kuroda, TS; Fukuda, M				Kuroda, TS; Fukuda, M			Functional analysis of Slac2-c/MyRIP as a linker protein between melanosomes and myosin VIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLP HOMOLOGY DOMAIN; USHER-SYNDROME; BINDING DOMAIN; RAB EFFECTOR; C2 DOMAINS; VA; MELANOCYTES; MUTATIONS; TRANSPORT; MICE	Slac2-c/MyRIP, an in vitro Rab27A- and myosin Va/VIIa-binding protein, has recently been proposed to regulate retinal melanosome transport in retinal pigment epithelium cells by directly linking melanosome-bound Rab27A and myosin VIIa; however, the exact function of Slac2-c in melanosome transport has never been clarified. In this study, we used melanosome transport in skin melanocytes as a model for retinal melanosome transport and analyzed the in vivo function of Slac2-c in melanosome transport by the ectopic expression of Slac2-c, together with myosin VIIa, in Slac2-a-depleted melanocytes. In vitro binding experiments revealed that myosin VIIa had a greater affinity for Slac2-c, compared with the binding affinity of myosin Va, and that the myosin VIIa-binding domain of Slac2-c is different from the previously characterized myosin Va-binding domain that is conserved between Slac2-a/melanophilin and Slac2-c. Consistent with this result, cyan fluorescent protein-tagged Slac2-c expressed in melanocytes was localized on melanosomes via the specific interaction with Rab27A and recruited co-expressed yellow fluorescent protein-tagged myosin VIIa to the melanosomes without interfering with the normal peripheral melanosome distribution, whereas when myosin VIIa alone was expressed in melanocytes, it was not localized on the melanosomes. Moreover, Slac2-c ectopically expressed in melanocytes did not rescue the perinuclear aggregation phenotype induced by the knockdown of endogenous Slac2-a with a specific small interfering RNA, whereas the expression of the Slac2-c.myosin VIIa complex supported the normal melanosome distribution in Slac2-a-depleted melanocytes, indicating that Slac2-c functions as a myosin VIIa receptor rather than a myosin Va receptor in melanosome transport. Based on these findings, we propose that Slac2-c acts as a functional myosin VIIa receptor and that the Rab27A.Slac2-c.myosin VIIa tripartite protein complex regulates the transport of retinal melanosomes in pigment epithelium cells.	RIKEN, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853; Kuroda, Taruho/0000-0001-6693-4496				BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Boissy RE, 2003, EXP DERMATOL, V12, P5, DOI 10.1034/j.1600-0625.12.s2.1.x; Desnos C, 2003, J CELL BIOL, V163, P559, DOI 10.1083/jcb.200302157; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2005, J BIOCHEM, V137, P9, DOI 10.1093/jb/mvi002; Fukuda M, 2004, J CELL SCI, V117, P583, DOI 10.1242/jcs.00891; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Futter CE, 2004, MOL BIOL CELL, V15, P2264, DOI 10.1091/mbc.E03-10-0772; GIBBS D, 2004, J CEL SCI, V117, P4509; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Imai A, 2004, J CELL SCI, V117, P1945, DOI 10.1242/jcs.01048; Izumi T, 2003, CELL STRUCT FUNCT, V28, P465, DOI 10.1247/csf.28.465; Keats BJB, 2004, AM J MED GENET A, V130A, P13, DOI 10.1002/ajmg.a.30052; Kuroda TS, 2004, NAT CELL BIOL, V6, P1195, DOI 10.1038/ncb1197; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lillo C, 2003, ADV EXP MED BIOL, V533, P143; Liu XR, 1998, NAT GENET, V19, P117, DOI 10.1038/470; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Menasche G, 2003, J CLIN INVEST, V112, P450, DOI 10.1172/JCI200318264; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Petit C, 2001, ANNU REV GENOM HUM G, V2, P271, DOI 10.1146/annurev.genom.2.1.271; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Seabra MC, 2004, TRAFFIC, V5, P393, DOI 10.1111/j.1398-9219.2004.00190.x; SEGEV N, 2001, SCI STKE, V100, pRE11; Seiberg M, 2001, PIGM CELL RES, V14, P236, DOI 10.1034/j.1600-0749.2001.140402.x; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	40	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28015	28022		10.1074/jbc.M501465200	http://dx.doi.org/10.1074/jbc.M501465200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15927964	hybrid			2022-12-25	WOS:000230678600064
J	Mahmmoud, YA; Vorum, H; Cornelius, F				Mahmmoud, YA; Vorum, H; Cornelius, F			Interaction of FXYD10 (PLMS) with Na,K-ATPase from shark rectal glands - Close proximity of Cys(74) of FXYD10 to Cys(254) in the A domain of the alpha-subunit revealed by intermolecular thiol cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; PHOSPHOLEMMAN-LIKE PROTEIN; GAMMA-SUBUNIT; CALCIUM-PUMP; RENAL NA,K-ATPASE; CRYSTAL-STRUCTURE; FUNCTIONAL-ROLE; EXPRESSION; REGULATOR; TRANSPORT	FXYD domain-containing proteins are tissue-specific regulators of the Na, K-ATPase that have been shown to have significant physiological implications. Information about the sites of interaction between some FXYD proteins and subunits of the Na, K-ATPase is beginning to emerge. We previously identified an FXYD protein in plasma membranes from shark rectal gland cells and demonstrated that this protein (FXYD10) modulates shark Na, K-ATPase activity. The present study was undertaken to identify the location of the C-terminal domain of FXYD10 on the alpha-subunit of Na, K-ATPase, using covalent cross-linking combined with proteolytic cleavage. Treatment of Na, K-ATPase-enriched membranes with the homobifunctional thiol cross-linker 1,4-bismaleimidyl-2,3- dihydroxybutane resulted in cross-linking of FXYD10 to the alpha-subunit. Cross-linking was not affected by preincubation with sodium or potassium but was significantly reduced after pre-incubation with the non-hydrolyzable ATP analog beta,gamma-methyleneadenosine 5'-triphosphate (AMP-PCP). A peptic assay was developed, in which pepsin treatment of Na, K-ATPase at low pH resulted in extensive cleavage of the alpha-subunit while FXYD10 was left intact. Proteolytic fragments of control and cross-linked preparations were isolated by immunoprecipitation and analyzed by gel electrophoresis. A proteolytic fragment containing FXYD10 cross-linked to a fragment from the alpha-subunit could be localized on SDS gels. Sequencing of this fragment showed the presence of FXYD10 as well as a fragment within the A domain of the alpha-subunit comprising 33 amino acids, including a single Cys residue, Cys(254). Thus, regulation of Na, K-ATPase by FXYD10 occurs in part via cytoplasmic interaction of FXYD10 with the A domain of the shark alpha- subunit.	Univ Aarhus, Inst Physiol & Biophys, DK-8000 Aarhus, Denmark; Univ Aarhus, Inst Med Biochem, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University	Mahmmoud, YA (corresponding author), Univ Aarhus, Inst Physiol & Biophys, Ole Worms Alle 185, DK-8000 Aarhus, Denmark.	yam@biophys.au.dk	Cornelius, Flemming/C-1912-2019	Cornelius, Flemming/0000-0003-1566-0020				Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2002, J BIOL CHEM, V277, P10162, DOI 10.1074/jbc.M111552200; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Cornelius F, 2003, ANN NY ACAD SCI, V986, P579, DOI 10.1111/j.1749-6632.2003.tb07256.x; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Crambert G, 2004, J BIOL CHEM, V279, P30888, DOI 10.1074/jbc.M313494200; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Crambert G, 2005, MOL BIOL CELL, V16, P2363, DOI 10.1091/mbc.E04-10-0878; CRAMBERT G, 2003, SCI STKE, V166, pRE1; Daly SE, 1997, J BIOL CHEM, V272, P6341, DOI 10.1074/jbc.272.10.6341; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Fuzesi M, 2005, J BIOL CHEM, V280, P18291, DOI 10.1074/jbc.M500080200; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; RAJAGOPALAN TG, 1966, J BIOL CHEM, V241, P4940; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; SKOU JC, 1979, BIOCHIM BIOPHYS ACTA, V567, P436, DOI 10.1016/0005-2744(79)90129-3; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2001, J BIOENERG BIOMEMBR, V33, P407, DOI 10.1023/A:1010619623841; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2003, P NATL ACAD SCI USA, V100, P467, DOI 10.1073/pnas.0237326100; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944	45	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27776	27782		10.1074/jbc.M503150200	http://dx.doi.org/10.1074/jbc.M503150200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15919665	hybrid			2022-12-25	WOS:000230678600037
J	Etzioni, S; Yafe, A; Khateb, S; Weisman-Shomer, P; Bengal, E; Fry, M				Etzioni, S; Yafe, A; Khateb, S; Weisman-Shomer, P; Bengal, E; Fry, M			Homodimeric MyoD preferentially binds tetraplex structures of regulatory sequences of muscle-specific genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-QUARTET FORMATION; DNA-BINDING; C-MYC; TELOMERIC DNA; EXPANDED SEQUENCE; SKELETAL MYOGENESIS; SITE SELECTION; UP-REGULATION; BETA-SUBUNIT; G-QUADRUPLEX	Myogenic transcription is activated by the binding of heterodimers of the basic helix-loop-helix proteins MyoD and E12 or E47 to a consensus E-box sequence, d(CANNTG), in promoter or enhancer regions of muscle-specific genes. Homodimers of MyoD bind E-box less tightly and are less efficient activators of transcription. Recent results from our laboratory (Yafe, A., Etzioni, S., Weisman-Shomer, P., and Fry, M. ( 2005) Nucleic Acids Res. 33, 2887-2900) indicate that regulatory sequences of several muscle-specific genes contain a disproportionate high content of guanine clusters that readily form hairpin and parallel-stranded unimolecular and bimolecular tetraplex structures. Here we have shown that homodimers of full-length recombinant MyoD formed complexes with bimolecular tetraplex structures of muscle-specific regulatory sequences but not with their double-stranded, hairpin, or unimolecular tetraplex forms. Preferential binding of homodimeric MyoD to bimolecular tetraplex DNA structures over E-box DNA was reflected by the 18.7-39.9-fold lower dissociation constants, K-d, of the MyoD-tetraplex DNA complexes. Conversely, MyoD-E47 heterodimers formed tighter complexes with E-box as indicated by their 6.8-19.0-fold lower K-d relative to complexes with bimolecular tetraplex DNA structures. Similarly, homodimers of the 60-amino acid basic helix-loop-helix domain of MyoD bound E-box more efficiently and tetraplex DNA less efficiently than homodimers of full-length MyoD. It might be that the favored binding of MyoD homodimers to tetraplex DNA structures lowers their ability to activate muscle-specific gene transcription, whereas the formation of MyoD-E47 heterodimers and their preferential binding to E-box DNA enhance transcription.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Fry, M (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.	mickey@tx.technion.ac.il						Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Erlitzki R, 1997, J BIOL CHEM, V272, P15881, DOI 10.1074/jbc.272.25.15881; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; Fukuda H, 2002, P NATL ACAD SCI USA, V99, P12685, DOI 10.1073/pnas.152456899; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; Grand CL, 2004, P NATL ACAD SCI USA, V101, P6140, DOI 10.1073/pnas.0400460101; Grand CL, 2002, MOL CANCER THER, V1, P565; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Khateb S, 2004, NUCLEIC ACIDS RES, V32, P4145, DOI 10.1093/nar/gkh745; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lemarteleur T, 2004, BIOCHEM BIOPH RES CO, V323, P802, DOI 10.1016/j.bbrc.2004.08.150; Lew A, 2000, P NATL ACAD SCI USA, V97, P12508, DOI 10.1073/pnas.97.23.12508; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; Lu Q, 1998, NUCLEIC ACIDS RES, V26, P1613, DOI 10.1093/nar/26.7.1613; Mal A, 2003, P NATL ACAD SCI USA, V100, P1735, DOI 10.1073/pnas.0437843100; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Phan AT, 2004, J AM CHEM SOC, V126, P8710, DOI 10.1021/ja048805k; RAWLS A, 1995, DEV BIOL, V172, P37, DOI 10.1006/dbio.1995.0004; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; Sarig G, 1997, BIOCHEM BIOPH RES CO, V237, P617, DOI 10.1006/bbrc.1997.7198; Schnorrer F, 2004, DEV CELL, V7, P9, DOI 10.1016/j.devcel.2004.06.010; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; Sun H, 2001, P NATL ACAD SCI USA, V98, P12444, DOI 10.1073/pnas.231479198; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; Tajbakhsh S, 2003, CURR OPIN GENET DEV, V13, P413, DOI 10.1016/S0959-437X(03)00090-X; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Uliel L, 2000, J BIOL CHEM, V275, P33134, DOI 10.1074/jbc.M005542200; WALSH K, 1992, J BIOL CHEM, V267, P13714; Weisman-Shomer P, 2000, J BIOL CHEM, V275, P2231, DOI 10.1074/jbc.275.3.2231; Weisman-Shomer P, 2002, NUCLEIC ACIDS RES, V30, P3672, DOI 10.1093/nar/gkf506; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; Yafe A, 2005, NUCLEIC ACIDS RES, V33, P2887, DOI 10.1093/nar/gki606; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	50	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26805	26812		10.1074/jbc.M500820200	http://dx.doi.org/10.1074/jbc.M500820200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15923190	hybrid			2022-12-25	WOS:000230589500022
J	Gibson, A; Lewis, AP; Affleck, K; Aitken, AJ; Meldrum, E; Thompson, N				Gibson, A; Lewis, AP; Affleck, K; Aitken, AJ; Meldrum, E; Thompson, N			hCLCA1 and mCLCA3 are secreted non-integral membrane proteins and therefore are not ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CHLORIDE CHANNEL; CA2+-ACTIVATED CL-CHANNEL; MUCUS OVERPRODUCTION; INCREASED EXPRESSION; BETA(4) INTEGRIN; CYSTIC-FIBROSIS; BOVINE TRACHEA; BREAST-CANCER; PREDICTION; CONDUCTANCE	Proteins of the CLCA gene family have been proposed to mediate calcium-activated chloride currents. In this study, we used detailed bioinformatics analysis and found that no transmembrane domains are predicted in hCLCA1 or mCLCA3 (Gob-5). Further analysis suggested that they are globular proteins containing domains that are likely to be involved in protein-protein interactions. In support of the bioinformatics analysis, biochemical studies showed that hCLCA1 and mCLCA3, when expressed in HEK293 cells, could be removed from the cell surface and could be detected in the extracellular medium, even after short incubation times. The accumulation in the medium was shown to be brefeldin A-sensitive, demonstrating that hCLCA1 is constitutively secreted. The N-terminal cleavage products of hCLCA1 and mCLCA3 could be detected in bronchoalveolar lavage fluid taken from asthmatic subjects and ovalbumin-challenged mice, demonstrating release from cells in a physiological setting. We conclude that hCLCA1 and mCLCA3 are non-integral membrane proteins and therefore cannot be chloride channels in their own right.	GlaxoSmithKline Inc, Stevenage SG1 2NY, Herts, England	GlaxoSmithKline	Affleck, K (corresponding author), GlaxoSmithKline Inc, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.	karen.x.affleck@gsk.com						Abdel-Ghany M, 2003, J BIOL CHEM, V278, P49406, DOI 10.1074/jbc.M309086200; Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Atherton H, 2003, N-S ARCH PHARMACOL, V367, P214, DOI 10.1007/s00210-002-0668-1; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; Bustin SA, 2001, DNA CELL BIOL, V20, P331, DOI 10.1089/10445490152122442; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Eggermont Jan, 2004, Proc Am Thorac Soc, V1, P22, DOI 10.1513/pats.2306010; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Gough J, 2001, J MOL BIOL, V313, P903, DOI 10.1006/jmbi.2001.5080; Greenwood IA, 2002, J BIOL CHEM, V277, P22119, DOI 10.1074/jbc.C200215200; Gruber A. D., 2000, Current Genomics, V1, P201, DOI 10.2174/1389202003351526; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1999, CANCER RES, V59, P5488; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Hauber HP, 2004, EUR RESPIR J, V23, P846, DOI 10.1183/09031936.04.00096504; Hauber HP, 2003, LARYNGOSCOPE, V113, P1037, DOI 10.1097/00005537-200306000-00022; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; Hoshino M, 2002, AM J RESP CRIT CARE, V165, P1132, DOI 10.1164/ajrccm.165.8.2107068; Ji HL, 1998, AM J PHYSIOL-CELL PH, V274, pC455, DOI 10.1152/ajpcell.1998.274.2.C455; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lange K, 2000, J CELL PHYSIOL, V185, P21, DOI 10.1002/1097-4652(200010)185:1<21::AID-JCP2>3.3.CO;2-4; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Leverkoehne I, 2002, J HISTOCHEM CYTOCHEM, V50, P829, DOI 10.1177/002215540205000609; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Loewen ME, 2004, AM J PHYSIOL-GASTR L, V287, pG33, DOI 10.1152/ajpgi.00023.2004; Loewen ME, 2002, BIOCHEM BIOPH RES CO, V298, P531, DOI 10.1016/S0006-291X(02)02498-1; Loewen ME, 2003, AM J PHYSIOL-CELL PH, V285, pC1314, DOI 10.1152/ajpcell.00210.2003; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Papassotiriou J, 2001, PFLUG ARCH EUR J PHY, V442, P273; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; RAN S, 1992, J BIOL CHEM, V267, P20630; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; Soding J, 2005, BIOINFORMATICS, V21, P951, DOI 10.1093/bioinformatics/bti125; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; Tuckwell D, 1999, BIOCHEM SOC T, V27, P835, DOI 10.1042/bst0270835; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847; Zhou YH, 2001, AM J RESP CELL MOL, V25, P486, DOI 10.1165/ajrcmb.25.4.4578	54	113	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27205	27212		10.1074/jbc.M504654200	http://dx.doi.org/10.1074/jbc.M504654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15919655	hybrid			2022-12-25	WOS:000230589500068
J	Imai, K; Nakata, K; Kawai, K; Hamano, T; Mei, N; Kasai, H; Okamoto, T				Imai, K; Nakata, K; Kawai, K; Hamano, T; Mei, N; Kasai, H; Okamoto, T			Induction of OGG1 gene expression by HIV-1 tat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; P53 TUMOR-SUPPRESSOR; NF-KAPPA-B; P-TEFB; PROTEIN; TYPE-1; RNA; DNA; CELLS; TRANSCRIPTION	To identify the cellular gene target for Tat, we performed gene expression profile analysis and found that Tat up-regulates the expression of the OGG1 (8-oxoguanine-DNA glycosylase-1) gene, which encodes an enzyme responsible for repairing the oxidatively damaged guanosine, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG). We observed that Tat induced OGG1 gene expression by enhancing its promoter activity without changing its mRNA stability. We found that the upstream AP-4 site within the OGG1 promoter is responsible and that Tat interacted with AP-4 and removed AP-4 from the OGG1 promoter by in vivo chromatin immunoprecipitation assay. Thus, Tat appears to activate OGG1 expression by sequestrating AP-4. Interestingly, although Tat induces oxidative stress known to generate 8-oxo-dG, which causes the G: C to T: A transversion, we observed that the amount of 8-oxo-dG was reduced by Tat. When OGG1 was knocked down by small interfering RNA, Tat increased the amount of 8-oxo-dG, thus confirming the role of OGG1 in preventing the formation of 8-oxo-dG. These findings collectively indicate the possibility that Tat may play a role in maintenance of the genetic integrity of the proviral and host cellular genomes by upregulating OGG1 as a feed-forward mechanism.	Nagoya City Univ, Grad Sch Med Sci, Dept Mol & Cellular Biol, Mizuho Ku, Aichi 4678601, Japan; Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Fukuoka 8078555, Japan; Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan	Nagoya City University; University of Occupational & Environmental Health - Japan; National Institute of Infectious Diseases (NIID)	Okamoto, T (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Mol & Cellular Biol, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Aichi 4678601, Japan.	tokamoto@med.nagoya-cu.ac.jp	Mei, Nan/E-8915-2011	Mei, Nan/0000-0002-3501-9014				Ando K, 2003, ONCOGENE, V22, P7796, DOI 10.1038/sj.onc.1206965; Andriamanalijaona R, 2003, ARTHRITIS RHEUM, V48, P1569, DOI 10.1002/art.11020; Ao Y, 2001, ONCOGENE, V20, P2720, DOI 10.1038/sj.onc.1204352; Arai T, 2003, CANCER RES, V63, P4287; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Choi J, 2000, J BIOL CHEM, V275, P3693, DOI 10.1074/jbc.275.5.3693; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; Cui Y, 1998, GENE, V224, P97, DOI 10.1016/S0378-1119(98)00512-5; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Hatahet Z, 1998, P NATL ACAD SCI USA, V95, P8556, DOI 10.1073/pnas.95.15.8556; Hussain SP, 1998, CANCER RES, V58, P4023; Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kumar A, 1998, J IMMUNOL, V161, P776; Kurdistani SK, 1998, CANCER RES, V58, P4439; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; LONGO F, 1995, BIOCHEM BIOPH RES CO, V206, P326, DOI 10.1006/bbrc.1995.1045; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MORIYAMA EN, 1991, J MOL EVOL, V32, P360, DOI 10.1007/BF02101275; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Okamoto H, 2000, VIROLOGY, V272, P402, DOI 10.1006/viro.2000.0396; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; PERRY ST, 1992, J VIROL, V66, P4085, DOI 10.1128/JVI.66.7.4085-4097.1992; PINCUS SH, 1994, J CLIN INVEST, V93, P140, DOI 10.1172/JCI116937; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Saez E, 2000, P NATL ACAD SCI USA, V97, P14512, DOI 10.1073/pnas.260499497; Sarol LC, 2002, BIOCHEM BIOPH RES CO, V291, P890, DOI 10.1006/bbrc.2002.6532; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; Takada N, 2002, J VIROL, V76, P8019, DOI 10.1128/JVI.76.16.8019-8030.2002; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Tsurudome Y, 1999, CARCINOGENESIS, V20, P1573, DOI 10.1093/carcin/20.8.1573; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Watanabe N, 2002, BIOCHEM BIOPH RES CO, V294, P1121, DOI 10.1016/S0006-291X(02)00608-3; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; ZAULI G, 1993, CANCER RES, V53, P4481; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	59	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26701	26713		10.1074/jbc.M503313200	http://dx.doi.org/10.1074/jbc.M503313200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15929986	hybrid			2022-12-25	WOS:000230589500010
J	Jacobs, A; Sen, J; Rong, LJ; Caffrey, M				Jacobs, A; Sen, J; Rong, LJ; Caffrey, M			Alanine scanning mutants of the HIV gp41 loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; 44 KDA ECTODOMAIN; ENVELOPE GLYCOPROTEIN; SIV GP41; CRYSTAL-STRUCTURE; DISULFIDE BOND; GP120; ASSOCIATION; INFECTIVITY; RESIDUES	Based on mutagenesis and structural studies of human immunodeficiency virus (HIV) envelope proteins, the loop region of gp41 is thought to directly interact with gp120. The importance of the HIV gp41 loop region to envelope function has been systematically examined by alanine scanning of all gp41 loop residues and the subsequent characterization of the mutagenic effects on viral entry, envelope expression, envelope processing, and gp120 association with gp41. With respect to the wild-type gp41, mutational effects on viral entry fall into four classes as follows: 1) little or no effect (G594A, S599A, G600A, K601A, N611A, S615A, N616A, and L619A); 2) significantly reduced entry (I595A, L602A, I603A, V608A, and K617A); 3) abolished entry (L593A, W596A, G597A, T606A, W610A, W614A, S618A, and I622A); and 4) enhanced entry (T605A, P609A, S613A, E620A, and Q621A). The reduced functionality of many mutants was apparently due to either disruption of envelope processing ( L593A and T606A), viral incorporation of the envelope (W610A, W614A, and I662A), or increased dissociation of gp120 ( W596A, G597A, and S618A). The extreme sensitivity of the gp120-gp41 interaction to alanine substitutions (e g. the G597A and S618A mutants are relatively conservative substitutions) suggests that this association is an attractive and novel target for future drug discovery efforts.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Caffrey, M (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	caffrey@uic.edu			NIAID NIH HHS [R01 AI47674] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047674] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrahamyan LG, 2003, J VIROL, V77, P5829, DOI 10.1128/JVI.77.10.5829-5836.2003; Binley JM, 2003, J VIROL, V77, P5678, DOI 10.1128/JVI.77.10.5678-5684.2003; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 2001, BBA-MOL BASIS DIS, V1536, P116, DOI 10.1016/S0925-4439(01)00042-4; Caffrey M, 1997, J MOL BIOL, V271, P819, DOI 10.1006/jmbi.1997.1217; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/0022-1317-83-8-1809; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DEDERA DA, 1992, VIROLOGY, V187, P377, DOI 10.1016/0042-6822(92)90331-I; DEDRA D, 1992, J VIROL, V66, P1207; Douglas NW, 1997, J MOL BIOL, V273, P122, DOI 10.1006/jmbi.1997.1277; FREED E, 1995, J BIOL CHEM, V270, P23833; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Johnson WE, 2001, J VIROL, V75, P11426, DOI 10.1128/JVI.75.23.11426-11436.2001; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Maerz AL, 2001, J VIROL, V75, P6635, DOI 10.1128/JVI.75.14.6635-6644.2001; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Merat R, 1999, J VIROL, V73, P5698, DOI 10.1128/JVI.73.7.5698-5706.1999; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; Park EJ, 1999, J VIROL, V73, P5707, DOI 10.1128/JVI.73.7.5707-5713.1999; TAN K, 1997, P NATL ACAD SCI USA, V94, P12203; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116; York J, 2004, J VIROL, V78, P4921, DOI 10.1128/JVI.78.9.4921-4926.2004	27	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27284	27288		10.1074/jbc.M414411200	http://dx.doi.org/10.1074/jbc.M414411200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917239	hybrid			2022-12-25	WOS:000230589500077
J	Mahoney, DJ; Mulloy, B; Forster, MJ; Blundell, CD; Fries, E; Milner, CM; Day, AJ				Mahoney, DJ; Mulloy, B; Forster, MJ; Blundell, CD; Fries, E; Milner, CM; Day, AJ			Characterization of the interaction between tumor necrosis factor-stimulated gene-6 and heparin - Implications for the inhibition of plasmin in extracellular matrix microenvironments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTER-ALPHA-INHIBITOR; HYALURONAN-BINDING PROTEIN; COLLAGEN-INDUCED ARTHRITIS; LINK MODULE; SULFATE PROTEOGLYCANS; GROWTH-FACTOR; CHROMOSOMAL LOCALIZATION; TRYPSIN INHIBITOR; UP-REGULATION; DBA/1J MICE	TSG-6, the secreted product of tumor necrosis factor-stimulated gene-6, is not constitutively expressed but is up-regulated in various cell-types during inflammatory and inflammation-like processes. The mature protein is comprised largely of contiguous Link and CUB modules, the former binding several matrix components such as hyaluronan ( HA) and aggrecan. Here we show that this domain can also associate with the glycosaminoglycan heparin/heparan sulfate. Docking predictions and site-directed mutagenesis demonstrate that this occurs at a site distinct from the HA binding surface and is likely to involve extensive electrostatic contacts. Despite these glycosaminoglycans binding to non-overlapping sites on the Link module, the interaction of heparin can inhibit subsequent binding to HA, and it is possible that this occurs via an allosteric mechanism. We also show that heparin can modify another property of the Link module, i.e. its potentiation of the anti-plasmin activity of inter-alpha-inhibitor ( I alpha I). Experiments using the purified components of I alpha I indicate that TSG-6 only binds to the bikunin chain and that this is at a site on the Link module that overlaps the HA binding surface. The association of heparin with the Link module significantly increases the antiplasmin activity of the TSG-6 center dot I alpha I complex. Changes in plasmin activity have been observed previously at sites of TSG-6 expression, and the results presented here suggest that TSG-6 is likely to contribute to matrix remodeling, at least in part, through down-regulation of the protease network, especially in locations containing heparin/heparan sulfate proteoglycans. The differential effects of HA and heparin on TSG-6 function provide a mechanism for its regulation and functional partitioning in particular tissue microenvironments.	Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England; Uppsala Univ, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	University of Oxford; University of Oxford; National Institute for Biological Standards & Control; Uppsala University	Day, AJ (corresponding author), Univ Oxford, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	caroline.milner@bioch.ox.ac.uk; tony.day@bioch.ox.ac.uk	Day, Anthony/O-1658-2015; Milner, Caroline M/P-5526-2015	Day, Anthony/0000-0002-1415-3134; Milner, Caroline M/0000-0001-7355-9655; Blundell, Charles/0000-0002-1439-9126	Medical Research Council [MC_U138274352] Funding Source: Medline; MRC [MC_U138274352] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akenami FOT, 2000, FIBRINOLYSIS PROTEOL, V14, P1, DOI 10.1054/fipr.2000.0056; BANGHAM D R, 1959, Bull World Health Organ, V20, P1209; Bardos T, 2001, AM J PATHOL, V159, P1711, DOI 10.1016/S0002-9440(10)63018-0; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Blom AM, 1999, J BIOL CHEM, V274, P298, DOI 10.1074/jbc.274.1.298; Blundell C. D., 2002, HYALURONAN, P161; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; Bobik A, 2003, CURR HYPERTENS REP, V5, P466, DOI 10.1007/s11906-003-0054-5; Busso N, 2002, ARTHRITIS RHEUM, V46, P2268, DOI 10.1002/art.10498; Calvete JJ, 1996, FEBS LETT, V399, P147, DOI 10.1016/S0014-5793(96)01310-5; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; Carrette O, 1997, BBA-PROTEIN STRUCT M, V1338, P21, DOI 10.1016/S0167-4838(96)00184-7; CASU B, 1983, ARZNEIMITTELFORSCH, V33-1, P135; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; D'Alessandris C, 2001, ENDOCRINOLOGY, V142, P3033, DOI 10.1210/en.142.7.3033; DAY AJ, 2004, HA2003 P; Dow MPD, 2002, REPRODUCTION, V123, P711, DOI 10.1530/reprod/123.5.711; Enghild JJ, 1999, BIOCHEMISTRY-US, V38, P11804, DOI 10.1021/bi9908540; Fries E, 2000, INT J BIOCHEM CELL B, V32, P125, DOI 10.1016/S1357-2725(99)00125-9; Fujimoto T, 2002, AM J PATHOL, V160, P1495, DOI 10.1016/S0002-9440(10)62575-8; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; Gray E, 2000, THROMB HAEMOSTASIS, V84, P1017; Hasan S, 2002, BIOL REPROD, V66, P144, DOI 10.1095/biolreprod66.1.144; Innis CA, 2003, J BIOL CHEM, V278, P39969, DOI 10.1074/jbc.M211284200; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kobayashi H, 1998, EUR J BIOCHEM, V253, P817, DOI 10.1046/j.1432-1327.1998.2530817.x; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Kraus M, 2001, J REPROD IMMUNOL, V51, P131, DOI 10.1016/S0165-0378(01)00072-9; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; Lindstrom KE, 1997, KIDNEY INT, V51, P1053, DOI 10.1038/ki.1997.147; Mahoney DJ, 2004, ANAL BIOCHEM, V330, P123, DOI 10.1016/j.ab.2004.03.055; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mindrescu C, 2000, ARTHRITIS RHEUM, V43, P2668, DOI 10.1002/1529-0131(200012)43:12<2668::AID-ANR6>3.0.CO;2-E; Mizon C, 1997, J CHROMATOGR B, V692, P281, DOI 10.1016/S0378-4347(97)00012-1; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Mulloy B, 2000, THROMB HAEMOSTASIS, V84, P1052; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; Murdoch WJ, 2003, CONNECT TISSUE RES, V44, P50, DOI 10.1080/03008200390151963; Murer V, 2001, P NATL ACAD SCI USA, V98, P3029, DOI 10.1073/pnas.051630698; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Nomura I, 2005, PEDIATR RES, V57, P49, DOI 10.1203/01.PDR.0000147745.52711.DD; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P1008, DOI 10.1210/en.2002-220435; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Princivalle M, 2001, GLYCOBIOLOGY, V11, P183, DOI 10.1093/glycob/11.3.183; Rakic JM, 2003, CELL MOL LIFE SCI, V60, P463, DOI 10.1007/s000180300039; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Sachchidanand, 2002, J BIOL CHEM, V277, P50629, DOI 10.1074/jbc.M208956200; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004; Sanggaard KW, 2005, J BIOL CHEM, V280, P11936, DOI 10.1074/jbc.M409016200; Seidita G, 2000, CARCINOGENESIS, V21, P2203, DOI 10.1093/carcin/21.12.2203; Szanto S, 2004, ARTHRITIS RHEUM-US, V50, P3012, DOI 10.1002/art.20655; Tesche F, 2005, HISTOL HISTOPATHOL, V20, P329, DOI 10.14670/HH-20.329; Tesche F, 2004, OSTEOARTHR CARTILAGE, V12, P852, DOI 10.1016/j.joca.2004.07.004; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Xu YB, 1998, J MOL BIOL, V276, P955, DOI 10.1006/jmbi.1997.1582; Ye L, 1997, CIRC RES, V81, P289, DOI 10.1161/01.RES.81.3.289; Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	80	76	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27044	27055		10.1074/jbc.M502068200	http://dx.doi.org/10.1074/jbc.M502068200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917224	hybrid			2022-12-25	WOS:000230589500050
J	Yon, C; Teramoto, T; Mueller, N; Phelan, J; Ganesh, VK; Murthy, KHM; Padmanabhan, R				Yon, C; Teramoto, T; Mueller, N; Phelan, J; Ganesh, VK; Murthy, KHM; Padmanabhan, R			Modulation of the nucleoside triphosphatase/RNA helicase and 5 '-RNA triphosphatase activities of dengue virus type 2 nonstructural protein 3 (NS3) by interaction with NS5, the RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; WEST-NILE-VIRUS; CRYSTAL-STRUCTURE; IN-VITRO; INORGANIC-PHOSPHATE; STIMULATED NTPASE; VIRAL POLYPROTEIN; MOLECULAR-BIOLOGY; BOX PROTEINS; DNA HELICASE	Dengue virus type 2 (DEN2), a member of the Flaviviridae family, is a re-emerging human pathogen of global significance. DEN2 nonstructural protein 3 (NS3) has a serine protease domain (NS3-pro) and requires the hydrophilic domain of NS2B (NS2BH) for activation. NS3 is also an RNA-stimulated nucleoside triphosphatase ( NTPase)/RNA helicase and a 5'-RNA triphosphatase (RTPase). In this study the first biochemical and kinetic properties of full-length NS3 (NS3(FL))-associated NTPase, RTPase, and RNA helicase are presented. The NS3FL showed an enhanced RNA helicase activity compared with the NS3-pro-minus NS3, which was further enhanced by the presence of the NS2BH (NS2BH-NS3(FL)). An active protease catalytic triad is not required for the stimulatory effect, suggesting that the overall folding of the N-terminal protease domain contributes to this enhancement. In DEN2-infected mammalian cells, NS3 and NS5, the viral 5'-RNA methyltransferase/ polymerase, exist as a complex. Therefore, the effect of NS5 on the NS3 NTPase activity was examined. The results show that NS5 stimulated the NS3 NTPase and RTPase activities. The NS5 stimulation of NS3 NTPase was dose-dependent until an equimolar ratio was reached. Moreover, the conserved motif, (RKRK)-R-184, of NS3 played a crucial role in binding to RNA substrate and modulating the NTPase/RNA helicase and RTPase activities of NS3.	Georgetown Univ, Sch Med, Dept Microbiol & Immunol, Washington, DC 20057 USA; Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA	Georgetown University; University of Alabama System; University of Alabama Birmingham	Padmanabhan, R (corresponding author), Georgetown Univ, Sch Med, Dept Microbiol & Immunol, 3900 Reservoir Rd, Washington, DC 20057 USA.	rp55@georgetown.edu	Utepbergenov, Darkhan/N-9881-2014	Utepbergenov, Darkhan/0000-0002-9005-4103; Huber, Otmar/0000-0003-4359-1747	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032078, R01AI045623, U01AI054776, R01AI032078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI54776, AI32078, AI45623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198; Bartelma G, 2002, VIROLOGY, V299, P122, DOI 10.1006/viro.2002.1504; BARTELS PC, 1975, CLIN CHIM ACTA, V61, P135, DOI 10.1016/0009-8981(75)90307-1; Benarroch D, 2004, VIROLOGY, V328, P208, DOI 10.1016/j.virol.2004.07.004; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; Campbell GL, 2002, LANCET INFECT DIS, V2, P519, DOI 10.1016/S1473-3099(02)00368-7; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; Cui TA, 1998, VIROLOGY, V246, P409, DOI 10.1006/viro.1998.9213; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gu BH, 2000, J VIROL, V74, P1794, DOI 10.1128/JVI.74.4.1794-1800.2000; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; Gwack Y, 1996, BIOCHEM BIOPH RES CO, V225, P654, DOI 10.1006/bbrc.1996.1225; Halstead SB, 2002, CURR OPIN INFECT DIS, V15, P471, DOI 10.1097/00001432-200210000-00003; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7; JIN L, 1995, ARCH BIOCHEM BIOPHYS, V323, P47, DOI 10.1006/abbi.1995.0008; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kim JW, 2003, J VIROL, V77, P571, DOI 10.1128/JVI.77.1.571-582.2003; Lam AMI, 2003, J VIROL, V77, P3950, DOI 10.1128/JVI.77.7.3950-3961.2003; LAWRENCE R, 1974, ANN CLIN BIOCHEM, V11, P234, DOI 10.1177/000456327401100168; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2004, J BIOL CHEM, V279, P26005, DOI 10.1074/jbc.M403257200; Levin MK, 2003, J BIOL CHEM, V278, P23311, DOI 10.1074/jbc.M301283200; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9; Matusan AE, 2001, J VIROL, V75, P9633, DOI 10.1128/JVI.75.20.9633-9643.2001; MELESE T, 1988, J BIOL CHEM, V263, P5833; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Roehrig JT, 2002, CURR TOP MICROBIOL, V267, P223; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Silverman E, 2003, GENE, V312, P1, DOI 10.1016/S0378-1119(03)00626-7; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tackett AJ, 2005, J BIOL CHEM, V280, P10797, DOI 10.1074/jbc.M407971200; Tackett AJ, 2001, NUCLEIC ACIDS RES, V29, P565, DOI 10.1093/nar/29.2.565; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; Utama A, 2000, FEBS LETT, V465, P74, DOI 10.1016/S0014-5793(99)01705-6; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; WARRENER P, 1995, J VIROL, V69, P1720, DOI 10.1128/JVI.69.3.1720-1726.1995; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; Westaway EG, 2003, ADV VIRUS RES, V59, P99, DOI 10.1016/S0065-3527(03)59004-2; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; You S, 1999, J BIOL CHEM, V274, P33714, DOI 10.1074/jbc.274.47.33714; ZHANG LW, 1992, J VIROL, V66, P7549, DOI 10.1128/JVI.66.12.7549-7554.1992; ZHAO LJ, 1993, METHOD ENZYMOL, V217, P218	55	173	186	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27412	27419		10.1074/jbc.M501393200	http://dx.doi.org/10.1074/jbc.M501393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917225	hybrid			2022-12-25	WOS:000230589500092
J	Praetorius-Ibba, M; Rogers, TE; Samson, R; Kelman, Z; Ibba, M				Praetorius-Ibba, M; Rogers, TE; Samson, R; Kelman, Z; Ibba, M			Association between archaeal prolyl- and leucyl-tRNA synthetases enhances tRNA(Pro) aminoacylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MULTISYNTHETASE COMPLEX; PROTEIN-PROTEIN INTERACTIONS; THERMOAUTOTROPHICUM DELTA-H; METHANOBACTERIUM-THERMOAUTOTROPHICUM; IN-VITRO; ARC1P; DOMAIN; COMPONENT; BINDING; TRANSFORMATION	Aminoacyl-tRNA synthetase-containing complexes have been identified in different eukaryotes, and their existence has also been suggested in some Archaea. To investigate interactions involving aminoacyl-tRNA synthetases in Archaea, we undertook a yeast two-hybrid screen for interactions between Methanothermobacter thermautotrophicus proteins using prolyl-tRNA synthetase (ProRS) as the bait. Interacting proteins identified included components of methanogenesis, protein-modifying factors, and leucyl-tRNA synthetase (LeuRS). The association of ProRS with LeuRS was confirmed in vitro by native gel electrophoresis and size exclusion chromatography. Determination of the steady-state kinetics of tRNAPro charging showed that the catalytic efficiency (k(cat)/K-m) of ProRS increased 5-fold in the complex with LeuRS compared with the free enzyme, whereas the Km for proline was unchanged. No significant changes in the steady-state kinetics of LeuRS aminoacylation were observed upon the addition of ProRS. These findings indicate that ProRS and LeuRS associate in M. thermautotrophicus and suggest that this interaction contributes to translational fidelity by enhancing tRNA aminoacylation by ProRS.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Maryland; University of Maryland Baltimore	Ibba, M (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.	ibba.1@osu.edu		Rogers, Theresa/0000-0002-9741-5768	NIGMS NIH HHS [R01 GM065183, GM 65183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEC G, 1994, J BIOL CHEM, V269, P2086; Behrens C, 2000, TETRAHEDRON, V56, P9443, DOI 10.1016/S0040-4020(00)00828-0; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; Dagkessamanskaia A, 2001, FEMS MICROBIOL LETT, V200, P53, DOI 10.1016/S0378-1097(01)00203-8; de Pouplana LR, 2001, J MOL EVOL, V53, P261, DOI 10.1007/s002390010216; Deinert K, 2001, J BIOL CHEM, V276, P6000, DOI 10.1074/jbc.M008682200; Francin M, 2002, J BIOL CHEM, V277, P1762, DOI 10.1074/jbc.M109759200; Fukunaga R, 2005, J MOL BIOL, V346, P57, DOI 10.1016/j.jmb.2004.11.060; GOLDGUR Y, 1994, BIOCHEM MOL BIOL INT, V32, P1075; Golinelli-Cohen MP, 2004, J MOL BIOL, V340, P15, DOI 10.1016/j.jmb.2004.04.040; Graindorge JS, 2005, BIOCHEMISTRY-US, V44, P1344, DOI 10.1021/bi049024z; Guigou L, 2004, BIOCHEMISTRY-US, V43, P4592, DOI 10.1021/bi036150e; Han JM, 2003, BIOCHEM BIOPH RES CO, V303, P985, DOI 10.1016/S0006-291X(03)00485-6; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOU YM, 1993, P NATL ACAD SCI USA, V90, P6776, DOI 10.1073/pnas.90.14.6776; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Kang J, 2000, J BIOL CHEM, V275, P31682, DOI 10.1074/jbc.M909965199; Kim JY, 2002, P NATL ACAD SCI USA, V99, P7912, DOI 10.1073/pnas.122110199; KRUEGER RD, 1986, SYST APPL MICROBIOL, V7, P388; Lee SW, 2004, J CELL SCI, V117, P3725, DOI 10.1242/jcs.01342; Lipman RSA, 2003, BIOCHEMISTRY-US, V42, P7487, DOI 10.1021/bi0344533; MAYER F, 1988, J BACTERIOL, V170, P1438, DOI 10.1128/jb.170.4.1438-1444.1988; MIRANDE M, 2005, AMINOACYL TRNA SYNTH, P298; Morales AJ, 1999, EMBO J, V18, P3475, DOI 10.1093/emboj/18.12.3475; Morgan RM, 1997, J BACTERIOL, V179, P889, DOI 10.1128/jb.179.3.889-898.1997; MUSIERFORSYTH K, 2005, AMINACYL RNA SYNTHET, P149; Nomanbhoy T, 2001, NAT STRUCT BIOL, V8, P344, DOI 10.1038/86228; Norcum MT, 2002, FEBS LETT, V512, P298, DOI 10.1016/S0014-5793(02)02262-7; Norcum MT, 2000, J BIOL CHEM, V275, P17921, DOI 10.1074/jbc.C000266200; Polycarpo C, 2003, MOL CELL, V12, P287, DOI 10.1016/S1097-2765(03)00280-6; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Reeve JN, 1997, J BACTERIOL, V179, P5975, DOI 10.1128/jb.179.19.5975-5986.1997; Rocak S, 2002, FEMS MICROBIOL LETT, V214, P101, DOI 10.1111/j.1574-6968.2002.tb11331.x; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SPROTT GD, 1981, CAN J MICROBIOL, V27, P444, DOI 10.1139/m81-067; Stehlin C, 1998, BIOCHEMISTRY-US, V37, P8605, DOI 10.1021/bi980364s; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wolfe CL, 2003, PROTEIN SCI, V12, P2282, DOI 10.1110/ps.03147903	46	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26099	26104		10.1074/jbc.M503539200	http://dx.doi.org/10.1074/jbc.M503539200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15917221	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000230386800021
J	Singh, TR; Shankar, S; Srivastava, RK				Singh, TR; Shankar, S; Srivastava, RK			HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma	ONCOGENE			English	Article						TRAIL/Apo-2L; apoptosis; histone deacetylase inhibitor; breast cancer; death receptors	NF-KAPPA-B; HISTONE-DEACETYLASE INHIBITORS; LIGAND-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; FAMILY-MEMBER BIM; CANCER IN-VITRO; IONIZING-RADIATION; MEDIATED APOPTOSIS; NUCLEAR-FACTOR; CELL-DEATH	Histone deacetylase ( HDAC) inhibitors induce differentiation and/or apoptosis in a variety of cell types by activating transcription of target genes. Activation of the death receptor (DR) pathway by tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) induces apoptosis preferentially in cancer cells. Here, we investigated the intracellular mechanisms by which HDAC inhibitors ( suberoylanilide hydroxamic acid, m-carboxycinnamic acid bis-hydroxamide, MS-275 and trichostatin A) enhance the apoptosis-inducing potential of TRAIL in breast cancer cells in vitro. A synergism in apoptosis was observed in both TRAIL-sensitive and -resistant cells upon sequential treatments with HDAC inhibitors followed by TRAIL. HDAC inhibitors synergized with TRAIL by inducing DRs DR4/TRAIL-R1 and DR5/TRAIL-R2 through NF kappa B activation and some of the proapoptotic members of the Bcl-2 family, and engaging the mitochondrial pathway. The ability of HDAC inhibitors to sensitize TRAIL-resistant cells suggests that HDAC inhibitors may induce fundamental alterations in cell signaling pathways. Thus, the sequential treatments with HDAC inhibitors followed by TRAIL may be used as a new therapeutic approach for the treatment of human cancers.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Mol & Cellular Biol Program,Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Srivastava, RK (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Mol & Cellular Biol Program,Greenebaum Canc Ctr, Pharm Hall,20 N Pine St, Baltimore, MD 21201 USA.	rsrivast@rx.umaryland.edu		singh, thiyam/0000-0002-0441-6818				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bernhard D, 1999, CELL DEATH DIFFER, V6, P609, DOI 10.1038/sj.cdd.4400531; Bernhard D, 2001, CELL DEATH DIFFER, V8, P1014, DOI 10.1038/sj.cdd.4400914; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Butler LM, 2000, CANCER RES, V60, P5165; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chen XF, 2003, CANCER RES, V63, P1059; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Gessner PK, 1995, TOXICOLOGY, V105, P161, DOI 10.1016/0300-483X(95)03210-7; Gil J, 2001, J GEN VIROL, V82, P3027, DOI 10.1099/0022-1317-82-12-3027; Glass CK, 2000, GENE DEV, V14, P121; Glick RD, 1999, CANCER RES, V59, P4392; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7; Herrera B, 2002, FEBS LETT, V520, P93, DOI 10.1016/S0014-5793(02)02774-6; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kandasamy K, 2003, CANCER RES, V63, P1712; Kandasamy K, 2002, CANCER RES, V62, P4929; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Keane MM, 1999, CANCER RES, V59, P734; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Nagane M, 2000, CANCER RES, V60, P847; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Neuzil H, 2004, BIOCHEM BIOPH RES CO, V314, P186, DOI 10.1016/j.bbrc.2003.12.074; NEWMARK HL, 1994, CANCER LETT, V78, P1, DOI 10.1016/0304-3835(94)90023-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Rosato RR, 2003, CANCER RES, V63, P3637; Rosato RR, 2003, CANCER BIOL THER, V2, P30; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Salvesen GS, 1999, APMIS, V107, P73, DOI 10.1111/j.1699-0463.1999.tb01528.x; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Shankar S, 2004, PROSTATE, V61, P35, DOI 10.1002/pros.20069; Shankar S, 2004, INT J ONCOL, V24, P1133; Shankar S, 2005, PROSTATE, V62, P165, DOI 10.1002/pros.20126; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Singh TR, 2003, CANCER RES, V63, P5390; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Srivastava Rakesh K., 2000, Molecular Cell Biology Research Communications, V4, P67, DOI 10.1006/mcbr.2001.0265; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Tallarida RJ, 2002, PAIN, V98, P163, DOI 10.1016/S0304-3959(02)00041-6; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; VanLint C, 1996, GENE EXPRESSION, V5, P245; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YOSHIZAWA H, 1994, J ADHES SCI TECHNOL, V8, P1; Zhang XD, 2003, BIOCHEM PHARMACOL, V66, P1537, DOI 10.1016/S0006-2952(03)00509-4	99	161	166	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4609	4623		10.1038/sj.onc.1208585	http://dx.doi.org/10.1038/sj.onc.1208585			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897906				2022-12-25	WOS:000230304500001
J	Lakshmana, MK; Araki, W; Tabira, T				Lakshmana, MK; Araki, W; Tabira, T			Amyloid beta peptide binds a novel death-inducing protein, AB-DIP	FASEB JOURNAL			English	Article						Alzheimer's disease; apoptosis; protein interaction	ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; COGNITIVE DECLINE; PRECURSOR PROTEIN; APOPTOSIS; ACTIVATION; NEURONS; PLAQUES; NEURODEGENERATION; ACCUMULATION	Amyloid beta-peptide (A beta) plays a central role in the pathogenesis of Alzheimer's disease (AD). It is toxic toneurons, but the mechanism for its action remains largely unknown. Here, we have identified a novel death-inducing protein, A beta-related DIP (AB-DIP), by two-hybrid screening of the human brain cDNA library and confirmed the binding of A beta with AB-DIP by coimmunoprecipitation. Overexpression of AB-DIP-induced cell death and coexpression of A beta enhanced the cell death. During apoptosis, the 97-kDa AB-DIP was cleaved to a 62-kDa protein (AB-DIPp62) at the caspase cleavage site, LEKD. It is more important that cotransfection of A beta with AB-DIP produced the AB-DIP p62 fragment. Small interfering RNA-mediated knockdown of AB-DIP protein expression significantly protected neuroblastoma cells from A beta-induced neurotoxicity. AB-DIP may mediate the neurotoxicity of A beta, and therefore, AB-DIP may be a potential, therapeutic target for AD.	Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Vasc Dementia Res, Aichi 4748522, Japan; Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo, Japan	National Center for Geriatrics & Gerontology; National Center for Neurology & Psychiatry - Japan	Lakshmana, MK (corresponding author), Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Vasc Dementia Res, 36-3 Gengo, Aichi 4748522, Japan.	laxman@nils.go.jp; tabira@nils.go.jp	Araki, Wataru/G-7913-2014	Araki, Wataru/0000-0001-8467-6937				Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Buckig A, 2002, HISTOCHEM CELL BIOL, V118, P353, DOI 10.1007/s00418-002-0459-2; Casley CS, 2002, NEUROBIOL DIS, V10, P258, DOI 10.1006/nbdi.2002.0516; Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x; Chan D, 2003, LANCET, V362, P1121, DOI 10.1016/S0140-6736(03)14469-8; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Fonte V, 2002, P NATL ACAD SCI USA, V99, P9439, DOI 10.1073/pnas.152313999; Fox NC, 1999, NEUROLOGY, V52, P1687, DOI 10.1212/WNL.52.8.1687; FOX NC, 2004, LANCET, V313, P92; FUKUTANI Y, 1995, NEUROSCI LETT, V200, P57, DOI 10.1016/0304-3940(95)12083-G; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; HYMAN BT, 1985, RES ADV ALZHEIMERS D, P453; Islam K, 1997, AM J PATHOL, V151, P265; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; LIPPA CF, 1992, NEUROBIOL AGING, V13, P405, DOI 10.1016/0197-4580(92)90115-E; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Smith MA, 2002, LANCET, V359, P1864, DOI 10.1016/S0140-6736(02)08695-6; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; vanderMaarel SM, 1996, HUM MOL GENET, V5, P887, DOI 10.1093/hmg/5.7.887; Wilson C, 2004, NEUROPATH APPL NEURO, V30, P19, DOI 10.1046/j.0305-1846.2003.00496.x; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Yan SD, 1997, NATURE, V389, P689; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	42	7	10	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1362	+		10.1096/fj.05-3672fje	http://dx.doi.org/10.1096/fj.05-3672fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15923395				2022-12-25	WOS:000229602600005
J	Dutertre, S; Nicke, A; Lewis, RJ				Dutertre, S; Nicke, A; Lewis, RJ			beta 2 subunit contribution to 4/7 alpha-conotoxin binding to the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONOTOXIN-MII; CRYSTAL-STRUCTURE; PNIA; SUBTYPES; SELECTIVITY; PROTEIN; DETERMINANTS; ELUCIDATION; ANTAGONIST; RESIDUES	The structures of acetylcholine-binding protein ( AChBP) and nicotinic acetylcholine receptor ( nAChR) homology models have been used to interpret data from mutagenesis experiments at the nAChR. However, little is known about AChBP-derived structures as predictive tools. Molecular surface analysis of nAChR models has revealed a conserved cleft as the likely binding site for the 4/7 alpha-conotoxins. Here, we used an alpha 3 beta 2 model to identify beta 2 subunit residues in this cleft and investigated their influence on the binding of alpha-conotoxins MII, PnIA, and GID to the alpha 3 beta 2 nAChR by two-electrode voltage clamp analysis. Although a beta 2-L119Q mutation strongly reduced the affinity of all three alpha-conotoxins, beta 2-F117A, beta 2-V109A, and beta 2-V109G mutations selectively enhanced the binding of MII and GID. An increased activity of alpha-conotoxins GID and MII was also observed when the beta 2-F117A mutant was combined with the alpha 4 instead of the alpha 3 subunit. Investigation of A10L-PnIA indicated that high affinity binding to beta 2-F117A, beta 2-V109A, and beta 2-V109G mutants was conferred by amino acids with a long side chain in position 10 (PnIA numbering). Docking simulations of 4/7 alpha-conotoxin binding to the alpha 3 beta 2 model supported a direct interaction between mutated nAChR residues and alpha-conotoxin residues 6, 7, and 10. Taken together, these data provide evidence that the beta subunit contributes to alpha-conotoxin binding and selectivity and demonstrate that a small cleft leading to the agonist binding site is targeted by alpha-conotoxins to block the nAChR.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Max Planck Inst Expt Med, D-37075 Gottingen, Germany	University of Queensland; Max Planck Society	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Lewis, Richard J/E-8674-2013; Lewis, Richard/T-8763-2019	Lewis, Richard J/0000-0003-3470-923X; Lewis, Richard/0000-0003-3470-923X; Dutertre, Sebastien/0000-0002-2945-1484; Nicke, Annette/0000-0001-6798-505X				Azam L, 2005, J BIOL CHEM, V280, P80, DOI 10.1074/jbc.M406281200; Blanchfield JT, 2003, J MED CHEM, V46, P1266, DOI 10.1021/jm020426j; BOURNE Y, 2005, IN PRESS EMBO J; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Dowell C, 2003, J NEUROSCI, V23, P8445; Dutertre S, 2004, J MOL RECOGNIT, V17, P339, DOI 10.1002/jmr.683; Dutertre S, 2004, EUR J BIOCHEM, V271, P2327, DOI 10.1111/j.1432-1033.2004.04147.x; Everhart D, 2004, BIOCHEMISTRY-US, V43, P2732, DOI 10.1021/bi036180h; Everhart D, 2003, J PHARMACOL EXP THER, V306, P664, DOI 10.1124/jpet.103.051656; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Gao F, 2003, J BIOL CHEM, V278, P23020, DOI 10.1074/jbc.M301151200; GLOOR S, 1995, GENE, V160, P213, DOI 10.1016/0378-1119(95)00226-V; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; Hill JM, 1998, BIOCHEMISTRY-US, V37, P15621, DOI 10.1021/bi981535w; Hogg RC, 2003, J BIOL CHEM, V278, P26908, DOI 10.1074/jbc.M212628200; Hogg RC, 1999, J BIOL CHEM, V274, P36559, DOI 10.1074/jbc.274.51.36559; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kuryatov A, 2000, NEUROPHARMACOLOGY, V39, P2570, DOI 10.1016/S0028-3908(00)00144-1; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; Luo S, 1999, BIOCHEMISTRY-US, V38, P14542, DOI 10.1021/bi991252j; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Molles BE, 2002, BIOCHEMISTRY-US, V41, P7895, DOI 10.1021/bi025732d; Nicke A, 2004, EUR J BIOCHEM, V271, P2305, DOI 10.1111/j.1432-1033.2004.04145.x; Nicke A, 2003, J BIOL CHEM, V278, P3137, DOI 10.1074/jbc.M210280200; Quik M, 2001, J NEUROSCI, V21, P5494, DOI 10.1523/JNEUROSCI.21-15-05494.2001; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salminen O, 2004, MOL PHARMACOL, V65, P1526, DOI 10.1124/mol.65.6.1526; Samson AO, 2002, NEURON, V35, P319, DOI 10.1016/S0896-6273(02)00773-0; Schapira Matthieu, 2002, BMC Structural Biology, V2, P1, DOI 10.1186/1472-6807-2-1; Vailati S, 1999, MOL PHARMACOL, V56, P11, DOI 10.1124/mol.56.1.11	31	60	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30460	30468		10.1074/jbc.M504229200	http://dx.doi.org/10.1074/jbc.M504229200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15929983	hybrid, Green Published			2022-12-25	WOS:000231362500059
J	El-Golli, N; Issertial, O; Rosa, JP; Briquet-Laugier, V				El-Golli, N; Issertial, O; Rosa, JP; Briquet-Laugier, V			Evidence for a granule targeting sequence within platelet factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAY PLATELET SYNDROME; P-SELECTIN; CYTOPLASMIC DOMAIN; CARBOXYPEPTIDASE E; CRYSTAL-STRUCTURE; SORTING SIGNAL; CHROMOGRANIN-B; FACTOR-IV; IDENTIFICATION; SECRETION	Platelets achieve bleeding arrest at sites of vascular injury via secretion of secretory proteins from their storage granules, termed alpha-granules. We have recently analyzed granule targeting of platelet factor 4 ( PF4), a secretory alpha-granule chemokine, and demonstrated that PF4 alpha-granule storage relied upon determinants within PF4 mature sequence. To define these determinants, PF4 mutants fused to the fluorescent reporter protein green fluorescent protein were generated by progressive deletions and site-directed mutagenesis. They were then transfected in AtT20 cells and assessed for granule targeting by colocalization with ACTH-containing granules, using laser scanning confocal microscopy. This strategy identified the amino acid 41 - 50 ( LIATLKNGRK) sequence as most critical for PF4 granule targeting and/or storage; its deletion from PF4 induced a marked decrease in granule storage ( from 81 +/- 2% to 17 +/- 3%, p <= 0.0001). Ala-scanning mutagenesis of LIATLKNGRK narrowed down the targeting motif to LKNG. A direct role for LKNG in alpha-granule targeting was confirmed in the thrombopoietin-induced human megakaryocytic Dami cells, in which the LKNG-green fluorescent protein chimera exhibited an 82.5 +/- 1.8% colocalization with the alpha-granule proteins von Willebrand factor and P-selectin. LKNG is poorly conserved within the chemokine family. However three-dimensional alignments of the human alpha-granule chemokines Nap-2 ( neutrophil-activating peptide) and RANTES ( Regulated upon Activation Normal T Cell Expressed and Secreted) with PF4 revealed that LKNG, a surface-exposed hydrophilic turn/loop, matched Nap- 2 ( LKDG) and RANTES ( TRKN) peptides with similar features. Moreover Nap-2 and RANTES peptides exhibited the same alpha-granule targeting efficiency than LKNG. We therefore postulate that the three-dimensional and physicochemical characteristics of PF4 LKNG are of general relevance to alpha-granule targeting of chemokines and possibly of other alpha-granule proteins.	Univ Paris 07, Lab Hemostasis & Thrombosis, Cardiovasc Res Ctr,Hop Lariboisiere, INSERM Lariboisiere,U689 E6 INSERMIFR 139, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	El-Golli, N (corresponding author), Univ Paris 07, Lab Hemostasis & Thrombosis, Cardiovasc Res Ctr,Hop Lariboisiere, INSERM Lariboisiere,U689 E6 INSERMIFR 139, 2 Rue Ambroise Pare, F-75010 Paris, France.	rosa@larib.inserm.fr	ROSA, JEAN-PHILIPPE/B-6245-2018	ROSA, JEAN-PHILIPPE/0000-0001-7342-0389				Blazquez M, 2000, BIOCHEM CELL BIOL, V78, P181, DOI 10.1139/bcb-78-3-181; Briquet-Laugier V, 2004, J THROMB HAEMOST, V2, P2231, DOI 10.1111/j.1538-7836.2004.01037.x; Briquet-Laugier V, 2004, PLATELETS, V15, P341, DOI 10.1080/09537100410001721342; Cawley NX, 2000, FEBS LETT, V481, P37, DOI 10.1016/S0014-5793(00)01961-X; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHIDGEY MAJ, 1993, BIOESSAYS, V15, P317, DOI 10.1002/bies.950150505; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Cramer E M, 1999, Curr Opin Hematol, V6, P354, DOI 10.1097/00062752-199909000-00014; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; Daragan VA, 1997, PROTEIN SCI, V6, P355; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; Haberichter SL, 2002, ARTERIOSCL THROM VAS, V22, P921, DOI 10.1161/01.ATV.0000017063.36768.87; HARRISON P, 1993, BLOOD REV, V7, P52, DOI 10.1016/0268-960X(93)90024-X; Hartwell DM, 1998, J CELL BIOL, V143, P1129, DOI 10.1083/jcb.143.4.1129; Horton R M, 1997, Methods Mol Biol, V67, P141; ILYINA E, 1994, BIOCHEMISTRY-US, V33, P13436, DOI 10.1021/bi00249a032; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; Lages B, 1997, J LAB CLIN MED, V129, P364, DOI 10.1016/S0022-2143(97)90185-2; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MAYO KH, 1995, BIOCHEMISTRY-US, V34, P11399, DOI 10.1021/bi00036a012; Methia N, 1999, EUR J CELL BIOL, V78, P884, DOI 10.1016/S0171-9335(99)80090-9; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; RICHARDSON UI, 1981, ENDOCRINOLOGY, V108, P281, DOI 10.1210/endo-108-1-281; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROSA JP, 1987, J CLIN INVEST, V80, P1138, DOI 10.1172/JCI113171; Rosenberg JB, 1998, J CLIN INVEST, V101, P613, DOI 10.1172/JCI1250; Shaw JP, 2004, STRUCTURE, V12, P2081, DOI 10.1016/j.str.2004.08.014; Smith MP, 1997, BAILLIERE CLIN HAEM, V10, P125, DOI 10.1016/S0950-3536(97)80054-6; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; Tanaka T, 1997, NAT MED, V3, P437, DOI 10.1038/nm0497-437; Taupenot L, 2005, J BIOL CHEM, V280, P3885, DOI 10.1074/jbc.M408197200; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025	38	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30329	30335		10.1074/jbc.M503847200	http://dx.doi.org/10.1074/jbc.M503847200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15964840	hybrid			2022-12-25	WOS:000231362500042
J	Bernard, R; El Ghachi, M; Mengin-Lecreulx, D; Chippaux, M; Denziot, F				Bernard, R; El Ghachi, M; Mengin-Lecreulx, D; Chippaux, M; Denziot, F			BcrC from Bacillus subtilis acts as an undecaprenyl pyrophosphate phosphatase in bacitracin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACID-PHOSPHATASE; ABC TRANSPORTER; ENDOPLASMIC-RETICULUM; GENE ENCODES; BACA GENE; EXPRESSION; CLONING; IDENTIFICATION; SEQUENCE	Overexpression of the BcrC(Bs) protein, formerly called YwoA, in Escherichia coli or in Bacillus subtilis allows these bacteria to stand higher concentrations of bacitracin. It was suggested that BcrCBs was a membrane-spanning domain of an ATP binding cassette (ABC) transporter involved in bacitracin resistance. However, we hypothesized that this protein has an undecaprenyl pyrophosphate (UPP) phosphatase activity able to compete with bacitracin for UPP. We found that overexpression of a recombinant His(6)-BcrC(Bs) protein in E. coli (i) increased the resistance of the cells to bacitracin and (ii) increased UPP phosphatase activity in membrane preparations by 600-fold. We solubilized and prepared an electrophoretically pure protein exhibiting a strong UPP phosphatase activity. BcrC(Bs), which belongs to the type 2 phosphatidic acid phosphatase (PAP2) phosphatase superfamily (PF01569), differs totally from the already known BacA UPP phosphatase from E. coli, a member of the PF02673 family of the Protein family (Pfam) database. Thus, BcrC(Bs) and its orthologs form a new class of proteins within the PAP2 phosphatase superfamily, and likely all of them share a UPP phosphatase activity.	CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille, France; Univ Paris 11, UMR 8619, CNRS, Lab Enveloppes Bacteriennes & Antibiot, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Denziot, F (corresponding author), CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.	denizot@ibsm.cnrs-mrs.fr		MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bernard R, 2003, FEMS MICROBIOL LETT, V228, P93, DOI 10.1016/S0378-1097(03)00738-9; Cao M, 2002, J BACTERIOL, V184, P6123, DOI 10.1128/JB.184.22.6123-6129.2002; Chalker AF, 2000, MICROBIOL-SGM, V146, P1547, DOI 10.1099/00221287-146-7-1547; Chen XC, 1999, J BACTERIOL, V181, P7107, DOI 10.1128/JB.181.22.7107-7114.1999; Choudhuri BS, 2002, BIOCHEM J, V367, P279, DOI 10.1042/BJ20020615; El Ghachi M, 2004, J BIOL CHEM, V279, P30106, DOI 10.1074/jbc.M401701200; Fernandez F, 2001, J BIOL CHEM, V276, P41455, DOI 10.1074/jbc.M105544200; Harel YM, 1999, J BACTERIOL, V181, P6176, DOI 10.1128/JB.181.19.6176-6178.1999; ICHO T, 1988, J BACTERIOL, V170, P5117, DOI 10.1128/jb.170.11.5117-5124.1988; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; ISHIHARA K, 1995, INFECT IMMUN, V63, P1147, DOI 10.1128/IAI.63.4.1147-1152.1995; Joseph P, 2004, MICROBIOL-SGM, V150, P2609, DOI 10.1099/mic.0.27155-0; Joseph P, 2001, FEMS MICROBIOL LETT, V205, P91; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; KASAHARA M, 1991, J BACTERIOL, V173, P6760, DOI 10.1128/jb.173.21.6760-6765.1991; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; Mascher T, 2003, MOL MICROBIOL, V50, P1591, DOI 10.1046/j.1365-2958.2003.03786.x; MOSZER I, 1995, MICROBIOL-SGM, V141, P261, DOI 10.1099/13500872-141-2-261; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; Ohki R, 2003, MOL MICROBIOL, V49, P1135, DOI 10.1046/j.1365-2958.2003.03653.x; Ohki R, 2003, J BACTERIOL, V185, P51, DOI 10.1128/JB.185.1.51-59.2003; Pasca MR, 2004, ANTIMICROB AGENTS CH, V48, P3175, DOI 10.1128/AAC.48.8.3175-3178.2004; PODLESEK Z, 1995, MOL MICROBIOL, V16, P969, DOI 10.1111/j.1365-2958.1995.tb02322.x; POND JL, 1989, J BACTERIOL, V171, P767, DOI 10.1128/jb.171.2.767-774.1989; Quentin Y, 1999, J MOL BIOL, V287, P467, DOI 10.1006/jmbi.1999.2624; Rush JS, 2002, J BIOL CHEM, V277, P45226, DOI 10.1074/jbc.M207076200; Sambrook J, 2001, MOL CLONING LAB MANU; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STORM DR, 1973, J BIOL CHEM, V248, P3940; THALLER MC, 1994, MICROBIOL-SGM, V140, P1341, DOI 10.1099/00221287-140-6-1341; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; Uchiya KI, 1996, J BACTERIOL, V178, P4548, DOI 10.1128/jb.178.15.4548-4554.1996; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C	40	76	79	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28852	28857		10.1074/jbc.M413750200	http://dx.doi.org/10.1074/jbc.M413750200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15946938	hybrid			2022-12-25	WOS:000231021300004
J	Marshall, CR; Pan, TC; Le, HD; Omelchenko, A; Hwang, PP; Hryshko, LV; Tibbits, GF				Marshall, CR; Pan, TC; Le, HD; Omelchenko, A; Hwang, PP; Hryshko, LV; Tibbits, GF			cDNA cloning and expression of the cardiac Na+/Ca2+ exchanger from Mozambique tilapia (Oreochromis mossambicus) reveal a teleost membrane transporter with mammalian temperature dependence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; SARCOLEMMAL NA+-CA2+ EXCHANGER; COLD ADAPTATION; HEART-FAILURE; CONFORMATIONAL FLEXIBILITY; TRANSMEMBRANE SEGMENTS; FUNCTIONAL EXPRESSION; VENTRICULAR MYOCYTES; MUTATIONAL ANALYSIS; THERMAL ADAPTATION	The complete cDNA sequence of the tilapia cardiac Na+/Ca2+ exchanger (NCX-TL1.0) was determined. The 3.1-kb transcript encodes a protein 957 amino acids in length, with a predicted signal peptide cleaved at residue 31 and two potential N-glycosylation sites in the extracellular N terminus. Hydropathy analysis and sequence comparison predicted a mature protein with nine transmembrane-spanning segments, consistent with the structural topologies of other known mammalian and teleost NCX isoforms. Overall sequence comparison shows high identity to both trout NCX-TR1.0 (similar to 1%) and mammalian NCX1.1 (similar to 73%), and phylogenetic analyses confirmed its identity as a member of the NCX1 gene family, expressing exons A, C, D, and F in the alternative splice site. Sequence identity is even higher in the alpha-repeats, the exchanger inhibitory peptide (XIP) site, and Ca2+-binding domains, which is reflected in the functional and regulatory properties of tilapia NCX-TL1.0. When NCX-TL1.0 was expressed in Xenopus oocytes and the currents were measured in giant excised patches, they displayed both positive regulation by Ca2+ and Na+-dependent inactivation in a manner similar to trout NCX-TR1.0. However, tilapia NCX-TL1.0 exhibited a relatively high sensitivity to temperature compared with trout NCX-TR1.0. Whereas trout NCX-TR1.0 currents displayed activation energies of similar to 7 kJ/mol, tilapia NCX-TL1.0 currents showed mammal-like temperature dependence, with peak and steady-state current activation energies of 53 +/- 9 and 67 +/- 21 kJ/ mol, respectively. Using comparative sequence analysis, we highlighted 10 residue positions in the N-terminal domain of the NCX that, in combination, may confer exchanger temperature dependence through subtle changes in protein flexibility. Tilapia NCX-TL1.0 represents the first non-mammalian NCX to exhibit a mammalian temperature dependence phenotype and will prove to be a useful model in defining the interplay between molecular flexibility and stability in NCX function.	Simon Fraser Univ, Cardiac Membrane Res Lab, Burnaby, BC V5A 1S6, Canada; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; British Columbia Res Inst Childrens & Womens Hlth, Vancouver, BC V5Z 4H4, Canada; Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan; Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada	Simon Fraser University; Simon Fraser University; Academia Sinica - Taiwan; University of Manitoba; Children's Hospital Research Institute of Manitoba	Tibbits, GF (corresponding author), Simon Fraser Univ, Cardiac Membrane Res Lab, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	tibbits@sfu.ca	Hwang, Pung-Pung/AEQ-4633-2022; hwang, pp/A-3641-2011; Pan, Francis T. C./L-6815-2019; Hwang, Pung-Pung/AAH-1538-2022; Pan, Francis T. C./E-5243-2019	Pan, Francis T. C./0000-0002-1550-4581; Pan, Francis T. C./0000-0002-1550-4581; Hryshko, Larry/0000-0003-1079-8549; Tibbits, Glen/0000-0002-2586-3115				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bers DM, 1996, ANN NY ACAD SCI, V779, P430, DOI 10.1111/j.1749-6632.1996.tb44818.x; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BERSOHN MM, 1991, BIOCHIM BIOPHYS ACTA, V1062, P19, DOI 10.1016/0005-2736(91)90329-7; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; BRIDGE JHB, 1988, SCIENCE, V241, P823, DOI 10.1126/science.3406740; Cai XJ, 2004, MOL BIOL EVOL, V21, P1692, DOI 10.1093/molbev/msh177; Chakravarty S, 2000, FEBS LETT, V470, P65, DOI 10.1016/S0014-5793(00)01267-9; COSTAPIERCE BA, 2000, TILAPIA AQUACULTURE, V2, P1; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; Dyck C, 1999, J GEN PHYSIOL, V114, P701, DOI 10.1085/jgp.114.5.701; Elias CL, 2001, AM J PHYSIOL-CELL PH, V281, pC993, DOI 10.1152/ajpcell.2001.281.3.C993; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; Fields PA, 2001, COMP BIOCHEM PHYS A, V129, P417, DOI 10.1016/S1095-6433(00)00359-7; He ZP, 1998, J GEN PHYSIOL, V111, P857, DOI 10.1085/jgp.111.6.857; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Hilgemann DW, 2004, AM J PHYSIOL-CELL PH, V287, pC1167, DOI 10.1152/ajpcell.00288.2004; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; Hryshko LV, 1996, J GEN PHYSIOL, V108, P67, DOI 10.1085/jgp.108.1.67; Imahashi K, 1999, CIRC RES, V84, P1401; Iwamoto T, 2004, J BIOL CHEM, V279, P7544, DOI 10.1074/jbc.M310491200; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KUSUOKA H, 1993, J AM COLL CARDIOL, V21, P240, DOI 10.1016/0735-1097(93)90743-K; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1994, J BIOL CHEM, V269, P17434; LONGONI S, 1988, AM J PHYSIOL, V255, pC870, DOI 10.1152/ajpcell.1988.255.6.C870; Loretz CA, 2004, J BIOL CHEM, V279, P53288, DOI 10.1074/jbc.M410098200; Maack C, 2005, CIRC RES, V96, P91, DOI 10.1161/01.RES.0000151334.48676.68; Maclean N, 2002, GENE, V295, P265, DOI 10.1016/S0378-1119(02)00735-7; Marshall C, 2002, AM J PHYSIOL-CELL PH, V283, pC512, DOI 10.1152/ajpcell.00558.2001; Marshall CR, 2005, PHYSIOL GENOMICS, V21, P161, DOI 10.1152/physiolgenomics.00286.2004; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Nicholas K B, 1997, DISTRIBUTED AUTHORS; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Olufsen M, 2005, J BIOL CHEM, V280, P18042, DOI 10.1074/jbc.M500948200; Ottolia M, 2005, J BIOL CHEM, V280, P1061, DOI 10.1074/jbc.M411899200; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Piacentino V, 2002, ANN NY ACAD SCI, V976, P466; Pogwizd SM, 2004, TRENDS CARDIOVAS MED, V14, P61, DOI 10.1016/j.tcm.2003.12.002; Pogwizd SM, 2001, CIRC RES, V88, P1159, DOI 10.1161/hh1101.091193; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; Ruknudin A, 2000, J PHYSIOL-LONDON, V529, P599, DOI 10.1111/j.1469-7793.2000.00599.x; Russell NJ, 2000, EXTREMOPHILES, V4, P83, DOI 10.1007/s007920050141; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Sardella BA, 2004, COMP BIOCHEM PHYS A, V137, P621, DOI 10.1016/j.cbpb.2003.12.003; Saunders NFW, 2003, GENOME RES, V13, P1580, DOI 10.1101/gr.1180903; Schulze DH, 2002, ANN NY ACAD SCI, V976, P187; Sipido KR, 2002, ANN NY ACAD SCI, V976, P438; Suhre K, 2003, J BIOL CHEM, V278, P17198, DOI 10.1074/jbc.M301327200; Svingor A, 2001, J BIOL CHEM, V276, P28121, DOI 10.1074/jbc.M104432200; TIBBITS GF, 1992, AM J PHYSIOL, V262, pC411, DOI 10.1152/ajpcell.1992.262.2.C411; Wasserstrom JA, 1996, J PHYSIOL-LONDON, V493, P529, DOI 10.1113/jphysiol.1996.sp021401; Weber CR, 2003, CIRCULATION, V108, P2224, DOI 10.1161/01.CIR.0000095274.72486.94; Weisser-Thomas J, 2003, CARDIOVASC RES, V57, P974, DOI 10.1016/S0008-6363(02)00732-0; Wilson PJ, 2004, PHYSIOL BIOCHEM ZOOL, V77, P537, DOI 10.1086/422054; Xue XH, 1999, AM J PHYSIOL-CELL PH, V277, pC693, DOI 10.1152/ajpcell.1999.277.4.C693; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	75	11	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28903	28911		10.1074/jbc.M504807200	http://dx.doi.org/10.1074/jbc.M504807200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15937330	hybrid			2022-12-25	WOS:000231021300010
J	Megy, S; Bertho, G; Gharbi-Benarous, J; Evrard-Todeschi, N; Coadou, G; Segeral, E; Iehle, C; Quemeneur, E; Benarous, R; Girault, JP				Megy, S; Bertho, G; Gharbi-Benarous, J; Evrard-Todeschi, N; Coadou, G; Segeral, E; Iehle, C; Quemeneur, E; Benarous, R; Girault, JP			STD and TRNOESY NMR studies on the conformation of the oncogenic protein beta-catenin containing the phosphorylated motif DpSGXXpS bound to the beta-TrCP protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; F-BOX PROTEIN; TRANSFER DIFFERENCE NMR; LIGAND-BINDING; UBIQUITIN; EPITOPE; IDENTIFICATION; DEGRADATION; PROTEOLYSIS; ANTIBODY	beta-TrCP is the F-box protein component of an Skp1/Cul1/F-box (SCF)-type ubiquitin ligase complex. Biochemical studies have suggested that beta-TrCP targets the oncogenic protein beta-catenin for ubiquitination and followed by proteasome degradation. To further elucidate the basis of this interaction, a complex between a 32-residue peptide from beta-catenin containing the phosphorylated motif DpSGXXpS (P-beta-Cat(17-48)) and beta-TrCP was studied using Saturation Transfer Difference (STD) Nuclear Magnetic Resonance (NMR) experiments. These experiments make it possible to identify the binding epitope of a ligand at atomic resolution. An analysis of STD spectra provided clear evidence that only a few of the 32 residues receive the largest saturation transfer. In particular, the amide protons of the residues in the phosphorylated motif appear to be in close contact to the amino acids of the beta-TrCP binding pocket. The amide and aromatic protons of the His(24) and Trp(25) residues also receive a significant saturation transfer. These findings are in keeping with a recently published x-ray structure of a shorter beta-catenin fragment with the beta-TrCP1-Skp1 complex and with the earlier findings from mutagenesis and activity assays. To better characterize the ligand-protein interaction, the bound conformation of the phosphorylated beta-catenin peptide was obtained using TRansfer Nuclear Overhauser Effect SpectroscopY (TRNOESY) experiments. Finally, we obtained the bound structure of the phosphorylated peptide showing the protons identified by STD NMR as exposed in close proximity to the molecule surface.	Univ Paris 05, Lab Chim & Biochim Pharmacol & Toxicol, CNRS, UMR 8601, F-75270 Paris, France; Hop Cochin, Inst Cochin, Dept Maladies Infect, INSERM U567,CNRS UMR 8104, F-75014 Paris, France; Commissariat Energie Atom Valrho, Direct Sci Vivant, Dept Ingn & Etud Prot, Serv Rech Biochim Post Genom & Toxicol Nucl, F-30207 Bagnols Sur Ceze, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CEA	Girault, JP (corresponding author), Univ Paris 05, Lab Chim & Biochim Pharmacol & Toxicol, CNRS, UMR 8601, 45 Rue St Peres, F-75270 Paris, France.	jean-pierre.girault@univ-paris5.fr	COADOU, Gael/M-3042-2015; Girault, Jean_Pierre JP/A-5403-2008	COADOU, Gael/0000-0003-0979-6706; Megy, Simon/0000-0001-6354-349X; Bertho, Gildas/0000-0002-4929-763X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Besnard-Guerin C, 2004, J BIOL CHEM, V279, P788, DOI 10.1074/jbc.M308068200; BODEUS M, 1995, J GEN VIROL, V76, P1337, DOI 10.1099/0022-1317-76-6-1337; Booth V, 2003, J MOL BIOL, V327, P329, DOI 10.1016/S0022-2836(03)00094-9; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clements WM, 2002, CANCER RES, V62, P3503; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; Coadou G, 2003, BIOCHEMISTRY-US, V42, P14741, DOI 10.1021/bi035207u; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1983, CELL, V34, P11, DOI 10.1016/0092-8674(83)90131-9; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Klein J, 1999, J AM CHEM SOC, V121, P5336, DOI 10.1021/ja990706x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Megy S, 2005, PEPTIDES, V26, P227, DOI 10.1016/j.peptides.2004.09.021; Moller H, 2002, EUR J BIOCHEM, V269, P1444, DOI 10.1046/j.1432-1033.2002.02787.x; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Verdier L., 2000, J CHEM SOC P2, V12, P2363; Vranken W, 2002, BIOCHEMISTRY-US, V41, P8570, DOI 10.1021/bi012169a; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yan JL, 2003, J MAGN RESON, V163, P270, DOI 10.1016/S1090-7807(03)00106-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	42	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29107	29116		10.1074/jbc.M501628200	http://dx.doi.org/10.1074/jbc.M501628200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15927956	hybrid			2022-12-25	WOS:000231021300037
J	Vanacore, RM; Friedman, DB; Ham, AJL; Sundaramoorthy, M; Hudson, BG				Vanacore, RM; Friedman, DB; Ham, AJL; Sundaramoorthy, M; Hudson, BG			Identification of S-hydroxylysyl-methionine as the covalent cross-link of the noncollagenous (NC1) hexamer of the alpha 1 alpha 1 alpha 2 collagen IV network - A role for the post-translational modification of lysine 211 to hydroxylysine 211 in hexamer assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; DISACCHARIDE UNIT; CRYSTAL-STRUCTURE; DISULFIDE BONDS; MOLECULAR-BASIS; DOMAIN; GOODPASTURE; STABILIZATION; BIOSYNTHESIS; ORGANIZATION	Collagen IV networks are present in all metazoans as components of basement membranes that underlie epithelia. They are assembled by the oligomerization of triple-helical protomers, composed of three alpha-chains. The trimeric noncollagenous domains (NC1) of each protomer interact forming a hexamer structure. Upon exposure to acidic pH or denaturants, the hexamer dissociates into monomer and dimer subunits, the latter reflect distinct interactions that reinforce/cross-link the quaternary structure of hexamer. Recently, the cross-link site of the alpha 1 alpha 1 alpha 2 network was identified, on the basis of x-ray crystal structures at 1.9-angstrom resolution, in which the side chains of Met(93) and Lys(211) were proposed to be connected by a novel thioether bond ( Than, M. E., Henrich, S., Huber, R., Ries, A., Mann, K., Kuhn, K., Timpl, R., Bourenkov, G. P., Bartunik, H. D., and Bode, W. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 6607-6612); however, at the higher resolution of 1.5 angstrom, we found no evidence for this cross-link (Vanacore, R. M., Shanmu-gasundararaj, S., Friedman, D. B., Bondar, O., Hudson, B. G., and Sundaramoorthy, M. (2004) J. Biol. Chem. 279, 44723-44730). Given this discrepancy in crystallographic findings, we sought chemical evidence for the location and nature of the reinforcement/cross-link site. Trypsin digestion of monomer and dimer subunits excised a similar to 5,000-Da complex that distinguished dimers from monomers; the complex was characterized by mass spectrometry, Edman degradation, and amino acid composition analyses. The tryptic complex, composed of two peptides of 44 residues derived from two alpha 1 NC1 monomers, contained Met93 and Lys211 post-translationally modified to hydroxylysine (Hyl(211)). Truncation of the tryptic complex with post-proline endopeptidase reduced its size to 14 residues to facilitate characterization by tandem mass spectrometry, which revealed a covalent linkage between Met(93) and Hyl(211). The novel cross-link, termed S-hydroxylysyl-methionine, reflects at least two post-translational events in its formation: the hydroxylation of Lys(211) to Hyl(211) within the NC1 domain during the biosynthesis of alpha-chains and the connection of Hyl211 to Met93 between the trimeric NC1 domains of two adjoining triple-helical protomers, reinforcing the stability of collagen IV networks.	Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Matrix Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Kansas; University of Kansas Medical Center	Hudson, BG (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, B-3102 Med Ctr N,11615 21st Ave S, Nashville, TN 37232 USA.	hudson@vanderbilt.edu	Vanacore, Roberto/C-9763-2012; Vanacore, Roberto/AAD-6399-2020	Vanacore, Roberto/0000-0002-2886-0606; Vanacore, Roberto/0000-0002-2886-0606; Hudson, Billy/0000-0002-5420-4100	NCRR NIH HHS [RR017806] Funding Source: Medline; NIDDK NIH HHS [R-37DK18381, R01DK62524, P01DK065123] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062524, P01DK065123, R37DK018381] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Borza DB, 2002, J BIOL CHEM, V277, P40075, DOI 10.1074/jbc.M207769200; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; BORZA DB, 2005, J BIOL CHEM; Burmeister WP, 2000, ACTA CRYSTALLOGR D, V56, P328, DOI 10.1107/S0907444999016261; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; Hansen BT, 2005, J PROTEOME RES, V4, P358, DOI 10.1021/pr0498234; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; Hudson BG, 2004, J AM SOC NEPHROL, V15, P2514, DOI 10.1097/01.ASN.0000141462.00630.76; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; LANGEVELD JPM, 1991, J BIOL CHEM, V266, P2622; NAIDER F, 1972, BIOCHEMISTRY-US, V11, P3208, DOI 10.1021/bi00767a011; Rautavuoma K, 2004, P NATL ACAD SCI USA, V101, P14120, DOI 10.1073/pnas.0404966101; ROBINS SP, 1975, BIOCHEM J, V149, P381, DOI 10.1042/bj1490381; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SPIRO RG, 1971, J BIOL CHEM, V246, P4899; SPIRO RG, 1971, J BIOL CHEM, V246, P4919; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; Vanacore RM, 2004, J BIOL CHEM, V279, P44723, DOI 10.1074/jbc.M406344200; WEBER S, 1988, EUR J BIOCHEM, V175, P229, DOI 10.1111/j.1432-1033.1988.tb14188.x; WU GY, 1981, BIOCHEMISTRY-US, V20, P4321, DOI 10.1021/bi00518a013; YOSHIMOTO T, 1980, J BIOL CHEM, V255, P4786	24	42	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29300	29310		10.1074/jbc.M502752200	http://dx.doi.org/10.1074/jbc.M502752200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15951440	hybrid			2022-12-25	WOS:000231021300061
J	Adams, M; Jia, ZC				Adams, M; Jia, ZC			Structural and biochemical analysis reveal pirins to possess quercetinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO METABOLITES; CRYSTAL-STRUCTURE; FUNCTIONAL-ANALYSIS; NUCLEAR-PROTEIN; 2,3-DIOXYGENASE; COPPER; BINDING; FLAVONOIDS; ENZYME; CRYSTALLOGRAPHY	Pirin is a recently identified eukaryotic protein implicated in transcriptional activation and apoptosis. Homologues of Pirin are highly conserved in both prokaryotes and eukaryotes, but their function remains poorly understood. We present here the crystal structure of the yhhW gene product, a putative Pirin homologue, from Escherichia coli and confirm its structural similarity to Pirin. The YhhW protein displays a bicupin fold with a single N-terminal metal coordination site. Molecular surface comparisons of YhhW and Pirin with structurally similar proteins suggested quercetin as a potential ligand. We demonstrate that both bacterial and human Pirins have quercetinase activity, which is inhibited by the addition of typical inhibitors of the quercetin 2,3-dioxygenase reaction. We also demonstrate the release of carbon monoxide as a reaction product. This is the first report of enzymatic activity for any member of the Pirin family and may be an important connection to their roles in transcriptional regulation.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Jia, ZC (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	jia@post.queensu.ca						Adachi M, 2001, J MOL BIOL, V305, P291, DOI 10.1006/jmbi.2000.4310; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; Boege F, 1996, J BIOL CHEM, V271, P2262, DOI 10.1074/jbc.271.4.2262; Bowater L, 2004, FEBS LETT, V557, P45, DOI 10.1016/S0014-5793(03)01439-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEARY RW, 1996, CCP14 POWDER DIFFRAC; Chen CC, 2004, MOL PHARMACOL, V66, P683; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Fusetti F, 2002, STRUCTURE, V10, P259, DOI 10.1016/S0969-2126(02)00704-9; Gopal B, 2005, BIOCHEMISTRY-US, V44, P193, DOI 10.1021/bi0484421; GRACY RW, 1968, J BIOL CHEM, V243, P4109; HANASAKI Y, 1994, FREE RADICAL BIO MED, V16, P845, DOI 10.1016/0891-5849(94)90202-X; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hihara Y, 2004, FEBS LETT, V574, P101, DOI 10.1016/j.febslet.2004.06.102; Hund HK, 1999, EUR J BIOCHEM, V263, P871, DOI 10.1046/j.1432-1327.1999.00574.x; Ko TP, 2000, ACTA CRYSTALLOGR D, V56, P411, DOI 10.1107/S0907444900002237; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E., 2003, P 5 INT C MOL STRUCT, P88; Lapik YR, 2003, PLANT CELL, V15, P1578, DOI 10.1105/tpc.011890; Maruyama N, 2001, EUR J BIOCHEM, V268, P3595, DOI 10.1046/j.1432-1327.2001.02268.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Odrcich MJ, 1998, PLACENTA, V19, P509, DOI 10.1016/S0143-4004(98)91044-X; OKA T, 1971, BIOCHEM BIOPH RES CO, V43, P1, DOI 10.1016/S0006-291X(71)80076-1; Orzaez D, 2001, PLANT MOL BIOL, V46, P459, DOI 10.1023/A:1010618515051; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pang H, 2004, J BIOL CHEM, V279, P1491, DOI 10.1074/jbc.M310022200; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; Plaper A, 2003, BIOCHEM BIOPH RES CO, V306, P530, DOI 10.1016/S0006-291X(03)01006-4; Que Jr L., 1999, BIOINORGANIC CATALYS, P269; SIMPSON FJ, 1960, BIOCHEM BIOPH RES CO, V2, P15, DOI 10.1016/0006-291X(60)90255-2; Spencer JPE, 2003, J BIOL CHEM, V278, P34783, DOI 10.1074/jbc.M305063200; Spencer JPE, 2003, BIOCHEM J, V372, P173, DOI 10.1042/BJ20021972; Steiner RA, 2002, P NATL ACAD SCI USA, V99, P16625, DOI 10.1073/pnas.262506299; Steiner RA, 2002, BIOCHEMISTRY-US, V41, P7955, DOI 10.1021/bi0159736; Steiner RA, 2002, BIOCHEMISTRY-US, V41, P7963, DOI 10.1021/bi015974y; SZYSZKA R, 1995, BIOCHEM BIOPH RES CO, V208, P418, DOI 10.1006/bbrc.1995.1354; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Wendler WMF, 1997, J BIOL CHEM, V272, P8482, DOI 10.1074/jbc.272.13.8482; Woo EJ, 2002, EMBO J, V21, P2877, DOI 10.1093/emboj/cdf291; Yoshikawa R, 2004, ONCOL REP, V12, P1287; Zeng Q, 2003, ACTA CRYSTALLOGR D, V59, P1496, DOI 10.1107/S0907444903012289	48	64	68	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28675	28682		10.1074/jbc.M501034200	http://dx.doi.org/10.1074/jbc.M501034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15951572	hybrid			2022-12-25	WOS:000230857300058
J	Horner, TJ; Osawa, S; Schaller, MD; Weiss, ER				Horner, TJ; Osawa, S; Schaller, MD; Weiss, ER			Phosphorylation of GRK1 and GRK7 by cAMP-dependent protein kinase attenuates their enzymatic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR KINASES; ROD OUTER SEGMENTS; DOMINANT-NEGATIVE MUTANT; SRC TYROSINE KINASE; RHODOPSIN KINASE; CYCLIC-AMP; RAT RETINA; CONE PHOTOTRANSDUCTION; PHOSDUCIN PHOSPHORYLATION; MULTIPLE PHOSPHORYLATION	Phosphorylation of G protein-coupled receptors is a critical step in the rapid termination of G protein signaling. In rod cells of the vertebrate retina, phosphorylation of rhodopsin is mediated by GRK1. In cone cells, either GRK1, GRK7, or both, depending on the species, are speculated to initiate signal termination by phosphorylating the cone opsins. To compare the biochemical properties of GRK1 and GRK7, we measured the Km and V-max of these kinases for ATP and rhodopsin, a model substrate. The results demonstrated that these kinases share similar kinetic properties. We also determined that cAMP-dependent protein kinase (PKA) phosphorylates GRK1 at Ser(21) and GRK7 at Ser(23) and Ser(36) in vitro. These sites are also phosphorylated when FLAG-tagged GRK1 and GRK7 are expressed in HEK-293 cells treated with forskolin to stimulate the endogenous production of cAMP and activation of PKA. Rod outer segments isolated from bovine retina phosphorylated the FLAG-tagged GRKs in the presence of dibutyryl-cAMP, suggesting that GRK1 and GRK7 are physiologically relevant substrates. Although both GRKs also contain putative phosphorylation sites for PKC and Ca2+/calmodulin-dependent protein kinase II, neither kinase phosphorylated GRK1 or GRK7. Phosphorylation of GRK1 and GRK7 by PKA reduces the ability of GRK1 and GRK7 to phosphorylate rhodopsin in vitro. Since exposure to light causes a decrease in cAMP levels in rod cells, we propose that phosphorylation of GRK1 and GRK7 by PKA occurs in the dark, when cAMP levels in photoreceptor cells are elevated, and represents a novel mechanism for regulating the activities of these kinases.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Weiss, ER (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090,108 Taylor Hall, Chapel Hill, NC 27599 USA.	erweiss@med.unc.edu	Weiss, Ellen/AAK-9868-2020		NATIONAL EYE INSTITUTE [R01EY012224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043582, R01GM043582] Funding Source: NIH RePORTER; NEI NIH HHS [EY12224] Funding Source: Medline; NIGMS NIH HHS [GM43582] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANANT JS, 1992, BIOCHEM BIOPH RES CO, V183, P468, DOI 10.1016/0006-291X(92)90505-F; Balasubramanian N, 2001, BIOCHEMISTRY-US, V40, P12619, DOI 10.1021/bi015624b; BIGAY J, 1994, METHOD ENZYMOL, V237, P139; BLAZYNSKI C, 1984, EXP EYE RES, V38, P279, DOI 10.1016/0014-4835(84)90166-0; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chen CK, 2001, MOL VIS, V7, P305; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Cideciyan AV, 2003, INVEST OPHTH VIS SCI, V44, P1268, DOI 10.1167/iovs.02-0494; Cideciyan AV, 1998, P NATL ACAD SCI USA, V95, P328, DOI 10.1073/pnas.95.1.328; Clapham DE, 1996, NATURE, V379, P297, DOI 10.1038/379297a0; COHEN AI, 1992, P NATL ACAD SCI USA, V89, P12093, DOI 10.1073/pnas.89.24.12093; COHEN AI, 1982, J NEUROCHEM, V38, P781, DOI 10.1111/j.1471-4159.1982.tb08699.x; COHEN AI, 1990, VISUAL NEUROSCI, V4, P43, DOI 10.1017/S0952523800002753; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; Elorza A, 2000, MOL PHARMACOL, V57, P778, DOI 10.1124/mol.57.4.778; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; FERUGSON SS, 1998, SEMIN CELL DEV BIOL, V9, P119; Fukuhara C, 2004, J NEUROSCI, V24, P1803, DOI 10.1523/JNEUROSCI.4988-03.2004; Green CB, 2004, J BIOL RHYTHM, V19, P91, DOI 10.1177/0748730404263002; HONG K, 1973, BIOCHEMISTRY-US, V12, P4517, DOI 10.1021/bi00746a033; HORNER TJ, 2003, INVEST OPHTHALMOL VI, V4; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; IUVONE PM, 1990, J NEUROCHEM, V54, P1562, DOI 10.1111/j.1471-4159.1990.tb01205.x; IUVONE PM, 1978, SCIENCE, V202, P901, DOI 10.1126/science.30997; Jindrova H, 2000, VISUAL NEUROSCI, V17, P887, DOI 10.1017/S0952523800176072; Kefalov V, 2003, NATURE, V425, P526, DOI 10.1038/nature01992; Kennedy MJ, 2004, NEURON, V41, P915, DOI 10.1016/S0896-6273(04)00086-8; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; KONG GH, 1994, J BIOL CHEM, V269, P13084; Krasel C, 2001, J BIOL CHEM, V276, P1911, DOI 10.1074/jbc.M008773200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee BY, 2004, J BIOL CHEM, V279, P54008, DOI 10.1074/jbc.M405669200; LEE RH, 1990, J BIOL CHEM, V265, P15860; Liu P, 2005, J NEUROCHEM, V93, P135, DOI 10.1111/j.1471-4159.2004.03003.x; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; Mundell SJ, 1997, MOL PHARMACOL, V51, P991, DOI 10.1124/mol.51.6.991; NGUYENLEGROS J, 1981, NEUROSCI LETT, V27, P255, DOI 10.1016/0304-3940(81)90439-0; OHKI K, 1994, CURR EYE RES, V13, P547, DOI 10.3109/02713689408999887; OSBORNE NN, 1992, BRAIN RES, V570, P161, DOI 10.1016/0006-8993(92)90577-V; PAGHROEHL K, 1995, J NEUROSCI, V15, P6475; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; Patel S, 2003, NEUROPHARMACOLOGY, V44, P1038, DOI 10.1016/S0028-3908(03)00112-6; Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; SALCEDA R, 1982, VISION RES, V22, P1469, DOI 10.1016/0042-6989(82)90211-5; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Sears S, 2000, INVEST OPHTH VIS SCI, V41, P971; Sokal I, 2003, J BIOL CHEM, V278, P8316, DOI 10.1074/jbc.M211782200; Thulin CD, 2001, J BIOL CHEM, V276, P23805, DOI 10.1074/jbc.M101482200; Thurmond RL, 1997, P NATL ACAD SCI USA, V94, P1715, DOI 10.1073/pnas.94.5.1715; Traverso V, 2002, INVEST OPHTH VIS SCI, V43, P1655; UDOVICHENKO IP, 1993, BIOCHEM J, V295, P49, DOI 10.1042/bj2950049; VERSAUXBOTTERI C, 1986, J COMP NEUROL, V243, P422, DOI 10.1002/cne.902430311; Weiss E R, 1998, Mol Vis, V4, P27; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; Weiss ER, 2001, J NEUROSCI, V21, P9175, DOI 10.1523/JNEUROSCI.21-23-09175.2001; WEISS ER, 1995, BIOCHEM BIOPH RES CO, V216, P755, DOI 10.1006/bbrc.1995.2686; Werry TD, 2003, BIOCHEM J, V374, P281, DOI 10.1042/BJ20030312; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; Williams DS, 1997, J NEUROCHEM, V69, P1693; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; WIRZJUSTICE A, 1984, NEUROSCI LETT, V45, P21, DOI 10.1016/0304-3940(84)90323-9; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; Yu QM, 1999, J NEUROCHEM, V73, P1222, DOI 10.1046/j.1471-4159.1999.0731222.x; Zhao XY, 1998, J BIOL CHEM, V273, P5124, DOI 10.1074/jbc.273.9.5124; Zhu XM, 2003, J NEUROSCI, V23, P6152, DOI 10.1523/JNEUROSCI.23-14-06152.2003	86	32	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28241	28250		10.1074/jbc.M505117200	http://dx.doi.org/10.1074/jbc.M505117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15946941	Green Published, hybrid			2022-12-25	WOS:000230857300010
J	Talmud, PJ; Palmen, J; Putt, W; Lins, L; Humphries, SE				Talmud, PJ; Palmen, J; Putt, W; Lins, L; Humphries, SE			Determination of the functionality of common APOA5 polymorphisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN A-V; B SIGNAL PEPTIDE; APOA1/C3/A4/A5 GENE-CLUSTER; PLASMA TRIGLYCERIDES; INITIATOR CODONS; VARIANTS; ASSOCIATION; SEQUENCE; MUTATION; HYPERTRIGLYCERIDEMIA	Common variants of APOA5 have consistently shown association with differences in plasma triglyceride (TG) levels. These single nucleotide polymorphisms (SNPs) fall into three common haplotypes: APOA5*1, with common alleles at all sites; APOA5*2, with rare alleles of -1131T -> C, -3A -> G, 751G -> T, and 1891T -> C; and APOA5*3, distinguished by the c56C -> G (S19W). Molecular modeling of the apoAV signal peptide (SP) showed an increased angle of insertion (65 degrees) at the lipid/water interface of Trp-19 SP compared with Ser-19 SP (40 degrees), predicting reduced translocation. This was confirmed by 50% reduction of Trp-19-encoded SP center dot secretory alkaline phosphatase (SEAP) fusion protein secreted into the medium from HepG2 cells compared with the Ser-19 center dot SEAP fusion protein (p < 0.002). Considering APOA5*2 SNPs, there was no significant difference in the relative luciferase expression in Huh7 cells transiently transfected with a -1131T construct compared with the -1131C (fragments -1177 to -516 or -1177 to -3). Similarly, for the -3A -> G in the Kozak sequence, in vitro transcription/translation assays and primer extension inhibition assays showed no alternate AUG initiation codon usage, demonstrating that -3A -> G did not influence translation efficiency. Although 1891T -> C in the 3'-untranslated region disrupts a putative Oct-1 transcription factor binding site, when inserted 3' of the luciferase gene the T -> C change demonstrated no significant difference in luciferase expression. Thus, association of APOA5*2 SNPs with TG levels is not due to the individual effects of any of these SNPs, although cooperativity between the SNPs cannot be excluded. Alternatively, the effect on TG levels may reflect the strong linkage disequilibrium with the functional APOC3 SNPs.	UCL Royal Free & Univ Coll Med Sch, Dept Med, Div Cardiovasc Genet, London WC1E 6JF, England; Fac Sci Agron Etat Gembloux, Ctr Biophys Mol Numer, B-5030 Gembloux, Belgium	University of London; University College London; UCL Medical School; University of Liege	Talmud, PJ (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Med, Div Cardiovasc Genet, 5 Univ St, London WC1E 6JF, England.	p.talmud@ucl.ac.uk	LINS, LAURENCE/Y-1661-2019; Talmud, Philippa J/C-4402-2008; Humphries, Stephen E/C-5075-2008	LINS, LAURENCE/0000-0001-7772-6748; Humphries, Stephen E/0000-0002-8221-6547; Talmud, Philippa/0000-0002-5560-1933				Austin MA, 2004, BBA-MOL BASIS DIS, V1688, P1, DOI 10.1016/j.bbadis.2003.10.003; Baum L, 2003, CLIN GENET, V63, P377, DOI 10.1034/j.1399-0004.2003.00063.x; Benhizia F, 2001, BIOCHEM BIOPH RES CO, V283, P149, DOI 10.1006/bbrc.2001.4740; Brasseur R, 2000, MOL MEMBR BIOL, V17, P31, DOI 10.1080/096876800294461; Byrne CD, 1996, ATHEROSCLEROSIS, V127, P35, DOI 10.1016/S0021-9150(96)05932-1; Chan D, 2001, J BIOL CHEM, V276, P7992, DOI 10.1074/jbc.M003361200; Ducarme P, 1998, PROTEINS, V30, P357, DOI 10.1002/(SICI)1097-0134(19980301)30:4<357::AID-PROT3>3.0.CO;2-G; Eichenbaum-Voline S, 2004, ARTERIOSCL THROM VAS, V24, P167, DOI 10.1161/01.ATV.0000099881.83261.D4; Fruchart-Najib J, 2004, BIOCHEM BIOPH RES CO, V319, P397, DOI 10.1016/j.bbrc.2004.05.003; Fullerton SM, 2004, HUM GENET, V115, P36, DOI 10.1007/s00439-004-1106-x; Gonzalez-Conejero R, 2002, BLOOD, V100, P2081, DOI 10.1182/blood.V100.6.2081.h81802002081_2081_2086; Khovidhunkit W, 2004, ATHEROSCLEROSIS, V176, P37, DOI 10.1016/j.atherosclerosis.2004.04.018; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; Kozak M, 1998, NUCLEIC ACIDS RES, V26, P4853, DOI 10.1093/nar/26.21.4853; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; MORGAN K, 1993, HUM MOL GENET, V2, P253, DOI 10.1093/hmg/2.3.253; Nabika T, 2002, ATHEROSCLEROSIS, V165, P201, DOI 10.1016/S0021-9150(02)00252-6; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oliva CP, 2005, ARTERIOSCL THROM VAS, V25, P411, DOI 10.1161/01.ATV.0000153087.36428.dd; Olivier M, 2004, GENOMICS, V83, P912, DOI 10.1016/j.ygeno.2003.11.016; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; Schaap FG, 2004, J BIOL CHEM, V279, P27941, DOI 10.1074/jbc.M403240200; Siggaard C, 1999, J CLIN ENDOCR METAB, V84, P2933, DOI 10.1210/jc.84.8.2933; STURLEY SL, 1994, J BIOL CHEM, V269, P21670; Sunthornthepvarakul T, 1999, J CLIN ENDOCR METAB, V84, P3792, DOI 10.1210/jc.84.10.3792; Talmud P, 1996, PROTEIN ENG, V9, P317, DOI 10.1093/protein/9.4.317; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; Tuohy TMF, 1998, HUM MUTAT, V12, P122; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; van Dijk KW, 2004, CURR OPIN LIPIDOL, V15, P239, DOI [10.1097/01.mol.00001300096.77252.1f, 10.1097/00041433-200406000-00002]; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Waterworth DM, 2003, BBA-MOL BASIS DIS, V1637, P200, DOI 10.1016/S0925-4439(03)00021-8; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200	36	100	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28215	28220		10.1074/jbc.M502144200	http://dx.doi.org/10.1074/jbc.M502144200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15941721	hybrid			2022-12-25	WOS:000230857300007
J	Tran, AX; Lester, ME; Stead, CM; Raetz, CRH; Maskell, DJ; McGrath, SC; Cotter, RJ; Trent, MS				Tran, AX; Lester, ME; Stead, CM; Raetz, CRH; Maskell, DJ; McGrath, SC; Cotter, RJ; Trent, MS			Resistance to the antimicrobial peptide polymyxin requires myristoylation of Escherichia coli and Salmonella typhimurium lipid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-DEFICIENT MUTANT; MSBB GENE; MULTICOPY SUPPRESSOR; PMRA-MUTANTS; ACYL CHAINS; 4-AMINO-4-DEOXY-L-ARABINOSE; PHOSPHOETHANOLAMINE; LIPOPOLYSACCHARIDE; VIRULENCE; SYSTEM	Attachment of positively charged, amine-containing residues such as 4-amino-4-deoxy-L-arabinose (L-Ara4N) and phosphoethanolamine (pEtN) to Escherichia coli and Salmonella typhimurium lipid A is required for resistance to the cationic antimicrobial peptide, polymyxin. In an attempt to discover additional lipid A modifications important for polymyxin resistance, we generated polymyxin-sensitive mutants of an E. coli pm-rAC strain, WD101. A subset of polymyxin-sensitive mutants produced a lipid A that lacked both the 3'-acyloxyacyllinked myristate (C-14) and L-Ara4N, even though the necessary enzymatic machinery required to synthesize L-Ara4N-modified lipid A was present. Inactivation of lpxM in both E. coli and S. typhimurium resulted in the loss of L-Ara4N addition, as well as, increased sensitivity to polymyxin. However, decoration of the lipid A phosphate groups with pEtN residues was not effected in lpxM mutants. In summary, we demonstrate that attachment of L-Ara4N to the phosphate groups of lipid A and the subsequent resistance to polymyxin is dependent upon the presence of the secondary linked myristoyl group.	E Tennessee State Univ, James H Quillen Coll Med, Dept Microbiol, Johnson City, TN 37614 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Cambridge, Ctr Vet Sci, Dept Vet Med, Cambridge CB3 0ES, England; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	East Tennessee State University; Duke University; University of Cambridge; Johns Hopkins University	Trent, MS (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Microbiol, Box 70579, Johnson City, TN 37614 USA.	trentms@mail.etsu.edu						Baker SJ, 1999, MICROBIOL-SGM, V145, P367, DOI 10.1099/13500872-145-2-367; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Clementz T, 1997, J BIOL CHEM, V272, P10353; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; Kawasaki K, 2005, J BACTERIOL, V187, P2448, DOI 10.1128/JB.187.7.2448-2457.2005; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; Kox LFF, 2000, EMBO J, V19, P1861, DOI 10.1093/emboj/19.8.1861; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205; Murray SR, 2001, J BACTERIOL, V183, P5554, DOI 10.1128/JB.183.19.5554-5561.2001; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1999, INFECT IMMUN, V67, P6583; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Stead C, 2005, J BACTERIOL, V187, P3374, DOI 10.1128/JB.187.10.3374-3383.2005; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	43	69	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28186	28194		10.1074/jbc.M505020200	http://dx.doi.org/10.1074/jbc.M505020200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15951433	hybrid, Green Published			2022-12-25	WOS:000230857300004
J	Fotso, P; Koryakina, Y; Pavliv, O; Tsiomenko, AB; Lupashin, VV				Fotso, P; Koryakina, Y; Pavliv, O; Tsiomenko, AB; Lupashin, VV			Cog1p plays a central role in the organization of the yeast conserved oligomeric golgi complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC RETICULUM RETRIEVAL; PROTEIN COMPLEX; CIS-GOLGI; VESICLE; TRANSPORT; IDENTIFICATION; COMPONENT; EFFECTOR; SEC34P; DSL1P	The conserved oligomeric Golgi ( COG) complex is an evolutionarily conserved peripheral membrane oligomeric protein complex that is involved in intra-Golgi protein trafficking. The COG complex is composed of eight subunits that are located in two lobes; Lobe A contains COG1-4, and Lobe B is composed of COG5-8. Both in vivo and in vitro protein-protein interaction techniques were applied to characterize interactions between individual COG subunits. In vitro assays revealed binary interactions between Cog2p and Cog3p, Cog2p and Cog4p, and Cog6p and Cog8p and a strong interaction between Cog5p and Cog7p. The two-hybrid assay confirmed these findings and revealed that Cog1p interacted with subunits from both lobes of the complex. Antibodies to COG subunits were utilized to determine the protein levels and membrane association of COG subunits in yeast Delta cog1-8 mutants. As a result, we created a model of the protein-protein interactions within the yeast COG complex and proposed that Cog1p is a bridging subunit between the two COG lobes. In support of this hypothesis, we have demonstrated that Cog1p is required for the stable association between two COG subcomplexes.	Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Lupashin, VV (corresponding author), Univ Arkansas Med Sci, Dept Physiol & Biophys, Biomed 261-2,Mail Slot 505,200 S Cedar St, Little Rock, AR 72205 USA.	vvlupashin@uams.edu	Lupashin, Vladimir/AAB-4312-2020; Lupashin, Vladimir/E-3013-2013	Lupashin, Vladimir/0000-0002-2350-1962; Lupashin, Vladimir/0000-0002-2350-1962				Andag U, 2003, J BIOL CHEM, V278, P51722, DOI 10.1074/jbc.M308740200; Andag U, 2001, J BIOL CHEM, V276, P39150, DOI 10.1074/jbc.M105833200; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brickner JH, 2001, J CELL BIOL, V155, P969, DOI 10.1083/jcb.200104093; Conibear E, 2003, MOL BIOL CELL, V14, P1610, DOI 10.1091/mbc.E02-10-0654; Conibear E, 2000, MOL BIOL CELL, V11, P305, DOI 10.1091/mbc.11.1.305; Farkas RM, 2003, MOL BIOL CELL, V14, P190, DOI 10.1091/mbc.E02-06-0343; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kim DW, 1999, MOL BIOL CELL, V10, P3317, DOI 10.1091/mbc.10.10.3317; Kim DW, 2001, TRAFFIC, V2, P820, DOI 10.1034/j.1600-0854.2001.21111.x; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; Loh E, 2004, J BIOL CHEM, V279, P24640, DOI 10.1074/jbc.M400662200; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; LUPASHIN VV, 1992, YEAST, V8, P157, DOI 10.1002/yea.320080302; Morsomme P, 2002, DEV CELL, V2, P307, DOI 10.1016/S1534-5807(02)00133-8; Oka T, 2005, J BIOCHEM, V137, P109, DOI 10.1093/jb/mvi024; Oka T, 2004, MOL BIOL CELL, V15, P2423, DOI 10.1091/mbc.E03-09-0699; Opat AS, 2001, BIOCHEM J, V358, P33, DOI 10.1042/0264-6021:3580033; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pfeffer S, 2001, MOL CELL, V8, P729, DOI 10.1016/S1097-2765(01)00371-9; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; PODOS SD, 1994, J CELL BIOL, V127, P679, DOI 10.1083/jcb.127.3.679; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Ram RJ, 2002, MOL BIOL CELL, V13, P1484, DOI 10.1091/mbc.01-10-0495; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; ROTHMAN JE, 1994, ADV SEC MESS PHOSPH, V29, P81; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Siniossoglou S, 2002, J BIOL CHEM, V277, P48318, DOI 10.1074/jbc.M209428200; Siniossoglou S, 2001, EMBO J, V20, P5991, DOI 10.1093/emboj/20.21.5991; Spelbrink RG, 1999, MOL BIOL CELL, V10, P4263, DOI 10.1091/mbc.10.12.4263; Suvorova ES, 2002, J CELL BIOL, V157, P631, DOI 10.1083/jcb.200111081; Suvorova ES, 2001, J BIOL CHEM, V276, P22810, DOI 10.1074/jbc.M011624200; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Ungar D, 2002, J CELL BIOL, V157, P405, DOI 10.1083/jcb.200202016; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; VanRheenen SM, 2001, TRAFFIC, V2, P212, DOI 10.1034/j.1600-0854.2001.020307.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; Whyte JRC, 2002, J CELL SCI, V115, P2627; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wuestehube LJ, 1996, GENETICS, V142, P393; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191; Zolov SN, 2005, J CELL BIOL, V168, P747, DOI 10.1083/jcb.200412003	52	70	73	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27613	27623		10.1074/jbc.M504597200	http://dx.doi.org/10.1074/jbc.M504597200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15932880	hybrid			2022-12-25	WOS:000230678600018
J	Kuliawat, R; Ramos-Castaneda, J; Liu, YF; Arvan, P				Kuliawat, R; Ramos-Castaneda, J; Liu, YF; Arvan, P			Intracellular trafficking of thyroid peroxidase to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROPEROXIDASE; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; MICROSOMAL ANTIGEN; EPITHELIAL-CELLS; EXPRESSION; THYROTROPIN; IODINATION; GLYCOSYLATION; THYROGLOBULIN	For thyroid hormone synthesis, thyroid peroxidase (TPO) molecules must be transported from the endoplasmic reticulum via the Golgi complex to be delivered at the cell surface to catalyze iodination of secreted thyroglobulin. Like other glycoproteins, TPO molecules in transit to the cell surface have the potential to acquire endoglycosidase H resistance as a consequence of Golgi-based modification of their N-linked carbohydrates, and measurement of the intracellular distribution of TPO has often relied on this assumption. To examine TPO surface distribution in thyrocyte cell lines, we prepared new antibodies against rat TPO. Antibody reactivity was first established upon expression of recombinant rat (r) TPO in 293 cells, which were heterogeneous for surface expression as determined by flow cytometry. By cell fractionation, surface rTPO fractionated distinctly from internal pools of TPO ( that co-fractionate with calnexin), yet surface TPO molecules remained endoglycosidase H (endo H)-sensitive. Although the FRTL5 ( and PC Cl3) rat thyrocyte cell line also exhibits almost no endo H-resistant TPO, much of the endogenous rTPO is localized to the cell surface by immunofluorescence. Similar results were obtained by fractionation of FRTL5 cell membranes on sucrose gradients. We conclude that in FRTL5 cells, a large fraction of rTPO is delivered to the plasma membrane yet does not acquire Golgi-type processing of its N-glycans. Rat and mouse thyroid tissue TPO also shows little or no endo H resistance, although cell fractionation still needs to be optimized for these tissues.	Univ Michigan, Sch Med, Div Endocrinol Diabet & Metab, Ann Arbor, MI 48109 USA; Univ Michigan, Program Mol Biol, Ann Arbor, MI 48109 USA; Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Ctr Invest Enfermedades Infecciosas, Cuernavaca 62508, Morelos, Mexico	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Univ Michigan, Sch Med, Div Endocrinol Diabet & Metab, MSRB2,Rm 5560,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	parvan@umich.edu	Ramos-Castañeda, jose/V-6678-2019	Kuliawat, Regina/0000-0001-8386-2279	NIDDK NIH HHS [DK56027, DK 40344] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040344, R01DK056027, R01DK040344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALQUIER C, 1989, AUTOIMMUNITY, V3, P113, DOI 10.3109/08916938909019960; Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163; ARVAN P, 1982, J CELL BIOL, V95, P8, DOI 10.1083/jcb.95.1.8; Bikker H, 1997, J CLIN ENDOCR METAB, V82, P649, DOI 10.1210/jc.82.2.649; BJORKMAN U, 1978, ENDOCRINOLOGY, V102, P460, DOI 10.1210/endo-102-2-460; BULLER AL, 1990, J MEMBRANE BIOL, V115, P179, DOI 10.1007/BF01869456; Caillou B, 2001, J CLIN ENDOCR METAB, V86, P3351, DOI 10.1210/jc.86.7.3351; Cals MM, 1996, MOL IMMUNOL, V33, P15, DOI 10.1016/0161-5890(95)00132-8; CASTLE JD, 1985, J MEMBRANE BIOL, V87, P13; CHIOVATO L, 1985, J CLIN ENDOCR METAB, V61, P12, DOI 10.1210/jcem-61-1-12; EKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141, DOI 10.1016/0303-7207(81)90056-3; Ekholm R, 1997, ENDOCRINOLOGY, V138, P2871, DOI 10.1210/en.138.7.2871; Fayadat L, 1998, ENDOCRINOLOGY, V139, P4277, DOI 10.1210/en.139.10.4277; Fayadat L, 2000, ENDOCRINOLOGY, V141, P959, DOI 10.1210/en.141.3.959; Fayadat L, 2000, J BIOL CHEM, V275, P15948, DOI 10.1074/jbc.M905763199; Ferrand M, 2003, J BIOL CHEM, V278, P3793, DOI 10.1074/jbc.M209513200; FOTI D, 1990, ENDOCRINOLOGY, V126, P2983, DOI 10.1210/endo-126-6-2983; FU DT, 1994, CARBOHYD RES, V261, P173, DOI 10.1016/0008-6215(94)84015-6; Hanigan MH, 1999, HUM PATHOL, V30, P300, DOI 10.1016/S0046-8177(99)90009-6; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; KOTANI T, 1987, ENDOCRINOL JAPON, V34, P407; KULIAWAT R, 1995, J BIOL CHEM, V270, P2478, DOI 10.1074/jbc.270.6.2478; Le Fourn V, 2005, J BIOL CHEM, V280, P4568, DOI 10.1074/jbc.M408042200; Le Fourn V, 2004, BBA-MOL BASIS DIS, V1689, P134, DOI 10.1016/j.bbadis.2004.03.001; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; Mengesdorf T, 2001, BIOCHEM J, V356, P805, DOI 10.1042/0264-6021:3560805; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; NIEPOMNISZCZE H, 1975, METABOLISM, V24, P57, DOI 10.1016/0026-0495(75)90007-4; NILSSON M, 1987, MOL CELL ENDOCRINOL, V53, P177, DOI 10.1016/0303-7207(87)90172-9; OFVERHOLM T, 1985, MOL CELL ENDOCRINOL, V40, P1, DOI 10.1016/0303-7207(85)90151-0; Park YN, 2004, J BIOL CHEM, V279, P17085, DOI 10.1074/jbc.M314042200; Penel C, 1998, J CELL PHYSIOL, V174, P160, DOI 10.1002/(SICI)1097-4652(199802)174:2<160::AID-JCP3>3.0.CO;2-M; PINCHERA A, 1987, ACTA ENDOCRINOL-COP, V115, P57; Rasmussen AK, 1999, AUTOIMMUNITY, V29, P323, DOI 10.3109/08916939908994752; ROBINSON PS, 1991, J CELL PHYSIOL, V148, P54, DOI 10.1002/jcp.1041480107; Sanchez VC, 2004, J CLIN INVEST, V114, P357, DOI 10.1172/jci200421620; STRUM J M, 1970, Journal of Cell Biology, V44, P655, DOI 10.1083/jcb.44.3.655; Taurog A, 1999, BIOCHIMIE, V81, P557, DOI 10.1016/S0300-9084(99)80110-2; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; WATANABE K, 1991, ENDOCRINOL JAPON, V38, P89; YAP AS, 1995, ENDOCRINOLOGY, V136, P4672, DOI 10.1210/en.136.10.4672; Zhang XQ, 2000, J BIOL CHEM, V275, P31946, DOI 10.1074/jbc.M003559200; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	45	13	13	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27713	27718		10.1074/jbc.M503804200	http://dx.doi.org/10.1074/jbc.M503804200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15917231	hybrid			2022-12-25	WOS:000230678600030
J	Rohrbach, P; Friedrich, O; Hentschel, J; Plattner, H; Fink, RHA; Lanzer, M				Rohrbach, P; Friedrich, O; Hentschel, J; Plattner, H; Fink, RHA; Lanzer, M			Quantitative calcium measurements in subcellular compartments of Plasmodium falciparum-infected erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-MICROANALYSIS; MALARIA PARASITE; FLUORESCENT CALCIUM; MEMBRANE-STRUCTURE; ACIDOCALCISOMES; CA2+; HOMEOSTASIS; CELLS; DYNAMICS; PH	The acidic food vacuole exerts several important functions during intraerythrocytic development of the human malarial parasite Plasmodium falciparum. Hemoglobin taken up from the host erythrocyte is degraded in the food vacuole, and the heme liberated during this process is crystallized to inert hemozoin. Several antimalarial drugs target food vacuolar pathways, such as hemoglobin degradation and heme crystallization. Resistance and sensitization to some antimalarials is associated with mutations in food vacuolar membrane proteins. Other studies suggest a role of the food vacuole in ion homeostasis, and release of Ca2+ from the food vacuole may mediate adopted physiological responses. To investigate whether the food vacuole is an intracellular Ca2+ store, which in turn may affect other physiological functions in which this organelle partakes, we have investigated total and exchangeable Ca2+ within the parasite's food vacuole using x-ray microanalysis and quantitative confocal live cell Ca2+ imaging. Apparent free Ca2+ concentrations of similar to 90, similar to 350, and similar to 400 nM were found in the host erythrocyte cytosol, the parasite cytoplasm, and the food vacuole, respectively. In our efforts to determine free intracellular Ca2+ concentrations, we evaluated several Ca2+-sensitive fluorochromes in a live cell confocal setting. We found that the ratiometric Ca2+ indicator Fura-Red provides reliable determinations, whereas measurements using the frequently used Fluo-4 are compromised due to problems arising from phototoxicity, photobleaching, and the strong pH dependence of the dye. Our data suggest that the food vacuole contains only moderate amounts of Ca2+, disfavoring a role as a major intracellular Ca2+ store.	Univ Klinikum Heidelberg, Abt Parasitol, Inst Hyg, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Konstanz	Lanzer, M (corresponding author), Univ Klinikum Heidelberg, Abt Parasitol, Inst Hyg, Im Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	michael_lanzer@med.uni-heidelberg.de	Rohrbach, Petra/F-3201-2011; Lanzer, Michael/E-9752-2013	Lanzer, Michael/0000-0002-0220-6526; Friedrich, Oliver/0000-0003-2238-2049				Alleva LM, 2001, MOL BIOCHEM PARASIT, V117, P121, DOI 10.1016/S0166-6851(01)00338-3; Bennett TN, 2004, MOL BIOCHEM PARASIT, V133, P99, DOI 10.1016/j.molbiopara.2003.09.008; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Biagini GA, 2003, J BIOL CHEM, V278, P27910, DOI 10.1074/jbc.M304193200; Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; Caldas ML, 2001, INT J PARASITOL, V31, P776, DOI 10.1016/S0020-7519(01)00189-8; Camacho P, 2003, J CELL BIOL, V161, P17, DOI 10.1083/jcb.200303116; Desai SA, 1996, AM J TROP MED HYG, V54, P464, DOI 10.4269/ajtmh.1996.54.464; Docampo R, 2005, NAT REV MICROBIOL, V3, P251, DOI 10.1038/nrmicro1097; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; DUNN T, 1994, J BIOL CHEM, V269, P7273; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; ENGELMANN B, 1991, KLIN WOCHENSCHR, V69, P137, DOI 10.1007/BF01665851; Friedrich O, 2004, J PHYSIOL-LONDON, V555, P251, DOI 10.1113/jphysiol.2003.054213; Garcia CRS, 1998, EUR J CELL BIOL, V76, P133, DOI 10.1016/S0171-9335(98)80026-5; Garcia CRS, 1996, EUR J CELL BIOL, V71, P409; Garcia CRS, 1999, PARASITOL TODAY, V15, P488, DOI 10.1016/S0169-4758(99)01571-9; Gazarini ML, 2003, J CELL BIOL, V161, P103, DOI 10.1083/jcb.200212130; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALACHMI D, 1989, FEBS LETT, V256, P55, DOI 10.1016/0014-5793(89)81717-X; Hardt M, 1999, J STRUCT BIOL, V128, P187, DOI 10.1006/jsbi.1999.4188; Hardt M, 2000, EUR J CELL BIOL, V79, P642, DOI 10.1078/0171-9335-00087; HARRISON DG, 1968, J PHYSIOL-LONDON, V199, P367, DOI 10.1113/jphysiol.1968.sp008658; Haugland R.P., 2002, HDB FLUORESCENT PROB; KNOLL G, 1993, CELL CALCIUM, V14, P173, DOI 10.1016/0143-4160(93)90065-E; KNOLL G, 1991, J CELL BIOL, V113, P1295, DOI 10.1083/jcb.113.6.1295; Krishna S, 2001, J BIOL CHEM, V276, P10782, DOI 10.1074/jbc.M010554200; LATTANZIO FA, 1991, BIOCHEM BIOPH RES CO, V177, P184, DOI 10.1016/0006-291X(91)91966-G; LATTANZIO FA, 1990, BIOCHEM BIOPH RES CO, V171, P102, DOI 10.1016/0006-291X(90)91362-V; LEE P, 1988, AM J TROP MED HYG, V39, P157, DOI 10.4269/ajtmh.1988.39.157; Lohr C, 2003, CELL CALCIUM, V34, P295, DOI 10.1016/S0143-4160(03)00105-2; Marchesini N, 2000, BIOCHEM J, V347, P243, DOI 10.1042/0264-6021:3470243; Miranda K, 2004, PROTIST, V155, P395, DOI 10.1078/1434461042650361; Miranda K, 2004, MICROSC MICROANAL, V10, P647, DOI 10.1017/S1431927604040887; Miranda K, 2004, HISTOCHEM CELL BIOL, V121, P407, DOI 10.1007/s00418-004-0646-4; Moreno SNJ, 2003, CURR OPIN MICROBIOL, V6, P359, DOI 10.1016/S1369-5274(03)00091-2; OLLIARO PL, 1995, PARASITOL TODAY, V11, P294, DOI 10.1016/0169-4758(95)80042-5; POENIE M, 1987, J HISTOCHEM CYTOCHEM, V35, P939, DOI 10.1177/35.9.3611737; Roos W, 2000, PLANTA, V210, P347, DOI 10.1007/PL00008144; Ruiz FA, 2004, MICROSC MICROANAL, V10, P563, DOI 10.1017/S1431927604040875; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; SHERMAN IW, 1985, PARASITOLOGY, V91, P609, DOI 10.1017/S0031182000062843; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; TANABE K, 1990, BLOOD CELLS, V16, P437; TANABE K, 1982, J CELL BIOL, V93, P680, DOI 10.1083/jcb.93.3.680; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Varotti FP, 2003, CELL CALCIUM, V33, P137, DOI 10.1016/S0143-4160(02)00224-5; WHO Expert Committee on Malaria, 2000, WHO TECH REP SER, V892, P1; Wissing F, 2002, J BIOL CHEM, V277, P37747, DOI 10.1074/jbc.M204845200; Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335; WUNSCH S, 1997, BEHRING I MITT, V199, P44	54	69	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27960	27969		10.1074/jbc.M500777200	http://dx.doi.org/10.1074/jbc.M500777200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15927958	Green Published, hybrid			2022-12-25	WOS:000230678600058
J	Xu, Z; Fukuda, T; Li, Y; Zha, XL; Qin, J; Wu, CY				Xu, Z; Fukuda, T; Li, Y; Zha, XL; Qin, J; Wu, CY			Molecular dissection of PINCH-1 reveals a mechanism of coupling and uncoupling of cell shape modulation and survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; FOCAL ADHESION PROTEIN; ADAPTER PROTEIN; ILK; DOMAIN; MATRIX; INTERACTS; LOCALIZATION; FIBRONECTIN; MORPHOLOGY	How cells couple and uncouple regulation of cellular processes such as shape change and survival is an important question in molecular cell biology. PINCH-1, a widely expressed protein consisting of five LIM domains and a C-terminal tail, is an essential focal adhesion protein with multiple functions including regulation of the integrin-linked kinase ( ILK) level, cell shape, and survival signaling. We show here that the LIM1-mediated interaction with ILK regulates all these three processes. By contrast, the LIM4-mediated interaction with Nck-2, which regulates cell morphology and migration, is not required for the control of the ILK level and survival. Remarkably, a short 15-residue tail C-terminal to LIM5 is required for both cell shape modulation and survival, albeit it is not required for the control of the ILK level. The C-terminal tail not only regulates PINCH-1 localization to focal adhesions but also functions after it localizes there. These findings suggest that PINCH-1 functions as a molecular platform for coupling and uncoupling diverse cellular processes via overlapping but yet distinct domain interactions.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Fudan Univ, Shanghai Med Coll, Dept Biochem & Mol Biol, Shanghai 200032, Peoples R China; Cleveland Clin Fdn, Lerner Res Inst, Struct Biol Program, Cleveland, OH 44195 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fudan University; Cleveland Clinic Foundation	Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, 707B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	carywu@pitt.edu	Qin, Jun/D-5559-2009; Li, Yong/B-3628-2011	Qin, Jun/0000-0002-2647-9270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54639] Funding Source: Medline; NIGMS NIH HHS [GM65188] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Braun A, 2003, EXP CELL RES, V284, P239, DOI 10.1016/S0014-4827(02)00039-3; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Campana WM, 2003, GLIA, V41, P213, DOI 10.1002/glia.10138; Clark KA, 2003, DEVELOPMENT, V130, P2611, DOI 10.1242/dev.00492; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Dougherty GW, 2005, EXP CELL RES, V306, P168, DOI 10.1016/j.yexcr.2005.01.025; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Grashoff C, 2004, CURR OPIN CELL BIOL, V16, P565, DOI 10.1016/j.ceb.2004.07.004; Guo L, 2002, FASEB J, V16, P1298, DOI 10.1096/fj.02-0089fje; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Kadrmas JL, 2004, J CELL BIOL, V167, P1019, DOI 10.1083/jcb.200408090; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; Li FG, 1999, J CELL SCI, V112, P4589; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Li YJ, 2003, J CLIN INVEST, V112, P503, DOI 10.1172/JCI200317913; Liang XQ, 2005, MOL CELL BIOL, V25, P3056, DOI 10.1128/MCB.25.8.3056-3062.2005; Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Vaynberg J, 2005, MOL CELL, V17, P513, DOI 10.1016/j.molcel.2004.12.031; Velyvis A, 2003, NAT STRUCT BIOL, V10, P558, DOI 10.1038/nsb938; Velyvis A, 2001, J BIOL CHEM, V276, P4932, DOI 10.1074/jbc.M007632200; Wang-Rodriguez J, 2002, CANCER-AM CANCER SOC, V95, P1387, DOI 10.1002/cncr.10878; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200	42	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27631	27637		10.1074/jbc.M504189200	http://dx.doi.org/10.1074/jbc.M504189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15941716	hybrid			2022-12-25	WOS:000230678600020
J	Bieler, S; Estrada, L; Lagos, R; Baeza, M; Castilla, J; Soto, C				Bieler, S; Estrada, L; Lagos, R; Baeza, M; Castilla, J; Soto, C			Amyloid formation modulates the biological activity of a bacterial protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROCIN E492; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; BETA-PEPTIDE; DISEASE; EXPRESSION; MECHANISM; FIBRILS; PORES	The aggregation of proteins into amyloid fibrils is the hallmark feature of a group of late-onset degenerative diseases including Alzheimer, Parkinson, and prion diseases. We report here that microcin E492, a peptide naturally produced by Klebsiella pneumoniae that kills bacteria by forming pores in the cytoplasmic membrane, assembles in vitro into amyloid-like fibrils. The fibrils have the same structural, morphological, tinctorial, and biochemical properties as the aggregates observed in the disease conditions. In addition, we found that amyloid formation also occurs in vivo where it is associated with a loss of toxicity of the protein. The finding that microcin E492 naturally exists both as functional toxic pores and as harmless fibrils suggests that protein aggregation into amyloid fibrils is an evolutionarily conserved property of proteins that can be successfully employed by bacteria to fulfill specific physiological needs.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Geneva, Dept Cell Biol, CH-1211 Geneva, Switzerland; Univ Chile, Dept Biol, Santiago, Chile	University of Texas System; University of Texas Medical Branch Galveston; University of Geneva; Universidad de Chile	Soto, C (corresponding author), Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA.	clsoto@utmb.edu	Castilla, Joaquín/J-8414-2019; Castilla, Joaquin/D-5261-2011; /C-6686-2008	Castilla, Joaquín/0000-0002-2216-1361; Castilla, Joaquin/0000-0002-2216-1361; 	NATIONAL INSTITUTE ON AGING [R01AG002246] Funding Source: NIH RePORTER; NIA NIH HHS [AG0224642] Funding Source: Medline; NINDS NIH HHS [NS549173] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anguiano M, 2002, BIOCHEMISTRY-US, V41, P11338, DOI 10.1021/bi020314u; Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0; BAQUERO F, 1984, FEMS MICROBIOL LETT, V23, P117; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Corsini G, 2002, BIOCHIMIE, V84, P539, DOI 10.1016/S0300-9084(02)01415-3; DELORENZO V, 1985, J ANTIBIOT, V38, P340, DOI 10.7164/antibiotics.38.340; DELORENZO V, 1984, J GEN MICROBIOL, V130, P391; DELORENZO V, 1985, ANTIMICROB AGENTS CH, V27, P666, DOI 10.1128/AAC.27.4.666; DELORENZO V, 1984, ARCH MICROBIOL, V139, P72, DOI 10.1007/BF00692715; Destoumieux-Garzon D, 2003, MOL MICROBIOL, V49, P1031, DOI 10.1046/j.1365-2958.2003.03610.x; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hetz C, 2002, P NATL ACAD SCI USA, V99, P2696, DOI 10.1073/pnas.052709699; Hotze EM, 2002, J BIOL CHEM, V277, P11597, DOI 10.1074/jbc.M111039200; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Lagos R, 2001, MOL MICROBIOL, V42, P229, DOI 10.1046/j.1365-2958.2001.02630.x; LAGOS R, 1993, FEBS LETT, V321, P145, DOI 10.1016/0014-5793(93)80096-D; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LeVine H, 1999, METHOD ENZYMOL, V309, P274; MAYR-HARTING A., 1972, METHODS MICROBIOLOGY, V7, P315, DOI DOI 10.1016/S0580-9517(08)70618-4; Miller J. H., 1972, EXPT MOL GENETICS, P431; NORDSTEDT C, 1994, J BIOL CHEM, V269, P30773; Orellana C, 1996, FEMS MICROBIOL LETT, V136, P297; Pons AM, 2002, ANTIMICROB AGENTS CH, V46, P229, DOI 10.1128/AAC.46.1.229-230.2002; Riley MA, 1998, ANNU REV GENET, V32, P255, DOI 10.1146/annurev.genet.32.1.255; Riley MA, 2003, J EVOLUTION BIOL, V16, P690, DOI 10.1046/j.1420-9101.2003.00575.x; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Thomas X, 2004, J BIOL CHEM, V279, P28233, DOI 10.1074/jbc.M400228200; Wilkens M, 1997, J BACTERIOL, V179, P4789, DOI 10.1128/jb.179.15.4789-4794.1997	40	99	104	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26880	26885		10.1074/jbc.M502031200	http://dx.doi.org/10.1074/jbc.M502031200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917245	hybrid			2022-12-25	WOS:000230589500030
J	Reinehr, R; Becker, S; Eberle, A; Grether-Beck, S; Haussinger, D				Reinehr, R; Becker, S; Eberle, A; Grether-Beck, S; Haussinger, D			Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HEPATIC STELLATE CELLS; TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; OXIDATIVE-STRESS; RESPIRATORY BURST; C-ZETA; ACID SPHINGOMYELINASE	CD95 ligand (CD95L) triggers a rapid formation of reactive oxygen species (ROS) as an upstream event of CD95 activation and apoptosis induction in rat hepatocytes. This ROS response was sensitive to inhibition by diphenyleneiodonium, apocynin, and neopterin, suggestive of an involvement of NADPH oxidases. In line with this, hepatocytes expressed mRNAs not only of the phagocyte gp91(phox) (Nox 2), but also of the homologs Nox 1 and 4 and Duox 1 and 2, as well as the regulatory subunit p47(phox). gp91(phox) (Nox 2) and p47(phox) were also identified at the protein level in rat hepatocytes. CD95L induced within 1 min ceramide formation and serine phosphorylation of p47(phox), which was sensitive to inhibitors of sphingomyelinase and protein kinase C zeta (PKC zeta). These inhibitors and p47(phox) protein knockdown inhibited the early CD95L-induced ROS response, suggesting that ceramide and PKC zeta are upstream events of the CD95L-induced Nox/Duox activation. CD95L also induced rapid activation of the Src family kinase Yes, being followed by activation of c-Src, Fyn, and c-Jun-N-terminal kinases (JNK). Only Yes and JNK activation were sensitive to N-acetylcysteine, inhibitors of NADPH oxidase, PKC zeta, or sphingomyelinase, indicating that the CD95L-induced ROS response is upstream of Yes and JNK but not of Fyn and c-Src activation. Activated Yes rapidly associated with the epidermal growth factor receptor ( EGFR), which became phosphorylated at Tyr(845) and Tyr(1173) but not at Tyr(1045). Activated EGFR then triggered an AG1478-sensitive CD95-tyrosine phosphorylation, which was a signal for membrane targeting of the EGFR/CD95 complex, subsequent recruitment of Fas-associated death domain and caspase 8, and apoptosis induction. All of these events were significantly blunted by inhibitors of sphingomyelinase, PKC zeta, NADPH oxidases, Yes, or EGFR-tyrosine kinase activity and after protein knockdown of either p47(phox), Yes, or EGFR. The data suggest that CD95L-induced apoptosis involves a sphingomyelinase- and PKC zeta-dependent activation of NADPH oxidase isoforms, which is required for Yes/EGFR/CD95 interactions as upstream events of CD95 activation.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany; Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Klinikum Dusseldorf, Klin Gastroenterol Hepatol & Infektiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de	Reinehr, Roland/G-6118-2016					ALBOUZ S, 1983, NEUROSCI LETT, V36, P311, DOI 10.1016/0304-3940(83)90018-6; Bataller R, 2003, J CLIN INVEST, V112, P1383, DOI 10.1172/JCI200318212; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Brock P, 1999, CYTOMETRY, V35, P353, DOI 10.1002/(SICI)1097-0320(19990401)35:4<353::AID-CYTO8>3.0.CO;2-M; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; Dickinson ME, 2003, J BIOMED OPT, V8, P329, DOI 10.1117/1.1583734; Ducher L, 1995, BIOCHEM BIOPH RES CO, V217, P546, DOI 10.1006/bbrc.1995.2810; Eberle A, 2005, HEPATOLOGY, V41, P315, DOI 10.1002/hep.20564; ElBenna J, 1996, J BIOL CHEM, V271, P6374; Fischer R, 2002, GASTROENTEROLOGY, V123, P845, DOI 10.1053/gast.2002.35384; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; FRANCKE U, 1990, AM J HUM GENET, V47, P483; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; Jin YJ, 1998, J IMMUNOL, V161, P1743; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KOJIMA S, 1993, FEBS LETT, V329, P125, DOI 10.1016/0014-5793(93)80207-B; KRAHENBUHL S, 1994, HEPATOLOGY, V19, P471, DOI 10.1016/0270-9139(94)90027-2; KUBICKAMURANYI M, 1993, INT J IMMUNOPHARMACO, V15, P151, DOI 10.1016/0192-0561(93)90091-C; Kubitz R, 2004, J BIOL CHEM, V279, P10323, DOI 10.1074/jbc.M306242200; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LEVY R, 1990, J IMMUNOL, V145, P2595; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Paclet MH, 2004, BIOCHEM J, V382, P981, DOI 10.1042/BJ20040954; Pani G, 2001, IUBMB LIFE, V52, P7, DOI 10.1080/15216540252774702; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Piiper A, 2003, J BIOL CHEM, V278, P7065, DOI 10.1074/jbc.M211234200; Poppleton HM, 1999, ARCH BIOCHEM BIOPHYS, V363, P227, DOI 10.1006/abbi.1998.1095; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Reinehr R, 2004, GASTROENTEROLOGY, V127, P1540, DOI 10.1053/j.gastro.2004.08.056; Reinehr R, 2004, J BIOL CHEM, V279, P23977, DOI 10.1074/jbc.M401519200; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Sanguinetti AR, 2003, BIOCHEM J, V376, P159, DOI 10.1042/BJ20030336; Sanz A, 2005, BIOGERONTOLOGY, V6, P15, DOI 10.1007/s10522-004-7380-0; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Seki Shuichi, 1999, Medical Electron Microscopy, V32, P199; SIES H, 1974, ANGEW CHEM INT EDIT, V13, P706, DOI 10.1002/anie.197407061; Sokol RJ, 1998, GASTROENTEROLOGY, V114, P164, DOI 10.1016/S0016-5085(98)70644-4; SOKOL RJ, 1995, GASTROENTEROLOGY, V109, P1249, DOI 10.1016/0016-5085(95)90585-5; STADLER J, 1992, ANN SURG, V216, P539, DOI 10.1097/00000658-199211000-00003; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Stravitz RT, 1996, AM J PHYSIOL-GASTR L, V271, pG293, DOI 10.1152/ajpgi.1996.271.2.G293; Suzuki Y, 1998, FEBS LETT, V425, P209, DOI 10.1016/S0014-5793(98)00228-2; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TIMMER A, 2004, PLANAR CHROMATOGR, V93, P2; Vejrazka M, 2005, BBA-GEN SUBJECTS, V1722, P143, DOI 10.1016/j.bbagen.2004.12.008; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Xu JH, 1996, J CELL BIOL, V134, P1301, DOI 10.1083/jcb.134.5.1301; YOSHIDA Y, 1985, J BIOCHEM-TOKYO, V98, P1669, DOI 10.1093/oxfordjournals.jbchem.a135438	83	207	210	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27179	27194		10.1074/jbc.M414361200	http://dx.doi.org/10.1074/jbc.M414361200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917250	hybrid			2022-12-25	WOS:000230589500066
J	Wood, KC; Hebbel, RP; Granger, DN				Wood, KC; Hebbel, RP; Granger, DN			Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice	FASEB JOURNAL			English	Article						inflammation; thrombogenesis; hypoxia/reoxygenation; leukocyte-endothelial cell adhesion	OXYGEN RADICAL GENERATION; SUPEROXIDE-DISMUTASE; PLATELET; AUTOXIDATION; GLUTATHIONE; HEMOGLOBIN; ADHESION; DISEASE; MODEL; IRON	Although blood cell-endothelial cell adhesion and oxidative stress have been implicated in the pathogenesis of sickle cell disease (SCD), the nature of the linkage between these vascular responses in SCD remains unclear. The objective of this study was to determine whether superoxide derived from endothelial cell-associated NADPH oxidase mediates the leukocyte-endothelial (L/E) and platelet-endothelial cell (P/E) adhesion that is observed in the cerebral microvasculature of sickle cell transgenic (Ps) mice. Intravital fluorescence microscopy was used to monitor L/E and P/E adhesion in brain postcapillary venules of wild-type (WT), SOD1 transgenic (SOD1-TgN), and gp91phox (NADPH oxidase)-deficient mice that were transplanted with bone marrow from beta(s) mice. Hypoxia/reoxygenation (H/R) yielded intense P/E and L/E adhesion responses in cerebral venules of beta(s)/WT chimeras that were significantly attenuated in both beta(s)/SOD1-TgN, and beta(s)/gp91phox(-/-) chimeras. Pretreatment of beta(s)/WT chimeras with the iron-chelator desferroxamine blunted the blood cell-endothelial cell adhesion responses to H/R, whereas pretreatment with the xanthine oxidase inhibitor allopurinol had no effect. These findings suggest that superoxide derived from endothelial cell NADPH-oxidase and catalytically active iron contribute to the proinflammatory and prothrombogenic responses associated with sickle cell disease.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; Univ Minnesota, Sch Med, Vasc Biol Ctr, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Div Hematol Oncol Transplantat, Minneapolis, MN 55455 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Granger, DN (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA.	dgrang@lsuhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055552] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK043785] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL055552, P01-HL55552] Funding Source: Medline; NIDDK NIH HHS [P01-DK43785] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akgur FM, 2000, AM J PHYSIOL-HEART C, V279, pH791, DOI 10.1152/ajpheart.2000.279.2.H791; Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Ballas SK, 1998, BAILLIERE CLIN HAEM, V11, P185, DOI 10.1016/S0950-3536(98)80075-9; Browne P, 1998, FREE RADICAL BIO MED, V24, P1040, DOI 10.1016/S0891-5849(97)00391-2; DAS SK, 1980, BRIT J HAEMATOL, V44, P87, DOI 10.1111/j.1365-2141.1980.tb01186.x; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Faraci FM, 2004, ARTERIOSCL THROM VAS, V24, P1367, DOI 10.1161/01.ATV.0000133604.20182.cf; Fukui T, 1997, CIRC RES, V80, P45, DOI 10.1161/01.RES.80.1.45; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Gurkan E, 2005, ANN HEMATOL, V84, P71, DOI 10.1007/s00277-004-0935-y; Harrison DG, 2003, J RENIN-ANGIO-ALDO S, V4, P51, DOI 10.3317/jraas.2003.014; HEBBEL RP, 1988, P NATL ACAD SCI USA, V85, P237, DOI 10.1073/pnas.85.1.237; HEBBEL RP, 1982, J CLIN INVEST, V70, P1253, DOI 10.1172/JCI110724; HEBBEL RP, 1985, CLIN HAEMATOL, V14, P129; Inwald DP, 2000, BRIT J HAEMATOL, V111, P474, DOI 10.1046/j.1365-2141.2000.02353.x; Ishikawa M, 2004, CIRC RES, V94, P239, DOI 10.1161/01.RES.0000111524.05779.60; JARASCH ED, 1986, ACTA PHYSIOL SCAND, V126, P39; Jeon BR, 2001, SHOCK, V15, P112, DOI 10.1097/00024382-200115020-00006; Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225; Kaul DK, 2004, AM J PHYSIOL-HEART C, V287, pH293, DOI 10.1152/ajpheart.01150.2003; MARVA E, 1994, BLOOD, V83, P242; Massberg S, 1998, BLOOD, V92, P507, DOI 10.1182/blood.V92.2.507; Noguchi CT, 2001, BLOOD CELL MOL DIS, V27, P971, DOI 10.1006/bcmd.2001.0469; Prass K, 2002, J CEREBR BLOOD F MET, V22, P520, DOI 10.1097/00004647-200205000-00003; REPKA T, 1991, BLOOD, V78, P2753; Rey FE, 2002, CIRCULATION, V106, P2497, DOI 10.1161/01.CIR.0000038108.71560.70; SAAD STO, 1991, NOUV REV FR HEMATOL, V33, P11; Tailor A, 2003, ARTERIOSCL THROM VAS, V23, P675, DOI 10.1161/01.ATV.0000056742.97580.79; TOMITA Y, 1994, BLOOD, V83, P939; Tsujikawa A, 2000, HYPERTENSION, V36, P250, DOI 10.1161/01.HYP.36.2.250; Turhan A, 2002, P NATL ACAD SCI USA, V99, P3047, DOI 10.1073/pnas.052522799; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; Wood KC, 2004, AM J PHYSIOL-HEART C, V286, pH1608, DOI 10.1152/ajpheart.01056.2003; Wun T, 2002, CLIN LAB HAEMATOL, V24, P81	35	89	93	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					989	+		10.1096/fj.04-3218fje	http://dx.doi.org/10.1096/fj.04-3218fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15923406				2022-12-25	WOS:000227901300009
J	Jinno-Oue, A; Shimizu, N; Soda, Y; Tanaka, A; Ohtsuki, T; Kurosaki, D; Suzuki, Y; Hoshino, H				Jinno-Oue, A; Shimizu, N; Soda, Y; Tanaka, A; Ohtsuki, T; Kurosaki, D; Suzuki, Y; Hoshino, H			The synthetic peptide derived from the NH2-terminal extracellular region of an orphan G protein-coupled receptor, GPR1, preferentially inhibits infection of X4 HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN GP120; AMINO-TERMINAL DOMAIN; V3 LOOP; NEUTRALIZING ANTIBODIES; CELL TROPISM; TYPE-1 ENTRY; ENV GENE; CORECEPTOR; CCR5	Several G protein-coupled receptors (GPCRs) serve as co-receptors for entry of human immunodeficiency virus type 1 (HIV-1) into target cells. Here we report that a synthetic peptide derived from the NH2-terminal extracellular region of an orphan GPCR, GPR1 (GPR1ntP-(1-27); MEDLEETLFEEFENYSYDLDYYSLESC), inhibited infection of not only an HIV-1 variant that uses GPR1 as a co-receptor, but also X4, R5, and R5X4 viruses. Among these HIV-1 strains tested, viruses that can utilize CXCR4 as their co-receptors were preferentially inhibited. Inhibition of early steps in X4 virus replication was also detected in the primary human peripheral blood lymphocytes. GPR1ntP-(1-27) directly interacted with recombinant X4 envelope glycoprotein (rgp120). This interaction was neither inhibited nor enhanced by the soluble CD4 (sCD4) but inhibited by the anti-third variable (V3) loop-specific monoclonal antibody and heparin known to bind to the V3 loop. Although the conformational changes in gp120, including the V3 loop, have been reported to be required for its interaction with a co-receptor after binding of gp120 to CD4, it has also been reported that the V3 loop is already exposed on the surface of virions before interaction with CD4. We found that GPR1ntP-(1-27) blocked binding of virus to the cells, and this peptide equally bound to rgp120 in the presence or absence of sCD4. Because we detected the binding of GPR1ntP-(1-27) to the highly purified virions even in the absence of sCD4, GPR1ntP-(1-27) probably recognized the V3 loop exposed on the virions, and this interaction was responsible for the anti-HIV-1 activity of GPR1ntP-(1-27).	Gunma Univ, Grad Sch Med, Dept Virol & Prevent Med, Maebashi, Gumma 3718511, Japan; Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan	Gunma University; University of Shizuoka	Hoshino, H (corresponding author), Gunma Univ, Grad Sch Med, Dept Virol & Prevent Med, Maebashi, Gumma 3718511, Japan.	hoshino@med.gunma-u.ac.jp		Yasuo, Suzuki/0000-0003-3518-5642				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BATINIC D, 1992, J BIOL CHEM, V267, P6664; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Cecilia D, 1998, J VIROL, V72, P6988, DOI 10.1128/JVI.72.9.6988-6996.1998; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Dragic T, 2001, J GEN VIROL, V82, P1807, DOI 10.1099/0022-1317-82-8-1807; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRUMKIN LR, 1995, J GEN VIROL, V76, P2467, DOI 10.1099/0022-1317-76-10-2467; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Genoud S, 1999, J VIROL, V73, P1645, DOI 10.1128/JVI.73.2.1645-1648.1999; Gorny MK, 2004, J VIROL, V78, P2394, DOI 10.1128/JVI.78.5.2394-2404.2004; Harrop HA, 1998, GLYCOBIOLOGY, V8, P131, DOI 10.1093/glycob/8.2.131; HART TK, 1993, J HISTOCHEM CYTOCHEM, V41, P265, DOI 10.1177/41.2.7678271; Hunter E., 1997, P71; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; Ikeda K, 2001, BIOORG MED CHEM LETT, V11, P2607, DOI 10.1016/S0960-894X(01)00503-0; Jacobson JM, 2000, J INFECT DIS, V182, P326, DOI 10.1086/315698; Jinno A, 1998, BIOCHEM BIOPH RES CO, V243, P497, DOI 10.1006/bbrc.1998.8130; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kozak SL, 1997, J VIROL, V71, P873, DOI 10.1128/JVI.71.2.873-882.1997; LaBranche CC, 2001, ANTIVIR RES, V50, P95, DOI 10.1016/S0166-3542(01)00130-9; LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E; Liu HY, 2000, VIROLOGY, V278, P276, DOI 10.1006/viro.2000.0623; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MCKEATING J, 1995, PRACTICAL APPROACH S, V1, P117; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; NAGUMO T, 1988, JPN J CANCER RES, V79, P9, DOI 10.1111/j.1349-7006.1988.tb00003.x; Nyambi PN, 1998, J VIROL, V72, P9384, DOI 10.1128/JVI.72.11.9384-9391.1998; ORAVECZ T, 1993, LEUKOCYTE TYPING, V5, P476; PINCUS SH, 1991, BIOTECHNIQUES, V10, P336; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; QUIROS E, 1995, J MED MICROBIOL, V42, P411, DOI 10.1099/00222615-42-6-411; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; RIDER CC, 1994, BIOCHEMISTRY-US, V33, P6974, DOI 10.1021/bi00188a029; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SCHNEIDER J, 1986, J GEN VIROL, V67, P2533, DOI 10.1099/0022-1317-67-11-2533; Shimizu N, 2000, J VIROL, V74, P619, DOI 10.1128/JVI.74.2.619-626.2000; Shimizu N, 1999, J VIROL, V73, P5231, DOI 10.1128/JVI.73.6.5231-5239.1999; SHIMIZU N, 1995, FEBS LETT, V358, P48, DOI 10.1016/0014-5793(94)01394-G; SHIMIZU NS, 1994, J VIROL, V68, P6130, DOI 10.1128/JVI.68.9.6130-6135.1994; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; Soda Y, 1999, BIOCHEM BIOPH RES CO, V258, P313, DOI 10.1006/bbrc.1999.0633; SRIVASTAVA BIS, 1983, LEUKEMIA RES, V7, P331; TAKEUCHI Y, 1987, JPN J CANCER RES, V78, P11; TAKEUCHI Y, 1991, J VIROL, V65, P1710, DOI 10.1128/JVI.65.4.1710-1718.1991; Valenzuela A, 1997, J VIROL, V71, P8289, DOI 10.1128/JVI.71.11.8289-8298.1997; VANOPSTAL O, 1995, PRACTICAL APPROACH S, V2, P105	65	9	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30924	30934		10.1074/jbc.M500195200	http://dx.doi.org/10.1074/jbc.M500195200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15919664	hybrid			2022-12-25	WOS:000231487800034
J	Keller, U; Nilsson, JA; Maclean, KH; Old, JB; Cleveland, JL				Keller, U; Nilsson, JA; Maclean, KH; Old, JB; Cleveland, JL			Nfkb1 is dispensable for Myc-induced lymphomagenesis	ONCOGENE			English	Article						NF-kappa B1; c-Myc; lymphomagenesis	NF-KAPPA-B; C-MYC; CELL-CYCLE; MEDIATED APOPTOSIS; INDUCTION; TRANSCRIPTION; SUPPRESSOR; GENE; REL; PROLIFERATION	Rel/NF-kappa B transcription factors are critical arbiters of immune responses, cell survival, and transformation, and are frequently deregulated in cancer. The p50 NF-kappa B1 component of Rel/NF-kappa B DNA-binding dimers regulates genes involved in both cell cycle traverse and apoptosis. Nfkb1 loss accelerates B cell growth and leads to increased B cell turnover in vivo, phenotypes akin to those manifested in B cells of E mu-Myc transgenic mice, a model of human Burkitt lymphoma. Interestingly, E mu-Myc B cells express reduced levels of cytoplasmic and nuclear NF-kappa B1 and have reduced Rel/NF-kappa B DNA-binding activity, suggesting that Myc-mediated repression of NF-kappa B1 might mediate its proliferative and apoptotic effects on B cells. Furthermore, Nfkb1 expression was reduced in the majority of E mu-Myc lymphomas and was also suppressed in human Burkitt lymphoma. Nonetheless, loss of Nfkb1 did not appreciably affect Myc's proliferative or apoptotic responses in B cells and had no effect on lymphoma development in E mu-Myc mice. Therefore, Nfkb1 is dispensable for Myc-induced lymphomagenesis.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Cleveland, JL (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale, Memphis, TN 38105 USA.	john.cleveland@stjude.org	Nilsson, Jonas/E-5346-2013	Nilsson, Jonas/0000-0003-0346-6837	NATIONAL CANCER INSTITUTE [F32CA099478, P30CA021765, R01CA076379] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA76379, F32 CA099478] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; ASKEW DS, 1991, ONCOGENE, V6, P1915; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kanda K, 2000, J BIOL CHEM, V275, P32338, DOI 10.1074/jbc.M004148200; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200; Zelazowski P, 1997, J IMMUNOL, V159, P3133; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	47	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6231	6240		10.1038/sj.onc.1208779	http://dx.doi.org/10.1038/sj.onc.1208779			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940251				2022-12-25	WOS:000231877100004
J	Kondo, H; Nifuji, A; Takeda, S; Ezura, Y; Rittling, SR; Denhardt, DT; Nakashima, K; Karsenty, G; Noda, M				Kondo, H; Nifuji, A; Takeda, S; Ezura, Y; Rittling, SR; Denhardt, DT; Nakashima, K; Karsenty, G; Noda, M			Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOPOROSIS; RESPONSES; THERAPY	Osteoporosis is one of the major health problems in our modern world. Especially, disuse ( unloading) osteoporosis occurs commonly in bedridden patients, a population that is rapidly increasing due to aging-associated diseases. However, the mechanisms underlying such unloading-induced pathological bone loss have not yet been fully understood. Since sympathetic nervous system could control bone mass, we examined whether unloading-induced bone loss is controlled by sympathetic nervous tone. Treatment with beta-blocker, propranolol, suppressed the unloading-induced reduction in bone mass. Conversely, beta-agonist, isoproterenol, reduced bone mass in loaded mice, and under such conditions, unloading no longer further reduced bone mass. Analyses on the cellular bases indicated that unloadinginduced reduction in the levels of osteoblastic cell activities, including mineral apposition rate, mineralizing surface, and bone formation rate, was suppressed by propranolol treatment and that isoproterenol-induced reduction in these levels of bone formation parameters was no longer suppressed by unloading. Unloading- induced reduction in the levels of mineralized nodule formation in bone marrow cell cultures was suppressed by propranolol treatment in vivo. In addition, loss of a half-dosage in the dopamine beta-hydroxylase gene suppressed the unloading-induced bone loss and reduction in mineralized nodule formation. Unloading-induced increase in the levels of osteoclastic activities such as osteoclast number and surface as well as urinary deoxypyridinoline was all suppressed by the treatment with propranolol. These observations indicated that sympathetic nervous tone mediates unloading-induced bone loss through suppression of bone formation by osteoblasts and enhancement of resorption by osteoclasts.	Tokyo Med & Dent Univ, Dept Mol Pharmacol, Inst Med Res, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, 21st Century Ctr Excellence Program Frontier Res, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, ABJS Integrated Act Initiat JSPS Core Core Progra, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1010062, Japan; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Rutgers State Univ, Piscataway, NJ 08854 USA	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Baylor College of Medicine; Rutgers State University New Brunswick	Noda, M (corresponding author), Tokyo Med & Dent Univ, Dept Mol Pharmacol, Inst Med Res, Chiyoda Ku, 3-10 Kanda Surugadai,2 Chome, Tokyo 1010062, Japan.	noda.mph@mri.tmd.ac.jp	Ezura, Yoichi/L-9485-2016; takeda, shu/B-5195-2012; Nifuji, Akira/AAX-7907-2021	Nifuji, Akira/0000-0002-8182-4380; Nakashima, Kazuhisa/0000-0003-0491-2149				Augat P, 2005, OSTEOPOROSIS INT, V16, pS36, DOI 10.1007/s00198-004-1728-9; Bikle Daniel D, 2003, Gravit Space Biol Bull, V16, P45; BIKLE DD, 1991, J BONE MINER RES, V6, P527; Commins SP, 2000, J BIOL CHEM, V275, P33059, DOI 10.1074/jbc.M006328200; Cox JF, 2002, J PHYSIOL-LONDON, V538, P309, DOI 10.1113/jphysiol.2001.012574; Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095; Fu Q, 2002, J PHYSIOL-LONDON, V544, P653, DOI 10.1113/jphysiol.2002.025098; Fuller KE, 2004, NEW ENGL J MED, V350, P190; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Ishijima M, 2002, J BONE MINER RES, V17, P661, DOI 10.1359/jbmr.2002.17.4.661; Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399; Lanyon L, 2001, J BONE MINER RES, V16, P1937, DOI 10.1359/jbmr.2001.16.11.1937; Mohamed AM, 2003, NEW ENGL J MED, V349, P1671; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Raisz LG, 2003, ENDOCRIN METAB CLIN, V32, P15, DOI 10.1016/S0889-8529(02)00055-5; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Riggs BL, 2003, J CELL BIOCHEM, V88, P209, DOI 10.1002/jcb.10345; Serhan CN, 2004, NEW ENGL J MED, V350, P1902, DOI 10.1056/NEJMcibr040318; Sherman BE, 2000, J BONE MINER RES, V15, P1354, DOI 10.1359/jbmr.2000.15.7.1354; Strewler GJ, 2004, NEW ENGL J MED, V350, P1172, DOI 10.1056/NEJMp048017; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0	22	145	157	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30192	30200		10.1074/jbc.M504179200	http://dx.doi.org/10.1074/jbc.M504179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15961387	hybrid			2022-12-25	WOS:000231362500027
J	Ikeda, Y; Aihara, K; Sato, T; Akaike, M; Yoshizumi, M; Suzaki, Y; Izawa, Y; Fujimura, M; Hashizume, S; Kato, M; Yagi, S; Tamaki, T; Kawano, H; Matsumoto, T; Azuma, H; Kato, S; Matsumoto, T				Ikeda, Y; Aihara, K; Sato, T; Akaike, M; Yoshizumi, M; Suzaki, Y; Izawa, Y; Fujimura, M; Hashizume, S; Kato, M; Yagi, S; Tamaki, T; Kawano, H; Matsumoto, T; Azuma, H; Kato, S; Matsumoto, T			Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC HEART-FAILURE; CONVERTING ENZYME-INHIBITION; LEFT-VENTRICULAR HYPERTROPHY; RAT VENTRAL PROSTATE; FACTOR-BETA FAMILY; PRESSURE-OVERLOAD; HYPERTENSIVE-RATS; NUCLEAR RECEPTORS; SEX-HORMONES; EXPRESSION	Androgen has anabolic effects on cardiac myocytes and has been shown to enhance left ventricular enlargement and function. However, the physiological and patho-physiological roles of androgen in cardiac growth and cardiac stress-induced remodeling remains unclear. We aimed to clarify whether the androgen-nuclear androgen receptor (AR) system contributes to the cardiac growth and angiotensin II (Ang II)-stimulated cardiac remodeling by using systemic AR-null male mice. AR knock-out (ARKO) male mice, at 25 weeks of age, and age-matched wild-type (WT) male mice were treated with or without Ang II stimulation (2.0 mg/kg/day) for 2 weeks. ARKO mice with or without Ang II stimulation showed a significant reduction in the heart-to-body weight ratio compared with those of WT mice. In addition, echocardiographic analysis demonstrated impairments of both the concentric hypertrophic response and left ventricular function in Ang II-stimulated ARKO mice. Western blot analysis of the myocardium revealed that activation of extracellular signal-regulated kinases (ERK) 1/2 and ERK5 by Ang II stimulation were lower in ARKO mice than those of WT mice. Ang II stimulation caused more prominent cardiac fibrosis in ARKO mice than in WT mice with enhanced expression of types I and III collagen and transforming growth factor-beta 1 genes and with increased Smad2 activation. These results suggest that, in male mice, the androgen-AR system participates in normal cardiac growth and modulates cardiac adaptive hypertrophy and fibrosis during the process of cardiac remodeling under hypertrophic stress.	Univ Tokushima, Grad Sch, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan; Univ Tokushima, Grad Sch, Dept Pharmacol, Inst Hlth Biosci, Tokushima 7708503, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan	Tokushima University; Tokushima University; University of Tokyo	Matsumoto, T (corresponding author), Univ Tokushima, Grad Sch, Dept Med & Bioregulatory Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	toshimat@clin.med.tokushima-u.ac.jp	Aihara, Ken-ichi/AEE-8245-2022	Aihara, Ken-ichi/0000-0001-8906-0920; Ikeda, Yasumasa/0000-0003-4318-7349				Aihara K, 2004, J BIOL CHEM, V279, P35798, DOI 10.1074/jbc.M404865200; Aihara K, 2004, CIRCULATION, V109, P2761, DOI 10.1161/01.CIR.0000129968.46095.F3; Anker SD, 1997, CIRCULATION, V96, P526; AURIGEMMA GP, 1995, J AM COLL CARDIOL, V26, P195, DOI 10.1016/0735-1097(95)00153-Q; Baltatu O, 2002, J AM SOC NEPHROL, V13, P2681, DOI 10.1097/01.ASN.0000033327.65390.CA; Boluyt MO, 1995, EUR HEART J, V16, P19, DOI 10.1093/eurheartj/16.suppl_N.19; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Campbell SE, 1997, J MOL CELL CARDIOL, V29, P1947, DOI 10.1006/jmcc.1997.0435; Cavasin MA, 2003, AM J PHYSIOL-HEART C, V284, pH1560, DOI 10.1152/ajpheart.01087.2002; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Glass CK, 2000, GENE DEV, V14, P121; Golden KL, 2003, AM J PHYSIOL-ENDOC M, V285, pE449, DOI 10.1152/ajpendo.00054.2003; GUPTA M, 1992, AM J PHYSIOL, V262, pR346, DOI 10.1152/ajpregu.1992.262.3.R346; Hao JM, 2000, AM J PHYSIOL-HEART C, V279, pH3020, DOI 10.1152/ajpheart.2000.279.6.H3020; Harris IS, 2004, CIRCULATION, V110, P718, DOI 10.1161/01.CIR.0000138190.50127.6A; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Hayward CS, 2001, LANCET, V357, P1354, DOI 10.1016/S0140-6736(00)04523-2; Hayward CS, 2000, CARDIOVASC RES, V46, P28, DOI 10.1016/S0008-6363(00)00005-5; Ichihara S, 2001, CIRCULATION, V104, P346, DOI 10.1161/01.CIR.104.3.346; Ishibashi M, 2004, CIRC RES, V94, P1203, DOI 10.1161/01.RES.0000126924.23467.A3; Izumiya Y, 2003, CIRC RES, V93, P874, DOI 10.1161/01.RES.0000100665.67510.F5; JALIL JE, 1989, CIRC RES, V64, P1041, DOI 10.1161/01.RES.64.6.1041; Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100; Kiilavuori K, 1999, EUR HEART J, V20, P456, DOI 10.1053/euhj.1998.1277; Kobori H, 2004, HYPERTENSION, V43, P1126, DOI 10.1161/01.HYP.0000122875.91100.28; Kontoleon PE, 2003, INT J CARDIOL, V87, P179, DOI 10.1016/S0167-5273(02)00212-7; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Leinwand LA, 2003, J CLIN INVEST, V112, P302, DOI 10.1172/JCI200319429; Li YH, 2004, ENDOCRINOLOGY, V145, P951, DOI 10.1210/en.2003-0816; MALHOTRA A, 1990, AM J PHYSIOL, V259, pH866, DOI 10.1152/ajpheart.1990.259.3.H866; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marsh JD, 1998, CIRCULATION, V98, P256, DOI 10.1161/01.CIR.98.3.256; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; MORANO I, 1990, CIRC RES, V66, P1585, DOI 10.1161/01.RES.66.6.1585; Moriyama Y, 2000, J CLIN ENDOCR METAB, V85, P1834, DOI 10.1210/jc.85.5.1834; Muller DN, 2002, HYPERTENSION, V40, P840, DOI 10.1161/01.HYP.0000039748.88581.A0; Nakaoka Y, 2003, CIRC RES, V93, P221, DOI 10.1161/01.RES.0000085562.48906.4A; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Nishiyama A, 2004, HYPERTENSION, V43, P841, DOI 10.1161/01.HYP.0000118519.66430.22; Pugh PJ, 2003, EUR HEART J, V24, P909, DOI 10.1016/S0195-668X(03)00083-6; Ryoke T, 1999, CIRCULATION, V100, P1734, DOI 10.1161/01.CIR.100.16.1734; Sato T, 2004, P NATL ACAD SCI USA, V101, P1673, DOI 10.1073/pnas.0305303101; Sato T, 2003, BIOCHEM BIOPH RES CO, V300, P167, DOI 10.1016/S0006-291X(02)02774-2; Suzaki Y, 2004, KIDNEY INT, V65, P1749, DOI 10.1111/j.1523-1755.2004.00576.x; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Weber KT, 1997, SEMIN NEPHROL, V17, P467; Weinberg EO, 1999, J AM COLL CARDIOL, V34, P264, DOI 10.1016/S0735-1097(99)00165-5; Wilson JD, 1999, ENDOCR REV, V20, P726, DOI 10.1210/er.20.5.726; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; YANO M, 1998, CIRC RES, V83, P752	55	109	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29661	29666		10.1074/jbc.M411694200	http://dx.doi.org/10.1074/jbc.M411694200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15961403	hybrid			2022-12-25	WOS:000231176200035
J	Arnold, JN; Wormald, MR; Suter, DM; Radcliffe, CM; Harvey, DJ; Dwek, RA; Rudd, PM; Sim, RB				Arnold, JN; Wormald, MR; Suter, DM; Radcliffe, CM; Harvey, DJ; Dwek, RA; Rudd, PM; Sim, RB			Human serum IgM glycosylation - Identification of glycoforms that can bind to mannan-binding lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH MANNOSE OLIGOSACCHARIDES; C1S-LIKE SERINE-PROTEASE; MOUSE IMMUNOGLOBULIN-M; J-CHAIN; COMPLEMENT ACTIVATION; STATISTICAL-ANALYSIS; N-GLYCOSYLATION; MYELOMA PROTEIN; PATHWAY; GLYCANS	The glycoprotein IgM is the major antibody produced in the primary immune response to antigens, circulating in the serum both as a pentamer and a hexamer. Pentameric IgM has a single J chain, which is absent in the hexamer. The mu ( heavy) chain of IgM has five N-linked glycosylation sites. Asn-171, Asn-332, and Asn-395 are occupied by complex glycans, whereas Asn-402 and Asn-563 are occupied by oligomannose glycans. The glycosylation of human polyclonal IgM from serum has been analyzed. IgM was found to contain 23.4% oligomannose glycans GlcNAc(2)Man(5-9), consistent with 100% occupancy of Asn-402 and 17% occupancy of the variably occupied site at Asn-563. Mannan-binding lectin (MBL) is a member of the collectin family of proteins, which bind to oligomannose and GlcNAc-terminating structures. A commercial affinity chromatography resin containing immobilized MBL has been reported to be useful for partial purification of mouse and also human IgM. Human IgM glycoforms that bind to immobilized MBL were isolated; these accounted for only 20% of total serum IgM. Compared with total serum IgM, the MBL-binding glycoforms contained 97% more GlcNAc-terminating structures and 8% more oligomannose structures. A glycosylated model of pentameric IgM was constructed, and from this model, it became evident that IgM has two distinct faces, only one of which can bind to antigen, as the J chain projects from the non-antigen-binding face. Antigen-bound IgM does not bind to MBL, as the target glycans appear to become inaccessible once IgM has bound antigen. Antigen-bound IgM pentamers therefore do not activate complement via the lectin pathway, but MBL might have a role in the clearance of aggregated IgM.	Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Oxford Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Sim, RB (corresponding author), Univ Oxford, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	bob.sim@bioch.ox.ac.uk	Sim, Bob/A-1354-2008; Arnold, James/ABE-3900-2021; Harvey, David/A-5579-2013; Wormald, Mark R/G-2785-2011; Suter, David/S-9210-2019	Sim, Bob/0000-0002-2855-7455; Arnold, James/0000-0002-6949-0613; Wormald, Mark R/0000-0002-4853-2773; Suter, David/0000-0001-5644-4899; Harvey, David/0000-0003-0544-771X				ANDERSON DR, 1983, BIOCHEM BIOPH RES CO, V116, P771, DOI 10.1016/0006-291X(83)90591-0; Arnold JN, 2004, J IMMUNOL, V173, P6831, DOI 10.4049/jimmunol.173.11.6831; BAKER MD, 1986, J IMMUNOL, V137, P1724; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; BRANDTZAEG P, 1984, NATURE, V311, P71, DOI 10.1038/311071a0; Butler M, 2003, GLYCOBIOLOGY, V13, P601, DOI 10.1093/glycob/cwg079; CHAPMAN A, 1979, J BIOL CHEM, V254, P816; CHAPMAN A, 1979, J BIOL CHEM, V254, P824; CHAPUIS RM, 1974, P NATL ACAD SCI USA, V71, P657, DOI 10.1073/pnas.71.3.657; Collins C, 2002, EUR J IMMUNOL, V32, P1802, DOI 10.1002/1521-4141(200206)32:6<1802::AID-IMMU1802>3.0.CO;2-C; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; FRUTIGER S, 1992, BIOCHEMISTRY-US, V31, P12643, DOI 10.1021/bi00165a014; Fukuta K, 2000, ARCH BIOCHEM BIOPHYS, V378, P142, DOI 10.1006/abbi.2000.1806; GOTTSCHALK A, 1957, BIOCHIM BIOPHYS ACTA, V23, P645, DOI 10.1016/0006-3002(57)90389-X; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; Hajela K, 2002, IMMUNOBIOLOGY, V205, P467, DOI 10.1078/0171-2985-00147; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; IOBST ST, 1994, J BIOL CHEM, V269, P15512; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC; Koppel R, 2001, J BIOCHEM BIOPH METH, V49, P641, DOI 10.1016/S0165-022X(01)00225-1; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Leibiger H, 1998, GLYCOBIOLOGY, V8, P497, DOI 10.1093/glycob/8.5.497; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; MESTECKY J, 1974, NATURE, V249, P650, DOI 10.1038/249650a0; MONICA TJ, 1995, GLYCOBIOLOGY, V5, P175, DOI 10.1093/glycob/5.2.175; NEVENS JR, 1992, J CHROMATOGR, V597, P247, DOI 10.1016/0021-9673(92)80117-D; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; PERKINS SJ, 1991, J MOL BIOL, V221, P1345; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; Petrescu AJ, 1999, GLYCOBIOLOGY, V9, P343, DOI 10.1093/glycob/9.4.343; Radcliffe CM, 2002, J BIOL CHEM, V277, P46415, DOI 10.1074/jbc.M202466200; RANDALL TD, 1992, J BIOL CHEM, V267, P18002; RANDALL TD, 1990, EUR J IMMUNOL, V20, P1971, DOI 10.1002/eji.1830200915; Roos A, 2003, MOL IMMUNOL, V39, P655, DOI 10.1016/S0161-5890(02)00254-7; Roos A, 2001, J IMMUNOL, V167, P2861, DOI 10.4049/jimmunol.167.5.2861; Royle L, 2002, ANAL BIOCHEM, V304, P70, DOI 10.1006/abio.2002.5619; Royle L, 2003, J BIOL CHEM, V278, P20140, DOI 10.1074/jbc.M301436200; SIM RB, 1993, METHOD ENZYMOL, V223, P13; SITIA R, 1984, MOL IMMUNOL, V21, P709, DOI 10.1016/0161-5890(84)90023-3; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIERSMA EJ, 1995, J IMMUNOL, V154, P5265; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; Wormald MR, 2002, CHEM REV, V102, P371, DOI 10.1021/cr990368i; Wu WX, 2004, VIROLOGY, V325, P340, DOI 10.1016/j.virol.2004.05.013; Zamze S, 1998, EUR J BIOCHEM, V258, P243, DOI 10.1046/j.1432-1327.1998.2580243.x	58	172	185	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29080	29087		10.1074/jbc.M504528200	http://dx.doi.org/10.1074/jbc.M504528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15955802	hybrid, Green Published			2022-12-25	WOS:000231021300034
J	Strissel, KJ; Lishko, PV; Trieu, LH; Kennedy, MJ; Hurley, JB; Arshavsky, VY				Strissel, KJ; Lishko, PV; Trieu, LH; Kennedy, MJ; Hurley, JB; Arshavsky, VY			Recoverin undergoes light-dependent intracellular translocation in rod photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING PROTEINS; GUANYLATE-CYCLASE; MOUSE RETINA; RHODOPSIN PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ELECTRON-MICROSCOPY; MAMMALIAN RETINAS; MYRISTOYL SWITCH; RAT RETINA; ADAPTATION	Photoreceptor cells have a remarkable capacity to adapt the sensitivity and speed of their responses to ever changing conditions of ambient illumination. Recent studies have revealed that a major contributor to this adaptation is the phenomenon of light-driven translocation of key signaling proteins into and out of the photoreceptor outer segment, the cellular compartment where phototransduction takes place. So far, only two such proteins, transducin and arrestin, have been established to be involved in this mechanism. To investigate the extent of this phenomenon we examined additional photoreceptor proteins that might undergo light-driven translocation, focusing on three Ca2+-binding proteins, recoverin and guanylate cyclase activating proteins 1 (GCAP1) and GCAP2. The changes in the subcellular distribution of each protein were assessed quantitatively using a recently developed technique combining serial tangential sectioning of mouse retinas with Western blot analysis of the proteins in the individual sections. Our major finding is that light causes a significant reduction of recoverin in rod outer segments, accompanied by its redistribution toward rod synaptic terminals. In both cases the majority of recoverin was found in rod inner segments, with similar to 12% present in the outer segments in the dark and less than 2% remaining in that compartment in the light. We suggest that recoverin translocation is adaptive because it may reduce the inhibitory constraint that recoverin imposes on rhodopsin kinase, an enzyme responsible for quenching the photoexcited rhodopsin during the photoresponse. To the contrary, no translocation of rhodopsin kinase itself or either GCAP was identified.	Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary; University of Washington; University of Washington Seattle	Arshavsky, VY (corresponding author), Duke Univ, Med Ctr, Dept Ophthalmol, 5008 AERI,Erwin Rd, Durham, NC 27710 USA.	vadim.arshavsky@duke.edu	Lishko, Polina/GQH-9569-2022; Lishko, Polina/L-1191-2017		NATIONAL EYE INSTITUTE [P30EY014104, R01EY010336, R01EY006641] Funding Source: NIH RePORTER; NEI NIH HHS [EY14104, EY10336, EY06641, R01 EY006641] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1996, CURR OPIN STRUC BIOL, V6, P432, DOI 10.1016/S0959-440X(96)80106-0; Arshavsky VY, 2002, TRENDS NEUROSCI, V25, P124, DOI 10.1016/S0166-2236(00)02094-4; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; ARSHAVSKY VY, 2003, SCI STKE, pE43; Bahner M, 2002, NEURON, V34, P83, DOI 10.1016/S0896-6273(02)00630-X; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BRANN MR, 1987, SCIENCE, V235, P585, DOI 10.1126/science.3101175; BROEKHUYSE RM, 1985, CURR EYE RES, V4, P613, DOI 10.3109/02713688508999993; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Burns ME, 2002, NEURON, V36, P81, DOI 10.1016/S0896-6273(02)00911-X; Calvert PD, 1998, J GEN PHYSIOL, V111, P39, DOI 10.1085/jgp.111.1.39; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Cuenca N, 1998, INVEST OPHTH VIS SCI, V39, P1243; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Dizhoor AM, 2000, CELL SIGNAL, V12, P711, DOI 10.1016/S0898-6568(00)00134-0; Erickson MA, 1998, P NATL ACAD SCI USA, V95, P6474, DOI 10.1073/pnas.95.11.6474; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; Hardie RC, 2003, CURR BIOL, V13, pR775, DOI 10.1016/j.cub.2003.09.021; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; Howes KA, 2002, EMBO J, V21, P1545, DOI 10.1093/emboj/21.7.1545; Kachi S, 1999, EXP EYE RES, V68, P465, DOI 10.1006/exer.1998.0629; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; Lee SJ, 2003, NEURON, V39, P121, DOI 10.1016/S0896-6273(03)00390-8; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Makino CL, 2004, J GEN PHYSIOL, V123, P729, DOI 10.1085/jgp.200308994; MCCARTHY ST, 1994, BIOPHYS J, V67, P2076, DOI 10.1016/S0006-3495(94)80691-5; McGinnis JF, 1997, J NEUROSCI RES, V50, P487, DOI 10.1002/(SICI)1097-4547(19971101)50:3<487::AID-JNR15>3.0.CO;2-3; Mendez A, 2001, P NATL ACAD SCI USA, V98, P9948, DOI 10.1073/pnas.171308998; MILAM AH, 1993, VISUAL NEUROSCI, V10, P1, DOI 10.1017/S0952523800003175; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; Otto-Bruce AE, 1998, P NATL ACAD SCI USA, V95, P15014, DOI 10.1073/pnas.95.25.15014; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; Rodieck R.W., 1998, 1 STEPS SEEING; ROOF DJ, 1988, SCIENCE, V241, P845, DOI 10.1126/science.3136548; Sampath AP, 2005, NEURON, V46, P413, DOI 10.1016/j.neuron.2005.04.006; Sokolov M, 2004, J BIOL CHEM, V279, P19149, DOI 10.1074/jbc.M311058200; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Strissel KJ, 2004, NEURON, V43, P2, DOI 10.1016/j.neuron.2004.06.026; STRISSEL KJ, 2004, RECENT ADV HUMAN BIO, P163; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	56	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29250	29255		10.1074/jbc.M501789200	http://dx.doi.org/10.1074/jbc.M501789200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15961391	hybrid			2022-12-25	WOS:000231021300054
J	Gu, LP; Esselman, WJ; Henry, RW				Gu, LP; Esselman, WJ; Henry, RW			Cooperation between small nuclear RNA-activating protein complex (SNAP(C)) and TATA-box-binding protein antagonizes protein kinase CK2 inhibition of DNA binding by SNAP(C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTION; PROXIMAL SEQUENCE ELEMENT; SNRNA GENE-TRANSCRIPTION; C-TERMINAL DOMAIN; OCT-1 POU DOMAIN; U2 SNRNA; HUMAN-CELLS; PROMOTER; SUBUNIT; TBP	Protein kinase CK2 regulates RNA polymerase III transcription of human U6 small nuclear RNA ( snRNA) genes both negatively and positively depending upon whether the general transcription machinery or RNA polymerase III is preferentially phosphorylated. Human U1 snRNA genes share similar promoter architectures as that of U6 genes but are transcribed by RNA polymerase II. Herein, we report that CK2 inhibits U1 snRNA gene transcription by RNA polymerase II. Decreased levels of endogenous CK2 correlates with increased U1 expression, whereas CK2 associates with U1 gene promoters, indicating that it plays a direct role in U1 gene regulation. CK2 phosphorylates the general transcription factor small nuclear RNA-activating protein complex (SNAP(C)) that is required for both RNA polymerase II and III transcription, and SNAP(C) phosphorylation inhibits binding to snRNA gene promoters. However, restricted promoter access by phosphorylated SNAP(C) can be overcome by cooperative interactions with TATA-box-binding protein at a U6 promoter but not at a U1 promoter. Thus, CK2 may have the capacity to differentially regulate U1 and U6 transcription even though SNAP(C) is universally utilized for human snRNA gene transcription.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Henry, RW (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	henryrw@msu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059805] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59805] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; Bai L, 1996, MOL CELL BIOL, V16, P5419; Cabart P, 2002, J BIOL CHEM, V277, P26831, DOI 10.1074/jbc.M203119200; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; Cabrejos ME, 2004, J CELL BIOCHEM, V93, P2, DOI 10.1002/jcb.20209; Fairley JA, 2003, EMBO J, V22, P5841, DOI 10.1093/emboj/cdg544; Ford E, 1998, GENE DEV, V12, P3528, DOI 10.1101/gad.12.22.3528; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Henry RW, 1996, EMBO J, V15, P7129, DOI 10.1002/j.1460-2075.1996.tb01104.x; Henry RW, 1998, GENE DEV, V12, P2664, DOI 10.1101/gad.12.17.2664; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; Hinkley CS, 2003, J BIOL CHEM, V278, P18649, DOI 10.1074/jbc.M204247200; Hirsch HA, 2004, MOL CELL BIOL, V24, P5989, DOI 10.1128/MCB.24.13.5989-5999.2004; Hockman DJ, 1996, MOL CELL BIOL, V16, P892; Hovde S, 2002, GENE DEV, V16, P2772, DOI 10.1101/gad.1021002; Hu P, 2004, MOL CELL, V16, P81, DOI 10.1016/j.molcel.2004.09.008; Hu P, 2003, MOL CELL, V12, P699, DOI 10.1016/j.molcel.2003.08.011; Jacobs EY, 2004, MOL CELL BIOL, V24, P846, DOI 10.1128/MCB.24.2.846-855.2004; Johnston IM, 2002, MOL CELL BIOL, V22, P3757, DOI 10.1128/MCB.22.11.3757-3768.2002; Kuhlman TC, 1999, MOL CELL BIOL, V19, P2130; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Ma B, 2001, J BIOL CHEM, V276, P5027, DOI 10.1074/jbc.M009301200; Ma BC, 2002, MOL CELL BIOL, V22, P8067, DOI 10.1128/MCB.22.22.8067-8078.2002; Medlin JE, 2003, EMBO J, V22, P925, DOI 10.1093/emboj/cdg077; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Myers JW, 2003, NAT BIOTECHNOL, V21, P324, DOI 10.1038/nbt792; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Sadowski CL, 1996, P NATL ACAD SCI USA, V93, P4289, DOI 10.1073/pnas.93.9.4289; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Yoon JB, 1996, MOL CELL BIOL, V16, P1; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; Zhao XM, 2003, MOL CELL, V11, P151, DOI 10.1016/S1097-2765(02)00797-9	52	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27697	27704		10.1074/jbc.M503206200	http://dx.doi.org/10.1074/jbc.M503206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15955816	hybrid			2022-12-25	WOS:000230678600028
J	Kim, CA; Sawaya, MR; Cascio, D; Kim, W; Bowie, JU				Kim, CA; Sawaya, MR; Cascio, D; Kim, W; Bowie, JU			Structural organization of a sex-comb-on-midleg/polyhomeotic copolymer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAM DOMAIN; POLYCOMB; PROTEINS; DROSOPHILA; REPRESSION; TEL; CRYSTALLOGRAPHY; COMPLEX; FAMILY; MEMORY	The polycomb group proteins are required for the stable maintenance of gene repression patterns established during development. They function as part of large multiprotein complexes created via a multitude of protein-protein interaction domains. Here we examine the interaction between the SAM domains of the polycomb group proteins polyhomeotic (Ph) and Sex-comb-on-midleg (Scm). Previously we showed that Ph-SAM polymerizes as a helical structure. We find that Scm-SAM also polymerizes, and a crystal structure reveals an architecture similar to the Ph-SAM polymer. These results suggest that Ph-SAM and Scm-SAM form a copolymer. Binding affinity measurements between Scm-SAM and Ph-SAM subunits in different orientations indicate a preference for the formation of a single junction copolymer. To provide a model of the copolymer, we determined the structure of the Ph-SAM/Scm-SAM junction. Similar binding modes are observed in both homo- and hetero-complex formation with minimal change in helix axis direction at the polymer joint. The copolymer model suggests that polymeric Scm complexes could extend beyond the local domains of polymeric Ph complexes on chromatin, possibly playing a role in long range repression.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Ctr Genom & Proteom, Dept Energy, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Bowie, JU (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA.	bowie@mbi.ucla.edu			NCI NIH HHS [R01 CA81000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Green JB, 2003, MOL CELL, V11, P1537, DOI 10.1016/S1097-2765(03)00178-3; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kasten M, 2001, ONCOGENE, V20, P1832, DOI 10.1038/sj.onc.1204295; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peterson AJ, 2004, GENETICS, V167, P1225, DOI 10.1534/genetics.104.027474; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Qiao F, 2004, CELL, V118, P163, DOI 10.1016/j.cell.2004.07.010; Ramachander R, 2002, J BIOL CHEM, V277, P39585, DOI 10.1074/jbc.M207273200; Roseman RR, 2001, GENETICS, V158, P291; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Tillib S, 1999, MOL CELL BIOL, V19, P5189; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhang H, 2004, NAT GENET, V36, P507, DOI 10.1038/ng1336	31	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27769	27775		10.1074/jbc.M503055200	http://dx.doi.org/10.1074/jbc.M503055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15905166	hybrid			2022-12-25	WOS:000230678600036
J	Celie, PHN; Klaassen, RV; van Rossum-Fikkert, SE; van Elk, R; van Nierop, P; Smit, AB; Sixma, TK				Celie, PHN; Klaassen, RV; van Rossum-Fikkert, SE; van Elk, R; van Nierop, P; Smit, AB; Sixma, TK			Crystal structure of acetylcholine-binding protein from Bulinus truncatus reveals the conserved structural scaffold and sites of variation in nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BUNGAROTOXIN; EXTRACELLULAR DOMAIN; AGONIST-BINDING; SUBUNIT; THERMODYNAMICS; COMPLEX; IDENTIFICATION; EXPRESSION; RESIDUES; DYNAMICS	The crystal structure of acetylcholine-binding protein (AChBP) from the mollusk Lymnaea stagnalis is the established model for the ligand binding domains of the ligand-gated ion channel family, which includes nicotinic acetylcholine, 5-hydroxytryptamine (5-HT3), gamma-aminobutyric acid (GABA), types A and C, and glycine receptors. Here we present the crystal structure of a remote homolog, AChBP from Bulinus truncatus, which reveals both the conserved structural scaffold and the sites of variation in this receptor family. These include rigid body movements of loops that are close to the transmembrane interface in the receptors and changes in the intermonomer contacts, which alter the pentamer stability drastically. Structural, pharmacological and mutational analysis of both AChBPs shows how 3 amino acid changes in the binding site contribute to a 5-10-fold difference in affinity for nicotinic ligands. Comparison of these structures will be valuable for improving structure-function studies of ligand-gated ion channel receptors, including signal transduction, homology modeling, and drug design.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Vrije Univ Amsterdam, Fac Earth & Life Sci, Ctr Neurogenom & Cognit Res, Dept Mol & Cellular Neurobiol, NL-1081 HV Amsterdam, Netherlands	Netherlands Cancer Institute; Vrije Universiteit Amsterdam	Sixma, TK (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	t.sixma@nki.nl	Smit, August B/E-8410-2011; Celie, Patrick/AAY-9559-2021	Sixma, Titia K/0000-0001-6180-0632				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balass M, 1997, P NATL ACAD SCI USA, V94, P6054, DOI 10.1073/pnas.94.12.6054; Banerjee B, 1996, EUR J PHARMACOL, V310, P13, DOI 10.1016/0014-2999(96)00360-3; BANERJEE B, 1995, BIOCHEM PHARMACOL, V49, P1713, DOI 10.1016/0006-2952(95)00076-C; Borea PA, 1998, BIOCHEM PHARMACOL, V55, P1189, DOI 10.1016/S0006-2952(97)00578-9; Borea PA, 2004, CURR TOP MED CHEM, V4, P361, DOI 10.2174/1568026043451410; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Chakrapani S, 2004, J GEN PHYSIOL, V123, P341, DOI 10.1085/jgp.200309004; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Gao F, 2003, J BIOL CHEM, V278, P23020, DOI 10.1074/jbc.M301151200; Goldberg F, 1999, J PHYSIOL-LONDON, V514, P759, DOI 10.1111/j.1469-7793.1999.759ad.x; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Hansen SB, 2004, J BIOL CHEM, V279, P24197, DOI 10.1074/jbc.M402452200; Harel M, 2001, NEURON, V32, P265, DOI 10.1016/S0896-6273(01)00461-5; Henchman RH, 2003, BIOPHYS J, V85, P3007, DOI 10.1016/S0006-3495(03)74720-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Laviolette SR, 2004, NAT REV NEUROSCI, V5, P55, DOI 10.1038/nrn1298; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; Levandoski MM, 1999, J BIOL CHEM, V274, P26113, DOI 10.1074/jbc.274.37.26113; Levin ED, 2002, J NEUROBIOL, V53, P633, DOI 10.1002/neu.10151; Lindstrom JM, 2003, ANN NY ACAD SCI, V998, P41, DOI 10.1196/annals.1254.007; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; Schapira Matthieu, 2002, BMC Structural Biology, V2, P1, DOI 10.1186/1472-6807-2-1; Schrattenholz A, 1998, J BIOL CHEM, V273, P32393, DOI 10.1074/jbc.273.49.32393; SHURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Spijker S, 1999, FASEB J, V13, P735, DOI 10.1096/fasebj.13.6.735; Sullivan D, 2002, MOL PHARMACOL, V61, P463, DOI 10.1124/mol.61.2.463; Tierney ML, 2000, J MOL BIOL, V303, P185, DOI 10.1006/jmbi.2000.4137; Trudell JR, 2002, BBA-BIOMEMBRANES, V1565, P91, DOI 10.1016/S0005-2736(02)00512-6; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Vallee B, 1999, EUR J BIOCHEM, V266, P40, DOI 10.1046/j.1432-1327.1999.00812.x; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; West AP, 1997, J BIOL CHEM, V272, P25468, DOI 10.1074/jbc.272.41.25468; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200	51	165	175	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26457	26466		10.1074/jbc.M414476200	http://dx.doi.org/10.1074/jbc.M414476200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899893	Green Published, hybrid			2022-12-25	WOS:000230386800061
J	Lue, NF				Lue, NF			A physical and functional constituent of telomerase anchor site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; TETRAHYMENA TELOMERASE; CATALYTIC SUBUNIT; TERMINAL DOMAINS; RNA; MOTIFS; IDENTIFICATION; ENZYME; PROCESSIVITY; SEQUENCE	Telomerase is a ribonucleoprotein reverse transcriptase responsible for the maintenance of one strand of the telomere terminal repeats. It consists minimally of a catalytic protein component (TERT) and an RNA subunit that provides the template. Compared with prototypical reverse transcriptases, telomerase is unique in possessing a DNA binding domain (anchor site) that is distinct from the catalytic site. Yeast TERT mutants bearing deletion or point mutations in an N-terminal domain (known as N-GQ) were found to be selectively impaired in extending primers that form short hybrids with telomerase RNA. The mutants also suffered a significant loss of repeat addition processivity but displayed an enhancement in nucleotide addition processivity. Furthermore, the mutants manifested altered primer utilization properties for oligonucleotides containing non-telomeric residues in the 5'-region. Crosslinking studies indicate that the N-GQ domain physically contacts the 5'-region of the DNA substrate in the context of a telomerase-telomere complex. Together, these results implicate the N-GQ domain of TERT as a physical and functional constituent of the telomerase anchor site. Coupled with previous genetic analysis, our data confirm that anchor site interaction is indeed important for telomerase function in vivo.	Cornell Univ, Weill Med Coll, WR Hearst Microbiol Res Ctr, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Lue, NF (corresponding author), Cornell Univ, Weill Med Coll, WR Hearst Microbiol Res Ctr, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10021 USA.	nflue@med.cornell.edu	Lue, Neal/AAO-6759-2020	Lue, Neal/0000-0001-9700-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062631] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062631] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Bachand F, 2001, MOL CELL BIOL, V21, P1888, DOI 10.1128/MCB.21.5.1888-1897.2001; Baran N, 2002, NUCLEIC ACIDS RES, V30, P5570, DOI 10.1093/nar/gkf676; Beattie TL, 2000, MOL BIOL CELL, V11, P3329, DOI 10.1091/mbc.11.10.3329; Bosoy D, 2003, J BIOL CHEM, V278, P3882, DOI 10.1074/jbc.M210645200; Bryan TM, 2000, MOL CELL, V6, P493, DOI 10.1016/S1097-2765(00)00048-4; Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370; Chen JL, 2004, P NATL ACAD SCI USA, V101, P14683, DOI 10.1073/pnas.0406204101; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Collins K, 1999, ANNU REV BIOCHEM, V68, P187, DOI 10.1146/annurev.biochem.68.1.187; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; Forstemann K, 2000, NUCLEIC ACIDS RES, V28, P2690, DOI 10.1093/nar/28.14.2690; Friedman KL, 2003, MOL BIOL CELL, V14, P1, DOI 10.1091/mbc.E02-06-0327; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; Fulton TB, 1998, MOL CELL BIOL, V18, P4961, DOI 10.1128/MCB.18.9.4961; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hammond PW, 1997, MOL CELL BIOL, V17, P296, DOI 10.1128/MCB.17.1.296; Harrington L, 2003, CANCER LETT, V194, P139, DOI 10.1016/S0304-3835(02)00701-2; Hossain S, 2002, J BIOL CHEM, V277, P36174, DOI 10.1074/JBC.m201976200; Huard S, 2003, NUCLEIC ACIDS RES, V31, P4059, DOI 10.1093/nar/gkg437; Karamysheva Z, 2003, CELL, V113, P565, DOI 10.1016/S0092-8674(03)00363-5; Kelleher C, 2002, TRENDS BIOCHEM SCI, V27, P572, DOI 10.1016/S0968-0004(02)02206-5; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; Lin J, 2004, P NATL ACAD SCI USA, V101, P14713, DOI 10.1073/pnas.0405879101; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1487, DOI 10.1093/nar/26.6.1487; Lue NF, 2004, BIOESSAYS, V26, P955, DOI 10.1002/bies.20093; Lue NF, 2003, MOL CELL BIOL, V23, P8440, DOI 10.1128/MCB.23.23.8440-8449.2003; LUE NF, 2002, MOL B INT U, V22, P239; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; MELEK M, 1994, MOL CELL BIOL, V14, P7827, DOI 10.1128/MCB.14.12.7827; Moriarty TJ, 2004, MOL CELL BIOL, V24, P3720, DOI 10.1128/MCB.24.9.3720-3733.2004; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Peng Y, 2001, MOL CELL, V7, P1201, DOI 10.1016/S1097-2765(01)00268-4; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Teixeira MT, 2004, CELL, V117, P323, DOI 10.1016/S0092-8674(04)00334-4; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000	42	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26586	26591		10.1074/jbc.M503028200	http://dx.doi.org/10.1074/jbc.M503028200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15905172	Green Accepted, hybrid			2022-12-25	WOS:000230386800075
J	Devlin, AM; Bottiglieri, T; Domann, FE; Lentz, SR				Devlin, AM; Bottiglieri, T; Domann, FE; Lentz, SR			Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATHIONINE BETA-SYNTHASE; S-ADENOSYLHOMOCYSTEINE; ENDOTHELIAL DYSFUNCTION; IMPRINTED EXPRESSION; DNA HYPOMETHYLATION; HOMOCYSTEINE; ATHEROSCLEROSIS; DEFICIENT; GENE; SUPEROXIDE	Expression of the imprinted genes H19 and insulinlike growth factor 2 ( Igf2), which lie in close proximity on mouse chromosome 7, is regulated by methylation of a differentially methylated domain ( DMD) located 5 ' to H19. Biallelic expression of H19 has been observed in renal disease patients with hyperhomocysteinemia, a cardiovascular disease risk factor. The present study determined whether hyperhomocysteinemia produces decreased tissue methylation capacity, hypomethylation of the H19 DMD, and altered expression of H19 and Igf2 in adult mice. Mice heterozygous for disruption of the gene for cystathionine-beta- synthase ( Cbs +/-) and C57BL/ 6 ( Cbs +/+) mice were fed a hyperhomocysteinemic or control diet, respectively, from weaning until 9 - 12 months of age. Higher plasma total homocysteine ( p < 0.001) was found in hyperhomocysteinemic mice than in control mice ( 95 +/- 12 versus 5.0 +/- 0.3 mu mol/ liter). Hyperhomocysteinemia was accompanied by higher levels of S- adenosylhomocysteine ( p < 0.05) and lower S- adenosylmethionine/ S- adenosylhomocysteine ratios ( p < 0.001) in liver and brain. The effect of hyperhomocysteinemia on H19 DMD methylation was tissuespecific. In liver, hyperhomocysteinemic mice had decreased H19 DMD methylation ( p < 0.001). In brain, hyperhomocysteinemia was accompanied by increased H19 DMD methylation ( p < 0.001) and a decrease in the ratio of H19/ Igf2 transcripts ( p < 0.05). In aorta, hyperhomocysteinemia produced an increase in H19 DMD methylation ( p < 0.001) and a 2.5- fold increase in expression of H19 transcripts ( p < 0.05). Levels of H19 transcripts in aorta correlated positively with plasma total homocysteine concentration ( p < 0.05, r = 0.620). We conclude that hyperhomocysteinemia produces tissuespecific changes in H19 DMD methylation and increased vascular expression of H19 in adult mice.	Univ Iowa, Dept Internal Med, Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Biol, Coll Med, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52246 USA; Baylor Inst Metabol Dis, Dallas, TX 75226 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Lentz, SR (corresponding author), Univ Iowa, Dept Internal Med, Coll Med, C32 GH, Iowa City, IA 52242 USA.	steven-lentz@uiowa.edu		Lentz, Steven/0000-0002-8885-4718; Domann, Frederick/0000-0002-0489-2179; Devlin, Angela/0000-0002-1390-6587	NHLBI NIH HHS [HL63943] Funding Source: Medline; NINDS NIH HHS [NS24621] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024621] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ariel I, 1998, J CLIN PATHOL-MOL PA, V51, P21, DOI 10.1136/mp.51.1.21; Ayesh S, 2002, MOL CARCINOGEN, V35, P63, DOI 10.1002/mc.10075; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BOTTIGLIERI T, 1990, BIOMED CHROMATOGR, V4, P239, DOI 10.1002/bmc.1130040606; Castro R, 2003, CLIN CHEM, V49, P1292, DOI 10.1373/49.8.1292; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Dayal S, 2004, STROKE, V35, P1957, DOI 10.1161/01.STR.0000131749.81508.18; Dayal S, 2001, CIRC RES, V88, P1203, DOI 10.1161/hh1101.092180; Devlin AM, 2004, BLOOD, V103, P2624, DOI 10.1182/blood-2003-09-3078; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Han DKM, 1996, J CLIN INVEST, V97, P1276, DOI 10.1172/JCI118543; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hiltunen M, 2002, VASC MED, V7, P5, DOI 10.1191/1358863x02vm418oa; Ingrosso D, 2003, LANCET, V361, P1693, DOI 10.1016/S0140-6736(03)13372-7; Kaffer CR, 2000, GENE DEV, V14, P1908; KIM DK, 1994, J CLIN INVEST, V93, P355, DOI 10.1172/JCI116967; Laukkanen MO, 1999, ARTERIOSCL THROM VAS, V19, P2171, DOI 10.1161/01.ATV.19.9.2171; Lund G, 2004, J BIOL CHEM, V279, P29147, DOI 10.1074/jbc.M403618200; Martin SC, 1999, BIOMED CHROMATOGR, V13, P81, DOI 10.1002/(SICI)1099-0801(199902)13:1<81::AID-BMC762>3.0.CO;2-U; Mudd SH, 2000, ARTERIOSCL THROM VAS, V20, P1704, DOI 10.1161/01.ATV.20.7.1704; Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Ungvari Z, 2003, ARTERIOSCL THROM VAS, V23, P418, DOI 10.1161/01.ATV.0000061735.85377.40; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Yap S, 2000, SEMIN THROMB HEMOST, V26, P335, DOI 10.1055/s-2000-8100; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; Zaina S, 2002, J BIOL CHEM, V277, P4505, DOI 10.1074/jbc.M108061200	32	70	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25506	25511		10.1074/jbc.M504815200	http://dx.doi.org/10.1074/jbc.M504815200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15899898	hybrid			2022-12-25	WOS:000230207900026
J	Hennig, J; Ottosson, L; Andresen, C; Horvath, L; Kuchroo, VK; Broo, K; Wahren-Herlenius, M; Sunnerhagen, M				Hennig, J; Ottosson, L; Andresen, C; Horvath, L; Kuchroo, VK; Broo, K; Wahren-Herlenius, M; Sunnerhagen, M			Structural organization and Zn2+-dependent subdomain interactions involving autoantigenic epitopes in the Ring-B-box-coiled-coil (RBCC) region of Ro52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; BINDING DOMAIN; RO/SS-A; MASS-SPECTROMETRY; SJOGRENS-SYNDROME; UBIQUITIN LIGASE; METAL-BINDING; FINGER DOMAIN; MUTATIONS	Ro52 is one of the major autoantigens targeted in the autoimmune disease Sjogren syndrome. By sequence similarity, Ro52 belongs to the RING-B-box-coiled-coil (RBCC) protein family. Disease-related antibodies bind Ro52 in a conformation-dependent way both in the coiled-coil region and in the Zn2+-binding Ring-B-box region. Primarily associated with Sjogren syndrome, Ro52 autoantibodies directed to a specific, partially structured epitope in the coiled-coil region may also induce a congenital heart block in the fetus of pregnant Ro52-positive mothers. To improve our understanding of the pathogenic effects of autoantibody binding to the Zn2+-binding region, a multianalytical mapping of its structural, biophysical, and antigenic properties is presented. Structure content and ligand binding of subregions, dissected by peptide synthesis and subcloning, were analyzed by fluorescence and circular dichroism spectroscopy. A novel matrix-assisted laser desorption ionization time-of-flight mass spectrometry strategy for time-resolved proteolysis experiments of large protein domains was developed to facilitate analysis and to help resolve the tertiary arrangement of the entire RBCC subregion. The linker region between the RING and B-box motifs is crucial for full folding, and Zn2+ affinity of the RING-B-box region is further protected in the entire RBCC region and appears to interact with the coiled-coil region. Murine monoclonal antibodies raised toward the RING-B-box region were primarily directed toward the linker, further supporting a highly functional role for the linker in a cellular environment. Taken together with our previous analysis of autoantigenic epitopes in the coiled-coil region, localization of autoantigenic epitopes in Ro52 appears closely related to molecular functionalities.	Linkoping Univ, IFM, S-58183 Linkoping, Sweden; Karolinska Hosp, Dept Med, Rheumatol Unit, S-17176 Stockholm, Sweden; Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Univ Gothenburg, Sahlgrenska Acad, Dept Occupat & Environm Med, S-41266 Gothenburg, Sweden	Linkoping University; Karolinska Institutet; Karolinska University Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Gothenburg	Sunnerhagen, M (corresponding author), Linkoping Univ, IFM, Campus Valla, S-58183 Linkoping, Sweden.	Maria.Sunnerhagen@ifm.liu.se	Wahren-Herlenius, Marie/AAN-6942-2021	Wahren-Herlenius, Marie/0000-0002-0915-7245; Hennig, Janosch/0000-0001-5214-7002				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BORDEN KLB, 1995, EMBO J, V14, P5947, DOI 10.1002/j.1460-2075.1995.tb00283.x; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORDEN KLB, 1993, FEBS LETT, V335, P255, DOI 10.1016/0014-5793(93)80741-C; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; BUYON JP, 1994, J IMMUNOL, V152, P3675; Cao TY, 1998, J CELL SCI, V111, P1319; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Carey J, 2000, METHOD ENZYMOL, V328, P499, DOI 10.1016/S0076-6879(00)28415-2; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; Di Donato F, 2001, INT J BIOCHEM CELL B, V33, P924, DOI 10.1016/S1357-2725(01)00055-3; Frank MB, 1999, BIOCHEM BIOPH RES CO, V259, P665, DOI 10.1006/bbrc.1999.0835; Fukuda-Kamitani T, 2002, BIOCHEM BIOPH RES CO, V295, P774, DOI 10.1016/S0006-291X(02)00750-7; Gaglia JL, 2001, CELL IMMUNOL, V213, P83, DOI 10.1006/cimm.2001.1867; Gaudenz K, 1998, AM J HUM GENET, V63, P703, DOI 10.1086/302010; Gervais V, 2001, J BIOL CHEM, V276, P7457, DOI 10.1074/jbc.M007963200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hanzawa H, 2001, J BIOL CHEM, V276, P10185, DOI 10.1074/jbc.M009298200; Henriksson EW, 1999, P NATL ACAD SCI USA, V96, P14487, DOI 10.1073/pnas.96.25.14487; Henry J, 1997, BIOCHEM BIOPH RES CO, V235, P162, DOI 10.1006/bbrc.1997.6751; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P667, DOI 10.1073/pnas.012317299; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Kriwacki R, 2004, SPECTROSC-INT J, V18, P37, DOI 10.1155/2004/407960; Kriwacki RW, 1997, J CHROMATOGR A, V777, P23, DOI 10.1016/S0021-9673(97)00527-X; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MAO D, 1982, BIOCHEMISTRY-US, V21, P4960, DOI 10.1021/bi00263a020; Ottosson L, 2005, SCAND J IMMUNOL, V61, P109, DOI 10.1111/j.0300-9475.2005.01542.x; OTTOSSON L, 2005, IN PRESS MOL IMMUNOL; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Pourmand N, 1998, J AUTOIMMUN, V11, P11, DOI 10.1006/jaut.1997.0171; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; RICCHIUTI V, 1994, CLIN EXP IMMUNOL, V95, P397; Roehm PC, 1997, BIOCHEMISTRY-US, V36, P10240, DOI 10.1021/bi970863d; Salomonsson S, 2005, J EXP MED, V201, P11, DOI 10.1084/jem.20041859; Salomonsson S, 2004, J AUTOIMMUN, V22, P167, DOI 10.1016/j.jaut.2003.11.004; Salomonsson S, 2002, ARTHRITIS RHEUM-US, V46, P1233, DOI 10.1002/art.10232; Shields SJ, 2003, J AM SOC MASS SPECTR, V14, P460, DOI 10.1016/S1044-0305(03)00129-6; Short KM, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-1; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trauger SA, 2002, SPECTROSC-INT J, V16, P15, DOI 10.1155/2002/320152; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; VEBER DF, 1972, J AM CHEM SOC, V94, P5456, DOI 10.1021/ja00770a600; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Wahren M, 1998, J AUTOIMMUN, V11, P29, DOI 10.1006/jaut.1997.0173; Wahren M, 1996, J AUTOIMMUN, V9, P537, DOI 10.1006/jaut.1996.0072; Wahren-Herlenius M, 1999, IMMUNOL TODAY, V20, P234, DOI 10.1016/S0167-5699(99)01458-9; Wahren-Herlenius M, 2002, NAT BIOTECHNOL, V20, P1205, DOI 10.1038/nbt1202-1205; Wang DR, 2001, BBA-GEN SUBJECTS, V1568, P155, DOI 10.1016/S0304-4165(01)00212-4; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	75	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33250	33261		10.1074/jbc.M503066200	http://dx.doi.org/10.1074/jbc.M503066200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	15964842	hybrid			2022-12-25	WOS:000232058100020
J	Brady, G; Boggan, L; Bowie, A; O'Neill, LAJ				Brady, G; Boggan, L; Bowie, A; O'Neill, LAJ			Schlafen-1 causes a cell cycle arrest by inhibiting induction of cyclin D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RETINOBLASTOMA PROTEIN; PDGF RECEPTOR; TRANSCRIPTIONAL REPRESSION; TYROSINE PHOSPHORYLATION; PHASE-TRANSITION; MESSENGER-RNA; BETA-RECEPTOR; AAA PROTEINS; KINASE	Schlafen- 1 ( Slfn- 1), the prototypic member of the family of proteins, was described as an inducer growth arrest in T- lymphocytes and causes a cell cycle in NIH3T3 fibroblasts prior to the G(1)/ S transition. Slfn- 1 exerts its effects on the cell cycle is not currently known. We report that synchronized murine fibroblasts expressing Slfn- 1 do not exit G(1) when stimulated fetal calf serum, platelet- derived growth factor BB PDGF- BB) or epidermal growth factor ( EGF). The induction of cyclin D1 by these stimuli was blocked in the presence of Slfn- 1 as were all downstream cell cycle processes. of cyclin D1 in growth- arrested, Slfn- 1cells induced an increase in cell growth consistent with this protein being the biological target of 1. Activation of the mitogen- activated protein kinase by EGF or phorbol 12- myristate 13- acetate was by Slfn- 1 expression. PDGF signaling was, almost completely blocked. This was due to a of PDGF receptor expression in Slfn- 1- expressing consistent with Slfn- 1 blocking the cell cycle in G1 PDGF receptor expression is normally down- regulated. Finally, overexpression of Slfn- 1 inhibited the activation of the cyclin D1 promoter. Slfn- 1 therefore causes a cycle arrest during G1 by inhibiting induction of cyclin D1 by mitogens.	Trinity Coll Dublin, Sch Biochem & Immunol, Cytokine Res Lab, Dublin 2, Ireland	Trinity College Dublin	Brady, G (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Cytokine Res Lab, Dublin 2, Ireland.	bradyg1@tcd.ie		O'Neill, Luke/0000-0002-4333-2748; Bowie, Andrew/0000-0001-5316-4373; Brady, Gareth/0000-0001-5376-0060				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BERNARDS R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P33; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; Eskra L, 2003, INFECT IMMUN, V71, P1125, DOI 10.1128/IAI.71.3.1125-1133.2003; FANGER BO, 1986, ARCH BIOCHEM BIOPHYS, V249, P116, DOI 10.1016/0003-9861(86)90566-7; Frickey T, 2004, J STRUCT BIOL, V146, P2, DOI 10.1016/j.jsb.2003.11.020; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Geng Y, 1996, ONCOGENE, V12, P1173; Geserick P, 2004, INT IMMUNOL, V16, P1535, DOI 10.1093/intimm/dxh155; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Izumi H, 2001, J CELL SCI, V114, P1533; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KELLY JD, 1991, J BIOL CHEM, V266, P8987; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; Lammer C, 1998, J CELL SCI, V111, P2445; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; LUKAS J, 1995, ONCOGENE, V10, P2125; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Meddows TR, 2004, MOL MICROBIOL, V52, P119, DOI 10.1111/j.1365-2958.2003.03970.x; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Nakamizo A, 2002, J NEURO-ONCOL, V59, P7, DOI 10.1023/A:1016342013616; NANBERG E, 1993, J BIOL CHEM, V268, P18187; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Schwarz DA, 1998, IMMUNITY, V9, P657, DOI 10.1016/S1074-7613(00)80663-9; SHERR CJ, 1991, SEMIN HEMATOL, V28, P143; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; Vadiveloo PK, 1998, J BIOL CHEM, V273, P23104, DOI 10.1074/jbc.273.36.23104; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; Wang JM, 2004, J STRUCT BIOL, V148, P259, DOI 10.1016/j.jsb.2004.07.003; Winston JT, 1996, ONCOGENE, V12, P127; Yamashita S, 2002, CARCINOGENESIS, V23, P923, DOI 10.1093/carcin/23.6.923; Yan XM, 2003, MOL CELL BIOL, V23, P414, DOI 10.1128/MCB.23.1.414-423.2003	58	60	72	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30723	30734		10.1074/jbc.M500435200	http://dx.doi.org/10.1074/jbc.M500435200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15946944	Green Published, hybrid			2022-12-25	WOS:000231487800011
J	Ishikawa, H; Tsuyama, N; Liu, SQ; Abroun, S; Li, FJ; Otsuyama, I; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM				Ishikawa, H; Tsuyama, N; Liu, SQ; Abroun, S; Li, FJ; Otsuyama, I; Zheng, X; Ma, Z; Maki, Y; Iqbal, MS; Obata, M; Kawano, MM			Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals	ONCOGENE			English	Article						cell proliferation; ERK1/2; FGFR3; IL-6; myeloma; STAT3	MULTIPLE-MYELOMA; CHROMOSOMAL TRANSLOCATION; SERINE PHOSPHORYLATION; STAT3; EXPRESSION; GENE; FAMILY; IL-6; ESTABLISHMENT; TRANSCRIPTION	Interleukin-6 (IL-6) is a cytokine that regulates the proliferation of some tumor cells including multiple myeloma (MM). Ectopic expression of fibroblast growth factor receptor 3 (FGFR3) associated with the chromosomal translocation, t(4;14)(p16.3;q32), is frequently found in MM, and therefore, has been implicated in the neoplastic transformation of this disease. Here, we show that IL-6 together with FGF enhanced proliferation of a myeloma cell line, KMS-11 carrying t(4;14)(p16.3;q32) and the FGFR3-transfected U266 myeloma cell line which ectopically expressed FGFR3 but responded to neither IL-6 nor FGF alone. In KMS-11, IL-6 activated signal transducer and activator of transcription 3 (STAT3) while FGF activated extracellular signal-regulated kinase 1/2 (ERK1/2) and phosphatidylinositol (PI)-3 kinase. As both MEK inhibitors and a PI 3-kinase inhibitor abolished the effect of IL-6 and FGF, the activation of both the ERK1/2 and PI 3-kinase signaling cascades is essential for the proliferation of KMS-11 enhanced by IL-6 and FGF. Furthermore, the FGF-induced activation of ERK1/2 contributed to the serine phosphorylation of STAT3, suggesting that the signaling crosstalk between the cytokine receptor, IL-6 receptor alpha/gp130 and the growth factor receptor tyrosine kinase, FGFR3. The se results indicate that FGFR3 plays a crucial role in the accelerated proliferation of MM carrying t(4;14)(p16.3;q32).	Yamaguchi Univ, Lab Cellular Signal Anal, Dept Bio Signal Anal, Grad Sch Med, Ube, Yamaguchi 7558505, Japan	Yamaguchi University	Ishikawa, H (corresponding author), Yamaguchi Univ, Lab Cellular Signal Anal, Dept Bio Signal Anal, Grad Sch Med, Ube, Yamaguchi 7558505, Japan.	hishika@yamaguchi-u.ac.jp	ABROUN, SAEID/GPF-5006-2022					Abroun S, 2004, BLOOD, V103, P2291, DOI 10.1182/blood-2003-07-2187; Avet-Loiseau H, 1998, CANCER RES, V58, P5640; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Duarte RF, 2000, BLOOD, V96, P3422; Fujii R, 1999, BRIT J HAEMATOL, V105, P131, DOI 10.1046/j.1365-2141.1999.01281.x; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Ishikawa H, 2002, BLOOD, V99, P2172, DOI 10.1182/blood.V99.6.2172; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; KLINT P, 1999, FRONT BIOSCI, V4, P165; Mahmoud MS, 1998, BLOOD, V92, P3887, DOI 10.1182/blood.V92.10.3887.422a48_3887_3897; Malgeri U, 2000, CANCER RES, V60, P4058; NAMBA M, 1989, IN VITRO CELL DEV B, V25, P723; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Otsuki T, 1998, INT J ONCOL, V12, P545; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	28	31	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6328	6332		10.1038/sj.onc.1208782	http://dx.doi.org/10.1038/sj.onc.1208782			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940250				2022-12-25	WOS:000231877100014
J	Corradini, F; Cesi, V; Bartella, V; Pani, E; Bussolari, R; Candini, O; Calabretta, B				Corradini, F; Cesi, V; Bartella, V; Pani, E; Bussolari, R; Candini, O; Calabretta, B			Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ACUTE LEUKEMIAS; F-BOX PROTEIN; MYELOGENOUS LEUKEMIA; ANTISENSE OLIGODEOXYNUCLEOTIDES; BONE-MARROW; STEM-CELLS; MYELOID CELLS; BETA-CATENIN; HEAT-SHOCK; GENE	The c-myb gene encodes a transcription factor required for proliferation, differentiation, and survival of hematopoietic cells. Expression of c-Myb is often increased in hematological malignancies, but the underlying mechanisms are poorly understood. We show here that c-Myb has a longer half-life ( at least 2-fold) in BCR/ABL-expressing than in normal hematopoietic cells. Such enhanced stability was dependent on a phosphatidylinositol 3-kinase ( PI-3K)/Akt/GSKIII beta pathway( s) as indicated by the suppression of c-Myb expression upon treatment with PI-3K inhibitors or co-expression with dominant negative Akt or constitutively active GSKIII beta. Moreover, inhibition of GSKIII beta by LiCl enhanced cMyb expression in parental 32Dcl3 cells. Compared with wild type c-Myb, three mutants ( Delta( 358 - 452), Delta( 389 - 418), and L389A/L396A c-Myb) of the leucine zipper domain had increased stability. However, only expression of Delta( 358 - 452) was not affected by inhibition of the PI-3K/Akt pathway and was not enhanced by a proteasome inhibitor, suggesting that leucine zipper-dependent and - independent mechanisms are involved in the regulation of c-Myb stability. Indeed, Delta( 389 - 418) carrying four lysine-to-alanine substitutions ( Delta( 389 - 418) K387A/K428A/ K442A/K445A) was as stable as Delta( 358 - 452) c-Myb. Compared with full-length c-Myb, constitutive expression of Delta( 358 - 452) and Delta( 389 - 418) c-Myb in Lin-Sca-1(+) mouse marrow cells increased cytokine-dependent primary and secondary colony formation. In K562 cells, expression of Delta( 358 - 452), Delta( 389 - 418), and L389A/L396A c-Myb led to enhanced proliferation after STI571 treatment. Thus, enhanced stability of c-Myb by activation of PI-3K-dependent pathway( s) might contribute to the higher proliferative potential of BCR/ABL-expressing and, perhaps, other leukemic cells.	Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Modena, Dept Med Sci, I-41100 Modena, Italy	Jefferson University; Universita di Modena e Reggio Emilia	Calabretta, B (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB, Rm 630,233 S 10th St, Philadelphia, PA 19107 USA.	bruno.calabretta@mail.tju.edu		Candini, Olivia/0000-0002-5749-9100	NATIONAL CANCER INSTITUTE [R01CA095111] Funding Source: NIH RePORTER; NCI NIH HHS [CA95111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bies J, 1999, J VIROL, V73, P2038, DOI 10.1128/JVI.73.3.2038-2044.1999; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Domen J, 2000, J EXP MED, V192, P1707, DOI 10.1084/jem.192.12.1707; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; FAVIER D, 1994, ONCOGENE, V9, P305; Feikova S, 2000, NEOPLASMA, V47, P212; FRAMPTON J, 1996, GENE DEV, V10, P2770; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1993, BLOOD, V82, P2813; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAWLEY RG, 1994, GENE THER, V1, P136; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; KENEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kumar A, 2003, MOL CELL BIOL, V23, P6631, DOI 10.1128/MCB.23.18.6631-6645.2003; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Luger SM, 2002, BLOOD, V99, P1150, DOI 10.1182/blood.V99.4.1150; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; Lutwyche JK, 2001, BRIT J HAEMATOL, V114, P632, DOI 10.1046/j.1365-2141.2001.02966.x; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MAVILIO F, 1986, P NATL ACAD SCI USA, V83, P4394, DOI 10.1073/pnas.83.12.4394; Melotti P, 1996, BLOOD, V87, P2221, DOI 10.1182/blood.V87.6.2221.bloodjournal8762221; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MIYAJIMA I, 1995, BLOOD, V85, P1246, DOI 10.1182/blood.V85.5.1246.bloodjournal8551246; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAMURA T, 1993, J BIOL CHEM, V268, P21914; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Salomoni P, 2000, BLOOD, V96, P676; SALOMONI P, 1997, P ANTL ACAD SCI US, V96, P3246; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TESCH H, 1992, LEUKEMIA RES, V16, P265, DOI 10.1016/0145-2126(92)90064-E; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; VALTIERI M, 1987, J IMMUNOL, V138, P3829; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	56	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30254	30262		10.1074/jbc.M504703200	http://dx.doi.org/10.1074/jbc.M504703200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15927960	hybrid			2022-12-25	WOS:000231362500034
J	Shirata, N; Kudoh, A; Daikoku, T; Tatsumi, Y; Fujita, M; Kiyono, T; Sugaya, Y; Isomura, H; Ishizaki, K; Tsurumi, T				Shirata, N; Kudoh, A; Daikoku, T; Tatsumi, Y; Fujita, M; Kiyono, T; Sugaya, Y; Isomura, H; Ishizaki, K; Tsurumi, T			Activation of ataxia telangiectasia-mutated DNA damage checkpoint signal transduction elicited by herpes simplex virus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; NIJMEGEN BREAKAGE SYNDROME; LYTIC REPLICATION; MRE11 COMPLEX; INDUCED PHOSPHORYLATION; RESPONSE PATHWAY; ATM ACTIVATION; CELLULAR DNA; MRN COMPLEX; VIRAL-DNA	Eukaryotic cells are equipped with machinery to monitor and repair damaged DNA. Herpes simplex virus ( HSV) DNA replication occurs at discrete sites in nuclei, the replication compartment, where viral replication proteins cluster and synthesize a large amount of viral DNA. In the present study, HSV infection was found to elicit a cellular DNA damage response, with activation of the ataxia-telangiectasia-mutated ( ATM) signal transduction pathway, as observed by autophosphorylation of ATM and phosphorylation of multiple downstream targets including Nbs1, Chk2, and p53, while infection with a UV-inactivated virus or with a replication-defective virus did not. Activated ATM and the DNA damage sensor MRN complex composed of Mre11, Rad50, and Nbs1 were recruited and retained at sites of viral DNA replication, probably recognizing newly synthesized viral DNAs as abnormal DNA structures. These events were not observed in ATM-deficient cells, indicating ATM dependence. In Nbs1-deficient cells, HSV infection induced an ATM DNA damage response that was delayed, suggesting a functional MRN complex requirement for efficient ATM activation. However, ATM silencing had no effect on viral replication in 293T cells. Our data open up an interesting question of how the virus is able to complete its replication, although host cells activate ATM checkpoint signaling in response to the HSV infection.	Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Cent Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Natl Canc Ctr, Div Virol, Chuo Ku, Tokyo 1040045, Japan	Aichi Cancer Center; Aichi Cancer Center; National Cancer Center - Japan	Tsurumi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ttsurumi@aichi-cc.jp	Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452; Tatsumi, Yasutoshi/0000-0003-2646-7410				Ahn JY, 2000, CANCER RES, V60, P5934; Aubert M, 1999, J VIROL, V73, P2803, DOI 10.1128/JVI.73.4.2803-2813.1999; Aubert M, 2001, J VIROL, V75, P1013, DOI 10.1128/JVI.75.2.1013-1030.2001; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Boutell C, 2004, J VIROL, V78, P8068, DOI 10.1128/JVI.78.15.8068-8077.2004; Boutell C, 2003, J BIOL CHEM, V278, P36596, DOI 10.1074/jbc.M300776200; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Daikoku T, 2005, J VIROL, V79, P3409, DOI 10.1128/JVI.79.6.3409-3418.2005; Daikoku T, 2004, J BIOL CHEM, V279, P54817, DOI 10.1074/jbc.M405911200; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Ehmann GL, 2000, VIROLOGY, V267, P335, DOI 10.1006/viro.1999.0147; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; George JW, 2001, P NATL ACAD SCI USA, V98, P8290, DOI 10.1073/pnas.131007598; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Huang KJ, 2002, J BIOL CHEM, V277, P21071, DOI 10.1074/jbc.M201785200; Jerome KR, 1999, J VIROL, V73, P8950, DOI 10.1128/JVI.73.11.8950-8957.1999; JOHNSON DC, 1988, J VIROL, V62, P4605, DOI 10.1128/JVI.62.12.4605-4612.1988; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KIMURA H, 1991, J INFECT DIS, V164, P289, DOI 10.1093/infdis/164.2.289; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kops AD, 1998, VIROLOGY, V252, P162, DOI 10.1006/viro.1998.9450; Kudoh A, 2005, J BIOL CHEM, V280, P8156, DOI 10.1074/jbc.M411405200; Kudoh A, 2003, J VIROL, V77, P851, DOI 10.1128/JVI.77.2.851-861.2003; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Milatovic D, 2002, J NEUROVIROL, V8, P295, DOI 10.1080/13550280290100743; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Nakamura H, 2002, J RADIAT RES, V43, P167, DOI 10.1269/jrr.43.167; Nimonkar AV, 2003, P NATL ACAD SCI USA, V100, P10201, DOI 10.1073/pnas.1534569100; NISHIYAMA Y, 1981, VIROLOGY, V110, P466, DOI 10.1016/0042-6822(81)90077-5; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; ROIZMAN B, 2002, FIELDS VIROLOGY, P2399; Saeki Y, 1998, HUM GENE THER, V9, P2787, DOI 10.1089/hum.1998.9.18-2787; Severini A, 1996, J VIROL, V70, P3169, DOI 10.1128/JVI.70.5.3169-3175.1996; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tomicic MT, 2002, MUTAT RES-FUND MOL M, V505, P1, DOI 10.1016/S0027-5107(02)00105-7; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Valyi-Nagy T, 2000, VIROLOGY, V278, P309, DOI 10.1006/viro.2000.0678; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WEBER PC, 1988, CELL, V54, P369, DOI 10.1016/0092-8674(88)90200-0; WESTPHAL CH, 1997, CURR BIOL, V7, P789; Wilkinson DE, 2004, J VIROL, V78, P4783, DOI 10.1128/JVI.78.9.4783-4796.2004; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; WOHLRAB F, 1991, P NATL ACAD SCI USA, V88, P6432, DOI 10.1073/pnas.88.15.6432; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	57	111	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30336	30341		10.1074/jbc.M500976200	http://dx.doi.org/10.1074/jbc.M500976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15964848	hybrid			2022-12-25	WOS:000231362500043
J	Aixinjueluo, W; Furukawa, K; Zhang, Q; Hamamura, K; Tokuda, N; Yoshida, S; Ueda, R; Furukawa, K				Aixinjueluo, W; Furukawa, K; Zhang, Q; Hamamura, K; Tokuda, N; Yoshida, S; Ueda, R; Furukawa, K			Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies - Roles of anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; HUMAN-MELANOMA CELLS; COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; VIRUS TYPE-I; DISIALOGANGLIOSIDE GD2; SIGNALING PATHWAY; MATRIX PROTEINS; TYROSINE KINASE; SYNTHASE GENE	Anti-GD2 ganglioside antibodies could be a promising, novel therapeutic approach to the eradication of human small cell lung cancers, as anti-GD2 monoclonal antibodies (mAbs) induced apoptosis of small cell lung cancer cells in culture. In this study, we analyzed the mechanisms for the apoptosis of these cells by anti-GD2 mAbs and elucidated the mechanisms by which apoptosis signals were transduced via reduction in the phosphorylation levels of focal adhesion kinase (FAK) and the activation of a MAPK family member, p38, upon the antibody binding. Knock down of FAK resulted in apoptosis and p38 activation. The inhibition of p38 activity blocked antibody-induced apoptosis, indicating that p38 is involved in this process. Immunoprecipitation-immunoblotting analysis of immune precipitates with anti-FAK or anti-integrin antibodies using an anti-GD2 mAb revealed that GD2 could be precipitated with integrin and/or FAK. These results suggested that GD2, integrin, and FAK form a huge molecular complex across the plasma membrane. Taken together with the fact that GD2+ cells showed marked detachment from the plate during apoptosis, GD2+ small cell lung cancer cells seemed to undergo anoikis through the conformational changes of integrin molecules and subsequent FAK dephosphorylation.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Sch Med, Dept Oral & Maxillofacial Surg, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya City Univ, Sch Med, Dept Internal Med 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya University; Nagoya University; Nagoya City University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp		Hamamura, Kazunori/0000-0002-8143-338X				Beviglia L, 2003, BIOCHEM J, V373, P201, DOI 10.1042/BJ20021846; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chen HH, 2003, INT J CANCER, V103, P169, DOI 10.1002/ijc.10797; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CHERESH DA, 1986, J CELL BIOL, V102, P1887, DOI 10.1083/jcb.102.5.1887; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukuda M, 1998, INT J MOL MED, V2, P471; FURUKAWA K, 1993, P NATL ACAD SCI USA, V90, P1972, DOI 10.1073/pnas.90.5.1972; Hakamori S, 1998, ACTA ANAT, V161, P79; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; KOJIMA N, 1991, Glycobiology, V1, P623, DOI 10.1093/glycob/1.6.623; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; Kushner BH, 2001, J CLIN ONCOL, V19, P4189, DOI 10.1200/JCO.2001.19.22.4189; Laprise P, 2002, J CELL PHYSIOL, V191, P69, DOI 10.1002/jcp.10075; LLOYD KO, 1989, CANCER RES, V49, P3445; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; Nakamura K, 1999, CANCER RES, V59, P5323; Okada M, 1996, CANCER RES, V56, P2844; Sakurai S, 2002, BIOCHEM BIOPH RES CO, V293, P174, DOI 10.1016/S0006-291X(02)00192-4; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Walsh MF, 2003, CELL PHYSIOL BIOCHEM, V13, P135, DOI 10.1159/000071864; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wang XQ, 2001, J BIOL CHEM, V276, P44504, DOI 10.1074/jbc.M106563200; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wei L, 2004, J CELL BIOCHEM, V91, P325, DOI 10.1002/jcb.10760; Willison HJ, 2002, BRAIN, V125, P2591, DOI 10.1093/brain/awf272; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Yoshida S, 2002, JPN J CANCER RES, V93, P816, DOI 10.1111/j.1349-7006.2002.tb01324.x; Yoshida S, 2001, CANCER RES, V61, P4244; Yu HG, 2004, BIOCHEM PHARMACOL, V67, P135, DOI 10.1016/j.bcp.2003.08.015	43	75	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29828	29836		10.1074/jbc.M414041200	http://dx.doi.org/10.1074/jbc.M414041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15923178	hybrid			2022-12-25	WOS:000231176200054
J	Arias-Salgado, EG; Lizano, S; Shattil, SJ; Ginsberg, MH				Arias-Salgado, EG; Lizano, S; Shattil, SJ; Ginsberg, MH			Specification of the direction of adhesive signaling by the integrin beta cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; MEMBRANE-PROXIMAL REGION; INSIDE-OUT; MONOCLONAL-ANTIBODIES; CELL-ADHESION; SELECTIVE-INHIBITION; KINASE ACTIVATION; LIGAND-BINDING; GPIIB-IIIA; TALIN	Integrin adhesion receptors can signal in two directions: first, they can regulate cellular behaviors by modulating cellular signaling enzymes ("outside-in signaling"); second, cells can regulate the affinity of integrins ("inside-out signaling") by such pathways. Integrin beta cytoplasmic domains ( tails) mediate both types of signaling, and Src family kinases (SFKs) and talin, which bind to beta tails, are important for integrin signaling. Here, we utilized "homology scanning" mutagenesis to identify beta tail mutants selectively defective in c-Src binding and found that amino acid exchanges affecting a combination of an Arg and Thr residue in the integrin beta 3 tail control the binding specificity for SFKs but have no effect on talin binding. Using beta tail mutants at these residues, we found that SFK binding to integrin beta tails is dispensable for inside-out signaling but is obligatory for cell spreading, a marker of outside-in signaling. Conversely, we found that point mutations that disrupt talin binding abolish integrin activation, but they do not inhibit SFK binding to the beta 3 tail or the initiation of out-side-in signaling once the integrins are in a high affinity form. Thus, we show that inside-out and outside-in integrin signaling are mediated by distinct and separable interactions of the integrin beta tails. Furthermore, based on our results, it is possible to discern the relative contributions of the direction of integrin signaling on biological functions in cell culture and, ultimately, in vivo.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ginsberg, MH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr,Mail Code 0726, La Jolla, CA 92093 USA.	mhginsberg@ucsd.edu		Garcia Arias-Salgado, Elena/0000-0002-3612-5791				Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200; Cram EJ, 2003, J CELL SCI, V116, P3871, DOI 10.1242/jcs.00705; de Virgilio M, 2004, J CELL BIOL, V165, P305, DOI 10.1083/jcb.200402064; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DU XP, 1993, J BIOL CHEM, V268, P23087; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; GINSBERG MH, 1990, BLOOD, V76, P2017; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries MJ, 2003, TRENDS BIOCHEM SCI, V28, P313, DOI 10.1016/S0968-0004(03)00112-9; Humphries MJ, 1998, TRENDS CELL BIOL, V8, P78, DOI 10.1016/S0962-8924(98)80016-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Liu SC, 2000, J CELL SCI, V113, P3563; Monkley SJ, 2000, DEV DYNAM, V219, P560, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1079>3.0.CO;2-Y; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Rose DM, 2001, J IMMUNOL, V167, P2824, DOI 10.4049/jimmunol.167.5.2824; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Ulmer TS, 2003, BIOCHEMISTRY-US, V42, P8307, DOI 10.1021/bi034384s; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Xi XD, 2003, J CELL BIOL, V162, P329, DOI 10.1083/jcb.200303120; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	49	77	80	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29699	29707		10.1074/jbc.M503508200	http://dx.doi.org/10.1074/jbc.M503508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15937333	Green Published, hybrid			2022-12-25	WOS:000231176200040
J	Jackson, TA; Taylor, HE; Sharma, D; Desiderio, S; Danoff, SK				Jackson, TA; Taylor, HE; Sharma, D; Desiderio, S; Danoff, SK			Vascular endothelial growth factor receptor-2 - Counter-regulation by the transcription factors, TFII-I AND TFII-IRD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILLIAMS-BEUREN-SYNDROME; TATA-LESS PROMOTER; GROWTH-FACTOR VEGF; HISTONE DEACETYLASE-3; BINDING INITIATOR; FLK-1/KDR GENE; FAMILY; EXPRESSION; RECEPTOR; INHIBITION	The vascular endothelial growth factor receptor-2 (VEGFR-2/KDR/flk-1) functions as the primary mediator of vascular endothelial growth factor activation in endothelial cells. Regulation of VEGFR-2 expression appears critical in mitogenesis, differentiation, and angiogenesis. Transcriptional regulation of the VEGFR-2 is complex and may involve multiple putative upstream regulatory elements including E boxes. Transcript initiation is dependent on an initiator (Inr) element flanking the transcriptional start site. The transcription factor, TFII-I, enhances VEGFR-2 transcription in an Inr-dependent fashion. TFII-I is unusual both structurally and functionally. The TFII-I transcription factor family members contain multiple putative DNA binding domains. Functionally, TFII-I acts at both the basal, Inr element as well as at several distinct upstream regulatory sites. It has been postulated that the structure of TFII- I might allow simultaneous interaction with both basal and regulatory sites in a given promoter. As TFII-I is known to act at regulatory sites including E boxes as well as at the basal Inr element, we evaluated the possibility of Inr-independent TFII- I activation of the VEGFR-2 promoter. We found that an Inr-mutated VEGFR-2 reporter construct retains TFII-I-stimulated activity. We demonstrated that TFII-I binds to both the Inr and to three regulatory E boxes in the human VEGFR-2 promoter. In addition, reduction in TFII- I expression by siRNA results in decreased VEGFR-2 expression. We also describe counter-regulation of the VEGFR-2 promoter by TFII-IRD1. We found that TFII-I is capable of acting at both basal and regulatory sites in one promoter and that the human VEGFR-2 promoter is functionally counter-regulated by TFII-I and TFII-IRD1.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Danoff, SK (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, 1830 E Monument St,5th Fl, Baltimore, MD 21205 USA.	sdanoff@jhmi.edu		Danoff, Sonye K./0000-0001-9172-8977; Jackson, Tanisha/0000-0001-9658-6365	NINDS NIH HHS [K08-NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020193] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bayarsaihan D, 2003, GENE EXPR PATTERNS, V3, P579, DOI 10.1016/S1567-133X(03)00118-2; Bayarsaihan D, 2000, P NATL ACAD SCI USA, V97, P7342, DOI 10.1073/pnas.97.13.7342; Brekken RA, 2000, CANCER RES, V60, P5117; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; Cheriyath V, 2001, J BIOL CHEM, V276, P8377, DOI 10.1074/jbc.M008411200; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P2813, DOI 10.1093/nar/26.11.2813; Danoff SK, 2004, NEUROSCIENCE, V123, P931, DOI 10.1016/j.neuroscience.2003.08.038; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Hinsley TA, 2004, PROTEIN SCI, V13, P2588, DOI 10.1110/ps.04747604; Illi B, 2000, CIRC RES, V86, pE110; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; Kazi AA, 2000, AM J PHYSIOL-LUNG C, V279, pL460, DOI 10.1152/ajplung.2000.279.3.L460; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Millauer B, 1996, CANCER RES, V56, P1615; Minami T, 2001, J BIOL CHEM, V276, P5395, DOI 10.1074/jbc.M008798200; Mobley CM, 2000, J VIROL, V74, P6511, DOI 10.1128/JVI.74.14.6511-6519.2000; Morikawa N, 2000, BIOL REPROD, V63, P1075, DOI 10.1095/biolreprod63.4.1075; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Osborne LR, 1999, GENOMICS, V57, P279, DOI 10.1006/geno.1999.5784; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Polly P, 2003, J BIOL CHEM, V278, P36603, DOI 10.1074/jbc.M212814200; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Tantin D, 2004, J BIOL CHEM, V279, P5460, DOI 10.1074/jbc.M311177200; Tipney HJ, 2004, EUR J HUM GENET, V12, P551, DOI 10.1038/sj.ejhg.5201174; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Tussie-Luna MI, 2001, P NATL ACAD SCI USA, V98, P7789, DOI 10.1073/pnas.141222298; Wen YD, 2003, J BIOL CHEM, V278, P1841, DOI 10.1074/jbc.M206528200; Wu YX, 1999, J BIOL CHEM, V274, P3207, DOI 10.1074/jbc.274.5.3207; Yan XM, 2000, BIOCHEM J, V345, P749, DOI 10.1042/0264-6021:3450749; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604	35	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29856	29863		10.1074/jbc.M500335200	http://dx.doi.org/10.1074/jbc.M500335200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15941713	hybrid			2022-12-25	WOS:000231176200057
J	Karaveg, K; Moremen, KW				Karaveg, K; Moremen, KW			Energetics of substrate binding and catalysis by class 1 (glycosylhydrolase family 47) alpha-mannosidases involved in N-glycan processing and endoplasmic reticulum quality control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I ALPHA-1,2-MANNOSIDASE; ASPARAGINE-LINKED OLIGOSACCHARIDES; ISOTHERMAL TITRATION CALORIMETRY; ACID-SEQUENCE SIMILARITIES; UNFOLDED PROTEIN RESPONSE; ER-ASSOCIATED DEGRADATION; SACCHAROMYCES-CEREVISIAE; GLYCOSYL HYDROLASES; MISFOLDED GLYCOPROTEINS; SECRETORY PATHWAY	Nascent glycoproteins are subject to quality control in the lumen of the endoplasmic reticulum ( ER) where they can either be effectively folded with the aid of a collection of ER chaperones or they can be targeted for disposal in a process known as ER-associated degradation. Initiation of the ER disposal process involves selective trimming of N-glycans by ER alpha-mannosidase I and subsequent recognition by the ER degradation-enhancing alpha-mannosidase- like protein family of lectins, both members of glycosylhydrolase family 47. The kinetics and energetics of substrate binding and catalysis by members of this family were investigated here by the analysis of wild type and mutant forms of human ER alpha-mannosidase I. The contributions of several amino acid residues and an enzyme-associated Ca2+ ion to substrate binding and catalysis were demonstrated by a combination of surface plasmon resonance and enzyme kinetic analyses. One mutant, E330Q, shown previously to alter general acid function within the catalytic site, resulted in an enzyme that possessed increased glycan binding affinity but compromised glycan hydrolysis. This mutant protein was used in a series of glycan binding studies with a library of mannose-containing ligands to examine the energetics of Man(9)GlcNAc(2) substrate interactions. These studies provide a framework for understanding the nature of the unusual substrate interactions within the family 47 mannosidases involved in glycan maturation and ER-associated glycoprotein degradation.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Moremen, KW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA.	moremen@uga.edu	Moremen, Kelley/AAD-4661-2019		NCRR NIH HHS [RR05351] Funding Source: Medline; NIGMS NIH HHS [GM47533] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; Chung DH, 2000, J BIOL CHEM, V275, P4981, DOI 10.1074/jbc.275.7.4981; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Day YSN, 2002, PROTEIN SCI, V11, P1017, DOI 10.1110/ps.4330102; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Henrissat B, 1998, BIOCHEM SOC T, V26, P153, DOI 10.1042/bst0260153; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; HERSCOVICS A, 1999, COMPREHENSIVE NATURA, V3, P13; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Karaveg K, 2005, J BIOL CHEM, V280, P16197, DOI 10.1074/jbc.M500119200; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; KOPITO RR, 1999, PHYSIOL REV, V79, P167; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAL A, 1994, J BIOL CHEM, V269, P9872; Lal A, 1998, GLYCOBIOLOGY, V8, P981, DOI 10.1093/glycob/8.10.981; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Lobsanov YD, 2002, J BIOL CHEM, V277, P5620, DOI 10.1074/jbc.M110243200; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; Lonhienne T, 2001, BBA-PROTEIN STRUCT M, V1545, P349, DOI 10.1016/S0167-4838(00)00296-X; Mast SW, 2005, GLYCOBIOLOGY, V15, P421, DOI 10.1093/glycob/cwi014; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Moremen K., 2000, OLIGOSACCHARIDES CHE, VII, P81; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Olivari S, 2005, J BIOL CHEM, V280, P2424, DOI 10.1074/jbc.C400534200; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852; POTTER JD, 1983, METHOD ENZYMOL, V102, P135; Romero PA, 2000, J BIOL CHEM, V275, P11071, DOI 10.1074/jbc.275.15.11071; SAHA SK, 1994, CARBOHYD RES, V254, P157; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; Sifers RN, 2004, NAT STRUCT MOL BIOL, V11, P108, DOI 10.1038/nsmb0204-108; Sifers RN, 2003, SCIENCE, V299, P1330, DOI 10.1126/science.1082718; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Sutton C W, 1997, Methods Mol Biol, V64, P73; Tempel W, 2004, J BIOL CHEM, V279, P29774, DOI 10.1074/jbc.M403065200; Tokunaga F, 2003, ARCH BIOCHEM BIOPHYS, V411, P235, DOI 10.1016/S0003-9861(02)00717-8; Tremblay LO, 2000, J BIOL CHEM, V275, P31655, DOI 10.1074/jbc.M004935200; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Van Petegem F, 2001, J MOL BIOL, V312, P157, DOI 10.1006/jmbi.2001.4946; Wang Y, 2000, BIOCHEM BIOPH RES CO, V271, P22, DOI 10.1006/bbrc.2000.2577; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	64	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29837	29848		10.1074/jbc.M505130200	http://dx.doi.org/10.1074/jbc.M505130200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15911611	hybrid			2022-12-25	WOS:000231176200055
J	Kathir, KM; Kumar, TKS; Rajalingam, D; Yu, C				Kathir, KM; Kumar, TKS; Rajalingam, D; Yu, C			Time-dependent changes in the denatured state(s) influence the folding mechanism of an all beta-sheet protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; UNFOLDED STATE; STABILITY; ASSOCIATION; PATHWAY	Newt fibroblast growth factor (nFGF-1) is an similar to 15-kDa all beta-sheet protein devoid of disulfide bonds. Urea-induced equilibrium unfolding of nFGF-1, monitored by steady state fluorescence and far-UV circular dichroism spectroscopy, is cooperative with no detectable intermediate(s). Urea-induced unfolding of nFGF-1 is reversible, but the percentage of the protein recovered in the native state depends on the time of incubation of the protein in the denaturant. The yield of the protein in the native state decreases with the increase in time of incubation in the denaturant. The failure of the protein to refold to its native state is not due to trivial chemical reactions that could possibly occur upon prolonged incubation in the denaturant. H-1-N-15 heteronuclear single quantum coherence (HSQC) spectra, limited proteolytic digestion, and fluorescence data suggest that the misfolded state( s) of nFGF-1 has structural features resembling that of the denatured state( s). GroEL, in the presence of ATP, is observed to rescue the protein from being trapped in the misfolded state( s). H-1-N-15 HSQC data of nFGF-1, acquired in the denatured state( s) ( in 8 M urea), suggest that the protein undergoes subtle time-dependent structural changes in the denaturant. To our knowledge, this report for the first time demonstrates that the commitment to adapt unproductive pathways leading to protein misfolding/aggregation occurs in the denatured state ensemble.	Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan	University of Arkansas System; University of Arkansas Fayetteville; National Tsing Hua University	Yu, C (corresponding author), Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA.	cyu@uark.edu	Kumar, Suresh Thallapuranam/R-5606-2016; KUMAR, P. SURESH/AAT-8951-2020; Kumar, Dr Suresh/HHZ-2615-2022	Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604; Kumar, Dr Suresh/0000-0002-2539-6553	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15569] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arunkumar AI, 2002, J BIOL CHEM, V277, P46424, DOI 10.1074/jbc.M207814200; BREMS DN, 1989, PROTEINS, V5, P93, DOI 10.1002/prot.340050110; Chi YH, 2002, BIOCHEMISTRY-US, V41, P15350, DOI 10.1021/bi026218a; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Choy WY, 2002, J MOL BIOL, V316, P101, DOI 10.1006/jmbi.2001.5328; Crowhurst KA, 2003, BIOCHEMISTRY-US, V42, P8687, DOI 10.1021/bi034601p; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Dyson HJ, 2004, CHEM REV, V104, P3607, DOI 10.1021/cr030403s; Fenton WA, 2003, Q REV BIOPHYS, V36, P229, DOI 10.1017/S0033583503003883; Garcia-Mira MM, 2002, SCIENCE, V298, P2191, DOI 10.1126/science.1077809; Hajduk PJ, 1999, Q REV BIOPHYS, V32, P211, DOI 10.1017/S0033583500003528; HUDSON ME, 2001, BIOCHEMISTRY-US, V40, P732; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; Jaenicke R, 1999, PROG BIOPHYS MOL BIO, V71, P155, DOI 10.1016/S0079-6107(98)00032-7; Jemth P, 2004, P NATL ACAD SCI USA, V101, P6450, DOI 10.1073/pnas.0401732101; Kazmirski SL, 2001, P NATL ACAD SCI USA, V98, P4349, DOI 10.1073/pnas.071054398; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; Kumar TKS, 2004, ACCOUNTS CHEM RES, V37, P929, DOI 10.1021/ar020156z; Lietzow MA, 2002, J MOL BIOL, V322, P655, DOI 10.1016/S0022-2836(02)00847-1; LYTE BL, 2000, ARCH BIOCHEM BIOPHYS, V374, P237; PACE NC, 1968, BIOCHEMISTRY-US, V7, P198; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Silow M, 1999, BIOCHEMISTRY-US, V38, P13006, DOI 10.1021/bi9909997; Srimathi T, 2003, BIOPHYS J, V85, P459, DOI 10.1016/S0006-3495(03)74491-9; Srisailam S, 2002, J AM CHEM SOC, V124, P1884, DOI 10.1021/ja012070r; Su ZD, 1996, P NATL ACAD SCI USA, V93, P2539, DOI 10.1073/pnas.93.6.2539; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; UVERSKY VN, 1992, FEBS LETT, V314, P89, DOI 10.1016/0014-5793(92)81468-2; Uversky VN, 1998, P NATL ACAD SCI USA, V95, P5480, DOI 10.1073/pnas.95.10.5480; WANG L, 1998, PROTEIN SCI, V7, P2360; Wong KB, 2000, J MOL BIOL, V296, P1257, DOI 10.1006/jmbi.2000.3523	34	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29682	29688		10.1074/jbc.M504389200	http://dx.doi.org/10.1074/jbc.M504389200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15941715	hybrid			2022-12-25	WOS:000231176200038
J	Seki, T; Adachi, N; Ono, Y; Mochizuki, H; Hiramoto, K; Amano, T; Matsubayashi, H; Matsumoto, M; Kawakami, H; Saito, N; Sakai, N				Seki, T; Adachi, N; Ono, Y; Mochizuki, H; Hiramoto, K; Amano, T; Matsubayashi, H; Matsumoto, M; Kawakami, H; Saito, N; Sakai, N			Mutant protein kinase C gamma found in spinocerebellar ataxia type 14 is susceptible to aggregation and causes cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-SYNUCLEIN; PKC-GAMMA; POLYGLUTAMINE DISEASE; CEREBELLAR-ATAXIA; IN-VITRO; MICE; MUTATION; ACTIVATION; DOMAIN; PHOSPHORYLATION	Spinocerebellar ataxia type 14 (SCA14) is an autosomal dominant neurodegenerative disease characterized by various symptoms including cerebellar ataxia. Recently, several missense mutations in the protein kinase C gamma (gamma PKC) gene have been found in different SCA14 families. To elucidate how the mutant gamma PKC causes SCA14, we examined the molecular properties of seven mutant (H101Y, G118D, S119P, S119F, Q127R, G128D, and F643L) gamma PKCs fused with green fluorescent protein (gamma PKC-GFP). Wild-type gamma PKC-GFP was expressed ubiquitously in the cytoplasm of CHO cells, whereas mutant gamma PKC-GFP tended to aggregate in the cytoplasm. The insolubility of mutant gamma PKC-GFP to Triton X-100 was increased and correlated with the extent of aggregation. gamma PKC-GFP in the Triton-insoluble fraction was rarely phosphorylated at Thr(514), whereas gamma PKC-GFP in the Triton-soluble fraction was phosphorylated. Furthermore, the stimulation of the P2Y receptor triggered the rapid aggregation of mutant gamma PKC-GFP within 10 min after transient translocation to the plasma membrane. Overexpression of the mutant gamma PKC-GFP caused cell death that was more prominent than wild type. The cytotoxicity was exacerbated in parallel with the expression level of the mutant. These results indicate that SCA14 mutations make gamma PKC form cytoplasmic aggregates, suggesting the involvement of this property in the etiology of SCA14.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Pharmacol Sci, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Neurosurg, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosci & Therapeut, Minami Ku, Hiroshima 7348551, Japan; Kobe Univ, Mol Pharmacol Lab, Kobe, Hyogo 6578501, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University; Kobe University; Kobe University	Sakai, N (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Pharmacol Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	nsakai@hiroshima-u.ac.jp	Kawakami, Hideshi/ABE-4077-2021; Sakai, Norio/AAM-5822-2021; Kawakami, Hideshi/A-2086-2009	Kawakami, Hideshi/0000-0002-1405-0901; Sakai, Norio/0000-0002-6648-8761; Kawakami, Hideshi/0000-0002-1405-0901; Seki, Takahiro/0000-0002-9894-4768; Adachi, Naoko/0000-0002-8797-0717				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; Chen DH, 2003, AM J HUM GENET, V72, P839, DOI 10.1086/373883; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Everett CM, 2004, BRAIN, V127, P2385, DOI 10.1093/brain/awh278; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; Irie K, 2002, PHARMACOL THERAPEUT, V93, P271, DOI 10.1016/S0163-7258(02)00196-1; Johnson WG, 2000, J ANAT, V196, P609, DOI 10.1046/j.1469-7580.2000.19640609.x; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Mariotti C, 2001, NEUROL SCI, V22, pS88, DOI 10.1007/s100720100042; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ORR JW, 1994, J BIOL CHEM, V269, P27715; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; SAITO N, 1988, J NEUROSCI, V8, P369; Saito N, 2002, J BIOCHEM, V132, P683, DOI 10.1093/oxfordjournals.jbchem.a003274; Sakai N, 2004, GENES CELLS, V9, P945, DOI 10.1111/j.1365-2443.2004.00779.x; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; Shirai Y, 1998, JPN J PHARMACOL, V78, P411, DOI 10.1254/jjp.78.411; Skinner PJ, 2001, AM J PATHOL, V159, P905, DOI 10.1016/S0002-9440(10)61766-X; Stevanin G, 2004, ARCH NEUROL-CHICAGO, V61, P1242, DOI 10.1001/archneur.61.8.1242; van de Warrenburg BPC, 2003, NEUROLOGY, V61, P1760, DOI 10.1212/01.WNL.0000098883.79421.73; Verbeek DS, 2005, BRAIN, V128, P436, DOI 10.1093/brain/awh378; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Yabe I, 2003, ARCH NEUROL-CHICAGO, V60, P1749, DOI 10.1001/archneur.60.12.1749; Zhou WB, 2004, J BIOL CHEM, V279, P10128, DOI 10.1074/jbc.M307563200	46	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29096	29106		10.1074/jbc.M501716200	http://dx.doi.org/10.1074/jbc.M501716200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15964845	hybrid			2022-12-25	WOS:000231021300036
J	Cejas, PJ; Carlson, LM; Zhang, J; Padmanabhan, S; Kolonias, D; Lindner, I; Haley, S; Boise, LH; Lee, KP				Cejas, PJ; Carlson, LM; Zhang, J; Padmanabhan, S; Kolonias, D; Lindner, I; Haley, S; Boise, LH; Lee, KP			Protein kinase C beta II plays an essential role in dendritic cell differentiation and autoregulates its own expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD34(+) HEMATOPOIETIC PROGENITORS; ACUTE MYELOGENOUS LEUKEMIA; CD40-CD40 LIGAND INTERACTION; SIGNAL-TRANSDUCTION PATHWAY; PERIPHERAL-BLOOD MONOCYTES; PHORBOL ESTER RECEPTORS; REGULATORY T-CELLS; MYELOID-LEUKEMIA; LINE KG-1; ANTIGEN PRESENTATION	Dendritic cells ( DC) arise from a diverse group of hematopoietic progenitors and have marked phenotypic and functional heterogeneity. The signal transduction pathways that regulate the ability of progenitors to undergo DC differentiation, as well as the specific characteristics of the resulting DC, are only beginning to be characterized. We have found previously that activation of protein kinase C ( PKC) by cytokines or phorbol esters drives normal human CD34(+) hematopoietic progenitors and myeloid leukemic blasts ( KG1, K562 cell lines, and primary patient blasts) to differentiate into DC. We now report that PKC activation is also required for cytokine-driven DC differentiation from monocytes. Of the cPKC isoforms, only PKC-beta II was consistently activated by DC differentiation-inducing stimuli in normal and leukemic progenitors. Transfection of PKC-beta II into the differentiation-resistant KG1a subline restored the ability to undergo DC differentiation in a signal strength-dependent fashion as follows: 1) by development of characteristic morphology; 2) the up-regulation of DC surface markers; 3) the induction of expression of the NF kappa B family member Rel B; and 4) the potent ability to stimulate allo-T cells. Most unexpectedly, the restoration of PKC-beta II signaling in KG1a was not directly due to overexpression of the transfected classical PKC ( alpha, beta II, or gamma) but rather through induction of endogenous PKC-beta gene expression by the transfected classical PKC. The mechanism of this positive autoregulation involves up-regulation of PKC-beta promoter activity by constitutive PKC signaling. These findings indicate that the regulation of PKC-beta II expression and signaling play critical roles in mediating progenitor to DC differentiation.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Roswell Pk Canc Inst, Leukemia Sect, Dept Med, Buffalo, NY 14263 USA	University of Miami; University of Miami; Roswell Park Cancer Institute	Lee, KP (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, Papanicolaou Bldg,Rm 211,1550 NW 10th Ave, Miami, FL 33136 USA.	klee@med.miami.edu	Iyer, Swaminathan Padmanabhan/AAB-6709-2020; Boise, Lawrence/AAD-2314-2019	Iyer, Swaminathan Padmanabhan/0000-0002-1646-813X; Boise, Lawrence/0000-0001-9436-8815	NCI NIH HHS [CA85208, CA95829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085208, R24CA095829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackerman AL, 2003, J IMMUNOL, V170, P4178, DOI 10.4049/jimmunol.170.8.4178; Albert ML, 2001, NAT IMMUNOL, V2, P1010, DOI 10.1038/ni722; Annels NE, 2003, J EXP MED, V197, P1385, DOI 10.1084/jem.20030137; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Benvenuti F, 2004, SCIENCE, V305, P1150, DOI 10.1126/science.1099159; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Cheng PY, 2003, BLOOD, V102, P3980, DOI 10.1182/blood-2003-04-1034; Clark JH, 2002, BIOCHEMISTRY-US, V41, P11847, DOI 10.1021/bi025600k; Czerniecki BJ, 1997, J IMMUNOL, V159, P3823; Davis TA, 1998, J IMMUNOL, V160, P3689; Do Y, 2004, CANCER RES, V64, P6756, DOI 10.1158/0008-5472.CAN-03-4002; Engels FHC, 1999, P NATL ACAD SCI USA, V96, P10332, DOI 10.1073/pnas.96.18.10332; FloresRomo L, 1997, J EXP MED, V185, P341, DOI 10.1084/jem.185.2.341; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; Hajas G, 2004, IMMUNOL LETT, V92, P97, DOI 10.1016/j.imlet.2003.11.021; Harrison BD, 2001, BLOOD, V97, P2764, DOI 10.1182/blood.V97.9.2764; HOOPER WC, 1989, BIOCHIM BIOPHYS ACTA, V1013, P47, DOI 10.1016/0167-4889(89)90126-2; Hulette BC, 2001, ARCH DERMATOL RES, V293, P147, DOI 10.1007/s004030000201; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; Kaneki M, 1999, MOL CELL BIOL, V19, P461; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; Kharfan-Dabaja MA, 2005, CANCER IMMUNOL IMMUN, V54, P25, DOI 10.1007/s00262-004-0562-4; Kiertscher SM, 1996, J LEUKOCYTE BIOL, V59, P208, DOI 10.1002/jlb.59.2.208; KOEFFLER HP, 1980, BLOOD, V56, P265; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; Koski GK, 2001, CRIT REV IMMUNOL, V21, P179; Laouar Y, 2003, IMMUNITY, V19, P903, DOI 10.1016/S1074-7613(03)00332-7; LEE KP, 1990, J IMMUNOL, V145, P344; Li J, 2004, CELL IMMUNOL, V227, P103, DOI 10.1016/j.cellimm.2004.02.002; Lindner I, 2003, J IMMUNOL, V171, P1780, DOI 10.4049/jimmunol.171.4.1780; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Liu Y, 2004, J BIOL CHEM, V279, P45556, DOI 10.1074/jbc.M407701200; Luft T, 2004, BLOOD, V104, P1066, DOI 10.1182/blood-2003-12-4146; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MAHAJNA J, 1995, DNA CELL BIOL, V14, P213, DOI 10.1089/dna.1995.14.213; Mahnke K, 2003, BLOOD, V101, P4862, DOI 10.1182/blood-2002-10-3229; Martin E, 2003, IMMUNITY, V18, P155, DOI 10.1016/S1074-7613(02)00503-4; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nefedova Y, 2004, J IMMUNOL, V172, P464, DOI 10.4049/jimmunol.172.1.464; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1992, J BIOL CHEM, V267, P20804; OBEID LM, 1990, J BIOL CHEM, V265, P2370; Oehler L, 1998, J EXP MED, V187, P1019, DOI 10.1084/jem.187.7.1019; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Oyama T, 1998, J IMMUNOL, V160, P1224; Pettit AR, 1997, J IMMUNOL, V159, P3681; Pickl WF, 1996, J IMMUNOL, V157, P3850; Ramadan G, 2001, CLIN EXP IMMUNOL, V125, P237, DOI 10.1046/j.1365-2249.2001.01605.x; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; Ryncarz RE, 1998, BLOOD, V91, P3892, DOI 10.1182/blood.V91.10.3892.3892_3892_3900; SAKAI N, 2003, JPN J PHARMACOL, V121, P421; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schlienger K, 2000, BLOOD, V96, P3490; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; St Louis DC, 1999, J IMMUNOL, V162, P3237; SUCIUFOCA CN, 2001, HUM IMMUNOL, V62, P1065; Szabolcs P, 1996, BLOOD, V87, P4520, DOI 10.1182/blood.V87.11.4520.bloodjournal87114520; Waclavicek M, 2001, BRIT J HAEMATOL, V114, P466, DOI 10.1046/j.1365-2141.2001.02970.x; Wang YF, 2001, IMMUNITY, V15, P971, DOI 10.1016/S1074-7613(01)00242-4; Yan JC, 2003, CLIN CHIM ACTA, V337, P133, DOI 10.1016/j.cccn.2003.08.007; Yan JC, 2003, ACTA PHARMACOL SIN, V24, P687; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	74	39	42	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28412	28423		10.1074/jbc.M500345200	http://dx.doi.org/10.1074/jbc.M500345200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15917249	hybrid			2022-12-25	WOS:000230857300030
J	Dulloo, I; Sabapathy, K				Dulloo, I; Sabapathy, K			Transactivation-dependent and -independent regulation of p73 stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; C-ABL; P53-RELATED PROTEIN; P53 STABILITY; DELTA-NP73; MDM2; DEGRADATION; TAP73; P300; POLYMORPHISM	The tumor suppressor p53 regulates its own stability by transcriptionally activating Mdm2, Pirh2, and COP1, which target p53 for degradation. However, whether such a negative feedback mechanism exists to regulate the stability of p73, the structural and functional homologue of p53, is unclear. Unlike p53, p73 is not mutated in cancers, but its expression is significantly elevated. Thus, we have investigated the regulation of p73 turnover. Our data suggest the existence of a negative feedback mechanism for p73 degradation. p73 mutants with compromised transactivation activity are generally more stable than the full-length TAp73 form. TAp73 appears to promote its own turnover as well as that of other p73 forms, including the Delta Np73 that lacks the amino-terminal transactivation domain, in a transactivation-dependent manner. This degradation-inducing property of TAp73 was inhibited only by p73 mutants that also inhibit the transactivation activity TAp73 but not by mutant p53, highlighting the specificity in the regulation of p73 stability. Moreover, regions in the amino and carboxyl termini of p73 confer both stabilizing and destabilizing effects on the protein, independent of its transactivation ability. Finally, we have identified the regions between amino acids 56 and 248 of p73 as being the region required for p73-mediated and for ubiquitin-mediated degradation. Taken together, the data suggest that p73 turnover is tightly regulated in a transactivation-dependent and -independent manner, resulting in the controlled expression of the various p73 forms.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore	Dulloo, I (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg		Dulloo, Iqbal/0000-0001-6899-8338				Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Kawai H, 2001, J BIOL CHEM, V276, P45928, DOI 10.1074/jbc.M107770200; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Lin KW, 2004, NEOPLASIA, V6, P546, DOI 10.1593/neo.04205; Maisse C, 2004, CELL DEATH DIFFER, V11, P685, DOI 10.1038/sj.cdd.4401376; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; Nakagawa T, 2003, CANCER LETT, V197, P105, DOI 10.1016/S0304-3835(03)00090-9; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Slade N, 2004, CELL DEATH DIFFER, V11, P357, DOI 10.1038/sj.cdd.4401335; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Toh WH, 2004, J BIOL CHEM, V279, P44713, DOI 10.1074/jbc.M407672200; Tsai KKC, 2003, CANCER RES, V63, P3418; Vikhanskaya F, 2005, CLIN CANCER RES, V11, P4348, DOI 10.1158/1078-0432.CCR-04-1547; Wu LQ, 2004, ONCOGENE, V23, P4032, DOI 10.1038/sj.onc.1207538; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zeng XY, 2001, J BIOL CHEM, V276, P48, DOI 10.1074/jbc.C000722200; Zhu JH, 1998, CANCER RES, V58, P5061	49	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28203	28214		10.1074/jbc.M501702200	http://dx.doi.org/10.1074/jbc.M501702200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15919663	hybrid			2022-12-25	WOS:000230857300006
J	Herman-Antosiewicz, A; Singh, SV				Herman-Antosiewicz, A; Singh, SV			Checkpoint kinase 1 regulates diallyl trisulfide-induced mitotic arrest in human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; OCCURRING ORGANOSULFUR COMPOUNDS; CHROMOSOME CONDENSATION; FLOW-CYTOMETRY; HISTONE H2AX; COLON-CANCER; S-ALLYLMERCAPTOCYSTEINE; MAMMARY CARCINOGENESIS; IONIZING-RADIATION; ALLIUM VEGETABLES	We have shown previously that diallyl trisulfide ( DATS), a constituent of processed garlic, inhibits proliferation of PC-3 and DU145 human prostate cancer cells by causing G(2)-M phase cell cycle arrest in association with inhibition of cyclin-dependent kinase 1 activity and hyperphosphorylation of Cdc25C at Ser(216). Here, we report that DATS-treated PC-3 and DU145 cells are also arrested in mitosis as judged by microscopy following staining with anti-alpha-tubulin antibody and 4', 6-diamidino-2- phenylindole and flow cytometric analysis of Ser(10) phosphorylation of histone H3. The DATS treatment caused activation of checkpoint kinase 1 and checkpoint kinase 2, which are intermediaries of DNA damage checkpoints and implicated in Ser(216) phosphorylation of Cdc25C. The diallyl trisulfide-induced Ser(216) phosphorylation of Cdc25C as well as mitotic arrest were significantly attenuated by knockdown of checkpoint kinase 1 protein in both PC-3 and DU145 cells. On the other hand, depletion of checkpoint kinase 2 protein did not have any appreciable effect on G(2) or M phase arrest or Cdc25C phosphorylation caused by diallyl trisulfide. The lack of a role of checkpoint kinase 2 in diallyl trisulfide-induced phosphorylation of Cdc25C or G2-M phase cell cycle arrest was confirmed using HCT-15 cells stably transfected with phosphorylation-deficient mutant ( T68A mutant) of checkpoint kinase 2. In conclusion, the results of the present study suggest existence of a checkpoint kinase 1-dependent mechanism for diallyl trisulfide-induced mitotic arrest in human prostate cancer cells.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Singh, SV (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Sch Med, Res Pavil Suite 2-32A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@upmc.edu		Herman-Antosiewicz, Anna/0000-0003-0526-2168	NCI NIH HHS [CA076348, CA113363, CA101753] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA113363, R01CA076348, R01CA101753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; AJIRO K, 1983, J BIOL CHEM, V258, P4534; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; BLOCK E, 1992, ANGEW CHEM INT EDIT, V31, P1135, DOI 10.1002/anie.199211351; Brennan RJ, 1998, MUTAT RES-FUND MOL M, V403, P65, DOI 10.1016/S0027-5107(98)00050-5; Challier B, 1998, EUR J EPIDEMIOL, V14, P737, DOI 10.1023/A:1007512825851; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; DORANT E, 1993, BRIT J CANCER, V67, P424, DOI 10.1038/bjc.1993.82; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Filomeni G, 2003, CANCER RES, V63, P5940; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Herman-Antosiewicz A, 2004, MUTAT RES-FUND MOL M, V555, P121, DOI 10.1016/j.mrfmmm.2004.04.016; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Hsing AW, 2002, J NATL CANCER I, V94, P1648, DOI 10.1093/jnci/94.21.1648; Huang XX, 2005, P NATL ACAD SCI USA, V102, P1065, DOI 10.1073/pnas.0409130102; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Knowles LM, 1998, NUTR CANCER, V30, P169, DOI 10.1080/01635589809514659; Knowles LM, 2000, CARCINOGENESIS, V21, P1129, DOI 10.1093/carcin/21.6.1129; Kwon KB, 2002, BIOCHEM PHARMACOL, V63, P41, DOI 10.1016/S0006-2952(01)00860-7; Liu QH, 2000, GENE DEV, V14, P1448; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Milner JA, 2001, J NUTR, V131, p1027S, DOI 10.1093/jn/131.3.1027S; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nakagawa H, 2001, CARCINOGENESIS, V22, P891, DOI 10.1093/carcin/22.6.891; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; REDDY BS, 1993, CANCER RES, V53, P3493; Robert V, 2001, CARCINOGENESIS, V22, P1155, DOI 10.1093/carcin/22.8.1155; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Schaffer EM, 1996, CANCER LETT, V102, P199, DOI 10.1016/0304-3835(96)04160-2; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shirin H, 2001, CANCER RES, V61, P725; Singh SV, 1996, BIOCHEM BIOPH RES CO, V225, P660, DOI 10.1006/bbrc.1996.1226; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; Singh SV, 2001, J NUTR, V131, p1046S, DOI 10.1093/jn/131.3.1046S; SPARNINS VL, 1988, CARCINOGENESIS, V9, P131, DOI 10.1093/carcin/9.1.131; SUMIYOSHI H, 1990, CANCER RES, V50, P5084; Sundaram SG, 1996, CARCINOGENESIS, V17, P669, DOI 10.1093/carcin/17.4.669; Suzui N, 1997, JPN J CANCER RES, V88, P705, DOI 10.1111/j.1349-7006.1997.tb00440.x; TAKADA N, 1994, CANCER RES, V54, P2895; TAKAHASHI S, 1992, CARCINOGENESIS, V13, P1513, DOI 10.1093/carcin/13.9.1513; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; WARGOVICH MJ, 1987, CARCINOGENESIS, V8, P487, DOI 10.1093/carcin/8.3.487; WARGOVICH MJ, 1988, CANCER RES, V48, P6872; WATTENBERG LW, 1989, CANCER RES, V49, P2689; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Widrow RJ, 1997, CYTOMETRY, V27, P250, DOI 10.1002/(SICI)1097-0320(19970301)27:3<250::AID-CYTO6>3.0.CO;2-I; Widrow RJ, 2000, CYTOMETRY, V39, P126, DOI 10.1002/(SICI)1097-0320(20000201)39:2<126::AID-CYTO5>3.0.CO;2-V; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; XIAO D, 2005, IN PRESS ONCOGENE; Xiao DH, 2003, CANCER RES, V63, P6825; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; YOU WC, 1989, J NATL CANCER I, V81, P162, DOI 10.1093/jnci/81.2.162; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	77	84	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28519	28528		10.1074/jbc.M501443200	http://dx.doi.org/10.1074/jbc.M501443200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15961392	hybrid			2022-12-25	WOS:000230857300042
J	Kim, J; Shen, R; Olcott, MC; Rajagopal, I; Mathews, CK				Kim, J; Shen, R; Olcott, MC; Rajagopal, I; Mathews, CK			Adenylate kinase of Escherichia coli, a component of the phage T4 dNTP synthetase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-INFECTED BACTERIA; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; DEOXYNUCLEOTIDE KINASE; DEOXYCYTIDYLATE HYDROXYMETHYLASE; REPLICATION HYPERSTRUCTURE; PHOSPHOLIPID-SYNTHESIS; NUCLEOTIDE-METABOLISM; THYMIDYLATE SYNTHASE; DNA PRECURSORS; AMBER MUTANTS	Adenylate kinase, which catalyzes the reversible ATP-dependent phosphorylation of AMP to ADP and dAMP to dADP, can also catalyze the conversion of nucleoside diphosphates to the corresponding triphosphates. Lu and Inouye (Lu, Q., and Inouye, M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5720-5725) showed that an Escherichia coli ndk mutant, lacking nucleoside diphosphate kinase, can use adenylate kinase as an alternative source of nucleoside triphosphates. Bacteriophage T4 can reproduce in an Escherichia coli ndk mutant, implying that adenylate kinase can meet a demand for deoxyribonucleoside triphosphates that increases by up to 10-fold as a result of T4 infection. In terms of kinetic linkage and specific protein-protein associations, NDP kinase is an integral component of T4 dNTP synthetase, a multienzyme complex containing phage-coded enzymes, which facilitates the synthesis of dNTPs and their flow into DNA. Here we asked whether, by similar criteria, adenylate kinase of the host cell is also a specific component of the complex. Experiments involving protein affinity chromatography, immunoprecipitation, optical biosensor measurements, and glutathione S-transferase pulldowns demonstrated direct interactions between adenylate kinase and several phage-coded enzymes, as well as E. coli nucleoside diphosphate kinase. These results identify adenylate kinase as a specific component of the complex. The rate of DNA synthesis after infection of an ndk mutant was found to be about 40% of the rate seen in wild-type infection, implying that complementation of the missing NDP kinase function by adenylate kinase is fairly efficient, but that adenylate kinase becomes rate-limiting for DNA synthesis when it is the sole source of dNTPs.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.	mathewsc@onid.orst.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 00210] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEN JR, 1983, J BIOL CHEM, V258, P5746; BELFORT M, 1983, J BIOL CHEM, V258, P2045; BELLO LJ, 1963, BIOCHIM BIOPHYS ACTA, V72, P647; BELLO LJ, 1963, J BIOL CHEM, V238, P1777; Bernard MA, 2000, J BIOENERG BIOMEMBR, V32, P259, DOI 10.1023/A:1005537013120; BERNARD MA, 1999, THESIS OREGON STATE; Boyer P.D, 1973, ENZYMES, P279; BRUSH GS, 1990, J BACTERIOL, V172, P2935, DOI 10.1128/jb.172.6.2935-2939.1990; COHEN SS, 1961, J BIOL CHEM, V237, P1376; COLLINSWORTH WL, 1974, J VIROL, V13, P908, DOI 10.1128/JVI.13.4.908-915.1974; CRONAN JE, 1972, MOL GEN GENET, V116, P199, DOI 10.1007/BF00269765; DUCKWORTH DH, 1967, J BIOL CHEM, V242, P2877; Giartosio A, 1996, J BIOL CHEM, V271, P17845, DOI 10.1074/jbc.271.30.17845; GOELZ SE, 1982, BIOCHEMISTRY-US, V21, P189, DOI 10.1021/bi00530a032; Guzman EC, 2002, MOL MICROBIOL, V43, P487, DOI 10.1046/j.1365-2958.2002.02761.x; HAASE GHW, 1989, J MOL BIOL, V207, P151, DOI 10.1016/0022-2836(89)90446-4; HANSON E, 1994, J BIOL CHEM, V269, P30999; Kim J, 2005, MOL MICROBIOL, V55, P1502, DOI 10.1111/j.1365-2958.2004.04486.x; Lu Q, 1996, P NATL ACAD SCI USA, V93, P5720, DOI 10.1073/pnas.93.12.5720; MATHEWS CK, 1966, BIOCHEMISTRY-US, V5, P2092, DOI 10.1021/bi00870a042; MATHEWS CK, 1982, P NATL ACAD SCI-BIOL, V79, P302, DOI 10.1073/pnas.79.2.302; MATHEWS CK, 1993, PROG NUCLEIC ACID RE, V44, P167, DOI 10.1016/S0079-6603(08)60220-2; Molina F, 2004, MOL MICROBIOL, V52, P1597, DOI 10.1111/j.1365-2958.2004.04097.x; MOORE JT, 1993, J BIOL CHEM, V268, P2288; PUROHIT S, 1984, J BIOL CHEM, V259, P6261; REDDY GPV, 1978, J BIOL CHEM, V253, P3461; Shen RK, 2004, J BIOL CHEM, V279, P32225, DOI 10.1074/jbc.M402750200; Shen Y, 2005, J BIOL CHEM, V280, P5740, DOI 10.1074/jbc.M408965200; TSENG MJ, 1992, J BACTERIOL, V174, P5740, DOI 10.1128/JB.174.17.5740-5744.1992; WHEELER L, 1992, J BIOL CHEM, V267, P7664; Wheeler LJ, 1996, J BIOL CHEM, V271, P11156, DOI 10.1074/jbc.271.19.11156; YOUNG JP, 1992, J BIOL CHEM, V267, P10786; Zhang XL, 1996, J BACTERIOL, V178, P4115, DOI 10.1128/jb.178.14.4115-4121.1996	33	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28221	28229		10.1074/jbc.M502201200	http://dx.doi.org/10.1074/jbc.M502201200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15941717	hybrid			2022-12-25	WOS:000230857300008
J	Li, J; Lim, SP; Beer, D; Patel, V; Wen, DY; Tumanut, C; Tully, DC; Williams, JA; Jiricek, J; Priestle, JP; Harris, JL; Vasudevan, SG				Li, J; Lim, SP; Beer, D; Patel, V; Wen, DY; Tumanut, C; Tully, DC; Williams, JA; Jiricek, J; Priestle, JP; Harris, JL; Vasudevan, SG			Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; IN-VITRO; NONSTRUCTURAL PROTEINS; CRYSTAL-STRUCTURE; VIRAL PROTEASE; TYPE-2; NS2B; POLYPROTEIN; CLEAVAGE; SPECIFICITY	Regulated proteolysis by the two-component NS2B/NS3 protease of dengue virus is essential for virus replication and the maturation of infectious virions. The functional similarity between the NS2B/NS3 proteases from the four genetically and antigenically distinct serotypes was addressed by characterizing the differences in their substrate specificity using tetrapeptide and octapeptide libraries in a positional scanning format, each containing 130,321 substrates. The proteases from different serotypes were shown to be functionally homologous based on the similarity of their substrate cleavage preferences. A strong preference for basic amino acid residues ( Arg/Lys) at the P1 positions was observed, whereas the preferences for the P2 - 4 sites were in the order of Arg > Thr > Gln/Asn/Lys for P2, Lys > Arg > Asn for P3, and Nle > Leu > Lys > Xaa for P4. The prime site substrate specificity was for small and polar amino acids in P1' and P3'. In contrast, the P2' and P4' substrate positions showed minimal activity. The influence of the P2 and P3 amino acids on ground state binding and the P4 position for transition state stabilization was identified through single substrate kinetics with optimal and suboptimal substrate sequences. The specificities observed for dengue NS2B/NS3 have features in common with the physiological cleavage sites in the dengue polyprotein; however, all sites reveal previously unrecognized suboptimal sequences.	Novartis Inst Trop Dis, Singapore 138670, Singapore; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	Novartis; Novartis; Novartis	Harris, JL (corresponding author), Novartis Inst Trop Dis, 10 Biopolis Rd,05-01 Chromos, Singapore 138670, Singapore.	jharris@gnf.org; subhash.vasudevan@group.novartis.com	Lim, Siew Pheng/P-8528-2016; Jiricek, Jan/AAA-4701-2021; Pheng, Lim Siew/AAG-4368-2021	Pheng, Lim Siew/0000-0002-7377-5662; Vasudevan, Subhash/0000-0002-5083-3831				ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; COPELAND RA, 2000, ENZYMES PRACTICAL IN, P313; ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Khumthong R, 2003, PROTEIN PEPTIDE LETT, V10, P19, DOI 10.2174/0929866033408228; Khumthong R, 2002, J BIOCHEM MOL BIOL, V35, P206; Kuzmic P, 2000, ANAL BIOCHEM, V281, P62, DOI 10.1006/abio.2000.4501; Leung D, 2001, J BIOL CHEM, V276, P45762, DOI 10.1074/jbc.M107360200; Matusan AE, 2001, J VIROL, V75, P9633, DOI 10.1128/JVI.75.20.9633-9643.2001; Matusan AE, 2001, J GEN VIROL, V82, P1647, DOI 10.1099/0022-1317-82-7-1647; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; Murthy HMK, 2000, J MOL BIOL, V301, P759, DOI 10.1006/jmbi.2000.3924; Nall TA, 2004, J BIOL CHEM, V279, P48535, DOI 10.1074/jbc.M406810200; Petrassi HM, 2005, BIOORG MED CHEM LETT, V15, P3162, DOI 10.1016/j.bmcl.2005.04.019; PETTIT SC, 1994, J VIROL, V68, P8017, DOI 10.1128/JVI.68.12.8017-8027.1994; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PINILLA C, 1992, BIOTECHNIQUES, V13, P904; PREUGSCHAT F, 1991, VIROLOGY, V185, P689, DOI 10.1016/0042-6822(91)90540-R; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rothman AL, 2004, J CLIN INVEST, V113, P946, DOI [10.1172/JCI200421512, 10.1172/JCI21512]; Shipway A, 2004, BIOCHEM BIOPH RES CO, V324, P953, DOI 10.1016/j.bbrc.2004.09.123; Stadler K, 1997, J VIROL, V71, P8475, DOI 10.1128/JVI.71.11.8475-8481.1997; Valle RPC, 1998, J VIROL, V72, P624, DOI 10.1128/JVI.72.1.624-632.1998; Wiegers K, 1998, J VIROL, V72, P2846, DOI 10.1128/JVI.72.4.2846-2854.1998; Yusof R, 2000, J BIOL CHEM, V275, P9963, DOI 10.1074/jbc.275.14.9963; ZERNER B, 1964, J AM CHEM SOC, V86, P3669, DOI 10.1021/ja01072a015; ZHANG LW, 1992, J VIROL, V66, P7549, DOI 10.1128/JVI.66.12.7549-7554.1992	38	206	213	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28766	28774		10.1074/jbc.M500588200	http://dx.doi.org/10.1074/jbc.M500588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15932883	hybrid			2022-12-25	WOS:000230857300068
J	Millard, EE; Gale, SE; Dudley, N; Zhang, J; Schaffer, JE; Ory, DS				Millard, EE; Gale, SE; Dudley, N; Zhang, J; Schaffer, JE; Ory, DS			The sterol-sensing domain of the Niemann-Pick C1 (NPC1) protein regulates trafficking of low density lipoprotein cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; INTRACELLULAR TRAFFICKING; VESICULAR TRAFFICKING; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; BINDING; HOMEOSTASIS; SCAP; MUTATIONS; TRANSPORT	The Niemann-Pick C1 ( NPC1) protein is a key participant in intracellular sterol trafficking and regulation of cholesterol homeostasis. NPC1 contains a pentahelical region that is evolutionarily related to sterol-sensing domains found in other polytopic proteins involved in sterol interactions or sterol metabolism, including sterol regulatory element-binding protein cleavage-activating protein and hydroxymethylglutaryl-CoA reductase. To gain insight into the role of the sterol-sensing domain of NPC1, we examined the effect of point mutations in the NPC1 sterol- sensing domain on the trafficking of low density lipoprotein-derived cholesterol and sphingolipids. We show that an NPC1 P692S loss of function mutation results in decreased cholesterol delivery to the plasma membrane and endoplasmic reticulum. By contrast, NPC1 proteins carrying a L657F or D787N point mutation, which correspond to the activating SCAP L315F and D443N mutations, respectively, exhibit a gain of function phenotype. Specifically, cell lines expressing the NPC1 L657F or D787N mutations show a nearly 2-fold increase in the rates of low density lipoprotein cholesterol trafficking to the plasma membrane and to the endoplasmic reticulum, and more rapid suppression of sterol regulatory element-binding protein-dependent gene expression. Trafficking of sphingolipids is intact in the D787N and L657F cell lines. Our finding that D787N and L657F are activating NPC1 mutations provide evidence for a conserved mechanism for the sterol- sensing domain among cholesterol homeostatic proteins.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Ory, DS (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, St Louis, MO 63110 USA.	dory@wustl.edu			NHLBI NIH HHS [HL67773, HL04482] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067773, K02HL004482] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; Frolov A, 2001, J BIOL CHEM, V276, P46414, DOI 10.1074/jbc.M108099200; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Malathi K, 2004, J CELL BIOL, V164, P547, DOI 10.1083/jcb.200310046; Martin V, 2001, CURR BIOL, V11, P601, DOI 10.1016/S0960-9822(01)00178-6; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; Ory DS, 2004, TRENDS CARDIOVAS MED, V14, P66, DOI 10.1016/j.tcm.2003.12.003; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Sugii S, 2003, J BIOL CHEM, V278, P27180, DOI 10.1074/jbc.M300542200; Sun XF, 2001, AM J HUM GENET, V68, P1361, DOI 10.1086/320599; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200; Zhang SC, 2004, TRAFFIC, V5, P1017, DOI 10.1111/j.1600-0854.2004.00241.x	37	81	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28581	28590		10.1074/jbc.M414024200	http://dx.doi.org/10.1074/jbc.M414024200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15908696	hybrid			2022-12-25	WOS:000230857300049
J	Mulero-Navarro, S; Pozo-Guisado, E; Perez-Mancera, PA; Alvarez-Barrientos, A; Catalina-Fernandez, I; Hernandez-Nieto, E; Saenz-Santamaria, J; Martinez, N; Rojas, JM; Sanchez-Garcia, I; Fernandez-Salguero, PM				Mulero-Navarro, S; Pozo-Guisado, E; Perez-Mancera, PA; Alvarez-Barrientos, A; Catalina-Fernandez, I; Hernandez-Nieto, E; Saenz-Santamaria, J; Martinez, N; Rojas, JM; Sanchez-Garcia, I; Fernandez-Salguero, PM			Immortalized mouse mammary fibroblasts lacking dioxin receptor have impaired tumorigenicity in a subcutaneous mouse xenograft model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; GROWTH-FACTOR-BETA; CYCLIN D1 EXPRESSION; AH RECEPTOR; CELL-CYCLE; NUCLEAR TRANSLOCATION; DEPENDENT ACTIVATION; DEFICIENT MICE; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; SIGNAL-TRANSDUCTION	Although the dioxin receptor, the aryl hydrocarbon receptor ( AhR), is considered a major regulator of xenobiotic-induced carcinogenesis, its role in tumor formation in the absence of xenobiotics is still largely unknown. Trying to address this question, we have produced immortalized cell lines from wild-type ( T-FGM-AhR+/+) and mutant ( T-FGM-AhR-/-) mouse mammary fibroblasts by stable co-transfection with the simian virus 40 ( SV-40) large T antigen and proto-oncogenic c-H-Ras. Both cell lines had a myofibroblast phenotype and similar proliferation, doubling time, SV-40 and c-H-Ras expression and activity, and cell cycle distribution. AhR+/+ and AhR-/- cells were also equally able to support growth factor- and anchorage-independent proliferation. However, the ability of T-FGM-AhR-/- to induce subcutaneous tumors ( leimyosarcomas) in NOD/SCID-immunodeficient mice was close to 4-fold lower than T-FGM-AhR-/-. In culture, T-FGM-AhR-/- had diminished migration in collagen-I and decreased lamellipodia formation. VEGFR-1/Flt-1, a VEGF receptor that regulates cell migration and blood vessel formation, was also down-regulated in AhR-/- cells. Signaling through the ERK-FAK-PKB/AKT-Rac-1 pathway, which contributes to cell motility and invasion, was also significantly inhibited in T-FGM-AhR-/-. Thus, the lower tumorigenic potential of T-FGM-AhR-/- could result from a compromised adaptability of these cells to the in vivo microenvironment, possibly because of an impaired ability to migrate and to respond to angiogenesis.	Univ Extremadura, Fac Ciencias, Dept Bioquim & Biol Mol, E-06071 Badajoz, Spain; Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain; Fdn Ctr Nacl Invest Cardiovasc Carlos 3, Madrid, Spain; Hosp Perpetuo Socorro, Badajoz 06010, Spain; Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biol Celular, Madrid, Spain	Universidad de Extremadura; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Fernandez-Salguero, PM (corresponding author), Univ Extremadura, Fac Ciencias, Dept Bioquim & Biol Mol, Avenida Elvas S-N, E-06071 Badajoz, Spain.	pmfersal@unex.es	SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Rojas, José M./AAA-3354-2021; Pozo-Guisado, Eulalia/AAP-4280-2021; CATALINA FERNANDEZ, INMACULADA/AAD-4131-2022; Alvarez-Barrientos, Alberto/L-9299-2014; Fernandez-Salguero, Pedro M./J-8437-2014; Rojas, José M/D-3718-2018	Rojas, José M./0000-0002-7547-2825; Pozo-Guisado, Eulalia/0000-0003-3486-6411; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Fernandez-Salguero, Pedro M./0000-0003-2839-5027; Rojas, José M/0000-0002-5383-3482; Mulero Navarro, Sonia/0000-0001-5739-8062; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				ABBOTT BD, 1995, DEV DYNAM, V204, P133, DOI 10.1002/aja.1002040204; Abbott BD, 1999, TOXICOL APPL PHARM, V155, P62, DOI 10.1006/taap.1998.8601; Abbott BD, 1999, TOXICOL SCI, V47, P62, DOI 10.1093/toxsci/47.1.62; Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Alexander DL, 1998, J CELL SCI, V111, P3311; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Beachy TM, 2002, J VIROL, V76, P3145, DOI 10.1128/JVI.76.7.3145-3157.2002; Berwick M, 2004, J CLIN ONCOL, V22, P3997, DOI 10.1200/JCO.2004.10.059; Bittinger MA, 2003, MOL PHARMACOL, V64, P550, DOI 10.1124/mol.64.3.550; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Cho YC, 2004, TOXICOL APPL PHARM, V199, P220, DOI 10.1016/j.taap.2003.12.025; Ciolino HP, 1998, CANCER RES, V58, P2754; Corchero J, 2004, INT J EXP PATHOL, V85, P295, DOI 10.1111/j.0959-9673.2004.00397.x; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Elizondo G, 2000, MOL PHARMACOL, V57, P1056; Enan E, 1996, BIOCHEM PHARMACOL, V52, P1599, DOI 10.1016/S0006-2952(96)00566-7; Enan E, 1998, J BIOCHEM MOL TOXIC, V12, P263, DOI 10.1002/(SICI)1099-0461(1998)12:5<263::AID-JBT2>3.0.CO;2-J; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Fisher C, 2004, ADV ANAT PATHOL, V11, P190, DOI 10.1097/01.pap.0000131773.16130.aa; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gazziola C, 2003, INT J ONCOL, V23, P343; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Hahn ME, 2002, CHEM-BIOL INTERACT, V141, P131, DOI 10.1016/S0009-2797(02)00070-4; Heidenreich R, 2004, INT J CANCER, V111, P348, DOI 10.1002/ijc.20260; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang GM, 2005, MOL PHARMACOL, V67, P88, DOI 10.1124/mol.104.002410; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Ito T, 2004, J BIOL CHEM, V279, P25204, DOI 10.1074/jbc.M402143200; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Long WP, 1998, MOL PHARMACOL, V53, P691, DOI 10.1124/mol.53.4.691; Marcoux N, 2003, ONCOGENE, V22, P6100, DOI 10.1038/sj.onc.1206712; Marlowe JL, 2004, J BIOL CHEM, V279, P29013, DOI 10.1074/jbc.M404315200; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Moennikes O, 2004, CANCER RES, V64, P4707, DOI 10.1158/0008-5472.CAN-03-0875; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Niermann T, 2003, BIOCHEM BIOPH RES CO, V300, P943, DOI 10.1016/S0006-291X(02)02970-4; Nievers MG, 1997, J CELL SCI, V110, P389; Noel A, 1998, J MAMMARY GLAND BIOL, V3, P215, DOI 10.1023/A:1018703208453; Oliva JL, 2004, J BIOL CHEM, V279, P33480, DOI 10.1074/jbc.M404058200; Puga A, 2005, BIOCHEM PHARMACOL, V69, P199, DOI 10.1016/j.bcp.2004.06.043; Puga A, 2002, CHEM-BIOL INTERACT, V141, P117, DOI 10.1016/S0009-2797(02)00069-8; Raul U, 2004, INT J CANCER, V111, P662, DOI 10.1002/ijc.20349; Reiners JJ, 1997, MOL CARCINOGEN, V19, P91, DOI 10.1002/(SICI)1098-2744(199707)19:2<91::AID-MC4>3.0.CO;2-O; Reiners JJ, 1998, MOL PHARMACOL, V53, P438, DOI 10.1124/mol.53.3.438; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Roovers K, 2003, DEV CELL, V5, P273, DOI 10.1016/S1534-5807(03)00206-5; SADEK CM, 1994, J BIOL CHEM, V269, P16067; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; Santiago-Josefat B, 2004, J CELL SCI, V117, P849, DOI 10.1242/jcs.00932; Santiago-Josefat B, 2003, J MOL BIOL, V333, P249, DOI 10.1016/j.jmb.2003.08.020; Santiago-Josefat B, 2001, MOL CELL BIOL, V21, P1700, DOI 10.1128/MCB.21.5.1700-1709.2001; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Smart J, 2000, PHARMACOGENETICS, V10, P11, DOI 10.1097/00008571-200002000-00003; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tohkin M, 2000, MOL PHARMACOL, V58, P845, DOI 10.1124/mol.58.4.845; Walisser JA, 2004, P NATL ACAD SCI USA, V101, P16677, DOI 10.1073/pnas.0404379101; Weaver VM, 1996, BIOCHEM CELL BIOL, V74, P833, DOI 10.1139/o96-089; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313; Zamir E, 2001, J CELL SCI, V114, P3583	75	75	81	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28731	28741		10.1074/jbc.M504538200	http://dx.doi.org/10.1074/jbc.M504538200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15946950	hybrid			2022-12-25	WOS:000230857300064
J	Barthet, G; Gaven, F; Framery, B; Shinjo, K; Nakamura, T; Claeysen, S; Bockaert, L; Dumuis, A				Barthet, G; Gaven, F; Framery, B; Shinjo, K; Nakamura, T; Claeysen, S; Bockaert, L; Dumuis, A			Uncoupling and endocytosis of 5-hydroxytryptamine 4 receptors - Distinct molecular events with different GRK2 requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; PHOSPHORYLATION-INDEPENDENT REGULATION; AGONIST-INDUCED INTERNALIZATION; BETA-ARRESTIN; ADENYLATE-CYCLASE; 5-HT4 RECEPTORS; MEDIATED ENDOCYTOSIS; PARATHYROID-HORMONE; COLLICULI NEURONS	The 5-hydroxytryptamine type 4 receptors (5-HT(4)Rs) are involved in memory, cognition, feeding, respiratory control, and gastrointestinal motility through activation of a G(s)/cAMP pathway. We have shown that 5-HT4R undergoes rapid and profound homologous uncoupling in neurons. However, no significant uncoupling was observed in COS-7 or HEK293 cells, which expressed either no or a weak concentration of GRK2, respectively. High expression of GRK2 in neurons is likely to be the reason for this difference because overexpression of GRK2 in COS-7 and HEK293 cells reproduced rapid and profound uncoupling of 5-HT4R. We have also shown, for the first time, that GRK2 requirements for uncoupling and endocytosis were very different. Indeed, beta-arrestin/dynamin-dependent endocytosis was observed in HEK293 cells without any need of GRK2 overexpression. In addition to this difference, uncoupling and beta-arrestin/dynamin-dependent endocytosis were mediated through distinct mechanisms. Neither uncoupling nor beta-arrestin/dynamin-dependent endocytosis required the serine and threonine residues localized within the specific C-terminal domains of the 5-HT4R splice variants. In contrast, a cluster of serines and threonines, common to all variants, was an absolute requirement for beta-arrestin/dynamin-dependent receptor endocytosis, but not for receptor uncoupling. Furthermore, beta-arrestin/dynamin-dependent endocytosis and uncoupling were dependent on and independent of GRK2 kinase activity, respectively. These results clearly demonstrate that the uncoupling and endocytosis of 5-HT4R require different GRK2 concentrations and involve distinct molecular events.	Inst Genom Fonct, Dept Neurobiol, F-34094 Montpellier, France; CNRS, UMR 5203, F-34094 Montpellier, France; INSERM, U661, F-34094 Montpellier, France; Univ Montpellier 1, F-34094 Montpellier, France; Univ Montpellier 2, F-34094 Montpellier, France; Pfizer Japan Inc, Nagoya Labs, Aichi 4702393, Japan	Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Universite de Montpellier; Pfizer	Bockaert, L (corresponding author), Inst Genom Fonct, Dept Neurobiol, 141 Rue Cardonille, F-34094 Montpellier, France.	joel.bockaert@igf.cnrs.fr	Claeysen, Sylvie/C-8599-2014	Claeysen, Sylvie/0000-0002-0576-5518; Barthet, Gael/0000-0003-4025-1616				ADAMUS G, 1991, J NEUROIMMUNOL, V34, P89, DOI 10.1016/0165-5728(91)90118-Q; ANSANAY H, 1992, MOL PHARMACOL, V42, P808; Bender E, 2000, J NEUROCHEM, V74, P478, DOI 10.1046/j.1471-4159.2000.740478.x; Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; Bockaert J, 2004, CNS NEUROL DISORD-DR, V3, P39, DOI 10.2174/1568007043482615; Bockaert J, 1997, HANDB EXP PHARM, V129, P439; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Cao H, 2000, J CELL SCI, V113, P1993; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Celver J, 2004, MOL PHARMACOL, V65, P528, DOI 10.1124/mol.65.3.528; Chen ZG, 2004, MOL PHARMACOL, V66, P377; Claeysen S, 1999, MOL PHARMACOL, V55, P910; Clark RB, 2003, MOL PHARMACOL, V64, P1015, DOI 10.1124/mol.64.5.1015; Compan V, 2004, J NEUROSCI, V24, P412, DOI 10.1523/JNEUROSCI.2806-03.2004; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; DUMUIS A, 1988, MOL PHARMACOL, V34, P880; FAGNI L, 1992, BRIT J PHARMACOL, V105, P973, DOI 10.1111/j.1476-5381.1992.tb09087.x; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gage RM, 2005, J BIOL CHEM, V280, P3305, DOI 10.1074/jbc.M406934200; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Gershon MD, 2004, ALIMENT PHARM THER, V20, P3, DOI 10.1111/j.1365-2036.2004.02180.x; Gray JA, 2003, MOL PHARMACOL, V63, P961, DOI 10.1124/mol.63.5.961; Gray JA, 2001, MOL PHARMACOL, V60, P1020, DOI 10.1124/mol.60.5.1020; Hiroi T, 2001, BIOCHEM BIOPH RES CO, V289, P337, DOI 10.1006/bbrc.2001.5979; Holliday ND, 2005, MOL PHARMACOL, V67, P655, DOI 10.1124/mol.104.006114; Iwata K, 2005, J BIOL CHEM, V280, P2197, DOI 10.1074/jbc.M408834200; Joubert L, 2004, J CELL SCI, V117, P5367, DOI 10.1242/jcs.01379; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lucas G, 2005, BIOL PSYCHIAT, V57, P918, DOI 10.1016/j.biopsych.2004.12.023; Luttrell LM, 2002, J CELL SCI, V115, P455; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; MarchettiGauthier E, 1997, NEUROPHARMACOLOGY, V36, P697, DOI 10.1016/S0028-3908(97)00058-0; Moser PC, 2002, J PHARMACOL EXP THER, V302, P731, DOI 10.1124/jpet.102.034249; MUKHERJEE C, 1975, P NATL ACAD SCI USA, V72, P1945, DOI 10.1073/pnas.72.5.1945; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Ponimaskin E, 2005, MOL PHARMACOL, V67, P1434, DOI 10.1124/mol.104.008748; Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; Smyth EM, 2000, J BIOL CHEM, V275, P32037, DOI 10.1074/jbc.M003873200; SU YF, 1980, J BIOL CHEM, V255, P7410; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tulipano G, 2004, J BIOL CHEM, V279, P21374, DOI 10.1074/jbc.M313522200; van Koppen CJ, 2003, PHARMACOL THERAPEUT, V98, P197, DOI 10.1016/S0163-7258(03)00032-9; Vines CM, 2003, J BIOL CHEM, V278, P41581, DOI 10.1074/jbc.C300291200; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Willets JM, 2004, J NEUROSCI, V24, P4157, DOI 10.1523/JNEUROSCI.5506-03.2004	64	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27924	27934		10.1074/jbc.M502272200	http://dx.doi.org/10.1074/jbc.M502272200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15919661	Green Published, hybrid			2022-12-25	WOS:000230678600055
J	Belcheva, MM; Clark, AL; Haas, PD; Serna, JS; Hahn, JW; Kiss, A; Coscia, CJ				Belcheva, MM; Clark, AL; Haas, PD; Serna, JS; Hahn, JW; Kiss, A; Coscia, CJ			mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; SIGNAL-REGULATED KINASE; COUPLED RECEPTORS; CALMODULIN-BINDING; EGF RECEPTOR; GLIOMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; DOWN-REGULATION; ERK ACTIVATION	Acute mu and kappa opioids activate the ERK/ MAPK phosphorylation cascade that represents an integral part of the signaling pathway of growth factors in astrocytes. By this cross-talk, opioids may impact neural development and plasticity among other basic neurobiological processes in vivo. The mu agonist, [D-ala(2), mephe(4), glyol(5)] enkephalin ( DAMGO), induces a transient stimulation of ERK phosphorylation, whereas kappa agonist, U69,593, engenders sustained ERK activation. Here we demonstrate that acute U69,593 and DAMGO stimulate ERK phosphorylation by utilization of different secondary messengers and protein kinase C (PKC) isoforms upstream of the growth factor pathway. Immortalized astrocytes transfected with either antisense calmodulin (CaM), a mutant mu opioid receptor that binds CaM poorly or a dominant negative mutant of PKC epsilon were used as a model system to study mu signaling. Evidence was gained to implicate CaM and PKC epsilon in DAMGO stimulation of ERK. DAMGO activation of PKC epsilon and/or ERK was insensitive to selective inhibitors of Ca2+ mobilization, but it was blocked upon phospholipase C inhibition. These results suggest a novel mechanism wherein, upon DAMGO binding, CaM is released from the mu receptor and activates phospholipase C. Subsequently, phospholipase C generates diacylglycerides that activate PKC epsilon. In contrast, U69,593 appears to act via phosphoinositide 3-kinase, PKC zeta, and Ca2+ mobilization. These signaling components were implicated based on studies with specific inhibitors and a dominant negative mutant of PKC zeta. Collectively, our findings on acute opioid effects suggest that differences in their mechanism of signaling may contribute to the distinct outcomes on ERK modulation induced by chronic mu and kappa opioids.	St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Coscia, CJ (corresponding author), St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	cosciacc@slu.edu	Kiss, Alexi/AAH-6830-2021	Kiss, Alexi/0000-0003-2330-6929	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005412, F32DA005412] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA005412-14, DA05412, R01 DA005412] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; Bandyopadhyay G, 2001, J BIOL CHEM, V276, P35537, DOI 10.1074/jbc.M106042200; BELCHEVA M, 1993, J NEUROSCI, V13, P104; Belcheva MM, 2000, CELL SIGNAL, V12, P481, DOI 10.1016/S0898-6568(00)00095-4; Belcheva MM, 2002, J PHARMACOL EXP THER, V303, P909, DOI 10.1124/jpet.102.038554; Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; Belcheva MM, 2003, MOL PHARMACOL, V64, P1391, DOI 10.1124/mol.64.6.1391; Belcheva MM, 2002, NEUROSIGNALS, V11, P34, DOI 10.1159/000057320; Belcheva MM, 1998, J NEUROCHEM, V70, P635; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; Bohn LM, 2000, J NEUROCHEM, V74, P574, DOI 10.1046/j.1471-4159.2000.740574.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Canto C, 2004, J BIOL CHEM, V279, P12260, DOI 10.1074/jbc.M308554200; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chakrabarti S, 2003, P NATL ACAD SCI USA, V100, P13686, DOI 10.1073/pnas.2335885100; CHEN CC, 1993, FEBS LETT, V332, P169, DOI 10.1016/0014-5793(93)80506-P; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Chow JYC, 2000, J BIOL CHEM, V275, P21169, DOI 10.1074/jbc.M002160200; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fedorov YV, 2002, MOL CELL BIOL, V22, P1140, DOI 10.1128/MCB.22.4.1140-1149.2002; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Ghosh PM, 2002, CANCER RES, V62, P2630; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hawes BE, 1998, J NEUROCHEM, V71, P1024; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Krotova KY, 2003, AM J PHYSIOL-LUNG C, V284, pL1037, DOI 10.1152/ajplung.00308.2002; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Liu KP, 2000, J NEUROSCI, V20, P1365; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Mangoura D, 1997, J NEUROSCI RES, V50, P391, DOI 10.1002/(SICI)1097-4547(19971101)50:3<391::AID-JNR5>3.0.CO;2-D; Mansat-De Mas V, 2003, BLOOD, V101, P1543, DOI 10.1182/blood-2002-05-1585; McCullar JS, 2003, J BIOL CHEM, V278, P33708, DOI 10.1074/jbc.M301940200; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; Narita M, 2001, J BIOL CHEM, V276, P15409, DOI 10.1074/jbc.M009716200; Nickols HH, 2004, J BIOL CHEM, V279, P46969, DOI 10.1074/jbc.M407351200; Olivares-Reyes JA, 2000, MOL PHARMACOL, V58, P1156, DOI 10.1124/mol.58.5.1156; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; RADANY EH, 1992, P NATL ACAD SCI USA, V89, P6467, DOI 10.1073/pnas.89.14.6467; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Shah BH, 2004, TRENDS NEUROSCI, V27, P48, DOI 10.1016/j.tins.2003.11.003; Shah BH, 2003, J BIOL CHEM, V278, P19118, DOI 10.1074/jbc.M212932200; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; Sweitzer SM, 2004, PAIN, V110, P281, DOI 10.1016/j.pain.2004.04.004; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	61	124	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27662	27669		10.1074/jbc.M502593200	http://dx.doi.org/10.1074/jbc.M502593200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15944153	Green Accepted, hybrid			2022-12-25	WOS:000230678600024
J	Etchells, SA; Meyer, AS; Yam, AY; Roobol, A; Miao, YW; Shao, YL; Carden, MJ; Skach, WR; Frydman, J; Johnson, AE				Etchells, SA; Meyer, AS; Yam, AY; Roobol, A; Miao, YW; Shao, YL; Carden, MJ; Skach, WR; Frydman, J; Johnson, AE			The cotranslational contacts between ribosome-bound nascent polypeptides and the subunits of the hetero-oligomeric chaperonin TRiC probed by photocross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; MOLECULAR CHAPERONES; CYTOSOLIC CHAPERONIN; MEMBRANE-PROTEINS; ER MEMBRANE; INTEGRATION; CHAINS; COMPLEX; BINDING; ACTIN	The hetero-oligomeric eukaryotic chaperonin TRiC (TCP-1-ring complex, also called CCT) interacts cotranslationally with a diverse subset of newly synthesized proteins, including actin, tubulin, and luciferase, and facilitates their correct folding. A photocross-linking approach has been used to map the contacts between individual chaperonin subunits and ribosome-bound nascent chains of increasing length. Whereas a cryo-EM study suggests that chemically denatured actin interacts with only two TRiC subunits (delta and either beta or epsilon), actin and luciferase chains photocross-link to at least six TRiC subunits (alpha, beta, delta, epsilon, xi, and theta) at different stages of translation. Furthermore, the photocross-linking of actin, but not luciferase, nascent chains to TRiC subunits xi and theta was length-dependent. In addition, a single photoreactive probe incorporated at a unique site in actin nascent chains of different lengths reacted covalently with multiple TRiC subunits, thereby indicating that the nascent chain samples the polypeptide binding sites of different subunits. We conclude that elongating actin and luciferase nascent chains contact multiple TRiC subunits upon emerging from the ribosome, and that the TRiC subunits contacted by nascent actin change as it elongates and starts to fold.	Texas A&M Univ, Ctr Hlth Sci, Coll Med, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Texas A&M Univ, Ctr Hlth Sci, Coll Med, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Oregon Hlth & Sci Univ, Div Mol Med, Portland, OR 97201 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Stanford University; University of Kent; Texas A&M University System; Texas A&M University College Station; Oregon Health & Science University	Johnson, AE (corresponding author), Texas A&M Univ, Ctr Hlth Sci, Coll Med, Dept Biochem & Biophys, TAMU 1114,116 Reynolds Med Bldg, College Stn, TX 77843 USA.	ajohnson@medicine.tamhsc.edu	Johnson, Arthur E/G-3457-2012; Carden, Martin/D-4135-2019	Carden, Martin/0000-0002-0609-4605; , judith/0000-0003-2302-6943; Meyer, Anne S./0000-0002-4164-0122	NIDDK NIH HHS [DK51818] Funding Source: Medline; NIGMS NIH HHS [GM26494, GM53457, GM56433] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053457, R01GM026494, R01GM056433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; Frydman J, 1999, NAT STRUCT BIOL, V6, P697, DOI 10.1038/10754; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; Hynes GM, 2000, J BIOL CHEM, V275, P18985, DOI 10.1074/jbc.M910297199; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; McCallum CD, 2000, J CELL BIOL, V149, P591, DOI 10.1083/jcb.149.3.591; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; Roobol A, 1999, J BIOL CHEM, V274, P19220, DOI 10.1074/jbc.274.27.19220; Spiess C, 2004, TRENDS CELL BIOL, V14, P598, DOI 10.1016/j.tcb.2004.09.015; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2; Ying BW, 2005, J BIOL CHEM, V280, P12035, DOI 10.1074/jbc.M500364200	28	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28118	28126		10.1074/jbc.M504110200	http://dx.doi.org/10.1074/jbc.M504110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15929940	hybrid			2022-12-25	WOS:000230678600075
J	Feng, RT; Lu, YJ; Bowman, LL; Qian, Y; Castranova, V; Ding, M				Feng, RT; Lu, YJ; Bowman, LL; Qian, Y; Castranova, V; Ding, M			Inhibition of activator protein-1, NF-kappa B, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; GLUTATHIONE-S-TRANSFERASE; TRANSCRIPTION FACTOR NRF2; GENE-EXPRESSION; NEOPLASTIC TRANSFORMATION; CELL-TRANSFORMATION; AP-1 ACTIVITY; CARCINOGENESIS; CHEMOPREVENTION; KINASE	Chlorogenic acid, the ester of caffeic acid with quinic acid, is one of the most abundant polyphenols in the human diet. The antioxidant and anticarcinogenic properties of chlorogenic acid have been established in animal studies. However, little is known about the molecular mechanisms through which chlorogenic acid inhibits carcinogenesis. In this study, we found that chlorogenic acid inhibited the proliferation of A549 human cancer cells in vitro. The results of the soft agar assay indicated that chlorogenic acid suppressed 12-O-tetradecanoylphorbol-13- acetate (TPA)-induced neoplastic transformation of JB6 P+ cells in a dose-dependent manner. Pretreatment of JB6 cells with chlorogenic acid blocked UVB- or TPA-induced transactivation of AP-1 and NF-kappa B over the same dose range. At low concentrations, chlorogenic acid decreased the phosphorylation of c-Jun NH2- terminal kinases, p38 kinase, and MAPK kinase 4 induced by UVB/ 12-O-tetradecanoylphorbol-13-acetate, yet higher doses were required to inhibit extracellular signal-regulated kinases. Chlorogenic acid also increased the enzymatic activities of glutathione S-transferases (GST) and NAD( P) H: quinone oxidoreductase. Further studies indicated that chlorogenic acid could stimulate the nuclear translocation of Nrf2 (NF-E2-related factor) as well as subsequent induction of GSTA1 antioxidant response element ( ARE)mediated GST activity. The phosphatidylinositol 3-kinase pathway might be involved in the activation of Nrf2 translocation. These results provide the first evidence that chlorogenic acid could protect against environmental carcinogen-induced carcinogenesis and suggest that the chemopreventive effects of chlorogenic acid may be through its up-regulation of cellular antioxidant enzymes and suppression of ROS-mediated NF-kappa B, AP-1, and MAPK activation.	NIOSH, Hlth Effect Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Ding, M (corresponding author), NIOSH, Hlth Effect Lab Div, Pathol & Physiol Res Branch, 1095 Willowdale Rd, Morgantown, WV 26505 USA.	mid5@cdc.gov						Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Bode A M, 2000, Lancet Oncol, V1, P181, DOI 10.1016/S1470-2045(00)00029-2; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen RF, 2000, RARE METALS, V19, P231; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Crosby LM, 2000, TOXICOL APPL PHARM, V169, P205, DOI 10.1006/taap.2000.9049; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; Ding M, 2004, J BIOL CHEM, V279, P10670, DOI 10.1074/jbc.M311465200; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; Feng R, 2004, NUTR CANCER, V50, P80, DOI 10.1207/s15327914nc5001_11; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0; Gilmore TD, 1996, ONCOGENE, V13, P1367; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Hou DX, 2004, CARCINOGENESIS, V25, P29, DOI 10.1093/carcin/bgg184; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; HUANG MT, 1988, CANCER RES, V48, P5941; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jang MS, 1998, CANCER LETT, V134, P81, DOI 10.1016/S0304-3835(98)00250-X; Johnson DA, 2002, J NEUROCHEM, V81, P1233, DOI 10.1046/j.1471-4159.2002.00913.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasai H, 2000, FOOD CHEM TOXICOL, V38, P467, DOI 10.1016/S0278-6915(00)00014-4; Katsuoka F, 2005, J BIOL CHEM, V280, P4483, DOI 10.1074/jbc.M411451200; Kensler TW, 1997, ENVIRON HEALTH PERSP, V105, P965, DOI 10.2307/3433311; KHAN SG, 1992, CANCER RES, V52, P4050; Kwak MK, 2003, BIOCHEM BIOPH RES CO, V305, P662, DOI 10.1016/S0006-291X(03)00834-9; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lee YS, 2002, FREE RADICAL RES, V36, P1283, DOI 10.1080/1071576021000016517; Li JJ, 1997, CANCER RES, V57, P3569; Lo CM, 1995, BIOPHYS J, V69, P2800, DOI 10.1016/S0006-3495(95)80153-0; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; McMahon M, 2001, CANCER RES, V61, P3299; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Ramos-Gomez M, 2003, CARCINOGENESIS, V24, P461, DOI 10.1093/carcin/24.3.461; Sonis SL, 2002, CRIT REV ORAL BIOL M, V13, P380, DOI 10.1177/154411130201300502; STRICKLAND PT, 1985, J NATL CANCER I, V74, P1129; Tamimi RM, 2002, J INTERN MED, V251, P286, DOI 10.1046/j.1365-2796.2002.00969.x; Thimmulappa RK, 2002, CANCER RES, V62, P5196; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Villafania A, 2000, ANN CLIN LAB SCI, V30, P57; Wolf CR, 2001, P NATL ACAD SCI USA, V98, P2941, DOI 10.1073/pnas.071042698; Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yoshitani SI, 2001, INT J ONCOL, V19, P929; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2001, MOL PHARMACOL, V60, P217, DOI 10.1124/mol.60.1.217	54	306	324	1	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27888	27895		10.1074/jbc.M503347200	http://dx.doi.org/10.1074/jbc.M503347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15944151	hybrid			2022-12-25	WOS:000230678600051
J	Nozawa, S; Ohno, T; Banno, Y; Dohjima, T; Wakahara, K; Fan, DG; Shimizu, K				Nozawa, S; Ohno, T; Banno, Y; Dohjima, T; Wakahara, K; Fan, DG; Shimizu, K			Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PHOSPHATIDIC-ACID; TRANSCRIPTIONAL ACTIVATOR; LYSOPHOSPHATIDIC ACID; 3T3 FIBROBLASTS; FUSION PROTEIN; CANCER-CELLS; DNA-BINDING; EWS GENE; FAMILY	EWS-Fli1, a fusion gene resulting from a chromosomal translocation t(11;22, q24;q12) and found in Ewing sarcoma and primitive neuroectodermal tumors, encodes a transcriptional activator and promotes cellular transformation. However, the precise biological functions of its products remain unknown. To investigate the role of EWS-Fli1 in cell growth signaling, we transfected Ewing sarcoma TC-135 cells with short interfering RNAs for EWS-Fli1. EWS-Fli1 knockdown reduced cell growth and platelet-derived growth factor (PDGF)-BB-induced activation of the growth signaling enzymes. Interestingly, phospholipase D2 ( but not the PDGF-BB receptor) showed marked down-regulation in the EWS-Fli1-knocked down TC-135 cells compared with the control cells. In Ewing sarcoma TC-135 cells, the PDGF-BB-induced phosphorylation of growth signaling involving extracellular signal-regulated kinase, Akt, p70S6K, and the expression of cyclin D3 were markedly inhibited by transfection with short interfering RNA phospholipase (PL)-D2. The PDGF-BB-induced activation of growth signaling was also suppressed by 1-butanol, which prevents the production of phosphatidic acid by phospholipase D (but not by t-butyl alcohol), thereby implicating PLD2 in PDGF-BB-mediated signaling in TC-135 cells. These results suggest that EWS-Fli1 may play a role in the regulation of tumor proliferation-signaling enzymes via PLD2 expression in Ewing sarcoma cells.	Gifu Univ, Sch Med, Dept Orthopaed Surg, Gifu 5011194, Japan; Gifu Univ, Sch Med, Dept Cell Signaling, Gifu 5011194, Japan	Gifu University; Gifu University	Ohno, T (corresponding author), Gifu Univ, Sch Med, Dept Orthopaed Surg, 1-1 Yanagido, Gifu 5011194, Japan.	ohnota@cc.gifu-u.ac.jp		Nozawa, Satoshi/0000-0001-7293-023X				Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; Banno Y, 2002, J BIOCHEM, V131, P301, DOI 10.1093/oxfordjournals.jbchem.a003103; Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; Banno Y, 1997, J BIOL CHEM, V272, P5208, DOI 10.1074/jbc.272.8.5208; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dohjima T, 2003, MOL THER, V7, P811, DOI 10.1016/S1525-0016(03)00101-1; Dohjima T, 2000, BRIT J CANCER, V82, P16, DOI 10.1054/bjoc.1998.0870; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fiucci G, 2000, INT J CANCER, V85, P882, DOI 10.1002/(SICI)1097-0215(20000315)85:6<882::AID-IJC24>3.0.CO;2-E; Foster DA, 2003, MOL CANCER RES, V1, P789; Hong JH, 2001, BIOCHEM BIOPH RES CO, V281, P1337, DOI 10.1006/bbrc.2001.4517; Joseph T, 2002, ONCOGENE, V21, P3651, DOI 10.1038/sj.onc.1205380; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; Nozawa Y, 2002, BBA-MOL CELL BIOL L, V1585, P77, DOI 10.1016/S1388-1981(02)00327-X; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sekiya F, 2004, J BIOL CHEM, V279, P32181, DOI 10.1074/jbc.M405116200; Seufferlein T, 1996, CANCER RES, V56, P3895; Silvany RE, 2000, ONCOGENE, V19, P4523, DOI 10.1038/sj.onc.1203811; Slaaby R, 2000, BIOCHEM J, V351, P613, DOI 10.1042/0264-6021:3510613; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; Yamada M, 2004, BIOCHEM J, V378, P649, DOI 10.1042/BJ20031398; Yoshida M, 1998, ONCOL RES, V10, P399; ZHANG J, 2003, CANCER RES, V64, P6026; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719	45	30	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27544	27551		10.1074/jbc.M411626200	http://dx.doi.org/10.1074/jbc.M411626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15919668	hybrid			2022-12-25	WOS:000230678600010
J	Odintsov, SG; Sabala, I; Bourenkov, G; Rybin, V; Bochtler, M				Odintsov, SG; Sabala, I; Bourenkov, G; Rybin, V; Bochtler, M			Staphylococcus aureus aminopeptidase S is a founding member of a new peptidase clan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS LEUCINE AMINOPEPTIDASE; METAL-LIGAND INTERACTIONS; ELECTRON-DENSITY MAPS; X-RAY CRYSTALLOGRAPHY; MACROMOLECULAR STRUCTURES; PROTEIN MODELS; REFINEMENT; RELEVANT; GEOMETRY; BINDING	Staphylococcus aureus aminopeptidase S (AmpS) has been named for its predicted, but experimentally untested, aminopeptidase activity. The enzyme is homologous to biochemically characterized aminopeptidases that contain two cobalt or zinc ions in their active centers, but it is unrelated to all structurally characterized metallopeptidases. Here, we demonstrate AmpS aminopeptidase activity experimentally, and we present the 1.8-angstrom crystal structure of the enzyme. Two metal ions with full occupancy and a third metal ion with low occupancy are present in the active site. A water molecule and Glu-319 serve as bridging ligands to the two metals with full occupancy. One of these metal ions is additionally coordinated by Glu-253 and His-348 and the other by His-381 and Asp-383. In addition, the metals are involved in weak metal-donor interactions to a water molecule and to Tyr-355. In the crystal, AmpS forms a dimer with a large internal cavity. The active sites are located at opposite ends of this internal cavity and are essentially inaccessible from the outside, suggesting that an inactive conformation was crystallized. Because gel filtration and analytical ultracentrifugation data also suggest dimer formation, the problem of substrate access to the active site cavity remains unresolved.	Max Planck Inst Mol Cell Biol & Genet, D-01309 Dresden, Germany; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Max Planck Arbeits Grp Strukt Mol Biol, DESY, D-22607 Hamburg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany	Max Planck Society; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; European Molecular Biology Laboratory (EMBL)	Bochtler, M (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauserstr 108, D-01309 Dresden, Germany.	MBochtler@iimcb.gov.pl	Bourenkov, Gleb P/C-7794-2017; Bochtler, Matthias/A-4514-2010; Sabała, Izabela/HGB-4142-2022	Bourenkov, Gleb P/0000-0002-2617-5920; Bochtler, Matthias/0000-0001-7884-4463; Sabala, Izabela/0000-0002-5481-8671				Barrett AJ, 1998, HDB PROTEOLYTIC ENZY, V1; BAZAN JF, 1994, P NATL ACAD SCI USA, V91, P2473, DOI 10.1073/pnas.91.7.2473; BURLEY SK, 1992, J MOL BIOL, V224, P113, DOI 10.1016/0022-2836(92)90580-D; Cohn E. J., 1943, PROTEINS AMINO ACIDS; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; Franzetti B, 2002, EMBO J, V21, P2132, DOI 10.1093/emboj/21.9.2132; Harding MM, 2000, ACTA CRYSTALLOGR D, V56, P857, DOI 10.1107/S0907444900005849; Harding MM, 1999, ACTA CRYSTALLOGR D, V55, P1432, DOI 10.1107/S0907444999007374; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; Ji YD, 2001, SCIENCE, V293, P2266, DOI 10.1126/science.1063566; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM HD, 1993, P NATL ACAD SCI USA, V90, P5006, DOI 10.1073/pnas.90.11.5006; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liu S, 2004, PROTEINS, V56, P93, DOI 10.1002/prot.20019; Marcyjaniak M, 2004, J BIOL CHEM, V279, P43982, DOI 10.1074/jbc.M406735200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MINAGAWA E, 1988, AGR BIOL CHEM, V52; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; MOTOSHIMA H, 1998, HDB PROTEOLYTIC ENZY, P1452; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MYRIN PA, 1974, BIOCHIM BIOPHYS ACTA, V350, P13, DOI 10.1016/0005-2744(74)90198-3; Odintsov SG, 2004, J MOL BIOL, V335, P775, DOI 10.1016/j.jmb.2003.11.009; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Russo S, 2004, J BIOL CHEM, V279, P51275, DOI 10.1074/jbc.M409455200; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Stoll E, 1976, Biochim Biophys Acta, V438, P213; STRATER N, 1995, BIOCHEMISTRY-US, V34, P14792, DOI 10.1021/bi00045a021; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wilce MCJ, 1998, P NATL ACAD SCI USA, V95, P3472, DOI 10.1073/pnas.95.7.3472	33	19	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27792	27799		10.1074/jbc.M502023200	http://dx.doi.org/10.1074/jbc.M502023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15932875	hybrid			2022-12-25	WOS:000230678600039
J	Osawa, Y; Uchinami, H; Bielawski, J; Schwabe, RF; Hannun, YA; Brenner, DA				Osawa, Y; Uchinami, H; Bielawski, J; Schwabe, RF; Hannun, YA; Brenner, DA			Roles for C-16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; MITOCHONDRIAL PERMEABILITY TRANSITION; PROGRAMMED CELL-DEATH; FULL-LENGTH CDNA; INHIBITS APOPTOSIS; MEDIATED APOPTOSIS; MOLECULAR-CLONING; NEUTRAL CERAMIDASE; ACTIVATION	Tumor necrosis factor (TNF)-alpha signals cell death and simultaneously induces the generation of ceramide, which is metabolized to sphingosine and sphingosine 1-phosphate (S1P) by ceramidase ( CDase) and sphingosine kinase. Because the dynamic balance between the intracellular levels of ceramide and S1P ( the "ceramide/ S1P rheostat") may determine cell survival, we investigated these sphingolipid signaling pathways in TNF-alpha-induced apoptosis of primary hepatocytes. Endogenous C-16-ceramide was elevated during TNF-alpha-induced apoptosis in both rat and mouse primary hepatocytes. The putative acid sphingomyelinase (ASMase) inhibitor imipramine inhibited TNF-alpha-induced apoptosis and C16-ceramide increase as did the knock out of ASMase. Overexpression of neutral CDase (NCDase) inhibited the TNF-alpha-induced increase of C16-ceramide and apoptosis in rat primary hepatocytes. Moreover, NCDase inhibited liver injury and hepatocyte apoptosis in mice treated with D- galactosamine plus TNF-alpha. This protective effect was abrogated by the sphingosine kinase inhibitor N,N-demethylsphingosine, suggesting that the survival effect of NCDase is due to not only C-16- ceramide reduction but also S1P formation. Administration of S1P or overexpression of NCDase activated the pro-survival kinase AKT, and overexpression of dominant negative AKT blocked the survival effect of NCDase. In conclusion, activation of ASMase and generation of C16- ceramide contributed to TNF-alpha-induced hepatocyte apoptosis. NCDase prevented apoptosis both by reducing C16- ceramide and by activation of AKT through S1P formation. Therefore, the cross-talk between sphingolipids and AKT pathway may determine hepatocyte apoptosis by TNF-alpha.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Columbia University; Medical University of South Carolina	Brenner, DA (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, 622 W 168th St,PH 8E-105J, New York, NY 10032 USA.	dab2106@columbia.edu	Schwabe, Robert/AAY-6506-2021	Brenner, David/0000-0003-2573-525X	NIDDK NIH HHS [DK59340] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059340] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; Cottin V, 2002, J IMMUNOL, V168, P4095, DOI 10.4049/jimmunol.168.8.4095; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Ding WX, 2004, J CELL MOL MED, V8, P445, DOI 10.1111/j.1582-4934.2004.tb00469.x; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Gupta S, 2004, J BIOL CHEM, V279, P5821, DOI 10.1074/jbc.M310979200; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357, DOI 10.1152/ajpgi.2001.281.6.G1357; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Ko YG, 1999, J IMMUNOL, V162, P7217; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Malisan F, 2002, BBA-MOL CELL BIOL L, V1585, P179, DOI 10.1016/S1388-1981(02)00339-6; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Moldeus P, 1978, Methods Enzymol, V52, P60; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Osawa Y, 2001, LIVER, V21, P309, DOI 10.1034/j.1600-0676.2001.210503.x; Osawa Y, 2003, J IMMUNOL, V170, P4053, DOI 10.4049/jimmunol.170.8.4053; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Schwabe RF, 2003, AM J PHYSIOL-GASTR L, V285, pG949, DOI 10.1152/ajpgi.00215.2003; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Sen P, 2003, MOL CELL BIOCHEM, V253, P241, DOI 10.1023/A:1026020101379; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; Takano R, 2000, J BIOL CHEM, V275, P16360, DOI 10.1074/jbc.M910419199; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yoshimura S, 1999, J NEUROCHEM, V73, P675, DOI 10.1046/j.1471-4159.1999.0730675.x; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	47	173	183	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27879	27887		10.1074/jbc.M503002200	http://dx.doi.org/10.1074/jbc.M503002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15946935	hybrid			2022-12-25	WOS:000230678600050
J	Seeds, AM; Bastidas, RJ; York, JD				Seeds, AM; Bastidas, RJ; York, JD			Molecular definition of a novel inositol polyphosphate metabolic pathway initiated by inositol 1,4,5-trisphosphate 3-kinase activity in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; KINASE-ACTIVITY; DROSOPHILA-MELANOGASTER; PHOSPHATE MULTIKINASE; HUMAN HOMOLOG; YEAST; HEXAKISPHOSPHATE; FAMILY; PROTEIN; PENTAKISPHOSPHATE	The production of inositol polyphosphate (IPs) and pyrophosphates (PP-IPs) from inositol 1,4,5-trisphosphate (I(1,4,5)P-3) requires the 6-/3-/5-kinase activity of Ipk2 (also known as Arg82 and inositol polyphosphate multikinase). Here, we probed the distinct roles for I(1,4,5)P-3 6- versus 3-kinase activities in IP metabolism and cellular functions reported for Ipk2. Expression of either I(1,4,5)P-3 6- or 3-kinase activity rescued growth of ipk2-deficient yeast at high temperatures, whereas only 6- kinase activity enabled growth on ornithine as the sole nitrogen source. Analysis of IP metabolism revealed that the 3-kinase initiated the synthesis of novel pathway consisting of over eleven IPs and PP-IPs. This pathway was present in wild-type and ipk2 null cells, albeit at low levels as compared with inositol hexakisphosphate synthesis. The primary route of synthesis was: I(1,4,5)P-3 -> I(1,3,4,5)P-4 -> I(1,2,3,4,5)P-5 -> PP-IP4 -> PP2-IP3 and required Kcs1 (or possibly Ipk2), Ipk1, a novel inositol pyrophosphate synthase, and then Kcs1 again, respectively. Mutation of kcs1 ablated this pathway in ipk2 null cells and overexpression of Kcs1 in ipk2 mutant cells phenocopied IP3K expression, confirming it harbors a novel 3-kinase activity. Our work provides a revised genetic map of IP metabolism in yeast and evidence for dosage compensation between IPs and PP-IPs downstream of I(1,4,5)P-3 in the regulation of nucleocytoplasmic processes.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	York, JD (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Howard Hughes Med Inst, DUMC Box 3813, Durham, NC 27710 USA.	yorkj@duke.edu		Seeds, Andrew/0000-0002-4932-6496	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R33DK070272] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-55672] Funding Source: Medline; NIDDK NIH HHS [DK070272] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; Dubois E, 2000, FEBS LETT, V486, P300, DOI 10.1016/S0014-5793(00)02318-8; El Alami M, 2003, MOL MICROBIOL, V49, P457, DOI 10.1046/j.1365-2958.2003.03562.x; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; Miller GJ, 2004, MOL CELL, V15, P703, DOI 10.1016/j.molcel.2004.08.005; Monnier V, 2002, FREE RADICAL BIO MED, V33, P1250, DOI 10.1016/S0891-5849(02)01019-5; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Seeds AM, 2004, J BIOL CHEM, V279, P47222, DOI 10.1074/jbc.M408295200; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Stevenson-Paulik J, 2002, J BIOL CHEM, V277, P42711, DOI 10.1074/jbc.M209112200; Stolz LE, 1998, GENETICS, V148, P1715; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X; YORK JD, 1990, P NATL ACAD SCI USA, V87, P9548, DOI 10.1073/pnas.87.24.9548; YORK JD, 2003, INOSITOL POLYPHOSPHA, V2, P229; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200	38	42	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27654	27661		10.1074/jbc.M505089200	http://dx.doi.org/10.1074/jbc.M505089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15944147	hybrid			2022-12-25	WOS:000230678600023
J	Valasek, MA; Weng, J; Shaul, PW; Anderson, RGW; Repa, JJ				Valasek, MA; Weng, J; Shaul, PW; Anderson, RGW; Repa, JJ			Caveolin-1 is not required for murine intestinal cholesterol transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CLASS-B; HEPATIC CHOLESTEROL; STEROL TRANSPORTERS; ACID SYNTHESIS; MESSENGER-RNA; ABSORPTION; MICE; PROTEIN; EXPRESSION; ABCG5	Caveolin-1 (CAV1) is the structural protein of the filamentous coat that decorates the cytoplasmic surface of each caveola. Cell culture studies have implicated CAV1 in playing an important role in intracellular cholesterol trafficking. In addition, it has been reported that CAV1 forms a detergent-resistant protein complex with Annexin-2 in enterocytes that can be disrupted by the cholesterol absorption inhibitor ezetimibe, suggesting a possible role for CAV1 in cholesterol absorption. In this report, we have evaluated cholesterol homeostasis in Cav1 knock-out mice. Deletion of CAV1 does not result in either a compensatory increase of CAV2 or CAV3 in intestine. In addition, Cav1 knock-out mice display normal mRNA and protein levels of Annexin-2 or the putative cholesterol transport protein Niemann-Pick C1-like 1 (NPC1L1) in proximal intestinal mucosa. Fractional cholesterol absorption and fecal neutral sterol excretion are statistically similar in Cav1 knock-out mice and their wild-type littermates. Moreover, oral administration of ezetimibe is equally effective in decreasing cholesterol absorption in Cav1 null mice and wild-type controls. The mRNA expression levels of genes sensitive to intracellular cholesterol concentration (ATP-binding cassette transporters ABCA1 and ABCG5, hydroxymethylglutaryl-CoA synthase and the LDL receptor) are similarly altered in the proximal intestinal mucosa of Cav1 null and wild-type mice following ezetimibe treatment. These results demonstrate that CAV1 is not required for cholesterol absorption or ezetimibe sensitivity in the mouse.	Univ Texas, SW Med Ctr, Touchstone Cr Diabet Res, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Repa, JJ (corresponding author), Univ Texas, SW Med Ctr, Touchstone Cr Diabet Res, Dept Physiol, 5323 Harrry Hines Blvd, Dallas, TX 75390 USA.	joyce.repa@utsouthwestern.edu		Repa, Joyce/0000-0001-5740-1954; Valasek, Mark/0000-0003-1721-3451	NHLBI NIH HHS [HL20948, HL58888] Funding Source: Medline; NIGMS NIH HHS [GM52016, GM07062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL058888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016, T32GM007062] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Altmann SW, 2002, BBA-MOL CELL BIOL L, V1580, P77, DOI 10.1016/S1388-1981(01)00190-1; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; Cao GW, 2003, AM J PATHOL, V162, P1241, DOI 10.1016/S0002-9440(10)63920-X; Davies JP, 2005, J BIOL CHEM, V280, P12710, DOI 10.1074/jbc.M409110200; Davis HR, 2004, J BIOL CHEM, V279, P33586, DOI 10.1074/jbc.M405817200; Davis HR, 2001, ARTERIOSCL THROM VAS, V21, P2032, DOI 10.1161/hq1201.100260; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; Frank PG, 2001, AM J PHYSIOL-CELL PH, V280, pC1204, DOI 10.1152/ajpcell.2001.280.5.C1204; Fu Y, 2004, J BIOL CHEM, V279, P14140, DOI 10.1074/jbc.M311061200; Fuchs M, 2001, HEPATOLOGY, V33, P1451, DOI 10.1053/jhep.2001.24373; Homan R, 1997, CURR PHARM DESIGN, V3, P29; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Iyer SPN, 2005, BBA-GEN SUBJECTS, V1722, P282, DOI 10.1016/j.bbagen.2004.12.021; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; Kurrasch DM, 2004, METHOD ENZYMOL, V389, P3; Lauvrak SU, 2005, FEBS LETT, V579, P203, DOI 10.1016/j.febslet.2004.11.076; Li WP, 2001, J CELL SCI, V114, P1397; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; Mardones P, 2001, J LIPID RES, V42, P170; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nakamura Y, 2000, GENE, V251, P55, DOI 10.1016/S0378-1119(00)00189-X; NGUYEN TT, 1998, POSTGRAD MED; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Razani B, 2001, J BIOL CHEM, V276, P38121; Repa JJ, 2005, J LIPID RES, V46, P779, DOI 10.1194/jlr.M400475-JLR200; Repa JJ, 2004, HEPATOLOGY, V40, P1088, DOI 10.1002/hep.20439; Repa JJ, 2002, J LIPID RES, V43, P1864, DOI 10.1194/jlr.M200144-JLR200; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Schwarz M, 1998, J LIPID RES, V39, P1833; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Smart EJ, 2004, P NATL ACAD SCI USA, V101, P3450, DOI 10.1073/pnas.0400441101; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Sudhop T, 2005, PHARMACOL THERAPEUT, V105, P333, DOI 10.1016/j.pharmthera.2004.10.011; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Turley SD, 1996, J CARDIOVASC PHARM, V27, P71, DOI 10.1097/00005344-199601000-00012; TURLEY SD, 1994, J LIPID RES, V35, P328; TURLEY SD, 1994, GASTROENTEROLOGY, V107, P444, DOI 10.1016/0016-5085(94)90170-8; Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	48	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28103	28109		10.1074/jbc.M504609200	http://dx.doi.org/10.1074/jbc.M504609200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15919660	hybrid			2022-12-25	WOS:000230678600073
J	Arva, NC; Gopen, TR; Talbott, KE; Campbell, LE; Chicas, A; White, DE; Bond, GL; Levine, AJ; Bargonetti, J				Arva, NC; Gopen, TR; Talbott, KE; Campbell, LE; Chicas, A; White, DE; Bond, GL; Levine, AJ; Bargonetti, J			A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 GENE-MUTATIONS; DNA-BINDING; IN-VIVO; ACTIVATION; PROTEIN; TRANSACTIVATION; ONCOPROTEIN; REPRESSION; NUCLEOLIN; MECHANISM	In cancer cells, the function of the tumor suppressor protein p53 is usually blocked. Impairment of the p53 pathway results in tumor cells with endogenous overexpression of Mdm2 via a naturally occurring single nucleotide polymorphism (SNP) in the mdm2 gene at position 309. Here we report that in mdm2 SNP309 cells, inactivation of p53 results in a chromatin-associated Mdm2-p53 complex without clearance of p53 by protein degradation. Nuclear accumulation of p53 protein in mdm2 SNP309 cells results after 6 h of camptothecin, etoposide, or mitomycin C treatment, with the p53 protein phosphorylated at Ser(15). Chromatin immunoprecipitation demonstrated p53 and Mdm2 bound to p53 responsive elements. Interestingly, although the p53 protein was able to bind to DNA, quantitative PCR showed compromised transcription of endogenous target genes. Additionally, exogenously introduced p53 was incapable of activating transcription from p53 responsive elements in SNP309 cells, confirming the trans-acting nature of the inhibitor. Inhibition of Mdm2 by siRNA resulted in transcriptional activation of these p53 targets. Our data suggest that overproduction of Mdm2, resulting from a naturally occurring SNP, inhibits chromatin-bound p53 from activating the transcription of its target genes.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; CUNY Hunter Coll, Inst Biomolec Struct & Funct, New York, NY 10021 USA; Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ 08903 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Bargonetti, J (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	bargonetti@genectr.hunter.cuny.edu		Bargonetti, Jill/0000-0003-2692-0991	NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [1S06 GM60754] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas T, 2002, J BIOL CHEM, V277, P40513, DOI 10.1074/jbc.M205495200; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chene P, 2004, MOL CANCER RES, V2, P20; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; LANDERS JE, 1994, ONCOGENE, V9, P2745; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; Molina Maria Patricia, 2003, Methods Mol Biol, V234, P151; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; WALDMAN T, 1995, CANCER RES, V55, P5187; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	32	103	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26776	26787		10.1074/jbc.M505203200	http://dx.doi.org/10.1074/jbc.M505203200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15908423	hybrid			2022-12-25	WOS:000230589500019
J	Castillo, M; Mulet, J; Gutierrez, LM; Ortiz, JA; Castelan, F; Gerber, S; Sala, S; Sala, F; Criado, M				Castillo, M; Mulet, J; Gutierrez, LM; Ortiz, JA; Castelan, F; Gerber, S; Sala, S; Sala, F; Criado, M			Dual role of the RIC-3 protein in trafficking of serotonin and nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE EXPRESSION; ALPHA-7 SUBUNIT; ENDOPLASMIC-RETICULUM; CHANNEL; GENE; DETERMINANTS; MODULATION; DIVERSITY; CALNEXIN; CALCIUM	The ric-3 gene is required for maturation of nicotinic acetylcholine receptors in Caenorhabditis elegans. The human homolog of RIC-3, hRIC-3, enhances expression of alpha 7 nicotinic receptors in Xenopus laevis oocytes, whereas it totally abolishes expression of alpha 4 beta 2 nicotinic and 5-HT3 serotonergic receptors. Both the N-terminal region of hRIC-3, which contains two transmembrane segments, and the C-terminal region are needed for these differential effects. hRIC-3 inhibits receptor expression by hindering export of mature receptors to the cell membrane. By using chimeric proteins made of alpha 7 and 5-HT3 receptors, we have shown that the presence of an extracellular isoleucine close to the first transmembrane receptor fragment is responsible for the transport arrest induced by hRIC-3. Enhancement of alpha 7 receptor expression occurs, at least, at two levels: by increasing the number of mature receptors and facilitating its transport to the membrane. Certain amino acids of a putative amphipathic helix present at the large cytoplasmic region of the alpha 7 subunit are required for these actions. Therefore, hRIC-3 can act as a specific regulator of receptor expression at different levels.	Univ Miguel Hernandez, CSIC, Inst Neurociencias Alicante, Alicante 03550, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Criado, M (corresponding author), Univ Miguel Hernandez, CSIC, Inst Neurociencias Alicante, Apartado 18, Alicante 03550, Spain.	Manuel.Criado@umh.es	Criado, Manuel/K-5109-2014; Mulet, Jose/K-6538-2014; Ortiz Salcedo, José Antonio/HHN-7691-2022; Gutierrez, Luis/K-8633-2014; Sala, Salvador/L-7104-2014	Criado, Manuel/0000-0002-3953-0346; Mulet, Jose/0000-0001-7506-4875; Ortiz Salcedo, José Antonio/0000-0003-0505-3032; Gutierrez, Luis/0000-0002-0512-7858; Sala, Francisco/0000-0002-2080-7683; Castelan, Francisco/0000-0002-9835-3335; Sala, Salvador/0000-0002-5607-0097				Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; Campos-Caro A, 2001, DNA CELL BIOL, V20, P657, DOI 10.1089/104454901753340640; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; Colquhoun D, 2004, TRENDS NEUROSCI, V27, P337, DOI 10.1016/j.tins.2004.04.010; Cooper ST, 1997, J NEUROCHEM, V68, P2140; Dineley KT, 2000, J BIOL CHEM, V275, P13974, DOI 10.1074/jbc.275.18.13974; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; GARCIAGUZMAN M, 1994, BIOCHEMISTRY-US, V33, P15198, DOI 10.1021/bi00254a031; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; Halevi S, 2003, J BIOL CHEM, V278, P34411, DOI 10.1074/jbc.M300170200; Halevi S, 2002, EMBO J, V21, P1012, DOI 10.1093/emboj/21.5.1012; Ibanez-Tallon I, 2002, NEURON, V33, P893, DOI 10.1016/S0896-6273(02)00632-3; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Keller SH, 1999, J GEN PHYSIOL, V113, P171, DOI 10.1085/jgp.113.2.171; Kittler JT, 2003, CURR OPIN NEUROBIOL, V13, P341, DOI 10.1016/S0959-4388(03)00064-3; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; Le Novere N, 2002, J NEUROBIOL, V53, P447, DOI 10.1002/neu.10153; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Lin L, 2002, J BIOL CHEM, V277, P41872, DOI 10.1074/jbc.M206857200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Millar NS, 2003, BIOCHEM SOC T, V31, P869, DOI 10.1042/BST0310869; Nelson ME, 1999, J PHYSIOL-LONDON, V516, P657, DOI 10.1111/j.1469-7793.1999.0657u.x; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Rakhilin S, 1999, J CELL BIOL, V146, P203; SEGUELA P, 1993, J NEUROSCI, V13, P596; SMITH MM, 1987, J BIOL CHEM, V262, P4367; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; UETZ P, 1994, FEBS LETT, V339, P302, DOI 10.1016/0014-5793(94)80435-4; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Valor LM, 2002, BIOCHEMISTRY-US, V41, P7931, DOI 10.1021/bi025831r; Vicente-Agullo F, 2001, BIOCHEMISTRY-US, V40, P8300, DOI 10.1021/bi010087g; Wanamaker CP, 2003, ANN NY ACAD SCI, V998, P66, DOI 10.1196/annals.1254.009; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Williams ME, 2005, J BIOL CHEM, V280, P1257, DOI 10.1074/jbc.M410039200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	42	75	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27062	27068		10.1074/jbc.M503746200	http://dx.doi.org/10.1074/jbc.M503746200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15927954	hybrid			2022-12-25	WOS:000230589500052
J	Kawakami, H; Keyamura, K; Katayama, T				Kawakami, H; Keyamura, K; Katayama, T			Formation of an ATP-DnaA-specific initiation complex requires DnaA arginine 285, a conserved motif in the AAA plus protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; POLYMERASE-III HOLOENZYME; LARGE TUMOR-ANTIGEN; REPLICATION ORIGIN; BINDING DOMAIN; SLIDING CLAMP; IN-VITRO; FUNCTIONAL DOMAINS; SEQUENTIAL BINDING; HELICASE	Escherichia coli DnaA protein, a member of the AAA+ superfamily, initiates replication from the chromosomal origin oriC in an ATP-dependent manner. Nucleoprotein complex formed on oriC with the ATP-DnaA multimer but not the ADP-DnaA multimer is competent to unwind the oriC duplex. The oriC region contains ATP-DnaA-specific binding sites termed I2 and I3, which stimulate ATP-DnaA-dependent oriC unwinding. In this study, we show that the DnaA R285A mutant is inactive for oriC replication in vivo and in vitro and that the mutation is associated with specific defects in oriC unwinding. In contrast, activities of DnaA R285A are sustained in binding to the typical DnaA boxes and to ATP and ADP, formation of multimeric complexes on oriC, and loading of the DnaB helicase onto single-stranded DNA. Footprint analysis of the DnaA-oriC complex reveals that the ATP form of DnaA R285A does not interact with ATP-DnaA-specific binding sites such as the I sites. A subgroup of DnaA molecules in the oriC complex must contain the Arg-285 residue for initiation. Sequence and structural analyses suggest that the DnaA Arg-285 residue is an arginine finger, an AAA + family-specific motif that recognizes ATP bound to an adjacent subunit in a multimeric complex. In the context of these and previous results, the DnaA Arg-285 residue is proposed to play a unique role in the ATP-dependent conformational activation of an initial complex by recognizing ATP bound to DnaA and by modulating the structure of the DnaA multimer to allow interaction with ATP-DnaA-specific binding sites in the complex.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Katayama, T (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	katayama@phar.kyushu-u.ac.jp	Kawakami, Hironori/H-6792-2017	Kawakami, Hironori/0000-0001-8971-1914; Katayama, Tsutomu/0000-0001-9994-1684				Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blaesing F, 2000, MOL MICROBIOL, V36, P557, DOI 10.1046/j.1365-2958.2000.01881.x; Carr KM, 2002, J BIOL CHEM, V277, P39815, DOI 10.1074/jbc.M205031200; Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Felczak MM, 2004, J BIOL CHEM, V279, P51156, DOI 10.1074/jbc.M409695200; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Fujikawa N, 2003, NUCLEIC ACIDS RES, V31, P2077, DOI 10.1093/nar/gkg309; Fujimitsu K, 2004, BIOCHEM BIOPH RES CO, V322, P411, DOI 10.1016/j.bbrc.2004.07.141; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Grimwade JE, 2000, MOL MICROBIOL, V35, P835, DOI 10.1046/j.1365-2958.2000.01755.x; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Ishida T, 2004, J BIOL CHEM, V279, P45546, DOI 10.1074/jbc.M402762200; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Katayama T, 1995, MOL MICROBIOL, V18, P813, DOI 10.1111/j.1365-2958.1995.18050813.x; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Katayama T, 2001, MOL MICROBIOL, V41, P9, DOI 10.1046/j.1365-2958.2001.02483.x; Kato J, 2001, EMBO J, V20, P4253, DOI 10.1093/emboj/20.15.4253; Kawakami H, 2001, MOL GENET GENOMICS, V266, P167, DOI 10.1007/s004380100546; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kornberg A., 1992, DNA REPLICATION; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; McGarry KC, 2004, P NATL ACAD SCI USA, V101, P2811, DOI 10.1073/pnas.0400340101; Messer W, 1999, BIOCHIMIE, V81, P819, DOI 10.1016/S0300-9084(00)87165-5; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Messer W, 2001, BIOCHIMIE, V83, P5, DOI 10.1016/S0300-9084(00)01216-5; Neuwald AF, 1999, GENOME RES, V9, P27; Nishida S, 2002, J BIOL CHEM, V277, P14986, DOI 10.1074/jbc.M108303200; Obita T, 2002, BIOCHEM BIOPH RES CO, V299, P42, DOI 10.1016/S0006-291X(02)02590-1; Ogura T, 2004, J STRUCT BIOL, V146, P106, DOI 10.1016/j.jsb.2003.11.008; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Shimuta T, 2004, GENES CELLS, V9, P1151, DOI 10.1111/j.1365-2443.2004.00800.x; Song HK, 2000, P NATL ACAD SCI USA, V97, P14103, DOI 10.1073/pnas.250491797; Speck C, 1999, EMBO J, V18, P6169, DOI 10.1093/emboj/18.21.6169; Speck C, 2001, EMBO J, V20, P1469, DOI 10.1093/emboj/20.6.1469; Su'etsugu M, 2005, J BIOL CHEM, V280, P6528, DOI 10.1074/jbc.M412060200; Su'etsugu M, 2004, GENES CELLS, V9, P509, DOI 10.1111/j.1356-9597.2004.00741.x; Sutton MD, 1997, J MOL BIOL, V274, P546, DOI 10.1006/jmbi.1997.1425; Takata M, 2000, MOL MICROBIOL, V35, P454, DOI 10.1046/j.1365-2958.2000.01722.x; Weigel C, 1997, EMBO J, V16, P6574, DOI 10.1093/emboj/16.21.6574; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	52	102	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27420	27430		10.1074/jbc.M502764200	http://dx.doi.org/10.1074/jbc.M502764200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15901724	hybrid			2022-12-25	WOS:000230589500093
J	Lawrence, MC; McGlynn, K; Park, BH; Cobb, MH				Lawrence, MC; McGlynn, K; Park, BH; Cobb, MH			ERK1/2-dependent activation of transcription factors required for acute and chronic effects of glucose on the insulin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-BETA; SHORT-TERM REGULATION; CHRONIC EXPOSURE; CELL; EXPRESSION; IDENTIFICATION; KINASE; MAFA; PATHWAYS; RIPE3B1	The insulin promoter is both positively and negatively regulated in response to conditions to which pancreatic beta-cells are exposed. Exposure of intact rat islets and INS-1 pancreatic beta-cells to 11 mM glucose for minutes to hours results in an enhancement in the rate of insulin gene transcription assessed with a reporter linked to the insulin gene promoter. In contrast, chronic exposure of rat islets or beta-cells to 11 mM glucose results in loss of the glucose responsiveness of the insulin gene promoter. By 48 h, glucose inhibits insulin gene promoter activity. Here we show that not only the acute effect of elevated glucose to stimulate the insulin gene promoter but also the chronic effect of elevated glucose to inhibit the insulin gene promoter depend on ERK1/2 mitogen-activated protein kinase activity. In examining the underlying mechanism, we found that acute exposure to 11 mM glucose resulted in the binding of the transcription factors NFAT and Maf to the glucose-responsive A2C1 element of the insulin gene promoter. An NFAT and C/EBP-beta complex was observed in cells chronically exposed to 11 mM glucose. Formation of NFAT-Maf and NFAT-C/EBP-beta complexes was sensitive to inhibitors of ERK1/2 and calcineurin, consistent with our previous finding that activation of ERK1/2 by glucose required calcineurin activity and the well documented regulation of NFAT by calcineurin. These results indicate that the ERK1/2 pathway modulates partners of NFAT, which may either stimulate or repress insulin gene transcription during stimulatory and chronic exposure to elevated glucose.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Ave, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu		Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK55310] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055310] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnette D, 2003, J BIOL CHEM, V278, P32517, DOI 10.1074/jbc.M301174200; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Gavin JR, 1997, DIABETES CARE, V20, P1183; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GIDDINGS SJ, 1982, DIABETES, V31, P624, DOI 10.2337/diabetes.31.7.624; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Harrington RH, 2001, J BIOL CHEM, V276, P104, DOI 10.1074/jbc.M008415200; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; Kataoka K, 2004, J MOL ENDOCRINOL, V32, P9, DOI 10.1677/jme.0.0320009; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Khoo S, 2003, J BIOL CHEM, V278, P32969, DOI 10.1074/jbc.M301198200; Lawrence MC, 2002, DIABETES, V51, P691, DOI 10.2337/diabetes.51.3.691; Lawrence MC, 2001, MOL ENDOCRINOL, V15, P1758, DOI 10.1210/me.15.10.1758; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Leibiger B, 2002, BIOCHEM SOC T, V30, P312, DOI 10.1042/bst0300312; Leibowitz G, 2002, ENDOCRINOLOGY, V143, P3214, DOI 10.1210/en.2002-220174; Lu M, 1997, J BIOL CHEM, V272, P28349, DOI 10.1074/jbc.272.45.28349; Marshak S, 1999, DIABETES, V48, P1230, DOI 10.2337/diabetes.48.6.1230; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Matsuoka T, 2004, P NATL ACAD SCI USA, V101, P2930, DOI 10.1073/pnas.0306233101; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Odagiri H, 1996, J BIOL CHEM, V271, P1909, DOI 10.1074/jbc.271.4.1909; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEYTON M, 1994, J BIOL CHEM, V269, P25936; Pilipuk GP, 2003, J BIOL CHEM, V278, P35668, DOI 10.1074/jbc.M305182200; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Robertson RP, 2003, DIABETES, V52, P581, DOI 10.2337/diabetes.52.3.581; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; Seufert J, 1998, J CLIN INVEST, V101, P2528, DOI 10.1172/JCI2401; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; Whitehurst A, 2004, MOL CELL BIOL, V24, P10145, DOI 10.1128/MCB.24.23.10145-10150.2004	56	95	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26751	26759		10.1074/jbc.M503158200	http://dx.doi.org/10.1074/jbc.M503158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15899886	hybrid			2022-12-25	WOS:000230589500016
J	Narasimhan, J; Wang, M; Fu, ZJ; Klein, JM; Haas, AL; Kim, JJP				Narasimhan, J; Wang, M; Fu, ZJ; Klein, JM; Haas, AL; Kim, JJP			Crystal structure of the interferon-induced ubiquitin-like protein ISG15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-REACTIVE PROTEIN; SECONDARY STRUCTURE; ACTIVATING ENZYME; STIMULATED GENES; UBP43 USP18; ALPHA; BETA; SITE; SUPERFAMILY; CONJUGATION	The biological effects of the ISG15 protein arise in part from its conjugation to cellular targets as a primary response to interferon-alpha/beta induction and other markers of viral or parasitic infection. Recombinant full-length ISG15 has been produced for the first time in high yield by mutating Cys(78) to stabilize the protein and by cloning in a C-terminal arginine cap to protect the C terminus against proteolytic inactivation. The cap is subsequently removed with carboxypeptidase B to yield mature biologically active ISG15 capable of stoichiometric ATP-dependent thiolester formation with its human UbE1L activating enzyme. The three-dimensional structure of recombinant ISG15C78S was determined at 2.4-angstrom resolution. The ISG15 structure comprises two beta-grasp folds having main chain root mean square deviation (r. m. s. d.) values from ubiquitin of 1.7 angstrom (N-terminal) and 1.0 angstrom ( C-terminal). The beta-grasp domains pack across two conserved 310 helices to bury 627 angstrom(2) that accounts for 7% of the total solvent-accessible surface area. The distribution of ISG15 surface charge forms a ridge of negative charge extending nearly the full-length of the molecule. Additionally, the N-terminal domain contains an apolar region comprising almost half its solvent accessible surface. The C-terminal domain of ISG15 was superimposed on the structure of Nedd8 ( r. m. s. d. = 0.84 angstrom) bound to its AppBp1-Uba3 activating enzyme to model ISG15 binding to UbE1L. The docking model predicts several key side-chain interactions that presumably define the specificity between the ubiquitin and ISG15 ligation pathways to maintain functional integrity of their signaling.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Medical College of Wisconsin	Haas, AL (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ahaas@lsuhsc.edu; jjkim@mcw.edu			NIGMS NIH HHS [GM29076, GM47426, GM15977] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015977, R01GM047426, R01GM029076] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andres G, 2001, J BIOL CHEM, V276, P780, DOI 10.1074/jbc.M006844200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; Bohnsack RN, 2003, J BIOL CHEM, V278, P26823, DOI 10.1074/jbc.M303177200; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1988, UBIQUITIN, P173; Hamerman JA, 2002, J IMMUNOL, V168, P2415, DOI 10.4049/jimmunol.168.5.2415; Huang DT, 2004, ONCOGENE, V23, P1958, DOI 10.1038/sj.onc.1207393; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; KORANT BD, 1984, J BIOL CHEM, V259, P4835; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunzi MS, 1996, J INTERF CYTOK RES, V16, P919, DOI 10.1089/jir.1996.16.919; LALELISAHIN EA, 2001, THESIS MED COLL WISC; Larsen CN, 2002, J PROTEOME RES, V1, P411, DOI 10.1021/pr025522n; Li XL, 1998, J INTERF CYTOK RES, V18, P947, DOI 10.1089/jir.1998.18.947; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LOEB KR, 1994, MOL CELL BIOL, V14, P8408, DOI 10.1128/MCB.14.12.8408; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; LOWE J, 1995, J PATHOL, V177, P163, DOI 10.1002/path.1711770210; MacQuillan GC, 2003, J MED VIROL, V70, P219, DOI 10.1002/jmv.10381; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; McPherson A., 1999, CRYSTALLIZATION BIOL; MEMET S, 1991, J INTERFERON RES, V11, P131, DOI 10.1089/jir.1991.11.131; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Potter JL, 1999, J BIOL CHEM, V274, P25061, DOI 10.1074/jbc.274.35.25061; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Ramelot Theresa A., 2003, Journal of Structural and Functional Genomics, V4, P25, DOI 10.1023/A:1024674220425; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133; ROUSSEL A, 1999, TURBO FRODO VERSION; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; SEGAL IH, 1975, ENZYME KINETICS; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; Walden H, 2003, MOL CELL, V12, P1427, DOI 10.1016/S1097-2765(03)00452-0; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Wieland SF, 2003, J VIROL, V77, P1227, DOI 10.1128/JVI.77.2.1227-1236.2003; Wilkinson KD, 1999, J MOL BIOL, V291, P1067; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; ZHU DX, 1986, INT J BIOCHEM, V18, P473, DOI 10.1016/0020-711X(86)90191-6	64	147	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27356	27365		10.1074/jbc.M502814200	http://dx.doi.org/10.1074/jbc.M502814200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917233	hybrid			2022-12-25	WOS:000230589500086
J	Rouzer, CA; Marnett, LJ				Rouzer, CA; Marnett, LJ			Glycerylprostaglandin synthesis by resident peritoneal macrophages in response to a zymosan stimulus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE-1; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ARACHIDONIC-ACID METABOLITES; TANDEM MASS-SPECTROMETRY; NECROSIS-FACTOR-ALPHA; HUMAN CYCLOOXYGENASE-2; SELF-INACTIVATION; E-2 ETHANOLAMIDE; GLYCEROL ESTERS; MESSENGER-RNA	Cyclooxygenase (COX)-2 oxygenates arachidonic acid (AA) and 2-arachidonylglycerol (2-AG) to endoperoxides, which are subsequently transformed to prostaglandins (PGs) and glycerylprostaglandins (PG-Gs). PG-G formation has not been demonstrated in intact cells treated with a physiological agonist. Resident peritoneal macrophages, which express COX-1, were pretreated with lipopolysaccharide to induce COX-2. Addition of zymosan caused release of 2-AG and production of the glyceryl esters of PGE(2) and PGI(2) over 60 min. The total quantity of PG-Gs (16 +/- 6 pmol/10(7) cells) was much lower than that of the corresponding PGs produced from AA (21,000 +/- 7,000 pmol/10(7) cells). The differences in PG-G and PG production were partially explained by differences in the amounts of 2-AG and AA released in response to zymosan. The selective COX-2 inhibitor, SC236, reduced PG-G and PG production by 49 and 17%, respectively, indicating a significant role for COX-1 in PG-G and especially PG synthesis. Time course studies indicated that COX-2- dependent oxygenation rapidly declined 20 min after zymosan addition. When exogenous 2-AG was added to macrophages, a substantial portion was hydrolyzed to AA and converted to PGs; 1 mu M 2-AG yielded 820 +/- 200 pmol of PGs/10(7) cells and 78 +/- 41 pmol of PG-Gs/10(7) cells. SC236 reduced PG-G and PG production from exogenous 2-AG by 88 and 76%, respectively, indicating a more significant role for COX-2 in the utilization of exogenous substrate. In conclusion, lipopolysaccharide-pretreated macrophages produce PG-Gs from endogenous 2-AG during zymosan phagocytosis, but PG-G formation is limited by substrate hydrolysis and inactivation of COX-2.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Pharmacol & Drug Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.	larry.marnett@vanderbilt.edu		Rouzer, Carol/0000-0001-6827-1534	NIGMS NIH HHS [GM15431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABIKO Y, 1983, FEBS LETT, V154, P297, DOI 10.1016/0014-5793(83)80170-7; Barbieri SS, 2004, FREE RADICAL BIO MED, V37, P156, DOI 10.1016/j.freeradbiomed.2004.04.020; BIRMELIN M, 1983, EUR J BIOCHEM, V131, P539, DOI 10.1111/j.1432-1033.1983.tb07295.x; BONNEY RJ, 1978, BIOCHEM J, V176, P433, DOI 10.1042/bj1760433; CHANG J, 1980, P NATL ACAD SCI-BIOL, V77, P4736, DOI 10.1073/pnas.77.8.4736; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; COHN ZA, 1965, J EXP MED, V122, P455, DOI 10.1084/jem.122.3.455; EGAN RW, 1976, J BIOL CHEM, V251, P7329; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMILTON JA, 1980, CANCER RES, V40, P2273; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOMMA Y, 1985, BIOCHEM J, V229, P643, DOI 10.1042/bj2290643; HUMES JL, 1977, NATURE, V269, P149, DOI 10.1038/269149a0; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kingsley PJ, 2003, ANAL BIOCHEM, V314, P8, DOI 10.1016/S0003-2697(02)00643-7; KINGSLEY PJ, 2005, IN PRESS ANAL BIOCH; Kozak KR, 2002, J BIOL CHEM, V277, P44877, DOI 10.1074/jbc.M206788200; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kozak KR, 2003, BIOCHEMISTRY-US, V42, P9041, DOI 10.1021/bi034471k; Kozak KR, 2001, J BIOL CHEM, V276, P36993, DOI 10.1074/jbc.M105854200; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MASON RJ, 1972, J CLIN INVEST, V51, P2399, DOI 10.1172/JCI107052; MEAGHER LC, 1991, BIOCHEM BIOPH RES CO, V177, P460, DOI 10.1016/0006-291X(91)92006-6; Nirodi CS, 2004, P NATL ACAD SCI USA, V101, P1840, DOI 10.1073/pnas.0303950101; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Posadas I, 2003, BRIT J PHARMACOL, V138, P1571, DOI 10.1038/sj.bjp.0705189; Pouliot M, 1998, FASEB J, V12, P1109, DOI 10.1096/fasebj.12.12.1109; Prusakiewicz JJ, 2002, BIOCHEM BIOPH RES CO, V296, P612, DOI 10.1016/S0006-291X(02)00915-4; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; REYER MD, 2000, AM J PHYSIOL, V279, pF12; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; Ross RA, 2002, J PHARMACOL EXP THER, V301, P900, DOI 10.1124/jpet.301.3.900; Rouzer CA, 2004, J BIOL CHEM, V279, P34256, DOI 10.1074/jbc.M402594200; Rouzer CA, 2003, CHEM REV, V103, P2239, DOI 10.1021/cr000068x; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; ROUZER CA, 1982, J EXP MED, V156, P1077, DOI 10.1084/jem.156.4.1077; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; SCOTT WA, 1982, J EXP MED, V155, P535, DOI 10.1084/jem.155.2.535; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Taniguchi Y, 1998, DRUG EXP CLIN RES, V24, P17; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Vicente AM, 2001, BRIT J PHARMACOL, V133, P920, DOI 10.1038/sj.bjp.0704145; Weber A, 2004, J LIPID RES, V45, P757, DOI 10.1194/jlr.M300475-JLR200; Wu G, 1999, J BIOL CHEM, V274, P9231, DOI 10.1074/jbc.274.14.9231; Wu G, 2001, J BIOL CHEM, V276, P19879, DOI 10.1074/jbc.M100628200; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181; Zhao XJ, 2003, INVEST OPHTH VIS SCI, V44, P1945, DOI 10.1167/iovs.02-0920	62	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26690	26700		10.1074/jbc.M501021200	http://dx.doi.org/10.1074/jbc.M501021200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917246	hybrid			2022-12-25	WOS:000230589500009
J	Sal-Man, N; Gerber, D; Shai, Y				Sal-Man, N; Gerber, D; Shai, Y			The identification of a minimal dimerization motif QXXS that enables homo- and hetero-association of transmembrane helices in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LIGAND-BINDING DOMAIN; GLYCOPHORIN-A; ASPARTATE RECEPTOR; POLAR RESIDUES; INTEGRIN ALPHA-IIB-BETA-3; CIRCULAR-DICHROISM; DRIVE ASSOCIATION; PEPTIDE; OLIGOMERIZATION	Assembly of transmembrane (TM) domains is a critical step in the function of membrane proteins, and therefore, determining the amino acid motifs that mediate this process is important. Studies along this line have shown that the GXXXG motif is involved in TM assembly. In this study we characterized the minimal dimerization motif in the bacterial Tar-1 homodimer TM domain, which does not contain a GXXXG sequence. We found that a short polar motif QXXS is sufficient to induce stable TM-TM interactions. Statistical analysis revealed that this motif appears to be significantly over-represented in a bacterial TM data base compared with its theoretical expectancy, suggesting a general role for this motif in TM assembly. A truncated short TM peptide ( 9 residues) that contains the QXXS motif interacted slightly with the wild-type Tar-1. However, the same short TM peptide regained wild-type-like activity when conjugated to an octanoyl aliphatic moiety. Biophysical studies indicated that this modification compensated for the missing hydrophobicity, stabilized alpha-helical structure, and enabled insertion of the peptide into the membrane core. These findings serve as direct evidence that even a short peptide containing a minimal recognition motif is sufficient to inhibit the proper assembly of TM domains. Interestingly, electron microscopy revealed that above the critical micellar concentration, the TM lipopeptide forms a network of nanofibers, which can serve for the slow release of the active lipopeptide.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il		Sal-Man, Neta/0000-0002-1109-479X				Arkin IT, 2002, BBA-BIOMEMBRANES, V1565, P347, DOI 10.1016/S0005-2736(02)00580-1; Brosig B, 1998, PROTEIN SCI, V7, P1052; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Dawson JP, 2003, J MOL BIOL, V331, P255, DOI 10.1016/S0022-2836(03)00714-9; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; ENGELHARD M, 1995, PROTEIN SCI, V4, P1553, DOI 10.1002/pro.5560040813; Freeman-Cook LL, 2004, J MOL BIOL, V338, P907, DOI 10.1016/j.jmb.2004.03.044; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; George SR, 2003, J PHARMACOL EXP THER, V307, P481, DOI 10.1124/jpet.103.053843; Gerber D, 2004, J BIOL CHEM, V279, P21177, DOI 10.1074/jbc.M400847200; Gerber D, 2004, J MOL BIOL, V339, P243, DOI 10.1016/j.jmb.2004.03.004; Gerber D, 2002, J MOL BIOL, V322, P491, DOI 10.1016/S0022-2836(02)00807-0; Gerber D, 2001, J BIOL CHEM, V276, P31229, DOI 10.1074/jbc.M101889200; Gerstein M, 1999, SCIENCE, V285, P1682, DOI 10.1126/science.285.5434.1682; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; Hantgan RR, 2003, J BIOL CHEM, V278, P3417, DOI 10.1074/jbc.M208869200; Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Huynh NT, 2003, IMMUNOLOGY, V108, P458, DOI 10.1046/j.1365-2567.2003.01614.x; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; KOLMAR H, 1994, BIOL CHEM H-S, V375, P61; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; Lee SP, 2000, NEUROPSYCHOPHARMACOL, V23, pS32, DOI 10.1016/S0893-133X(00)00155-X; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; Li R, 2004, BIOCHEM SOC T, V32, P412, DOI 10.1042/BST0320412; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Liu F, 2004, BIOPHYS J, V87, P2470, DOI 10.1529/biophysj.104.046342; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; Melnyk RA, 2002, J MOL BIOL, V315, P63, DOI 10.1006/jmbi.2001.5214; Melnyk RA, 2001, BIOCHEMISTRY-US, V40, P11106, DOI 10.1021/bi010642e; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Oren Z, 2000, BIOCHEMISTRY-US, V39, P6103, DOI 10.1021/bi992408i; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; Park PSH, 2004, BIOCHEMISTRY-US, V43, P15643, DOI 10.1021/bi047907k; Park S, 2002, FASEB J, V16, P1964, DOI 10.1096/fj.02-0395fje; Partridge AW, 2003, J BIOL CHEM, V278, P22056, DOI 10.1074/jbc.M210685200; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; ROTHEMUND S, 1995, BIOCHEMISTRY-US, V34, P12954, DOI 10.1021/bi00040a005; Sal-Man N, 2005, BIOCHEM J, V385, P29, DOI 10.1042/BJ20041022; Sal-Man N, 2004, BIOCHEMISTRY-US, V43, P2309, DOI 10.1021/bi0356294; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Shaw N, 1974, Adv Appl Microbiol, V17, P63, DOI 10.1016/S0065-2164(08)70555-0; von Heijne G, 1999, Q REV BIOPHYS, V32, P285, DOI 10.1017/S0033583500003541; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Yagyu T, 2004, FEBS LETT, V576, P408, DOI 10.1016/j.febslet.2004.09.048; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	54	52	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27449	27457		10.1074/jbc.M503095200	http://dx.doi.org/10.1074/jbc.M503095200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911619	hybrid			2022-12-25	WOS:000230589500097
J	Touroutine, D; Fox, RM; Von Stetina, SE; Burdina, A; Miller, DM; Richmond, JE				Touroutine, D; Fox, RM; Von Stetina, SE; Burdina, A; Miller, DM; Richmond, JE			acr-16 encodes an essential subunit of the levamisole-resistant nicotinic receptor at the Caenorhabditis elegans neuromuscular junction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ALPHA-7 SUBUNIT; GENE ENCODES; GABA; NEURONS; CLONING; FUSION	The Caenorhabditis elegans neuromuscular junction (NMJ) contains three pharmacologically distinct ionotropic receptors: gamma-aminobutyric acid receptors, levamisole-sensitive nicotinic receptors, and levamisole-insensitive nicotinic receptors. The subunit compositions of the gamma-aminobutyric acid- and levamisole-sensitive receptors have been elucidated, but the levamisole-insensitive acetylcholine receptor is uncharacterized. To determine which of the similar to 40 putative nicotinic receptor subunit genes in the C. elegans genome encodes the levamisole-resistant receptor, we utilized MAPCeL, a microarray profiling strategy. Of seven nicotinic receptor subunit transcripts found to be enriched in muscle, five encode the levamisole receptor subunits, leaving two candidates for the levamisole-insensitive receptor: acr-8 and acr-16. Electrophysiological analysis of the acr-16 deletion mutant showed that the levamisole-insensitive muscle acetylcholine current was eliminated, whereas deletion of acr-8 had no effect. These data suggest that ACR-16, like its closest vertebrate homolog, the nicotinic receptor alpha 7-subunit, may form homomeric receptors in vivo. Genetic ablation of both the levamisole-sensitive receptor and acr-16 abolished all cholinergic synaptic currents at the NMJ and severely impaired C. elegans locomotion. Therefore, ACR-16-containing receptors account for all non-levamisole-sensitive nicotinic synaptic signaling at the C. elegans NMJ. The determination of subunit composition for all three C. elegans body wall muscle ionotropic receptors provides a critical foundation for future research at this tractable model synapse.	Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Univ Illinois, Dept Biol, Chicago, IL 60607 USA	Vanderbilt University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Richmond, JE (corresponding author), Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.	jer@uic.edu			NCI NIH HHS [P30 CA68485] Funding Source: Medline; NEI NIH HHS [P30 EY08126] Funding Source: Medline; NHLBI NIH HHS [1 P01 HL6744-01] Funding Source: Medline; NICHD NIH HHS [HD15052] Funding Source: Medline; NIDDK NIH HHS [DK58749, P01 DK58212, P30 DK58404, P60 DK20593] Funding Source: Medline; NINDS NIH HHS [R01 NS041477, R01 NS041477-01A1, R01 NS41477, R01 NS041477-02, R01 NS26115, F31 NS046923, F31 NS043068, R01 NS041477-03] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD015052] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, U24DK058749, P30DK058404, P01DK058212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026115, F31NS046923, R01NS041477, F31NS043068] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ballivet M, 1996, J MOL BIOL, V258, P261, DOI 10.1006/jmbi.1996.0248; Bamber BA, 1999, J NEUROSCI, V19, P5348; Bamber BA, 2005, BRIT J PHARMACOL, V144, P502, DOI 10.1038/sj.bjp.0706052; Bamber BA, 2003, BRIT J PHARMACOL, V138, P883, DOI 10.1038/sj.bjp.0705119; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BRENNER S, 1974, GENETICS, V77, P71; Broide RS, 1999, MOL NEUROBIOL, V20, P1, DOI 10.1007/BF02741361; Christensen M, 2002, NEURON, V33, P503, DOI 10.1016/S0896-6273(02)00591-3; Chu LW, 2005, DEMENT GERIATR COGN, V19, P106, DOI 10.1159/000082661; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Culetto E, 2004, J BIOL CHEM, V279, P42476, DOI 10.1074/jbc.M404370200; DELTORO ED, 1994, J COMP NEUROL, V349, P325, DOI 10.1002/cne.903490302; Drago J, 2003, CELL MOL LIFE SCI, V60, P1267, DOI 10.1007/s00018-003-2259-9; Drisdel RC, 2000, J NEUROSCI, V20, P133, DOI 10.1523/JNEUROSCI.20-01-00133.2000; Fabian-Fine R, 2001, J NEUROSCI, V21, P7993, DOI 10.1523/JNEUROSCI.21-20-07993.2001; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fleming JT, 1997, J NEUROSCI, V17, P5843; Fox RM, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-42; Francis MM, 2003, TRENDS NEUROSCI, V26, P90, DOI 10.1016/S0166-2236(02)00041-3; Gally C, 2004, NATURE, V431, P578, DOI 10.1038/nature02893; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Halevi S, 2002, EMBO J, V21, P1012, DOI 10.1093/emboj/21.5.1012; Hill AA, 2001, GENOME BIOL, V2; Hobert O, 2002, BIOTECHNIQUES, V32, P728, DOI 10.2144/02324bm01; Jorgensen Erik M., 1995, Seminars in Developmental Biology, V6, P207, DOI 10.1016/S1044-5781(06)80030-7; Kim J, 2001, GENETICS, V157, P1599; Levin ED, 2002, J NEUROBIOL, V53, P633, DOI 10.1002/neu.10151; Levy RB, 2002, J NEUROSCI, V22, P5001, DOI 10.1523/JNEUROSCI.22-12-05001.2002; LEWIS JA, 1980, GENETICS, V95, P905; Liu ZP, 2005, J NEUROSCI, V25, P1159, DOI 10.1523/JNEUROSCI.3953-04.2005; MADURO M, 1995, GENETICS, V141, P977; MESSING A, 1982, BRAIN RES, V232, P479, DOI 10.1016/0006-8993(82)90292-X; Millar NS, 2003, BIOCHEM SOC T, V31, P869, DOI 10.1042/BST0310869; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; Mongan NP, 1998, RECEPTOR CHANNEL, V6, P213; Richmond JE, 1999, NAT NEUROSCI, V2, P959, DOI 10.1038/12160; Schafer WR, 2002, J NEUROBIOL, V53, P535, DOI 10.1002/neu.10154; SEGUELA P, 1993, J NEUROSCI, V13, P596; STOLLBERG J, 1987, J NEUROSCI, V7, P1809; Towers PR, 2005, J NEUROCHEM, V93, P1, DOI 10.1111/j.1471-4159.2004.02951.x; Waggoner LE, 2000, J NEUROSCI, V20, P8802	41	107	114	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27013	27021		10.1074/jbc.M502818200	http://dx.doi.org/10.1074/jbc.M502818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917232	hybrid			2022-12-25	WOS:000230589500046
J	Tropis, M; Meniche, X; Wolf, A; Gebhardt, H; Strelkov, S; Chami, M; Schomburg, D; Kramer, R; Morbach, S; Daffe, M				Tropis, M; Meniche, X; Wolf, A; Gebhardt, H; Strelkov, S; Chami, M; Schomburg, D; Kramer, R; Morbach, S; Daffe, M			The crucial role of trehalose and structurally related oligosaccharides in the biosynthesis and transfer of mycolic acids in corynebacterineae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; BETA-KETO ESTER; MYCOBACTERIUM-TUBERCULOSIS; ELECTRON-MICROSCOPY; PALMITIC ACID; 3 PATHWAYS; WALL; GLUTAMICUM; SMEGMATIS; ENVELOPE	Trehalose (alpha-D-glucopyranosyl-alpha'-D-glucopyranoside) is essential for the growth of the human pathogen Mycobacterium tuberculosis but not for the viability of the phylogenetically related corynebacteria. To determine the role of trehalose in the physiology of these bacteria, the so-called Corynebacterineae, mutant strains of Corynebacterium glutamicum unable to synthesize trehalose due to the knock-out of the genes of the three pathways of trehalose biosynthesis, were biochemically analyzed. We demonstrated that the synthesis of trehalose under standard conditions is a prerequisite for the production of mycolates, major and structurally important constituents of the cell envelope of Corynebacterineae. Consistently, the trehalose-less cells also lack the cell wall fracture plane that typifies mycolate-containing bacteria. Importantly, however, the mutants were able to synthesize mycolates when grown on glucose, maltose, and maltotriose but not on other carbon sources known to be used for the production of internal glucose phosphate such as fructose, acetate, and pyruvate. The mycoloyl residues synthesized by the mutants grown on alpha-D-glucopyranosyl-containing oligosaccharides were transferred both onto the cell wall and free sugar acceptors. A combination of chemical analytical approaches showed that the newly synthesized glycolipids consisted of 1 mol of mycolate located on carbon 6 of the non reducing glucopyranosyl unit. Additionally, experiments with radioactively labeled trehalose showed that the transfer of mycoloyl residues onto sugars occurs outside the plasma membrane. Finally, and in contradiction to published data, we demonstrated that trehalose 6-phosphate has no impact on mycolate synthesis in vivo.	CNRS, UMR 5089, Dept Mol Mech Mycobacterial Infect, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Univ Toulouse 3, F-31077 Toulouse, France; Univ Cologne, Inst Biochem, D-50674 Cologne, Germany; Univ Basel, Biozentrum, ME Muller Inst Struct Biol, CH-4056 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Cologne; University of Basel	Daffe, M (corresponding author), CNRS, UMR 5089, Dept Mol Mech Mycobacterial Infect, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.	mamadou.daffe@ipbs.fr		Schomburg, Dietmar/0000-0002-3354-822X				ABE S, 1967, J GEN APPL MICROBIOL, V13, P279, DOI 10.2323/jgam.13.279; AGGERBECK LP, 1986, METHOD ENZYMOL, V128, P457; Arguelles JC, 2000, ARCH MICROBIOL, V174, P217, DOI 10.1007/s002030000192; AURELLE H, 1980, TETRAHEDRON LETT, V21, P3277, DOI 10.1016/S0040-4039(00)78666-7; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAMI M, 1995, BIOL CELL, V83, P219, DOI 10.1016/0248-4900(96)81311-6; DAFFE M, 1989, J GEN MICROBIOL, V135, P2759; DAFFE M, 1988, EUR J BIOCHEM, V172, P579, DOI 10.1111/j.1432-1033.1988.tb13928.x; DAFFE M, 1983, ANN INST PASTEUR MIC, VB134, P241, DOI 10.1016/S0769-2609(83)80037-4; DAFFE M, 1991, BIOCHEMISTRY-US, V30, P378, DOI 10.1021/bi00216a011; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Daffe M., 2005, HDB CORYNEBACTERIUM, P121; DATTA AK, 1993, BIOCHIM BIOPHYS ACTA, V1169, P135, DOI 10.1016/0005-2760(93)90198-I; De Smet KAL, 2000, MICROBIOL-UK, V146, P199, DOI 10.1099/00221287-146-1-199; De Sousa-D'Auria C, 2003, FEMS MICROBIOL LETT, V224, P35, DOI 10.1016/S0378-1097(03)00396-3; DITTMER JC, 1964, J LIPID RES, V5, P126; Draper P, 1998, Front Biosci, V3, pD1253; Gao LY, 2003, MOL MICROBIOL, V49, P1547, DOI 10.1046/j.1365-2958.2003.03667.x; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; Kacem R, 2004, MICROBIOL-SGM, V150, P73, DOI 10.1099/mic.0.26583-0; LACAVE C, 1990, BIOCHIM BIOPHYS ACTA, V1042, P315, DOI 10.1016/0005-2760(90)90159-U; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; LOPEZMARIN LM, 1991, BIOCHIM BIOPHYS ACTA, V1086, P22, DOI 10.1016/0005-2760(91)90150-G; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; Morbach S, 2002, CHEMBIOCHEM, V3, P385, DOI 10.1002/1439-7633(20020503)3:5<384::AID-CBIC384>3.0.CO;2-H; Murphy HN, 2005, J BIOL CHEM, V280, P14524, DOI 10.1074/jbc.M414232200; Padilla L, 2004, APPL ENVIRON MICROB, V70, P370, DOI 10.1128/AEM.70.1.370-376.2004; Portevin D, 2005, J BIOL CHEM, V280, P8862, DOI 10.1074/jbc.M408578200; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; PROME JC, 1974, CR ACAD SCI C CHIM, V278, P1065; Puech V, 2001, MICROBIOL-SGM, V147, P1365, DOI 10.1099/00221287-147-5-1365; Puech V, 2000, MOL MICROBIOL, V35, P1026, DOI 10.1046/j.1365-2958.2000.01738.x; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; SATHYAMOORTHY N, 1987, J BIOL CHEM, V262, P13417; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SCHWIND H, 1978, J CLIN CHEM CLIN BIO, V16, P145; Shimakata T, 2000, ARCH BIOCHEM BIOPHYS, V380, P331, DOI 10.1006/abbi.2000.1924; SHIMAKATA T, 1986, ARCH BIOCHEM BIOPHYS, V247, P302, DOI 10.1016/0003-9861(86)90588-6; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005; Tzvetkov M, 2003, MICROBIOL-SGM, V149, P1659, DOI 10.1099/mic.0.26205-0; WALKER RW, 1973, BIOCHIM BIOPHYS ACTA, V326, P52, DOI 10.1016/0005-2760(73)90027-1; Wang J, 2004, BIOORGAN MED CHEM, V12, P6397, DOI 10.1016/j.bmc.2004.09.033; WHEELER PR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P182, DOI 10.1016/0005-2760(93)90160-B; Wolf A, 2003, MOL MICROBIOL, V49, P1119, DOI 10.1046/j.1365-2958.2003.03625.x; Woodruff PJ, 2004, J BIOL CHEM, V279, P28835, DOI 10.1074/jbc.M313103200	52	61	64	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26573	26585		10.1074/jbc.M502104200	http://dx.doi.org/10.1074/jbc.M502104200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901732	hybrid, Green Published			2022-12-25	WOS:000230386800074
J	Ferraro, F; Eipper, BA; Mains, RE				Ferraro, F; Eipper, BA; Mains, RE			Retrieval and reuse of pituitary secretory granule proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; MEMBRANE-PROTEIN; ANTERIOR-PITUITARY; CYTOSOLIC DOMAIN; ENDOCRINE-CELLS; ATT-20 CELLS; NEUROENDOCRINE CELLS; TRAFFICKING; PHOSPHORYLATION; EXOCYTOSIS	The pituitary contains professional secretory cells, devoting a large fraction of their energy to the synthesis of hormones that are stored for secretion in response to a complex mixture of inputs. Ba2+, a substitute for Ca2+, and phorbol ester, a mimic for diacylglycerol, have a synergistic effect on exocytosis. By using these secretagogues, we developed a paradigm in which phorbol ester potentiation of Ba2+- evoked exocytosis produces a robust secretory response in multiple pituitary cell types. Because cells subjected to this stimulatory paradigm remain healthy despite their greatly reduced hormone content, we used this paradigm to study the fate of granule membrane proteins. We examined the turnover of peptidylglycine alpha-amidating monooxygenase (PAM), a membrane enzyme involved in the final maturation of many peptides, and VAMP2, a vesicle soluble N-ethylmaleimidesensitive factor attachment protein receptor ( SNARE). The stability of recently synthesized PAM was increased by sustained exocytosis. Biotinylation studies established that the appearance of integral membrane PAM at the plasma membrane was stimulated along with hormone secretion. PAM biotinylated on the cell surface undergoes cleavage to yield soluble peptidylglycine-alpha-hydroxylating monooxygenase that can then be secreted in a regulated fashion. Consistent with a kiss-and-run or cavicapture mode of secretion (Taraska, J. W., Perrais, D., Ohara-Imaizumi, M., Nagamatsu, S., and Almers, W. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 2070 - 2075), biotinylated prolactin was also retained by the cells and later released in response to secretagogues. Thus, pituitary cells can retrieve and reuse components of the machinery involved in the final stages of exocytosis (the SNAREs) as well as soluble and membrane granule proteins.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA	University of Connecticut	Mains, RE (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	mains@uchc.edu	Ferraro, Francesco/R-3660-2018	Ferraro, Francesco/0000-0002-6199-637X	NIDDK NIH HHS [DK32948] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032948, R37DK032948, R01DK032948] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam MR, 2001, MOL BIOL CELL, V12, P629, DOI 10.1091/mbc.12.3.629; Bauer RA, 2004, J CELL SCI, V117, P2193, DOI 10.1242/jcs.01093; Bell-Parikh LC, 2001, J BIOL CHEM, V276, P29854, DOI 10.1074/jbc.M103936200; Ben-Jonathan N, 2001, ENDOCR REV, V22, P724, DOI 10.1210/er.22.6.724; Ciccotosto GD, 1999, J CELL BIOL, V144, P459, DOI 10.1083/jcb.144.3.459; DAVIDSON JS, 1987, J ENDOCRINOL, V114, P11, DOI 10.1677/joe.0.1140011; DICKERSON IM, 1990, ENDOCRINOLOGY, V127, P133, DOI 10.1210/endo-127-1-133; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Eipper B A, 1980, Endocr Rev, V1, P1; El Meskini R, 2001, J BIOL CHEM, V276, P3384, DOI 10.1074/jbc.M008062200; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; HUNTER A, 1989, EXP CELL RES, V182, P445, DOI 10.1016/0014-4827(89)90249-8; HURTLEY SM, 1993, J CELL SCI, V106, P649; Jacobsson G, 1996, ENDOCRINOLOGY, V137, P5344, DOI 10.1210/en.137.12.5344; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; MAY V, 1986, ENDOCRINOLOGY, V118, P1284, DOI 10.1210/endo-118-4-1284; Meskini RE, 2000, ENDOCRINOLOGY, V141, P3020; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; Oyarce AM, 1996, J NEUROCHEM, V67, P229; OYARCE AM, 1995, J CELL SCI, V108, P287; PATZAK A, 1986, J CELL BIOL, V102, P510, DOI 10.1083/jcb.102.2.510; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; Schwartz J, 2000, ENDOCR REV, V21, P488, DOI 10.1210/er.21.5.488; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; Steveson TC, 2001, J BIOL CHEM, V276, P40326, DOI 10.1074/jbc.M011460200; Steveson TC, 1999, J BIOL CHEM, V274, P21128, DOI 10.1074/jbc.274.30.21128; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; TERBUSH DR, 1992, J NEUROCHEM, V58, P680, DOI 10.1111/j.1471-4159.1992.tb09771.x; Vo YP, 2004, BIOCHEM BIOPH RES CO, V324, P1004, DOI 10.1016/j.bbrc.2004.09.147; VONRUDEN L, 1993, ANN REV PHARM TOXICO, V36, P481; YUN HY, 1995, J BIOL CHEM, V270, P30075	38	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25424	25435		10.1074/jbc.M414156200	http://dx.doi.org/10.1074/jbc.M414156200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15905171	hybrid			2022-12-25	WOS:000230207900017
J	Lutzelberger, M; Backstrom, E; Akusjarvi, G				Lutzelberger, M; Backstrom, E; Akusjarvi, G			Substrate-dependent differences in U2AF requirement for splicing in adenovirus-infected cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; SEQUENCES; RECOGNITION; ENHANCER; BINDING; PROTEIN; SITES; MUD2; AG	U2AF has been characterized as an essential splicing factor required for efficient recruitment of U2 small nuclear ribonucleoprotein to the 3 '- splice site in a pre- mRNA. The U2AF(65) subunit binds to the pyrimidine tract of the pre- mRNA, whereas the U2AF(35) subunit contacts the 3 '- splice site AG. Here we show that U2AF35 appears to be completely dispensable for splicing in nuclear extracts prepared from adenovirus late- infected cells ( Ad- NE). As a consequence, the viral IIIa and cellular IgM introns, which both have suboptimal 3 '- splice sites and require U2AF35 for splicing in nuclear extracts from uninfected cells, are transformed to U2AF(35)- independent introns in Ad- NE. Furthermore, we present evidence that two parallel pathways of 3 '- splice site recognition exist in Ad- NE. We show that the viral 52,55K intron, which has an extended pyrimidine tract, requires U2AF for activity in Ad- NE. In contrast, the IgM intron, which has a weak 3 '- splice site sequence context, undergoes the first catalytic step of splicing in U2AFdepleted Ad- NE, suggesting that spliceosome assembly occurs through a novel U2AF- independent pathway in Ad- NE.	Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Uppsala University	Akusjarvi, G (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, Husargatan 3,Box 582, S-75123 Uppsala, Sweden.	goran.akusjarvi@imbim.uu.se						ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Akusjarvi G, 2003, CURR TOP MICROBIOL, V272, P253; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; Clarke PA, 1999, METH MOL B, V118, P1; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; Guth S, 1999, MOL CELL BIOL, V19, P8263; Guth S, 2001, MOL CELL BIOL, V21, P7673, DOI 10.1128/MCB.21.22.7673-7681.2001; Huang TS, 2002, EMBO REP, V3, P1088, DOI 10.1093/embo-reports/kvf217; Kambach C, 1999, CURR OPIN STRUC BIOL, V9, P222, DOI 10.1016/S0959-440X(99)80032-3; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P2379, DOI 10.1093/nar/19.9.2379; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P6956, DOI 10.1093/nar/19.24.6956; KREIVI JP, 1994, NUCLEIC ACIDS RES, V22, P332, DOI 10.1093/nar/22.3.332; LAMOND AI, 1993, BIOESSAYS, V15, P595, DOI 10.1002/bies.950150905; LAMOND AI, 1994, PRACT APPROACH SER, V135, P103; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MacMillan AM, 1997, P NATL ACAD SCI USA, V94, P133, DOI 10.1073/pnas.94.1.133; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Muhlemann O, 2000, MOL CELL BIOL, V20, P2317, DOI 10.1128/MCB.20.7.2317-2325.2000; MUHLEMANN O, 1995, J VIROL, V69, P7324; MULHEMANN O, 1998, METHODS MOL MED, V21, P203; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; VALCARCEL J, 1997, MRNA FORMATION FUNCT, P31; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zorio DAR, 1999, RNA, V5, P487, DOI 10.1017/S1355838299982225; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	34	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25478	25484		10.1074/jbc.M413737200	http://dx.doi.org/10.1074/jbc.M413737200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15899895	hybrid			2022-12-25	WOS:000230207900022
J	Maier, TJ; Janssen, A; Schmidt, R; Geisslinger, G; Grosch, S				Maier, TJ; Janssen, A; Schmidt, R; Geisslinger, G; Grosch, S			Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells	FASEB JOURNAL			English	Article						colon cancer; nonsteroidal anti-inflammatory drugs; apoptosis	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GLYCOGEN-SYNTHASE KINASE-3; ADENOMATOUS POLYPOSIS; INHIBITOR CELECOXIB; COLORECTAL-CANCER; CYCLE ARREST; APOPTOSIS; ACTIVATION; PROTEIN; EXPRESSION	CCelecoxib, a cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug, is a new anticarcinogenic agent. Its antitumor effects depend on the one hand on its COX-2-inhibiting potency, but on the other hand on COX-2-independent mechanisms, which until now have not been fully understood. Here, we investigated whether celecoxib has an impact on the APC/beta-catenin pathway, which has been shown to play a pivotal role in the development of various cancers, especially of the colon. After only 2 h of treatment of human Caco-2 colon carcinoma cells with 100 mu M celecoxib, we observed a rapid translocation of beta-catenin from its predominant membrane localization to the cytoplasm. Inhibition of the glycogen-synthase-kinase-3 beta (GSK-3 beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3 beta kinase was essential for this release. Furthermore, the cytosolic accumulation was accompanied by a rapid increase of beta-catenin in the nuclei, starting already 30 min after celecoxib treatment. The DNA binding activity of beta-catenin time dependently decreased 2 h after celecoxib treatment. After this cellular reorganization, we observed a caspase- and proteasome-dependent degradation of beta-catenin after 8 h of drug incubation. Celecoxib-induced beta-catenin degradation was also observed in various other tumor cell lines (HCT-116, MCF-7, and LNCAP) but was not seen after treatment of Caco-2 cells with either the anticarcinogenic nonsteroidal anti-inflammatory drug R-flurbiprofen or the highly COX-2-selective inhibitor rofecoxib. These findings indicate that the anticarcinogenic effects of celecoxib can be explained, at least partly, by an extensive degradation of beta-catenin in human colon carcinoma cells.	Univ Frankfurt Klinikum, Inst Klin Pharmakol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Grosch, S (corresponding author), Univ Frankfurt Klinikum, Inst Klin Pharmakol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	groesch@em.uni-frankfurt.de	Groesch, Sabine/H-4251-2018	Groesch, Sabine/0000-0002-7262-6307				Abou-Issa Hussein, 2004, Expert Rev Anticancer Ther, V4, P725, DOI 10.1586/14737140.4.5.725; Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; Basu GD, 2004, MOL CANCER RES, V2, P632; Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505; Brautigam L, 2001, J CHROMATOGR B, V761, P203, DOI 10.1016/S0378-4347(01)00333-4; Brown WA, 2001, DIGEST DIS SCI, V46, P2314, DOI 10.1023/A:1012326525692; Brozovic A, 2004, INT J CANCER, V112, P974, DOI 10.1002/ijc.20522; Chen TA, 2003, CANCER RES, V63, P4368; Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-10; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Dihlmann S, 2003, MOL CANCER THER, V2, P509; Easwaran V, 2003, CANCER RES, V63, P3145; Gardner SH, 2004, BRIT J CANCER, V91, P153, DOI 10.1038/sj.bjc.6601901; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Grosch S, 2003, FASEB J, V17, P1316, DOI 10.1096/fj.02-0919fje; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heinen CD, 2002, GASTROENTEROLOGY, V123, P751, DOI 10.1053/gast.2002.35382; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Hugh TJ, 1999, BRIT J CANCER, V80, P1046, DOI 10.1038/sj.bjc.6690461; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Maier TJ, 2004, BIOCHEM PHARMACOL, V67, P1469, DOI 10.1016/j.bcp.2003.12.014; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Maruyama K, 2000, ONCOLOGY-BASEL, V59, P302, DOI 10.1159/000012187; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje; Ougolkov AV, 2002, GASTROENTEROLOGY, V122, P60, DOI 10.1053/gast.2002.30306; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rask K, 2003, BRIT J CANCER, V89, P1298, DOI 10.1038/sj.bjc.6601265; Rice PL, 2003, MOL CANCER THER, V2, P885; Roh H, 2001, CANCER RES, V61, P6563; Sadot E, 2002, J CELL SCI, V115, P2771; Sanz-Ortega J, 1999, PATHOL RES PRACT, V195, P677; SILENI VC, 1992, CANCER CHEMOTH PHARM, V30, P221, DOI 10.1007/BF00686317; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Yamada Y, 2001, JPN J CANCER RES, V92, P617, DOI 10.1111/j.1349-7006.2001.tb01139.x; Yang HM, 2004, CIRCULATION, V110, P301, DOI 10.1161/01.CIR.0000135467.43430.16; Zhang ZC, 2004, HEPATOLOGY, V39, P1028, DOI 10.1002/hep.20143; Zhu JX, 2004, CANCER RES, V64, P4309, DOI 10.1158/0008-5472.CAN-03-4063	56	115	121	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1353	+		10.1096/fj.04-3274fje	http://dx.doi.org/10.1096/fj.04-3274fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946992				2022-12-25	WOS:000230207800024
J	Peter, JC; Tugler, J; Eftekhari, P; Maurice, D; Hoebeke, J; Roegel, JC				Peter, JC; Tugler, J; Eftekhari, P; Maurice, D; Hoebeke, J; Roegel, JC			Effects on heart rate of an anti-M2 acetylcholine receptor immune response in mice	FASEB JOURNAL			English	Article						electrocardiography; heart rate; acetylcholine; receptors; antibodies	IDIOPATHIC DILATED CARDIOMYOPATHY; CARDIAC MUSCARINIC RECEPTORS; HUMAN CHAGASIC IGG; MONOCLONAL-ANTIBODY; ANTAGONIST BINDING; K+ CHANNEL; AUTOANTIBODIES; AGONIST; DISEASE; AUTOIMMUNITY	Autoantibodies in vitro modulating the M2 acetylcholine receptor (M2ACh-R) were observed in patients with idiopathic dilated cardiomyopathy (IDC) or Chagas' cardiomyopathy (ChC). We investigated the in vivo consequences on heart rate of such antibodies in mice immunized with a peptide derived from the second extracellular loop of the M2ACh-R compared with mice immunized with an irrelevant peptide. Sera of mice immunized with the M2ACh-R- derived peptide recognized the M2ACh-R on immunoblots and enhanced agonist activity of carbachol toward the M2ACh-R transfected in CHO cells. In vivo, no difference could be shown in heart rate or heart rate variability between the two groups of mice. The decrease in heart rate induced by carbachol was more pronounced, however, in the M2ACh-R immunized mice. The increase in heart rate induced by atropine, gallamine, and isoproterenol was significantly attenuated in the M2ACh-R immunized mice. Analysis of heart rate variability further argued for an increased parasympathetic response to different drugs in the M2ACh-R immunized mice. Antibodies raised against the M2ACh-R can behave as positive M2AChR allosteric modulators in vivo. They might be protective in boosting the activity of the parasympathetic drive to the heart, especially in patients with a high sympathetic tone.	Sch Med, Inst Pharmacol, F-68250 Rouffach, France; CNRS, Inst Biol Mol & Cellulaire, Lab Immunol & Therapeut Chem, UPR 9021, F-67084 Strasbourg, France	Universite de Franche-Comte; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Roegel, JC (corresponding author), Sch Med, Inst Pharmacol, 27 Rue 4eme RSM, F-68250 Rouffach, France.	jcroegel@free.fr	Maurice, Donald/AAE-9332-2019					Brown F, 1999, VACCINE, V18, P50, DOI 10.1016/S0264-410X(99)00169-3; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; Chaves AA, 2003, LIFE SCI, V72, P2401, DOI 10.1016/S0024-3205(03)00137-1; Chiale PA, 2001, AUTOIMMUNITY, V34, P205, DOI 10.3109/08916930109007386; Chiale PA, 2001, CIRCULATION, V103, P1765, DOI 10.1161/01.CIR.103.13.1765; del Corsso C, 2004, AM J PHYSIOL-HEART C, V287, pH1928, DOI 10.1152/ajpheart.00044.2004; Elies R, 1996, J IMMUNOL, V157, P4203; Elies R, 1998, EUR J BIOCHEM, V251, P659, DOI 10.1046/j.1432-1327.1998.2510659.x; Fisher JT, 2004, FASEB J, V18, P711, DOI 10.1096/fj.03-0648fje; FU LX, 1993, J CLIN INVEST, V91, P1964, DOI 10.1172/JCI116416; Goin JC, 1997, FASEB J, V11, P77, DOI 10.1096/fasebj.11.1.9034169; Goin Juan Carlos, 1994, Neuroimmunomodulation, V1, P284; Hernandez CCQ, 2003, CARDIOVASC RES, V58, P55, DOI 10.1016/S0008-6363(02)00811-8; Jahns R, 2004, J CLIN INVEST, V113, P1419, DOI 10.1172/JCI200420149; Leiros CP, 1997, J BIOL CHEM, V272, P12989, DOI 10.1074/jbc.272.20.12989; LEPPIK RA, 1994, MOL PHARMACOL, V45, P983; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUETJE CW, 1988, J BIOL CHEM, V263, P13357; MAGNUSSON Y, 1994, CIRCULATION, V89, P2760, DOI 10.1161/01.CIR.89.6.2760; Matsui S, 1999, J Card Fail, V5, P246, DOI 10.1016/S1071-9164(99)90009-X; Matsui S, 2001, J CARDIOVASC PHARM, V38, pS43, DOI 10.1097/00005344-200110001-00010; Mijares A, 1996, MOL CELL BIOCHEM, V164, P107, DOI 10.1007/BF00408646; Nascimento JHM, 2001, AM J PHYSIOL-CELL PH, V281, pC1251, DOI 10.1152/ajpcell.2001.281.4.C1251; NEIMARK J, 1993, PEPTIDE RES, V6, P219; Nevo U, 2004, J THEOR BIOL, V227, P583, DOI 10.1016/j.jtbi.2003.11.031; Peter JC, 2003, J BIOL CHEM, V278, P36740, DOI 10.1074/jbc.M306877200; Sowell MO, 1997, P NATL ACAD SCI USA, V94, P7921, DOI 10.1073/pnas.94.15.7921; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Wallukat G, 1999, LIFE SCI, V64, P465, DOI 10.1016/S0024-3205(98)00589-X; Wallukat G, 2002, NEW ENGL J MED, V347, P1806, DOI 10.1056/NEJM200211283472220; Yamada M, 1998, PHARMACOL REV, V50, P723; Zhang L, 2002, CHINESE MED J-PEKING, V115, P1127	32	16	16	4	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					943	949		10.1096/fj.04-3042com	http://dx.doi.org/10.1096/fj.04-3042com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923404				2022-12-25	WOS:000230207800041
J	Arimon, M; Diez-Perez, I; Kogan, MJ; Durany, N; Giralt, E; Sanz, F; Fernandez-Busquets, X				Arimon, M; Diez-Perez, I; Kogan, MJ; Durany, N; Giralt, E; Sanz, F; Fernandez-Busquets, X			Fine structure study of A beta(1-42) fibrillogenesis with atomic force microscopy	FASEB JOURNAL			English	Article						amyloid-beta peptide; Alzheimer; amyloid-beta fibrils; amyloid-beta protofibrils	AMYLOID-BETA-PROTEIN; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; RAPID CELLULAR DEGENERATION; NUCLEAR-MAGNETIC-RESONANCE; IN-VITRO GROWTH; ALZHEIMERS-DISEASE; ELECTRON-MICROSCOPY; FIBRIL FORMATION; PEPTIDE; TOXICITY	One of the hallmarks of Alzheimer's disease is the self-aggregation of the amyloid beta peptide (A beta) in extracellular amyloid fibrils. Among the different forms of A beta, the 42-residue fragment (A beta(1-42)) readily self-associates and forms nucleation centers from where fibrils can quickly grow. The strong tendency of A beta(1-42) to aggregate is one of the reasons for the scarcity of data on its fibril formation process. We have used atomic force microscopy (AFM) to visualize in liquid environment the fibrillogenesis of synthetic A beta(1-42) on hydrophilic and hydrophobic surfaces. The results presented provide nanometric resolution of the main structures characteristic of the several steps from monomeric A beta(1-42) to mature fibrils in vitro. Oligomeric globular aggregates of A beta(1-42) precede the appearance of protofibrils, the first fibrillar species,although we have not obtained direct evidence of oligomer-protofibril interconversion. The protofibril dimensions deduced from our AFM images are consistent with a model that postulates the stacking of the peptide in a hairpin conformation perpendicular to the long axis of the protofibril, forming single-sheets ribbon-shaped. The most abundant form of A beta(1-42) fibril exhibits a nodular structure with a similar to 100-nm periodicity. This length is very similar 1) to the length of protofibril bundles that are the dominant feature at earlier stages in the aggregation process,2) to the period of helical structures that have been observed in the core of fibrils, and 3) to the distance between regularly spaced, structurally weak fibril points. Taken together, these data are consistent with the existence of a similar to 100-nm long basic protofibril unit that is a key fibril building block.	Univ Barcelona, Lab Recerca Nanobioengn, Barcelona, Spain; Univ Barcelona, Dept Quim Fis, E-08028 Barcelona, Spain; Inst Recerca Biomed Barcelona, Barcelona, Spain; Univ Int Catalunya, Fac Ciencies Salut, Barcelona, Spain; Univ Barcelona, Dept Quim Organ, Barcelona, Spain	University of Barcelona; University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Universitat Internacional de Catalunya (UIC); University of Barcelona	Fernandez-Busquets, X (corresponding author), Res Ctr Bioelect & Nanobiosci, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.	xfemandez_busquets@ub.edu	Díez-Pérez, Ismael/F-6402-2014; Fernàndez-Busquets, Xavier/K-1323-2014; kogan, Marcelo/I-2868-2013; giralt, ernest/N-1669-2014; Arimon, Muriel/I-4054-2015	Díez-Pérez, Ismael/0000-0003-0513-8888; Fernàndez-Busquets, Xavier/0000-0002-4622-9631; giralt, ernest/0000-0001-8381-1797; Arimon, Muriel/0000-0002-0894-3324				Antzutkin ON, 2004, MAGN RESON CHEM, V42, P231, DOI 10.1002/mrc.1341; Antzutkin ON, 2002, BIOCHEMISTRY-US, V41, P15436, DOI 10.1021/bi0204185; Benzinger TLS, 2000, BIOCHEMISTRY-US, V39, P3491, DOI 10.1021/bi991527v; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Brown CL, 2002, J AM CHEM SOC, V124, P6846, DOI 10.1021/ja0261271; Chamberlain AK, 2000, BIOPHYS J, V79, P3282, DOI 10.1016/S0006-3495(00)76560-X; Chaney MO, 1998, PROTEIN ENG, V11, P761, DOI 10.1093/protein/11.9.761; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Foguel D, 2003, P NATL ACAD SCI USA, V100, P9831, DOI 10.1073/pnas.1734009100; Goldsbury CS, 2000, J STRUCT BIOL, V130, P217, DOI 10.1006/jsbi.2000.4259; Gomez E, 1995, J ELECTROCHEM SOC, V142, P4091, DOI 10.1149/1.2048469; Guo JT, 2004, PROTEINS, V57, P357, DOI 10.1002/prot.20222; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; Kawahara M, 2000, BRAIN RES BULL, V53, P389, DOI 10.1016/S0361-9230(00)00370-1; Kawooya JK, 2003, ANAL BIOCHEM, V323, P103, DOI 10.1016/j.ab.2003.08.027; KELLER D, 1991, SURF SCI, V253, P353, DOI 10.1016/0039-6028(91)90606-S; Khurana R, 2003, BIOPHYS J, V85, P1135, DOI 10.1016/S0006-3495(03)74550-0; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Koudinov AR, 1996, BIOCHEM BIOPH RES CO, V223, P592, DOI 10.1006/bbrc.1996.0940; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li LP, 1999, BIOPHYS J, V76, P2871, DOI 10.1016/S0006-3495(99)77442-4; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; Parbhu A, 2002, PEPTIDES, V23, P1265, DOI 10.1016/S0196-9781(02)00061-X; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; POLLARD HB, 1993, ANN NY ACAD SCI, V695, P165, DOI 10.1111/j.1749-6632.1993.tb23046.x; Roher AE, 2000, BBA-MOL BASIS DIS, V1502, P31, DOI 10.1016/S0925-4439(00)00030-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Serpell LC, 2000, BIOCHEMISTRY-US, V39, P13269, DOI 10.1021/bi000637v; Serpell LC, 2000, J MOL BIOL, V300, P1033, DOI 10.1006/jmbi.2000.3908; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; VESENKA J, 1992, ULTRAMICROSCOPY, V42, P1243, DOI 10.1016/0304-3991(92)90430-R; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wang ZG, 2003, ULTRAMICROSCOPY, V97, P73, DOI 10.1016/S0304-3991(03)00031-7; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yip CM, 2002, J MOL BIOL, V318, P97, DOI 10.1016/S0022-2836(02)00028-1; Zagorski MG, 1999, METHOD ENZYMOL, V309, P189; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244	52	135	137	0	51	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1344	+		10.1096/fj.04-3137fje	http://dx.doi.org/10.1096/fj.04-3137fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15919759				2022-12-25	WOS:000229602600009
J	Funderburgh, ML; Du, YQ; Mann, MM; SundarRaj, N; Funderburgh, JL				Funderburgh, ML; Du, YQ; Mann, MM; SundarRaj, N; Funderburgh, JL			PAX6 expression identifies progenitor cells for corneal keratocytes	FASEB JOURNAL			English	Article						cornea; keratan sulfate; stem cell	MESENCHYMAL STEM-CELLS; BOVINE KERATOCYTES; IN-VITRO; PROTEOGLYCAN EXPRESSION; SKELETAL-MUSCLE; BONE-MARROW; PHENOTYPE; DIFFERENTIATION; FIBROBLASTS; SULFATE	Keratocytes of the corneal stroma produce a transparent extracellular matrix required for vision. During wound-healing and in vitro,keratocytes proliferate, becoming fibroblastic, and lose biosynthesis of unique corneal matrix components. This study sought identification of cells in the corneal stroma capable of assuming a keratocyte phenotype after extensive proliferation. About 3% of freshly isolated bovine stromal cells exhibited clonal growth. In low-mitogen media, selected clonal cultures displayed dendritic morphology and expressed high levels of keratan sulfate, aldehyde dehydrogenase 3A1, and keratocan, molecular markers of keratocyte phenotype. In protein-free media, both primary keratocytes and selected clonal cells aggregated to form attachment-independent spheroids expressing elevated levels of those marker molecules. The selected clonal cells exhibited normal karyotype and underwent replicative senescence after 65-70 population doublings;however, they continued expression of keratocyte phenotypic markers throughout their replicative life span. The progenitor cells expressed elevated mRNA for several genes characteristic of stem cells and also for genes expressed during ocular development PAX6, Six2, and Six3. PAX6 protein was detected in the cultured progenitor cells and a small number of stromal cells in intact tissue but was absent in cultured keratocytes and fibroblasts. Cytometry demonstrated PAX6 protein in 4% of freshly isolated stromal cells. These results demonstrate the presence of a previously unrecognized population of PAX6-positive cells in adult corneal stroma that maintain the potential to assume a keratocyte phenotype even after extensive replication. The presence of such progenitor cells has implications for corneal biology and for cell-based therapies targeting corneal scarring.	Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Funderburgh, JL (corresponding author), Eye & Ear Inst Pittsburgh, Rm 1009,203 Lothrop St, Pittsburgh, PA 15213 USA.	jlfunder@pitt.edu	DU, YIQIN/AAO-1566-2020; Du, Yiqin/A-7727-2018	DU, YIQIN/0000-0002-4330-0957; 	NEI NIH HHS [R01 EY016415, P30 EY008098-179003, EY09368, P30 EY008098, R03 EY013806, EY013806, R01 EY016415-01A1, R01 EY009368, 30-EY08098, R01 EY003263, EY003263] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY016415, R01EY003263, R01EY009368, P30EY008098, R03EY013806] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alsalameh S, 2004, ARTHRITIS RHEUM-US, V50, P1522, DOI 10.1002/art.20269; Arsenijevic Y, 2001, EXP NEUROL, V170, P48, DOI 10.1006/exnr.2001.7691; Baroffio A, 1996, DIFFERENTIATION, V60, P47, DOI 10.1046/j.1432-0436.1996.6010047.x; BAYANI J, 2004, CURRENT PROTOCOLS CE; Beales MP, 1999, INVEST OPHTH VIS SCI, V40, P1658; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; Berryhill BL, 2002, INVEST OPHTH VIS SCI, V43, P3416; Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061; Bourges JL, 2003, OPHTHALMOLOGY, V110, P1920, DOI 10.1016/S0161-6420(03)00617-1; Carlson EC, 2003, MOL VIS, V9, P615; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chun MH, 2000, CRIT REV ONCOL HEMAT, V36, P89, DOI 10.1016/S1040-8428(00)00079-2; Collinson JM, 2003, DEV BIOL, V255, P303, DOI 10.1016/S0012-1606(02)00095-7; Connon CJ, 2003, OPHTHALMIC RES, V35, P177, DOI 10.1159/000071168; CONRAD AH, 1995, CELL MOTIL CYTOSKEL, V31, P93, DOI 10.1002/cm.970310203; CONRAD GW, 1974, EXP EYE RES, V18, P421, DOI 10.1016/0014-4835(74)90079-7; De Bari C, 2003, J CELL BIOL, V160, P909, DOI 10.1083/jcb.200212064; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Espana EM, 2003, INVEST OPHTH VIS SCI, V44, P5136, DOI 10.1167/iovs.03-0484; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; Funderburgh JL, 2003, J BIOL CHEM, V278, P45629, DOI 10.1074/jbc.M303292200; Funderburgh JL, 2001, J BIOL CHEM, V276, P44173, DOI 10.1074/jbc.M107596200; Gao R, 2003, DIABETES, V52, P2007, DOI 10.2337/diabetes.52.8.2007; GARANA RMR, 1992, INVEST OPHTH VIS SCI, V33, P3271; Ghanbari H, 2001, MECH DEVELOP, V101, P271, DOI 10.1016/S0925-4773(00)00572-4; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341; Leppert G S, 1999, Ophthalmic Genet, V20, P7, DOI 10.1076/opge.20.1.7.2298; Liu CY, 2003, J BIOL CHEM, V278, P21672, DOI 10.1074/jbc.M301169200; Liu HW, 1997, J BONE MINER RES, V12, P1691, DOI 10.1359/jbmr.1997.12.10.1691; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1; Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264; Marcon AS, 2003, CORNEA, V22, P19, DOI 10.1097/00003226-200301000-00005; Moller-Pedersen T, 1998, INVEST OPHTH VIS SCI, V39, P487; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MULLER LJ, 1995, INVEST OPHTH VIS SCI, V36, P2557; Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100; Ramaesh T, 2003, INVEST OPHTH VIS SCI, V44, P1871, DOI 10.1167/iovs.02-0576; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Schwartz M F, 1985, Cornea, V4, P58; Sell S, 2003, INT J BIOCHEM CELL B, V35, P267, DOI 10.1016/S1357-2725(02)00182-6; Shimano K, 2003, AM J PATHOL, V163, P3, DOI 10.1016/S0002-9440(10)63624-3; SUNDARRAJ N, 1985, CURR EYE RES, V4, P49; Tallheden T, 2003, J BONE JOINT SURG AM, V85A, P93, DOI 10.2106/00004623-200300002-00012; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Tuli R, 2003, STEM CELLS, V21, P681, DOI 10.1634/stemcells.21-6-681; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; Vourc'h P, 2004, BIOCHEM BIOPH RES CO, V317, P893, DOI 10.1016/j.bbrc.2004.03.121; Yamamoto S, 2001, J NEUROSCI, V21, P9814, DOI 10.1523/JNEUROSCI.21-24-09814.2001; Yin L, 2002, HEPATOLOGY, V35, P315, DOI 10.1053/jhep.2002.31355; Yoon YD, 1998, CORNEA, V17, P180, DOI 10.1097/00003226-199803000-00011; Zhang Y, 2004, EXP HEMATOL, V32, P657, DOI 10.1016/j.exphem.2004.04.001; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	60	87	90	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1371	+		10.1096/fj.04-2770fje	http://dx.doi.org/10.1096/fj.04-2770fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15901670	Green Accepted			2022-12-25	WOS:000229602600010
J	MacPartlin, M; Zeng, S; Lee, H; Stauffer, D; Jin, YT; Thayer, M; Lu, H				MacPartlin, M; Zeng, S; Lee, H; Stauffer, D; Jin, YT; Thayer, M; Lu, H			p300 regulates p63 transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN CBP; HAY-WELLS-SYNDROME; DNA-DAMAGE; P53 HOMOLOG; BINDING-PROTEIN; ACETYLASE ACTIVITY; FOOT MALFORMATION; TERMINAL DOMAIN; RETINOIC-ACID; TARGET GENES	The transcriptional co-activator p300 has been reported to regulate the tumor suppressor p53 and its ortholog p73. Here we describe a study showing that this coactivator also regulates the transcriptional function of p63. p300 bound to the N-terminal domain of p63 gamma, and p63 gamma bound to the N terminus of p300 in vitro and in cells. p300, but not its acetylase-defective mutant AT2, stimulated p63 gamma-dependent transcription and induction of p21 in cells, consequently leading to G(1) arrest. Inversely, the Delta N-p63 gamma isoform as well as p300AT2 inhibited the induction of p21 by p63 gamma. These results suggest that p300 regulates p63-dependent transcription of p21.	OR Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; OR Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Lu, H (corresponding author), OR Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	luh@ohsu.edu			NCI NIH HHS [CA079721, CA095441, CA93614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079721, R01CA095441, R01CA093614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Goodman RH, 2000, GENE DEV, V14, P1553; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HANNON GJ, 1991, J BIOL CHEM, V266, P22796; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Ianakiev P, 2000, AM J HUM GENET, V67, P59, DOI 10.1086/302972; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kuninger D, 2004, HUM GENE THER, V15, P1287, DOI 10.1089/hum.2004.15.1287; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Levrero M, 2000, J CELL SCI, V113, P1661; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; OGRZYKO VV, 1996, CELL, V87, P953; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Scolnick DM, 1997, CANCER RES, V57, P3693; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shimada A, 1999, CANCER RES, V59, P2781; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng SX, 2003, J BIOL CHEM, V278, P7453, DOI 10.1074/jbc.M209030200; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540; Zeng XY, 1998, P NATL ACAD SCI USA, V95, P6681, DOI 10.1073/pnas.95.12.6681; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zeng XY, 2001, J BIOL CHEM, V276, P48, DOI 10.1074/jbc.C000722200	58	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30604	30610		10.1074/jbc.M503352200	http://dx.doi.org/10.1074/jbc.M503352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15965232	hybrid			2022-12-25	WOS:000231362500077
J	Chaturvedi, V; Sitailo, LA; Qin, JZ; Bodner, B; Denning, MF; Curry, J; Zhang, WG; Brash, D; Nickoloff, BJ				Chaturvedi, V; Sitailo, LA; Qin, JZ; Bodner, B; Denning, MF; Curry, J; Zhang, WG; Brash, D; Nickoloff, BJ			Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis	ONCOGENE			English	Article						p53; UV-light; keratinocytes; apoptosis; E2F-1; Mcl-1; Bcl-x	C-TERMINAL DOMAIN; SKIN-CANCER; MALIGNANT PROGRESSION; GENE DOSAGE; G2/M ARREST; MUTANT P53; MUTATIONS; PROTEIN; DEATH; BAX	Ultraviolet (UV) light exposure is a common cause of epithelial-derived skin cancers, and the epidermal response to UV-light has been extensively studied using both mouse models and cultured human keratinocytes (KCs). Elimination of cells with UV-induced DNA damage via apoptosis provides a powerful mechanism to minimize retention or expansion of genetically abnormal cells. This cell editing function has largely been ascribed to the biological role of the p53 tumor suppressor gene, as mutations or deletions involving p53 have been linked to skin cancer development. Rather than introducing mutations, or using cells with complete loss of wild-type p53, we used an siRNA-based approach to knockdown, but not eliminate, p53 levels in primary cultures of human KCs followed by UV-irradiation. Surprisingly, when p53 levels were reduced by 50-80% the apoptosis induced by exposure to UV-light was accelerated and markedly enhanced (two- to three-fold) compared to control siRNA treated KCs. The p53 siRNA treated KCs were characterized by elevated E2F-1 levels accompanied by accelerated elimination of the Mcl-1 and Bcl-x(L) antiapoptotic proteins, as well as enhanced Bax oligomerization. Forced overexpression of either Mcl-1 or Bcl-x(L) reduced the UV-light enhanced apoptotic response in p53 siRNA treated KCs. We conclude that p53 not only can provide proapoptotic signals but also regulates a survival pathway influencing Mcl-1 and Bcl-x(L) levels. This overlooked survival function of p53 may explain previous paradoxical responses noted by investigators using p53 heterozygous and knockout mouse models, and opens up the possibility that not all liaisons within the cell involving p53 necessarily represent fatal attractions.	Loyola Univ, Inst Oncol, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Yale Univ, Sch Med, Dept Radiat Oncol, New Haven, CT 06520 USA	Loyola University Chicago; Yale University	Nickoloff, BJ (corresponding author), Loyola Univ, Inst Oncol, Med Ctr, Dept Pathol, Bldg 112,Room 301,2160 S 1st Ave, Maywood, IL 60153 USA.	bnickol@lumc.edu		Zhang, Wengeng/0000-0002-1000-4692	NATIONAL CANCER INSTITUTE [R01CA083784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047814, R01AR047307] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83784] Funding Source: Medline; NIAMS NIH HHS [AR 47814, AR 47307] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Bolshakov S, 2003, CLIN CANCER RES, V9, P228; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Campisi J, 2004, NAT MED, V10, P231, DOI 10.1038/nm0304-231; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Chaturvedi V, 2004, J INVEST DERMATOL, V123, P1200, DOI 10.1111/j.0022-202X.2004.23514.x; Chaturvedi V, 2001, J DERMATOL SCI, V26, P67, DOI 10.1016/S0923-1811(00)00157-2; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Greenhalgh DA, 1996, CANCER RES, V56, P4413; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hawkins DS, 1996, CANCER RES, V56, P892; Honeycutt KA, 2004, J INVEST DERM SYMP P, V9, P261, DOI 10.1111/j.1087-0024.2004.09312.x; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Knezevic D, 2004, CELL CYCLE, V3, P729; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leffell DJ, 1996, SCI AM, V275, P52, DOI 10.1038/scientificamerican0796-52; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maeda T, 2002, J INVEST DERMATOL, V119, P22, DOI 10.1046/j.1523-1747.2002.01781.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; Nickoloff BJ, 2002, J INVEST DERM SYMP P, V7, P27, DOI 10.1046/j.1523-1747.2002.19633.x; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Ouhtit A, 1998, J NATL CANCER I, V90, P523, DOI 10.1093/jnci/90.7.523; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Qin JZ, 2004, J CELL PHYSIOL, V200, P155, DOI 10.1002/jcp.20017; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Rambhatla L., 2001, J BIOMED BIOTECHNOL, V1, P28, DOI DOI 10.1155/S1110724301000079; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Tsai KY, 2004, AM J MED GENET C, V131C, P82, DOI 10.1002/ajmg.c.30037; Tudor D, 2004, J INVEST DERM SYMP P, V9, P208, DOI 10.1111/j.1087-0024.2004.09310.x; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Oosten M, 2005, DNA REPAIR, V4, P81, DOI 10.1016/j.dnarep.2004.08.008; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; WEINBERG WC, 1994, CANCER RES, V54, P5584; Zhang WG, 2005, CARCINOGENESIS, V26, P249, DOI 10.1093/carcin/bgh300; Zhao RB, 2000, GENE DEV, V14, P981; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	66	38	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5299	5312		10.1038/sj.onc.1208650	http://dx.doi.org/10.1038/sj.onc.1208650			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15940268				2022-12-25	WOS:000231158500004
J	Hajarnis, S; Schroeder, JM; Curthoys, NP				Hajarnis, S; Schroeder, JM; Curthoys, NP			3 '-untranslated region of phosphoenolpyruvate carboxykinase mRNA contains multiple instability elements that bind AUF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; 3' UNTRANSLATED REGION; MAMMALIAN-CELLS; GENE-EXPRESSION; RICH ELEMENTS; HNRNP-D; C-FOS; TURNOVER; DEGRADATION; ISOFORMS	Phosphoenolpyruvate carboxykinase ( PEPCK) is regulated solely by alterations in gene expression that involve changes in rates of PEPCK mRNA transcription and degradation. A tetracycline-responsive promoter system was used to quantify the half-life of various chimeric beta-globin-PEPCK (beta G-PCK) mRNAs in LLC-PK1-F+ cells. The control beta G mRNA was extremely stable (t(1/2) = 5 days). However, beta G-PCK-1 mRNA, which contains the entire 3'-UTR of the PEPCK mRNA, was degraded with a half-life of 1.2 h. RNase H treatment indicated that rapid deadenylation occurred concomitant with degradation of the beta G-PCK-1 mRNA. Previous studies indicate that PCK-7, a 50-nucleotide segment at the 3'-end of the 3'-UTR, binds an unidentified protein that may contribute to the rapid decay of the PEPCK mRNA. However, the chimeric beta G-PCK-7 mRNA has a half-life of 17 h. Inclusion of the adjacent PCK-6 segment, a 23-bp AU-rich region, produced the beta G-PCK-6/7 mRNA, which has a half-life of 3.6 h. The beta G-PCK-3 mRNA that contains the 3'-half of 3'-UTR was degraded with the same half-life. Surprisingly, the beta G-PCK-2 mRNA, containing the 5'-end of the 3'-UTR, was also degraded rapidly (t(1/2) = 5.4 h). RNA gel shift analyses established that AUF1 ( hnRNP D) binds to the PCK-7, PCK-6, and PCK-2 segments with high affinity and specificity. Mutational analysis indicated that AUF1 binds to a UUAUUUUAU sequence within PCK-6 and the stem-loop structure and adjacent CU-region of PCK-7. Thus, AUF1 binds to multiple destabilizing elements within the 3'-UTR that participate in the rapid turnover of the PEPCK mRNA.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Curthoys, NP (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	Norman.Curthoys@ColoState.edu			NIDDK NIH HHS [DK-43704] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043704] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V177, P1273, DOI 10.1016/0006-291X(91)90679-2; DALESSIO JM, 1981, BIOCHEMISTRY-US, V20, P3822, DOI 10.1021/bi00516a024; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GSTRAUNTHALER G, 1987, AM J PHYSIOL, V252, pC232, DOI 10.1152/ajpcell.1987.252.2.C232; Hansen WR, 1996, AM J PHYSIOL-RENAL, V271, pF126, DOI 10.1152/ajprenal.1996.271.1.F126; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; HARGROVE JL, 1993, FASEB J, V7, P1163, DOI 10.1096/fasebj.7.12.8375615; HOD Y, 1988, J BIOL CHEM, V263, P7747; Holcomb T, 1996, AM J PHYSIOL-RENAL, V271, pF340, DOI 10.1152/ajprenal.1996.271.2.F340; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Laterza OF, 2000, AM J PHYSIOL-RENAL, V279, pF866, DOI 10.1152/ajprenal.2000.279.5.F866; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Loflin PT, 1999, METHODS, V17, P11, DOI 10.1006/meth.1998.0702; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Moraes KCM, 2003, BIOL CHEM, V384, P25, DOI 10.1515/BC.2003.004; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; Porter D, 1997, ANAL BIOCHEM, V247, P279, DOI 10.1006/abio.1997.2059; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; WATFORD M, 1990, ARCH BIOCHEM BIOPHYS, V282, P399, DOI 10.1016/0003-9861(90)90135-L; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; WILSON GM, 2002, RNA BINDING PROTEINS, P101; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	39	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28272	28280		10.1074/jbc.M501204200	http://dx.doi.org/10.1074/jbc.M501204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15951444	hybrid			2022-12-25	WOS:000230857300013
J	Tykocinski, LO; Hajkova, P; Chang, HD; Stamm, T; Sozeri, O; Lohning, M; Hu-Li, J; Niesner, U; Kreher, S; Friedrich, B; Pannetier, C; Grutz, G; Walter, J; Paul, WE; Radbruch, A				Tykocinski, LO; Hajkova, P; Chang, HD; Stamm, T; Sozeri, O; Lohning, M; Hu-Li, J; Niesner, U; Kreher, S; Friedrich, B; Pannetier, C; Grutz, G; Walter, J; Paul, WE; Radbruch, A			A critical control element for interleukin-4 memory expression in T helper lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; CYTOKINE GENE-EXPRESSION; IL-4 GENE; CUTTING EDGE; TH2-SPECIFIC EXPRESSION; CELL-DIFFERENTIATION; HISTONE ACETYLATION; REGULATORY ELEMENTS; P300 PROTEIN; IFN-GAMMA	Naive T helper (Th) lymphocytes are induced to express the il4 (interleukin-4) gene by simultaneous signaling through the T cell receptor and the interleukin (IL)-4 receptor. Upon restimulation with antigen, such preactivated Th lymphocytes can reexpress the il4 gene independent of IL-4 receptor signaling. This memory for expression of the il4 gene depends on epigenetic modification of the il4 gene locus and an increased expression of GATA-3, the key transcription factor for Th2 differentiation. Here, we have identified a phylogenetically conserved sequence, the conserved intronic regulatory element, in the first intron of the il4 gene containing a tandem GATA-3 binding site. We show that GATA-3 binds to this sequence in a position-and orientation-dependent manner, in vitro and in vivo. DNA demethylation and histone acetylation of this region occurs early and selectively in differentiating, IL-4-secreting Th2 lymphocytes. Deletion of the conserved element by replacement of the first exon and part of the first intron of the il4 gene with gfp leads to a defect in the establishment of memory for expression of IL-4, in that reexpression of IL-4 still requires costimulation by exogenous IL-4. The conserved intronic regulatory element thus links the initial epigenetic modification of the il4 gene to GATA-3 and serves as a genetic control element for memory expression of IL-4.	Deutsch Rheumaforschungszentrum Berlin, D-10117 Berlin, Germany; Wellcome Trust CR UK Inst, Cambridge CB2 1QR, England; Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland; NIH, Immunol Lab, Bethesda, MD 20892 USA; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Humboldt Univ, Univ Hosp Charite, D-10117 Berlin, Germany; Univ Saarland, D-66041 Saarbrucken, Germany	Deutsches Rheuma-Forschungszentrum (DRFZ); University of Zurich; University Zurich Hospital; National Institutes of Health (NIH) - USA; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Saarland University	Radbruch, A (corresponding author), Deutsch Rheumaforschungszentrum Berlin, Schumannstr 21-22, D-10117 Berlin, Germany.	radbruch@drfz.de	Chang, Hyun-Dong/T-3697-2017; Löhning, Max/AAL-2967-2021	Chang, Hyun-Dong/0000-0002-7341-4533; Löhning, Max/0000-0001-6382-7281; Hajkova, Petra/0000-0003-4145-1468; Tykocinski, Lars-Oliver/0000-0002-7645-1559; Radbruch, Andreas/0000-0001-5753-0000	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000493, Z01AI000493] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal S, 1998, CURR OPIN IMMUNOL, V10, P345, DOI 10.1016/S0952-7915(98)80174-X; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Assenmacher M, 1998, J IMMUNOL, V161, P2825; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COFFMAN RL, 1991, RES IMMUNOL, V142, P7, DOI 10.1016/0923-2494(91)90002-Z; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Guo LY, 2002, P NATL ACAD SCI USA, V99, P10623, DOI 10.1073/pnas.162360199; Hajkova Petra, 2002, Methods Mol Biol, V200, P143; Hayakawa F, 2004, J LEUKOCYTE BIOL, V75, P529, DOI 10.1189/jlb.0603289; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Hofer T, 2002, P NATL ACAD SCI USA, V99, P9364, DOI 10.1073/pnas.142284699; Hu-Li J, 2001, IMMUNITY, V14, P1, DOI 10.1016/S1074-7613(01)00084-X; Hural JA, 2000, J IMMUNOL, V165, P3239, DOI 10.4049/jimmunol.165.6.3239; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414; Kress C, 2001, FEBS LETT, V494, P135, DOI 10.1016/S0014-5793(01)02328-6; Kubo M, 1997, EMBO J, V16, P4007, DOI 10.1093/emboj/16.13.4007; Lavenu-Bombled C, 2002, J BIOL CHEM, V277, P18313, DOI 10.1074/jbc.M110013200; Lee DU, 2004, P NATL ACAD SCI USA, V101, P16010, DOI 10.1073/pnas.0407031101; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lee HJ, 1998, J IMMUNOL, V160, P2343; Lohning M, 2003, P NATL ACAD SCI USA, V100, P12307, DOI 10.1073/pnas.2035254100; Lohning M, 2002, ADV IMMUNOL, V80, P115, DOI 10.1016/S0065-2776(02)80014-1; Makar KW, 2003, NAT IMMUNOL, V4, P1183, DOI 10.1038/ni1004; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Ranganath S, 1998, J IMMUNOL, V161, P3822; Richter A, 1999, J EXP MED, V190, P1439, DOI 10.1084/jem.190.10.1439; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; Wada H, 2000, J BIOL CHEM, V275, P25330, DOI 10.1074/jbc.M000828200; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; Yamashita M, 2004, J BIOL CHEM, V279, P39454, DOI 10.1074/jbc.M405989200; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou MX, 2001, J EXP MED, V194, P1461, DOI 10.1084/jem.194.10.1461; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	61	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28177	28185		10.1074/jbc.M502038200	http://dx.doi.org/10.1074/jbc.M502038200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15941711	hybrid			2022-12-25	WOS:000230857300003
J	Frirdich, E; Bouwman, C; Vinogradov, E; Whitfield, C				Frirdich, E; Bouwman, C; Vinogradov, E; Whitfield, C			The role of galacturonic acid in outer membrane stability in Klebsiella pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR TOXIC COMPLEX; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; CORE LIPOPOLYSACCHARIDE; VIBRIO-CHOLERAE; MOLECULAR-BASIS; POLYACRYLAMIDE GELS; STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE	In most members of the Enterobacteriaceae, including Escherichia coli and Salmonella, the lipopolysaccharide core oligosaccharide backbone is modified by phosphoryl groups. The negative charges provided by these residues are important in maintaining the barrier function of the outer membrane. Mutants lacking the core heptose region and the phosphate residues display pleiotrophic defects collectively known as the deep-rough phenotype, characterized by changes in outer membrane structure and function. Klebsiella pneumoniae lacks phosphoryl residues in its core, but instead contains galacturonic acid. The goal of this study was to determine the contribution of galacturonic acid as a critical source of negative charge. A mutant was created lacking all galacturonic acid by targeting UDP-galacturonic acid precursor synthesis through a mutation in gla(KP). Gla(KP) is a K. pneumoniae UDP-galacturonic acid C4 epimerase providing UDP-galacturonic acid for core synthesis. The glaKP gene was inactivated and the structure of the mutant lipopolysaccharide was determined by mass spectrometry. The mutant displayed characteristics of a deep-rough phenotype, exhibiting a hypersensitivity to hydrophobic compounds and polymyxin B, an altered outer membrane profile, and the release of the periplasmic enzyme beta-lactamase. These results indicate that the negative charge provided by the carboxyl groups of galacturonic acid do play an equivalent role to the core oligosaccharide phosphate residues in establishing outer membrane integrity in E. coli and Salmonella.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Whitfield, C (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca		Vinogradov, Evgeny/0000-0002-5364-1376				ALBERTI S, 1995, INFECT IMMUN, V63, P903; BINOTTO J, 1991, CAN J MICROBIOL, V37, P474, DOI 10.1139/m91-078; Bos MP, 2004, CURR OPIN MICROBIOL, V7, P610, DOI 10.1016/j.mib.2004.10.011; Bulieris PV, 2003, J BIOL CHEM, V278, P9092, DOI 10.1074/jbc.M211177200; CHATTERJEE AK, 1976, CAN J MICROBIOL, V22, P1549, DOI 10.1139/m76-227; Climent N, 1997, RES MICROBIOL, V148, P133, DOI 10.1016/S0923-2508(97)87644-9; Collins Carleen M., 1996, P299; Conter A, 2002, J BACTERIOL, V184, P2850, DOI 10.1128/JB.184.10.2850-2853.2002; Costello GM, 1996, J BACTERIOL, V178, P1623, DOI 10.1128/jb.178.6.1623-1630.1996; Crowley B, 2002, ANTIMICROB AGENTS CH, V46, P3679, DOI 10.1128/AAC.46.11.3679-3682.2002; de Cock H, 1999, J BIOL CHEM, V274, P5114, DOI 10.1074/jbc.274.8.5114; deCock H, 1996, EMBO J, V15, P5567, DOI 10.1002/j.1460-2075.1996.tb00941.x; Deng W, 2002, J BACTERIOL, V184, P4601, DOI 10.1128/JB.184.16.4601-4611.2002; DOMENICO P, 1985, CAN J MICROBIOL, V31, P472, DOI 10.1139/m85-088; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Enderle PJ, 1998, BIOTECHNIQUES, V25, P954, DOI 10.2144/98256bm05; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, STRUCTURE, V8, P585; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Frirdich E, 2005, J BACTERIOL, V187, P4104, DOI 10.1128/JB.187.12.4104-4115.2005; Frirdich E, 2004, J BIOL CHEM, V279, P27928, DOI 10.1074/jbc.M402549200; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Genevrois S, 2003, EMBO J, V22, P1780, DOI 10.1093/emboj/cdg174; GOTTESMAN S, 1995, 2 COMPONENT SIGNAL T, P253; Gupta Archana, 2003, J Perinatol, V23, P439, DOI 10.1038/sj.jp.7210973; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hagge SO, 2002, J BIOL CHEM, V277, P34247, DOI 10.1074/jbc.M201950200; Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317, DOI 10.1128/AAC.43.6.1317; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; HERNANDEZALLES S, 1995, CAN J MICROBIOL, V41, P399, DOI 10.1139/m95-053; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; Holst O, 2000, METH MOL B, V145, P345; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; Izquierdo L, 2003, J BACTERIOL, V185, P7213, DOI 10.1128/JB.185.24.7213-7221.2003; Izquierdo L, 2002, MICROBIOL-SGM, V148, P3485, DOI 10.1099/00221287-148-11-3485; Izquierdo L, 2002, FEMS MICROBIOL LETT, V216, P211, DOI 10.1016/S0378-1097(02)01027-3; KAMIO Y, 1976, BIOCHEMISTRY-US, V15, P2561, DOI 10.1021/bi00657a012; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Kramer RA, 2000, EUR J BIOCHEM, V267, P885, DOI 10.1046/j.1432-1327.2000.01073.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert H. P, 1992, ANTIBIOTIC CHEMOTHER; LARSEN BS, 1993, ANAL BIOCHEM, V214, P212, DOI 10.1006/abio.1993.1479; LINDSAY SS, 1973, CAN J MICROBIOL, V19, P335, DOI 10.1139/m73-056; MASSAD G, 1994, GENE, V150, P101, DOI 10.1016/0378-1119(94)90866-4; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; McManus MC, 1997, AM J HEALTH-SYST PH, V54, P1420, DOI 10.1093/ajhp/54.12.1420; MILLER JH, 1992, SHORT COURSE BACTERI, P439; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Mouslim C, 2003, J BIOL CHEM, V278, P50588, DOI 10.1074/jbc.M309433200; Mouslim C, 2003, MOL MICROBIOL, V47, P335, DOI 10.1046/j.1365-2958.2003.03318.x; Nesper J, 2002, INFECT IMMUN, V70, P2419, DOI 10.1128/IAI.70.5.2419-2433.2002; Nguyen TN, 1998, GENE, V210, P93, DOI 10.1016/S0378-1119(98)00060-2; Niedziela T, 2002, J BIOL CHEM, V277, P11653, DOI 10.1074/jbc.M111885200; Nieweg A, 1997, MICROBIOL-SGM, V143, P603, DOI 10.1099/00221287-143-2-603; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; PARKER CT, 1992, J BACTERIOL, V174, P2525, DOI 10.1128/jb.174.8.2525-2538.1992; Podschun R, 1998, CLIN MICROBIOL REV, V11, P589, DOI 10.1128/CMR.11.4.589; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Regue M, 2004, INFECT IMMUN, V72, P54, DOI 10.1128/IAI.72.1.54-61.2004; Regue M, 2001, J BACTERIOL, V183, P3564, DOI 10.1128/JB.183.12.3564-3573.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMID K, 1991, MOL MICROBIOL, V5, P941, DOI 10.1111/j.1365-2958.1991.tb00769.x; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHULEIN K, 1991, MOL MICROBIOL, V5, P2233, DOI 10.1111/j.1365-2958.1991.tb02153.x; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; Srimal S, 1996, BIOCHEM J, V315, P679, DOI 10.1042/bj3150679; STRAUS DC, 1985, INFECT IMMUN, V50, P787, DOI 10.1128/IAI.50.3.787-795.1985; STRAUS DC, 1987, INFECT IMMUN, V55, P44, DOI 10.1128/IAI.55.1.44-48.1987; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; Vinogradov E, 2002, J BIOL CHEM, V277, P25070, DOI 10.1074/jbc.M202683200; Vinogradov E, 2001, CARBOHYD RES, V335, P291, DOI 10.1016/S0008-6215(01)00216-6; Walsh TR, 2005, CLIN MICROBIOL REV, V18, P306, DOI 10.1128/CMR.18.2.306-325.2005; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030; WHITFIELD C, 1991, J BACTERIOL, V173, P1420, DOI 10.1128/jb.173.4.1420-1431.1991; Wiese A, 2003, J ENDOTOXIN RES, V9, P67, DOI 10.1179/096805103125001441; Wiese A, 1998, J MEMBRANE BIOL, V162, P127, DOI 10.1007/s002329900350; Yethon JA, 1998, J BIOL CHEM, V273, P26310, DOI 10.1074/jbc.273.41.26310; Yethon JA, 2000, INFECT IMMUN, V68, P4485, DOI 10.1128/IAI.68.8.4485-4491.2000	87	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27604	27612		10.1074/jbc.M504987200	http://dx.doi.org/10.1074/jbc.M504987200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15929980	hybrid			2022-12-25	WOS:000230678600017
J	Streb, JW; Miano, JM				Streb, JW; Miano, JM			Cross-species sequence analysis reveals multiple charged residue-rich domains that regulate nuclear/cytoplasmic partitioning and membrane localization of a kinase anchoring protein 12 (SSeCKS/Gravin)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKC-BINDING-PROTEIN; C SUBSTRATE; EXPRESSION; GRAVIN; SERUM; SUBUNIT; SIGNAL	A kinase anchoring proteins (AKAPs) assemble and compartmentalize multiprotein signaling complexes at discrete subcellular locales and thus confer specificity to transduction cascades using ubiquitous signaling enzymes, such as protein kinase A. Intrinsic targeting domains in each AKAP determine the subcellular localization of these complexes and, along with protein-protein interaction domains, form the core of AKAP function. As a foundational step toward elucidating the relationship between location and function, we have used cross-species sequence analysis and deletion mapping to facilitate the identification of the targeting determinants of AKAP12 ( also known as SSeCKS or Gravin). Three charged residue-rich regions were identified that regulate two aspects of AKAP12 localization, nuclear/cytoplasmic partitioning and perinuclear/cell periphery targeting. Using deletion mapping and green fluorescent protein chimeras, we uncovered a heretofore unrecognized nuclear localization potential. Five nuclear localization signals, including a novel class of this type of signal termed X2-NLS, are found in the central region of AKAP12 and are important for nuclear targeting. However, this nuclear localization is suppressed by the negatively charged C terminus that mediates nuclear exclusion. In this condition, the distribution of AKAP12 is regulated by an N-terminal targeting domain that simultaneously directs perinuclear and peripheral AKAP12 localization. Three basic residue-rich regions in the N-terminal targeting region have similarity to the MARCKS proteins and were found to control AKAP12 localization to ganglioside-rich regions at the cell periphery. Our data suggest that AKAP12 localization is regulated by a hierarchy of targeting domains and that the localization of AKAP12-assembled signaling complexes may be dynamically regulated.	Univ Rochester, Sch Med, Aab Inst Biomed Sci, Cardiovasc Res Ctr, Rochester, NY 14642 USA	University of Rochester	Miano, JM (corresponding author), Univ Rochester, Sch Med, Aab Inst Biomed Sci, Cardiovasc Res Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.	j.m.miano@rochester.edu	Miano, Joseph/L-5634-2018	Miano, Joseph/0000-0001-7522-3207	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007949, R01HL070077] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07949, R01 HL70077] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Canaves JM, 2002, J MOL EVOL, V54, P17, DOI 10.1007/s00239-001-0013-1; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; Grove BD, 2001, J VASC RES, V38, P163, DOI 10.1159/000051043; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Gu JY, 2003, GENE, V317, P49, DOI 10.1016/S0378-1119(03)00696-6; Indolfi C, 2001, CIRC RES, V88, P319, DOI 10.1161/01.RES.88.3.319; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; Lin XY, 2002, BIOCHEM BIOPH RES CO, V290, P1368, DOI 10.1006/bbrc.2002.6357; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Ovcharenko I, 2004, GENOME RES, V14, P1191, DOI 10.1101/gr.1773104; RECH J, 1994, J CELL SCI, V107, P3029; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Streb JW, 2004, J BIOL CHEM, V279, P56014, DOI 10.1074/jbc.M408828200; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; Tao JC, 2003, EMBO J, V22, P6419, DOI 10.1093/emboj/cdg628	26	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28007	28014		10.1074/jbc.M414017200	http://dx.doi.org/10.1074/jbc.M414017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923193	hybrid			2022-12-25	WOS:000230678600063
J	Tamboli, IY; Prager, K; Barth, E; Heneka, M; Sandhoff, K; Walter, J				Tamboli, IY; Prager, K; Barth, E; Heneka, M; Sandhoff, K; Walter, J			Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; ALZHEIMERS-DISEASE; CELL-SURFACE; LIPID RAFTS; CHOLESTEROL; GENERATION; TRANSPORT; ENDOCYTOSIS; BRAIN; METABOLISM	Alzheimer disease is associated with extracellular deposits of amyloid beta-peptides in the brain. Amyloid beta-peptides are generated by proteolytic processing of the beta-amyloid precursor protein by beta- and gamma-secretases. The cleavage by secretases occurs predominantly in post-Golgi secretory and endocytic compartments and is influenced by cholesterol, indicating a role of the membrane lipid composition in proteolytic processing of the beta-amyloid precursor protein. To analyze the role of glycosphingolipids in these processes we inhibited glycosyl ceramide synthase, which catalyzes the first step in glycosphingolipid biosynthesis. The depletion of glycosphingolipids markedly reduced the secretion of endogenous beta-amyloid precursor protein in different cell types, including human neuroblastoma SH-SY5Y cells. Importantly, secretion of amyloid beta-peptides was also strongly decreased by inhibition of glycosphingolipid biosynthesis. Conversely, the addition of exogenous brain gangliosides to cultured cells reversed these effects. Biochemical and cell biological experiments demonstrate that the pharmacological reduction of cellular glycosphingolipid levels inhibited maturation and cell surface transport of the beta-amyloid precursor protein. In the glycosphingolipid-deficient cell line GM95, cellular levels and maturation of beta-amyloid precursor protein were also significantly reduced as compared with normal B16 cells. Together, these data demonstrate that glycosphingolipids are implicated in the regulation of the subcellular transport of the beta-amyloid precursor protein in the secretory pathway and its proteolytic processing. Thus, enzymes involved in glycosphingolipid metabolism might represent targets to inhibit the production of amyloid beta-peptides.	Univ Bonn, Dept Neurol, D-53127 Bonn, Germany; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	University of Bonn; University of Bonn	Walter, J (corresponding author), Univ Bonn, Dept Neurol, Siegmund Freud Str 25, D-53127 Bonn, Germany.	Jochen.Walter@ukb.uni-bonn.de	Wang, Caihong/T-5837-2019; Heneka, Michael/AAE-8011-2019; Walter, Jochen/B-3677-2014; Heneka, Michael/E-8072-2015	Wang, Caihong/0000-0002-6808-3709; Heneka, Michael/0000-0003-4996-1630; Walter, Jochen/0000-0002-4678-2912				Abad-Rodriguez J, 2004, J CELL BIOL, V167, P953, DOI 10.1083/jcb.200404149; Aguzzi A, 2003, SCIENCE, V302, P814, DOI 10.1126/science.1087348; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fluhrer R, 2003, J BIOL CHEM, V278, P5531, DOI 10.1074/jbc.M211485200; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1992, NATURE, V359, P325; Harter D, 2001, BEHAV BRAIN SCI, V24, P45, DOI 10.1017/S0140525X01303916; Hayashi H, 2004, J NEUROSCI, V24, P4894, DOI 10.1523/JNEUROSCI.0861-04.2004; Hutter-Paier B, 2004, NEURON, V44, P227, DOI 10.1016/j.neuron.2004.08.043; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kok JW, 1998, J CELL BIOL, V142, P25, DOI 10.1083/jcb.142.1.25; Kolter T, 2002, J BIOL CHEM, V277, P25859, DOI 10.1074/jbc.R200001200; Kolter T, 1998, BRAIN PATHOL, V8, P79; Komori H, 1999, J BIOL CHEM, V274, P8981, DOI 10.1074/jbc.274.13.8981; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee EB, 2003, J BIOL CHEM, V278, P4458, DOI 10.1074/jbc.M210105200; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; Matsuoka Y, 2003, J NEUROSCI, V23, P29; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Mutoh T, 1998, J BIOL CHEM, V273, P26001, DOI 10.1074/jbc.273.40.26001; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Opekarova M, 2003, BBA-BIOMEMBRANES, V1610, P11, DOI 10.1016/S0005-2736(02)00708-3; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Rawat SS, 2004, VIROLOGY, V318, P55, DOI 10.1016/j.virol.2003.08.042; ROSENWALD AG, 1994, J LIPID RES, V35, P1232; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Sawamura N, 2004, J BIOL CHEM, V279, P11984, DOI 10.1074/jbc.M309832200; Schuette CG, 1999, BIOL CHEM, V380, P759, DOI 10.1515/BC.1999.096; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Smith AE, 2003, FEBS LETT, V555, P199, DOI 10.1016/S0014-5793(03)01220-1; Spillsberg B, 2003, TRAFFIC, V4, P544, DOI 10.1034/j.1600-0854.2003.00111.x; Sprong H, 2001, J CELL BIOL, V155, P369, DOI 10.1083/jcb.200106104; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Sutterlin C, 1997, J CELL SCI, V110, P2703; Veldman RJ, 2003, FASEB J, V17, P1144, DOI 10.1096/fj.02-1053fje; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Walter J, 1997, J BIOL CHEM, V272, P1896, DOI 10.1074/jbc.272.3.1896; Watanabe R, 2002, J BIOL CHEM, V277, P49538, DOI 10.1074/jbc.M206209200; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yanagisawa K, 1998, NEUROBIOL AGING, V19, pS65, DOI 10.1016/S0197-4580(98)00032-3; ZHA Q, 2004, MOL PSYCHIAT	54	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28110	28117		10.1074/jbc.M414525200	http://dx.doi.org/10.1074/jbc.M414525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923191	hybrid			2022-12-25	WOS:000230678600074
J	Potter, JA; Fyfe, PK; Frolov, D; Wakeham, MC; van Grondelle, R; Robert, B; Jones, MR				Potter, JA; Fyfe, PK; Frolov, D; Wakeham, MC; van Grondelle, R; Robert, B; Jones, MR			Strong effects of an individual water molecule on the rate of light-driven charge separation in the Rhodobacter sphaeroides reaction center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; BACTERIAL REACTION CENTERS; BOUND REACTION CENTERS; RESONANCE RAMAN-SPECTROSCOPY; PRIMARY ELECTRON-DONOR; RHODOPSEUDOMONAS-VIRIDIS; CRYSTAL-STRUCTURES; BACTERIOCHLOROPHYLL DIMER; ANGSTROM RESOLUTION; OPTICAL-PROPERTIES	The role of a water molecule (water A) located between the primary electron donor (P) and first electron acceptor bacteriochlorophyll (B-A) in the purple bacterial reaction center was investigated by mutation of glycine M203 to leucine (GM203L). The x-ray crystal structure of the GM203L reaction center shows that the new leucine residue packs in such a way that water A is sterically excluded from the complex, but the structure of the protein-cofactor system around the mutation site is largely undisturbed. The results of absorbance and resonance Raman spectroscopy were consistent with either the removal of a hydrogen bond interaction between water A and the keto carbonyl group of B-A or a change in the local electrostatic environment of this carbonyl group. Similarities in the spectroscopic properties and x-ray crystal structures of reaction centers with leucine and aspartic acid mutations at the M203 position suggested that the effects of a glycine to aspartic acid substitution at the M203 position can also be explained by steric exclusion of water A. In the GM203L mutant, loss of water A was accompanied by an similar to 8-fold slowing of the rate of decay of the primary donor excited state, indicating that the presence of water A is important for optimization of the rate of primary electron transfer. Possible functions of this water molecule are discussed, including a switching role in which the redox potential of the B-A acceptor is rapidly modulated in response to oxidation of the primary electron donor.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Free Univ Amsterdam, Dept Phys & Astron, NL-1081 HV Amsterdam, Netherlands; CEA, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires, F-91191 Gif Sur Yvette, France; CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France	University of Bristol; Vrije Universiteit Amsterdam; CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Jones, MR (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	m.r.jones@bristol.ac.uk	Robert, Bruno/D-1264-2012	Robert, Bruno/0000-0001-5999-4538; Fyfe, Paul/0000-0003-3541-2294	Biotechnology and Biological Sciences Research Council [B18667] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALLEN JP, 1995, J BIOENERG BIOMEMBR, V27, P275, DOI 10.1007/BF02110097; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; Beekman LMP, 1996, J PHYS CHEM-US, V100, P7256, DOI 10.1021/jp953054h; BEEKMAN LMP, 1995, BIOCHEMISTRY-US, V34, P14712, DOI 10.1021/bi00045a012; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Braun P, 2003, BBA-BIOENERGETICS, V1607, P19, DOI 10.1016/j.bbabio.2003.08.004; BYLINA EJ, 1988, NATURE, V336, P182, DOI 10.1038/336182a0; Camara-Artigas A, 2002, P NATL ACAD SCI USA, V99, P11055, DOI 10.1073/pnas.162368399; Camara-Artigas A, 2002, PHOTOSYNTH RES, V74, P87, DOI 10.1023/A:1020882402389; Camara-Artigas A, 2001, ACTA CRYSTALLOGR D, V57, P1281, DOI 10.1107/S090744490101109X; CHANG CH, 1991, BIOCHEMISTRY-US, V30, P5352, DOI 10.1021/bi00236a005; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Czarnecki K, 1999, J PHYS CHEM A, V103, P2235, DOI 10.1021/jp983558q; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; ECCLES J, 1983, P NATL ACAD SCI-BIOL, V80, P4959, DOI 10.1073/pnas.80.16.4959; ERMLER U, 1994, J BIOENERG BIOMEMBR, V26, P5, DOI 10.1007/BF00763216; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; Frolov D, 2002, J PHYS CHEM A, V106, P3605, DOI 10.1021/jp0133586; Fyfe PK, 2000, BIOCHEMISTRY-US, V39, P5953, DOI 10.1021/bi9925017; Gall A, 1997, BIOCHEMISTRY-US, V36, P16282, DOI 10.1021/bi9717237; Gradinaru CC, 2000, J PHYS CHEM B, V104, P9330, DOI 10.1021/jp001752i; HANSON LK, 1987, J AM CHEM SOC, V109, P4728, DOI 10.1021/ja00249a050; HELLER BA, 1995, SCIENCE, V269, P940, DOI 10.1126/science.7638616; Heller BA, 1996, BIOCHEMISTRY-US, V35, P15418, DOI 10.1021/bi961362f; Hoff A. J., 1997, PHYS REP, V287, P2; Ivancich A, 1998, BIOCHEMISTRY-US, V37, P11812, DOI 10.1021/bi9806908; JONES MR, 1994, FEBS LETT, V339, P18, DOI 10.1016/0014-5793(94)80376-5; Jones MR, 2002, BBA-BIOMEMBRANES, V1565, P206, DOI 10.1016/S0005-2736(02)00570-9; JONES MR, 1992, MOL MICROBIOL, V6, P1173, DOI 10.1111/j.1365-2958.1992.tb01556.x; JONES MR, 1992, BIOCHEMISTRY-US, V31, P4458, DOI 10.1021/bi00133a011; Katona G, 2003, J MOL BIOL, V331, P681, DOI 10.1016/S0022-2836(03)00751-4; Kirmaier C, 1999, BIOCHEMISTRY-US, V38, P11516, DOI 10.1021/bi9908585; KIRMAIER C, 1995, J PHYS CHEM-US, V99, P8903, DOI 10.1021/j100021a067; Lancaster CRD, 1999, J MOL BIOL, V286, P883, DOI 10.1006/jmbi.1998.2532; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; Lapouge K, 1998, J RAMAN SPECTROSC, V29, P977, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<977::AID-JRS325>3.0.CO;2-K; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATTIOLI TA, 1991, BIOCHEMISTRY-US, V30, P4648, DOI 10.1021/bi00233a002; MATTIOLI TA, 1995, BIOCHEMISTRY-US, V34, P6142, DOI 10.1021/bi00018a017; McAuley KE, 1999, P NATL ACAD SCI USA, V96, P14706, DOI 10.1073/pnas.96.26.14706; McAuley KE, 2000, BIOCHEMISTRY-US, V39, P15032, DOI 10.1021/bi000557r; McAuley-Hecht KE, 1998, BIOCHEMISTRY-US, V37, P4740, DOI 10.1021/bi971717a; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nogi T, 2000, P NATL ACAD SCI USA, V97, P13561, DOI 10.1073/pnas.240224997; Okamura MY, 2000, BBA-BIOENERGETICS, V1458, P148, DOI 10.1016/S0005-2728(00)00065-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parson William W., 1996, P125; PARSON WW, 1991, CHLOROPHYLLS, P1153; Pokkuluri PR, 2002, BIOCHEMISTRY-US, V41, P5998, DOI 10.1021/bi0118963; ROBERT B, 1988, BIOCHEMISTRY-US, V27, P5108, DOI 10.1021/bi00414a024; Roszak AW, 2004, STRUCTURE, V12, P765, DOI 10.1016/j.str.2004.02.037; Sandberg L, 2001, J PHYS CHEM B, V105, P273, DOI 10.1021/jp002110y; SCHMIDT S, 1993, BIOCHIM BIOPHYS ACTA, V1144, P385, DOI 10.1016/0005-2728(93)90124-X; Spiedel D, 2002, FEBS LETT, V527, P171, DOI 10.1016/S0014-5793(02)03203-9; THOMPSON MA, 1991, J PHYS CHEM-US, V95, P5693, DOI 10.1021/j100167a058; Treynor TP, 2004, J PHYS CHEM B, V108, P13523, DOI 10.1021/jp048986c; VANBREDERODE ME, 2000, ENZYME CATALYSED ELE, P621; VANSTOKKUM IHM, 1994, J PHYS CHEM-US, V98, P852, DOI 10.1021/j100054a021; Vos MH, 1998, PHOTOSYNTH RES, V55, P181, DOI 10.1023/A:1005951717594; Wakeham MC, 2003, BBA-BIOENERGETICS, V1607, P53, DOI 10.1016/j.bbabio.2003.08.008; WAKEHAM MC, 2004, THESIS U BRISTOL; WILLIAMS JC, 1992, BIOCHEMISTRY-US, V31, P11029, DOI 10.1021/bi00160a012; Woodbury NW, 1995, ANOXYGENIC PHOTOSYNT, P527, DOI [DOI 10.1007/0-306-47954-0_24, 10.1007/0-306-47954-0_24]; Wraight CA, 2004, FRONT BIOSCI-LANDMRK, V9, P309, DOI 10.2741/1236; Xu Q, 2004, STRUCTURE, V12, P703, DOI 10.1016/j.str.2004.03.001	66	44	52	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27155	27164		10.1074/jbc.M501961200	http://dx.doi.org/10.1074/jbc.M501961200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15908429	Green Published, hybrid			2022-12-25	WOS:000230589500063
J	Zhang, ML; Mizrachi, D; Fanelli, F; Segaloff, DL				Zhang, ML; Mizrachi, D; Fanelli, F; Segaloff, DL			The formation of a salt bridge between helices 3 and 6 is responsible for the constitutive activity and lack of hormone responsiveness of the naturally occurring L457R mutation of the human lutropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; INDEPENDENT PRECOCIOUS PUBERTY; FOLLICLE-STIMULATING-HORMONE; TRANSMEMBRANE HELIX; ACTIVATING MUTATION; OVERLAP EXTENSION; RHODOPSIN; PHYSIOLOGY; MODEL	The human lutropin receptor (hLHR) plays a pivotal role in reproductive endocrinology. A number of naturally occurring mutations of the hLHR have been identified that cause the receptor to become constitutively active. To gain further insights into the structural basis for the activation of the hLHR by activating mutations, we chose to examine a particularly strong constitutively activating mutation of this receptor, L457R, in which a leucine that is highly conserved among rhodopsin-like G protein-coupled receptors in helix 3 has been substituted with arginine. Using both disruptive as well as reciprocal mutagenesis strategies, our studies demonstrate that the ability of L457R to stabilize an active form of the hLHR is because of the formation of a salt bridge between the replacing amino acid and Asp-578 in helix 6. Such a lock between the transmembrane portions of helices 3 and 6 is concurrent with weakening the connections between the cytosolic ends of the same helices, including the interaction found in the wild-type receptor between Arg-464, of the (E/D) R(Y/W) motif, and Asp-564. This structural effect is properly marked by the increase in the solvent accessibility of selected amino acids at the cytosolic interfaces between helices 3 and 6. The integrity of the conserved amino acids Asn-615 and Asn-619 in helix 7 is required for the transfer of the structural change from the activating mutation site to the cytosolic interface between helices 3 and 6. The results of in vitro and computational experiments further suggest that the structural trigger of the constitutive activity of the L457R mutant may also be responsible for its lack of hormone responsiveness.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Modena, Dulbecco Telethon Inst, I-41100 Modena, Italy; Univ Modena, Dept Chem, I-41100 Modena, Italy	University of Iowa; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia	Segaloff, DL (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-470 Bowen Sci Bldg, Iowa City, IA 52242 USA.	deborah-segaloff@uiowa.edu	Fanelli, Francesca/O-8807-2014	Fanelli, Francesca/0000-0002-7620-6895	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD022196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22196, R01 HD022196, R37 HD022196] Funding Source: Medline; NIDDK NIH HHS [DK25295, DK07759] Funding Source: Medline; Telethon [TCP00068] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		Angelova K, 2002, J BIOL CHEM, V277, P32202, DOI 10.1074/jbc.M203272200; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; Fanelli F, 2000, J MOL BIOL, V296, P1333, DOI 10.1006/jmbi.2000.3516; Fanelli F, 2004, MOL ENDOCRINOL, V18, P1499, DOI 10.1210/me.2003-0050; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; Latronico AC, 1999, AM J HUM GENET, V65, P949, DOI 10.1086/302602; Latronico AC, 1998, J CLIN ENDOCR METAB, V83, P2435, DOI 10.1210/jc.83.7.2435; Latronico AC, 2000, J CLIN ENDOCR METAB, V85, P4799, DOI 10.1210/jc.85.12.4799; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Shinozaki H, 2003, J CLIN ENDOCR METAB, V88, P1194, DOI 10.1210/jc.2002-021051; Shinozaki H, 2001, MOL ENDOCRINOL, V15, P972, DOI 10.1210/me.15.6.972; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; Tao YX, 2002, MOL ENDOCRINOL, V16, P1881, DOI 10.1210/me.2001-0199; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006	31	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26169	26176		10.1074/jbc.M502102200	http://dx.doi.org/10.1074/jbc.M502102200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15908694	Green Accepted, hybrid			2022-12-25	WOS:000230386800030
J	Curley, JP; Pinnock, SB; Dickson, SL; Thresher, R; Miyoshi, N; Surani, MA; Keverne, EB				Curley, JP; Pinnock, SB; Dickson, SL; Thresher, R; Miyoshi, N; Surani, MA; Keverne, EB			Increased body fat in mice with a targeted mutation of the paternally expressed imprinted gene Peg3	FASEB JOURNAL			English	Article						Pw1; phenotype	PROTEIN; EVOLUTION; MEDIATOR; OBESITY; GROWTH; LOCUS; BAX	Peg3 encodes a C2H2 type zinc finger protein that is implicated in a novel physiological pathway regulating core body temperature, feeding behavior, and obesity in mice. Peg3(+/-) mutant mice develop an excess of abdominal, subcutaneous, and intra-scapular fat, despite a lifetime of lower food intake than wild-type animals. However, they start life with reduced fat reserves and are slower to enter puberty. These mice maintain a lower core body temperature, fail to respond to a cold challenge, and have lower metabolic activity as measured by oxygen consumption. Plasma leptin levels are significantly higher than in wild types, and Peg3(+/-) mice appear to have developed leptin resistance. Administration of exogenous leptin resulted in a significant reduction in food intake in wild-type mice that was not observed in Peg(3+/)- mutants. This mutation, which is strongly expressed in hypothalamic tissue during development, has the capacity to regulate multiple events relating to energy homeostasis.	Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England; Dept Physiol, SE-40530 Gothenburg, Sweden; Univ Cambridge, Wellcome Trust Canc Res UK, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge; Cancer Research UK; University of Cambridge	Curley, JP (corresponding author), Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England.	jpc38@cam.ac.uk	Dickson, Suzanne L/U-4628-2019	Dickson, Suzanne/0000-0002-3822-5294; Surani, Azim/0000-0002-8640-4318; Curley, James/0000-0001-5546-007X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barker DJP, 1998, MOTHERS BABIES HLTH; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Blum W F, 1994, Growth Regul, V4 Suppl 1, P11; Charalambous M, 2003, P NATL ACAD SCI USA, V100, P8292, DOI 10.1073/pnas.1532175100; Charlier C, 2001, NAT GENET, V27, P367, DOI 10.1038/86856; Curley JP, 2004, P ROY SOC B-BIOL SCI, V271, P1303, DOI 10.1098/rspb.2004.2725; de Koning DJ, 2000, P NATL ACAD SCI USA, V97, P7947, DOI 10.1073/pnas.140216397; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Freking BA, 2002, GENOME RES, V12, P1496, DOI 10.1101/gr.571002; GALLOU C, 2004, GEN IMPR WORKSH MONT; Haig D, 2004, ANNU REV GENET, V38, P553, DOI 10.1146/annurev.genet.37.110801.142741; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953; Hiby SE, 2001, HUM MOL GENET, V10, P1093, DOI 10.1093/hmg/10.10.1093; Johnson MD, 2002, J BIOL CHEM, V277, P23000, DOI 10.1074/jbc.M201907200; Keverne EB, 1997, CURR OPIN NEUROBIOL, V7, P463, DOI 10.1016/S0959-4388(97)80023-2; Kim J, 2004, GENOMICS, V84, P47, DOI 10.1016/j.ygeno.2004.02.007; KIM YR, 1997, LAB HEMATOL, V3, P19; Kohda T, 2001, GENES CELLS, V6, P237, DOI 10.1046/j.1365-2443.2001.00412.x; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330; Lummaa V, 2002, TRENDS ECOL EVOL, V17, P141, DOI 10.1016/S0169-5347(01)02414-4; Ma D, 2004, J CLIN INVEST, V114, P339, DOI 10.1172/jci200419876; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Morison IM, 1998, HUM MOL GENET, V7, P1599, DOI 10.1093/hmg/7.10.1599; Murphy SK, 2003, BIOESSAYS, V25, P577, DOI 10.1002/bies.10277; Murphy SK, 2001, GENOMICS, V71, P110, DOI 10.1006/geno.2000.6419; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; Paulsen M, 2001, GENOME RES, V11, P2085, DOI 10.1101/gr.206901; Pinnock SB, 2001, EUR J NEUROSCI, V13, P576, DOI 10.1046/j.0953-816x.2000.01406.x; Plagge A, 2004, NAT GENET, V36, P818, DOI 10.1038/ng1397; Prentice AM, 2001, BRIT MED BULL, V60, P51, DOI 10.1093/bmb/60.1.51; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Schneider JE, 2000, HORM BEHAV, V37, P306, DOI 10.1006/hbeh.2000.1590; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; SMITH F, 2004, GEN IMPR WORKSH MONT; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Temple IK, 2002, J MED GENET, V39, P872, DOI 10.1136/jmg.39.12.872; TRIVERS R, 1999, GENOMIC IMPRINTING I, P1; Tycko B, 2002, J CELL PHYSIOL, V192, P245, DOI 10.1002/jcp.10129; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Welberg LAM, 2001, J NEUROENDOCRINOL, V13, P113, DOI 10.1046/j.1365-2826.2001.00601.x; Yamaguchi A, 2002, J BIOL CHEM, V277, P623, DOI 10.1074/jbc.M107435200; Yu SH, 2000, J CLIN INVEST, V105, P615, DOI 10.1172/JCI8437	48	87	90	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1302	+		10.1096/fj.04-3216fje	http://dx.doi.org/10.1096/fj.04-3216fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15928196				2022-12-25	WOS:000229602600004
J	Curry, CL; Reed, LL; Golde, TE; Miele, L; Nickoloff, BJ; Foreman, KE				Curry, CL; Reed, LL; Golde, TE; Miele, L; Nickoloff, BJ; Foreman, KE			Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells	ONCOGENE			English	Article						Kaposi's sarcoma; Notch; gamma-secretase; apoptosis; growth arrest; KSHV	NF-KAPPA-B; EMBRYONIC LETHALITY; HUMAN KERATINOCYTES; ENDOTHELIAL-CELLS; MAMMALIAN NOTCH; EXPRESSION; DIFFERENTIATION; PATHWAY; GENE; TRANSFORMATION	Kaposi's sarcoma (KS) is a common neoplasm in HIV-1-infected individuals causing significant morbidity and mortality. Despite recent advances, the pathogenesis of this potentially life-threatening neoplasm remains unclear, and there is currently no cure for KS. Notch proteins are known to play a fundamental role in cell fate decisions including proliferation, differentiation, and apoptosis. It is, therefore, not surprising that Notch proteins have been implicated in tumorigenesis and appear to function as either oncogenes or tumor suppressor proteins depending on cellular context. In this report, we demonstrate elevated levels of activated Notch-1, -2, and -4 in KS tumor cells in vivo and in vitro compared to endothelial cells, the precursor of the KS cell. Notch activation was confirmed through luciferase reporter assays and localization of Hes (Hairy/Enhancer of Split)-1 and Hey (Hairy/Enhancer of Split related with YRPW)1 (primary targets of the Notch pathway) in KS cell nuclei. Studies using gamma-secretase inhibitors (GSI and LY- 411,575), which block Notch activation, resulted in apoptosis in primary and immortalized KS cells. Similar studies injecting GSI into established KS cell tumors on mice demonstrated growth inhibition or tumor regression that was characterized by apoptosis in treated, but not control tumors. The results indicate that KS cells overexpress activated Notch and interruption of Notch signaling inhibits KS cell growth. Thus, targeting Notch signaling may be of therapeutic value in KS patients.	Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Inst Oncol, Maywood, IL USA; Loyola Univ, Med Ctr, Dept Microbiol & Immunol, Maywood, IL USA; Mayo Clin, Dept Neurosci, Jacksonville, FL USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Mayo Clinic	Foreman, KE (corresponding author), Loyola Univ, Med Ctr, Dept Pathol, 2160 S 1st Ave, Maywood, IL 60153 USA.	kforema@lumc.edu		Curry, Christine L/0000-0003-4783-9623; Miele, Lucio/0000-0002-5853-7287	NATIONAL CANCER INSTITUTE [P01CA059327, R21CA108450] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA59327, CA108450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; da Costa CA, 2004, J NEUROCHEM, V90, P800, DOI 10.1111/j.1471-4159.2004.02512.x; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Foreman KE, 1996, AM J PATHOL, V149, P795; Gallahan D, 1996, CANCER RES, V56, P1775; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Hayward SD, 2004, SEMIN CANCER BIOL, V14, P387, DOI 10.1016/j.semcancer.2004.04.018; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Jang MS, 2004, J CELL PHYSIOL, V199, P418, DOI 10.1002/jcp.10467; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Lathion S, 2003, CANCER RES, V63, P8687; Leimeister C, 2000, MECH DEVELOP, V98, P175, DOI 10.1016/S0925-4773(00)00459-7; Lu C, 2002, ARCH PATHOL LAB MED, V126, P941; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Qin JZ, 2004, MOL CANCER THER, V3, P895; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Shimazaki T, 2001, J NEUROSCI, V21, P7642, DOI 10.1523/JNEUROSCI.21-19-07642.2001; Shutter JR, 2000, GENE DEV, V14, P1313; Soriano JV, 2000, INT J CANCER, V86, P652; Tang J, 2003, J VIROL, V77, P5975, DOI 10.1128/JVI.77.10.5975-5984.2003; Tsai S, 2000, BLOOD, V96, P950, DOI 10.1182/blood.V96.3.950.015k43_950_957; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	49	177	204	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6333	6344		10.1038/sj.onc.1208783	http://dx.doi.org/10.1038/sj.onc.1208783			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	15940249				2022-12-25	WOS:000232038200001
J	De Falco, V; Guarino, V; Malorni, L; Cirafici, AM; Troglio, F; Erreni, M; Pelicci, G; Santoro, M; Melillo, RM				De Falco, V; Guarino, V; Malorni, L; Cirafici, AM; Troglio, F; Erreni, M; Pelicci, G; Santoro, M; Melillo, RM			RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors	ONCOGENE			English	Article						thyroid tumor; RET oncogenes; RAI and GAB1 adaptors	PHOSPHOTYROSINE-BINDING DOMAINS; TERMINAL SH3 DOMAIN; SRC HOMOLOGY 2; ADAPTER PROTEIN; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; N-SHC; ACTIVATION; RECEPTOR; EXPRESSION	RAI, also named ShcC/N-Shc, one of the members of the Shc proteins family, is a substrate of the RET receptor tyrosine kinase. Here, we show that RAI forms a protein complex with both RET/MEN2A and RET/PTC oncoproteins. By coimmunoprecipitation, we found that RAI associates with the Grb2-associated binder1 (GAB1) adapter. This association is constitutive, but, in the presence of RET oncoproteins, both RAI and GAB1 are tyrosine-phosphorylated, and the stoichiometry of this interaction remarkably increases. Consequently, the p85 regulatory subunit of phosphatidylinositol-3 kinase (PI3K) is recruited to the complex, and its downstream effector Akt is activated. We show that human thyroid cancer cell lines derived from papillary or medullary thyroid carcinoma (PTC or MTC) carrying, respectively, RET/PTC and RET/MEN2A oncoproteins express RAI proteins. We also show that human PTC samples express higher levels of RAI, when compared to normal thyroid tissue. In thyroid cells expressing RET/PTC1, ectopic expression of RAI protects cells from apoptosis; on the other hand, the silencing of endogenous RAI by small inhibitory duplex RNAs in a PTC cell line that expresses endogenous RET/PTC1, increases the rate of spontaneous apoptosis. These data suggest that RAI is a critical substrate for RET oncoproteins in thyroid carcinomas.	CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); IRCCS European Institute of Oncology (IEO)	Melillo, RM (corresponding author), CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	rosmelil@unina.it	Troglio, Flavia/AAQ-4789-2020; Erreni, Marco/K-2522-2016; Malorni, Luca/J-1973-2019; Pelicci, Giuliana/AAA-8921-2022; melillo, rosa marina/O-5255-2015; DE FALCO, VALENTINA/C-2061-2015	Troglio, Flavia/0000-0002-0226-8241; Erreni, Marco/0000-0002-1922-0818; Malorni, Luca/0000-0002-4297-2997; Pelicci, Giuliana/0000-0003-0986-8255; DE FALCO, VALENTINA/0000-0002-8972-7921; MELILLO, Rosa Marina/0000-0002-9233-5275				Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Carlomagno F, 2002, CANCER RES, V62, P1077; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; COOLEY LD, 1995, CANCER GENET CYTOGEN, V80, P138, DOI 10.1016/0165-4608(94)00185-E; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ganju P, 1998, EUR J NEUROSCI, V10, P1995, DOI 10.1046/j.1460-9568.1998.00209.x; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hingorani SR, 2003, CANCER RES, V63, P5198; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; Liu HY, 2002, J BIOL CHEM, V277, P26046, DOI 10.1074/jbc.M111659200; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; Maeda K, 2004, BIOCHEM BIOPH RES CO, V323, P345, DOI 10.1016/j.bbrc.2004.08.095; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nakamura T, 2002, ONCOGENE, V21, P22, DOI 10.1038/sj.onc.1205019; Nakazawa T, 2002, J NEUROSCI RES, V68, P668, DOI 10.1002/jnr.10259; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Pelicci G, 1996, ONCOGENE, V13, P633; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Tanabe K, 1998, MOL BRAIN RES, V53, P291, DOI 10.1016/S0169-328X(97)00264-7; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041	44	24	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6303	6313		10.1038/sj.onc.1208776	http://dx.doi.org/10.1038/sj.onc.1208776			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940252				2022-12-25	WOS:000231877100011
J	Abid, MR; Yano, K; Guo, SD; Patel, VI; Shrikhande, G; Spokes, KC; Ferran, C; Aird, WC				Abid, MR; Yano, K; Guo, SD; Patel, VI; Shrikhande, G; Spokes, KC; Ferran, C; Aird, WC			Forkhead transcription factors inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FIBROBLAST-GROWTH-FACTOR; DRUG-ELUTING STENTS; FACTOR-ALPHA; INTIMAL HYPERPLASIA; IN-VITRO; GENE-EXPRESSION; TNF-ALPHA; PROGENITOR CELLS; FACTOR-BINDING	Vascular smooth muscle cell (VSMC) proliferation and migration contribute significantly to atherosclerosis, postangioplasty restenosis, and transplant vasculopathy. Forkhead transcription factors belonging to the FoxO subfamily have been shown to inhibit growth and cell cycle progression in a variety of cell types. We hypothesized that forkhead proteins may play a role in VSMC biology. Under in vitro conditions, platelet- derived growth factor (PDGF)-BB, tumor necrosis factor-alpha, and insulin-like growth factor 1 stimulated phosphorylation of FoxO in human coronary artery smooth muscle cells via MEK1/2 and/or phosphatidylinositol 3-kinase-dependent signaling pathways. PDGF-BB, tumor necrosis factor-alpha, and insulin-like growth factor 1 treatment resulted in the nuclear exclusion of FoxO, whereas PDGF-BB alone down-regulated the FoxO target gene, p27(kip1), and enhanced cell survival and progression through the cell cycle. These effects were abrogated by overexpression of a constitutively active, phosphorylationresistant mutant of the FoxO family member, TM-FKHRL1. The anti-proliferative effect of TM-FKHRL1 was partially reversed by small interfering RNA against p27(kip1). In a rat balloon carotid arterial injury model, adenovirus-mediated gene transfer of FKHRL1 caused an increase in the expression of p27(kip1) in the VSMC and inhibition of neointimal hyperplasia. These data suggest that FoxO activity inhibits VSMC proliferation and activation and that this signaling axis may represent a therapeutic target in vasculopathic disease states.	Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Mol & Vasc Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Vasc Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Cambridge, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University	Aird, WC (corresponding author), Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, RW-663,330 Brookline Ave, Boston, MA 02215 USA.	waird@bidmc.harvard.edu			NHLBI NIH HHS [T32 HL07734-08, HL65216, HL63609, HL60585, HL57791-04, HL36028] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060585, R01HL057791, P50HL063609, T32HL007734, R01HL065216, P01HL036028] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; BARATH P, 1990, AM J PATHOL, V137, P503; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Brasen JH, 2001, ARTERIOSCL THROM VAS, V21, P1720, DOI 10.1161/hq1101.098230; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Castro C, 2003, J BIOL CHEM, V278, P4482, DOI 10.1074/jbc.M204716200; CLAUSELL N, 1994, CIRCULATION, V89, P2768, DOI 10.1161/01.CIR.89.6.2768; CLOWES AW, 1983, LAB INVEST, V49, P327; CLOWES AW, 1983, LAB INVEST, V49, P208; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COUFFINHAL T, 1993, ARTERIOSCLER THROMB, V13, P407, DOI 10.1161/01.ATV.13.3.407; Desfaits AC, 2000, STROKE, V31, P498, DOI 10.1161/01.STR.31.2.498; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; FERNS GAA, 1991, AM J PATHOL, V138, P1045; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Haery C, 2004, CLEV CLIN J MED, V71, P815, DOI 10.3949/ccjm.71.10.815; Hall JL, 2002, AM J PHYSIOL-ENDOC M, V283, pE465, DOI 10.1152/ajpendo.00072.2002; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; IKEDA U, 1990, ATHEROSCLEROSIS, V84, P183, DOI 10.1016/0021-9150(90)90089-2; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P490, DOI 10.1161/01.ATV.17.3.490; KARIYA K, 1987, ATHEROSCLEROSIS, V63, P251, DOI 10.1016/0021-9150(87)90128-6; KHORSANDI MJ, 1992, J CLIN INVEST, V90, P1926, DOI 10.1172/JCI116070; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Machida S, 2003, J CELL PHYSIOL, V196, P523, DOI 10.1002/jcp.10339; MARMUR JD, 1992, CIRCULATION, V86, P53; Mattana J, 1997, KIDNEY INT, V52, P1478, DOI 10.1038/ki.1997.478; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mehta D, 1998, NAT MED, V4, P235, DOI 10.1038/nm0298-235; Miao RQ, 2000, CIRC RES, V86, P418, DOI 10.1161/01.RES.86.4.418; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Myit S, 2003, J VASC RES, V40, P97, DOI 10.1159/000070706; Myllarniemi M, 1999, CARDIOVASC DRUG THER, V13, P159, DOI 10.1023/A:1007700629728; Nakae J, 2001, BIOCHEMISTRY-US, V40, P11768, DOI 10.1021/bi015532m; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nili N, 2003, AM J PATHOL, V163, P869, DOI 10.1016/S0002-9440(10)63447-5; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oliva G, 2004, REV ESP CARDIOL, V57, P617, DOI 10.1157/13064187; Park KW, 2005, ARTERIOSCL THROM VAS, V25, P742, DOI 10.1161/01.ATV.0000156288.70849.26; Rayment NB, 1996, CARDIOVASC RES, V32, P1123, DOI 10.1016/S0008-6363(96)00145-9; Rectenwald JE, 2000, CIRCULATION, V102, P1697, DOI 10.1161/01.CIR.102.14.1697; Religa P, 2002, TRANSPLANTATION, V74, P1310, DOI 10.1097/00007890-200211150-00019; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; SAWADA H, 1990, IN VITRO CELL DEV B, V26, P213; Sawada M, 1999, STROKE, V30, P644, DOI 10.1161/01.STR.30.3.644; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Selzman CH, 1998, J MOL CELL CARDIOL, V30, P889, DOI 10.1006/jmcc.1998.0642; Selzman CH, 1999, CIRC RES, V84, P867; Selzman CH, 1998, J SURG RES, V80, P352, DOI 10.1006/jsre.1998.5486; Sidawy AN, 1996, J VASC SURG, V23, P308, DOI 10.1016/S0741-5214(96)70275-6; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Stracke S, 2002, KIDNEY INT, V61, P1011, DOI 10.1046/j.1523-1755.2002.00191.x; Strehlow K, 2003, CIRCULATION, V107, P3059, DOI 10.1161/01.CIR.0000077911.81151.30; Tanaka H, 1996, ARTERIOSCL THROM VAS, V16, P12, DOI 10.1161/01.ATV.16.1.12; TANAKA H, 1995, AM J PATHOL, V147, P617; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; TIPPING PG, 1993, AM J PATHOL, V142, P1721; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Vazquez-Padron RI, 2004, J VASC SURG, V40, P1199, DOI 10.1016/j.jvs.2004.08.034; WARNER SJC, 1989, J IMMUNOL, V142, P100; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Young W, 2000, CIRC RES, V86, P906, DOI 10.1161/01.RES.86.8.906; Zernecke A, 2005, CIRC RES, V96, P784, DOI 10.1161/01.RES.0000162100.52009.38; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2; Zhu BH, 2001, ENDOCRINOLOGY, V142, P3598, DOI 10.1210/en.142.8.3598; Zimmerman MA, 2003, AM J PHYSIOL-REG I, V284, pR1213, DOI 10.1152/ajpregu.00434.2002; Zimmerman MA, 2002, AM J PHYSIOL-REG I, V283, pR505, DOI 10.1152/ajpregu.00033.2002	83	92	101	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29864	29873		10.1074/jbc.M502149200	http://dx.doi.org/10.1074/jbc.M502149200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15961397	hybrid			2022-12-25	WOS:000231176200058
J	Fu, MF; Wang, CG; Rao, M; Wu, XF; Bouras, T; Zhang, XP; Li, ZP; Jiao, XM; Yang, JG; Li, AP; Perkins, ND; Thimmapaya, B; Kung, AL; Munoz, A; Giordano, A; Lisanti, MP; Pestell, RG				Fu, MF; Wang, CG; Rao, M; Wu, XF; Bouras, T; Zhang, XP; Li, ZP; Jiao, XM; Yang, JG; Li, AP; Perkins, ND; Thimmapaya, B; Kung, AL; Munoz, A; Giordano, A; Lisanti, MP; Pestell, RG			Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; RUBINSTEIN-TAYBI-SYNDROME; MAMMARY-GLAND DEVELOPMENT; CREB-BINDING PROTEIN; NF-KAPPA-B; TRANSCRIPTIONAL REPRESSION; HISTONE ACETYLTRANSFERASE; ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; DNA-BINDING	Cyclin D1 encodes a regulatory subunit, which with its cyclin-dependent kinase (Cdk)-binding partner forms a holoenzyme that phosphorylates and inactivates the retinoblastoma protein. In addition to its Cdk binding-dependent functions, cyclin D1 regulates cellular differentiation in part by modifying several transcription factors and nuclear receptors. The molecular mechanism through which cyclin D1 regulates the function of transcription factors involved in cellular differentiation remains to be clarified. The histone acetyltransferase protein p300 is a co-integrator required for regulation of multiple transcription factors. Here we show that cyclin D1 physically interacts with p300 and represses p300 transactivation. We demonstrated further that the interaction of the two proteins occurs at the peroxisome proliferator-activated receptor gamma-responsive element of the lipoprotein lipase promoter in the context of the local chromatin structure. We have mapped the domains in p300 and cyclin D1 involved in this interaction. The bromo domain and cysteine- and histidine-rich domains of p300 were required for repression by cyclin D1. Cyclin D1 repression of p300 was independent of the Cdk-and retinoblastoma protein-binding domains of cyclin D1. Cyclin D1 inhibits histone acetyltransferase activity of p300 in vitro. Microarray analysis identified a signature of genes repressed by cyclin D1 and induced by p300 that promotes cellular differentiation and induces cell cycle arrest. Together, our results suggest that cyclin D1 plays an important role in cellular proliferation and differentiation through regulation of p300.	Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Univ Dundee, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland; Northwestern Univ, Feinberg Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, E-28029 Madrid, Spain; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol, Philadelphia, PA 19107 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Georgetown University; University of Dundee; Northwestern University; Feinberg School of Medicine; Harvard University; Dana-Farber Cancer Institute; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Jefferson University; Yeshiva University; Albert Einstein College of Medicine	Pestell, RG (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Res Bldg,Rm E501,3970 Reservoir Rd NW,Box 571468, Washington, DC 20057 USA.	pestell@georgetown.edu	Lisanti, Michael P/C-6866-2013; Giordano, Antonio/F-1927-2010; Kung, Andrew L/AEU-0826-2022; Munoz, Alberto/O-6393-2014; Lisanti, Michael/B-6131-2018; Kung, Andrew/AAL-2384-2020	Giordano, Antonio/0000-0002-5959-016X; Kung, Andrew L/0000-0002-9091-488X; Munoz, Alberto/0000-0003-3890-4251; Lisanti, Michael/0000-0003-2034-1382; Wu, Xiaofang/0000-0002-3782-7701	NCI NIH HHS [R01CA93596, R01CA86072, R01CA75503, R01CA70896, R01CA107382, CA51008-14] Funding Source: Medline; NIDDK NIH HHS [1R21DK065220-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093596, R01CA107382, R01CA070896, R01CA086072, R01CA075503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bearss DJ, 2002, CANCER RES, V62, P2077; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; Bottomley MJ, 2004, EMBO REP, V5, P464, DOI 10.1038/sj.embor.7400146; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Brakenhielm E, 2004, P NATL ACAD SCI USA, V101, P2476, DOI 10.1073/pnas.0308671100; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; CHALLUIN C, 1999, NATURE, V399, P491; Coupry I, 2004, HUM MUTAT, V23, P278, DOI 10.1002/humu.20001; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Fu MF, 2002, CYTOKINE GROWTH F R, V13, P259, DOI 10.1016/S1359-6101(02)00003-5; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Goodman RH, 2000, GENE DEV, V14, P1553; Gregory DJ, 2002, CELL CYCLE, V1, P343, DOI 10.4161/cc.1.5.153; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Kanno T, 2004, MOL CELL, V13, P33, DOI 10.1016/S1097-2765(03)00482-9; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102; Nishimura T, 2000, AM J REPROD IMMUNOL, V43, P351, DOI 10.1111/j.8755-8920.2000.430604.x; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Roelfsema JH, 2005, AM J HUM GENET, V76, P572, DOI 10.1086/429130; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shigeno K, 2004, CANCER LETT, V213, P11, DOI 10.1016/S0304-3835(03)00442-7; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Takahashi N, 2002, J BIOL CHEM, V277, P16906, DOI 10.1074/jbc.M200585200; Valls E, 2003, NUCLEIC ACIDS RES, V31, P3114, DOI 10.1093/nar/gkg418; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang YM, 2004, GENE CHROMOSOME CANC, V41, P257, DOI 10.1002/gcc.20077	88	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29728	29742		10.1074/jbc.M503188200	http://dx.doi.org/10.1074/jbc.M503188200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15951563	hybrid			2022-12-25	WOS:000231176200043
J	Naiki, Y; Michelsen, KS; Schroder, NWJ; Alsabeh, R; Slepenkin, A; Zhang, WX; Chen, S; Wei, B; Bulut, Y; Wong, MH; Peterson, EM; Arditi, M				Naiki, Y; Michelsen, KS; Schroder, NWJ; Alsabeh, R; Slepenkin, A; Zhang, WX; Chen, S; Wei, B; Bulut, Y; Wong, MH; Peterson, EM; Arditi, M			MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; MYELOID DIFFERENTIATION FACTOR-88; SURFACE PROTEIN-A; CUTTING EDGE; LISTERIA-MONOCYTOGENES; STAPHYLOCOCCUS-AUREUS; BORRELIA-BURGDORFERI; ADAPTIVE IMMUNITY; INFECTION; ACTIVATION	Chlamydia pneumoniae is the causative agent of respiratory tract infections and a number of chronic diseases. Here we investigated the involvement of the common TLR adaptor molecule MyD88 in host responses to C. pneumoniae-induced pneumonia in mice. MyD88-deficient mice were severely impaired in their ability to mount an acute early inflammatory response toward C. pneumoniae. Although the bacterial burden in the lungs was comparable 5 days after infection, MyD88-deficient mice exhibited only minor signs of pneumonia and reduced expression of inflammatory mediators. MyD88-deficient mice were unable to up-regulate proinflammatory cytokines and chemokines, demonstrated delayed recruitment of CD8+ and CD4+ T cells to the lungs, and were unable to clear the pathogen from their lungs at day 14. At day 14 the MyD88-deficent mice developed a severe, chronic lung inflammation with elevated IL-1 beta and IFN-gamma leading to increased mortality, whereas wild-type mice as well as TLR2- or TLR4-deficient mice recovered from acute pneumonia and did not show delayed bacterial clearance. Thus, MyD88 is essential to recognize C. pneumoniae infection and initiate a prompt and effective immune host response against this organism leading to clearance of bacteria from infected lungs.	Univ Calif Los Angeles, Div Pediat Infect Dis & Immunol, Cedars Sinai Med Ctr, David Geffen Sch Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Cedars Sinai Med Ctr, David Geffen Sch Med, Los Angeles, CA 90048 USA; Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Irvine; University of California System; University of California Los Angeles	Arditi, M (corresponding author), Univ Calif Los Angeles, Div Pediat Infect Dis & Immunol, Cedars Sinai Med Ctr, David Geffen Sch Med, 8700 Beverly Blvd,Rm 4220, Los Angeles, CA 90048 USA.	moshe.arditi@cshs.org	Bulut, Yonca/V-3290-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058128] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 66436] Funding Source: Medline; NIAID NIH HHS [AI 058128, AI-3248] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Belland R, 2004, NAT REV MICROBIOL, V2, P530, DOI 10.1038/nrmicro931; Belland RJ, 2004, CELL MICROBIOL, V6, P117, DOI 10.1046/j.1462-5822.2003.00352.x; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; Campbell LA, 2004, NAT REV MICROBIOL, V2, P23, DOI 10.1038/nrmicro796; Doherty TM, 2004, J CLIN INVEST, V114, P1699, DOI 10.1172/JCI200423867; Edelson BT, 2002, J IMMUNOL, V169, P3869, DOI 10.4049/jimmunol.169.7.3869; Hansbro PM, 2004, PHARMACOL THERAPEUT, V101, P193, DOI 10.1016/j.pharmthera.2003.10.007; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451; Mueller M, 2004, IMMUNOBIOLOGY, V209, P599, DOI 10.1016/j.imbio.2004.08.003; Netea MG, 2002, EUR J IMMUNOL, V32, P1188, DOI 10.1002/1521-4141(200204)32:4<1188::AID-IMMU1188>3.3.CO;2-1; Opitz B, 2004, J BIOL CHEM, V279, P36426, DOI 10.1074/jbc.M403861200; Ossewaarde JM, 1996, APPL ENVIRON MICROB, V62, P328, DOI 10.1128/AEM.62.2.328-331.1996; Pal S, 2003, VACCINE, V21, P1455, DOI 10.1016/S0264-410X(02)00680-1; PETERSON EM, 1988, INFECT IMMUN, V56, P885, DOI 10.1128/IAI.56.4.885-891.1988; Peterson EM, 1998, INFECT IMMUN, V66, P3848, DOI 10.1128/IAI.66.8.3848-3855.1998; Prebeck S, 2001, J IMMUNOL, V167, P3316, DOI 10.4049/jimmunol.167.6.3316; Rodriguez N, 2005, J IMMUNOL, V174, P4836, DOI 10.4049/jimmunol.174.8.4836; Rothfuchs AG, 2004, J IMMUNOL, V172, P6345, DOI 10.4049/jimmunol.172.10.6345; Rottenberg ME, 1999, J IMMUNOL, V162, P2829; Sasu S, 2001, CIRC RES, V89, P244, DOI 10.1161/hh1501.094184; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Seki E, 2002, J IMMUNOL, V169, P3863, DOI 10.4049/jimmunol.169.7.3863; Skerrett SJ, 2004, J IMMUNOL, V172, P3377, DOI 10.4049/jimmunol.172.6.3377; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Way SS, 2003, J IMMUNOL, V171, P533, DOI 10.4049/jimmunol.171.2.533; Zhou SH, 2005, EUR J IMMUNOL, V35, P822, DOI 10.1002/eji.200425730	29	81	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29242	29249		10.1074/jbc.M503225200	http://dx.doi.org/10.1074/jbc.M503225200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15964841	hybrid			2022-12-25	WOS:000231021300053
J	Zeng, L; Hu, YY; Li, BJ				Zeng, L; Hu, YY; Li, BJ			Identification of TopBP1 as a c-Abl-interacting protein and a repressor for c-Abl expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CELL-CYCLE CHECKPOINT; DNA-DAMAGE RESPONSE; TYROSINE KINASE; FAMILY KINASES; BRCT DOMAIN; METHYLATION; ACTIVATION; COMPLEX; ATM	Expression of BCR-ABL is the leading cause of chronic myelogenous leukemia. In chronic myelogenous leukemia cells, c-Abl expression is silenced by promoter methylation. In addition, the level of c-Abl needs to be tightly and constantly regulated due to its cytotoxicity and its rapid degradation after activation. Yet the regulation of c-Ab1 expression remains unclear. In an effort to gain better understanding of c-Ab1 function, we performed a glutathione S-transferase-Ab1 pull-down screen and identified TopBP1, a topoisomerase II beta-binding protein that contains Brca1 C-terminal motifs and has been implicated in DNA damage response. Their physical interaction was verified by in vitro and in vivo assays with TopBP1 found as a substrate of Ab1 proteins. TopBP1 could repress the expression of c-Ab1 at both mRNA and protein levels. Reporter assays indicate that TopBP1 directly repressed the promoter activity of c-Abl. Furthermore, TopBP1 repressed expression of c-Abl through a novel mechanism that involved histone deacetylation and DNA methylation. This transcriptional repression was inhibited by c-Abl in a kinase-dependent manner. The dual antagonistic interplay between c-Abl and TopBP1 may also provide a mechanism for fine-tuning of c-Abl levels.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 138673, Singapore	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Li, BJ (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	libj@imcb.a-star.edu.sg		Hu, Yuanyu/0000-0001-5457-4331				ANDREWS DF, 1989, P NATL ACAD SCI USA, V86, P6788, DOI 10.1073/pnas.86.17.6788; Asimakopoulos FA, 1999, BLOOD, V94, P2452, DOI 10.1182/blood.V94.7.2452.419k23_2452_2460; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BERNARDS A, 1988, ONCOGENE, V2, P297; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Collins I, 2001, MOL CELL BIOL, V21, P8437, DOI 10.1128/MCB.21.24.8437-8451.2001; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Issa JPJ, 1999, BLOOD, V93, P2075, DOI 10.1182/blood.V93.6.2075.406k29_2075_2080; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Li BJ, 2004, GENE DEV, V18, P1824, DOI 10.1101/gad.1223504; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Li BJ, 2002, J BIOL CHEM, V277, P28870, DOI 10.1074/jbc.M202388200; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; O'Dwyer ME, 2002, ANNU REV MED, V53, P369, DOI 10.1146/annurev.med.53.082901.103853; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Suzuki J, 2004, ONCOGENE, V23, P8527, DOI 10.1038/sj.onc.1207894; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Yamane K, 2003, CANCER RES, V63, P3049; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	42	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29374	29380		10.1074/jbc.M503016200	http://dx.doi.org/10.1074/jbc.M503016200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15961388	hybrid			2022-12-25	WOS:000231021300069
J	Olry, A; Chastagner, P; Israel, A; Brou, C				Olry, A; Chastagner, P; Israel, A; Brou, C			Generation and characterization of mutant cell lines defective in gamma-secretase processing of Notch and amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; COMPLEMENTATION CLONING; TRANSMEMBRANE DOMAIN; RECOMBINASE ACTIVITY; ALPHA-INTERFERON; BETA-APP; NICASTRIN; COMPLEX; APH-1; CLEAVAGE	Several type I integral membrane proteins, such as the Notch receptor or the amyloid precursor protein, are cleaved in their intramembrane domain by a gamma-secretase enzyme, which is carried within a multiprotein complex. These cleavages generate molecules that are involved in intracellular or extracellular signaling. At least four transmembrane proteins belong to the gamma-secretase complex: presenilin, nicastrin, Aph-1, and Pen-2. It is still unclear whether these proteins are the only components of the complex and whether a unique complex is involved in the different gamma-secretase cleavage events. We have set up a genetic screen based on the permanent acquisition or loss of an antibiotic resistance depending on the presence of an active gamma-secretase able to cleave a Notch-derived substrate. We selected clones deficient in gamma-secretase activity using this screen on mammalian cells after random mutagenesis. We further analyzed two of these clones and identified previously undescribed mutations in the nicastrin gene. The first mutation abolishes nicastrin production, and the second mutation, a point mutation in the ectodomain, abolishes nicastrin maturation. In both cases, gamma-secretase activity on Notch and APP is impaired.	Inst Pasteur, CNRS, URA 2582, Unite Signalisat Mol & Activat Cellulaire, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Brou, C (corresponding author), Inst Pasteur, CNRS, URA 2582, Unite Signalisat Mol & Activat Cellulaire, 25 Rue Dr Roux, F-75724 Paris, France.	cbrou@pasteur.fr						Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Capell A, 2003, J BIOL CHEM, V278, P52519, DOI 10.1074/jbc.C300435200; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chinanonwait N, 2002, FEBS LETT, V531, P553, DOI 10.1016/S0014-5793(02)03618-9; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Fortna RR, 2004, J BIOL CHEM, V279, P3685, DOI 10.1074/jbc.M310505200; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; FUSCOE JC, 1979, CANCER RES, V39, P4875; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Landman N, 2004, CYTOKINE GROWTH F R, V15, P337, DOI 10.1016/j.cytogfr.2004.04.001; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Morais VA, 2003, J BIOL CHEM, V278, P43284, DOI 10.1074/jbc.M305685200; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; Shirotani K, 2004, J BIOL CHEM, V279, P41340, DOI 10.1074/jbc.M405768200; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	39	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28564	28571		10.1074/jbc.M502199200	http://dx.doi.org/10.1074/jbc.M502199200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15958385	hybrid			2022-12-25	WOS:000230857300047
J	Dashper, SG; Butler, CA; Lissel, JP; Paolini, RA; Hoffmann, B; Veith, PD; O'Brien-Simpson, NM; Snelgrove, SL; Tsiros, JT; Reynolds, EC				Dashper, SG; Butler, CA; Lissel, JP; Paolini, RA; Hoffmann, B; Veith, PD; O'Brien-Simpson, NM; Snelgrove, SL; Tsiros, JT; Reynolds, EC			A novel Porphyromonas gingivalis FeoB plays a role in manganese accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERROUS IRON TRANSPORTER; CORYNEBACTERIUM-DIPHTHERIAE; BACTEROIDES-GINGIVALIS; ESCHERICHIA-COLI; VIRULENCE; SEQUENCE; W50; BACTERIA; GROWTH; IDENTIFICATION	FeoB is an atypical transporter that has been shown to exclusively mediate ferrous ion transport in some bacteria. Unusually the genome of the periodontal pathogen Porphyromonas gingivalis has two genes (feoB1 and feoB2) encoding FeoB homologs, both of which are expressed in bicistronic operons. Kinetic analysis of ferrous ion transport by P. gingivalis W50 revealed the presence of a single, high affinity system with a Kt of 0.31 mu M. FeoB1 was found to be solely responsible for this transport as energized cells of the isogenic FeoB1 mutant (W50FB1) did not transport radiolabeled iron, while the isogenic FeoB2 mutant (W50FB2) transported radiolabeled iron at a rate similar to wild type. This was reflected in the iron content of W50FB1 grown in iron excess conditions which was approximately half that of the wild type and W50FB2. The W50FB1 mutant had increased sensitivity to both oxygen and hydrogen peroxide and was avirulent in an animal model of infection whereas W50FB2 exhibited the same virulence as the wild type. Analysis of manganous ion uptake using inductively coupled plasma-mass spectrometry revealed a greater than 3-fold decrease in intracellular manganese accumulation in W50FB2 which was also unable to grow in manganese-limited media. The protein co-expressed with FeoB2 appears to be a novel FeoA-MntR fusion protein that exhibits homology to a manganese-responsive, DNA-binding metalloregulatory protein. These results indicate that FeoB2 is not involved in iron transport but plays a novel role in manganese transport.	Univ Melbourne, Sch Dent Sci, Ctr Oral Hlth Sci, Melbourne, Vic 3010, Australia; Monash Univ, Sch Geosci, Clayton, Vic 3168, Australia	University of Melbourne; Monash University	Reynolds, EC (corresponding author), Univ Melbourne, Sch Dent Sci, Ctr Oral Hlth Sci, Melbourne, Vic 3010, Australia.	e.reynolds@unimelb.edu.au	Hoffmann, Brigitte/AAH-4345-2021; O'Brien-Simpson, Neil/B-2901-2009	Hoffmann, Brigitte/0000-0002-0306-278X; O'Brien-Simpson, Neil/0000-0001-8462-5603; Butler, Catherine/0000-0001-6371-3954; Reynolds, Eric/0000-0002-6618-4856; Dashper, Stuart/0000-0003-0106-8691; Paolini, Rita/0000-0002-2170-4723; Veith, Paul/0000-0002-7344-1662				AIBA H, 1981, J BIOL CHEM, V256, P1905; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMANO A, 1990, J BACTERIOL, V172, P1457, DOI 10.1128/jb.172.3.1457-1463.1990; [Anonymous], 1993, SPSS WINDOWS BASE SY; Armitage G C, 1999, Ann Periodontol, V4, P1, DOI 10.1902/annals.1999.4.1.1; BOYD J, 1990, P NATL ACAD SCI USA, V87, P5968, DOI 10.1073/pnas.87.15.5968; BRAMANTI TE, 1991, J BACTERIOL, V173, P7330, DOI 10.1128/jb.173.22.7330-7339.1991; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Brochu V, 2001, ORAL MICROBIOL IMMUN, V16, P79, DOI 10.1034/j.1399-302x.2001.016002079.x; Brown T., 2004, CURR PROTOCOLS MOL B, V67, p4.9.1; CHEN HS, 1991, IEEE ELECTR DEVICE L, V12, P13, DOI 10.1109/55.75682; Dashper SG, 2001, J BACTERIOL, V183, P4142, DOI 10.1128/JB.183.14.4142-4148.2001; FLETCHER HM, 1995, INFECT IMMUN, V63, P1521, DOI 10.1128/IAI.63.4.1521-1528.1995; Genco C A, 1995, Adv Dent Res, V9, P41; Guedon E, 2003, MOL MICROBIOL, V48, P495, DOI 10.1046/j.1365-2958.2003.03445.x; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; Hantke K, 2003, TRENDS MICROBIOL, V11, P192, DOI 10.1016/S0966-842X(03)00100-8; Horsburgh MJ, 2002, TRENDS MICROBIOL, V10, P496, DOI 10.1016/S0966-842X(02)02462-9; Jakubovics NS, 2001, MICROBIOL-SGM, V147, P1709, DOI 10.1099/00221287-147-7-1709; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lee JH, 1997, INFECT IMMUN, V65, P4273, DOI 10.1128/IAI.65.10.4273-4280.1997; MALEY J, 1992, FEMS MICROBIOL LETT, V93, P75, DOI 10.1016/0378-1097(92)90492-7; Marlovits TC, 2002, P NATL ACAD SCI USA, V99, P16243, DOI 10.1073/pnas.242338299; MARSH PD, 1994, MICROBIOL-UK, V140, P861, DOI 10.1099/00221287-140-4-861; MCKEE AS, 1986, INFECT IMMUN, V52, P349, DOI 10.1128/IAI.52.2.349-355.1986; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NIKOLICH MP, 1992, ANTIMICROB AGENTS CH, V36, P1005, DOI 10.1128/AAC.36.5.1005; O'Brien-Simpson NM, 2001, INFECT IMMUN, V69, P7527, DOI 10.1128/IAI.69.12.7527-7534.2001; Robey M, 2002, INFECT IMMUN, V70, P5659, DOI 10.1128/IAI.70.10.5659-5669.2002; Roper JM, 2000, J BIOL CHEM, V275, P40316, DOI 10.1074/jbc.M007146200; Schifferle RE, 1996, J ENDODONT, V22, P352, DOI 10.1016/S0099-2399(96)80216-0; Schmitt MP, 2002, J BACTERIOL, V184, P6882, DOI 10.1128/JB.184.24.6882-6892.2002; Shi Y, 1999, J BIOL CHEM, V274, P17955, DOI 10.1074/jbc.274.25.17955; SHIZUKUISHI S, 1995, FEMS MICROBIOL LETT, V131, P313; Socransky SS, 1998, J CLIN PERIODONTOL, V25, P134, DOI 10.1111/j.1600-051X.1998.tb02419.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tseng HJ, 2001, MOL MICROBIOL, V40, P1175, DOI 10.1046/j.1365-2958.2001.02460.x; Tsolis RM, 1996, INFECT IMMUN, V64, P4549, DOI 10.1128/IAI.64.11.4549-4556.1996; Veith PD, 2002, BIOCHEM J, V363, P105, DOI 10.1042/0264-6021:3630105; Velayudhan J, 2000, MOL MICROBIOL, V37, P274, DOI 10.1046/j.1365-2958.2000.01987.x; WOOLDRIDGE KG, 1993, FEMS MICROBIOL REV, V12, P325, DOI 10.1016/0168-6445(93)90011-W	42	69	80	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28095	28102		10.1074/jbc.M503896200	http://dx.doi.org/10.1074/jbc.M503896200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15901729	hybrid			2022-12-25	WOS:000230678600072
J	Ashikov, A; Routier, F; Fuhlrott, J; Helmus, Y; Wild, M; Gerardy-Schahn, R; Bakker, H				Ashikov, A; Routier, F; Fuhlrott, J; Helmus, Y; Wild, M; Gerardy-Schahn, R; Bakker, H			The human solute carrier gene SLC35B4 encodes a bifunctional nucleotide sugar transporter with specificity for UDP-xylose and UDP-N-acetylglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CMP-SIALIC ACID; GDP-FUCOSE TRANSPORTER; RAT-LIVER GOLGI; ADENOSINE 3'-PHOSPHATE 5'-PHOSPHOSULFATE; MOLECULAR-CLONING; SUBSTRATE-SPECIFICITY; ENDOPLASMIC-RETICULUM; GLUCURONIC ACID; PHOSPHATE TRANSLOCATOR; FUNCTIONAL EXPRESSION	The transport of nucleotide sugars from the cytoplasm into the Golgi apparatus is mediated by specialized type III proteins, the nucleotide sugar transporters (NSTs). Transport assays carried out in vitro with Golgi vesicles from mammalian cells showed specific uptake for a total of eight nucleotide sugars. When this study was started, NSTs with transport activities for all but two nucleotide sugars (UDP-Xyl and UDP-Glc) had been cloned. Aiming at identifying these elusive NSTs, bioinformatic methods were used to display putative NST sequences in the human genome. Ten open reading frames were identified, cloned, and heterologously expressed in yeast. Transport capabilities for UDP-Glc and UDP-Xyl were determined with Golgi vesicles isolated from transformed cells. Although a potential UDP-Glc transporter could not be identified due to the high endogenous transport background, the measurement of UDP-Xyl transport was possible on a zero background. Vesicles from yeast cells expressing the human gene SLC35B4 showed specific uptake of UDP-Xyl, and subsequent testing of other nucleotide sugars revealed a second activity for UDP-GlcNAc. Expression of the epitope-tagged SLC35B4 in mammalian cells demonstrated strict Golgi localization. Because decarboxylation of UDP-GlcA is known to produce UDP-Xyl directly in the endoplasmic reticulum and Golgi lumen, our data demonstrate that two ways exist to deliver UDP-Xyl to the Golgi apparatus.	Hannover Med Sch, Zentrum Biochem, D-30625 Hannover, Germany; Univ Munster, Zentrum Mol Biol Entzundung, Inst Cell Biol, D-48148 Munster, Germany; Max Planck Inst Mol Biomed, Munster, Germany	Hannover Medical School; University of Munster; Max Planck Society	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Zentrum Biochem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Gerardy-schahn.rita@mh-hannover.de	Bakker, Hans/A-1787-2017; Ashikov, Angel/N-7714-2015; Bakker, Hans/AAA-1623-2020; Routier, Francoise/O-1611-2019	Bakker, Hans/0000-0002-1364-9154; Ashikov, Angel/0000-0001-9679-7955; Bakker, Hans/0000-0002-1364-9154; Routier, Francoise/0000-0002-7163-0590				Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Aoki K, 2003, J BIOL CHEM, V278, P22887, DOI 10.1074/jbc.M302620200; Aoki K, 2001, J BIOL CHEM, V276, P21555, DOI 10.1074/jbc.M101462200; Bakker H, 2005, GLYCOBIOLOGY, V15, P193, DOI 10.1093/glycob/cwh159; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CAREY DJ, 1980, CELL, V19, P597, DOI 10.1016/S0092-8674(80)80036-5; CIPOLLO JF, 2004, J BIOL CHEM; COATES SW, 1980, J BIOL CHEM, V255, P9225; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; CREEK KE, 1981, BIOCHIM BIOPHYS ACTA, V643, P292, DOI 10.1016/0005-2736(81)90075-4; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Eicks M, 2002, PLANT PHYSIOL, V128, P512, DOI 10.1104/pp.010576; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; Gillissen B, 2000, PLANT CELL, V12, P291, DOI 10.1105/tpc.12.2.291; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Harper AD, 2002, PLANT PHYSIOL, V130, P2188, DOI 10.1104/pp.009654; HASE S, 1988, J BIOCHEM-TOKYO, V104, P867, DOI 10.1093/oxfordjournals.jbchem.a122571; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hoflich J, 2004, J BIOL CHEM, V279, P30440, DOI 10.1074/jbc.M402429200; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Ishida N, 2005, GENOMICS, V85, P106, DOI 10.1016/j.ygeno.2004.09.010; Ishida N, 2004, PFLUG ARCH EUR J PHY, V447, P768, DOI 10.1007/s00424-003-1093-0; Ishida N, 1999, J BIOCHEM, V126, P68, DOI 10.1093/oxfordjournals.jbchem.a022437; Jack DL, 2001, EUR J BIOCHEM, V268, P3620, DOI 10.1046/j.1432-1327.2001.02265.x; JOHN KV, 1977, J BIOL CHEM, V252, P6707; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; Kotake T, 2004, J BIOL CHEM, V279, P45728, DOI 10.1074/jbc.M408716200; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Luders F, 2003, EMBO J, V22, P3635, DOI 10.1093/emboj/cdg345; Luhn K, 2004, EXP CELL RES, V301, P242, DOI 10.1016/j.yexcr.2004.08.043; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Martinez-Duncker I, 2003, BIOCHIMIE, V85, P245, DOI 10.1016/S0300-9084(03)00046-4; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MILLA ME, 1992, J BIOL CHEM, V267, P103; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Moriarity JL, 2002, J BIOL CHEM, V277, P16968, DOI 10.1074/jbc.M109316200; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; Pattathil S, 2005, PLANTA, V221, P538, DOI 10.1007/s00425-004-1471-7; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; SCHWARZ JK, 1984, J BIOL CHEM, V259, P3554; Segawa H, 1999, FEBS LETT, V451, P295, DOI 10.1016/S0014-5793(99)00596-7; Segawa H, 2005, J BIOL CHEM, V280, P2028, DOI 10.1074/jbc.M404915200; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; SOMMERS LW, 1982, J BIOL CHEM, V257, P811; Suda T, 2004, J BIOL CHEM, V279, P26469, DOI 10.1074/jbc.M311353200; WEST DW, 1984, BIOCHEM J, V219, P181, DOI 10.1042/bj2190181; Zhang Wen, 2004, J Biol, V3, P21, DOI 10.1186/jbiol16	63	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27230	27235		10.1074/jbc.M504783200	http://dx.doi.org/10.1074/jbc.M504783200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911612	hybrid			2022-12-25	WOS:000230589500071
J	Ramirez, DC; Mejiba, SEG; Mason, RP				Ramirez, DC; Mejiba, SEG; Mason, RP			Copper-catalyzed protein oxidation and its modulation by carbon dioxide - Enhancement of protein radicals in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; HYDROGEN-PEROXIDE; CU,ZN-SUPEROXIDE DISMUTASE; SUPEROXIDE-DISMUTASE; DEPENDENT HYDROXYL; TRANSITION-METALS; ALBUMIN; BICARBONATE; GENERATION; DAMAGE	It is well known that hydrogen peroxide (H2O2)-induced copper-catalyzed fragmentation of proteins follows a site-specific oxidative mechanism mediated by hydroxyl radical-like species (i.e. Cu(I) O, Cu( II)/(OH)-O-center dot or Cu(III)) that ends in increased carbonyl formation and protein fragmentation. We have found that the nitrone spin trap DMPO ( 5,5-dimethyl-1-pyrroline N-oxide) prevented such processes by trapping human serum albumin (HSA)-centered radicals, in situ and in real time, before they reacted with oxygen. When (bi) carbonate (CO2, H2CO3, HCO3-, and CO3-2) was added to the reaction mixture, it blocked fragmentation mediated by hydroxyl radical-like species but enhanced DMPO-trappable radical sites in HSA. In the past, this effect would have been explained by oxidation of ( bi) carbonate to a carbonate radical anion (CO3radical anion) by a bound hydroxyl radical-like species. We now propose that the CO3radial anion radical is formed by the reduction of HOOCO2- ( a complex of H2O2 with CO2) by the protein- Cu( I) complex. CO3radical anion diffuses and produces more DMPO-trappable radical sites but does not fragment HSA. We were also able, for the first time, to detect discrete but highly specific H2O2-induced copper-catalyzed CO3radical anion-mediated induction of DMPO-trappable protein radicals in functioning RAW 264.7 macrophages. We conclude that carbon dioxide modulates H2O2-induced copper-catalyzed oxidative damage to proteins by preventing site-specific fragmentation and enhancing DMPO-trappable protein radicals in functioning cells. The pathophysiological significance of our findings is discussed.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Ramirez, DC (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, 111 TW Alexander Dr,Bldg 101,MD F0-02, Res Triangle Pk, NC 27709 USA.	ramirez1@niehs.nih.gov	RAMIREZ, DARIO C/K-3312-2013; Mason, Ronald P/G-5967-2019	RAMIREZ, DARIO C/0000-0001-6725-3326; Mason, Ronald P/0000-0002-1859-9109; GOMEZ MEJIBA, SANDRA/0000-0002-8515-0483	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050139, Z01ES050139] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMICI A, 1989, J BIOL CHEM, V264, P3341; Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4; Bal W, 1998, J INORG BIOCHEM, V70, P33, DOI 10.1016/S0162-0134(98)00010-5; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Beshgetoor D, 1998, AM J CLIN NUTR, V67, p1017S, DOI 10.1093/ajcn/67.5.1017S; Bonini MG, 2004, BIOCHEMISTRY-US, V43, P344, DOI 10.1021/bi035606p; BREWER GJ, 1990, NEUROLOGY, V40, P725; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7; Chevion M, 2000, FREE RADICAL RES, V33, pS99; Davies MJ, 2004, FREE RADICAL BIO MED, V36, P1072, DOI 10.1016/j.freeradbiomed.2003.12.013; DEAN RT, 1989, FREE RADICAL RES COM, V7, P97, DOI 10.3109/10715768909087929; Deterding LJ, 2004, J BIOL CHEM, V279, P11600, DOI 10.1074/jbc.M310704200; Detweiler CD, 2002, FREE RADICAL BIO MED, V33, P364, DOI 10.1016/S0891-5849(02)00895-X; Gabaldon M, 2004, ARCH BIOCHEM BIOPHYS, V431, P178, DOI 10.1016/j.abb.2004.08.028; Gaetke LM, 2003, TOXICOLOGY, V189, P147, DOI 10.1016/S0300-483X(03)00159-8; GUTTERIDGE JMC, 1986, BIOCHIM BIOPHYS ACTA, V869, P119, DOI 10.1016/0167-4838(86)90286-4; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776; HALLIWELL B, 1985, PHILOS T ROY SOC B, V311, P659, DOI 10.1098/rstb.1985.0171; Halliwell B, 1996, PATHOL BIOL, V44, P6; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V296, P640, DOI 10.1016/0003-9861(92)90620-C; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V295, P205, DOI 10.1016/0003-9861(92)90507-S; Hawkins CL, 2001, BBA-BIOENERGETICS, V1504, P196, DOI 10.1016/S0005-2728(00)00252-8; He YY, 2003, PHOTOCHEM PHOTOBIOL, V77, P585, DOI 10.1562/0031-8655(2003)077<0585:UHRDBI>2.0.CO;2; Ivanov AI, 2000, J BIOL INORG CHEM, V5, P102, DOI 10.1007/s007750050013; Khan N, 2003, FREE RADICAL BIO MED, V34, P1473, DOI 10.1016/S0891-5849(03)00182-5; Kocha T, 1997, BBA-PROTEIN STRUCT M, V1337, P319, DOI 10.1016/S0167-4838(96)00180-X; KOPPENOL WH, 1987, BIOELECTROCH BIOENER, V18, P3, DOI 10.1016/0302-4598(87)85002-X; LEVINSKY NG, 1994, HARRISONS PRINCIPLES, P253; Lin JM, 1997, JPN J OPHTHALMOL, V41, P130, DOI 10.1016/S0021-5155(97)00030-0; Linder MC, 2001, MUTAT RES-FUND MOL M, V475, P141, DOI 10.1016/S0027-5107(01)00076-8; Liochev SI, 2004, FREE RADICAL BIO MED, V36, P1444, DOI 10.1016/j.freeradbiomed.2004.03.006; Liochev SI, 2004, P NATL ACAD SCI USA, V101, P743, DOI 10.1073/pnas.0307635100; Liochev SI, 2004, P NATL ACAD SCI USA, V101, P12485, DOI 10.1073/pnas.0404911101; Liochev SI, 2004, ARCH BIOCHEM BIOPHYS, V421, P255, DOI 10.1016/j.abb.2003.11.015; Mason RP, 2004, FREE RADICAL BIO MED, V36, P1214, DOI 10.1016/j.freeradbiomed.2004.02.077; Mason RP, 2000, TOXICOLOGY HUMAN ENV, P49; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; Pryor WA, 1997, FREE RADICAL BIO MED, V23, P331, DOI 10.1016/S0891-5849(97)00121-4; Ramirez DC, 2005, FREE RADICAL BIO MED, V38, P201, DOI 10.1016/j.freeradbiomed.2004.10.008; Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5; Sankarapandi S, 1999, J BIOL CHEM, V274, P34576, DOI 10.1074/jbc.274.49.34576; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; Schumann K, 2002, EUR J CLIN NUTR, V56, P469, DOI 10.1038/sj.ejcn.1601315; SENTJURC M, 1995, NITROXIDE SPIN LABEL; Shvedova AA, 2002, CHEM RES TOXICOL, V15, P1451, DOI 10.1021/tx0200313; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; Stadtman ER, 2002, FREE RADICAL BIO MED, V33, P597, DOI 10.1016/S0891-5849(02)00904-8; STADTMAN ER, 1995, METHOD ENZYMOL, V258, P379; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; TACHON P, 1990, FREE RADICAL RES COM, V9, P39, DOI 10.3109/10715769009148571; Tien M, 1999, P NATL ACAD SCI USA, V96, P7809, DOI 10.1073/pnas.96.14.7809; Vesela A, 2002, PHYSIOL RES, V51, P335; Yao HR, 2003, J AM CHEM SOC, V125, P6211, DOI 10.1021/ja0274756; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038	59	63	68	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27402	27411		10.1074/jbc.M504241200	http://dx.doi.org/10.1074/jbc.M504241200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15905164	hybrid			2022-12-25	WOS:000230589500091
J	Hinkovska-Galcheva, V; Boxer, LA; Kindzelskii, A; Hiraoka, M; Abe, A; Goparju, S; Spiegel, S; Petty, HR; Shayman, JA				Hinkovska-Galcheva, V; Boxer, LA; Kindzelskii, A; Hiraoka, M; Abe, A; Goparju, S; Spiegel, S; Petty, HR; Shayman, JA			Ceramide 1-phosphate, a mediator of phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA HL-60 CELLS; FC-GAMMA-RIIA; LIPID RAFTS; APPARENT ROLE; KINASE-ACTIVITY; DOMAINS; PHOSPHORYLATION; CAVEOLINS; PROTEINS; DYNAMICS	The agonist-stimulated metabolism of membrane lipids produces potent second messengers that regulate phagocytosis. We studied whether human ceramide kinase (hCERK) activity and ceramide 1-phosphate formation could lead to enhanced phagocytosis through a mechanism involving modulation of the membrane-structural order parameter. hCERK was stably transfected into COS-1 cells that were stably transfected with the Fc gamma RIIA receptor. hCERK-transfected cells displayed a significant increase in phagocytic index in association with increased ceramide kinase activation and translocation to lipid rafts after activation with opsonized erythrocytes. When challenged with opsonized erythrocytes, hCERK-transfected cells increased phagocytosis by 1.5-fold compared with vector control and simultaneously increased ceramide 1-phosphate levels 2-fold compared with vector and unstimulated control cells. Control and hCERK-transfected cells were subjected to cellular fractionation. Utilizing an antibody against hCERK, we observed that CERK translocates during activation from the cytosol to a lipid raft fraction. The plasma membrane-structural order parameter of the transfectants was measured by labeling cells with Laurdan. Cells transfected with hCERK showed a higher liquid crystalline order than control cells with stimulation, conditions that are favorable for the promotion of membrane fusion at the sites of phagocytosis. The change in the structural order parameter of the lipid rafts probably contributes to phagocytosis by promoting phagosome formation.	Virginia Commonwealth Univ, Dept Pediat, Sch Med, Div Hematol Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Ophthalmol & Visual Sci, Sch Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Internal Med, Sch Med, Div Nephrol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Biochem, Sch Med, Richmond, VA 23298 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Michigan System; University of Michigan	Shayman, JA (corresponding author), 1150 W Med Ctr Dr,1560 MSRB II, Ann Arbor, MI 48109 USA.				NIAID NIH HHS [AI20065] Funding Source: Medline; NIDDK NIH HHS [DK055823] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055823] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; Blackwood RA, 1996, J LEUKOCYTE BIOL, V59, P663, DOI 10.1002/jlb.59.5.663; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hinkovska-Galcheva V, 1998, BLOOD, V91, P4761, DOI 10.1182/blood.V91.12.4761.412k24_4761_4769; Hinkovska-Galcheva V, 2003, J BIOL CHEM, V278, P974, DOI 10.1074/jbc.M206199200; Hinkovska-Galcheva VT, 1998, J BIOL CHEM, V273, P33203, DOI 10.1074/jbc.273.50.33203; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Kindzelskii AL, 2004, J IMMUNOL, V172, P4681, DOI 10.4049/jimmunol.172.8.4681; Kindzelskii AL, 2002, P NATL ACAD SCI USA, V99, P9207, DOI 10.1073/pnas.132630999; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; Kwiatkowska K, 2003, J CELL SCI, V116, P537, DOI 10.1242/jcs.00254; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; Mitsutake S, 2004, J BIOL CHEM, V279, P17570, DOI 10.1074/jbc.M312885200; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ottico E, 2003, J LIPID RES, V44, P2142, DOI 10.1194/jlr.M300247-JLR200; PAPAHADJOPOULOS D, 1977, BIOCHIM BIOPHYS ACTA, V465, P579, DOI 10.1016/0005-2736(77)90275-9; Parasassi T, 1997, BIOPHYS J, V72, P2413, DOI 10.1016/S0006-3495(97)78887-8; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; Shakor ABA, 2004, J BIOL CHEM, V279, P36778, DOI 10.1074/jbc.M402170200; SHINGHAL R, 1993, J NEUROCHEM, V61, P2279, DOI 10.1111/j.1471-4159.1993.tb07470.x; Shu LM, 2000, ARCH BIOCHEM BIOPHYS, V373, P83, DOI 10.1006/abbi.1999.1553; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Suchard SJ, 1997, BLOOD, V89, P2139, DOI 10.1182/blood.V89.6.2139; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200; VANVELDHOVEN PP, 1995, BIOCHEM MOL BIOL INT, V36, P21; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Worth RG, 2003, P NATL ACAD SCI USA, V100, P4533, DOI 10.1073/pnas.0836650100	34	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26612	26621		10.1074/jbc.M501359200	http://dx.doi.org/10.1074/jbc.M501359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899891	hybrid			2022-12-25	WOS:000230386800078
J	Greenberg, VL; Zimmer, SG				Greenberg, VL; Zimmer, SG			Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism	ONCOGENE			English	Article						translation; eIF-4E; 4E-BP1; paclitaxel; cdk1; G2/M arrest; cyclin B	CAP-BINDING PROTEIN; INDUCED CELL-DEATH; MESSENGER-RNA; OVARIAN-CANCER; FACTOR EIF-4E; DEPENDENT PHOSPHORYLATION; PHOSPHATASE 2A; (S/T)P SITES; S6 KINASE; FACTOR 4E	Initial chemotherapeutic treatment triggers a stress-related response, which can lead to an increase in the expression of survival proteins. In this study we examine whether paclitaxel (PTX) alters the expression and/ or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state. We found that PTX induced the hyperphosphorylation of 4E-BP1 in the breast cancer cell line, MDA MB 231, which reduced its association with eIF-4E, but did not alter the expression and phosphorylation of eIF-4E. The hyperphosphorylation of 4E-BP1 correlated with G2/M accumulation and with an increase in the phosphorylation of cdk1 substrates. Cotreatment with a histone deacetylase inhibitor (an indirect inhibitor of cdk activity), purvalanol A and roscovitine (direct cdk inhibitors), and the reduction of cyclin B expression using RNA interference decreased the hyperphosphorylation of 4E-BP1 in PTX treated cells. The hyperphosphorylation of 4E-BP1 by PTX increased the association of eIF- 4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association of eIF-4E with eIF-4G in PTX treated cells. Taken together, our data suggest that PTX-increases the functional level of eIF-4E by promoting the hyperphosphorylation and release of 4E-BP1 through a cdk1-dependent mechanism.	Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA	University of Kentucky	Zimmer, SG (corresponding author), Univ Kentucky, Dept Microbiol Immunol & Mol Genet, 800 Rose St, Lexington, KY 40536 USA.	szimm1@uky.edu			NATIONAL CANCER INSTITUTE [R01CA077614] Funding Source: NIH RePORTER; NCI NIH HHS [CA77614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Asnaghi L, 2004, PHARMACOL RES, V50, P545, DOI 10.1016/j.phrs.2004.03.007; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Chobanian NH, 2004, ANTICANCER RES, V24, P539; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; du Bois A, 2001, EUR J CANCER, V37, pS1; Ferlini C, 2003, MOL PHARMACOL, V64, P51, DOI 10.1124/mol.64.1.51; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Greenberg VL, 2001, THYROID, V11, P315, DOI 10.1089/10507250152039046; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038/sj.onc.1206409; Herbert TP, 2000, CURR BIOL, V10, P793, DOI 10.1016/S0960-9822(00)00567-4; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Meric F, 2002, MOL CANCER THER, V1, P971; Minamoto T, 2001, CRIT REV ONCOL HEMAT, V40, P195, DOI 10.1016/S1040-8428(01)00098-1; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Shapiro GI, 2004, CLIN CANCER RES, V10, p4270S, DOI 10.1158/1078-0432.CCR-040020; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogel C L, 1999, Oncologist, V4, P17; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	52	30	33	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4851	4860		10.1038/sj.onc.1208624	http://dx.doi.org/10.1038/sj.onc.1208624			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897904				2022-12-25	WOS:000230477900012
J	Salsmann, A; Schaffner-Reckinger, E; Kabile, F; Plancon, S; Kieffer, N				Salsmann, A; Schaffner-Reckinger, E; Kabile, F; Plancon, S; Kieffer, N			A new functional role of the fibrinogen RGD motif as the molecular switch that selectively triggers integrin alpha IIb beta 3-dependent RhoA activation during cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PROTEIN-TYROSINE KINASES; SURFACE-BOUND FIBRINOGEN; CARBOXY-TERMINAL SEGMENT; CYSTEINE-RICH REPEAT; INTEGRIN ALPHA(IIB)BETA(3); GAMMA-CHAIN; LIGAND-BINDING; PLATELET-AGGREGATION; CYTOPLASMIC DOMAIN	A number of RGD-type integrins rely on a synergistic site in addition to the canonical RGD site for ligand binding and signaling, although it is still unclear whether these two recognition sites function independently, synergistically, or competitively. Experimental evidence has suggested that fibrinogen binding to the RGD-type integrin alpha IIb beta 3 occurs exclusively through the synergistic gamma(400-411) sequence, thus questioning the functional role of the RGD recognition site. Here we have investigated the respective role of the fibrinogen gamma(400-411) sequence and the RGD motif in the molecular events leading to ligand-induced alpha IIb beta 3-dependent Chinese hamster ovary (CHO) cell or platelet spreading, by using intact fibrinogen and well characterized plasmin-generated fibrinogen fragments containing either the RGD motif ( fragment C) or the gamma(400-411) sequence ( fragment D), and CHO cells expressing resting wild type (alpha IIb beta 3wt), constitutively active (alpha IIb beta 3T562N), or non-functional (alpha IIb beta 3D119Y) receptors. Our data provide evidence that the gamma(400-411) site by itself is able to initiate alpha IIb beta 3 clustering and recruitment of intracellular proteins to early focal complexes, mediating cell attachment, FAK phosphorylation, and Rac1 activation, while the RGD motif subsequently acts as a molecular switch on the beta 3 subunit to trigger cell spreading. More importantly, we show that the premier functional role of the RGD site is not to reinforce cell attachment but, rather, to imprint a conformational change on the beta 3 subunit leading to maximal RhoA activation and actin cytoskeleton organization in CHO cells as well as in platelets. Finally, alpha IIb beta 3-dependent RhoA stimulation and cell spreading, but not cell attachment, are Src-dependent and phosphoinositide 3-kinase-independent and are inhibited by the Src antagonist PP2.	Univ Luxembourg, CNRS, GDRE IT, Lab Biol & Physiol Integree, L-1511 Luxembourg, Luxembourg	University of Luxembourg	Kieffer, N (corresponding author), Univ Luxembourg, CNRS, GDRE IT, Lab Biol & Physiol Integree, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	nelly.kieffer@uni.lu						Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Bennett JS, 2001, ANN NY ACAD SCI, V936, P340; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BINI A, 2000, ENCY REFERENCE VASCU, P107; Chen P, 2001, J BIOL CHEM, V276, P38628, DOI 10.1074/jbc.M105737200; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; Cierniewski CS, 1999, J BIOL CHEM, V274, P16923, DOI 10.1074/jbc.274.24.16923; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Corbett SA, 1999, J BIOL CHEM, V274, P20943, DOI 10.1074/jbc.274.30.20943; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; de Virgilio M, 2004, J CELL BIOL, V165, P305, DOI 10.1083/jcb.200402064; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; French DL, 2000, ARTERIOSCL THROM VAS, V20, P607, DOI 10.1161/01.ATV.20.3.607; GARTNER TK, 1993, THROMB RES, V71, P47; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Holmback K, 1996, EMBO J, V15, P5760, DOI 10.1002/j.1460-2075.1996.tb00962.x; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Kashiwagi H, 1999, BLOOD, V93, P2559, DOI 10.1182/blood.V93.8.2559.408k12_2559_2568; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KIEFFER N, 1991, BLOOD, V78, pA281; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; Miao H, 2002, J CELL SCI, V115, P2199; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Payrastre B, 2000, BIOCHEM PHARMACOL, V60, P1069, DOI 10.1016/S0006-2952(00)00417-2; Plancon S, 2001, BIOCHEM J, V357, P529, DOI 10.1042/0264-6021:3570529; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1995, J BIOL CHEM, V270, P28812, DOI 10.1074/jbc.270.48.28812; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schoenwaelder SM, 2002, J BIOL CHEM, V277, P14738, DOI 10.1074/jbc.M200661200; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMITH JW, 1990, J BIOL CHEM, V265, P12267; STRICKLAND DK, 1982, BIOCHEMISTRY-US, V21, P721, DOI 10.1021/bi00533a021; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200; Zaidi TN, 1996, BLOOD, V88, P2967, DOI 10.1182/blood.V88.8.2967.bloodjournal8882967	58	44	46	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33610	33619		10.1074/jbc.M500146200	http://dx.doi.org/10.1074/jbc.M500146200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	15955823	hybrid			2022-12-25	WOS:000232058100062
J	Hwang, SG; Yu, SS; Poo, H; Chun, JS				Hwang, SG; Yu, SS; Poo, H; Chun, JS			c-Jun/activator protein-1 mediates interleukin-1 beta-induced dedifferentiation but not cyclooxygenase-2 expression in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; GENE-EXPRESSION; FOS; AP-1; CARTILAGE; CELL; JUN; INHIBITION; KINASE; TARGET	Interleukin (IL)-1 beta is a major catabolic pro-inflammatory cytokine involved in cartilage destruction-associated processes, such as loss of the differentiated chondrocyte phenotype ( dedifferentiation) and inflammation. Here, we investigated the role of c-Jun and activator protein-1 (AP-1) in IL-1 beta-induced dedifferentiation and cyclooxygenase ( COX)-2 expression in primary cultured chondrocytes. IL-1 beta induced expression and transient phosphorylation of c-Jun in primary cultured chondrocytes. Ectopic expression of c-Jun was sufficient to cause dedifferentiation, whereas expression of dominant negative c-Jun blocked IL-1 beta-induced dedifferentiation. Interestingly, modulation of c-Jun expression did not affect IL-1 beta-induced COX-2 expression. Further experiments revealed that c-Jun phosphorylation was mediated by c-Jun N-terminal kinase and was required for IL-1 beta-induced dedifferentiation but not COX-2 expression. Consistent with its ability to induce phosphorylation of c-Jun, IL-1 beta caused transient activation of AP-1, which is necessary for IL-1 beta-induced dedifferentiation. IL-1 beta treatment suppressed expression of Sox-9, a major transcription factor that regulates type II collagen expression. Inhibition of c-Jun N-terminal kinase or AP-1 reversed IL-1 beta-induced suppression of Sox- 9, and ectopic expression of c-Jun was sufficient to cause suppression of Sox-9. Our results collectively suggest that IL-1 beta suppresses type II collagen expression in articular chondrocytes by inducing expression and phosphorylation of c-Jun, AP-1 activation, and subsequent suppression of Sox-9.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Korea Res Inst Biosci & Biotechnol, Proteome Res Lab, Taejon 305600, South Korea	Gwangju Institute of Science & Technology (GIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Chun, JS (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.	jschun@gist.ac.kr						Abramson SB, 1999, OSTEOARTHR CARTILAGE, V7, P380, DOI 10.1053/joca.1998.0217; Abulencia JP, 2003, J BIOL CHEM, V278, P28388, DOI 10.1074/jbc.M301378200; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Behrens A, 2003, DEVELOPMENT, V130, P103, DOI 10.1242/dev.00186; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BERGELSON S, 1994, CANCER RES, V54, P36; Clancy R, 2001, OSTEOARTHR CARTILAGE, V9, P294, DOI 10.1053/joca.2000.0388; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; Hess J, 2003, J CELL SCI, V116, P4587, DOI 10.1242/jcs.00772; Ionescu AM, 2001, J BIOL CHEM, V276, P11639, DOI 10.1074/jbc.M006564200; JACENKO O, 1995, BIOESSAYS, V17, P277, DOI 10.1002/bies.950170402; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kameda T, 1997, CELL GROWTH DIFFER, V8, P495; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kojima F, 2004, ARTHRITIS RES THER, V6, pR355, DOI 10.1186/ar1195; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Martel-Pelletier J, 1999, FRONT BIOSCI, V4, pD694; Miyazaki Y, 2000, OSTEOARTHR CARTILAGE, V8, P378, DOI 10.1053/joca.1999.0313; Moritani NH, 2003, J BONE MINER METAB, V21, P205, DOI 10.1007/s00774-003-0410-1; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Thomas DP, 2000, J CELL SCI, V113, P439; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; Tsuji M, 1996, FEBS LETT, V381, P222, DOI 10.1016/0014-5793(96)00118-4; Tufan AC, 2002, EXP CELL RES, V273, P197, DOI 10.1006/excr.2001.5448; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P3994, DOI 10.1073/pnas.94.8.3994; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	41	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29780	29787		10.1074/jbc.M411793200	http://dx.doi.org/10.1074/jbc.M411793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15961395	hybrid			2022-12-25	WOS:000231176200048
J	Lee, FYI; Kim, DW; Karmin, JA; Hong, DW; Chang, SS; Fujisawa, M; Takayanagi, H; Bigliani, LU; Blaine, TA; Lee, HJ				Lee, FYI; Kim, DW; Karmin, JA; Hong, DW; Chang, SS; Fujisawa, M; Takayanagi, H; Bigliani, LU; Blaine, TA; Lee, HJ			mu-Calpain regulates receptor activator of NF-kappa B ligand (RANKL)-supported osteoclastogenesis via NF-kappa B activation in RAW 264.7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; IN-VITRO; C-FOS; DIFFERENTIATION; PROTEOLYSIS; INHIBITION; PATHWAY; CALPASTATIN; TRANCE	To clarify the role of calpain in the receptor activator of NF-kappa beta ligand (RANKL)-supported osteoclastogenesis, RANKL-induced calpain activation was examined by using murine RAW 264.7 cells and bone marrow-derived monocyte/macrophage progenitors. We found that calpain activity increased in response to RANKL in both cell types based on alpha-spectrinolysis and that alpha-calpain, rather than m-calpain, was activated during RANKL-supported osteoclastogenesis in RAW 264.7 cells. Overexpression of mu-calpain clearly augmented RANKL-supported osteoclastogenesis in RAW 264.7 cells, thereby implicating its pivotal role in this process. Cell-permeable calpain inhibitors, including calpastatin and calpeptin, were sufficient to suppress RANKL-supported osteoclastogenesis based on decreased expression of the osteoclastogenic marker, matrix metalloproteinase 9, and the generation of tartrate-resistant acid phosphatase-positive multinucleated cells in both cell types. Calpain inhibitors suppressed NF-kappa B activation via inhibition of the cleavage of inhibitor of NF-kappa B (I kappa B alpha) in RAW 264.7 cells. Taken together, our findings suggest that mu-calpain is essential to the regulation of RANKL-supported osteoclastogenesis via NF-kappa B activation.	Columbia Univ, Coll Phys & Surg, Dept Orthopaed Surg, Ctr Orthopaed Res, New York, NY 10032 USA; Tokyo Med & Dent Univ, Grad Sch, Dept Cellular Physiol Chem, Bunkyo Ku, Tokyo 1138549, Japan; COE Program Frontier Res Mol Destruct & Resconstr, Bunkyo Ku, Tokyo 1138549, Japan	Columbia University; Tokyo Medical & Dental University (TMDU)	Lee, HJ (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Orthopaed Surg, Ctr Orthopaed Res, 630 W 168th,BB14-1411, New York, NY 10032 USA.	hl2004@columbia.edu						Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940; Chikazu D, 2001, J BONE MINER RES, V16, P2074, DOI 10.1359/jbmr.2001.16.11.2074; Chung H, 2001, J KOREAN MED SCI, V16, P769, DOI 10.3346/jkms.2001.16.6.769; Clohisy JC, 2004, J ORTHOPAED RES, V22, P13, DOI 10.1016/S0736-0266(03)00156-6; Deyama Y, 2002, BIOCHEM BIOPH RES CO, V298, P240, DOI 10.1016/S0006-291X(02)02440-3; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; JarielEncontre I, 1997, MOL BIOL REP, V24, P51, DOI 10.1023/A:1006804723722; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kunimatsu M, 1999, CARDIOVASC PATHOL, V8, P7, DOI 10.1016/S1054-8807(98)00018-0; Landman N, 2004, CYTOKINE GROWTH F R, V15, P337, DOI 10.1016/j.cytogfr.2004.04.001; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756-3282(02)00683-X; Milligan SA, 1996, ARCH BIOCHEM BIOPHYS, V335, P388, DOI 10.1006/abbi.1996.9998; Murray SS, 1997, EXP CELL RES, V233, P297, DOI 10.1006/excr.1997.3550; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; Rubin J, 2002, J CLIN ENDOCR METAB, V87, P4273, DOI 10.1210/jc.2002-020656; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290; Wendt A, 2004, BIOL CHEM, V385, P465, DOI 10.1515/BC.2004.054; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355	34	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29929	29936		10.1074/jbc.M414600200	http://dx.doi.org/10.1074/jbc.M414600200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15955824	hybrid			2022-12-25	WOS:000231176200065
J	Mueller, A; Schafer, BW; Ferrari, S; Weibel, M; Makek, M; Hochli, M; Heizmann, CW				Mueller, A; Schafer, BW; Ferrari, S; Weibel, M; Makek, M; Hochli, M; Heizmann, CW			The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE TUMOR-SUPPRESSOR; SQUAMOUS-CELL CARCINOMA; AMINO-ACID-SEQUENCE; SUBCELLULAR-LOCALIZATION; PROGNOSTIC-SIGNIFICANCE; EPITHELIAL TUMORS; ANTIBODY-RESPONSE; BREAST-CANCER; EXPRESSION; HEAD	Head and neck squamous cell carcinoma express high levels of the EF-hand calcium-binding protein S100A2 in contrast to other tumorigenic tissues and cell lines where the expression of this protein is reduced. Subtractive hybridization of tumorigenic versus normal tumor-derived mammary epithelial cells has previously identified the S100A2 protein as potential tumor suppressor. The biological function of S100A2 in carcinogenesis, however, has not been elucidated to date. Here, we report for the first time that during recovery from hydroxyurea treatment, the S100A2 protein translocated from the cytoplasm to the nucleus and co-localized with the tumor suppressor p53 in two different oral carcinoma cells (FADU and SCC-25). Co-immunoprecipitation experiments and electrophoretic mobility shift assay showed that the interaction between S100A2 and p53 is Ca2+-dependent. Preliminary characterization of this interaction indicated that the region in p53 involved with binding to S100A2 is located at the C terminus of p53. Finally, luciferase-coupled transactivation assays, where a p53-reporter construct was used, indicated that interaction with S100A2 increased p53 transcriptional activity. Our data suggest that in oral cancer cells the Ca2+-and cell cycle- dependent p53-S100A2 interaction might modulate proliferation.	Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; Dept Pediat, Div Oncogen, CH-8032 Zurich, Switzerland; Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; Pathol Inst Biopt Diagnost, CH-8029 Zurich, Switzerland; Univ Zurich, Ctr Microsc, CH-8006 Zurich, Switzerland	University of Zurich; University of Zurich	Heizmann, CW (corresponding author), Dept Pediat, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	claus.heizmann@kispi.unizh.ch	Ferrari, Stefano/I-7357-2016	Ferrari, Stefano/0000-0002-6607-215X; Schafer, Beat/0000-0001-5988-2915				Atema A, 2002, CANCER LETT, V185, P103, DOI 10.1016/S0304-3835(02)00318-X; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bhattacharya S, 2004, BBA-MOL CELL RES, V1742, P69, DOI 10.1016/j.bbamcr.2004.09.002; BOSARI S, 1995, AM J PATHOL, V147, P790; Bosch FX, 2004, INT J CANCER, V111, P530, DOI 10.1002/ijc.11698; Bronckart Y, 2001, HISTOL HISTOPATHOL, V16, P707, DOI 10.14670/HH-16.707; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Chene P, 1999, INT J CANCER, V82, P17, DOI 10.1002/(SICI)1097-0215(19990702)82:1<17::AID-IJC4>3.0.CO;2-6; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Deshpande R, 2000, J INVEST DERMATOL, V115, P477, DOI 10.1046/j.1523-1747.2000.00078.x; Feng G, 2001, CANCER RES, V61, P7999; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; Franz C, 1998, J BIOL CHEM, V273, P18826, DOI 10.1074/jbc.273.30.18826; FRITZ G, 2004, HDB METALLOPROTEINS, V3, P529; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gleich LL, 1996, LARYNGOSCOPE, V106, P1378, DOI 10.1097/00005537-199611000-00013; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; Green A R, 1999, Haematologica, V84 Suppl EHA-4, P36; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hibi K, 2003, CLIN CANCER RES, V9, P4282; Hoffmann TK, 2002, CANCER RES, V62, P3521; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Ilg EC, 1996, BIOCHEM BIOPH RES CO, V225, P146, DOI 10.1006/bbrc.1996.1144; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koch WM, 1996, JNCI-J NATL CANCER I, V88, P1580, DOI 10.1093/jnci/88.21.1580; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lauriola L, 2000, INT J CANCER, V89, P345, DOI 10.1002/1097-0215(20000720)89:4<345::AID-IJC5>3.0.CO;2-T; Lavieille JP, 1998, ORAL ONCOL, V34, P84, DOI 10.1016/S1368-8375(97)00054-7; Lavieille JP, 1996, ANTICANCER RES, V16, P2385; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; Lin J, 2004, J BIOL CHEM, V279, P34071, DOI 10.1074/jbc.M405419200; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; Maelandsmo GM, 1997, INT J CANCER, V74, P464, DOI 10.1002/(SICI)1097-0215(19970822)74:4<464::AID-IJC19>3.0.CO;2-9; Mandinova A, 1998, J CELL SCI, V111, P2043; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Mueller A, 1999, HISTOCHEM CELL BIOL, V111, P453, DOI 10.1007/s004180050381; Nagy N, 2002, HISTOL HISTOPATHOL, V17, P123, DOI 10.14670/HH-17.123; Nagy N, 2001, LAB INVEST, V81, P599, DOI 10.1038/labinvest.3780269; NYLANDER K, 1995, CANCER, V75, P87, DOI 10.1002/1097-0142(19950101)75:1<87::AID-CNCR2820750115>3.0.CO;2-V; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Park HR, 2003, J CUTAN PATHOL, V30, P373, DOI 10.1034/j.1600-0560.2003.00081.x; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; RaybaudDiogene H, 1996, ORAL ONCOL, V32B, P143; Rich TA, 2004, J CLIN ONCOL, V22, P2214, DOI 10.1200/JCO.2004.08.009; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Scotto C, 1999, MOL CELL BIOL, V19, P7168; Shrestha P, 1998, VIRCHOWS ARCH, V432, P53, DOI 10.1007/s004280050134; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; TAYLOR DA, 1989, J BIOL CHEM, V264, P6207; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4; Wilder PT, 1998, PROTEIN SCI, V7, P794, DOI 10.1002/pro.5560070330; Zhang T, 2002, J INVEST DERMATOL, V119, P1196, DOI 10.1046/j.1523-1747.2002.19520.x	63	114	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29186	29193		10.1074/jbc.M505000200	http://dx.doi.org/10.1074/jbc.M505000200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15941720	hybrid, Green Accepted			2022-12-25	WOS:000231021300046
J	Zhu, HY; Nie, LH; Maki, CG				Zhu, HY; Nie, LH; Maki, CG			Cdk2-dependent inhibition of p21 stability via a C-terminal cyclin-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILIZATION; DEPENDENT KINASES; P21(WAF1/CIP1) EXPRESSION; PROTEASOMAL TURNOVER; CDK INHIBITORS; UV-LIGHT; S-PHASE; PROTEIN; CELLS; DEGRADATION	p21 is a member of the Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors that includes p21, p27, and p57. Recent studies have suggested that Cdk2 activity may promote p21 degradation through a pathway similar to that for p27, although the mechanism by which this occurs has not been clarified. In the current report, co-expression with cyclin E and Cdk2 stabilized p21 in a manner that required the CDK-binding site of p21 and a cyclin-binding site (cy1) located in the p21 N terminus. Strikingly, however, a kinase-dead Cdk2 mutant stabilized p21 to a greater extent than did wild-type Cdk2, consistent with the notion that Cdk2 activity can destabilize p21. The ability of wild-type Cdk2 to destabilize p21 required a potential Cdk2 phosphorylation site in p21 at serine 130 and an intact cyclin-binding motif (cy2) in the p21 C terminus. Finally, p21 was phosphorylated by Cdk2 at Ser-130 in vitro, and this ability of Cdk2 to phosphorylate p21 was dependent, in large part, on the presence of cy2. These results support a model in which active Cdk2 destabilizes p21 via the cy2 cyclin-binding motif and p21 phosphorylation.	Univ Chicago, Ctr Mol Oncol, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Ctr Mol Oncol, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave,MC 1105,Rm G-06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu						Adams PD, 1996, MOL CELL BIOL, V16, P6623; Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deshaies RJ, 2001, CELL, V107, P819, DOI 10.1016/S0092-8674(01)00620-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukuchi K, 2002, BIOCHEM BIOPH RES CO, V293, P120, DOI 10.1016/S0006-291X(02)00198-5; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li XS, 1996, CANCER RES, V56, P5055; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	44	38	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29282	29288		10.1074/jbc.M407352200	http://dx.doi.org/10.1074/jbc.M407352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15964852	hybrid			2022-12-25	WOS:000231021300059
J	Ellis, CD; MacDiarmid, CW; Eide, DJ				Ellis, CD; MacDiarmid, CW; Eide, DJ			Heteromeric protein complexes mediate zinc transport into the secretory pathway of eukaryotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; FUNCTIONAL-CHARACTERIZATION; GENE-EXPRESSION; BUDDING YEAST; DNAJ HOMOLOG; FAMILY; IDENTIFICATION; OVEREXPRESSION	The cation diffusion facilitator ( CDF) family of metal ion transporters plays important roles in zinc transport at all phylogenetic levels. In this report, we describe a novel interaction between two members of the CDF family in Saccharomyces cerevisiae. One CDF member in yeast, Msc2p, was shown recently to be involved in zinc transport into the endoplasmic reticulum ( ER) and required for ER function. We describe here a newly recognized CDF family member in yeast, Zrg17p. ZRG17 was previously identified as a zinc-regulated gene controlled by the zinc-responsive Zap1p transcription factor. A zrg17 mutant exhibits the same zinc-suppressible phenotypes as an msc2 mutant, including an induction of the unfolded protein response in low zinc. Moreover, a significant fraction of the total Zrg17p protein appears to localize to the ER. Their common phenotypes and localization suggested that these two proteins function together to mediate zinc transport into the ER. Consistent with this hypothesis, Msc2p and Zrg17p physically interact with each other, as determined by co-immunoprecipitation. Therefore, we propose that Msc2p and Zrg17p form a heteromeric zinc transport complex in the ER membrane. We also demonstrate that ZnT5 and ZnT6, mammalian homologues of Msc2p and Zrg17p, functionally interact as well. These results suggest that heteromeric complexes formed by different CDF members may be a common phenomenon for this ubiquitous family of metal ion transporters.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Eide, DJ (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr,Rm 340B, Madison, WI 53706 USA.	eide@nutrisci.wisc.edu	MacDiarmid, Colin/AAV-5920-2021	MacDiarmid, Colin/0000-0001-8578-5756	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285, R01GM069786] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07665] Funding Source: Medline; NIGMS NIH HHS [GM56285, GM69786] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bauer A, 2003, EUR J BIOCHEM, V270, P570, DOI 10.1046/j.1432-1033.2003.03428.x; Blaudez D, 2003, PLANT CELL, V15, P2911, DOI 10.1105/tpc.017541; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; Devergnas S, 2004, BIOCHEM PHARMACOL, V68, P699, DOI 10.1016/j.bcp.2004.05.024; Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Galperin MY, 2001, PROTEINS, V45, P318, DOI 10.1002/prot.1152; Gao CY, 2000, BIOTECHNIQUES, V29, P1226, DOI 10.2144/00296st02; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; HUANG XF, 1995, J BIOL CHEM, V270, P20417, DOI 10.1074/jbc.270.35.20417; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; Li LT, 1997, J BIOL CHEM, V272, P28485, DOI 10.1074/jbc.272.45.28485; Linke K, 2003, J BIOL CHEM, V278, P44457, DOI 10.1074/jbc.M307491200; LIU HP, 1992, GENETICS, V132, P665; Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MacDiarmid CW, 2002, J BIOL CHEM, V277, P39187, DOI 10.1074/jbc.M205052200; Mann KJ, 2001, BIOCHEMISTRY-US, V40, P1205, DOI 10.1021/bi0024512; Mrsa V, 1999, YEAST, V15, P813, DOI 10.1002/(SICI)1097-0061(199907)15:10A<813::AID-YEA421>3.0.CO;2-Y; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Rock KL, 2004, NAT IMMUNOL, V5, P670, DOI 10.1038/ni1089; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P3671, DOI 10.1073/pnas.89.9.3671; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Seve M, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-32; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Silberstein S, 1998, J CELL BIOL, V143, P921, DOI 10.1083/jcb.143.4.921; Suzuki T, 2005, J BIOL CHEM, V280, P637, DOI 10.1074/jbc.M411247200; Toh-e A, 1999, GENES GENET SYST, V74, P241, DOI 10.1266/ggs.74.241; van der Zaal BJ, 1999, PLANT PHYSIOL, V119, P1047, DOI 10.1104/pp.119.3.1047; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; Wei YN, 2004, J BIOL CHEM, V279, P39251, DOI 10.1074/jbc.M407044200; Yuan DS, 2000, GENETICS, V156, P45; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	50	87	88	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28811	28818		10.1074/jbc.M505500200	http://dx.doi.org/10.1074/jbc.M505500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15961382	hybrid			2022-12-25	WOS:000230857300073
J	Gray, SG; Iglesias, AH; Lizcano, F; Villanueva, R; Camelo, S; Jingu, H; Teh, BT; Koibuchi, N; Chin, WW; Kokkotou, E; Dangond, F				Gray, SG; Iglesias, AH; Lizcano, F; Villanueva, R; Camelo, S; Jingu, H; Teh, BT; Koibuchi, N; Chin, WW; Kokkotou, E; Dangond, F			Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; GENE; FAMILY; IDENTIFICATION; EXPRESSION; CLONING; COMPLEX; TUDOR; E2F; TRICHOSTATIN	To effectively direct targeted repression, the class I histone deacetylases ( HDACs) associate with many important regulatory proteins. In this paper we describe the molecular characterization of a member of the Jumonji domain 2 ( JMJD2) family of proteins, and demonstrate its binding to both class I HDACs and the retinoblastoma protein ( pRb). JMJD2 proteins are characterized by the presence of two leukemia-associated protein/plant homeodomain ( LAP/PHD) zinc fingers, one JmjN, one JmjC ( containing an internal retinoblastoma-binding protein 2 ( RBBP2)-like sequence), and two Tudor domains. The first member of this group, JMJD2A, is widely expressed in human tissues and cell lines, and high endogenous expression of JMJD2A mRNA was found in several cell types, including human T-cell lymphotropic virus 1 ( HTLV-1)-infected cell lines. JMJD2A and JMJD2B exhibit cell type-specific responses to the HDAC inhibitor trichostatin A. We show that the JMJD2A protein associates in vivo with pRb and class I HDACs, and mediates repression of E2F-regulated promoters. In HTLV-1 virus-infected cells, we find that JMJD2A binds to the viral Tax protein. Antibodies to JMJD2A recognize the native protein but also a half-sized protein fragment, the latter up-regulated in THP-1 cells during the G(2)/M phase of the cell cycle. The ability of JMJD2A to associate with pRb and HDACs and potentiate pRb-mediated repression of E2F-regulated promoters implies an important role for this protein in cell proliferation and oncogenesis.	Brigham & Womens Hosp Labs, Lab Transcript & Immune Regulat, Cambridge, MA 02139 USA; Hagedorn Res Inst, Receptor Biol Lab, DK-2820 Gentofte, Denmark; Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; St James Hosp, Thorac Oncol Res Grp, Dept Oncol, Dublin, Ireland; St James Hosp, Dept Clin Med, Inst Mol Med, Trinity Sci Hlth Ctr, Dublin, Ireland; La Sabana Univ, Sch Med, Mol Biol Lab, Bogota, Colombia; Gunma Univ, Sch Med, Dept Physiol, Maebashi, Gumma 3718511, Japan; Eli Lilly Co, Gene Regulat Res, Indianapolis, IN 46285 USA; Harvard Univ, Sch Med, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Macromol Crystallog Unit, Div Expt Med,Dept Med,Beth Israel Deaconess Med C, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Novo Nordisk; Hagedorn Research Institute; Van Andel Institute; Trinity College Dublin; Trinity College Dublin; Universidad de La Sabana; Gunma University; Eli Lilly; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Dangond, F (corresponding author), Brigham & Womens Hosp Labs, Lab Transcript & Immune Regulat, 3rd Floor,65 Landsdowne St, Cambridge, MA 02139 USA.	fdangond@rics.bwh.harvard.edu	Lizcano, Fernando/B-5349-2012; Gray, Steven G./I-3081-2019; Lizcano, Fernando/AAZ-9598-2020	Gray, Steven G./0000-0002-5850-6392; Lizcano, Fernando/0000-0002-2414-6894; Camelopiragua, Sandra/0000-0002-9606-9402; Koibuchi, Noriyuki/0000-0002-2247-9740; Teh, Bin Tean/0000-0003-1514-1124				Ahmed S, 2004, MOL CELL BIOL, V24, P3660, DOI 10.1128/MCB.24.9.3660-3669.2004; Balciunas D, 2000, TRENDS BIOCHEM SCI, V25, P274, DOI 10.1016/S0968-0004(00)01593-0; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; GOLUMBESKI GS, 1991, GENE DEV, V5, P2060, DOI 10.1101/gad.5.11.2060; Gray S. G., 2001, Current Molecular Medicine (Hilversum), V1, P401, DOI 10.2174/1566524013363537; Gray SG, 2004, INT J ONCOL, V24, P773; Gray SG, 2003, GENE EXPRESSION, V11, P13, DOI 10.3727/000000003783992342; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Gray SG, 1998, BIOCHEM BIOPH RES CO, V245, P423, DOI 10.1006/bbrc.1998.8449; Gray SG, 1999, EXP CELL RES, V253, P618, DOI 10.1006/excr.1999.4661; Green VJ, 1998, J BIOL CHEM, V273, P29950, DOI 10.1074/jbc.273.45.29950; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Katoh M, 2004, INT J ONCOL, V24, P1623; KOIBUCHI N, 1991, ENDOCRINOLOGY, V129, P3208, DOI 10.1210/endo-129-6-3208; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Laj A, 1999, MOL CELL BIOL, V19, P6632; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Noh B, 2004, PLANT CELL, V16, P2601, DOI 10.1105/tpc.104.025353; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Sun Y, 2005, HUM MUTAT, V25, P64, DOI 10.1002/humu.20111; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yang L, 2003, BIOCHEM J, V369, P651, DOI 10.1042/BJ20020854; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang ZQ, 2000, CANCER RES, V60, P4735; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	50	103	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28507	28518		10.1074/jbc.M413687200	http://dx.doi.org/10.1074/jbc.M413687200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15927959	hybrid, Green Published			2022-12-25	WOS:000230857300041
J	Lee, H; Jun, DJ; Suh, BC; Choi, BH; Lee, JH; Do, MS; Suh, BS; Ha, HJ; Kim, KT				Lee, H; Jun, DJ; Suh, BC; Choi, BH; Lee, JH; Do, MS; Suh, BS; Ha, HJ; Kim, KT			Dual roles of P2 purinergic receptors in insulin-stimulated leptin production and lipolysis in differentiated rat white adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; SYMPATHETIC-NERVOUS-SYSTEM; OB GENE-EXPRESSION; OBESE GENE; ADIPOSE-TISSUE; SECRETION; PROTEIN; ATP; TRANSLOCATION; IDENTIFICATION	ATP is co-localized with norepinephrine at the sympathetic nerve terminals and may be released simultaneously upon neuronal stimulation, which results in activation of purinergic receptors. To examine whether leptin synthesis and lipolysis are influenced by P2 purinergic receptor activation, the effects of ATP and other nucleotides on leptin secretion and glycerol release have been investigated in differentiated rat white adipocytes. Firstly, insulin-induced leptin secretion was inhibited by nucleotide treatment with the following efficacy order: 3'-O-( 4-benzoyl) benzoyl ATP ( BzATP) > ATP >> UTP. Secondly, treatment of adipocytes with ATP increased both intracellular Ca2+ concentration and cAMP content. Intracellular calcium concentration was increased by ATP and UTP, but not BzATP, an effect attributed to phospholipase C-coupled P2Y(2). On the other hand, cAMP was generated by treatment with BzATP and ATP gamma S, but not UTP, indicating functional expression of adenylyl cyclase-coupled P2Y(11) receptors in white adipocytes. Thirdly, lipolysis was significantly activated by BzATP and ATP, which correlated with the characteristics of the P2Y(11) subtype. Taken together, the data presented here suggest that white adipocytes express at least two different types of P2Y receptors and that activation of P2Y(11) receptor might be involved in inhibition of leptin production and stimulation of lipolysis, suggesting that purinergic transmission can play an important role in white adipocyte physiology.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Handong Global Univ, Sch Biosci & Food Technol, Pohang 791940, South Korea; Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Cheongju 361736, South Korea	Pohang University of Science & Technology (POSTECH); Handong Global University; Chungbuk National University	Kim, KT (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea.	ktk@postech.ac.kr		KIM, KYONG-TAI/0000-0001-7292-2627				Arai T, 2002, BIOCHEM BIOPH RES CO, V297, P1291, DOI 10.1016/S0006-291X(02)02376-8; ATKIN SL, 1995, IN VITRO CELL DEV-AN, V31, P657; Bamshad M, 1998, AM J PHYSIOL-REG I, V275, pR291, DOI 10.1152/ajpregu.1998.275.1.R291; Bowers RR, 2004, AM J PHYSIOL-REG I, V286, pR1167, DOI 10.1152/ajpregu.00558.2003; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BURNSTOCK G, 1990, ARCH INT PHARMACOD T, V304, P7; Cammisotto PG, 2003, AM J PHYSIOL-ENDOC M, V285, pE521, DOI 10.1152/ajpendo.00052.2003; Cammisotto PG, 2002, AM J PHYSIOL-CELL PH, V283, pC244, DOI 10.1152/ajpcell.00033.2002; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; Choi BH, 2004, J NEUROCHEM, V90, P442, DOI 10.1111/j.1471-4159.2004.02495.x; Choi SY, 1997, BIOCHEM PHARMACOL, V53, P429, DOI 10.1016/S0006-2952(96)00719-8; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Communi D, 1999, BRIT J PHARMACOL, V128, P1199, DOI 10.1038/sj.bjp.0702909; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DOLE VP, 1960, J BIOL CHEM, V235, P2595; Evans BA, 1999, FEBS LETT, V444, P149, DOI 10.1016/S0014-5793(99)00049-6; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; Gettys TW, 1996, ENDOCRINOLOGY, V137, P4054, DOI 10.1210/en.137.9.4054; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; Hur EM, 2004, J BIOL CHEM, V279, P5852, DOI 10.1074/jbc.M311687200; LARGERCRANTZ H, 1976, NEUROSCIENCE, V1, P81; Lee JH, 2004, J NEUROCHEM, V91, P634, DOI 10.1111/j.1471-4159.2004.02770.x; Lee SC, 1997, AM J PHYSIOL-CELL PH, V273, pC679, DOI 10.1152/ajpcell.1997.273.2.C679; Lee SC, 1999, BIOPHYS J, V76, P2297, DOI 10.1016/S0006-3495(99)77385-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; McKnight GS, 1998, RECENT PROG HORM RES, V53, P139; Mitchell SE, 1997, BIOCHEM BIOPH RES CO, V230, P360, DOI 10.1006/bbrc.1996.5964; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; Pappone PA, 1996, J GEN PHYSIOL, V108, P393, DOI 10.1085/jgp.108.5.393; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Rayner DV, 2001, J MOL MED, V79, P8, DOI 10.1007/s001090100198; Rayner DV, 1998, FEBS LETT, V429, P395, DOI 10.1016/S0014-5793(98)00642-5; REAVEN GM, 1988, AM J PHYSIOL, V254, pE23, DOI 10.1152/ajpendo.1988.254.1.E23; RODBELL M, 1964, J BIOL CHEM, V239, P375; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; SNEDDON P, 1984, J PHYSIOL-LONDON, V347, P561, DOI 10.1113/jphysiol.1984.sp015083; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Suh BC, 1997, J NEUROCHEM, V68, P1622; Sullivan DM, 1997, J NEUROSCI RES, V49, P43, DOI 10.1002/(SICI)1097-4547(19970701)49:1<43::AID-JNR5>3.0.CO;2-D; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; TRAYHURN P, 1995, BIOCHEM J, V311, P729, DOI 10.1042/bj3110729; Turban S, 2002, BIOCHEM J, V362, P113, DOI 10.1042/0264-6021:3620113; Westfall DP, 2002, J PHARMACOL EXP THER, V303, P439, DOI 10.1124/jpet.102.035113; Williams M, 2000, BIOCHEM PHARMACOL, V59, P1173, DOI 10.1016/S0006-2952(99)00341-X; Wilson SM, 1999, CELL PROLIFERAT, V32, P131, DOI 10.1046/j.1365-2184.1999.32230131.x; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	55	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28556	28563		10.1074/jbc.M411253200	http://dx.doi.org/10.1074/jbc.M411253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15955812	hybrid			2022-12-25	WOS:000230857300046
J	Th'ng, JPH; Sung, R; Ye, M; Hendzel, MJ				Th'ng, JPH; Sung, R; Ye, M; Hendzel, MJ			H1 family histones in the nucleus - Control of binding and localization by the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBULAR DOMAIN; CHROMATIN STRUCTURE; GENE-EXPRESSION; IN-VIVO; DNA; CELLS; MOUSE; DIFFERENTIATION; LOCATION; SUBTYPES	H1 histones bind to DNA as they enter and exit the nucleosome. H1 histones have a tripartite structure consisting of a short N-terminal domain, a highly conserved central globular domain, and a lysine-and arginine-rich C-terminal domain. The C-terminal domain comprises approximately half of the total amino acid content of the protein, is essential for the formation of compact chromatin structures, and contains the majority of the amino acid variations that define the individual histone H1 family members. This region contains several cell cycle-regulated phosphorylation sites and is thought to function through a charge-neutralization process, neutralizing the DNA phosphate backbone to allow chromatin compaction. In this study, we use fluorescence microscopy and fluorescence recovery after photobleaching to define the behavior of the individual histone H1 subtypes in vivo. We find that there are dramatic differences in the binding affinity of the individual histone H1 subtypes in vivo and differences in their preference for euchromatin and heterochromatin. Further, we show that subtype-specific properties originate with the C terminus and that the differences in histone H1 binding are not consistent with the relatively small changes in the net charge of the C-terminal domains.	Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; No Ontario Sch Med, Thunder Bay Reg Hlth Sci Ctr, Div Med Sci, Thunder Bay, ON P7B 6V4, Canada	University of Alberta; Northern Ontario School of Medicine	Hendzel, MJ (corresponding author), Univ Alberta, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	michaelh@cancerboard.ab.ca	Hendzel, Michael/C-3391-2009	Hendzel, Michael/0000-0002-9603-7945				ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ANDREEVA NB, 1978, MOL BIOL+, V12, P91; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BERGMAN MG, 1988, J CELL SCI, V91, P201; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; Carrero G, 2004, METHOD ENZYMOL, V375, P415; CHAN DCF, 1984, J BIOMOL STRUCT DYN, V2, P319, DOI 10.1080/07391102.1984.10507570; De S, 2002, GENE, V292, P173, DOI 10.1016/S0378-1119(02)00675-3; DOENECKE D, 1988, ADV ENZYME REGUL, V27, P107; Doenecke D, 1997, HISTOCHEM CELL BIOL, V107, P1, DOI 10.1007/s004180050083; FURRER P, 1995, J STRUCT BIOL, V114, P177, DOI 10.1006/jsbi.1995.1017; Gabrilovich DI, 2002, J LEUKOCYTE BIOL, V72, P285; GOLDBERG RB, 1977, DIFFERENTIATION, V7, P167, DOI 10.1111/j.1432-0436.1977.tb01508.x; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; Hendzel MJ, 2004, J BIOL CHEM, V279, P20028, DOI 10.1074/jbc.M400070200; JACKOWSKI G, 1982, CELL BIOL INT REP, V6, P867, DOI 10.1016/0309-1651(82)90147-3; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; LARUE H, 1983, CAN J BIOCHEM CELL B, V61, P1197, DOI 10.1139/o83-154; LENNOX RW, 1986, DEV BIOL, V118, P319, DOI 10.1016/0012-1606(86)90100-4; LENNOX RW, 1983, J BIOL CHEM, V258, P262; LENNOX RW, 1984, DEV BIOL, V103, P80, DOI 10.1016/0012-1606(84)90009-5; LENNOX RW, 1984, J BIOL CHEM, V259, P669; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; LOGAN KA, 1988, J BIOL CHEM, V263, P9658; Lu X, 2004, J BIOL CHEM, V279, P8701, DOI 10.1074/jbc.M311348200; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; MOORMAN AFM, 1987, DIFFERENTIATION, V35, P100, DOI 10.1111/j.1432-0436.1987.tb00156.x; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; PINA B, 1984, BIOCHEM BIOPH RES CO, V123, P697, DOI 10.1016/0006-291X(84)90285-7; Ponte I, 1998, MOL BIOL EVOL, V15, P702, DOI 10.1093/oxfordjournals.molbev.a025973; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Schulze E, 1995, J MOL EVOL, V41, P833; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; Talasz H, 1998, J BIOL CHEM, V273, P32236, DOI 10.1074/jbc.273.48.32236; Tanaka M, 2001, DEVELOPMENT, V128, P655; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; Vila R, 2001, J BIOL CHEM, V276, P46429, DOI 10.1074/jbc.M106952200; WHITLOCK JP, 1976, BIOCHEMISTRY-US, V15, P3307, DOI 10.1021/bi00660a022; Wolffe AP, 2001, CELL, V104, P631, DOI 10.1016/S0092-8674(02)01453-8	41	160	173	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27809	27814		10.1074/jbc.M501627200	http://dx.doi.org/10.1074/jbc.M501627200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15911621	hybrid			2022-12-25	WOS:000230678600041
J	Antos, LK; Abbey-Hosch, SE; Flora, DR; Potter, LR				Antos, LK; Abbey-Hosch, SE; Flora, DR; Potter, LR			ATP-independent activation of natriuretic peptide receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL CYCLASE-A; ADENINE-NUCLEOTIDES; DEPENDENT DESENSITIZATION; SIGNAL-TRANSDUCTION; REGULATORY MODULE; CYCLIC-GMP; NPR-B; PROTEINS; PHOSPHORYLATION; BINDING	Natriuretic peptide receptor A (NPR-A) is an essential cardiovascular regulator that is stimulated by atrial natriuretic peptide and B-type natriuretic peptide, whereas natriuretic peptide receptor B (NPR-B) stimulates long bone growth in a C-type natriuretic peptide-dependent manner. Many reports indicate that ATP is essential for NPR-A and NPR-B activation. Current models suggest that natriuretic peptide binding to receptor extracellular domains causes ATP binding to intracellular kinase homology domains, which derepresses adjacent catalytic domains. Here, we report 100-fold activations of natriuretic peptide receptors in the absence of ATP. The addition of a nonhydrolyzable ATP analog had no effect at early time periods ( measured in seconds) but increased cGMP production about 2-fold after longer incubations ( measured in minutes), consistent with a stabilization, not activation, mechanism. These data indicate that ATP does not activate natriuretic peptide receptors as has been repeatedly reported. Instead, ATP increases activity primarily by maintaining proper receptor phosphorylation status but also serves a previously unappreciated enzyme stabilizing function.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Potter, LR (corresponding author), 6-155 Jackson,321 Church St SE, Minneapolis, MN 55455 USA.	potter@umn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066397] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL066397, R01HL66397] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbey SE, 2002, J BIOL CHEM, V277, P42423, DOI 10.1074/jbc.M206686200; Bartels CF, 2004, AM J HUM GENET, V75, P27, DOI 10.1086/422013; Bryan PM, 2002, J BIOL CHEM, V277, P16041, DOI 10.1074/jbc.M110626200; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; DELEAN A, 1986, LIFE SCI, V39, P1109, DOI 10.1016/0024-3205(86)90203-1; DUDA T, 1993, FEBS LETT, V335, P309, DOI 10.1016/0014-5793(93)80408-M; DUDA T, 1993, BIOCHEMISTRY-US, V32, P1391, DOI 10.1021/bi00057a001; Fan DH, 2005, MOL PHARMACOL, V67, P174, DOI 10.1124/mol.104.002436; Foster DC, 1998, J BIOL CHEM, V273, P16311, DOI 10.1074/jbc.273.26.16311; Garbers DL, 1999, METHODS, V19, P477, DOI 10.1006/meth.1999.0890; GAZZANO H, 1991, BIOCHIM BIOPHYS ACTA, V1077, P99, DOI 10.1016/0167-4838(91)90531-4; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; JEWETT JRS, 1993, EMBO J, V12, P769, DOI 10.1002/j.1460-2075.1993.tb05711.x; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; Kuhn M, 2003, CIRC RES, V93, P700, DOI 10.1161/01.RES.0000094745.28948.4D; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; Labrecque J, 2001, J BIOL CHEM, V276, P8064, DOI 10.1074/jbc.M005550200; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; Lucas KA, 2000, PHARMACOL REV, V52, P375; MARALA RB, 1991, FEBS LETT, V281, P73, DOI 10.1016/0014-5793(91)80361-6; Nakayama T, 2000, CIRC RES, V86, P841, DOI 10.1161/01.RES.86.8.841; Ogawa H, 2004, J BIOL CHEM, V279, P28625, DOI 10.1074/jbc.M313222200; Potter LR, 2005, FRONT BIOSCI-LANDMRK, V10, P1205, DOI 10.2741/1613; Potter LR, 1998, J BIOL CHEM, V273, P15533, DOI 10.1074/jbc.273.25.15533; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Potthast R, 2004, J BIOL CHEM, V279, P48513, DOI 10.1074/jbc.M408247200; Sengenes C, 2000, FASEB J, V14, P1345, DOI 10.1096/fj.14.10.1345; SONG DL, 1988, FEBS LETT, V232, P125, DOI 10.1016/0014-5793(88)80400-9; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Tremblay J, 2002, MOL CELL BIOCHEM, V230, P31, DOI 10.1023/A:1014260204524; Tucker CL, 1997, BIOCHEMISTRY-US, V36, P11995, DOI 10.1021/bi971212k; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P19598; Wong SKF, 1995, J BIOL CHEM, V270, P30818, DOI 10.1074/jbc.270.51.30818; Yamazaki A, 2003, J BIOL CHEM, V278, P33150, DOI 10.1074/jbc.M303678200	42	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26928	26932		10.1074/jbc.M505648200	http://dx.doi.org/10.1074/jbc.M505648200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911610	hybrid			2022-12-25	WOS:000230589500036
J	Sandhoff, R; Geyer, R; Jennemann, R; Paret, C; Kiss, E; Yamashita, T; Gorgas, K; Sijmonsma, TP; Iwamori, M; Finaz, C; Proia, RL; Wiegandt, H; Grone, HJ				Sandhoff, R; Geyer, R; Jennemann, R; Paret, C; Kiss, E; Yamashita, T; Gorgas, K; Sijmonsma, TP; Iwamori, M; Finaz, C; Proia, RL; Wiegandt, H; Grone, HJ			Novel class of glycosphingolipids involved in male fertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN FATTY-ACIDS; MICE; GANGLIOSIDE; EXPRESSION; METHYLATION; CELLS; LONG; SPHINGOMYELIN; INFERTILITY; SENSITIVITY	Mice require testicular glycosphingolipids (GSLs) for proper spermatogenesis. Mutant mice strains deficient in specific genes encoding biosynthetic enzymes of the GSL pathway including Galgt1 ( encoding GM2 synthase) and Siat9 ( encoding GM3 synthase) have been established lacking various overlapping subsets of GSLs. Although male Galgt1 -/- mice are infertile, male Siat9 -/- mice are fertile. Interestingly, GSLs thought to be essential for male spermatogenesis are not synthesized in either of these mice strains. Hence, these GSLs cannot account for the different phenotypes. A novel class of GSLs was observed composed of eight fucosylated molecules present in fertile but not in infertile mutant mice. These GSLs contain polyunsaturated very long chain fatty acid residues in their ceramide moieties. GSLs of this class are expressed differentially in testicular germ cells. More importantly, the neutral subset of this new GSL class strictly correlates with male fertility. These data implicate polyunsaturated, fucosylated GSLs as essential for spermatogenesis and male mouse fertility.	German Canc Res Ctr, Dept Cellular & Mol Pathol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Tumor Progress & Tumor Def, D-69120 Heidelberg, Germany; Univ Giessen, Fac Med, Inst Biochem, D-35392 Giessen, Germany; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Heidelberg, Dept Anat & Cell Biol 2, D-69120 Heidelberg, Germany; Kinki Univ, Fac Sci & Technol, Dept Biochem, Osaka 5778502, Japan; Univ Paris 7 11, INSERM,U566, CEA,Atom Energy Dept,Radiobiol & Radiopathol Dept, Lab Gametogenesis Apoptosis & Genotox, F-92265 Fontenay Aux Roses, France	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Justus Liebig University Giessen; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Ruprecht Karls University Heidelberg; Kindai University (Kinki University); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay	Sandhoff, R (corresponding author), German Canc Res Ctr, Dept Cellular & Mol Pathol, INF 280, D-69120 Heidelberg, Germany.	r.sandhoff@dkfz-heidelberg.de; h.-j.groene@dkfz.de	Proia, Richard L/A-7908-2012; Paret, Claudia/T-2913-2019	Paret, Claudia/0000-0002-9094-1634; Proia, Richard/0000-0003-0456-1270; , Eva/0000-0003-4052-2797	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVELDANO MI, 1993, J BIOL CHEM, V268, P11663; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREDMAN P, 1986, BIOCHIM BIOPHYS ACTA, V875, P316, DOI 10.1016/0005-2760(86)90182-7; GEYER R, 1982, ANAL BIOCHEM, V121, P263, DOI 10.1016/0003-2697(82)90478-X; GEYER R, 1994, METHOD ENZYMOL, V230, P86; Grone HJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134957; HIGGINS TJ, 1985, MOL IMMUNOL, V22, P1265, DOI 10.1016/0161-5890(85)90045-8; Iwamori M, 2004, BIOCHEM J, V380, P75, DOI 10.1042/BJ20031668; JENNEMANN R, 1990, CANCER RES, V50, P7444; KANAI Y, 1990, HISTOCHEMISTRY, V94, P561; Kawai H, 2001, J BIOL CHEM, V276, P6885, DOI 10.1074/jbc.C000847200; Kolter T, 1999, ANGEW CHEM INT EDIT, V38, P1532, DOI 10.1002/(SICI)1521-3773(19990601)38:11<1532::AID-ANIE1532>3.0.CO;2-U; Kurita T, 2000, J LIPID RES, V41, P846; Lin B, 2000, BBA-MOL CELL BIOL L, V1487, P275, DOI 10.1016/S1388-1981(00)00103-7; Lin B, 2001, ARCH BIOCHEM BIOPHYS, V388, P207, DOI 10.1006/abbi.2001.2303; Liu YJ, 1999, J CLIN INVEST, V103, P497, DOI 10.1172/JCI5542; Lochnit G, 1997, GLYCOCONJUGATE J, V14, P389, DOI 10.1023/A:1018530914067; NAKAMURA K, 1988, J BIOCHEM-TOKYO, V103, P201, DOI 10.1093/oxfordjournals.jbchem.a122232; Okada M, 2002, J BIOL CHEM, V277, P1633, DOI 10.1074/jbc.C100395200; Ottico E, 2003, J LIPID RES, V44, P2142, DOI 10.1194/jlr.M300247-JLR200; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; Porubsky S, 2004, AM J PATHOL, V164, P2175, DOI 10.1016/S0002-9440(10)63775-3; POULOS A, 1987, BIOCHEM J, V248, P961, DOI 10.1042/bj2480961; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; ROBINSON BS, 1992, J BIOL CHEM, V267, P1746; Rodemer C, 2003, HUM MOL GENET, V12, P1881, DOI 10.1093/hmg/ddg191; SAITO T, 1971, J LIPID RES, V12, P257; SANDHOFF K, 1971, J NEUROCHEM, V18, P2469, DOI 10.1111/j.1471-4159.1971.tb00204.x; Sandhoff R, 2002, J BIOL CHEM, V277, P20386, DOI 10.1074/jbc.M110641200; Schuette CG, 2001, GLYCOBIOLOGY, V11, P549, DOI 10.1093/glycob/11.7.549; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SUZUKI A, 1975, J BIOCHEM-TOKYO, V78, P947, DOI 10.1093/oxfordjournals.jbchem.a131001; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; Takamiya K, 1998, P NATL ACAD SCI USA, V95, P12147, DOI 10.1073/pnas.95.21.12147; TENEBERG S, 1994, J BIOCHEM-TOKYO, V116, P697, DOI 10.1093/oxfordjournals.jbchem.a124583; van der Spoel AC, 2002, P NATL ACAD SCI USA, V99, P17173, DOI 10.1073/pnas.262586099; WESKE B, 1990, EUR J BIOCHEM, V191, P379, DOI 10.1111/j.1432-1033.1990.tb19133.x; WIEGANDT H, 1973, H-S Z PHYSIOL CHEM, V354, P1049, DOI 10.1515/bchm2.1973.354.2.1049; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; [No title captured]	40	72	75	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27310	27318		10.1074/jbc.M502775200	http://dx.doi.org/10.1074/jbc.M502775200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917254	hybrid			2022-12-25	WOS:000230589500081
J	Lee, J; Hever, A; Willhite, D; Zlotnik, A; Hevezi, P				Lee, J; Hever, A; Willhite, D; Zlotnik, A; Hevezi, P			Effects of RNA degradation on gene expression analysis of human postmortem tissues	FASEB JOURNAL			English	Article						thymus; RNA quality; GPCR	MESSENGER-RNA; DENDRITIC CELLS; RECEPTOR; PROFILE; STABILITY; CHEMOKINE; QUALITY; BRAIN; ASPM; RAT	The Affymetrix GeneChip platform was used to build a gene expression database of the normal human body. Postmortem human tissues represent a valuable source of biological materials for this type of study, but their use entails some delays before harvesting such tissues. We first evaluated the RNA quality obtained from tissues obtained 3-5 h postmortem and found variations that were both tissue and donor-dependent. RNAs extracted from brain regions were of higher quality than those obtained from the gut, while the cause of death was a significant factor in donor-dependent differences. To avoid these variables, we used rat duodenum to determine the effects of RNA degradation on the analysis of gene expression. Surprisingly, even samples exhibiting significant RNA degradation yielded robust gene expression results, comparable to those obtained using intact samples at a certain signal intensity cutoff. We extended these findings to our human expression database and obtained similar results, indicating that the Affymetrix platform, which is biased to the 3' end of transcripts for detection, can tolerate significant RNA degradation, while still yielding high quality expression data. Our resulting body index expression database is a valuable research tool. As examples of potential uses, we report novel expression sites for four potential therapeutic targets-CCL27, GPR22, GPR113 and GPR128-and as well as a set of thymus-specific genes, including three not previously associated with the thymus.	Neurocrine Biosci Inc, Dept Mol Med, San Diego, CA 92130 USA	Neurocrine Biosciences	Hevezi, P (corresponding author), Neurocrine Biosci Inc, Dept Mol Med, 12790 El Camino Real, San Diego, CA 92130 USA.	phevezi@neurocrine.com	Zlotnik, Albert/C-3791-2011					Auer H, 2003, NAT GENET, V35, P292, DOI 10.1038/ng1203-292; Bahn S, 2001, J CHEM NEUROANAT, V22, P79, DOI 10.1016/S0891-0618(01)00099-0; Bond J, 2003, AM J HUM GENET, V73, P1170, DOI 10.1086/379085; Bond J, 2002, NAT GENET, V32, P316, DOI 10.1038/ng995; Fredriksson R, 2003, FEBS LETT, V554, P381, DOI 10.1016/S0014-5793(03)01196-7; Gonzalez-Maeso J, 2002, NEUROPSYCHOPHARMACOL, V26, P468, DOI 10.1016/S0893-133X(01)00342-6; Granucci F, 2001, EUR J IMMUNOL, V31, P2539, DOI 10.1002/1521-4141(200109)31:9<2539::AID-IMMU2539>3.0.CO;2-9; Greenberg SA, 2002, NEUROLOGY, V59, P1170, DOI 10.1212/WNL.59.8.1170; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Hsiao LL, 2001, PHYSIOL GENOMICS, V7, P97, DOI 10.1152/physiolgenomics.00040.2001; Huang Shuguang, 2003, Am J Pharmacogenomics, V3, P279, DOI 10.2165/00129785-200303040-00005; HUMPHREYS-BEHER M G, 1986, Biotechnology and Applied Biochemistry, V8, P392; Inoue H, 2002, FORENSIC SCI INT, V130, P127, DOI 10.1016/S0379-0738(02)00352-3; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Iwamoto K, 2004, MOL PSYCHIATR, V9, P406, DOI 10.1038/sj.mp.4001437; Jewell SD, 2002, AM J CLIN PATHOL, V118, P733; JOHNSON SA, 1986, J NEUROSCI RES, V16, P267, DOI 10.1002/jnr.490160123; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Malboeuf CM, 2001, BIOTECHNIQUES, V30, P1074, DOI 10.2144/01305rr06; Malnic B, 2004, P NATL ACAD SCI USA, V101, P2584, DOI 10.1073/pnas.0307882100; Mimmack ML, 2004, BIOL PSYCHIAT, V55, P337, DOI 10.1016/j.biopsych.2003.09.007; Norment AM, 2000, J IMMUNOL, V164, P639, DOI 10.4049/jimmunol.164.2.639; ODowd BF, 1997, GENE, V187, P75, DOI 10.1016/S0378-1119(96)00722-6; PAPSIDERO LD, 1981, J NATL CANCER I, V66, P37; Preece P, 2003, MOL BRAIN RES, V116, P7, DOI 10.1016/S0169-328X(03)00208-0; Ryan CA, 2004, TOXICOL LETT, V150, P301, DOI 10.1016/j.toxlet.2004.02.002; Sanoudou D, 2004, PHYSIOL GENOMICS, V16, P222, DOI 10.1152/physiolgenomics.00137.2003; Schmidt W. M., 2003, International Journal of Clinical Pharmacology and Therapeutics, V41, P624; Schmidt WM, 2004, INT J CANCER, V112, P200, DOI 10.1002/ijc.20401; Schoor O, 2003, BIOTECHNIQUES, V35, P1192, DOI 10.2144/03356rr01; Selinger DW, 2003, GENOME RES, V13, P216, DOI 10.1101/gr.912603; Serralta A, 2003, TOXICOL IN VITRO, V17, P769, DOI 10.1016/S0887-2333(03)00122-X; Shippy R, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-61; Tebo J, 2003, J BIOL CHEM, V278, P12085, DOI 10.1074/jbc.M212992200; Tomita H, 2004, BIOL PSYCHIAT, V55, P346, DOI 10.1016/j.biopsych.2003.10.013; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Yang E, 2003, GENOME RES, V13, P1863, DOI 10.1101/gr.1272403	40	84	86	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1356	+		10.1096/fj.04-3552fje	http://dx.doi.org/10.1096/fj.04-3552fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15955843				2022-12-25	WOS:000230207800017
J	Jong, YJI; Kumar, V; Kingston, AE; Romano, C; O'Malley, KL				Jong, YJI; Kumar, V; Kingston, AE; Romano, C; O'Malley, KL			Functional metabotropic glutamate receptors on nuclei from brain and primary cultured striatal neurons - Role of transporters in delivering ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DIFFERENTIAL DISTRIBUTION; ACTIVATION; ACID; CA2+; LOCALIZATION; MEMBRANE; ENVELOPE; SIGNAL; MGLU5	G-protein-coupled receptors are well known for converting an extracellular signal into an intracellular response. Here we showed that the metabotropic glutamate receptor 5 (mGlu5) plays a dynamic intracellular role in signal transduction. Activation of endogenously expressed mGlu5 on striatal nuclear membranes leads to rapid, sustained calcium (Ca2+) responses within the nucleoplasm that can be blocked by receptor-specific antagonists. Extracellular ligands such as glutamate and quisqualate reach nuclear receptors via both sodium-dependent transporters and cystine glutamate exchangers. Inhibition of either transport system blocks radiolabeled agonist uptake as well as agonist-induced nuclear Ca2+ changes. Impermeable antagonists like LY393053 and LY367366 not only blocked [H-3] quisqualate binding but also prevented nontransported agonists such as (RS)-3,5-dihydroxyphenylglycine from inducing intracellular Ca2+ changes in heterologous cells. In contrast, neither LY compound prevented quisqualate or glutamate from activating intracellular receptors leading to Ca2+ responses. Inasmuch as Ca2+ can enter the nucleoplasm via the nuclear pore complex or from the nuclear lumen, the presence of nuclear mGlu5 receptors appeared to amplify the latter process generating a faster nuclear response in heterologous cells. In isolated striatal nuclei, nuclear receptor activation results in the de novo appearance of phosphorylated CREB protein. Thus, activation of nuclear mGlu5 receptors initiates a signaling cascade that is known to alter gene transcription and regulate many paradigms of synaptic plasticity. These studies demonstrated that mGlu5 receptors play a dynamic role in signaling both on and off the plasma membrane.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA; Eli Lilly & Co Ltd, Indianapolis, IN 46285 USA	Washington University (WUSTL); Washington University (WUSTL); Eli Lilly	O'Malley, KL (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	omalleyk@pcg.wustl.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH069646, R01MH057817] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57817, MH069646] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Baker DA, 2002, J NEUROSCI, V22, P9134; BANNAI S, 1984, BIOCHIM BIOPHYS ACTA, V779, P289, DOI 10.1016/0304-4157(84)90014-5; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; Bkaily G, 2000, J CARDIOVASC PHARM, V36, pS414, DOI 10.1097/00005344-200036051-00121; Boivin B, 2003, J BIOL CHEM, V278, P29153, DOI 10.1074/jbc.M301738200; Cavelier P, 2005, PROG BIOPHYS MOL BIO, V87, P3, DOI 10.1016/j.pbiomolbio.2004.06.001; Chase LA, 2001, NEUROSCIENCE, V106, P287, DOI 10.1016/S0306-4522(01)00278-0; Chen R, 2000, AM J PHYSIOL-RENAL, V279, pF440, DOI 10.1152/ajprenal.2000.279.3.F440; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; DOLMETSCH R, 2003, SCI STKE 2003; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Erickson ES, 2004, BIOPHYS CHEM, V112, P1, DOI 10.1016/j.bpc.2004.06.010; Ferraguti F, 1998, J COMP NEUROL, V400, P391; Flint AC, 1999, P NATL ACAD SCI USA, V96, P12144, DOI 10.1073/pnas.96.21.12144; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; Funicello M, 2004, MOL PHARMACOL, V66, P522; Gassmann M, 2005, MOL PHARMACOL, V68, P137, DOI 10.1124/mol.104.010256; Gerasimenko JV, 2003, J CELL BIOL, V163, P271, DOI 10.1083/jcb.200306134; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Gerevini VDD, 2004, DEV BRAIN RES, V150, P17, DOI 10.1016/j.devbrainres.2004.02.003; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Goudet C, 2005, J BIOL CHEM, V280, P24380, DOI 10.1074/jbc.M502642200; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Kanai Y, 2004, PFLUG ARCH EUR J PHY, V447, P469, DOI 10.1007/s00424-003-1146-4; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; Kettunen P, 2002, J NEUROSCI, V22, P1868, DOI 10.1523/JNEUROSCI.22-05-01868.2002; KHARAZIA VN, 1994, J NEUROSCI, V14, P6021; Kingston AE, 2002, NEUROSCI LETT, V330, P127, DOI 10.1016/S0304-3940(02)00751-6; Kniazeff J, 2004, NAT STRUCT MOL BIOL, V11, P706, DOI 10.1038/nsmb794; Lee DK, 2004, J BIOL CHEM, V279, P7901, DOI 10.1074/jbc.M306377200; Limback-Stokin K, 2004, J NEUROSCI, V24, P10858, DOI 10.1523/JNEUROSCI.1022-04.2004; Lopez-Bendito G, 2002, CEREB CORTEX, V12, P625, DOI 10.1093/cercor/12.6.625; Mao LM, 2003, J NEUROCHEM, V84, P233, DOI 10.1046/j.1471-4159.2003.01256.x; Mao LM, 2001, MOL BRAIN RES, V86, P125, DOI 10.1016/S0169-328X(00)00276-X; Marchenko SM, 2005, J PHYSIOL-LONDON, V565, P897, DOI 10.1113/jphysiol.2004.081299; Marino MJ, 2002, NEUROPHARMACOLOGY, V43, P147, DOI 10.1016/S0028-3908(02)00097-7; Moughal NA, 2004, CELL SIGNAL, V16, P127, DOI 10.1016/j.cellsig.2003.08.004; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; O'Malley KL, 2003, J BIOL CHEM, V278, P28210, DOI 10.1074/jbc.M300792200; Ott CM, 2002, J CELL SCI, V115, P2003; Paquet M, 2003, J NEUROSCI, V23, P7659; Patel SA, 2004, NEUROPHARMACOLOGY, V46, P273, DOI 10.1016/j.neuropharm.2003.08.006; Prothero LS, 1998, BRIT J PHARMACOL, V125, P1551, DOI 10.1038/sj.bjp.0702203; Ralphe JC, 2004, J MOL CELL CARDIOL, V37, P33, DOI 10.1016/j.yjmcc.2004.04.008; Romano C, 1996, J COMP NEUROL, V367, P403, DOI 10.1002/(SICI)1096-9861(19960408)367:3<403::AID-CNE6>3.0.CO;2-9; Romano C, 2001, MOL PHARMACOL, V59, P46, DOI 10.1124/mol.59.1.46; Scholze P, 2002, J BIOL CHEM, V277, P21505, DOI 10.1074/jbc.M112265200; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835	54	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30469	30480		10.1074/jbc.M501775200	http://dx.doi.org/10.1074/jbc.M501775200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15958386	hybrid			2022-12-25	WOS:000231362500060
J	Di Marco, S; Volpari, C; Tomei, L; Altamura, S; Harper, S; Narjes, F; Koch, U; Rowley, M; De Francesco, R; Migliaccio, G; Carfi, A				Di Marco, S; Volpari, C; Tomei, L; Altamura, S; Harper, S; Narjes, F; Koch, U; Rowley, M; De Francesco, R; Migliaccio, G; Carfi, A			Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; DE-NOVO INITIATION; CRYSTAL-STRUCTURE; MECHANISM; NS5B; CONFORMATIONS; RHINOVIRUS	The hepatitis C virus (HCV) polymerase is required for replication of the viral genome and is a key target for therapeutic intervention against HCV. We have determined the crystal structures of the HCV polymerase complexed with two indole-based allosteric inhibitors at 2.3- and 2.4-angstrom resolution. The structures show that these inhibitors bind to a site on the surface of the thumb domain. A cyclohexyl and phenyl ring substituents, bridged by an indole moiety, fill two closely spaced pockets, whereas a carboxylate substituent forms a salt bridge with an exposed arginine side chain. Interestingly, in the apoenzyme, the inhibitor binding site is occupied by a small alpha-helix at the tip of the N-terminal loop that connects the fingers and thumb domains. Thus, these molecules inhibit the enzyme by preventing formation of intramolecular contacts between these two domains and consequently precluding their coordinated movements during RNA synthesis. Our structures identify a novel mechanism by which a new class of allosteric inhibitors inhibits the HCV polymerase and open the way to the development of novel antiviral agents against this clinically relevant human pathogen.	Ist Ric Biol Mol P Angeletti, I-00040 Rome, Italy	Merck & Company	Carfi, A (corresponding author), Ist Ric Biol Mol P Angeletti, Via Pontina Km30-600, I-00040 Rome, Italy.	andrea_carfi@merck.com	Di Marco, Stefania -/C-3859-2009; De Francesco, Raffaele/J-6003-2012	De Francesco, Raffaele/0000-0001-8754-5123; Narjes, Frank/0000-0002-3104-7771				Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Appleby TC, 2005, J VIROL, V79, P277, DOI 10.1128/JVI.79.1.277-288.2005; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biswal BK, 2005, J BIOL CHEM, V280, P18202, DOI 10.1074/jbc.M413410200; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Choi KH, 2004, P NATL ACAD SCI USA, V101, P4425, DOI 10.1073/pnas.0400660101; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Cohen J, 1999, SCIENCE, V285, P26, DOI 10.1126/science.285.5424.26; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Harper S, 2005, J MED CHEM, V48, P1314, DOI 10.1021/jm049122i; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Labonte P, 2002, J BIOL CHEM, V277, P38838, DOI 10.1074/jbc.M204657200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Love RA, 2004, STRUCTURE, V12, P1533, DOI 10.1016/j.str.2004.05.024; Love RA, 2003, J VIROL, V77, P7575, DOI 10.1128/JVI.77.13.7575-7581.2003; McHutchison JG, 2002, HEPATOLOGY, V36, pS245, DOI 10.1053/jhep.2002.36795; McKercher G, 2004, NUCLEIC ACIDS RES, V32, P422, DOI 10.1093/nar/gkh160; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Shim JH, 2002, J VIROL, V76, P7030, DOI 10.1128/JVI.76.14.7030-7039.2002; Tao YZ, 2002, CELL, V111, P733, DOI 10.1016/S0092-8674(02)01110-8; Thompson AA, 2004, EMBO J, V23, P3462, DOI 10.1038/sj.emboj.7600357; Tomei L, 2004, J VIROL, V78, P938, DOI 10.1128/JVI.78.2.938-946.2004; Tomei L, 2003, J VIROL, V77, P13225, DOI 10.1128/JVI.77.24.13225-13231.2003; Tomei L, 2000, J GEN VIROL, V81, P759, DOI 10.1099/0022-1317-81-3-759; van Dijk AA, 2004, J GEN VIROL, V85, P1077, DOI 10.1099/vir.0.19731-0; Wang MT, 2003, J BIOL CHEM, V278, P9489, DOI 10.1074/jbc.M209397200; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000	34	146	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29765	29770		10.1074/jbc.M505423200	http://dx.doi.org/10.1074/jbc.M505423200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15955819	hybrid, Green Published			2022-12-25	WOS:000231176200046
J	Mikhailov, VS; Okano, K; Rohrmann, GF				Mikhailov, VS; Okano, K; Rohrmann, GF			The redox state of the baculovirus single-stranded DNA-binding protein LEF-3 regulates its DNA binding, unwinding, and annealing activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; PUTATIVE HELICASE P143; HERPES-SIMPLEX VIRUS-1; IN-VITRO; ALKALINE NUCLEASE; CONFORMATIONAL CHANGE; EXONUCLEASE ACTIVITY; REPLICATION; ICP8; DOMAIN	The single-stranded (ss) DNA-binding protein LEF-3 of Autographa californica multinucleocapsid nucleopolyhedrovirus promoted Mg2+-independent unwinding of DNA duplexes and annealing of complementary DNA strands. The unwinding and annealing activities of LEF-3 appeared to act in a competitive manner and were determined by the ratio of protein to DNA. At sub-saturating and saturating concentrations, LEF-3 promoted annealing, whereas it promoted unwinding at oversaturation of DNA substrates. The LEF-3 binding to ssDNA and unwinding activity were sensitive to redox agents and were inhibited by oxidation of thiol groups in LEF-3 with 1,1'-azobis(N, N-dimethylformamide) ( diamide) or by modification with the thiol-conjugating agent N-ethylmaleimide. Both oxidation and alkylation increased the dissociation constant of the interaction with model oligonucleotides indicating a decrease in an intrinsic affinity of LEF-3 for ssDNA. These results proved that free thiol groups are essential both for LEF-3 interaction with ssDNA and for DNA unwinding. In contrast, oxidation or modification of thiol groups stimulated the annealing activity of LEF-3 partially due to suppression of its unwinding activity. Treatment of LEF-3 with the reducing agent dithiothreitol inhibited annealing, indicating association of this activity with the oxidized protein. Thus, the balance between annealing and unwinding activities of LEF-3 was determined by the redox state of protein with the oxidized state favoring annealing and the reduced state favoring unwinding. An LEF-3 mutant in which the conservative cysteine Cys(214) was replaced with serine showed both a decreased binding to DNA and a reduced unwinding activity, thus indicating that this residue might participate in the regulation of LEF-3 activities.	Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Russian Acad Sci, Inst Dev Biol, Moscow 117808, Russia	Oregon State University; Russian Academy of Sciences; Koltzov Institute of Developmental Biology of the Russian Academy of Sciences	Mikhailov, VS (corresponding author), Oregon State Univ, Dept Microbiol, Nash Hall 220, Corvallis, OR 97331 USA.	Victor.Mikhailov@orst.edu	Mikhailov, Victor S/O-2063-2016	Mikhailov, Victor/0000-0002-3324-8921	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM099825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM9982536] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; Chen T, 2004, J VIROL, V78, P329, DOI 10.1128/JVI.78.1.329-339.2004; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; Dekker J, 1998, J MOL BIOL, V277, P825, DOI 10.1006/jmbi.1998.1652; Dudas KC, 1998, J VIROL, V72, P257, DOI 10.1128/JVI.72.1.257-265.1998; Dudas KC, 2001, BIOCHEM BIOPH RES CO, V288, P184, DOI 10.1006/bbrc.2001.5766; DUTCH RE, 1993, J VIROL, V67, P6945, DOI 10.1128/JVI.67.12.6945-6949.1993; Evans JT, 1999, J GEN VIROL, V80, P493, DOI 10.1099/0022-1317-80-2-493; Evans JT, 1997, J VIROL, V71, P3574, DOI 10.1128/JVI.71.5.3574-3579.1997; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; HANG X, 1995, J VIROL, V69, P3924, DOI 10.1128/JVI.69.6.3924-3928.1995; Harwood SH, 1998, VIROLOGY, V250, P118, DOI 10.1006/viro.1998.9334; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; KNIPE DM, 1982, J VIROL, V44, P736, DOI 10.1128/JVI.44.2.736-741.1982; KOOL M, 1994, P NATL ACAD SCI USA, V91, P11212, DOI 10.1073/pnas.91.23.11212; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LU A, 1995, J VIROL, V69, P975, DOI 10.1128/JVI.69.2.975-982.1995; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; McDougal VV, 1999, J VIROL, V73, P4908, DOI 10.1128/JVI.73.6.4908-4918.1999; Mikhailov VS, 1998, J VIROL, V72, P3107, DOI 10.1128/JVI.72.4.3107-3116.1998; Mikhailov VS, 2000, VIROLOGY, V270, P180, DOI 10.1006/viro.2000.0270; Mikhailov VS, 2004, J BIOL CHEM, V279, P14734, DOI 10.1074/jbc.M311658200; Mikhailov VS, 1996, J BIOL CHEM, V271, P18939, DOI 10.1074/jbc.271.31.18939; Mikhailov VS, 2003, J VIROL, V77, P2436, DOI 10.1128/JVI.77.4.2436-2444.2003; Nimonkar AV, 2003, J BIOL CHEM, V278, P9678, DOI 10.1074/jbc.M212555200; Nimonkar AV, 2002, J BIOL CHEM, V277, P15182, DOI 10.1074/jbc.M109988200; Okano K, 1999, J VIROL, V73, P110, DOI 10.1128/JVI.73.1.110-119.1999; Reuven NB, 2003, J VIROL, V77, P7425, DOI 10.1128/JVI.77.13.7425-7433.2003; RUYECHAN WT, 1988, J VIROL, V62, P810, DOI 10.1128/JVI.62.3.810-817.1988; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TOMALSKI MD, 1991, VIROLOGY, V184, P149, DOI 10.1016/0042-6822(91)90831-U; Uprichard SL, 2003, J VIROL, V77, P7467, DOI 10.1128/JVI.77.13.7467-7476.2003; Vanarsdall AL, 2004, VIROLOGY, V326, P191, DOI 10.1016/j.virol.2004.06.003; VILLEMAIN JL, 1993, BIOCHEMISTRY-US, V32, P11235, DOI 10.1021/bi00092a038; Wang Y, 2001, FREE RADICAL BIO MED, V31, P1448, DOI 10.1016/S0891-5849(01)00728-6; Wu YT, 1998, VIROLOGY, V247, P32, DOI 10.1006/viro.1998.9235; You JS, 2000, BIOCHEMISTRY-US, V39, P12953, DOI 10.1021/bi001206f	45	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29444	29453		10.1074/jbc.M503235200	http://dx.doi.org/10.1074/jbc.M503235200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15944160	hybrid			2022-12-25	WOS:000231176200009
J	Li, KQ; Zhao, KH; Ossareh-Nazari, B; Da, GP; Dargemont, C; Marmorstein, R				Li, KQ; Zhao, KH; Ossareh-Nazari, B; Da, GP; Dargemont, C; Marmorstein, R			Structural basis for interaction between the Ubp3 deubiquitinating enzyme and its Bre5 cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT FACTOR-2 NTF2; RESOLUTION CRYSTAL-STRUCTURE; NUCLEOPORIN FXFG REPEATS; N-TERMINAL SEQUENCES; SACCHAROMYCES-CEREVISIAE; NTF2-LIKE DOMAIN; NUCLEAR IMPORT; 26S PROTEASOME; UBIQUITIN; PROTEIN	The Bre5 protein is a cofactor for the deubiquitinating enzyme Ubp3, and it contains a nuclear transfer factor 2 (NTF2)- like protein recognition module that is essential for Ubp3 activity. In this study, we report the x-ray crystal structure of the Bre5 NTF2-like domain and show that it forms a homodimeric structure that is similar to other NTF2-like domains, except for the presence of an intermolecular disulfide bond in the crystals. Sedimentation equilibrium studies reveal that under nonreducing conditions, the Bre5 NTF2-like domain is exclusively dimeric, whereas a disulfide bond-deficient mutant undergoes a monomer-dimer equilibrium with a dissociation constant in the midnanomolar range, suggesting that dimer formation and possibly also disulfide bond formation may modulate Bre5 function in vivo. Using deletion analysis, we also identify a novel N-terminal domain of Ubp3 that is necessary and sufficient for interaction with Bre5 and use isothermal titration calorimetry to show that Bre5 and Ubp3 form a 2:1 complex, in contrast to other reported NTF2-like domain/protein interactions that form 1:1 complexes. Finally, we employ structure-based mutagenesis to map the Ubp3 binding surface of Bre5 to a region near the Bre5 dimer interface and show that this binding surface of Bre5 is important for Ubp3 function in vivo. Together, these studies provide novel insights into protein recognition by NTF2-like domains and provide a molecular scaffold for understanding how Ubp3 function is regulated by Bre5 cofactor binding.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Paris 06, Inst Jacques Monod, CNRS, UMR7592, F-75251 Paris, France; Univ Paris 07, Inst Jacques Monod, CNRS, UMR7592, F-75251 Paris, France	The Wistar Institute; University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Marmorstein, R (corresponding author), Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.	marmor@wistar.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061262] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061262-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Bayliss R, 2000, J STRUCT BIOL, V131, P240, DOI 10.1006/jsbi.2000.4297; Bayliss R, 1999, J MOL BIOL, V293, P579, DOI 10.1006/jmbi.1999.3166; Bayliss R, 2002, EMBO J, V21, P2843, DOI 10.1093/emboj/cdf305; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullock TL, 1996, J MOL BIOL, V260, P422, DOI 10.1006/jmbi.1996.0411; Castagnoli L, 2004, FEBS LETT, V567, P74, DOI 10.1016/j.febslet.2004.03.116; Chaillan-Huntington C, 2001, J MOL BIOL, V314, P465, DOI 10.1006/jmbi.2001.5136; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; Cohen M, 2003, J BIOL CHEM, V278, P51989, DOI 10.1074/jbc.C300451200; Cohen M, 2003, NAT CELL BIOL, V5, P661, DOI 10.1038/ncb1003; Fischer JA, 2003, INT REV CYTOL, V229, P43, DOI 10.1016/S0074-7696(03)29002-1; Fribourg S, 2003, EMBO REP, V4, P699, DOI 10.1038/sj.embor.embor883; Fribourg S, 2001, MOL CELL, V8, P645, DOI 10.1016/S1097-2765(01)00348-3; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Iyer LM, 2004, CELL CYCLE, V3, P1440, DOI 10.4161/cc.3.11.1206; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim JH, 2003, J BIOCHEM, V134, P9, DOI 10.1093/jb/mvg107; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lin HJ, 2000, MOL CELL BIOL, V20, P6568, DOI 10.1128/MCB.20.17.6568-6578.2000; Lin HJ, 2001, J BIOL CHEM, V276, P20357, DOI 10.1074/jbc.M008761200; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Morrison J, 2003, J MOL BIOL, V333, P587, DOI 10.1016/j.jmb.2003.08.050; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Senay C, 2003, J BIOL CHEM, V278, P48395, DOI 10.1074/jbc.M308275200; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; Stewart M, 1998, J MOL BIOL, V284, P1517, DOI 10.1006/jmbi.1998.2204; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Stewart M, 2000, J MOL BIOL, V299, P213, DOI 10.1006/jmbi.2000.3733; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	44	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29176	29185		10.1074/jbc.M502975200	http://dx.doi.org/10.1074/jbc.M502975200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15955808	hybrid			2022-12-25	WOS:000231021300045
J	Li, M; Craigie, R				Li, M; Craigie, R			Processing of viral DNA ends channels the HIV-1 integration reaction to concerted integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RETROVIRUS-LIKE DNA; IN-VITRO; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; ACTIVE-SITE; PREINTEGRATION COMPLEXES; TERMINAL DOMAINS; PROTEIN; INVITRO	Retroviral DNA made by reverse transcription is blunt-ended, and the viral integrase protein must remove two nucleotides from each 3' end prior to integration into chromosomal DNA. Under most reaction conditions for integration in vitro, the majority of the reaction products are "half-site" products that result from integration of only one viral DNA end into one strand of the target DNA. Preprocessed DNA substrates are more efficient substrates for half-site reactions than are blunt-ended substrates, which require the removal of two nucleotides prior to integration. In contrast, we find that blunt-ended DNA is a better substrate for the biologically relevant reaction of concerted integration of pairs of viral DNA ends. The reaction pathway is channeled to concerted integration, and half-site integration products are reduced with blunt-ended DNA substrate that must first be processed by integrase. In addition, the terminal nucleotide requirements for concerted integration are more stringent than for the half-site reaction. Longer DNA is more efficient for the concerted reaction than is shorter DNA that is capable of efficient half-site integration. This suggests that nonspecific interactions of integrase with viral DNA distant from the termini contribute to the assembly of a complex that is competent for concerted integration. Finally, differential effects of mutation of a residue in the C-terminal domain of integrase on concerted versus half-site integration implicate protein-protein interactions involving this domain as important for concerted integration.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Craigie, R (corresponding author), NIDDK, Mol Biol Lab, NIH, Bldg 5,Rm 301,5 Ctr Dr MSC 0560, Bethesda, MD 20892 USA.	bobc@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036108] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DK999999] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Bischerour J, 2003, J VIROL, V77, P135, DOI 10.1128/JVI.77.1.135-141.2003; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BUSHMAN FD, 1990, J VIROL, V64, P5645, DOI 10.1128/JVI.64.11.5645-5648.1990; Cannon PM, 1996, J VIROL, V70, P651, DOI 10.1128/JVI.70.1.651-657.1996; CANNON PM, 1994, J VIROL, V68, P4768, DOI 10.1128/JVI.68.8.4768-4775.1994; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; Chiu R, 2003, J VIROL, V77, P6482, DOI 10.1128/JVI.77.11.6482-6492.2003; Chiu R, 2000, J VIROL, V74, P8292, DOI 10.1128/JVI.74.18.8292-8298.2000; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; Craigie R, 2002, MOBILE DNA, P613; CRAIGIE R, 1997, HIV PRACTICAL APPROA, V2, P53; Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; FITZGERALD ML, 1992, J VIROL, V66, P6257, DOI 10.1128/JVI.66.11.6257-6263.1992; FUJIWARA T, 1989, P NATL ACAD SCI USA, V86, P3065, DOI 10.1073/pnas.86.9.3065; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; GOODARZI G, 1995, J VIROL, V69, P6090, DOI 10.1128/JVI.69.10.6090-6097.1995; Goodarzi G, 1999, J VIROL, V73, P8104, DOI 10.1128/JVI.73.10.8104-8111.1999; Greenwald J, 1999, BIOCHEMISTRY-US, V38, P8892, DOI 10.1021/bi9907173; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; Hindmarsh P, 1999, ADV VIRUS RES, V52, P397, DOI 10.1016/S0065-3527(08)60308-5; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; Sinha S, 2002, J VIROL, V76, P3105, DOI 10.1128/JVI.76.7.3105-3113.2002; VORA AC, 1995, J VIROL, V69, P7483, DOI 10.1128/JVI.69.12.7483-7488.1995; VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wei SQ, 1997, EMBO J, V16, P7511, DOI 10.1093/emboj/16.24.7511; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	48	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29334	29339		10.1074/jbc.M505367200	http://dx.doi.org/10.1074/jbc.M505367200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15958388	hybrid, Green Accepted			2022-12-25	WOS:000231021300064
J	Pei, LM; Castrillo, A; Chen, MY; Hoffmann, A; Tontonoz, P				Pei, LM; Castrillo, A; Chen, MY; Hoffmann, A; Tontonoz, P			Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; NEURONAL CELLS; T-LYMPHOCYTES; MICE LACKING; ATHEROSCLEROSIS; APOPTOSIS; NURR1; PATHWAY; NUR77	Oxidized lipids and inflammatory cytokines are believed to play a causal role in atherosclerosis through the regulation of gene expression in macrophages and other cells. Previous work has implicated the nuclear receptors peroxisome proliferator-activated receptor and liver X receptor in the control of lipid-dependent gene expression and inflammation. Here we demonstrate that expression of a third group of nuclear receptors, the NR4A ligand-independent orphan receptors, is highly inducible in macrophages by diverse inflammatory stimuli. Treatment of macrophages with lipopolysaccharide (LPS), cytokines, or oxidized lipids triggers the transcriptional induction of Nur77 (NR4A1), Nurr1 (NR4A2), and NOR1 (NR4A3) expression. Several lines of evidence point to the NF-kappa B signaling pathway as a principal mediator of inducible NR4A expression in macrophages. Analysis of the murine and human Nur77 promoters revealed two highly conserved NF-kappa B response elements. Mutation of these elements inhibited LPS-dependent expression of the Nur77 promoter in transient transfection assays. Furthermore, induction of Nur77 expression by LPS was severely compromised in fibroblasts lacking the three NF-kappa B subunits, Nfkb1, c-Rel, and RelA. Consistent with its ability to be induced by oxidized lipids, Nur77 was expressed in macrophages within human atherosclerotic lesions. These results identified NR4A nuclear receptors as potential transcriptional mediators of inflammatory signals in activated macrophages.	Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California San Diego	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Box 951662, Los Angeles, CA 90095 USA.	ptontonoz@mednet.ucla.edu	Hoffmann, Ary/R-2972-2019; Eckhardt, Erik/G-1567-2010	Hoffmann, Ary/0000-0001-9497-7645; Pei, Liming/0000-0002-1924-0333	NHLBI NIH HHS [HL3 0568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; IMAI H, 1980, SCIENCE, V207, P651, DOI 10.1126/science.7352277; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kim SO, 2003, J EXP MED, V197, P1441, DOI 10.1084/jem.20021842; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; McEvoy AN, 2002, J IMMUNOL, V168, P2979, DOI 10.4049/jimmunol.168.6.2979; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MORIN RJ, 1989, ANN CLIN LAB SCI, V19, P225; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Sakurada K, 1999, DEVELOPMENT, V126, P4017; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Wallen-Mackenzie A, 2003, GENE DEV, V17, P3036, DOI 10.1101/gad.276003; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhang J, 1999, COLD SPRING HARB SYM, V64, P363, DOI 10.1101/sqb.1999.64.363	36	214	225	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29256	29262		10.1074/jbc.M502606200	http://dx.doi.org/10.1074/jbc.M502606200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15964844	hybrid			2022-12-25	WOS:000231021300055
J	Tang, RH; Tng, E; Law, SKA; Tan, SM				Tang, RH; Tng, E; Law, SKA; Tan, SM			Epitope mapping of monoclonal antibody to integrin alpha(L)beta(2) hybrid domain suggests different requirements of affinity states for intercellular adhesion molecules (ICAM)-1 and ICAM-3 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; GLYCOPROTEIN-IIB-IIIA; I-LIKE DOMAIN; LEUKOCYTE INTEGRINS; BETA(2) SUBUNIT; AMINO-ACIDS; EXTRACELLULAR SEGMENT; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; TERMINAL REGION	Integrin undergoes different activation states by changing its quaternary conformation. The integrin beta hybrid domain acts as a lever for the transmission of activation signal. The displacement of the hybrid domain can serve to report different integrin activation states. The monoclonal antibody (mAb) MEM148 is a reporter antibody that recognizes Mg/EGTA-activated but not resting integrin alpha(L)beta(2). Herein, we mapped its epitope to the critical residue Pro(374) located on the inner face of the beta(2) hybrid domain. Integrin alpha(L)beta(2) binds to its ligands ICAM-1 and ICAM-3 with different affinities. Integrin is proposed to have at least three affinity states, and the position of the hybrid domain differs in each. We made use of the property of mAb MEM148 to analyze and correlate these affinity states in regard to alpha(L)beta(2). intercellular adhesion molecule (ICAM) binding. Our study showed that Mg/EGTA-activated alpha(L)beta(2) can adopt a different conformation from that activated by activating mAbs KIM185 or MEM48. Unlike ICAM-1 binding, which required only one activating agent, alpha(L)beta(2)/ICAM-3 binding required both Mg/EGTA and an activating mAb. This suggests that alpha(L)beta(2). with intermediate affinity is sufficient to bind ICAM-1 but not ICAM-3, which requires a high affinity state. Furthermore, we showed that the conformation adopted by alpha(L)beta(2) in the presence of Mg/EGTA, depicting an intermediate activation state, could be reverted to its resting conformation.	Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; University of Oxford	Tan, SM (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	smtan@ntu.edu.sg	Law, Alex/A-2212-2011; Tan, Suet/A-2224-2011	Tan, Suet-Mien/0000-0003-2371-8739				Al-Shamkhani A, 1998, EUR J IMMUNOL, V28, P3291, DOI 10.1002/(SICI)1521-4141(199810)28:10<3291::AID-IMMU3291>3.0.CO;2-E; BARCLAY AN, 1997, LEUCOCYTE ANTIGEN FA, P177; Buckley CD, 1997, EUR J IMMUNOL, V27, P957, DOI 10.1002/eji.1830270423; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; Douglass WA, 1998, FEBS LETT, V440, P414, DOI 10.1016/S0014-5793(98)01498-7; Drbal K, 2001, BLOOD, V98, P1561, DOI 10.1182/blood.V98.5.1561; Drbal K, 2001, IMMUNOBIOLOGY, V203, P687, DOI 10.1016/S0171-2985(01)80017-6; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jin M, 2004, STRUCTURE, V12, P2137, DOI 10.1016/j.str.2004.10.005; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Luo BH, 2004, J BIOL CHEM, V279, P27466, DOI 10.1074/jbc.M404354200; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; Song G, 2005, P NATL ACAD SCI USA, V102, P3366, DOI 10.1073/pnas.0500200102; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tan SM, 2001, J BIOL CHEM, V276, P36370, DOI 10.1074/jbc.M102392200; Tng E, 2004, J BIOL CHEM, V279, P54334, DOI 10.1074/jbc.M407818200; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Woska JR, 1998, J BIOL CHEM, V273, P4725, DOI 10.1074/jbc.273.8.4725; WRIGHT AH, 1995, EUR J IMMUNOL, V25, P717, DOI 10.1002/eji.1830250313; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	46	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29208	29216		10.1074/jbc.M503239200	http://dx.doi.org/10.1074/jbc.M503239200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15958383	hybrid			2022-12-25	WOS:000231021300049
J	Spelbrink, REJ; Kolkman, A; Slijper, M; Killian, JA; de Kruijff, B				Spelbrink, REJ; Kolkman, A; Slijper, M; Killian, JA; de Kruijff, B			Detection and identification of stable oligomeric protein complexes in Escherichi coli inner membranes - A proteomics approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; POTASSIUM CHANNEL; SUGAR-TRANSPORT; KCSA TETRAMER; PHOSPHOENOLPYRUVATE; STABILITY; SECA; TRANSLOCATION; PHOSPHORYLATION; CONDUCTION	In this study we present a new technology to detect stable oligomeric protein complexes in membranes. The technology is based on the ability of small membrane-active alcohols to dissociate the highly stable homotetrameric potassium channel KcsA. It is shown via a proteomics approach, using diagonal electrophoresis and nano-flow liquid chromatography coupled to tandem mass spectrometry, that a large number of both integral and peripheral Escherichia coli inner membrane proteins are part of stable oligomeric complexes that can be dissociated by small alcohols. This study gives insight into the composition and stability of these complexes.	Univ Utrecht, Biomembrane Inst, Dept Biochem Membranes, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spect, NL-3584 CA Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University; Utrecht University	Spelbrink, REJ (corresponding author), Univ Utrecht, Biomembrane Inst, Dept Biochem Membranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	r.e.j.spelbrink@chem.uu.nl	Killian, J. Antoinette/I-3001-2016	Killian, J. Antoinette/0000-0001-8010-3816				Aboulwafa M, 2004, ARCH MICROBIOL, V181, P26, DOI 10.1007/s00203-003-0623-7; Aboulwafa M, 2002, RES MICROBIOL, V153, P667, DOI 10.1016/S0923-2508(02)01376-1; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Cantor RS, 1997, J PHYS CHEM B, V101, P1723, DOI 10.1021/jp963911x; Charpentier X, 2002, J BACTERIOL, V184, P3749, DOI 10.1128/JB.184.13.3749-3752.2002; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; ENDERMANN R, 1979, FEBS LETT, V97, P339, DOI 10.1016/0014-5793(79)80117-9; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Koprowski P, 2001, BIOESSAYS, V23, P1148, DOI 10.1002/bies.10017; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; LUCKEY M, 1991, J BIOL CHEM, V266, P1866; Meiring HD, 2002, J SEP SCI, V25, P557, DOI 10.1002/1615-9314(20020601)25:9<557::AID-JSSC557>3.0.CO;2-F; MILLER C, 2000, GENOME BIOL 2000; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Phale PS, 1998, BIOCHEMISTRY-US, V37, P15663, DOI 10.1021/bi981215c; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Tziatzios C, 2004, J MOL BIOL, V340, P513, DOI 10.1016/j.jmb.2004.04.076; van Dalen A, 2002, FEBS LETT, V525, P33, DOI 10.1016/S0014-5793(02)03061-2; van Dalen A, 2002, FEBS LETT, V511, P51, DOI 10.1016/S0014-5793(01)03278-1; van den Brink-van der Laan E, 2004, BIOCHEMISTRY-US, V43, P5937, DOI 10.1021/bi0496079; van den Brink-van der Laan E, 2004, BIOCHEMISTRY-US, V43, P4240, DOI 10.1021/bi036129d; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; Vollmer W, 1999, J BIOL CHEM, V274, P6726, DOI 10.1074/jbc.274.10.6726; Wallin E, 1998, PROTEIN SCI, V7, P1029, DOI 10.1002/pro.5560070420; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Woodbury RL, 2000, J BIOL CHEM, V275, P24191, DOI 10.1074/jbc.M002885200	38	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28742	28748		10.1074/jbc.M501617200	http://dx.doi.org/10.1074/jbc.M501617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15919657	hybrid			2022-12-25	WOS:000230857300065
J	Sulochana, KN; Fan, HP; Jois, S; Subramanian, V; Sun, F; Kini, RM; Ge, RW				Sulochana, KN; Fan, HP; Jois, S; Subramanian, V; Sun, F; Kini, RM; Ge, RW			Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; DERMATAN SULFATE PROTEOGLYCAN; GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; TUBE FORMATION; PROTEIN CORE; SUPPRESSION; MIGRATION; BINDING; EXPRESSION	Excessive angiogenesis is involved in many human diseases, and inhibiting angiogenesis is an important area of drug development. There have been conflicting reports as to whether decorin could function as an angiogenic inhibitor when used as an extracellular soluble factor. In this study, we demonstrated that not only purified decorin but also the 26-residue leucine-rich repeat 5 (LRR5) of decorin core protein functions as angiogenesis inhibitor by inhibiting both vascular endothelial growth factor ( VEGF) and basic fibroblast growth factor-induced angiogenesis. Peptide LRR5 inhibited angiogenesis through multiple mechanisms, including inhibiting VEGF-stimulated endothelial cell (EC) migration, tube formation on Matrigel, cell attachment to fibronectin, as well as induction of EC apoptosis without significantly affecting their proliferation. We further demonstrated that different subregions of LRR5 inhibited different aspects of angiogenesis, with the middle region (LRR5M, 12 residues) inhibiting endothelial cell tube formation up to 1000 times more potently than LRR5. Although the C-terminal region (LRR5C) potently inhibited VEGF-stimulated endothelial cell migration, the N-terminal region (LRR5N) is as active as LRR5 in inhibiting endothelial cell attachment to fibronectin. Although both LRR5M and LRR5N induced EC apoptosis dose-dependently similar to LRR5 through a caspase-dependent pathway, LRR5C has no such function. We further showed that the inhibition of tube formation by LRR5 and LRR5M is linked with their ability to suppress VEGF-induced focal adhesion kinase phosphorylation and the assembly of focal adhesions and actin stress fibers in ECs, but not their ability to interfere with endothelial cell attachment to the matrix. Circular dichroism studies revealed that LRR5 undergoes an inter-conversion between 310 helix and beta-sheet structure in solution, a characteristic potentially important for its anti-angiogenic activity. Peptide LRR5 and its derivatives are therefore novel angiogenesis inhibitors that may serve as prototypes for further development into anti-angiogenic drugs.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Dept Pharm, Singapore 119260, Singapore	National University of Singapore; National University of Singapore	Ge, RW (corresponding author), Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore.	dbsgerw@nus.edu.sg	Fan, Huapeng/P-1338-2015; Kini, Manjunatha/H-8029-2012; Ge, Ruowen/D-8352-2012	Ge, Ruowen/0000-0002-0750-7336; Kini, Manjunatha/0000-0002-6100-3251; Fan, Huapeng/0000-0001-5635-2353				Abbi S, 2002, HISTOL HISTOPATHOL, V17, P1163, DOI 10.14670/HH-17.1163; Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dings RPM, 2003, BIOCHEM J, V373, P281, DOI 10.1042/BJ20030295; Fairlie DP, 1998, CURR MED CHEM, V5, P29; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Griffioen AW, 2001, BIOCHEM J, V354, P233, DOI 10.1042/0264-6021:3540233; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Kaneko Y, 2004, J CELL SCI, V117, P407, DOI 10.1242/jcs.00871; KEE KS, 2003, CURR PHARM DESIGN, V9, P1208; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; Lien S, 2003, TRENDS BIOTECHNOL, V21, P556, DOI 10.1016/j.tibtech.2003.10.005; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; Mayo Kevin H., 2001, Angiogenesis, V4, P45, DOI 10.1023/A:1016672117477; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; NIECKO VG, 2003, CANC METASTASIS REV, V22, P359; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Tan DCW, 2001, FEBS LETT, V494, P150, DOI 10.1016/S0014-5793(01)02314-6; Wickstrom SA, 2004, J BIOL CHEM, V279, P20178, DOI 10.1074/jbc.M312921200; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114	43	64	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27935	27948		10.1074/jbc.M414320200	http://dx.doi.org/10.1074/jbc.M414320200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923192	hybrid			2022-12-25	WOS:000230678600056
J	Wall, AA; Phillips, AM; Kelly, LE				Wall, AA; Phillips, AM; Kelly, LE			Effective translation of the second cistron in two Drosophila dicistronic transcripts is determined by the absence of in-frame AUG codons in the first cistron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAMES; MESSENGER-RNA; STONED LOCUS; NEUROTRANSMITTER RELEASE; INTERNAL INITIATION; MELANOGASTER; PROTEINS; REINITIATION; ENDOCYTOSIS; CLATHRIN	The novel dicistronic transcript encoded by the Drosophila melanogaster stoned gene was recognized as being unusual in that the protein encoded by the first open reading frame, stoned-A (STNA), contains no internal methionine residues in a protein of 93 kDa. The dicistronic nature of the stoned locus and the lack of methionine residues in STNA is conserved across dipteran species. A second methionine-free cistron, encoding Snapin, was identified in Drosophila and also found to be dicistronic, the second open reading frame (ORF) encoding a methyltransferase. We have replaced the methyltransferase cistron with green fluorescent protein (GFP) and used this dicistronic construct to show that the GFP cistron is translated in Drosophila S2 cells. The insertion of in-frame AUG codons into the snapin ORF attenuates the translation of GFP, and the level of attenuation correlates with the number of inserted AUGs. Increasing the efficiency of translation-initiation of the Snapin cistron also attenuates the translation of GFP. This indicates that failure to initiate translation at the first AUG allows ribosomes to scan through the Snapin ORF and to initiate translation of the second cistron, unless new AUG codons are inserted. These data are used to interpret the expression of the stoned locus and in particular, to explain the altered stoned protein levels in the stoned-temperature-sensitive mutant allele, which replaces a lysine with a methionine codon early in the first, stonedA, cistron.	Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia	University of Melbourne	Kelly, LE (corresponding author), Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia.	lekelly@unimelb.edu.au	Wall, Adam/C-5985-2017	Wall, Adam/0000-0001-8301-2899				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; Andrews J, 1996, GENETICS, V143, P1699; Brogna S, 1997, EMBO J, V16, P2023, DOI 10.1093/emboj/16.8.2023; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; Fergestad T, 1999, J NEUROSCI, V19, P5847, DOI 10.1523/JNEUROSCI.19-14-05847.1999; Futterer J, 1997, J VIROL, V71, P7984; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; Kelly LE, 2005, BIOCHEM J, V388, P195, DOI 10.1042/BJ20041797; KOSAK M, 2001, NUCLEIC ACIDS RES, V29, P5225; KOSAK M, 1987, MOL CELL BIOL, V7, P3438; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P102; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; MIKLOS GLG, 1987, J NEUROGENET, V4, P1, DOI 10.3109/01677068709102329; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Palfrey HC, 1998, NEUROSCIENCE, V83, P969, DOI 10.1016/S0306-4522(97)00453-3; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PETROVICH TZ, 1993, GENETICS, V133, P955; Phillips AM, 2000, J NEUROSCI, V20, P8254, DOI 10.1523/JNEUROSCI.20-22-08254.2000; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Sivakumaran K, 1998, VIROLOGY, V246, P34, DOI 10.1006/viro.1998.9183; Stimson DT, 2001, J NEUROSCI, V21, P3034, DOI 10.1523/JNEUROSCI.21-09-03034.2001; Stimson DT, 1998, J NEUROSCI, V18, P9638; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Walther K, 2001, EMBO REP, V2, P634, DOI 10.1093/embo-reports/kve134; WANG F, 1987, J VIROL, V61, P945, DOI 10.1128/JVI.61.4.945-954.1987	32	13	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27670	27678		10.1074/jbc.M500255200	http://dx.doi.org/10.1074/jbc.M500255200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15951443	hybrid			2022-12-25	WOS:000230678600025
J	Andric, SA; Zivadinovic, D; Gonzalez-Iglesias, AE; Lachowicz, A; Tomic, M; Stojilkovic, SS				Andric, SA; Zivadinovic, D; Gonzalez-Iglesias, AE; Lachowicz, A; Tomic, M; Stojilkovic, SS			Endothelin-induced, long lasting, and Ca2+ influx-independent blockade of intrinsic secretion in pituitary cells by G(z) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR ACTIVATION; HORMONE-SECRETION; CALCIUM; EXOCYTOSIS; PROLACTIN; INHIBITION; RELEASE; POOL; PHOSPHORYLATION	The G protein-coupled receptors in excitable cells have prominent roles in controlling Ca2+-triggered secretion by modulating voltage-gated Ca2+ influx. In pituitary lactotrophs, spontaneous voltage-gated Ca2+ influx is sufficient to maintain prolactin release high. Here we show that endothelin in picomolar concentrations can interrupt such release for several hours downstream of spontaneous and high K+-stimulated voltage-gated Ca2+ influx. This action occurred through the G(z) signaling pathway; the adenylyl cyclase-signaling cascade could mediate sustained inhibition of secretion, whereas rapid inhibition also occurred at elevated cAMP levels regardless of the status of phospholipase C, tyrosine kinases, and protein kinase C. In a nanomolar concentration range, endothelin also inhibited voltage-gated Ca2+ influx through the G(i/o) signaling pathway. Thus, the coupling of seven-transmembrane domain endothelin receptors to Gz proteins provided a pathway that effectively blocked hormone secretion distal to Ca2+ entry, whereas the cross-coupling to G(i/o) proteins reinforced such inhibition by simultaneously reducing the pacemaking activity.	NICHD, Sect Cellular Signaling, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHD, Sect Cellular Signaling, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A-36,49 Convent Dr, Bethesda, MD 20892 USA.	stankos@helix.nih.gov	Tomic, Melanija/C-3371-2016	Andric, Silvana/0000-0002-2908-8136	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		An SJ, 2004, SCIENCE, V306, P1042, DOI 10.1126/science.1102559; Ashworth R, 1996, ENDOCRINOLOGY, V137, P5205, DOI 10.1210/en.137.12.5205; Ben-Jonathan N, 2001, ENDOCR REV, V22, P724, DOI 10.1210/er.22.6.724; Blackmer T, 2005, NAT NEUROSCI, V8, P421, DOI 10.1038/nn1423; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Bluet-Pajot MT, 1998, CELL MOL NEUROBIOL, V18, P101, DOI 10.1023/A:1022579327647; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Felmy F, 2003, P NATL ACAD SCI USA, V100, P15200, DOI 10.1073/pnas.2433276100; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Gerachshenko T, 2005, NAT NEUROSCI, V8, P597, DOI 10.1038/nn1439; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Grishanin RN, 2004, NEURON, V43, P551, DOI 10.1016/j.neuron.2004.07.028; Harada N, 2002, CELL MOL NEUROBIOL, V22, P207, DOI 10.1023/A:1019822107048; KANYICSKA B, 1991, BIOCHEM BIOPH RES CO, V174, P338, DOI 10.1016/0006-291X(91)90525-C; KANYICSKA B, 1993, AM J PHYSIOL, V265, pE601, DOI 10.1152/ajpendo.1993.265.4.E601; Kedzierski RM, 2001, ANNU REV PHARMACOL, V41, P851, DOI 10.1146/annurev.pharmtox.41.1.851; Koshimizu T, 2000, ENDOCRINOLOGY, V141, P4091, DOI 10.1210/en.141.11.4091; Krsmanovic LZ, 1998, ENDOCRINOLOGY, V139, P4037, DOI 10.1210/en.139.10.4037; Lachowicz A, 1997, J BIOL CHEM, V272, P28308, DOI 10.1074/jbc.272.45.28308; Lange M, 2002, EXP CLIN ENDOCR DIAB, V110, P103, DOI 10.1055/s-2002-29086; Martin TFJ, 2003, BBA-MOL CELL RES, V1641, P157, DOI 10.1016/S0167-4889(03)00093-4; Nagy G, 2004, NEURON, V41, P417, DOI 10.1016/S0896-6273(04)00038-8; Nagy G, 2002, J NEUROSCI, V22, P9278; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Sakaba T, 2003, NATURE, V424, P775, DOI 10.1038/nature01859; SAMSON WK, 1990, BIOCHEM BIOPH RES CO, V169, P737, DOI 10.1016/0006-291X(90)90393-2; SAMSON WK, 1992, BIOCHEM BIOPH RES CO, V187, P590, DOI 10.1016/0006-291X(92)91235-I; SanchezBlazquez P, 1995, J PHARMACOL EXP THER, V275, P1590; Serres F, 2000, J NEUROSCI, V20, P3095, DOI 10.1523/JNEUROSCI.20-09-03095.2000; SILINSKY EM, 1984, J PHYSIOL-LONDON, V346, P243, DOI 10.1113/jphysiol.1984.sp015019; SILINSKY EM, 1992, J PHYSIOL-LONDON, V457, P315, DOI 10.1113/jphysiol.1992.sp019380; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; STOJILKOVIC SS, 1992, ENDOCRINOLOGY, V130, P465, DOI 10.1210/en.130.1.465; STOJILKOVIC SS, 1995, J NEUROENDOCRINOL, V7, P739, DOI 10.1111/j.1365-2826.1995.tb00711.x; STOJILKOVIC SS, 1991, MOL PHARMACOL, V39, P762; Tomic M, 1999, J NEUROSCI, V19, P7721; Tomic M, 2002, MOL PHARMACOL, V61, P1329, DOI 10.1124/mol.61.6.1329; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; Van Goor F, 2001, J BIOL CHEM, V276, P33840, DOI 10.1074/jbc.M105386200; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Wolfe JT, 2003, NATURE, V424, P209, DOI 10.1038/nature01772; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; Yang Y, 2002, P NATL ACAD SCI USA, V99, P17060, DOI 10.1073/pnas.242624699; ZHENG LX, 1995, ENDOCRINOLOGY, V136, P1079, DOI 10.1210/en.136.3.1079; Zhu HL, 2002, P NATL ACAD SCI USA, V99, P17055, DOI 10.1073/pnas.232588899; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	49	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26896	26903		10.1074/jbc.M502226200	http://dx.doi.org/10.1074/jbc.M502226200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15919662	hybrid			2022-12-25	WOS:000230589500032
J	de Sanctis, D; Dewilde, S; Vonrhein, C; Pesce, A; Moens, L; Ascenzi, P; Hankeln, T; Burmester, T; Ponassi, M; Nardini, M; Bolognesi, M				de Sanctis, D; Dewilde, S; Vonrhein, C; Pesce, A; Moens, L; Ascenzi, P; Hankeln, T; Burmester, T; Ponassi, M; Nardini, M; Bolognesi, M			Bishistidyl heme hexacoordination, a key structural property in Drosophila melanogaster hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONVERTEBRATE HEMOGLOBINS; MAXIMUM-LIKELIHOOD; CRYSTAL-STRUCTURE; HUMAN CYTOGLOBIN; FERRIC APLYSIA; GLOBIN GENE; X-RAY; CHIRONOMUS; NEUROGLOBIN; EVOLUTION	Hemoglobins at high concentration have been isolated long ago from some insect larvae living in hypoxic environments. Conversely, a monomeric hemoglobin has been discovered recently in the fruit fly Drosophila melanogaster as intracellular protein expressed both in larvae and in the adult fly. Such a finding indicates that the oxygen supply in insects may be more complex than previously thought, relying not only on O-2 diffusion through the tubular tracheal system, but also on carrier-mediated transport and storage. We present here the crystal structure of recombinant D. melanogaster hemoglobin at 1.20 angstrom resolution. Spectroscopic data show that the protein displays a hexacoordinated heme, whose axial ligands are the proximal and distal His residues. Such bis-His ligation of the heme has sizable effects on the protein local structure. Three protein matrix cavities, comparable in size but not in topological locations with those of sperm whale myoglobin, are spread through the protein matrix; one of these can host a xenon atom. Additionally, D. melanogaster hemoglobin binds one molecule of 3-(cyclohexylamino) propanesulfonic acid ( CAPS) buffer at a surface pocket, next to the EF hinge. Despite the high resolution achieved, no sequence/structure features specifically supporting the heme hexa- to pentacoordination transition required for diatomic ligand binding could be recognized.	Univ Milan, INFM, Dept Biomol Sci & Biotechnol, I-20131 Milan, Italy; Univ Genoa, Dept Phys, Natl Inst Phys Matter, I-16146 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16146 Genoa, Italy; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium; Global Phasing Ltd, Cambridge CB3 0AX, England; Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; Univ Roma Tre, Interdept Lab Electron Microscopy, I-00146 Rome, Italy; Natl Inst Invect Dis Lazzaro Spallanzani, I-00149 Rome, Italy; Johannes Gutenberg Univ Mainz, Inst Genet Mol, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Natl Canc Inst Genova, Struct Biol Unit, I-16132 Genoa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Genoa; University of Genoa; University of Antwerp; Global Phasing Limited; Roma Tre University; Roma Tre University; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Bolognesi, M (corresponding author), Univ Milan, INFM, Dept Biomol Sci & Biotechnol, Via Celoria 26, I-20131 Milan, Italy.	martino.bolognesi@unimi.it	Burmester, Thorsten/I-7225-2013; Pesce, Alessandra/A-3660-2015; Ponassi, Marco/K-8000-2016; Nardini, Marco/B-7842-2017; Bolognesi, Martino/B-7924-2017	Burmester, Thorsten/0000-0002-5772-7863; Nardini, Marco/0000-0002-3718-2165; Bolognesi, Martino/0000-0002-9253-5170; Ponassi, Marco/0000-0002-5418-2458				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BASHFORD D, 1999, LECT NOTES COMPUTER, V1343, P233; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; BOLOGNESI M, 1982, J MOL BIOL, V158, P305, DOI 10.1016/0022-2836(82)90435-1; Brunori M, 2004, J STRUCT BIOL, V147, P223, DOI 10.1016/j.jsb.2004.04.008; Burmester T, 1999, MOL BIOL EVOL, V16, P1809, DOI 10.1093/oxfordjournals.molbev.a026093; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2004, NEWS PHYSIOL SCI, V19, P110, DOI 10.1152/nips.01513.2003; Burmester T, 2002, J COMP PHYSIOL B, V172, P95, DOI 10.1007/s00360-001-0247-7; Coletta M, 1996, EUR J BIOCHEM, V235, P49, DOI 10.1111/j.1432-1033.1996.00049.x; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; de Sanctis D, 2004, IUBMB LIFE, V56, P643, DOI 10.1080/15216540500059640; de Sanctis D, 2004, BIOCHEM BIOPH RES CO, V316, P1217, DOI 10.1016/j.bbrc.2004.03.007; de Sanctis D, 2004, J MOL BIOL, V336, P917, DOI 10.1016/j.jmb.2003.12.063; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dewilde S, 1998, J BIOL CHEM, V273, P32467, DOI 10.1074/jbc.273.49.32467; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; GIACOMETTI GM, 1981, J MOL BIOL, V151, P315, DOI 10.1016/0022-2836(81)90518-0; Green BN, 1998, BBA-PROTEIN STRUCT M, V1383, P143, DOI 10.1016/S0167-4838(97)00195-7; Hagner-Holler S, 2004, P NATL ACAD SCI USA, V101, P871, DOI 10.1073/pnas.0305872101; Hankeln T, 1997, GENE, V205, P151, DOI 10.1016/S0378-1119(97)00518-0; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Hankeln T, 2002, J BIOL CHEM, V277, P29012, DOI 10.1074/jbc.M204009200; Hankeln T, 1998, J MOL EVOL, V46, P589, DOI 10.1007/PL00006339; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; HOLM L, 1993, FEBS LETT, V315, P301, DOI 10.1016/0014-5793(93)81183-Z; HUBER R, 1971, EUR J BIOCHEM, V19, P42, DOI 10.1111/j.1432-1033.1971.tb01285.x; Jentzen W, 1997, J PHYS CHEM B, V101, P1684, DOI 10.1021/jp963142h; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamimura S, 2003, EUR J BIOCHEM, V270, P1424, DOI 10.1046/j.1432-1033.2003.03498.x; LAMAR GN, 1978, BIOCHEMISTRY-US, V17, P352, DOI 10.1021/bi00595a025; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGM, 2003, MOSFLM USER GUIDE MO; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Milani M, 2005, J INORG BIOCHEM, V99, P97, DOI 10.1016/j.jinorgbio.2004.10.035; Milani M, 2004, J BIOL CHEM, V279, P21520, DOI 10.1074/jbc.M401320200; Milani M, 2003, BIOCHEM MOL BIOL EDU, V31, P228, DOI 10.1002/bmb.2003.494031040239; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; MILLER PL, 1966, J EXP BIOL, V44, P529; MITCHELL DT, 1995, J MOL BIOL, V251, P421, DOI 10.1006/jmbi.1995.0445; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OSMULSKI PA, 1986, COMP BIOCHEM PHYS B, V85, P701, DOI 10.1016/0305-0491(86)90166-5; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; PERUTZ MF, 1989, TRENDS BIOCHEM SCI, V14, P42, DOI 10.1016/0968-0004(89)90039-X; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, STRUCTURE, V10, P725, DOI 10.1016/S0969-2126(02)00763-3; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; Sugimoto H, 2004, J MOL BIOL, V339, P873, DOI 10.1016/j.jmb.2004.04.024; Teeter MM, 2004, PROTEIN SCI, V13, P313, DOI 10.1110/ps.03334304; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vallone B, 2004, PROTEINS, V56, P85, DOI 10.1002/prot.20113; Vallone B, 2004, P NATL ACAD SCI USA, V101, P17351, DOI 10.1073/pnas.0407633101; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WEBER RE, 1985, COMP BIOCHEM PHYS B, V80, P747, DOI 10.1016/0305-0491(85)90456-0; Weber RE, 2004, RESP PHYSIOL NEUROBI, V144, P141, DOI 10.1016/j.resp.2004.04.018; WEBER RE, 1978, J COMP PHYSIOL, V123, P177; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; Weiland TR, 2004, J AM CHEM SOC, V126, P11930, DOI 10.1021/ja046990w; WELLS RMG, 1981, J COMP PHYSIOL, V142, P515, DOI 10.1007/BF00688984; Willmer P., 2000, ENV PHYSL ANIMALS; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Wu GH, 2003, ADV MICROB PHYSIOL, V47, P255, DOI 10.1016/S0065-2911(03)47005-7	75	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27222	27229		10.1074/jbc.M503814200	http://dx.doi.org/10.1074/jbc.M503814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917230	hybrid			2022-12-25	WOS:000230589500070
J	Hong, WZ; Jiao, WW; Hu, JC; Zhang, JR; Liu, C; Fu, XM; Shen, D; Xia, B; Chang, ZY				Hong, WZ; Jiao, WW; Hu, JC; Zhang, JR; Liu, C; Fu, XM; Shen, D; Xia, B; Chang, ZY			Periplasmic protein HdeA exhibits chaperone-like activity exclusively within stomach pH range by transforming into disordered conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACID-RESISTANCE; SHIGELLA-FLEXNERI; ENTERIC BACTERIA; RELEASE; ENZYMES; STRESS; SHOCK	The extremely acidic environment of the mammalian stomach, with a pH range usually between 1 and 3, represents a stressful challenge for enteric pathogenic bacteria such as Escherichia coli before they enter into the intestine. The hdeA gene of E. coli was found to be acid inducible and was revealed by genetic studies to be important for the acid survival of the strain. This study was performed in an attempt to characterize the mechanism of the activity of the HdeA protein. Our data provided in this report strongly suggest that HdeA employs a novel strategy to modulate its chaperone activity: it possesses an ordered conformation that is unable to bind denatured substrate proteins under normal physiological conditions (i.e. at neutral pH) and transforms into a globally disordered conformation that is able to bind substrate proteins under stress conditions (i.e. at a pH below 3). Furthermore, our data indicate that HdeA exposes hydrophobic surfaces that appear to be involved in the binding of denatured substrate proteins at extremely low pH values. In light of our observations, models are proposed to explain the action of HdeA in both a physiological and a molecular context.	Peking Univ, Natl Lab Prot Engn & Plant Genet Engn, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China; Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China; Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China	Peking University; Peking University; Peking University; Tsinghua University	Chang, ZY (corresponding author), Peking Univ, Natl Lab Prot Engn & Plant Genet Engn, Beijing 100871, Peoples R China.	changzy@pku.edu.cn	Fu, Xinmiao/ABE-9050-2020; Zhang, Junrui/J-2684-2012; Hong, Weizhe/E-3164-2010; Xia, Bin/O-1160-2016; Hong, Weizhe/AAD-7172-2020; Liu, Chong/G-3514-2011	Fu, Xinmiao/0000-0003-3361-6904; Hong, Weizhe/0000-0003-1523-8575; Xia, Bin/0000-0002-2197-6403; Hong, Weizhe/0000-0003-1523-8575; 				Audia JP, 2001, INT J MED MICROBIOL, V291, P97, DOI 10.1078/1438-4221-00106; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; FINK AL, 1999, PHYSIOL REV, V2, P435; Foster JW, 2004, NAT REV MICROBIOL, V2, P898, DOI 10.1038/nrmicro1021; Fu XM, 2005, J BIOL CHEM, V280, P6337, DOI 10.1074/jbc.M406319200; Gajiwala KS, 2000, J MOL BIOL, V295, P605, DOI 10.1006/jmbi.1999.3347; GORDEN J, 1993, INFECT IMMUN, V61, P364, DOI 10.1128/IAI.61.1.364-367.1993; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HEPPEL LA, 1967, SCIENCE, V156, P1451, DOI 10.1126/science.156.3781.1451; Jiao WW, 2005, J MOL BIOL, V347, P871, DOI 10.1016/j.jmb.2005.01.029; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Liu Y, 2004, BIOCHEM BIOPH RES CO, V316, P795, DOI 10.1016/j.bbrc.2004.02.125; NEU HC, 1965, J BIOL CHEM, V240, P3685; Papoian GA, 2004, P NATL ACAD SCI USA, V101, P3352, DOI 10.1073/pnas.0307851100; Poon S, 2002, J BIOL CHEM, V277, P39532, DOI 10.1074/jbc.M204855200; Raivio TL, 2001, ANNU REV MICROBIOL, V55, P591, DOI 10.1146/annurev.micro.55.1.591; Schirmer T, 1998, J STRUCT BIOL, V121, P101, DOI 10.1006/jsbi.1997.3946; SMALL P, 1994, J BACTERIOL, V176, P1729, DOI 10.1128/jb.176.6.1729-1737.1994; Smith JL, 2003, J FOOD PROTECT, V66, P1292, DOI 10.4315/0362-028X-66.7.1292; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Tompa P, 2004, FASEB J, V18, P1169, DOI 10.1096/fj.04-1584rev; Tucker DL, 2002, J BACTERIOL, V184, P6551, DOI 10.1128/JB.184.23.6551-6558.2002; Wang KY, 2001, BIOCHEM BIOPH RES CO, V287, P642, DOI 10.1006/bbrc.2001.5636; Waterman SR, 1996, MOL MICROBIOL, V21, P925, DOI 10.1046/j.1365-2958.1996.00058.x; Yang F, 1998, NAT STRUCT BIOL, V5, P763, DOI 10.1038/1796	29	111	117	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27029	27034		10.1074/jbc.M503934200	http://dx.doi.org/10.1074/jbc.M503934200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911614	hybrid			2022-12-25	WOS:000230589500048
J	Shields, DJ; Lingrell, S; Agellon, LB; Brosnan, JT; Vance, DE				Shields, DJ; Lingrell, S; Agellon, LB; Brosnan, JT; Vance, DE			Localization-independent regulation of homocysteine secretion by phosphatidylethanolamine N-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATHIONINE BETA-SYNTHASE; ENDOPLASMIC-RETICULUM; RISK-FACTOR; PLASMA HOMOCYSTEINE; LIVER PHOSPHATIDYLCHOLINE; TRANSMEMBRANE PROTEINS; MEMBRANE-FRACTION; MICE DEFICIENT; RAT-LIVER; ASSOCIATION	Genetic ablation of phosphatidylethanolamine N-methyltransferase (PEMT) in mice causes a 50% reduction in plasma homocysteine (Hcy) levels. Because hyperhomocysteinemia is an independent risk factor for cardiovascular disease, resolution of the molecular basis for this reduction is of significant clinical interest. The PEMT pathway is a metabolically channeled process localized to the endoplasmic reticulum ( ER). To assess the importance of PEMT localization for Hcy homeostasis, we identified and ablated the minimal ER targeting motif. Mutagenesis of a conserved, C-terminal lysine residue ( 197) relocalized the enzyme to the Golgi, demonstrating that Lys-197 is essential for targeting PEMT to the ER. To evaluate the functional significance of PEMT localization, hepatoma cell lines were generated that stably expressed either ER- or Golgi-localized PEMT only. Intriguingly, stable expression of PEMT in either the ER or the Golgi caused increased Hcy secretion. Moreover, PEMT-mediated Hcy secretion correlated with the methyltransferase activity of the enzyme, independently of subcellular localization. Thus, our data suggest that Hcy homeostasis is regulated concomitantly with PEMT activity but independently of PEMT localization.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Mem Univ Newfoundland, Dept Biochem, St John, NF A1B 3X9, Canada	University of Alberta; University of Alberta; Memorial University Newfoundland	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, 328 HMRC, Edmonton, AB T6G 2S2, Canada.	Dennis.Vance@ualberta.ca						Benghezal M, 2000, PLANT CELL, V12, P1179, DOI 10.1105/tpc.12.7.1179; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; CUI Z, 1993, J BIOL CHEM, V268, P16655; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; FAROOQUI JZ, 1983, BIOCHIM BIOPHYS ACTA, V757, P342; FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001; Finkelstein JD, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P92; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; FUJIOKA M, 1992, INT J BIOCHEM, V24, P1917, DOI 10.1016/0020-711X(92)90287-B; Gauthier GM, 2003, CLIN CARDIOL, V26, P563, DOI 10.1002/clc.4960261204; Gilham D, 2003, FASEB J, V17, P1685, DOI 10.1096/fj.02-0728fje; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gupta M, 2005, CLIN CHIM ACTA, V352, P121, DOI 10.1016/j.cccn.2004.08.005; Hardt B, 2002, BIOCHEM BIOPH RES CO, V291, P751, DOI 10.1006/bbrc.2002.6515; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kuipers F, 1997, Subcell Biochem, V28, P295; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Matetzky S, 2003, ARCH INTERN MED, V163, P1933, DOI 10.1001/archinte.163.16.1933; MUDD SH, 1980, METABOLISM, V29, P707, DOI 10.1016/0026-0495(80)90192-4; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Noga AA, 2003, J BIOL CHEM, V278, P5952, DOI 10.1074/jbc.M212194200; PANAGIA V, 1984, BIOCHIM BIOPHYS ACTA, V792, P245, DOI 10.1016/0005-2760(84)90192-9; Parnetti L, 2004, NEUROL SCI, V25, P13, DOI 10.1007/s10072-004-0219-5; PRASAD C, 1981, J BIOL CHEM, V256, P3000; Reo NV, 2000, TOXICOL APPL PHARM, V164, P113, DOI 10.1006/taap.2000.8901; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; Satoh A, 2003, TRAFFIC, V4, P153, DOI 10.1034/j.1600-0854.2003.00103.x; Scott M, 2004, BIOINFORMATICS, V20, P937, DOI 10.1093/bioinformatics/bth010; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Shai I, 2004, ATHEROSCLEROSIS, V177, P375, DOI 10.1016/j.atherosclerosis.2004.07.020; Shields DJ, 2003, J BIOL CHEM, V278, P35826, DOI 10.1074/jbc.M306308200; Shields DJ, 2003, J BIOL CHEM, V278, P2956, DOI 10.1074/jbc.M210904200; Stead LM, 2000, BIOCHEM J, V350, P685, DOI 10.1042/0264-6021:3500685; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tehlivets O, 2004, FEBS LETT, V577, P501, DOI 10.1016/j.febslet.2004.10.057; UELAND PM, 1979, FEBS LETT, V101, P184, DOI 10.1016/0014-5793(79)81322-8; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VESTER B, 1991, EUR J CLIN CHEM CLIN, V29, P549; Wang LQ, 2004, CIRC RES, V94, P1318, DOI 10.1161/01.RES.0000129182.46440.4a; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507	52	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27339	27344		10.1074/jbc.M504658200	http://dx.doi.org/10.1074/jbc.M504658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15927961	hybrid			2022-12-25	WOS:000230589500084
J	Pietila, EM; Tuusa, JT; Apaja, PM; Aatsinki, JT; Hakalahti, AE; Rajaniemi, HJ; Petaja-Repo, UE				Pietila, EM; Tuusa, JT; Apaja, PM; Aatsinki, JT; Hakalahti, AE; Rajaniemi, HJ; Petaja-Repo, UE			Inefficient maturation of the rat luteinizing hormone receptor - A putative way to regulate receptor numbers at the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM DEGRADATION; CHORIONIC-GONADOTROPIN-RECEPTOR; UBIQUITIN-PROTEASOME SYSTEM; OVARIAN LUTROPIN RECEPTOR; WILD-TYPE; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; STRUCTURAL-CHARACTERIZATION; INTRACELLULAR TRAFFICKING	Increasing evidence suggests that the folding and maturation of monomeric proteins and assembly of multimeric protein complexes in the endoplasmic reticulum ( ER) may be inefficient not only for mutants that carry changes in the primary structure but also for wild type proteins. In the present study, we demonstrate that the rat luteinizing hormone receptor, a G protein-coupled receptor, is one of these proteins that matures inefficiently and appears to be very prone to premature degradation. A substantial portion of the receptors in stably transfected human embryonic kidney 293 cells existed in immature form of M-r 73,000, containing high man-nose-type N-linked glycans. In metabolic pulse-chase studies, only similar to 20% of these receptor precursors were found to gain hormone binding ability and matured to a form of Mr 90,000, containing bi- and multiantennary sialylated N-linked glycans. The rest had a propensity to form disulfide-bonded complexes with a Mr 120,000 protein in the ER membrane and were eventually targeted for degradation in proteasomes. The number of membrane-bound receptor precursors increased when proteasomal degradation was inhibited, and no cytosolic receptor forms were detected, suggesting that retro-translocation of the misfolded/incompletely folded receptors is tightly coupled to proteasomal function. Furthermore, a proteasomal blockade was found to increase the number of receptors that were capable of hormone binding. Thus, these results raise the interesting possibility that luteinizing hormone receptor expression at the cell surface may be controlled at the ER level by regulating the number of newly synthesized proteins that will mature and escape the ER quality control and premature degradation.	Univ Oulu, Dept Anat & Cell Biol, FI-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FI-90014 Oulu, Finland	University of Oulu; University of Oulu	Petaja-Repo, UE (corresponding author), Univ Oulu, Dept Anat & Cell Biol, POB 5000, FI-90014 Oulu, Finland.	Ulla.Petaja-Repo@oulu.fi	Petäjä-Repo, Ulla/AAV-6115-2021	Apaja, Pirjo/0000-0002-1622-2332				AASTSINKI JT, 2005, PROTEIN EXPRES PURIF, V40, P287; Andersson H, 2003, MOL PHARMACOL, V64, P570, DOI 10.1124/mol.64.3.570; Apaja PM, 2004, J BIOL CHEM, V279, P1899, DOI 10.1074/jbc.M311395200; APAJA PM, 2005, IN PRESS ENDOCRINOLO; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Ayalon-Soffer M, 1999, FEBS LETT, V460, P112, DOI 10.1016/S0014-5793(99)01321-6; Beau I, 1997, J BIOL CHEM, V272, P5241, DOI 10.1074/jbc.272.8.5241; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; CAPPS GG, 1993, J IMMUNOL, V151, P159; Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; Cook LB, 2003, MOL ENDOCRINOL, V17, P1777, DOI 10.1210/me.2003-0073; Dangoria NS, 2002, J BIOL CHEM, V277, P23459, DOI 10.1074/jbc.M110336200; Fabritz J, 1998, BIOCHEMISTRY-US, V37, P664, DOI 10.1021/bi972355+; Fayadat L, 1998, ENDOCRINOLOGY, V139, P4277, DOI 10.1210/en.139.10.4277; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; Floyd DH, 2003, J BIOL CHEM, V278, P35354, DOI 10.1074/jbc.M305607200; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; KEARSE KP, 1994, EMBO J, V13, P4504, DOI 10.1002/j.1460-2075.1994.tb06772.x; KEINANEN KP, 1987, J BIOL CHEM, V262, P7920; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li L, 2003, TRENDS CELL BIOL, V13, P507, DOI 10.1016/j.tcb.2003.08.002; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Lu M, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-34; Lu M, 2003, TRAFFIC, V4, P416, DOI 10.1034/j.1600-0854.2003.00097.x; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Mear JP, 1999, J IMMUNOL, V163, P6665; METSIKKO K, 1979, FEBS LETT, V106, P193, DOI 10.1016/0014-5793(79)80726-7; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Pareek S, 1997, J NEUROSCI, V17, P7754; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; PETAJAREPO UE, 1994, BIOCHEM J, V298, P361, DOI 10.1042/bj2980361; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Saliba RS, 2002, J CELL SCI, V115, P2907; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; SOJAR HT, 1989, J BIOL CHEM, V264, P2552; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Vannier B, 1996, BIOCHEMISTRY-US, V35, P1358, DOI 10.1021/bi952290f; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; VUHAILUUTHI MT, 1992, BIOCHEMISTRY-US, V31, P8377, DOI 10.1021/bi00150a035; WARD CL, 1994, J BIOL CHEM, V269, P25710; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wuller S, 2004, J BIOL CHEM, V279, P47254, DOI 10.1074/jbc.M408154200; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835	70	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26622	26629		10.1074/jbc.M413815200	http://dx.doi.org/10.1074/jbc.M413815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901736	hybrid			2022-12-25	WOS:000230386800079
J	Ito, N; Ito, T; Kromminga, A; Bettermann, A; Takigawa, M; Kees, F; Straub, RH; Paus, R				Ito, N; Ito, T; Kromminga, A; Bettermann, A; Takigawa, M; Kees, F; Straub, RH; Paus, R			Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal (HPA) axis and synthesize cortisol	FASEB JOURNAL			English	Article						CRH; ACTH; alpha-MSH; proopiomelanocortin; stress	CORTICOTROPIN-RELEASING HORMONE; MELANOCYTE-STIMULATING HORMONE; CYCLE-DEPENDENT EXPRESSION; HUMAN SKIN; MELANOCORTIN-1 RECEPTOR; MESSENGER-RNA; FACTOR CRF; PROOPIOMELANOCORTIN; STRESS; POMC	The skin and its major appendages are prominent target organs and potent sources of key players along the classical hypothalamic-pituitary axis, such as corticotropin releasing hormone (CRH), adrenocorticotropic hormone ( ACTH), and a melanocyte stimulating hormone (alpha-MSH), and even express key steroidogenic enzymes. Therefore, it may have established local stress response systems that resemble the hypothalamic-pituitary-adrenal (HPA) axis. However, functional evidence that this is indeed the case in normal human skin in situ has still been missing. We show that microdissected, organ-cultured human scalp hair follicles respond to CRH stimulation by up-regulating proopiomelanocortin ( POMC) transcription and immunoreactivity (IR) for ACTH and alpha-MSH, which must have been processed from POMC. CRH, alpha-MSH, and ACTH also modulate expression of their cognate receptors (CRH-R1, MC1-R, MC2-R). In addition, the strongest stimulus for adrenal cortisol production, ACTH, also up-regulates cortisol-IR in the hair follicles. Isolated human hair follicles secrete substantial levels of cortisol into the culture medium, and this activity is further up-regulated by CRH. CRH also modulates important functional hair growth parameters in vitro (hair shaft elongation, catagen induction, hair keratinocyte proliferation, melanin production). Finally, human hair follicles display HPA axis-like regulatory feedback systems, since the glucocorticoid receptor agonist hydrocortisone down-regulates follicular CRH expression. Thus, even in the absence of endocrine, neural, or vascular systemic connections, normal human scalp hair follicles directly respond to CRH stimulation in a strikingly similar manner to what is seen in the classical HPA axis, including synthesis and secretion of cortisol and activation of prototypic neuroendocrine feedback loops.	Univ Hamburg, Dept Dermatol, Univ Hosp Hamburg Eppendorf, D-20246 Hamburg, Germany; Hamamatsu Univ Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 43131, Japan; Inst Immunol, Clin Pathol & Mol Med, Hamburg, Germany; Univ Regensburg, Dept Pharmacol, Regensburg, Germany; Univ Med Ctr Regensburg, Dept Internal Med 1, Regensburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Hamamatsu University School of Medicine; University of Regensburg; University of Regensburg	Paus, R (corresponding author), Univ Hamburg, Dept Dermatol, Univ Hosp Hamburg Eppendorf, Martinistr 52, D-20246 Hamburg, Germany.	paus@uke.uni-hamburg.de	Paus, Ralf/F-6243-2011	Straub, Rainer H/0000-0003-1165-4555				AGREN UM, 1995, J CELL PHYSIOL, V164, P240, DOI 10.1002/jcp.1041640204; Aoki E, 2003, EXP DERMATOL, V12, P371, DOI 10.1034/j.1600-0625.2002.120403.x; Arck PC, 2001, FASEB J, V15, P2536, DOI 10.1096/fj.00-0699fje; AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; Bohm M, 2002, J INVEST DERMATOL, V118, P533, DOI 10.1046/j.0022-202x.2001.01704.x; Bohm M, 2000, HORM RES, V54, P287, DOI 10.1159/000053273; Botchkarev VA, 2000, FASEB J, V14, P1931, DOI 10.1096/fj.99-0930com; Botchkarev VA, 2003, AM J PATHOL, V162, P709, DOI 10.1016/S0002-9440(10)63866-7; Botchkarev VA, 1999, ANN NY ACAD SCI, V885, P433; Burton PJ, 1998, ENDOCRINOLOGY, V139, P376, DOI 10.1210/en.139.1.376; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Deplewski D, 2000, ENDOCR REV, V21, P363, DOI 10.1210/er.21.4.363; Dodds HM, 1997, ANAL BIOCHEM, V247, P342, DOI 10.1006/abio.1997.2074; Elliott RJ, 2004, J INVEST DERMATOL, V122, P1010, DOI 10.1111/j.0022-202X.2004.22404.x; Ermak G, 1997, J INVEST DERMATOL, V108, P160, DOI 10.1111/1523-1747.ep12332925; Flint MS, 2003, STRESS, V6, P59, DOI 10.1080/1025389031000088426; Foitzik K, 2003, AM J PATHOL, V162, P1611, DOI 10.1016/S0002-9440(10)64295-2; Fritsch M, 2001, J INVEST DERMATOL, V116, P793, DOI 10.1046/j.1523-1747.2001.01312.x; GOODYER CG, 1981, CIBA F SYMP, V86, P89; Greenspan F. S., 2004, BASIC CLIN ENDOCRINO; Harbuz MS, 2003, ANN NY ACAD SCI, V992, P99, DOI 10.1111/j.1749-6632.2003.tb03141.x; Hoffman R, 2001, EUR J DERMATOL, V11, P296; Ito N, 2004, J INVEST DERMATOL, V122, P235, DOI 10.1046/j.1523-1747.2003.22145.x; Ito T, 2005, BRIT J DERMATOL, V152, P623, DOI 10.1111/j.1365-2133.2005.06453.x; Ito T, 2004, AM J PATHOL, V164, P623, DOI 10.1016/S0002-9440(10)63151-3; Kaneko K, 2003, EXP DERMATOL, V12, P47, DOI 10.1034/j.1600-0625.2003.120106.x; Kauser S, 2004, J INVEST DERMATOL, V123, P184, DOI 10.1111/j.0022-202X.2004.22724.x; Kono M, 2001, FASEB J, V15, P2297, DOI 10.1096/fj.01-0254fje; Lechner O, 2000, EUR J IMMUNOL, V30, P337; Lindner G, 1997, AM J PATHOL, V151, P1601; Luger TA, 1998, ANN NY ACAD SCI, V840, P381, DOI 10.1111/j.1749-6632.1998.tb09577.x; Maurer M, 1997, LAB INVEST, V77, P319; Mazurkiewicz JE, 1999, ANN NY ACAD SCI, V885, P427; Miller DB, 2002, METABOLISM, V51, P5, DOI 10.1053/meta.2002.33184; Moustafa M, 2002, J INVEST DERMATOL, V119, P1244, DOI 10.1046/j.1523-1747.2002.19602.x; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Paus R, 1999, ANN NY ACAD SCI, V885, P350; Paus R, 2005, TRENDS IMMUNOL, V26, P32, DOI 10.1016/j.it.2004.09.014; Paus R, 2003, J INVEST DERM SYMP P, V8, P188, DOI 10.1046/j.1087-0024.2003.00807.x; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1994, DEV BIOL, V163, P230, DOI 10.1006/dbio.1994.1139; Paus R, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P61, DOI 10.1038/jidsymp.1997.13; Paus R, 1999, J INVEST DERM SYMP P, V4, P226, DOI 10.1038/sj.jidsp.5640217; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 2003, DERMATOLOGY, V68, P1007; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; Petraglia F, 1998, J REPROD IMMUNOL, V39, P221, DOI 10.1016/S0165-0378(98)00024-2; PHILPOTT MP, 1994, J DERMATOL SCI, V7, P55; Quevedo ME, 2001, IN VITRO CELL DEV-AN, V37, P50; QUIRK SJ, 1990, J STEROID BIOCHEM, V35, P623, DOI 10.1016/0022-4731(90)90208-A; Rogoff D, 2001, J STEROID BIOCHEM, V78, P77, DOI 10.1016/S0960-0760(01)00076-0; Roloff B, 1998, FASEB J, V12, P287, DOI 10.1096/fasebj.12.3.287; Roth KA, 1999, J HISTOCHEM CYTOCHEM, V47, P1644; Serres M, 1996, ARCH DERMATOL RES, V288, P140, DOI 10.1007/BF02505823; Sinclair R, 1999, HDB DIS HAIR SCALP, P3; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; SLOMINSKI A, 1992, EXPERIENTIA, V48, P50, DOI 10.1007/BF01923606; Slominski A, 2005, AM J PHYSIOL-ENDOC M, V288, pE701, DOI 10.1152/ajpendo.00519.2004; SLOMINSKI A, 1993, MOL CELL ENDOCRINOL, V93, pC1, DOI 10.1016/0303-7207(93)90131-3; Slominski A, 1996, INT J DERMATOL, V35, P849, DOI 10.1111/j.1365-4362.1996.tb05049.x; SLOMINSKI A, 1993, J LAB CLIN MED, V122, P658; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; Slominski A, 1996, J CLIN ENDOCR METAB, V81, P2746, DOI 10.1210/jc.81.7.2746; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2004, ENDOCRINOLOGY, V145, P941, DOI 10.1210/en.2003-0851; Slominski A, 1996, FEBS LETT, V399, P175, DOI 10.1016/S0014-5793(96)01315-4; SLOMINSKI A, 1998, BIOCHIM BIOPHYS ACTA, V19, P147; SLOMINSKI A, 1996, BIOCHIM BIOPHYS ACTA, V15, P247; SLOMINSKI A, 2003, REGULATION PERIPHERA, P149; Slominski AT, 1999, ANN NY ACAD SCI, V885, P287; Stander S, 2002, EXP DERMATOL, V11, P42, DOI 10.1034/j.1600-0625.2002.110105.x; STENN KS, 1993, SKIN PHARMACOL, V6, P125; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; STEWART PM, 2003, WILLIAMS TXB ENDOCRI, P493; Straub RH, 2003, ARTHRITIS RHEUM, V48, P1504, DOI 10.1002/art.11036; Thiboutot D, 2003, J INVEST DERMATOL, V120, P905, DOI 10.1046/j.1523-1747.2003.12244.x; Tobin DJ, 2001, EXP GERONTOL, V36, P29, DOI 10.1016/S0531-5565(00)00210-2; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; Wang GM, 2002, ENDOCRINOLOGY, V143, P621, DOI 10.1210/en.143.2.621; WEIHUA Z, 2001, P NATL ACAD SCI USA, V22, P6330; Whiting DA, 2004, STRUCTURE HUMAN HAIR; WHITING DA, 1996, COLOR ATLAS DIFFEREN, P4; Yong PYK, 2000, J CLIN ENDOCR METAB, V85, P4728, DOI 10.1210/jc.85.12.4728; Yu L, 2002, MOL CELL ENDOCRINOL, V190, P9, DOI 10.1016/S0303-7207(02)00041-2; Zbytek B, 2004, J ENDOCRINOL, V181, pR1, DOI 10.1677/joe.0.181R001; Zouboulis CC, 2002, P NATL ACAD SCI USA, V99, P7148, DOI 10.1073/pnas.102180999; Zouboulis CC, 2000, HORM RES, V54, P230, DOI 10.1159/000053265	88	375	389	4	57	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1332	+		10.1096/fj.04-1968fje	http://dx.doi.org/10.1096/fj.04-1968fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946990				2022-12-25	WOS:000230207800022
J	Kwidzinski, E; Bunse, J; Aktas, O; Richter, D; Mutlu, L; Zipp, F; Nitsch, R; Bechmann, I				Kwidzinski, E; Bunse, J; Aktas, O; Richter, D; Mutlu, L; Zipp, F; Nitsch, R; Bechmann, I			Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation	FASEB JOURNAL			English	Article						IDO; EAE; tryptophan; microglia	QUINOLINIC ACID CONCENTRATIONS; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; IFN-GAMMA; IMMUNE PRIVILEGE; INTERFERON-GAMMA; FAS LIGAND; RELAPSING PARALYSIS; MICROGLIAL CELLS; HUMAN BRAIN	The tryptophan (trp)-catabolizing enzyme indolamine 2,3-dioxygenase (IDO) is induced by the T helper 1 ( Th 1) cytokine IFN-gamma during infections in various tissues including the brain. Recent studies demonstrated an immune modulatory function of this enzyme, since IDO-mediated depletion of trp hinders T cell proliferation, while its inhibition by 1-methyl-tryptophan (1-Mt) induces breakdown of immune tolerance in the placenta, leading to rejection of allogeneic concepti. Here, we tested IDO expression and function during experimental autoimmune encephalomyelitis (EAE) actively induced in adult SJL mice by immunization with PLP139-151. IDO activity ( determined by HPLC analysis of the kynurenine/tryptophan ratio) was increased in the spleen during the preclinical phase, and within the brain and spinal cord at the onset of symptoms. Immunocytochemistry revealed macrophages/activated microglia expressing IDO during EAE and in vitro experiments confirmed IDO induction in microglia upon IFN-gamma. treatment with synergistic effects of TNF-alpha. Inhibition of IDO by systemic administration of 1-Mt at clinical onset significantly exacerbated disease scores. From these data, it is tempting to speculate that IFN-alpha. from encephalitogenic Th 1 cells induces local IDO expression, thereby initiating a negative feedback loop which may underlie the self-limitation of autoimmune inflammation during EAE and multiple sclerosis.	Charite, Inst Cell Biol & Neurobiol, Ctr Anat, Berlin, Germany; Charite, Inst Neuroimmunol Clin & Expt Neuroimmunol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kwidzinski, E (corresponding author), Charite, Inst Cell Biol & Neurobiol, Ctr Anat, Berlin, Germany.	kwidzinski@charite.de	Aktas, Orhan/B-7623-2009; Nitsch, Robert/AAI-9129-2021; Zipp, Frauke/C-9968-2015	Aktas, Orhan/0000-0002-2020-9210; Zipp, Frauke/0000-0002-1231-1928				Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; AlberatiGiani D, 1996, J NEUROCHEM, V66, P996; AlberatiGiani D, 1997, J IMMUNOL, V159, P419; Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Bechmann I, 2002, J NEUROIMMUNOL, V132, P60, DOI 10.1016/S0165-5728(02)00311-9; Bechmann I, 2001, EUR J NEUROSCI, V14, P1651, DOI 10.1046/j.0953-816x.2001.01793.x; BECHMANN I, 2005, FASEB J; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; Burudi EME, 2002, J VIROL, V76, P12233, DOI 10.1128/JVI.76.23.12233-12241.2002; CARLIN JM, 1989, J LEUKOCYTE BIOL, V45, P29, DOI 10.1002/jlb.45.1.29; Choi C, 1999, J IMMUNOL, V162, P1889; Currier AR, 2000, J INTERF CYTOK RES, V20, P369, DOI 10.1089/107999000312306; Daubener W, 1999, ADV EXP MED BIOL, V467, P517; Depboylu C, 2004, EUR J NEUROSCI, V19, P2997, DOI 10.1111/j.0953-816X.2004.03404.x; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; Diestel A, 2003, J EXP MED, V198, P1729, DOI 10.1084/jem.20030975; Dorr J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-04-j0001.2002; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Guillemin GJ, 2005, GLIA, V49, P15, DOI 10.1002/glia.20090; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1990, BRAIN RES, V531, P148, DOI 10.1016/0006-8993(90)90768-7; Heyes MP, 1998, FASEB J, V12, P881, DOI 10.1096/fasebj.12.10.881; Hobom M, 2004, BRAIN PATHOL, V14, P148, DOI 10.1111/j.1750-3639.2004.tb00047.x; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427; Krakowski M, 1996, EUR J IMMUNOL, V26, P1641, DOI 10.1002/eji.1830260735; Kwidzinski E, 2003, J NEURAL TRANSM-SUPP, P29, DOI 10.1007/978-3-7091-0643-3_2; Laich A, 2002, CLIN CHEM, V48, P579; Lee GK, 2002, IMMUNOLOGY, V107, P452, DOI 10.1046/j.1365-2567.2002.01526.x; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Nettelnbreker E, 1998, J MED MICROBIOL, V47, P141, DOI 10.1099/00222615-47-2-141; OHMORI K, 1992, LAB INVEST, V66, P54; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; Phillips TA, 1999, J IMMUNOL, V162, P6053; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Robinson CM, 2003, J INTERF CYTOK RES, V23, P413, DOI 10.1089/107999003322277829; Sakurai K, 2002, J NEUROIMMUNOL, V129, P186, DOI 10.1016/S0165-5728(02)00176-5; SANDYK R, 1988, INT J NEUROSCI, V43, P207, DOI 10.3109/00207458808986171; SARDAR AM, 1995, NEUROSCI LETT, V187, P9, DOI 10.1016/0304-3940(95)11324-P; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Widner B, 1997, CLIN CHEM, V43, P2424; Willenborg DO, 1996, J IMMUNOL, V157, P3223	48	232	243	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1347	+		10.1096/fj.04-3228fje	http://dx.doi.org/10.1096/fj.04-3228fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15939737				2022-12-25	WOS:000230207800033
J	Manoli, I; Le, H; Alesci, S; McFann, KK; Su, YA; Kino, T; Chrousos, GP; Blackman, MR				Manoli, I; Le, H; Alesci, S; McFann, KK; Su, YA; Kino, T; Chrousos, GP; Blackman, MR			Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells	FASEB JOURNAL			English	Article						dexamethasone; myopathy; mitochondria; catecholamine; hydrogen peroxide	MAO-A; MITOCHONDRIAL DYSFUNCTION; EXPRESSION; DEXAMETHASONE; STRESS; ACTIVATION; PROTEASOME; APOPTOSIS; PROMOTER; PATHWAY	Skeletal myopathy is a common complication of endogenous and exogenous glucocorticoid excess, yet its pathogenetic mechanisms remain unclear. There is accumulating evidence that mitochondrial dysfunction and oxidative stress are involved in this process. To explore the glucocorticoid-induced transcriptional adaptations that may affect mitochondrial function in skeletal muscle, we studied gene expression profiles in dexamethasone-treated primary human skeletal myocytes using a cDNA microarray, which contains 501 mitochondria-related genes. We found that monoamine oxidase A (MAO-A) was the most significantly up-regulated gene. MAO-A is the primary enzyme metabolizing catecholamines and dietary amines, and its role in skeletal muscle remains largely unexplored. Dexamethasone induced dose- and time- dependent increases of MAO-A gene and protein expression, while its effects on MAO-B were minimal. Both the glucocorticoid receptor ( GR) and the Sp1 transcription factor were required for dexamethasone-induced MAO-A mRNA expression, as blockade of the GR with RU 486 or ablation of Sp1 binding with mithramycin abrogated MAO-A mRNA induction. The observed dexamethasone effect was biologically functional, as this steroid significantly increased MAO-mediated hydrogen peroxide production. We suggest that MAO-A-mediated oxidative stress can lead to cell damage, representing a novel pathogenetic mechanism for glucocorticoid-induced myopathy and a potential target for therapeutic intervention.	Natl Ctr Complementary & Alternat Med, Endocrine Sect, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; UOA, Dept Pediat 1, GR-11527 Athens, Greece; NIMH, Clin Neuroendocrinol Branch, NIH, Bethesda, MD 20892 USA; NCCAM, Off Clin & Regulat Affairs, NIH, Bethesda, MD 20892 USA; LUMC, Dept Pathol, Maywood, IL 60153 USA; NICHD, Reprod Biol & Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Manoli, I (corresponding author), Natl Ctr Complementary & Alternat Med, Endocrine Sect, Clin Invest Lab, NIH, 9 Mem Dr,Bldg 9,Room 1N105, Bethesda, MD 20892 USA.	manolii@mail.nih.gov	Blackman, Marc/AAT-5771-2021	Manoli, Irini/0000-0003-1543-2941	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000618, ZIAHD008732, ZIAHD000615] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD000618, Z01HD008732] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002659, ZIAMH002659] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alesci S, 2004, 17TH IEEE SYMPOSIUM ON COMPUTER-BASED MEDICAL SYSTEMS, PROCEEDINGS, P329, DOI 10.1109/CBMS.2004.1311736; ARORA RC, 1977, EXP NEUROL, V55, P318, DOI 10.1016/0014-4886(77)90003-6; Auclair D, 1997, AM J PHYSIOL-CELL PH, V272, pC1007; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Bianchi P, 2003, J AM SOC NEPHROL, V14, P855, DOI 10.1097/01.ASN.0000058909.00567.5C; BLACKMAN MR, 1995, ENDOCRINOLOGY, P2702; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Burke WJ, 2004, NEUROTOXICOLOGY, V25, P101, DOI 10.1016/S0161-813X(03)00090-1; Carlo P, 1996, BRAIN RES, V711, P175, DOI 10.1016/0006-8993(95)01353-9; Chrousos GP, 2000, INT J OBESITY, V24, pS50, DOI 10.1038/sj.ijo.0801278; Chrousos GP, 2004, AM J MED, V117, P204, DOI 10.1016/j.amjmed.2004.05.006; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Combaret L, 2004, BIOCHEM J, V378, P239, DOI 10.1042/BJ20031660; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; CVIJIC G, 1995, FUNCT NEUROL, V10, P175; DENNEY RM, 1994, J NEUROCHEM, V63, P843; Denney RM, 1995, PROG BRAIN RES, V106, P57; Duclos M, 2004, AM J PHYSIOL-ENDOC M, V286, pE159, DOI 10.1152/ajpendo.00281.2003; EDELSTEIN SB, 1986, CELL MOL NEUROBIOL, V6, P121, DOI 10.1007/BF00711066; Frost RA, 1997, ENDOCRINOLOGY, V138, P4153, DOI 10.1210/en.138.10.4153; Furlong RA, 1999, AM J MED GENET, V88, P398, DOI 10.1002/(SICI)1096-8628(19990820)88:4<398::AID-AJMG18>3.3.CO;2-P; Gold PW, 2002, MOL PSYCHIATR, V7, P254, DOI 10.1038/sj.mp.4001032; Gomes-Marcondes MCC, 2002, CANCER LETT, V180, P69, DOI 10.1016/S0304-3835(02)00006-X; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Hasselgren P O, 1999, Curr Opin Clin Nutr Metab Care, V2, P201, DOI 10.1097/00075197-199905000-00002; Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510; Haynes LE, 2004, BRAIN RES, V1026, P157, DOI 10.1016/j.brainres.2004.05.117; Isaeva EV, 2003, J PHYSIOL-LONDON, V547, P453, DOI 10.1113/jphysiol.2002.036129; Iuchi T, 2003, CIRC RES, V92, P81, DOI 10.1161/01.RES.0000050588.35034.3C; Jenkins BD, 2001, TRENDS ENDOCRIN MET, V12, P122, DOI 10.1016/S1043-2760(00)00357-X; Kennedy BP, 2003, J NEURAL TRANSM, V110, P789, DOI 10.1007/s00702-003-0828-6; KHALEELI AA, 1983, CLIN ENDOCRINOL, V18, P155, DOI 10.1111/j.1365-2265.1983.tb03198.x; Kopin IJ, 1998, AM J PHYSIOL-REG I, V275, pR165, DOI 10.1152/ajpregu.1998.275.1.R165; Kunduzova OR, 2002, FASEB J, V16, P1129, DOI 10.1096/fj.01-1008fje; LaFramboise WA, 2003, J MOL CELL CARDIOL, V35, P1307, DOI 10.1016/S0022-2828(03)00245-1; Li SW, 2001, MOL BRAIN RES, V93, P1, DOI 10.1016/S0169-328X(01)00120-6; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Malorni W, 1998, FEBS LETT, V426, P155, DOI 10.1016/S0014-5793(98)00315-9; Marinovic AC, 2002, J BIOL CHEM, V277, P16673, DOI 10.1074/jbc.M200501200; MAROLDA M, 1991, ITAL J NEUROL SCI, V12, P409; MARONE JR, 1994, J APPL PHYSIOL, V77, P1685; Maurel A, 2003, AM J PHYSIOL-HEART C, V284, pH1460, DOI 10.1152/ajpheart.00700.2002; Mitsui T, 2002, J NEUROL, V249, P1004, DOI 10.1007/s00415-002-0774-5; Navegantes LCC, 2004, AM J PHYSIOL-ENDOC M, V286, pE642, DOI 10.1152/ajpendo.00371.2003; Orzechowski A, 2002, REPROD NUTR DEV, V42, P197, DOI 10.1051/rnd:2002018; Orzechowski A, 2003, J MUSCLE RES CELL M, V24, P33, DOI 10.1023/A:1024887431768; Oshima Y, 2004, MUSCLE NERVE, V30, P49, DOI 10.1002/mus.20036; Ponchel F, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-18; Qu Z, 2000, GENE THER, V7, P428, DOI 10.1038/sj.gt.3301103; Ruest LB, 2002, J BIOL CHEM, V277, P5418, DOI 10.1074/jbc.M110685200; Seymour CB, 2003, BRIT J CANCER, V89, P1979, DOI 10.1038/sj.bjc.6601361; Shih JC, 1995, PROG BRAIN RES, V106, P49; Shih JC, 2004, CURR MED CHEM, V11, P1995, DOI 10.2174/0929867043364757; SHIH JC, 1990, J NEUR TR S, P41; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Slotkin TA, 1998, BRAIN RES BULL, V47, P345, DOI 10.1016/S0361-9230(98)00111-7; Stangel M, 1996, J NEUROPATH EXP NEUR, V55, P36, DOI 10.1097/00005072-199601000-00004; Thompson MG, 1999, J CELL PHYSIOL, V181, P455, DOI 10.1002/(SICI)1097-4652(199912)181:3<455::AID-JCP9>3.0.CO;2-K; Tokunaga N, 2003, NEUROCHEM INT, V43, P573, DOI 10.1016/S0197-0186(03)00064-0; Vgontzas AN, 2003, J CLIN ENDOCR METAB, V88, P2087, DOI 10.1210/jc.2002-021176; YOUDIM MBH, 1972, NATURE, V236, P225, DOI 10.1038/236225b0; YOUDIM MBH, 1989, FASEB J, V3, P1753, DOI 10.1096/fasebj.3.6.2495232; ZHU QS, 1994, J NEUROSCI, V14, P7393	64	58	60	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1359	+		10.1096/fj.04-3660fje	http://dx.doi.org/10.1096/fj.04-3660fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946989				2022-12-25	WOS:000230207800021
J	Nielsen, PR; Nietlispach, D; Buscaino, A; Warner, RJ; Akhtar, A; Murzin, AG; Murzina, NV; Laue, ED				Nielsen, PR; Nietlispach, D; Buscaino, A; Warner, RJ; Akhtar, A; Murzin, AG; Murzina, NV; Laue, ED			Structure of the chromo barrel domain from the MOF acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE METHYLTRANSFERASE ACTIVITY; DOSAGE COMPENSATION; CRYSTAL-STRUCTURE; SHADOW DOMAIN; LYSINE 9; H3; PROTEIN; METHYLATION; CHROMODOMAINS; TRANSCRIPTION	We report here the structure of the putative chromo domain from MOF, a member of the MYST family of histone acetyltransferases that acetylates histone H4 at Lys-16 and is part of the dosage compensation complex in Drosophila. We found that the structure of this domain is a beta-barrel that is distinct from the alpha + beta fold of the canonical chromo domain. Despite the differences, there are similarities that support an evolutionary relationship between the two domains, and we propose the name "chromo barrel." The chromo barrel domains may be divided into two groups, MSL3-like and MOF-like, on the basis of whether a group of conserved aromatic residues is present or not. The structure suggests that, although the MOF-like domains may have a role in RNA binding, the MSL3- like domains could instead bind methylated residues. The MOF chromo barrel shares a common fold with other chromatin-associated modules, including the MBT-like repeat, Tudor, and PWWP domains. This structural similarity suggests a probable evolutionary pathway from these other modules to the canonical chromo domains (or vice versa) with the chromo barrel domain representing an intermediate structure.	Univ Cambridge, Cambridge Ctr Mol Recognit, Dept Biochem, Cambridge CB2 1GA, England; European Mol Biol Lab, Gene Express Program, D-69117 Heidelberg, Germany; Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge; European Molecular Biology Laboratory (EMBL); University of Cambridge	Murzina, NV (corresponding author), Univ Cambridge, Cambridge Ctr Mol Recognit, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	nm@mole.bio.cam.ac.uk	Buscaino, Alessia/AAK-2976-2020	Buscaino, Alessia/0000-0002-1704-3168; Nietlispach, Daniel/0000-0003-4364-9291; Laue, Ernest/0000-0002-7476-4148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Akhtar A, 2003, CURR OPIN GENET DEV, V13, P161, DOI 10.1016/S0959-437X(03)00016-9; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bouazoune K, 2002, EMBO J, V21, P2430, DOI 10.1093/emboj/21.10.2430; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; Brehm A, 2004, BIOESSAYS, V26, P133, DOI 10.1002/bies.10392; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buscaino A, 2003, MOL CELL, V11, P1265, DOI 10.1016/S1097-2765(03)00140-0; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X; EPSTEIN H, 1992, J CELL SCI, V101, P463; Gao YG, 1998, NAT STRUCT BIOL, V5, P782, DOI 10.1038/1822; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; MARTIN I, 2000, MOL BIOL EVOL, V17, P1240; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nielsen PR, 2004, METHOD ENZYMOL, V376, P148; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; Sathyamurthy A, 2003, J BIOL CHEM, V278, P46968, DOI 10.1074/jbc.M306469200; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Thiru A, 2004, EMBO J, V23, P489, DOI 10.1038/sj.emboj.7600088; Wang WK, 2003, STRUCTURE, V11, P775, DOI 10.1016/S0969-2126(03)00127-8	35	42	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32326	32331		10.1074/jbc.M501347200	http://dx.doi.org/10.1074/jbc.M501347200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	15964847	hybrid			2022-12-25	WOS:000231794800036
J	Yin, YL; Liu, CD; Tsai, SN; Zhou, B; Ngai, SM; Zhu, G				Yin, YL; Liu, CD; Tsai, SN; Zhou, B; Ngai, SM; Zhu, G			SET8 recognizes the sequence (RHRKVLRDN)-V-20 within the N terminus of histone H4 and mono-methylates lysine 20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; METHYLTRANSFERASE SET7/9; HETEROCHROMATIN DOMAIN; PRODUCT SPECIFICITY; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; CHROMATIN; H3; H4; PR-SET7	Methylation of lysine 20 in histone H4 has been proven to play important roles in chromatin structure and gene regulation. SET8 is one of the methyltransferases identified to be specific for this modification. In this study, the minimal active SET domain of SET8 has been mapped to the region of amino acids 195 - 352. This region completely retains the same methylation activity and substrate specificity as the full-length SET8. The SET domain recognizes a stretch of specific amino acid sequence around lysine 20 of H4 for its methylation activity. Methylation assays with N terminus mutants of H4 that contain deletions and single alanine or glutamine substitutions of charged residues revealed that SET8 requires the sequence (RHRKVLRDN)-V-20 for methylation at lysine 20. The individual mutation of any charged residue in this sequence to alanine or glutamine abolished or greatly decreased levels of methylation of lysine 20 of H4 by SET8. Interestingly, mutation of lysine 16 to alanine, arginine, glutamine, or methionine did not affect methylation of lysine 20 by the SET domain. Mass spectrometric analysis of synthesized H4 N-terminal peptides modified by SET8 showed that SET8 selectively mono-methylates lysine 20 of H4. Taken together, our results suggested that the coordination between the amino acid sequence (RHRKVLRDN)-V-20 and the SET domain of SET8 determines the substrate specificity and multiplicity of methylation of lysine 20 of H4.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Biol, Shatin, Hong Kong, Peoples R China; E China Normal Univ, Dept Phys, Shanghai 200062, Peoples R China	Hong Kong University of Science & Technology; Chinese University of Hong Kong; East China Normal University	Zhu, G (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	gzhu@ust.hk	Ngai, Sai Ming/S-4898-2018	Ngai, Sai Ming/0000-0002-4484-2483				ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Collins RE, 2005, J BIOL CHEM, V280, P5563, DOI 10.1074/jbc.M410483200; Dutnall RN, 2003, MOL CELL, V12, P3, DOI 10.1016/S1097-2765(03)00282-X; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Jacobs SA, 2002, NAT STRUCT BIOL, V9, P833, DOI 10.1038/nsb861; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kwon T, 2003, EMBO J, V22, P292, DOI 10.1093/emboj/cdg025; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Manzur KL, 2003, NAT STRUCT BIOL, V10, P187, DOI 10.1038/nsb898; Marmorstein R, 2003, TRENDS BIOCHEM SCI, V28, P59, DOI 10.1016/S0968-0004(03)00007-0; Min JR, 2002, NAT STRUCT BIOL, V9, P828, DOI 10.1038/nsb860; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Trievel RC, 2003, NAT STRUCT BIOL, V10, P545, DOI 10.1038/nsb946; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wilson JR, 2002, CELL, V111, P105, DOI 10.1016/S0092-8674(02)00964-9; XCHULTZ DC, 2002, GENE DEV, V16, P919; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378; Xiao B, 2005, GENE DEV, V19, P1444, DOI 10.1101/gad.1315905; Xiao B, 2003, CURR OPIN STRUC BIOL, V13, P699, DOI 10.1016/j.sbi.2003.10.003; Zhang X, 2002, CELL, V111, P117, DOI 10.1016/S0092-8674(02)00999-6; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	41	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30025	30031		10.1074/jbc.M501691200	http://dx.doi.org/10.1074/jbc.M501691200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15964846	hybrid, Green Published			2022-12-25	WOS:000231362500007
J	Lavoie, JF; LeSauteur, L; Kohn, J; Wong, J; Furtoss, O; Thiele, CJ; Miller, FD; Kaplan, DR				Lavoie, JF; LeSauteur, L; Kohn, J; Wong, J; Furtoss, O; Thiele, CJ; Miller, FD; Kaplan, DR			TrkA induces apoptosis of neuroblastoma cells and does so via a p53-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FACTOR-INDUCED DIFFERENTIATION; DRUG-INDUCED APOPTOSIS; NEUROTROPHIC FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; CYTOPLASMIC SEQUESTRATION; SYMPATHETIC NEURONS; PROMOTES SURVIVAL; FACTOR RECEPTOR	Neuroblastoma (NB) is the most frequent solid extracranial tumor in children. Its clinical prognosis correlates with the expression of members of the Trk neurotrophin receptor family, which includes TrkA and TrkB. TrkA expression is associated with favorable prognosis, whereas TrkB expression is associated with poor prognosis. Here we show that TrkA expression induces the apoptosis of NB cells and does so by modulating the levels or activities of a number of proteins involved in regulating cell survival and apoptosis, including p53, Bcl-2, and caspase-3. TrkA increased the expression of p53 target proteins and failed to induce apoptosis in cells where p53 was inactivated by mutation or via expression of dominant inhibitory p53 or E1B55K, indicating that TrkA mediates apoptosis, at least in part, through p53. Treatment with a caspase inhibitor or overexpression of Bcl-X-L also prevented TrkA from inducing apoptosis. In contrast, elevated expression of TrkA in non-transformed sympathetic neurons resulted in the suppression of p53 levels and enhanced survival. These results identify apoptosis as a novel biological response of TrkA in NB cells and imply that TrkA is a good prognosis marker for NB due in part to its ability to mediate apoptosis when expressed at sufficient levels.	Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; McGill Univ, Brain Tumor Res Ctr, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaplan, DR (corresponding author), Hosp Sick Children, Canc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	dkaplan@sickkids.ca			DIVISION OF CLINICAL SCIENCES - NCI [Z01SC006813] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Aoyama M, 2001, CANCER LETT, V164, P51, DOI 10.1016/S0304-3835(00)00715-1; Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; BARNES EN, 1981, IN VITRO CELL DEV B, V17, P619, DOI 10.1007/BF02618461; Belliveau DJ, 1997, J CELL BIOL, V136, P375, DOI 10.1083/jcb.136.2.375; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brown A, 2000, ONCOGENE, V19, P3032, DOI 10.1038/sj.onc.1203619; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; CHEN J, 1990, CELL GROWTH DIFFER, V1, P79; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chou TT, 2000, J BIOL CHEM, V275, P565, DOI 10.1074/jbc.275.1.565; Chou TT, 2001, J BIOL CHEM, V276, P41120, DOI 10.1074/jbc.M102832200; CICCARONE V, 1989, CANCER RES, V49, P219; Cui HJ, 2002, MOL CANCER THER, V1, P679; Fulda S, 1997, CANCER RES, V57, P3823; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Ho R, 2002, CANCER RES, V62, P6462; HOEHNER JC, 1995, AM J PATHOL, V147, P102; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; IMAMURA J, 1993, CANCER RES, V53, P4053; Jaboin J, 2002, CANCER RES, V62, P6756; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; Keshelava N, 2001, CANCER RES, V61, P6185; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; KOMURO H, 1993, CANCER RES, V53, P5284; Krasnoselsky AL, 2005, ONCOGENE, V24, P1533, DOI 10.1038/sj.onc.1208341; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Lucarelli E, 1997, EUR J CANCER, V33, P2068, DOI 10.1016/S0959-8049(97)00266-9; LucidiPhillipi CA, 1996, NEURON, V16, P653, DOI 10.1016/S0896-6273(00)80084-7; MASSIE B, 1995, BIO-TECHNOL, V13, P602, DOI 10.1038/nbt0695-602; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Middlemas DS, 1999, J BIOL CHEM, V274, P16451, DOI 10.1074/jbc.274.23.16451; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Muragaki Y, 1997, J NEUROSCI, V17, P530; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Narendran A, 2003, EXP HEMATOL, V31, P693, DOI 10.1016/S0301-472X(03)00159-0; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; POLUHA W, 1995, ONCOGENE, V10, P185; Scala S, 1996, CANCER RES, V56, P3737; Schulte JH, 2005, ONCOGENE, V24, P165, DOI 10.1038/sj.onc.1208000; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torkin R, 2005, MOL CANCER THER, V4, P1; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Tweddle DA, 2001, CANCER RES, V61, P8; Vaghefi H, 2004, ONCOGENE, V23, P8078, DOI 10.1038/sj.onc.1207953; VOGAN K, 1993, CANCER RES, V53, P5269; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Yan CH, 2002, CANCER RES, V62, P4867; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G	63	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29199	29207		10.1074/jbc.M502364200	http://dx.doi.org/10.1074/jbc.M502364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15961390	hybrid			2022-12-25	WOS:000231021300048
J	Manel, N; Battini, JL; Sitbon, M				Manel, N; Battini, JL; Sitbon, M			Human T cell leukemia virus envelope binding and virus entry are mediated by distinct domains of the glucose transporter GLUT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-RANGE; RETROVIRUS INFECTION; EXTRACELLULAR DOMAIN; CARBOXY-TERMINUS; DISULFIDE-BOND; HTLV RECEPTOR; MURINE; SEQUENCE; PROTEIN; FUSION	The glucose transporter GLUT1, a member of the multimembrane-spanning facilitative nutrient transporter family, serves as a receptor for human T cell leukemia virus ( HTLV) infection. Here, we show that the 7 amino acids of the extracellular loop 6 of GLUT1(ECL6) placed in the context of the related GLUT3 transporter were sufficient for HTLV envelope binding. Glutamate residue 426 in ECL6 was identified as critical for binding. However, binding to ECL6 was not sufficient for HTLV envelope-driven infection. Infection required two additional determinants located in ECL1 and ECL5, which otherwise did not influence HTLV envelope binding. Moreover the single N-glycosylation chain located in ECL1 was not required for HTLV infection. Therefore, binding involves a discrete determinant in the carboxyl terminal ECL6, whereas post-binding events engage extracellular sequences in the amino and carboxyl terminus of GLUT1.	Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 122, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Sitbon, M (corresponding author), Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 122, 1919 Route de Mende, F-34293 Montpellier, France.	marc.sitbon@igmm.cnrs.fr	Sitbon, Marc/A-6771-2010; Manel, Nicolas/E-2128-2011	Sitbon, Marc/0000-0003-3616-2338; Manel, Nicolas/0000-0002-1481-4430; Battini, Jean-Luc/0000-0002-5884-9934				ALBRITTON LM, 1993, J VIROL, V67, P2091, DOI 10.1128/JVI.67.4.2091-2096.1993; Anderson MM, 2000, SCIENCE, V287, P1828, DOI 10.1126/science.287.5459.1828; APPLEMAN JR, 1989, BIOCHEMISTRY-US, V28, P8221, DOI 10.1021/bi00446a038; Barnett AL, 2001, P NATL ACAD SCI USA, V98, P4113, DOI 10.1073/pnas.071432398; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; BATTINI JL, 1995, J VIROL, V69, P713, DOI 10.1128/JVI.69.2.713-719.1995; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; Benit L, 2001, J VIROL, V75, P11709, DOI 10.1128/JVI.75.23.11709-11719.2001; Clapham PR, 2001, BRIT MED BULL, V58, P43, DOI 10.1093/bmb/58.1.43; Coskun AK, 2005, J VIROL, V79, P4150, DOI 10.1128/JVI.79.7.4150-4158.2005; DUNN KJ, 1993, J VIROL, V67, P4704, DOI 10.1128/JVI.67.8.4704-4711.1993; Farrell KB, 2002, J VIROL, V76, P7683, DOI 10.1128/JVI.76.15.7683-7693.2002; Feldman SA, 2004, J VIROL, V78, P595, DOI 10.1128/JVI.78.2.595-602.2004; HEARD JM, 1991, J VIROL, V65, P4026, DOI 10.1128/JVI.65.8.4026-4032.1991; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; Inukai K, 2004, MOL ENDOCRINOL, V18, P339, DOI 10.1210/me.2003-0089; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Kim Felix J, 2004, Retrovirology, V1, P41, DOI 10.1186/1742-4690-1-41; Kim FJ, 2000, J BIOL CHEM, V275, P23417, DOI 10.1074/jbc.C901002199; Kim FJ, 2004, VIROLOGY, V318, P183, DOI 10.1016/j.virol.2003.09.026; Kim FJ, 2003, J VIROL, V77, P963, DOI 10.1128/JVI.77.2.963-969.2003; KOCH W, 1983, J VIROL, V45, P1; Lauring AS, 2002, J VIROL, V76, P8069, DOI 10.1128/JVI.76.16.8069-8078.2002; Lavillette D, 2001, J VIROL, V75, P3685, DOI 10.1128/JVI.75.8.3685-3695.2001; Leverett BD, 1998, J VIROL, V72, P4956, DOI 10.1128/JVI.72.6.4956-4961.1998; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Manel N, 2003, BLOOD, V101, P1913, DOI 10.1182/blood-2002-09-2681; Marin M, 2003, J VIROL, V77, P2936, DOI 10.1128/JVI.77.5.2936-2945.2003; MCMAHON RJ, 1995, J BIOL CHEM, V270, P12094, DOI 10.1074/jbc.270.20.12094; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER DG, 1993, J VIROL, V67, P5346, DOI 10.1128/JVI.67.9.5346-5352.1993; MILLER DG, 1992, J VIROL, V66, P78, DOI 10.1128/JVI.66.1.78-84.1992; Overbaugh J, 2001, MICROBIOL MOL BIOL R, V65, P371, DOI 10.1128/MMBR.65.3.371-389.2001; PEDERSEN L, 1995, J VIROL, V69, P2401, DOI 10.1128/JVI.69.4.2401-2405.1995; Pinter A, 1997, J VIROL, V71, P8073, DOI 10.1128/JVI.71.10.8073-8077.1997; SITBON M, 1991, P NATL ACAD SCI USA, V88, P5932, DOI 10.1073/pnas.88.13.5932; Sutton RE, 1996, J VIROL, V70, P7322, DOI 10.1128/JVI.70.10.7322-7326.1996; Tailor CS, 2003, CURR TOP MICROBIOL, V281, P29; Trejo SR, 2000, VIROLOGY, V268, P41, DOI 10.1006/viro.2000.0143; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wallin M, 2004, EMBO J, V23, P54, DOI 10.1038/sj.emboj.7600012; WILSON CA, 1991, J VIROL, V65, P5975, DOI 10.1128/JVI.65.11.5975-5982.1991; Wu XH, 2002, GENOMICS, V80, P553, DOI 10.1006/geno.2002.7010	45	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29025	29029		10.1074/jbc.M504549200	http://dx.doi.org/10.1074/jbc.M504549200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15955807	hybrid			2022-12-25	WOS:000231021300026
J	Wang, AH; Gregoire, S; Zika, E; Xiao, L; Li, CS; Li, HW; Wright, KL; Ting, JP; Yang, XJ				Wang, AH; Gregoire, S; Zika, E; Xiao, L; Li, CS; Li, HW; Wright, KL; Ting, JP; Yang, XJ			Identification of the ankyrin repeat proteins ANKRA and RFXANK as novel partners of class IIa histone deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARE LYMPHOCYTE SYNDROME; COMPLEX CLASS-II; CREB BINDING-PROTEIN; GENE-EXPRESSION; NUCLEAR EXPORT; TRANSCRIPTION; CIITA; TRANSACTIVATOR; ACETYLATION; DOMAIN	Eighteen human histone deacetylases (HDACs) have been identified, and according to their sequence similarity to yeast homologs, these enzymes are grouped into distinct classes. Within class II, HDAC4, HDAC5, HDAC7, and HDAC9 share similar domain organization both within the N-terminal extension and the C-terminal catalytic domain, thus forming a subclass known as class IIa. These HDACs function as signal-responsive transcriptional corepressors. To gain further insight into their function and regulation, we utilized an N-terminal fragment of HDAC4 as bait in yeast two-hybrid screens, which uncovered myocyte enhancer factor 2C, 14-3-3 zeta, and ankyrin repeat family A protein (ANKRA). ANKRA is a poorly characterized protein with an ankyrin repeat domain similar to RFXANK, a subunit of the trimeric transcription factor RFX. Mutations on genes of the RFX subunits and the coactivator CIITA are responsible for the bare lymphocyte syndrome, an immunodeficiency disorder attributed to the lack of major histocompatibility complex class II (MHCII) antigens. Through its ankyrin repeat domain, RFXANK interacted with HDAC4. Two RFXANK-binding sites were found on HDAC4 with one located within residues 118-279 and another within residues 448-666. Interestingly, this deacetylase also interacted with CIITA. Consistent with the physical interaction with RFXANK and CIITA, HDAC4 and homologs repressed MHCII expression. These results identify ANKRA, RFXANK, and CIITA as novel targets of class IIa HDACs and suggest that these deacetylases play a role in regulating MHCII expression.	McGill Univ, Ctr Hlth, RVH, Dept Med,Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA	McGill University; Royal Victoria Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; State University System of Florida; University of South Florida	Yang, XJ (corresponding author), McGill Univ, Ctr Hlth, RVH, Dept Med,Mol Oncol Grp, Rm H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	xiang-jiao.yang@mcgill.ca						Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Bertos NR, 2004, J BIOL CHEM, V279, P48246, DOI 10.1074/jbc.M408583200; Boss JM, 2003, CURR OPIN IMMUNOL, V15, P105, DOI 10.1016/S0952-7915(02)00015-8; Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5; Cao DS, 2005, MOL CELL BIOL, V25, P364, DOI 10.1128/MCB.25.1.364-376.2005; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Chang SR, 2005, P NATL ACAD SCI USA, V102, P8120, DOI 10.1073/pnas.0503275102; COHEN T, 2004, SCI STKE; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; DeSandro AM, 2000, MOL CELL BIOL, V20, P6587, DOI 10.1128/MCB.20.17.6587-6599.2000; Dong YS, 1999, J IMMUNOL, V162, P4731; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2000, GENE DEV, V14, P55; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Landmann S, 2001, J EXP MED, V194, P379, DOI 10.1084/jem.194.4.379; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Lim HH, 2005, MOL BIOL CELL, V16, P1013, DOI 10.1091/mbc.E04-06-0537; Long AB, 2005, IMMUNOGENETICS, V56, P788, DOI 10.1007/s00251-004-0738-2; Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Nagarajan UM, 1999, IMMUNITY, V10, P153, DOI 10.1016/S1074-7613(00)80016-3; Nekrep N, 2000, MOL CELL BIOL, V20, P4455, DOI 10.1128/MCB.20.12.4455-4461.2000; Nekrep N, 2001, MOL CELL BIOL, V21, P5566, DOI 10.1128/MCB.21.16.5566-5576.2001; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Nozell S, 2004, J BIOL CHEM, V279, P38577, DOI 10.1074/jbc.M403738200; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; Palazzo A, 2003, NATURE, V421, P230, DOI 10.1038/421230a; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Rader K, 2000, J AM SOC NEPHROL, V11, P2167, DOI 10.1681/ASN.V11122167; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Ting JPY, 2005, ANNU REV IMMUNOL, V23, P387, DOI 10.1146/annurev.immunol.23.021704.115616; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wong AW, 2002, J IMMUNOL, V169, P3112, DOI 10.4049/jimmunol.169.6.3112; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; Xu Y, 2004, J BIOL CHEM, V279, P41319, DOI 10.1074/jbc.M404174200; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	68	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29117	29127		10.1074/jbc.M500295200	http://dx.doi.org/10.1074/jbc.M500295200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15964851	Green Published, hybrid			2022-12-25	WOS:000231021300038
J	Hahne, JC; Okuducu, AF; Kaminski, A; Florin, A; Soncin, F; Wernert, N				Hahne, JC; Okuducu, AF; Kaminski, A; Florin, A; Soncin, F; Wernert, N			Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth	ONCOGENE			English	Article						Ets-1; epithelial HeLa-tumor cells; migration; invasion; anchorage-independent growth	TRANSCRIPTION FACTOR; STROMAL EXPRESSION; GENE-EXPRESSION; CHICK-EMBRYO; INTEGRINS; PROTOONCOGENE; ANGIOGENESIS; C-ETS-1; BINDING; PROTEIN	Ets-1 is the prototype of the family of ETS transcription factors. In human tumors, Ets-1 is expressed in endothelial cells and fibroblasts of the tumor stroma and is proposed to play a role in tumor vascularization and invasion by upregulating expression of matrix-degrading proteases. In human carcinomas, Ets-1 is also expressed by neoplastic cells, but little is known about the functional implications of this observation. We have addressed the role of Ets-1 in epithelial HeLa tumor cells by selecting stably Ets-1 over and underexpressing HeLa cells. Ets-1 expression increases the transformed phenotype of HeLa cells, by promoting cell migration, invasion and anchorage-independent growth, while Ets-1 downregulation reduces cell attachment. In correlation with these results, Ets-1 upregulation increases integrin beta 2 expression but not that of other integrins. These results suggest that, in addition to its role in the tumor stroma, Ets-1 may also promote tumor development and progression by increasing neoplastic transformation.	Univ Bonn, Inst Pathol, D-53011 Bonn, Germany; Inst Biol Lille, CNRS, UMR8526, F-59021 Lille, France	University of Bonn; Centre National de la Recherche Scientifique (CNRS)	Wernert, N (corresponding author), Univ Bonn, Inst Pathol, POB 2120, D-53011 Bonn, Germany.	nicolas.wernert@ukb.uni-bonn.de	SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673				Adam M, 2003, EUR UROL, V44, P329, DOI 10.1016/S0302-2838(03)00262-8; Adriaenssens E, 2002, EXP CELL RES, V275, P215, DOI 10.1006/excr.2002.5500; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Behrens P, 2003, INT J CANCER, V107, P183, DOI 10.1002/ijc.11336; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Ishii Y, 2003, INT J CANCER, V103, P161, DOI 10.1002/ijc.10808; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Maubant S, 2002, B CANCER, V89, P923; Maurer P, 2003, ONCOGENE, V22, P3319, DOI 10.1038/sj.onc.1206572; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; Nishikawa A, 2000, GYNECOL ONCOL, V79, P256, DOI 10.1006/gyno.2000.5944; Paumelle R, 2000, MOL BIOL CELL, V11, P3751, DOI 10.1091/mbc.11.11.3751; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Peterson EJ, 2003, IMMUNOL REV, V192, P113, DOI 10.1034/j.1600-065X.2003.00026.x; Petrella A, 1998, BLOOD, V91, P4554, DOI 10.1182/blood.V91.12.4554.412k26_4554_4560; Pourtier-Manzanedo A, 2003, ONCOGENE, V22, P1795, DOI 10.1038/sj.onc.1206215; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sato Y, 1998, Hum Cell, V11, P207; Schwartz MA, 2001, J CELL SCI, V114, P2553; SETH A, 1990, ONCOGENE, V5, P1761; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; Waga K, 2003, ONCOGENE, V22, P59, DOI 10.1038/sj.onc.1206072; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119	38	56	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5384	5388		10.1038/sj.onc.1208761	http://dx.doi.org/10.1038/sj.onc.1208761			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15940256				2022-12-25	WOS:000231158500012
J	Fingerman, IM; Wu, CL; Wilson, BD; Briggs, SD				Fingerman, IM; Wu, CL; Wilson, BD; Briggs, SD			Global loss of Set1-mediated H3 Lys(4) trimethylation is associated with silencing defects in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE METHYLTRANSFERASE COMPLEX; LYSINE-4 METHYLATION; PRODUCT SPECIFICITY; TRITHORAX FAMILY; SET1; CHROMATIN; PROTEINS; COMPASS; YEAST; H2B	Post-translational histone modifications, such as acetylation, phosphorylation, ubiquitination, and methylation, have been correlated with regulation of gene expression. In Saccharomyces cerevisiae, Set1 has been identified as the sole histone methyltransferase required for histone H3 lysine 4 ( Lys(4)) methylation. Yeast cells that do not express Set1 have several apparent phenotypes, including slow growth and defects in telomere, HML, and rDNA silencing. However, the mechanism by which the Set1 methyltransferase mediates differential histone H3 methylation ( mono-, di-, and tri-) is still not understood, and the involvement of domains or regions in Set1 contributing to H3 Lys(4) methylation has not been well characterized. In this study, the N terminus of Set1 was shown to be important for global and gene specific histone H3 trimethylation. We show that Set1 trimethyl-defective mutants can rescue a set1 Delta slow growth defect. In contrast, Set1 trimethyl mutants were defective in telomere, rDNA, HML, and HMR silencing. Taken together, these data suggest that histone H3 Lys4 trimethylation is required for proper silencing, while mono- and/or dimethylation is sufficient for cell growth.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Purdue Univ, Ctr Canc, W Lafayette, IN 47907 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Walther Cancer Institute	Briggs, SD (corresponding author), Purdue Univ, Dept Biochem, 175 S Univ, W Lafayette, IN 47907 USA.	sdbriggs@purdue.edu		Briggs, Scott D/0000-0003-2852-3594	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074183] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM074183-03, R01 GM074183, R01 GM074183-01A1, R01 GM074183-02, R01 GM074183-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Carvin CD, 2004, J BIOL CHEM, V279, P33057, DOI 10.1074/jbc.M405033200; Collins RE, 2005, J BIOL CHEM, V280, P5563, DOI 10.1074/jbc.M410483200; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Dichtl E, 2004, RNA, V10, P965, DOI 10.1261/rna.7090104; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; MURRAY K, 1964, BIOCHEMISTRY-US, V3, P10, DOI 10.1021/bi00889a003; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Santos-Rosa H, 2004, J BIOL CHEM, V279, P47506, DOI 10.1074/jbc.M407949200; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schlichter A, 2005, EMBO J, V24, P1222, DOI 10.1038/sj.emboj.7600607; Singer MS, 1998, GENETICS, V150, P613; Stefl R, 2005, EMBO REP, V6, P33, DOI 10.1038/sj.embor.7400325; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; van Leeuwen F, 2002, CURR OPIN CELL BIOL, V14, P756, DOI 10.1016/S0955-0674(02)00393-9; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Xiao TJ, 2005, MOL CELL BIOL, V25, P637, DOI 10.1128/MCB.25.2.637-651.2005; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7	39	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28761	28765		10.1074/jbc.C500097200	http://dx.doi.org/10.1074/jbc.C500097200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15964832	Green Accepted, hybrid			2022-12-25	WOS:000230857300067
J	Karmakar, S; Cummings, RD; McEver, RP				Karmakar, S; Cummings, RD; McEver, RP			Contributions of Ca2+ to galectin-1-induced exposure of phosphatidylserine on activated neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; HUMAN-ENDOTHELIAL-CELLS; C-DEPENDENT PROCESSES; PHOSPHOLIPASE-C; APOPTOTIC CELLS; POLYMORPHONUCLEAR NEUTROPHILS; EXTRACELLULAR CALCIUM; SIGNAL-TRANSDUCTION; SURFACE EXPOSURE; T-LYMPHOCYTES	Apoptotic cells redistribute phosphatidylserine ( PS) to the cell surface by both Ca2+-dependent and -independent mechanisms. Binding of dimeric galectin-1 (dGal-1) to glycoconjugates on N-formyl-Met-Leu-Phe ( fMLP)-activated neutrophils exposes PS and facilitates neutrophil phagocytosis by macrophages, yet it does not initiate apoptosis. We asked whether dGal-1 initiated Ca2+ fluxes that are required to redistribute PS to the surface of activated neutrophils. Prolonged occupancy by dGal-1 was required to maximally mobilize PS to the surfaces of fMLP-activated neutrophils. Like fMLP, dGal-1 rapidly elevated cytosolic Ca2+ levels in Fluo-4-loaded neutrophils. An initial Ca2+ mobilization from intracellular stores was followed by movement of extracellular Ca2 to the cytosolic compartment, with return to basal Ca2+ levels within 10 min. Chelation of extracellular Ca2+ did not prevent PS mobilization. Chelation of intracellular Ca2+ revealed that fMLP and dGal-1 independently release Ca2+ from intracellular stores that cooperate to induce optimal redistribution of PS. Ca2+ mobilization by ionomycin did not permit dGal-1 to mobilize PS, indicating that fMLP initiated both Ca2+-dependent and -independent signals that facilitated dGal-1-induced exposure of PS. dGal-1 elevated cytosolic Ca2+ and mobilized PS through a pathway that required action of Src kinases and phospholipase C gamma. These results demonstrate that transient Ca2+ fluxes contribute to a sustained redistribution of PS on neutrophils activated with fMLP and dGal-1.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	McEver, RP (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	rodger-mcever@omrf.ouhsc.edu			NCRR NIH HHS [RR 15577] Funding Source: Medline; NHLBI NIH HHS [HL 34363] Funding Source: Medline; NIAID NIH HHS [AI 48075] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015577] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034363, R01HL034363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adayev T, 1998, J NEUROCHEM, V71, P1854; ALLEN HJ, 1991, TUMOR BIOL, V12, P52, DOI 10.1159/000217688; BAUM LG, 1995, GLYCOCONJUGATE J, V12, P63, DOI 10.1007/BF00731870; BIANCHINI L, 1993, J BIOL CHEM, V268, P3357; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Bratton DL, 1999, J BIOL CHEM, V274, P28113, DOI 10.1074/jbc.274.40.28113; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; Courageot MP, 2002, ANN NY ACAD SCI, V973, P186, DOI 10.1111/j.1749-6632.2002.tb04630.x; de Jong K, 2002, BIOCHEMISTRY-US, V41, P12562, DOI 10.1021/bi025882o; Dias-Baruffi M, 2003, J BIOL CHEM, V278, P41282, DOI 10.1074/jbc.M306624200; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; Fecho K, 1998, J LEUKOCYTE BIOL, V64, P373, DOI 10.1002/jlb.64.3.373; Fecho K, 1998, CELL IMMUNOL, V188, P19, DOI 10.1006/cimm.1998.1339; Ferraro-Peyret C, 2002, J IMMUNOL, V169, P4805, DOI 10.4049/jimmunol.169.9.4805; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hampton MB, 1996, FEBS LETT, V399, P277, DOI 10.1016/S0014-5793(96)01341-5; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Homburg C H, 1996, Curr Opin Hematol, V3, P94; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; Kashio Y, 2003, J IMMUNOL, V170, P3631, DOI 10.4049/jimmunol.170.7.3631; Kim-Park WK, 1997, ANN NY ACAD SCI, V832, P394, DOI 10.1111/j.1749-6632.1997.tb46267.x; King MA, 2000, CYTOMETRY, V40, P10, DOI 10.1002/(SICI)1097-0320(20000501)40:1<10::AID-CYTO2>3.0.CO;2-F; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LENNON SV, 1992, CLIN EXP IMMUNOL, V87, P465; LOTAN R, 1994, GLYCOCONJUGATE J, V11, P462, DOI 10.1007/BF00731282; Lowell CA, 1999, J LEUKOCYTE BIOL, V65, P313, DOI 10.1002/jlb.65.3.313; Maianski NA, 2003, BLOOD, V101, P1987, DOI 10.1182/blood-2002-02-0522; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; Mogami H, 1997, BIOCHEM J, V324, P645, DOI 10.1042/bj3240645; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; SMALLRIDGE RC, 1992, ENDOCRINOLOGY, V131, P1883, DOI 10.1210/en.131.4.1883; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Stahnke K, 1998, EXP HEMATOL, V26, P844; Stout JG, 1998, BIOCHEMISTRY-US, V37, P14860, DOI 10.1021/bi9812930; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Traxler P, 1997, J MED CHEM, V40, P3601, DOI 10.1021/jm970124v; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Verhoven B, 1999, CELL DEATH DIFFER, V6, P262, DOI 10.1038/sj.cdd.4400491; Walzel H, 1996, GLYCOCONJUGATE J, V13, P99, DOI 10.1007/BF01049685; Walzel H, 2000, GLYCOBIOLOGY, V10, P131, DOI 10.1093/glycob/10.2.131; WASANO K, 1990, CELL TISSUE RES, V259, P43, DOI 10.1007/BF00571428; WHYTE MKB, 1993, J CLIN INVEST, V92, P446, DOI 10.1172/JCI116587; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; Williamson P, 2001, BIOCHEMISTRY-US, V40, P8065, DOI 10.1021/bi001929z; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	53	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28623	28631		10.1074/jbc.M414140200	http://dx.doi.org/10.1074/jbc.M414140200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15929990	hybrid			2022-12-25	WOS:000230857300053
J	Hoffmann, A; Preobrazhenska, O; Wodarczyk, C; Medler, Y; Winkel, A; Shahab, S; Huylebroeck, D; Gross, G; Verschueren, K				Hoffmann, A; Preobrazhenska, O; Wodarczyk, C; Medler, Y; Winkel, A; Shahab, S; Huylebroeck, D; Gross, G; Verschueren, K			Transforming growth factor-beta-activated kinase-1 (TAK1), a MAP3K, interacts with Smad proteins and interferes with osteogenesis in murine mesenchymal progenitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; SIGNAL-TRANSDUCTION; P38 MAPK; PATHWAY; DIFFERENTIATION; ACTIVATION; C3H10T1/2; CELLS; EXPRESSION; TARGET	TAK1 (transforming growth factor-beta-activated kinase-1), a MAP3K with considerable sequence similarity to Raf-1 and MEKK-1, has been identified as a transforming growth factor-beta/bone morphogenetic protein (BMP)-activated cytosolic component of the MAPK pathways. In this investigation, the molecular interactions between TAK1 and Smad proteins were characterized as well as their influence on BMP-mediated mesenchymal cell differentiation along the osteogenic/chondrogenic pathway. In co-immunoprecipitations we found an interaction of TAK1 with all Smads tested, R-Smads Smads1-5, the co-Smad Smad4, and the inhibitory Smads (I-Smad6 and I-Smad7). Smad interaction with TAK1 takes place through their MH2 domain. This interaction is dependent on the presence of an active kinase domain in TAK1. TAK1 dramatically interferes with R-Smad transactivation in reporter assays and affects subcellular distribution of Smad proteins. Activated TAK1 also interferes with BMP-dependent osteogenic development in murine mesenchymal progenitor cells (C3H10T1/2). A potential TAK1-mediated apoptosis process could be excluded for these cells. Both synergistic and interfering influences of TAK1 on BMP-mediated Smad-signaling have been reported previously. We suggest that TAK1 is a factor that is involved in the fine-tuning of BMP effects during osteogenic development.	Gesell Biotechnol Forsch mbH, Signal Transduct & Gene Regulat, D-38124 Braunschweig, Germany; Univ Leuven, Lab Mol Biol Celgen, B-3000 Louvain, Belgium; Univ Leuven VIB, Dept Dev Biol, B-3000 Louvain, Belgium	Gesellschaft fur Biotechnologische Forschung mbH; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Gross, G (corresponding author), Gesell Biotechnol Forsch mbH, Signal Transduct & Gene Regulat, Mascheroder Weg 1, D-38124 Braunschweig, Germany.	ggr@gbf.de	Hoffmann, Andrea/AAG-4488-2020	Hoffmann, Andrea/0000-0003-2318-8985; Huylebroeck, Danny/0000-0003-4862-1079				AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bachner D, 1998, DEV DYNAM, V213, P398; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; Cocolakis E, 2001, J BIOL CHEM, V276, P18430, DOI 10.1074/jbc.M010768200; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoffmann A, 2002, J CELL SCI, V115, P769; Hoffmann A, 2001, CRIT REV EUKAR GENE, V11, P23; Hollnagel A, 1997, J BONE MINER RES, V12, P1993, DOI 10.1359/jbmr.1997.12.12.1993; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Ju WJ, 2000, J BONE MINER RES, V15, P1889, DOI 10.1359/jbmr.2000.15.10.1889; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ninomiya-Tsuji J, 1999, NATURE, V398, P252; Ohkawara B, 2004, GENE DEV, V18, P381, DOI 10.1101/gad.1166904; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Reguly T, 2003, TRENDS CELL BIOL, V13, P216, DOI 10.1016/S0962-8924(03)00075-8; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Smit L, 2004, J BIOL CHEM, V279, P17232, DOI 10.1074/jbc.M307801200; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Uchida K, 2001, BIOCHEM BIOPH RES CO, V289, P376, DOI 10.1006/bbrc.2001.5984; Vallejo LF, 2002, J BIOTECHNOL, V94, P185, DOI 10.1016/S0168-1656(01)00425-4; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yanagisawa M, 2001, GENES CELLS, V6, P1091, DOI 10.1046/j.1365-2443.2001.00483.x; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	49	65	69	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27271	27283		10.1074/jbc.M503368200	http://dx.doi.org/10.1074/jbc.M503368200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911626	hybrid			2022-12-25	WOS:000230589500076
J	Horning, C; Albert, D; Fischer, L; Hornig, M; Radmark, O; Steinhilber, D; Werz, O				Horning, C; Albert, D; Fischer, L; Hornig, M; Radmark, O; Steinhilber, D; Werz, O			1-Oleoyl-2-acetylglycerol stimulates 5-lipoxygenase activity via a putative (phospho)lipid binding site within the N-terminal C2-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CYTOSOLIC PHOSPHOLIPASE A(2); PROTEIN-KINASE-C; BETA-BARREL DOMAIN; ARACHIDONIC-ACID; PHOSPHATIDYLCHOLINE VESICLES; MEMBRANE TRANSLOCATION; LEUKOTRIENE SYNTHESIS; NUCLEAR-MEMBRANE; MONO-MAC-6 CELLS	5-Lipoxygenase (5-LO) catalysis is positively regulated by Ca2+ ions and phospholipids that both act via the N-terminal C2-like domain of 5-LO. Previously, we have shown that 1-oleoyl-2-acetylglycerol (OAG) functions as an agonist for human polymorphonuclear leukocytes (PMNL) in stimulating 5-LO product formation. Here we have demonstrated that OAG directly stimulates 5-LO catalysis in vitro. In the absence of Ca2+ ( chelated using EDTA), OAG strongly and concentration-dependently stimulated crude 5-LO in 100,000 x g supernatants as well as purified 5-LO enzyme from PMNL. Also, the monoglyceride 1-O-oleyl-rac-glycerol and 1,2-dioctanoyl-sn-glycerol were effective, whereas various phospholipids did not stimulate 5-LO. However, in the presence of Ca2+, OAG caused no stimulation of 5-LO. Also, phospholipids or cellular membranes abolished the effects of OAG. As found previously for Ca2+, OAG renders 5-LO activity resistant against inhibition by glutathione peroxidase activity, and this effect of OAG is reversed by phospholipids. Intriguingly, a 5-LO mutant lacking tryptophan residues (Trp-13, -75, and -102) important for the binding of the 5-LO C2-like domain to phospholipids was not stimulated by OAG. We conclude that OAG directly stimulates 5-LO by acting at a phospholipid binding site located within the C2-like domain.	Univ Frankfurt, Inst Pharmaceut Chem, ZAFES, D-60439 Frankfurt, Germany; Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden	Goethe University Frankfurt; Karolinska Institutet	Werz, O (corresponding author), Univ Frankfurt, Inst Pharmaceut Chem, ZAFES, Marie Curie Str 9, D-60439 Frankfurt, Germany.	o.werz@pharmchem.uni-frankfurt.de	Steinhilber, Dieter/J-3221-2012					AHARONY D, 1986, J BIOL CHEM, V261, P1512; Albert D, 2003, BBA-MOL CELL BIOL L, V1631, P85, DOI 10.1016/S1388-1981(02)00359-1; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; Burkert E, 2003, J BIOL CHEM, V278, P42846, DOI 10.1074/jbc.M302471200; Burkert E, 2002, BIOCHEM BIOPH RES CO, V295, P985, DOI 10.1016/S0006-291X(02)00791-X; CHASTEEN ND, 1993, BIOCHEMISTRY-US, V32, P9763, DOI 10.1021/bi00088a031; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; DeCarolis E, 1996, EUR J BIOCHEM, V235, P416; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2001, BIOCHEMISTRY-US, V40, P6371, DOI 10.1021/bi001595d; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; HATZELMANN A, 1987, EUR J BIOCHEM, V169, P175, DOI 10.1111/j.1432-1033.1987.tb13595.x; Hemak J, 2002, J MOL MODEL, V8, P102, DOI 10.1007/s00894-002-0076-y; Huwiler A, 2001, FASEB J, V15, P7; JAKOBSSON PJ, 1995, EUR J BIOCHEM, V232, P37, DOI 10.1111/j.1432-1033.1995.tb20778.x; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Luo M, 2004, J BIOL CHEM, V279, P41512, DOI 10.1074/jbc.M312568200; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NOGUCHI M, 1994, BBA-LIPID LIPID MET, V1215, P300, DOI 10.1016/0005-2760(94)90057-4; Ochoa WF, 2003, BIOCHEMISTRY-US, V42, P8774, DOI 10.1021/bi034713g; Pande AH, 2004, BIOCHEMISTRY-US, V43, P14653, DOI 10.1021/bi048775y; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; PUUSTINEN T, 1988, BIOCHIM BIOPHYS ACTA, V960, P261, DOI 10.1016/0005-2760(88)90033-1; Radmark O, 2002, PROSTAG OTH LIPID M, V68-9, P211, DOI 10.1016/S0090-6980(02)00032-1; RADMARK O, 1995, J LIPID MEDIAT CELL, V12, P171, DOI 10.1016/0929-7855(95)00017-K; Reddy KV, 2000, BIOCHEMISTRY-US, V39, P1840, DOI 10.1021/bi9919246; RIENDEAU D, 1993, J LIPID MEDIATOR, V6, P23; RIENDEAU D, 1989, BIOCHEM J, V263, P565, DOI 10.1042/bj2630565; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; ROUZER CA, 1987, P NATL ACAD SCI USA, V84, P7393, DOI 10.1073/pnas.84.21.7393; ROUZER CA, 1986, FEBS LETT, V204, P293, DOI 10.1016/0014-5793(86)80831-6; Skorey KI, 1998, BIOCHEMISTRY-US, V37, P8027, DOI 10.1021/bi980371g; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; Wendel A, 1981, Methods Enzymol, V77, P325; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; Werz O, 2000, EUR J BIOCHEM, V267, P1263, DOI 10.1046/j.1432-1327.2000.01000.x; Werz Oliver, 2002, Current Drug Targets - Inflammation and Allergy, V1, P23, DOI 10.2174/1568010023344959; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018	51	30	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26913	26921		10.1074/jbc.M500068200	http://dx.doi.org/10.1074/jbc.M500068200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15923196	hybrid			2022-12-25	WOS:000230589500034
J	Royer, Y; Staerk, J; Costuleanu, M; Courtoy, PJ; Constantinescu, SN				Royer, Y; Staerk, J; Costuleanu, M; Courtoy, PJ; Constantinescu, SN			Janus kinases affect thrombopoietin receptor cell surface localization and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MPL LIGAND; PROTEIN-TYROSINE PHOSPHORYLATION; INTERFERON-ALPHA/BETA RECEPTOR; HUMAN BLOOD-PLATELETS; RAT-LIVER LYSOSOMES; ERYTHROPOIETIN RECEPTOR; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE DISORDERS; JUXTAMEMBRANE DOMAIN; CYTOPLASMIC DOMAIN	The thrombopoietin receptor (TpoR) regulates hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. TpoR signals by activating Janus kinases JAK2 and Tyk2. Here we show that, in addition to signaling downstream from the activated TpoR, JAK2 and Tyk2 strongly promote cell surface localization and enhance total protein levels of the TpoR. This effect is caused by stabilization of the mature endoglycosidase H-resistant form of the receptor. Confocal microscopy indicates that TpoR colocalizes partially with recycling transferrin in Ba/F3 cells. The interaction with JAK2 or Tyk2 appears to protect the receptor from proteasome degradation. Sequences encompassing Box1 and Box2 regions of the receptor cytosolic domain and an intact JAK2 or Tyk2 FERM domain are required for these effects. We discuss the relevance of our results to the reported defects of TpoR processing in myeloproliferative diseases and to the mechanisms of Tpo signaling and clearance via the TpoR.	Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Gr T Popa Univ, Fac Dent Med & Pharm, RO-700115 Iasi, Romania; Univ Louvain, Christian de Duve Inst Cellular Pathol, MEXP Unit, B-1200 Brussels, Belgium; Univ Louvain, Christian de Duve Inst Cellular Pathol, CELL Unit, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Grigore T Popa University of Medicine & Pharmacy; Universite Catholique Louvain; Universite Catholique Louvain	Constantinescu, SN (corresponding author), Ludwig Inst Canc Res, Ave Hippocrate74,UCL 74-59, B-1200 Brussels, Belgium.	stefan.constantinescu@bru.licr.org	Constantinescu, Stefan N/E-5277-2012; Costuleanu, Marcel A/A-6807-2010	Costuleanu, Marcel A/0000-0003-2645-9533; Staerk, Judith/0000-0001-8698-6998; Constantinescu, Stefan N./0000-0002-8599-2699				Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Behrmann I, 2004, J BIOL CHEM, V279, P35486, DOI 10.1074/jbc.M404202200; Broudy VC, 1997, BLOOD, V89, P1896, DOI 10.1182/blood.V89.6.1896; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Cohen-Solal K, 1999, BLOOD, V93, P2859; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Dahlen DD, 2003, BLOOD, V102, P102, DOI 10.1182/blood-2002-11-3468; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; EZUMI Y, 1995, FEBS LETT, V374, P48, DOI 10.1016/0014-5793(95)01072-M; Fielder PJ, 1996, BLOOD, V87, P2154, DOI 10.1182/blood.V87.6.2154.bloodjournal8762154; Fielder PJ, 1997, BLOOD, V89, P2782, DOI 10.1182/blood.V89.8.2782; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Greiser JS, 2002, J BIOL CHEM, V277, P26959, DOI 10.1074/jbc.M204113200; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hofmann SR, 2004, MOL CELL BIOL, V24, P5039, DOI 10.1128/MCB.24.11.5039-5049.2004; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KIRSCHKE H, 1977, EUR J BIOCHEM, V74, P293, DOI 10.1111/j.1432-1033.1977.tb11393.x; KIRSCHKE H, 1976, ACTA BIOL MED GER, V35, P285; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Li JZ, 1999, BRIT J HAEMATOL, V106, P345, DOI 10.1046/j.1365-2141.1999.01571.x; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; Moliterno AR, 1999, BLOOD, V94, P2555, DOI 10.1182/blood.V94.8.2555.420k14_2555_2561; Moliterno AR, 1998, NEW ENGL J MED, V338, P572, DOI 10.1056/NEJM199802263380903; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; MULLERSMAN JE, 1995, TRENDS BIOCHEM SCI, V20, P55, DOI 10.1016/S0968-0004(00)88956-2; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; Oda A, 1996, BLOOD, V88, P4304; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; RodriguezLinares B, 1996, BIOCHEM J, V316, P93, DOI 10.1042/bj3160093; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Walrafen P, 2005, BLOOD, V105, P600, DOI 10.1182/blood-2004-03-1216; Watowich SS, 1999, J BIOL CHEM, V274, P5415, DOI 10.1074/jbc.274.9.5415; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430	61	123	130	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27251	27261		10.1074/jbc.M501376200	http://dx.doi.org/10.1074/jbc.M501376200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15899890	hybrid			2022-12-25	WOS:000230589500074
J	Wang, GL; Yamasaki, K; Daiho, T; Suzuki, H				Wang, GL; Yamasaki, K; Daiho, T; Suzuki, H			Critical hydrophobic interactions between phosphorylation and actuator domains of Ca2+-ATPase for hydrolysis of phosphorylated intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; INSENSITIVE PHOSPHOENZYME INTERMEDIATE; CALCIUM-PUMP; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; A-DOMAIN; CONFORMATIONAL TRANSITION; ADENOSINE-TRIPHOSPHATE; CRYSTAL-STRUCTURE; ATP BINDING	Functional roles of seven hydrophobic residues on the interface between the actuator ( A) and phosphorylation (P) domains of sarcoplasmic reticulum Ca2+-ATPase were explored by alanine and serine substitutions. The residues examined were Ile(179)/Leu(180)/ Ile(232) on the A domain, Val(705)/Val(726) on the P domain, and Leu(119)/Tyr(122) on the loop linking the A domain and M2 ( the second transmembrane helix). These residues gather to form a hydrophobic cluster around Tyr(122) in the crystal structures of Ca2+-ATPase in Ca2+-unbound E2 (unphosphorylated) and E2P ( phosphorylated) states but are far apart in those of Ca2+- bound E1 ( unphosphorylated) and E1P ( phosphorylated) states. The substitution-effects were also compared with those of Ile(235) on the A domain/M3 linker and those of T(181)GE of the A domain, since they are in the immediate vicinity of the Tyr(122)-cluster. All these substitutions almost completely inhibited ATPase activity without inhibiting Ca2+-activated E1P formation from ATP. Substitutions of Ile(235) and T(181)GE blocked the E1P to E2P transition, whereas those in the Tyr(122)-cluster blocked the subsequent E2P hydrolysis. Substitutions of Ile(235) and Glu(183) also blocked EP hydrolysis. Results indicate that the Tyr(122)-cluster is formed during the E1P to E2P transition to configure the catalytic site and position Glu(183) properly for hydrolyzing the acylphosphate. Ile(235) on the A domain/M3 linker likely forms hydrophobic interactions with the A domain and thereby allowing the strain of this linker to be utilized for large motions of the A domain during these processes. The Tyr(122)-cluster, Ile(235), and T(181)GE thus seem to have different roles and are critical in the successive events in processing phosphorylated intermediates to transport Ca2+.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan; China Med Univ, Clin Coll 1, Dept Nucl Med, Shenyang 110001, Peoples R China	Asahikawa Medical College; China Medical University	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Daiho T, 2003, J BIOL CHEM, V278, P39197, DOI 10.1074/jbc.M305200200; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1988, METHOD ENZYMOL, V157, P154; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V67, P693, DOI 10.1093/oxfordjournals.jbchem.a129297; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Lenoir G, 2004, J BIOL CHEM, V279, P9156, DOI 10.1074/jbc.M311411200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 2004, J BIOL CHEM, V279, P32515, DOI 10.1074/jbc.M403242200; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; PICK U, 1982, J BIOL CHEM, V257, P6120; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sorensen TLM, 2004, J BIOL CHEM, V279, P46355, DOI 10.1074/jbc.C400414200; Toustrup-Jensen M, 2005, J BIOL CHEM, V280, P10210, DOI 10.1074/jbc.M411214200; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WEBB MR, 1981, J BIOL CHEM, V256, P4884; WEBER K, 1969, J BIOL CHEM, V244, P4406; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200	44	27	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26508	26516		10.1074/jbc.M503789200	http://dx.doi.org/10.1074/jbc.M503789200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901722	hybrid, Green Submitted			2022-12-25	WOS:000230386800067
J	Sun, JZ; Wang, DA; Jain, RK; Carie, A; Paquette, S; Ennis, E; Blaskovich, MA; Baldini, L; Coppola, D; Hamilton, AD; Sebti, SM				Sun, JZ; Wang, DA; Jain, RK; Carie, A; Paquette, S; Ennis, E; Blaskovich, MA; Baldini, L; Coppola, D; Hamilton, AD; Sebti, SM			Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors	ONCOGENE			English	Article						PDGF; VEGF; angiogenesis inhibitors; tumorigenesis; growth factor binders	ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; ESTABLISHED TUMORS; ANTITUMOR EFFICACY; KINASE INHIBITORS; FACTOR-BB; IN-VIVO; REGRESSION; CANCER; EXPRESSION	Angiogenesis depends on vascular endothelial growth factor ( VEGF) for initiation and platelet-derived growth factor ( PDGF) for maintenance of blood vessels. We have designed a targeted library of compounds from which we identified a novel molecule, GFB-204, that binds PDGF and VEGF, blocks binding of PDGF and VEGF to their receptors (200-500 nM) and subsequently inhibits PDGFR and Flk-1 tyrosine phosphorylation and stimulation of the protein kinases Erk1, Erk2 and Akt and the signal transducer and activator of transcription STAT3. GFB204 is selective for PDGF and VEGF and does not inhibit EGF, IGF-1 and FGF stimulation of Erk1/2, Akt and STAT3. GFB-204 inhibits endothelial cell migration and capillary network formation in vitro. Finally, treatment of mice with GFB-204 suppresses human tumor growth and angiogenesis. Thus, inhibition of VEGF and PDGF receptor binding with a synthetic molecule results in potent inhibition of angiogenesis and tumorigenesis.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program,MRC DRDIS, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33412 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33412 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program,MRC DRDIS, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Andew.hamilton@yale.edu; Sebti@moffitt.usf.edu	Jain, Rakesh K/I-1384-2017; Baldini, Laura/N-3588-2014	Jain, Rakesh K/0000-0001-7571-3548; Baldini, Laura/0000-0002-0985-4331; Baldini, Luca/0000-0003-2964-9981; Carie, Adam/0000-0001-7804-0465	NCI NIH HHS [CA78038] Funding Source: Medline; NIGMS NIH HHS [GM35208] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON M, 1995, GROWTH FACTORS, V12, P159, DOI 10.3109/08977199509028962; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Blaskovich MA, 2003, CANCER RES, V63, P1270; Blaskovich MA, 2000, NAT BIOTECHNOL, V18, P1065, DOI 10.1038/80257; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Laird AD, 2000, CANCER RES, V60, P4152; Miao RQ, 2002, BLOOD, V100, P3245, DOI 10.1182/blood-2002-01-0185; Morin MJ, 2000, ONCOGENE, V19, P6574, DOI 10.1038/sj.onc.1204102; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Papadimitriou E, 2001, BIOCHEM BIOPH RES CO, V282, P306, DOI 10.1006/bbrc.2001.4574; Paris Daniel, 2004, Angiogenesis, V7, P75, DOI 10.1023/B:AGEN.0000037335.17717.bf; Relf M, 1997, CANCER RES, V57, P963; Sun JZ, 1999, CANCER RES, V59, P4919; Wedge SR, 2000, CANCER RES, V60, P970; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	28	83	90	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4701	4709		10.1038/sj.onc.1208391	http://dx.doi.org/10.1038/sj.onc.1208391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897913				2022-12-25	WOS:000230304500008
J	Wechselberger, C; Strizzi, L; Kenney, N; Hirota, M; Sun, YP; Ebert, A; Orozco, O; Bianco, C; Khan, NI; Wallace-Jones, B; Normanno, N; Adkins, H; Sanicola, M; Salomon, DS				Wechselberger, C; Strizzi, L; Kenney, N; Hirota, M; Sun, YP; Ebert, A; Orozco, O; Bianco, C; Khan, NI; Wallace-Jones, B; Normanno, N; Adkins, H; Sanicola, M; Salomon, DS			Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma	ONCOGENE			English	Article						Cripto-1; transgenic mice; mammary development; mammary tumorigenesis; MMTV-LTR	INTEGRIN-LINKED KINASE; COLON-CANCER CELLS; HUMAN BREAST CARCINOMAS; FACTOR-RELATED PROTEINS; GROWTH-FACTOR-ALPHA; TRANSGENIC MICE; SIGNALING PATHWAY; EPITHELIAL-CELLS; ANTISENSE OLIGONUCLEOTIDES; BRANCHING MORPHOGENESIS	Human Cripto-1 (CR-1) is overexpressed in approximately 80% of human breast, colon and lung carcinomas. Mouse Cr-1 upregulation is also observed in a number of transgenic (Tg) mouse mammary tumors. To determine whether CR-1 can alter mammary gland development and/or may contribute to tumorigenesis in vivo, we have generated Tg mouse lines that express human CR-1 under the transcriptional control of the mouse mammary tumor virus ( MMTV). Stable Tg MMTV/CR-1 FVB/N lines expressing different levels of CR-1 were analysed. Virgin female MMTV/CR-1 Tg mice exhibited enhanced ductal branching, dilated ducts, intraductal hyperplasia, hyperplastic alveolar nodules and condensation of the mammary stroma. Virgin aged MMTV/CR-1 Tg mice also possessed persistent end buds. In aged multiparous MMTV/ CR-1 mice, the hyperplastic phenotype was most pronounced with multifocal hyperplasias. In the highest CR1-expressing subline, G4,38% (12/31) of the multiparous animals aged 12 - 20 months developed hyperplasias and approximately 33% (11/31) developed papillary adenocarcinomas. The long latency period suggests that additional genetic alterations are required to facilitate mammary tumor formation in conjunction with CR-1. This is the first in vivo study that shows hyperplasia and tumor growth in CR-1-overexpressing animals.	NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Bethesda, MD 20892 USA; Hampton Univ, Dept Biol Sci, Hampton, VA 23668 USA; Free Univ Berlin, Med Ctr Benjamin Franklin, Dept Obstet & Gynecol, D-12200 Berlin, Germany; Biogen Idec Inc, Cambridge, MA 02142 USA; IT Fdn, Div Haematol Oncol, I-80131 Naples, Italy; IT Fdn, Dept Expt Oncol, I-80131 Naples, Italy	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hampton University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Biogen	Salomon, DS (corresponding author), NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Bldg 10,Room 5B39,10 Ctr Dr, Bethesda, MD 20892 USA.	salomond@mail.nih.gov	Sun, Youping/AAX-7058-2021; Normanno, Nicola/AAT-1107-2021	Hirota, Morihisa/0000-0001-5682-0911; Normanno, Nicola/0000-0002-7158-2605; Wechselberger, Christian/0000-0002-2164-3019	NATIONAL CANCER INSTITUTE [Z01BC009003, ZIABC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson ED, 2002, J CELL PHYSIOL, V190, P267, DOI 10.1002/jcp.10072; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; Brisken C, 2000, GENE DEV, V14, P650; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; Carpenter MK, 2004, DEV DYNAM, V229, P243, DOI 10.1002/dvdy.10431; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Colas JF, 2000, GENE, V255, P205, DOI 10.1016/S0378-1119(00)00337-1; De Luca A, 1999, INT J CANCER, V80, P589, DOI 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeLuca A, 1997, INT J CANCER, V73, P277, DOI 10.1002/(SICI)1097-0215(19971009)73:2<277::AID-IJC19>3.3.CO;2-J; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DONO R, 1993, DEVELOPMENT, V118, P1157; Ebert AD, 2000, EXP CELL RES, V257, P223, DOI 10.1006/excr.2000.4881; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; Herrington EE, 1997, J CELL PHYSIOL, V170, P47; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902; Kenney N., 1997, PATHOGENESIS, V1, P57; Kenney NJ, 1996, MOL CARCINOGEN, V15, P44; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Morkel M, 2003, DEVELOPMENT, V130, P6283, DOI 10.1242/dev.00859; Naylor MJ, 2002, DEV DYNAM, V225, P100, DOI 10.1002/dvdy.10133; Niemeyer CC, 1999, INT J CANCER, V81, P588, DOI 10.1002/(SICI)1097-0215(19990517)81:4<588::AID-IJC14>3.0.CO;2-I; Niemeyer CC, 1998, CELL DEATH DIFFER, V5, P440, DOI 10.1038/sj.cdd.4400368; Normanno N, 1999, ONCOL REP, V6, P1105; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; Normanno N, 1996, CLIN CANCER RES, V2, P601; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; POLLARD JW, 2001, BREAST CANCER RES, V3, P320; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Robinson GW, 1997, DEVELOPMENT, V124, P2701; Robinson GW, 2000, GENE DEV, V14, P889; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Salomon DS, 1999, BIOESSAYS, V21, P61, DOI 10.1002/(SICI)1521-1878(199901)21:1&lt;61::AID-BIES8&gt;3.0.CO;2-H; Salomon DS, 2000, ENDOCR-RELAT CANCER, V7, P199, DOI 10.1677/erc.0.0070199; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shen MM, 1997, DEVELOPMENT, V124, P429; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Soriano JV, 1998, J MAMMARY GLAND BIOL, V3, P133, DOI 10.1023/A:1018790705727; Srinivasan R, 2000, CANCER RES, V60, P1483; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Webster MA, 1998, ONCOGENE, V16, P1963, DOI 10.1038/sj.onc.1201707; WECHSELBERGER C, 1992, P NATL ACAD SCI USA, V89, P9819, DOI 10.1073/pnas.89.20.9819; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Xing PX, 2004, CANCER RES, V64, P4018, DOI 10.1158/0008-5472.CAN-03-3888; Xu CH, 1999, DEVELOPMENT, V126, P483; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Yokota C, 2003, DEVELOPMENT, V130, P2199, DOI 10.1242/dev.00434; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	71	64	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4094	4105		10.1038/sj.onc.1208417	http://dx.doi.org/10.1038/sj.onc.1208417			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15897912				2022-12-25	WOS:000229680300008
J	Pandey, M; Loskutoff, DJ; Samad, F				Pandey, M; Loskutoff, DJ; Samad, F			Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes	FASEB JOURNAL			English	Article						obesity; insulin resistance; insulin; transforming growth factor-beta; PKC; P44/42; NF-kappa B	PROTEIN-KINASE-C; GROWTH-FACTOR-BETA; PAI-1 GENE-EXPRESSION; ADIPOSE-TISSUE; MESSENGER-RNA; TNF-ALPHA; UP-REGULATION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; PHORBOL ESTERS	Increased expression of plasminogen activator inhibitor - 1 (PAI-1) in adipose tissues is thought to contribute to both the cardiovascular and metabolic complications associated with obesity. Tumor necrosis factor alpha (TNF-alpha) is chronically elevated in adipose tissues of obese rodents and humans and has been directly implicated to induce PAI-1 in adipocytes. In this study, we used 3T3-L1 adipocytes to examine the mechanism by which TNF-alpha up-regulates PAI-1 in the adipocyte. Acute ( 3 h) and chronic ( 24 h) exposure of 3T3-L1 adipocytes to TNF-alpha induces PAI-1 mRNA by increasing the rate of transcription of the PAI-1 gene, and de novo protein synthesis is not required for this process. Although the p44/42 and PKC signaling pathways appear to be significant in the induction of PAI-1 mRNA in response to acute treatment with TNF-alpha, the more dramatic induction of PAI-1 mRNA observed in response to chronic exposure of adipocytes to TNF-alpha was mediated by these and additional signaling molecules, including p38, PI3-kinase, tyrosine kinases, and the transcription factor NF-kappa B. Moreover, the dramatic increase in PAI-1 observed after chronic exposure of adipocytes to TNF-alpha was accompanied by increased metabolic insulin resistance. Finally, we demonstrate that the PKC pathway is also central for PAI-1 induction in response to insulin and transforming growth factor-beta (TGF-beta), two additional molecules which are elevated in obesity and shown to directly induce PAI-1 in the adipocyte. The understanding of the mechanism of regulating PAI-1 expression in the adipocytes at the molecular level provides new insight to help identify novel targets in fighting the pathological complications of obesity.	La Jolla Inst Mol Med, Div Vasc Biol, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	Samad, F (corresponding author), La Jolla Inst Mol Med, Div Vasc Biol, 4570 Execut Dr,Suite 100, San Diego, CA 92121 USA.	fsamad@ljimm.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071146] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HLO71146-01A2] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Alexander JP, 2001, INVEST OPHTH VIS SCI, V42, P2831; Arts J, 1999, ARTERIOSCL THROM VAS, V19, P39, DOI 10.1161/01.ATV.19.1.39; Bazzoni F, 1995, J INFLAMM, V45, P221; Bigda Jacek, 1997, Archivum Immunologiae et Therapiae Experimentalis, V45, P263; CHRISTENSEN RL, 1987, INT J BIOCHEM, V19, P259; Cigolini M, 1999, ATHEROSCLEROSIS, V143, P81, DOI 10.1016/S0021-9150(98)00281-0; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; Claycombe KJ, 2002, J BIOL CHEM, V277, P30784, DOI 10.1074/jbc.M204463200; FEARNS C, 1995, VASCULAR CONTROL HEM, P207; Fluckey JD, 2004, AM J PHYSIOL-ENDOC M, V286, pE753, DOI 10.1152/ajpendo.00155.2003; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; GEORG B, 1989, MOL CELL ENDOCRINOL, V61, P87, DOI 10.1016/0303-7207(89)90192-5; Goeddel DV, 1999, CHEST, V116, p69S, DOI 10.1378/chest.116.suppl_1.69S; Gottschling-Zeller H, 2000, METABOLISM, V49, P666, DOI 10.1016/S0026-0495(00)80046-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hamaguchi E, 2003, J PHARMACOL EXP THER, V307, P987, DOI 10.1124/jpet.103.054346; Harp JB, 2004, CURR OPIN LIPIDOL, V15, P303, DOI 10.1097/00041433-200406000-00010; HAUSS P, 1993, CELL IMMUNOL, V150, P439, DOI 10.1006/cimm.1993.1211; HEATON JH, 1992, MOL ENDOCRINOL, V6, P53, DOI 10.1210/me.6.1.53; Hershko DD, 2004, J CELL BIOCHEM, V91, P951, DOI 10.1002/jcb.20014; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Hostamisligil GS, 1999, EXP CLIN ENDOCR DIAB, V107, P119, DOI 10.1055/s-0029-1212086; Hotamisligil Gokhan S., 1996, P554; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200; IMAKI T, 1995, J CLIN INVEST, V96, P231, DOI 10.1172/JCI118026; Ishizuka T, 2004, ENDOCR RES, V30, P287, DOI 10.1081/ERC-120039580; Jain RG, 1999, J CELL PHYSIOL, V179, P58, DOI 10.1002/(SICI)1097-4652(199904)179:1<58::AID-JCP8>3.0.CO;2-1; Juhan-Vague I, 2003, J THROMB HAEMOST, V1, P1575, DOI 10.1046/j.1538-7836.2003.00279.x; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Kim JK, 2004, J CLIN INVEST, V114, P823, DOI 10.1172/JCI200422230; Kumakura S, 2003, LEUKEMIA LYMPHOMA, V44, P497, DOI 10.1080/1042819021000047010; Kye KC, 2004, J INVEST DERMATOL, V122, P1365, DOI 10.1111/j.0022-202X.2004.22615.x; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; LeMagueresseBattistoni B, 1996, ENDOCRINOLOGY, V137, P4243, DOI 10.1210/en.137.10.4243; LEVIN EG, 1988, FIBRINOLYSIS S, V2, P19; Lopez S, 1999, THROMB HAEMOSTASIS, V81, P415, DOI 10.1055/s-0037-1614488; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; LOSKUTOFF DJ, 2000, NEW FRONTIER VASCULA, P151; LOSKUTOFF DJ, 2000, EXCERPTA MED INT C S; Lundgren CH, 1996, CIRCULATION, V93, P106, DOI 10.1161/01.CIR.93.1.106; MAYER M, 1988, J BIOL CHEM, V263, P15688; MEULDERS Q, 1992, KIDNEY INT, V42, P327, DOI 10.1038/ki.1992.293; MOHAMED F, 1995, ARTERIOSCL THROM VAS, V15, P52, DOI 10.1161/01.ATV.15.1.52; Morange PE, 2000, ARTERIOSCL THROM VAS, V20, P1150, DOI 10.1161/01.ATV.20.4.1150; Motojima M, 1999, BBA-MOL CELL RES, V1449, P217, DOI 10.1016/S0167-4889(99)00014-2; Naaz A, 2003, ENDOCRINOLOGY, V144, P3315, DOI 10.1210/en.2003-0076; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Okada H, 1998, CIRCULATION, V97, P2175, DOI 10.1161/01.CIR.97.21.2175; Pandey M, 2003, AM J PATHOL, V162, P933, DOI 10.1016/S0002-9440(10)63888-6; Penhoat A, 1996, MOL CELL ENDOCRINOL, V121, P57, DOI 10.1016/0303-7207(96)03851-8; PERALDI MN, 1992, BIOCHIM BIOPHYS ACTA, V1134, P189, DOI 10.1016/0167-4889(92)90175-B; PERSHADSINGH HA, 1987, BIOCHEM BIOPH RES CO, V145, P1384, DOI 10.1016/0006-291X(87)91591-9; Samad F, 1999, THROMB HAEMOSTASIS, V82, P742, DOI 10.1055/s-0037-1615906; Samad F, 1997, MOL MED, V3, P37, DOI 10.1007/BF03401666; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Samad F, 2000, MOL MED, V6, P680, DOI 10.1007/BF03402048; SAMAD F, 1997, FIBRINOLYSIS PROTEOL, V11, P17; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; Schafer K, 2001, FASEB J, V15, P1840, DOI 10.1096/fj.00-0750fje; SCHNEIDER DJ, 1992, DIABETES, V41, P890, DOI 10.2337/diabetes.41.7.890; Seidell JC, 2000, BRIT J NUTR, V83, pS5, DOI 10.1017/S000711450000088X; Sharma AM, 2002, INT J OBESITY, V26, pS5, DOI 10.1038/sj.ijo.0802210; Treichel JA, 1998, J NEUROCHEM, V71, P1944; Uno S, 1998, J BIOCHEM, V123, P806; Valverde AM, 1996, ENDOCRINOLOGY, V137, P3832, DOI 10.1210/en.137.9.3832; VAN OX, 1993, NATURE, V361, P266; VANHINSBERGH VWM, 1994, BLOOD, V84, P2984; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092	73	66	67	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1317	+		10.1096/fj.04-3459fje	http://dx.doi.org/10.1096/fj.04-3459fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15928193				2022-12-25	WOS:000229602600001
J	Marshall, KR; Gong, M; Wodke, L; Lamb, JH; Jones, DJL; Farmer, PB; Scrutton, NS; Munro, AW				Marshall, KR; Gong, M; Wodke, L; Lamb, JH; Jones, DJL; Farmer, PB; Scrutton, NS; Munro, AW			The human apoptosis-inducing protein AMID is an oxidoreductase with a modified flavin cofactor and DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFERRING FLAVOPROTEIN; INDEPENDENT CELL-DEATH; D-ASPARTATE OXIDASE; FACTOR AIF; CELLOBIOSE DEHYDROGENASE; MEGASPHAERA-ELSDENII; MITOCHONDRIA; PURIFICATION	AMID (apoptosis-inducing factor-homologous mitochondrion-associated inducer of death; also known as PRG3 (p53-responsive gene 3)) is a human caspase-independent pro-apoptotic protein with some similarity to apoptosis-inducing factor. AMID was purified from a recombinant bacterial host, enabling biochemical analysis of the protein. AMID is a flavoprotein; possesses NAD(P)H oxidase activity; and catalyzes NAD(P)H-dependent reduction of cytochrome c and other electron acceptors, including molecular oxygen. NADPH binds similar to 10-fold tighter than NADH. AMID binds 6-hydroxy-FAD (a cofactor that accumulates only adventitiously and at low abundance in other flavoprotein enzymes) to form a stoichiometric cofactor center dot protein complex. AMID has a distinctive electronic spectrum due to the modified flavin. NAD(P)(+) binding perturbed the spectrum, enabling determination of K-d values for these coenzymes. 6-Hydroxy-FAD could be removed from AMID and the apoprotein reconstituted with FAD. FAD was converted to 6-hydroxy-FAD in reconstituted AMID during aerobic turnover with NADPH. AMID is a DNA-binding protein that lacks apparent DNA sequence specificity. Formation of the protein center dot DNA complex (i) effected a major protein conformational change and (ii) was prevented in the presence of nicotinamide coenzyme. Apo-AMID retains DNA binding activity. Our studies establish a link between coenzyme and DNA binding that likely impacts on the physiological role of AMID in cellular apoptosis.	Univ Leicester, Dept Biochem, Leicester LE1 9NH, Leics, England	University of Leicester	Marshall, KR (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE1 9NH, Leics, England.	krm4@le.ac.uk; awm9@le.ac.uk	Munro, Andrew/G-5639-2019; Jones, Donald/Y-6803-2019	Munro, Andrew/0000-0002-4642-180X; Jones, Donald/0000-0001-6583-870X				Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; GHISLA S, 1986, BIOCHEM J, V239, P1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hallberg BM, 2002, J MOL BIOL, V315, P421, DOI 10.1006/jmbi.2001.5246; Hefti MH, 2003, EUR J BIOCHEM, V270, P4227, DOI 10.1046/j.1432-1033.2003.03802.x; Igarashi K, 1999, J BIOL CHEM, V274, P3338, DOI 10.1074/jbc.274.6.3338; Jaattela M, 2004, CELL DEATH DIFFER, V11, P135, DOI 10.1038/sj.cdd.4401333; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lorenzo HK, 2004, FEBS LETT, V557, P14, DOI 10.1016/S0014-5793(03)01464-9; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; NEGRI A, 1987, J BIOL CHEM, V262, P10026; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; PACE CP, 1987, BIOCHIM BIOPHYS ACTA, V911, P267, DOI 10.1016/0167-4838(87)90067-7; Roitel O, 2003, BIOCHEMISTRY-US, V42, P10809, DOI 10.1021/bi034562h; Sato K, 2003, J BIOCHEM, V134, P719, DOI 10.1093/jb/mvg199; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; TEDESCHI G, 1994, BBA-PROTEIN STRUCT M, V1207, P217, DOI 10.1016/0167-4838(94)00071-9; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836	28	67	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30735	30740		10.1074/jbc.M414018200	http://dx.doi.org/10.1074/jbc.M414018200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15958387	hybrid			2022-12-25	WOS:000231487800012
J	de Graauw, M; Tijdens, I; Cramer, R; Corless, S; Timms, JF; van de Water, B				de Graauw, M; Tijdens, I; Cramer, R; Corless, S; Timms, JF; van de Water, B			Heat shock protein 27 is the major differentially phosphorylated protein involved in renal epithelial cellular stress response and controls focal adhesion organization and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INDUCED FUNCTIONAL INJURY; JUN NH2-TERMINAL KINASE; KIDNEY PROXIMAL TUBULES; CONJUGATE BETA-LYASE; GEL-ELECTROPHORESIS; HEAT-SHOCK; MASS-SPECTROMETRY; CYTOCHROME-C; HUMAN HSP27	We used two-dimensional difference gel electrophoresis to determine early changes in the stress-response pathways that precede focal adhesion disorganization linked to the onset of apoptosis of renal epithelial cells. Treatment of LLC-PK1 cells with the model nephrotoxicant 1,2-(dichlorovinyl)-L-cysteine ( DCVC) resulted in a > 1.5-fold up- and down-regulation of 14 and 9 proteins, respectively, preceding the onset of apoptosis. Proteins included those involved in metabolism, i.e. aconitase and pyruvate dehydrogenase, and those related to stress responses and cytoskeletal reorganization, i.e. cofilin, Hsp27, and alpha-b-crystallin. The most prominent changes were found for Hsp27, which was related to a pI shift in association with an altered phosphorylation status of serine residue 82. Although both p38 and JNK were activated by DCVC, only inhibition of p38 with SB203580 reduced Hsp27 phosphorylation, which was associated with accelerated reorganization of focal adhesions, cell detachment, and apoptosis. In contrast, inhibition of JNK with SP600125 maintained cell adhesion as well as protection against apoptosis. Active JNK co-localized at focal adhesions after DCVC treatment in a FAK-dependent manner. Inhibition of active JNK localization at focal adhesions did not prevent DCVC-induced phosphorylation of Hsp27. Overexpression of a phosphorylation-defective mutant Hsp27 acted as a dominant negative and accelerated the DCVC-induced changes in the focal adhesions as well as the onset of apoptosis. Our data fit a model whereby early p38 activation results in a rapid phosphorylation of Hsp27, a requirement for proper maintenance of cell adhesion, thus suppressing renal epithelial cell apoptosis.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, NL-2300 RA Leiden, Netherlands; Univ Reading, Bioctr, Reading RG6 6AS, Berks, England; UCL, Ludwig Inst Canc Res, London WC1E 6BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Leiden University; Leiden University - Excl LUMC; University of Reading; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	van de Water, B (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, NL-2300 RA Leiden, Netherlands.	b.water@LACDR.LeidenUniv.nl	Timms, John/A-1556-2010	Timms, John/0000-0002-4507-835X; Cramer, Rainer/0000-0002-8037-2511				Aoudjit L, 2003, AM J PHYSIOL-RENAL, V285, pF765, DOI 10.1152/ajprenal.00100.2003; Benvenuti S, 2002, MOL CELL PROTEOMICS, V1, P280, DOI 10.1074/mcp.M100028-MCP200; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CHEN JC, 1990, TOXICOL APPL PHARM, V103, P463, DOI 10.1016/0041-008X(90)90319-P; CHEN Q, 1992, J BIOL CHEM, V267, P24322; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Cramer Rainer, 2004, Methods Mol Biol, V261, P499; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DiMari J, 1997, AM J PHYSIOL-RENAL, V272, pF292, DOI 10.1152/ajprenal.1997.272.3.F292; Dong J, 2004, AM J PHYSIOL-RENAL, V287, pF1049, DOI 10.1152/ajprenal.00132.2004; GAILIT J, 1993, AM J PHYSIOL, V264, P149; Garay M, 2000, BIOCHEM PHARMACOL, V59, P1033, DOI 10.1016/S0006-2952(99)00412-8; Gharbi S, 2002, MOL CELL PROTEOMICS, V1, P91, DOI 10.1074/mcp.T100007-MCP200; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hayakawa J, 2003, J BIOL CHEM, V278, P20582, DOI 10.1074/jbc.M210992200; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Ilic D, 1998, J CELL BIOL, V143, P547; James EA, 2002, BIOCHEMISTRY-US, V41, P6789, DOI 10.1021/bi020038j; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kunduzova OR, 2002, FASEB J, V16, P1129, DOI 10.1096/fj.01-1008fje; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; Molitoris BA, 1999, AM J MED, V106, P583, DOI 10.1016/S0002-9343(99)00061-3; Naaby-Hansen S, 2001, TRENDS PHARMACOL SCI, V22, P376, DOI 10.1016/S0165-6147(00)01663-1; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Park KM, 2002, J BIOL CHEM, V277, P2040, DOI 10.1074/jbc.M107525200; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; SCHAEFFER VH, 1987, MOL PHARMACOL, V32, P293; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tonge R, 2001, PROTEOMICS, V1, P377; Towndrow KM, 2000, CHEM RES TOXICOL, V13, P111, DOI 10.1021/tx990160s; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; van de Water B, 2001, J BIOL CHEM, V276, P36183, DOI 10.1074/jbc.M102091200; VANDEWATER B, 1994, AM J PHYSIOL-RENAL, V267, pF888, DOI 10.1152/ajprenal.1994.267.5.F888; VanDeWater B, 1996, AM J PHYSIOL-RENAL, V270, pF593, DOI 10.1152/ajprenal.1996.270.4.F593; Weinberg JM, 2001, AM J PATHOL, V158, P2153, DOI 10.1016/S0002-9440(10)64687-1; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; ZHANG GH, 1989, TOXICOL APPL PHARM, V100, P51, DOI 10.1016/0041-008X(89)90091-4	54	74	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29885	29898		10.1074/jbc.M412708200	http://dx.doi.org/10.1074/jbc.M412708200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15944157	Green Published, hybrid			2022-12-25	WOS:000231176200060
J	Pashov, A; Canziani, G; Monzavi-Karbassi, B; Kaveri, SV; MacLeod, S; Saha, R; Perry, M; VanCott, TC; Kieber-Emmons, T				Pashov, A; Canziani, G; Monzavi-Karbassi, B; Kaveri, SV; MacLeod, S; Saha, R; Perry, M; VanCott, TC; Kieber-Emmons, T			Antigenic properties of peptide mimotopes of HIV-1-associated carbohydrate antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTRALIZING ANTI-HIV-1 ANTIBODY; TYPE-1 GLYCOPROTEIN GP120; VACCINE DESIGN; ENVELOPE GLYCOPROTEIN; DENDRITIC CELLS; DC-SIGN; HIV-1; BINDING; LECTIN	The glycan shield of the human immunodeficiency virus (HIV) envelope protein presents many potential epitopes for vaccine development. To augment immune responses to HIV, type 1 (HIV-1), envelope-associated carbohydrate antigens, we are defining peptide mimics of HIV-associated carbohydrate antigens that function as antigen mimotopes that upon immunization will induce antibodies cross-reactive with carbohydrate antigens. We have previously defined peptides with a putative sequence tract RYRY that mimic concanavalin A-binding glycans. To imitate the multivalent binding of carbohydrates, we compared the avidity of a linear ( 911) and cyclic peptide (D002) reactive with concanavalin A presented in a multiple antigen peptide ( MAP) format. The affinity of the MAP-D002 peptide was higher than that of the peptide MAP-911, whereas the avidity of D002 peptide was lower than that of 911. Serum from mice immunized with MAP-911 had lower titer for oligoman-nose-9 than those elicited by MAP-D002 under the same conditions, but both immunogens elicited antibodies that can block the binding of GP120 to dendritic cells. Antibodies that bind to the studied MAPs were found in a preparation of normal human immunoglobulin for intravenous use. Those that were purified on 911 bound back to 911 and D002, whereas anti-D002 antibodies were specific only for D002. Human antibodies reactive with both mimotopes and with a mannosyl preparation were observed to bind to envelope protein. These results suggested the potential to fine-tune the antibody response to carbohydrate antigens by modifying structural features of peptide mimotope-based immunogens.	Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; Centocor Inc, Radnor, PA 19087 USA; Ouachita Baptist Univ, Dept Chem, Arkadelphia, AR 71998 USA; Adv Biosci Labs Inc, Kensington, MD 20895 USA; Inst Biomed Cordeliers, INSERM U681, F-75006 Paris, France	University of Arkansas System; University of Arkansas Medical Sciences; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Kieber-Emmons, T (corresponding author), Univ Arkansas Med Sci, Dept Pathol, ACRC 824,4301 Markham St, Little Rock, AR 72205 USA.	tke@uams.edu	Pashov, Anastas/AAE-7997-2019	Pashov, Anastas/0000-0002-6033-3566	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049092] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI049092] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agadjanyan M, 1997, NAT BIOTECHNOL, V15, P547, DOI 10.1038/nbt0697-547; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; Bewley CA, 2004, J MOL BIOL, V339, P901, DOI 10.1016/j.jmb.2004.04.019; BOLMSTEDT A, 1992, J GEN VIROL, V73, P3099, DOI 10.1099/0022-1317-73-12-3099; Botos I, 2003, CELL MOL LIFE SCI, V60, P277, DOI 10.1007/s000180300023; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Cunto-Amesty G, 2001, J BIOL CHEM, V276, P30490, DOI 10.1074/jbc.M103257200; Dam TK, 2000, J BIOL CHEM, V275, P14223, DOI 10.1074/jbc.275.19.14223; Dudkin VY, 2004, J AM CHEM SOC, V126, P9560, DOI 10.1021/ja047720g; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; Ferrantelli F, 2003, AIDS, V17, P301, DOI 10.1097/00002030-200302140-00003; GATTEGNO L, 1992, AIDS RES HUM RETROV, V8, P27, DOI 10.1089/aid.1992.8.27; HAMMAR L, 1995, AIDS RES HUM RETROV, V11, P87, DOI 10.1089/aid.1995.11.87; HANSEN JES, 1989, AIDS, V3, P635, DOI 10.1097/00002030-198910000-00003; HAURY M, 1994, SCAND J IMMUNOL, V39, P79, DOI 10.1111/j.1365-3083.1994.tb03343.x; Lee HK, 2004, ANGEW CHEM INT EDIT, V43, P1000, DOI 10.1002/anie.200353105; Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430; Li HG, 2004, ORG BIOMOL CHEM, V2, P483, DOI 10.1039/b314565d; Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003; Monzavi-Karbassi B, 2004, ARCH VIROL, V149, P75, DOI 10.1007/s00705-003-0198-2; Monzavi-Karbassi B, 2003, VACCINE, V21, P753, DOI 10.1016/S0264-410X(02)00703-X; Monzavi-Karbassi B, 2001, BIOLOGICALS, V29, P249, DOI 10.1006/biol.2001.0307; Muller KM, 1998, ANAL BIOCHEM, V261, P149, DOI 10.1006/abio.1998.2725; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Pantophlet R, 2003, J VIROL, V77, P5889, DOI 10.1128/JVI.77.10.5889-5901.2003; Pashov A, 2002, INT IMMUNOL, V14, P453, DOI 10.1093/intimm/14.5.453; ROBINSON WE, 1987, AIDS RES HUM RETROV, V3, P265, DOI 10.1089/aid.1987.3.265; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Scanlan CN, 2003, ADV EXP MED BIOL, V535, P205; Shinohara Y, 1997, GLYCOBIOLOGY, V7, P1201, DOI 10.1093/glycob/7.8.1201; Turville SG, 2001, BLOOD, V98, P2482, DOI 10.1182/blood.V98.8.2482; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Wang LX, 2004, CHEM BIOL, V11, P127, DOI 10.1016/j.chembiol.2003.12.020	33	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28959	28965		10.1074/jbc.M502964200	http://dx.doi.org/10.1074/jbc.M502964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15955803	hybrid			2022-12-25	WOS:000231021300017
J	Cote, J; Richard, S				Cote, J; Richard, S			Tudor domains bind symmetrical dimethylated arginines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; MOTOR-NEURON PROTEIN; SPLICEOSOMAL SM PROTEINS; DISEASE GENE-PRODUCT; SARCOMA EWS PROTEIN; RNA-POLYMERASE-II; HISTONE H3; U SNRNPS; METHYLTRANSFERASE PRMT5; PROTEOMIC ANALYSIS	The Tudor domain is an similar to 60-amino acid structure motif in search of a function. Herein we show that the Tudor domains of the spinal muscular atrophy gene product SMN, the splicing factor 30 kDa ( SPF30), and the Tudor domain-containing 3 ( TDRD3) proteins interacted with arginine-glycine-rich motifs in a methylarginine-dependent manner. The Tudor domains also associated with methylarginine-containing cellular proteins, providing evidence that methylated arginines represent physiological ligands for this protein module. In addition, we report that spliceosomal small nuclear ribonucleoprotein particles core Sm proteins accumulated in the cytoplasm when arginine methylation was inhibited with adenosine dialdehyde or in the presence of an excessive amount of unmethylated arginine-glycine-rich peptides. These data provide in vivo evidence in support of a role for arginine methylation in the proper assembly and localization of spliceosomal Sm proteins.	Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Richard, S (corresponding author), Lady Davis Inst, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	stephane.richard@mcgill.ca	Cote, Jocelyn/O-2351-2018	Cote, Jocelyn/0000-0001-9551-2284				Amente S, 2005, FEBS LETT, V579, P683, DOI 10.1016/j.febslet.2004.12.045; Bachand F, 2002, MOL BIOL CELL, V13, P3192, DOI 10.1091/mbc.E02-04-0216; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barth S, 2003, J VIROL, V77, P5008, DOI 10.1128/JVI.77.8.5008-5013.2003; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Belyanskaya LL, 2003, EXP CELL RES, V288, P374, DOI 10.1016/S0014-4827(03)00221-0; Belyanskaya LL, 2001, J BIOL CHEM, V276, P18681, DOI 10.1074/jbc.M011446200; Boisvert FM, 2002, J CELL BIOL, V159, P957, DOI 10.1083/jcb.200207028; Boisvert FM, 2003, MOL CELL PROTEOMICS, V2, P1319, DOI 10.1074/mcp.M300088-MCP200; BOISVERT FM, 2005, SCI STKE, pRE2, DOI DOI 10.1126/STKE.2712005RE2; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; BRINGMANN P, 1983, EMBO J, V2, P1129, DOI 10.1002/j.1460-2075.1983.tb01557.x; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; Charier G, 2004, STRUCTURE, V12, P1551, DOI 10.1016/j.str.2004.06.014; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Cusco I, 2004, NEUROLOGY, V63, P146, DOI 10.1212/01.WNL.0000132634.48815.13; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gangwani L, 2001, NAT CELL BIOL, V3, P376, DOI 10.1038/35070059; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; Hartmuth K, 2002, P NATL ACAD SCI USA, V99, P16719, DOI 10.1073/pnas.262483899; Hebert MD, 2001, GENE DEV, V15, P2720, DOI 10.1101/gad.908401; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Jones KW, 2001, J BIOL CHEM, V276, P38645, DOI 10.1074/jbc.M106161200; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; Lefebvre S, 1998, HUM MOL GENET, V7, P1531, DOI 10.1093/hmg/7.10.1531; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Massenet S, 2002, MOL CELL BIOL, V22, P6533, DOI 10.1128/MCB.22.18.6533-6541.2002; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Meister G, 2001, EMBO J, V20, P2304, DOI 10.1093/emboj/20.9.2304; Melki J, 1997, CURR OPIN NEUROL, V10, P381, DOI 10.1097/00019052-199710000-00005; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Mohaghegh P, 1999, EUR J HUM GENET, V7, P519, DOI 10.1038/sj.ejhg.5200346; Mourelatos Z, 2001, EMBO J, V20, P5443, DOI 10.1093/emboj/20.19.5443; Mowen KA, 2004, MOL CELL, V15, P559, DOI 10.1016/j.molcel.2004.06.042; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Narayanan U, 2004, MOL CELL, V16, P223, DOI 10.1016/j.molcel.2004.09.024; Narayanan U, 2002, HUM MOL GENET, V11, P1785, DOI 10.1093/hmg/11.15.1785; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Pellizzoni L, 2001, CURR BIOL, V11, P1079, DOI 10.1016/S0960-9822(01)00316-5; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; Pu WT, 1999, MOL CELL BIOL, V19, P4113; Rappsilber J, 2001, J BIOL CHEM, V276, P31142, DOI 10.1074/jbc.M103620200; Richard S, 2005, BIOCHEM J, V388, P379, DOI 10.1042/BJ20040373; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sprangers R, 2003, J MOL BIOL, V327, P507, DOI 10.1016/S0022-2836(03)00148-7; SUN Y, 2004, UM MUTAT, V25, P64; Talbot K, 1998, HUM MOL GENET, V7, P2149, DOI 10.1093/hmg/7.13.2149; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang J, 2001, J BIOL CHEM, V276, P45387, DOI 10.1074/jbc.M105059200; Whitehead SE, 2002, J BIOL CHEM, V277, P48087, DOI 10.1074/jbc.M204551200; Wirth B, 2000, HUM MUTAT, V15, P228, DOI 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9; Young PJ, 2003, MOL BRAIN RES, V119, P37, DOI 10.1016/j.molbrainres.2003.08.011; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	88	183	190	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28476	28483		10.1074/jbc.M414328200	http://dx.doi.org/10.1074/jbc.M414328200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15955813	hybrid			2022-12-25	WOS:000230857300037
J	Kim, YB; Yu, JY; Lee, SY; Lee, MS; Ko, SG; Ye, SK; Jong, HS; Kim, TY; Bang, YJ; Lee, JW				Kim, YB; Yu, JY; Lee, SY; Lee, MS; Ko, SG; Ye, SK; Jong, HS; Kim, TY; Bang, YJ; Lee, JW			Cell adhesion status-dependent histone acetylation is regulated through intracellular contractility-related signaling activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; GASTRIC-CARCINOMA CELLS; GENE-EXPRESSION; RHO; PHOSPHORYLATION; TRANSDUCTION; PROTEIN; DEACETYLASES; CYTOSKELETON; MAINTENANCE	Although histone acetylation is important for epigenetic gene transcription, histone acetylation regulation by extracellular cues has rarely been evidenced. Here, we examined whether and how histone acetylation is regulated by cell adhesion-mediated signaling. Gastric carcinoma cells in suspension showed a higher histone acetylation, compared with fibronectin-adherent cells. This difference was supported by a decreased histone deacetylases activity. Furthermore, trichostatin A (TSA)-mediated histone acetylation was significantly increased only in suspended, but not in fibronectin-adherent, cells. Pharmacological inhibition of intracellular contractility-related myosin light chain kinase or RhoA-kinase (ROCK) or expression of ROCK1 small interfering RNA, dominant negative RhoA, or active Rac1 decreased basal and TSA-mediated histone H3 acetylationsin suspended cells, whereas inhibition of calmodulin-dependent protein kinase II or transient overexpression of wild type myosin light chain kinase enhanced the acetylations. Meanwhile, chromatin immunoprecipitation showed higher basal and TSA-enhanced associations of ROCK1 promoter regions with Lys(9)-acetylated histone 3 in suspended cells than in fibronectin-adherent cells and expression of ROCK1 was higher and further increased by TSA treatment in suspension. In addition, phosphorylation of myosin light chain was further increased by TSA in suspension and higher in anchorage-independent cells over adherently growing cells, indicating an inverse relationship between ROCK1 expression-mediated contractility and cell adhesion abilities. Cell adhesion analysis showed that pharmacological activation of intracellular contractility-related signaling activities decreased cell adhesion abilities, whereas inhibition of them increased the adhesion. Taken together, these observations suggest that cell adhesion-related signal transduction regulates histone acetylation, presumably through a close functional linkage between intracellular contractility and histone deacetylases activity/histone acetylation.	Seoul Natl Univ, Canc Res Inst, Dept Tumor Biol, Seoul 110799, South Korea; Seoul Natl Univ, Dept Mol & Clin Oncol, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Lee, JW (corresponding author), Seoul Natl Univ, Canc Res Inst, Dept Tumor Biol, 28,Yeongeon Dong, Seoul 110799, South Korea.	jwl@snu.ac.kr	Bang, Yung Jue/J-2759-2012; Lee, Jung Weon/F-9149-2012; Lee, Jung Weon/AAC-1146-2020; Kim, Tae-You/J-2750-2012; Ye, Sang Kyu/J-2768-2012	Bang, Yung Jue/0000-0001-6000-4597; Lee, Jung Weon/0000-0003-2722-8200; 				Allard S, 2004, BBA-GENE STRUCT EXPR, V1677, P158, DOI 10.1016/j.bbaexp.2003.10.016; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Balda MS, 2003, TRENDS CELL BIOL, V13, P310, DOI 10.1016/S0962-8924(03)00105-3; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ehrenhofer-Murray AE, 2004, EUR J BIOCHEM, V271, P2335, DOI 10.1111/j.1432-1033.2004.04162.x; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Juliano RL, 2004, BIOCHEM SOC T, V32, P443, DOI 10.1042/BST0320443; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kim HP, 2004, BIOCHEM J, V379, P141, DOI 10.1042/BJ20031408; Lee JW, 2004, MOL CELLS, V17, P188; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lee MS, 2004, INT J ONCOL, V24, P1229; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Olson MF, 2004, TRENDS CELL BIOL, V14, P111, DOI 10.1016/j.tcb.2004.01.005; Pfitzer G, 2001, J APPL PHYSIOL, V91, P497, DOI 10.1152/jappl.2001.91.1.497; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2004, J CELL SCI, V117, P3511, DOI 10.1242/jcs.01205; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; Ye SK, 2001, IMMUNITY, V15, P813, DOI 10.1016/S1074-7613(01)00230-8	33	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28357	28364		10.1074/jbc.M412608200	http://dx.doi.org/10.1074/jbc.M412608200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15961394	Green Submitted, hybrid			2022-12-25	WOS:000230857300023
J	Song, IS; Tatebe, S; Dai, WP; Kuo, MT				Song, IS; Tatebe, S; Dai, WP; Kuo, MT			Delayed mechanism for induction of gamma-glutamylcysteine synthetase heavy subunit mRNA stability by oxidative stress involving p38 mitogen-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MRP/GS-X PUMP; ANTIOXIDANT RESPONSE ELEMENT; GENE-EXPRESSION; MISSENSE MUTATION; BINDING PROTEIN; OXIDANT STRESS; LIGHT SUBUNIT; GLUTATHIONE; NRF2; HUR	Expression of the gamma-glutamylcysteine synthetase heavy subunit (gamma-GCSh), which encodes the rate-limiting enzymes for glutathione biosynthesis, is regulated by many cytotoxic agents. Moreover, gamma-GCSh mRNA expression is elevated in colorectal cancer, but how gamma-GCSh expression is regulated is not completely understood. By using actinomycin D, which inhibits new RNA synthesis, we showed that treatment of human colorectal cancer cells with the prooxidant sulindac increased the half-life of gamma-GCSh mRNA. By using a tetracycline-regulated gamma-GCSh mRNA assay system, we systematically dissected the cis-acting sequence and trans-acting factors that regulate the stability of gamma-GCSh by cytotoxic prooxidants. We demonstrated that a HuR recognition sequence, AUUUA, in the 3'-untranslated region is responsible for the decay of gamma-GCSh mRNA. Oxidative stress enhanced cytoplasmic content of HuR. Overexpression of HuR by transfection stabilized gamma-GCSh mRNA, whereas overexpression of a dominant-negative HuR mutant suppressed the induced stability. Furthermore, prooxidant-induced gamma-GCSh mRNA stabilization and HuR binding were blocked by p38 mitogen-activated protein kinase inhibitors. We provide the first evidence that reduction-oxidation regulation of gamma-GCSh expression, itself a reduction-oxidation sensor and regulator, is mediated at least in part by the p38 mitogenactivated protein kinase signaling through the HuR RNA-binding protein.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Unit 89, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kuo, MT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Unit 89, 1515 Holcombe Blvd, Houston, TX 77030 USA.	tkuo@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA072404, R01CA079085] Funding Source: NIH RePORTER; NCI NIH HHS [CA72404, CA79085, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RG, 2002, FREE RADIC BIOL MED, V28, P463; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Buckley BJ, 2003, BIOCHEM BIOPH RES CO, V307, P973, DOI 10.1016/S0006-291X(03)01308-1; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; Cook HL, 2004, MOL CELL BIOL, V24, P4522, DOI 10.1128/MCB.24.10.4522-4533.2004; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V279, P324, DOI 10.1006/bbrc.2000.3930; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Deng L, 2001, J BIOL CHEM, V276, P413, DOI 10.1074/jbc.M004551200; Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; Gomi A, 1997, CANCER RES, V57, P5292; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hamilton D, 2003, BLOOD, V102, P725, DOI 10.1182/blood-2002-11-3622; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ikegami Y, 2000, J CELL PHYSIOL, V185, P293, DOI 10.1002/1097-4652(200011)185:2<293::AID-JCP14>3.0.CO;2-C; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kobayashi A, 2004, METHOD ENZYMOL, V378, P273; Kuo MT, 1996, CANCER RES, V56, P3642; Lang CH, 1999, AM J PHYSIOL-GASTR L, V276, pG719, DOI 10.1152/ajpgi.1999.276.3.G719; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Laufs U, 2003, J BIOL CHEM, V278, P5956, DOI 10.1074/jbc.M209813200; Lin-Lee YC, 2001, BIOCHEM PHARMACOL, V61, P555, DOI 10.1016/S0006-2952(00)00592-X; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Moran JA, 2002, BIOCHEM J, V361, P371, DOI 10.1042/0264-6021:3610371; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nakatani T, 2002, J BIOL CHEM, V277, P9562, DOI 10.1074/jbc.M110132200; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nieto N, 2003, HEPATOLOGY, V37, P96, DOI 10.1053/jhep.2003.50003; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rahman I, 1996, FEBS LETT, V396, P21, DOI 10.1016/0014-5793(96)01027-7; Ray S, 2002, CLIN EXP ALLERGY, V32, P571, DOI 10.1046/j.0954-7894.2002.01294.x; Ristoff E, 2000, BLOOD, V95, P2193; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11; Tatebe S, 2002, BIOCHEM BIOPH RES CO, V290, P1427, DOI 10.1006/bbrc.2002.6367; Tomonari A, 1997, BIOCHEM BIOPH RES CO, V232, P522, DOI 10.1006/bbrc.1997.6319; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Urata Y, 1999, FREE RADICAL BIO MED, V27, P838, DOI 10.1016/S0891-5849(99)00131-8; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wang L, 2000, BIOCHEM BIOPH RES CO, V269, P336, DOI 10.1006/bbrc.2000.2286; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wassmann S, 2004, CIRC RES, V94, P534, DOI 10.1161/01.RES.0000115557.25127.8D; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001; Yamane Y, 1998, J BIOL CHEM, V273, P31075, DOI 10.1074/jbc.273.47.31075; Yun H, 2005, J BIOL CHEM, V280, P9963, DOI 10.1074/jbc.M412994200; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	65	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28230	28240		10.1074/jbc.M413103200	http://dx.doi.org/10.1074/jbc.M413103200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15946948	hybrid			2022-12-25	WOS:000230857300009
J	Doerrler, WT; Raetz, CRH				Doerrler, WT; Raetz, CRH			Loss of outer membrane proteins without inhibition of lipid export in an Escherichia coli YaeT mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRACTED ARTICLE. SEE; CRYSTAL-STRUCTURE; BACTERIAL PROTEIN; TRANSLOCATION; CLONING; GENE; SECA; LIPOPOLYSACCHARIDE; IDENTIFICATION; MSBA	Escherichia coli yaeT encodes an essential, conserved outer membrane ( OM) protein that is an ortholog of Neisseria meningitidis Omp85. Conflicting data with N. meningitidis indicate that Omp85 functions either in assembly of OM proteins or in export of OM lipids. The role of YaeT in E. coli was investigated with a new temperature-sensitive mutant harboring nine amino acid substitutions. The mutant stops growing after 60 min at 44 degrees C. After 30 min at 44 degrees C, incorporation of [S-35] methionine into newly synthesized OM proteins is selectively inhibited. Synthesis and export of OM phospholipids and lipopolysaccharide are not impaired. OM protein levels are low, even at 30 degrees C, and the buoyant density of the OM is correspondingly lower. By Western blotting, we show that levels of the major OM protein OmpA are lower in the mutant in whole cells, membranes, and the growth medium. SecA functions as a multicopy suppressor of the temperature-sensitive phenotype and partially restores OM proteins. Our data are consistent with a critical role for YaeT in OM protein assembly in E. coli.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIAID NIH HHS [1 F32 AI-10613-01] Funding Source: Medline; NIGMS NIH HHS [GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alba BM, 2004, MOL MICROBIOL, V52, P613, DOI 10.1111/j.1365-2958.2003.03982.x; AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; Andersen C, 2000, EMBO REP, V1, P313, DOI 10.1093/embo-reports/kvd075; AONO R, 1994, APPL ENVIRON MICROB, V60, P4624, DOI 10.1128/AEM.60.12.4624-4626.1994; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bos MP, 2004, P NATL ACAD SCI USA, V101, P9417, DOI 10.1073/pnas.0402340101; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Braun M, 2002, MOL MICROBIOL, V45, P1289, DOI 10.1046/j.1365-2958.2002.03091.x; Bulieris PV, 2003, J BIOL CHEM, V278, P9092, DOI 10.1074/jbc.M211177200; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P31; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; Eichler J, 1998, J BACTERIOL, V180, P5776, DOI 10.1128/JB.180.21.5776-5779.1998; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Genevrois S, 2003, EMBO J, V22, P1780, DOI 10.1093/emboj/cdg174; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; ICHO T, 1985, J BIOL CHEM, V260, P2078; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; ITO K, 1989, J BACTERIOL, V171, P1742, DOI 10.1128/jb.171.3.1742-1743.1989; KAMEYAMA K, 1982, BIOCHIM BIOPHYS ACTA, V706, P19, DOI 10.1016/0167-4838(82)90370-3; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lazar K, 2002, CURR OPIN CHEM BIOL, V6, P786, DOI 10.1016/S1367-5931(02)00355-1; Masuda K, 2002, P NATL ACAD SCI USA, V99, P7390, DOI 10.1073/pnas.112085599; MISRA R, 1993, J BACTERIOL, V175, P5049, DOI 10.1128/JB.175.16.5049-5056.1993; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; NIKAIDO H, 1996, ESCHERICHIA COLI SAL, P29; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; OLIVER DB, 1982, J BACTERIOL, V150, P686, DOI 10.1128/JB.150.2.686-691.1982; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; Osborn M J, 1974, Methods Enzymol, V31, P642; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; Reumann S, 1999, P NATL ACAD SCI USA, V96, P784, DOI 10.1073/pnas.96.2.784; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; Ruiz N, 2005, CELL, V121, P307, DOI 10.1016/j.cell.2005.02.014; Sambrook J, 2001, MOL CLONING LAB MANU; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; Silhavy T.J., 1984, EXPT GENE FUSIONS; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sorensen PG, 1996, J BIOL CHEM, V271, P25898, DOI 10.1074/jbc.271.42.25898; Steeghs L, 1998, NATURE, V392, P449, DOI 10.1038/33046; Thomas KL, 2001, INFECT IMMUN, V69, P4438, DOI 10.1128/IAI.69.7.4438-4446.2001; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Wang HW, 2003, P NATL ACAD SCI USA, V100, P4221, DOI 10.1073/pnas.0737415100; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; Wimley WC, 2003, CURR OPIN STRUC BIOL, V13, P404, DOI 10.1016/S0959-440X(03)00099-X; Woodbury RL, 2002, PROTEIN SCI, V11, P875, DOI 10.1110/ps.4090102; Wu HC, 1996, ESCHERICHIA COLI SAL, V1, P1005; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yang YB, 1997, J BIOL CHEM, V272, P13660, DOI 10.1074/jbc.272.21.13660; Yang YB, 1997, J BACTERIOL, V179, P7386, DOI 10.1128/jb.179.23.7386-7393.1997; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	74	100	104	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27679	27687		10.1074/jbc.M504796200	http://dx.doi.org/10.1074/jbc.M504796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15951436	hybrid, Green Published			2022-12-25	WOS:000230678600026
J	Lucker, BF; Behal, RH; Qin, HM; Siron, LC; Taggart, WD; Rosenbaum, JL; Cole, DG				Lucker, BF; Behal, RH; Qin, HM; Siron, LC; Taggart, WD; Rosenbaum, JL; Cole, DG			Characterization of the intraflagellar transport complex B core - Direct interaction of the IFT81 AND IFT74/72 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; LIGHT INTERMEDIATE CHAIN; CHLAMYDOMONAS FLAGELLA; CYTOPLASMIC DYNEIN; PRIMARY CILIA; KINESIN-II; GENE; IDENTIFICATION; MATRIX; LOCALIZATION	Required for the assembly and maintenance of eukaryotic cilia and flagella, intraflagellar transport (IFT) consists of the bidirectional movement of large protein particles between the base and the distal tip of the organelle. Anterograde movement of particles away from the cell body is mediated by kinesin-2, whereas retrograde movement away from the flagellar tip is powered by cytoplasmic dynein 1b/2. IFT particles contain multiple copies of two distinct protein complexes, A and B, which contain at least 6 and 11 protein subunits, respectively. In this study, we have used increased ionic strength to remove four peripheral subunits from the IFT complex B of Chlamydomonas reinhardtii, revealing a 500-kDa core that contains IFT88, IFT81, IFT74/72, IFT52, IFT46, and IFT27. This result demonstrates that the complex B subunits, IFT172, IFT80, IFT57, and IFT20 are not required for the core subunits to stay associated. Chemical cross-linking of the complex B core resulted in multiple IFT81-74/72 products. Yeast-based two-hybrid and three-hybrid analyses were then used to show that IFT81 and IFT74/72 directly interact to form a higher order oligomer consistent with a tetrameric complex. Similar analysis of the vertebrate IFT81 and IFT74/72 homologues revealed that this interaction has been evolutionarily conserved. We hypothesize that these proteins form a tetrameric complex, (IFT81)(2)(IFT74/ 72)(2), which serves as a scaffold for the formation of the intact IFT complex B.	Univ Idaho, Dept Microbiol Mol Biol & Biochem, Moscow, ID 83844 USA; Univ Idaho, Ctr Reprod Biol, LSS142, Moscow, ID 83844 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Idaho; University of Idaho; Idaho; University of Idaho; Yale University	Cole, DG (corresponding author), Univ Idaho, Dept Microbiol Mol Biol & Biochem, Life Sci S 142, Moscow, ID 83844 USA.	dcole@uidaho.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014642, R37GM014642, R01GM061920] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR16454] Funding Source: Medline; NIGMS NIH HHS [GM61920, GM14642] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; [Anonymous], 2004, CELL BIOL INT, V28, P1, DOI 10.1016/j.cellbi.2003.11.001; Asamiziu E, 2000, DNA RES, V7, P305, DOI 10.1093/dnares/7.5.305; Asamizu E, 1999, DNA Res, V6, P369, DOI 10.1093/dnares/6.6.369; Bell SE, 2001, J CELL SCI, V114, P2755; Besharse JC, 2003, ADV EXP MED BIOL, V533, P157; Blacque OE, 2004, GENE DEV, V18, P1630, DOI 10.1101/gad.1194004; Bray D, 2001, CELL MOVEMENTS MOL M; Brazelton WJ, 2001, CURR BIOL, V11, P1591, DOI 10.1016/S0960-9822(01)00485-7; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Cole DG, 2003, TRAFFIC, V4, P435, DOI 10.1034/j.1600-0854.2003.t01-1-00103.x; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Deane JA, 2001, CURR BIOL, V11, P1586, DOI 10.1016/S0960-9822(01)00484-5; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Geremek Maciej, 2004, Journal of Applied Genetics, V45, P347; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; HARLOW E, 1999, USING ANTIBODIES LAB, P70; Hou YQ, 2004, MOL BIOL CELL, V15, P4382, DOI 10.1091/mbc.E04-05-0377; Iomini C, 2004, J CELL BIOL, V164, P811, DOI 10.1083/jcb.200312133; Iomini C, 2001, J CELL BIOL, V153, P13, DOI 10.1083/jcb.153.1.13; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Masuda M, 1997, FEBS LETT, V408, P221, DOI 10.1016/S0014-5793(97)00429-8; Matsuura K, 2002, CELL MOTIL CYTOSKEL, V52, P195, DOI 10.1002/cm.10051; Mueller J, 2005, MOL BIOL CELL, V16, P1341, DOI 10.1091/mbc.E04-10-0931; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pazour GJ, 1999, J CELL BIOL, V144, P473, DOI 10.1083/jcb.144.3.473; Pazour GJ, 2004, J AM SOC NEPHROL, V15, P2528, DOI 10.1097/01.ASN.0000141055.57643.E0; Pedersen LB, 2005, CURR BIOL, V15, P262, DOI 10.1016/j.cub.2005.01.037; Peng JS, 2002, MOL BIOL REP, V29, P353, DOI 10.1023/A:1021232518628; Perrone CA, 2003, MOL BIOL CELL, V14, P2041, DOI 10.1091/mbc.e02-10-0682; Piperno G, 1998, J CELL BIOL, V143, P1591, DOI 10.1083/jcb.143.6.1591; Piperno G, 1997, P NATL ACAD SCI USA, V94, P4457, DOI 10.1073/pnas.94.9.4457; Porter ME, 1999, MOL BIOL CELL, V10, P693, DOI 10.1091/mbc.10.3.693; Praetorius HA, 2005, ANNU REV PHYSIOL, V67, P515, DOI 10.1146/annurev.physiol.67.040403.101353; Qin HM, 2004, J CELL BIOL, V164, P255, DOI 10.1083/jcb.200308132; SAGER R, 1953, ANN NY ACAD SCI, V56, P831, DOI 10.1111/j.1749-6632.1953.tb30261.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLOSS JA, 1991, J CELL SCI, V100, P877; Scholey JM, 2003, ANNU REV CELL DEV BI, V19, P423, DOI 10.1146/annurev.cellbio.19.111401.091318; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sun ZX, 2004, DEVELOPMENT, V131, P4085, DOI 10.1242/dev.01240; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; Wilson PD, 2004, INT J BIOCHEM CELL B, V36, P1868, DOI 10.1016/j.biocel.2004.03.012; WITMAN GB, 1972, J CELL BIOL, V54, P507, DOI 10.1083/jcb.54.3.507; Zhang KX, 2005, ARCH ANDROLOGY, V51, P7, DOI 10.1080/014850190512914; [No title captured]	57	139	153	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27688	27696		10.1074/jbc.M505062200	http://dx.doi.org/10.1074/jbc.M505062200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15955805	hybrid			2022-12-25	WOS:000230678600027
J	Young, DB; Jonnalagadda, J; Gatei, M; Jans, DA; Meyn, S; Khanna, KK				Young, DB; Jonnalagadda, J; Gatei, M; Jans, DA; Meyn, S; Khanna, KK			Identification of domains of ataxia-telangiectasia mutated required for nuclear localization and chromatin association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; ATM PROTEIN; CELLULAR-RESPONSES; IONIZING-RADIATION; GENE-PRODUCT; EXPRESSION; TRANSPORT; COMPLEX; KINASE; PHOSPHORYLATION	Ataxia-telangiectasia mutated (ATM) is essential for rapid induction of cellular responses to DNA double strand breaks (DSBs). In this study, we mapped a nuclear localization signal (NLS), (KRKK388)-K-385, within the amino terminus of ATM and demonstrate its recognition by the conventional nuclear import receptor, the importin alpha 1/beta 1 heterodimer. Although mutation of this NLS resulted in green fluorescent protein (GFP)(.)ATM(NLSm) localizing predominantly within the cytoplasm, small amounts of nuclear GFP(.)ATM(NLSm) were still sufficient to elicit a DNA damage response. Insertion of an heterologous nuclear export signal between GFP and ATM( NLSm) resulted in complete cytoplasmic localization of ATM, concomitantly reducing the level of substrate phosphorylation and increasing radiosensitivity, which indicates a functional requirement for ATM nuclear localization. Interestingly, the carboxyl-terminal half of ATM, containing the kinase domain, which localizes to the cytoplasm, could not autophosphorylate itself or phosphorylate substrates, nor could it correct radiosensitivity in response to DSBs even when targeted to the nucleus by insertion of an exogenous NLS, demonstrating that the ATM amino terminus is required for optimal ATM function. Moreover, we have shown that the recruitment/retention of ATM at DSBs requires its kinase activity because a kinase-dead mutant of GFP(.)ATM failed to form damage-induced foci. Using deletion mutation analysis we mapped a domain in ATM (amino acids 5-224) required for its association with chromatin, which may target ATM to sites of DNA damage. Combined, these data indicate that the amino terminus of ATM is crucial not only for nuclear localization but also for chromatin association, thereby facilitating the kinase activity of ATM in vivo.	Queensland Inst Med Res, Signal Transduct Lab, Brisbane, Qld 4029, Australia; Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia; Hosp Sick Children, Toronto, ON 5MG 1X8, Canada	QIMR Berghofer Medical Research Institute; Monash University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Signal Transduct Lab, Brisbane, Qld 4029, Australia.	kumkumK@qimr.edu.au	Khanna, Kum Kum/I-1747-2013	Khanna, Kum Kum/0000-0001-8650-5381; Jans, David/0000-0001-5115-4745				Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chapman CR, 1999, MOL BIOL CELL, V10, P3223, DOI 10.1091/mbc.10.10.3223; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Delia D, 2000, BRIT J CANCER, V82, P1938; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fernet M, 2004, BRIT J CANCER, V90, P866, DOI 10.1038/sj.bjc.6601549; Gatei M, 2000, CANCER RES, V60, P3299; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	23	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27587	27594		10.1074/jbc.M411689200	http://dx.doi.org/10.1074/jbc.M411689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15929992	hybrid			2022-12-25	WOS:000230678600015
J	Chow, G; Knudson, W				Chow, G; Knudson, W			Characterization of promoter elements of the human HYAL-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR CHONDROCYTES; RECEPTOR-MEDIATED ENDOCYTOSIS; TRANSCRIPTION FACTORS; HYALURONAN-BINDING; EXPRESSION; CELLS; CD44; METABOLISM; CARTILAGE; PROTEIN	The regulated catabolism of hyaluronan is critical to the function of many connective tissues. In cartilage, hyaluronan catabolism occurs locally by resident chondrocytes. To determine whether the expression of lysosomal hyaluronidases contributes to this regulation, the promoter elements associated with HYAL-2 gene expression were characterized. Human articular chondrocytes were found to express all three lysosomal hyaluronidases, HYAL-1, HYAL-2, and HYAL-3. HYAL- 2 was the predominant gene product. Using 5' RACE ( rapid amplification of cDNA ends) analysis, multiple transcription initiation sites were identified including a novel initiation site located within intron 1 of the gene expressed by human articular chondrocytes. The presence of multiple transcriptional initiation sites is a typical feature of TATA-less promoter regions, such as those of HYAL-2. Approximately 4000 bp of 5' flanking sequence of the HYAL- 2 gene was characterized. Transient transfection of C-28/I2 cells with various 5' deletion constructs indicated that the region between + 959 to + 1158 (within intron 1) contains the basal promoter for HYAL-2 in chondrocytes. In addition, the region + 224 to + 958 contained a negative modulator that could control the basal expression level of HYAL-2. Treatment of human articular chondrocytes or C-28/I2 cells with various catabolic cytokines did not alter HYAL- 2 mRNA expression, luciferase promoter expression, or hyaluronidase enzymatic activity. Thus, in chondrocytes HYAL- 2 appears to be constitutively expressed and not inducibly regulated by catabolic agents. As such, it appears that the expression of lysosomal hyaluronidase participates little in the overall regulation of hyaluronan catabolism.	Rush Univ, Med Ctr, Rush Med Coll, Dept Biochem, Chicago, IL 60612 USA	Rush University	Knudson, W (corresponding author), Rush Univ, Med Ctr, Rush Med Coll, Dept Biochem, 1735 W Harrison St, Chicago, IL 60612 USA.	Warren_Knudson@rush.edu			NIAMS NIH HHS [T32-AR07590, P50 AR039239-11, R01 AR043384-11, P50-AR39239, P50 AR039239, R01-AR43384, T32 AR007590, T32 AR007590-05, R01 AR043384] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007590, P50AR039239, R01AR043384] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIRD WC, 1994, J BIOL CHEM, V269, P883; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOUDREAU N, 1991, DEV BIOL, V143, P235, DOI 10.1016/0012-1606(91)90074-D; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; BUCKWALTER JA, 1982, J BIOL CHEM, V257, P9830; CHOW G, 1995, J BIOL CHEM, V270, P27734, DOI 10.1074/jbc.270.46.27734; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Embry JJ, 2003, ARTHRITIS RHEUM-US, V48, P3431, DOI 10.1002/art.11323; Flannery CR, 1998, BIOCHEM BIOPH RES CO, V251, P824, DOI 10.1006/bbrc.1998.9561; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hapgood JP, 2001, CELL BIOL INT, V25, P17, DOI 10.1006/cbir.2000.0674; Henrotin YE, 2000, OSTEOARTHR CARTILAGE, V8, P474, DOI 10.1053/joca.1999.0323; HUA Q, 1993, J CELL SCI, V106, P365; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; Knudson CB, 2004, CLIN ORTHOP RELAT R, pS152, DOI 10.1097/01.blo.0000143804.26638.82; Knudson W, 2002, MATRIX BIOL, V21, P15, DOI 10.1016/S0945-053X(01)00186-X; KNUDSON W, 2004, CURR OPIN ORTHOP, V15, P369; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Li YJ, 2000, AM J RESP CELL MOL, V23, P411, DOI 10.1165/ajrcmb.23.3.4102; MIURA RO, 1995, ANAL BIOCHEM, V225, P333, DOI 10.1006/abio.1995.1163; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; MORALES TI, 1988, J BIOL CHEM, V263, P3632; Mullegger J, 2002, MECH DEVELOP, V111, P25, DOI 10.1016/S0925-4773(01)00593-7; NG KC, 1992, ARCH BIOCHEM BIOPHYS, V298, P70; Nicoll SB, 2002, BIOCHEM BIOPH RES CO, V292, P819, DOI 10.1006/bbrc.2002.6697; Nishida Y, 2000, ARTHRITIS RHEUM, V43, P1315, DOI 10.1002/1529-0131(200006)43:6<1315::AID-ANR14>3.0.CO;2-#; Novak U, 1999, CANCER RES, V59, P6246; Ohno S, 2002, J PERIODONTOL, V73, P1331, DOI 10.1902/jop.2002.73.11.1331; ORKIN RW, 1978, DEV BIOL, V66, P308, DOI 10.1016/0012-1606(78)90240-3; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; Selbi W, 2004, J AM SOC NEPHROL, V15, P1199, DOI 10.1097/01.ASN.0000125619.27422.8E; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Sun LK, 1998, KIDNEY BLOOD PRESS R, V21, P413, DOI 10.1159/000025893; Tammi RH, 2004, CHEMISTRY AND BIOLOGY OF HYALURONAN, P395; TOOLE BP, 1971, DEV BIOL, V25, P57, DOI 10.1016/0012-1606(71)90019-4; TOOLE BP, 1972, DEV BIOL, V29, P321, DOI 10.1016/0012-1606(72)90071-1; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566	44	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26904	26912		10.1074/jbc.M413845200	http://dx.doi.org/10.1074/jbc.M413845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15923194	Green Accepted, hybrid			2022-12-25	WOS:000230589500033
J	Dagda, RK; Barwacz, CA; Cribbs, JT; Strack, S				Dagda, RK; Barwacz, CA; Cribbs, JT; Strack, S			Unfolding-resistant translocase targeting - A novel mechanism for outer mitochondrial membrane localization exemplified by the B-beta 2 regulatory subunit of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORT; BINDING; FAMILY; DEPHOSPHORYLATION; PURIFICATION; SEQUENCE; REPEAT; STEPS	Heterotrimeric serine/threonine protein phosphatase 2A (PP2A) consists of scaffolding ( A), catalytic ( C), and variable ( B, B', and B '') subunits. Variable subunits dictate subcellular localization and substrate specificity of the PP2A holoenzyme. The B beta regulatory subunit gene is mutated in spinocerebellar ataxia type 12, and one of its splice variants, B beta 2, targets PP2A to mitochondria to promote apoptosis in PC12 cells (Dagda, R. K., Zaucha, J. A., Wadzinski, B. E., and Strack, S. ( 2003) J. Biol. Chem. 278, 24976 - 24985). Here, we report that B beta 2 is localized to the outer mitochondrial membrane by a novel mechanism, combining a cryptic mitochondrial import signal with a structural arrest domain. Scanning mutagenesis demonstrates that basic and hydrophobic residues mediate mitochondrial association and the proapoptotic activity of B beta 2. When fused to green fluorescent protein, the N terminus of B beta 2 acts as a cleavable mitochondrial import signal. Surprisingly, full-length B beta 2 is not detectably cleaved and is retained at the outer mitochondrial membrane, even though it interacts with the TOM22 import receptor, as shown by luciferase complementation in intact cells. Mutations that open the C-terminal beta-propeller of B beta 2 facilitate mitochondrial import, indicating that this rigid fold acts as a stop-transfer domain by resisting the partial unfolding step prerequisite for matrix translocation. Because hybrids of prototypical import and beta-propeller domains recapitulate this behavior, we predict the existence of other similarly localized proteins and a selection against highly stable protein folds in the mitochondrial matrix. This unfolding-resistant targeting to the mitochondrial translocase is necessary but not sufficient for the proapoptotic activity of B beta 2, which also requires association with the rest of the PP2A holoenzyme.	Univ Iowa, Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Strack, S (corresponding author), Univ Iowa, Carver Coll Med, Dept Pharmacol, 2-432 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	stefan-strack@uiowa.edu		Strack, Stefan/0000-0002-6175-7280; Dagda, Ruben/0000-0002-9946-9591	NINDS NIH HHS [R01 NS043254, NS43254, F31 NS049659] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043254, F31NS049659] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Dagda RK, 2003, J BIOL CHEM, V278, P24976, DOI 10.1074/jbc.M302832200; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; Holmes SE, 1999, NAT GENET, V23, P391, DOI 10.1038/70493; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; Li XH, 2002, EUR J BIOCHEM, V269, P546, DOI 10.1046/j.0014-2956.2001.02680.x; Luker KE, 2004, P NATL ACAD SCI USA, V101, P12288, DOI 10.1073/pnas.0404041101; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Schmidt K, 2002, EUR J NEUROSCI, V16, P2039, DOI 10.1046/j.1460-9568.2002.02274.x; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; VANKUILENBURG ABP, 1988, FEBS LETT, V240, P127, DOI 10.1016/0014-5793(88)80353-3; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200	33	26	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27375	27382		10.1074/jbc.M503693200	http://dx.doi.org/10.1074/jbc.M503693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15923182	hybrid, Green Accepted			2022-12-25	WOS:000230589500088
J	D'Souza, T; Agarwal, R; Morin, PJ				D'Souza, T; Agarwal, R; Morin, PJ			Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; GENE-EXPRESSION; CYCLIC-AMP; MOLECULAR PHYSIOLOGY; MAP KINASE; C ISOFORMS; PATHOPHYSIOLOGY; OVEREXPRESSION; IDENTIFICATION; DISRUPTION	Claudins are integral membrane proteins essential in the formation and function of tight junctions (TJs). Disruption of TJs, which have essential roles in cell permeability and polarity, is thought to contribute to epithelial tumorigenesis. Claudin-3 and -4 are frequently overexpressed in ovarian cancer, but the molecular pathways involved in the regulation of these proteins are unclear. Interestingly, several studies have demonstrated a role for phosphorylation in the regulation of TJ complexes, although evidence for claudin phosphorylation is scarce. Here, we showed that claudin-3 and -4 can be phosphorylated in ovarian cancer cells. In vitro phosphorylation assays using glutathione S-transferase fusion constructs demonstrated that the C terminus of claudin-3 is an excellent substrate for cAMP-dependent protein kinase (PKA). Using site-directed mutagenesis, we identified a PKA phosphorylation site at amino acid 192 in the C terminus of claudin-3. Overexpression of the protein containing a T192D mutation, mimicking the phosphorylated state, resulted in a decrease in TJ strength in ovarian cancer cell line OVCA433. Our results suggest that claudin-3 phosphorylation by PKA, a kinase frequently activated in ovarian cancer, may provide a mechanism for the disruption of TJs in this cancer. In addition, our findings may have general implications for the regulation of TJs in normal epithelial cells.	NIA, Cellular & Mol Biol Lab, Ctr Gerontol Res, NIH, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins Medicine	Morin, PJ (corresponding author), NIA, Cellular & Mol Biol Lab, Ctr Gerontol Res, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	morinp@grc.nia.nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alper O, 1999, ONCOGENE, V18, P4999, DOI 10.1038/sj.onc.1202830; Avila-Flores A, 2001, BIOCHEM J, V360, P295, DOI 10.1042/0264-6021:3600295; Boucher MJ, 2005, J CELL PHYSIOL, V202, P178, DOI 10.1002/jcp.20104; Cho-Chung YS, 2002, ANN NY ACAD SCI, V968, P22, DOI 10.1111/j.1749-6632.2002.tb04324.x; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; Clarke H, 2000, ADV DRUG DELIVER REV, V41, P283, DOI 10.1016/S0169-409X(00)00047-8; Eckert JJ, 2004, REPRODUCTION, V127, P653, DOI 10.1530/rep.1.00150; Fujibe M, 2004, EXP CELL RES, V295, P36, DOI 10.1016/j.yexcr.2003.12.014; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Gregoire L, 1998, IN VITRO CELL DEV-AN, V34, P636; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; Hibbs K, 2004, AM J PATHOL, V165, P397, DOI 10.1016/S0002-9440(10)63306-8; Hough CD, 2000, CANCER RES, V60, P6281; Ishizaki T, 2003, EXP CELL RES, V290, P275, DOI 10.1016/S0014-4827(03)00354-9; Itoh M, 2003, J MAMMARY GLAND BIOL, V8, P449, DOI 10.1023/B:JOMG.0000017431.45314.07; Kale G, 2003, BIOCHEM BIOPH RES CO, V302, P324, DOI 10.1016/S0006-291X(03)00167-0; Karczewski J, 2000, AM J PHYSIOL-GASTR L, V279, pG660, DOI 10.1152/ajpgi.2000.279.4.G660; Klingler C, 2000, HISTOCHEM CELL BIOL, V113, P349; Langbein L, 2003, EUR J CELL BIOL, V82, P385, DOI 10.1078/0171-9335-00330; Lawrence DW, 2002, AM J PHYSIOL-CELL PH, V282, pC1235, DOI 10.1152/ajpcell.00288.2001; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; Martin TA, 2001, HISTOL HISTOPATHOL, V16, P1183, DOI 10.14670/HH-16.1183; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; MULLIN JM, 2004, SCI STKE, pPE2, DOI DOI 10.1126/STKE.2162004PE2; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Soma T, 2004, EXP CELL RES, V300, P202, DOI 10.1016/j.yexcr.2004.07.012; Song JC, 2001, AM J PHYSIOL-CELL PH, V281, pC649, DOI 10.1152/ajpcell.2001.281.2.C649; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Wang Y, 2004, EXP EYE RES, V78, P125, DOI 10.1016/j.exer.2003.09.002; Yamauchi K, 2004, P NATL ACAD SCI USA, V101, P4690, DOI 10.1073/pnas.0306924101; Zar JH, 1999, BIOSTATISTICAL ANAL	36	172	178	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26233	26240		10.1074/jbc.M502003200	http://dx.doi.org/10.1074/jbc.M502003200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15905176	hybrid			2022-12-25	WOS:000230386800038
J	Gu, SM; Villegas, CJ; Jiang, JX				Gu, SM; Villegas, CJ; Jiang, JX			Differential regulation of amino acid transporter SNAT3 by insulin in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEM-A; NITROGEN-METABOLISM; CALORIE RESTRICTION; UP-REGULATION; RAT-LIVER; GLUTAMINE; MUSCLE; EXPRESSION; KINASE; CLONING	The liver is a metabolism and transfer center of amino acids as well as the prime target organ of insulin. In this report, we characterized the regulation of system N/A transporter 3 (SNAT3) in the liver of dietary-restricted mice and in hepatocytes treated with serum starvation and insulin. The expression of SNAT3 was up-regulated in dietary-restricted mice. The expression of SNAT3 protein was detected on the plasma membrane of hepatocyte-like H2.35 cells with a half-life of 6-8 h. When H2.35 cells were depleted of serum, the expression of SNAT3 was increased. An increased concentration of insulin, however, suppressed SNAT3 expression. Interestingly, the down-regulation of SNAT3 expression by insulin was blocked by the specific phosphoinositide 3-kinase inhibitor LY294002 and mammalian target of rapamycin inhibitor, but not by MAPK inhibitor PD98059, suggesting that insulin exerts its effect on SNAT3 through phosphoinositide 3-kinase-mammalian target of rapamycin signaling. Surface biotinylation assay showed an increased level of SNAT3 on the cell surface after 0.5 h of insulin treatment, although no effect was observed after 24 h of treatment. Consistently, the transport of the substrate L-histidine was increased with short, but not long, treatment by insulin in both H2.35- and SNAT3-transfected COS-7 cells. The L-histidine uptake was inhibited significantly by L-histidine followed by 2-endoamino-bicycloheptane-2-carboxylic acid and L-cysteine and to a lesser extent by L-alanine and aminoisobutyric acid, but was not inhibited by alpha-(methylamino) isobutyric acid, implying that uptake of L-histidine in H2.35 cells is primarily mediated by system N transporters. In conclusion, differential regulation of SNAT3 by insulin and serum starvation reinforces the functional significance of this transporter in liver physiology.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Jiang, JX (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jiangj@uthscsa.edu		Jiang, Jean/0000-0002-2185-5716				Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Boehmer C, 2003, BIOCHEM BIOPH RES CO, V306, P156, DOI 10.1016/S0006-291X(03)00921-5; CARIAPPA R, 1992, AM J PHYSIOL, V263, pE1021; Castagna M, 1997, J EXP BIOL, V200, P269; Chan BS, 2002, BIOCHEMISTRY-US, V41, P9215, DOI 10.1021/bi0203031; Chaudhry FA, 2002, J NEUROSCI, V22, P62, DOI 10.1523/JNEUROSCI.22-01-00062.2002; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Cheng CM, 2003, ENDOCRINOLOGY, V144, P2676, DOI 10.1210/en.2002-0057; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Fei YJ, 2000, J BIOL CHEM, V275, P23707, DOI 10.1074/jbc.M002282200; Gu S., 2003, J LANZHOU U, V39, P28; Gu SM, 2003, BIOCHEM J, V371, P721, DOI 10.1042/BJ20030049; Gu SM, 2001, GENOMICS, V74, P262, DOI 10.1006/geno.2001.6567; Gu SM, 2001, J BIOL CHEM, V276, P24137, DOI 10.1074/jbc.M009003200; Gu SM, 2000, P NATL ACAD SCI USA, V97, P3230, DOI 10.1073/pnas.050318197; HARRIS TE, 2003, SCI STKE, V212, P1; Hatanaka T, 2001, BBA-BIOMEMBRANES, V1510, P10, DOI 10.1016/S0005-2736(00)00390-4; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hyde R, 2002, J BIOL CHEM, V277, P13628, DOI 10.1074/jbc.M108609200; JIANG JX, 1994, MOL BIOL CELL, V5, P363, DOI 10.1091/mbc.5.3.363; JIANG JX, 1995, DEV BIOL, V168, P649, DOI 10.1006/dbio.1995.1109; Karlsen TV, 2002, ANN NY ACAD SCI, V971, P573, DOI 10.1111/j.1749-6632.2002.tb04529.x; Liu XM, 2004, FASEB J, V18, P768, DOI 10.1096/fj.03-0886fje; LONGO N, 1985, BIOCHIM BIOPHYS ACTA, V844, P216, DOI 10.1016/0167-4889(85)90093-X; LOW SY, 1992, BIOCHEM J, V284, P333, DOI 10.1042/bj2840333; Low SY, 1997, FASEB J, V11, P1111, DOI 10.1096/fasebj.11.13.9367345; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; Mai V, 2003, CANCER RES, V63, P1752; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MASORO EJ, 1992, J GERONTOL, V47, pB202, DOI 10.1093/geronj/47.6.B202; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; Mehrens T, 2000, J AM SOC NEPHROL, V11, P1216, DOI 10.1681/ASN.V1171216; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pawlik TM, 2000, AM J PHYSIOL-GASTR L, V278, pG532, DOI 10.1152/ajpgi.2000.278.4.G532; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Peyrollier K, 2000, BIOCHEM J, V350, P361, DOI 10.1042/0264-6021:3500361; Roth GS, 2001, ANN NY ACAD SCI, V928, P305; SCHENERMAN MA, 1986, BIOCHIM BIOPHYS ACTA, V856, P428, DOI 10.1016/0005-2736(86)90133-1; Su TZ, 1998, J BIOL CHEM, V273, P3173, DOI 10.1074/jbc.273.6.3173; Sugawara M, 2000, BBA-BIOMEMBRANES, V1509, P7, DOI 10.1016/S0005-2736(00)00349-7; TADROS LB, 1993, AM J PHYSIOL, V265, pE135, DOI 10.1152/ajpendo.1993.265.1.E135; TAMARAPPOO BK, 1993, AM J PHYSIOL, V264, pE526, DOI 10.1152/ajpendo.1993.264.4.E526; Tokunaga C, 2004, BIOCHEM BIOPH RES CO, V313, P443, DOI 10.1016/j.bbrc.2003.07.019; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Varoqui H, 2002, BIOCHEM BIOPH RES CO, V290, P903, DOI 10.1006/bbrc.2001.6281; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Watford M, 2002, NUTRITION, V18, P301, DOI 10.1016/S0899-9007(02)00739-6; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Zorzano A, 2000, BIOCHEM J, V349, P667, DOI 10.1042/bj3490667	55	31	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26055	26062		10.1074/jbc.M504401200	http://dx.doi.org/10.1074/jbc.M504401200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899884	hybrid			2022-12-25	WOS:000230386800015
J	Raffaghello, L; Prigione, I; Bocca, P; Morandi, F; Camoriano, M; Gambini, C; Wang, XH; Ferrone, S; Pistoia, V				Raffaghello, L; Prigione, I; Bocca, P; Morandi, F; Camoriano, M; Gambini, C; Wang, XH; Ferrone, S; Pistoia, V			Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications	ONCOGENE			English	Article						pediatric tumor; antigen-processing machinery; MHC downregulation; immune evasion	HLA-CLASS-I; MHC CLASS-I; NEURONAL CELL-LINES; MONOCLONAL-ANTIBODIES; FLOW-CYTOMETRY; HEAVY-CHAINS; ENDOPLASMIC-RETICULUM; KILLER-CELLS; EXPRESSION; INTERFERON	Low expression of human leukocyte antigen (HLA) class I in human tumors may be related to defects of the antigen-processing machinery (APM) components. Neuroblastoma cells are virtually HLA class I negative, but (i) the underlying mechanisms are unknown, and (ii) expression of the APM components has never been investigated. Here we have used a panel of novel monoclonal antibodies to proteasomal and immunoproteasomal components, chaperons and transporter associated with antigen processing (TAP) to characterize 24 stroma-poor neuroblastoma tumors and six neuroblastoma cell lines. Primary tumors showed defects in the expression of zeta, tapasin, TAP1 or TAP2, HLA class I heavy chain and 2 microglobulin, LMP2 and LMP7, as compared to normal adrenal medulla. Neuroblastoma cell lines displayed roughly similar patterns of APM expression in comparison to primary tumors. Incubation of neuroblastoma cell lines with interferon-gamma caused upregulation of HLA class I molecules and reduced lysis by killer inhibitory receptor HLA ligand-matched NK cells. Defects in APM components explain reduced peptide loading on HLA class I molecules, their instability and failure to be expressed on the cell surface. HLA class I upregulation by interferon-gamma, although enhancing neuroblastoma cell recognition by cytotoxic T cells, dampens their susceptibility to NK cells.	G Gaslini Inst Children, Lab Oncol, Genoa, Italy; G Gaslini Inst Children, Pathol Lab, Genoa, Italy; Roswell Pk Canc Ctr, Dept Immunol, Buffalo, NY USA	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini; Roswell Park Cancer Institute	Raffaghello, L (corresponding author), G Gaslini Inst Children, Lab Oncol, Largo G Gaslini, Genoa, Italy.	lizziaraffaghello@ospedale-gaslini.ge.it	Prigione, Ignazia/K-3011-2016; Bocca, Paola/AAB-3381-2021; Morandi, Fabio/I-1185-2012	Prigione, Ignazia/0000-0002-0877-6255; Bocca, Paola/0000-0002-7498-209X; Morandi, Fabio/0000-0002-2849-7595; Raffaghello, Lizzia/0000-0003-2357-0607	NCI NIH HHS [R01 CA 67108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Airoldi I, 2004, BRIT J CANCER, V90, P2210, DOI 10.1038/sj.bjc.6601842; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Corrias MV, 2001, TISSUE ANTIGENS, V57, P110, DOI 10.1034/j.1399-0039.2001.057002110.x; Desai SA, 2000, J IMMUNOL, V165, P3275, DOI 10.4049/jimmunol.165.6.3275; Facchetti P, 1996, CANCER IMMUNOL IMMUN, V42, P170, DOI 10.1007/s002620050267; Facchetti P, 1999, EXP CELL RES, V253, P440, DOI 10.1006/excr.1999.4697; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; HEDLEY DW, 1985, CYTOMETRY, V6, P327, DOI 10.1002/cyto.990060409; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Kageshita T, 1999, AM J PATHOL, V154, P745, DOI 10.1016/S0002-9440(10)65321-7; Kishore R, 1998, TISSUE ANTIGENS, V51, P129; LAMPSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P6476, DOI 10.1073/pnas.81.20.6476; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; LAMPSON LA, 1986, J INTERFERON RES, V6, P257, DOI 10.1089/jir.1986.6.257; MAROZZI A, 1993, SCAND J IMMUNOL, V37, P661, DOI 10.1111/j.1365-3083.1993.tb01680.x; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; Neal ZC, 2004, CANCER IMMUNOL IMMUN, V53, P41, DOI 10.1007/s00262-003-0435-2; Ogino T, 2003, TISSUE ANTIGENS, V62, P385, DOI 10.1034/j.1399-0039.2003.00114.x; Ogino T, 2003, J IMMUNOL METHODS, V278, P33, DOI 10.1016/S0022-1759(03)00224-2; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; Passoni L, 2002, BLOOD, V99, P2100, DOI 10.1182/blood.V99.6.2100; PICKL WF, 1993, J IMMUNOL, V151, P2613; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PONZONI M, 1993, INT J CANCER, V55, P817, DOI 10.1002/ijc.2910550521; Puppo F, 1999, TISSUE ANTIGENS, V53, P253, DOI 10.1034/j.1399-0039.1999.530305.x; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Sarkar AK, 2000, CANCER RES, V60, P1908; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Seliger B, 2002, SEMIN CANCER BIOL, V12, P3, DOI 10.1006/scbi.2001.0404; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; STAM NJ, 1986, J IMMUNOL, V137, P2299; Tanaka K, 1998, IMMUNOL REV, V163, P161; TEMPONI M, 1993, J IMMUNOL METHODS, V161, P239, DOI 10.1016/0022-1759(93)90300-V; THIELE CJ, 1999, NEUROBLASTOMA, P21; Tonini GP, 1997, J CLIN ONCOL, V15, P85, DOI 10.1200/JCO.1997.15.1.85; Vertuani S, 2003, CANCER RES, V63, P8006; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Wolfl M, 2005, CANCER IMMUNOL IMMUN, V54, P400, DOI 10.1007/s00262-004-0603-z; Zarling AL, 2003, J IMMUNOL, V171, P5287, DOI 10.4049/jimmunol.171.10.5287; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	45	76	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2005	24	29					4634	4644		10.1038/sj.onc.1208594	http://dx.doi.org/10.1038/sj.onc.1208594			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897905				2022-12-25	WOS:000230304500003
J	Bernardini, G; Kim, JY; Gismondi, A; Butcher, EC; Santoni, A				Bernardini, G; Kim, JY; Gismondi, A; Butcher, EC; Santoni, A			Chemoattractant induces LFA-1 associated PI3K activity and cell migration that are dependent on Fyn signaling	FASEB JOURNAL			English	Article						Src; leukocytes; fMLP-stimulation	PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; INTEGRIN ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; LEUKOCYTE TRANSMIGRATION; T-LYMPHOCYTES; KINASE; NEUTROPHIL; PROTEIN; CHEMOKINES	The activation state of integrins on leukocytes is tightly controlled by the association of intracellular molecules to the cytoplasmic domain of the integrin. To identify signaling intermediates involved in chemoattractant receptor-induced integrin activation, we analyzed the ability of LFA-1 integrin to associate with members of Src tyrosine kinase and phosphatidylinositol 3Kinase (PI 3K) families following fMLP stimulation of a lymphoid T cell line stably expressing the fMLP receptor (fPR). fMLP- induced cell activation resulted in a rapid increase of integrin-associated PI 3Kinase activity in G protein and Src kinase dependent manner. We show, upon fMLP- stimulation, a rapid and transient association of the Src tyrosine kinase Fyn with LFA-1. Also, by transiently expressing mutant forms of this kinase, we demonstrated that Fyn is required for the integrin associated PI 3K activity. Furthermore, overexpression of the mutant form of Fyn resulted in a significant impairment of fMLP- induced cell migration through ICAM-1-coated filters, while ICAM-1 independent migration was not affected. Our observations indicate that chemoattractant receptor engagement induces Fyn-dependent PI 3K activation in association with LFA-1 and suggests that Fyn is necessary to initiate and/or to regulate chemoattractant-mediated LFA-1 activation to promote directional migration.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Univ Roma La Sapienza, Ist Pasteur, Fondaz Cenci Bolognetti, Rome, Italy; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA USA; Vet Affair Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA USA	Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; Stanford University	Bernardini, G (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, Via Regina Elena 324, I-00161 Rome, Italy.	giovanni.bernardini@uniroma1.it	santoni, angela/K-8997-2016; BERNARDINI, Giovanni/AAA-8160-2019	santoni, angela/0000-0003-1206-7731; BERNARDINI, Giovanni/0000-0002-3705-2598				Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Caveggion E, 2003, J CELL PHYSIOL, V195, P276, DOI 10.1002/jcp.10236; Cerboni C, 1998, EUR J IMMUNOL, V28, P1005, DOI 10.1002/(SICI)1521-4141(199803)28:03<1005::AID-IMMU1005>3.0.CO;2-O; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Chodniewicz D, 2003, BLOOD, V102, P2251, DOI 10.1182/blood-2002-09-2936; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dustin ML, 2004, NAT IMMUNOL, V5, P363, DOI 10.1038/ni1057; Giagulli C, 2004, IMMUNITY, V20, P25, DOI 10.1016/S1074-7613(03)00350-9; Griffiths EK, 2002, CURR OPIN IMMUNOL, V14, P317, DOI 10.1016/S0952-7915(02)00334-5; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Laudanna C, 2002, IMMUNOL REV, V186, P37, DOI 10.1034/j.1600-065X.2002.18604.x; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Liu Y, 2004, J IMMUNOL, V172, P7, DOI 10.4049/jimmunol.172.1.7; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Miura Y, 2000, BLOOD, V96, P1733, DOI 10.1182/blood.V96.5.1733.h8001733_1733_1739; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Pribila JT, 2004, ANNU REV IMMUNOL, V22, P157, DOI 10.1146/annurev.immunol.22.012703.104649; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Reif K, 2004, J IMMUNOL, V173, P2236, DOI 10.4049/jimmunol.173.4.2236; Rose DM, 2001, J IMMUNOL, V167, P2824, DOI 10.4049/jimmunol.167.5.2824; Sadhu C, 2003, BIOCHEM BIOPH RES CO, V308, P764, DOI 10.1016/S0006-291X(03)01480-3; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; TAKATA M, 1995, FEBS LETT, V374, P407, DOI 10.1016/0014-5793(95)01160-G; TURNER L, 1995, J IMMUNOL, V155, P2437; Uhlemann AC, 1997, BIOCHEM BIOPH RES CO, V239, P68, DOI 10.1006/bbrc.1997.7429; Weber KSC, 2001, MOL BIOL CELL, V12, P3074, DOI 10.1091/mbc.12.10.3074; Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241	40	10	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1305	+		10.1096/fj.04-3352fje	http://dx.doi.org/10.1096/fj.04-3352fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15955842				2022-12-25	WOS:000230207800015
J	Chen, QH; Thorpe, J; Keller, JN				Chen, QH; Thorpe, J; Keller, JN			alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; ENDOPLASMIC-RETICULUM-STRESS; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; YEAST; EXPRESSION; MUTANT; INHIBITION; SURVIVAL	alpha-Synuclein appears to play a role in mediating neurotoxicity in a number of neurodegenerative disorders, collectively referred to as synucleinopathies. Most of these disorders are associated with aging and a probable impairment of the proteasome-proteolytic pathway, although the relationship between aging, proteasome inhibition, and alpha-synuclein toxicity has not been fully elucidated. Recent studies suggest that yeast may provide a useful system for studying the biology and toxicity of alpha-synuclein in mitotic cells, recapitulating many features observed in the various synucleinopathy disorders. Additional studies indicate that the stationary phase model of aging in yeast provides a useful system for understanding the biochemistry and regulation of aging in post-mitotic cells. In the present study we examined the effect of wild type and mutant alpha-synuclein (A30P) on multiple aspects of proteasome homeostasis, protein synthesis, as well as the ability of cells to survive stationary phase aging. These data demonstrate that alpha-synuclein alters proteasome composition, impairs proteasome-mediated protein degradation, impairs protein synthesis, and impairs the ability of cells to withstand stationary phase aging. Interestingly, alpha-synuclein had little effect on intracellular proteasome content or protein ubiquitination, and did not increase the vulnerability of cells to a variety of stressors. Together, these data suggest that yeast may be useful for understanding the ability of alpha-synuclein to impair proteasome-mediated protein degradation, as well as for understanding the basis for age-related alpha-synuclein cytotoxicity.	Univ Kentucky, Sanders Brown Ctr Aging 205, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky	Keller, JN (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging 205, Dept Anat & Neurobiol, 800 S Limestone, Lexington, KY 40536 USA.	jnkell0@pop.uky.edu	Keller, Jeffrey N/N-1975-2017	keller, jeffrey/0000-0002-9892-7423	NATIONAL INSTITUTE ON AGING [R01AG018437] Funding Source: NIH RePORTER; NIA NIH HHS [AG018437, AG005119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Amici M, 2003, FREE RADICAL BIO MED, V34, P987, DOI 10.1016/S0891-5849(02)01369-2; Chen QH, 2005, BIOGERONTOLOGY, V6, P1, DOI 10.1007/s10522-004-7379-6; Chen QH, 2005, FREE RADICAL BIO MED, V38, P226, DOI 10.1016/j.freeradbiomed.2004.10.019; Chen QH, 2004, FREE RADICAL BIO MED, V37, P859, DOI 10.1016/j.freeradbiomed.2004.05.025; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Ding QX, 2003, FEBS LETT, V546, P228, DOI 10.1016/S0014-5793(03)00582-9; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; Fabrizio P, 2005, MECH AGEING DEV, V126, P11, DOI 10.1016/j.mad.2004.09.015; Fabrizio P, 2003, AGING CELL, V2, P73, DOI 10.1046/j.1474-9728.2003.00033.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Groettrup M, 2001, CRIT REV IMMUNOL, V21, P339; Hashimoto M, 2003, ANN NY ACAD SCI, V991, P171; Hashimoto M, 1999, BRAIN PATHOL, V9, P707; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kaplan B, 2003, J MOL NEUROSCI, V20, P83, DOI 10.1385/JMN:20:2:83; Keller JN, 2004, INT J BIOCHEM CELL B, V36, P2376, DOI 10.1016/j.biocel.2004.05.003; Kheradpezhouh M, 2003, NEUROSIGNALS, V12, P315, DOI 10.1159/000075314; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee VMY, 2004, TRENDS NEUROSCI, V27, P129, DOI 10.1016/j.tins.2004.01.007; Li J, 2002, NEUROTOXICOLOGY, V23, P553, DOI 10.1016/S0161-813X(02)00066-9; Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Maclean MJ, 2003, AGING CELL, V2, P93, DOI 10.1046/j.1474-9728.2003.00041.x; Martin-Clemente B, 2004, J BIOL CHEM, V279, P52984, DOI 10.1074/jbc.M409028200; McMurray MA, 2004, CURR OPIN MICROBIOL, V7, P673, DOI 10.1016/j.mib.2004.10.008; Meredith GE, 2002, BRAIN RES, V956, P156, DOI 10.1016/S0006-8993(02)03514-X; Munoz E, 1997, NEUROSCI LETT, V235, P57, DOI 10.1016/S0304-3940(97)00710-6; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Perrone GG, 2005, MOL BIOL CELL, V16, P218, DOI 10.1091/mbc.E04-07-0560; Pocsi I, 2004, ADV MICROB PHYSIOL, V49, P1, DOI 10.1016/S0065-2911(04)49001-8; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Popescu A, 2004, ARCH NEUROL-CHICAGO, V61, P1915, DOI 10.1001/archneur.61.12.1915; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; Rodgers KJ, 2003, INT J BIOCHEM CELL B, V35, P716, DOI 10.1016/S1357-2725(02)00391-6; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Sawada H, 2004, J BIOL CHEM, V279, P10710, DOI 10.1074/jbc.M308434200; Sinclair DA, 1999, CELL MOL LIFE SCI, V56, P807, DOI 10.1007/s000180050027; Snyder H, 2005, J BIOL CHEM, V280, P7562, DOI 10.1074/jbc.M412887200; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Willingham S, 2003, SCIENCE, V302, P1769, DOI 10.1126/science.1090389	52	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30009	30017		10.1074/jbc.M501308200	http://dx.doi.org/10.1074/jbc.M501308200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15941712	hybrid			2022-12-25	WOS:000231362500005
J	Satheshkumar, PS; Gayathri, P; Prasad, K; Savithri, HS				Satheshkumar, PS; Gayathri, P; Prasad, K; Savithri, HS			"Natively unfolded" VPg is essential for Sesbania mosaic virus serine protease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN SIDE-CHAINS; NS3 PROTEASE; CIRCULAR-DICHROISM; PROTEOLYTIC ACTIVITIES; GENUS SOBEMOVIRUS; PROTEINS; POLYPROTEIN; COFACTOR; CLEAVAGE; SEQUENCE	Polyprotein processing is a major strategy used by many plant and animal viruses to maximize the number of protein products obtainable from a single open reading frame. In Sesbania mosaic virus, open reading frame-2 codes for a polyprotein that is cleaved into different functional proteins in cis by the N-terminal serine protease domain. The soluble protease domain lacking 70-amino-acid residues from the N terminus ( Delta N70Pro, where Pro is protease) was not active in trans. Interestingly, the protease domain exhibited trans-catalytic activity when VPg ( viral protein genome-linked) was present at the C terminus. Bioinformatic analysis of VPg primary structure suggested that it could be a disordered protein. Biophysical studies validated this observation, and VPg resembled "natively unfolded" proteins. CD spectral analysis showed that the Delta N70Pro-VPg fusion protein had a characteristic secondary structure with a 230 nm positive CD peak. Mutation of Trp-43 in the VPg domain to phenylalanine abrogated the positive peak with concomitant loss in cis- and trans-proteolytic activity of the Delta N70Pro domain. Further, deletion of VPg domain from the polyprotein completely abolished proteolytic processing. The results suggested a novel mechanism of activation of the protease, wherein the interaction between the natively unfolded VPg and the protease domains via aromatic amino acid residues alters the conformation of the individual domains and the active site of the protease. Thus, VPg is an activator of protease in Sesbania mosaic virus, and probably by this mechanism, the polyprotein processing could be regulated in planta.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Savithri, HS (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	bchss@biochem.iisc.ernet.in		Gayathri, Pananghat/0000-0002-2242-4619				Arakaki TL, 2002, PROTEIN EXPRES PURIF, V25, P241, DOI 10.1016/S1046-5928(02)00005-0; BHUVANESHWARI M, 1995, STRUCTURE, V3, P1021, DOI 10.1016/S0969-2126(01)00238-6; Daughenbaugh KF, 2003, EMBO J, V22, P2852, DOI 10.1093/emboj/cdg251; DESSENS JT, 1992, VIROLOGY, V189, P225, DOI 10.1016/0042-6822(92)90698-O; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; GRISHINA IB, 1994, FARADAY DISCUSS, V99, P245, DOI 10.1039/fd9949900245; Leonard S, 2004, J GEN VIROL, V85, P1055, DOI 10.1099/vir.0.19706-0; Lokesh GL, 2001, ARCH VIROL, V146, P209, DOI 10.1007/s007050170170; Makinen K, 2000, J GEN VIROL, V81, P2783, DOI 10.1099/0022-1317-81-11-2783; MARGIS R, 1994, VIROLOGY, V200, P79, DOI 10.1006/viro.1994.1165; McCoy MA, 2001, J MOL BIOL, V305, P1099, DOI 10.1006/jmbi.2000.4365; Merits A, 2002, J GEN VIROL, V83, P1211, DOI 10.1099/0022-1317-83-5-1211; MOLLA A, 1994, J BIOL CHEM, V269, P27015; MURPHY JF, 1991, J VIROL, V65, P511, DOI 10.1128/JVI.65.1.511-513.1991; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; Niyomrattanakit P, 2004, J VIROL, V78, P13708, DOI 10.1128/JVI.78.24.13708-13716.2004; Parrot I, 2002, J BIOL CHEM, V277, P45572, DOI 10.1074/jbc.M207606200; Satheshkumar PS, 2004, VIROLOGY, V318, P429, DOI 10.1016/j.virol.2003.09.035; Shimizu Y, 1996, J VIROL, V70, P127, DOI 10.1128/JVI.70.1.127-132.1996; Tamm T, 2000, J VIROL, V74, P6231, DOI 10.1128/JVI.74.14.6231-6241.2000; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Van der Wilk F, 1998, VIRUS GENES, V17, P21, DOI 10.1023/A:1008044715899; VANDEVEN FJM, 1990, EUR J BIOCHEM, V190, P583, DOI 10.1111/j.1432-1033.1990.tb15613.x; Wang AM, 1999, J GEN VIROL, V80, P799, DOI 10.1099/0022-1317-80-3-799; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WOODY RW, 1994, EUR BIOPHYS J BIOPHY, V23, P253, DOI 10.1007/BF00213575; Yusof R, 2000, J BIOL CHEM, V275, P9963, DOI 10.1074/jbc.275.14.9963; Zeev-Ben-Mordehai T, 2003, PROTEINS, V53, P758, DOI 10.1002/prot.10471	31	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30291	30300		10.1074/jbc.M504122200	http://dx.doi.org/10.1074/jbc.M504122200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15944159	hybrid			2022-12-25	WOS:000231362500038
J	Buch, MH; Pickard, A; Rodriguez, A; Gillies, S; Maass, AH; Emerson, M; Cartwright, EJ; Williams, JC; Oceandy, D; Redondo, JM; Neyses, L; Armesilla, AL				Buch, MH; Pickard, A; Rodriguez, A; Gillies, S; Maass, AH; Emerson, M; Cartwright, EJ; Williams, JC; Oceandy, D; Redondo, JM; Neyses, L; Armesilla, AL			The sarcolemmal calcium pump inhibits the calcineurin/nuclear factor of activated T-cell pathway via interaction with the calcineurin A catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CA2+ PUMP; MOLECULAR-CLONING; BINDING DOMAIN; PLASMA; NFAT; PROTEIN; TRANSCRIPTION; REGULATOR; DISTINCT; ISOFORM	The calcineurin/nuclear factor of activated T-cell ( NFAT) pathway represents a crucial transducer of cellular function. There is increasing evidence placing the sarcolemmal calcium pump, or plasma membrane calcium/calmodulin ATPase pump (PMCA), as a potential modulator of signal transduction pathways. We demonstrate a novel interaction between PMCA and the calcium/calmodulin-dependent phosphatase, calcineurin, in mammalian cells. The interaction domains were located to the catalytic domain of PMCA4b and the catalytic domain of the calcineurin A subunit. Endogenous calcineurin activity, assessed by measuring the transcriptional activity of its best characterized substrate, NFAT, was significantly inhibited by 60% in the presence of ectopic PMCA4b. This inhibition was notably reversed by the co-expression of the PMCA4b interaction domain, demonstrating the functional significance of this interaction. PMCA4b was, however, unable to confer its inhibitory effect in the presence of a calcium/calmodulin-independent constitutively active mutant calcineurin A suggesting a calcium/calmodulin-dependent mechanism. The modulatory function of PMCA4b is further supported by the observation that endogenous calcineurin moves from the cytoplasm to the plasma membrane when PMCA4b is overexpressed. We suggest recruitment by PMCA4b of calcineurin to a low calcium environment as a possible explanation for these findings. In summary, our results offer strong evidence for a novel functional interaction between PMCA and calcineurin, suggesting a role for PMCA as a negative modulator of calcineurin-mediated signaling pathways in mammalian cells. This study reinforces the emerging role of PMCA as a molecular organizer and regulator of signaling transduction pathways.	Univ Manchester, Div Cardiol, Manchester M13 9PT, Lancs, England; Univ Autonoma Madrid, CSIC, E-28049 Madrid, Spain; Univ Wurzburg, Dept Med, D-97080 Wurzburg, Germany	University of Manchester; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Wurzburg	Neyses, L (corresponding author), Univ Manchester, Div Cardiol, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	ludwig.neyses@cmmc.nhs.uk	Redondo, Juan Miguel/H-6351-2015; Maass, Alexander/B-8534-2008; Oceandy, Delvac/G-9911-2015; Marquez, Antonio A. Rodriguez/L-2422-2013; Neyses, Ludwig/AGY-7446-2022	Redondo, Juan Miguel/0000-0001-5779-9122; Maass, Alexander/0000-0002-7936-360X; Oceandy, Delvac/0000-0002-6242-6491; Marquez, Antonio A. Rodriguez/0000-0003-2455-6583; Cartwright, Elizabeth/0000-0002-6836-7795; pickard, adam/0000-0001-9757-143X; Armesilla, Angel/0000-0003-3546-5580	Medical Research Council [G0200020] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Armesilla AL, 2004, J BIOL CHEM, V279, P31318, DOI 10.1074/jbc.M307557200; Brown BJ, 1996, BBA-BIOMEMBRANES, V1283, P10, DOI 10.1016/0005-2736(96)00108-3; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Carnegie GK, 2003, GENE DEV, V17, P1557, DOI 10.1101/gad.1095803; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; deBlaquiere J, 1999, J Biomol Tech, V10, P64; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; FAUX MC, 1996, CELL, V70, P8; GREEB J, 1989, J BIOL CHEM, V264, P18569; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HEIM R, 1992, J BIOL CHEM, V267, P24476; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Huai Q, 2002, P NATL ACAD SCI USA, V99, P12037, DOI 10.1073/pnas.192206699; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Martinez-Martinez S, 2004, CURR MED CHEM, V11, P997, DOI 10.2174/0929867043455576; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Sambrook J., 2002, MOL CLONING LAB MANU; Schuh K, 2003, J BIOL CHEM, V278, P9778, DOI 10.1074/jbc.M212507200; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Vega RB, 2003, J BIOL CHEM, V278, P36981, DOI 10.1074/jbc.R300023200; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	39	76	80	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29479	29487		10.1074/jbc.M501326200	http://dx.doi.org/10.1074/jbc.M501326200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15955804	hybrid, Green Published			2022-12-25	WOS:000231176200013
J	Grunkemeyer, JA; Kwoh, C; Huber, TB; Shaw, AS				Grunkemeyer, JA; Kwoh, C; Huber, TB; Shaw, AS			CD2-associated protein (CD2AP) expression in podocytes rescues lethality of CD2AP deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; DOWN-REGULATION; CELL CONTACTS; NEPHRIN; CIN85; RECEPTORS; MOUSE; GENE	Mice born without CD2-associated protein (CD2AP) develop renal failure and nephrotic syndrome about 4 weeks after birth and die around 6 weeks of age. Although CD2AP is widely expressed, the severity of the renal failure precludes a clear determination of the role of CD2AP in other tissues. Here we generated transgenic mice expressing CD2AP using a podocyte-specific promoter. Podocyte-specific expression of CD2AP prevented the development of proteinuria, demonstrating that the renal failure is solely due to loss of CD2AP in podocytes and not in other renal or in immune cells. CD2AP-deficient mice are long-lived and appear phenotypically normal. Histological analysis demonstrated testicular abnormalities that were age-related. CIN85, a paralog of CD2AP, is poorly expressed in both the podocyte and the basal seminiferous tubule, suggesting that the loss of CD2AP in specific tissues may be compensated for by CIN85.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Renal, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Shaw, AS (corresponding author), Washington Univ, Sch Med, Dept Pathol, Box 8118,660 S Euclid, St Louis, MO 63110 USA.	shaw@pathbox.wustl.edu		Huber, Tobias B./0000-0001-7175-5062				Bogler O, 2000, NEURO-ONCOLOGY, V2, P6, DOI 10.1093/neuonc/2.1.6; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Kuusniemi AM, 2004, PEDIATR RES, V55, P774, DOI 10.1203/01.PDR.0000117842.10241.2C; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Li C, 2000, AM J PHYSIOL-RENAL, V279, pF785, DOI 10.1152/ajprenal.2000.279.4.F785; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Putaala H, 2000, J AM SOC NEPHROL, V11, P991, DOI 10.1681/ASN.V116991; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Tibaldi EV, 2003, INT IMMUNOL, V15, P313, DOI 10.1093/intimm/dxg032; Wong MA, 2000, AM J PHYSIOL-RENAL, V279, pF1027, DOI 10.1152/ajprenal.2000.279.6.F1027	19	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29677	29681		10.1074/jbc.M504004200	http://dx.doi.org/10.1074/jbc.M504004200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15951437	hybrid			2022-12-25	WOS:000231176200037
J	Daley, JM; Vander Laan, RL; Suresh, A; Wilson, TE				Daley, JM; Vander Laan, RL; Suresh, A; Wilson, TE			DNA joint dependence of Pol X family polymerase action in nonhomologous end joining	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; BASE-EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; LIGASE-IV; POLYNUCLEOTIDE KINASE; TRANSFERASE-ACTIVITY; V(D)J RECOMBINATION; PROTEIN-KINASE; LAMBDA; YEAST	DNA double strand breaks (DSBs) can be rejoined directly by the nonhomologous end-joining (NHEJ) pathway of repair. Nucleases and polymerases are required to promote accurate NHEJ when the terminal bases of the DSB are damaged. The same enzymes also participate in imprecise rejoining and joining of incompatible ends, important mutagenic events. Previous work has shown that the Pol X family polymerase Pol4 is required for some but not all NHEJ events that require gap filling in Saccharomyces cerevisiae. Here, we systematically analyzed DSB end configurations and found that gaps on both strands and overhang polarity are the principal factors that determine whether a joint requires Pol4. DSBs with 3'-overhangs and a gap on each strand strongly depended on Pol4 for repair, DSBs with 5'-overhangs of the same sequence did not. Pol4 was not required when 3'-overhangs contained a gap on only one strand, however. Pol4 was equally required at 3'-overhangs of all lengths within the NHEJ-dependent range but was dispensable outside of this range, indicating that Pol4 is specific to NHEJ. Loss of Pol4 did not affect the rejoining of DSBs that utilized a recessed microhomology or DSBs bearing 5'-hydroxyls but no gap. Finally, mammalian Pol X polymerases were able to differentially complement a pol4 mutation depending on the joint structure, demonstrating that these polymerases can participate in yeast NHEJ but with distinct properties.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Grad Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Wilson, TE (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Med Sci I M4214-0602,1301 Catherine Rd, Ann Arbor, MI 48109 USA.	wilsonte@umich.edu			NATIONAL CANCER INSTITUTE [R01CA090911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER; NCI NIH HHS [CA90911] Funding Source: Medline; NIGMS NIH HHS [T32 GM007315] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bebenek K, 2005, J BIOL CHEM, V280, P20051, DOI 10.1074/jbc.M501981200; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Brachmann CB, 1998, YEAST, V14, P115; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; COQUERELLE T, 1973, INT J RADIAT BIOL, V24, P397, DOI 10.1080/09553007314551251; Covo S, 2004, J BIOL CHEM, V279, P859, DOI 10.1074/jbc.M310447200; Daley JM, 2005, MOL CELL BIOL, V25, P896, DOI 10.1128/MCB.25.3.896-906.2005; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Fan W, 2004, BIOCHEM BIOPH RES CO, V323, P1328, DOI 10.1016/j.bbrc.2004.09.002; Frank-Vaillant M, 2002, MOL CELL, V10, P1189, DOI 10.1016/S1097-2765(02)00705-0; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Karathanasis E, 2002, GENETICS, V161, P1015; Kaye JA, 2004, CURR BIOL, V14, P2096, DOI 10.1016/j.cub.2004.10.051; Koch CA, 2004, EMBO J, V23, P3874, DOI 10.1038/sj.emboj.7600375; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; Ma JL, 2003, MOL CELL BIOL, V23, P8820, DOI 10.1128/MCB.23.23.8820-8828.2003; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; McElhinny SAN, 2004, IMMUNOL REV, V200, P156, DOI 10.1111/j.0105-2896.2004.00160.x; McElhinny SAN, 2003, MOL CELL BIOL, V23, P2309, DOI 10.1128/MCB.23.7.2309-2315.2003; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Pastwa E, 2003, RADIAT RES, V159, P251, DOI 10.1667/0033-7587(2003)159[0251:RORIDD]2.0.CO;2; Pospiech H, 2001, NUCLEIC ACIDS RES, V29, P3277, DOI 10.1093/nar/29.15.3277; Ramadan K, 2003, J MOL BIOL, V328, P63, DOI 10.1016/S0022-2836(03)00265-1; Shimizu K, 2002, P NATL ACAD SCI USA, V99, P9133, DOI 10.1073/pnas.142277999; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Tseng HM, 2004, J BIOL CHEM, V279, P47580, DOI 10.1074/jbc.M404492200; Tseng HM, 2002, J BIOL CHEM, V277, P45630, DOI 10.1074/jbc.M206861200; Vance JR, 2001, J BIOL CHEM, V276, P15073, DOI 10.1074/jbc.M011075200; Wilson TE, 2002, GENETICS, V162, P677; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303	43	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29030	29037		10.1074/jbc.M505277200	http://dx.doi.org/10.1074/jbc.M505277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15964833	hybrid			2022-12-25	WOS:000231021300027
J	Timperio, AM; Zolla, L				Timperio, AM; Zolla, L			Investigation of the lateral light-induced migration of photosystem II light-harvesting proteins by nano-high performance liquid chromatography electrospray ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B-PROTEIN; THYLAKOID MEMBRANE; EXCITATION-ENERGY; ANTENNA PROTEINS; LHC-II; PHOSPHORYLATION; COMPLEX; PHOTOSYNTHESIS; SPINACH; PLANTS	This study reports a detailed analysis of the light-induced lateral migration of the photosystem II (PSII) antennae between appressed and non-appressed thylakoid membranes. The relative PSII antennae that migrated to stroma lamellae were readily established on the basis of peak areas of the separated stroma proteins in the ultraviolet chromatograms. Phosphorylation was predicted by intact molecular mass measurements, and this was confirmed by immunoblotting. When thylakoid membrane and chloroplasts were illuminated at 100 mu E m(-2) s(-1), light-harvesting complex type II (Lhcb2) was the first PSII antenna to migrate, preferentially in phosphorylated form. However, the amount of Lhcb2 that migrated decreased after the first 20 min when the total amount of the three different Lhcb1 isoforms (1.1, 1.2, and 1.3) reached maximum. Lhcb1.1 was always found in the unphosphorylated form and migrated later than the other two isoforms, although the latter were also found to have low levels of phosphorylation. At the same time, major antennae on the grana were not found to be phosphorylated, whereas Lhcb4 showed a significant increase in molecular mass. At higher light intensity Lhcb2 migration was negligible, whereas migration of Lhcb1 isoforms was little changed, increasing in irradiated chloroplasts. Because there was no significant phosphorylation at high light intensity, and yet pigments were found to have significantly increased on the stroma lamellae, it may be that pigments play a role in migration and that, in fact, there is no direct correlation between phosphorylation and migration. We hypothesize that the Lhcb1 isoforms expressed by the multigene families play a role in plant adaptation.	Univ Tuscia, Dept Environm Sci, I-01100 Viterbo, Italy	Tuscia University	Zolla, L (corresponding author), Univ Tuscia, Dept Environm Sci, Via S Camillo De Lellis,Blocco D, I-01100 Viterbo, Italy.	zolla@unitus.it	Timperio, Anna Maria/AAN-4248-2020	Timperio, Anna Maria/0000-0001-8457-042X				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ANDERSON JM, 1966, BIOCHIM BIOPHYS ACTA, V112, P403, DOI 10.1016/0926-6585(66)90244-5; ANDERSSON B, 1982, FEBS LETT, V149, P181, DOI 10.1016/0014-5793(82)81097-1; [Anonymous], METHODS CHLOROPLAST; ARO EM, 2004, J EXP BOT, V29, P1; BARBER J, 1982, ANNU REV PLANT PHYS, V33, P261, DOI 10.1146/annurev.pp.33.060182.001401; BENNETT J, 1983, BIOCHEM J, V212, P1; BENNETT J, 1984, PHYSIOL PLANTARUM, V60, P583, DOI 10.1111/j.1399-3054.1984.tb04932.x; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Boekema EJ, 1999, EUR J BIOCHEM, V266, P444, DOI 10.1046/j.1432-1327.1999.00876.x; Chitnis PR, 2001, ANNU REV PLANT PHYS, V52, P593, DOI 10.1146/annurev.arplant.52.1.593; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; Corradini D, 2005, CHROMATOGRAPHIA, V61, P1, DOI 10.1365/s10337-004-0459-6; Danielsson R, 2004, BBA-BIOENERGETICS, V1608, P53, DOI 10.1016/j.bbabio.2003.10.005; Garab G, 2002, BIOCHEMISTRY-US, V41, P15121, DOI 10.1021/bi026157g; GILMORE AM, 1991, J CHROMATOGR, V543, P137, DOI 10.1016/S0021-9673(01)95762-0; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Horton P, 2000, PHILOS T R SOC B, V355, P1361, DOI 10.1098/rstb.2000.0698; Hou CX, 2003, BIOCHEMISTRY-US, V42, P5828, DOI 10.1021/bi0343119; Huber CG, 2001, J BIOL CHEM, V276, P45755, DOI 10.1074/jbc.M106700200; Jackowski G, 2001, BBA-BIOENERGETICS, V1504, P340, DOI 10.1016/S0005-2728(00)00262-0; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; JOHNSON GN, 1993, PLANT CELL ENVIRON, V16, P681, DOI 10.1111/j.1365-3040.1993.tb00486.x; KYLE DJ, 1983, ARCH BIOCHEM BIOPHYS, V222, P527, DOI 10.1016/0003-9861(83)90551-9; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P69, DOI 10.1016/0005-2728(87)90213-1; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Rintamaki E, 1997, J BIOL CHEM, V272, P30476, DOI 10.1074/jbc.272.48.30476; Rogner M, 1996, TRENDS BIOCHEM SCI, V21, P44, DOI 10.1016/0968-0004(96)80862-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHELLER HV, 2001, BIOCHIM BIOPHYS ACTA, V1507, P41; Timperio AM, 2004, J CHROMATOGR A, V1040, P73, DOI 10.1016/j.chroma.2004.03.068; Walcher W, 2003, ANAL CHEM, V75, P6775, DOI 10.1021/ac034866+; WALKER DA, 1987, METHOD ENZYMOL, V148, P145; Wentworth M, 2004, BIOCHEMISTRY-US, V43, P501, DOI 10.1021/bi034975i; Wentworth M, 2003, J BIOL CHEM, V278, P21845, DOI 10.1074/jbc.M302586200; ZHANG R, 2004, J BIOL CHEM, V30, P3180; Zolla L, 2003, PLANT PHYSIOL, V131, P198, DOI 10.1104/pp.012823	39	11	12	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28858	28866		10.1074/jbc.M504998200	http://dx.doi.org/10.1074/jbc.M504998200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15944149	hybrid			2022-12-25	WOS:000231021300005
J	Li, QT; Price, JP; Byers, SA; Cheng, DM; Peng, JM; Price, DH				Li, QT; Price, JP; Byers, SA; Cheng, DM; Peng, JM; Price, DH			Analysis of the large inactive P-TEFb complex indicates that it contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb molecules containing Cdk9 phosphorylated at threonine 186	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ELONGATION-FACTOR-B; CYCLIN-DEPENDENT KINASES; POSITIVE TRANSCRIPTION; HIV-1 TAT; INK4 INHIBITORS; SNRNA; ACTIVATION; BINDING; IDENTIFICATION	Positive transcription elongation factor b ( P-TEFb) regulates eukaryotic gene expression at the level of elongation, and is itself controlled by the reversible association of 7SK RNA and an RNA-binding protein, HEXIM1 or HEXIM2. To further understand how P-TEFb is regulated, we analyzed the stoichiometry of all the known components of the large, inactive P-TEFb complex. Mutational analyses of a putative coiled coil region in the carboxyl-terminal portion of HEXIM1 revealed that the protein is a dimer in solution and remains a dimer after binding to 7SK. Although a HEXIM1 dimer contains two potential RNA binding motifs and ultimately recruits two P-TEFb molecules, it associates with only one molecule of RNA. The first 172 nucleotides of the 330-nucleotide 7SK are sufficient to bind HEXIM1 or HEXIM2, and then recruit and inhibit P-TEFb. Deletion of the first 121 amino acids of HEXIM1 allowed it to inhibit P-TEFb partially in the absence of 7SK RNA. Mutation of a conserved tyrosine ( Tyr(271) in HEXIM1) to alanine or glutamate or mutation of a conserved phenylalanine ( Phe(208)) to alanine, aspartate, or lysine, resulted in loss of inhibition of P-TEFb, but did not affect formation of the 7SK(.)HEXIM(.)P-TEFb complex. Analysis of T-loop phosphorylation in Cdk9 indicated that phosphorylation of Thr(186), but not Ser(175), was essential for kinase activity and for recruitment of P-TEFb to the 7SK(.)HEXIM complex. A model illustrates what is currently known about how HEXIM proteins, 7SK, and P-TEFb assemble to maintain an activated kinase in a readily available, but inactive form.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA; Emory Sch Med, Ctr Neurodegenerat Dis, Dept Human Genet, Atlanta, GA 30322 USA	University of Iowa; University of Iowa; Emory University	Price, DH (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.	david-price@uiowa.edu	Price, David H/F-6173-2010; Peng, Junmin/N-2614-2018	Peng, Junmin/0000-0003-0472-7648; Li, Qintong/0000-0002-8447-9770; Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIAID NIH HHS [AI54340] Funding Source: Medline; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Byers SA, 2005, J BIOL CHEM; Chen RC, 2004, J BIOL CHEM, V279, P4153, DOI 10.1074/jbc.M310044200; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Garriga J, 2004, GENE, V337, P15, DOI 10.1016/j.gene.2004.05.007; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Kulkarni PA, 2004, RECENT PROG HORM RES, V59, P125, DOI 10.1210/rp.59.1.125; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Michels AA, 2004, EMBO J, V23, P2608, DOI 10.1038/sj.emboj.7600275; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Napolitano G, 2002, INT J ONCOL, V21, P171, DOI 10.3892/ijo.21.1.171; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sano M, 2003, CELL CYCLE, V2, P99, DOI 10.4161/cc.2.2.332; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shore SM, 2003, GENE, V307, P175, DOI 10.1016/S0378-1119(03)00466-9; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yik JHN, 2005, J BIOL CHEM, V280, P16368, DOI 10.1074/jbc.M500912200; Yik JHN, 2004, MOL CELL BIOL, V24, P5094, DOI 10.1128/MCB.24.12.5094-5105.2004; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	34	148	160	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28819	28826		10.1074/jbc.M502712200	http://dx.doi.org/10.1074/jbc.M502712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15965233	hybrid			2022-12-25	WOS:000230857300074
J	Moise, AR; Kuksa, V; Blaner, WS; Baehr, W; Palczewski, K				Moise, AR; Kuksa, V; Blaner, WS; Baehr, W; Palczewski, K			Metabolism and transactivation activity of 13,14-dihydroretinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; RETINALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; HUMAN CYTOCHROME-P450; 9-CIS-RETINOIC ACID; GENETIC-EVIDENCE; X-RECEPTOR; EXPRESSION; CLONING; IDENTIFICATION	The metabolism of vitamin A is a highly regulated process that generates essential mediators involved in the development, cellular differentiation, immunity, and vision of vertebrates. Retinol saturase converts all-trans-retinol to all-trans-13,14-dihydroretinol (Moise, A. R., Kuksa, V., Imanishi, Y., and Palczewski, K. ( 2004) J. Biol. Chem. 279, 50230 - 50242). Here we demonstrate that the enzymes involved in oxidation of retinol to retinoic acid and then to oxidized retinoic acid metabolites are also involved in the synthesis and oxidation of alltrans13,14- dihydroretinoic acid. All-trans-13,14- dihydroretinoic acid can activate retinoic acid receptor/retinoid X receptor heterodimers but not retinoid X receptor homodimers in reporter cell assays. All-trans13,14- dihydroretinoic acid was detected in vivo in Lrat-/- mice supplemented with retinyl palmitate. Thus, all-trans-13,14- dihydroretinoic acid is a naturally occurring retinoid and a potential ligand for nuclear receptors. This new metabolite can also be an intermediate in a retinol degradation pathway or it can serve as a precursor for the synthesis of bioactive 13,14- dihydroretinoid metabolites.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA; Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Inst Human Nutr, New York, NY 10032 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Columbia University; Columbia University	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	AR, Moise/P-2474-2019; Moise, Alexander/A-7186-2008; Moise, Alexander R/C-9498-2009	AR, Moise/0000-0003-2307-6035; Moise, Alexander R/0000-0003-2307-6035	NATIONAL EYE INSTITUTE [R01EY008123, R29EY008061, R01EY008061] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008061, R01 EY008123, EY08061, EY08123] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Achkar CC, 1996, P NATL ACAD SCI USA, V93, P4879, DOI 10.1073/pnas.93.10.4879; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Blumberg B, 1996, P NATL ACAD SCI USA, V93, P4873, DOI 10.1073/pnas.93.10.4873; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; DERGUINI F, 1995, J BIOL CHEM, V270, P18875, DOI 10.1074/jbc.270.32.18875; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Duester G, 2003, CHEM-BIOL INTERACT, V143, P201, DOI 10.1016/S0009-2797(02)00204-1; Fischer AJ, 1999, J NEUROCYTOL, V28, P597, DOI 10.1023/A:1007071406746; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; Gagnon I, 2003, BIOCHEM PHARMACOL, V65, P1685, DOI 10.1016/S0006-2952(03)00150-3; Gagnon I, 2002, BBA-PROTEIN STRUCT M, V1596, P156, DOI 10.1016/S0167-4838(02)00213-3; Goldstein JT, 2003, ARCH BIOCHEM BIOPHYS, V420, P185, DOI 10.1016/j.abb.2003.09.034; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Haeseleer F, 2000, METHOD ENZYMOL, V316, P372; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Lemotte PK, 1996, EUR J BIOCHEM, V236, P328, DOI 10.1111/j.1432-1033.1996.00328.x; Lin M, 2003, J BIOL CHEM, V278, P9856, DOI 10.1074/jbc.M211417200; MacLean G, 2001, MECH DEVELOP, V107, P195, DOI 10.1016/S0925-4773(01)00463-4; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Mey J, 2001, DEV BRAIN RES, V127, P135, DOI 10.1016/S0165-3806(01)00127-4; Mic FA, 2000, MECH DEVELOP, V97, P227, DOI 10.1016/S0925-4773(00)00434-2; Mic FA, 2004, DEV DYNAM, V231, P270, DOI 10.1002/dvdy.20128; Moise AR, 2004, J BIOL CHEM, V279, P50230, DOI 10.1074/jbc.M409130200; Molotkov A, 2004, BIOCHEM J, V383, P295, DOI 10.1042/BJ20040621; Molotkov A, 2003, J BIOL CHEM, V278, P36085, DOI 10.1074/jbc.M303709200; Molotkov A, 2002, J BIOL CHEM, V277, P13804, DOI 10.1074/jbc.M112039200; Niederreither K, 2002, NAT GENET, V31, P84, DOI 10.1038/ng876; Niederreither K, 2003, DEVELOPMENT, V130, P2525, DOI 10.1242/dev.00463; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; Pijnappel WWM, 1998, P NATL ACAD SCI USA, V95, P15424, DOI 10.1073/pnas.95.26.15424; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; ROBERTS AB, 1968, J LIPID RES, V9, P501; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Schmidt CK, 2003, ANAL BIOCHEM, V315, P36, DOI 10.1016/S0003-2697(02)00662-0; Shirley MA, 1996, DRUG METAB DISPOS, V24, P293; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Taimi M, 2004, J BIOL CHEM, V279, P77, DOI 10.1074/jbc.M308337200; Wagner E, 2000, DEV BIOL, V222, P460, DOI 10.1006/dbio.2000.9719; WAGNER M, 1992, DEVELOPMENT, V116, P55; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; White JA, 2000, P NATL ACAD SCI USA, V97, P6403, DOI 10.1073/pnas.120161397; WOLF G, 1957, J AM CHEM SOC, V79, P1208, DOI 10.1021/ja01562a047; YAGISHITA K, 1964, NATURE, V203, P410, DOI 10.1038/203410b0; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	51	44	46	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27815	27825		10.1074/jbc.M503520200	http://dx.doi.org/10.1074/jbc.M503520200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15911617	Green Accepted, hybrid			2022-12-25	WOS:000230678600042
J	Borza, DB; Bondar, O; Colon, S; Todd, P; Sado, Y; Neilson, EG; Hudson, BG				Borza, DB; Bondar, O; Colon, S; Todd, P; Sado, Y; Neilson, EG; Hudson, BG			Goodpasture autoantibodies unmask cryptic epitopes by selectively dissociating autoantigen complexes lacking structural reinforcement - Novel mechanisms for immune privilege and autoimmune pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; ALPHA-3(IV) COLLAGEN CHAIN; CLASS-II GENES; IV COLLAGEN; NC1 DOMAINS; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; GLOBULAR DOMAIN; T-CELLS; DISEASE	Rapidly progressive glomerulonephritis in Goodpasture disease is mediated by autoantibodies binding to the non-collagenous NC1 domain of alpha 3(IV) collagen in the glomerular basement membrane. Goodpasture epitopes in the native autoantigen are cryptic (sequestered) within the NC1 hexamers of the alpha 3 alpha 4 alpha 5(IV) collagen network. The biochemical mechanism for crypticity and exposure for autoantibody binding is not known. We now report that crypticity is a feature of the quaternary structure of two distinct subsets of alpha 3 alpha 4 alpha 5(IV) NC1 hexamers: autoantibody-reactive M-hexamers containing only monomer subunits and autoantibody-impenetrable D-hexamers composed of both dimer and monomer subunits. Goodpasture antibodies only breach the quaternary structure of M-hexamers, unmasking the cryptic epitopes, whereas D-hexamers are resistant to autoantibodies under native conditions. The epitopes of D-hexamers are structurally sequestered by dimer reinforcement of the quaternary complex, which represents a new molecular solution for conferring immunologic privilege to a potential autoantigen. Dissociation of non-reinforced M-alpha 3 alpha 4 alpha 5(IV) hexamers by Goodpasture antibodies is a novel mechanism whereby pathogenic autoantibodies gain access to cryptic B cell epitopes. These findings provide fundamental new insights into immune privilege and the molecular mechanisms underlying the pathogenesis of human autoimmune Goodpasture disease.	Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol, Nashville, TN 37232 USA; Shigei Med Res Inst, Okayama 701, Japan	Vanderbilt University	Borza, DB (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol, S-3223 MCN, Nashville, TN 37232 USA.	Dorin-Bogdan.Borza@vanderbilt.edu	Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Hudson, Billy/0000-0002-5420-4100	NIDDK NIH HHS [R01 DK46282, P01 DK65123, R37 DK18381] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, P01DK065123, R01DK046282] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOMBASSEI GJ, 1992, AM J IND MED, V21, P141, DOI 10.1002/ajim.4700210204; Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; Borza DB, 2002, J BIOL CHEM, V277, P40075, DOI 10.1074/jbc.M207769200; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; BURNS AP, 1995, QJM-MON J ASSOC PHYS, V88, P93; D'Orazio TJ, 1998, J IMMUNOL, V160, P2089; David M, 2001, J BIOL CHEM, V276, P6370, DOI 10.1074/jbc.M008956200; DONAGHY M, 1983, LANCET, V2, P1390; Ferguson TA, 1997, IMMUNOL REV, V156, P167, DOI 10.1111/j.1600-065X.1997.tb00967.x; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Gunnarsson A, 2000, J BIOL CHEM, V275, P30844, DOI 10.1074/jbc.M004717200; Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+; Heidet L, 2003, AM J PATHOL, V163, P1633, DOI 10.1016/S0002-9440(10)63520-1; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kalluri R, 1997, J CLIN INVEST, V100, P2263, DOI 10.1172/JCI119764; Kalluri R, 2000, J BIOL CHEM, V275, P20027, DOI 10.1074/jbc.M904549199; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; SADO Y, 1995, HISTOCHEM CELL BIOL, V104, P267, DOI 10.1007/BF01464322; Salama AD, 2001, J AM SOC NEPHROL, V12, P1908, DOI 10.1681/ASN.V1291908; SAUS J, 1988, J BIOL CHEM, V263, P13374; SCHWAB C, 1992, J IMMUNOL METHODS, V147, P125, DOI 10.1016/S0022-1759(12)80037-8; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; STEVENSON A, 1995, QJM-MON J ASSOC PHYS, V88, P23; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; Vanacore RM, 2004, J BIOL CHEM, V279, P44723, DOI 10.1074/jbc.M406344200; VANACORE RM, 2005, J BIOL CHEM     0610; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; Wong DC, 2001, KIDNEY INT, V60, P1777, DOI 10.1046/j.1523-1755.2001.00014.x; YOSHIOKA K, 1988, CLIN EXP IMMUNOL, V74, P419; YOSHIOKA K, 1985, AM J PATHOL, V121, P156	35	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27147	27154		10.1074/jbc.M504050200	http://dx.doi.org/10.1074/jbc.M504050200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917228	hybrid			2022-12-25	WOS:000230589500062
J	Esser, C; Scheffner, M; Hohfeld, J				Esser, C; Scheffner, M; Hohfeld, J			The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; MUTANT P53; MOLECULAR CHAPERONES; ACTIVATING MUTATIONS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NEGATIVE REGULATOR; PROTEIN LIGASE; MDM2; DOMAIN	The cellular level of the tumor suppressor p53 is tightly regulated through induced degradation via the ubiquitin/proteasome system. The ubiquitin ligase Mdm2 plays a pivotal role in stimulating p53 turnover. However, recently additional ubiquitin ligases have been identified that participate in the degradation of the tumor suppressor. Apparently, multiple degradation pathways are employed to ensure proper destruction of p53. Here we show that the chaperone-associated ubiquitin ligase CHIP is able to induce the proteasomal degradation of p53. CHIP-induced degradation was observed for mutant p53, which was previously shown to associate with the chaperones Hsc70 and Hsp90, and for the wild-type form of the tumor suppressor. Our data reveal that mutant and wild-type p53 transiently associate with molecular chaperones and can be diverted onto a degradation pathway through this association.	Univ Bonn, Inst Cell Biol, D-53121 Bonn, Germany; Univ Bonn, Bonner Forum Biomed, D-53121 Bonn, Germany; Univ Konstanz, Dept Biol, Biochem Lab, D-78457 Constance, Germany	University of Bonn; University of Bonn; University of Konstanz	Hohfeld, J (corresponding author), Univ Bonn, Inst Cell Biol, Ulrich Haberland Str 61A, D-53121 Bonn, Germany.	hoehfeld@uni-bonn.de	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Alberti S, 2004, MOL BIOL CELL, V15, P4003, DOI 10.1091/mbc.E04-04-0293; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Burch L, 2004, J MOL BIOL, V337, P129, DOI 10.1016/j.jmb.2004.01.017; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Esser C, 2004, BBA-MOL CELL RES, V1695, P171, DOI 10.1016/j.bbamcr.2004.09.020; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; Harper JW, 2004, CELL, V118, P2, DOI 10.1016/j.cell.2004.06.015; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; LUNA RMD, 1995, NATURE, V378, P203; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MILNER J, 1990, ONCOGENE, V5, P1683; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Prives C, 1999, J PATHOL, V187, P112; Rudiger S, 2002, P NATL ACAD SCI USA, V99, P11085, DOI 10.1073/pnas.132393699; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Woods Yvonne L, 2003, Hematol J, V4, P233, DOI 10.1038/sj.thj.6200260; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	69	203	213	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27443	27448		10.1074/jbc.M501574200	http://dx.doi.org/10.1074/jbc.M501574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911628	hybrid, Green Published			2022-12-25	WOS:000230589500096
J	Li, Q; Luo, X; Muallem, S				Li, Q; Luo, X; Muallem, S			Regulation of the P2X7 receptor permeability to large molecules by extracellular Cl- and Na+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; P2X(7) RECEPTOR; DUCT CELLS; ANTIMICROBIAL PEPTIDES; SALIVARY-GLANDS; PANCREATIC-DUCT; ATP; ACTIVATION; EXPRESSION; TRANSPORT	Upon continuous stimulation, the pore of the monovalent cation-selective P2X7 receptor (P2X7R) expands to accommodate large molecules such as N-methyl-D-glucamine (NMDG(+)). How the change in P2X7R permeability is regulated is not known. Here we report that extracellular Cl- (Cl-o(-)) regulates the outward current, whereas extracellular Na+ (Na-o(+)) regulates the inward current of large molecules by P2X7Rs. The P2X7R-mediated current was measured in parotid acinar and duct cells of wild type and P2X7R(-/-) mice and in HEK293 cells expressing the human or mouse P2X7R isoforms. In symmetrical NaCl, triethylammonium chloride, and NMDG(+) chloride solutions, the P2X7R current followed a linear current/voltage relationship. In symmetrical NaCl, removal of Cl-o(-) reduced the inward Na+ current by similar to 35% and the outward Na+ current by only 10%. By contrast, in the absence of Na-i(+) and the presence of Na-o(+) or NMDG(o)(+), the removal of Cl-o(-) reduced the inward Na+ or NMDG(+) currents by 35% but the outward NMDG(+) current by > 95%. The effect of Cl-o(-) was half-maximal at similar to 60 mM. Reducing Cl-i(-) from 150 to 10 mM did not reproduce the effects of Cl-o(-). All currents were eliminated in P2X7R(-/-) cells and reproduced by expressing the P2X7Rs in HEK cells. These findings suggest that Cl-o(-) primarily regulates the outward P2X7R current of large molecules. When cells dialyzed with NMDG(+) were stimulated in the presence of Na-o(+), subsequent removal of Na-o(+) resulted in a strongly outward rectifying NMDG(+) current, indicating maintained high selectivity for Na+ over NMDG(+). During continuous incubation in Na+-free medium, the permeability of the P2X7Rs to NMDG(+) gradually increased. On the other hand, when the cells were incubated in symmetrical NMDG(+) and only then stimulated with ATP, the NMDG(+) current by P2X7Rs followed a linear current/voltage relationship and did not change with time. These findings suggest that the P2X7R has a "Na-o(+) memory" and that Na-o(+) regulates the inward permeability of P2X7Rs to large molecules. The novel regulation of P2X7R outward and inward permeability to large molecules by Cl-o(-) and Na-o(+), respectively, may have an important protective function, particularly in secretory epithelial cells.	Univ Texas, SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Muallem, S (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	shmuel.muallem@utsouthwestern.edu						Arreola J, 2003, J PHYSIOL-LONDON, V547, P197, DOI 10.1113/jphysiol.2002.028373; Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Bradford MD, 2002, BIOCHEM J, V366, P745, DOI 10.1042/BJ20020358; Brogden KA, 2003, INT J ANTIMICROB AG, V22, P465, DOI 10.1016/S0924-8579(03)00180-8; Brown DA, 2004, J BIOL CHEM, V279, P39485, DOI 10.1074/jbc.M406201200; Bulanova E, 2005, J IMMUNOL, V174, P3880, DOI 10.4049/jimmunol.174.7.3880; COOK DI, 1994, TXB PHYSL GASTROINTE, P1061; Dehaye JP, 1999, ARCH ORAL BIOL, V44, pS39, DOI 10.1016/S0003-9969(99)00048-5; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Feranchak AP, 2002, SEMIN LIVER DIS, V22, P251, DOI 10.1055/s-2002-34503; Gartland A, 2003, CRIT REV EUKAR GENE, V13, P237; Gibbons SJ, 2001, J AUTON PHARMACOL, V21, P181, DOI 10.1046/j.1365-2680.2001.00224.x; Kahlenberg JM, 2004, AM J PHYSIOL-CELL PH, V286, pC1100, DOI 10.1152/ajpcell.00494.2003; Ko SBH, 2004, NAT CELL BIOL, V6, P343, DOI 10.1038/ncb1115; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Leipziger J, 2003, AM J PHYSIOL-RENAL, V284, pF419, DOI 10.1152/ajprenal.00075.2002; Li Q, 2003, J BIOL CHEM, V278, P47554, DOI 10.1074/jbc.M308306200; Luo X, 1999, AM J PHYSIOL-CELL PH, V277, pC205, DOI 10.1152/ajpcell.1999.277.2.C205; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; Melvin JE, 2005, ANNU REV PHYSIOL, V67, P445, DOI 10.1146/annurev.physiol.67.041703.084745; Michel AD, 1999, N-S ARCH PHARMACOL, V359, P102, DOI 10.1007/PL00005328; Murakami M, 2002, J DENT RES, V81, P845, DOI 10.1177/154405910208101210; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; Slater M, 2000, HISTOCHEM J, V32, P365, DOI 10.1023/A:1004017714702; Sluyter R, 2004, J BIOL CHEM, V279, P44749, DOI 10.1074/jbc.M405631200; Steward MC, 2005, ANNU REV PHYSIOL, V67, P377, DOI 10.1146/annurev.physiol.67.031103.153247; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Szucs A, 2004, HEARING RES, V196, P2, DOI 10.1016/j.heares.2004.04.008; Tenneti L, 1998, J BIOL CHEM, V273, P26799, DOI 10.1074/jbc.273.41.26799; Tsukimoto M, 2005, J BIOL CHEM, V280, P2653, DOI 10.1074/jbc.M411072200; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; Yamamoto K, 2003, AUTOIMMUN REV, V2, P13, DOI 10.1016/S1568-9972(02)00121-0; Zeng WZ, 1997, J BIOL CHEM, V272, P32956, DOI 10.1074/jbc.272.52.32956; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442	36	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26922	26927		10.1074/jbc.M504966200	http://dx.doi.org/10.1074/jbc.M504966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15923180	hybrid			2022-12-25	WOS:000230589500035
J	Bruewer, M; Utech, M; Ivanov, AI; Hopkins, AM; Parkos, CA; Nusrat, A				Bruewer, M; Utech, M; Ivanov, AI; Hopkins, AM; Parkos, CA; Nusrat, A			Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process	FASEB JOURNAL			English	Article						cytokines; inflammation; mucosa	INFLAMMATORY-BOWEL-DISEASE; NECROSIS-FACTOR-ALPHA; BARRIER FUNCTION; IFN-GAMMA; GROWTH-FACTOR; INTESTINAL EPITHELIUM; DISTINCT ROLES; CLASS-I; ENDOCYTOSIS; CELLS	IIncreased epithelial permeability is observed in inflammatory states. However, the mechanism by which inflammatory mediators such as IFN-gamma increase epithelial permeability is unknown. We recently observed that IFN-gamma induces disassembly of tight junctions (TJ); in this study we asked whether such TJ disassembly is mediated by endocytosis of junctional proteins. The role of three major internalization pathways in disruption of TJ in IFN-gamma-treated intestinal epithelial cells was analyzed using selective inhibitors and markers of the pathways. No role for the clathrin-and caveolar-mediated endocytosis in the IFN-gamma-induced internalization of TJ proteins was observed. However, inhibitors of macropinocytosis blocked internalization of TJ proteins and junctional proteins colocalized with macropinocytosis markers, dextran and phosphatidylinositol-3,4,5-trisphosphate. Internalized TJ proteins were identified in early and recycling endosomes but not in late endosomes/lysosomes. These results for the first time suggest that IFN-gamma produces a leaky epithelial barrier by inducing macropinoytosis of TJ proteins.	Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Univ Munster, Dept Gen Surg, D-4400 Munster, Germany	Emory University; University of Munster	Nusrat, A (corresponding author), Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Whitehead Res Bldg,Room 105E,615 Michael St, Atlanta, GA 30322 USA.	anusrat@emory.edu	Parkos, Charles a/B-3896-2009; Nusrat, Asma/B-3887-2009; Hopkins, Ann/C-3400-2012	Hopkins, Ann/0000-0003-2836-6584	NIDDK NIH HHS [DK 61379, DK 59888, DK 55679] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK055679, R01DK055679, R01DK061379, R01DK059888] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS RB, 1993, J IMMUNOL, V150, P2356; Ahdieh M, 2001, AM J PHYSIOL-CELL PH, V281, pC2029, DOI 10.1152/ajpcell.2001.281.6.C2029; Amyere M, 2002, INT J MED MICROBIOL, V291, P487; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Basuroy S, 2003, J BIOL CHEM, V278, P11916, DOI 10.1074/jbc.M211710200; Bossuyt J, 2002, FEBS LETT, V511, P113, DOI 10.1016/S0014-5793(01)03323-3; Brossart P, 1997, BLOOD, V90, P1594, DOI 10.1182/blood.V90.4.1594.1594_1594_1599; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Bush J, 1996, MOL BIOL CELL, V7, P1623, DOI 10.1091/mbc.7.10.1623; CALDWELL RB, 1984, EXP CELL RES, V150, P104, DOI 10.1016/0014-4827(84)90706-7; Clayburgh DR, 2004, LAB INVEST, V84, P282, DOI 10.1038/labinvest.3700050; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Grisendi S, 1998, J CELL PHYSIOL, V176, P465, DOI 10.1002/(SICI)1097-4652(199809)176:3<465::AID-JCP3>3.0.CO;2-M; Hamasaki M, 2004, ANAT REC PART A, V277A, P298, DOI 10.1002/ar.a.20027; Han XN, 2003, SHOCK, V19, P229, DOI 10.1097/00024382-200303000-00006; Harhaj NS, 2002, J CELL PHYSIOL, V193, P349, DOI 10.1002/jcp.10183; Harris E, 2001, J CELL SCI, V114, P3035; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hoekstra D, 2004, J CELL SCI, V117, P2183, DOI 10.1242/jcs.01217; Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300; ILLINGER D, 1990, BIOCHIM BIOPHYS ACTA, V1030, P82, DOI 10.1016/0005-2736(90)90241-F; Ivanov AI, 2004, MOL BIOL CELL, V15, P2639, DOI 10.1091/mbc.E04-02-0163; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; IVANOV AI, 2004, INFLAMM BOWEL DIS, P115; KATZ KD, 1989, GASTROENTEROLOGY, V97, P927, DOI 10.1016/0016-5085(89)91499-6; Kauppi M, 2002, J CELL SCI, V115, P899; Kim S, 2002, MICROB PATHOGENESIS, V33, P225, DOI 10.1006/mpat.2002.0531; Kohler K, 2004, J CELL BIOL, V165, P175, DOI 10.1083/jcb.200312118; Liu Y, 2000, J CELL SCI, V113, P2363; MADARA JL, 1992, J CLIN INVEST, V89, P1938, DOI 10.1172/JCI115800; MADARA JL, 1987, GASTROENTEROLOGY, V92, P1133, DOI 10.1016/S0016-5085(87)91069-9; MADARA JL, 1990, J MEMBRANE BIOL, V116, P177, DOI 10.1007/BF01868675; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; Mankertz J, 2000, J CELL SCI, V113, P2085; Marano CW, 1998, J MEMBRANE BIOL, V161, P263, DOI 10.1007/s002329900333; Matsuda M, 2004, J CELL SCI, V117, P1247, DOI 10.1242/jcs.00972; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; McKay DM, 1997, J IMMUNOL, V159, P2382; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; Mesa R, 2001, J CELL SCI, V114, P4041; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; Montaner LJ, 1999, J IMMUNOL, V162, P4606; MOSS AL, 1991, J CELL PHYSIOL, V149, P319, DOI 10.1002/jcp.1041490220; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NIESSNER M, 1995, CLIN EXP IMMUNOL, V101, P428; Nusrat A, 2001, INFECT IMMUN, V69, P1329, DOI 10.1128/IAI.69.3.1329-1336.2001; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; O'Neil D, 1999, J IMMUNOL, V162, P791; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; PITELKA DR, 1983, J CELL BIOL, V96, P613, DOI 10.1083/jcb.96.3.613; POLAKCHARCON S, 1979, J CELL SCI, V35, P393; POLAKCHARCON S, 1980, J NATL CANCER I, V65, P53; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; RISINGER MA, 1981, TISSUE CELL, V13, P413, DOI 10.1016/0040-8166(81)90015-X; SANDLE GI, 1990, GASTROENTEROLOGY, V99, P97, DOI 10.1016/0016-5085(90)91235-X; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Shurety W, 1996, J CELL SCI, V109, P2927; So ALP, 2000, DIGEST DIS SCI, V45, P1130, DOI 10.1023/A:1005593717644; STAEHELIN LA, 1973, J CELL SCI, V13, P763; Stallmach Andreas, 2004, Int J Colorectal Dis, V19, P308, DOI 10.1007/s00384-003-0554-4; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Van Dyke RW, 2000, HEPATOLOGY, V32, P1357, DOI 10.1053/jhep.2000.19790; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yamamoto Y, 2003, BIOCHEM BIOPH RES CO, V308, P270, DOI 10.1016/S0006-291X(03)01358-5; Youakim A, 1999, AM J PHYSIOL-GASTR L, V276, pG1279, DOI 10.1152/ajpgi.1999.276.5.G1279; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	74	278	286	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					923	933		10.1096/fj.04-3260com	http://dx.doi.org/10.1096/fj.04-3260com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923402				2022-12-25	WOS:000230207800039
J	Louis, NA; Hamilton, KE; Kong, TQ; Colgan, SP				Louis, NA; Hamilton, KE; Kong, TQ; Colgan, SP			HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils	FASEB JOURNAL			English	Article						inflammation; adhesion; mucosa; leukocyte; resolution	DECAY-ACCELERATING FACTOR; HYPOXIA-INDUCIBLE FACTOR; VASCULAR ENDOTHELIAL-CELLS; INTERCELLULAR-ADHESION MOLECULE-1; INFLAMMATORY-BOWEL-DISEASE; NECROSIS-FACTOR-ALPHA; TRANSEPITHELIAL MIGRATION; INTESTINAL EPITHELIA; NITRIC-OXIDE; FACTOR-I	Sites of inflammation are associated with dramatic shifts in tissue metabolism. Inflammation can result in significant tissue hypoxia, with resultant induction of hypoxia-responsive genes. Given this association, we hypothesized that neutrophil (PMN) ligands expressed on epithelial cells may be regulated by hypoxia. Initial studies confirmed earlier results that epithelial hypoxia enhances PMN transepithelial migration and promotes apical clearance of PMN from the epithelial surface. A screen of known PMN ligands revealed a surprisingly stable expression pattern in hypoxia. However, this screen identified one gene, CD55, as a highly hypoxia-inducible molecule expressed on the apical membrane of mucosal epithelia. Subsequent studies verified the induction of CD55 mRNA and protein expression by hypoxia. Overexpression of CD55 by transfection in nonhypoxic epithelia resulted in a similar pattern of apical PMN clearance, and peptide mimetics corresponding to the PMN binding site on DAF blocked such apical clearance of PMN. Studies directed at understanding molecular pathways of hypoxia inducibility revealed that a similar to 200 bp region of the CD55 gene conferred hypoxia inducibility for CD55. These studies identified a functional binding site for the transcriptional regulator hypoxia-inducible factor (HIF). Taken together, these results identify HIF-dependent induction of epithelial CD55 in the resolution of ongoing inflammation through clearance of apical PMN.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Neonatol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Colgan, SP (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Neonatol, Thorn Bldg 704,20 Shattuck St, Boston, MA 02115 USA.	colgan@zeus.bwh.harvard.edu	Louis, Nancy/G-5163-2011; Hamilton, Kathryn/AAA-9643-2022; Colgan, Sean P./B-4573-2009	Louis, Nancy/0000-0001-7092-8136; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050189, R01DK050189, R29DK050189] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE161191] Funding Source: Medline; NIDDK NIH HHS [DK50189, DK62007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad SR, 2003, IMMUNOLOGY, V110, P258, DOI 10.1046/j.1365-2567.2003.01733.x; Berstad AE, 1998, GUT, V42, P522, DOI 10.1136/gut.42.4.522; Colgan SP, 1996, J EXP MED, V184, P1003, DOI 10.1084/jem.184.3.1003; Collard CD, 1999, AM J PHYSIOL-CELL PH, V276, pC450, DOI 10.1152/ajpcell.1999.276.2.C450; Collard CD, 1997, CIRCULATION, V96, P326; Comerford KM, 2002, CANCER RES, V62, P3387; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Friedman GB, 1998, J CELL PHYSIOL, V176, P76, DOI 10.1002/(SICI)1097-4652(199807)176:1<76::AID-JCP9>3.0.CO;2-5; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Haddad JJ, 2003, CRIT CARE, V7, P47, DOI 10.1186/cc1840; Hatoum OA, 2003, GASTROENTEROLOGY, V125, P58, DOI 10.1016/S0016-5085(03)00699-1; HAUSER CJ, 1988, J LAB CLIN MED, V112, P68; Huber D, 2000, J BIOL CHEM, V275, P5773, DOI 10.1074/jbc.275.8.5773; Inaba T, 1998, CLIN EXP IMMUNOL, V112, P237; Jaye DL, 2000, ANN NY ACAD SCI, V915, P151; Karhausen J, 2005, CELL CYCLE, V4, P256; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; KING PD, 1990, EUR J IMMUNOL, V20, P363, DOI 10.1002/eji.1830200220; Kokura S, 2002, FREE RADICAL BIO MED, V33, P427, DOI 10.1016/S0891-5849(02)00852-3; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; KORETZ K, 1992, BRIT J CANCER, V66, P810, DOI 10.1038/bjc.1992.365; Kruschewski M, 2001, DIGEST DIS SCI, V46, P2336, DOI 10.1023/A:1012334727509; Lawrence DW, 2003, J EXP MED, V198, P999, DOI 10.1084/jem.20030380; Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889; Lin F, 2004, J IMMUNOL, V172, P3836, DOI 10.4049/jimmunol.172.6.3836; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Mason JC, 1999, BLOOD, V94, P1673, DOI 10.1182/blood.V94.5.1673.417a05_1673_1682; Mason JC, 2002, AM J PHYSIOL-CELL PH, V282, pC578, DOI 10.1152/ajpcell.00339.2001; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; Oshima T, 2000, J IMMUNOL, V164, P1078, DOI 10.4049/jimmunol.164.2.1078; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Roth U, 2004, BIOL CHEM, V385, P239, DOI 10.1515/BC.2004.018; Saadi S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0690hyp; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Shafren DR, 2000, J GEN VIROL, V81, P889, DOI 10.1099/0022-1317-81-4-889; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Song WC, 2004, CURR DIRECT AUTOIMMU, V7, P181; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Taylor CT, 1998, GASTROENTEROLOGY, V114, P657, DOI 10.1016/S0016-5085(98)70579-7; THOMAS DJ, 1993, J IMMUNOL, V150, P151; Wartenberg M, 2003, FASEB J, V17, P503, DOI 10.1096/fj.02-0358fje; Yamada K, 2004, J IMMUNOL, V172, P3869, DOI 10.4049/jimmunol.172.6.3869; Yokoyama K, 2001, HEPATO-GASTROENTEROL, V48, P401; Zampetaki A, 2004, FASEB J, V18, P1090, DOI 10.1096/fj.03-0991fje; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317	53	60	62	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					950	959		10.1096/fj.04-3251com	http://dx.doi.org/10.1096/fj.04-3251com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923405				2022-12-25	WOS:000230207800042
J	Roche, E; Sepulcre, P; Reig, JA; Santana, A; Soria, B				Roche, E; Sepulcre, P; Reig, JA; Santana, A; Soria, B			Ectodermal commitment of insulin-producing cells derived from mouse embryonic stem cells	FASEB JOURNAL			English	Article						neuroectoderm; pancreatic beta-cells; diabetes	SECRETING CELLS; TRANSCRIPTION FACTORS; ENDOCRINE PANCREAS; PLASMA-ALBUMIN; DIFFERENTIATION; EXPRESSION; GENES; PRECURSORS; PROGENITOR; LIVER	Embryonic stem cells possess the ability to differentiate in vitro into a variety of cell lineages, including insulin-producing cells. Pancreatic beta-cells derive from foregut endoderm during embryonic development. However, previous reports using transgenic mice strongly indicate that insulin-positive cells may be generated also through the neuroectoderm pathway. To analyze this point, a culture system was performed in which only ectoderm committed cells were present. Based on published work, we achieved this by maintaining transfected clonal R1 mouse embryonic stem cells in monolayer in the absence of LIF. Contrary to differentiation protocols via embryoid body formation, monolayer cultured cells displayed ectodermal fates according to the marker gene expression pattern. Under these particular conditions, neomycin was added in order to select insulin-expressing cells. The cell lineage obtained expressed Pdx1, Pax6, Isl1, AChE, MBP, TH, and GS genes, confirming ectodermal commitment, even though some of these factors are also expressed in endoderm. In addition these cells displayed excitatory properties similar to astrocytes. Co-expression of insulin II and nestin was observed in monolayer culture and in the presence of specific conditioned media. No expression of early endodermal markers was detected along monolayer cultures. Altogether, these observations suggest that cells with ectoderm fates could participate in vitro in the derivation of insulin-producing cells. These results have implications for insulin gene regulation and hormone secretion in order to generate insulin-producing cells for replacement protocols in the treatment of diabetes.	Univ Miguel Hernandez, Inst Bioingn, Alicante 03550, Spain; Natl Univ Singapore, Dept Surg, Singapore 117548, Singapore	Universidad Miguel Hernandez de Elche; National University of Singapore	Soria, B (corresponding author), Univ Miguel Hernandez, Inst Bioingn, Alicante 03550, Spain.	bemat.soria@umh.es	RODRIGUEZ, ALFREDO SANTANA/AAE-2934-2019; , Bernat/AAL-6470-2021; Roche, Enrique/V-5738-2017	RODRIGUEZ, ALFREDO SANTANA/0000-0002-1075-9948; Roche, Enrique/0000-0001-5128-1672; REIG MACIA, JUAN ANTONIO/0000-0002-5947-7183; Soria, Bernat/0000-0002-2356-0380				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; Anisimov SV, 2002, GENOMICS, V79, P169, DOI 10.1006/geno.2002.6687; Atouf F, 1995, J NEUROENDOCRINOL, V7, P957, DOI 10.1111/j.1365-2826.1995.tb00741.x; Blyszczuk P, 2003, P NATL ACAD SCI USA, V100, P998, DOI 10.1073/pnas.0237371100; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Chakrabarti SK, 2003, TRENDS ENDOCRIN MET, V14, P78, DOI 10.1016/S1043-2760(02)00039-5; Chu K, 2001, RECENT PROG HORM RES, V56, P23, DOI 10.1210/rp.56.1.23; de la Rosa EJ, 2000, TRENDS NEUROSCI, V23, P454, DOI 10.1016/S0166-2236(00)01628-3; DELTOUR L, 1993, P NATL ACAD SCI USA, V90, P527, DOI 10.1073/pnas.90.2.527; Dunn-Meynell AA, 1998, BRAIN RES, V814, P41, DOI 10.1016/S0006-8993(98)00956-1; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; HAKELIEN AM, 2004, BIOCH BIOPHYS RES CO; Hamazaki T, 2001, FEBS LETT, V497, P15, DOI 10.1016/S0014-5793(01)02423-1; Hernandez-Sanchez C, 2003, EMBO J, V22, P5582, DOI 10.1093/emboj/cdg515; Hernandez-Sanchez C, 2002, DIABETES, V51, P770, DOI 10.2337/diabetes.51.3.770; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Hori Y, 2002, P NATL ACAD SCI USA, V99, P16105, DOI 10.1073/pnas.252618999; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Kahan BW, 2003, DIABETES, V52, P2016, DOI 10.2337/diabetes.52.8.2016; Kim SK, 2001, GENE DEV, V15, P111, DOI 10.1101/gad.859401; Kojima H, 2004, P NATL ACAD SCI USA, V101, P2458, DOI 10.1073/pnas.0308690100; Kojima H, 2002, DIABETES, V51, P1398, DOI 10.2337/diabetes.51.5.1398; Kojima H, 2003, NAT MED, V9, P596, DOI 10.1038/nm867; Ku HT, 2004, STEM CELLS, V22, P1205, DOI 10.1634/stemcells.2004-0027; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Lemke Greg, 1993, Current Opinion in Neurobiology, V3, P703, DOI 10.1016/0959-4388(93)90141-K; Leon-Quinto T, 2004, DIABETOLOGIA, V47, P1442, DOI 10.1007/s00125-004-1458-8; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Maestre I, 2003, ENDOCRINOLOGY, V144, P335, DOI 10.1210/en.2001-211282; MARTIN F, 1995, DIABETOLOGIA, V38, P860, DOI 10.1007/s001250050364; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; NADAL A, 1995, P NATL ACAD SCI USA, V92, P1426, DOI 10.1073/pnas.92.5.1426; Nadal A, 1997, GLIA, V19, P343, DOI 10.1002/(SICI)1098-1136(199704)19:4<343::AID-GLIA7>3.0.CO;2-Y; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; Pachernik J, 2002, REPROD NUTR DEV, V42, P317, DOI 10.1051/rnd:2002028; Paparella M, 2002, TOXICOL IN VITRO, V16, P589, DOI 10.1016/S0887-2333(02)00052-8; Pattyn A, 2003, DEVELOPMENT, V130, P4149, DOI 10.1242/dev.00641; Perez-Villamil B, 1999, ENDOCRINOLOGY, V140, P3857, DOI 10.1210/en.140.8.3857; PEREZVILLAMIL B, 1994, ENDOCRINOLOGY, V135, P2342, DOI 10.1210/en.135.6.2342; PERLER F, 1980, CELL, V20, P555, DOI 10.1016/0092-8674(80)90641-8; Piper K, 2002, DIABETOLOGIA, V45, P1045, DOI 10.1007/s00125-002-0864-z; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Roche E, 2003, MED BIOL ENG COMPUT, V41, P384, DOI 10.1007/BF02348079; Roche E, 2003, CYTOTECHNOLOGY, V41, P145, DOI 10.1023/A:1024878807264; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Sipione S, 2004, DIABETOLOGIA, V47, P499, DOI 10.1007/s00125-004-1349-z; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Soria B, 2001, DIFFERENTIATION, V68, P205, DOI 10.1046/j.1432-0436.2001.680408.x; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Vicario-Abejon C, 2003, J NEUROSCI, V23, P895; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Wells JM, 2003, DIABETES-METAB RES, V19, P191, DOI 10.1002/dmrr.364; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Yamada T, 2002, STEM CELLS, V20, P41, DOI 10.1634/stemcells.20-1-41; Yang XJ, 1999, DIABETES, V48, P1763, DOI 10.2337/diabetes.48.9.1763; Yin Y, 2002, STEM CELLS, V20, P338, DOI 10.1634/stemcells.20-4-338; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Zalzman M, 2003, P NATL ACAD SCI USA, V100, P7253, DOI 10.1073/pnas.1136854100	67	29	72	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1341	+		10.1096/fj.04-3024fje	http://dx.doi.org/10.1096/fj.04-3024fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15928194	Green Published			2022-12-25	WOS:000229602600002
J	Loughran, G; Huigsloot, M; Kiely, PA; Smith, LM; Floyd, S; Ayllon, V; O'Connor, R				Loughran, G; Huigsloot, M; Kiely, PA; Smith, LM; Floyd, S; Ayllon, V; O'Connor, R			Gene expression profiles in cells transformed by overexpression of the IGF-I receptor	ONCOGENE			English	Article						IGF-I receptor; cancer; transformation; apoptosis; Mystique; lasp-1	INSULIN-LIKE-GROWTH; BREAST-CANCER; HEMATOPOIETIC-CELLS; MICROARRAY ANALYSIS; PROSTATE-CANCER; PROTEIN FAMILY; ANTISENSE RNA; FIBROBLASTS; BINDING; IDENTIFICATION	To identify genes associated with insulin-like growth factor-I receptor ( IGF-IR)-mediated cellular transformation, we isolated genes that are differentially expressed in R- cells ( derived from the IGF-IR knockout mouse) and R+ cells ( R- cells that overexpress the IGF-IR). From these, 45 genes of known function were expressed at higher levels in R+ cells and 22 were expressed at higher levels in R- cells. Differential expression was confirmed by Northern blot analysis of R+ and R+ cells. Genes expressed more abundantly in R+ cells are associated with ( 1) tumour growth and metastasis including, beta ig H3, mts1, igfbp5 protease, and mystique; ( 2) cell division, including cyclin A1 and cdk1; ( 3) signal transduction, including pkc delta bp and lmw-ptp; and ( 4) metabolism including ATPase H+ transporter and ferritin. In MCF-7 cells IGF-I induced expression of two genes, lasp-1 and mystique, which could contribute to metastasis. Lasp-1 expression required activity of the PI3-kinase signalling pathway. Mystique was highly expressed in metastatic but not in androgen-dependent prostate cancer cell lines and Mystique overexpression in MCF-7 cells promoted cell migration and invasion. We conclude that genes identified in this screen may mediate IGF-IR function in cancer progression.	Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Cork, Ireland	University College Cork	O'Connor, R (corresponding author), Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014; Ayllon, Veronica/L-7069-2014; Loughran, Gary/AAQ-8791-2020	O'Connor, Rosemary/0000-0002-0687-3422; Ayllon, Veronica/0000-0002-7322-9282; Loughran, Gary/0000-0002-2683-5597; Atkins, John/0000-0001-7933-0165				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dunn SE, 1998, CANCER RES, V58, P3353; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FIASCHI T, 2001, J BIOL CHEM, V10, P10; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hellawell GO, 2002, CANCER RES, V62, P2942; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Lee CT, 1996, CANCER RES, V56, P3038; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Liu TJ, 2001, CIRC RES, V88, P1231, DOI 10.1161/hh1201.092036; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1995, CANCER RES, V55, P1006; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; Mauro L, 2001, J BIOL CHEM, V276, P39892, DOI 10.1074/jbc.M106673200; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Tsujimoto H, 1999, MOL CARCINOGEN, V26, P298, DOI 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	43	36	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6185	6193		10.1038/sj.onc.1208772	http://dx.doi.org/10.1038/sj.onc.1208772			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940254				2022-12-25	WOS:000231718100012
J	Young, T; Mei, F; Liu, JS; Bast, RC; Kurosky, A; Cheng, XD				Young, T; Mei, F; Liu, JS; Bast, RC; Kurosky, A; Cheng, XD			Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defned human ovarian cancer model	ONCOGENE			English	Article						caspase 4; mass spectrometry; ovarian cancer; proteomics; ras; transformation	EPITHELIAL-CELLS; CATHEPSIN-D; POLYACRYLAMIDE-GELS; SIGNALING PATHWAY; MASS-SPECTROMETRY; GENE-MUTATIONS; CALPAIN; EXPRESSION; CARCINOMA; IDENTIFICATION	RAS is a small GTP binding protein mutated in approximately 30% human cancer. Despite its important role in the initiation and progression of human cancer, the underlying mechanism of RAS-induced human epithelial transformation remains elusive. In this study, we probe the cellular and molecular mechanisms of RAS-mediated transformation, by pro. ling two human ovarian epithelial cell lines. One cell line was immortalized with SV40T/t antigens and the human catalytic subunit of telomerase ( T29), while the second cell line was transformed with an additional oncogenic ras(V12) allele ( T29H). In total, 32 proteins associated with RAS-mediated transformation have been identified using peptide mass fingerprinting. These protein targets are involved in several cellular pathways, including metabolism, redox balance, calcium signaling, apoptosis, and cellular methylation. One such target, the 40kDa procaspase 4 is significantly upregulated at the protein level in RAS-transformed T29H cells, related directly to signaling through MEK, but not PI3 kinase. Cellular caspase 4 activity is, however, suppressed in the T29H cells, suggesting that the maturation process of caspase 4 is abrogated in RAS-transformed T29H cells. Consistent with this notion, transformed T29H cells were less susceptible to the toxic effects of anti-Fas antibody than were immortalized, nontransformed T29 cells, associated with less activation of caspase 4. This study demonstrates that functional proteomic analysis of a genetically defined cancer model provides a powerful approach toward systematically identifying cellular targets associated with oncogenic transformation.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	xcheng@utmb.edu	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R24CA088317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066170, R01GM060170] Funding Source: NIH RePORTER; NCI NIH HHS [R24CA88317, R24 CA088317] Funding Source: Medline; NHLBI NIH HHS [N01HV28184, N01-HV-28184] Funding Source: Medline; NIEHS NIH HHS [ES06676, P30 ES006676] Funding Source: Medline; NIGMS NIH HHS [GM060170, R01 GM066170, R01 GM060170] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; ARGILES JM, 1988, MOL CELL BIOCHEM, V81, P3; Balabanov S, 2001, EUR J BIOCHEM, V268, P5977, DOI 10.1046/j.0014-2956.2001.02546.x; Bao JJ, 2002, CANCER RES, V62, P7264; BERCHUCK A, 1990, CANCER RES, V50, P4087; Bernard K, 2003, CANCER RES, V63, P6716; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOS JL, 1989, CANCER RES, V49, P4682; CALAF G, 1994, BREAST CANCER RES TR, V29, P169, DOI 10.1007/BF00665678; Cao QJ, 2001, INT J GYNECOL PATHOL, V20, P346, DOI 10.1097/00004347-200110000-00006; Demoz M, 1999, J CELL BIOCHEM, V73, P370, DOI 10.1002/(SICI)1097-4644(19990601)73:3<370::AID-JCB8>3.0.CO;2-N; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jones MB, 2002, PROTEOMICS, V2, P76, DOI 10.1002/1615-9861(200201)2:1<76::AID-PROT76>3.3.CO;2-F; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li G, 2002, P NATL ACAD SCI USA, V99, P13254, DOI 10.1073/pnas.202355799; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Losch A, 2004, GYNECOL ONCOL, V92, P545, DOI 10.1016/j.ygyno.2003.11.016; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; Martin CA, 2002, AM J PHYSIOL-GASTR L, V282, pG92, DOI 10.1152/ajpgi.2002.282.1.G92; MATTHAEI KI, 1987, JNCI-J NATL CANCER I, V79, P805; Ostergaard M, 1997, CANCER RES, V57, P4111; Park KS, 2002, INT J CANCER, V97, P261, DOI 10.1002/ijc.1585; Patton SE, 1998, CANCER RES, V58, P2253; Rich JN, 2001, CANCER RES, V61, P3556; ROGERS J, 1990, ADV EXP MED BIOL, V269, P195; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Varras MN, 1999, ONCOLOGY-BASEL, V56, P89, DOI 10.1159/000011946; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Yu LR, 2000, ELECTROPHORESIS, V21, P3058, DOI 10.1002/1522-2683(20000801)21:14<3058::AID-ELPS3058>3.0.CO;2-U	43	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6174	6184		10.1038/sj.onc.1208753	http://dx.doi.org/10.1038/sj.onc.1208753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940260	Green Accepted			2022-12-25	WOS:000231718100011
J	Grewal, T; Evans, R; Rentero, C; Tebar, F; Cubells, L; de Diego, I; Kirchhoff, MF; Hughes, WE; Heeren, J; Rye, KA; Rinninger, F; Daly, RJ; Pol, A; Enrich, C				Grewal, T; Evans, R; Rentero, C; Tebar, F; Cubells, L; de Diego, I; Kirchhoff, MF; Hughes, WE; Heeren, J; Rye, KA; Rinninger, F; Daly, RJ; Pol, A; Enrich, C			Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity	ONCOGENE			English	Article						Ras; Raf-1; HDL; EGF; annexin 6A; p120GAP	PROTEIN-PROTEIN INTERACTIONS; DENSITY-LIPOPROTEINS INDUCE; SMOOTH-MUSCLE CELLS; KINASE-C-ALPHA; BINDING DOMAIN; SCAVENGER RECEPTOR; PLASMA-MEMBRANE; VI; CALCIUM; ACTIVATION	Annexin A6 is a calcium-dependent membrane-binding protein that interacts with signalling proteins, including the GTPase-activating protein p120GAP, one of the most important inactivators of Ras. Since we have demonstrated that annexin A6 inhibits EGF- and TPA-induced Ras signalling, we investigated whether modulation of Ras activity by annexin A6 was mediated via altered subcellular localization of p120GAP. First, we exploited our observation that high-density lipoproteins (HDL) can activate the Ras/MAP kinase pathway. Expression of annexin A6 caused a significant reduction in HDL-induced activation of Ras and Raf-1. Annexin A6 promoted membrane binding of p120GAP in vitro, and plasma membrane targeting of p120GAP in living cells, both in a Ca2+-dependent manner, which is consistent with annexin A6 promoting the Ca2+-dependent assembly of p120GAP-Ras at the plasma membrane. We then extended these studies to other cell types and stimuli. Expression of annexin A6 in A431 cells reduced, while RNAi-mediated suppression of annexin A6 in HeLa cells enhanced EGF- induced Ras and Erk activation. Importantly, the enhancement of Ras activation following RNAi-mediated reduction in p120GAP levels was more marked in annexin A6-expressing A431 cells than controls, indicating that the effect of annexin A6 on Ras was mediated via p120GAP. Finally, we demonstrated that annexin A6 promotes plasma membrane targeting of p120GAP in A431 cells in response to a variety of stimuli, resulting in colocalization with H-Ras. These findings demonstrate an important role for annexin A6 in regulating plasma membrane localization of p120GAP and hence Ras activity.	Univ Barcelona, Fac Med, Dept Cellular Biol, IDIBAPS, E-08036 Barcelona, Spain; Univ New S Wales, St Vincents Hosp, Ctr Immunol, Kensington, NSW 2033, Australia; Univ Hamburg, Hosp Eppendorf, Dept Mol Cell Biol, Inst Med Biochem & Mol Biol, D-20246 Hamburg, Germany; Garvan Inst Med Res, Sydney, NSW, Australia; Heart Res Inst, Camperdown, NSW, Australia; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of New South Wales Sydney; University of Hamburg; Garvan Institute of Medical Research; University of Sydney; Heart Research Institute; University of Hamburg	Enrich, C (corresponding author), Univ Barcelona, Fac Med, Dept Cellular Biol, IDIBAPS, Casanova 143, E-08036 Barcelona, Spain.	enrich@ub.edu	de Diego Martinez, Iñaki/AAB-4712-2019; Rentero Alfonso, Carles/L-4430-2017; Tebar, Francesc/H-1498-2015; Daly, Roger J/C-8179-2009; Pol, Albert/M-1865-2014	de Diego Martinez, Iñaki/0000-0002-6156-4032; Rentero Alfonso, Carles/0000-0003-4684-0278; Tebar, Francesc/0000-0002-9522-9726; Pol, Albert/0000-0002-1750-1085; Hughes, William/0000-0002-7149-3987; Daly, Roger/0000-0002-5739-8027; Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				BANDOROWICZPIKU.J, 2004, ANNEXINS, V1, P68; BAREL M, 1991, J IMMUNOL, V147, P1286; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; BOCHKOV V, 1992, BIOCHEM BIOPH RES CO, V188, P1295, DOI 10.1016/0006-291X(92)91372-W; CHECUTI A, 2001, CANCER RES, V61, P6331; Chow A, 1999, FEBS LETT, V460, P166, DOI 10.1016/S0014-5793(99)01336-8; Chow A, 1999, CELL SIGNAL, V11, P443, DOI 10.1016/S0898-6568(99)00015-7; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Fleet A, 1999, BIOCHEM BIOPH RES CO, V260, P540, DOI 10.1006/bbrc.1999.0915; Francia G, 1996, CANCER RES, V56, P3855; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; GAWLER DJ, 1995, ONCOGENE, V10, P817; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; GREWAL T, 2004, ANNEXINS, V1, P62; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hawkins TE, 1999, MOL CELL BIOL, V19, P8028; Hayes MJ, 2004, BIOCHEM BIOPH RES CO, V322, P1166, DOI 10.1016/j.bbrc.2004.07.124; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Honda HM, 1999, ATHEROSCLEROSIS, V143, P299, DOI 10.1016/S0021-9150(98)00302-5; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; KING ICL, 1986, BIOCHEM BIOPH RES CO, V140, P837, DOI 10.1016/0006-291X(86)90710-2; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; Ling Q, 2004, J CLIN INVEST, V113, P38, DOI 10.1172/JCI200419684; Liu JW, 2003, ONCOGENE, V22, P1475, DOI 10.1038/sj.onc.1206196; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; Nofer JR, 2000, BIOCHEMISTRY-US, V39, P15199, DOI 10.1021/bi001162a; O'Malley DM, 1999, METH MOL B, V122, P261; Orito A, 2001, J NEUROSCI RES, V64, P235, DOI 10.1002/jnr.1071; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Pons M, 2001, FEBS LETT, V501, P69, DOI 10.1016/S0014-5793(01)02635-7; PORN MI, 1991, BIOCHEM J, V279, P29; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; Schmitz-Peiffer C, 1998, BIOCHEM J, V330, P675, DOI 10.1042/bj3300675; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THEOBALD J, 1994, BBA-MOL CELL RES, V1223, P383, DOI 10.1016/0167-4889(94)90099-X; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Van Ginkel PR, 1998, BBA-MOL CELL RES, V1448, P290, DOI 10.1016/S0167-4889(98)00133-5; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Walker SA, 2003, FEBS LETT, V546, P6, DOI 10.1016/S0014-5793(03)00412-5; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123	56	81	86	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5809	5820		10.1038/sj.onc.1208743	http://dx.doi.org/10.1038/sj.onc.1208743			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15940262				2022-12-25	WOS:000231590400003
J	Anyatonwu, GI; Ehrlich, BE				Anyatonwu, GI; Ehrlich, BE			Organic cation permeation through the channel formed by polycystin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR-CHANNEL; CALCIUM-RELEASE CHANNEL; KIDNEY-DISEASE; PORE ARCHITECTURE; POTASSIUM; EXPRESSION; CONDUCTANCE; MECHANISMS; CURRENTS; SODIUM	Polycystin-2 (PC2), a member of the transient receptor potential family of ion channels (TRPP2), forms a calcium-permeable cation channel. Mutations in PC2 lead to polycystic kidney disease. From the primary sequence and by analogy with other channels in this family, PC2 is modeled to have six transmembrane domains. However, most of the structural features of PC2, such as how large the channel is and how many subunits make up the pore of the channel, are unknown. In this study, we estimated the pore size of PC2 from the permeation properties of the channel. Organic cations of increasing size were used as current carriers through the PC2 channel after PC2 was incorporated into lipid bilayers. We found that dimethylamine, triethylamine, tetraethylammonium, tetrabutylammonium, tetrapropylammonium, and tetrapentylammonium were permeable through the PC2 channel. The slope conductance of the PC2 channel decreased as the ionic diameter of the organic cation increased. For each organic cation tested, the currents were inhibited by gadolinium and anti-PC2 antibody. Using the dimensions of the largest permeant cation, the minimum pore diameter of the PC2 channel was estimated to be at least 11 angstrom. The large pore size suggests that the primary state of this channel found in vivo is closed to avoid rundown of cation gradients across the plasma membrane and excessive calcium leak from endoplasmic reticulum stores.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Ehrlich, BE (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	barbara.ehrlich@yale.edu	/AAX-8408-2021	/0000-0001-9657-9704	NIDDK NIH HHS [5F31DK062635] Funding Source: Medline; NIGMS NIH HHS [T32-GM07324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F31DK062635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Anyatonwu GI, 2003, J BIOL CHEM, V278, P45528, DOI 10.1074/jbc.M307863200; CAI Y, 2004, J BIOL CHEM; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Devuyst O, 1996, AM J PHYSIOL-RENAL, V271, pF169, DOI 10.1152/ajprenal.1996.271.1.F169; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Gustafsson AJ, 2004, FASEB J, V18, P301, DOI 10.1096/fj.04-2621fje; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hanaoka K, 2000, J AM SOC NEPHROL, V11, P1179, DOI 10.1681/ASN.V1171179; Hille B, 2001, ION CHANNELS EXCITAB, P21; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Huang CJ, 2000, J GEN PHYSIOL, V115, P435, DOI 10.1085/jgp.115.4.435; Ikeda M, 2002, CURR OPIN NEPHROL HY, V11, P539, DOI 10.1097/00041552-200209000-00010; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; KIM DH, 1983, J BIOL CHEM, V258, P9662; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; LINDSAY ARG, 1991, J PHYSIOL-LONDON, V439, P463, DOI 10.1113/jphysiol.1991.sp018676; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Ohki G, 2000, J BIOL CHEM, V275, P39055, DOI 10.1074/jbc.M003606200; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Quinn KE, 1997, J GEN PHYSIOL, V109, P255, DOI 10.1085/jgp.109.2.255; RAYMOND L, 1985, J MEMBRANE BIOL, V84, P173, DOI 10.1007/BF01872215; Schwiebert EM, 2002, AM J PHYSIOL-RENAL, V282, pF763, DOI 10.1152/ajprenal.0337.2000; Tarroni P, 1997, J BIOL CHEM, V272, P19808, DOI 10.1074/jbc.272.32.19808; TINKER A, 1992, BIOPHYS J, V61, P1122, DOI 10.1016/S0006-3495(92)81922-7; TINKER A, 1993, J GEN PHYSIOL, V102, P1107, DOI 10.1085/jgp.102.6.1107; TINKER A, 1993, BIOPHYS J, V65, P1678, DOI 10.1016/S0006-3495(93)81201-3; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Voets T, 2004, J BIOL CHEM, V279, P15223, DOI 10.1074/jbc.M312076200; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Williams AJ, 2001, Q REV BIOPHYS, V34, P61, DOI 10.1017/S0033583501003675; Wilson PD, 2000, AM J PATHOL, V156, P253, DOI 10.1016/S0002-9440(10)64726-8; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; Wu GQ, 1997, GENOMICS, V45, P220, DOI 10.1006/geno.1997.4920; Wu GQ, 2000, MOL GENET METAB, V69, P1, DOI 10.1006/mgme.1999.2943; XU M, 1993, J BIOL CHEM, V268, P21505; Zhorov BS, 2004, J NEUROCHEM, V88, P782, DOI 10.1111/j.1471-4159.2004.02261.x	44	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29488	29493		10.1074/jbc.M504359200	http://dx.doi.org/10.1074/jbc.M504359200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15961385	hybrid			2022-12-25	WOS:000231176200014
J	Hicks, SW; Machamer, CE				Hicks, SW; Machamer, CE			Isoform-specific interaction of golgin-160 with the Golgi-associated protein PIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY GTPASE TC10; COILED-COIL; MOLECULAR CHARACTERIZATION; MEMBRANE-PROTEIN; DOMAIN; COMPLEX; EFFECTOR; IDENTIFICATION; EXPRESSION; APOPTOSIS	Golgin-160 belongs to the golgin family of Golgi-localized proteins, which have been implicated in Golgi structure and function. Golgin-160 possesses an N-terminal non-coiled- coil "head" domain followed by an extensive coiled-coil region. Using the N-terminal head domain of golgin-160 as bait in a yeast two-hybrid screen, the postsynaptic density-95/Discs large/zona occludens-1 ((P) under bar DZ) domain protein interacting specifically with (T) under bar C10 ( PIST) was identified to interact with golgin-160. PIST ( also known as GOPC, CAL, and FIG) has been implicated in the trafficking of a subset of plasma membrane proteins, supporting a role of golgin-160 in vesicular trafficking. Golgin-160 and PIST colocalize to Golgi membranes and interact in vivo. Glutathione S-transferase binding experiments identified an internal region of PIST that includes a coiled-coil domain, which interacts directly with golgin-160. Similar binding experiments identified a leucine-rich repeat within golgin-160 necessary for interaction with PIST. Therefore, our data suggest that golgin-160 may participate in PIST-dependent trafficking of cargo. Interestingly, we also discovered a widely expressed isoform of golgin-160, golgin-160B, which lacks the exon encoding the leucine repeat that mediates binding to PIST. As predicted, golgin-160B was unable to bind PIST. Full-length golgin-160 and golgin-160B may link distinct subsets of proteins to effect specific membrane trafficking pathways.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Machamer, CE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 Wolfe St, Baltimore, MD 21205 USA.	machamer@jhmi.edu	Hicks, Stuart/R-9815-2019		NIGMS NIH HHS [GM42522] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Bascom RA, 1999, J BIOL CHEM, V274, P2953, DOI 10.1074/jbc.274.5.2953; Cha H, 2004, J CELL SCI, V117, P751, DOI 10.1242/jcs.00897; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2005, J BIOL CHEM, V280, P3731, DOI 10.1074/jbc.M410026200; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Diao A, 2003, J CELL BIOL, V160, P201, DOI 10.1083/jcb.200207045; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; He JQ, 2004, J BIOL CHEM, V279, P50190, DOI 10.1074/jbc.M404876200; Hicks SW, 2002, J BIOL CHEM, V277, P35833, DOI 10.1074/jbc.M206280200; Hruska-Hageman AM, 2004, J BIOL CHEM, V279, P46962, DOI 10.1074/jbc.M405874200; Ives JH, 2004, J BIOL CHEM, V279, P31002, DOI 10.1074/jbc.M402214200; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lu L, 2004, MOL BIOL CELL, V15, P4426, DOI 10.1091/mbc.E03-12-0872; Maag RS, 2005, MOL BIOL CELL, V16, P3019, DOI 10.1091/mbc.E04-11-0971; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Selimi F, 2003, NEURON, V37, P813, DOI 10.1016/S0896-6273(03)00093-X; Short B, 2001, J CELL BIOL, V155, P877, DOI 10.1083/jcb.200108079; Shorter J, 2002, J CELL BIOL, V157, P45, DOI 10.1083/jcb.200112127; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430	34	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28944	28951		10.1074/jbc.M504937200	http://dx.doi.org/10.1074/jbc.M504937200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15951434	hybrid			2022-12-25	WOS:000231021300015
J	Padyana, AK; Qiu, HF; Roll-Mecak, A; Hinnebusch, AG; Burley, SK				Padyana, AK; Qiu, HF; Roll-Mecak, A; Hinnebusch, AG; Burley, SK			Structural basis for autoinhibition and mutational activation of eukaryotic initiation factor 2 alpha protein kinase GCN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; UNCHARGED TRANSFER-RNA; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; BINDING; DOMAIN; PHOSPHORYLATION; DIMERIZATION; RIBOSOMES; INTERACTS	The GCN2 protein kinase coordinates protein synthesis with levels of amino acid stores by phosphorylating eukaryotic translation initiation factor 2. The autoinhibited form of GCN2 is activated in cells starved of amino acids by binding of uncharged tRNA to a histidyl-tRNA synthetase-like domain. Replacement of Arg-794 with Gly in the PK domain (R794G) activates GCN2 independently of tRNA binding. Crystal structures of the GCN2 protein kinase domain have been determined for wild-type and R794G mutant forms in the apo state and bound to ATP/AMPPNP. These structures reveal that GCN2 autoinhibition results from stabilization of a closed conformation that restricts ATP binding. The R794G mutant shows increased flexibility in the hinge region connecting the N- and C- lobes, resulting from loss of multiple interactions involving Arg(794). This conformational change is associated with intradomain movement that enhances ATP binding and hydrolysis. We propose that intramolecular interactions following tRNA binding remodel the hinge region in a manner similar to the mechanism of enzyme activation elicited by the R794G mutation.	Struct GenomiX Inc, San Diego, CA 92121 USA; Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94107 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California San Francisco	Burley, SK (corresponding author), Struct GenomiX Inc, 10505 Roselle St, San Diego, CA 92121 USA.	sburley@stromix.com		Burley, Stephen K./0000-0002-2487-9713; Roll-Mecak, Antonina/0000-0003-2621-7307	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061262] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061262-05] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberg A, 1997, BIOCHEMISTRY-US, V36, P3084, DOI 10.1021/bi9618373; Adams J, 2002, CURR OPIN CHEM BIOL, V6, P486, DOI 10.1016/S1367-5931(02)00357-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARNEZ JG, 1995, EMBO J, V14, P4143, DOI 10.1002/j.1460-2075.1995.tb00088.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hao SZ, 2005, SCIENCE, V307, P1776, DOI 10.1126/science.1104882; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kubota H, 2001, J BIOL CHEM, V276, P17591, DOI 10.1074/jbc.M011793200; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Narasimhan J, 2004, J BIOL CHEM, V279, P22820, DOI 10.1074/jbc.M402228200; Qiu H, 2001, EMBO J, V20, P1425, DOI 10.1093/emboj/20.6.1425; Qiu HF, 2002, GENE DEV, V16, P1271, DOI 10.1101/gad.979402; Qiu HF, 1998, MOL CELL BIOL, V18, P2697, DOI 10.1128/MCB.18.5.2697; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sood R, 2000, GENETICS, V154, P787; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	53	85	88	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29289	29299		10.1074/jbc.M504096200	http://dx.doi.org/10.1074/jbc.M504096200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15964839	hybrid			2022-12-25	WOS:000231021300060
J	Choi, YJ; Ryu, KS; Ko, YM; Chae, YK; Pelton, JG; Wemmer, DE; Choi, BS				Choi, YJ; Ryu, KS; Ko, YM; Chae, YK; Pelton, JG; Wemmer, DE; Choi, BS			Biophysical characterization of the interaction domains and mapping of the contact residues in the XPF-ERCC1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; DNA-BINDING; PROTEIN; ERCC1; ENDONUCLEASE; XPF; NUCLEASE; RECOGNITION	XPF and ERCC1 exist as a heterodimer to be stable and active in cells and catalyze DNA cleavage on the 5'-side of a lesion during nucleotide excision repair. To characterize the specific interaction between XPF and ERCC1, we expressed the human ERCC1 binding domain of XPF (XPF-EB) and the XPF binding domain of ERCC1 (ERCC1-FB) in Escherichia coli. Milligram quantities of a heterodimer were characterized with gel filtration chromatography, an Ni2+-NTA binding assay, and analytical ultracentrifugation. Cross-linking experiments at high salt concentrations revealed that XPF interacts with ERCC1 mainly through hydrophobic interactions. XPF-EB was also shown to homodimerize in the absence of ERCC1. NMR cross-saturation methods were applied to map the residues involved in formation of the XPF-(EBXPF)-X-.-EB homodimer and the XPF-EB -ERCC1-FB heterodimer. Helix H3 and the C-terminal region of XPF-EB were either within or in close proximity to the homodimer interface, whereas the ERCC1-FB binding site of XPF-EB was distributed across helix H1, a small part of H2, H3, and the C-terminal region, most of which exhibited large changes in chemical shift upon ERCC1 binding. The XPF-EB heterodimeric interface is larger than the XPF-EB homodimeric one, which could explain why XPF has a stronger affinity for ERCC1 than for a second molecule of XPF. The XPF binding sites of ERCC1 were located in helices H1 and H3 and in the C-terminal region, similar to the involved surface of XPF. We used cross-saturation data and the crystal structure of related proteins to model the two complexes.	Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Sejong Univ, Dept Appl Chem, Seoul 143747, South Korea; Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr, Taejon 305701, South Korea	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Sejong University; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Wemmer, DE (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA.	dewemmer@lbl.gov; byongseok.choi@kaist.ac.kr	Choi, Byong-Seok/C-1937-2011					ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; Benhamou S, 2000, MUTAT RES-REV MUTAT, V462, P149, DOI 10.1016/S1383-5742(00)00032-6; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Creighton TE, 1997, BIOL CHEM, V378, P731; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; de Laat WL, 1998, NUCLEIC ACIDS RES, V26, P4146, DOI 10.1093/nar/26.18.4146; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gaillard PHL, 2001, NUCLEIC ACIDS RES, V29, P872, DOI 10.1093/nar/29.4.872; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; Kupce E, 1995, J MAGN RESON SER A, V117, P246, DOI 10.1006/jmra.1995.0750; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; McCutchen-Maloney SL, 1999, BIOCHEMISTRY-US, V38, P9417, DOI 10.1021/bi990591+; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Newman M, 2005, EMBO J, V24, P895, DOI 10.1038/sj.emboj.7600581; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shao XG, 2000, NUCLEIC ACIDS RES, V28, P2643, DOI 10.1093/nar/28.14.2643; Sijbers AM, 1998, J INVEST DERMATOL, V110, P832, DOI 10.1046/j.1523-1747.1998.00171.x; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Singh S, 2002, EMBO J, V21, P6257, DOI 10.1093/emboj/cdf627; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Suenaga M, 1998, BIOTECHNOL APPL BIOC, V28, P119; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; VANDUIN M, 1989, MUTAT RES, V217, P83, DOI 10.1016/0921-8777(89)90059-1; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; Wishart DS, 1997, J BIOMOL NMR, V10, P329, DOI 10.1023/A:1018373822088; Wuthrich K, 2000, NAT STRUCT BIOL, V7, P188, DOI 10.1038/73278; Yagi T, 1997, MUTAGENESIS, V12, P41, DOI 10.1093/mutage/12.1.41; Yagi T, 1998, CARCINOGENESIS, V19, P55, DOI 10.1093/carcin/19.1.55	43	37	38	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28644	28652		10.1074/jbc.M501083200	http://dx.doi.org/10.1074/jbc.M501083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15932882	hybrid			2022-12-25	WOS:000230857300055
J	Vassilopoulos, S; Thevenon, D; Rezgui, SS; Brocard, J; Chapel, A; Lacampagne, A; Lunardi, J; DeWaard, M; Marty, I				Vassilopoulos, S; Thevenon, D; Rezgui, SS; Brocard, J; Chapel, A; Lacampagne, A; Lunardi, J; DeWaard, M; Marty, I			Triadins are not triad-specific proteins - Two new skeletal muscle triadins possibly involved in the architecture of sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL FOOT PROTEIN; RYANODINE RECEPTOR; DIHYDROPYRIDINE RECEPTOR; MOLECULAR DETERMINANTS; MONOCLONAL-ANTIBODIES; GLYCOPROTEIN TRIADIN; CARDIAC TRIADIN; MESSENGER-RNA; LOCALIZATION; CA2+	We have cloned two new triadin isoforms from rat skeletal muscle, Trisk 49 and Trisk 32, which were named according to their theoretical molecular masses ( 49 and 32 kDa, respectively). Specific antibodies directed against each protein were produced to characterize both new triadins. Both are expressed in adult rat skeletal muscle, and their expression in slow twitch muscle is lower than that in fast twitch muscle. Using double immunofluorescent labeling, the localization of these two triadins was studied in comparison to well-characterized proteins such as ryanodine receptor, calsequestrin, desmin, Ca2+-ATPase, and titin. None of these two triadins are localized within the rat skeletal muscle triad. Both are instead found in different parts of the longitudinal sarcoplasmic reticulum. We attempted to identify partners for each isoform: neither is associated with ryanodine receptor; Trisk 49 could be associated with titin or another sarcomeric protein; and Trisk 32 could be associated with IP3 receptor. These results open further fields of research concerning the functions of these two proteins; in particular, they could be involved in the set up and maintenance of a precise sarcoplasmic reticulum structure.	CEA, DRDC, INSERM, CCFP,U607,Lab Chim Prot, F-38054 Grenoble, France; INSERM, U607, Lab Canaux Cal Fonct & Pathol, F-38054 Grenoble, France; Univ Grenoble 1, F-38000 Grenoble, France; INSERM, U637, IFR 3, F-34095 Montpellier, France; CHU Arnaud Villeneuve, F-3400 Montpellier, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Marty, I (corresponding author), CEA, DRDC, INSERM, CCFP,U607,Lab Chim Prot, 17 Rue Martyrs, F-38054 Grenoble, France.	imarty@cea.fr	Marty, Isabelle/N-7114-2017; De Waard, Michel/G-7406-2014; vassilopoulos, stéphane/F-6041-2014; Marty, Isabelle/ABF-5362-2020; vassilopoulos, stephane/AAF-3865-2021; Lacampagne, Alain/S-3719-2016	De Waard, Michel/0000-0002-2782-9615; Marty, Isabelle/0000-0003-3625-913X; vassilopoulos, stephane/0000-0003-0172-330X; Lacampagne, Alain/0000-0003-0264-1787; Brocard, Julie/0000-0001-9345-5191				Bagnato P, 2003, J CELL BIOL, V160, P245, DOI 10.1083/jcb.200208109; Bottinelli R, 2000, PROG BIOPHYS MOL BIO, V73, P195, DOI 10.1016/S0079-6107(00)00006-7; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; Brini M, 2003, CELL CALCIUM, V34, P399, DOI 10.1016/S0143-4160(03)00145-3; Brown IE, 1998, J MUSCLE RES CELL M, V19, P473, DOI 10.1023/A:1005309107903; Carninci P, 1998, P NATL ACAD SCI USA, V95, P520, DOI 10.1073/pnas.95.2.520; Caswell AH, 1999, BIOCHEMISTRY-US, V38, P90, DOI 10.1021/bi981306+; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; DeSmedt H, 1997, BIOCHEM J, V322, P575; EISENBERG BR, 1976, J ULTRA MOL STRUCT R, V54, P76, DOI 10.1016/S0022-5320(76)80010-X; ENOUF J, 1988, J BIOL CHEM, V263, P13922; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; Filippin L, 2003, J BIOL CHEM, V278, P39224, DOI 10.1074/jbc.M302301200; FLUCHER BE, 1992, DEV BIOL, V154, P245, DOI 10.1016/0012-1606(92)90065-O; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; Franzini-Armstrong C, 1994, MYOLOGY, V1, P176; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1990, FEBS LETT, V267, P85, DOI 10.1016/0014-5793(90)80294-S; Groh S, 1999, J BIOL CHEM, V274, P12278, DOI 10.1074/jbc.274.18.12278; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; Hong CS, 2001, GENE, V278, P193, DOI 10.1016/S0378-1119(01)00718-1; Ito K, 2001, J CELL BIOL, V154, P1059, DOI 10.1083/jcb.200105040; JORGENSEN AO, 1982, J CELL BIOL, V92, P409, DOI 10.1083/jcb.92.2.409; Kaisto T, 2003, EXP CELL RES, V289, P47, DOI 10.1016/S0014-4827(03)00231-3; Kee AJ, 2004, J CELL BIOL, V166, P685, DOI 10.1083/jcb.200406181; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; Kobayashi YM, 2000, J BIOL CHEM, V275, P17639, DOI 10.1074/jbc.M002091200; Kobayashi YM, 1999, J BIOL CHEM, V274, P28660, DOI 10.1074/jbc.274.40.28660; KOPACZYK K, 1968, ARCH BIOCHEM BIOPHYS, V123, P602, DOI 10.1016/0003-9861(68)90181-1; Lee HG, 2001, J BIOL CHEM, V276, P39533, DOI 10.1074/jbc.M010664200; Lee JM, 2004, J BIOL CHEM, V279, P6994, DOI 10.1074/jbc.M312446200; LIU GH, 1994, J BIOL CHEM, V269, P33028; LUNARDI J, 1989, FEBS LETT, V245, P223, DOI 10.1016/0014-5793(89)80226-1; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MARTY I, 1995, BIOCHEM J, V307, P769, DOI 10.1042/bj3070769; Marty I, 2000, J BIOL CHEM, V275, P8206, DOI 10.1074/jbc.275.11.8206; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; Mizuno Y, 1999, NUCLEIC ACIDS RES, V27, P1345, DOI 10.1093/nar/27.5.1345; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; Powell JA, 2001, J CELL SCI, V114, P3673; Rudolf R, 2004, J CELL BIOL, V166, P527, DOI 10.1083/jcb.200403102; Salanova M, 2002, CELL CALCIUM, V32, P193, DOI 10.1016/S0143416002001549; Shin DW, 2000, FEBS LETT, V486, P178, DOI 10.1016/S0014-5793(00)02246-8; Skeie GO, 2000, CELL MOL LIFE SCI, V57, P1570, DOI 10.1007/PL00000642; Sorrentino V, 2004, BBA-MOL CELL RES, V1742, P113, DOI 10.1016/j.bbamcr.2004.08.016; Thevenon D, 2003, BIOCHEM BIOPH RES CO, V303, P669, DOI 10.1016/S0006-291X(03)00406-6; TOKUYASU KT, 1983, J CELL BIOL, V96, P1727, DOI 10.1083/jcb.96.6.1727; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Vermassen E, 2004, BIOL CELL, V96, P3, DOI 10.1016/j.biolcel.2003.11.004; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	55	31	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28601	28609		10.1074/jbc.M501484200	http://dx.doi.org/10.1074/jbc.M501484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15927957	Green Submitted, hybrid, Green Accepted			2022-12-25	WOS:000230857300051
J	Torrano, V; Chernukhin, I; Docquier, F; D'Arcy, V; Leon, J; Klenova, E; Delgado, MD				Torrano, V; Chernukhin, I; Docquier, F; D'Arcy, V; Leon, J; Klenova, E; Delgado, MD			CTCF regulates growth and erythroid differentiation of human myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULATOR PROTEIN CTCF; C-MYC GENE; TRANSCRIPTION FACTOR; ENHANCER BLOCKING; BINDING-SITES; EXPRESSION; METHYLATION; DNA; PHOSPHORYLATION; EPIGENETICS	CTCF is a transcription factor and a candidate tumor suppressor that contains a DNA-binding domain composed of 11 zinc fingers. We reported previously that CTCF is differentially regulated during differentiation of human myeloid leukemia cells. In this study we aimed to investigate the role of CTCF in myeloid cell differentiation. A human cell line, K562, that can be chemically induced to differentiate into various hematopoietic lineages was chosen as a model system for this study. Several K562 cell lines with constitutive and conditional expression of CTCF have been generated. By using these model systems we demonstrated that: (i) ectopic expression of CTCF in K562 cells led to growth retardation and promotion of differentiation into the erythroid lineage; (ii) CTCF knock-down significantly inhibited differentiation of K562 cells into erythroid lineage; (iii) differentiation of K562 into the megakaryocytic lineage was not significantly affected; and (iv) down-regulation of MYC has been identified as one of the mechanisms by which CTCF promotes erythroid differentiation. Taken together our results demonstrate that CTCF is involved in the control of myeloid cell growth and differentiation.	Univ Essex, Dept Sci Biol, Colchester CO4 3SQ, Essex, England; Univ Cantabria, CSIC, Dept Biol Mol, Grp Biol Mol Canc,Unidad Biomed, Santander 39011, Spain	University of Essex; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC)	Klenova, E (corresponding author), Univ Essex, Dept Sci Biol, Wivenhoe Pk,Cent Campus, Colchester CO4 3SQ, Essex, England.	klenovae@essex.ac.uk	Leon, Javier/K-4615-2014; Torrano Moya, Veronica/D-3285-2014; Delgado, M. Dolores/K-9056-2014	Leon, Javier/0000-0001-5803-0112; Delgado, M. Dolores/0000-0003-4682-4040; Torrano, Veronica/0000-0002-4252-1977	Wellcome Trust Funding Source: Medline; Breast Cancer Now [2000:137] Funding Source: Medline; Worldwide Cancer Research [99-0514] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission); Breast Cancer Now; Worldwide Cancer Research		Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bieker J J, 1998, Curr Opin Hematol, V5, P145; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; Chao W, 2002, SCIENCE, V295, P345, DOI 10.1126/science.1065982; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DELGADO MD, 1992, CANCER RES, V52, P5979; Delgado MD, 1999, FEBS LETT, V444, P5, DOI 10.1016/S0014-5793(99)00013-7; DELGADO MD, 1995, ONCOGENE, V10, P1659; Drexler HG, 2000, LEUKEMIA RES, V24, P881, DOI 10.1016/S0145-2126(00)00070-9; Dunn KL, 2003, BIOCHEM CELL BIOL, V81, P161, DOI 10.1139/o03-052; El-Kady A, 2005, FEBS LETT, V579, P1424, DOI 10.1016/j.febslet.2005.01.044; Farrell CM, 2002, MOL CELL BIOL, V22, P3820, DOI 10.1128/MCB.22.11.3820-3831.2002; Filippova GN, 2002, CANCER RES, V62, P48; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; Filippova GN, 2001, NAT GENET, V28, P335, DOI 10.1038/ng570; Garrick D, 1996, NUCLEIC ACIDS RES, V24, P4902, DOI 10.1093/nar/24.24.4902; Gombert WM, 2003, MOL CELL BIOL, V23, P9338, DOI 10.1128/MCB.23.24.9338-9348.2003; GOMEZCASARES MT, 1993, LEUKEMIA, V7, P1824; Harlow E., 1988, ANTIBODIES LAB MANUA; HENRY C, 1980, SELECTED METHODS CEL, P138; Jones  LK, 2002, BRIT J HAEMATOL, V118, P714, DOI 10.1046/j.1365-2141.2002.03586.x; Kang CD, 1999, EXP MOL MED, V31, P76, DOI 10.1038/emm.1999.13; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Klenova E, 2005, CELL CYCLE, V4, P96, DOI 10.4161/cc.4.1.1398; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Klenova EM, 2001, MOL CELL BIOL, V21, P2221, DOI 10.1128/MCB.21.6.2221-2234.2001; Kuzmin I, 2005, J MOL BIOL, V346, P411, DOI 10.1016/j.jmb.2004.11.066; Lerga A, 1999, CELL GROWTH DIFFER, V10, P639; Lewis JL, 2001, BLOOD, V97, P2604, DOI 10.1182/blood.V97.9.2604; Lutz M, 2003, EMBO J, V22, P1579, DOI 10.1093/emboj/cdg147; Mukhopadhyay R, 2004, GENOME RES, V14, P1594, DOI 10.1101/gr.2408304; Munoz-Alonso MJ, 2005, J BIOL CHEM, V280, P18120, DOI 10.1074/jbc.M500758200; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Perry C, 2002, EUR J BIOCHEM, V269, P3607, DOI 10.1046/j.1432-1033.2002.02999.x; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Qi CF, 2003, P NATL ACAD SCI USA, V100, P633, DOI 10.1073/pnas.0237127100; Rakha EA, 2004, BRIT J CANCER, V91, P1591, DOI 10.1038/sj.bjc.6602144; Rasko JEJ, 2001, CANCER RES, V61, P6002; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; Sambrook J, 2001, MOL CLONING LAB MANU; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; Yeh A, 2002, GENE CHROMOSOME CANC, V35, P156, DOI 10.1002/gcc.10110; Youssef EM, 2004, CANCER RES, V64, P2411, DOI 10.1158/0008-5472.CAN-03-0164; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426; Zhang R, 2004, EXP CELL RES, V294, P86, DOI 10.1016/j.yexcr.2003.11.015	54	49	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28152	28161		10.1074/jbc.M501481200	http://dx.doi.org/10.1074/jbc.M501481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15941718	hybrid			2022-12-25	WOS:000230678600079
J	Zeenko, V; Gallie, DR				Zeenko, V; Gallie, DR			Cap-independent translation of tobacco etch virus is conferred by an RNA pseudoknot in the 5 '-leader	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITE; POLIOVIRUS MESSENGER-RNA; 5' UNTRANSLATED REGION; INTERNAL INITIATION; CONFORMATIONAL-CHANGES; SECONDARY STRUCTURE; FUNCTIONAL-ANALYSIS; POLYRIBOSOMAL RNA; NONCODING REGION; BINDING-PROTEIN	The tobacco etch virus (TEV)5'-leader promotes cap-independent translation in a 5'-proximal position and promotes internal initiation when present in the intercistronic region of a dicistronic mRNA, indicating that the leader contains an internal ribosome entry site. The TEV 143-nucleotide 5'-leader folds into a structure that contains two domains, each of which contains an RNA pseudoknot. Mutational analysis of the TEV 5'-leader identified pseudoknot (PK) 1 within the 5'-proximal domain and an upstream single-stranded region flanking PK1 as necessary to promote cap-independent translation. Mutations to either stem or to loops 2 or 3 of PK1 substantially disrupted cap-independent translation. The sequence of loop 3 in PK1 is complementary to a region in 18 S rRNA that is conserved throughout eukaryotes. Mutations within L3 that disrupted its potential base pairing with 18 S rRNA reduced cap-independent translation, whereas mutations that maintained the potential for base pairing with 18 S rRNA had little effect. These results indicated that the TEV 5'-leader functionally substitutes for a 5'-cap and promotes cap-independent translation through a 45-nucleotide pseudoknot-containing domain.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Gallie, DR (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	drgallie@citrus.ucr.edu		Zeenko, Vladimir/0000-0002-2267-4722				Akbergenov RZ, 2004, NUCLEIC ACIDS RES, V32, P239, DOI 10.1093/nar/gkh176; ALLISON R, 1986, VIROLOGY, V154, P9, DOI 10.1016/0042-6822(86)90425-3; ALLISON RF, 1985, P NATL ACAD SCI USA, V82, P3969, DOI 10.1073/pnas.82.12.3969; Belsham GJ, 2000, COLD SPRING HARBOR M, V39, P869; BLACKBURN P, 1979, J BIOL CHEM, V254, P2484; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Chappell SA, 2004, P NATL ACAD SCI USA, V101, P9590, DOI 10.1073/pnas.0308759101; Chappell SA, 2003, J BIOL CHEM, V278, P33793, DOI 10.1074/jbc.M303495200; Chappell SA, 2001, J BIOL CHEM, V276, P36917, DOI 10.1074/jbc.M106008200; Chen XY, 1996, J MOL BIOL, V260, P479, DOI 10.1006/jmbi.1996.0415; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; DOUGHERTY WG, 1988, ANNU REV PHYTOPATHOL, V26, P123, DOI 10.1146/annurev.py.26.090188.001011; Draper DE, 2004, RNA, V10, P335, DOI 10.1261/rna.5205404; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; FAVOROVA OO, 1981, BIOCHEMISTRY-US, V20, P1006, DOI 10.1021/bi00507a055; Fletcher SP, 2002, J VIROL, V76, P5024, DOI 10.1128/JVI.76.10.5024-5033.2002; Gallie DR, 2002, PLANT MOL BIOL, V50, P949, DOI 10.1023/A:1021220910664; GALLIE DR, 1992, NUCLEIC ACIDS RES, V20, P4631, DOI 10.1093/nar/20.17.4631; GALLIE DR, 1995, GENE, V165, P233, DOI 10.1016/0378-1119(95)00521-7; Gallie DR, 2001, J VIROL, V75, P12141, DOI 10.1128/JVI.75.24.12141-12152.2001; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P3257, DOI 10.1093/nar/15.8.3257; Han KS, 2003, NUCLEIC ACIDS RES, V31, P3432, DOI 10.1093/nar/gkg539; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HEWLETT MJ, 1976, P NATL ACAD SCI USA, V73, P327, DOI 10.1073/pnas.73.2.327; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Hunt SL, 1999, RNA, V5, P344, DOI 10.1017/S1355838299981414; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Kanamori Y, 2001, RNA, V7, P266, DOI 10.1017/S1355838201001741; Kang HS, 1997, NUCLEIC ACIDS RES, V25, P1943, DOI 10.1093/nar/25.10.1943; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KUHN R, 1990, J VIROL, V64, P4625; Lytle JR, 2002, RNA, V8, P1045, DOI 10.1017/S1355838202029965; MATVEEVA OV, 1993, NUCLEIC ACIDS RES, V21, P1007, DOI 10.1093/nar/21.4.1007; Niepel M, 1999, J VIROL, V73, P9080, DOI 10.1128/JVI.73.11.9080-9088.1999; NOMOTO A, 1977, P NATL ACAD SCI USA, V74, P5345, DOI 10.1073/pnas.74.12.5345; NOMOTO A, 1976, P NATL ACAD SCI USA, V73, P375, DOI 10.1073/pnas.73.2.375; Owens GC, 2001, P NATL ACAD SCI USA, V98, P1471, DOI 10.1073/pnas.98.4.1471; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; PETTERSSON RF, 1977, NATURE, V268, P270, DOI 10.1038/268270a0; Rijnbrand R, 1997, J VIROL, V71, P451, DOI 10.1128/JVI.71.1.451-457.1997; ROMER R, 1975, EUR J BIOCHEM, V55, P271, DOI 10.1111/j.1432-1033.1975.tb02160.x; Sczyrba A, 2003, NUCLEIC ACIDS RES, V31, P3767, DOI 10.1093/nar/gkg576; SHEN LX, 1995, J MOL BIOL, V247, P963, DOI 10.1006/jmbi.1995.0193; STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025; WANG CY, 1995, RNA, V1, P526; Wells DR, 1998, GENE DEV, V12, P3236, DOI 10.1101/gad.12.20.3236; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	53	60	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26813	26824		10.1074/jbc.M503576200	http://dx.doi.org/10.1074/jbc.M503576200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911616	hybrid			2022-12-25	WOS:000230589500023
J	Choi, MG; Kurnov, V; Kersting, MC; Sreenivas, A; Carman, GM				Choi, MG; Kurnov, V; Kersting, MC; Sreenivas, A; Carman, GM			Phosphorylation of the yeast choline kinase by protein kinase C - Identification of Ser(25) and Ser(30) as major sites of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES PHOSPHATIDYLCHOLINE SYNTHESIS; SACCHAROMYCES-CEREVISIAE; CTP SYNTHETASE; PHOSPHOLIPID BIOSYNTHESIS; COORDINATE REGULATION; CKI GENE; METABOLISM; TRANSFORMATION; APOPTOSIS; PURIFICATION	The Saccharomyces cerevisiae CKI1-encoded choline kinase catalyzes the committed step in phosphatidylcholine synthesis via the Kennedy pathway. The enzyme is phosphorylated on multiple serine residues, and some of this phosphorylation is mediated by protein kinase A. In this work we examined the hypothesis that choline kinase is also phosphorylated by protein kinase C. Using choline kinase as a substrate, protein kinase C activity was dose- and time-dependent and dependent on the concentrations of choline kinase (K-m = 27 mu g/ml) and ATP (K-m = 15 mu M). This phosphorylation, which occurred on a serine residue, was accompanied by a 1.6-fold stimulation of choline kinase activity. The synthetic peptide SRSSSQRRHS (V-max/K-m = 17.5 mM(-1) mu mol min(-1) mg(-1)) that contains the protein kinase C motif for Ser(25) was a substrate for protein kinase C. A Ser25 to Ala (S25A) mutation in choline kinase resulted in a 60% decrease in protein kinase C phosphorylation of the enzyme. Phosphopeptide mapping analysis of the S25A mutant enzyme confirmed that Ser25 was a protein kinase C target site. In vivo the S25A mutation correlated with a decrease (55%) in phosphatidylcholine synthesis via the Kennedy pathway, whereas an S25D phosphorylation site mimic correlated with an increase (44%) in phosphatidylcholine synthesis. Although the S25A ( protein kinase C site) mutation did not affect the phosphorylation of choline kinase by protein kinase A, the S30A ( protein kinase A site) mutation caused a 46% reduction in enzyme phosphorylation by protein kinase C. A choline kinase synthetic peptide (SQRRHSLTRQ) containing Ser(30) was a substrate (V-max/K-m = 3.0 mM(-1) mu mol min(-1) mg(-1)) for protein kinase C. Comparison of phosphopeptide maps of the wild type and S30A mutant choline kinase enzymes phosphorylated by protein kinase C confirmed that Ser(30) was also a target site for protein kinase C.	Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050679, GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aboagye EO, 1999, CANCER RES, V59, P80; Agellon LB, 1999, HEPATOLOGY, V30, P725, DOI 10.1002/hep.510300305; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; Campos J, 2000, BIOORG MED CHEM LETT, V10, P767, DOI 10.1016/S0960-894X(00)00080-9; Campos JM, 2002, BIOORGAN MED CHEM, V10, P2215, DOI 10.1016/S0968-0896(02)00054-8; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; Choi MG, 2003, J BIOL CHEM, V278, P23610, DOI 10.1074/jbc.M303337200; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Cui Z, 2002, BBA-MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388-1981(02)00328-1; DeGrado TR, 2001, J NUCL MED, V42, P1805; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; EXTON JH, 1990, J BIOL CHEM, V265, P1; Hara T, 2002, J NUCL MED, V43, P187; Harlow E., 1988, ANTIBODIES LAB MANUA; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; INNIS MA, 1990, GUIDE METHODS APPLIC, P3; Ishidate K, 1997, BBA-LIPID LIPID MET, V1348, P70, DOI 10.1016/S0005-2760(97)00118-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwaki S, 2005, J BIOL CHEM, V280, P6520, DOI 10.1074/jbc.M410908200; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; Kim KH, 1998, J BIOL CHEM, V273, P6844, DOI 10.1074/jbc.273.12.6844; Kim KS, 1999, J BIOL CHEM, V274, P14857, DOI 10.1074/jbc.274.21.14857; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; MORASH SC, 1994, J BIOL CHEM, V269, P28769; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; Nakagami K, 1999, JPN J CANCER RES, V90, P1212, DOI 10.1111/j.1349-7006.1999.tb00698.x; Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; Peisach D, 2003, STRUCTURE, V11, P703, DOI 10.1016/S0969-2126(03)00094-7; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PORTER TJ, 1992, METHOD ENZYMOL, V209, P134; RAMIREZ DM, 2001, BIOCHEM BIOPH RES CO, V285, P873; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROONEY SA, 1985, AM REV RESPIR DIS, V131, P439; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Segel IH, 1975, ENZYME KINETICS BEHA; SIMON AJ, 1991, P ROY SOC B-BIOL SCI, V243, P165, DOI 10.1098/rspb.1991.0027; SPECTOR AA, 1985, J LIPID RES, V26, P1015; Sreenivas A, 2001, J BIOL CHEM, V276, P29915, DOI 10.1074/jbc.M105147200; Street JC, 1997, MAGNET RESON MED, V38, P769, DOI 10.1002/mrm.1910380513; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; VANCE JE, 1985, CAN J BIOCHEM CELL B, V63, P870, DOI 10.1139/o85-108; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WITTENBERG J, 1953, J BIOL CHEM, V202, P431; Wright MM, 2001, J BIOL CHEM, V276, P25254, DOI 10.1074/jbc.M011552200; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Yamashita S, 1997, BBA-LIPID LIPID MET, V1348, P63, DOI 10.1016/S0005-2760(97)00104-5; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983; Yu Y, 2002, J BIOL CHEM, V277, P34978, DOI 10.1074/jbc.M205316200; Yuan C, 2004, J BIOL CHEM, V279, P17801, DOI 10.1074/jbc.M401382200	91	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26105	26112		10.1074/jbc.M503551200	http://dx.doi.org/10.1074/jbc.M503551200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15919656	hybrid, Green Accepted			2022-12-25	WOS:000230386800022
J	Day, B; To, C; Himanen, JP; Smith, FM; Nikolov, DB; Boyd, AW; Lackmann, M				Day, B; To, C; Himanen, JP; Smith, FM; Nikolov, DB; Boyd, AW; Lackmann, M			Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; CRYSTAL-STRUCTURE; LIGAND-BINDING; ATTACHMENT; EPHB2; HEK; DIMERIZATION; DOMAIN	Eph receptor tyrosine kinases (Ephs) function as molecular relays that interact with cell surface-bound ephrin ligands to direct the position of migrating cells. Structural studies revealed that, through two distinct contact surfaces on opposite sites of each protein, Eph and ephrin binding domains assemble into symmetric, circular heterotetramers. However, Eph signal initiation requires the assembly of higher order oligomers, suggesting additional points of contact. By screening a random library of EphA3 binding-compromised ephrin-A5 mutants, we have now determined ephrin-A5 residues that are essential for the assembly of high affinity EphA3 signaling complexes. In addition to the two interfaces predicted from the crystal structure of the homologous EphB2 center dot ephrin-B2 complex, we identified a cluster of 10 residues on the ephrin-A5 E alpha-helix, the E-F loop, the underlying H beta-strand, as well as the nearby B - C loop, which define a distinct third surface required for oligomerization and activation of EphA3 signaling. Together with a corresponding third surface region identified recently outside of the minimal ephrin binding domain of EphA3, our findings provide experimental evidence for the essential contribution of three distinct protein-interaction interfaces to assemble functional EphA3 signaling complexes.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3168, Australia; Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA; Univ Queensland, PO Royal Brisbane Hosp, Dept Med, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Monash University; Memorial Sloan Kettering Cancer Center; Royal Brisbane & Women's Hospital; University of Queensland	Lackmann, M (corresponding author), Monash Univ, Dept Biochem & Mol Biol, POB 13D, Clayton, Vic 3800, Australia.	martin.lackmann@med.monash.edu.au	Boyd, Andrew/G-2083-2010; Day, Bryan/AAV-6170-2020; Day, Bryan/O-4469-2015	Day, Bryan/0000-0002-8948-9089	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038486] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS38486] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1997, CELL, V90, P403, DOI DOI 10.1016/S0092-8674(00)80500-0; BOYD AW, 1992, J BIOL CHEM, V267, P3262; BOYD AW, 2001, SCI STKE; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Himanen JP, 2003, TRENDS NEUROSCI, V26, P46, DOI 10.1016/S0166-2236(02)00005-X; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lackmann M, 1996, P NATL ACAD SCI USA, V93, P2523, DOI 10.1073/pnas.93.6.2523; Lackmann M, 1997, J BIOL CHEM, V272, P16521, DOI 10.1074/jbc.272.26.16521; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Reber M, 2004, NATURE, V431, P847, DOI 10.1038/nature02957; Smith FM, 2004, J BIOL CHEM, V279, P9522, DOI 10.1074/jbc.M309326200; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Toth J, 2001, DEV CELL, V1, P83, DOI 10.1016/S1534-5807(01)00002-8; Wimmer-Kleikamp SH, 2004, J CELL BIOL, V164, P661, DOI 10.1083/jcb.200312001; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2	26	30	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26526	26532		10.1074/jbc.M504972200	http://dx.doi.org/10.1074/jbc.M504972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901737	hybrid			2022-12-25	WOS:000230386800069
J	Nyunoya, T; Monick, MM; Powers, LS; Yarovinsky, TO; Hunninghake, GW				Nyunoya, T; Monick, MM; Powers, LS; Yarovinsky, TO; Hunninghake, GW			Macrophages survive hyperoxia via prolonged ERK activation due to phosphatase down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASES; MAP KINASE; CELL-DEATH; OXIDATIVE STRESS; EPITHELIAL-CELLS; INDUCED APOPTOSIS; REDOX REGULATION; A549 CELLS; T-CELLS	Macrophages exposed to hyperoxia in the lung continue to survive for prolonged periods. We previously reported (Nyunoya, T., Powers, L. S., Yarovinsky, T. O., Butler, N. S., Monick, M. M., and Hunninghake, G. W. ( 2003) J. Biol. Chem. 278, 36099-36106) that hyperoxia induces cell cycle arrest and sustained extracellular signal-related kinase (ERK) activity in macrophages. In this study, we determined the mechanisms of hyperoxia-induced ERK activation and how ERK activity plays a pro-survival role in hyperoxia-exposed cells. Inhibition of ERK activity decreased survival of hyperoxia-exposed macrophages. This was due, at least in part, to down-regulation of the pro-apoptotic Bcl-2 family member, BimEL. In determining the mechanism of ERK activation by hyperoxia, we found that ERK activation was not associated with hyperoxia-induced activation of the upstream ERK kinase mitogen- activated protein kinase/extracellular signal-regulated kinase kinase 1/2. When we examined the ability of whole cell lysates from hyperoxia-exposed cells to dephosphorylate purified phosphorylated ERK, we found decreased ERK-directed phosphatase activity. Two particular ERK-directed phosphatases ( protein phosphatase 2A and MAPK phosphatase-3) demonstrated decreased activity in hyperoxia-exposed cells. Moreover, whole cell lysates from normoxia-exposed cells depleted of PP2A or MAPK phosphatase-3 were also less able to dephosphorylate ERK. These data demonstrate that, in hyperoxia-exposed macrophages, sustained activation of ERK due to phosphatase down-regulation permits macrophage survival via effects on the balance between pro-and antiapoptotic Bcl-2 family proteins.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Dept Vet Affairs, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Nyunoya, T (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, 100 EMRB, Iowa City, IA 52242 USA.	toru-nyunoya@uiowa.edu	NYUNOYA, TORU/AAX-1482-2021	NYUNOYA, TORU/0000-0002-0688-4607	NCRR NIH HHS [RR00059] Funding Source: Medline; NHLBI NIH HHS [HL-077431, HL-60316] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000059] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316, R01HL077431] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad A, 2002, AM J PHYSIOL-LUNG C, V283, pL573, DOI 10.1152/ajplung.00410.2001; Ahmad S, 2004, J BIOL CHEM, V279, P16317, DOI 10.1074/jbc.M313890200; Ahmad S, 2003, AM J RESP CELL MOL, V28, P179, DOI 10.1165/rcmb.2002-0004OC; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Buccellato LJ, 2004, J BIOL CHEM, V279, P6753, DOI 10.1074/jbc.M310145200; Budinger GRS, 2002, J BIOL CHEM, V277, P15654, DOI 10.1074/jbc.M109317200; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Foley TD, 2005, BIOCHEM BIOPH RES CO, V330, P1224, DOI 10.1016/j.bbrc.2005.03.108; Foley TD, 2004, BIOCHEM BIOPH RES CO, V315, P568, DOI 10.1016/j.bbrc.2004.01.096; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hancock CN, 2005, J BIOL CHEM, V280, P11590, DOI 10.1074/jbc.M408273200; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang ZH, 2004, J BIOL CHEM, V279, P52150, DOI 10.1074/jbc.M407820200; KAHAN C, 1992, J BIOL CHEM, V267, P13369; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim HS, 2003, J BIOL CHEM, V278, P37497, DOI 10.1074/jbc.M211739200; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Li Y, 2003, AM J RESP CELL MOL, V29, P779, DOI 10.1165/rcmb.2003-0087RC; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; Lu YB, 2001, J EXP MED, V193, P545, DOI 10.1084/jem.193.4.545; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; Marques LJ, 1997, AM J RESP CRIT CARE, V156, P1700, DOI 10.1164/ajrccm.156.5.9611052; Mishra OP, 2004, NEUROSCIENCE, V129, P665, DOI 10.1016/j.neuroscience.2004.09.005; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nair VD, 2004, J BIOL CHEM, V279, P27494, DOI 10.1074/jbc.M312135200; Nyunoya T, 2003, J BIOL CHEM, V278, P36099, DOI 10.1074/jbc.M304370200; O'Reilly MA, 2003, AM J PHYSIOL-LUNG C, V284, pL368, DOI 10.1152/ajplung.00299.2002; Ogunlesi F, 2004, BBA-MOL BASIS DIS, V1688, P112, DOI 10.1016/j.bbadis.2003.10.008; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; Petrache I, 1999, AM J PHYSIOL-LUNG C, V277, pL589, DOI 10.1152/ajplung.1999.277.3.L589; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Ray P, 2003, P NATL ACAD SCI USA, V100, P6098, DOI 10.1073/pnas.1031851100; Samavati L, 2002, AM J PHYSIOL-CELL PH, V283, pC273, DOI 10.1152/ajpcell.00514.2001; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tomita K, 2002, AM J RESP CRIT CARE, V166, P724, DOI 10.1164/rccm.2104010; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu JJ, 2005, J BIOL CHEM, V280, P16461, DOI 10.1074/jbc.M501762200	55	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26295	26302		10.1074/jbc.M500185200	http://dx.doi.org/10.1074/jbc.M500185200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901735	hybrid			2022-12-25	WOS:000230386800045
J	Shi, ML; Sundramurthy, K; Liu, B; Tan, SM; Law, SKA; Lescar, J				Shi, ML; Sundramurthy, K; Liu, B; Tan, SM; Law, SKA; Lescar, J			The crystal structure of the plexin-semaphorin-integrin domain/hybrid domain/I-EGF1 segment from the human integrin beta(2) subunit at 1.8-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-V-BETA-3; EXTRACELLULAR SEGMENT; TERMINAL REGION; EGF-LIKE; DOMAINS; COMPLEX; ACTIVATION; ANTIBODIES; REVEALS; MAPS	Integrins are modular ( alpha beta) heterodimeric proteins that mediate cell adhesion and convey signals across the plasma membrane. Interdomain motions play a key role in signal transduction by propagating structural changes through the molecule, thus controlling the activation state and adhesive properties of the integrin. We expressed a soluble fragment of the human integrin beta(2) subunit comprising the plexin-semaphorin-integrin domain ( PSI)/hybrid domain/I-EGF1 fragment and present its crystal structure at 1.8-angstrom resolution. The structure reveals an elongated molecule with a rigid architecture stabilized by nine disulfide bridges. The PSI domain is located centrally and participates in the formation of extended interfaces with the hybrid domain and I-EGF1 domains, respectively. The hybrid domain/PSI interface involves the burial of an Arg residue, and contacts between PSI and I-EGF1 are mainly mediated by well conserved Arg and Trp residues. Conservation of key interacting residues across the various integrin beta subunits sequences suggests that our structure represents a good model for the entire integrin family. Superposition with the integrin beta(3) receptor in its bent conformation suggests that an articulation point is present at the linkage between its I-EGF1 and I-EGF2 modules and underlines the importance of this region for the control of integrin-mediated cell adhesion.	Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Law, SKA (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	alaw@ntu.edu.sg; julien@ntu.edu.sg	Liu, Bin/G-1591-2012; shi, minlong/G-8734-2013; Law, Alex/A-2212-2011; Tan, Suet/A-2224-2011	Liu, Bin/0000-0002-6581-780X; Tan, Suet-Mien/0000-0003-2371-8739				Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Berg RW, 1999, GENOMICS, V56, P169, DOI 10.1006/geno.1998.5707; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Freedman SJ, 1996, BIOCHEMISTRY-US, V35, P13733, DOI 10.1021/bi9610257; Hynes RO, 2003, SCIENCE, V300, P755, DOI 10.1126/science.1084854; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Liddington RC, 2002, STRUCTURE, V10, P605, DOI 10.1016/S0969-2126(02)00766-9; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Mould AP, 2005, J BIOL CHEM, V280, P4238, DOI 10.1074/jbc.M412240200; Raymond T, 2005, P NATL ACAD SCI USA, V102, P1163, DOI 10.1073/pnas.0406743102; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, P NATL ACAD SCI USA, V98, P11175, DOI 10.1073/pnas.201420198; Tan SM, 2001, FEBS LETT, V505, P27, DOI 10.1016/S0014-5793(01)02778-8; Tan SM, 2001, J BIOL CHEM, V276, P36370, DOI 10.1074/jbc.M102392200; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2004, J BIOL CHEM, V279, P40252, DOI 10.1074/jbc.C400362200; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	29	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30586	30593		10.1074/jbc.M502525200	http://dx.doi.org/10.1074/jbc.M502525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15965234	hybrid			2022-12-25	WOS:000231362500075
J	Shi, J; Scita, G; Casanova, JE				Shi, J; Scita, G; Casanova, JE			WAVE2 signaling mediates invasion of polarized epithelial cells by Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN NUCLEATION; BINDING-PROTEIN; ARP2/3 COMPLEX; RHO-GTPASES; WASP; CDC42; ACTIVATION; CYTOSKELETAL; MEMBRANE; RAC1	The bacterial pathogen Salmonella penetrates the intestinal epithelium by inducing its own phagocytosis into epithelial cells. The dramatic reorganization of the actin cytoskeleton required for internalization is driven by bacterial manipulation of host signaling pathways, including activation of the Rho family GTPase Rac1 and subsequent activation of the Arp2/3 complex. However, the mechanisms linking these two events remain poorly understood. Rac1 is thought to promote activation of the Arp2/3 complex through its interaction with suppressor of cAMP receptor/WASP family verprolin-homologous (SCAR/WAVE) family proteins, but this interaction is apparently indirect. Two different Rac1 effectors have been shown to bind WAVE2: IRSp53, the SH3 domain of which binds the WAVE2 proline-rich domain, and PIR121/Sra-1, which forms a pentameric complex containing WAVE, Abi1, Nap1, and HSPC300. However, the extent to which each of these complexes contributes to Arp2/3 complex activation in the context of Salmonella infection is unclear. Here, we show that WAVE2 is necessary for efficient invasion of epithelial cells by Salmonella typhimurium. We found that although Salmonella infection strongly promotes the formation of an IRSp53/ WAVE2 complex, IRSp53 is not necessary for bacterial internalization. In contrast, disruption of the PIR121/ Nap1/Abi1/WAVE2/HSPC300 complex potently inhibits bacterial uptake. These results indicate that WAVE2 is an important component in signaling pathways leading to Salmonella invasion. Although infection leads to the formation of an IRSp53/ WAVE2 complex, it is the association of WAVE2 with the Abi1/Nap1/PIR121/HSPC300 complex that regulates bacterial internalization.	Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA; IFOM Ist FIRC Oncol Mol, I-20134 Milan, Italy; Ist Europeo Oncol, Dept Expt Oncol, I-20141 Milan, Italy	University of Virginia; IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO)	Casanova, JE (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Box 800732,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jec9e@virginia.edu	Scita, Giorgio/J-9670-2012	Scita, Giorgio/0000-0001-7984-1889	NIDDK NIH HHS [DK52351] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakshi CS, 2000, J BACTERIOL, V182, P2341, DOI 10.1128/JB.182.8.2341-2344.2000; Blagg SL, 2003, CURR BIOL, V13, P1480, DOI 10.1016/S0960-9822(03)00580-3; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Collazo CM, 1997, GENE, V192, P51, DOI 10.1016/S0378-1119(96)00825-6; Criss AK, 2003, INFECT IMMUN, V71, P2885, DOI 10.1128/IAI.71.5.2885-2891.2003; Criss AK, 2001, J CELL SCI, V114, P1331; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FINLAY BB, 1991, J CELL SCI, V99, P283; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hayward RD, 1999, EMBO J, V18, P4926, DOI 10.1093/emboj/18.18.4926; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; HUECK CJ, 1995, MOL MICROBIOL, V18, P479, DOI 10.1111/j.1365-2958.1995.mmi_18030479.x; Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kunda P, 2003, CURR BIOL, V13, P1867, DOI 10.1016/j.cub.2003.10.005; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; Lorenzi R, 2000, BLOOD, V95, P2943, DOI 10.1182/blood.V95.9.2943.009k17_2943_2946; McGhie EJ, 2004, MOL CELL, V13, P497, DOI 10.1016/S1097-2765(04)00053-X; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Steffen A, 2004, EMBO J, V23, P749, DOI 10.1038/sj.emboj.7600084; Stender S, 2000, MOL MICROBIOL, V36, P1206, DOI 10.1046/j.1365-2958.2000.01933.x; Takenawa T, 2001, J CELL SCI, V114, P1801; Unsworth KE, 2004, CELL MICROBIOL, V6, P1041, DOI 10.1111/j.1462-5822.2004.00417.x; Wiedemann A, 2001, CELL MICROBIOL, V3, P693, DOI 10.1046/j.1462-5822.2001.00149.x; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092; Zhou DG, 1999, P NATL ACAD SCI USA, V96, P10176, DOI 10.1073/pnas.96.18.10176	32	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29849	29855		10.1074/jbc.M500617200	http://dx.doi.org/10.1074/jbc.M500617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15929989	hybrid			2022-12-25	WOS:000231176200056
J	Nakahara, M; Shimozawa, M; Nakamura, Y; Irino, Y; Morita, M; Kudo, Y; Fukami, K				Nakahara, M; Shimozawa, M; Nakamura, Y; Irino, Y; Morita, M; Kudo, Y; Fukami, K			A novel phospholipase C, PLC eta 2, is a neuron-specific isozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ACTIVATION; PROTEIN; PLC; IDENTIFICATION; C-DELTA-1; EPSILON; DOMAIN; GAMMA; CELL	Twelve phospholipase C ( PLC) isozymes have been cloned so far, and they are divided into six classes, beta-, gamma-, delta-, is an element of-, zeta-, and eta- type, on the basis of structure and activation mechanisms. Here we report the identification of a novel PLC isozyme, PLC eta 2. PLC eta 2 is composed of conserved domains including pleckstrin homology, EF-hand, X and Y catalytic, and C2 domains and the isozyme-specific C-terminal region. PLC eta 2 consists of 1164 amino acids with a molecular mass of 125 kDa. The PLC activity of PLC eta 2 was more sensitive to calcium concentration than the PLC activity of the PLC delta-type enzyme, which is thought to be the most calcium-sensitive PLC. Immunofluorescence analysis showed that PLC eta 2 was localized predominantly to the plasma membrane at resting state via the pleckstrin homology domain. This observation was supported by Western blot analysis of cytosol and membrane fractions. In addition, expression of PLC eta 2 was detected after birth and showed a restricted distribution in the brain; it was particularly abundant in the hippocampus, cerebral cortex, and olfactory bulb. The pattern was similar to that of the neuronal marker microtubule-associated protein by Western blot. Furthermore, in situ hybridization showed positive signals for PLC eta 2 in pyramidal cells of the hippocampus. Finally, we found that PLC eta 2 was expressed abundantly in neuron-containing primary culture but not in astrocyte-enriched culture. These results indicate that PLC eta 2 is a neuron-specific isozyme that may be important for the formation and/or maintenance of the neuronal network in the postnatal brain.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Genome & Biosignal, Hachioji, Tokyo 1920392, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Cellular Neurobiol, Hachioji, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences; Tokyo University of Pharmacy & Life Sciences	Fukami, K (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Genome & Biosignal, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	kfukami@ls.toyaku.ac.jp	Shimozawa, Makoto/AHB-3369-2022	Shimozawa, Makoto/0000-0001-9618-0533; Kudo, Yoshihisa/0000-0002-5978-8264; Nakamura, Yoshikazu/0000-0001-8355-1091; Morita, Mitsuhiro/0000-0002-9891-0242				Abe S, 2003, AM J HUM GENET, V72, P73, DOI 10.1086/345398; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; ELLIS MV, 1995, BIOCHEM J, V307, P69, DOI 10.1042/bj3070069; FLESCH FM, 2005, IN PRESS BIOCH J; Fujii M, 1999, BIOCHEM BIOPH RES CO, V254, P284, DOI 10.1006/bbrc.1998.9936; Fukami K, 2002, J BIOCHEM, V131, P293, DOI 10.1093/oxfordjournals.jbchem.a003102; Fukami K, 2001, SCIENCE, V292, P920, DOI 10.1126/science.1059042; HWANG JI, 2005, IN PRESS BIOCH J; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Morita M, 2003, J NEUROSCI, V23, P10944; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ochocka AM, 2003, ACTA BIOCHIM POL, V50, P1097; Otsuki M, 1999, BIOCHEM BIOPH RES CO, V266, P97, DOI 10.1006/bbrc.1999.1784; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Sekiya F, 1999, CHEM PHYS LIPIDS, V98, P3, DOI 10.1016/S0009-3084(99)00013-4; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Tsuchiya R, 2002, BRAIN RES, V956, P221, DOI 10.1016/S0006-8993(02)03518-7; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X	29	77	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29128	29134		10.1074/jbc.M503817200	http://dx.doi.org/10.1074/jbc.M503817200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15899900	hybrid			2022-12-25	WOS:000231021300039
J	Ohkura, N; Takahashi, M; Yaguchi, H; Nagamura, Y; Tsukada, T				Ohkura, N; Takahashi, M; Yaguchi, H; Nagamura, Y; Tsukada, T			Coactivator-associated arginine methyltransferase 1, CARM1, affects pre-mRNA splicing in an isoform-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							U1 SNRNP; IN-VIVO; NUCLEAR RIBONUCLEOPROTEIN; BINDING PROTEINS; SR PROTEINS; TRANSCRIPTION; METHYLTRANSFERASE; VARIANT; CD44; GENE	Molecular diversity through alternative splicing is important for cellular function and development. However, little is known about the factors that regulate alternative splicing. Here we demonstrate that one isoform of coactivator-associated arginine methyltransferase 1 (named CARM1-v3) associates with the U1 small nuclear RNP-specific protein U1C and affects 5' splice site selection of the pre-mRNA splicing. CARM1-v3 was generated by the retention of introns 15 and 16 of the primary transcript of CARM1. Its deduced protein lacks the C-terminal domain of the major isoform of CARM1 and instead has v3-specific sequences at the C terminus. CARM1-v3, but not the other isoforms, strongly stimulates a shift to the distal 5' splice site of the pre-mRNA when the adenoviral E1A minigene is used as a reporter and enhances the exon skips in the CD44 reporter. A CARM1-v3 mutant lacking the v3- specific sequences completely lost the ability to regulate the alternative splicing patterns. In addition, CARM1-v3 shows tissue-specific expression patterns distinct from those of the other isoforms. These results suggest that the transcriptional coactivator can affect the splice site decision in an isoform-specific manner.	Natl Canc Ctr, Res Inst, Tumor Endocrinol Project, Tokyo 1040045, Japan	National Cancer Center - Japan	Ohkura, N (corresponding author), Natl Canc Ctr, Res Inst, Tumor Endocrinol Project, Tokyo 1040045, Japan.	nohkura@gan2.res.ncc.go.jp						ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; Bose S, 2004, BIOCHEM J, V378, P177, DOI 10.1042/BJ20031122; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Chansky HA, 2001, CANCER RES, V61, P3586; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; Du HS, 2002, NATURE, V419, P86, DOI 10.1038/nature00947; Eperon IC, 2000, MOL CELL BIOL, V20, P8303, DOI 10.1128/MCB.20.22.8303-8318.2000; Forch P, 2002, EMBO J, V21, P6882, DOI 10.1093/emboj/cdf668; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Jin Y, 2003, EMBO J, V22, P905, DOI 10.1093/emboj/cdg089; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lai MC, 2003, EMBO J, V22, P1359, DOI 10.1093/emboj/cdg126; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lisbin MJ, 2001, GENE DEV, V15, P2546, DOI 10.1101/gad.903101; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; Ohkura N, 2002, J BIOL CHEM, V277, P535, DOI 10.1074/jbc.M109018200; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; Sherman L, 1998, GENE DEV, V12, P1058, DOI 10.1101/gad.12.7.1058; Teyssier C, 2002, J BIOL CHEM, V277, P46066, DOI 10.1074/jbc.M207623200; WANG J, 1995, RNA, V1, P335; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924	35	69	73	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28927	28935		10.1074/jbc.M502173200	http://dx.doi.org/10.1074/jbc.M502173200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15944154	hybrid			2022-12-25	WOS:000231021300013
J	Shacham, S; Cheifetz, MN; Fridkin, M; Pawson, AJ; Millar, RP; Naor, Z				Shacham, S; Cheifetz, MN; Fridkin, M; Pawson, AJ; Millar, RP; Naor, Z			Identification of Ser(153) in ICL2 of the gonadotropin-releasing hormone (GnRH) receptor as a phosphorylation-independent site for inhibition of G(q) coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND INTRACELLULAR LOOP; PROTEIN-KINASE-C; MOLECULAR-MECHANISMS; SIGNAL-TRANSDUCTION; PITUITARY-CELLS; DESENSITIZATION; PEPTIDES; ACTIVATION; RGS3; INTERNALIZATION	Type I gonadotropin-releasing hormone ( GnRH) receptor (GnRHR) is unique among mammalian G-protein-coupled receptors (GPCRs) in lacking a C-terminal tail, which is involved in desensitization in GPCRs. Therefore, we searched for inhibitory sites in the intracellular loops (ICLs) of the GnRHR. Synthetic peptides corresponding to the three ICLs were inserted into permeabilized alpha T3-1 gonadotrope cells, and GnRH-induced inositol phosphate ( InsP) formation was determined. GnRH-induced InsP production was potentiated by ICL2 > ICL3 but not by the ICL1 peptides, suggesting they are acting as decoy peptides. We examined the effects of six peptides in which only one of the Ser or Thr residues was substituted with Ala or Glu. Only substitution of Ser(153) with Ala or Glu ablated the potentiating effect upon GnRH-induced InsP elevation. ERK activation was enhanced, and the rate of GnRH-induced InsP formation was about 6.5-fold higher in the first 10 min in COS-1 cells that were transfected with mutants of the GnRHR in which the ICL2 Ser/Thr residues (Ser(151), Ser153, and Thr(142)) or only Ser153 was mutated to Ala as compared with the wild type GnRHR. The data indicate that ICL2 harbors an inhibitory domain, such that exogenous ICL2 peptide serves as a decoy for the inhibitory site (Ser153) of the GnRHR, thus enabling further activation. GnRH does not induce receptor phosphorylation in alpha T3-1 cells. Because the phosphomimetic ICL2-S153E peptide did not mimic the stimulatory effect of the ICL2 peptide, the inhibitory effect of Ser153 operates through a phosphorylation-independent mechanism.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; Univ Edinburgh, MRC, Human Reprod Sci Unit, Edinburgh EH16 4SB, Midlothian, Scotland	Tel Aviv University; Weizmann Institute of Science; University of Edinburgh	Naor, Z (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	z.naor@hrsu.mrc.ac.uk	Millar, Robert P/A-4853-2012; Pawson, Adam J/Q-5678-2016	Pawson, Adam J/0000-0003-2280-845X; Millar, Robert P/0000-0003-3606-2708	Medical Research Council [U.1276.00.005.00002.01 (85842), MC_U127685842] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Albert PR, 1998, ANN NY ACAD SCI, V861, P146, DOI 10.1111/j.1749-6632.1998.tb10186.x; Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Castro-Fernandez C, 2002, ENDOCRINOLOGY, V143, P1310, DOI 10.1210/en.143.4.1310; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Grosse R, 2000, J BIOL CHEM, V275, P9193, DOI 10.1074/jbc.275.13.9193; Guarnieri F, 1996, J AM CHEM SOC, V118, P5580, DOI 10.1021/ja952745o; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lembo PMC, 1997, MOL PHARMACOL, V52, P164, DOI 10.1124/mol.52.1.164; Liu FJ, 2003, ENDOCRINOLOGY, V144, P4354, DOI 10.1210/en.2003-0204; Luttrell LM, 2002, J CELL SCI, V115, P455; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; McArdle CA, 2002, J ENDOCRINOL, V173, P1, DOI 10.1677/joe.0.1730001; Millar RP, 2004, ENDOCR REV, V25, P235, DOI 10.1210/er.2003-0002; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; NAOR Z, 1989, P NATL ACAD SCI USA, V86, P4501, DOI 10.1073/pnas.86.12.4501; NAOR Z, 1986, J BIOL CHEM, V261, P2506; NAOR Z, 1980, ENDOCRINOLOGY, V107, P1144, DOI 10.1210/endo-107-4-1144; Neill JD, 1997, MOL CELL ENDOCRINOL, V127, P143, DOI 10.1016/S0303-7207(96)04003-8; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Neill JD, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-21; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Smith RD, 1998, MOL ENDOCRINOL, V12, P634, DOI 10.1210/me.12.5.634; ULLOAAGUIRRE A, 1998, HDB PHYSL ENDOCRINOL, P60; Wade SM, 1996, MOL PHARMACOL, V50, P351; WADE SM, 1994, MOL PHARMACOL, V45, P1191; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146	37	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28981	28988		10.1074/jbc.M500312200	http://dx.doi.org/10.1074/jbc.M500312200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15964850	hybrid			2022-12-25	WOS:000231021300020
J	Wooten, LG; Ogretmen, B				Wooten, LG; Ogretmen, B			Sp1/Sp3-dependent regulation of human telomerase reverse transcriptase promoter activity by the bioactive sphingolipid ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITORS; REPRESS TRANSCRIPTION; ENDOGENOUS CERAMIDE; HTERT GENE; SP-FAMILY; SP3; ACTIVATION; CELLS; BINDING; CANCER	In this study, the roles of Sp1/Sp3 transcription factors in the regulation of the activity of human telomerase reverse transcriptase ( hTERT) promoter in response to ceramide were examined in the A549 human lung adenocarcinoma cells. The activity of the N-terminal truncated hTERT promoter, lacking the c-Myc recognition (E-box) region but containing multiple Sp1/Sp3 sites, was also significantly inhibited by C-6-ceramide, indicating a role for ceramide in the regulation of Sp1/Sp3 function. Partial inhibition of Sp1 expression using small interfering RNA resulted in a significant inhibition of the hTERT promoter. Treatment with C-6-ceramide inhibited the trans-activation function of overexpressed Sp1, whereas it induced the repressor effects of exogenous Sp3 on the hTERT promoter. The interaction between Sp1 and hTERT promoter DNA was significantly reduced in response to ceramide as assessed by chromatin immunoprecipitation analysis. In contrast, the promoter DNA-binding activity of Sp3 was slightly increased in response to C-6-ceramide, resulting in the increased ratio of Sp3/Sp1 on the hTERT promoter, which was concomitant with the reduced recruitment of RNA polymerase II to the promoter. Furthermore, mutations of various Sp1/Sp3 recognition sequences significantly attenuated the activity of the promoter in the presence or absence of ceramide, demonstrating the importance of multiple Sp1/Sp3 recognition sites for the promoter activity. Mechanistically, the data demonstrated that C-6-ceramide reduced the acetylation of Sp3 protein and partially blocked the activation of the hTERT promoter by the histone deacetylase inhibitor trichostatin A. The roles of endogenous long chain ceramide generated in response to gemcitabine in the inhibition of hTERT promoter activity and the regulation of Sp3 acetylation were also demonstrated.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Ogretmen, B (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,BSB-518E, Charleston, SC 29425 USA.	ogretmen@musc.edu			NATIONAL CANCER INSTITUTE [R01CA088932] Funding Source: NIH RePORTER; NCI NIH HHS [CA-88932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; Banchio C, 2004, J BIOL CHEM, V279, P40220, DOI 10.1074/jbc.M406468200; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Braunstein I, 2001, CANCER RES, V61, P5529; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; Desmaze C, 2003, CANCER LETT, V194, P173, DOI 10.1016/S0304-3835(02)00704-8; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Ehlting C, 2005, BIOCHEM J, V387, P737, DOI 10.1042/BJ20041101; Fidlerova H, 2005, J CELL BIOCHEM, V94, P899, DOI 10.1002/jcb.20374; Granger MP, 2002, CRIT REV ONCOL HEMAT, V41, P29, DOI 10.1016/S1040-8428(01)00188-3; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hasan NM, 2002, GENE, V296, P221, DOI 10.1016/S0378-1119(02)00865-X; Hess-Stumpp H, 2005, EUR J CELL BIOL, V84, P109, DOI 10.1016/j.ejcb.2004.12.010; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Horikawa I, 1999, CANCER RES, V59, P826; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Kraveka JM, 2003, ARCH BIOCHEM BIOPHYS, V419, P110, DOI 10.1016/j.abb.2003.08.034; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lv JJ, 2003, BIOCHEM BIOPH RES CO, V311, P506, DOI 10.1016/j.bbrc.2003.09.235; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Manelli-Oliveira R, 2001, HISTOCHEM CELL BIOL, V115, P403; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Reddel RR, 2003, CANCER LETT, V194, P155, DOI 10.1016/S0304-3835(02)00702-4; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sprott KM, 2002, BIOCHEM J, V365, P181, DOI 10.1042/BJ20020215; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Wang SW, 2003, J BIOL CHEM, V278, P18842, DOI 10.1074/jbc.M209544200; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198	48	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28867	28876		10.1074/jbc.M413444200	http://dx.doi.org/10.1074/jbc.M413444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15951564	hybrid			2022-12-25	WOS:000231021300006
J	Wiens, M; Korzhev, M; Krasko, A; Thakur, NL; Perovic-Ottstadt, S; Breter, HJ; Ushijima, H; Diehl-Seifert, R; Muller, IM; Muller, WEG				Wiens, M; Korzhev, M; Krasko, A; Thakur, NL; Perovic-Ottstadt, S; Breter, HJ; Ushijima, H; Diehl-Seifert, R; Muller, IM; Muller, WEG			Innate immune defense of the sponge Suberites domuncula against bacteria involves a MyD88-dependent signaling pathway - Induction of a perforin-like molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEODIA-CYDONIUM; ANTIBACTERIAL ACTIVITY; AGGREGATION FACTOR; MARINE SPONGES; PROTEIN; RECEPTOR; EXPRESSION; GENE; IDENTIFICATION; RECOGNITION	Sponges ( phylum Porifera) are the phylogenetically oldest metazoa; as filter feeders, they are abundantly exposed to marine microorganisms. Here we present data indicating that the demosponge Suberites domuncula is provided with a recognition system for Gram-negative bacteria. The lipopolysaccharide (LPS)-interacting protein was identified as a receptor on the sponge cell surface, which recognizes the bacterial endotoxin LPS. The cDNA was isolated, and the protein (M-r 49,937) was expressed. During binding to LPS, the protein dimerizes and interacts with MyD88, which was also identified and cloned. The sponge MyD88 (M-r 28,441) is composed of two protein interaction domains, a Toll/interleukin-1 receptor domain (found in MyD88 and in Toll-like receptors) and a death domain (present in MyD88 and interleukin-1 receptor-associated kinase). Northern blot experiments and in situ hybridization studies showed that after LPS treatment, the level of the LPS-interacting protein remains unchanged, whereas MyD88 is strongly up-regulated. A perforin-like molecule (M-r 74,171), the macrophage-expressed protein, was identified as an executing molecule of this pathway. This gene is highly expressed after LPS treatment, especially at the surfaces of the animals. The recombinant protein possesses biological activity and eliminates Gram-negative bacteria; it is inactive against Gram-positive bacteria. These data indicate that S. domuncula is provided with an innate immune system against Gramnegative bacteria; the ligand LPS (a pathogen-associated molecular pattern) is recognized by the pattern recognition receptor (LPS-interacting protein), which interacts with MyD88. A signal transduction is established, which results in an elevated expression of MyD88 as well as of the macrophage-expressed protein as an executing protein.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, D-55099 Mainz, Germany; Univ Tokyo, Dept Dev Med Sci, Inst Int Hlth, Grad Sch Med,Bunkyo Ku, Tokyo 1130033, Japan	Johannes Gutenberg University of Mainz; University of Tokyo	Muller, WEG (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, Duesbergweg 6, D-55099 Mainz, Germany.	wmueller@uni-mainz.de	Müller, W. E. G./AAR-8651-2020	Müller, W. E. G./0000-0002-8223-3689; Wiens, Matthias/0000-0001-9219-0478; Krasko, Anatoli/0000-0002-2765-3525				Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Ambach A, 2004, MOL IMMUNOL, V40, P1307, DOI 10.1016/j.molimm.2004.01.002; BERGH O, 1989, NATURE, V340, P467, DOI 10.1038/340467a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Bohm M, 2000, BIOL CELL, V92, P95, DOI 10.1016/S0248-4900(00)89017-6; Bohm M, 2001, MAR BIOL, V139, P1037; Coligan J.E., 2000, CURRENT PROTOCOLS PR; Dayhoff M, 1978, ATLAS PROTEIN SEQ ST, P345; Felsenstein J., 1993, PHYLIP VERSION 3 5; FernandezBusquets X, 1997, J BIOL CHEM, V272, P27839, DOI 10.1074/jbc.272.44.27839; Gan XQ, 2004, J BIOL CHEM, V279, P49741, DOI 10.1074/jbc.M407570200; Gonzalez JM, 1997, APPL ENVIRON MICROB, V63, P4237; Grebenjuk VA, 2002, EUR J BIOCHEM, V269, P1382, DOI 10.1046/j.1432-1033.2002.02781.x; Hardiman G, 1996, ONCOGENE, V13, P2467; Klenova E, 2002, METHODS, V26, P254, DOI 10.1016/S1046-2023(02)00029-4; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; Krasko A, 2000, EUR J BIOCHEM, V267, P4878, DOI 10.1046/j.1432-1327.2000.01547.x; Kruse M, 1997, MOL BIOL EVOL, V14, P1326, DOI 10.1093/oxfordjournals.molbev.a025742; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mah SA, 2004, BIOCHEM BIOPH RES CO, V316, P468, DOI 10.1016/j.bbrc.2004.02.073; Maldonado M, 1999, NATURE, V401, P785, DOI 10.1038/44560; MANGEL A, 1992, EUR J BIOCHEM, V210, P499, DOI 10.1111/j.1432-1033.1992.tb17448.x; May AP, 1999, TRENDS BIOCHEM SCI, V24, P12, DOI 10.1016/S0968-0004(98)01310-3; McGettrick AF, 2004, MOL IMMUNOL, V41, P577, DOI 10.1016/j.molimm.2004.04.006; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; METCHNIKOFF E, 1992, LECONS PATHOLOGIE CO; Moore DD, 1995, GLOB MOB SURV; Muller WEG, 2004, INT REV CYTOL, V235, P53, DOI 10.1016/S0074-7696(04)35002-3; Muller WEG, 2003, INTEGR COMP BIOL, V43, P281, DOI 10.1093/icb/43.2.281; Muller WEG, 2001, GENE, V276, P161, DOI 10.1016/S0378-1119(01)00669-2; Muller WEG, 1999, MICROSC RES TECHNIQ, V44, P219, DOI 10.1002/(SICI)1097-0029(19990215)44:4<219::AID-JEMT3>3.0.CO;2-7; MULLER WEG, 2005, ENCY MOL CELL BIOL M; Muller Werner E G, 2004, Keio J Med, V53, P159, DOI 10.2302/kjm.53.159; Osinga R, 2003, J BIOTECHNOL, V100, P141, DOI 10.1016/S0168-1656(02)00257-2; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Perovic S, 2003, EVOL DEV, V5, P240, DOI 10.1046/j.1525-142X.2003.03023.x; Perovic-Ottstadt S, 2004, EUR J BIOCHEM, V271, P1924, DOI 10.1111/j.1432-1033.2004.04102.x; PROKSCH P, 1994, TOXICON, V32, P639, DOI 10.1016/0041-0101(94)90334-4; Reiswig H.M., 1990, P504; Ruetzler K., 2004, BOLL MUS IST BIOL UN, V68, P85; Schroder HC, 2003, J BIOL CHEM, V278, P32810, DOI 10.1074/jbc.M304116200; Schutze J, 2001, J CELL SCI, V114, P3189; Schwarz E, 1999, TRENDS BIOCHEM SCI, V24, P260, DOI 10.1016/S0968-0004(99)01422-X; Thakur NL, 2005, MAR BIOL, V146, P271, DOI 10.1007/s00227-004-1438-z; Thakur NL, 2003, AQUAT MICROB ECOL, V31, P77, DOI 10.3354/ame031077; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tunkijjanukij S, 1998, DEV COMP IMMUNOL, V22, P139, DOI 10.1016/S0145-305X(98)00017-2; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; WARREN L, 1966, J CELL PHYSIOL, V68, P269, DOI 10.1002/jcp.1040680308; Wiens M, 2000, J MOL EVOL, V50, P520, DOI 10.1007/s002390010055; Wiens M, 1998, MAR ECOL PROG SER, V165, P247, DOI 10.3354/meps165247; [No title captured]	54	133	137	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27949	27959		10.1074/jbc.M504049200	http://dx.doi.org/10.1074/jbc.M504049200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923643	hybrid			2022-12-25	WOS:000230678600057
J	Kawakita, T; Espana, EM; He, H; Hornia, A; Yeh, LK; Ouyang, J; Liu, CY; Tseng, SCG				Kawakita, T; Espana, EM; He, H; Hornia, A; Yeh, LK; Ouyang, J; Liu, CY; Tseng, SCG			Keratocan expression of murine keratocytes is maintained on amniotic membrane by down-regulating transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL STROMA CELLS; MYOFIBROBLAST DIFFERENTIATION; IN-VITRO; FIBROBLASTS; CULTURES; BIOSYNTHESIS; PHENOTYPE; GENE; PROTEOGLYCANS; SUPPRESSION	Keratocytes in the corneal stroma express keratan sulfate-containing proteoglycans including cornea-specific keratocan. On plastic dishes, human, bovine, and rabbit keratocytes lose their characteristic dendritic morphology and keratocan expression when cultured in serum-containing media. Herein, we demonstrated that murine keratocytes also acquired a fibroblastic shape and lost keratocan expression after first passage when cultured on plastic in the presence of serum. In contrast, cells expanded on human amniotic membrane (AM) stromal matrix maintained a three-dimensional dendritic morphology and expressed keratocan mRNA and protein for at least 8 passages before senescence. When keratocytes were cultured on AM, the promoter activity of transforming growth factor (TGF)-beta 2 and TGF-beta receptor II was down-regulated as compared with that on plastic. Furthermore, cells on AM continuously retained Smad 2 and Smad 4 in the cytoplasm and did not express alpha-smooth muscle actin, even when 10 ng/ml TGF-beta 1 was added in a serum-free medium for up to 5 days. In parallel to such down-regulation of TGF-beta signaling, keratocan promoter-driven ECFP expression was observed in cells cultured either on AM in the presence of serum or on plastic containing serum treated with a neutralizing antibody to TGF-beta. Collectively, these results indicate that down-regulation of Smad-mediated TGF-beta signaling is an important mechanism for cultured keratocytes to maintain a normal phenotype while continuously expanded in a serum-containing medium. This strategy of suppressing TGF-beta signaling, achieved by AM stromal matrix in part via suppression of TGF-beta gene transcription, can be used to expand keratocytes in culture without the use of AM in the future.	Ocular Surface Ctr, Miami, FL 33173 USA; TissueTech Inc, Miami, FL 33173 USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA	Bascom Palmer Eye Institute; University of Miami	Tseng, SCG (corresponding author), Ocular Surface Ctr, 7000 SW 97 Ave,Ste 213, Miami, FL 33173 USA.	stseng@ocularsurface.com		Liu, Chia-yang/0000-0002-8398-5516	NATIONAL EYE INSTITUTE [R01EY012486, R01EY006819] Funding Source: NIH RePORTER; NEI NIH HHS [EY12486, EY06819, R01 EY012486, R01 EY006819] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Beales MP, 1999, INVEST OPHTH VIS SCI, V40, P1658; Chen J, 2001, J IMMUNOL, V167, P1297, DOI 10.4049/jimmunol.167.3.1297; DAHL IM, 1974, EXP CELL RES, V88, P193, DOI 10.1016/0014-4827(74)90634-X; DAHL IM, 1981, EXP EYE RES, V32, P419, DOI 10.1016/S0014-4835(81)80021-8; DAHL IMS, 1978, EXP EYE RES, V27, P175, DOI 10.1016/0014-4835(78)90087-8; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dua HS, 2004, SURV OPHTHALMOL, V49, P51, DOI 10.1016/j.survophthal.2003.10.004; Espana EM, 2004, INVEST OPHTH VIS SCI, V45, P2985, DOI 10.1167/iovs.04-0201; Espana EM, 2003, INVEST OPHTH VIS SCI, V44, P4275, DOI 10.1167/iovs.03-0089; Espana EM, 2003, INVEST OPHTH VIS SCI, V44, P5136, DOI 10.1167/iovs.03-0484; Funderburgh JL, 2003, J BIOL CHEM, V278, P45629, DOI 10.1074/jbc.M303292200; Funderburgh JL, 2001, J BIOL CHEM, V276, P44173, DOI 10.1074/jbc.M107596200; Gendron RL, 2001, MOL VIS, V7, P107; Ghahary A, 1998, J CELL PHYSIOL, V174, P301, DOI 10.1002/(SICI)1097-4652(199803)174:3<301::AID-JCP4>3.3.CO;2-2; Grueterich M, 2002, INVEST OPHTH VIS SCI, V43, P63; HASSELL JR, 1992, INVEST OPHTH VIS SCI, V33, P547; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Jester JV, 1996, CORNEA, V15, P505; Jester JV, 2003, EXP EYE RES, V77, P581, DOI 10.1016/S0014-4835(03)00188-X; Jester JV, 1999, PROG RETIN EYE RES, V18, P311, DOI 10.1016/S1350-9462(98)00021-4; Kawakita T, 2004, INVEST OPHTH VIS SCI, V45, P3507, DOI 10.1167/iovs.04-0266; Kropf J, 1997, CLIN CHEM, V43, P1965; Lan HY, 2003, J AM SOC NEPHROL, V14, P1535, DOI 10.1097/01.ASN.0000067632.04658.B8; Lee SB, 2000, CURR EYE RES, V20, P325, DOI 10.1076/0271-3683(200004)20:4;1-5;FT325; Liu CY, 1998, J BIOL CHEM, V273, P22584, DOI 10.1074/jbc.273.35.22584; Liu CY, 2000, GENE, V250, P85, DOI 10.1016/S0378-1119(00)00165-7; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Meller D, 2002, BRIT J OPHTHALMOL, V86, P463, DOI 10.1136/bjo.86.4.463; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; Petridou S, 1996, INVEST OPHTH VIS SCI, V37, P1740; POOLE CA, 1993, J CELL SCI, V106, P685; Saika S, 2001, DEV BIOL, V240, P419, DOI 10.1006/dbio.2001.0480; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sippel KC, 2001, CURR OPIN OPHTHALMOL, V12, P269, DOI 10.1097/00055735-200108000-00006; Tseng SCG, 1999, J CELL PHYSIOL, V179, P325, DOI 10.1002/(SICI)1097-4652(199906)179:3<325::AID-JCP10>3.0.CO;2-X; Tseng SCG, 2001, BIOSCIENCE REP, V21, P481, DOI 10.1023/A:1017995810755; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Yeh LK, 2005, INVEST OPHTH VIS SCI, V46, P479, DOI 10.1167/iovs.04-1014	41	44	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27085	27092		10.1074/jbc.M409567200	http://dx.doi.org/10.1074/jbc.M409567200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15908433	hybrid, Green Accepted			2022-12-25	WOS:000230589500055
J	Kashlan, OB; Sheng, SH; Kleyman, TR				Kashlan, OB; Sheng, SH; Kleyman, TR			On the interaction between amiloride and its putative alpha-subunit epithelial Na+ channel binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONO-VALENT CATIONS; SODIUM-CHANNEL; PORE REGION; VOLTAGE DEPENDENCE; ION PERMEATION; GAMMA-SUBUNIT; FROG-SKIN; IDENTIFICATION; EXPRESSION; MECHANISM	The epithelial Na+ channel ( ENaC) belongs to the structurally conserved ENaC/Degenerin superfamily. These channels are blocked by amiloride and its analogues. Several amino acid residues have been implicated in amiloride binding. Primary among these are alpha Ser-583, beta Gly-525, and gamma Gly-542, which are present at a homologous site within the three subunits of ENaC. Mutations of the beta and gamma glycines greatly weakened amiloride block, but, surprisingly, mutation of the serine of the alpha subunit resulted in moderate (< 5-fold) weakening of amiloride K-i. We investigated the role of alpha Ser-583 in amiloride binding by systematically mutating alpha Ser-583 and analyzing the mutant channels with two-electrode voltage clamp. We observed that most mutations had moderate effects on amiloride block, whereas those introducing rings showed dramatic effects on amiloride block. In addition, mutations introducing a beta-methyl group at this site altered the electric field of ENaC, affecting both amiloride binding and the voltage dependence of channel gating. We also found that the His mutation, in addition to greatly weakening amiloride binding, appends a voltage-sensitive gate within the pore of ENaC at low pH. Because diverse residues at alpha 583, such as Asn, Gln, Ser, Gly, Thr, and Ala, have similar amiloride binding affinities, our results suggest that the wild type Ser side chain is not important for amiloride binding. However, given that some alpha Ser-583 mutations affect the electrical properties of the channel whereas those introducing rings greatly weaken amiloride block, we conclude that amiloride binds at or near this site and that alpha Ser-583 may have a role in ion permeation through ENaC.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kleyman, TR (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, 3550 Terrace St, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NIDDK NIH HHS [DK066883, DK061296, DK054354, F32 DK066883] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354, F32DK066883, T32DK061296] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; BENOS DJ, 1980, J MEMBRANE BIOL, V56, P149, DOI 10.1007/BF01875966; BENOS DJ, 1979, J GEN PHYSIOL, V73, P307, DOI 10.1085/jgp.73.3.307; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Carattino MD, 2004, J BIOL CHEM, V279, P4120, DOI 10.1074/jbc.M311783200; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; Crouzy S, 2001, J GEN PHYSIOL, V118, P207, DOI 10.1085/jgp.118.2.207; Eyring H., 1963, MODERN CHEM KINETICS; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; Grunder S, 1999, PFLUG ARCH EUR J PHY, V438, P709, DOI 10.1007/s004240051097; HAMILTON KL, 1986, MEMBRANE BIOCHEM, V6, P149, DOI 10.3109/09687688609065447; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Ji HL, 2004, J BIOL CHEM, V279, P8428, DOI 10.1074/jbc.M312012200; Kellenberger S, 2003, MOL PHARMACOL, V64, P848, DOI 10.1124/mol.64.4.848; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Kelly O, 2003, AM J PHYSIOL-RENAL, V285, pF1279, DOI 10.1152/ajprenal.00094.2003; Kieber-Emmons T, 1999, J BIOL CHEM, V274, P9648, DOI 10.1074/jbc.274.14.9648; Kleyman TR, 1999, SEMIN NEPHROL, V19, P524; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; LI JHY, 1983, J MEMBRANE BIOL, V75, P179, DOI 10.1007/BF01871949; Li JQ, 2003, J BIOL CHEM, V278, P13867, DOI 10.1074/jbc.M300149200; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LI XJ, 1994, P NATL ACAD SCI USA, V91, P1814, DOI 10.1073/pnas.91.5.1814; Lu Z, 2004, ANNU REV PHYSIOL, V66, P103, DOI 10.1146/annurev.physiol.66.032102.150822; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PALMER LG, 1985, J MEMBRANE BIOL, V87, P191, DOI 10.1007/BF01871218; PALMER LG, 1989, BIOPHYS J, V55, P779, DOI 10.1016/S0006-3495(89)82876-0; PALMER LG, 1988, J GEN PHYSIOL, V92, P121, DOI 10.1085/jgp.92.1.121; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Sheng SH, 2005, J BIOL CHEM, V280, P8513, DOI 10.1074/jbc.M413880200; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Spassova MA, 1998, J GEN PHYSIOL, V112, P211, DOI 10.1085/jgp.112.2.211; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; WARNCKE J, 1985, PFLUG ARCH EUR J PHY, V405, pS89, DOI 10.1007/BF00581786; WARNCKE J, 1985, J MEMBRANE BIOL, V86, P255, DOI 10.1007/BF01870605; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; Zeslawska E, 2000, J MOL BIOL, V301, P465, DOI 10.1006/jmbi.2000.3966	48	28	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26206	26215		10.1074/jbc.M503500200	http://dx.doi.org/10.1074/jbc.M503500200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15908426	hybrid			2022-12-25	WOS:000230386800035
J	Oh, SW; Moon, JD; Lim, HJ; Park, SY; Kim, T; Park, J; Han, MH; Snyder, M; Choi, EY				Oh, SW; Moon, JD; Lim, HJ; Park, SY; Kim, T; Park, J; Han, MH; Snyder, M; Choi, EY			Calixarene derivative as a tool for highly sensitive detection and oriented immobilization of proteins in a microarray format through noncovalent molecular interaction	FASEB JOURNAL			English	Article						protein microarray; Calixcrown; antibody; orientation; diagnostic application	LINKED-IMMUNOSORBENT-ASSAY; RAT-LIVER; ACID; ANTIBODIES; COMPLEXES; FIBROSIS; BINDING	One important factor in fabricating protein microarray is to immobilize proteins without losing their activity on a solid phase. To keep them functional, it is necessary to immobilize proteins in a way that preserve their folded structural integrity. In a previous study, we developed novel Calixarene derivatives for the immobilization of proteins on the surface of a glass slide (1). In this study, we compared the sensitivity and the specificity of the linker molecules with those of five other protein attachment agents on glass slides using a prostate- specific antigen and its antibodies as a model system. The Calixcrown- coated protein chip showed a superior sensitivity and a much lower detection limit than those chips prepared by other methods. When we tested the capability of Calixcrown to immobilize antibody molecules, it appeared that Calixcrown makes arrangement of antibody be more regular with the vertical orientation than the covalent- bond agent. We also observed that the Calixcrown chip could be used for the diagnostic application with clinical samples from prostate cancer and HIV patients. Finally, we applied the Calixcrown chip using an antibody microarray to identify up- or down-regulated proteins in specific tissue and detected several up- or down-regulated proteins from a rat liver by administering toxin. Thus, the Calixcrown chip can be used as a powerful tool with a wide range of applications, including protein-protein interaction, protein-DNA interaction, and an enzyme activity assay.	Hallym Univ, Dept Genet Engn, Chunchon 200702, South Korea; BodiTech MedInc, Chunchon 200160, South Korea; Hallym Univ, Dept Chem, Chunchon 200702, South Korea; Protogen Inc, Chunchon 200160, South Korea; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Hallym University; Hallym University; Yale University	Choi, EY (corresponding author), Hallym Univ, Dept Genet Engn, Chunchon 200702, South Korea.	euichoi@hallym.ac.kr						Angenendt P, 2002, ANAL BIOCHEM, V309, P253, DOI 10.1016/S0003-2697(02)00257-9; Belov L, 2001, CANCER RES, V61, P4483; Benters R, 2001, CHEMBIOCHEM, V2, P686, DOI 10.1002/1439-7633(20010903)2:9<686::AID-CBIC686>3.0.CO;2-S; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER JE, 1992, J IMMUNOL METHODS, V150, P77, DOI 10.1016/0022-1759(92)90066-3; Cahill DJ, 2001, J IMMUNOL METHODS, V250, P81, DOI 10.1016/S0022-1759(01)00325-8; Casnati A, 2001, CALIXARENES 2001, P365; CHOI EY, 1995, J NEUROCHEM, V64, P371; Diamond D, 2001, ANAL CHEM, V73, p22A, DOI 10.1021/ac012376g; Emili AQ, 2000, NAT BIOTECHNOL, V18, P393, DOI 10.1038/74442; Galfre G, 1981, Methods Enzymol, V73, P3; GE H, 2000, NUCLEIC ACIDS RES, V28, P3; Gutsche C. D., 1998, MONOGRAPHS SUPRAMOLE; Haab BB, 2001, GENOME BIOL, V2; Hayami S, 1999, BIOCHEM PHARMACOL, V58, P1941, DOI 10.1016/S0006-2952(99)00295-6; HEYSEL S, 1995, PROTEIN SCI, V4, P2532, DOI 10.1002/pro.5560041210; Joos TO, 2000, ELECTROPHORESIS, V21, P2641, DOI 10.1002/1522-2683(20000701)21:13<2641::AID-ELPS2641>3.3.CO;2-X; Kudo M., 1996, NATURE, V382, P522; Lee Y, 2003, PROTEOMICS, V3, P2289, DOI 10.1002/pmic.200300541; Lin Q, 1998, BIOPOLYMERS, V47, P285, DOI 10.1002/(SICI)1097-0282(1998)47:4<285::AID-BIP4>3.3.CO;2-3; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 2000, SCIENCE, V289, P1760; Mandolini L., 2000, CALIXARENES ACTION; Martin BD, 1998, LANGMUIR, V14, P3971, DOI 10.1021/la9713311; Mendoza LG, 1999, BIOTECHNIQUES, V27, P778, DOI 10.2144/99274rr01; Nejjari M, 2001, J PATHOL, V195, P473, DOI 10.1002/path.964; Oshima T, 2002, BIOMACROMOLECULES, V3, P438, DOI 10.1021/bm010148q; PAN T, 1989, P NATL ACAD SCI USA, V86, P3145, DOI 10.1073/pnas.86.9.3145; Peluso P, 2003, ANAL BIOCHEM, V312, P113, DOI 10.1016/S0003-2697(02)00442-6; Ramirez J, 2000, J AM CHEM SOC, V122, P6884, DOI 10.1021/ja000717m; Sakaida I, 2003, LIFE SCI, V72, P943, DOI 10.1016/S0024-3205(02)02342-1; SHENG YJ, 2002, PHYS REV E, V66; Song D, 2000, J COLLOID INTERF SCI, V221, P25, DOI 10.1006/jcis.1999.6560; Sreekumar A, 2001, CANCER RES, V61, P7585; Stone MM, 2002, J AM SOC MASS SPECTR, V13, P964, DOI 10.1016/S1044-0305(02)00417-8; Tannapfel A, 2003, J PATHOL, V201, P238, DOI 10.1002/path.1420; Tsai MY, 2001, J BIOMED MATER RES, V55, P554, DOI 10.1002/1097-4636(20010615)55:4<554::AID-JBM1049>3.0.CO;2-V; Turkova J, 1999, J CHROMATOGR B, V722, P11, DOI 10.1016/S0378-4347(98)00434-4; Zhu H, 2003, CURR OPIN CHEM BIOL, V7, P55, DOI 10.1016/S1367-5931(02)00005-4; Zlatanova J, 2001, Methods Mol Biol, V170, P17	40	72	77	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1335	+		10.1096/fj.04-2098fje	http://dx.doi.org/10.1096/fj.04-2098fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15939735				2022-12-25	WOS:000230207800031
J	Kus, B; Gajadhar, A; Stanger, K; Cho, R; Sun, W; Rouleau, N; Lee, T; Chan, D; Wolting, C; Edwards, A; Bosse, R; Rotin, D				Kus, B; Gajadhar, A; Stanger, K; Cho, R; Sun, W; Rouleau, N; Lee, T; Chan, D; Wolting, C; Edwards, A; Bosse, R; Rotin, D			A high throughput screen to identify substrates for the ubiquitin ligase Rsp5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; EPITHELIAL NA+ CHANNEL; HIPPEL-LINDAU PROTEIN; LARGE SUBUNIT; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL INTERACTION; INDUCED DEGRADATION; MEMBRANE-PROTEINS; LIDDLES-SYNDROME; WW DOMAINS	Ubiquitin-protein ligases (E3s) are implicated in various human disorders and are attractive targets for therapeutic intervention. Although most cellular proteins are ubiquitinated, ubiquitination cannot be linked directly to a specific E3 for a large fraction of these proteins, and the substrates of most E3 enzymes are unknown. We have developed a luminescent assay to detect ubiquitination in vitro, which is more quantitative, effective, and sensitive than conventional ubiquitination assays. By taking advantage of the abundance of purified proteins made available by genomic efforts, we screened hundreds of purified yeast proteins for ubiquitination, and we identified previously reported and novel substrates of the yeast E3 ligase Rsp5. The relevance of these substrates was confirmed in vivo by showing that a number of them interact genetically with Rsp5, and some were ubiquitinated by Rsp5 in vivo. The combination of this sensitive assay and the availability of purified substrates will enable the identification of substrates for any purified E3 enzyme.	Hosp Sick Children, Program Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; PerkinElmer Life Sci, Biosignal, Montreal, PQ H3J 1R4, Canada; Univ Turin, Dept Biochem, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Turin	Rotin, D (corresponding author), Hosp Sick Children, Program Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	drotin@sickkids.ca		Edwards, Aled/0000-0002-4782-6016				Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Burger AM, 2004, EUR J CANCER, V40, P2217, DOI 10.1016/j.ejca.2004.07.006; Cattaneo M, 2004, GENE, V326, P149, DOI 10.1016/j.gene.2003.10.021; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Gwizdek C, 2005, J BIOL CHEM, V280, P13401, DOI 10.1074/jbc.C500040200; He CH, 1999, BIOCHEM CELL BIOL, V77, P375; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Horak J, 2003, BBA-BIOMEMBRANES, V1614, P139, DOI 10.1016/S0005-2736(03)00195-0; Hu H, 2004, PROTEOMICS, V4, P643, DOI 10.1002/pmic.200300632; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kus BM, 2004, PROTEINS, V54, P455, DOI 10.1002/prot.10620; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Na X, 2003, EMBO J, V22, P4249, DOI 10.1093/emboj/cdg410; Orlowski Robert Z, 2004, Expert Rev Anticancer Ther, V4, P171, DOI 10.1586/14737140.4.2.171; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Rouleau N, 2003, J BIOMOL SCREEN, V8, P191, DOI 10.1177/1087057103252605; Shcherbik N, 2004, J BIOL CHEM, V279, P53892, DOI 10.1074/jbc.M410325200; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Wang GL, 1999, MOL CELL BIOL, V19, P342; Warner G, 2004, CURR MED CHEM, V11, P721, DOI 10.2174/0929867043455693; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wong BR, 2003, DRUG DISCOV TODAY, V8, P746, DOI 10.1016/S1359-6446(03)02780-6; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	36	34	37	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29470	29478		10.1074/jbc.M502197200	http://dx.doi.org/10.1074/jbc.M502197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15955809	hybrid			2022-12-25	WOS:000231176200012
J	Napp, J; Monje, F; Stuhmer, W; Pardo, LA				Napp, J; Monje, F; Stuhmer, W; Pardo, LA			Glycosylation of Eag1 (Kv10.1) potassium channels - Intracellular trafficking and functional consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; SHAKER K+ CHANNEL; CELL-SURFACE EXPRESSION; ELECTROSTATIC INTERACTIONS; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; QUALITY-CONTROL; PROTEIN; OLIGOSACCHARIDES; GLYCOPROTEIN	N-Linked glycosylation is a common post-translational modification of membrane proteins. Here we report that mature Eag1 potassium channels carry sugar moieties linked to asparagines at positions 388 and 406. Asn-388 seems to undergo only core glycosylation, but complex sugars are bound to Asn-406. Correct complex glycosylation is required for proper trafficking of Eag1 to the plasma membrane but is also crucial for the correct function of channels already inserted in the membrane.	Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, D-37075 Gottingen, Germany	Max Planck Society	Pardo, LA (corresponding author), Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, Hermann Rein Str 3, D-37075 Gottingen, Germany.	Pardo@em.mpg.de	Pardo, Luis/C-5066-2013; Stuehmer, Walter/A-2176-2009	Pardo, Luis/0000-0003-1375-4349; Stuehmer, Walter/0000-0002-0642-7764; Napp, Joanna/0000-0002-9034-9980				Cayabyab FS, 2002, J BIOL CHEM, V277, P13673, DOI 10.1074/jbc.M108211200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Conti LR, 2002, J BIOL CHEM, V277, P25416, DOI 10.1074/jbc.M203109200; de Souza NF, 2002, BIOCHEMISTRY-US, V41, P11351, DOI 10.1021/bi0258041; Dijkink L, 2002, PFLUG ARCH EUR J PHY, V444, P549, DOI 10.1007/s00424-002-0855-4; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Gavrilova-Ruch O, 2002, J MEMBRANE BIOL, V188, P137, DOI 10.1007/s00232-001-0181-3; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; He JQ, 2002, BIOCHEM BIOPH RES CO, V297, P565, DOI 10.1016/S0006-291X(02)02259-3; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Imperiali B, 1999, CURR OPIN CHEM BIOL, V3, P643, DOI 10.1016/S1367-5931(99)00021-6; Jeng CJ, 2005, NEUROREPORT, V16, P229, DOI 10.1097/00001756-200502280-00005; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kundra R, 1999, J BIOL CHEM, V274, P31039, DOI 10.1074/jbc.274.43.31039; Moreno J, 2002, J MEMBRANE BIOL, V190, P175, DOI 10.1007/s00232-002-1034-4; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; OLSEN O, 1991, MOL GEN GENET, V225, P177, DOI 10.1007/BF00269845; Ouadid-Ahidouch H, 2001, RECEPTOR CHANNEL, V7, P345; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Park KH, 2003, FASEB J, V17, DOI 10.1096/fj.03-0577fje; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Rettinger J, 2000, J BIOL CHEM, V275, P33542, DOI 10.1074/jbc.M002918200; Saito Y, 2003, FEBS LETT, V533, P29, DOI 10.1016/S0014-5793(02)03744-4; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; STUHMER W, 1992, METHOD ENZYMOL, V207, P353; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Watanabe I, 2004, J BIOL CHEM, V279, P8879, DOI 10.1074/jbc.M309802200; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	48	47	48	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29506	29512		10.1074/jbc.M504228200	http://dx.doi.org/10.1074/jbc.M504228200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15964838	hybrid			2022-12-25	WOS:000231176200016
J	Tian, XY; Guo, JX; Yao, FM; Yang, DP; Makriyannis, A				Tian, XY; Guo, JX; Yao, FM; Yang, DP; Makriyannis, A			The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-RESONANCE NMR; SOLID-STATE H-2-NMR; CANNABINOID RECEPTOR; INTERNUCLEAR DISTANCES; PHOSPHOLIPID-BILAYERS; DPPC BILAYERS; MODEL; ANALOGS; PRINCIPLES; PACKING	The endogenous cannabinoid ligand anandamide is biosynthesized from membrane phospholipid precursors and is believed to reach its sites of action on the CB1 and CB2 receptors through fast lateral diffusion within the cell membrane. To gain a better insight on the stereochemical features of its association with the cell membrane and its interaction with the cannabinoid receptors, we have studied its conformation, location, and dynamic properties in a dipalmitoylphosphatidylcholine multilamellar model membrane bilayer system. By exploiting the bilayer lattice as an internal three-dimensional reference grid, the conformation and location of anandamide were determined by measuring selected inter- and intramolecular distances between strategically introduced isotopic labels using the rotational echo double resonance (REDOR) NMR method. A molecular model was proposed to represent the structural features of our anandamide/lipid system and was subsequently used in calculating the multispin dephasing curves. Our results demonstrate that anandamide adopts an extended conformation within the membrane with its headgroup at the level of the phospholipid polar group and its terminal methyl group near the bilayer center. Parallel static H-2 NMR experiments further confirmed these findings and provided evidence that anandamide experiences dynamic properties similar to those of the membrane phospholipids and produces no perturbation to the bilayer. Our results are congruent with a hypothesis that anandamide approaches its binding site by laterally diffusing within one membrane leaflet in an extended conformation and interacts with a hydrophobic groove formed by helices 3 and 6 of CB1, where its terminal carbon is positioned close to a key cysteine residue in helix 6 leading to receptor activation.	Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA; Coll Holy Cross, Dept Phys, Worcester, MA 01610 USA	Northeastern University; College of the Holy Cross	Makriyannis, A (corresponding author), Northeastern Univ, Ctr Drug Discovery, Rm 116,Mugar Hall, Boston, MA 02115 USA.	a.makriyannis@neu.edu	Makriyannis, Alexandros/GRF-1518-2022	Makriyannis, Alexandros/0000-0003-3272-3687	NIDA NIH HHS [T32-DA7312, DA3801, DA7251] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003801, T32DA007312, R37DA003801] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		APPLEGATE KR, 1991, J LIPID RES, V32, P1635; APPLEGATE KR, 1986, J LIPID RES, V27, P658; Barnett-Norris J, 1998, J MED CHEM, V41, P4861, DOI 10.1021/jm9803471; Barnett-Norris J, 2002, INT J QUANTUM CHEM, V88, P76, DOI 10.1002/qua.10093; BARRY JA, 1991, BIOCHEMISTRY-US, V30, P8386, DOI 10.1021/bi00098a016; Binder H, 2001, J PHYS CHEM B, V105, P12378, DOI 10.1021/jp010118h; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Cadas H, 1996, J NEUROSCI, V16, P3934; Childers SR, 1998, DRUG ALCOHOL DEPEN, V51, P173, DOI 10.1016/S0376-8716(98)00075-1; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Goetz JM, 1997, J MAGN RESON, V127, P147, DOI 10.1006/jmre.1997.1198; GULLION T, 1989, J MAGN RESON, V81, P196, DOI 10.1016/0022-2364(89)90280-1; Guo JX, 2003, J MED CHEM, V46, P4838, DOI 10.1021/jm020385r; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; HERBETTE LG, 1986, BIOPHYS J, V49, P91, DOI 10.1016/S0006-3495(86)83605-0; Hirsh DJ, 1996, BIOCHEMISTRY-US, V35, P12733, DOI 10.1021/bi961468a; HUCHO F, 1993, NEUROTRANSMITTER REC, V24, P3; Inooka H, 2001, NAT STRUCT BIOL, V8, P161, DOI 10.1038/84159; KATSARAS J, 1995, BIOCHEMISTRY-US, V34, P4684, DOI 10.1021/bi00014a023; MAKRIYANNIS A, 1989, BIOCHIM BIOPHYS ACTA, V986, P141, DOI 10.1016/0005-2736(89)90283-6; MAKRIYANNIS A, 1995, CANNABINOID RECEPTOR, P87; MCDONNELL PA, 1993, J MAGN RESON SER B, V102, P120, DOI 10.1006/jmrb.1993.1073; MUELLER DD, 1995, BIOCHEMISTRY-US, V34, P5597, DOI 10.1021/bi00016a034; Neidigh JW, 2002, BIOPOLYMERS, V65, P354, DOI 10.1002/bip.10272; Palian MM, 2003, J AM CHEM SOC, V125, P5823, DOI 10.1021/ja0268635; PAN Y, 1990, J MAGN RESON, V90, P330, DOI 10.1016/0022-2364(90)90138-Y; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Sack I, 1999, J MAGN RESON, V138, P54, DOI 10.1006/jmre.1999.1710; SCHAEFER J, 1998, E SCHERING RES FDN W, V26, P25; Song ZH, 1996, MOL PHARMACOL, V49, P891; Tong WD, 1998, J MED CHEM, V41, P4207, DOI 10.1021/jm970239z; Xie XQ, 1996, J BIOL CHEM, V271, P10640, DOI 10.1074/jbc.271.18.10640; YANG DP, 1992, BIOCHIM BIOPHYS ACTA, V1103, P25, DOI 10.1016/0005-2736(92)90053-O; Yao FM, 2003, J LABELLED COMPD RAD, V46, P115, DOI 10.1002/jlcr.650	35	60	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29788	29795		10.1074/jbc.M502925200	http://dx.doi.org/10.1074/jbc.M502925200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15964843	hybrid			2022-12-25	WOS:000231176200049
J	Sayasith, K; Lussier, JG; Sirois, J				Sayasith, K; Lussier, JG; Sirois, J			Role of upstream stimulatory factor phosphorylation in the regulation of the prostaglandin G/H synthase-2 promoter in granulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; RAT PREOVULATORY FOLLICLES; MESSENGER-RIBONUCLEIC-ACID; CAMP-RESPONSE ELEMENT; HELIX-LOOP-HELIX; VASCULAR ENDOTHELIAL-CELLS; DEPENDENT PROTEIN-KINASE; NF-KAPPA-B; ENDOPEROXIDE SYNTHASE-2; TRANSCRIPTION FACTOR	To investigate the role of USF phosphorylation in the regulation of the PGHS-2 promoter in granulosa cells, promoter activity assays were performed in primary cultures of bovine granulosa cells transfected with the chimeric PGHS-2 promoter/luciferase (LUC) construct -149/-2PGHS-2.LUC. Transfections were done in the absence or presence of forskolin; the protein kinase A (PKA) inhibitor H-89; or an expression vector encoding USF1, USF2, the catalytic subunit of PKA (cPKA), or a PKA inhibitor protein (PKI). Electrophoretic mobility shift assays were performed to study USF/DNA interactions using granulosa cell nuclear extracts and a P-32-labeled proximal PGHS-2 promoter fragment containing the E-box element. The results show that forskolin stimulation and cPKA overexpression caused a marked and significant increase in USF-dependent DNA binding and PGHS-2 promoter activities (p < 0.05). In contrast, both activities were decreased by H-89 treatment or PKI overexpression. Reverse transcription-PCR analyses revealed that these treatments had similar effects on endogenous PGHS-2 mRNA levels in granulosa cells. Cotransfection studies with a USF2 mutant lacking N-terminal activation domains (U2 Delta 1-220) repressed forskolin, cPKA-, and USF- dependent PGHS-2 promoter activities. Electrophoretic mobility shift assays showed that U2 Delta 1-220 was able to compete with full-length USF proteins and to saturate the E-box element. Immunoprecipitation/ Western blot analyses revealed an increase in the levels of phosphorylated USF1 and USF2 after forskolin treatment, whereas chromatin immunoprecipitation assays showed that binding of USF proteins to the endogenous PGHS-2 promoter was stimulated by forskolin. Site- directed mutagenesis of a consensus PKA phosphorylation site within USF proteins abolished their transactivating capacity. Collectively, these results characterize the role of USF phosphorylation in PGHS-2 expression and identify the phosphorylation-dependent increase in USF binding to the E-box as a putative molecular basis for the increase in PGHS-2 promoter transactivation in granulosa cells.	Univ Montreal, Fac Med Vet, CRRA, St Hyacinthe, PQ J2S 7C6, Canada; Univ Montreal, Fac Med Vet, Dept Biomed Vet, St Hyacinthe, PQ J2S 7C6, Canada	Universite de Montreal; Universite de Montreal	Sirois, J (corresponding author), Univ Montreal, Fac Med Vet, CRRA, 3200 Sicotte,CP 5000, St Hyacinthe, PQ J2S 7C6, Canada.	jean.sirois@umontreal.ca						ARMSTRONG DT, 1981, J REPROD FERTIL, V62, P283; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Billack B, 2002, AM J PHYSIOL-CELL PH, V283, pC1267, DOI 10.1152/ajpcell.00609.2001; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brule S, 2003, HISTOCHEM CELL BIOL, V119, P371, DOI 10.1007/s00418-003-0521-8; Cheung E, 1999, BIOCHEM J, V344, P145, DOI 10.1042/0264-6021:3440145; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; DAY RN, 1989, J BIOL CHEM, V264, P431; Duffy DM, 2002, HUM REPROD, V17, P2825, DOI 10.1093/humrep/17.11.2825; ESPEY LL, 1980, BIOL REPROD, V22, P73, DOI 10.1095/biolreprod22.1.73; ESPEY LL, 1994, PHYSL REPROD, V1, P725; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Galibert MD, 1997, J IMMUNOL, V159, P6176; Goueli BS, 2003, ONCOGENE, V22, P8042, DOI 10.1038/sj.onc.1206847; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Harris AN, 1998, MOL ENDOCRINOL, V12, P714, DOI 10.1210/me.12.5.714; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HUSLIG RL, 1987, MOL CELL ENDOCRINOL, V50, P237, DOI 10.1016/0303-7207(87)90022-0; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Jiang B, 2003, MOL CELL BIOL, V23, P6117, DOI 10.1128/MCB.23.17.6117-6128.2003; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Joyce IM, 2001, ENDOCRINOLOGY, V142, P3187, DOI 10.1210/en.142.7.3187; Juttner S, 2003, CELL MICROBIOL, V5, P821, DOI 10.1046/j.1462-5822.2003.00324.x; Kanamoto N, 2004, ENDOCRINOLOGY, V145, P4144, DOI 10.1210/en.2003-1718; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Lange CA, 2004, MOL ENDOCRINOL, V18, P269, DOI 10.1210/me.2003-0331; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu JM, 1998, BIOL REPROD, V58, P1527, DOI 10.1095/biolreprod58.6.1527; Liu JM, 1999, J BIOL CHEM, V274, P35037, DOI 10.1074/jbc.274.49.35037; Lobo FM, 1999, J IMMUNOL, V162, P2057; Mestre JR, 2001, FEBS LETT, V496, P147, DOI 10.1016/S0014-5793(01)02422-X; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURDOCH WJ, 1993, PROSTAG OTH LIPID M, V46, P85, DOI 10.1016/0090-6980(93)90037-8; Naz RK, 1999, BIOL REPROD, V60, P1402, DOI 10.1095/biolreprod60.6.1402; Nomura K, 2003, J NEUROSCI RES, V72, P384, DOI 10.1002/jnr.10581; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Okada Y, 2004, BLOOD, V104, P2027, DOI 10.1182/blood-2003-09-3107; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Reese J, 2001, ENDOCRINOLOGY, V142, P3198, DOI 10.1210/en.142.7.3198; Richards JS, 2002, RECENT PROG HORM RES, V57, P195, DOI 10.1210/rp.57.1.195; Sayasith K, 2004, J BIOL CHEM, V279, P6327, DOI 10.1074/jbc.M311222200; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Seals RC, 2004, ENDOCRINOLOGY, V145, P5616, DOI 10.1210/en.2003-1528; Segi E, 2003, BIOL REPROD, V68, P804, DOI 10.1095/biolreprod.102.003590; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P425; Sirito Mario, 1992, Gene Expression, V2, P231; Sirois J, 2004, HUM REPROD UPDATE, V10, P373, DOI 10.1093/humupd/dmh032; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Sirois J, 1997, ENDOCRINOLOGY, V138, P4427, DOI 10.1210/en.138.10.4427; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tremblay JJ, 2003, J STEROID BIOCHEM, V85, P291, DOI 10.1016/S0960-0760(03)00211-5; Tsai SJ, 1996, ENDOCRINOLOGY, V137, P3348, DOI 10.1210/en.137.8.3348; Vanden Berghe W, 2003, ADV EXP MED BIOL, V544, P181; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wang HB, 2004, J BIOL CHEM, V279, P10649, DOI 10.1074/jbc.M312203200; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu YL, 2002, BIOL REPROD, V66, P1505, DOI 10.1095/biolreprod66.5.1505; Wu YL, 2001, PROSTAG OTH LIPID M, V65, P103, DOI 10.1016/S0090-6980(01)00121-6; Xiao QX, 2002, AM J PHYSIOL-HEART C, V283, pH213, DOI 10.1152/ajpheart.01085.2001; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Zhu J, 2003, BLOOD, V102, P2420, DOI 10.1182/blood-2003-01-0251	73	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28885	28893		10.1074/jbc.M413434200	http://dx.doi.org/10.1074/jbc.M413434200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15927963	hybrid			2022-12-25	WOS:000231021300008
J	Heung, LJ; Kaiser, AE; Luberto, C; Del Poeta, M				Heung, LJ; Kaiser, AE; Luberto, C; Del Poeta, M			The role and mechanism of diacylglycerol-protein kinase C1 signaling in melanogenesis by Cryptococcus neoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STRESS RESPONSE; SACCHAROMYCES-CEREVISIAE; VIRULENCE; YEAST; PKC1; HOMOLOG; PATHWAY; MELANIN; ALPHA; IDENTIFICATION	The fungus Cryptococcus neoformans is an opportunistic human pathogen that causes a life-threatening meningoencephalitis by expression of virulence factors such as melanin, a black pigment produced by the cell wall-associated enzyme laccase. In previous studies ( Heung, L. J., Luberto, C., Plowden, A., Hannun, Y. A., and Del Poeta, M. ( 2004) J. Biol. Chem. 279, 21144 - 21153) we proposed that the sphingolipid enzyme inositolphosphoryl ceramide synthase 1 ( Ipc1) regulates melanin production through the generation of diacylglycerol ( DAG), which was found to activate in vitro protein kinase C1 ( Pkc1). Here, we investigated the molecular mechanisms by which DAG regulates Pkc1 in vivo and the effect of this regulation on laccase activity and melanin synthesis. To this end we deleted the putative DAG binding C1 domain of C. neoformans Pkc1 and found that the C1 deletion abolished the activation of Pkc1 by DAG. Deletion of the C1 domain repressed laccase activity and, consequently, melanin production. Finally, we show that these biological effects observed in the C1 deletion mutant are mediated by alteration of cell wall integrity and displacement of laccase from the cell wall. These studies define novel molecular mechanisms addressing Pkc1-laccase regulation by the sphingolipid pathway of C. neoformans, with important implications for understanding and targeting the Ipc1-Pkc1-laccase cascade as a regulator of virulence of this important human pathogen.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Del Poeta, M (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	delpoeta@musc.edu	Heung, Lena/AAH-5866-2021	Heung, Lena/0000-0002-6655-575X	NCRR NIH HHS [RR17677] Funding Source: Medline; NIAID NIH HHS [AI56168] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alspaugh JA, 2002, EUKARYOT CELL, V1, P75, DOI 10.1128/EC.1.1.75-84.2002; Alspaugh JA, 1997, GENE DEV, V11, P3206, DOI 10.1101/gad.11.23.3206; AMES BN, 1960, J BIOL CHEM, V235, P769; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; Aschrafi A, 2003, BBA-MOL CELL BIOL L, V1634, P30, DOI 10.1016/j.bbalip.2003.08.004; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Casadevall A, 2000, CURR OPIN MICROBIOL, V3, P354, DOI 10.1016/S1369-5274(00)00103-X; CASADEVALL A, 1998, CRYPTOCOCCUS NEOFORM, P381; Chang YC, 2000, J EXP MED, V191, P871, DOI 10.1084/jem.191.5.871; Chang YC, 2001, P NATL ACAD SCI USA, V98, P3258, DOI 10.1073/pnas.061031998; CHASKES S, 1975, J CLIN MICROBIOL, V1, P509, DOI 10.1128/JCM.1.6.509-514.1975; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; Cowart LA, 2003, J BIOL CHEM, V278, P30328, DOI 10.1074/jbc.M300656200; D'Souza CA, 2001, MOL CELL BIOL, V21, P3179, DOI 10.1128/MCB.21.9.3179-3191.2001; Eisenman HC, 2005, BIOCHEMISTRY-US, V44, P3683, DOI 10.1021/bi047731m; Gomez BL, 2003, CURR OPIN INFECT DIS, V16, P91, DOI 10.1097/00001432-200304000-00005; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HashidaOkado T, 1996, MOL GEN GENET, V251, P236; Heung LJ, 2004, J BIOL CHEM, V279, P21144, DOI 10.1074/jbc.M312995200; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; LEVIN DE, 1994, CELL MOL BIOL RES, V40, P229; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; Luberto C, 2001, GENE DEV, V15, P201, DOI 10.1101/gad.856001; Mednick AJ, 2005, INFECT IMMUN, V73, P2012, DOI 10.1128/IAI.73.4.2012-2019.2005; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Paravicini G, 1996, YEAST, V12, P741, DOI 10.1002/(SICI)1097-0061(19960630)12:8<741::AID-YEA967>3.0.CO;2-G; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Reese AJ, 2003, MOL MICROBIOL, V50, P1401, DOI 10.1046/j.1365-2958.2003.03780.x; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; Schmitz HP, 2003, CURR GENET, V43, P245, DOI 10.1007/s00294-003-0403-6; TOFFALETTI DL, 1993, J BACTERIOL, V175, P1405, DOI 10.1128/JB.175.5.1405-1411.1993; Valdivia RH, 2003, P NATL ACAD SCI USA, V100, P10287, DOI 10.1073/pnas.1834246100; Wang P, 2001, EMBO REP, V2, P511, DOI 10.1093/embo-reports/kve109; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WILLIAMSON PR, 1994, J BACTERIOL, V176, P656, DOI 10.1128/jb.176.3.656-664.1994; WILLIAMSON PR, 1997, FRONT BIOSCI, V2, P99; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhu XD, 2001, INFECT IMMUN, V69, P5589, DOI 10.1128/IAI.69.9.5589-5596.2001	42	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28547	28555		10.1074/jbc.M503404200	http://dx.doi.org/10.1074/jbc.M503404200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15946943	hybrid			2022-12-25	WOS:000230857300045
J	Kaul, S; Anantharam, V; Yang, YJ; Choi, CJ; Kanthasamy, A; Kanthasamy, AG				Kaul, S; Anantharam, V; Yang, YJ; Choi, CJ; Kanthasamy, A; Kanthasamy, AG			Tyrosine phosphorylation regulates the proteolytic activation of protein kinase C delta in dopaminergic neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-INDUCED APOPTOSIS; NF-KAPPA-B; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; PKC-DELTA; H2O2-INDUCED APOPTOSIS; CASPASE-3 ACTIVATION; PARKINSONS-DISEASE; DNA FRAGMENTATION; AMYLOID-BETA	Oxidative stress is a key apoptotic stimulus in neuronal cell death and has been implicated in the pathogenesis of many neurodegenerative disorders, including Parkinson disease ( PD). Recently, we demonstrated that protein kinase C-delta ( PKC delta) is an oxidative stress-sensitive kinase that can be activated by caspase-3-dependent proteolytic cleavage to induce apoptotic cell death in cell culture models of Parkinson disease (Kaul, S., Kanthasamy, A., Kitazawa, M., Anantharam, V., and Kanthasamy, A. G. (2003) Eur. J. Neurosci. 18, 1387 - 1401 and Kanthasamy, A. G., Kitazawa, M., Kanthasamy, A., and Anantharam, V. ( 2003) Antioxid. Redox. Signal. 5, 609 - 620). Here we showed that the phosphorylation of a tyrosine residue in PKC delta can regulate the proteolytic activation of the kinase during oxidative stress, which consequently influences the apoptotic cell death in dopaminergic neuronal cells. Exposure of a mesencephalic dopaminergic neuronal cell line (N27 cells) to H2O2 (0-300 mu M) induced a dose-dependent increase in cytotoxicity, caspase-3 activation and PKC delta cleavage. H2O2-induced proteolytic activation of PKC delta was mediated by the activation of caspase-3. Most interestingly, both the general Src tyrosine kinase inhibitor genistein ( 25 mu M) and the p60(Src) tyrosine-specific kinase inhibitor ( TSKI; 5 mu M) dramatically inhibited H2O2 and the Parkinsonian toxin 1-methyl-4-phenylpyridinium-induced PKC delta cleavage, kinase activation, and apoptotic cell death. H2O2 treatment also increased phosphorylation of PKC delta at tyrosine site 311, which was effectively blocked by co-treatment with TSKI. Furthermore, N27 cells overexpressing a PKC delta(Y311F) mutant protein exhibited resistance to H2O2-induced PKC delta cleavage, caspase activation, and apoptosis. To our knowledge, these data demonstrate for the first time that phosphorylation of Tyr-311 on PKC delta can regulate the proteolytic activation and proapoptotic function of the kinase in dopaminergic neuronal cells.	Iowa State Univ, Dept Biomed Sci, Parkinsons Disorder Res Lab, Ames, IA 50011 USA	Iowa State University	Kanthasamy, AG (corresponding author), Iowa State Univ, Dept Biomed Sci, Parkinsons Disorder Res Lab, 2062 Vet Med Bldg, Ames, IA 50011 USA.	akanthas@iastate.edu		Kanthasamy, Arthi/0000-0003-4654-9907; Kanthasamy, Anumantha/0000-0002-6454-4264	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038644, R01NS045133] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES10586] Funding Source: Medline; NINDS NIH HHS [NS45133, NS38644] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anantharam V, 2002, J NEUROSCI, V22, P1738, DOI 10.1523/JNEUROSCI.22-05-01738.2002; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Banan A, 2002, J PHARMACOL EXP THER, V303, P17, DOI 10.1124/jpet.102.037218; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Borlongan C V, 1996, J Fla Med Assoc, V83, P335; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7; Chang H, 2003, FREE RADICAL RES, V37, P655, DOI 10.1080/1071576031000094907; Choi C, 2003, BIOSCI BIOTECH BIOCH, V67, P1916, DOI 10.1271/bbb.67.1916; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Crosby D, 2003, J BIOL CHEM, V278, P24533, DOI 10.1074/jbc.M301847200; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Demelash A, 2004, EUR J ENDOCRINOL, V150, P841, DOI 10.1530/eje.0.1500841; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DiPietrantonio AM, 1999, BIOCHEM BIOPH RES CO, V255, P477, DOI 10.1006/bbrc.1999.0208; Gille G, 2004, ANN NY ACAD SCI, V1018, P533, DOI 10.1196/annals.1296.066; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Haendeler J, 2003, MOL CELL BIOL, V23, P4598, DOI 10.1128/MCB.23.13.4598-4610.2003; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Ishikawa Daisuke, 1996, Kobe Journal of Medical Sciences, V42, P243; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jiang B, 2003, CELL BIOL INT, V27, P1025, DOI 10.1016/j.cellbi.2003.09.007; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Kanthasamy AG, 2003, ANTIOXID REDOX SIGN, V5, P609, DOI 10.1089/152308603770310275; KANTHASAMY AG, 2003, ANN NY ACAD SCI, V1010, P883; Kaul S, 2003, EUR J NEUROSCI, V18, P1387, DOI 10.1046/j.1460-9568.2003.02864.x; Kawahara A, 1998, GENES CELLS, V3, P297, DOI 10.1046/j.1365-2443.1998.00189.x; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Kitazawa M, 2003, NEUROSCIENCE, V119, P945, DOI 10.1016/S0306-4522(03)00226-4; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Latchoumycandane C, 2005, J PHARMACOL EXP THER, V313, P46, DOI 10.1124/jpet.104.078469; Lewis AE, 2005, CELL SIGNAL, V17, P253, DOI 10.1016/j.cellsig.2004.07.005; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; Niwa K, 2002, FREE RADICAL RES, V36, P1147, DOI 10.1080/1071576021000016409; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Prasad KN, 1998, MOL GENET METAB, V65, P1, DOI 10.1006/mgme.1998.2726; Pratico D, 2004, J ALZHEIMERS DIS, V6, P171; Przedborski S, 2003, ANN NY ACAD SCI, V991, P189; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Roth BL, 1997, APPL ENVIRON MICROB, V63, P2421, DOI 10.1128/AEM.63.6.2421-2431.1997; Rybin VO, 2004, J BIOL CHEM, V279, P19350, DOI 10.1074/jbc.M311096200; Sakurai Y, 2001, BIOL PHARM BULL, V24, P973, DOI 10.1248/bpb.24.973; Schapira AHV, 1996, CURR OPIN NEUROL, V9, P260, DOI 10.1097/00019052-199608000-00003; Sharif-Askari E, 2001, EMBO J, V20, P3101, DOI 10.1093/emboj/20.12.3101; Sherer TB, 2002, J NEUROSCI, V22, P7006; Sonee M, 2004, NEUROTOXICOLOGY, V25, P885, DOI 10.1016/j.neuro.2003.11.001; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tamagno E, 2003, EXP NEUROL, V180, P144, DOI 10.1016/S0014-4886(02)00059-6; Tamura H, 2003, INT J MOL MED, V11, P369; Tan SL, 1998, J NEUROCHEM, V71, P95; Veurink G, 2003, ANN HUM BIOL, V30, P639, DOI 10.1080/03014460310001620144; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Yamakawa H, 2000, NEUROL RES, V22, P556; Yang YJ, 2004, MOL CELL NEUROSCI, V25, P406, DOI 10.1016/j.mcn.2003.11.011; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Youdim MBH, 2004, ANN NY ACAD SCI, V1012, P306, DOI 10.1196/annals.1306.025; Yuan J, 2003, BBA-MOL CELL RES, V1641, P35, DOI 10.1016/S0167-4889(03)00047-8; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0	73	84	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28721	28730		10.1074/jbc.M501092200	http://dx.doi.org/10.1074/jbc.M501092200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15961393	hybrid			2022-12-25	WOS:000230857300063
J	Kinebuchi, T; Kagawa, W; Kurumizaka, H; Yokoyama, S				Kinebuchi, T; Kagawa, W; Kurumizaka, H; Yokoyama, S			Role of the N-terminal domain of the human DMC1 protein in octamer formation and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RAD51 PROTEIN; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; YEAST RAD51; RECOMBINATION; MEIOSIS; PROMOTES; HOMOLOG; COMPLEXES; CATALYSIS	The DMC1 protein, a eukaryotic homologue of RecA that shares significant amino acid identity with RAD51, exhibits two oligomeric DNA binding forms, an octameric ring and a helical filament. In the crystal structure of the octameric ring form, the DMC1 N-terminal domain (1-81 amino acid residues) was highly flexible, with multiple conformations. On the other hand, the N-terminal domain of Rad51 makes specific interactions with the neighboring ATPase domain in the helical filament structure. To gain insights into the functional role of the N-terminal domain of DMC1, we prepared a deletion mutant, DMC1-(82-340), that lacks the N-terminal 81 amino acid residues from the human DMC1 protein. Analytical ultracentrifugation experiments revealed that, whereas full-length DMC1 forms a octamer, DMC1(82-340) is a heptamer. Furthermore, DNA binding experiments showed that DMC1-(82-340) was completely defective in both single-stranded and double-stranded DNA binding activities. Therefore, the N-terminal domain of DMC1 is required for the formation of the octamer, which may support the proper DNA binding activity of the DMC1 protein.	RIKEN, Genom Sci Ctr, Prot Res Grp, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan; RIKEN, Harima Inst, Sayo, Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; Waseda University; RIKEN; University of Tokyo	Kurumizaka, H (corresponding author), RIKEN, Genom Sci Ctr, Prot Res Grp, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	kurumizaka@waseda.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kagawa, Wataru/0000-0002-8801-6589; Kurumizaka, Hitoshi/0000-0001-7412-3722				Aihara H, 1999, J MOL BIOL, V290, P495, DOI 10.1006/jmbi.1999.2904; Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P15770, DOI 10.1073/pnas.2632890100; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Chen YK, 2004, P NATL ACAD SCI USA, V101, P10572, DOI 10.1073/pnas.0404195101; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; Enomoto R, 2004, J BIOL CHEM, V279, P35263, DOI 10.1074/jbc.M402481200; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Hayase A, 2004, CELL, V119, P927, DOI 10.1016/j.cell.2004.10.031; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kinebuchi T, 2004, MOL CELL, V14, P363, DOI 10.1016/S1097-2765(04)00218-7; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Passy SI, 1999, P NATL ACAD SCI USA, V96, P10684, DOI 10.1073/pnas.96.19.10684; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Tsubouchi H, 2004, GENETICS, V168, P1219, DOI 10.1534/genetics.103.025700; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; Wu Y, 2004, MOL CELL, V15, P423, DOI 10.1016/j.molcel.2004.07.014; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	34	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28382	28387		10.1074/jbc.M503372200	http://dx.doi.org/10.1074/jbc.M503372200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15917243	hybrid			2022-12-25	WOS:000230857300026
J	Michalska, K; Brzezinski, K; Jaskolski, M				Michalska, K; Brzezinski, K; Jaskolski, M			Crystal structure of isoaspartyl aminopeptidase in complex with L-aspartate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; 7-AMINOCEPHALOSPORANIC ACID ACYLASE; N-TERMINAL NUCLEOPHILE; X-RAY-STRUCTURE; ESCHERICHIA-COLI; AUTOPROTEOLYTIC ACTIVATION; L-ASPARAGINASE; PROTEIN METHYLTRANSFERASE; REPAIR HYPOTHESIS; AMINO-ACID	The crystal structure of Escherichia coli isoaspartyl aminopeptidase/asparaginase ( EcAIII), an enzyme belonging to the N-terminal nucleophile ( Ntn)-hydrolases family, has been determined at 1.9-angstrom resolution for a complex obtained by cocrystallization with L-aspartate, which is a product of both enzymatic reactions catalyzed by EcAIII. The enzyme is a dimer of heterodimers, ( alpha beta)(2). The ( alpha beta) heterodimer, which arises by autoproteolytic cleavage of the immature protein, exhibits an alpha beta beta alpha-sandwich fold, typical for Ntn-hydrolases. The asymmetric unit contains one copy of the EcAIII(.)Asp complex, with clearly visible L-aspartate ligands, one bound in each of the two active sites of the enzyme. The L-aspartate ligand is located near Thr(179), the N-terminal residue of subunit beta liberated in the autoproteolytic event. Structural comparisons with the free form of EcAIII reveal that there are no major rearrangements of the active site upon aspartate binding. Although the ligand binding mode is similar to that observed in an L-aspartate complex of the related enzyme human aspartylglucosaminidase, the architecture of the EcAIII active site sheds light on the question of substrate specificity and explains why EcAIII is not able to hydrolyze glycosylated asparagine substrates.	Adam Mickiewicz Univ Poznan, Fac Chem, Dept Crystallog, PL-60780 Poznan, Poland; Polish Acad Sci, Inst Bioorgan Chem, Ctr Biocrystallog Res, PL-61704 Poznan, Poland	Adam Mickiewicz University; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Jaskolski, M (corresponding author), Adam Mickiewicz Univ Poznan, Fac Chem, Dept Crystallog, PL-60780 Poznan, Poland.	mariuszj@amu.edu.pl	Brzezinski, Krzysztof/R-8406-2019	Brzezinski, Krzysztof/0000-0001-9339-7745; Jaskolski, Mariusz/0000-0003-1587-6489				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bond CS, 2003, BIOINFORMATICS, V19, P311, DOI 10.1093/bioinformatics/19.2.311; Borek D., 1999, Plant Physiology, V119, P1568; Borek D, 2000, ACTA CRYSTALLOGR D, V56, P1505, DOI 10.1107/S0907444900010076; Borek D, 2004, EUR J BIOCHEM, V271, P3215, DOI 10.1111/j.1432-1033.2004.04254.x; Borek D, 2001, ACTA BIOCHIM POL, V48, P893; BOREK D, 2001, THESIS MICHIEWICZ U; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CERTER P, 1988, NATURE, V332, P564; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; DORER FE, 1968, ARCH BIOCHEM BIOPHYS, V127, P490, DOI 10.1016/0003-9861(68)90253-1; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Elkins JM, 2005, BIOCHEM J, V385, P565, DOI 10.1042/BJ20040814; GARY JD, 1995, J BIOL CHEM, V270, P4076, DOI 10.1074/jbc.270.8.4076; GEIGER T, 1987, J BIOL CHEM, V262, P785; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guo HC, 1998, J BIOL CHEM, V273, P20205, DOI 10.1074/jbc.273.32.20205; HALEY EE, 1968, J BIOL CHEM, V243, P5748; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Jozic D, 2003, J MOL BIOL, V332, P243, DOI 10.1016/S0022-2836(03)00845-3; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kim JK, 2003, BIOCHEMISTRY-US, V42, P4084, DOI 10.1021/bi027181x; Kim Y, 2000, STRUCTURE, V8, P1059, DOI 10.1016/S0969-2126(00)00505-0; Larsen RA, 2001, J BACTERIOL, V183, P3089, DOI 10.1128/JB.183.10.3089-3097.2001; Lee YS, 2000, J BIOL CHEM, V275, P39200, DOI 10.1074/jbc.M002504200; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LOWENSON JD, 1990, J BIOL CHEM, V265, P3106; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mudgett MB, 1997, PLANT PHYSIOL, V115, P1481, DOI 10.1104/pp.115.4.1481; Muller P, 2003, ACTA CRYSTALLOGR D, V59, P32, DOI 10.1107/S0907444902018000; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OCONNOR CM, 1985, BIOCHEM BIOPH RES CO, V132, P1144, DOI 10.1016/0006-291X(85)91926-6; Oinonen C, 2000, PROTEIN SCI, V9, P2329, DOI 10.1110/ps.9.12.2329; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peltola M, 1996, HUM MOL GENET, V5, P737, DOI 10.1093/hmg/5.6.737; Prahl A, 2004, ACTA CRYSTALLOGR D, V60, P1173, DOI 10.1107/S0907444904003403; Qian XF, 2003, STRUCTURE, V11, P997, DOI 10.1016/S0969-2126(03)00150-3; Radisky ES, 2002, P NATL ACAD SCI USA, V99, P10316, DOI 10.1073/pnas.112332899; Riikonen A, 1996, J BIOL CHEM, V271, P21340, DOI 10.1074/jbc.271.35.21340; Saarela J, 2004, BIOCHEM J, V378, P363, DOI 10.1042/BJ20031496; Saarela J, 2001, HUM MOL GENET, V10, P983, DOI 10.1093/hmg/10.9.983; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Suresh CG, 1999, NAT STRUCT BIOL, V6, P414, DOI 10.1038/8213; SWAIN AL, 1993, P NATL ACAD SCI USA, V90, P1474, DOI 10.1073/pnas.90.4.1474; Thoden JB, 2003, BIOCHEMISTRY-US, V42, P4874, DOI 10.1021/bi034233p; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xuan JC, 1998, PROTEIN SCI, V7, P774, DOI 10.1002/pro.5560070327	54	39	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28484	28491		10.1074/jbc.M504501200	http://dx.doi.org/10.1074/jbc.M504501200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15946951	hybrid			2022-12-25	WOS:000230857300038
J	Whittle, E; Cahoon, EB; Subrahmanyam, S; Shanklin, J				Whittle, E; Cahoon, EB; Subrahmanyam, S; Shanklin, J			A multifunctional acyl-acyl carrier protein desaturase from Hedera helix L. (English ivy) can synthesize 16-and 18-carbon monoene and diene products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; TRANSGENIC TOBACCO; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; RICINUS-COMMUNIS; PLANTS; SEED; EXPRESSION; GENE; MUTAGENESIS	A desaturase with 83% sequence identity to the coriander Delta(4)-16:0-ACP desaturase was isolated from developing seeds of Hedera helix ( English ivy). Expression of the ivy desaturase in Arabidopsis resulted in the accumulation of 16: 1 Delta(4) and its expected elongation product 18: 1 Delta(6) ( petroselinic acid). Expression in Escherichia coli resulted in the accumulation of soluble, active protein that was purified to apparent homogeneity. In vitro assays confirmed Delta(4) desaturation with 16:0-ACP; however, with 18:0-acyl acyl carrier protein (ACP) desaturation occurred at the Delta(9) position. The ivy desaturase also converted 16:1 Delta(9)-ACP and 18: 1 Delta(9)-ACP to the corresponding Delta(4,9) dienes. These data suggest at least two distinct substrate binding modes, one placing C4 at the diiron active site and the other placing C9 at the active site. In the latter case, 18: 0 would likely bind in an extended conformation as described for the castor desaturase with 9-carbons accommodated in the cavity beyond the dirron site. However, Delta(4) desaturation would require the accommodation of 12 carbons for C16 substrates or 14 carbons for C18 substrates. The amino acids lining the substrate binding cavity of ivy and castor desaturases are conserved except for T117R and P179I ( castor/ivy). Paradoxically, both substitutions, when introduced into the castor desaturase, favored the binding of shorter acyl chains. Thus, it seems likely that Delta(4) desaturation would require a non-extended, perhaps U-shaped, substrate conformation. A cis double bond may facilitate the initiation of such a non-extended conformation in the monounsaturated substrates. The multifunctional properties of the ivy desaturase make it well suited for further dissection of the determinants of regiospecificity.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; USDA ARS, Res Serv, Plant Genet Res Res Unit, Donald Danforth Plant Sci Ctr, St Louis, MO USA	United States Department of Energy (DOE); Brookhaven National Laboratory; Donald Danforth Plant Science Center; United States Department of Agriculture (USDA)	Shanklin, J (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463,50 Bell Ave, Upton, NY 11973 USA.	shanklin@bnl.gov		Shanklin, John/0000-0002-6774-8043				ANDERSON BA, 1973, LIPIDS, V9, P185; ANDERSSON S, 1974, J SOLID STATE CHEM, V10, P219, DOI 10.1016/0022-4596(74)90029-2; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Behrouzian B, 2002, J AM CHEM SOC, V124, P3277, DOI 10.1021/ja012252l; BLOOMFIELD DK, 1960, J BIOL CHEM, V235, P337; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; CAHOON EB, 1994, PLANT PHYSIOL, V104, P827, DOI 10.1104/pp.104.3.827; Cahoon EB, 1997, PLANT MOL BIOL, V33, P1105, DOI 10.1023/A:1005821007291; Cahoon EB, 1998, PLANT PHYSIOL, V117, P593, DOI 10.1104/pp.117.2.593; Cahoon EB, 2000, P NATL ACAD SCI USA, V97, P12350, DOI 10.1073/pnas.210276297; Cahoon EB, 1997, P NATL ACAD SCI USA, V94, P4872, DOI 10.1073/pnas.94.10.4872; Cahoon EB, 1999, P NATL ACAD SCI USA, V96, P12935, DOI 10.1073/pnas.96.22.12935; CAHOON EB, 1992, P NATL ACAD SCI USA, V89, P11184, DOI 10.1073/pnas.89.23.11184; CAHOON EB, 1994, PROG LIPID RES, V33, P155, DOI 10.1016/0163-7827(94)90018-3; CAHOON EB, 1994, J BIOL CHEM, V269, P27519; DATLA RSS, 1992, GENE, V122, P383, DOI 10.1016/0378-1119(92)90232-E; Dyer JM, 2002, PLANT PHYSIOL, V130, P2027, DOI 10.1104/pp.102.010835; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; Goldstein RA, 2001, NATO SCI SER I LIFE, V333, P185, DOI 10.1017/CBO9780511560125.013; Haas JA, 1999, BIOCHEMISTRY-US, V38, P12833, DOI 10.1021/bi991318a; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kridl J. C., 1991, Seed Science Research, V1, P209, DOI 10.1017/S0960258500000921; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; Moche M, 2003, J BIOL CHEM, V278, P25072, DOI 10.1074/jbc.M301662200; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; SCHROEPF.GJ, 1965, J BIOL CHEM, V240, P54; Schultz DJ, 1996, P NATL ACAD SCI USA, V93, P8771, DOI 10.1073/pnas.93.16.8771; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; Sperling P, 2000, EUR J BIOCHEM, V267, P3801, DOI 10.1046/j.1432-1327.2000.01418.x; Sperling P, 2003, PROSTAG LEUKOTR ESS, V68, P73, DOI 10.1016/S0952-3278(02)00258-2; Thelen JJ, 2002, METAB ENG, V4, P12, DOI 10.1006/mben.2001.0204; THOMPSON GA, 1991, P NATL ACAD SCI USA, V88, P2578, DOI 10.1073/pnas.88.6.2578; Voelker T, 1996, Genet Eng (N Y), V18, P111; Whittle E, 2001, J BIOL CHEM, V276, P21500, DOI 10.1074/jbc.M102129200; YAMAMOTO K, 1991, CHEM PHYS LIPIDS, V60, P39, DOI 10.1016/0009-3084(91)90013-2	39	32	47	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28169	28176		10.1074/jbc.M504205200	http://dx.doi.org/10.1074/jbc.M504205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15939740	hybrid			2022-12-25	WOS:000230857300002
J	Zhang, ZM; Olland, AM; Zhu, Y; Cohen, J; Berrodin, T; Chippari, S; Appavu, C; Li, S; Wilhem, J; Chopra, R; Fensome, A; Zhang, PW; Wrobel, J; Unwalla, RJ; Lyttle, R; Winneker, RC				Zhang, ZM; Olland, AM; Zhu, Y; Cohen, J; Berrodin, T; Chippari, S; Appavu, C; Li, S; Wilhem, J; Chopra, R; Fensome, A; Zhang, PW; Wrobel, J; Unwalla, RJ; Lyttle, R; Winneker, RC			Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-METABOLIZING-ENZYMES; REPRODUCTIVE FUNCTIONS; CONFORMATIONAL-CHANGES; ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; BINDING GLOBULIN; HORMONE RECEPTOR; GENE-EXPRESSION; MICE LACKING; NORETHINDRONE	Progesterone receptor ( PR) agonists have several important applications in women's health, such as in oral contraception and post-menopausal hormone therapy. Currently, all PR agonists used clinically are steroids. Because of their interactions with other steroid receptors, steroid-metabolizing enzymes, or other steroid-signaling pathways, these drugs can pose significant side effects in some women. Efforts to discover novel nonsteroidal PR agonists with improved biological properties led to the discovery of tanaproget ( TNPR). TNPR binds to the PR from various species with a higher relative affinity than reference steroidal progestins. In T47D cells, TNPR induces alkaline phosphatase activity with an EC50 value of 0.1 nM, comparable with potent steroidal progestins such as medroxyprogesterone acetate ( MPA) and trimegestone ( TMG), albeit with a reduced efficacy ( similar to 60%). In a mammalian two-hybrid assay to measure PR agonist-induced interaction between steroid receptor co-activator-1 and PR, TNPR showed similar potency ( EC50 value of 0.02 nM) and efficacy to MPA and TMG. Importantly, in key animal models such as the rat ovulation inhibition assay, TNPR demonstrates full efficacy and an enhanced progestational potency ( 30-fold) when compared with MPA and TMG. Furthermore, TNPR has relatively weak interactions with other steroid receptors and binding proteins and little effect on cytochrome P450 metabolic pathways. Finally, the three-dimensional crystal structure of the PR ligand binding domain with TNPR has been delineated to demonstrate how this nonsteroidal ligand achieves its high binding affinity. Therefore, TNPR is a structurally novel and very selective PR agonist with an improved preclinical pharmacological profile.	Womens Hlth Res Inst, Div Endocrinol & Reprod Disorders, Wyeth Res, Malvern, PA 19355 USA; Wyeth Res, Dept Chem & Screening Sci, Collegeville, PA 16426 USA; Wyeth Res, Dept Drug Safety & Metab, Collegeville, PA 16426 USA; Wyeth Res, Cambridge, MA 02140 USA	Pfizer; Pfizer; Pfizer; Pfizer	Zhang, ZM (corresponding author), Womens Hlth Res Inst, Div Endocrinol & Reprod Disorders, Wyeth Res, 500 Arcola Rd, Malvern, PA 19355 USA.	zhangz@wyeth.com	Zhang, Puwen/AAY-6815-2020					ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Back D J, 1983, IPPF Med Bull, V17, P1; Benowitz NL, 2004, CLIN PHARMACOL THER, V75, pP36, DOI 10.1016/j.clpt.2003.11.135; Bitran D, 1999, BRAIN RES, V850, P217, DOI 10.1016/S0006-8993(99)02150-2; Bitran D, 2000, PSYCHOPHARMACOLOGY, V151, P31, DOI 10.1007/s002130000472; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Bramley T, 2003, REPRODUCTION, V125, P3, DOI 10.1530/reprod/125.1.3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG CY, 1983, J CLIN ENDOCR METAB, V56, P68, DOI 10.1210/jcem-56-1-68; Conneely OM, 2003, STEROIDS, V68, P771, DOI 10.1016/S0039-128X(03)00126-0; Conneely OM, 2002, RECENT PROG HORM RES, V57, P339, DOI 10.1210/rp.57.1.339; CONNEELY OM, 1989, J BIOL CHEM, V264, P14062; DeLano WL, 2002, PYMOL USERS MANUAL; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P313; GODSLAND IF, 1990, NEW ENGL J MED, V323, P1375, DOI 10.1056/NEJM199011153232003; Hatcher R A, 1993, Contracept Technol Update, V14, P114; JUCHEM M, 1990, AM J OBSTET GYNECOL, V163, P2171, DOI 10.1016/0002-9378(90)90559-P; KAMDEM L, 1981, XENOBIOTICA, V11, P275, DOI 10.3109/00498258109045302; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200; LAROSA JC, 1988, AM J OBSTET GYNECOL, V158, P1621, DOI 10.1016/0002-9378(88)90200-1; Leonhardt SA, 2003, STEROIDS, V68, P761, DOI 10.1016/S0039-128X(03)00129-6; Lundeen SG, 2001, J STEROID BIOCHEM, V78, P137, DOI 10.1016/S0960-0760(01)00091-7; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Madauss KP, 2004, J MED CHEM, V47, P3381, DOI 10.1021/jm030640n; Mani SK, 1997, HORM BEHAV, V31, P244, DOI 10.1006/hbeh.1997.1393; Mani SK, 1996, MOL ENDOCRINOL, V10, P1728, DOI 10.1210/me.10.12.1728; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mulac-Jericevic B, 2004, REPRODUCTION, V128, P139, DOI 10.1530/rep.1.00189; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nugent AG, 2003, CLIN ENDOCRINOL, V59, P690, DOI 10.1046/j.1365-2265.2003.01907.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palovaara S, 2003, BRIT J CLIN PHARMACO, V56, P232, DOI 10.1046/j.1365-2125.2003.01868.x; PHILLIPS A, 1990, STEROIDS, V55, P373, DOI 10.1016/0039-128X(90)90062-G; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Psychoyos A, 1973, Vitam Horm, V31, P201; Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WADE AE, 1977, PHARMACOLOGY, V15, P289, DOI 10.1159/000136702; WEIGEL NL, 1995, J STEROID BIOCHEM, V53, P509, DOI 10.1016/0960-0760(95)00098-K; WHITE INH, 1977, BIOCHEM J, V166, P57, DOI 10.1042/bj1660057; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; WINNEKER RC, 1989, ENDOCRINOLOGY, V125, P715, DOI 10.1210/endo-125-2-715; Winneker RC, 2003, STEROIDS, V68, P915, DOI 10.1016/S0039-128X(03)00142-9; Zhang PW, 2002, BIOORG MED CHEM LETT, V12, P787, DOI 10.1016/S0960-894X(02)00025-2; ZHANG ZM, 1994, ENDOCRINOLOGY, V135, P1256, DOI 10.1210/en.135.3.1256; Zhang ZM, 2000, STEROIDS, V65, P637, DOI 10.1016/S0039-128X(00)00120-3; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	62	64	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28468	28475		10.1074/jbc.M504144200	http://dx.doi.org/10.1074/jbc.M504144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15937332	hybrid			2022-12-25	WOS:000230857300036
J	Lee, DK; Kang, JE; Park, HJ; Kim, MH; Yim, TH; Kim, JM; Heo, MK; Kim, KY; Kwon, HJ; Hur, MW				Lee, DK; Kang, JE; Park, HJ; Kim, MH; Yim, TH; Kim, JM; Heo, MK; Kim, KY; Kwon, HJ; Hur, MW			FBI-1 enhances transcription of the nuclear factor-kappa B (NF-kappa B)-responsive E-selectin gene by nuclear localization of the p65 subunit of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POZ DOMAIN; ZINC-FINGER; DNA-BINDING; BTB/POZ DOMAIN; ACTIN-BINDING; ALPHA; PROTEINS; DEGRADATION; INTERACT; INDUCER	The POZ domain is a highly conserved protein-protein interaction motif found in many regulatory proteins. Nuclear factor-kappa B ( NF-kappa B) plays a key role in the expression of a variety of genes in response to infection, inflammation, and stressful conditions. We found that the POZ domain of FBI-1 ( factor that binds to the inducer of short transcripts of human immunodeficiency virus-1) interacted with the Rel homology domain of the p65 subunit of NF-kappa B in both in vivo and in vitro protein-protein interaction assays. FBI-1 enhanced NF-kappa B-mediated transcription of E-selectin genes in HeLa cells upon phorbol 12-myristate 13-acetate stimulation and overcame gene repression by I kappa B alpha or I kappa B alpha. In contrast, the POZ domain of FBI-1, which is a dominant-negative form of FBI-1, repressed NF-kappa B-mediated transcription, and the repression was cooperative with I kappa B beta or I kappa B beta. In contrast, the POZ domain tagged with a nuclear localization sequence polypeptide of FBI-1 enhanced NF-kappa B kappa B-responsive gene transcription, suggesting that the molecular interaction between the POZ domain and the Rel homology domain of p65 and the nuclear localization by the nuclear localization sequence are important in the transcription enhancement mediated by FBI-1. Confocal microscopy showed that FBI-1 increased NF-kappa B movement into the nucleus and increased the stability of NF-kappa B in the nucleus, which enhanced NF-kappa B -mediated transcription of the E-selectin gene. FBI-1 also interacted with I kappa B alpha and I kappa B alpha.	Yonsei Univ, Sch Med, Dept Biochem & Mol Biol, Seoul 120752, South Korea; Yonsei Univ, Sch Med, Inst Genet Sci, BK21 Project Med Sci, Seoul 120752, South Korea; Ewha Womans Univ, Dept Biol Sci, Seoul 120750, South Korea; Sejong Univ, Dept Biol Engn, Seoul 143747, South Korea	Yonsei University; Yonsei University; Ewha Womans University; Sejong University	Hur, MW (corresponding author), Yonsei Univ, Sch Med, Dept Biochem & Mol Biol, 134 ShinChon Dong, Seoul 120752, South Korea.	mwhur2@yumc.yonsei.ac.kr	권, 호정/AAS-3642-2021					ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; Kroll M, 1997, ONCOGENE, V15, P1841, DOI 10.1038/sj.onc.1201560; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; Pendergrast PS, 2002, MOL BIOL CELL, V13, P915, DOI 10.1091/mbc.01-08-0383; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shishodia Shishir, 2004, Cancer Treat Res, V119, P139; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058	38	48	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27783	27791		10.1074/jbc.M504909200	http://dx.doi.org/10.1074/jbc.M504909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15917220	hybrid			2022-12-25	WOS:000230678600038
J	Newton, CS; Loukinova, E; Mikhailenko, I; Ranganathan, S; Gao, YM; Haudenschild, C; Strickland, DK				Newton, CS; Loukinova, E; Mikhailenko, I; Ranganathan, S; Gao, YM; Haudenschild, C; Strickland, DK			Platelet-derived growth factor receptor-beta (PDGFR-beta) activation promotes its association with the low density lipoprotein receptor-related protein (LRP) - Evidence for co-receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CELL-MIGRATION; ALPHA-2-MACROGLOBULIN RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; IN-VITRO; BINDING; SHC; KINASE; INTERNALIZATION	Activation of the platelet-derived growth factor receptor-beta PDGFR-beta leads to tyrosine phosphorylation of the cytoplasmic domain of LRP and alters its association with adaptor and signaling proteins, such as Shc. The mechanism of the PDGF-induced LRP tyrosine phosphorylation is not well understood, especially since PDGF not only activates PDGF receptor but also binds directly to LRP. To gain insight into this mechanism, we used a chimeric receptor in which the ligand binding domain of the PDGFR-beta was replaced with that from the macrophage colony-stimulating factor (M-CSF) receptor, a highly related receptor tyrosine kinase of the same subfamily, but with different ligand specificity. Activation of the chimeric receptor upon the addition of M-CSF readily mediated the tyrosine phosphorylation of LRP. Since M-CSF is not recognized by LRP, these results indicated that growth factor binding to LRP is not necessary for this phosphorylation event. Using a panel of cytoplasmic domain mutants of the chimeric M-CSF/PDGFR-beta, we confirmed that the kinase domain of PDGFR-beta is absolutely required for LRP tyrosine phosphorylation but that PDGFR-beta-mediated activation of phosphatidylinositol 3- kinase, RasGAP, SHP-2, phospholipase C-gamma, and Src are not necessary for LRP tyrosine phosphorylation. To identify the cellular compartment where LRP and the PDGFR-beta may interact, we employed immunofluorescence and immunogold electron microscopy. In WI-38 fibroblasts, these two receptors co-localized in coated pits and endosomal compartments following PDGF stimulation. Further, phosphorylated forms of the PDGFR-beta coimmunoprecipitated with LRP following PDGF treatment. Together, these studies revealed close association between activated PDGFR-beta and LRP, suggesting that LRP functions as a co-receptor capable of modulating the signal transduction pathways initiated by the PDGF receptor from endosomes.	Univ Maryland, Sch Med, Dept Surg, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Physiol, Rockville, MD 20855 USA; George Washington Univ, Inst Biomed Sci, Med Ctr, Washington, DC 20037 USA	George Washington University	Strickland, DK (corresponding author), Univ Maryland, Sch Med, Dept Surg, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	dstrickland@som.umaryland.edu	Christian, Haudenschild C/D-1602-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50784, HL54710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; OLSON JE, 1990, J BIOL CHEM, V265, P1847; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pelkmans L, 2004, CELL, V118, P767, DOI 10.1016/j.cell.2004.09.003; Ranganathan S, 2004, J BIOL CHEM, V279, P40536, DOI 10.1074/jbc.M407592200; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Takayama Y, 2005, J BIOL CHEM, V280, P18504, DOI 10.1074/jbc.M410265200; WALKER F, 1991, J BIOL CHEM, V266, P2746; Wang Y, 2004, J BIOL CHEM, V279, P8038, DOI 10.1074/jbc.M311494200; Wijnberg MJ, 1997, THROMB HAEMOSTASIS, V78, P880; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Wu LH, 2004, J CELL BIOCHEM, V93, P1169, DOI 10.1002/jcb.20288; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212	38	75	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27872	27878		10.1074/jbc.M505410200	http://dx.doi.org/10.1074/jbc.M505410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15944146	hybrid			2022-12-25	WOS:000230678600049
J	Pappa, A; Brown, D; Koutalos, Y; DeGregori, J; White, C; Vasiliou, V				Pappa, A; Brown, D; Koutalos, Y; DeGregori, J; White, C; Vasiliou, V			Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; BINDING-PROTEIN; ULTRAVIOLET-LIGHT; INDUCED APOPTOSIS; STEM-CELLS; LENS; ALDH3A1; ACTIVATION; EXPRESSION; MICE	Aldehyde dehydrogenase 3A1 (ALDH3A1) is a NAD(P)(+)-dependent enzyme that is highly expressed in mammalian corneal epithelial cells and has been shown to protect against UV- and 4-hydroxynonenal-induced cellular damage, mainly by metabolizing toxic lipid peroxidation aldehydes. Here we report a novel function of ALDH3A1 as a negative cell cycle regulator. We noticed a reduction in ALDH3A1 gene expression in actively proliferating primary human corneal epithelium explant cultures, indicating that ALDH3A1 expression is inversely correlated with replication. To examine this further, a human corneal epithelial cell line (HCE) lacking endogenous ALDH3A1 was stably transfected to express ALDH3A1 at levels similar to those found in vivo. ALDH3A1-transfected cells exhibited an elongated cell cycle, decreased plating efficiency, and reduced DNA synthesis compared with the mock-transfected cells. These effects were associated with reduced cyclin A- and cyclin B-dependent kinase activities and reduced phosphorylation of the retinoblastoma protein (pRb) as well as decreased protein levels of cyclins A, B, and E, the transcription factor E2F1, and the cyclin-dependent kinase inhibitor p21. These observations were further expanded and confirmed on human keratinocyte cells (NCTC-2544) overexpressing ALDH3A1. Consistent with a protective role of an elongated cell cycle, ALDH3A1-transfected cells exhibited increased resistance to the cytotoxic effects of the DNA-damaging agents mitomycin C and Vp-16. Immunohistochemistry and biochemical fractionation revealed that ALDH3A1 is localized both in the nucleus and cytosol of ALDH3A1-transfected cells, implying a possible association between the nuclear localization of the enzyme and its proliferation-suppressive functions. In conclusion, these results suggest that ALDH3A1 may protect corneal epithelial cells against oxidative damage not only through its metabolic function but also by prolonging the cell cycle.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci,Mol Toxicol & Environm Hlth, Denver, CO 80262 USA; Univ Calif Irvine, Dept Ophthalmol, Irvine, CA 92868 USA; Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California Irvine; Medical University of South Carolina; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Vasiliou, V (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci,Mol Toxicol & Environm Hlth, 4200 E 9th Ave, Denver, CO 80262 USA.	vasilis.vasiliou@uchsc.edu	Pappa, Aglaia/P-4663-2019; Pappa, Aglaia/E-8663-2011	Pappa, Aglaia/0000-0003-0913-4315; vasiliou, vasilis/0000-0003-2552-3118; DeGregori, James/0000-0002-1287-1976	NATIONAL CANCER INSTITUTE [R01CA077314] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY011490, R01EY011490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007464] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA077314, R01 CA077314-07] Funding Source: Medline; NEI NIH HHS [EY11490] Funding Source: Medline; NIAAA NIH HHS [T32 AA07464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252; Andley UP, 2001, FASEB J, V15, P221, DOI 10.1096/fj.00-0296com; ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614; BANFI P, 1994, MOL PHARMACOL, V46, P896; Boesch JS, 1996, J BIOL CHEM, V271, P5150; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Cai CX, 1998, MOL BIOL CELL, V9, P1037, DOI 10.1091/mbc.9.5.1037; Cenedella RJ, 2001, OPHTHALMIC RES, V33, P210, DOI 10.1159/000055672; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; CROOKE ST, 1976, CANCER TREAT REV, V3, P121, DOI 10.1016/S0305-7372(76)80019-9; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dianzani Mario Umberto, 2003, Molecular Aspects of Medicine, V24, P263; DOWNES JE, 1994, CORNEA, V13, P67, DOI 10.1097/00003226-199401000-00011; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Jester JV, 1999, J CELL SCI, V112, P613; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KRUSE FE, 1993, INVEST OPHTH VIS SCI, V34, P2976; KRUSE FE, 1994, EYE, V8, P170, DOI 10.1038/eye.1994.42; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lehrer MS, 1998, J CELL SCI, V111, P2867; Manzer R, 2003, CHEM-BIOL INTERACT, V143, P45, DOI 10.1016/S0009-2797(02)00171-0; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Marcotte R, 2004, MECH AGEING DEV, V125, P777, DOI 10.1016/j.mad.2004.07.007; Nees DW, 2002, MOL CELL BIOL, V22, P849, DOI 10.1128/MCB.22.3.849-855.2002; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Pappa A, 2003, BIOCHEM J, V376, P615, DOI 10.1042/BJ20030810; Pappa A, 2003, FREE RADICAL BIO MED, V34, P1178, DOI 10.1016/S0891-5849(03)00070-4; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; Piatigorsky J, 2000, J OCUL PHARMACOL TH, V16, P173, DOI 10.1089/jop.2000.16.173; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; Piatigorsky J, 2000, J BIOL CHEM, V275, P41064, DOI 10.1074/jbc.M005625200; Piatigorsky J, 2001, CORNEA, V20, P853, DOI 10.1097/00003226-200111000-00015; Poli G, 2000, IUBMB LIFE, V50, P315, DOI 10.1080/15216540051081092; Ren HW, 1996, INVEST OPHTH VIS SCI, V37, P1017; Schnier JB, 1999, FEBS LETT, V454, P100, DOI 10.1016/S0014-5793(99)00773-5; Shiao T, 1999, PHARMACOGENETICS, V9, P145; Vasiliou V, 1999, PHARMACOGENETICS, V9, P569, DOI 10.1097/01213011-199910000-00004; Vasiliou V, 2003, ARCH BIOCHEM BIOPHYS, V413, P164, DOI 10.1016/S0003-9861(03)00095-X; Vasiliou V, 2000, CHEM-BIOL INTERACT, V129, P1, DOI 10.1016/S0009-2797(00)00211-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wunderlich M, 2002, ONCOGENE, V21, P4414, DOI 10.1038/sj.onc.1205541; Yamauchi K, 1999, J BIOL CHEM, V274, P8460, DOI 10.1074/jbc.274.13.8460; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X; Zieske JD, 2004, EXP EYE RES, V78, P447, DOI 10.1016/S0014-4835(03)00205-7; ZINOVIEVA RD, 1993, J BIOL CHEM, V268, P11449	47	73	78	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27998	28006		10.1074/jbc.M503698200	http://dx.doi.org/10.1074/jbc.M503698200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15905174	hybrid			2022-12-25	WOS:000230678600062
J	Bugreev, DV; Golub, EI; Stasiak, AZ; Stasiak, A; Mazin, AV				Bugreev, DV; Golub, EI; Stasiak, AZ; Stasiak, A; Mazin, AV			Activation of human meiosis-specific recombinase Dmc1 by Ca2(+)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; RECA PROTEIN; CHROMOSOME SYNAPSIS; CRYSTAL-STRUCTURE; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR CA2+; RAD51 PROTEIN; DUPLEX DNA; EXCHANGE	Rad51 and its meiotic homolog Dmc1 are key proteins of homologous recombination in eukaryotes. These proteins form nucleoprotein complexes on single-stranded DNA that promote a search for homology and that perform DNA strand exchange, the two essential steps of genetic recombination. Previously, we demonstrated that Ca2+ greatly stimulates the DNA strand exchange activity of human ( h) Rad51 protein ( Bugreev, D. V., and Mazin, A. V. ( 2004) Proc. Natl. Acad. Sci. U. S. A. 101, 9988 - 9993). Here, we show that the DNA strand exchange activity of hDmc1 protein is also stimulated by Ca2+. However, the mechanism of stimulation of hDmc1 protein appears to be different from that of hRad51 protein. In the case of hRad51 protein, Ca2+ acts primarily by inhibiting its ATPase activity, thereby preventing self-conversion into an inactive ADP-bound complex. In contrast, we demonstrate that hDmc1 protein does not self-convert into a stable ADP-bound complex. The results indicate that activation of hDmc1 is mediated through conformational changes induced by free Ca2+ ion binding to a protein site that is distinct from the Mg2+center dot ATP-binding center. These conformational changes are manifested by formation of more stable filamentous hDmc1 center dot single-stranded DNA complexes. Our results demonstrate a universal role of Ca2+ in stimulation of mammalian DNA strand exchange proteins and reveal diversity in the mechanisms of this stimulation.	Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA; Russian Acad Sci, Inst Chem Biol & Fundamental Med, Siberian Branch, Novosibirsk 630090, Russia; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Univ Lausanne, Lab Anal Ultrastruct, CH-1015 Lausanne, Switzerland	Drexel University; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; Yale University; University of Lausanne	Mazin, AV (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, MS 497,NCB,Rm 10103, Philadelphia, PA 19102 USA.	avm28@drexel.edu	Stasiak, Andrzej/E-5551-2010	Stasiak, Andrzej/0000-0002-0398-1989	NATIONAL CANCER INSTITUTE [R56CA100839, R01CA100839] Funding Source: NIH RePORTER; NCI NIH HHS [CA100839] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Bishop DK, 2004, CELL, V117, P9, DOI 10.1016/S0092-8674(04)00297-1; BRYANT FR, 1984, COLD SPRING HARB SYM, V49, P535, DOI 10.1101/SQB.1984.049.01.060; Bugreev DV, 2004, P NATL ACAD SCI USA, V101, P9988, DOI 10.1073/pnas.0402105101; CARROLL J, 1994, DEVELOPMENT, V120, P3507; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; FLORY SS, 1984, COLD SPRING HARB SYM, V49, P513, DOI 10.1101/SQB.1984.049.01.058; Gupta RC, 2001, P NATL ACAD SCI USA, V98, P8433, DOI 10.1073/pnas.121005298; Haber JE, 1998, CURR BIOL, V8, pR832, DOI 10.1016/S0960-9822(07)00524-6; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kinebuchi T, 2004, MOL CELL, V14, P363, DOI 10.1016/S1097-2765(04)00218-7; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Korzets A, 1999, J LAB CLIN MED, V133, P362, DOI 10.1016/S0022-2143(99)90067-7; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Kumasaka S, 1999, ANTIOXID REDOX SIGN, V1, P55, DOI 10.1089/ars.1999.1.1-55; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Lynn A, 2004, ANNU REV GENOM HUM G, V5, P317, DOI 10.1146/annurev.genom.4.070802.110217; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; Mazina OM, 2004, J BIOL CHEM, V279, P52042, DOI 10.1074/jbc.M410244200; NEGRESALVAYRE A, 1992, FEBS LETT, V299, P60, DOI 10.1016/0014-5793(92)80101-L; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Romani AMP, 2000, FRONT BIOSCI, V5, pD720, DOI 10.2741/Romani; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; SAKAI H, 1994, BBA-GEN SUBJECTS, V1201, P259, DOI 10.1016/0304-4165(94)90049-3; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; SOGO JM, 1987, ELECTRON MICROS, P61; SPIELBERG H, 1991, EXP HEMATOL, V19, P742; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Tan TLR, 2003, DNA REPAIR, V2, P787, DOI 10.1016/S1568-7864(03)00070-3; Wu Y, 2004, MOL CELL, V15, P423, DOI 10.1016/j.molcel.2004.07.014; Wu Y, 2005, J BIOL CHEM, V280, P722, DOI 10.1074/jbc.M411093200; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2	43	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26886	26895		10.1074/jbc.M502248200	http://dx.doi.org/10.1074/jbc.M502248200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917244	hybrid			2022-12-25	WOS:000230589500031
J	Li, D; Yea, S; Li, S; Chen, Z; Narla, G; Banck, M; Laborda, J; Tan, S; Friedman, JM; Friedman, SL; Walsh, MJ				Li, D; Yea, S; Li, S; Chen, Z; Narla, G; Banck, M; Laborda, J; Tan, S; Friedman, JM; Friedman, SL; Walsh, MJ			Kruppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; MOLECULAR REGULATION; RETINOBLASTOMA PROTEIN; HEPATIC-FIBROSIS; PROSTATE-CANCER; CLASS-I; EXPRESSION; KLF6	Preadipocyte differentiation occurs during distinct periods of human development and is a key determinant of body mass. Transcriptional events underlying adipogenesis continue to emerge, but the link between chromatin remodeling of specific target loci and preadipocyte differentiation remains elusive. We have identified Kruppel-like factor-6 (KLF6), a recently described tumor suppressor gene, as a repressor of the proto-oncogene Delta-like 1 (Dlk1), a gene encoding a transmembrane protein that inhibits adipocyte differentiation. Forced expression of KLF6 strongly inhibits Dlk1 expression in preadipocytes and NIH 3T3 cells in vivo, whereas down-regulation of KLF6 in 3T3-L1 cells by small interfering RNA prevents adipogenesis. Repression of Dlk1 requires HDAC3 deacetylase activity, which is recruited to the endogenous Dlk1 promoter where it interacts with KLF6. Our studies identify the interaction between HDAC3 and KLF6 as a potential mechanism underlying human adipogenesis, and highlight the role of KLF6 as a multifunctional transcriptional regulator capable of mediating adipocyte differentiation through gene repression.	Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA; Univ Castilla La Mancha, Sch Med, Dept Inorgan & Organ Chem & Biochem, Mol Biol Branch, Albacete 02071, Spain; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Penn State Univ, Dept Biochem & Mol Biol, Ctr Gene Regulat, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, Genet Mol Lab, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Universidad de Castilla-La Mancha; Icahn School of Medicine at Mount Sinai; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Howard Hughes Medical Institute; Rockefeller University	Friedman, SL (corresponding author), Mt Sinai Sch Med, Dept Med, Div Liver Dis, Box 1123,1425 Madison Ave,Rm 11-70C, New York, NY 10029 USA.	scott.friedman@mssm.edu	Narla, Goutham/AAZ-5710-2020; Laborda, Jorge/L-5726-2014	Narla, Goutham/0000-0003-4098-4203; Laborda, Jorge/0000-0002-9210-838X	NATIONAL CANCER INSTITUTE [R01CA098552] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340, R01DK056621, R01DK041096, R56DK056621] Funding Source: NIH RePORTER; NCI NIH HHS [CA98552] Funding Source: Medline; NHLBI NIH HHS [HL67099] Funding Source: Medline; NIDDK NIH HHS [DK41096, DK56621, DK37340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Blanchon L, 2001, MECH DEVELOP, V105, P185, DOI 10.1016/S0925-4773(01)00391-4; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Dangond F, 1999, Mol Cell Biol Res Commun, V2, P91, DOI 10.1006/mcbr.1999.0156; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Ferreira R, 2001, ONCOGENE, V20, P3128, DOI 10.1038/sj.onc.1204337; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; Inuzuka H, 1999, BBA-GENE STRUCT EXPR, V1447, P199, DOI 10.1016/S0167-4781(99)00161-X; Kao HY, 2000, GENE DEV, V14, P55; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Kojima S, 2000, BLOOD, V95, P1309; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; LABORDA J, 1993, J BIOL CHEM, V268, P3817; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Nicolas E, 2001, NUCLEIC ACIDS RES, V29, P3131, DOI 10.1093/nar/29.15.3131; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Suzuki T, 1998, J BIOCHEM, V124, P389, DOI 10.1093/oxfordjournals.jbchem.a022124; Tan S, 2001, PROTEIN EXPRES PURIF, V21, P224, DOI 10.1006/prep.2000.1363; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Turner J, 2003, J BIOL CHEM, V278, P12786, DOI 10.1074/jbc.M300587200; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wen YD, 2003, J BIOL CHEM, V278, P1841, DOI 10.1074/jbc.M206528200; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9	53	132	147	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26941	26952		10.1074/jbc.M500463200	http://dx.doi.org/10.1074/jbc.M500463200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917248	hybrid			2022-12-25	WOS:000230589500038
J	Mishra, JP; Mishra, S; Gee, K; Kumar, A				Mishra, JP; Mishra, S; Gee, K; Kumar, A			Differential involvement of calmodulin-dependent protein kinase II-activated AP-1 and c-Jun N-terminal kinase-activated EGR-1 signaling pathways in tumor necrosis factor-alpha and lipopolysaccharide-induced CD44 expression in human monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B TRANSCRIPTION FACTORS; GENE-EXPRESSION; CALCIUM-ENTRY; CUTTING EDGE; TNF-ALPHA; HYALURONAN; BINDING; INDUCTION; PROMOTER; INFLAMMATION	CD44 plays a crucial role in cell migration, inflammation, and immune responses. Alteration in the levels of CD44 expression on monocytic cells by endotoxins and immunoregulatory cytokines may modulate the migration of immune cells to inflammatory sites and the development of immune responses. Lipopolysaccharide (LPS) and the proinflammatory cytokine, tumor necrosis factor-alpha(TNF-alpha), act as important regulators of CD44 expression in human monocytic cells. We previously demonstrated that the c-Jun N-terminal kinase (JNK), a mitogen-activated protein kinase (MAPK), differentially regulated LPS-but not TNF-alpha-induced CD44 expression in monocytic cells. In this study, our results suggest that the calcium signaling pathway, in particular calmodulin (CaM) and CaM-dependent protein kinase II (CaMK-II), is involved in TNF-alpha- but not LPS-induced CD44 expression. CD44 promoter analysis suggested the participation of distinct transcription factors AP-1 and Egr-1 in TNF-alpha- and LPS-induced CD44 expression, respectively. Furthermore, TNF-alpha-induced CD44 expression was regulated by AP-1 through the activation of the CaMK-II pathway, whereas LPS-induced CD44 transcription was regulated specifically by Egr-1 through JNK activation. Overall, the results suggest the involvement of two distinct and independent signaling pathways involved in the regulation of CD44 transcription that may represent potential targets for anti-inflammatory agents capable of inhibiting CD44-mediated cell migration.	Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1N 6N5, Canada; Childrens Hosp Eastern Ontario, Res Inst, Div Virol & Mol Immunol, Ottawa, ON K1H 8L1, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario	Kumar, A (corresponding author), Univ Ottawa, Childrens Hosp Eastern Ontario, Div Virol, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	akumar@uottawa.ca	Gee, Katrina/H-3093-2016	Gee, Katrina/0000-0002-7535-2882				Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Bultynck G, 2003, BIOCHEM BIOPH RES CO, V311, P1181, DOI 10.1016/j.bbrc.2003.08.084; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008; Dallaire MJ, 2002, CLIN EXP ALLERGY, V32, P898, DOI 10.1046/j.1365-2222.2002.01377.x; DeFranco AL, 1998, PROG CLIN BIOL RES, V397, P119; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; Fichter M, 1997, ONCOGENE, V14, P2817, DOI 10.1038/sj.onc.1201127; Fitzgerald KA, 1999, J IMMUNOL, V162, P4920; Foster LC, 2000, FASEB J, V14, P368, DOI 10.1096/fasebj.14.2.368; Fujii K, 2001, J IMMUNOL, V167, P1198, DOI 10.4049/jimmunol.167.3.1198; Gee K, 2003, J BIOL CHEM, V278, P37275, DOI 10.1074/jbc.M302309200; Gee K, 2002, J IMMUNOL, V169, P5660, DOI 10.4049/jimmunol.169.10.5660; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Houston P, 2001, BIOCHEM BIOPH RES CO, V283, P480, DOI 10.1006/bbrc.2001.4810; Kasri NN, 2004, EMBO J, V23, P312, DOI 10.1038/sj.emboj.7600037; Katoh S, 1999, J IMMUNOL, V162, P5058; Kryworuchko M, 1999, EXP CELL RES, V250, P241, DOI 10.1006/excr.1999.4524; Legras S, 1997, BLOOD, V89, P1905, DOI 10.1182/blood.V89.6.1905; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Levesque MC, 1997, J IMMUNOL, V159, P6184; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; Ma W, 2004, J IMMUNOL, V172, P318, DOI 10.4049/jimmunol.172.1.318; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; NAOT D, 1997, ADV CANCER RES, V71, P241; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Sague SL, 2004, J INTERF CYTOK RES, V24, P301, DOI 10.1089/107999004323065093; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Sionov RV, 1998, CELL ADHES COMMUN, V6, P503, DOI 10.3109/15419069809010798; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Spencer VA, 2000, J CELL BIOCHEM, P27; Stallmach A, 2003, EXP MOL PATHOL, V74, P262, DOI 10.1016/S0014-4800(03)00025-X; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; Stoop R, 2001, ARTHRITIS RHEUM, V44, P2922, DOI 10.1002/1529-0131(200112)44:12<2922::AID-ART480>3.0.CO;2-7; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Verhasselt V, 1997, J IMMUNOL, V158, P2919; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; Wittig B, 1998, J IMMUNOL, V161, P1069; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zhang M, 1997, J BIOL CHEM, V272, P14139, DOI 10.1074/jbc.272.22.14139	55	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26825	26837		10.1074/jbc.M500244200	http://dx.doi.org/10.1074/jbc.M500244200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15923644	hybrid			2022-12-25	WOS:000230589500024
J	Pike, LJ; Han, XL; Gross, RW				Pike, LJ; Han, XL; Gross, RW			Epidermal growth factor receptors are localized to lipid rafts that contain a balance of inner and outer leaflet lipids - A shotgun lipidomics study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED MEMBRANE DOMAINS; CELLULAR LIPIDOMES; SPECTROMETRIC ANALYSIS; CHOLESTEROL DEPLETION; ALKALINE-PHOSPHATASE; BIOLOGICAL SAMPLES; ANCHORED PROTEINS; CAVEOLAE MEMBRANE; EPITHELIAL-CELLS; SURFACE	The epidermal growth factor (EGF) receptor partitions into lipid rafts made using a detergent-free method, but is extracted from low density fractions by Triton X-100. By screening several detergents, we identified Brij 98 as a detergent in which the EGF receptor is retained in detergent-resistant membrane fractions. To identify the difference in lipid composition between those rafts that harbored the EGF receptor (detergent-free and Brij 98-resistant) and those that did not (Triton X-100-resistant), we used multidimensional electrospray ionization mass spectrometry to perform a lipidomics study on these three raft preparations. Although all three raft preparations were similarly enriched in cholesterol, the EGF receptor-containing rafts contained more ethanolamine glycerophospholipids and less sphingomyelin than did the non-EGF receptor-containing Triton X-100 rafts. As a result, the detergent-free and Brij 98-resistant rafts exhibited a balance of inner and outer leaflet lipids, whereas the Triton X-100 rafts contained a preponderance of outer leaflet lipids. Furthermore, in all raft preparations, the outer leaflet phospholipid species were significantly different from those in the bulk membrane, whereas the inner leaflet lipids were quite similar to those found in the bulk membrane. These findings indicate that the EGF receptor is retained only in rafts that exhibit a lipid distribution compatible with a bilayer structure and that the selection of phospholipids for inclusion into rafts occurs mainly on the outer leaflet lipids.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Chem, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Pike, LJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, POB 8231,660 S Euclid Ave, St Louis, MO 63110 USA.	pike@wustl.edu			NHLBI NIH HHS [R01 HL41250, P01 HL57278, R01 HL041250, P01 HL057278] Funding Source: Medline; NIGMS NIH HHS [R01 GM064491, GM64491] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041250, P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064491] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Han XL, 2005, EXPERT REV PROTEOMIC, V2, P253, DOI 10.1586/14789450.2.2.253; Han XL, 2004, BIOCHEMISTRY-US, V43, P15584, DOI 10.1021/bi048307o; Han XL, 2004, ANAL BIOCHEM, V330, P317, DOI 10.1016/j.ab.2004.04.004; Han XL, 2005, MASS SPECTROM REV, V24, P367, DOI 10.1002/mas.20023; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Heerklotz H, 2003, J MOL BIOL, V329, P793, DOI 10.1016/S0022-2836(03)00504-7; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Milhiet PE, 2002, EMBO REP, V3, P485, DOI 10.1093/embo-reports/kvf096; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Niu SL, 2002, BIOPHYS J, V83, P3408, DOI 10.1016/S0006-3495(02)75340-X; OMARY MB, 1981, J BIOL CHEM, V256, P4715; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Prinetti A, 2000, J BIOL CHEM, V275, P11658, DOI 10.1074/jbc.275.16.11658; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Ringerike T, 2002, J CELL SCI, V115, P1331; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Saslowsky DE, 2002, J BIOL CHEM, V277, P26966, DOI 10.1074/jbc.M204669200; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Shogomori H, 2003, BIOL CHEM, V384, P1259, DOI 10.1515/BC.2003.139; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	43	172	174	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26796	26804		10.1074/jbc.M503805200	http://dx.doi.org/10.1074/jbc.M503805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917253	Green Accepted, hybrid			2022-12-25	WOS:000230589500021
J	Yang, G; Gao, YP; Dong, J; Liu, C; Xue, YN; Fan, M; Shen, BF; Shao, NS				Yang, G; Gao, YP; Dong, J; Liu, C; Xue, YN; Fan, M; Shen, BF; Shao, NS			A novel peptide screened by phage display can mimic TRAP antigen epitope against Staphylococcus aureus infections	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNAIII-INHIBITING PEPTIDE; IN-VIVO; PATHOGENESIS; EPIDERMIDIS; ANTIBODIES; VIRULENCE; TARGET; RAP	Staphylococcus aureus is a major human pathogen. Pathogenic effects are largely due to production of bacterial toxins, whose synthesis is controlled by an mRNA molecule termed RNAIII. The S. aureus protein called RAP (RNAIII-activating protein) is secreted and activates RNAIII production by inducing the phosphorylation of its target protein TRAP ( target of RAP). Antibodies to TRAP have been shown to suppress exotoxin production by S. aureus in vitro, suggesting that TRAP may be a useful vaccine target site. Here we showed that a peptide TA21 was identified by screening a phage display library using anti-TRAP antibodies. Mice vaccinated with Escherichia coli engineered to express TA21 on their surface (FTA21) were protected from S. aureus infections, using sepsis and cellulitis mice models. By sequence analysis, it was found that the TA21 is highly homologous to the C-terminal sequence of TRAP which is conserved among S. aureus and Staphylococcus epidermidis, suggesting that peptide TA21 may be a useful broad vaccine to protect from infection caused by various staphylococcal strains.	Beijing Inst Basic Med Sci, Beijing 100850, Peoples R China	Academy of Military Medical Sciences - China	Shao, NS (corresponding author), Beijing Inst Basic Med Sci, Beijing 100850, Peoples R China.	shaons@yahoo.com						Balaban N, 2003, J INFECT DIS, V187, P625, DOI 10.1086/345879; Balaban N, 1998, SCIENCE, V280, P438, DOI 10.1126/science.280.5362.438; Balaban N, 2001, J BIOL CHEM, V276, P2658, DOI 10.1074/jbc.M005446200; Dell'Acqua G, 2004, J INFECT DIS, V190, P318, DOI 10.1086/386546; Gov Y, 2004, J BIOL CHEM, V279, P14665, DOI 10.1074/jbc.M311106200; Korem M, 2003, FEMS MICROBIOL LETT, V223, P167, DOI 10.1016/S0378-1097(03)00326-4; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Normanno G, 2001, MICROBIOLOGICA, V24, P341; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; Otto M, 2001, PEPTIDES, V22, P1603, DOI 10.1016/S0196-9781(01)00495-8; Phalipon A, 1997, EUR J IMMUNOL, V27, P2620, DOI 10.1002/eji.1830271022; Ribeiro PD, 2003, PEPTIDES, V24, P1829, DOI 10.1016/j.peptides.2003.08.022; Sibille P, 1997, EUR J IMMUNOL, V27, P1221, DOI 10.1002/eji.1830270525; VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5; Vieira-da-Motta O, 2001, PEPTIDES, V22, P1621, DOI 10.1016/S0196-9781(01)00497-1; Yang G, 2003, PEPTIDES, V24, P1823, DOI 10.1016/j.peptides.2003.09.017	16	23	36	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27431	27435		10.1074/jbc.M501127200	http://dx.doi.org/10.1074/jbc.M501127200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15908434	hybrid			2022-12-25	WOS:000230589500094
J	Bentzinger, CF; Barzaghi, P; Lin, S; Ruegg, MA				Bentzinger, CF; Barzaghi, P; Lin, S; Ruegg, MA			Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha 2-deficient mice	FASEB JOURNAL			English	Article						muscular dystrophy; laminin-alpha 2 deficiency; muscle regeneration	CONGENITAL MUSCULAR-DYSTROPHY; MUTANT MICE; DYSTROGLYCAN BINDING; LAMININ ALPHA-1; LAMA2 GENE; G-DOMAIN; CHAIN; MOUSE; EXPRESSION; FORM	Mutations in the gene encoding the alpha 2 subunit of laminins cause the severe "merosin- deficient congenital muscular dystrophy" ( MDC1A). We have recently shown that overexpression of a miniaturized form of the molecule agrin (mini-agrin) counteracts the disease in dy(W)/dy(W) mice, a model for MDC1A. However, these mice express some residual truncated laminin- 2, suggesting that the observed amelioration might be due to mini-agrin's presenting the residual laminin-alpha 2 2 to its receptors. Here we show that the mini-agrin counteracts the disease in dy(3K)/ dy(3K) mice, which are null for laminin-alpha 2. As in dy(W)/ dy(W) mice, mini-agrin improves both the function and structure of muscle. We show that muscle regeneration after injury is severely impaired in dy3K/ dy3K mice but is restored in the mini-agrin-expressing littermates. In summary, our results 1) show that the direct linkage of muscle basal lamina with the sarcolemma is the basis of mini-agrin-mediated amelioration and 2) provide unprecedented evidence that this linkage is important for proper regeneration of muscle fibers after injury. Our findings thus suggest that treatment with mini-agrin might be beneficial over the entire spectrum of the MDC1A disease, whose severity inversely correlates with expression levels and the size of the truncation in laminin- alpha 2.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel	Ruegg, MA (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	markus-a.ruegg@unibas.ch	Ruegg, Markus/X-7256-2019; Bentzinger, C. Florian/A-1151-2015	Ruegg, Markus/0000-0002-4974-9384; Bentzinger, C. Florian/0000-0003-0422-9622; Lin, Shuo/0000-0003-2317-0339				AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; Briguet A, 2004, NEUROMUSCULAR DISORD, V14, P675, DOI 10.1016/j.nmd.2004.06.008; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Colognato H, 1999, CURR BIOL, V9, P1327, DOI 10.1016/S0960-9822(00)80056-1; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; COVAULT J, 1986, J CELL BIOL, V102, P731, DOI 10.1083/jcb.102.3.731; Gawlik K, 2004, HUM MOL GENET, V13, P1775, DOI 10.1093/hmg/ddh190; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Guo LT, 2003, NEUROMUSCULAR DISORD, V13, P207, DOI 10.1016/s0960-8966(02)00266-3; HARRIS JB, 1990, ELECTRON MICROSC REV, V3, P183, DOI 10.1016/0892-0354(90)90001-9; HARRIS JB, 1978, CLIN EXP PHARMACOL P, V5, P587, DOI 10.1111/j.1440-1681.1978.tb00714.x; Jones G, 1999, J NEUROSCI, V19, P3376; Jones KJ, 2001, J MED GENET, V38, P649, DOI 10.1136/jmg.38.10.649; Kammerer RA, 1999, EMBO J, V18, P6762, DOI 10.1093/emboj/18.23.6762; Kuang W, 1998, J CLIN INVEST, V102, P844, DOI 10.1172/JCI3705; Kuang W, 1999, LAB INVEST, V79, P1601; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; Li SH, 2003, DEV CELL, V4, P613, DOI 10.1016/S1534-5807(03)00128-X; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; MEIER H, 1970, LIFE SCI 2-BIOCH GEN, V9, P137, DOI 10.1016/0024-3205(70)90306-1; MICHELSON AM, 1955, P NATL ACAD SCI USA, V41, P1079, DOI 10.1073/pnas.41.12.1079; Miyagoe Y, 1997, FEBS LETT, V415, P33, DOI 10.1016/S0014-5793(97)01007-7; Moll J, 2001, NATURE, V413, P302, DOI 10.1038/35095054; Moore C, 2001, P NATL ACAD SCI USA, V98, P14655, DOI 10.1073/pnas.251291598; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Ringelmann B, 1999, EXP CELL RES, V246, P165, DOI 10.1006/excr.1998.4244; RUEGG MA, 2005, IN PRESS MOL MECH MU; Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7; Spence HJ, 2004, EMBO REP, V5, P484, DOI 10.1038/sj.embor.7400140; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; Yu H, 2003, BIOCHEM J, V371, P289, DOI 10.1042/BJ20021500	35	75	76	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					934	942		10.1096/fj.04-3376com	http://dx.doi.org/10.1096/fj.04-3376com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923403				2022-12-25	WOS:000230207800040
J	Xiao, D; Herman-Antosiewicz, A; Antosiewicz, J; Xiao, H; Brisson, M; Lazo, JS; Singh, SV				Xiao, D; Herman-Antosiewicz, A; Antosiewicz, J; Xiao, H; Brisson, M; Lazo, JS; Singh, SV			Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc25C	ONCOGENE			English	Article						diallyl trisulfide; ROS; Cdc25C; cell cycle arrest; prostate cancer; chemoprevention	OCCURRING ORGANOSULFUR COMPOUNDS; P34(CDC2) KINASE-ACTIVITY; 14-3-3 PROTEIN-BINDING; DNA-DAMAGE; ALLIUM VEGETABLES; COLON-CANCER; S-ALLYLMERCAPTOCYSTEINE; MAMMARY CARCINOGENESIS; APOPTOSIS INDUCTION; CHECKPOINT PATHWAY	Molecular mechanism of cell cycle arrest caused by diallyl trisulfide (DATS), a garlic-derived cancer chemopreventive agent, has been investigated using PC-3 and DU145 human prostate cancer cells as a model. Treatment of PC-3 and DU145 cells, but not a normal prostate epithelial cell line (PrEC), with growth suppressive concentrations of DATS caused enrichment of the G(2)-M fraction. The DATS-induced cell cycle arrest in PC-3 cells was associated with increased Tyr(15) phosphorylation of cyclin-dependent kinase 1 (Cdk1) and inhibition of Cdk1/cyclinB1 kinase activity. The DATS-treated PC-3 and DU145 cells also exhibited a decrease in the protein level of Cdc25C and an increase in its Ser(216) phosphorylation. The DATS-mediated decrease in protein level and Ser216 phosphorylation of Cdc25C as well as G(2)-M phase cell cycle arrest were significantly attenuated in the presence of N-acetylcysteine implicating reactive oxygen species (ROS) in cell cycle arrest caused by DATS. ROS generation was observed in DATS-treated PC-3 and DU145 cells. DATS treatment also caused an increase in the protein level of Cdk inhibitor p21, but DATS-induced G(2)-M phase arrest was not affected by antisense-mediated suppression of p21 protein level. In conclusion, the results of the present study indicate that DATS-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by ROS-mediated destruction and hyperphosphorylation of Cdc25C.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Singh, SV (corresponding author), 2 32A Hillman Canc Ctr Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@upmc.edu		Herman-Antosiewicz, Anna/0000-0003-0526-2168	NCI NIH HHS [R01 CA113363-01, R01 CA101753-02, R01 CA076348-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076348, R01CA113363, R01CA101753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; BLOCK E, 1992, ANGEW CHEM INT EDIT, V31, P1135, DOI 10.1002/anie.199211351; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campbell CL, 1999, INT J CANCER, V80, P868, DOI 10.1002/(SICI)1097-0215(19990315)80:6<868::AID-IJC12>3.0.CO;2-1; Challier B, 1998, EUR J EPIDEMIOL, V14, P737, DOI 10.1023/A:1007512825851; Charrier-Savournin FB, 2004, MOL BIOL CELL, V15, P3965, DOI 10.1091/mbc.E03-12-0871; Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085; Choi S, 2005, CANCER RES, V65, P2035, DOI 10.1158/0008-5472.CAN-04-3616; DAUSCH JG, 1990, PREV MED, V19, P346, DOI 10.1016/0091-7435(90)90034-H; Druesne N, 2004, CARCINOGENESIS, V25, P1227, DOI 10.1093/carcin/bgh123; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Filomeni G, 2003, CANCER RES, V63, P5940; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gao CM, 1999, JPN J CANCER RES, V90, P614, DOI 10.1111/j.1349-7006.1999.tb00791.x; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; HARPER JW, 1993, CELL, V75, P805; Herman-Antosiewicz A, 2004, MUTAT RES-FUND MOL M, V555, P121, DOI 10.1016/j.mrfmmm.2004.04.016; Hsing AW, 2002, J NATL CANCER I, V94, P1648, DOI 10.1093/jnci/94.21.1648; Knowles LM, 1998, NUTR CANCER, V30, P169, DOI 10.1080/01635589809514659; Knowles LM, 2000, CARCINOGENESIS, V21, P1129, DOI 10.1093/carcin/21.6.1129; Kwon KB, 2002, BIOCHEM PHARMACOL, V63, P41, DOI 10.1016/S0006-2952(01)00860-7; Lan H, 2004, ACTA PHARMACOL SIN, V25, P219; Li Y, 2002, DNA CELL BIOL, V21, P771, DOI 10.1089/104454902320908423; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Milner JA, 2001, J NUTR, V131, p1027S, DOI 10.1093/jn/131.3.1027S; Mitchell S, 2000, BJU INT, V85, P932, DOI 10.1046/j.1464-410x.2000.00606.x; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; NAGAE S, 1994, PLANTA MED, V60, P214, DOI 10.1055/s-2006-959461; Nakagawa H, 2001, CARCINOGENESIS, V22, P891, DOI 10.1093/carcin/22.6.891; NAKAMOTO T, 1992, CANCER RES, V52, P571; Narayanan PK, 1997, CANCER RES, V57, P3963; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; REDDY BS, 1993, CANCER RES, V53, P3493; Robert V, 2001, CARCINOGENESIS, V22, P1155, DOI 10.1093/carcin/22.8.1155; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schaffer EM, 1996, CANCER LETT, V102, P199, DOI 10.1016/0304-3835(96)04160-2; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; Shirin H, 2001, CANCER RES, V61, P725; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; SPARNINS VL, 1988, CARCINOGENESIS, V9, P131, DOI 10.1093/carcin/9.1.131; SUMIYOSHI H, 1990, CANCER RES, V50, P5084; Sundaram SG, 1996, CARCINOGENESIS, V17, P669, DOI 10.1093/carcin/17.4.669; Suzui N, 1997, JPN J CANCER RES, V88, P705, DOI 10.1111/j.1349-7006.1997.tb00440.x; TAKAHASHI S, 1992, CARCINOGENESIS, V13, P1513, DOI 10.1093/carcin/13.9.1513; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vogt A, 2000, J PHARMACOL EXP THER, V294, P1070; WARGOVICH MJ, 1987, CARCINOGENESIS, V8, P487, DOI 10.1093/carcin/8.3.487; WARGOVICH MJ, 1988, CANCER RES, V48, P6872; WATTENBERG LW, 1989, CANCER RES, V49, P2689; Webber MM, 1997, PROSTATE, V30, P58; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Widrow RJ, 1997, CYTOMETRY, V27, P250, DOI 10.1002/(SICI)1097-0320(19970301)27:3<250::AID-CYTO6>3.0.CO;2-I; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Xiao D, 2002, CANCER RES, V62, P3615; Xiao DH, 2003, CANCER RES, V63, P6825; YOU WC, 1989, J NATL CANCER I, V81, P162, DOI 10.1093/jnci/81.2.162	67	158	164	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6256	6268		10.1038/sj.onc.1208759	http://dx.doi.org/10.1038/sj.onc.1208759			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940258				2022-12-25	WOS:000231877100007
J	Misra, S; Tripathi, MK; Chaudhuri, G				Misra, S; Tripathi, MK; Chaudhuri, G			Down-regulation of 7SL RNA expression and impairment of vesicular protein transport pathways by Leishmania infection of macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; TRANSCRIPTION-FACTOR; GENE-EXPRESSION; SRP; AMASTIGOTES; CLUSTER	The parasitic protozoan Leishmania specifically manipulates the expression of host macrophage genes during initial interactions, as revealed by mRNA differential display reverse transcription-PCR and cDNA microarray analyses. The genes that are down-regulated in mouse (J774G8) or human (U937) macrophages upon exposure to Leishmania include small RNA transcripts from the short interspersed element sequences. Among the short interspersed element RNAs that are down-regulated is 7SL RNA, which is the RNA component of the signal recognition particle. Because the microbicidal functions of macrophages profoundly count on vesicular protein transport processes, down-regulation of 7SL RNA may be significant in the establishment of infection by Leishmania in macrophage phagolysosomes. To evaluate whether down-regulation of 7SL RNA results in inhibition of signal recognition particle-mediated vesicular protein transport processes, we have tested and found that the targeting of proteins to the endoplasmic reticulum and plasma membrane and the secretion of proteins by macrophages are compromised in Leishmania-infected J774G8 and U937 cells. Knocking down 7SL RNA using small interfering RNA mimicked the effect of exposure of macrophages to Leishmania. The overexpression of 7SL RNA in J774G8 or U937 cells made these cells resistant to Leishmania infection, suggesting the possible biological significance of down-regulation of 7SL RNA synthesis in the establishment of infection by Leishmania. We conclude that Leishmania down-regulates 7SL RNA in macrophages to manipulate the targeting of many proteins that use the vesicular transport pathway and thus favors its successful establishment of infection in macrophages.	Meharry Med Coll, Dept Biomed Sci, Div Microbial Pathogenesis & Immune Response, Nashville, TN 37208 USA	Meharry Medical College	Chaudhuri, G (corresponding author), Meharry Med Coll, Dept Biomed Sci, Div Microbial Pathogenesis & Immune Response, 1005 DB Todd Jr Blvd, Nashville, TN 37208 USA.	gchaudhuri@mmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008037] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI042327-03, 5-RO1AI42327-03] Funding Source: Medline; NIGMS NIH HHS [S06 GM008037-33, 3-SO6GM008037-33S1, S06 GM008037, 2-SO6GM08037-24] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertholet S, 2003, INFECT IMMUN, V71, P2095, DOI 10.1128/IAI.71.4.2095-2101.2003; Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9; BREDOW S, 1990, GENE, V86, P217, DOI 10.1016/0378-1119(90)90282-V; BREDOW S, 1990, NUCLEIC ACIDS RES, V18, P6779, DOI 10.1093/nar/18.23.6779; CAMPBELL MJ, 1994, MED STAT COMMONSENSE; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; Chaudhuri G, 1997, BIOCHEM PHARMACOL, V53, P385, DOI 10.1016/S0006-2952(96)00763-0; Denkers EY, 2005, TRENDS PARASITOL, V21, P35, DOI 10.1016/j.pt.2004.10.004; Doudna JA, 2004, ANNU REV BIOCHEM, V73, P539, DOI 10.1146/annurev.biochem.73.011303.074048; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emde G, 1997, RNA, V3, P538; Guizani-Tabbane L, 2004, INFECT IMMUN, V72, P2582, DOI 10.1128/IAI.72.5.2582-2589.2004; Halic M, 2005, CURR OPIN STRUC BIOL, V15, P116, DOI 10.1016/j.sbi.2005.01.013; Hamilton TA, 1999, PATHOBIOLOGY, V67, P241, DOI 10.1159/000028101; Hamilton TA, 2002, IMMUNOL RES, V25, P229, DOI 10.1385/IR:25:3:229; Handman E, 2002, TRENDS PARASITOL, V18, P332, DOI 10.1016/S1471-4922(02)02352-8; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; Kane MM, 2000, CURR OPIN HEMATOL, V7, P26, DOI 10.1097/00062752-200001000-00006; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; Kuglstatter A, 2002, NAT STRUCT BIOL, V9, P740, DOI 10.1038/nsb843; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LIAO X, 1992, NUCLEIC ACIDS RES, V20, P1607, DOI 10.1093/nar/20.7.1607; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Mishra M, 2001, BIOCHEM PHARMACOL, V62, P569, DOI 10.1016/S0006-2952(01)00695-5; Mishra M, 2001, BIOCHEM PHARMACOL, V61, P467, DOI 10.1016/S0006-2952(00)00568-2; SAMBROOK J, 2000, MOL CLONING LAB MANU; Sarret P, 2004, J BIOL CHEM, V279, P8029, DOI 10.1074/jbc.M310792200; Seay MB, 1996, INFECT IMMUN, V64, P5129, DOI 10.1128/IAI.64.12.5129-5137.1996; Shan SO, 2005, FEBS LETT, V579, P921, DOI 10.1016/j.febslet.2004.11.049; Solbach W, 2000, Adv Immunol, V74, P275, DOI 10.1016/S0065-2776(08)60912-8; Sollner TH, 2004, CURR OPIN CELL BIOL, V16, P429, DOI 10.1016/j.ceb.2004.06.015; TITUS RG, 1994, MACROPHAGE PATHOGEN, P437; Tripathi MK, 2005, BIOCHEM BIOPH RES CO, V328, P43, DOI 10.1016/j.bbrc.2004.12.142; Tripathi MK, 2005, J BIOL CHEM, V280, P17163, DOI 10.1074/jbc.M501375200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ueda Y, 2000, J BIOL CHEM, V275, P19428, DOI 10.1074/jbc.M001336200; ULLU E, 1984, EMBO J, V3, P3303, DOI 10.1002/j.1460-2075.1984.tb02294.x; Walker R, 2005, MOL BIOCHEM PARASIT, V139, P153, DOI 10.1016/j.molbiopara.2004.11.003; Wild K, 2004, NAT STRUCT MOL BIOL, V11, P1049, DOI 10.1038/nsmb853; Zwieb C, 2005, RNA, V11, P7, DOI 10.1261/rna.7203605	40	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29364	29373		10.1074/jbc.M504162200	http://dx.doi.org/10.1074/jbc.M504162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15955815	hybrid, Green Accepted			2022-12-25	WOS:000231021300068
J	Qi, AD; Wolff, SC; Nicholas, RA				Qi, AD; Wolff, SC; Nicholas, RA			The apical targeting signal of the P2Y(2) receptor is located in its first extracellular loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS GENE; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; EPITHELIAL-CELLS; BASOLATERAL LOCALIZATION; PHOSPHOLIPASE-C; SORTING SIGNAL; MDCK CELLS; IDENTIFICATION; EXPRESSION	P2Y(2) and P2Y(4) receptors, which have 52% sequence identity, are both expressed at the apical membrane of Madin-Darby canine kidney cells, but the locations of their apical targeting signals are distinctly different. The targeting signal of the P2Y(2) receptor is located between the N terminus and 7TM, whereas that of the P2Y(4) receptor is present in its C-terminal tail. To identify the apical targeting signal in the P2Y(2) receptor, regions of the P2Y(2) receptor were progressively substituted with the corresponding regions of the P2Y(4) receptor lacking its targeting signal. Characterization of these chimeras and subsequent mutational analysis revealed that four amino acids (Arg(95), Gly(96), Asp(97), and Leu(108)) in the first extracellular loop play a major role in apical targeting of the P2Y(2) receptor. Mutation of RGD to RGE had no effect on P2Y(2) receptor targeting, indicating that receptor-integrin interactions are not involved in apical targeting. P2Y(2) receptor mutants were localized in a similar manner in Caco-2 colon epithelial cells. This is the first identification of an extracellular protein-based targeting signal in a seven-transmembrane receptor.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Nicholas, RA (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	nicholas@med.unc.edu	Wolff, Sam/ABG-3414-2020	Wolff, Sam/0000-0002-3726-3459	NHLBI NIH HHS [R01 HL71131] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071131] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschuler Y, 2003, CURR OPIN CELL BIOL, V15, P423, DOI 10.1016/S0955-0674(03)00084-X; Beau I, 1998, J BIOL CHEM, V273, P18610, DOI 10.1074/jbc.273.29.18610; Beau I, 2004, MOL ENDOCRINOL, V18, P733, DOI 10.1210/me.2003-0130; Beau I, 1997, J BIOL CHEM, V272, P5241, DOI 10.1074/jbc.272.8.5241; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; Brinson AE, 2001, J BIOL CHEM, V276, P11939, DOI 10.1074/jbc.M009909200; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Comstock K E, 1997, Methods Mol Biol, V62, P207; Cressman VL, 1999, J BIOL CHEM, V274, P26461, DOI 10.1074/jbc.274.37.26461; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; DONALDSON SH, 1997, P2 NUCLEOTIDE RECEPT; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; Harden TK, 1998, DEV CARDIOVASC MED, V209, P187; Herold CL, 2004, J BIOL CHEM, V279, P11456, DOI 10.1074/jbc.M301734200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffmann C, 1999, J BIOL CHEM, V274, P14639, DOI 10.1074/jbc.274.21.14639; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Insel PA, 2001, CLIN EXP PHARMACOL P, V28, P351, DOI 10.1046/j.1440-1681.2001.03452.x; Jolimay N, 2000, J NEUROSCI, V20, P9111; Kennedy C, 2000, MOL PHARMACOL, V57, P926; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Koivisto UM, 2001, CELL, V105, P575, DOI 10.1016/S0092-8674(01)00371-3; Mall M, 2000, AM J RESP CELL MOL, V23, P755, DOI 10.1165/ajrcmb.23.6.4207; Matlin KS, 2003, METHODS, V30, P235, DOI 10.1016/S1046-2023(03)00030-6; McAlroy HL, 2000, BRIT J PHARMACOL, V131, P1651, DOI 10.1038/sj.bjp.0703743; Moro S, 1999, BIOCHEMISTRY-US, V38, P3498, DOI 10.1021/bi982369v; Nadler LS, 2001, J BIOL CHEM, V276, P10539, DOI 10.1074/jbc.M007190200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Paradiso AM, 2001, J GEN PHYSIOL, V117, P53, DOI 10.1085/jgp.117.1.53; Qi AD, 2001, BRIT J PHARMACOL, V132, P318, DOI 10.1038/sj.bjp.0703788; Ralevic V, 1998, PHARMACOL REV, V50, P413; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Saunders C, 1998, J BIOL CHEM, V273, P24196, DOI 10.1074/jbc.273.37.24196; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; Schuck S, 2004, J CELL SCI, V117, P5955, DOI 10.1242/jcs.01596; Sromek SM, 1998, MOL PHARMACOL, V54, P485, DOI 10.1124/mol.54.3.485; Torres B, 2002, J BIOL CHEM, V277, P7761, DOI 10.1074/jbc.M110352200; Toye AM, 2004, J CELL SCI, V117, P1399, DOI 10.1242/jcs.00974; Wolff SC, 2005, AM J PHYSIOL-CELL PH, V288, pC624, DOI 10.1152/ajpcell.00338.2004; Yerxa BR, 2002, J PHARMACOL EXP THER, V302, P871, DOI 10.1124/jpet.102.035485	48	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29169	29175		10.1074/jbc.M501301200	http://dx.doi.org/10.1074/jbc.M501301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15908695	Green Published, hybrid			2022-12-25	WOS:000231021300044
J	Fu, LZ; Ishizuya-Oka, A; Buchholz, DR; Amano, T; Matsuda, H; Shi, YB				Fu, LZ; Ishizuya-Oka, A; Buchholz, DR; Amano, T; Matsuda, H; Shi, YB			A causative role of stromelysin-3 in extracellular matrix remodeling and epithelial apoptosis during intestinal metamorphosis in Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RESPONSE GENES; CONNECTIVE-TISSUE; METALLOPROTEINASE STROMELYSIN-3; MOUSE STROMELYSIN-3; EXPRESSION PATTERN; TADPOLE TAIL; MEMBRANE; BREAST; GROWTH; MICE	The matrix metalloproteinases are a family of proteases capable of degrading various components of the extracellular matrix. Expression studies have implicated the involvement of the matrix metalloproteinase stromelysin-3 (ST3) in tissue remodeling and pathogenesis. However, the in vivo role of ST3 has been difficult to study because of a lack of good animal models. Here we used intestinal remodeling during thyroid hormone-dependent metamorphosis of Xenopus laevis as a model to investigate in vivo the role of ST3 during postembryonic organ development in vertebrates. We generated transgenic tadpoles expressing ST3 under control of a heat shock-inducible promoter. We showed for the first time in vivo that wild type ST3 but not a catalytically inactive mutant was sufficient to induce larval epithelial cell death and fibroblast activation, events that normally occur only in the presence of thyroid hormone. We further demonstrated that these changes in cell fate are associated with altered gene expression in the intestine and remodeling of the intestinal basal lamina. These results thus suggest that ST3 regulates cell fate and tissue morphogenesis through direct or indirect ECM remodeling.	NICHD, NIH, LGRD, Bethesda, MD 20892 USA; Nippon Med Coll, Dept Biol, Kawasaki, Kanagawa 2110063, Japan	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Nippon Medical School	Shi, YB (corresponding author), NICHD, NIH, LGRD, Bldg 18 T,Rm 106, Bethesda, MD 20892 USA.	Shi@helix.nih.gov	Matsuda, Hiroki/K-5055-2019	Shi, Yun-Bo/0000-0002-6330-0639	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amano T, 2005, CELL RES, V15, P150, DOI 10.1038/sj.cr.7290280; Basset P, 1997, CRIT REV ONCOL HEMAT, V26, P43, DOI 10.1016/S1040-8428(97)00010-3; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; Berry DL, 1998, DEV BIOL, V203, P12, DOI 10.1006/dbio.1998.8974; Berry DL, 1998, DEV BIOL, V203, P24, DOI 10.1006/dbio.1998.8975; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Brown Karen E., 1995, Seminars in Developmental Biology, V6, P69, DOI 10.1016/S1044-5781(06)80016-2; Buchholz DR, 2003, MOL CELL BIOL, V23, P6750, DOI 10.1128/MCB.23.19.6750-6758.2003; Buchholz DR, 2004, MOL REPROD DEV, V67, P65, DOI 10.1002/mrd.20005; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Chin JR, 1997, DEVELOPMENT, V124, P1519; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Damjanovski S, 1999, CELL RES, V9, P91, DOI 10.1038/sj.cr.7290009; Damjanovski S, 2001, DEV DYNAM, V221, P37, DOI 10.1002/dvdy.1123; Fingleton BM, 1999, APMIS, V107, P102, DOI 10.1111/j.1699-0463.1999.tb01532.x; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fu LZ, 2002, MOL REPROD DEV, V62, P470, DOI 10.1002/mrd.10137; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Ishizuya-Oka A, 2000, J CELL BIOL, V150, P1177, DOI 10.1083/jcb.150.5.1177; ISHIZUYAOKA A, 1994, CELL TISSUE RES, V277, P427, DOI 10.1007/s004410050170; IshizuyaOka A, 1996, CELL TISSUE RES, V286, P467, DOI 10.1007/s004410050716; ISHIZUYAOKA A, 1992, ROUX ARCH DEV BIOL, V201, P322, DOI 10.1007/BF00592113; Jung JC, 2002, DEV DYNAM, V223, P402, DOI 10.1002/dvdy.10069; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Lee MH, 2004, J CELL SCI, V117, P4015, DOI 10.1242/jcs.01223; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; Lochter A, 1999, APMIS, V107, P128, DOI 10.1111/j.1699-0463.1999.tb01535.x; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Mark D, 2000, EMERGING THERAPEUTIC, V4, P609, DOI DOI 10.1517/14728222.4.5.609; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; Matsuda H, 2001, DEV BIOL, V229, P351, DOI 10.1006/dbio.2000.9973; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; MURPHY G, 1993, J BIOL CHEM, V268, P15435; Nagase H, 1998, Cell Res, V8, P179; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Parks WC, 1998, BIOL EXTRAC, P263; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shi Y.-B., 1999, AMPHIBIAN METAMORPHO; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; Shi YB, 1998, INT J MOL MED, V2, P273; Shi YB, 1996, CURR TOP DEV BIOL, V32, P205, DOI 10.1016/S0070-2153(08)60429-9; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; Su Y, 1997, FASEB J, V11, P559, DOI 10.1096/fasebj.11.7.9212079; Su Y, 1997, J CELL BIOL, V139, P1533, DOI 10.1083/jcb.139.6.1533; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; Tetu B, 1998, HUM PATHOL, V29, P979, DOI 10.1016/S0046-8177(98)90204-0; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wheeler GN, 2000, CURR BIOL, V10, P849, DOI 10.1016/S0960-9822(00)00596-0; Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; WITTY JP, 1995, CANCER RES, V55, P1401; Woessner JF, 2004, HDB PROTEOLYTIC ENZY; ZernickaGoetz M, 1996, DEVELOPMENT, V122, P3719; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	67	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27856	27865		10.1074/jbc.M413275200	http://dx.doi.org/10.1074/jbc.M413275200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15929979	hybrid			2022-12-25	WOS:000230678600047
J	Prieur, X; Huby, T; Coste, H; Schaap, FG; Chapman, MJ; Rodriguez, JC				Prieur, X; Huby, T; Coste, H; Schaap, FG; Chapman, MJ; Rodriguez, JC			Thyroid hormone regulates the hypotriglyceridemic gene APOA5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN A-V; PLASMA TRIGLYCERIDE LEVELS; TISSUE LIPOPROTEIN-LIPASE; ACTIVATED RECEPTOR-ALPHA; RESPONSE ELEMENTS; AGONIST GC-1; LIVER-X; PROMOTER; TRIIODOTHYRONINE; METABOLISM	The apolipoprotein AV gene (APOA5) is a key determinant of plasma triglyceride levels, a major risk factor for coronary artery disease and a biomarker for the metabolic syndrome. Since thyroid hormones influence very low density lipoprotein triglyceride metabolism and clinical studies have demonstrated an inverse correlation between thyroid status and plasma triglyceride levels, we examined whether APOA5 is regulated by thyroid hormone. Here we report that 3,5,3'-triiodo-L-thyronine (T-3) and a synthetic thyroid receptor beta (TR beta) ligand increase APOA5 mRNA and protein levels in hepatocytes. Our data revealed that T-3-activated TR directly regulates APOA5 promoter through a functional direct repeat separated by four nucleotides (DR4). Interestingly, we show that upstream stimulatory factor 1, a transcription factor associated with familial combined hyperlipidemia and elevated triglyceride levels in humans, and upstream stimulatory factor 2 cooperate with TR, resulting in a synergistic activation of APOA5 promoter in a ligand-dependent manner via an adjacent E-box motif. In rats, we observed that apoAV levels declines with thyroid hormone depletion but returned to normal levels upon T-3 administration. In addition, treatments with a TR beta-selective agonist increased apoAV and diminished triglyceride levels. The identification of APOA5 as a T-3 target gene provides a new potential mechanism whereby thyroid hormones can influence triglyceride homeostasis. Additionally, these data suggest that TR beta may be a potential pharmacological target for the treatment of hypertriglyceridemia.	GlaxoSmithKline, F-91951 Les Ulis, France; AMC Liver Ctr, NL-1105 BK Amsterdam, Netherlands; Hop Pitie, Dyslipoproteinemia & Atherosclerosis Res Unit U55, Natl Inst Hlth & Med Res, Paris 13, France	GlaxoSmithKline; University of Amsterdam; Academic Medical Center Amsterdam; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Rodriguez, JC (corresponding author), GlaxoSmithKline, 25 Ave Quebec, F-91951 Les Ulis, France.	jcrodrig@freesurf.fr	Prieur, Xavier/D-4760-2015; HUBY, Thierry/N-4820-2019; chapman, john/Y-2742-2019; Huby, Thierry/E-6768-2017	Prieur, Xavier/0000-0003-0215-5447; HUBY, Thierry/0000-0001-6634-551X; Huby, Thierry/0000-0001-6634-551X; Schaap, Frank/0000-0002-1597-572X				ABRAMS JJ, 1981, J LIPID RES, V22, P307; Applied Biosystems, 2001, US B 2 ABI PRISM 770; Bakker O, 1998, BIOCHEM BIOPH RES CO, V249, P517, DOI 10.1006/bbrc.1998.9174; Barrero MJ, 2000, BIOCHEM BIOPH RES CO, V279, P81, DOI 10.1006/bbrc.2000.3893; Berkenstam A, 2004, MECH AGEING DEV, V125, P707, DOI 10.1016/j.mad.2004.05.005; Coste H, 2002, J BIOL CHEM, V277, P27120, DOI 10.1074/jbc.M203421200; Cullen P, 2000, AM J CARDIOL, V86, P943, DOI 10.1016/S0002-9149(00)01127-9; DORY L, 1981, J LIPID RES, V22, P287; Drover VAB, 2002, MOL ENDOCRINOL, V16, P14, DOI 10.1210/me.16.1.14; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Fruchart-Najib J, 2004, BIOCHEM BIOPH RES CO, V319, P397, DOI 10.1016/j.bbrc.2004.05.003; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Grover GJ, 2004, ENDOCRINOLOGY, V145, P1656, DOI 10.1210/en.2003-0973; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; Hatzivassiliou E, 2003, BIOCHEM J, V376, P423, DOI 10.1042/BJ20030549; Hubacek JA, 2004, CLIN GENET, V65, P126, DOI 10.1111/j.0009-9163.2004.00199.x; Ichikawa K, 2000, J ENDOCRINOL, V165, P391, DOI 10.1677/joe.0.1650391; Ito M, 2003, CLIN ENDOCRINOL, V58, P621, DOI 10.1046/j.1365-2265.2003.01762.x; Jackson-Hayes L, 2003, J BIOL CHEM, V278, P7964, DOI 10.1074/jbc.M211062200; Jakel H, 2004, J BIOL CHEM, V279, P45462, DOI 10.1074/jbc.M404744200; Jansen MS, 2000, J BIOL CHEM, V275, P34989, DOI 10.1074/jbc.M001752200; Jiang W, 2004, J ENDOCRINOL, V182, P295, DOI 10.1677/joe.0.1820295; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kern PA, 1996, J LIPID RES, V37, P2332; KEYES WG, 1979, J CLIN INVEST, V64, P182, DOI 10.1172/JCI109438; Lai CQ, 2004, J LIPID RES, V45, P2096, DOI 10.1194/jlr.M400192-JLR200; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; Luo X, 1996, MOL CELL BIOL, V16, P1367; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MEYER BJ, 1989, BIOCHIM BIOPHYS ACTA, V1004, P73, DOI 10.1016/0005-2760(89)90215-4; Mukhopadhyay D, 2003, ENDOCRINOLOGY, V144, P711, DOI 10.1210/en.2002-220741; Ness GC, 1998, BIOCHEM PHARMACOL, V56, P121, DOI 10.1016/S0006-2952(98)00119-1; NIKKILA EA, 1972, J CLIN INVEST, V51, P2103, DOI 10.1172/JCI107017; Nowak M, 2005, MOL CELL BIOL, V25, P1537, DOI 10.1128/MCB.25.4.1537-1548.2005; OBRIEN T, 1993, MAYO CLIN PROC, V68, P860, DOI 10.1016/S0025-6196(12)60694-6; OHARA DD, 1966, METABOLIS, V15, P123, DOI 10.1016/0026-0495(66)90033-3; Oliva CP, 2005, ARTERIOSCL THROM VAS, V25, P411, DOI 10.1161/01.ATV.0000153087.36428.dd; Pajukanta P, 2004, NAT GENET, V36, P371, DOI 10.1038/ng1320; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; Popovic L, 1998, HORM METAB RES, V30, P137, DOI 10.1055/s-2007-978852; PORTE D, 1966, METABOLIS, V15, P107, DOI 10.1016/0026-0495(66)90031-X; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; PYKALISTO O, 1976, J CLIN ENDOCR METAB, V43, P591, DOI 10.1210/jcem-43-3-591; Ribalta J, 2002, CLIN CHEM, V48, P1597; SAFFARI B, 1992, J LIPID RES, V33, P241; Schaap FG, 2004, J BIOL CHEM, V279, P27941, DOI 10.1074/jbc.M403240200; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; Shin DJ, 2003, J BIOL CHEM, V278, P34114, DOI 10.1074/jbc.M305417200; SUZUKI S, 1994, MOL ENDOCRINOL, V8, P305, DOI 10.1210/me.8.3.305; Tan KCB, 1998, J CLIN ENDOCR METAB, V83, P2921, DOI 10.1210/jc.83.8.2921; Taylor AH, 1997, MOL PHARMACOL, V52, P542, DOI 10.1124/mol.52.3.542; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; Vacca RA, 2003, ENDOCRINOLOGY, V144, P3783, DOI 10.1210/en.2003-0310; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; VANHERLE AJ, 1975, J CLIN INVEST, V56, P1073, DOI 10.1172/JCI108181; Varas SM, 1999, HORM METAB RES, V31, P514, DOI 10.1055/s-2007-978786; Vu-Dac N, 2003, J BIOL CHEM, V278, P17982, DOI 10.1074/jbc.M212191200; Wada Y, 2000, J MOL ENDOCRINOL, V25, P299, DOI 10.1677/jme.0.0250299; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; WILCOX HG, 1982, J LIPID RES, V23, P1159; Williams GR, 2000, MOL CELL BIOL, V20, P8329, DOI 10.1128/MCB.20.22.8329-8342.2000; Xiong SB, 1998, P NATL ACAD SCI USA, V95, P12260, DOI 10.1073/pnas.95.21.12260; YAMADA T, 1981, J ENDOCRINOL INVEST, V4, P379, DOI 10.1007/BF03348299; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zannis VI, 2001, CURR OPIN LIPIDOL, V12, P181, DOI 10.1097/00041433-200104000-00012	72	58	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27533	27543		10.1074/jbc.M503139200	http://dx.doi.org/10.1074/jbc.M503139200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15941710	Green Published, hybrid			2022-12-25	WOS:000230678600009
J	Yang, SY; Huang, XY				Yang, SY; Huang, XY			Ca2+ influx through L-type Ca2+ channels controls the trailing tail contraction in growth factor-induced fibroblast cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CALCIUM-CHANNELS; SMOOTH-MUSCLE-CELLS; NEURONAL MIGRATION; MYOSIN-II; NEUTROPHIL MIGRATION; CHEMOTAXIS; ACTIVATION; KINASES; SIGNALS; PHOSPHORYLATION	Growth factor-induced cell migration underlies various physiological and pathological processes. The mechanisms by which growth factors regulate cell migration are not completely understood. Although intracellular elevation of Ca2+ is known to be critical in cell migration, the source of this Ca2+ elevation and the mechanism by which Ca2+ modulates this process in fibroblast cells are not well defined. Here we show that increase of cellular Ca2+ through Ca2+ influx, rather than Ca2+ release from intracellular stores, is essential for growth factor-induced fibroblast cell migration. Voltage-gated L-type Ca2+ channels, previously known to exist in excitable cells such as neurons and muscle cells, are shown here to be present in fibroblasts as well. Furthermore, these channels are responsible for the Ca2+ influx. L-type Ca2+ channel inhibitors block growth factor-induced Ca2+ influx and fibroblast cell migration. One mechanism by which Ca2+ signals control cell migration is to regulate the contraction of the trailing edge of migrating fibroblasts; this process is controlled by the small GTPase Rho in fast migrating cells such as leukocytes. Downstream of Ca2+, both calmodulin and myosin light chain kinase, but not calcineurin, are involved leading to phosphorylation of the myosin light chain at the trailing end. Thus, trailing edge contraction is critically regulated by Ca2+ influx through L-type Ca2+ channels in growth factor-induced fibroblast cell migration.	Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA	Cornell University	Huang, XY (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA.	xyhuang@med.cornell.edu	Yang, Shengyu/I-9531-2012	Yang, Shengyu/0000-0002-7933-6118				Badou A, 2005, SCIENCE, V307, P117, DOI 10.1126/science.1100582; Bence-Hanulec KK, 2000, NEURON, V27, P121, DOI 10.1016/S0896-6273(00)00014-3; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; CASSCELLS W, 1992, CIRCULATION, V86, P723, DOI 10.1161/01.CIR.86.3.723; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CHEN WT, 1981, J CELL BIOL, V90, P187, DOI 10.1083/jcb.90.1.187; Cvejic S, 2004, NAT CELL BIOL, V6, P540, DOI 10.1038/ncb1133; DEUEL TF, 1991, ANNU REV MED, V42, P567, DOI 10.1146/annurev.me.42.020191.003031; Eddy RJ, 2000, J CELL SCI, V113, P1287; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; HAHN K, 1992, NATURE, V359, P736, DOI 10.1038/359736a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1988, CELL MOTIL CYTOSKEL, V10, P117, DOI 10.1002/cm.970100116; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; JAY PY, 1995, J CELL SCI, V108, P387; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lautermilch NJ, 2000, J NEUROSCI, V20, P315, DOI 10.1523/JNEUROSCI.20-01-00315.2000; Lee J, 1999, NATURE, V400, P382, DOI 10.1038/22578; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nebl T, 1997, J CELL SCI, V110, P2845; Nishiyama M, 2003, NATURE, V423, P990, DOI 10.1038/nature01751; PAULY RR, 1995, CIRCULATION, V91, P1107, DOI 10.1161/01.CIR.91.4.1107; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; RuizVelasco V, 1996, EUR J PHARMACOL, V296, P327, DOI 10.1016/0014-2999(95)00710-5; Saito H, 2002, J LEUKOCYTE BIOL, V72, P829; Scherberich A, 2000, J CELL SCI, V113, P653; Shan DD, 2005, P NATL ACAD SCI USA, V102, P3772, DOI 10.1073/pnas.0500658102; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; SPUDICH JA, 1989, CELL REGUL, V1, P1; Tam T, 2000, DEV BIOL, V226, P104, DOI 10.1006/dbio.2000.9854; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Xu HT, 2004, P NATL ACAD SCI USA, V101, P4296, DOI 10.1073/pnas.0303893101; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Yumura S, 1996, J CELL SCI, V109, P2673	47	122	125	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27130	27137		10.1074/jbc.M501625200	http://dx.doi.org/10.1074/jbc.M501625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911622	hybrid			2022-12-25	WOS:000230589500060
J	Young, GW; Hoofring, SA; Mamula, MJ; Doyle, HA; Bunick, GJ; Hu, YL; Aswad, DW				Young, GW; Hoofring, SA; Mamula, MJ; Doyle, HA; Bunick, GJ; Hu, YL; Aswad, DW			Protein L-isoaspartyl methyltransferase catalyzes in vivo racemization of aspartate-25 in mammalian histone H2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL METHYLTRANSFERASE; DAMAGED PROTEINS; O-METHYLTRANSFERASE; REPAIR ENZYME; D-ASPARTYL; DEAMIDATION; METHYLATION; ACCUMULATION; RESIDUES; RECOGNITION	Protein L-isoaspartyl methyltransferase ( PIMT) has been implicated in the repair or metabolism of proteins containing atypical L-isoaspartyl peptide bonds. The repair hypothesis is supported by previous studies demonstrating in vitro repair of isoaspartyl peptides via formation of a succinimide intermediate. Utilization of this mechanism in vivo predicts that PIMT modification sites should exhibit significant racemization as a side reaction to the main repair pathway. We therefore studied the D/L ratio of aspartic acid at specific sites in histone H2B, a known target of PIMT in vivo. Using H2B from canine brain, we found that Asp(25) ( the major PIMT target site in H2B) was significantly racemized, exhibiting D/L ratios as high as 0.12, whereas Asp(51), a comparison site, exhibited negligible racemization (D/L <= 0.01). Racemization of Asp25 was independent of animal age over the range of 2-15 years. Using H2B from 2-3-week mouse brain, we found a similar D/L ratio (0.14) at Asp25 in wild type mice, but substantially less racemization (D/L = 0.035) at Asp(25) in PIMT-deficient mice. These findings suggest that PIMT functions in the repair, rather than the metabolic turnover, of isoaspartyl proteins in vivo. Because PIMT has numerous substrates in cells, these findings also suggest that D- aspartate may be more common in cellular proteins than hitherto imagined and that its occurrence, in some proteins at least, is independent of animal age.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Yale Univ, Sch Med, Dept Internal Med, Rheumatol Sect, New Haven, CT USA; Univ Tennessee, Oak Ridge Grad Sch Genome Sci & Technol, Div Life Sci, Oak Ridge, TN 37831 USA	University of California System; University of California Irvine; Yale University; University of Tennessee System; University of Tennessee Knoxville	Aswad, DW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	dwaswad@uci.edu						ARTIGUES A, 1990, J BIOL CHEM, V265, P4853; Aswad D W, 1988, Adv Exp Med Biol, V231, P247; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; Clarke S, 2003, AGEING RES REV, V2, P263, DOI 10.1016/S1568-1637(03)00011-4; Doyle HA, 2001, TRENDS IMMUNOL, V22, P443, DOI 10.1016/S1471-4906(01)01976-7; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; HARDIN JA, 1983, P NATL ACAD SCI-BIOL, V80, P7410, DOI 10.1073/pnas.80.24.7410; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, J BIOL CHEM, V268, P6174; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; JOHNSON BA, 1995, DEAMIDATION ISOASPAR, P91; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Kinzel V, 2000, PROTEIN SCI, V9, P2269, DOI 10.1110/ps.9.11.2269; Lowenson J. D., 1995, DEAMIDATION ISOASPAR, P47; Lowenson JD, 2001, J BIOL CHEM, V276, P20695, DOI 10.1074/jbc.M100987200; Mamula MJ, 1999, J BIOL CHEM, V274, P22321, DOI 10.1074/jbc.274.32.22321; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MURRAY ED, 1984, J BIOL CHEM, V259, P722; OCONNOR CM, 1984, P NATL ACAD SCI-BIOL, V81, P7757, DOI 10.1073/pnas.81.24.7757; Perna AF, 1997, J AM SOC NEPHROL, V8, P95; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; Robinson NE, 2004, J PEPT RES, V63, P426, DOI 10.1111/j.1399-3011.2004.00151.x; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Yamamoto A, 1998, J NEUROSCI, V18, P2063; Young AL, 2001, J BIOL CHEM, V276, P37161, DOI 10.1074/jbc.M106682200	28	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26094	26098		10.1074/jbc.M503624200	http://dx.doi.org/10.1074/jbc.M503624200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15908425	hybrid			2022-12-25	WOS:000230386800020
J	Zomot, E; Zhou, YG; Kanner, BI				Zomot, E; Zhou, YG; Kanner, BI			Proximity of transmembrane domains 1 and 3 of the gamma-aminobutyric acid transporter GAT-1 inferred from paired cysteine mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN TRANSPORTER; DOPAMINE TRANSPORTER; DOMAIN-I; CROSS-LINKING; ION-BINDING; RAT-BRAIN; SODIUM; IDENTIFICATION; RESIDUES; PERMEATION	GAT- 1 is a sodium- and chloride- dependent gamma- aminobutyric acid transporter and is the first identified member of a family of transporters that maintain low synaptic neurotransmitter levels and thereby enable efficient synaptic transmission. Because transmembrane domains 1 and 3 contain amino acid residues important for transport activity, we hypothesized that these domains may participate in the formation of the binding pocket of the transporter. Pairwise substitutions have been introduced in several predicted transmembrane domains and in the first extracellular loop of GAT- 1. In the double mutant W68C/ I143C, in which the cysteines were introduced at locations at the extracellular part of transmembrane domains 1 and 3, respectively, similar to 70% inhibition of transport was observed by cadmium with an IC50 of similar to 10 mu M. This inhibition was not observed in the corresponding single mutants and also not in > 10 other double mutants, except for V67C/ I143C, where the half maximal effect was obtained at similar to 50 mu M. The inhibition by cadmium was only observed when the cysteine pairs were introduced in the same polypeptide. Our results suggest that transmembrane domains 1 and 3 come in close proximity within the transporter monomer.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il						Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; Horiuchi M, 2001, P NATL ACAD SCI USA, V98, P1448, DOI 10.1073/pnas.041329498; Kanner BI, 2003, J BIOL CHEM, V278, P3705, DOI 10.1074/jbc.M210525200; KANNER BI, 1994, J EXP BIOL, V196, P237; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lee DJ, 2000, J BIOL CHEM, V275, P141, DOI 10.1074/jbc.275.1.141; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Nelson N, 1998, J NEUROCHEM, V71, P1785; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Ponce J, 2000, J BIOL CHEM, V275, P13856, DOI 10.1074/jbc.275.18.13856; RADIAN R, 1986, J BIOL CHEM, V261, P5437; Sato Y, 2004, J BIOL CHEM, V279, P22926, DOI 10.1074/jbc.M312194200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; WANG JB, 1995, J NEUROCHEM, V64, P1416; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200	43	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25512	25516		10.1074/jbc.M503864200	http://dx.doi.org/10.1074/jbc.M503864200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15905165	hybrid			2022-12-25	WOS:000230207900027
J	Liou, AKF; Zhou, ZG; Pei, W; Lim, TM; Yin, XM; Chen, J				Liou, AKF; Zhou, ZG; Pei, W; Lim, TM; Yin, XM; Chen, J			BimEL up-regulation potentiates AIF translocation and cell death in response to MPTP	FASEB JOURNAL			English	Article						mitochondria; calpain I; MPP plus treatment	APOPTOSIS-INDUCING FACTOR; SPINAL-CORD-INJURY; DOPAMINERGIC NEURONAL CELLS; CEREBELLAR GRANULE NEURONS; CYTOCHROME-C RELEASE; BH3-ONLY PROTEIN BIM; BCL-2 FAMILY MEMBER; PARKINSONS-DISEASE; OXIDATIVE STRESS; PC12 CELLS	This study attempted to elucidate the signaling mechanism underlying dopaminergic cell death in the MPP+ model for Parkinson's disease. In neuronal-differentiated PC12 cells, through the regulation by activated JNK and c-jun, BimEL expression was markedly increased in response to MPP+ treatment, which led to the cell degeneration. In lieu of Smac translocation as seen in other paradigms, up-regulation of BimEL effected an increase in calpain I activity that, in turn, mediated AIF release from the mitochondria. In support, we found that knocking down BimEL expression resulted in a decrease in calpain I activity, as well as AIF release from the mitochondria and cell death. Finally, inhibition of calpain activity mitigated AIF release from the mitochondria and cell death. Under cell-free conditions, activated purified calpain I could induce the release of AIF from isolated mitochondria without the participation of BimEL or activated JNK, suggesting that AIF release is a direct consequence of calpain I activity. In concert, the results suggest a novel signaling pathway for dopaminergic cell degeneration, in which MPP+ induces the up-regulation of BimEL, which in turn potentiates an elevation in calpain I activity that mediates AIF release and cell death in a caspase-independent manner.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Pittsburgh Inst Neurodegenerat Disorders, Pittsburgh, PA USA; Natl Univ Singapore, Dept Sci Biol, Singapore 117548, Singapore; Vet Affairs Pittsburgh Hlth Care Syst, Educ & Clin Ctr, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National University of Singapore; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Liou, AKF (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, S507 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA.	lioukf@upmc.edu		Chen, Jun/0000-0002-8077-3403	NINDS NIH HHS [NS45048, NS44178, NS43802] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043802, R01NS044178, R01NS045048] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai J, 2002, NEUROSCI LETT, V321, P81, DOI 10.1016/S0304-3940(02)00058-7; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bizat N, 2003, J NEUROSCI, V23, P5020; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cao GD, 2004, J NEUROSCI, V24, P6189, DOI 10.1523/JNEUROSCI.1426-04.2004; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chera B, 2002, ANN NY ACAD SCI, V965, P274; Choi WS, 1999, EXP NEUROL, V159, P274, DOI 10.1006/exnr.1999.7133; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Crocker SJ, 2003, J NEUROSCI, V23, P4081; Crocker SJ, 2001, P NATL ACAD SCI USA, V98, P13385, DOI 10.1073/pnas.231177098; Du YS, 1997, J NEUROCHEM, V69, P1382; Eberhardt O, 2000, J NEUROSCI, V20, P9126; Fennell DA, 2001, BRIT J CANCER, V84, P1397, DOI 10.1054/bjoc.2001.1788; Fonfria E, 2002, EUR J NEUROSCI, V16, P2013, DOI 10.1046/j.1460-9568.2002.02269.x; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Friedrich P, 2004, BIOCHEM BIOPH RES CO, V323, P1131, DOI 10.1016/j.bbrc.2004.08.194; Gelinas S, 2002, J NEUROSCI RES, V70, P90, DOI 10.1002/jnr.10315; Gomez C, 2001, J NEUROSCI RES, V63, P421, DOI 10.1002/1097-4547(20010301)63:5<421::AID-JNR1037>3.0.CO;2-4; Gonzalez-Polo RA, 2003, J NEUROCHEM, V84, P305, DOI 10.1046/j.1471-4159.2003.01520.x; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Jiang ZH, 2004, J NEUROCHEM, V89, P168, DOI 10.1111/j.1471-4159.2004.02319.x; Kaul S, 2003, EUR J NEUROSCI, V18, P1387, DOI 10.1046/j.1460-9568.2003.02864.x; Kim HE, 2001, BIOCHEM BIOPH RES CO, V286, P659, DOI 10.1006/bbrc.2001.5446; Kovacsovics M, 2002, CURR BIOL, V12, P838, DOI 10.1016/S0960-9822(02)00842-4; Kowaltowski AJ, 2004, FREE RADICAL BIO MED, V37, P1845, DOI 10.1016/j.freeradbiomed.2004.09.005; Krepela E, 2004, BIOL CHEM, V385, P153, DOI 10.1515/BC.2004.034; Kulich SM, 2003, J BIOSCIENCES, V28, P83, DOI 10.1007/BF02970136; Lee CS, 2003, NEUROCHEM INT, V43, P147, DOI 10.1016/S0197-0186(02)00214-0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linseman DA, 2002, J NEUROSCI, V22, P9287; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Marti A, 2001, MECH DEVELOP, V104, P89, DOI 10.1016/S0925-4773(01)00381-1; McMahon A, 1998, MOL BRAIN RES, V54, P56, DOI 10.1016/S0169-328X(97)00305-7; Napankangas U, 2003, MOL BRAIN RES, V120, P30, DOI 10.1016/j.molbrainres.2003.09.016; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Plenchette S, 2001, LEUKEMIA, V15, P1572, DOI 10.1038/sj.leu.2402231; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Ray SK, 2003, J CHEM NEUROANAT, V26, P119, DOI 10.1016/S0891-0618(03)00044-9; Ray SK, 2001, ANN NY ACAD SCI, V939, P436; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Sun DS, 2003, CELL BIOL INT, V27, P769, DOI 10.1016/S1065-6995(03)00165-3; Tretter L, 2004, NEUROCHEM RES, V29, P569, DOI 10.1023/B:NERE.0000014827.94562.4b; Villunger A, 2003, BLOOD, V101, P2393, DOI 10.1182/blood-2002-07-2132; Wang HM, 2003, ANN NY ACAD SCI, V991, P132; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yang LC, 1998, J NEUROSCI, V18, P8145; Yin KJ, 2002, J NEUROSCI, V22, P9764; Yokoyama T, 2002, IMMUNOL LETT, V81, P107, DOI 10.1016/S0165-2478(02)00003-2; Zhang J, 2000, J NEUROPATH EXP NEUR, V59, P53, DOI 10.1093/jnen/59.1.53; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	63	61	63	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1350	+		10.1096/fj.04-3258fje	http://dx.doi.org/10.1096/fj.04-3258fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15941767				2022-12-25	WOS:000230207800029
J	Gomes, AV; Liang, JS; Potter, JD				Gomes, AV; Liang, JS; Potter, JD			Mutations in human cardiac Troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T ISOFORMS AFFECT; REGULATORY SITES; CA2+ SENSITIVITY; SKELETAL; FILAMENT; ACTIN; TROPOMYOSIN; ENERGETICS; INSIGHTS; AFFINITY	Human cardiac Troponin I (cTnI) is the first sarcomeric protein for which mutations have been associated with restrictive cardiomyopathy. To determine whether five mutations in cTnI (L144Q, R145W, A171T, K178E, and R192H) associated with restrictive cardiomyopathy were distinguishable from hypertrophic cardiomyopathy-causing mutations in cTnI, actomyosin ATPase activity and skinned fiber studies were carried out. All five mutations investigated showed an increase in the Ca2+ sensitivity of force development compared with wildtype cTnI. The two mutations with the worst clinical phenotype (K178E and R192H) both showed large increases in Ca2+ sensitivity (Delta pCa(50) = 0.47 and 0.36, respectively). Although at least one of these mutations is not in the known inhibitory regions of cTnI, all of the mutations investigated caused a decrease in the ability of cTnI to inhibit actomyosin ATPase activity. Mixtures of wild-type and mutant cTnI showed that cTnI mutants could be classified into three different groups: dominant (L144Q, A171T and R192H), equivalent (K178E), or weaker (R145W) than wild-type cTnI in actomyosin ATPase assays in the absence of Ca2+. Although most of the mutants were able to activate actomyosin ATPase similarly to wild-type cTnI, L144Q had significantly lower maximal ATPase activities than any of the other mutants or wild-type cTnI. Three mutants (L144Q, R145W, and K178E) were unable to fully relax contraction in the absence of Ca2+. The inability of the five cTnI mutations investigated to fully inhibit ATPase activity/force development and the generally larger increases in Ca2+ sensitivity than observed for most hypertrophic cardiomyopathy mutations would likely lead to severe diastolic dysfunction and may be the major physiological factors responsible for causing the restrictive cardiomyopathy phenotype in some of the genetically affected individuals.	Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA	University of Miami	Potter, JD (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	jdpotter@miami.edu	Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042325, R37HL042325, R01HL067415] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67415, HL42325] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ammash NM, 2000, CIRCULATION, V101, P2490, DOI 10.1161/01.CIR.101.21.2490; Angelini A, 1997, AM J CARDIOL, V80, P1046, DOI 10.1016/S0002-9149(97)00601-2; Artz, 2000, Curr Treat Options Cardiovasc Med, V2, P431, DOI 10.1007/s11936-000-0038-6; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gomes AV, 2004, ANN NY ACAD SCI, V1015, P214, DOI 10.1196/annals.1302.018; Gomes AV, 2004, MOL CELL BIOCHEM, V263, P99, DOI 10.1023/B:MCBI.0000041852.42291.aa; Gomes AV, 2004, J BIOL CHEM, V279, P49579, DOI 10.1074/jbc.M407340200; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; GUTH K, 1987, J BIOL CHEM, V262, P13627; HILL LE, 1992, J BIOL CHEM, V267, P16106; James J, 2000, CIRC RES, V87, P805, DOI 10.1161/01.RES.87.9.805; Javadpour MM, 2003, J CLIN INVEST, V112, P768, DOI 10.1172/JC1200315967; Kushwaha SS, 1997, NEW ENGL J MED, V336, P267, DOI 10.1056/NEJM199701233360407; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Mogensen J, 2003, J CLIN INVEST, V111, P209, DOI 10.1172/JCI200316336; Moore DD, 1995, GLOB MOB SURV; Palka P, 2003, CARDIOL YOUNG, V13, P469, DOI 10.1017/S1047951103000970; Parsons B, 1997, J MUSCLE RES CELL M, V18, P599, DOI 10.1023/A:1018623604365; RAPEZZI C, 1990, INT J CARDIOL, V29, P121, DOI 10.1016/0167-5273(90)90214-P; Rivenes SM, 2000, CIRCULATION, V102, P876; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Schwartz ML, 2003, AM J CARDIOL, V92, P636, DOI 10.1016/S0002-9149(03)00744-6; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takahashi-Yanaga F, 2000, J BIOCHEM-TOKYO, V127, P355, DOI 10.1093/oxfordjournals.jbchem.a022615; Takahashi-Yanaga F, 2001, J MOL CELL CARDIOL, V33, P2095, DOI 10.1006/jmcc.2001.1473; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Venkatraman G, 2003, J BIOL CHEM, V278, P41670, DOI 10.1074/jbc.M302148200; Zachara E, 1997, G Ital Cardiol, V27, P436; Zhang J, 2001, CLIN GENET, V59, P248, DOI 10.1034/j.1399-0004.2001.590406.x	35	78	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30909	30915		10.1074/jbc.M500287200	http://dx.doi.org/10.1074/jbc.M500287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15961398	hybrid			2022-12-25	WOS:000231487800032
J	Psylinakis, E; Boneca, IG; Mavromatis, K; Deli, A; Hayhurst, E; Foster, SJ; Varum, KM; Bouriotis, V				Psylinakis, E; Boneca, IG; Mavromatis, K; Deli, A; Hayhurst, E; Foster, SJ; Varum, KM; Bouriotis, V			Peptidoglycan N-acetylglucosamine deacetylases from Bacillus cereus, highly conserved proteins in Bacillus anthracis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE ESTERASE; GENOME SEQUENCE; CHITIN; CHITOSANS; RESIDUES; LACTAM; CELLS; PDAA	The genomes of Bacillus cereus and its closest relative Bacillus anthracis contain 10 polysaccharide deacetylase homologues. Six of these homologues have been proposed to be peptidoglycan N-acetylglucosamine deacetylases. Two of these genes, namely bc1960 and bc3618, have been cloned and expressed in Escherichia coli, and the recombinant enzymes have been purified to homogeneity and further characterized. Both enzymes were effective in deacetylating cell wall peptidoglycan from the Gram(+) Bacillus cereus and Bacillus subtilis and the Gram(-) Helicobacter pylori as well as soluble chitin substrates and N-acetylchitooligomers. However, the enzymes were not active on acetylated xylan. These results provide insight into the substrate specificity of carbohydrate esterase family 4 enzymes. It was revealed that both enzymes deacetylated only the GlcNAc residue of the synthetic muropeptide N-acetyl-D-glucosamine-(beta-1,4)-N-acetylmuramyl-L-alanine-D-isoglutamine. Analysis of the constituent muropeptides of peptidoglycan from B. subtilis and H. pylori resulting from incubation of the enzymes BC1960 and BC3618 with these polymers and subsequent hydrolysis by Cellosyl and mutanolysin, respectively, similarly revealed that both enzymes deacetylate GlcNAc residues of peptidoglycan. Kinetic analysis toward GlcNAc(2-6) revealed that GlcNAc(4) was the favorable substrate for both enzymes. Identification of the sequence of N-acetychitooligosaccharides (GlcNAc(2-4)) following enzymatic deacetylation by using H-1 NMR revealed that both enzymes deacetylate all GlcNAc residues of the oligomers except the reducing end ones. Enzymatic deacetylation of chemically acetylated vegetative peptidoglycan from B. cereus by BC1960 and BC3618 resulted in increased resistance to lysozyme digestion. This is the first biochemical study of bacterial peptidoglycan N-acetylglucosamine deacetylases.	Univ Crete, Dept Biol, Ebzyme Biotechnol Grp, Iraklion 71409, Crete, Greece; Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris, France; JGI Prod Genom Facil, Walnut Creek, CA 94598 USA; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Norwegian Univ Sci & Technol, Norwegian Biopolymer Lab, Dept Biotechnol, N-7034 Trondheim, Norway	University of Crete; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Sheffield; Norwegian University of Science & Technology (NTNU)	Bouriotis, V (corresponding author), Univ Crete, Dept Biol, Ebzyme Biotechnol Grp, POB 2208,Vasilika Vouton, Iraklion 71409, Crete, Greece.	bouriotis@imbb.forth.gr	Boneca, Ivo G/H-1677-2014	Boneca, Ivo G/0000-0001-8122-509X				Antignac A, 2003, J BIOL CHEM, V278, P31521, DOI 10.1074/jbc.M304749200; ARAKI Y, 1980, J BIOCHEM-TOKYO, V88, P469, DOI 10.1093/oxfordjournals.jbchem.a132994; Atrih A, 1999, J BACTERIOL, V181, P3956, DOI 10.1128/JB.181.13.3956-3966.1999; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V2, P1; Blair DE, 2004, FEBS LETT, V570, P13, DOI 10.1016/j.febslet.2004.06.013; Caufrier F, 2003, CARBOHYD RES, V338, P687, DOI 10.1016/S0008-6215(03)00002-8; Costa K, 1999, J BACTERIOL, V181, P3710, DOI 10.1128/JB.181.12.3710-3715.1999; Coutinho PM, 1999, ROY SOC CH, P3; Fukushima T, 2002, J BACTERIOL, V184, P6007, DOI 10.1128/JB.184.21.6007-6015.2002; Gilmore ME, 2004, J BACTERIOL, V186, P80, DOI 10.1128/JB.186.1.80-89.2004; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; ISHIGURO K, 1992, CARBOHYD RES, V237, P333, DOI 10.1016/S0008-6215(92)84257-S; Ivanova N, 2003, NATURE, V423, P87, DOI 10.1038/nature01582; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P2564, DOI 10.1073/pnas.90.7.2564; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Overbeek R, 2003, NUCLEIC ACIDS RES, V31, P164, DOI 10.1093/nar/gkg148; Read TD, 2003, NATURE, V423, P81, DOI 10.1038/nature01586; Severin A, 2004, MICROB DRUG RESIST, V10, P77, DOI 10.1089/1076629041310082; Sorbotten A, 2005, FEBS J, V272, P538, DOI 10.1111/j.1742-4658.2004.04495.x; Tsigos I, 2000, TRENDS BIOTECHNOL, V18, P305, DOI 10.1016/S0167-7799(00)01462-1; VARUM KM, 1991, CARBOHYD RES, V211, P17, DOI 10.1016/0008-6215(91)84142-2; Vollmer W, 2000, J BIOL CHEM, V275, P20496, DOI 10.1074/jbc.M910189199	22	69	75	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30856	30863		10.1074/jbc.M407426200	http://dx.doi.org/10.1074/jbc.M407426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15961396	hybrid			2022-12-25	WOS:000231487800026
J	Zochbauer-Muller, S; Fong, KM; Geradts, J; Xu, X; Seidl, S; End-Pfutzenreuter, A; Lang, G; Heller, G; Zielinski, CC; Gazdar, AF; Minna, JD				Zochbauer-Muller, S; Fong, KM; Geradts, J; Xu, X; Seidl, S; End-Pfutzenreuter, A; Lang, G; Heller, G; Zielinski, CC; Gazdar, AF; Minna, JD			Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation	ONCOGENE			English	Article						tumor suppressor gene; lung cancer; hSRBC; epigenetic; methylation-specific PCR	ABERRANT PROMOTER METHYLATION; EPIGENETIC INACTIVATION; MULTIPLE GENES; BREAST; HETEROZYGOSITY; SMOKERS; CARCINOMAS; CHROMOSOME-11; PROGRESSION; EPITHELIUM	Recently, the human SRBC (hSRBC) gene, a candidate tumor suppressor gene (TSG), has been mapped to the chromosomal region 11p15.5-p15.4 where frequent allele loss has been described in lung cancer. Aberrant methylation ( referred to as methylation) of the promoter region of TSGs has been identified as an important mechanism for gene silencing. Loss of hSRBC protein expression occurs frequently in lung cancer cell lines and sodium bisulfite sequencing of the promoter region of hSRBC in several lung cancer cell lines suggested that methylation plays an important role in inactivating hSRBC. To determine the methylation status of hSRBC in a large collection of primary lung cancer samples, corresponding nonmalignant lung tissues and lung cancer cell lines (N=52), we designed primers for a methylation-specific PCR assay. Methylation was detected in 41% of primary non-small-cell lung cancers (NSCLC)(N=107) and in 80% of primary small-cell lung cancers (SCLC)(N=5), but was seen only in 4% of corresponding nonmalignant lung tissues (N=103). In all, 79% of lung cancer cell lines were methylated and the frequency of hSRBC methylation was significantly higher in SCLC (100%) than in NSCLC (58%) cell lines. Normal hSRBC protein expression was detected in only 18% of primary NSCLCs (N=93) by immunostaining and a significant association between loss of protein expression and methylation was found. hSRBC re-expression was observed after treatment of lung cancer cells with the demethylating agent 5-aza-2'-deoxycytidine. In addition, 45% of the 76 hSRBC immunostaining-negative NSCLCs did not have hSRBC promoter methylation, indicating that other mechanisms of hSRBC expression silencing also exist. Both hSRBC immunostaining and methylation results did not correlate with clinicopathological characteristics of these patients. Our ndings suggest that hSRBC is a candidate TSG involved in lung cancer pathogenesis, where expression is frequently inactivated by methylation and other mechanisms.	Univ Hosp Vienna, Clin Div Oncol, Dept Med 1, A-1090 Vienna, Austria; Univ Hosp Vienna, Ctr Excellence Clin & Expt Oncol, Vienna, Austria; Prince Charles Hosp, Brisbane, Qld 4032, Australia; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Sagres Discovery, Davis, CA USA; Univ Hosp Vienna, Dept Cardiothorac Surg, Vienna, Austria; Koranyi Natl Inst Pulmonol, Dept Thorac Surg, Budapest, Hungary; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75230 USA	University Hospital Vienna; University Hospital Vienna; Prince Charles Hospital; Roswell Park Cancer Institute; University Hospital Vienna; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zochbauer-Muller, S (corresponding author), Univ Hosp Vienna, Clin Div Oncol, Dept Med 1, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	sabine.zoechbauer-mueller@meduniwien.ac.at	heller, gerwin/E-6521-2011; Zöchbauer-Müller, Sabine/B-8399-2012; Fong, Kwun M/G-6369-2010	heller, gerwin/0000-0001-8742-5631; Zöchbauer-Müller, Sabine/0000-0002-6777-1729; Fong, Kwun/0000-0002-6507-1403	NCI NIH HHS [CA709907] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Baffa R, 1996, CANCER RES, V56, P268; Belinsky SA, 2002, CANCER RES, V62, P2370; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; FONG KM, 1995, CANCER RES, V55, P220; FONG KM, 1995, CANCER RES, V55, P28; Fong KM, 1996, BRIT J CANCER, V74, P1975, DOI 10.1038/bjc.1996.662; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Phelps RM, 1996, J CELL BIOCHEM, P32; Soria JC, 2002, CANCER RES, V62, P351; Toyooka S, 2001, MOL CANCER THER, V1, P61; Tran YK, 1996, CANCER RES, V56, P2916; VANDAMME B, 1992, CANCER RES, V52, P6646; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WINQVIST R, 1995, CANCER RES, V55, P2660; Wistuba II, 1999, CLIN CANCER RES, V5, P991; Xu XL, 2001, CANCER RES, V61, P7943; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2003, INT J CANCER, V107, P612, DOI 10.1002/ijc.11458; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	24	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6249	6255		10.1038/sj.onc.1208775	http://dx.doi.org/10.1038/sj.onc.1208775			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940253				2022-12-25	WOS:000231877100006
J	Srivastava, SK; Tripathi, RP; Ramachandran, R				Srivastava, SK; Tripathi, RP; Ramachandran, R			NAD(+)-dependent DNA ligase (Rv3014c) from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING ENZYME; MUTATIONAL ANALYSIS; IN-VIVO; CLONING; GENE; REPLICATION; SUPERFAMILY; INHIBITION; GROWTH; DOMAIN	DNA ligases utilize either ATP or NAD(+) as cofactors to catalyze the formation of phosphodiester bonds in nicked DNA. Those utilizing NAD(+) are attractive drug targets because of the unique cofactor requirement for ligase activity. We report here the crystal structure of the adenylation domain of the Mycobacterium tuberculosis NAD(+)-dependent ligase with bound AMP. The adenosine nucleoside moiety of AMP adopts a syn-conformation. The structure also captures a new spatial disposition between the two subdomains of the adenylation domain. Based on the crystal structure and an in-house compound library, we have identified a novel class of inhibitors for the enzyme using in silico docking calculations. The glycosyl ureide-based inhibitors were able to distinguish between NAD(+)-and ATP-dependent ligases as evidenced by in vitro assays using T4 ligase and human DNA ligase I. Moreover, assays involving an Escherichia coli strain harboring a temperature-sensitive ligase mutant and a ligase-deficient Salmonella typhimurium strain suggested that the bactericidal activity of the inhibitors is due to inhibition of the essential ligase enzyme. The results can be used as the basis for rational design of novel antibacterial agents.	Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India; Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Ramachandran, R (corresponding author), Cent Drug Res Inst, Mol & Struct Biol Div, POB 173, Lucknow 226001, Uttar Pradesh, India.	ravi_anitha@yahoo.com	Ramachandran, Ravishankar/D-1979-2010	SRIVASTAVA, SANDEEP/0000-0003-4484-0223; Ramachandran, Ravishankar/0000-0002-0723-9861				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brotz-Oesterhelt H, 2003, J BIOL CHEM, V278, P39435, DOI 10.1074/jbc.M306479200; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; Cheng CH, 1997, NUCLEIC ACIDS RES, V25, P1369, DOI 10.1093/nar/25.7.1369; Ciarrocchi G, 1999, ANTIMICROB AGENTS CH, V43, P2766, DOI 10.1128/AAC.43.11.2766; DERMODY JJ, 1979, J BACTERIOL, V139, P701, DOI 10.1128/JB.139.2.701-704.1979; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Doherty AJ, 1996, J BIOL CHEM, V271, P11083, DOI 10.1074/jbc.271.19.11083; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; Gajiwala KS, 2004, STRUCTURE, V12, P1449, DOI 10.1016/j.str.2004.05.017; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Kaczmarek FS, 2001, J BACTERIOL, V183, P3016, DOI 10.1128/JB.183.10.3016-3024.2001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lavesa-Curto M, 2004, MICROBIOL-SGM, V150, P4171, DOI 10.1099/mic.0.27287-0; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK UE, 1989, J BACTERIOL, V171, P2173, DOI 10.1128/jb.171.4.2173-2180.1989; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Petit MA, 2000, NUCLEIC ACIDS RES, V28, P4642, DOI 10.1093/nar/28.23.4642; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Ren ZJ, 1997, GENE, V195, P303, DOI 10.1016/S0378-1119(97)00186-8; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Shuman S, 2004, CURR OPIN STRUC BIOL, V14, P757, DOI 10.1016/j.sbi.2004.10.006; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 2001, J BIOL CHEM, V276, P36100, DOI 10.1074/jbc.M105643200; SRISKANDA V, 2002, J BIOL CHEM, V277, P9685; Timson DJ, 1999, J MOL BIOL, V285, P73, DOI 10.1006/jmbi.1998.2302; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; Wilkinson A, 2003, PROTEINS, V51, P321, DOI 10.1002/prot.10361; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x; WILSON GG, 1979, J MOL BIOL, V132, P471, DOI 10.1016/0022-2836(79)90270-5; Zhu H, 2005, J BIOL CHEM, V280, P12137, DOI 10.1074/jbc.M413685200	44	145	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30273	30281		10.1074/jbc.M503780200	http://dx.doi.org/10.1074/jbc.M503780200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15901723	hybrid			2022-12-25	WOS:000231362500036
J	Ciferri, C; De Luca, J; Monzani, S; Ferrari, KJ; Ristic, D; Wyman, C; Stark, H; Kilmartin, J; Salmon, ED; Musacchio, A				Ciferri, C; De Luca, J; Monzani, S; Ferrari, KJ; Ristic, D; Wyman, C; Stark, H; Kilmartin, J; Salmon, ED; Musacchio, A			Architecture of the human Ndc80-Hec1 complex, a critical constituent of the outer kinetochore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUDDING YEAST KINETOCHORE; SPINDLE CHECKPOINT; MICROTUBULE ATTACHMENT; CHROMOSOME CONGRESSION; CONSERVED PROTEIN; COILED COILS; CENP-E; CENTROMERE; PLATE; HEC1	The Ndc80 complex is a constituent of the outer plate of the kinetochore and plays a critical role in establishing the stable kinetochore-microtubule interactions required for chromosome segregation in mitosis. The Ndc80 complex is evolutionarily conserved and contains the four subunits Spc24, Spc25, Nuf2, and Ndc80 ( whose human homologue is called Hec1). All four subunits are predicted to contain globular domains and extensive coiled coil regions. To gain an insight into the organization of the human Ndc80 complex, we reconstituted it using recombinant methods. The hydrodynamic properties of the recombinant Ndc80 complex are identical to those of the endogenous HeLa cell complex and are consistent with a 1: 1: 1: 1 stoichiometry of the four subunits and a very elongated shape. Two tight Hec1-Nuf2 and Spc24-Spc25 subcomplexes, each stabilized by a parallel heterodimeric coiled coil, maintain this organization. These subcomplexes tetramerize via an interaction of the C- and N-terminal portions of the Hec1-Nuf2 and Spc24-Spc25 coiled coils, respectively. The recombinant complex displays normal kinetochore localization upon injection in HeLa cells and is therefore a faithful copy of the endogenous Ndc80 complex.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Inst Mol Oncol Fdn, Italian Fdn Canc Res FIRC, I-20139 Milan, Italy; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Dr Daniel Den Hoed Canc Ctr, Dept Radiat Oncol, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Ctr Med, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; University of North Carolina; University of North Carolina Chapel Hill; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Max Planck Society; MRC Laboratory Molecular Biology	Musacchio, A (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	andrea.musacchio@ifomieo-campus.it	Ferrari, Karin/AAO-2727-2020	Holger, Stark/0000-0002-6161-1118; Ferrari, Karin/0000-0002-9877-632X; Musacchio, Andrea/0000-0003-2362-8784	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024364] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM024364] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amor DJ, 2004, TRENDS CELL BIOL, V14, P359, DOI 10.1016/j.tcb.2004.05.009; Bharadwaj R, 2004, J BIOL CHEM, V279, P13076, DOI 10.1074/jbc.M310224200; Cheeseman IM, 2004, GENE DEV, V18, P2255, DOI 10.1101/gad.1234104; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Cooke CA, 1997, CHROMOSOMA, V106, P446, DOI 10.1007/s004120050266; De Antoni A, 2005, CURR BIOL, V15, P214, DOI 10.1016/j.cub.2005.01.038; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DeLuca JG, 2002, J CELL BIOL, V159, P549, DOI 10.1083/jcb.200208159; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; DeLuca JG, 2003, CURR BIOL, V13, P2103, DOI 10.1016/j.cub.2003.10.056; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Gillett ES, 2004, J CELL BIOL, V164, P535, DOI 10.1083/jcb.200308100; HARDING SE, 1995, ANAL BIOCHEM, V228, P131, DOI 10.1006/abio.1995.1324; Hayashi T, 2004, CELL, V118, P715, DOI 10.1016/j.cell.2004.09.002; Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645; Howe M, 2001, J CELL BIOL, V153, P1227, DOI 10.1083/jcb.153.6.1227; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Janke C, 2001, EMBO J, V20, P777, DOI 10.1093/emboj/20.4.777; JOKELAINEN PT, 1967, J ULTRA MOL STRUCT R, V19, P19, DOI 10.1016/S0022-5320(67)80058-3; Kline-Smith SL, 2005, CURR OPIN CELL BIOL, V17, P35, DOI 10.1016/j.ceb.2004.12.009; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maiato H, 2004, J CELL SCI, V117, P5461, DOI 10.1242/jcs.01536; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McAinsh AD, 2003, ANNU REV CELL DEV BI, V19, P519, DOI 10.1146/annurev.cellbio.19.111301.155607; McCleland ML, 2004, CURR BIOL, V14, P131, DOI 10.1016/j.cub.2003.12.058; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; McEwen BF, 1997, J CELL BIOL, V137, P1567, DOI 10.1083/jcb.137.7.1567; MCEWEN BF, 1993, J CELL BIOL, V120, P301, DOI 10.1083/jcb.120.2.301; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nabetani A, 2001, CHROMOSOMA, V110, P322, DOI 10.1007/s004120100153; Nekrasov VS, 2003, MOL BIOL CELL, V14, P4931, DOI 10.1091/mbc.E03-06-0419; Newman JRS, 2000, P NATL ACAD SCI USA, V97, P13203, DOI 10.1073/pnas.97.24.13203; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Pinsky BA, 2003, DEV CELL, V5, P735, DOI 10.1016/S1534-5807(03)00322-8; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Wei RR, 2005, P NATL ACAD SCI USA, V102, P5363, DOI 10.1073/pnas.0501168102; Westermann S, 2003, J CELL BIOL, V163, P215, DOI 10.1083/jcb.200305100; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435	42	138	148	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29088	29095		10.1074/jbc.M504070200	http://dx.doi.org/10.1074/jbc.M504070200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15961401	Green Published, hybrid			2022-12-25	WOS:000231021300035
J	Hofmann, TG; Jaffray, E; Stollberg, N; Hay, RT; Will, H				Hofmann, TG; Jaffray, E; Stollberg, N; Hay, RT; Will, H			Regulation of homeodomain-interacting protein kinase 2 (HIPK2) effector function through dynamic small ubiquitin-related modifier-1 (SUMO-1) modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN-INTERACTING PROTEIN-KINASE-2; AXIN-BINDING PROTEIN; C-JUN; TRANSCRIPTIONAL ACTIVATION; COVALENT MODIFICATION; NUCLEAR-BODIES; BETA-CATENIN; P53 ACTIVITY; PML; UBIQUITIN	Homeodomain-interacting protein kinase 2 (HIPK2) is involved in transcriptional regulation, growth suppression, and apoptosis. Previous reports showed that HIPK2 can signal cell death via p53, and independently of p53 by activating the c-Jun NH2-terminal kinase (JNK) pathway or mediating CtBP degradation. Here we demonstrate that human HIPK2 is small ubiquitin-related modifier-1 (SUMO-1)-modified in vitro and in vivo at lysine residue 25, a SUMO consensus modification motif conserved in human and mouse HIPK family proteins. SUMO modification of HIPK2 altered neither its nuclear body localization nor its recruitment to promyelocytic leukemia-nuclear bodies. However, SUMO-1 modification inhibited HIPK2-induced JNK activation and p53-independent antiproliferative function. HIPK2 with a mutated SUMO acceptor lysine residue was refractory to inhibition of HIPK2-mediated JNK activation by SUMO-1. Furthermore, we demonstrate that SUMO protease SuPr-1 interacts with HIPK2, and both proteins predominantly colocalize in promyelocytic leukemia-nuclear bodies. SuPr-1 deconjugates SUMO-1 from HIPK2 in vitro and in vivo, which results in modestly increased HIPK2-induced JNK activity. Thus, our data demonstrate that HIPK2 effector function on JNK is modulated through dynamic SUMO-1 modification.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Deutsch Krebsforschungszentrum, Arbeitsgrp Zellulare Seneszenz, D-69120 Heidelberg, Germany; Heidelberg Univ, Deutsches Zentrum Alternsforsch, D-69120 Heidelberg, Germany	Heinrich Pette Institute; University of Hamburg; University of St Andrews; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Hofmann, TG (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	t.hofmann@dkfz.de	Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024				Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Everett RD, 1999, J CELL SCI, V112, P4581; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 2003, CURR OPIN CELL BIOL, V15, P351, DOI 10.1016/S0955-0674(03)00038-3; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gresko E, 2005, BIOCHEM BIOPH RES CO, V329, P1293, DOI 10.1016/j.bbrc.2005.02.113; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann TG, 2003, CANCER RES, V63, P8271; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Kadoya T, 2002, MOL CELL BIOL, V22, P3803, DOI 10.1128/MCB.22.11.3803-3819.2002; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Moller A, 2003, CANCER RES, V63, P4310; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	44	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29224	29232		10.1074/jbc.M503921200	http://dx.doi.org/10.1074/jbc.M503921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15958389	hybrid			2022-12-25	WOS:000231021300051
J	Vaaje-Kolstad, G; Horn, SJ; van Aalten, DMF; Synstad, B; Eijsink, VGH				Vaaje-Kolstad, G; Horn, SJ; van Aalten, DMF; Synstad, B; Eijsink, VGH			The non-catalytic chitin-binding protein CBP21 from Serratia marcescens is essential for chitin degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; EXPOSED AROMATIC RESIDUES; NON-HYDROLYTIC DISRUPTION; ALPHA-CHITIN; GENE; SEQUENCE; DOMAIN; IDENTIFICATION; RESISTANCE; LARVAE	The Gram-negative soil bacterium Serratia marcescens uses three different family 18 chitinases to degrade chitin, an abundant insoluble carbohydrate polymer composed of beta( 1,4)-linked units of N-acetylglucosamine. We show that efficient chitin degradation additionally depends on the action of a small noncatalytic protein, CBP21, which binds to the insoluble crystalline substrate, leading to structural changes in the substrate and increased substrate accessibility. CBP21 strongly promoted hydrolysis of crystalline beta-chitin by chitinases A and C, while it was essential for full degradation by chitinase B. CBP21 variants with single mutations on the largely polar binding surface lost their ability to promote chitin degradation, while retaining considerable affinity for the polymer. Thus, binding alone is not sufficient for CBP21 functionality, which seems to depend on specific, mostly polar interactions between the protein and crystalline chitin. This is the first time a secreted binding protein is shown to assist in the enzymatic degradation of an insoluble carbohydrate via non-hydrolytic disruption of the substrate. Interestingly, homologues of CBP21 occur in most chitin-degrading microorganisms, suggesting a general mechanism by which chitin-binding proteins enhance chitinolytic activity. Homologues also occur in chitinase-containing insect viruses, whose infectiousness is known to depend on chitinase efficiency.	Norwegian Univ Life Sci, Dept Chem Biotechnol & Food Sci, N-1432 As, Norway; Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	Norwegian University of Life Sciences; University of Dundee	Eijsink, VGH (corresponding author), Norwegian Univ Life Sci, Dept Chem Biotechnol & Food Sci, POB 5003, N-1432 As, Norway.	vincent.eijsink@umb.no	Horn, Svein Jarle/C-6258-2008; Horn, Svein/F-9723-2010	Horn, Svein Jarle/0000-0002-1590-9001; van Aalten, Daan/0000-0002-1499-6908				Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; BROGLIE K, 1991, SCIENCE, V254, P1194, DOI 10.1126/science.254.5035.1194; BRURBERG MB, 1994, FEMS MICROBIOL LETT, V124, P399, DOI 10.1016/0378-1097(94)00462-5; Brurberg MB, 1996, MICROBIOL-SGM, V142, P1581, DOI 10.1099/13500872-142-7-1581; BRURBERG MB, 1995, MICROBIOL-SGM, V141, P123, DOI 10.1099/00221287-141-1-123; BRURBERG MB, 2001, RRD MICROBIOL 1, V5, P187; Chu HH, 2001, MICROBIOL-SGM, V147, P1793, DOI 10.1099/00221287-147-7-1793; Dall D, 2001, BIOESSAYS, V23, P184, DOI 10.1002/1521-1878(200102)23:2&lt;184::AID-BIES1026&gt;3.0.CO;2-H; DIN N, 1994, P NATL ACAD SCI USA, V91, P11383, DOI 10.1073/pnas.91.24.11383; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; Ding XF, 1998, TRANSGENIC RES, V7, P77, DOI 10.1023/A:1008820507262; Folders J, 2000, J BACTERIOL, V182, P1257, DOI 10.1128/JB.182.5.1257-1263.2000; FUCHS RL, 1986, APPL ENVIRON MICROB, V51, P504, DOI 10.1128/AEM.51.3.504-509.1986; Gao PJ, 2001, ACTA BIOCH BIOPH SIN, V33, P13; Gilbert HJ, 2002, ROY SOC CH, P89, DOI 10.1039/9781847550323-00089; GOODAY GW, 1990, ADV MICROB ECOL, V11, P387; Harman GE, 2004, NAT REV MICROBIOL, V2, P43, DOI 10.1038/nrmicro797; Hawtin RE, 1997, VIROLOGY, V238, P243, DOI 10.1006/viro.1997.8816; HAWTIN RE, 1995, VIROLOGY, V212, P673, DOI 10.1006/viro.1995.1525; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hukuhara T, 1999, NAT BIOTECHNOL, V17, P1122, DOI 10.1038/15110; JACH G, 1995, PLANT J, V8, P97, DOI 10.1046/j.1365-313X.1995.08010097.x; Kasprzewska A, 2003, CELL MOL BIOL LETT, V8, P809; Katouno F, 2004, J BIOCHEM, V136, P163, DOI 10.1093/jb/mvh105; Kolbe S, 1998, MICROBIOL-SGM, V144, P1291, DOI 10.1099/00221287-144-5-1291; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Li ZF, 2003, VIRUS RES, V96, P113, DOI 10.1016/S0168-1702(03)00179-5; Mitsuhashi W, 1998, J INVERTEBR PATHOL, V71, P186, DOI 10.1006/jipa.1997.4732; Mitsuhashi W, 2003, J INVERTEBR PATHOL, V82, P34, DOI 10.1016/S0022-2011(02)00203-3; MONREAL J, 1969, CAN J MICROBIOL, V15, P689, DOI 10.1139/m69-122; Pijlman GP, 2003, J GEN VIROL, V84, P2041, DOI 10.1099/vir.0.19133-0; REESE ET, 1950, J BACTERIOL, V59, P485, DOI 10.1128/JB.59.4.485-497.1950; Saito Y, 2000, INT J BIOL MACROMOL, V28, P81, DOI 10.1016/S0141-8130(00)00147-1; Saito Y, 2002, BIOMACROMOLECULES, V3, P407, DOI 10.1021/bm015646d; Saloheimo M, 2002, EUR J BIOCHEM, V269, P4202, DOI 10.1046/j.1432-1033.2002.03095.x; SCHLEIN Y, 1992, P NATL ACAD SCI USA, V89, P9944, DOI 10.1073/pnas.89.20.9944; SCHNELLMANN J, 1994, MOL MICROBIOL, V13, P807, DOI 10.1111/j.1365-2958.1994.tb00473.x; Southall SM, 1999, FEBS LETT, V447, P58, DOI 10.1016/S0014-5793(99)00263-X; Suzuki K, 2002, BIOSCI BIOTECH BIOCH, V66, P1075, DOI 10.1271/bbb.66.1075; Suzuki K, 2001, BIOSCI BIOTECH BIOCH, V65, P338, DOI 10.1271/bbb.65.338; Suzuki K, 1998, BIOSCI BIOTECH BIOCH, V62, P128, DOI 10.1271/bbb.62.128; Suzuki K, 1999, BIOCHEM J, V343, P587, DOI 10.1042/0264-6021:3430587; Uchiyama T, 2001, J BIOL CHEM, V276, P41343, DOI 10.1074/jbc.M103610200; Vaaje-Kolstad G, 2005, J BIOL CHEM, V280, P11313, DOI 10.1074/jbc.M407175200; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; Vinetz JM, 1999, P NATL ACAD SCI USA, V96, P14061, DOI 10.1073/pnas.96.24.14061; Watanabe T, 1997, J BACTERIOL, V179, P7111, DOI 10.1128/jb.179.22.7111-7117.1997; WATANABE T, 1994, J BACTERIOL, V176, P4465, DOI 10.1128/JB.176.15.4465-4472.1994; XU JH, 1992, J INVERTEBR PATHOL, V60, P259, DOI 10.1016/0022-2011(92)90007-Q; XU JH, 1994, J INVERTEBR PATHOL, V63, P14, DOI 10.1006/jipa.1994.1003; ZELTINS A, 1995, ANAL BIOCHEM, V231, P287, DOI 10.1006/abio.1995.0053	52	274	291	0	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28492	28497		10.1074/jbc.M504468200	http://dx.doi.org/10.1074/jbc.M504468200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15929981	hybrid			2022-12-25	WOS:000230857300039
J	Moran, JM; Buller, RML; McHowat, J; Turk, J; Wohltmann, M; Gross, RW; Corbett, JA				Moran, JM; Buller, RML; McHowat, J; Turk, J; Wohltmann, M; Gross, RW; Corbett, JA			Genetic and pharmacologic evidence that calcium-independent phospholipase A(2)beta regulates virus-induced inducible nitric-oxide synthase expression by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; NF-KAPPA-B; MECHANISM-BASED DISCRIMINATION; MEDIATES CREB PHOSPHORYLATION; PROTEIN-KINASE; ENCEPHALOMYOCARDITIS VIRUS; SUICIDE INHIBITION; ENDOTHELIAL-CELLS; VIRAL-INFECTION; POTENTIAL ROLE	Recent evidence supports a regulatory role for the calcium-independent phospholipase A(2) (iPLA2) in the antiviral response of inducible nitric-oxide synthase ( iNOS) expression by macrophages. Because two mammalian isoforms of iPLA(2) (iPLA(2)beta and iPLA(2)gamma) have been cloned and characterized, the aim of this study was to identify the specific isoform(s) in macrophages that regulates the expression of iNOS in response to virus infection. Bromoenol lactone (BEL), a suicide substrate inhibitor of iPLA(2), inhibits the activity of both isoforms at low micromolar concentrations. However, the R- and S-enantiomers of BEL display similar to 10-fold greater potency for inhibition of the enzymatic activity of iPLA(2)beta and iPLA(2)gamma, respectively. In this study, we show that the iPLA(2)beta-selective (S)-BEL inhibits encephalomyocarditis virus (EMCV)-induced iNOS expression, nitric oxide production, and iPLA(2) enzymatic activity in macrophages in a concentration-related manner that closely resembles the inhibitory properties of racemic BEL. cAMP response element-binding protein ( CREB) is one downstream target of iPLA(2) that is required for the transcriptional activation of iNOS in response to virus infection, and consistent with the effects of BEL enantiomers on iNOS expression,(S)-BEL more effectively inhibits EMCV-induced CREB phosphorylation than (R)-BEL in macrophages. Using macrophages isolated from iPLA(2)beta-null mice, virus infection fails to stimulate iNOS mRNA accumulation and protein expression, thus providing genetic evidence that iPLA(2)beta is required for EMCV-induced iNOS expression. These findings provide evidence for a signaling role for iPLA(2)beta in virus-induced iNOS expression by macrophages.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Med, Div Endocrinol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Bioorgan Chem & Mol Pharmacol, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Saint Louis University; Washington University (WUSTL); Washington University (WUSTL)	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	corbettj@slu.edu		McHowat, Jane/0000-0003-3133-3388	NHLBI NIH HHS [P01 HL57278-08, HL41250, HL68588] Funding Source: Medline; NIAID NIH HHS [AI-44458] Funding Source: Medline; NIDDK NIH HHS [DK34388, DK-52194] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041250, P01HL057278, R01HL068588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052194, R01DK034388, R37DK034388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnush M, 1998, J IMMUNOL, V160, P2684; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Balsinde J, 1997, ADV EXP MED BIOL, V407, P99; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; Blair LA, 2002, J BIOL CHEM, V277, P359, DOI 10.1074/jbc.M109819200; Flodstrom M, 2001, VIROLOGY, V281, P205, DOI 10.1006/viro.2000.0801; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Glaser K B, 1990, Adv Exp Med Biol, V275, P1; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gross RW, 1998, BIOCHEM SOC T, V26, P345, DOI 10.1042/bst0260345; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; Hirasawa K, 1999, J VIROL, V73, P8541, DOI 10.1128/JVI.73.10.8541-8548.1999; Horrocks L A, 1978, Adv Exp Med Biol, V100, P423; HUBER SA, 1994, J VIROL, V68, P3453, DOI 10.1128/JVI.68.6.3453-3458.1994; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Maggi LB, 2003, J BIOL CHEM, V278, P16683, DOI 10.1074/jbc.M211744200; Maggi LB, 2002, J BIOL CHEM, V277, P38449, DOI 10.1074/jbc.M206247200; Maggi LB, 2000, EMBO J, V19, P3630, DOI 10.1093/emboj/19.14.3630; MALEWICZ B, 1981, BIOCHEM BIOPH RES CO, V101, P404, DOI 10.1016/0006-291X(81)91274-2; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Martinson BD, 2003, J LIPID RES, V44, P1686, DOI 10.1194/jlr.M300018-JLR200; McHowat J, 2000, AM J PHYSIOL-HEART C, V278, pH1933, DOI 10.1152/ajpheart.2000.278.6.H1933; MORAN JM, 2005, IN PRESS J VIROL; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; Steer SA, 2003, VIRAL IMMUNOL, V16, P447, DOI 10.1089/088282403771926283; Steer SA, 2003, J IMMUNOL, V170, P1070, DOI 10.4049/jimmunol.170.2.1070; Williams SD, 2001, AM J PHYSIOL-HEART C, V281, pH168, DOI 10.1152/ajpheart.2001.281.1.H168; WOLF RA, 1985, J BIOL CHEM, V260, P7295; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	36	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28162	28168		10.1074/jbc.M500013200	http://dx.doi.org/10.1074/jbc.M500013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15946940	hybrid			2022-12-25	WOS:000230678600080
J	Savinov, AY; Rozanov, DV; Golubkov, VS; Wong, FS; Strongin, AY				Savinov, AY; Rozanov, DV; Golubkov, VS; Wong, FS; Strongin, AY			Inhibition of membrane type-1 matrix metalloproteinase by cancer drugs interferes with the homing of diabetogenic T cells into the pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; HEMOPEXIN-LIKE DOMAIN; CD44; MT1-MMP; MICE; COLLAGENASE; PROGRESSION; ACTIVATION; SITE; NOD	We have discovered that clinically tested inhibitors of matrix metalloproteinases can control the functional activity of T cell membrane type-1 matrix metalloproteinase (MT1-MMP) and the onset of disease in a rodent model of type 1 diabetes in non-obese diabetic mice. We determined that MT1-MMP proteolysis of the T cell surface CD44 adhesion receptor affects the homing of T cells into the pancreas. We also determined that both the induction of the intrinsic T cell MT1-MMP activity and the shedding of cellular CD44 follow the adhesion of insulin-specific, CD8-positive, K-d-restricted T cells to the matrix. Conversely, inhibition of these events by AG3340 ( a potent hydroxamate inhibitor that was widely used in clinical trials in cancer patents) impedes the transmigration of diabetogenic T cells into the pancreas and protects non-obese diabetic mice from diabetes onset. Overall, our studies have divulged a previously unknown function of MT1-MMP and identified a promising novel drug target in type I diabetes.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England	Sanford Burnham Prebys Medical Discovery Institute; University of Bristol	Strongin, AY (corresponding author), Burnham Inst, Canc Res Ctr, 1091 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Golubkov, Vladislav/L-6828-2017; Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016; Wong, F. Susan/0000-0002-2812-8845	NATIONAL CANCER INSTITUTE [R01CA077470, R01CA083017] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NCI NIH HHS [CA83017, CA77470] Funding Source: Medline; NCRR NIH HHS [RR020843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Hande KR, 2004, CLIN CANCER RES, V10, P909, DOI 10.1158/1078-0432.CCR-0981-3; Homann D, 2004, CLIN IMMUNOL, V112, P202, DOI 10.1016/j.clim.2004.03.020; ITOH Y, 2005, IN PRESS J CELL PHYS; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Morimoto Y, 1997, LIFE SCI, V61, P795, DOI 10.1016/S0024-3205(97)00561-4; Nakamura H, 2004, CANCER RES, V64, P876, DOI 10.1158/0008-5472.CAN-03-3502; Pomerleau DP, 2005, DIABETES, V54, P1603, DOI 10.2337/diabetes.54.5.1603; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Ryan ME, 1999, ANN NY ACAD SCI, V878, P311, DOI 10.1111/j.1749-6632.1999.tb07692.x; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Savinov AY, 2003, J EXP MED, V197, P643, DOI 10.1084/jem.20021378; Savinov AY, 2001, J IMMUNOL, V167, P6637, DOI 10.4049/jimmunol.167.11.6637; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suenaga N, 2005, ONCOGENE, V24, P859, DOI 10.1038/sj.onc.1208258; TRAISMAN HS, 1973, CLIN PEDIATR, V12, P357, DOI 10.1177/000992287301200612; Weiss L, 2000, P NATL ACAD SCI USA, V97, P285, DOI 10.1073/pnas.97.1.285; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465	26	20	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27755	27758		10.1074/jbc.M506016200	http://dx.doi.org/10.1074/jbc.M506016200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15944163	hybrid			2022-12-25	WOS:000230678600034
J	Celie, JWAM; Keuning, ED; Beelen, RHJ; Drager, AM; Zweegman, S; Kessler, FL; Soininen, R; van den Born, J				Celie, JWAM; Keuning, ED; Beelen, RHJ; Drager, AM; Zweegman, S; Kessler, FL; Soininen, R; van den Born, J			Identification of L-selectin binding heparan sulfates attached to collagen type XVIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; P-SELECTIN; CHONDROITIN SULFATE; LYMPH-NODE; LIGANDS; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; KIDNEY; SPECIFICITIES; BIOSYNTHESIS	L-selectin is a C-type lectin expressed on leukocytes that is involved in both lymphocyte homing to the lymph node and leukocyte extravasation during inflammation. Known L-selectin ligands include sulfated Lewis-type carbohydrates, glycolipids, and proteoglycans. Previously, we have shown that in situ detection of different types of L-selectin ligands is highly dependent on the tissue fixation protocol used. Here we use this knowledge to specifically examine the expression of L-selectin binding proteoglycans in normal mouse tissues. We show that L-selectin binding chondroitin/dermatan sulfate proteoglycans are present in cartilage, whereas L-selectin binding heparan sulfate proteoglycans are present in spleen and kidney. Furthermore, we show that L-selectin only binds a subset of renal heparan sulfates, attached to a collagen type XVIII protein backbone and predominantly present in medullary tubular and vascular basement membranes. As L-selectin does not bind other renal heparan sulfate proteoglycans such as perlecan, agrin, and syndecan-4, and not all collagen type XVIII expressed in the kidney binds L-selectin, this indicates that there is a specific L-selectin binding domain on heparan sulfate glycosaminoglycan chains. Using an in vitro L-selectin binding assay, we studied the contribution of N-sulfation, O-sulfation, C5-epimerization, unsubstituted glucosamine residues, and chain length in L-selectin binding to heparan sulfate/heparin glycosaminoglycan chains. Based on our results and the accepted model of heparan sulfate domain organization, we propose a model for the interaction of L-selectin with heparan sulfate glycosaminoglycan chains. Interestingly, this opens the possibility of active regulation of L-selectin binding to heparan sulfate proteoglycans, e. g. under inflammatory conditions.	VU Univ Med Ctr, Dept Mol Cell Biol & Immunol, NL-1007 MB Amsterdam, Netherlands; VU Univ Med Ctr, Dept Hematol, NL-1007 MB Amsterdam, Netherlands; Univ Oulu, Bioctr Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Oulu	Celie, JWAM (corresponding author), VU Univ Med Ctr, Dept Mol Cell Biol & Immunol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	p.celie@vumc.nl						Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Celie JWAM, 2005, J IMMUNOL METHODS, V298, P155, DOI 10.1016/j.jim.2005.01.009; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Grayson MH, 2003, AM J PHYSIOL-HEART C, V284, pH2213, DOI 10.1152/ajpheart.00999.2002; Habuchi H, 2003, BIOCHEM J, V371, P131, DOI 10.1042/BJ20021259; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; Kawashima H, 2003, J BIOL CHEM, V278, P13069, DOI 10.1074/jbc.M212244200; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Li YF, 1999, FEBS LETT, V444, P201, DOI 10.1016/S0014-5793(99)00046-0; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MEBIUS RE, 1993, J IMMUNOL, V151, P3252; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nakato H, 2002, BBA-GEN SUBJECTS, V1573, P312, DOI 10.1016/S0304-4165(02)00398-7; Nolte MA, 2002, IMMUNOLOGY, V106, P299, DOI 10.1046/j.1365-2567.2002.01443.x; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Prydz K, 2000, J CELL SCI, V113, P193; REJ RN, 1991, CARBOHYD RES, V210, P299, DOI 10.1016/0008-6215(91)80130-F; Robertson H, 2003, AM J TRANSPLANT, V3, P3, DOI 10.1034/j.1600-6143.2003.30102.x; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Rossi M, 2003, EMBO J, V22, P236, DOI 10.1093/emboj/cdg019; Rouschop KMA, 2004, J AM SOC NEPHROL, V15, P674, DOI 10.1097/01.ASN.0000115703.30835.96; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wang LC, 2002, J CLIN INVEST, V110, P127, DOI 10.1172/JCI200214996; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	44	32	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26965	26973		10.1074/jbc.M502188200	http://dx.doi.org/10.1074/jbc.M502188200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917223	Green Submitted, hybrid			2022-12-25	WOS:000230589500040
J	Hague, C; Bernstein, LS; Ramineni, S; Chen, ZJ; Minneman, KP; Hepler, JR				Hague, C; Bernstein, LS; Ramineni, S; Chen, ZJ; Minneman, KP; Hepler, JR			Selective inhibition of alpha(1A)-adrenergic receptor signaling by RGS2 association with the receptor third intracellular loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; MUSCARINIC ACETYLCHOLINE-RECEPTOR; PLASMA-MEMBRANE; GENE-EXPRESSION; ANGIOTENSIN-II; MESSENGER-RNA; REGULATORS; GAIP; LOCALIZATION; SUBTYPES	Regulators of G-protein signaling (RGS) proteins act directly on G alpha subunits to increase the rate of GTP hydrolysis and to terminate signaling. However, the mechanisms involved in determining their specificities of action in cells remain unclear. Recent evidence has raised the possibility that RGS proteins may interact directly with G-protein-coupled receptors to modulate their activity. By using biochemical, fluorescent imaging, and functional approaches, we found that RGS2 binds directly and selectively to the third intracellular loop of the alpha(1A)-adrenergic receptor (AR) in vitro, and is recruited by the unstimulated alpha(1A)-AR to the plasma membrane in cells to inhibit receptor and G(q/11) signaling. This interaction was specific, because RGS2 did not interact with the highly homologous alpha(1B)- or alpha(1D)-ARs, and the closely related RGS16 did not interact with any alpha(1)-ARs. The N terminus of RGS2 was required for association with alpha(1A)-ARs and inhibition of signaling, and amino acids Lys(219), Ser(220), and Arg(238) within the alpha(1A)-AR i3 loop were found to be essential for this interaction. These findings demonstrate that certain RGS proteins can directly interact with preferred G-protein-coupled receptors to modulate their signaling with a high degree of specificity.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Hague, C (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	chague@emory.edu			NIGMS NIH HHS [R01-GM61847] Funding Source: Medline; NINDS NIH HHS [R01-NS37112] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037112] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; Bell SE, 2001, J CELL SCI, V114, P2755; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Cabrera-Vera TM, 2004, P NATL ACAD SCI USA, V101, P16339, DOI 10.1073/pnas.0407416101; Chalothorn D, 2002, MOL PHARMACOL, V61, P1008, DOI 10.1124/mol.61.5.1008; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chen JG, 2003, SCIENCE, V301, P1728, DOI 10.1126/science.1087790; Cho H., 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P107, DOI 10.2174/1568008043339938; Cho H, 2003, BIOCHEM J, V371, P973, DOI 10.1042/BJ20021769; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Doupnik CA, 2001, BBA-GENE STRUCT EXPR, V1522, P97, DOI 10.1016/S0167-4781(01)00342-6; Erami C, 2002, AM J PHYSIOL-HEART C, V283, pH1577, DOI 10.1152/ajpheart.00218.2002; ESBENSHADE TA, 1995, EUR J PHARM-MOLEC PH, V289, P305, DOI 10.1016/0922-4106(95)90108-6; Grant SL, 2000, MOL PHARMACOL, V57, P460, DOI 10.1124/mol.57.3.460; Hague C, 2004, J PHARMACOL EXP THER, V309, P388, DOI 10.1124/jpet.103.060509; Hague C, 2003, LIFE SCI, V74, P411, DOI 10.1016/j.lfs.2003.07.008; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 2003, MOL PHARMACOL, V64, P547, DOI 10.1124/mol.64.3.547; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Heximer SP, 2004, METHOD ENZYMOL, V390, P65; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jeanneteau F, 2004, MOL BIOL CELL, V15, P4926, DOI 10.1091/mbc.E04-04-0285; Jeong SW, 2001, J PHYSIOL-LONDON, V535, P335, DOI 10.1111/j.1469-7793.2001.00335.x; Kardestuncer T, 1998, FEBS LETT, V438, P285, DOI 10.1016/S0014-5793(98)01319-2; Kirsch T, 2001, BRAIN RES, V910, P106, DOI 10.1016/S0006-8993(01)02670-1; Mittmann C, 2002, CARDIOVASC RES, V55, P778, DOI 10.1016/S0008-6363(02)00459-5; Mittmann C, 2001, N-S ARCH PHARMACOL, V363, P456; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Owen VJ, 2001, EUR HEART J, V22, P1015, DOI 10.1053/euhj.2000.2578; Rokosh DG, 2002, P NATL ACAD SCI USA, V99, P9474, DOI 10.1073/pnas.132552699; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587; Sambrook J, 2001, MOL CLONING LAB MANU; Sierra DA, 2000, TRENDS CARDIOVAS MED, V10, P263, DOI 10.1016/S1050-1738(00)00072-4; Tamirisa P, 1999, CIRCULATION, V99, P441, DOI 10.1161/01.CIR.99.3.441; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; Tovey SC, 2004, MOL PHARMACOL, V66, P1453, DOI 10.1124/mol.104.005827; Vicentic A, 2002, J PHARMACOL EXP THER, V302, P58, DOI 10.1124/jpet.302.1.58; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang H, 2004, AM J PHYSIOL-HEART C, V287, pH2106, DOI 10.1152/ajpheart.00290.2004; Zhang SA, 1998, J MOL CELL CARDIOL, V30, P269, DOI 10.1006/jmcc.1997.0591; Zhong HY, 1999, EUR J PHARMACOL, V375, P261, DOI 10.1016/S0014-2999(99)00222-8	53	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27289	27295		10.1074/jbc.M502365200	http://dx.doi.org/10.1074/jbc.M502365200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917235	hybrid			2022-12-25	WOS:000230589500078
J	Segura-Morales, C; Pescia, C; Chatellard-Causse, C; Sadoul, R; Bertrand, E; Basyuk, E				Segura-Morales, C; Pescia, C; Chatellard-Causse, C; Sadoul, R; Bertrand, E; Basyuk, E			Tsg101 and Alix interact with murine leukemia virus Gag and cooperate with Nedd4 ubiquitin ligases during budding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; PROTEIN-SORTING PATHWAY; IMMUNODEFICIENCY-VIRUS; MULTIVESICULAR BODY; PARTICLE RELEASE; PLASMA-MEMBRANE; ESCRT-I; INTRACELLULAR TRAFFICKING; ENDOSOMAL TRAFFICKING; MAMMALIAN-CELLS	Retroviruses use endosomal machinery to bud out of infected cells, and various Gag proteins recruit this machinery by interacting with either of three cellular factors as follows: ubiquitin ligases of the Nedd4 family, Tsg101, or Alix/Aip1. Here we show that the murine leukemia virus Gag has the unique ability to interact with all three factors. Small interfering RNAs against Tsg101 or Alix and dominant-negative forms of Nedd4 can all reduce production of virus-like particles. However, inactivating the Nedd4-binding site abolishes budding, whereas disrupting Tsg101 or Alix binding has milder effects. Nedd4 ubiquitin ligases are therefore essential, and Tsg101 and Alix play auxiliary roles. Most interestingly, overexpression of Alix can stimulate the release of Gag, and this occurs independently of most Alix partners Tsg101, Cin85, Alg-2, and endophilins. In addition, Gag mutants that do not bind Tsg101 or Alix concentrate on late endosomes and become very sensitive to dominant-negative forms of Nedd4 that do not conjugate ubiquitin. This suggests that the direct interaction of Gag with Tsg101 and Alix favors budding from the plasma membrane and relieves a requirement for ubiquitination by Nedd4.1. Other Nedd4-dependent Gag proteins also contain binding sites for Tsg101 or Alix, suggesting that this could be a common feature of retroviruses.	CNRS, IGMM, F-34293 Montpellier, France; UJF, INSERM, EMI 0108, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Basyuk, E (corresponding author), CNRS, IGMM, 1919 Route de Mende, F-34293 Montpellier, France.	Eugenia.Basyuk@igmm.cnrs.fr	Morales, Carolina Segura/AAL-1694-2021; Segura Morales, Carolina/H-7862-2015	Morales, Carolina Segura/0000-0002-1746-6865; Segura Morales, Carolina/0000-0002-1746-6865; SADOUL, Remy/0000-0002-4763-0320; PESCIA, Christina/0000-0002-0508-6013; bertrand, edouard/0000-0002-9642-7994; Basyuk, Eugenia/0000-0001-9768-4557				Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Blot V, 2004, J CELL SCI, V117, P2357, DOI 10.1242/jcs.01095; Bouamr F, 2003, J VIROL, V77, P11882, DOI 10.1128/JVI.77.22.11882-11895.2003; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Dewannieux M, 2004, NAT GENET, V36, P534, DOI 10.1038/ng1353; Dong XH, 2005, CELL, V120, P663, DOI 10.1016/j.cell.2004.12.023; Eastman SW, 2005, J BIOL CHEM, V280, P628, DOI 10.1074/jbc.M410384200; Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gottwein E, 2003, J VIROL, V77, P9474, DOI 10.1128/JVI.77.17.9474-9485.2003; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Heidecker G, 2004, J VIROL, V78, P6636, DOI 10.1128/JVI.78.12.6636-6648.2004; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Kurakin AV, 2003, J BIOL CHEM, V278, P34102, DOI 10.1074/jbc.M305264200; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Martin-Serrano J, 2005, J CELL BIOL, V168, P89, DOI 10.1083/jcb.200408155; Martin-Serrano J, 2004, J VIROL, V78, P5554, DOI 10.1128/JVI.78.11.5554-5563.2004; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Martinez-Arca S, 2003, P NATL ACAD SCI USA, V100, P9011, DOI 10.1073/pnas.1431910100; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Myers EL, 2002, J VIROL, V76, P11226, DOI 10.1128/JVI.76.22.11226-11235.2002; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Ono A, 2004, J VIROL, V78, P1552, DOI 10.1128/JVI.78.3.1552-1563.2004; Ott DE, 1998, J VIROL, V72, P2962, DOI 10.1128/JVI.72.4.2962-2968.1998; Ott DE, 2003, J VIROL, V77, P3384, DOI 10.1128/JVI.77.6.3384-3393.2003; Ott DE, 2000, VIROLOGY, V278, P111, DOI 10.1006/viro.2000.0648; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Sherer NM, 2003, TRAFFIC, V4, P785, DOI 10.1034/j.1600-0854.2003.00135.x; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Stuchell MD, 2004, J BIOL CHEM, V279, P36059, DOI 10.1074/jbc.M405226200; Suomalainen M, 1996, J CELL BIOL, V135, P1841, DOI 10.1083/jcb.135.6.1841; Tanzi GO, 2003, J VIROL, V77, P8440, DOI 10.1128/JVI.77.15.8440-8447.2003; Trioulier Y, 2004, J BIOL CHEM, V279, P2046, DOI 10.1074/jbc.M309243200; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Wang Margaret Q, 2003, J Biol, V3, P4, DOI 10.1186/1475-4924-3-4; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747; Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700; Zhang YQ, 1998, J VIROL, V72, P1782, DOI 10.1128/JVI.72.3.1782-1789.1998	65	84	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27004	27012		10.1074/jbc.M413735200	http://dx.doi.org/10.1074/jbc.M413735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15908698	hybrid			2022-12-25	WOS:000230589500045
J	Saalbach, A; Wetzel, A; Haustein, UF; Sticherling, M; Simon, JC; Anderegg, U				Saalbach, A; Wetzel, A; Haustein, UF; Sticherling, M; Simon, JC; Anderegg, U			Interaction of human Thy-1 (CD 90) with the integrin alpha v beta 3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium	ONCOGENE			English	Article						Thy-1; alpha v beta 3; endothelial cell; adhesion; melanoma	IN-VITRO; MATRIX METALLOPROTEINASE-1; INTEGRIN ALPHA(V)BETA(3); ALPHA-V-BETA-3 INTEGRIN; MALIGNANT-MELANOMA; MOLECULE L1; FIBROBLASTS; EXPRESSION; METASTASIS; LYMPHOCYTES	The expression of the alpha v beta 3 integrin (CD51/CD61) on human melanoma cells has been shown to be associated most closely with tumor progression and metastases formation in melanoma. Here, we demonstrated a specific interaction of the avb3 integrin on melanoma cells with the human Thy-1, an inducible cell adhesion molecule expressed on the cell surface of activated endothelial cells (EC). The interaction was shown by the binding of purified Thy-1 protein to alpha(V)beta(3) transfected cells, to alpha v beta 3-expressing melanoma cells and to purified alpha(V)beta(3) integrin. Moreover, melanoma cells adhere specifically to Thy-1 transfectants via avb3 on melanoma cells showing the functional relevance of this interaction for cell adhesion. Finally, the importance of the alpha v beta 3/Thy-1 interaction for the adhesion of melanoma cells to the activated endothelium was confirmed under static and flow conditions by the inhibition of melanoma cell adhesion to and transmigration across activated EC by blocking the avb3/Thy-1 interaction. In conclusion, we have identified a new pair of adhesion molecules Thy-1 and avb3 mediating the interaction of melanoma cells and activated EC. These data explain at least in part the high tumorigenicity of avb3-expressing melanoma cells and the association of alpha v beta 3-positive melanoma cells with a high risk of metastasis and poor prognosis.	Saxon Acad Sci, D-04107 Leipzig, Germany; Univ Leipzig, Dept Dermatol Venerol & Allergol, D-04103 Leipzig, Germany	Leipzig University	Saalbach, A (corresponding author), Saxon Acad Sci, D-04107 Leipzig, Germany.	saalbach@medizin.uni-leipzig.de	Saalbach, Anja/ABD-4003-2021	Saalbach, Anja/0000-0002-1084-3875				Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; Anasagasti MJ, 1997, J NATL CANCER I, V89, P645, DOI 10.1093/jnci/89.9.645; AUBERT C, 1993, INT J CANCER, V54, P784, DOI 10.1002/ijc.2910540513; Averbeck M, 2004, EUR J IMMUNOL, V34, P2708, DOI 10.1002/eji.200425355; BEAN MA, 1975, CANCER RES, V35, P2902; Buckley CD, 1996, J CELL SCI, V109, P437; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; CRAWFORD JM, 1986, LAB INVEST, V54, P122; Duczmal A, 1997, BIOCHEM BIOPH RES CO, V232, P236, DOI 10.1006/bbrc.1997.6265; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kumar CC, 2000, ADV EXP MED BIOL, V476, P169; Leyton L, 2001, CURR BIOL, V11, P1028, DOI 10.1016/S0960-9822(01)00262-7; LOCKSHIN A, 1985, J NATL CANCER I, V74, P899; Meyer T, 1998, EUR J CANCER, V34, P214, DOI 10.1016/S0959-8049(97)10129-0; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; OROSZ P, 1995, INT J CANCER, V60, P867, DOI 10.1002/ijc.2910600624; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Saalbach A, 1999, CELL TISSUE RES, V298, P307, DOI 10.1007/s004419900079; Saalbach A, 2000, J INVEST DERMATOL, V115, P882, DOI 10.1046/j.1523-1747.2000.00104.x; Saalbach A, 1996, J INVEST DERMATOL, V106, P1314, DOI 10.1111/1523-1747.ep12349035; Saalbach A, 2002, MICROVASC RES, V64, P86, DOI 10.1006/mvre.2002.2401; Saalbach A, 1998, ARCH DERMATOL RES, V290, P360, DOI 10.1007/s004030050318; SMITH JW, 1990, J BIOL CHEM, V265, P2168; VARNER JA, 1996, ADV ONCOL, P69; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Wandel E, 2002, ARCH DERMATOL RES, V293, P601, DOI 10.1007/s00403-001-0289-4; Wandel E, 2000, EXP DERMATOL, V9, P34, DOI 10.1034/j.1600-0625.2000.009001034.x; Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595; Wetzel A, 2004, J IMMUNOL, V172, P3850, DOI 10.4049/jimmunol.172.6.3850; WILLIAMS AF, 1982, BIOSCIENCE REP, V2, P277, DOI 10.1007/BF01115113; Yoshizaki T, 1997, CANCER, V79, P139, DOI 10.1002/(SICI)1097-0142(19970101)79:1<139::AID-CNCR20>3.0.CO;2-4	44	83	84	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4710	4720		10.1038/sj.onc.1208559	http://dx.doi.org/10.1038/sj.onc.1208559			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897908				2022-12-25	WOS:000230304500009
J	Duquette, ML; Pham, P; Goodman, MF; Maizels, N				Duquette, ML; Pham, P; Goodman, MF; Maizels, N			AID binds to transcription-induced structures in c-MYC that map to regions associated with translocation and hypermutation	ONCOGENE			English	Article						AID; hypermutation; translocation; Burkitt's lymphoma	INDUCED CYTIDINE DEAMINASE; CLASS-SWITCH RECOMBINATION; SINGLE-STRANDED-DNA; ABERRANT SOMATIC HYPERMUTATION; CENTER B-CELLS; B29 IG-BETA; CHROMOSOMAL TRANSLOCATIONS; MULTIPLE-MYELOMA; BURKITTS-LYMPHOMA; NEOPLASTIC DEVELOPMENT	Translocation and aberrant hypermutation of c-MYC are common in B-cell lymphomas. Activation-induced Cytidine Deaminase (AID) initiates switch recombination and somatic hypermutation in B cells by targeted deamination of transcribed genes. We show that transcription of the immunoglobulin S regions and c-MYC results in formation of similar DNA structures, 'G-loops', which contain a cotranscriptional RNA: DNA hybrid on the C-rich strand and single-stranded regions and G4 DNA on the G-rich strand. AID binds specifically to G-loops within transcribed S regions and c-MYC, and G-loops in c-MYC map to the regions associated with translocation breakpoints and aberrant hypermutation in B-cell lymphomas. Aberrant targeting of AID to DNA structures formed upon c-MYC transcription may therefore contribute to the genetic instability of c-MYC in B-cell malignancies.	Univ Washington, Dept Immunol, Sch Med, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Sch Med, Seattle, WA 98195 USA; Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Dept Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Southern California; University of Southern California	Maizels, N (corresponding author), Univ Washington, Dept Immunol, Sch Med, Room H474A,1959 NE Pacific St, Seattle, WA 98195 USA.	maizels@u.washington.edu	yang, xiao-jun/B-1927-2009; Duquette, Michelle/B-6899-2009		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM065988, R01GM041712, R01GM039799] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES13192] Funding Source: Medline; NIGMS NIH HHS [R01 GM041712, R01 GM039799, R01 GM65988, R01 GM065988, R01 GM39799, R37 GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akasaka H, 2000, CANCER RES, V60, P2335; APEL TW, 1992, ONCOGENE, V7, P1267; Avet-Loiseau H, 2001, BLOOD, V98, P3082, DOI 10.1182/blood.V98.10.3082; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; CHOW LT, 1989, METHOD ENZYMOL, V180, P239; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Duquette ML, 2004, GENE DEV, V18, P1618, DOI 10.1101/gad.1200804; Durandy A, 2003, EUR J IMMUNOL, V33, P2069, DOI 10.1002/eji.200324133; Fenton JAL, 2002, BLOOD, V99, P716, DOI 10.1182/blood.V99.2.716; Gaidano G, 2003, BLOOD, V102, P1833, DOI 10.1182/blood-2002-11-3606; Gordon MS, 2000, P NATL ACAD SCI USA, V97, P5504, DOI 10.1073/pnas.090087097; Gordon MS, 2003, P NATL ACAD SCI USA, V100, P4126, DOI 10.1073/pnas.0735266100; Greeve J, 2003, BLOOD, V101, P3574, DOI 10.1182/blood-2002-08-2424; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Larson ED, 2005, CURR BIOL, V15, P470, DOI 10.1016/j.cub.2004.12.077; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; MAIZELS N, 2004, MOL BIOL B CELLS, P327; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Montesinos-Rongen M, 2004, BLOOD, V103, P1869, DOI 10.1182/blood-2003-05-1465; MULLER JR, 1995, CANCER RES, V55, P5012; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Muschen M, 2000, CANCER RES, V60, P5640; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; Muto T, 2000, GENOMICS, V68, P85, DOI 10.1006/geno.2000.6268; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Pasqualucci L, 2004, BLOOD, V104, P3318, DOI 10.1182/blood-2004-04-1558; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Potter M, 2003, IMMUNOL REV, V194, P177, DOI 10.1034/j.1600-065X.2003.00061.x; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; Ramiro AR, 2005, NAT IMMUNOL, V6, P117, DOI 10.1038/ni0205-117; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Senthilkumar K, 2003, J AM CHEM SOC, V125, P13658, DOI 10.1021/ja037027d; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; SMELAND EB, 1988, EUR J IMMUNOL, V18, P1847, DOI 10.1002/eji.1830181131; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Unniraman S, 2004, NAT IMMUNOL, V5, P1117, DOI 10.1038/ni1127	61	105	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5791	5798		10.1038/sj.onc.1208746	http://dx.doi.org/10.1038/sj.onc.1208746			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15940261	Bronze			2022-12-25	WOS:000231590400001
J	Mullan, PB; Hosey, AM; Buckley, NE; Quinn, JE; Kennedy, RD; Johnston, PG; Harkin, DP				Mullan, PB; Hosey, AM; Buckley, NE; Quinn, JE; Kennedy, RD; Johnston, PG; Harkin, DP			The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1-and interferon-gamma-mediated apoptosis	ONCOGENE			English	Article						BRCA1; 2,5 OAS; RNaseL; IFN-gamma; apoptosis	SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; PROSTATE-CANCER; RIBONUCLEASE-L; RNASEL GENE; DNA-REPAIR; IFN-GAMMA; EXPRESSION; INTERACTS; MUTATION	BRCA1 has been reported to have roles in DNA damage repair, cell cycle checkpoint control, transcriptional regulation and ubiquitination. We have previously demonstrated that BRCA1 is a potent activator of a subset of interferon (IFN)-regulated genes and that BRCA1 synergistically activated a number of these genes in the presence of IFN-gamma, but not type I IFNs. Here we report that one of these targets, 2,5 oligoadenylate synthetase (2,5 OAS), is a mediator of BRCA1/IFN-gamma-induced apoptosis. We show that the induction of 2,5 OAS in response to IFN-gamma is BRCA1 and STAT1 dependent. Consistent with a role as a negative regulator of proliferation, transient transfection of 2,5 OAS into breast cancer cell lines results in decreased colony growth and apoptosis. Furthermore we show that IFN-gamma-induced apoptosis is dependent on functional BRCA1 and STAT1 and we demonstrate that IFN-gamma-induced apoptosis is dependent on 2,5 OAS induction. 2,5 OAS is the only known upstream regulator of RNaseL. a recently identified hereditary prostate tumour suppressor gene implicated in apoptosis. We propose that BRCA1 may be an upstream regulator of RNaseL, acting in concert with IFN-gamma to transcriptionally activate 2,5 OAS, leading to the downstream activation of RNaseL and apoptosis.	Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Harkin, DP (corresponding author), Queens Univ Belfast, Belfast City Hosp, Ctr Canc Res & Cell Biol, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.harkin@qub.ac.uk	Kennedy, Richard/J-3489-2012	Kennedy, Richard/0000-0003-4737-6163; Buckley, Niamh/0000-0001-9326-8513				Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Castelli JC, 1998, CELL DEATH DIFFER, V5, P313, DOI 10.1038/sj.cdd.4400352; Gilmore PM, 2004, CANCER RES, V64, P4148, DOI 10.1158/0008-5472.CAN-03-4080; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; Moynahan ME, 2001, CANCER RES, V61, P4842; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Quinn JE, 2003, CANCER RES, V63, P6221; Rennert H, 2002, AM J HUM GENET, V71, P981, DOI 10.1086/342775; Rokman A, 2002, AM J HUM GENET, V70, P1299, DOI 10.1086/340450; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; STARK GR, 1979, NATURE, V278, P471, DOI 10.1038/278471a0; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	32	45	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5492	5501		10.1038/sj.onc.1208698	http://dx.doi.org/10.1038/sj.onc.1208698			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15940267				2022-12-25	WOS:000231222300009
J	Habran, L; Bontems, S; Di Valentin, E; Sadzot-Delvaux, C; Piette, J				Habran, L; Bontems, S; Di Valentin, E; Sadzot-Delvaux, C; Piette, J			Varicella-Zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; IMMEDIATE-EARLY PROTEIN; REPLICATION IN-VITRO; GENE-EXPRESSION; NUCLEAR-LOCALIZATION; MUTATIONAL ANALYSIS; HUMAN GANGLIA; TESTER VIRUS; TRANSCRIPTION; LATENCY	During the first stage of Varicella-Zoster virus (VZV) infection, IE63 (immediate early 63 protein) is mostly expressed in the nucleus and also slightly in the cytoplasm, and during latency, IE63 localizes in the cytoplasm quite exclusively. Because phosphorylation is known to regulate various cellular mechanisms, we investigated the impact of phosphorylation by roscovitine-sensitive cyclin-dependent kinase (RSC) on the localization and functional properties of IE63. We demonstrated first that IE63 was phosphorylated on Ser-224 in vitro by CDK1 and CDK5 but not by CDK2, CDK7, or CDK9. Furthermore, by using roscovitine and CDK1 inhibitor III (CiIII), we showed that CDK1 phosphorylated IE63 on Ser-224 in vivo. By mutagenesis and the use of inhibitors, we demonstrated that phosphorylation on Ser-224 was important for the correct localization of the protein. Indeed, the substitution of these residues by alanine led to an exclusive nuclear localization of the protein, whereas mutations into glutamic acid did not modify its subcellular distribution. When transfected or VZV-infected cells were treated with roscovitine or CiIII, an exclusive nuclear localization of IE63 was also observed. By using a transfection assay, we also showed that phosphorylation on Ser-224 and Thr-222 was essential for the down-regulation of the basal activity of the VZV DNA polymerase gene promoter. Similarly, roscovitine and CiIII impaired these properties of the wild-type form of IE63. These observations clearly demonstrated the importance of CDK1-mediated IE63 phosphorylation for a correct distribution of IE63 between both cellular compartments and for its repressive activity toward the promoter tested.	Univ Liege, Inst Pathol, Ctr Biomed Genoproteom, Lab Virol & Immunol, B-4000 Cointe Ougree, Belgium	University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol, Ctr Biomed Genoproteom, Lab Virol & Immunol, B23, B-4000 Cointe Ougree, Belgium.	jpiette@ulg.ac.be		Di Valentin, Emmanuel/0000-0002-5287-7950				Advani SJ, 2000, P NATL ACAD SCI USA, V97, P10996, DOI 10.1073/pnas.200375297; Baiker A, 2004, J VIROL, V78, P1181, DOI 10.1128/JVI.78.3.1181-1194.2004; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; BAUDOUX L, 1995, NUCLEIC ACIDS RES, V23, P1341, DOI 10.1093/nar/23.8.1341; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Blom N, 1998, NUCLEIC ACIDS RES, V26, P382, DOI 10.1093/nar/26.1.382; Bontems S, 2002, J BIOL CHEM, V277, P21050, DOI 10.1074/jbc.M111872200; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; Cheng K, 2003, NEUROSIGNALS, V12, P180, DOI 10.1159/000074619; Cohen JI, 2005, J VIROL, V79, P5069, DOI 10.1128/JVI.79.8.5069-5077.2005; COHEN JI, 2001, VIROLOGY, P2707; Cohrs RJ, 1996, J VIROL, V70, P2789, DOI 10.1128/JVI.70.5.2789-2796.1996; CROEN KD, 1988, P NATL ACAD SCI USA, V85, P9773, DOI 10.1073/pnas.85.24.9773; Davido DJ, 2002, J VIROL, V76, P1077, DOI 10.1128/JVI.76.3.1077-1088.2002; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DEBRUS S, 1995, J VIROL, V69, P3240, DOI 10.1128/JVI.69.5.3240-3245.1995; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Di Valentin E, 2005, BIOL CHEM, V386, P255, DOI 10.1515/BC.2005.031; EVERETT RD, 1987, ANTICANCER RES, V7, P589; Flisser A, 1999, Contrib Microbiol, V3, P76; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; HAY J, 1994, SEMIN VIROL, V5, P241, DOI 10.1006/smvy.1994.1026; INCHAUSPE G, 1989, VIROLOGY, V173, P700, DOI 10.1016/0042-6822(89)90583-7; JACKERS P, 1992, J VIROL, V66, P3899, DOI 10.1128/JVI.66.6.3899-3903.1992; Jung EY, 2001, VIRUS RES, V79, P109, DOI 10.1016/S0168-1702(01)00335-5; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kennedy PGE, 2000, J VIROL, V74, P11893, DOI 10.1128/JVI.74.24.11893-11898.2000; Kennedy PGE, 2001, VIROLOGY, V289, P218, DOI 10.1006/viro.2001.1173; Kenyon TK, 2001, J VIROL, V75, P8854, DOI 10.1128/JVI.75.18.8854-8858.2001; KINCHINGTON PR, 1992, J VIROL, V66, P359, DOI 10.1128/JVI.66.1.359-366.1992; Kinchington PR, 2001, J VIROL, V75, P9106, DOI 10.1128/JVI.75.19.9106-9113.2001; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOST RG, 1995, VIROLOGY, V209, P218, DOI 10.1006/viro.1995.1246; Kudoh A, 2004, J VIROL, V78, P104, DOI 10.1128/JVI.78.1.104-115.2004; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1995, NEUROBIOL AGING, V16, P263, DOI 10.1016/0197-4580(95)00014-6; Lim ACB, 2003, NEUROSIGNALS, V12, P230, DOI 10.1159/000074625; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; Longshaw VM, 2004, J CELL SCI, V117, P701, DOI 10.1242/jcs.00905; Lungu O, 1999, Contrib Microbiol, V3, P61; Lungu O, 1998, P NATL ACAD SCI USA, V95, P7080, DOI 10.1073/pnas.95.12.7080; Lynch JM, 2002, VIROLOGY, V302, P71, DOI 10.1006/viro.2002.1555; Mahalingam R, 1996, P NATL ACAD SCI USA, V93, P2122, DOI 10.1073/pnas.93.5.2122; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Moffat JF, 2004, BBA-PROTEINS PROTEOM, V1697, P225, DOI 10.1016/j.bbapap.2003.11.026; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; PERERA LP, 1992, J VIROL, V66, P5298, DOI 10.1128/JVI.66.9.5298-5304.1992; PERERA LP, 1992, VIROLOGY, V191, P346, DOI 10.1016/0042-6822(92)90197-W; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUYECHAN WT, 1999, ENCY VIROLOGY, P1878; Schang LM, 2002, J VIROL, V76, P7724, DOI 10.1128/JVI.76.15.7724-7735.2002; Schang LM, 2002, J VIROL, V76, P7874, DOI 10.1128/JVI.76.15.7874-7882.2002; Schang LM, 1998, J VIROL, V72, P5626, DOI 10.1128/JVI.72.7.5626-5637.1998; Sommer MH, 2001, J VIROL, V75, P8224, DOI 10.1128/JVI.75.17.8224-8239.2001; Spengler M, 2001, ARCH VIR S, V17, P71; Stevenson D, 1996, J VIROL, V70, P658, DOI 10.1128/JVI.70.1.658-662.1996; Taylor SL, 2004, J VIROL, V78, P2853, DOI 10.1128/JVI.78.6.2853-2862.2004; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084	59	25	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29135	29143		10.1074/jbc.M503312200	http://dx.doi.org/10.1074/jbc.M503312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15955820	Green Published, hybrid			2022-12-25	WOS:000231021300040
J	Galdiero, S; Falanga, A; Vitiello, M; Browne, H; Pedone, C; Galdiero, M				Galdiero, S; Falanga, A; Vitiello, M; Browne, H; Pedone, C; Galdiero, M			Fusogenic domains in herpes simplex virus type 1 glycoprotein H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 FUSION PEPTIDE; VIRAL MEMBRANE-FUSION; ENVELOPE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; HEPTAD REPEAT; CELL-FUSION; TRANSMEMBRANE PROTEINS; CONFORMATIONAL-CHANGE; RECEPTOR-BINDING; ALPHA-HELIX	Infection of eukaryotic cells by enveloped viruses requires fusion between the viral envelope and the cellular plasma or endosomal membrane. The actual merging of the two membranes is mediated by viral envelope glycoproteins, which generally contain a highly hydrophobic region termed the fusion peptide. The entry of herpesviruses is mediated by three conserved proteins: glycoproteins B, H (gH), and L. However, how fusion is executed remains unknown. Herpes simplex virus type 1 gH exhibits features typical of viral fusion glycoproteins, and its ectodomain seems to contain a putative internal fusion peptide. Here, we have identified additional internal segments able to interact with membranes and to induce membrane fusion of large unilamellar vesicles. We have applied the hydrophobicity-at-interface scale proposed by Wimley and White ( Wimley, W. C., and White, S. H. ( 1996) Nat. Struct. Biol. 3, 842 - 848) to identify six hydrophobic stretches within gH with a tendency to partition into the membrane interface, and four of them were able to induce membrane fusion. Experiments in which equimolar mixtures of gH peptides were used indicated that different fusogenic regions may act in a synergistic way. The functional and structural characterization of these segments suggests that herpes simplex virus type 1 gH possesses several fusogenic internal peptides that could participate in the actual fusion event.	Univ Naples 2, Dept Expt Med 2, I-80138 Naples, Italy; Univ Naples 2, Dept Pathol, I-80138 Naples, Italy; Univ Naples Federico II, Dept Biol Sci, Div Biostruct, I-80134 Naples, Italy; Univ Naples Federico II, Ctr Interuniv Ric Peptidi Bioattivi, I-80134 Naples, Italy; CNR, Ist Biostrutt & Bioimmagini, I-80134 Naples, Italy; Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); University of Cambridge	Galdiero, M (corresponding author), Univ Naples 2, Dept Expt Med 2, Via Crecchio 7, I-80138 Naples, Italy.	massimiliano.galdiero@unina2.it	Galdiero, Stefania/M-3225-2019; galdiero, stefania/B-1357-2010	Galdiero, Stefania/0000-0002-7849-7024; Galdiero, Massimiliano/0000-0002-1576-6290; FALANGA, Annarita/0000-0001-6538-8585				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bender FC, 2003, J VIROL, V77, P9542, DOI 10.1128/JVI.77.17.9542-9552.2003; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064; Browne H, 2001, J GEN VIROL, V82, P1419, DOI 10.1099/0022-1317-82-6-1419; Cairns TM, 2005, VIROLOGY, V332, P550, DOI 10.1016/j.virol.2004.12.006; CAL WH, 1988, J VIROL, V62, P2596, DOI 10.1128/JVI.62.8.2596-2604.1988; Carneiro FA, 2002, J VIROL, V76, P3756, DOI 10.1128/JVI.76.8.3756-3764.2002; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Cocchi F, 2004, P NATL ACAD SCI USA, V101, P7445, DOI 10.1073/pnas.0401883101; Cole NL, 2003, REV MED VIROL, V13, P207, DOI 10.1002/rmv.377; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Durell SR, 1997, MOL MEMBR BIOL, V14, P97, DOI 10.3109/09687689709048170; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; EPAND RF, 1994, BIOCHEM BIOPH RES CO, V205, P1938, DOI 10.1006/bbrc.1994.2897; Epand RM, 2003, BBA-BIOMEMBRANES, V1614, P116, DOI 10.1016/S0005-2736(03)00169-X; Fiske CH, 1925, J BIOL CHEM, V66, P375; FORRESTER A, 1992, J VIROL, V66, P341, DOI 10.1128/JVI.66.1.341-348.1992; Galdiero M, 1997, J VIROL, V71, P2163, DOI 10.1128/JVI.71.3.2163-2170.1997; Gallaher WR, 1996, CELL, V85, P477, DOI 10.1016/S0092-8674(00)81248-9; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; Garry RF, 2003, VIROLOGY, V307, P255, DOI 10.1016/S0042-6822(02)00065-X; Ghosh JK, 2000, BIOCHEMISTRY-US, V39, P11581, DOI 10.1021/bi0005963; Ghosh JK, 1999, J MOL BIOL, V292, P531, DOI 10.1006/jmbi.1999.3097; Gianni T, 2005, J VIROL, V79, P7042, DOI 10.1128/JVI.79.11.7042-7049.2005; Gianni T, 2005, J VIROL, V79, P2931, DOI 10.1128/JVI.79.5.2931-2940.2005; Gibbons DL, 2004, NATURE, V427, P320, DOI 10.1038/nature02239; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; Han X, 1999, BIOCHEMISTRY-US, V38, P15052, DOI 10.1021/bi991232h; Harman A, 2002, J VIROL, V76, P10708, DOI 10.1128/JVI.76.21.10708-10716.2002; Heinz FX, 2003, ADV VIRUS RES, V59, P63, DOI 10.1016/S0065-3527(03)59003-0; Heinz FX, 2001, CURR OPIN MICROBIOL, V4, P450, DOI 10.1016/S1369-5274(00)00234-4; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Jardetzky TS, 2004, NATURE, V427, P307, DOI 10.1038/427307a; KILLIAN JA, 1994, FEBS LETT, V348, P161, DOI 10.1016/0014-5793(94)00594-X; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEAR JD, 1987, J BIOL CHEM, V262, P6500; Martin I, 1996, J VIROL, V70, P298, DOI 10.1128/JVI.70.1.298-304.1996; Martin I, 1999, ADV DRUG DELIVER REV, V38, P233, DOI 10.1016/S0169-409X(99)00031-9; McShane MP, 2004, P NATL ACAD SCI USA, V101, P17474, DOI 10.1073/pnas.0404535101; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Molesworth SJ, 2000, J VIROL, V74, P6324, DOI 10.1128/JVI.74.14.6324-6332.2000; Mukherjee S, 2004, ANNU REV CELL DEV BI, V20, P839, DOI 10.1146/annurev.cellbio.20.010403.095451; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; Nieva JL, 2003, BBA-BIOMEMBRANES, V1614, P104, DOI 10.1016/S0005-2736(03)00168-8; Nir S, 2000, PROG LIPID RES, V39, P181, DOI 10.1016/S0163-7827(00)00004-7; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; Peisajovich SG, 2000, J MOL BIOL, V296, P1353, DOI 10.1006/jmbi.2000.3543; Peisajovich SG, 2003, BBA-BIOMEMBRANES, V1614, P122, DOI 10.1016/S0005-2736(03)00170-6; PEREIRA FB, 1995, FEBS LETT, V362, P243, DOI 10.1016/0014-5793(95)00257-A; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; Rawat SS, 2003, MOL MEMBR BIOL, V20, P243, DOI 10.1080/0968768031000104944; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Saez-Cirion A, 2002, BBA-BIOMEMBRANES, V1564, P57, DOI 10.1016/S0005-2736(02)00400-5; Silva AL, 2004, J VIROL, V78, P5946, DOI 10.1128/JVI.78.11.5946-5956.2004; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000; Tamm LK, 2002, BIOPOLYMERS, V66, P249, DOI 10.1002/bip.10261; Tamm LK, 2000, BIOSCIENCE REP, V20, P501, DOI 10.1023/A:1010406920417; Turner A, 1998, J VIROL, V72, P873, DOI 10.1128/JVI.72.1.873-875.1998; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842	74	98	98	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28632	28643		10.1074/jbc.M505196200	http://dx.doi.org/10.1074/jbc.M505196200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15937337	hybrid			2022-12-25	WOS:000230857300054
J	Minor, KH; Schar, CR; Blouse, GE; Shores, JD; Lawrence, DA; Schuck, P; Peterson, CB				Minor, KH; Schar, CR; Blouse, GE; Shores, JD; Lawrence, DA; Schuck, P; Peterson, CB			A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATOMEDIN-B DOMAIN; REACTIVE-CENTER LOOP; SIZE-DISTRIBUTION ANALYSIS; HUMAN PLASMA VITRONECTIN; UROKINASE RECEPTOR; CELL-ADHESION; ANALYTICAL ULTRACENTRIFUGATION; ENDOTHELIAL-CELLS; SELF-ASSOCIATION; LIGAND-BINDING	Plasminogen activator inhibitor-1 ( PAI-1) and vitronectin are cofactors involved in pathological conditions such as injury, inflammation, and cancer, during which local levels of PAI-1 are increased and the active serpin forms complexes with vitronectin. These complexes become deposited into surrounding tissue matrices, where they regulate cell adhesion and pericellular proteolysis. The mechanism for their co- localization has not been elucidated. We hypothesize that PAI-1-vitronectin complexes form in a stepwise and concentration-dependent fashion via 1: 1 and 2: 1 intermediates, with the 2: 1 complex serving a key role in assembly of higher order complexes. To test this hypothesis, sedimentation velocity experiments in the analytical ultracentrifuge were performed to identify different PAI-1-vitronectin complexes. Analysis of sedimentation data invoked a novel multisignal method to discern the stoichiometry of the two proteins in the higher-order complexes formed ( Balbo, A., Minor, K. H., Velikovsky, C. A., Mariuzza, R. A., Peterson, C. B., and Schuck, P. ( 2005) Proc. Natl. Acad. Sci. U. S. A. 102, 81-86). Our results demonstrate that PAI-1 and vitronectin assemble into higher order forms via a pathway that is triggered upon saturation of the two PAI-1-binding sites of vitronectin to form the 2: 1 complex. This 2: 1 PAI-1-vitronectin complex, with a sedimentation coefficient of 6.5 S, is the key intermediate for the assembly of higher order complexes.	Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Ctr Excellence Struct Biol, Knoxville, TN 37996 USA; Henry Ford Hlth Syst, Dept Pathol, Div Biochem Res, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Univ Maryland, Sch Med, Dept Surg, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Physiol, Rockville, MD 20855 USA; NIH, Div Bioengn & Phys Sci, Off Res Serv, Off Director, Bethesda, MD 20892 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; Henry Ford Health System; Henry Ford Hospital; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; National Institutes of Health (NIH) - USA	Peterson, CB (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.	cynthia_peterson@utk.edu	Schuck, Peter/AAA-6888-2020	Schuck, Peter/0000-0002-8859-6966; Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050676, R29HL050676] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL050676, HL50676] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Balbo A, 2005, P NATL ACAD SCI USA, V102, P81, DOI 10.1073/pnas.0408399102; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Bloemendal HJ, 2004, CANCER IMMUNOL IMMUN, V53, P799, DOI 10.1007/s00262-004-0506-z; Blouse GE, 2003, BIOCHEMISTRY-US, V42, P12260, DOI 10.1021/bi034737n; Blouse GE, 2002, BIOCHEMISTRY-US, V41, P11997, DOI 10.1021/bi025967p; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chambers SK, 1998, INT J CANCER, V79, P449; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; Dam J, 2004, METHOD ENZYMOL, V384, P185; de Waard V, 2002, ARTERIOSCL THROM VAS, V22, P1978, DOI 10.1161/01.ATV.0000042231.04318.E6; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Dobrovolsky AB, 2002, BIOCHEMISTRY-MOSCOW+, V67, P99, DOI 10.1023/A:1013960416302; Durand MK, 2004, THROMB HAEMOSTASIS, V91, P438, DOI 10.1160/TH03-12-0784; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; Eitzman DT, 2000, BLOOD, V95, P577, DOI 10.1182/blood.V95.2.577; Francois PP, 1999, J BIOL CHEM, V274, P37611, DOI 10.1074/jbc.274.53.37611; GEBB C, 1986, J BIOL CHEM, V261, P6698; Gibson AD, 1999, J BIOL CHEM, V274, P6432, DOI 10.1074/jbc.274.10.6432; GILBERT GA, 1956, NATURE, V177, P853, DOI 10.1038/177853a0; Gladson CL, 2000, NEUROSCI LETT, V283, P157, DOI 10.1016/S0304-3940(00)00876-4; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hagglof P, 2004, J MOL BIOL, V335, P823, DOI 10.1016/j.jmb.2003.11.005; Huang YF, 2003, J CLIN INVEST, V112, P379, DOI 10.1172/JCI200318038; Inuzuka S, 1997, SCAND J GASTROENTERO, V32, P1052, DOI 10.3109/00365529709011224; Jang YC, 2000, SURGERY, V127, P696, DOI 10.1067/msy.2000.105858; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KEIJER J, 1991, BLOOD, V78, P1254; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Lamm O., 1929, ARK MAT ASTR FYS, V21B, P1; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Levi M, 2003, CRIT CARE MED, V31, pS238, DOI 10.1097/01.CCM.0000057849.53689.65; LEVIN EG, 1987, BLOOD, V70, P1090; LI S, 2003, 9 INT WORKSH MOL CEL; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; LYNN GS, 2004, IN PRESS BIOCH; Mayasundari A, 2004, J BIOL CHEM, V279, P29359, DOI 10.1074/jbc.M401279200; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Nielsen HJ, 2000, ANN SURG ONCOL, V7, P617, DOI 10.1007/BF02725342; Okumura Y, 2002, J BIOL CHEM, V277, P9395, DOI 10.1074/jbc.M111225200; Peng L, 2002, ARTERIOSCL THROM VAS, V22, P934, DOI 10.1161/01.ATV.0000019360.14554.53; Peterson CB, 1998, TRENDS CARDIOVAS MED, V8, P124, DOI 10.1016/S1050-1738(97)00136-9; PODOR TJ, 1992, ANN NY ACAD SCI, V667, P173, DOI 10.1111/j.1749-6632.1992.tb51609.x; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; Rezaie AR, 2001, J BIOL CHEM, V276, P15567, DOI 10.1074/jbc.C100123200; Rosenblatt S, 1997, BIOCHEM J, V324, P311, DOI 10.1042/bj3240311; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Seiffert D, 1996, J BIOL CHEM, V271, P29644, DOI 10.1074/jbc.271.47.29644; Seiffert D, 1997, J BIOL CHEM, V272, P9971; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; SHAFFER MC, 1984, J LAB CLIN MED, V103, P783; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Stoop AA, 2000, ARTERIOSCL THROM VAS, V20, P1143, DOI 10.1161/01.ATV.20.4.1143; TOMASINI BR, 1988, BLOOD, V72, P903; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Waltz DA, 2000, AM J RESP CELL MOL, V22, P316, DOI 10.1165/ajrcmb.22.3.3713; Wilkins-Port CE, 2003, CELL COMMUN ADHES, V10, P85, DOI 10.1080/714040415; WIMAN B, 1995, THROMB HAEMOSTASIS, V74, P71; Wind T, 2002, BIOL CHEM, V383, P21, DOI 10.1515/BC.2002.003; Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	79	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28711	28720		10.1074/jbc.M500478200	http://dx.doi.org/10.1074/jbc.M500478200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15905170	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000230857300062
J	Pieren, M; Galli, C; Denzel, A; Molinari, M				Pieren, M; Galli, C; Denzel, A; Molinari, M			The use of calnexin and calreticulin by cellular and viral glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES CALNEXIN; ENDOPLASMIC-RETICULUM; INFLUENZA HEMAGGLUTININ; QUALITY-CONTROL; SECRETORY PATHWAY; SPERM FERTILITY; LIVING CELLS; G-PROTEIN; DEGRADATION; OLIGOSACCHARIDE	Calnexin and calreticulin are homologous lectin chaperones that assist maturation of cellular and viral glycoproteins in the mammalian endoplasmic reticulum. Calnexin and calreticulin share the same specificity for monoglucosylated protein-bound N-glycans but associate with a distinct set of newly synthesized polypeptides. We report here that most calnexin substrates do not associate with calreticulin even upon selective calnexin inactivation, while BiP associates more abundantly with nascent polypeptides under these conditions. Calreticulin associated more abundantly with orphan calnexin substrates only in infected cells and preferentially with polypeptides of viral origin, showing stronger dependence of model viral glycoproteins on endoplasmic reticulum lectins. This may explain why inactivation of the calnexin cycle affects viral replication and infectivity but not viability of mammalian cells.	Inst Biomed Res, CH-6500 Bellinzona, Switzerland; St Thomas Sch Med, London SE1 9RT, England	Universita della Svizzera Italiana; University of London; King's College London	Molinari, M (corresponding author), Inst Biomed Res, CH-6500 Bellinzona, Switzerland.	maurizio.molinari@irb.unisi.ch	Molinari, Maurizio/N-2587-2019	Molinari, Maurizio/0000-0002-7636-5829				Allen S, 1997, BIOCHEM J, V328, P113, DOI 10.1042/bj3280113; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Chen W, 2000, MOL BIOL CELL, V11, P765, DOI 10.1091/mbc.11.2.765; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Chevet E, 1999, EMBO J, V18, P3655, DOI 10.1093/emboj/18.13.3655; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Danilczyk UG, 2000, J BIOL CHEM, V275, P13089, DOI 10.1074/jbc.275.17.13089; Denzel A, 2002, MOL CELL BIOL, V22, P7398, DOI 10.1128/MCB.22.21.7398-7404.2002; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; ELGUINDI SB, 1993, CELL, V75, P717; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Eriksson KK, 2004, J BIOL CHEM, V279, P44600, DOI 10.1074/jbc.M407972200; Fischer PB, 1996, J VIROL, V70, P7143, DOI 10.1128/JVI.70.10.7143-7152.1996; Gardner TG, 2000, ARCH BIOCHEM BIOPHYS, V378, P182, DOI 10.1006/abbi.2000.1804; GRUTERS RA, 1987, NATURE, V330, P74, DOI 10.1038/330074a0; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; Hendershot LM, 2004, MT SINAI J MED, V71, P289; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; HOWELL DN, 1985, J IMMUNOL, V134, P971; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Ikawa M, 2001, DEV BIOL, V240, P254, DOI 10.1006/dbio.2001.0462; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Kapoor M, 2003, J BIOL CHEM, V278, P6194, DOI 10.1074/jbc.M209132200; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Malyguine AM, 1998, IMMUNOL LETT, V61, P67, DOI 10.1016/S0165-2478(97)00164-8; Mehta A, 1998, FEBS LETT, V430, P17, DOI 10.1016/S0014-5793(98)00525-0; Mehta A, 1997, P NATL ACAD SCI USA, V94, P1822, DOI 10.1073/pnas.94.5.1822; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Nakanishi T, 2004, BIOL REPROD, V71, P959, DOI 10.1095/biolreprod.104.028647; Olivari S, 2005, J BIOL CHEM, V280, P2424, DOI 10.1074/jbc.C400534200; Ouzounov S, 2002, ANTIVIR RES, V55, P425, DOI 10.1016/S0166-3542(02)00075-X; Paganetti P, 2005, J CELL BIOL, V168, P863, DOI 10.1083/jcb.200410047; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Prasad SA, 1998, EUR J IMMUNOL, V28, P907, DOI 10.1002/(SICI)1521-4141(199803)28:03<907::AID-IMMU907>3.3.CO;2-W; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; SCOTT JE, 1995, J IMMUNOL, V155, P143; Snapp EL, 2004, J CELL BIOL, V164, P997, DOI 10.1083/jcb.200312079; Trombetta ES, 2003, GLYCOBIOLOGY, V13, p77R, DOI 10.1093/glycob/cwg075; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; Wu SF, 2002, J VIROL, V76, P3596, DOI 10.1128/JVI.76.8.3596-3604.2002; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	57	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28265	28271		10.1074/jbc.M501020200	http://dx.doi.org/10.1074/jbc.M501020200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15951445	hybrid			2022-12-25	WOS:000230857300012
J	Wang, RX; Clark, RAF; Mosher, DF; Ren, XD				Wang, RX; Clark, RAF; Mosher, DF; Ren, XD			Fibronectin's central cell-binding domain supports focal adhesion formation and rho signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; ACTIN STRESS FIBERS; PROTEIN-KINASE-C; MYOSIN PHOSPHATASE; MEMBRANE PROTRUSION; MAMMALIAN-CELLS; FAMILY GTPASES; SYNDECAN-4; PHOSPHORYLATION; INTEGRINS	Fibroblast adhesion to fibronectin ( FN) induces formation of focal adhesions ( FAs), structures that have significant effect on cell migration and signaling. FA formation requires actomyosin-based contractility that is regulated by Rho-dependent myosin light chain ( MLC) phosphorylation. Previous studies indicated that the FN central cell-binding ( and integrin- binding) domain ( CBD) is insufficient for FA formation and that the major heparin-binding domain ( HepII) facilitates FA formation in a Rho-dependent manner. We describe here conditions under which FN CBD alone is sufficient for FA formation in both human dermal fibroblasts and the FN-null murine fibroblasts. CBD-mediated FA formation is dependent on its surface adsorption and the adhesion activity of the cells. Attachment of FN-null fibroblasts to CBD elicits the same biphasic regulation of Rho activity as seen on intact FN, whereas adhesion to HepII alone does not activate Rho. Activation of Rho requires high levels of integrin occupancy. However, FN or CBD may induce FAs without increased activation of Rho ( i.e. the basal level of GTP-Rho induces sufficient phospho-MLC for FA assembly under this condition). In contrast, adhesion to HepII alone does not sustain MLC phosphorylation. Pulse stimulation of cells on CBD or HepII with lysophosphatidic acid elevates Rho GTP loading to the same level, but the lysophosphatidic acid-stimulated MLC phosphorylation is significantly lower in cells on HepII than on CBD. Coating HepII with suboptimal concentrations of CBD induces FAs without increased activation of Rho. Therefore, FN CBD can support FA formation and generate contraction by activating Rho or by facilitating Rho downstream signaling.	SUNY Stony Brook, Dept Dermatol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wisconsin System; University of Wisconsin Madison	Ren, XD (corresponding author), SUNY Stony Brook, Dept Dermatol, Life Sci Bldg,Rm 004, Stony Brook, NY 11794 USA.	xiang-dong.ren@sunysb.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR047894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010143, R01AG010143] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47894] Funding Source: Medline; NIA NIH HHS [AG10143] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA SK, 1995, CELL ADHES COMMUN, V3, P13, DOI 10.3109/15419069509081275; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Hartshorne DJ, 1998, ACTA PHYSIOL SCAND, V164, P483; HUMPHRIES MJ, 1993, SEMIN CANCER BIOL, V4, P293; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; IZZARD CS, 1986, EXP CELL RES, V165, P320, DOI 10.1016/0014-4827(86)90586-0; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; Miao H, 2002, J CELL SCI, V115, P2199; Miyamoto S, 1998, ANN NY ACAD SCI, V857, P119, DOI 10.1111/j.1749-6632.1998.tb10112.x; Mosher, 1989, FIBRONECTIN, P1; MOSHER DF, 1984, ANNU REV MED, V35, P561, DOI 10.1146/annurev.me.35.020184.003021; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2004, J CELL SCI, V117, P3511, DOI 10.1242/jcs.01205; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SANCHEZAPARICIO P, 1993, J IMMUNOL, V150, P3506; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Velasco G, 2002, FEBS LETT, V527, P101, DOI 10.1016/S0014-5793(02)03175-7; VERFAILLIE CM, 1994, BLOOD, V84, P1802; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Wilcox-Adelman SA, 2002, J BIOL CHEM, V277, P32970, DOI 10.1074/jbc.M201283200; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Yamada K. M., 1996, PROVISIONAL MATRIX M, P51; YAMADA KM, 1989, FIBRONECTIN, P8; YONEDA J, 1995, EXP CELL RES, V217, P169, DOI 10.1006/excr.1995.1076; Zhang QH, 1999, BLOOD, V93, P2984	63	34	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28803	28810		10.1074/jbc.M501421200	http://dx.doi.org/10.1074/jbc.M501421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15964831	hybrid			2022-12-25	WOS:000230857300072
J	Kothe, M; Ye, YH; Wagner, JS; De Luca, HE; Kern, E; Rapoport, TA; Lencer, WI				Kothe, M; Ye, YH; Wagner, JS; De Luca, HE; Kern, E; Rapoport, TA; Lencer, WI			Role of p97 AAA-ATPase in the retrotranslocation of the cholera toxin A1 chain, a non-ubiquitinated substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RETRO-TRANSLOCATION; PROTEIN; ER; TRANSPORT; MEMBRANE; RECOGNITION; COMPLEX	The enzymatic A1 chain of cholera toxin retrotranslocates across the endoplasmic reticulum membrane into the cytosol, where it induces toxicity. Almost all other retrotranslocation substrates are modified by the attachment of polyubiquitin chains and moved into the cytosol by the ubiquitin-interacting p97 ATPase complex. The cholera toxin A1 chain, however, can induce toxicity in the absence of ubiquitination, and the motive force that drives retrotranslocation is not known. Here, we use adenovirus expressing dominant-negative mutants of p97 to test whether p97 is required for toxin action. We find that cholera toxin still functions with only a small decrease in potency in cells that cannot retrotranslocate other substrates at all. These results suggest that p97 does not provide the primary driving force for extracting the A1 chain from the endoplasmic reticulum, a finding that is consistent with a requirement for polyubiquitination in p97 function.	Childrens Hosp, GI Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Digest Dis Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Lencer, WI (corresponding author), Childrens Hosp, GI Cell Biol, Enderes 720,300 Longwood Ave, Boston, MA 02115 USA.	lencer@childrens.harvard.edu		Lencer, Wayne/0000-0001-7346-2730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854, R37DK048106, R01DK048106, Z01DK033008] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48106, DK34854] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbuJarour RJ, 2005, J BIOL CHEM, V280, P15865, DOI 10.1074/jbc.M406316200; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; Flierman D, 2003, J BIOL CHEM, V278, P34774, DOI 10.1074/jbc.M303360200; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Henkel JR, 1998, MOL BIOL CELL, V9, P2477, DOI 10.1091/mbc.9.9.2477; Iwawaki T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Lee RJ, 2004, EMBO J, V23, P2206, DOI 10.1038/sj.emboj.7600232; Lencer WI, 2003, TRENDS BIOCHEM SCI, V28, P639, DOI 10.1016/j.tibs.2003.10.002; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Rodighiero C, 2002, EMBO REP, V3, P1222, DOI 10.1093/embo-reports/kvf239; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a	20	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28127	28132		10.1074/jbc.M503138200	http://dx.doi.org/10.1074/jbc.M503138200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15932873	hybrid			2022-12-25	WOS:000230678600076
J	Zhu, JH; Burgner, JW; Harms, E; Belitsky, BR; Smith, JL				Zhu, JH; Burgner, JW; Harms, E; Belitsky, BR; Smith, JL			A new arrangement of (beta/alpha)(8) barrels in the synthase subunit of PLP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; TRIOSEPHOSPHATE ISOMERASE; VITAMIN-B6 BIOSYNTHESIS; INCORPORATION PATTERN; PYRIDOXINE SYNTHESIS; PHOSPHATE SYNTHASE; GENE FAMILIES; NITROGEN ATOM	Pyridoxal 5'-phosphate (PLP, vitamin B-6), a cofactor in many enzymatic reactions, has two distinct biosynthetic routes, which do not coexist in any organism. Two proteins, known as PdxS and PdxT, together form a PLP synthase in plants, fungi, archaea, and some eubacteria. PLP synthase is a heteromeric glutamine amidotransferase in which PdxT produces ammonia from glutamine and PdxS combines ammonia with five- and three-carbon phosphosugars to form PLP. In the 2.2-angstrom crystal structure, PdxS is a cylindrical dodecamer of subunits having the classic (beta/alpha) 8 barrel fold. PdxS subunits form two hexameric rings with the active sites positioned on the inside. The hexamer and dodecamer forms coexist in solution. A novel phosphate-binding site is suggested by bound sulfate. The sulfate and another bound molecule, methyl pentanediol, were used to model the substrate ribulose 5- phosphate, and to propose catalytic roles for residues in the active site. The distribution of conserved surfaces in the PdxS dodecamer was used to predict a docking site for the glutaminase partner, PdxT.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	University of Michigan System; University of Michigan; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Tufts University	Smith, JL (corresponding author), Univ Michigan, Inst Life Sci, 210 Washtenaw Ave, Ann Arbor, MI 48109 USA.	JanetSmith@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303, R37DK042303] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42303] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balbo A, 2005, P NATL ACAD SCI USA, V102, P81, DOI 10.1073/pnas.0408399102; Bauer JA, 2004, J BIOL CHEM, V279, P2704, DOI 10.1074/jbc.M310311200; Bean LE, 2001, GENETICS, V157, P1067; Belitsky BR, 2004, J BACTERIOL, V186, P1191, DOI 10.1128/JB.186.4.1191-1196.2004; Binda C, 2000, STRUCTURE, V8, P1299, DOI 10.1016/S0969-2126(00)00540-2; Burns KE, 2005, J AM CHEM SOC, V127, P3682, DOI 10.1021/ja042792t; Cane DE, 2003, CHIMIA, V57, P75; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; Chaudhuri BN, 2003, BIOCHEMISTRY-US, V42, P7003, DOI 10.1021/bi034320h; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; Chiu HJ, 1999, BIOCHEMISTRY-US, V38, P6460, DOI 10.1021/bi982903z; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dong YX, 2004, EUR J BIOCHEM, V271, P745, DOI 10.1111/j.1432-1033.2003.03973.x; Drewke C, 2001, VITAM HORM, V61, P121; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Ehrenshaft M, 1999, CURR GENET, V34, P478, DOI 10.1007/s002940050423; Ehrenshaft M, 2001, J BACTERIOL, V183, P3383, DOI 10.1128/JB.183.11.3383-3390.2001; Galperin MY, 1997, MOL MICROBIOL, V24, P443, DOI 10.1046/j.1365-2958.1997.3671706.x; Garrido-Franco M, 2002, J MOL BIOL, V321, P601, DOI 10.1016/S0022-2836(02)00695-2; Guerrero SA, 2001, APPL MICROBIOL BIOT, V56, P718, DOI 10.1007/s002530100690; Gupta RN, 2001, J AM CHEM SOC, V123, P11353, DOI 10.1021/ja0113201; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hao Q, 2003, J APPL CRYSTALLOGR, V36, P1274, DOI 10.1107/S0021889803014031; HILL RE, 1996, ESCHERICHIA COLI SAL, V1, P695; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Knochel T, 1999, P NATL ACAD SCI USA, V96, P9479, DOI 10.1073/pnas.96.17.9479; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NOBLE MEM, 1991, PROTEINS, V10, P50, DOI 10.1002/prot.340100106; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rodriguez-Navarro S, 2002, YEAST, V19, P1261, DOI 10.1002/yea.916; Sakai A, 2002, J BIOSCI BIOENG, V93, P309, DOI 10.1263/jbb.93.309; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Seack J, 2001, BBA-GENE STRUCT EXPR, V1520, P21, DOI 10.1016/S0167-4781(01)00246-9; Tanaka K, 2000, J NUTR SCI VITAMINOL, V46, P55; Tanaka T, 2005, MOL BIOL EVOL, V22, P243, DOI 10.1093/molbev/msi011; TAZUYA K, 1995, BBA-GEN SUBJECTS, V1244, P113, DOI 10.1016/0304-4165(94)00205-C; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Walden H, 2004, J MOL BIOL, V342, P861, DOI 10.1016/j.jmb.2004.07.067; Weeks CM, 2002, Z KRISTALLOGR, V217, P686, DOI 10.1524/zkri.217.12.686.20659; WIERENGA RK, 1992, FEBS LETT, V307, P34, DOI 10.1016/0014-5793(92)80897-P; Wrenger C, 2005, J BIOL CHEM, V280, P5242, DOI 10.1074/jbc.M412475200; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yao JX, 2002, ACTA CRYSTALLOGR D, V58, P1941, DOI 10.1107/S0907444902016621; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; Zeidler J, 2003, J ORG CHEM, V68, P3486, DOI 10.1021/jo020730k	58	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27914	27923		10.1074/jbc.M503642200	http://dx.doi.org/10.1074/jbc.M503642200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15911615	hybrid			2022-12-25	WOS:000230678600054
J	Gonzalez-Gronow, M; Misra, UK; Gawdi, G; Pizzo, SV				Gonzalez-Gronow, M; Misra, UK; Gawdi, G; Pizzo, SV			Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL FIBROBLASTS; INTRACELLULAR PH; MOLECULAR-CLONING; BRUSH-BORDER; FUNCTIONAL EXPRESSION; TOPOLOGY PREDICTION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; CANCER CELLS; CALCIUM	Binding of plasminogen type II (Pg 2) to dipeptidyl peptidase IV (DPP IV) on the surface of the highly invasive 1-LN human prostate tumor cell line induces an intracellular Ca2+([Ca2+](i)) signaling cascade accompanied by a rise in intracellular pH (pH(i)). In endothelial cells, Pg 2 regulates intracellular pH via Na+/H+ exchange (NHE) antiporters; however, this mechanism has not been demonstrated in any other cell type including prostate cancer cells. Because the Pg 2 receptor DPP IV is associated with NHE3 in kidney cell plasma membranes, we investigated a similar association in 1-LN human prostate cancer cells and a mechanistic explanation for changes in [Ca2+](i) or pH(i) induced by Pg 2 in these cells. Our results suggest that the signaling cascade initiated by Pg 2 and its receptor proceeds via activation of phospholipase C, which promotes formation of inositol 3,4,5-trisphosphate, an inducer of Ca2+ release from endoplasmic reticulum stores. Furthermore, our results suggest that Pg 2 may regulate pH(i) via an association with NHE3 linked to DPP IV in these cells. These associations suggest that Pg has the potential to simultaneously regulate calcium signaling pathways and Na+/H+ exchanges necessary for tumor cell proliferation and invasiveness.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Gonzalez-Gronow, M (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	gonza002@mc.duke.edu			NCI NIH HHS [CA-86344] Funding Source: Medline; NHLBI NIH HHS [HL-24066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086344] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED Z, 1980, J GEN PHYSIOL, V75, P403, DOI 10.1085/jgp.75.4.403; ALBINI A, 1987, CANCER RES, V47, P3239; Alfonso A, 2000, BRIT J PHARMACOL, V130, P1809, DOI 10.1038/sj.bjp.0703490; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; Cabado AG, 2000, CELL SIGNAL, V12, P573, DOI 10.1016/S0898-6568(00)00101-7; Cavet ME, 2001, AM J PHYSIOL-CELL PH, V281, pC2039, DOI 10.1152/ajpcell.2001.281.6.C2039; Choi JY, 2000, J CLIN INVEST, V105, P1141, DOI 10.1172/JCI9260; De Smet P, 1999, PFLUG ARCH EUR J PHY, V438, P154, DOI 10.1007/s004240050893; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Girardi ACC, 2004, AM J PHYSIOL-CELL PH, V287, pC1238, DOI 10.1152/ajpcell.00186.2004; Girardi ACC, 2001, J BIOL CHEM, V276, P46671, DOI 10.1074/jbc.M106897200; Gonzalez-Gronow M, 2005, EXP CELL RES, V303, P22, DOI 10.1016/j.yexcr.2004.09.008; Gonzalez-Gronow M, 2003, J BIOL CHEM, V278, P27312, DOI 10.1074/jbc.M303172200; Gonzalez-Gronow M, 2001, BIOCHEM J, V355, P397, DOI 10.1042/0264-6021:3550397; Gonzalez-Gronow M, 1998, FIBRINOLYSIS PROTEOL, V12, P366, DOI 10.1016/S0268-9499(98)80395-0; GONZALEZGRONOW M, 1984, BIOCHEMISTRY-US, V23, P190, DOI 10.1021/bi00297a003; GONZALEZGRONOW M, 1993, J BIOL CHEM, V268, P20791; Humez S, 1996, CELL SIGNAL, V8, P375, DOI 10.1016/0898-6568(96)00082-4; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; KAGEN A, 1979, METHOD HORM RADIOIMM, P328; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lecrone V, 2000, CELL CALCIUM, V27, P35, DOI 10.1054/ceca.1999.0083; MACCHIARINI P, 1992, LANCET, V340, P145, DOI 10.1016/0140-6736(92)93217-B; Malakooti J, 1999, AM J PHYSIOL-GASTR L, V277, pG383, DOI 10.1152/ajpgi.1999.277.2.G383; McLean LA, 2000, AM J PHYSIOL-CELL PH, V278, pC676, DOI 10.1152/ajpcell.2000.278.4.C676; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; Misra UK, 2005, J IMMUNOL, V174, P2092, DOI 10.4049/jimmunol.174.4.2092; MISRA UK, 1994, J BIOL CHEM, V269, P12541; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Pizzonia JH, 1998, AM J PHYSIOL-RENAL, V275, pF510, DOI 10.1152/ajprenal.1998.275.4.F510; Praetorius J, 2000, AM J PHYSIOL-GASTR L, V278, pG197, DOI 10.1152/ajpgi.2000.278.2.G197; PRPIC V, 1989, SCIENCE, V244, P469, DOI 10.1126/science.2541500; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rich IN, 2000, BLOOD, V95, P1427, DOI 10.1182/blood.V95.4.1427.004k48_1427_1434; Schwiening CJ, 2002, J PHYSIOL-LONDON, V538, P371, DOI 10.1113/jphysiol.2001.013055; Shrode LD, 1997, J BIOENERG BIOMEMBR, V29, P393, DOI 10.1023/A:1022407116339; Slimane TA, 2001, EXP CELL RES, V270, P45, DOI 10.1006/excr.2001.5337; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Szaszi K, 2002, J BIOL CHEM, V277, P42623, DOI 10.1074/jbc.M206629200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Turner T, 1997, CLIN CANCER RES, V3, P2275; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Vereninov AA, 2001, CELL PHYSIOL BIOCHEM, V11, P19, DOI 10.1159/000047788; Wahl ML, 2002, ENDOTHELIUM-J ENDOTH, V9, P205, DOI 10.1080/10623320213633; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P409; Yamagata M, 1996, BRIT J CANCER, V73, P1328, DOI 10.1038/bjc.1996.254; YAMASHITA T, 1992, J BIOCHEM-TOKYO, V111, P162, DOI 10.1093/oxfordjournals.jbchem.a123731; Yoshioka S, 1997, J BIOCHEM-TOKYO, V122, P641; Zachos NC, 2005, ANNU REV PHYSIOL, V67, P411, DOI 10.1146/annurev.physiol.67.031103.153004	52	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27173	27178		10.1074/jbc.M500383200	http://dx.doi.org/10.1074/jbc.M500383200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911629	hybrid			2022-12-25	WOS:000230589500065
J	Jitrapakdee, S; Slawik, M; Medina-Gomez, G; Campbell, M; Wallace, JC; Sethi, JK; O'Rahilly, S; Vidal-Puig, AJ				Jitrapakdee, S; Slawik, M; Medina-Gomez, G; Campbell, M; Wallace, JC; Sethi, JK; O'Rahilly, S; Vidal-Puig, AJ			The peroxisome proliferator-activated receptor-gamma regulates murine pyruvate carboxylase gene expression in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; CAUSES INSULIN-RESISTANCE; UNCOUPLING PROTEIN GENE; FATTY-ACID SYNTHESIS; ADIPOCYTE CELL-LINE; PPAR-GAMMA; RESPONSE ELEMENT; MOLECULAR REGULATION; 3T3-L1 CELLS; ENZYME GENE	Pyruvate carboxylase ( PC) plays a crucial role in various metabolic pathways, including gluconeogenesis, lipogenesis, and glucose-induced insulin secretion. Here we showed for the first time that the PC gene is transcriptionally regulated by peroxisome proliferator-activated receptor-gamma (PPAR gamma) in vitro and in vivo in white and brown adipose tissue. PC mRNA and protein are markedly increased during differentiation of 3T3-L1 cells and HIB-1B, in parallel with the expression of the adipogenic transcription factors, CCAAT-enhancer binding protein alpha, PPAR gamma 1, and PPAR gamma 2. Tumor necrosis factor-alpha, a cytokine that blocks differentiation of 3T3- L1 cells, suppressed PC expression. Co-transfection studies in 3T3-L1 preadipocytes or HEK293T cells with a 2.3-kb promoter fragment of mouse PC gene linked to a luciferase reporter construct and with plasmids overexpressing retinoid X receptor alpha/PPAR gamma 1 or retinoid X receptor alpha/ PPAR gamma 2 showed a 6 - 8-fold increase above the basal promoter activity. Furthermore, treatment of these transfected cells with the PPAR gamma agonist doubled the promoter activity. Mutation of the putative PPAR-response element-( -386/-374) of this 2.3-kb PC promoter fragment abolished the PPAR gamma response. Gel shift and chromatin immunoprecipitation assays demonstrated that endogenous PPAR gamma binds to this functional PPAR-response element of the PC promoter. Mice with targeted disruption of the PPAR gamma 2 gene displayed similar to 50 - 60% reduction of PC mRNA and protein in white adipose tissue. Similarly, in brown adipose tissue of PPAR gamma 2-deficient mice subjected to cold exposure, PC mRNA was 40% lower than that of wild type mice. Impaired in vitro differentiation of white adipocytes of PPAR gamma 2 knock-out mice was also associated with a marked reduction of PC mRNA. Our findings identified PC as a PPAR gamma-regulated gene and suggested a role for PPAR gamma regulating intermediary metabolism.	Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Diabet Endocrinol & Metab, Cambridge CB2 2QR, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Adelaide	Jitrapakdee, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Diabet Endocrinol & Metab, Cambridge CB2 2QR, England.	scsji@mahidol.ac.th	Sethi, Jaswinder K./B-1413-2008; Medina-Gomez, Gema/CAI-1063-2022; O'Rahilly, Stephen/ABF-6509-2020; , John/AAP-5150-2020; Medina-Gomez, Gema/F-5667-2016; Medina-Gomez, Gema/CAF-4668-2022	Sethi, Jaswinder K./0000-0003-4157-0475; Medina-Gomez, Gema/0000-0001-8169-681X; O'Rahilly, Stephen/0000-0003-2199-4449; Medina-Gomez, Gema/0000-0001-8169-681X; Medina-Gomez, Gema/0000-0001-8169-681X; Vidal-Puig, Antonio/0000-0003-4220-9577	Biotechnology and Biological Sciences Research Council [JF16994] Funding Source: Medline; Medical Research Council [G0400192] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0400192] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; BALLARD FJ, 1967, J LIPID RES, V8, P73; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; CANNON B, 1979, EUR J BIOCHEM, V94, P419, DOI 10.1111/j.1432-1033.1979.tb12909.x; Carbone MA, 1998, AM J HUM GENET, V62, P1312, DOI 10.1086/301884; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FREYTAG SO, 1983, J BIOL CHEM, V258, P6307; Frohnert BI, 1999, J BIOL CHEM, V274, P3970, DOI 10.1074/jbc.274.7.3970; GIRUNN GD, 2002, MOL ENDOCRINOL, V16, P2793; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Jitrapakdee S, 1996, BIOCHEM BIOPH RES CO, V223, P695, DOI 10.1006/bbrc.1996.0958; Jitrapakdee S, 2001, BIOCHEM BIOPH RES CO, V287, P411, DOI 10.1006/bbrc.2001.5599; Jitrapakdee S, 1999, BIOCHEM J, V340, P1, DOI 10.1042/bj3400001; Jitrapakdee S, 1998, J BIOL CHEM, V273, P34422, DOI 10.1074/jbc.273.51.34422; JITRAPAKDEE S, 2004, ENCY BIOL CHEM, V3, P606; JITRAPAKDEE S, 1997, J BIOL CHEM, V272, P20520; Kim H, 2000, DIABETES, V49, P1517, DOI 10.2337/diabetes.49.9.1517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH CJ, 1992, AM J PHYSIOL, V262, pE608, DOI 10.1152/ajpendo.1992.262.5.E608; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; Medina-Gomez G, 2005, DIABETES, V54, P1706, DOI 10.2337/diabetes.54.6.1706; Meirhaeghe A, 2003, BIOCHEM J, V373, P155, DOI 10.1042/BJ20030200; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; ROHDE M, 1991, ARCH BIOCHEM BIOPHYS, V290, P197, DOI 10.1016/0003-9861(91)90608-L; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; WEXLER ID, 1994, BBA-MOL BASIS DIS, V1227, P46, DOI 10.1016/0925-4439(94)90105-8; Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752; Yu XX, 2002, FASEB J, V16, P155, DOI 10.1096/fj.01-0568com; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P1766, DOI 10.1073/pnas.90.5.1766; ZHANG J, 1995, BIOCHEM J, V306, P205, DOI 10.1042/bj3060205; Zhang JF, 2004, P NATL ACAD SCI USA, V101, P10703, DOI 10.1073/pnas.0403652101; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	54	70	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27466	27476		10.1074/jbc.M503836200	http://dx.doi.org/10.1074/jbc.M503836200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917242	Green Accepted, hybrid			2022-12-25	WOS:000230589500099
J	Paul, BD; Buchholz, DR; Fu, LZ; Shi, YB				Paul, BD; Buchholz, DR; Fu, LZ; Shi, YB			Tissue- and gene-specific recruitment of steroid receptor coactivator-3 by thyroid hormone receptor during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO ANALYSIS; TRANSCRIPTIONAL COACTIVATOR; EMBRYONIC-DEVELOPMENT; COREPRESSOR COMPLEX; NUCLEAR RECEPTORS; 1 SRC-1; XENOPUS; PROTEIN; ACTIVATION; REPRESSION	Numerous coactivators that bind nuclear hormone receptors have been isolated and characterized in vitro. Relatively few studies have addressed the developmental roles of these cofactors in vivo. By using the total dependence of amphibian metamorphosis on thyroid hormone (T-3) as a model, we have investigated the role of steroid receptor coactivator 3 (SRC3) in gene activation by thyroid hormone receptor (TR) in vivo. First, expression analysis showed that SRC3 was expressed in all tadpole organs analyzed. In addition, during natural as well as T-3-induced metamorphosis, SRC3 was up-regulated in both the tail and intestine, two organs that undergo extensive transformations during metamorphosis and the focus of the current study. We then performed chromatin immunoprecipitation assays to investigate whether SRC3 is recruited to endogenous T-3 target genes in vivo in developing tadpoles. Surprisingly, we found that SRC3 was recruited in a gene- and tissue-dependent manner to target genes by TR, both upon T-3 treatment of premetamorphic tadpoles and during natural metamorphosis. In particular, in the tail, SRC3 was not recruited in a T-3-dependent manner to the target TR beta A promoter, suggesting either no recruitment or constitutive association. Finally, by using transgenic tadpoles expressing a dominant negative SRC3 (F-dnSRC3), we demonstrated that F-dnSRC3 was recruited in a T-3-dependent manner in both the intestine and tail, blocking the recruitment of endogenous coactivators and histone acetylation. These results suggest that SRC3 is utilized in a gene- and tissue-specific manner by TR during development.	NICHD, LGRD, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Shi, YB (corresponding author), NICHD, LGRD, NIH, Bldg 18T,Rm 106, Bethesda, MD 20892 USA.	shi@heliz.nih.gov		Shi, Yun-Bo/0000-0002-6330-0639	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1989, STORY IODINE DEFICIE; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ATKINSON BG, 1994, DEV GENET, V15, P313, DOI 10.1002/dvg.1020150402; Auger AP, 2000, P NATL ACAD SCI USA, V97, P7551, DOI 10.1073/pnas.97.13.7551; Buchholz DR, 2003, MOL CELL BIOL, V23, P6750, DOI 10.1128/MCB.23.19.6750-6758.2003; Buchholz DR, 2004, MOL CELL BIOL, V24, P9026, DOI 10.1128/MCB.24.20.9026-9037.2004; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen JD, 1998, CRIT REV EUKAR GENE, V8, P169, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.40; Damjanovski Sashko, 2002, Methods Mol Biol, V202, P153; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Dodd M.H.I., 1976, P467; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fu LZ, 2002, MOL REPROD DEV, V62, P470, DOI 10.1002/mrd.10137; Furlow JD, 1999, MOL ENDOCRINOL, V13, P2076, DOI 10.1210/me.13.12.2076; Gehin M, 2002, MOL CELL BIOL, V22, P5923, DOI 10.1128/MCB.22.16.5923-5937.2002; Guenther MG, 2000, GENE DEV, V14, P1048; Havis E, 2003, EMBO REP, V4, P883, DOI 10.1038/sj.embor.embor908; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jepsen K, 2002, J CELL SCI, V115, P689; Jones PL, 2003, CURR TOP MICROBIOL, V274, P237; Kim HJ, 1998, MOL ENDOCRINOL, V12, P1038, DOI 10.1210/me.12.7.1038; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Metz A, 1998, MECH DEVELOP, V74, P29, DOI 10.1016/S0925-4773(98)00059-8; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; ONATE SA, 1995, SCIENCE, V270, P1354; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PAUL BD, 2005, IN PRESS MOL CELL BI; Paul DB, 2003, CELL RES, V13, P459, DOI 10.1038/sj.cr.7290188; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Puzianowska-Kuznicka M, 1997, MOL CELL BIOL, V17, P4738, DOI 10.1128/MCB.17.8.4738; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Sachs LM, 2000, P NATL ACAD SCI USA, V97, P13138, DOI 10.1073/pnas.260141297; Sachs LM, 2002, MOL CELL BIOL, V22, P8527, DOI 10.1128/MCB.22.24.8527-8538.2002; Sachs LM, 2000, COMP BIOCHEM PHYS B, V126, P199, DOI 10.1016/S0305-0491(00)00198-X; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; Shi Y.-B., 1999, AMPHIBIAN METAMORPHO; SHI YB, 1994, BBA-GENE STRUCT EXPR, V1217, P227, DOI 10.1016/0167-4781(94)90042-6; SHI YB, 1996, METAMORPHOSIS POSTEM, P508; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; TATA JR, 1993, BIOESSAYS, V15, P239, DOI 10.1002/bies.950150404; Tomita A, 2004, MOL CELL BIOL, V24, P3337, DOI 10.1128/MCB.24.8.3337-3346.2004; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; Westin S, 2000, ADV PHARMACOL, V47, P89; WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Yuan YH, 2002, CIRCULATION, V105, P2653, DOI 10.1161/01.CIR.0000018947.95555.65; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	79	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27165	27172		10.1074/jbc.M503999200	http://dx.doi.org/10.1074/jbc.M503999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15901728	hybrid			2022-12-25	WOS:000230589500064
J	Pozzi, A; Macias-Perez, I; Abair, T; Wei, SZ; Su, Y; Zent, R; Falck, JR; Capdevila, JH				Pozzi, A; Macias-Perez, I; Abair, T; Wei, SZ; Su, Y; Zent, R; Falck, JR; Capdevila, JH			Characterization of 5,6-and 8,9-epoxyeicosatrienoic acids (5,6-and 8,9-EET) as potent in vivo angiogenic lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; EPOXYEICOSATRIENOIC ACIDS; ENDOTHELIAL-CELLS; EPOXYGENASE METABOLITES; HYPERPOLARIZING FACTOR; TUMOR ANGIOGENESIS; EPOXIDE HYDROLASE; EPITHELIAL-CELLS; GROWTH-FACTOR; UP-REGULATION	The cytochrome P450 arachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (EETs) are powerful, nonregioselective, stimulators of cell proliferation. In this study we compared the ability of the four EETs (5,6-, 8,9-, 11,12-, and 14,15-EETs) to regulate endothelial cell proliferation in vitro and angiogenesis in vivo and determined the molecular mechanism by which EETs control these events. Inhibition of the epoxygenase blocked serum-induced endothelial cell proliferation, and exogenously added EETs rescued cell proliferation from epoxygenase inhibition. Studies with selective ERK, p38 MAPK, or PI3K inhibitors revealed that whereas activation of p38 MAPK is required for the proliferative responses to 8,9- and 11,12-EET, activation of PI3K is necessary for the cell proliferation induced by 5,6- and 14,15-EET. Among the four EETs, only 5,6- and 8,9-EET are capable of promoting endothelial cell migration and the formation of capillary-like structures, events that are dependent on EET-mediated activation of ERK and PI3K. Using subcutaneous sponge models, we showed that 5,6- and 8,9-EET are pro-angiogenic in mice and that their neo-vascularization effects are enhanced by the co-administration of an inhibitor of EET enzymatic hydration, presumably because of reduced EET metabolism and inactivation. These studies identify 5,6- and 8,9- EET as powerful and selective angiogenic lipids, provide a functional link between the EET proliferative chemotactic properties and their angiogenic activity, and suggest a physiological role for them in angiogenesis and de novo vascularization.	Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vet Affairs Hosp, Nashville, TN 37212 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pozzi, A (corresponding author), Vanderbilt Univ, Med Ctr N, Dept Med, Div Nephrol & Hypertens, B3109, Nashville, TN 37215 USA.	ambra.pozzi@vanderbilt.edu		Falck, John/0000-0002-9219-7845	NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009592, R01CA094849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NCI NIH HHS [CA94849-01, T32 CA009592, CA-68485] Funding Source: Medline; NIDDK NIH HHS [DK069921] Funding Source: Medline; NIGMS NIH HHS [GM31278, GM 37922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amaral SL, 2003, AM J PHYSIOL-HEART C, V284, pH1528, DOI 10.1152/ajpheart.00406.2002; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Capdevila JH, 2000, J LIPID RES, V41, P163; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Chen JK, 2002, P NATL ACAD SCI USA, V99, P6029, DOI 10.1073/pnas.092671899; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; Chen P, 2005, AM J PATHOL, V166, P615, DOI 10.1016/S0002-9440(10)62282-1; DeLozier TC, 2004, J PHARMACOL EXP THER, V310, P845, DOI 10.1124/jpet.104.067819; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Fleming I, 2004, PHARMACOL RES, V49, P525, DOI 10.1016/j.phrs.2003.11.016; Fosslien E, 2001, ANN CLIN LAB SCI, V31, P325; Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; Hoebel BG, 1998, CLIN EXP PHARMACOL P, V25, P826, DOI 10.1111/j.1440-1681.1998.tb02162.x; Holla VR, 1999, J CLIN INVEST, V104, P751, DOI 10.1172/JCI7013; Imig JD, 2001, J VASC RES, V38, P247, DOI 10.1159/000051053; Jiang M, 2004, CIRC RES, V94, P167, DOI 10.1161/01.RES.0000111523.12842.FC; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Medhora M, 2003, AM J PHYSIOL-HEART C, V284, pH215, DOI 10.1152/ajpheart.01118.2001; Michaelis UR, 2005, ARTERIOSCL THROM VAS, V25, P321, DOI 10.1161/01.ATV.0000151648.58516.eb; Michaelis UR, 2003, FASEB J, V17, P770, DOI 10.1096/fj.02-0640fje; Nie DT, 2004, SEMIN THROMB HEMOST, V30, P119; Potente M, 2003, J BIOL CHEM, V278, P29619, DOI 10.1074/jbc.M305385200; Potente M, 2002, J BIOL CHEM, V277, P15671, DOI 10.1074/jbc.M110806200; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pratt Phillip F, 2004, Curr Opin Investig Drugs, V5, P952; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Ruoslahti E, 2000, SEMIN CANCER BIOL, V10, P435, DOI 10.1006/scbi.2000.0334; Shi Y, 2005, AM J PATHOL, V166, P303, DOI 10.1016/S0002-9440(10)62254-7; Spector AA, 2004, PROG LIPID RES, V43, P55, DOI 10.1016/S0163-7827(03)00049-3; Tsao CC, 2001, J PHARMACOL EXP THER, V299, P39; Wang H, 2003, J PHARMACOL EXP THER, V307, P753, DOI 10.1124/jpet.103.052787; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966; Weintraub NL, 1997, CIRC RES, V81, P258, DOI 10.1161/01.RES.81.2.258; Yu ZG, 2000, CIRC RES, V87, P992, DOI 10.1161/01.RES.87.11.992; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zhang CY, 2002, STROKE, V33, P2957, DOI 10.1161/01.STR.0000037787.07479.9A	40	139	142	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27138	27146		10.1074/jbc.M501730200	http://dx.doi.org/10.1074/jbc.M501730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917237	hybrid			2022-12-25	WOS:000230589500061
J	Yan, W; Jenkins, CM; Han, XL; Mancuso, DJ; Sims, HF; Yang, K; Gross, RW				Yan, W; Jenkins, CM; Han, XL; Mancuso, DJ; Sims, HF; Yang, K; Gross, RW			The highly selective production of 2-arachidonoyl lysophosphatidylcholine catalyzed by purified calcium-independent phospholipase A(2)gamma - Identification of a novel enzymatic mediator for the generation of a key branch point intermediate in eicosanoid signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; ARACHIDONIC-ACID RELEASE; SMOOTH-MUSCLE-CELLS; MOUSE NEUROBLASTOMA-CELLS; BIOLOGICAL SAMPLES; BOVINE BRAIN; STRUCTURAL DETERMINATION; PHOSPHATIDIC-ACID; CRUDE EXTRACTS; A(2) ENZYMES	Herein, we report the heterologous expression of the human peroxisomal 63-kDa calcium-independent phospholipase A(2)gamma (iPLA(2)gamma) isoform in Sf9 cells, purification of the N-terminal His-tagged enzyme by affinity chromatography, and the identification of its remarkable substrate selectivity that results in the highly selective generation of 2-arachidonoyl lysophosphatidylcholine. Mass spectrometric analyses demonstrated that purified iPLA(2)gamma hydrolyzed saturated or monounsaturated aliphatic groups readily from either the sn-1 or sn-2 positions of phospholipids. In addition, purified iPLA(2)gamma effectively liberated arachidonic acid from the sn-2 position of plasmenylcholine substrates. In contrast, incubation of iPLA(2)gamma with 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine resulted in the rapid release of palmitic acid and the selective accumulation of 2-arachidonoyl lysophosphatidylcholine (LPC), which was not metabolized further by iPLA(2)gamma. The putative regiospecificity of the 2-arachidonoyl LPC product was authenticated by its diagnostic fragmentation pattern during tandem mass spectrometric analysis. To identify the physiological relevance of iPLA(2)gamma-mediated 2-arachidonoyl LPC production utilizing naturally occurring membranes, we incubated purified rat hepatic peroxisomes with iPLA(2)gamma and similarly identified the selective accumulation of 2-arachidonoyl LPC. Furthermore, tandem mass spectrometric analysis demonstrated that 2-arachidonoyl LPC is a natural product in human myocardium, a tissue in which iPLA(2)gamma expression is robust. Because 2-arachidonoyl LPC represents a key branch point intermediate that can potentially lead to a variety of bioactive molecules in eicosanoid signaling (e.g. arachidonic acid, 2-arachidonoylglycerol), these results have uncovered a novel eicosanoid selective pathway through iPLA(2)gamma-mediated 2-arachidonoyl LPC production to amplify and diversify the repertoire of biologic lipid second messengers in response to cellular stimulation.	Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Chem, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gross, RW (corresponding author), Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Internal Med, 660 S Euclid Ave,Campus Box 8020, St Louis, MO 63110 USA.	rgross@wustl.edu			NHLBI NIH HHS [5R01HL41250-12, 5P01HL05728-08] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041250] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; Aoki J, 2002, BBA-MOL CELL BIOL L, V1582, P26, DOI 10.1016/S1388-1981(02)00134-8; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; Bisogno T, 1999, J NEUROCHEM, V72, P2113, DOI 10.1046/j.1471-4159.1999.0722113.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CREER MH, 1985, LIPIDS, V20, P922, DOI 10.1007/BF02534778; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; DiMarzo V, 1996, BIOCHEM BIOPH RES CO, V227, P281, DOI 10.1006/bbrc.1996.1501; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; GROSS RW, 1982, CIRC RES, V51, P27, DOI 10.1161/01.RES.51.1.27; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; Han XL, 1996, BIOCHEMISTRY-US, V35, P5822, DOI 10.1021/bi952927v; Han XL, 2001, ANAL BIOCHEM, V295, P88, DOI 10.1006/abio.2001.5178; Han XL, 2004, BIOCHEMISTRY-US, V43, P15584, DOI 10.1021/bi048307o; Han XL, 1995, J AM SOC MASS SPECTR, V6, P1202, DOI 10.1016/1044-0305(95)00568-4; Han XL, 2004, ANAL BIOCHEM, V330, P317, DOI 10.1016/j.ab.2004.04.004; Han XL, 2003, J LIPID RES, V44, P1071, DOI 10.1194/jlr.R300004-JLR200; Han XL, 2005, MASS SPECTROM REV, V24, P367, DOI 10.1002/mas.20023; Han XL, 1996, J AM CHEM SOC, V118, P451, DOI 10.1021/ja952326r; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; Harano T, 2001, BIOCHEM J, V357, P157, DOI 10.1042/0264-6021:3570157; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; Hirabayashi T, 2004, BIOL PHARM BULL, V27, P1168, DOI 10.1248/bpb.27.1168; Hiramatsu T, 2003, J BIOL CHEM, V278, P49438, DOI 10.1074/jbc.M213018200; Hirano K, 2000, BBA-MOL CELL BIOL L, V1483, P325, DOI 10.1016/S1388-1981(99)00190-0; Jenkins CM, 2003, BIOCHEMISTRY-US, V42, P11798, DOI 10.1021/bi034611q; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kozak KR, 2002, J BIOL CHEM, V277, P44877, DOI 10.1074/jbc.M206788200; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kozak KR, 2002, J BIOL CHEM, V277, P23278, DOI 10.1074/jbc.M201084200; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Mancuso DJ, 2004, EUR J BIOCHEM, V271, P4709, DOI 10.1111/j.1432-1033.2004.04435.x; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Nirodi CS, 2004, P NATL ACAD SCI USA, V101, P1840, DOI 10.1073/pnas.0303950101; Pawliczak R, 2004, J BIOL CHEM, V279, P48550, DOI 10.1074/jbc.M408926200; PETE MJ, 1994, J BIOL CHEM, V269, P19494; Pete MJ, 1996, J BIOL CHEM, V271, P18114, DOI 10.1074/jbc.271.30.18114; Pete MJ, 1996, BBA-LIPID LIPID MET, V1299, P325, DOI 10.1016/0005-2760(95)00225-1; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Stewart A, 2002, J BIOL CHEM, V277, P29526, DOI 10.1074/jbc.M204856200; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Tanaka H, 2000, BIOCHEM BIOPH RES CO, V272, P320, DOI 10.1006/bbrc.2000.2776; Tatulian SA, 2001, BIOPHYS J, V80, P789, DOI 10.1016/S0006-3495(01)76058-4; Tay HK, 2004, J BIOL CHEM, V279, P22505, DOI 10.1074/jbc.M308788200; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Williams SD, 2000, J LIPID RES, V41, P1585; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Yang JY, 2003, FEBS LETT, V546, P247, DOI 10.1016/S0014-5793(03)00581-7; Yellaturu CR, 2003, J BIOL CHEM, V278, P43831, DOI 10.1074/jbc.M301472200; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090; Zhou L, 1997, J NUTR BIOCHEM, V8, P641, DOI 10.1016/S0955-2863(97)00114-9	66	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26669	26679		10.1074/jbc.M502358200	http://dx.doi.org/10.1074/jbc.M502358200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15908428	hybrid			2022-12-25	WOS:000230589500007
J	Holz, MK; Blenis, J				Holz, MK; Blenis, J			Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR COMPLEX; P70 S6 KINASE; CELL-GROWTH; GENE-PRODUCTS; MTOR; PHOSPHORYLATION; INSULIN; TSC2; RHEB; ACTIVATION	Here we demonstrate that mammalian target of rapamycin ( mTOR) is phosphorylated in a rapamycin-sensitive manner. We show that S6 kinase 1 (S6K1), but not Akt, directly phosphorylates mTOR in cell-free in vitro system and in cells. Expression of a constitutively active, rapamycin- and wortmannin-resistant S6K1 leads to constitutive phosphorylation of mTOR, whereas knock-down of S6K1 using small inhibitory RNA greatly reduces mTOR phosphorylation despite elevated Akt activity. Importantly, phosphorylation of mTOR by S6K1 occurs at threonine 2446/serine 2448. This region has been shown previously to be part of a regulatory repressor domain. These sites are also constitutively phosphorylated in the breast cancer cell line MCF7 carrying an amplification of the S6K1 gene, but not in a less tumorigenic cell line, MCF10a. Many models for Akt signaling to mTOR have been presented, suggesting direct phosphorylation by Akt. These models must be reconsidered in light of the present findings.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA.	jblenis@hms.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fox Heather L., 1998, American Journal of Physiology, V275, pC1232; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Lawrence J C Jr, 2001, Prog Mol Subcell Biol, V26, P1; Lynch CJ, 2000, J CELL BIOCHEM, V77, P234, DOI 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Wu GJ, 2000, CANCER RES, V60, P5371; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	36	269	279	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26089	26093		10.1074/jbc.M504045200	http://dx.doi.org/10.1074/jbc.M504045200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15905173	hybrid			2022-12-25	WOS:000230386800019
J	Malakhova, ML; Malinina, L; Pike, HM; Kanack, AT; Patel, DJ; Brown, RE				Malakhova, ML; Malinina, L; Pike, HM; Kanack, AT; Patel, DJ; Brown, RE			Point mutational analysis of the liganding site in human glycolipid transfer protein - Functionality of the complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	48th Annual Meeting of the Biophysical-Society	FEB 14-18, 2004	Baltimore, MD	Biophys Soc			STEROL CARRIER PROTEIN-2; CRYSTAL-STRUCTURE; PIG BRAIN; MICELLAR PROPERTIES; MEDIATED TRANSFER; BOVINE; MEMBRANE; GLYCOSPHINGOLIPIDS; GANGLIOSIDES; PURIFICATION	Mammalian glycolipid transfer proteins (GLTPs) facilitate the selective transfer of glycolipids between lipid vesicles in vitro. Recent structural determinations of the apo- and glycolipid-liganded forms of human GLTP have provided the first insights into the molecular architecture of the protein and its glycolipid binding site (Malinina, L., Malakhova, M. L., Brown, R. E., and Patel, D. J. ( 2004) Nature 430, 1048 - 1053). In the present study, we have evaluated the functional consequences of point mutation of the glycolipid liganding site of human GLTP within the context of a carrier-based mechanism of glycolipid intermembrane transfer. Different approaches were developed to rapidly and efficiently assess the uptake and release of glycolipid by GLTP. They included the use of glass-immobilized, glycolipid films to load GLTP with glycolipid and separation of GLTP/glycolipid complexes from vesicles containing glycolipid ( galactosylceramide or lactosylceramide) or from monosialoganglioside dispersions by employing nickel-nitrilotriacetic acid-based affinity or gel filtration strategies. Point mutants of the sugar headgroup recognition center ( Trp-96, Asp-48, Asn-52) and of the ceramide-accommodating hydrophobic tunnel ( Phe-148, Phe-183, Leu-136) were analyzed for their ability to acquire and release glycolipid ligand. Two manifestations of point mutation within the liganding site were apparent: (i) impaired formation of the GLTP/glycolipid complex; (ii) impaired acquisition and release of bound glycolipid by GLTP. The results are consistent with a carrier-based mode of GLTP action to accomplish the intermembrane transfer of glycolipid. Also noteworthy was the inefficient release of glycolipid by wtGLTP into phosphatidylcholine acceptor vesicles, raising the possibility of a function other than intermembrane glycolipid transfer in vivo.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA	University of Minnesota System; Memorial Sloan Kettering Cancer Center	Brown, RE (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	reb@umn.edu	Malinina, Lucy/B-8161-2013	Malinina, Lucy/0000-0001-7973-1831; Brown, Rhoderick/0000-0002-7337-3604	NIGMS NIH HHS [R01 GM045928] Funding Source: Medline; PHS HHS [45928] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE A, 1982, BIOCHEM BIOPH RES CO, V104, P1386, DOI 10.1016/0006-291X(82)91403-6; ABE A, 1984, BIOCHIM BIOPHYS ACTA, V778, P239, DOI 10.1016/0005-2736(84)90364-X; ABE A, 1985, J BIOL CHEM, V260, P1231; Ahn VE, 2003, P NATL ACAD SCI USA, V100, P38, DOI 10.1073/pnas.0136947100; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Brodersen P, 2002, GENE DEV, V16, P490, DOI 10.1101/gad.218202; BROWN RE, 1985, BIOCHEMISTRY-US, V24, P4082, DOI 10.1021/bi00336a042; BROWN RE, 1990, BIOCHIM BIOPHYS ACTA, V1044, P77, DOI 10.1016/0005-2760(90)90221-I; BROWN RE, 1987, BIOCHEMISTRY-US, V26, P5454, DOI 10.1021/bi00391a036; BROWN RE, 1985, CHEM PHYS LIPIDS, V38, P79, DOI 10.1016/0009-3084(85)90059-3; BROWN RE, 1992, BIOCHEMISTRY-US, V31, P10602, DOI 10.1021/bi00158a024; Campanacci V, 2004, FEBS LETT, V562, P183, DOI 10.1016/S0014-5793(04)00199-1; Cantu L, 1997, J PHYS-CONDENS MAT, V9, P5033, DOI 10.1088/0953-8984/9/24/005; Choinowski T, 2000, BIOCHEMISTRY-US, V39, P1897, DOI 10.1021/bi992742e; CORTI M, 1980, CHEM PHYS LIPIDS, V26, P225, DOI 10.1016/0009-3084(80)90053-5; de Alba E, 2003, BIOCHEMISTRY-US, V42, P14729, DOI 10.1021/bi0301338; De Matteis MA, 2004, BBA-BIOMEMBRANES, V1666, P264, DOI 10.1016/j.bbamem.2004.07.002; FORMISANO S, 1979, BIOCHEMISTRY-US, V18, P1119, DOI 10.1021/bi00573a028; Gadola SD, 2002, NAT IMMUNOL, V3, P721, DOI 10.1038/ni821; GAMMON CM, 1987, BIOCHEMISTRY-US, V26, P6239, DOI 10.1021/bi00393a043; Gelb MH, 2000, BBA-MOL CELL BIOL L, V1488, P20, DOI 10.1016/S1388-1981(00)00106-2; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; Hamilton JA, 2004, PROG LIPID RES, V43, P177, DOI 10.1016/j.plipres.2003.09.002; HOWARD RE, 1964, BIOCHIM BIOPHYS ACTA, V84, P435, DOI 10.1016/0926-6542(64)90007-1; Huang C, 1974, Methods Enzymol, V32, P485; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; KOYNOVA R, 1995, BBA-LIPID LIPID MET, V1255, P213, DOI 10.1016/0005-2760(94)00202-A; Li XM, 2004, BIOCHEMISTRY-US, V43, P10285, DOI 10.1021/bi0495432; Lin X, 2000, J BIOL CHEM, V275, P5104, DOI 10.1074/jbc.275.7.5104; Malinina L, 2004, NATURE, V430, P1048, DOI 10.1038/nature02856; Mattjus P, 2003, BIOCHEMISTRY-US, V42, P535, DOI 10.1021/bi026896x; Mattjus P, 2000, BIOCHEMISTRY-US, V39, P1067, DOI 10.1021/bi991810u; METZ RJ, 1982, J BIOL CHEM, V257, P2901; Rao CS, 2005, BIOPHYS J, V88, p428A; Rao CS, 2004, BIOCHEMISTRY-US, V43, P13805, DOI 10.1021/bi0492197; RAUVALA H, 1979, EUR J BIOCHEM, V97, P555, DOI 10.1111/j.1432-1033.1979.tb13144.x; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; SASAKI T, 1990, EXPERIENTIA, V46, P611, DOI 10.1007/BF01939700; Sasaki T, 1990, Subcell Biochem, V16, P113; SASAKI T, 1985, BIOCHEMISTRY-US, V24, P1079, DOI 10.1021/bi00326a002; Schuette CG, 2001, GLYCOBIOLOGY, V11, p81R, DOI 10.1093/glycob/11.6.81R; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; SONNINO S, 1994, CHEM PHYS LIPIDS, V71, P21, DOI 10.1016/0009-3084(94)02304-2; Stolowich NJ, 2002, CELL MOL LIFE SCI, V59, P193, DOI 10.1007/s00018-002-8416-8; Tischer W, 1999, TRENDS BIOTECHNOL, V17, P326, DOI 10.1016/S0167-7799(99)01322-0; Tringali C, 2004, J BIOL CHEM, V279, P3169, DOI 10.1074/jbc.M308381200; ULRICHBOTT B, 1984, J LIPID RES, V25, P1233; WIRTZ KWA, 1977, BIOCHEM J, V324, P353; WONG M, 1984, BIOCHEMISTRY-US, V23, P6498, DOI 10.1021/bi00321a035; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; YAMADA K, 1985, J BIOL CHEM, V260, P4615; YAMADA K, 1986, BIOCHIM BIOPHYS ACTA, V879, P345; YOHE HC, 1972, CHEM PHYS LIPIDS, V9, P279, DOI 10.1016/0009-3084(72)90015-1; Zajonc DM, 2003, NAT IMMUNOL, V4, P808, DOI 10.1038/ni948; Zhou DP, 2004, SCIENCE, V303, P523, DOI 10.1126/science.1092009	56	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26312	26320		10.1074/jbc.M500481200	http://dx.doi.org/10.1074/jbc.M500481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	943WT	15901739	hybrid, Green Accepted			2022-12-25	WOS:000230386800047
J	Shao, JY; Jung, CY; Liu, CM; Sheng, HM				Shao, JY; Jung, CY; Liu, CM; Sheng, HM			Prostaglandin E-2 stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; GLYCOGEN-SYNTHASE KINASE-3; CYCLOOXYGENASE-2 INHIBITOR; INTESTINAL POLYPOSIS; CARCINOMA CELLS; CYCLIN D1; KNOCKOUT MICE; IN-VIVO; GROWTH; RECEPTOR	Cyclooxygenase and its derived prostaglandin E-2 (PGE(2)) have been shown to stimulate the growth of cancer cells and promote tumor angiogenesis. Here, we show that PGE2 activated the beta-catenin/T cell factor-dependent transcription in colon cancer cells through the cAMP/protein kinase A pathway. The expression of cyclin D1 and vascular endothelial growth factor was induced by PGE(2) in LS-174T cells. Moreover, PGE(2) and mutated beta-catenin stimulated the transcription of cyclin D1 and vascular endothelial growth factor in a synergistic fashion. Mechanistically, PGE(2) increased the phosphorylation of glycogen synthase kinase-3 and consequently accumulated beta-catenin. In addition, PGE(2) induced the expression of T cell factor-4 transcription factor, which formed transcriptionally active complex with beta-catenin. In animal experiments, administration of 16,16-dimethyl PGE(2) strongly increased the expression of cyclin D1 and vascular endothelial growth factor in APC(min/+) mouse polyps. Thus, our results provide a novel mechanism, suggesting that cyclooxygenase-2/PGE(2) may exert pro-oncogenic actions through stimulating the beta-catenin/T cell factor-mediated transcription, which plays critical roles in colorectal carcinogenesis.	Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Urol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Canc, Indianapolis, IN 46202 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; University of Texas Medical Branch Galveston	Sheng, HM (corresponding author), Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA.	hsheng@iupui.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064593, R01DK065615] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-64593, DK-065615] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Easwaran V, 2003, CANCER RES, V63, P3145; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Fukuda R, 2003, CANCER RES, V63, P2330; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jacoby RF, 2000, CANCER RES, V60, P5040; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; KINZLER WK, 1996, CELL, V87, P159; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee EO, 2004, J NEUROIMMUNOL, V155, P21, DOI 10.1016/j.jneuroim.2004.05.012; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Reuter BK, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-19; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Shao JY, 2003, CANCER RES, V63, P5218; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Zhang T, 1997, CANCER RES, V57, P169; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	45	168	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26565	26572		10.1074/jbc.M413056200	http://dx.doi.org/10.1074/jbc.M413056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899904	hybrid			2022-12-25	WOS:000230386800073
J	Jung, JE; Lee, HG; Cho, IH; Chung, DH; Yoon, SH; Yang, YM; Lee, JW; Choi, S; Park, JW; Ye, SK; Chung, MH				Jung, JE; Lee, HG; Cho, IH; Chung, DH; Yoon, SH; Yang, YM; Lee, JW; Choi, S; Park, JW; Ye, SK; Chung, MH			STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells	FASEB JOURNAL			English	Article						vascular endothelial growth factor; hypoxia inducible factor 1; signal transducers and activators of transcription	HYPOXIA-INDUCIBLE FACTOR-1; CONSTITUTIVE ACTIVATION; NUCLEAR TRANSLOCATION; TRANSCRIPTION FACTOR; ANGIOGENESIS; MECHANISMS; CBP/P300; REQUIRES; BINDING; PROTEIN	Aberrantly enhanced vascular endothelial growth factor (VEGF) gene expression is associated with increased tumor growth and metastatic spread of solid malignancies, including human renal carcinomas. Persistent activation of STAT3 is linked to tumor-associated angiogenesis, but underlying mechanisms remain unclear. Therefore, we examined whether STAT3 modulates the stability and activity of hypoxia-inducible factor-1 alpha (HIF-1 alpha), and in turn enhances VEGF expression. We found that STAT3 was activated in ischemic rat kidneys and hypoxic human renal carcinoma cells. We also found that hypoxia-induced activation of STAT3 transactivated the VEGF promoter and increased the expression of VEGF transcripts. Consistent with these findings,STAT3 inhibition attenuated the hypoxic induction of VEGF. Interestingly,activated STAT3 increased HIF-1 alpha protein levels due to the HIF-1 alpha stability by blocking HIF-1 alpha degradation and accelerated its de novo synthesis. The novel interaction of STAT3 with HIF-1 alpha was identified in hypoxic renal carcinoma cells. Furthermore, hypoxia recruited STAT3,HIF-1 alpha, and p300 to the VEGF promoter and induced histone H3 acetylation. Therefore, these findings provide compelling evidence that a causal relationship exists between STAT3 activation and HIF-1-dependent angiogenesis and suggest that therapeutic modalities designed to disrupt STAT3 signaling hold considerable promise for the blocking tumor growth and enhancing apoptosis of cancer cells and tissues.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea; Seoul Natl Univ, Coll Dent, Dept Physiol, Seoul, South Korea; Seoul Natl Univ, Inst Dent Res, Seoul, South Korea; Konkuk Univ, Coll Med, Dept Premed Sci, Chungju, South Korea; Konkuk Univ, Biofood & Drug Res Ctr, Chungju, South Korea; Seoul Natl Univ, Coll Med, Dept Tumor Biol, Canc Res Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Konkuk University; Konkuk University Medical Center; Konkuk University; Seoul National University (SNU)	Ye, SK (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, 28 Yongon Dong, Seoul 110799, South Korea.	sangkyu@snu.ac.kr	Ye, Sang Kyu/J-2768-2012; Chung, Doo Hyun/J-2791-2012; Park, Jong-Wan/J-2758-2012; Lee, Jung Weon/F-9149-2012; Lee, Jung Weon/AAC-1146-2020	Lee, Jung Weon/0000-0003-2722-8200				Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chun YS, 2000, BIOCHEM BIOPH RES CO, V268, P652, DOI 10.1006/bbrc.2000.2180; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harmey JH, 1998, ANN SURG ONCOL, V5, P271, DOI 10.1007/BF02303785; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Liu K, 2005, J IMMUNOL, V174, P1630, DOI 10.4049/jimmunol.174.3.1630; Mol JC, 2002, GREEN CHEM, V4, P5, DOI 10.1039/b109896a; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; ROLAND H, 2002, FASEB J, V16, P1151; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Ye SK, 2001, IMMUNITY, V15, P813, DOI 10.1016/S1074-7613(01)00230-8	32	339	366	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1296	+		10.1096/fj.04-3099fje	http://dx.doi.org/10.1096/fj.04-3099fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15919761				2022-12-25	WOS:000229602600007
J	Wittmann, BM; Fujinaga, K; Deng, HY; Ogba, N; Montano, MM				Wittmann, BM; Fujinaga, K; Deng, HY; Ogba, N; Montano, MM			The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1	ONCOGENE			English	Article						estrogen receptor; breast cancer; cyclin T1	POLYMERASE-II TRANSCRIPTION; SMOOTH-MUSCLE-CELLS; P-TEFB; RNA; EXPRESSION; MECHANISMS; PROMOTER; KINASE; HEXIM1; CDK9	Estrogen receptor alpha (ER alpha) regulates transcription of specific genes and is believed to play a major role in breast tumorigenesis. We previously identified estrogen down regulated gene 1 (EDG1 (also known as HEXIM1)) using the C-terminus of ER alpha (E/F domain) as bait in yeast two-hybrid screenings. Here we report on the role of EDG1 as a coregulator of ER alpha transcriptional activity. We observe an interaction between EDG1 and ER alpha. EDG1 inhibits the transcriptional activity of ER alpha and this is dependent upon the C-terminus of EDG1. The C-terminus of EDG1/ HEXIM1 was recently shown to inhibit the positive transcription elongation factor b (P-TEFb) by interacting with the cyclin T1 subunit. Here we show that ER alpha interacts with cyclin T1, cyclin T1 and ER co-occupancy on the promoter region of an ER target gene, and that this interaction plays an important role in ER alpha-induced gene expression. The interaction of ER alpha with cyclin T1 also allows ER alpha to compete with EDG1 for cyclin T1, and may release cyclin T1 from EDG1 repression. Conversely, increased EDG1 expression results in inhibition of cyclin T1 recruitment and ER alpha DNA binding. Our results support a novel functional interaction between ER alpha and cyclin T1 that is modulated by EDG1.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Div Infect Dis, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, HG Wood Bldg,W307,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu	Ogba, Ndiya/K-8429-2014	Ogba, Ndiya/0000-0003-0453-3763	NCI NIH HHS [CA92440] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092440] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Bianco NR, 2005, BIOCHEM J, V385, P279, DOI 10.1042/BJ20040959; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carlson B, 1999, CANCER RES, V59, P4634; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Flototto T, 2001, HORM METAB RES, V33, P451, DOI 10.1055/s-2001-16936; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Glass CK, 2000, GENE DEV, V14, P121; HENDERSON BE, 1982, CANCER RES, V42, P3232; Huang FC, 2002, GENE, V292, P245, DOI 10.1016/S0378-1119(02)00596-6; Kanazawa S, 2003, ONCOGENE, V22, P5707, DOI 10.1038/sj.onc.1206800; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kino T, 2002, J BIOL CHEM, V277, P2396, DOI 10.1074/jbc.M106312200; Kusuhara M, 1999, BIOMED RES-TOKYO, V20, P273, DOI 10.2220/biomedres.20.273; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nahta R, 2003, CANCER RES, V63, P3626; Napolitano G, 2003, ONCOGENE, V22, P4882, DOI 10.1038/sj.onc.1206785; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Ouchida R, 2003, GENES CELLS, V8, P95, DOI 10.1046/j.1365-2443.2003.00618.x; Sano M, 2004, EMBO J, V23, P3559, DOI 10.1038/sj.emboj.7600351; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wittmann BM, 2003, CANCER RES, V63, P5151; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5	33	65	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5576	5588		10.1038/sj.onc.1208728	http://dx.doi.org/10.1038/sj.onc.1208728			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15940264				2022-12-25	WOS:000231296100005
J	Zang, H; Goodenough, AK; Choi, JY; Irimia, A; Loukachevitch, LV; Kozekov, ID; Angel, KC; Rizzo, CJ; Egli, M; Guengerich, FP				Zang, H; Goodenough, AK; Choi, JY; Irimia, A; Loukachevitch, LV; Kozekov, ID; Angel, KC; Rizzo, CJ; Egli, M; Guengerich, FP			DNA adduct bypass polymerization by Sulfolobus solfataricus DNA polymerase Dpo4 - Analysis and crystal structures of multiple base pair substitution and frameshift products with the adduct 1,N-2-ethenoguanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-1 REVERSE-TRANSCRIPTASE; RAY-DIFFRACTION DATA; ESCHERICHIA-COLI; Y-FAMILY; MASS-SPECTROMETRY; STEADY-STATE; ERROR-PRONE; IN-VITRO; REPLICATION; LESION	1,N-2-Etheno(epsilon) guanine is a mutagenic DNA lesion derived from lipid oxidation products and also from some chemical carcinogens. Gel electrophoretic analysis of the products of primer extension by Sulfolobus solfataricus P2 DNA polymerase IV ( Dpo4) indicated preferential incorporation of A opposite 3'-( 1, N-2-epsilon-G) TACT-5', among the four dNTPs tested individually. With the template 3'-(1,N-2-epsilon-G)CACT-5', both G and A were incorporated. When primer extension was done in the presence of a mixture of all four dNTPs, high pressure liquid chromatography-mass spectrometry analysis of the products indicated that ( opposite 3'-(1,N-2-epsilon-G) CACT-5', the major product was 5'-GTGA-3' and the minor product was 5'-AGTGA-3'. With the template 3'-(1,N-2-epsilon-G) TACT-5', the following four products were identified by high pressure liquid chromatography-mass spectrometry: 5'-AATGA-3', 5'-ATTGA-3', 5'-ATGA-3', and 5'-TGA-3'. An x-ray crystal structure of Dpo4 was solved (2.1 angstrom) with a primer-template and A placed in the primer to be opposite the 3'-(1, N-2-epsilon-G)TACT-5', in the template 3'(1,N-2-epsilon-G)TACT 5'. The added A in the primer was paired across the template T with classic Watson-Crick geometry. Similar structures were observed in a ternary Dpo4DNA-dATP complex and a ternary Dpo4-DNA-ddATP complex, with d(d)ATP opposite the template T. A similar structure was observed with a ddGTP adjacent to the primer and opposite the C next to 1,N-2-epsilon-G in 3'-(1,N-2-epsilon-G) CACT-5'. We concluded that Dpo4 uses several mechanisms, including A incorporation opposite 1, N-2-epsilon-G and also a variation of dNTP-stabilized misalignment, to generate both base pair and frameshift mutations.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Chem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 638 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu		Rizzo, Carmelo/0000-0001-9005-611X	NIEHS NIH HHS [P01 ES05355, T32 ES07028, R01 ES11331, P30 ES00267, R01 ES10375] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005355, P30ES000267, T32ES007028, R01ES011331, R01ES010375] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akasaka S, 1999, CHEM RES TOXICOL, V12, P501, DOI 10.1021/tx980259j; AMES BN, 1973, P NATL ACAD SCI USA, V70, P2281, DOI 10.1073/pnas.70.8.2281; Boudsocq F, 2004, J BIOL CHEM, V279, P32932, DOI 10.1074/jbc.M405249200; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMBILLAU C, 1997, TURBO FRODO VERSION; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; DING J, 2000, TRENDS BIOCHEM SCI, V25, P74; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; GUENGERICH FP, 1993, CHEM RES TOXICOL, V6, P635, DOI 10.1021/tx00035a008; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; HECHT SS, 1992, CHEM RES TOXICOL, V5, P706, DOI 10.1021/tx00029a018; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kornberg A., 1992, DNA REPLICATION; KRONBERG L, 1992, CHEM RES TOXICOL, V5, P852, DOI 10.1021/tx00030a019; Langouet S, 1998, BIOCHEMISTRY-US, V37, P5184, DOI 10.1021/bi972327r; Langouet S, 1997, BIOCHEMISTRY-US, V36, P6069, DOI 10.1021/bi962526v; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee SH, 2005, CHEM RES TOXICOL, V18, P780, DOI 10.1021/tx0497088; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Morinello EJ, 2001, CHEM RES TOXICOL, V14, P327, DOI 10.1021/tx0002076; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ni JS, 1996, ANAL CHEM, V68, P1989, DOI 10.1021/ac960270t; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owens DR, 1998, BIOORGAN MED CHEM, V6, P1547, DOI 10.1016/S0968-0896(98)00098-4; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P155; Saparbaev M, 2002, J BIOL CHEM, V277, P26987, DOI 10.1074/jbc.M111100200; SATTSANGI PD, 1977, J ORG CHEM, V42, P3292, DOI 10.1021/jo00440a020; SEARLE C, 1984, CHEM CARCINOGENS, V1; Singer B., 1999, EXOCYCLIC DNA ADDUCT; SODUM RS, 1988, CANCER RES, V48, P320; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Tippin B, 2004, J BIOL CHEM, V279, P45360, DOI 10.1074/jbc.M408600200; Trincao J, 2004, NAT STRUCT MOL BIOL, V11, P457, DOI 10.1038/nsmb755; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; Vellieux FMD, 1997, J APPL CRYSTALLOGR, V30, P396, DOI 10.1107/S0021889896012551; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; Wang LH, 2005, CHEM RES TOXICOL, V18, P441, DOI 10.1021/tx049786v; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yang W, 2005, FEBS LETT, V579, P868, DOI 10.1016/j.febslet.2004.11.047; Zang H, 2005, J BIOL CHEM, V280, P1165, DOI 10.1074/jbc.M405996200	57	128	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29750	29764		10.1074/jbc.M504756200	http://dx.doi.org/10.1074/jbc.M504756200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15965231	hybrid			2022-12-25	WOS:000231176200045
J	Kim, HI; Lee, ST				Kim, HI; Lee, ST			An intramolecular interaction between SH2-kinase linker and kinase domain is essential for the catalytic activity of protein-tyrosine kinase-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; C-SRC; REGULATORY INTERACTIONS; GASTROINTESTINAL-TRACT; CRYSTAL-STRUCTURE; DISTINCT FAMILY; SH2 DOMAIN; BRK; EXPRESSION; CARCINOMA	Protein-tyrosine kinase-6 (PTK6, also known as Brk) is a non-receptor tyrosine kinase that contains SH3, SH2, and catalytic (Kinase) domains. We have identified an intramolecular interaction between the linker (Linker) region connecting the SH2 and Kinase domains and the Kinase domain. Residue Trp-184 within the Linker region is essential for the Linker-Kinase interaction but not for the Linker-SH3 interaction. A recombinant PTK6 Kinase domain connected to the Linker region had catalytic activity in terms of autophosphorylation, phosphorylation of a PTK6 substrate, BKS, and phosphorylation of an oligopeptide substrate, whereas the Kinase domain itself, or one connected to a Linker region containing a W184A substitution, did not. The introduction of the W184A mutation into PTK6 also abrogated autophosphorylation and phosphorylation of another PTK6 substrate, Sam68, as well as phosphorylation of intracellular proteins. It also abolished the ability of PTK6 to promote proliferation and prevent apoptosis of HEK 293 cells, as well as to permit anchorage-independent colony formation. Therefore, unlike Src family members, in which the Linker-Kinase interaction inhibits catalytic activity, in PTK6 this interaction has an essential positive role.	Yonsei Univ, Coll Sci, Dept Biochem, Natl Res Lab Cellular Biochem, Seoul 120749, South Korea; Yonsei Univ, Protein Network Res Ctr, Seoul 120749, South Korea	Yonsei University; Yonsei University	Lee, ST (corresponding author), Yonsei Univ, Coll Sci, Dept Biochem, Natl Res Lab Cellular Biochem, Seoul 120749, South Korea.	stlee@yonsei.ac.kr		Lee, Seung-Taek/0000-0001-7300-9784				Bae JS, 2001, J BIOCHEM MOL BIOL, V34, P33; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Chen WS, 1999, INT J CANCER, V83, P579, DOI 10.1002/(SICI)1097-0215(19991126)83:5<579::AID-IJC1>3.0.CO;2-R; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; Harvey AJ, 2004, ANTI-CANCER DRUG, V15, P107, DOI 10.1097/01.cad.0000113339.62364.b5; Hong EM, 2004, J BIOL CHEM, V279, P29700, DOI 10.1074/jbc.M313185200; Jung JW, 2004, GENE, V328, P75, DOI 10.1016/j.gene.2003.12.006; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Lee HY, 1998, MOL CELLS, V8, P401; Lee SJ, 2003, BIOCHEM BIOPH RES CO, V312, P1196, DOI 10.1016/j.bbrc.2003.11.050; Lee SJ, 2002, FEBS LETT, V519, P147, DOI 10.1016/S0014-5793(02)02742-4; LEE ST, 1992, J BIOL CHEM, V267, P24126; LEE ST, 1993, ONCOGENE, V8, P3403; LIU XQ, 1993, ONCOGENE, V8, P1119; Llor X, 1999, CLIN CANCER RES, V5, P1767; Mikkola ET, 2003, FEBS LETT, V544, P11, DOI 10.1016/S0014-5793(03)00405-8; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Park M, 1999, BIOCHEM BIOPH RES CO, V264, P730, DOI 10.1006/bbrc.1999.1580; Petro BJ, 2004, ORAL ONCOL, V40, P1040, DOI 10.1016/j.oraloncology.2004.05.010; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Schedin PJ, 2004, ONCOGENE, V23, P1766, DOI 10.1038/sj.onc.1207391; Serfas MS, 2003, ONCOL RES, V13, P409; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhang P, 2005, J BIOL CHEM, V280, P1982, DOI 10.1074/jbc.M412038200	42	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28973	28980		10.1074/jbc.M504568200	http://dx.doi.org/10.1074/jbc.M504568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15961400	hybrid			2022-12-25	WOS:000231021300019
J	Valiente, M; Andres-Pons, A; Gomar, B; Torres, J; Gil, A; Tapparel, C; Antonarakis, SE; Pulido, R				Valiente, M; Andres-Pons, A; Gomar, B; Torres, J; Gil, A; Tapparel, C; Antonarakis, SE; Pulido, R			Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; TYROSINE-PHOSPHATASE; CELL-MIGRATION; ORGANIZATION; MECHANISM; RECEPTOR; GROWTH; RECOGNITION; INHIBITION; ARREST	The tumor suppressor phosphatase PTEN is a key regulator of cell growth and apoptosis that interacts with PDZ domains from regulatory proteins, including MAGI-1/2/3, hDlg, and MAST205. Here we identified novel PTEN-binding PDZ domains within the MAST205-related proteins, syntrophin-associated serine/threonine kinase and MAST3, characterized the regions of PTEN involved in its interaction with distinctive PDZ domains, and analyzed the functional consequences on PTEN of PDZ domain binding. Using a panel of PTEN mutations, as well as PTEN chimeras containing distinct domains of the related protein TPTE, we found that the PTP and C2 domains of PTEN do not affect PDZ domain binding and that the C-terminal tail of PTEN (residues 350-403) provides selectivity to recognize specific PDZ domains from MAGI-2, hDlg, and MAST205. Binding of PTEN to the PDZ-2 domain from MAGI-2 increased PTEN protein stability. Furthermore, binding of PTEN to the PDZ domains from microtubule-associated serine/threonine kinases facilitated PTEN phosphorylation at its C terminus by these kinases. Our results suggest an important role for the C-terminal region of PTEN in the selective association with scaffolding and/ or regulatory molecules and provide evidence that PDZ domain binding stabilizes PTEN and targets this tumor suppressor for phosphorylation by microtubule- associated serine/threonine kinases.	Ctr Invest Principe Felipe, Valencia 46013, Spain; Univ Geneva, Sch Med, Ctr Med Univ, Div Med Genet, CH-1211 Geneva, Switzerland	Prince Felipe Research Center; University of Geneva	Pulido, R (corresponding author), Ctr Invest Principe Felipe, Avda Autopista del Saler 16-3, Valencia 46013, Spain.	rpulido@ochoa.fib.es	Torres, Josema/F-7070-2013; Antonarakis, Stylianos E/N-8866-2014	Torres, Josema/0000-0001-6906-7164; Antonarakis, Stylianos E/0000-0001-8907-5823; Pulido, Rafael/0000-0001-9100-248X; Andres-Pons, Amparo/0000-0001-5801-4024; Tapparel Vu, Caroline/0000-0002-0411-6567				Adamsky K, 2003, J CELL SCI, V116, P1279, DOI 10.1242/jcs.00302; Adey NB, 2000, CANCER RES, V60, P35; Andres-Pons A, 2005, CANCER LETT, V223, P303, DOI 10.1016/j.canlet.2004.09.047; Birle D, 2002, J IMMUNOL, V169, P286, DOI 10.4049/jimmunol.169.1.286; Caenepeel S, 2004, P NATL ACAD SCI USA, V101, P11707, DOI 10.1073/pnas.0306880101; Chen HM, 1999, HUM GENET, V105, P399, DOI 10.1007/s004390051122; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Fan JS, 2002, NEUROSIGNALS, V11, P315, DOI 10.1159/000068256; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Goberdhan DCI, 2003, HUM MOL GENET, V12, pR239, DOI 10.1093/hmg/ddg288; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hlobilkova A, 2000, EXP CELL RES, V256, P571, DOI 10.1006/excr.2000.4867; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Nakamura H, 1998, FEBS LETT, V433, P63, DOI 10.1016/S0014-5793(98)00882-5; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Park MJ, 2002, CANCER RES, V62, P6318; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Sumitomo M, 2004, CANCER CELL, V5, P67, DOI 10.1016/S1535-6108(03)00331-3; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; TAPPAREL C, 2003, GENE, V24, P189; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; WALDEN PD, 1993, MOL CELL BIOL, V13, P7625, DOI 10.1128/MCB.13.12.7625; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamada KM, 2001, J CELL SCI, V114, P2375; Zhou H, 2004, J IMMUNOL, V172, P2559, DOI 10.4049/jimmunol.172.4.2559	48	168	178	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28936	28943		10.1074/jbc.M504761200	http://dx.doi.org/10.1074/jbc.M504761200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15951562	Green Published, hybrid			2022-12-25	WOS:000231021300014
J	Lazzereschi, D; Nardi, F; Turco, A; Ottini, L; D'Amico, C; Mariani-Costantini, R; Gulino, A; Coppa, A				Lazzereschi, D; Nardi, F; Turco, A; Ottini, L; D'Amico, C; Mariani-Costantini, R; Gulino, A; Coppa, A			A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours	ONCOGENE			English	Article						TGF-beta signalling; Smad4; thyroid tumours; somatic mutations; abnormal splicing; molecular pathology	GROWTH-FACTOR-BETA; COLORECTAL CANCERS; JUVENILE POLYPOSIS; MESSENGER-RNA; SOMATIC ALTERATIONS; DPC4/SMAD4 GENE; CHROMOSOME 18Q; II RECEPTOR; CELLS; DPC4	Sensitivity to transforming growth factor-beta is impaired in thyroid tumours. Similar to Mad - Mother Against Decapentaplegic-(Smad)4 is frequently altered in cancers, but its involvement in this system is unknown. We analysed 56 thyroid tumours of various histotypes for Smad4 mutations by PCR-SSCP and sequencing, linking them to Smad4 reactivity as examined by immunohistochemistry (IHC), and 29 of them also for abnormalities in RNA expression due to alternative splicing. In all, 15/56 cases (27%), both benign and malignant lesions, harbour alterations of Smad4 coding sequence. We found several novel intragenic mutations (13 missense, two silent, one frameshift and one large insertion-deletion), with high incidence in the linker region. A subset of mutated tumours failed to express Smad4 protein by IHC. We have also detected four alternatively spliced tumour-associated Smad4 isoforms, lacking portions of the linker region, and three more due to unreported internal exon-exon rearrangements. Smad4 is both frequently mutated and deregulated by aberrant splicing in thyroid tumours and these alterations may contribute as an early event to thyroid tumorigenesis.	Univ Roma La Sapienza, Fac Med 1, Dept Expt Med & Pathol, I-00161 Rome, Italy; Univ G Dannunzio, Fac Med, Dept Oncol & Neurosci, I-66013 Chieti, Italy; Univ G dAnnunzio, Ageing Res Ctr, I-66013 Chieti, Italy	Sapienza University Rome; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Lazzereschi, D (corresponding author), Univ Roma La Sapienza, Fac Med 1, Dept Expt Med & Pathol, V Regina Elena 324, I-00161 Rome, Italy.	davide.lazzereschi@uniroma1.it; anna.coppa@uniroma1.it	coppa, anna/N-3274-2016; Mariani-Costantini, Renato/B-6637-2012	Mariani-Costantini, Renato/0000-0002-4440-1848; coppa, anna/0000-0001-9758-5444; OTTINI, LAURA/0000-0001-8030-0449				Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; BERTAUX F, 1991, BIOCHEM BIOPH RES CO, V178, P586, DOI 10.1016/0006-291X(91)90148-Z; Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; COLLETTA G, 1989, CANCER RES, V49, P3457; Coppa A, 1997, J CELL PHYSIOL, V172, P200, DOI 10.1002/(SICI)1097-4652(199708)172:2<200::AID-JCP7>3.0.CO;2-S; COPPA A, 1995, CELL GROWTH DIFFER, V6, P281; Costamagna E, 2004, J BIOL CHEM, V279, P3439, DOI 10.1074/jbc.M307138200; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Ermak G, 1996, CLIN CANCER RES, V2, P1251; Ferrand M, 2003, J BIOL CHEM, V278, P3793, DOI 10.1074/jbc.M209513200; Fluge O, 2001, ONCOGENE, V20, P885, DOI 10.1038/sj.onc.1204161; Gallione CJ, 2004, LANCET, V363, P852, DOI 10.1016/S0140-6736(04)15732-2; Hahn SA, 1998, CANCER RES, V58, P1124; Hayashi M, 2002, BIOCHEM BIOPH RES CO, V297, P1253, DOI 10.1016/S0006-291X(02)02371-9; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Iacobuzio-Donahue CA, 2004, CLIN CANCER RES, V10, P1597, DOI 10.1158/1078-0432.CCR-1121-3; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Ju HR, 2003, CANCER LETT, V196, P197, DOI 10.1016/S0304-3835(03)00237-4; Kageyama H, 1998, CANCER LETT, V122, P187, DOI 10.1016/S0304-3835(97)00389-3; Kim SK, 1996, CANCER RES, V56, P2519; Koyama M, 1999, MUTAT RES-GENOMICS, V406, P71, DOI 10.1016/S1383-5726(99)00003-5; Kuang CZ, 2004, ONCOGENE, V23, P1021, DOI 10.1038/sj.onc.1207219; Lazzereschi D, 1997, CANCER RES, V57, P2071; Maru D, 2004, ONCOGENE, V23, P859, DOI 10.1038/sj.onc.1207194; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; Nicolussi A, 2003, MOL CELL ENDOCRINOL, V207, P1, DOI 10.1016/S0303-7207(03)00238-7; Ohtaki N, 2001, INT J ONCOL, V18, P265; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takakura S, 1999, GENE CHROMOSOME CANC, V24, P264, DOI 10.1002/(SICI)1098-2264(199903)24:3<264::AID-GCC12>3.0.CO;2-Y; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Turco A, 1999, INT J CANCER, V80, P85, DOI 10.1002/(SICI)1097-0215(19990105)80:1<85::AID-IJC17>3.0.CO;2-P; Woodford-Richens KL, 2001, AM J PATHOL, V159, P1293, DOI 10.1016/S0002-9440(10)62516-3; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866	43	39	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5344	5354		10.1038/sj.onc.1208603	http://dx.doi.org/10.1038/sj.onc.1208603			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15940269				2022-12-25	WOS:000231158500008
J	Gibson, KJC; Gilleron, M; Constant, P; Sichi, B; Puzo, G; Besra, GS; Nigou, J				Gibson, KJC; Gilleron, M; Constant, P; Sichi, B; Puzo, G; Besra, GS; Nigou, J			A lipomannan variant with strong TLR-2-dependent pro-inflammatory activity in Saccharothrix aerocolonigenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; BACILLUS-CALMETTE-GUERIN; MYCOBACTERIUM-BOVIS BCG; MYO-INOSITOL ANCHOR; LIPOARABINOMANNAN-LIKE LIPOGLYCAN; DENDRITIC CELL-FUNCTION; SURFACTANT PROTEIN-A; NMR-SPECTROSCOPY; STRUCTURAL FEATURES; MULTIACYLATED FORMS	Lipomannans (LMs) are powerful pro-inflammatory lipoglycans found in mycobacteria and related genera, however the molecular bases of their activity are not fully understood. We report here the isolation and the structural and functional characterization of a new lipomannan variant present in the Pseudonocardineae, Saccharothrix aerocolonigenes, designated SaeLM. Using a range of chemical degradations, NMR experiments, and mass spectrometry analyses, SaeLM revealed a mannosylphosphatidyl-myo-inositol (MPI) anchor glycosylated by an original carbohydrate structure whereby an (alpha 1 -> 36)-Manp backbone is substituted at > 80% of the O-2 position by side chains composed of Manp-(alpha 1 -> 2)- Manp-(alpha 1 ->. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis indicated a distribution of SaeLM glyco-forms ranging from 19 to 61 Manp units, which centered on species containing 37 or 40 Manp units. SaeLM induced a Toll-like receptor 2 (TLR-2)-dependent production of tumor necrosis factor-alpha (TNF-alpha) by human THP-1 monocyte/macrophage cell lines and interestingly was found to be the strongest inducer of this pro-inflammatory cytokine when compared with other LAM/LM-like molecules. We previously established that a linear (alpha 1 -> 6)-Manp chain, linked to the MPI anchor, is sufficient in providing proinflammatory activity. We demonstrate here that by adding side chains and increasing their size, one may potentiate this activity. These findings should enable a better understanding of the structure/function relationships of TLR-2-dependent lipoglycan signaling.	CNRS, UMR 5089, Inst Pharmacol & BIol Struct, Dept Mol Mechanisms Mycobacterial Infect, F-31077 Toulouse, France; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Birmingham	Nigou, J (corresponding author), CNRS, UMR 5089, Inst Pharmacol & BIol Struct, Dept Mol Mechanisms Mycobacterial Infect, 205 Route Narbonne, F-31077 Toulouse, France.	jerome.nigou@ipbs.fr	Nigou, Jérôme/D-6802-2019	Nigou, Jérôme/0000-0002-6233-2487; GILLERON, Martine/0000-0002-2581-3302; Besra, Gurdyal/0000-0002-5605-0395	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS LB, 1993, INFECT IMMUN, V61, P4173, DOI 10.1128/IAI.61.10.4173-4181.1993; BARNES PF, 1992, J IMMUNOL, V149, P541; Basu S, 2004, AM J PHYSIOL-LUNG C, V286, pL887, DOI 10.1152/ajplung.00323.2003; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BOCK K, 1974, J CHEM SOC        P2, V2, P293; Bosco M, 1997, ANAL BIOCHEM, V245, P38, DOI 10.1006/abio.1996.9907; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Dao DN, 2004, INFECT IMMUN, V72, P2067, DOI 10.1128/IAI.72.4.2067-2074.2004; Flaherty C, 1999, SYST APPL MICROBIOL, V22, P530, DOI 10.1016/S0723-2020(99)80005-8; Garton NJ, 2002, J BIOL CHEM, V277, P31722, DOI 10.1074/jbc.M203008200; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Gibson KJC, 2004, J BIOL CHEM, V279, P22973, DOI 10.1074/jbc.M310906200; Gibson KJC, 2003, BIOCHEM J, V372, P821, DOI 10.1042/BJ20030197; Gibson KJC, 2003, MICROBIOL-SGM, V149, P1437, DOI 10.1099/mic.0.26161-0; Gilleron M, 2000, J BIOL CHEM, V275, P677, DOI 10.1074/jbc.275.1.677; Gilleron M, 2005, J BACTERIOL, V187, P854, DOI 10.1128/JB.187.3.854-861.2005; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 1997, J BIOL CHEM, V272, P117; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; GILLERON M, 2001, GLYCANS CELL INTERAC, P113; Guerardel Y, 2003, J BIOL CHEM, V278, P36637, DOI 10.1074/jbc.M305427200; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; Heldwein KA, 2003, J LEUKOCYTE BIOL, V74, P277, DOI 10.1189/jlb.0103026; Heldwein KA, 2002, MICROBES INFECT, V4, P937, DOI 10.1016/S1286-4579(02)01611-8; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; Labeda DP, 2001, INT J SYST EVOL MICR, V51, P1045, DOI 10.1099/00207713-51-3-1045; Lee SD, 2000, INT J SYST EVOL MICR, V50, P1315, DOI 10.1099/00207713-50-3-1315; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; Ludwiczak P, 2002, MICROBIOL-SGM, V148, P3029, DOI 10.1099/00221287-148-10-3029; Means TK, 1999, J IMMUNOL, V163, P6748; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 1999, BIOCHEM J, V337, P453, DOI 10.1042/0264-6021:3370453; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; Quesniaux VJ, 2004, J IMMUNOL, V172, P4425, DOI 10.4049/jimmunol.172.7.4425; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Sidobre S, 2002, BIOCHEM J, V365, P89, DOI 10.1042/BJ20011659; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; Sutcliffe IC, 1995, ARCH ORAL BIOL, V40, P1119, DOI 10.1016/0003-9969(95)00086-0; Tailleux L, 2003, TRENDS MICROBIOL, V11, P259, DOI 10.1016/S0966-842X(03)00102-1; TAKAYAMA K, 1969, BIOCHIM BIOPHYS ACTA, V176, P196, DOI 10.1016/0005-2760(69)90089-7; Tapping RI, 2003, J ENDOTOXIN RES, V9, P264, DOI 10.1179/096805103225001477; VENISSE A, 1993, J BIOL CHEM, V268, P12401; Vignal C, 2003, J IMMUNOL, V171, P2014, DOI 10.4049/jimmunol.171.4.2014	56	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28347	28356		10.1074/jbc.M505498200	http://dx.doi.org/10.1074/jbc.M505498200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15955814	hybrid, Green Published			2022-12-25	WOS:000230857300022
J	Huang, TJ; Lu, CC; Tsai, JC; Yao, WJ; Lu, XY; Lai, MD; Liu, HS; Shiau, AL				Huang, TJ; Lu, CC; Tsai, JC; Yao, WJ; Lu, XY; Lai, MD; Liu, HS; Shiau, AL			Novel autoregulatory function of hepatitis B virus M protein on surface gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; S-PROMOTER; HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL REGULATION; ANTIGEN PROMOTER; CONTROL ELEMENTS; BINDING PROTEIN; TRANSCRIPTION; SECRETION; TRANSACTIVATOR	The hepatitis B virus surface gene consists of a single open reading frame divided into three coding regions: pre-S1, pre-S2, and S. By alternate translation at each of the three initiation codons, L, M, and S proteins can be synthesized. Studies have shown that M protein is not essential for viral replication, virion morphogenesis, or in vitro infectivity. In this study, we show that native M protein can regulate surface gene expression at the transcriptional level. The regulatory effect of M protein is mediated through the CCAAT box within the S promoter. Deletion mapping analysis indicated that the transactivating effect of M protein is mediated through amino acids 1-57 of M protein ( the MHBs(au) domain), although its maximal transactivation activity coincides with that of the pre-S2 domain. This conclusion is supported by the fact that disruption of the putative V8 protease site at the pre-S2/S domain junction not only rendered M protein incapable of transactivating the S promoter but also inactivated its nuclear translocation potential. Immunoprecipitation and immunoblot experiments demonstrated that pre-S2 interacts with the three subunits of the CCAAT box-binding factor/nuclear factor Y, the cognate binding protein of the CCAAT box. These results demonstrate and define a novel regulatory role of M protein, which, under natural conditions, may undergo a proteolytic process to generate an MHBsau species that will be translocated inside the nucleus, where it will interact with the CCAAT box-binding factor to regulate surface gene expression. Because the CCAAT box is located at a fixed position within numerous promoters, these observations might provide a plausible explanation for hepatitis B virus-associated hepatocarcinogenesis.	Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm, Dept Pathol, Tainan 70428, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70428, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pathol, Tainan 70428, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Nucl Med, Tainan 70428, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan 70428, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Immunol & Microbiol, Tainan 70428, Taiwan; Natl Cheng Kung Univ, Coll Med, Ctr Biosci & Biotechnol, Tainan 70428, Taiwan; Thomas Jefferson Univ, Jefferson Med Coll, Dept Immunol & Microbiol, Viral Hepatitis Grp, Philadelphia, PA 19107 USA	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Jefferson University	Lu, CC (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm, Dept Pathol, 138 Sheng Li Rd, Tainan 70428, Taiwan.	cclu@mail.ncku.edu.tw	Lai, Ming-Derg/M-8028-2014; shiau, A-Li/C-2885-2012	shiau, A-Li/0000-0003-2449-8547; Liu, Hsiao-Sheng/0000-0003-0576-7203				BEASLEY RP, 1981, LANCET, V2, P1129; Beland M, 2004, MOL CELL BIOL, V24, P5028, DOI 10.1128/MCB.24.11.5028-5038.2004; BLUM HE, 1991, J VIROL, V65, P1836, DOI 10.1128/JVI.65.4.1836-1842.1991; Bock CT, 1999, HEPATOLOGY, V29, P1236, DOI 10.1002/hep.510290426; Bruss V, 1996, INTERVIROLOGY, V39, P23, DOI 10.1159/000150471; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; Cho EW, 2001, J CELL SCI, V114, P1115; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; DEMEDINA T, 1988, MOL CELL BIOL, V8, P2449, DOI 10.1128/MCB.8.6.2449; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Fan YF, 2000, J GASTROEN HEPATOL, V15, P519, DOI 10.1046/j.1440-1746.2000.02187.x; Fan YF, 2001, HEPATOLOGY, V33, P277, DOI 10.1053/jhep.2001.21163; FERNHOLZ D, 1991, J HEPATOL, V13, pS102, DOI 10.1016/0168-8278(91)90036-B; FERNHOLZ D, 1993, VIROLOGY, V194, P137, DOI 10.1006/viro.1993.1243; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; GALLE PR, 1994, GASTROENTEROLOGY, V106, P664, DOI 10.1016/0016-5085(94)90700-5; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GANEM D, 1996, FIELDS VIROLOGY, V3, P2703; GERLICH WH, 1993, J HEPATOL, V17, pS10, DOI 10.1016/S0168-8278(05)80417-9; GILLES PN, 1992, HEPATOLOGY, V16, P655, DOI 10.1002/hep.1840160308; GUIDOTTI LG, 1994, J VIROL, V68, P5469, DOI 10.1128/JVI.68.9.5469-5475.1994; HILDT E, 1995, ONCOGENE, V11, P2055; HUANG JK, 1993, MOL CELL BIOL, V13, P7476, DOI 10.1128/MCB.13.12.7476; Huang TJ, 2001, BIOL REPROD, V64, P163, DOI 10.1095/biolreprod64.1.163; HUANG ZM, 1993, J VIROL, V67, P7032, DOI 10.1128/JVI.67.12.7032-7040.1993; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Kuo YL, 1997, DNA CELL BIOL, V16, P545, DOI 10.1089/dna.1997.16.545; KURAI K, 1989, HEPATOLOGY, V9, P175, DOI 10.1002/hep.1840090202; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LAUER U, 1994, HEPATOLOGY, V19, P23, DOI 10.1002/hep.1840190106; Le Seyec J, 1998, J VIROL, V72, P5573, DOI 10.1128/JVI.72.7.5573-5578.1998; Lin Xu, 2001, Journal of Medical Virology, V64, P299, DOI 10.1002/jmv.1050; LU CC, 1995, VIROLOGY, V206, P1155, DOI 10.1006/viro.1995.1042; Lu CC, 1996, VIROLOGY, V225, P387, DOI 10.1006/viro.1996.0613; Lu XY, 1996, J VIROL, V70, P2277, DOI 10.1128/JVI.70.4.2277-2285.1996; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Melegari M, 1997, J VIROL, V71, P5449, DOI 10.1128/JVI.71.7.5449-5454.1997; Moolla N, 2002, J VIRAL HEPATITIS, V9, P323, DOI 10.1046/j.1365-2893.2002.00381.x; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; OU JH, 1987, J VIROL, V61, P782, DOI 10.1128/JVI.61.3.782-786.1987; PERSING DH, 1986, SCIENCE, V234, P1388, DOI 10.1126/science.3787251; Pollicino T, 1997, HEPATOLOGY, V26, P495, DOI 10.1002/hep.510260235; RANEY AK, 1995, VIROLOGY, V208, P399, DOI 10.1006/viro.1995.1167; RANEY AK, 1992, J VIROL, V66, P6912, DOI 10.1128/JVI.66.12.6912-6921.1992; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIDDIQUI A, 1986, P NATL ACAD SCI USA, V83, P566, DOI 10.1073/pnas.83.3.566; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Sterneck M, 1998, J INFECT DIS, V177, P1378, DOI 10.1086/515269; Szmuness W, 1978, Prog Med Virol, V24, P40; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; YEN TSB, 1993, SEMIN VIROL, V4, P33; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873; ZHOU DX, 1991, J BIOL CHEM, V266, P23416; ZHOU DX, 1990, J BIOL CHEM, V265, P20731	58	9	10	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27742	27754		10.1074/jbc.M502209200	http://dx.doi.org/10.1074/jbc.M502209200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15899887	hybrid			2022-12-25	WOS:000230678600033
J	Sharma, S; Sommers, JA; Choudhary, S; Faulkner, JK; Cui, S; Andreoli, L; Muzzolini, L; Vindigni, A; Brosh, RM				Sharma, S; Sommers, JA; Choudhary, S; Faulkner, JK; Cui, S; Andreoli, L; Muzzolini, L; Vindigni, A; Brosh, RM			Biochemical analysis of the DNA unwinding and strand annealing activities catalyzed by human RECQ1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STALLED REPLICATION FORKS; SYNDROME PROTEIN; D-LOOPS; SUBSTRATE-SPECIFICITY; HOLLIDAY JUNCTIONS; SYNDROME HELICASE; ROTHMUND-THOMSON; BLOOMS; REPAIR; RECOMBINATION	RecQ helicases play an important role in preserving genomic integrity, and their cellular roles in DNA repair, recombination, and replication have been of considerable interest. Of the five human RecQ helicases identified, three are associated with genetic disorders characterized by an elevated incidence of cancer or premature aging: Werner syndrome, Bloom syndrome, and Rothmund-Thomson syndrome. Although the biochemical properties and protein interactions of the WRN and BLM helicases defective in Werner syndrome and Bloom syndrome, respectively, have been extensively investigated, less information is available concerning the functions of the other human RecQ helicases. We have focused our attention on human RECQ1, a DNA helicase whose cellular functions remain largely uncharacterized. In this work, we have characterized the DNA substrate specificity and optimal cofactor requirements for efficient RECQ1-catalyzed DNA unwinding and determined that RECQ1 has certain properties that are distinct from those of other RecQ helicases. RECQ1 stably bound to a variety of DNA structures, enabling it to unwind a diverse set of DNA substrates. In addition to its DNA binding and helicase activities, RECQ1 catalyzed efficient strand annealing between complementary single-stranded DNA molecules. The ability of RECQ1 to promote strand annealing was modulated by ATP binding, which induced a conformational change in the protein. The enzymatic properties of the RECQ1 helicase and strand annealing activities are discussed in the context of proposed cellular DNA metabolic pathways that are important in the maintenance of genomic stability.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); International Center for Genetic Engineering & Biotechnology (ICGEB)	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	BroshR@grc.nia.nih.gov	Cui, Sheng/AAQ-1721-2020; Sheng, CUI/M-6405-2013; Sharma, Sudha/AAV-6152-2021	Sheng, CUI/0000-0001-6329-3582; Sharma, Sudha/0000-0003-2765-2482	NATIONAL INSTITUTE ON AGING [ZIAAG000741, Z01AG000741] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2001, EMBO J, V20, P5791; Choudhary S, 2004, J BIOL CHEM, V279, P34603, DOI 10.1074/jbc.M401901200; Cobb JA, 2003, EMBO J, V22, P4325, DOI 10.1093/emboj/cdg391; Cobb JA, 2002, FEBS LETT, V529, P43, DOI 10.1016/S0014-5793(02)03269-6; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cui S, 2003, J BIOL CHEM, V278, P1424, DOI 10.1074/jbc.M209407200; Cui S, 2004, NUCLEIC ACIDS RES, V32, P2158, DOI 10.1093/nar/gkh540; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; Doherty KM, 2005, J BIOL CHEM, V280, P28085, DOI 10.1074/jbc.M500265200; Garcia PL, 2004, EMBO J, V23, P2882, DOI 10.1038/sj.emboj.7600301; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Harrigan JA, 2003, BIOCHIMIE, V85, P1185, DOI 10.1016/j.biochi.2003.10.006; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Johnson FB, 2000, CANCER RES, V60, P1162; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Khakhar RR, 2003, TRENDS CELL BIOL, V13, P493, DOI 10.1016/S0962-8924(03)00171-5; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; McVey M, 2004, GENETICS, V167, P699, DOI 10.1534/genetics.103.025411; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Orren DK, 2002, BIOCHEMISTRY-US, V41, P13483, DOI 10.1021/bi0266986; Ozsoy AZ, 2003, NUCLEIC ACIDS RES, V31, P1554, DOI 10.1093/nar/gkg243; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Tracy RB, 1997, GENE DEV, V11, P3423, DOI 10.1101/gad.11.24.3423; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; Wang WS, 2003, MOL CELL BIOL, V23, P3527, DOI 10.1128/MCB.23.10.3527-3535.2003; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yin JH, 2004, HUM MOL GENET, V13, P2421, DOI 10.1093/hmg/ddh269	46	145	147	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28072	28084		10.1074/jbc.M500264200	http://dx.doi.org/10.1074/jbc.M500264200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15899892	hybrid			2022-12-25	WOS:000230678600070
J	Flores-Diaz, M; Alape-Giron, A; Clark, G; Catimel, B; Hirabayashi, Y; Nice, E; Gutierrez, JM; Titball, R				Flores-Diaz, M; Alape-Giron, A; Clark, G; Catimel, B; Hirabayashi, Y; Nice, E; Gutierrez, JM; Titball, R			A cellular deficiency of gangliosides causes hypersensitivity to Clostridium perfringens phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN-LAYER CHROMATOGRAPHY; ALPHA-TOXIN; GAS-GANGRENE; BIOLOGICAL-ACTIVITIES; BILAYER VESICLES; MAMMALIAN-CELLS; KEY TOXIN; BIOSYNTHESIS; VIRULENCE; GLUCOSE	Clostridium perfringens phospholipase C (Cp-PLC), also called alpha-toxin, is the major virulence factor in the pathogenesis of gas gangrene. Previously, a cellular UDP-Glc deficiency was related with a hypersensitivity to the cytotoxic effect of Cp-PLC. Because UDP-Glc is required in the synthesis of proteoglycans, N-linked glycoproteins, and glycosphingolipids, the role of these glycoconjugates in the cellular sensitivity to Cp-PLC was studied. The cellular sensitivity to Cp-PLC was significantly enhanced by glycosphingolipid synthesis inhibitors, and a mutant cell line deficient in gangliosides was found to be hypersensitive to Cp-PLC. Gangliosides protected hypersensitive cells from the cytotoxic effect of Cp-PLC and prevented its membrane-disrupting effect on artificial membranes. Removal of sialic acids by C. perfringens sialidase increases the sensitivity of cultured cells to Cp-PLC and intramuscular co-injection of C. perfringens sialidase, and Cp-PLC in mice potentiates the myotoxic effect of the latter. This work demonstrated that a reduction in gangliosides renders cells more susceptible to the membrane damage caused by Cp-PLC and revealed a previously unrecognized synergism between Cp-PLC and C. perfringens sialidase, providing new insights toward understanding the pathogenesis of clostridial myonecrosis.	Univ Costa Rica, Fac Microbiol, Inst Clodomiro Picado, San Jose 2060, Costa Rica; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Costa Rica, Fac Med, Dept Bioquim, San Jose 2060, Costa Rica; Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England; PO Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; RIKEN, Inst Phys & Chem Res, Wako, Saitama 35101, Japan	Universidad Costa Rica; Karolinska Institutet; Universidad Costa Rica; Defence Science & Technology Laboratory; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; RIKEN	Alape-Giron, A (corresponding author), Univ Costa Rica, Fac Microbiol, Inst Clodomiro Picado, San Jose 2060, Costa Rica.	aalape@cariari.ucr.ac.cr	Nice, Edouard C/B-1026-2011; Gutiérrez, José/GSJ-1846-2022	Hirabayashi, Yoshio/0000-0002-5774-7354; Gutierrez, Jose Maria/0000-0001-8385-3081; CATIMEL, Bruno/0000-0002-4350-6875; Alape-Giron, Alberto/0000-0003-3934-8496				Alape-Giron A, 2000, EUR J BIOCHEM, V267, P5191, DOI 10.1046/j.1432-1327.2000.01588.x; AWAD MM, 1995, MOL MICROBIOL, V15, P191, DOI 10.1111/j.1365-2958.1995.tb02234.x; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Basanez G, 1996, BIOCHEMISTRY-US, V35, P7506, DOI 10.1021/bi953084a; Basu A, 2000, DIABETES, V49, P272, DOI 10.2337/diabetes.49.2.272; BIANCO ID, 1990, BIOCHIM BIOPHYS ACTA, V1026, P179, DOI 10.1016/0005-2736(90)90062-S; Bonadonna RC, 1996, DIABETES, V45, P915, DOI 10.2337/diabetes.45.7.915; Brade L, 2000, GLYCOBIOLOGY, V10, P629, DOI 10.1093/glycob/10.6.629; Bunting M, 1997, J CLIN INVEST, V100, P565, DOI 10.1172/JCI119566; Burke MP, 1999, AM J FOREN MED PATH, V20, P158, DOI 10.1097/00000433-199906000-00011; Catimel B, 1998, GLYCOBIOLOGY, V8, P927, DOI 10.1093/glycob/8.9.927; Clark GC, 2003, J MOL BIOL, V333, P759, DOI 10.1016/j.jmb.2003.07.016; Daniele JJ, 1996, EUR J BIOCHEM, V239, P105, DOI 10.1111/j.1432-1033.1996.0105u.x; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; DOHI T, 1988, CANCER RES, V48, P5680; Eaton JT, 2002, J MOL BIOL, V319, P275, DOI 10.1016/S0022-2836(02)00290-5; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Flores-Diaz M, 1998, J BIOL CHEM, V273, P24433, DOI 10.1074/jbc.273.38.24433; Flores-Diaz M, 2004, ANAEROBE, V10, P115, DOI 10.1016/j.anaerobe.2003.11.002; FloresDiaz M, 1997, J BIOL CHEM, V272, P23784, DOI 10.1074/jbc.272.38.23784; FLORIN I, 1991, MICROB PATHOGENESIS, V11, P337, DOI 10.1016/0882-4010(91)90019-7; GUARNACCIA SP, 1983, P NATL ACAD SCI-BIOL, V80, P1551, DOI 10.1073/pnas.80.6.1551; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Jepson M, 2001, FEBS LETT, V495, P172, DOI 10.1016/S0014-5793(01)02385-7; Jepson M, 1999, INFECT IMMUN, V67, P3297, DOI 10.1128/IAI.67.7.3297-3301.1999; Karasawa T, 2003, INFECT IMMUN, V71, P641, DOI 10.1128/IAI.71.2.641-646.2003; KAZUYA IP, 1996, J BIOL CHEM, V271, P14636; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; Liu WK, 2004, J CELL BIOCHEM, V91, P1159, DOI 10.1002/jcb.10755; LOMONTE B, 1994, TOXICON, V32, P1359, DOI 10.1016/0041-0101(94)90408-1; Lunn MPT, 2000, J NEUROCHEM, V75, P404, DOI 10.1046/j.1471-4159.2000.0750404.x; MAGGIO B, 1994, PROG BIOPHYS MOL BIO, V62, P55, DOI 10.1016/0079-6107(94)90006-X; MAGGIO B, 1994, BIOCHIM BIOPHYS ACTA, V199, P137; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Muthing J, 1997, GLYCOCONJUGATE J, V14, P19, DOI 10.1023/A:1018552729572; Muthing J, 1998, CARBOHYD RES, V307, P135, DOI 10.1016/S0008-6215(98)00027-5; Nagahama M, 1998, MICROBIOL IMMUNOL, V42, P533, DOI 10.1111/j.1348-0421.1998.tb02321.x; Nagahama M, 1996, BBA-BIOMEMBRANES, V1280, P120, DOI 10.1016/0005-2736(95)00288-X; Naylor CE, 1998, NAT STRUCT BIOL, V5, P738, DOI 10.1038/1447; Prydz K, 2000, J CELL SCI, V113, P193; ROGGENTIN P, 1995, BIOL CHEM H-S, V376, P569; ROGGENTIN T, 1993, J IMMUNOL METHODS, V157, P125, DOI 10.1016/0022-1759(93)90078-L; Rood JI, 1998, ANNU REV MICROBIOL, V52, P333, DOI 10.1146/annurev.micro.52.1.333; ROTHE B, 1991, MOL GEN GENET, V226, P190, DOI 10.1007/BF00273603; SCHAUER R, 1985, CLIN CHIM ACTA, V146, P119, DOI 10.1016/0009-8981(85)90050-6; Schwarzmann G, 2001, SEMIN CELL DEV BIOL, V12, P163, DOI 10.1006/scdb.2000.0233; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; SLEIGHT R, 1983, J BIOL CHEM, V258, P824; Songer JG, 1997, TRENDS MICROBIOL, V5, P156, DOI 10.1016/S0966-842X(97)01005-6; Stevens DL, 2000, INT J MED MICROBIOL, V290, P497; Stonehouse MJ, 2002, MOL MICROBIOL, V46, P661, DOI 10.1046/j.1365-2958.2002.03194.x; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Tettamanti G, 2003, GLYCOCONJUGATE J, V20, P301, DOI 10.1023/B:GLYC.0000033627.02765.cc; Titball RV, 1999, ANAEROBE, V5, P51, DOI 10.1006/anae.1999.0191; TITBALL RW, 1999, COMPREHENSIVE SOURCE, P310; TRAVING C, 1994, GLYCOCONJUGATE J, V11, P141, DOI 10.1007/BF00731154; Tsai B, 2003, EMBO J, V22, P4346, DOI 10.1093/emboj/cdg439; Vazquez-Boland JA, 2001, CLIN MICROBIOL REV, V14, P584, DOI 10.1128/CMR.14.3.584-640.2001; Walker N, 2000, ARCH BIOCHEM BIOPHYS, V384, P24, DOI 10.1006/abbi.2000.2065; WILLIAMSON ED, 1993, VACCINE, V11, P1253, DOI 10.1016/0264-410X(93)90051-X; Yu RK, 2000, METHOD ENZYMOL, V312, P115; YUSUF HKM, 1983, P NATL ACAD SCI-BIOL, V80, P7075, DOI 10.1073/pnas.80.23.7075; Zhao H, 2003, FASEB J, V17, P723, DOI 10.1096/fj.02-0806fje	64	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26680	26689		10.1074/jbc.M500278200	http://dx.doi.org/10.1074/jbc.M500278200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15919667	Green Published, hybrid			2022-12-25	WOS:000230589500008
J	Lee, SJ; Richardson, CC				Lee, SJ; Richardson, CC			Acidic residues in the nucleotide-binding site of the bacteriophage T7 DNA primase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PRIMASE; RNA-POLYMERASE DOMAIN; GENE 4 PROTEIN; CRYSTAL-STRUCTURE; PRIMER SYNTHESIS; TEMPLATE RECOGNITION; ANGSTROM RESOLUTION; HELICASE ACTIVITY; LINKER REGION; SEQUENCE	DNA primases catalyze the synthesis of oligoribonucleotides to initiate lagging strand DNA synthesis during DNA replication. Like other prokaryotic homologs, the primase domain of the gene 4 helicase-primase of bacteriophage T7 contains a zinc motif and a catalytic core. Upon recognition of the sequence, 5'-GTC-3' by the zinc motif, the catalytic site condenses the cognate nucleotides to produce a primer. The TOPRIM domain in the catalytic site contains several charged residues presumably involved in catalysis. Each of eight acidic residues in this region was replaced with alanine, and the properties of the altered primases were examined. Six of the eight residues (Glu-157, Glu-159, Asp-161, Asp-207, Asp-209, and Asp-237) are essential in that altered gene 4 proteins containing these mutations cannot complement T7 phage lacking gene 4 for T7 growth. These six altered gene 4 proteins can neither synthesize primers de novo nor extend an oligoribonucleotide. Despite the inability to catalyze phosphodiester bond formation, the altered proteins recognize the sequence 5'-GTC-3' in the template and deliver preformed primer to T7 DNA polymerase. The alterations in the TOPRIM domain result in the loss of binding affinity for ATP as measured by surface plasmon resonance assay together with ATP-agarose affinity chromatography.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	ccr@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54397] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Aravind L, 2002, CURR OPIN STRUC BIOL, V12, P392, DOI 10.1016/S0959-440X(02)00334-2; Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; Augustin MA, 2001, NAT STRUCT BIOL, V8, P57, DOI 10.1038/83060; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Frick DN, 1999, J BIOL CHEM, V274, P35889, DOI 10.1074/jbc.274.50.35889; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Frick DN, 1999, J BIOL CHEM, V274, P35899, DOI 10.1074/jbc.274.50.35899; Frick DN, 2001, ANNU REV BIOCHEM, V70, P39, DOI 10.1146/annurev.biochem.70.1.39; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Godson GN, 2000, BIOCHEMISTRY-US, V39, P332, DOI 10.1021/bi9916628; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Ito N, 2003, GENES CELLS, V8, P913, DOI 10.1111/j.1365-2443.2003.00693.x; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; Kato M, 2003, MOL CELL, V11, P1349, DOI 10.1016/S1097-2765(03)00195-3; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; Kusakabe T, 1999, P NATL ACAD SCI USA, V96, P4295, DOI 10.1073/pnas.96.8.4295; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee SJ, 2004, J BIOL CHEM, V279, P23384, DOI 10.1074/jbc.M400857200; Lee SJ, 2001, J BIOL CHEM, V276, P49419, DOI 10.1074/jbc.M108443200; Lee SJ, 2002, P NATL ACAD SCI USA, V99, P12703, DOI 10.1073/pnas.202471499; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; Podobnik M, 2000, J MOL BIOL, V300, P353, DOI 10.1006/jmbi.2000.3844; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STRACK B, 1992, J BIOL CHEM, V267, P13062; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752	35	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26984	26991		10.1074/jbc.M504817200	http://dx.doi.org/10.1074/jbc.M504817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917241	hybrid			2022-12-25	WOS:000230589500042
J	Mather, MW; Darrouzet, E; Valkova-Valchanova, M; Cooley, JW; McIntosh, MT; Daldal, F; Vaidya, AB				Mather, MW; Darrouzet, E; Valkova-Valchanova, M; Cooley, JW; McIntosh, MT; Daldal, F; Vaidya, AB			Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; PLASMODIUM-FALCIPARUM MALARIA; IRON-SULFUR PROTEIN; RHODOBACTER-CAPSULATUS; ELECTRON-TRANSFER; DOMAIN MOVEMENT; SACCHAROMYCES-CEREVISIAE; CONFERRING RESISTANCE; ENERGY-CONVERSION; OXIDATION SITE	Atovaquone is an antiparasitic drug that selectively inhibits electron transport through the parasite mitochondrial cytochrome bc(1) complex and collapses the mitochondrial membrane potential at concentrations far lower than those at which the mammalian system is affected. Because this molecule represents a new class of antimicrobial agents, we seek a deeper understanding of its mode of action. To that end, we employed site-directed mutagenesis of a bacterial cytochrome b, combined with biophysical and biochemical measurements. A large scale domain movement involving the iron-sulfur protein subunit is required for electron transfer from cytochrome b-bound ubihydroquinone to cytochrome c(1) of the cytochrome bc(1) complex. Here, we show that atovaquone blocks this domain movement by locking the iron-sulfur subunit in its cytochrome b-binding conformation. Based on our malaria atovaquone resistance data, a series of cytochrome b mutants was produced that were predicted to have either enhanced or reduced sensitivity to atovaquone. Mutations altering the bacterial cytochrome b at its ef loop to more closely resemble Plasmodium cytochrome b increased the sensitivity of the cytochrome bc(1) complex to atovaquone. A mutation within the ef loop that is associated with resistant malaria parasites rendered the complex resistant to atovaquone, thereby providing direct proof that the mutation causes atovaquone resistance. This mutation resulted in a 10-fold reduction in the in vitro activity of the cytochrome bc(1) complex, suggesting that it may exert a cost on efficiency of the cytochrome bc(1) complex.	Drexel Univ, Coll Med, Dept Microbiol & Immunol, Ctr Mol Parasitol, Philadelphia, PA 19129 USA; Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	Drexel University; University of Pennsylvania	Vaidya, AB (corresponding author), Drexel Univ, Coll Med, Dept Microbiol & Immunol, Ctr Mol Parasitol, 2900 Queen Lane, Philadelphia, PA 19129 USA.	av27@drexel.edu		Mather, Michael/0000-0002-1062-0137	NIAID NIH HHS [R56 AI028398, R01 AI028398] Funding Source: Medline; NIGMS NIH HHS [R01 GM038237] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI028398, R01AI028398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038237] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BEATTY JT, 1981, ARCH MICROBIOL, V129, P335, DOI 10.1007/BF00406457; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Berry EA, 2004, PHOTOSYNTH RES, V81, P251, DOI 10.1023/B:PRES.0000036888.18223.0e; Chiodini PL, 1995, J ANTIMICROB CHEMOTH, V36, P1073, DOI 10.1093/jac/36.6.1073; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2004, PHOTOSYNTH RES, V79, P25, DOI 10.1023/B:PRES.0000011926.47778.4e; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; Fivelman QL, 2004, ANTIMICROB AGENTS CH, V48, P4097, DOI 10.1128/AAC.48.11.4097-4102.2004; Fivelman Quinton L, 2002, Malar J, V1, P1; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P723, DOI 10.1021/bi00169a014; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Kessl JJ, 2004, J BIOL CHEM, V279, P2817, DOI 10.1074/jbc.M309984200; Kessl JJ, 2003, J BIOL CHEM, V278, P31312, DOI 10.1074/jbc.M304042200; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Korsinczky M, 2000, ANTIMICROB AGENTS CH, V44, P2100, DOI 10.1128/AAC.44.8.2100-2108.2000; Kublin JG, 2003, J INFECT DIS, V187, P1870, DOI 10.1086/375419; Lacy MD, 2002, CLIN INFECT DIS, V35, pE92, DOI 10.1086/343750; Ling J, 2002, CLIN INFECT DIS, V35, P825, DOI 10.1086/342578; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P533, DOI 10.4269/ajtmh.1999.60.533; Myllykallio H, 1999, P NATL ACAD SCI USA, V96, P4348, DOI 10.1073/pnas.96.8.4348; Peters JM, 2002, ANTIMICROB AGENTS CH, V46, P2435, DOI 10.1128/AAC.46.8.2435-2441.2002; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Saribas AS, 1998, BIOCHEMISTRY-US, V37, P8105, DOI 10.1021/bi973146s; Schutz M, 2000, J MOL BIOL, V300, P663, DOI 10.1006/jmbi.2000.3915; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; Srivastava IK, 1999, ANTIMICROB AGENTS CH, V43, P1334, DOI 10.1128/AAC.43.6.1334; Srivastava IK, 1997, J BIOL CHEM, V272, P3961, DOI 10.1074/jbc.272.7.3961; Syafruddin D, 1999, MOL BIOCHEM PARASIT, V104, P185, DOI 10.1016/S0166-6851(99)00148-6; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Valkova-Valchanova M, 2000, BIOCHEMISTRY-US, V39, P15484, DOI 10.1021/bi000751d; Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224; Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200; ZANNONI D, 1992, ARCH MICROBIOL, V157, P367, DOI 10.1007/BF00248683; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	43	69	73	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27458	27465		10.1074/jbc.M502319200	http://dx.doi.org/10.1074/jbc.M502319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917236	Green Accepted, hybrid			2022-12-25	WOS:000230589500098
J	Shirogane, T; Jin, JP; Ang, XL; Harper, JW				Shirogane, T; Jin, JP; Ang, XL; Harper, JW			SCF beta-TRCP controls Clock-dependent transcription via casein kinase 1-dependent degradation of the mammalian Period-1 (Per1) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-I-EPSILON; ANAPHASE-PROMOTING COMPLEX; UBIQUITIN-LIGASE COMPLEX; DROSOPHILA CIRCADIAN CLOCK; F-BOX PROTEINS; KAPPA-B-ALPHA; DESTRUCTION MOTIF; CKI-EPSILON; DOUBLE-TIME; GENE	Circadian rhythms are controlled by the periodic accumulation of Period proteins, which act as transcriptional repressors of Clock-dependent genes. Period genes are themselves Clock targets, thereby establishing a negative transcriptional feedback circuit controlling circadian periodicity. Previous data have implicated the CK1 epsilon isolog Doubletime (Dbt) and the F-box protein Slimb in the regulation of Drosophila Period ( Per) through an unknown mechanism. In this work, we have identified components of the machinery involved in regulating the abundance of human Per1 in tissue culture cells. CK1 epsilon and CK1 gamma 2 were found to bind to Per1 and to promote its degradation in an in vivo degradation assay. Per1 turnover was blocked by a dominant negative version of the Cul1 protein, a component of the SCF (Skp1-Cul1-F-box protein) ubiquitin ligase. We screened a panel of F-box proteins for those that would associate with Per1 in a CK1 epsilon-dependent manner, and we identified beta-TRCP1 and beta-TRCP2, isologs of the Drosophila Slimb protein. RNA interference against beta-transducin repeat-containing protein (beta-TRCP) stabilizes endogenous and exogenous Per1. beta-TRCP associates with sequences near the N terminus of Per1 in a region distinct from the previously characterized CK1 epsilon-binding site. beta-TRCP and CK1 epsilon promote Per1 ubiquitination in vitro. Finally, RNA interference against beta-TRCP greatly decreases Clock-dependent gene expression in tissue culture cells, indicating that beta-TRCP controls endogenous Per1 activity and the circadian clock by directly targeting Per1 for degradation.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Harper, JW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	wade_harper@hms.harvard.edu	Jin, Jianping/K-5002-2018; Cambronne, Xiaolu Ang/GRY-7149-2022	Jin, Jianping/0000-0003-4175-9104; Cambronne, Xiaolu Ang/0000-0002-3547-448X; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS054507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG011085, AG11085] Funding Source: Medline; NINDS NIH HHS [F31 NS054507, F31 NS054507-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 2004, DEV CELL, V6, P160, DOI 10.1016/S1534-5807(04)00030-9; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Grima B, 2002, NATURE, V420, P178, DOI 10.1038/nature01122; Hansen DV, 2004, MOL BIOL CELL, V15, P5623, DOI 10.1091/mbc.E04-07-0598; Hastings MH, 2004, J BIOL RHYTHM, V19, P400, DOI 10.1177/0748730404268786; He Q, 2003, EMBO J, V22, P4421, DOI 10.1093/emboj/cdg425; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JIN J, 2005, IN PRESS METHODS ENZ; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Ko HW, 2002, NATURE, V420, P673, DOI 10.1038/nature01272; Kumar KGS, 2003, EMBO J, V22, P5480; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee C, 2004, MOL CELL BIOL, V24, P584, DOI 10.1128/MCB.24.2.584-594.2004; Lin JM, 2002, NATURE, V420, P816, DOI 10.1038/nature01235; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; Nawathean P, 2004, MOL CELL, V13, P213, DOI 10.1016/S1097-2765(03)00503-3; Okamura H, 2004, J BIOL RHYTHM, V19, P388, DOI 10.1177/0748730404269169; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Panda S, 2004, J BIOL RHYTHM, V19, P374, DOI 10.1177/0748730404269008; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Shigeyoshi Y, 2002, GENES CELLS, V7, P163, DOI 10.1046/j.1356-9597.2001.00503.x; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Tung JJ, 2005, P NATL ACAD SCI USA, V102, P4318, DOI 10.1073/pnas.0501108102; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	62	209	227	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26863	26872		10.1074/jbc.M502862200	http://dx.doi.org/10.1074/jbc.M502862200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917222	hybrid			2022-12-25	WOS:000230589500028
J	Taggart, AKP; Kero, J; Gan, XD; Cai, TQ; Cheng, K; Ippolito, M; Ren, N; Kaplan, R; Wu, K; Wu, TJ; Jin, L; Liaw, C; Chen, RP; Richman, J; Connolly, D; Offermanns, S; Wright, SD; Waters, MG				Taggart, AKP; Kero, J; Gan, XD; Cai, TQ; Cheng, K; Ippolito, M; Ren, N; Kaplan, R; Wu, K; Wu, TJ; Jin, L; Liaw, C; Chen, RP; Richman, J; Connolly, D; Offermanns, S; Wright, SD; Waters, MG			(D)-beta-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KETONE-BODY METABOLISM; CHAIN FATTY-ACIDS; ADIPOSE-TISSUE; MOLECULAR-IDENTIFICATION; BODIES	As a treatment for dyslipidemia, oral doses of 1-3 grams of nicotinic acid per day lower serum triglycerides, raise high density lipoprotein cholesterol, and reduce mortality from coronary heart disease (Tavintharan, S., and Kashyap, M. L. (2001) Curr. Atheroscler. Rep. 3, 74-82). These benefits likely result from the ability of nicotinic acid to inhibit lipolysis in adipocytes and thereby reduce serum non-esterified fatty acid levels (Carlson, L. A. (1963) Acta Med. Scand. 173, 719-722). In mice, nicotinic acid inhibits lipolysis via PUMA-G, a G(i/o)-coupled seven-transmembrane receptor expressed in adipocytes and activated macrophages (Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., and Offermanns, S. (2003) Nat. Med. 9, 352-355). The human ortholog HM74a is also a nicotinic acid receptor and likely has a similar role in anti-lipolysis. Endogenous levels of nicotinic acid are too low to significantly impact receptor activity, hence the natural ligands(s) of HM74a/PUMA-G remain to be elucidated. Here we show that the fatty acid-derived ketone body (D)-beta-hydroxybutyrate ((D)-beta-OHB) specifically activates PUMA-G/HM74a at concentrations observed in serum during fasting. Like nicotinic acid, (D)-beta-OHB inhibits mouse adipocyte lipolysis in a PUMA-G-dependent manner and is thus the first endogenous ligand described for this orphan receptor. These findings suggests a homeostatic mechanism for surviving starvation in which (D)-beta-OHB negatively regulates its own production, thereby preventing ketoacidosis and promoting efficient use of fat stores.	Merck Res Labs, Dept Cardiovasc Dis, Div Cardiovasc Dis, Rahway, NJ 07065 USA; Heidelberg Univ, Inst Pharmacol, D-69120 Heidelberg, Germany; Arena Pharmaceut Inc, San Diego, CA 92121 USA	Merck & Company; Ruprecht Karls University Heidelberg	Taggart, AKP (corresponding author), Merck Res Labs, Dept Cardiovasc Dis, Div Cardiovasc Dis, 126 E Lincoln Ave, Rahway, NJ 07065 USA.	andy_taggart@merck.com	kero, jukka/G-3448-2014; Offermanns, Stefan/L-3313-2017	kero, jukka/0000-0001-8767-7222; Offermanns, Stefan/0000-0001-8676-6805				BATES MW, 1976, METABOLISM, V25, P685, DOI 10.1016/0026-0495(76)90066-4; BJORNTOR.P, 1966, METABOLIS, V15, P191, DOI 10.1016/0026-0495(66)90016-3; BJORNTORP P, 1966, J LIPID RES, V7, P621; BJORNTORP P, 1967, AM J PHYSIOL, V212, P683, DOI 10.1152/ajplegacy.1967.212.3.683; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; CARLSON LA, 1963, ACTA MED SCAND, V173, P719; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; FELIG P, 1970, NEW ENGL J MED, V282, P166; Fukao T, 2004, PROSTAG LEUKOTR ESS, V70, P243, DOI 10.1016/j.plefa.2003.11.001; Laffel L, 1999, DIABETES-METAB RES, V15, P412, DOI 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Lee DK, 2001, GENE, V275, P83, DOI 10.1016/S0378-1119(01)00651-5; METZ SHM, 1974, FEBS LETT, V47, P19, DOI 10.1016/0014-5793(74)80416-3; OWEN OE, 1975, ISRAEL J MED SCI, V11, P560; Pike Nicholas B, 2004, Curr Opin Investig Drugs, V5, P271; RODBELL M, 1964, J BIOL CHEM, V239, P375; SENIOR B, 1968, NATURE, V219, P83, DOI 10.1038/219083a0; Soga T, 2003, BIOCHEM BIOPH RES CO, V303, P364, DOI 10.1016/S0006-291X(03)00342-5; Tavintharan S, 2001, Curr Atheroscler Rep, V3, P74, DOI 10.1007/s11883-001-0014-y; Tunaru S, 2003, NAT MED, V9, P352, DOI 10.1038/nm824; Van Hove JLK, 2003, LANCET, V361, P1433, DOI 10.1016/S0140-6736(03)13105-4; Wise A, 2003, J BIOL CHEM, V278, P9869, DOI 10.1074/jbc.M210695200; Xiong YM, 2004, P NATL ACAD SCI USA, V101, P1045, DOI 10.1073/pnas.2637002100	23	406	425	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26649	26652		10.1074/jbc.C500213200	http://dx.doi.org/10.1074/jbc.C500213200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15929991	hybrid			2022-12-25	WOS:000230589500004
J	Cipollo, JF; Awad, AM; Costello, CE; Hirschberg, CB				Cipollo, JF; Awad, AM; Costello, CE; Hirschberg, CB			N-glycans of Caenorhabditis elegans are specific to developmental stages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; MOLECULAR-CLONING; OLIGOSACCHARIDES; EXPRESSION; GLYCOSYLATION; BINDING	We have examined the N-glycans present during the developmental stages of Caenorhabditis elegans using two approaches, 1) a combination of permethylation followed by MALDI-TOF mass spectrometry (MS) and 2) derivatization with 2-aminobenzamide followed by separation by high-performance liquid chromatography and analyses by MALDI-TOF MS, post source decay (PSD) MS, and MALDI-QoTOF MS/MS. The N-glycan profile of each developmental stage ( Larva 1, Larva 2, Larva 3, Larva 4, and Dauer and adult) appears to be unique. The pattern of complex N-glycans was stage-specific with the general trend of number and abundance of glycans being Dauer approximate to L1 > adult approximate to L4 > L3 approximate to L2. Dauer larvae contained complex N-glycans with higher molecular masses than those seen in other stages. MALDI-QoTOF MS/MS of Hex(4)HexNAc(4) showed an N-acetyllactosamine substitution not previously observed in C. elegans. Phosphorylcholine (Pc)-substituted glycans were also found to be stage-specific. Higher molecular weight Pc-containing glycans, including fucose-containing ones such as difucosyl Pc-glycan (Pc(1)dHex(2)Hex(5)HexNAc(6)) seen in Dauer larvae, have not been observed in any organism. Pc(2)Hex(4)HexNAc(3), from Dauer larvae, when subjected to PSD MS analyses, showed Pc may substitute both core and terminally linked GlcNAc; no such structure has previously been reported in any organism. C. elegans-specific fucosyl and native methylated glycans were found in all developmental stages. Taken together, the above results demonstrate that in-depth investigation of the role of the above N-glycans during C. elegans development should lead to a better understanding of their significance and the ways that they may govern interactions, both within the organism during development and between the mobile nematode and its pathogens.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Mass Spectrometry Resource, Boston, MA 02118 USA	Boston University; Boston University	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, 715 Albany St,Evans 437, Boston, MA 02118 USA.	chirschb@bu.edu		Hirschberg, Carlos/0000-0003-2299-7721; Costello, Catherine/0000-0003-1594-5122	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015942, P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030365, F32GM066486] Funding Source: NIH RePORTER; NCRR NIH HHS [S10-RR15942, P41-RR10888] Funding Source: Medline; NIGMS NIH HHS [R01-GM30365, F32 GM66486] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; Chen SH, 1999, J BIOL CHEM, V274, P288, DOI 10.1074/jbc.274.1.288; Chen SH, 2002, BBA-GEN SUBJECTS, V1573, P271, DOI 10.1016/S0304-4165(02)00393-8; Cipollo JF, 2002, J BIOL CHEM, V277, P49143, DOI 10.1074/jbc.M208020200; Cipollo JF, 2004, J BIOL CHEM, V279, P52893, DOI 10.1074/jbc.M409557200; Cipollo JF, 2004, P NATL ACAD SCI USA, V101, P3404, DOI 10.1073/pnas.0400384101; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DeBose-Boyd RA, 1998, GLYCOBIOLOGY, V8, P905, DOI 10.1093/glycob/8.9.905; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Epstein H F, 1995, CAENORHABDITIS ELEGA; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; GERWIG GJ, 1989, J BIOL CHEM, V264, P1027; Gorelik E, 2001, CANCER METAST REV, V20, P245, DOI 10.1023/A:1015535427597; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Harris TW, 2004, NUCLEIC ACIDS RES, V32, pD411, DOI 10.1093/nar/gkh066; Harvey DJ, 1999, MASS SPECTROM REV, V18, P349, DOI 10.1002/(SICI)1098-2787(1999)18:6<349::AID-MAS1>3.3.CO;2-8; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; Haslam SM, 1999, J BIOL CHEM, V274, P20953, DOI 10.1074/jbc.274.30.20953; Haslam SM, 2003, BIOCHIMIE, V85, P25, DOI 10.1016/S0300-9084(03)00041-5; Haslam SM, 2002, BIOCHEM SOC SYMP, V69, P117; Haslam SM, 1998, MOL BIOCHEM PARASIT, V93, P143, DOI 10.1016/S0166-6851(98)00020-6; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; Khoo KH, 2001, GLYCOBIOLOGY, V11, P149, DOI 10.1093/glycob/11.2.149; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; Natsuka S, 2002, J BIOCHEM, V131, P807, DOI 10.1093/oxfordjournals.jbchem.a003169; Nyame AK, 1998, GLYCOBIOLOGY, V8, P615, DOI 10.1093/glycob/8.6.615; Routier FH, 1998, J IMMUNOL METHODS, V213, P113, DOI 10.1016/S0022-1759(98)00032-5; Schachter H, 2002, BIOCHEM SOC SYMP, V69, P1; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Tomiya N, 2004, GLYCOCONJUGATE J, V21, P343, DOI 10.1023/B:GLYC.0000046275.28315.87; VANKUIK JA, 1987, EUR J BIOCHEM, V169, P399; Verostek MF, 2000, ANAL BIOCHEM, V278, P111, DOI 10.1006/abio.1999.4433; Warren CE, 2002, J BIOL CHEM, V277, P22829, DOI 10.1074/jbc.M201390200; Watanabe T, 2000, BIOL PHARM BULL, V23, P269; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931; ZHU Z, 2004, BIOCHEM J, V382, P995	37	78	79	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26063	26072		10.1074/jbc.M503828200	http://dx.doi.org/10.1074/jbc.M503828200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899899	hybrid			2022-12-25	WOS:000230386800016
J	Li, CH; Tzeng, SL; Cheng, YW; Kang, JJ				Li, CH; Tzeng, SL; Cheng, YW; Kang, JJ			Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CYTOCHROME-C; CANCER CELLS; SENESCENCE; DEATH; P21(WAF1); DNA; P21(CIP1/WAF1); REQUIREMENT; SUPPRESSION	Pretreatment of HepG2 and H1299 cells with chloramphenicol rendered the cells resistant to mitomycin-induced apoptosis. Both mitomycin-induced caspase 3 activity and PARP activation were also inhibited. The mitochondrial DNA-encoded Cox I protein, but not nuclear-encoded proteins, was down-regulated in chloramphenicol-treated cells. Cellular levels of the p21(waf1/cip1) protein and p21(waf1/cip1) mRNA were increased through a p53-independent pathway, possibly because of the stabilization of p(21waf1/cip1) mRNA in chloramphenicol-treated cells. The p(21waf1/cip1) was redistributed from the perinuclear region to the cytoplasm and co-localized with mitochondrial marker protein. Several morphological changes and activation of the senescence-associated biomarker, SA beta-galactosidase, were observed in these cells. Both p21(waf1/cip1) antisense and small interfering RNA could restore apoptotic-associated caspase 3 activity, PARP activation, and sensitivity to mitomycin-induced apoptosis. Similar effects were seen with other antibiotics that inhibit mitochondrial translation, including minocycline, doxycycline, and clindamycin. These findings suggested that mitochondrial stress causes resistance to apoptosis through a p21-dependent pathway.	Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 100, Taiwan	National Taiwan University	Kang, JJ (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, 1 Jenai Rd,Sect 1, Taipei 100, Taiwan.	jjkang@ha.mc.ntu.edu.tw		KANG, JAW-JOU/0000-0002-6350-3997				Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cowan DB, 2003, ARTERIOSCL THROM VAS, V23, P1754, DOI 10.1161/01.ATV.0000093546.10162.B2; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gartel AL, 2002, MOL CANCER THER, V1, P639; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Hammett-Stabler CA, 1998, CLIN CHEM, V44, P1129; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hirsch CL, 2004, FEBS LETT, V570, P37, DOI 10.1016/j.febslet.2004.06.018; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Karbowski M, 1999, BBA-MOL CELL RES, V1449, P25, DOI 10.1016/S0167-4889(98)00167-0; Kasten MJ, 1999, MAYO CLIN PROC, V74, P825, DOI 10.4065/74.8.825; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAFARGEFRAYSSINET C, 1994, MUTAT RES, V320, P207, DOI 10.1016/0165-1218(94)90047-7; Lee CC, 2002, CHEM RES TOXICOL, V15, P1534, DOI 10.1021/tx0255727; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Liu J, 2000, J BIOL CHEM, V275, P11846, DOI 10.1074/jbc.275.16.11846; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MORAIS R, 1994, CANCER RES, V54, P3889; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Park JW, 2001, BIOCHEM BIOPH RES CO, V280, P244, DOI 10.1006/bbrc.2000.4105; Pfeuty A, 2000, FEBS LETT, V468, P43, DOI 10.1016/S0014-5793(00)01188-1; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Ramachandran A, 2002, P NATL ACAD SCI USA, V99, P6643, DOI 10.1073/pnas.102019899; RobbanaBarnat S, 1997, DRUG CHEM TOXICOL, V20, P239, DOI 10.3109/01480549709003880; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Scarabelli TM, 2004, J AM COLL CARDIOL, V43, P865, DOI 10.1016/j.jacc.2003.09.050; Soldner F, 1999, EXP CELL RES, V250, P75, DOI 10.1006/excr.1999.4504; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; Suh Y, 2002, MECH AGEING DEV, V123, P881, DOI 10.1016/S0047-6374(02)00025-8; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Tonomura N, 2003, J IMMUNOL, V170, P2469, DOI 10.4049/jimmunol.170.5.2469; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Xu D, 2002, BIOCHEM BIOPH RES CO, V294, P245, DOI 10.1016/S0006-291X(02)00464-3; Yoon G, 2002, BIOCHEM J, V366, P613, DOI 10.1042/BJ20011445; Yoon YS, 2003, J BIOL CHEM, V278, P51577, DOI 10.1074/jbc.M308489200; You HH, 2002, MOL CARCINOGEN, V33, P228, DOI 10.1002/mc.10040; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	50	43	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26193	26199		10.1074/jbc.M501371200	http://dx.doi.org/10.1074/jbc.M501371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15905168	hybrid			2022-12-25	WOS:000230386800033
J	Uesugi, Y; Mori, K; Arima, J; Iwabuchi, M; Hatanaka, T				Uesugi, Y; Mori, K; Arima, J; Iwabuchi, M; Hatanaka, T			Recognition of phospholipids in Streptomyces phospholipase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC CONVERSION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; D SUPERFAMILY; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; THERMOSTABILITY; INTERMEDIATE; MUTAGENESIS; MECHANISM	To investigate the contribution of amino acid residues to the enzyme reaction of Streptomyces phospholipase D (PLD), we constructed a chimeric gene library between two highly homologous plds, which indicated different activity in transphosphatidylation, using RIBS (repeat-length independent and broad spectrum) in vivo DNA shuffling. By comparing the activities of chimeras, six candidate residues related to transphosphatidylation activity were shown. Based on the above result, we constructed several mutants to identify the key residues involved in the recognition of phospholipids. By kinetic analysis, we identified that Gly(188) and Asp(191) of PLD from Streptomyces septatus TH-2, which are not present in the highly conserved catalytic HXKXXXXD (HKD) motifs, are key amino acid residues related to the transphosphatidylation activity. To investigate the role of two residues in the recognition of phospholipids, the effects of these residues on binding to substrates were analyzed by surface plasmon spectroscopy. The result suggests that Gly(188) and Asp(191) are involved in the recognition of phospholipids in correlation with the N-terminal HKD motif. Furthermore, this study also provides experimental evidence that the N-terminal HKD motif contains the catalytic nucleophile, which attacks the phosphatidyl group of the substrate.	Res Inst Biol Sci, Okayama 7161241, Japan		Hatanaka, T (corresponding author), Res Inst Biol Sci, 7549-1 Kibichuocho, Okayama 7161241, Japan.	hatanaka@bio-ribs.com	Mori, Koichi/ABC-7268-2021; MORI, Koichi/B-2567-2011	Mori, Koichi/0000-0001-8865-2107; 				Aikens CL, 2004, PROTEINS, V57, P27, DOI 10.1002/prot.20180; DARRIGO P, 1995, ANAL CHIM ACTA, V304, P249, DOI 10.1016/0003-2670(94)00613-Q; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; Hagishita T, 2000, BIOTECHNOL LETT, V22, P1587, DOI 10.1023/A:1005644032415; Hatanaka T, 2004, BBA-PROTEINS PROTEOM, V1696, P75, DOI 10.1016/j.bbapap.2003.09.013; Hatanaka T, 2002, ENZYME MICROB TECH, V31, P233, DOI 10.1016/S0141-0229(02)00121-7; Hatanaka T, 2002, BBA-PROTEINS PROTEOM, V1598, P156, DOI 10.1016/S0167-4838(02)00363-1; Hirche F, 1997, ENZYME MICROB TECH, V20, P453, DOI 10.1016/S0141-0229(97)00172-5; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; JUNEJA LR, 1989, BIOCHIM BIOPHYS ACTA, V1003, P277, DOI 10.1016/0005-2760(89)90233-6; JUNEJA LR, 1987, APPL MICROBIOL BIOT, V27, P146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leiros I, 2000, STRUCTURE, V8, P655, DOI 10.1016/S0969-2126(00)00150-7; Leiros I, 2004, J MOL BIOL, V339, P805, DOI 10.1016/j.jmb.2004.04.003; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Mishima N, 1997, BIOTECHNOL PROGR, V13, P864, DOI 10.1021/bp970084o; Mori K, 2005, APPL ENVIRON MICROB, V71, P754, DOI 10.1128/AEM.71.2.754-760.2005; RAETZ CRH, 1987, BIOCHEMISTRY-US, V26, P4022, DOI 10.1021/bi00387a042; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TAKAHARA M, 1993, Patent No. 993252935A1; TAKAMI M, 1994, BIOSCI BIOTECH BIOCH, V58, P1716, DOI 10.1271/bbb.58.1716; Waite M, 1999, BBA-MOL CELL BIOL L, V1439, P187, DOI 10.1016/S1388-1981(99)00094-3; Xie Z, 2000, J BIOL CHEM, V275, P24962, DOI 10.1074/jbc.M909745199; Yang HY, 2003, PROTEIN SCI, V12, P2087, DOI 10.1110/ps.03192503; Yang HY, 2002, PROTEIN SCI, V11, P2958, DOI 10.1110/ps.0225302; Zambonelli C, 2003, J BIOL CHEM, V278, P52282, DOI 10.1074/jbc.M310252200	31	20	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26143	26151		10.1074/jbc.M414319200	http://dx.doi.org/10.1074/jbc.M414319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899903	hybrid			2022-12-25	WOS:000230386800027
J	Kola, B; Hubina, E; Tucci, SA; Kirkham, TC; Garcia, EA; Mitchell, SE; Williams, LM; Hawley, SA; Hardie, DG; Grossman, AB; Korbonits, M				Kola, B; Hubina, E; Tucci, SA; Kirkham, TC; Garcia, EA; Mitchell, SE; Williams, LM; Hawley, SA; Hardie, DG; Grossman, AB; Korbonits, M			Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE SECRETAGOGUE RECEPTOR; FATTY-ACID OXIDATION; FOOD-INTAKE; MESSENGER-RNA; PEPTIDE GHRELIN; GENE-EXPRESSION; ADIPOSE-TISSUE; HEART-FAILURE; ENERGY STATUS; RAT-HEART	Endocannabinoids and ghrelin are potent appetite stimulators and are known to interact at a hypothalamic level. However, both also have important peripheral actions, including beneficial effects on the ischemic heart and increasing adipose tissue deposition, while ghrelin has direct effects on carbohydrate metabolism. The AMP-activated protein kinase ( AMPK) is a heterotrimeric enzyme that functions as a fuel sensor to regulate energy balance at both cellular and whole body levels, and it may mediate the action of anti-diabetic drugs such as metformin and peroxisome proliferator-activated receptor gamma agonists. Here we show that both cannabinoids and ghrelin stimulate AMPK activity in the hypothalamus and the heart, while inhibiting AMPK in liver and adipose tissue. These novel effects of cannabinoids on AMPK provide a mechanism for a number of their known actions, such as the reduction in infarct size in the myocardium, an increase in adipose tissue, and stimulation of appetite. The beneficial effects of ghrelin on heart function, including reduction of myocyte apoptosis, and its effects on lipogenesis and carbohydrate metabolism, can also be explained by its ability to activate AMPK. Our data demonstrate that AMPK not only links the orexigenic effects of endocannabinoids and ghrelin in the hypothalamus but also their effects on the metabolism of peripheral tissues.	Barts & London Med Sch, Dept Endocrinol, John Vane Sci Ctr, William Harvey Res Inst, London EC1M 6BQ, England; Univ Ancona, Dept Internal Med, I-60100 Ancona, Italy; Univ Liverpool, Dept Psychol, Liverpool L69 7ZA, Merseyside, England; Rowett Res Inst, Aberdeen AB21 9SB, Scotland; Univ Dundee, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of London; Queen Mary University London; Marche Polytechnic University; University of Liverpool; University of Aberdeen; University of Dundee	Korbonits, M (corresponding author), Barts & London Med Sch, Dept Endocrinol, John Vane Sci Ctr, William Harvey Res Inst, Rm 114C,Charterhouse Sq, London EC1M 6BQ, England.	m.korbonits@qmul.ac.uk	Hardie, David/Z-1979-2019	Korbonits, Marta/0000-0002-4101-9432; Hardie, Grahame/0000-0002-8373-7379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200; Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Barazzoni R, 2005, AM J PHYSIOL-ENDOC M, V288, pE228, DOI 10.1152/ajpendo.00115.2004; Batkai S, 2004, AM J PHYSIOL-HEART C, V287, pH595, DOI 10.1152/ajpheart.00184.2004; Bensaid M, 2003, MOL PHARMACOL, V63, P908, DOI 10.1124/mol.63.4.908; Camina JP, 2004, ENDOCRINOLOGY, V145, P930, DOI 10.1210/en.2003-0974; Chang L, 2004, J CARDIOVASC PHARM, V43, P165, DOI 10.1097/00005344-200402000-00001; Cheng J, 1997, LIFE SCI, V60, P1385, DOI 10.1016/S0024-3205(96)00655-8; Choi KC, 2003, ENDOCRINOLOGY, V144, P754, DOI 10.1210/en.2002-220783; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Frascarelli S, 2003, BASIC RES CARDIOL, V98, P401, DOI 10.1007/s00395-003-0434-7; Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988; Gomez R, 2002, J NEUROSCI, V22, P9612; Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5; GUZMAN M, 1995, BIOCHEM PHARMACOL, V50, P885, DOI 10.1016/0006-2952(95)00198-9; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 2004, J CLIN INVEST, V114, P465, DOI 10.1172/JCI200422683; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hiley CR, 2004, BIOL REV, V79, P187, DOI 10.1017/S1464793103006201; Iglesias MJ, 2004, CARDIOVASC RES, V62, P481, DOI 10.1016/j.cardiores.2004.01.024; Jamshidi N, 2001, BRIT J PHARMACOL, V134, P1151, DOI 10.1038/sj.bjp.0704379; Joyeux M, 2002, CARDIOVASC RES, V55, P619, DOI 10.1016/S0008-6363(02)00268-7; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200; Kirkham TC, 2002, BRIT J PHARMACOL, V136, P550, DOI 10.1038/sj.bjp.0704767; Kirkham Tim C, 2004, Treat Endocrinol, V3, P345, DOI 10.2165/00024677-200403060-00003; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Korbonits M, 2004, FRONT NEUROENDOCRIN, V25, P27, DOI 10.1016/j.yfrne.2004.03.002; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; Lee K, 2005, ENDOCRINOLOGY, V146, P3, DOI 10.1210/en.2004-0968; Lihn A, 2004, BIOCHEM BIOPH RES CO, V316, P853, DOI 10.1016/j.bbrc.2004.02.139; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Murata M, 2002, J BIOL CHEM, V277, P5667, DOI 10.1074/jbc.M103898200; Nagaya N, 2003, REGUL PEPTIDES, V114, P71, DOI 10.1016/S0167-0115(03)00117-4; Nogueiras R, 2004, DIABETES, V53, P2552, DOI 10.2337/diabetes.53.10.2552; Orkin RD, 2003, J ENDOCRINOL INVEST, V26, P743, DOI 10.1007/BF03347357; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Poirier B, 2005, DIABETES OBES METAB, V7, P65, DOI 10.1111/j.1463-1326.2004.00374.x; RAVINETTRILLOU C, 2003, AM J PHYSIOL-REG I, V284, pR345; ROMERO J, 1995, PHARMACOL BIOCHEM BE, V51, P731, DOI 10.1016/0091-3057(95)00023-P; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Sabbah HN, 2001, CARDIOVASC DRUG THER, V15, P525, DOI 10.1023/A:1013719821673; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Sugden C, 1999, PLANT J, V19, P433, DOI 10.1046/j.1365-313X.1999.00532.x; THOMPSON NM, 2004, ENDOCRINOLOGY, V145, P232; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Tucci SA, 2004, BRIT J PHARMACOL, V143, P520, DOI 10.1038/sj.bjp.0705968; Weekers F, 2000, ENDOCRINOLOGY, V141, P3993, DOI 10.1210/en.141.11.3993; Williams CM, 2002, PHARMACOL BIOCHEM BE, V71, P333, DOI 10.1016/S0091-3057(01)00694-3; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	58	376	403	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25196	25201		10.1074/jbc.C500175200	http://dx.doi.org/10.1074/jbc.C500175200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15899896	hybrid			2022-12-25	WOS:000230114000104
J	Bentwich, I				Bentwich, I			A postulated role for microRNA in cellular differentiation	FASEB JOURNAL			English	Article						embryogenesis; UTR; genomic module; protein coding genes; microRNA gene cluster	POSTTRANSCRIPTIONAL REGULATION; GERM-CELLS; P-GRANULES; RNAS; TRANSCRIPTOME; SEQUENCES; EXPRESSION; DENSITY; ENCODES; PATTERN	Over the past two decades a variety of mechanisms regulating cellular differentiation have been uncovered. These include signaling by morphogens or membrane-associated ligands and asymmetric segregation of cytoplasmic components. Most of these processes are driven by protein coding genes. Here I describe another possible cellular differentiation mechanism that involves asymmetric segregation of micro RNAs, a group of recently discovered non-protein coding genes that have been shown to be involved in differentiation.-Bentwich, I. A postulated role for microRNA in cellular differentiation.	Rosetta Genom, IL-76706 Rehovot, Israel		Bentwich, I (corresponding author), Rosetta Genom, 10 Plaut St, IL-76706 Rehovot, Israel.	bentwich@rosettagenomics.com						Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; [Anonymous], ART GENES ORGANISMS; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cook T, 2003, BIOESSAYS, V25, P921, DOI 10.1002/bies.10356; CRICK FHC, 1966, SCI AM, V215, P55, DOI 10.1038/scientificamerican1066-55; Davidson E. H., 2001, DEV EVOLUTION; Dubrulle J, 2004, NATURE, V427, P419, DOI 10.1038/nature02216; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; Duret L, 1997, CURR OPIN STRUC BIOL, V7, P399, DOI 10.1016/S0959-440X(97)80058-9; Hobert O, 2004, TRENDS BIOCHEM SCI, V29, P462, DOI 10.1016/j.tibs.2004.07.001; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; Mattick JS, 2003, BIOESSAYS, V25, P930, DOI 10.1002/bies.10332; Meehan RR, 2003, SEMIN CELL DEV BIOL, V14, P53, DOI 10.1016/S1084-9521(02)00137-4; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; PAGEL M, 1992, P ROY SOC B-BIOL SCI, V249, P119, DOI 10.1098/rspb.1992.0093; Paratore C, 2002, INT J DEV BIOL, V46, P193; Pitt JN, 2000, DEV BIOL, V219, P315, DOI 10.1006/dbio.2000.9607; Podbilewicz B, 2003, DEV CELL, V5, P5, DOI 10.1016/S1534-5807(03)00202-8; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Schisa JA, 2001, DEVELOPMENT, V128, P1287; Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171; Shabalina SA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-105; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Tjaden B, 2002, NUCLEIC ACIDS RES, V30, P3732, DOI 10.1093/nar/gkf505; Versteeg R, 2003, GENOME RES, V13, P1998, DOI 10.1101/gr.1649303; Voas MG, 2004, DEV DYNAM, V229, P162, DOI 10.1002/dvdy.10449; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	39	34	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					875	879		10.1096/fj.04-3609hyp	http://dx.doi.org/10.1096/fj.04-3609hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923397				2022-12-25	WOS:000230207800034
J	Bibillo, A; Lener, D; Tewari, A; Le Grice, SFJ				Bibillo, A; Lener, D; Tewari, A; Le Grice, SFJ			Interaction of the Ty3 reverse transcriptase thumb subdomain with template-primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DOUBLE-STRANDED DNA; POLYMERASE ACTIVE-SITE; GROOVE-BINDING TRACK; VERTICAL-SCANNING MUTAGENESIS; NUCLEIC ACID INTERACTIONS; MURINE LEUKEMIA-VIRUS; RNASE-H DOMAIN; POLYPURINE TRACT; MINOR-GROOVE	Amino acid sequence alignment was used to identify the putative thumb subdomain of reverse transcriptase ( RT) from the Saccharomyces cerevisiae long terminal repeat-containing retrotransposon Ty3. The counterpart to helix alpha H of human immunodeficiency virus type 1 ( HIV-1) RT, which mediates important interactions with a duplex nucleic acid similar to 3 - 6 bp behind the DNA polymerase catalytic center, was identified between amino acids 290 and 298 of the Ty3 enzyme. The consequences of substituting Ty3 RT Gln(290), Phe(292), Gly(294), Asn(297), and Tyr(298) ( the counterparts of HIV-1 RT Gln(258), Leu(260), Gly(262), Asn(265), and Trp(266), respectively) for both DNA polymerase and RNase H activities were examined. DNA-dependent DNA synthesis was evaluated on unmodified substrates and on duplexes containing targeted insertion of locked nucleic acid analogs and abasic lesions in either the template or primer. Based on this combined strategy, our data suggest an interaction of Ty3 RT Tyr298 with primer nucleotide - 3, Gly294 with primer nucleotide - 4, and Asn297 with template nucleotide - 6. Substitution of Ala for Gln290 was well tolerated, despite the high degree of conservation at this position. Mutations in the thumb subdomain of Ty3 also affected RNase H activity, suggesting a closer spatial relationship between its N- and C-terminal catalytic centers compared with HIV-1 RT.	NCI, Reverse Transcriptase Biochem Sect, Resistance Mech Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Le Grice, SFJ (corresponding author), NCI, Reverse Transcriptase Biochem Sect, Resistance Mech Lab, HIV Drug Resistance Program,NIH, Bldg 535, Frederick, MD 21702 USA.	slegrice@ncifcrf.gov		Lener, Daniela/0000-0001-8266-8810	DIVISION OF BASIC SCIENCES - NCI [Z01BC010492] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC010493, Z01BC010493] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayadi L, 2000, J BIOMOL STRUCT DYN, V17, P645, DOI 10.1080/07391102.2000.10506555; Beard WA, 1998, J BIOL CHEM, V273, P30435, DOI 10.1074/jbc.273.46.30435; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; Bibillo A, 2005, NUCLEIC ACIDS RES, V33, P171, DOI 10.1093/nar/gki150; Bolton EC, 2005, RNA, V11, P308, DOI 10.1261/rna.7860605; CAI H, 1993, J BIOL CHEM, V268, P23567; Cheng Z, 2004, SCIENCE, V303, P240, DOI 10.1126/science.1087023; Coppel Y, 1997, BIOCHEMISTRY-US, V36, P4817, DOI 10.1021/bi962677y; Cote ML, 2003, J MOL BIOL, V330, P57, DOI 10.1016/S0022-2836(03)00554-0; Cristofaro JV, 2002, BIOCHEMISTRY-US, V41, P10968, DOI 10.1021/bi025871v; Das D, 2004, STRUCTURE, V12, P819, DOI 10.1016/j.str.2004.02.032; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Ding JP, 1997, BIOPOLYMERS, V44, P125, DOI 10.1002/(SICI)1097-0282(1997)44:2&lt;125::AID-BIP2&gt;3.0.CO;2-X; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; Fisher TS, 2003, J VIROL, V77, P5837, DOI 10.1128/JVI.77.10.5837-5845.2003; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; Gelfand CA, 1998, BIOCHEMISTRY-US, V37, P7321, DOI 10.1021/bi9803372; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; HEYMAN T, 1995, J MOL BIOL, V253, P291, DOI 10.1006/jmbi.1995.0553; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P26472; Julias JG, 2003, J VIROL, V77, P8548, DOI 10.1128/JVI.77.15.8548-8554.2003; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; Kanagawa M, 1998, NUCLEOS NUCLEOT NUCL, V17, P831, DOI 10.1080/07328319808004678; Ke N, 1999, RNA, V5, P929, DOI 10.1017/S1355838299990015; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; Klarmann GJ, 2000, J BIOL CHEM, V275, P359, DOI 10.1074/jbc.275.1.359; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; Latham GJ, 2000, J BIOL CHEM, V275, P15025, DOI 10.1074/jbc.M000279200; Lener D, 2003, J BIOL CHEM, V278, P26526, DOI 10.1074/jbc.M302374200; Lener D, 2002, J BIOL CHEM, V277, P26486, DOI 10.1074/jbc.M200496200; Levin HL, 1996, MOL CELL BIOL, V16, P5645; Lin Z, 1998, NUCLEIC ACIDS RES, V26, P2385, DOI 10.1093/nar/26.10.2385; Malik HS, 2001, GENOME RES, V11, P1187, DOI 10.1101/gr.185101; Marin V, 2004, J BIOMOL STRUCT DYN, V21, P841, DOI 10.1080/07391102.2004.10506974; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Petersen M, 2002, J AM CHEM SOC, V124, P5974, DOI 10.1021/ja012288d; Petersen M, 2000, J MOL RECOGNIT, V13, P44, DOI 10.1002/(SICI)1099-1352(200001/02)13:1<44::AID-JMR486>3.0.CO;2-6; Powell MD, 1999, J BIOL CHEM, V274, P19885, DOI 10.1074/jbc.274.28.19885; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; Rausch JW, 2002, BIOCHEMISTRY-US, V41, P4856, DOI 10.1021/bi015970t; Rausch JW, 2000, J BIOL CHEM, V275, P13879, DOI 10.1074/jbc.275.18.13879; Ren J, 2002, P NATL ACAD SCI USA, V99, P14410, DOI 10.1073/pnas.222366699; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Steitz TA, 2004, PHILOS T R SOC B, V359, P17, DOI 10.1098/rstb.2003.1374; Wilhelm FX, 2003, J BIOL CHEM, V278, P47678, DOI 10.1074/jbc.M305162200; Wilhelm M, 1999, NUCLEIC ACIDS RES, V27, P4547, DOI 10.1093/nar/27.23.4547; Wilhelm M, 2000, BIOCHEM J, V348, P337, DOI 10.1042/0264-6021:3480337; Wisniewski M, 1999, J BIOL CHEM, V274, P28175, DOI 10.1074/jbc.274.40.28175; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Zang H, 2005, J BIOL CHEM, V280, P1165, DOI 10.1074/jbc.M405996200; Zhang WH, 2002, P NATL ACAD SCI USA, V99, P10090, DOI 10.1073/pnas.152186199	59	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30282	30290		10.1074/jbc.M502457200	http://dx.doi.org/10.1074/jbc.M502457200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15944162	hybrid			2022-12-25	WOS:000231362500037
J	Stojanovic, M; Germain, M; Nguyen, M; Shore, GC				Stojanovic, M; Germain, M; Nguyen, M; Shore, GC			BAP31 and its caspase cleavage product regulate cell surface expression of tetraspanins and integrin-mediated cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE-4 SUPERFAMILY; CONFORMATIONAL-CHANGE; MATRIX INTERACTIONS; CD9; ASSOCIATION; ADHESION; PROTEIN; MEMBRANE	BAP31, a resident integral protein of the endoplasmic reticulum membrane, regulates the export of other integral membrane proteins to the downstream secretory pathway. Here we show that cell surface expression of the tetraspanins CD9 and CD81 is compromised in mouse cells from which the Bap31 gene has been deleted. CD9 and CD81 facilitate the function of multiprotein complexes at the plasma membrane, including integrins. Of note, BAP31 does not appear to influence the egress of alpha 5 beta 1 or alpha v beta 3 integrins to the cell surface, but in Bap31-null mouse cells, these integrins are not able to maintain cellular adhesion to the extracellular matrix in the presence of reduced serum. Consequently, Bap31-null cells are sensitive to serum starvation-induced apoptosis. Reconstitution of wild-type BAP31 into these Bap31-null cells restores integrin-mediated cell attachment and cell survival after serum stress, whereas interference with the functions of CD9, alpha 5 beta 1, or alpha v beta 3 by antagonizing antibodies makes BAP31 cells act similar to Bap31-null cells in these respects. Finally, in human KB epithelial cells protected from apoptosis by BCL-2, the caspase-8 cleavage product, p20 BAP31, inhibits egress of tetraspanin and integrin-mediated cell attachment. Thus, p20 BAP31 can operate upstream of BCL-2 in living cells to influence cell surface properties due to its effects on protein egress from the endoplasmic reticulum.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, Med Sci Bldg,3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	gordon.shore@mcgill.ca						Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berman AE, 2003, BIOCHEMISTRY-MOSCOW+, V68, P1284, DOI 10.1023/B:BIRY.0000011649.03634.74; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CARMO AM, 1995, EUR J IMMUNOL, V25, P2090, DOI 10.1002/eji.1830250743; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Charrin S, 2003, BIOCHEM BIOPH RES CO, V304, P107, DOI 10.1016/S0006-291X(03)00545-X; CLARK K, 2004, J CELL SCI; Cook GA, 2002, BLOOD, V100, P4502, DOI 10.1182/blood.V100.13.4502; Cook GA, 1999, EXP CELL RES, V251, P356, DOI 10.1006/excr.1999.4596; Ducret A, 2003, EUR J BIOCHEM, V270, P342, DOI 10.1046/j.1432-1033.2003.03395.x; Feigelson SW, 2003, J BIOL CHEM, V278, P51203, DOI 10.1074/jbc.M303601200; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Gutierrez-Lopez MD, 2003, J BIOL CHEM, V278, P208, DOI 10.1074/jbc.M207805200; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hirano T, 1999, MOL HUM REPROD, V5, P162, DOI 10.1093/molehr/5.2.162; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; IMAI T, 1993, J IMMUNOL, V151, P6470; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; Lambert G, 2001, J BIOL CHEM, V276, P20340, DOI 10.1074/jbc.M011209200; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Lussier C, 2000, MICROSC RES TECHNIQ, V51, P169; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; MOULD AP, 2004, J BIOL CHEM; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Oritani K, 1996, BLOOD, V87, P2252, DOI 10.1182/blood.V87.6.2252.bloodjournal8762252; Paquet ME, 2004, J IMMUNOL, V172, P7548, DOI 10.4049/jimmunol.172.12.7548; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SanchezMateos P, 1996, SEMIN CANCER BIOL, V7, P99, DOI 10.1006/scbi.1996.0015; Schamel WWA, 2003, P NATL ACAD SCI USA, V100, P9861, DOI 10.1073/pnas.1633363100; SCHULTZ JF, 1995, J BIOL CHEM, V270, P11522, DOI 10.1074/jbc.270.19.11522; Secrist H, 1996, EUR J IMMUNOL, V26, P1435, DOI 10.1002/eji.1830260706; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Shigeta M, 2003, J CELL BIOL, V163, P165, DOI 10.1083/jcb.200301075; Spiliotis ET, 2000, IMMUNITY, V13, P841, DOI 10.1016/S1074-7613(00)00081-9; Tsuchida J, 1998, J CELL SCI, V111, P1759; Wang B, 2004, MOL CELL BIOL, V24, P2767, DOI 10.1128/MCB.24.7.2767-2778.2004; Wang B, 2003, J BIOL CHEM, V278, P14461, DOI 10.1074/jbc.M209684200; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zen K, 2004, J BIOL CHEM, V279, P44924, DOI 10.1074/jbc.M402115200; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	56	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30018	30024		10.1074/jbc.M501306200	http://dx.doi.org/10.1074/jbc.M501306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15946936	hybrid			2022-12-25	WOS:000231362500006
J	Burrell, HE; Wlodarski, B; Foster, BJ; Buckley, KA; Sharpe, GR; Quayle, JM; Simpson, AWM; Gallagher, JA				Burrell, HE; Wlodarski, B; Foster, BJ; Buckley, KA; Sharpe, GR; Quayle, JM; Simpson, AWM; Gallagher, JA			Human keratinocytes release ATP and utilize three mechanisms for nucleotide interconversion at the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN EPIDERMAL-KERATINOCYTES; ADENYLATE KINASE; NUCLEOSIDE DIPHOSPHOKINASE; ADENOSINE-TRIPHOSPHATE; RECEPTOR ACTIVATION; ENDOTHELIAL-CELLS; EXTRACELLULAR ATP; ABC TRANSPORTERS; P2Y(2) RECEPTORS	Nucleotide activation of P2 receptors is important in autocrine and paracrine regulation in many tissues. In the epidermis, nucleotides are involved in proliferation, differentiation, and apoptosis. In this study, we have used a combination of luciferin-luciferase luminometry, pharmacological inhibitors, and confocal microscopy to demonstrate that HaCaT keratinocytes release ATP into the culture medium, and that there are three mechanisms for nucleotide interconversion, resulting in ATP generation at the cell surface. Addition of ADP, GTP, or UTP to culture medium elevated the ATP concentration. ADP to ATP conversion was inhibited by diadenosine pentaphosphate, oligomycin, and UDP, suggesting the involvement of cell surface adenylate kinase, F1F0 ATP synthase, and nucleoside diphosphokinase (NDPK), respectively, which was supported by immunohistochemistry. Simultaneous addition of ADP and GTP elevated ATP above that for each nucleotide alone indicating that GTP acts as a phosphate donor. However, the activity of NDPK, F1F0 ATP synthase or the forward reaction of adenylate kinase could not fully account for the culture medium ATP content. We postulate that this discrepancy is due to the reverse reaction of adenylate kinase utilizing AMP. In normal human skin, F1F0 ATP synthase and NDPK were differentially localized, with mitochondrial expression in the basal layer, and cell surface expression in the differentiated layers. We and others have previously demonstrated that keratinocytes express multiple P2 receptors. In this study we now identify the potential sources of extracellular ATP required to activate these receptors and provide better understanding of the role of nucleotides in normal epidermal homeostasis and wound healing.	Univ Liverpool, Sch Biomed Sci, Dept Human Anat & Cell Biol, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Dept Med, Dermatol Unit, Liverpool L69 3GA, Merseyside, England	University of Liverpool; University of Liverpool	Burrell, HE (corresponding author), Univ Liverpool, Sch Biomed Sci, Dept Human Anat & Cell Biol, Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	H.E.Burrell@liv.ac.uk		Buckley, Katherine/0000-0002-6585-8943				Abbracchio MP, 2003, TRENDS PHARMACOL SCI, V24, P52, DOI 10.1016/S0165-6147(02)00038-X; ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; ARARAKI N, 2003, MOL CANCER RES, V1, P931; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Buckley KA, 2003, FASEB J, V17, P1401, DOI 10.1096/fj.02-0940com; Burrell HE, 2003, J INVEST DERMATOL, V120, P440, DOI 10.1046/j.1523-1747.2003.12050.x; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; Cantiello HF, 2001, PFLUG ARCH EUR J PHY, V443, pS22; Cantiello HF, 1997, BIOSCIENCE REP, V17, P147, DOI 10.1023/A:1027381412574; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; Conant AR, 1998, BRIT J PHARMACOL, V125, P357, DOI 10.1038/sj.bjp.0702082; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P2462, DOI 10.1021/bi00737a015; Dixon CJ, 2003, BRIT J PHARMACOL, V138, P272, DOI 10.1038/sj.bjp.0705016; Dixon CJ, 1999, BRIT J PHARMACOL, V127, P1680, DOI 10.1038/sj.bjp.0702653; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Gallagher BC, 2003, J CELL SCI, V116, P3239, DOI 10.1242/jcs.00630; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; Greig AVH, 2003, J INVEST DERMATOL, V120, P1007, DOI 10.1046/j.1523-1747.2003.12261.x; Grobben B, 1999, J NEUROCHEM, V72, P826, DOI 10.1046/j.1471-4159.1999.0720826.x; Groschel-Stewart U, 1999, CELL TISSUE RES, V296, P599, DOI 10.1007/s004410051321; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; Joseph SM, 2003, J BIOL CHEM, V278, P23331, DOI 10.1074/jbc.M302680200; Khakh BS, 2001, PHARMACOL REV, V53, P107; KIMURA N, 1990, J BIOL CHEM, V265, P15744; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P237, DOI 10.1023/A:1005532912212; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Linnett P E, 1979, Methods Enzymol, V55, P472; Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Picher M, 2003, J BIOL CHEM, V278, P11256, DOI 10.1074/jbc.M208071200; PILLAI S, 1992, J CLIN INVEST, V90, P42, DOI 10.1172/JCI115854; PLESNER L, 1995, INT REV CYTOL, V158, P141; Prat AG, 1996, AM J PHYSIOL-CELL PH, V270, pC538, DOI 10.1152/ajpcell.1996.270.2.C538; Ralevic V, 1998, PHARMACOL REV, V50, P413; REIMER WJ, 1992, AM J PHYSIOL, V263, pC1040, DOI 10.1152/ajpcell.1992.263.5.C1040; REISIN IL, 1994, J BIOL CHEM, V269, P20584; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sinev MA, 1996, BIOCHEMISTRY-US, V35, P6425, DOI 10.1021/bi952687j; UNSWORTH CD, 1990, ANN NY ACAD SCI, V603, P353; Van Rompay AR, 1999, EUR J BIOCHEM, V261, P509, DOI 10.1046/j.1432-1327.1999.00294.x; WILSON DE, 1976, ANN HUM GENET, V39, P305, DOI 10.1111/j.1469-1809.1976.tb00134.x; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; Yoneda T, 1998, MOL BRAIN RES, V62, P187, DOI 10.1016/S0169-328X(98)00249-6; Zimmermann H, 1996, DRUG DEVELOP RES, V39, P337, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<337::AID-DDR15>3.0.CO;2-Z; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; Zimmermann H, 1999, TRENDS PHARMACOL SCI, V20, P231, DOI 10.1016/S0165-6147(99)01293-6	56	98	104	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29667	29676		10.1074/jbc.M505381200	http://dx.doi.org/10.1074/jbc.M505381200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15958381	hybrid			2022-12-25	WOS:000231176200036
J	Fortune, JM; Pavlov, YI; Welch, CM; Johansson, E; Burgers, PMJ; Kunkel, TA				Fortune, JM; Pavlov, YI; Welch, CM; Johansson, E; Burgers, PMJ; Kunkel, TA			Saccharomyces cerevisiae DNA polymerase delta - High fidelity for base substitutions but lower fidelity for single- and multi-base deletions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION; EPSILON; HOLOENZYME; ERRORS; PROCESSIVITY; MUTAGENESIS; FRAMESHIFT; COMPLEX; ALPHA	Eukaryotic DNA polymerase delta ( Pol delta) plays an essential role in replicating large nuclear genomes, a process that must be accurate to maintain stability over many generations. Based on kinetic studies of insertion of individual dNTPs opposite a template guanine, Pol delta is believed to have high selectivity for inserting correct nucleotides. This high selectivity, in conjunction with an intrinsic 3'-exonuclease activity, implies that Pol delta should have high base substitution fidelity. Here we demonstrate that the wild type Saccharomyces cerevisiae three-subunit Pol delta does indeed have high base substitution fidelity for the 12 possible base-base mismatches, producing on average less than 1.3 stable misincorporations/ 100,000 nucleotides polymerized. Measurements with exonuclease-deficient Pol delta confirm the high nucleotide selectivity of the polymerase and further indicate that proofreading enhances the base substitution fidelity of the wild type enzyme by at least 60-fold. However, Pol delta inefficiently proofreads single nucleotide deletion mismatches in homopolymeric runs, such that the error rate is 30 single nucleotide deletions/ 100,000 nucleotides polymerized. Moreover, wild type Pol delta frequently deletes larger numbers of nucleotides between distantly spaced direct repeats of three or more base pairs. Although wild type Pol delta and Pol delta both have high base substitution fidelity, Pol delta is much less accurate than Pol epsilon for deletions involving repetitive sequences. Thus, strand slippage during replication by wild type Pol delta may be a primary source of insertion and deletion mutagenesis in eukaryotic genomes.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Washington Univ, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Washington University (WUSTL); Umea University	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233,MD E-3-01, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Kunkel, Thomas A./D-5088-2019; Burgers, Peter M/AAW-6621-2021; Pavlov, Youri/T-7532-2017	Kunkel, Thomas A./0000-0002-9900-1788; Pavlov, Youri/0000-0003-1179-5796; Johansson, Erik/0000-0002-8526-6224	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065070, Z01ES065070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bebenek K, 2004, ADV PROTEIN CHEM, V69, P137; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Chen XL, 2000, J BIOL CHEM, V275, P17677, DOI 10.1074/jbc.M910278199; Chilkova O, 2003, J BIOL CHEM, V278, P14082, DOI 10.1074/jbc.M211818200; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Garg P, 2005, CRIT REV BIOCHEM MOL, V40, P115, DOI 10.1080/10409230590935433; Goldsby RE, 2002, P NATL ACAD SCI USA, V99, P15560, DOI 10.1073/pnas.232340999; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Hashimoto K, 2003, BIOCHEMISTRY-US, V42, P14207, DOI 10.1021/bi0348359; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; KUNKEL TA, 1987, P NATL ACAD SCI USA, V84, P4865, DOI 10.1073/pnas.84.14.4865; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Pavlov YI, 2002, MOL CELL, V10, P207, DOI 10.1016/S1097-2765(02)00567-1; Shcherbakova Polina V, 2003, Sci Aging Knowledge Environ, V2003, pRE3, DOI 10.1126/sageke.2003.8.re3; Shcherbakova PV, 2003, J BIOL CHEM, V278, P43770, DOI 10.1074/jbc.M306893200; Shimizu K, 2002, J BIOL CHEM, V277, P37422, DOI 10.1074/jbc.M204476200; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; WEISER T, 1991, J BIOL CHEM, V266, P10420	36	101	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29980	29987		10.1074/jbc.M505236200	http://dx.doi.org/10.1074/jbc.M505236200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15964835	hybrid			2022-12-25	WOS:000231176200071
J	Fu, CH; Ahmed, K; Ding, HS; Ding, X; Lan, JP; Yang, ZH; Miao, Y; Zhu, YY; Shi, YY; Zhu, JD; Huang, H; Yao, XB				Fu, CH; Ahmed, K; Ding, HS; Ding, X; Lan, JP; Yang, ZH; Miao, Y; Zhu, YY; Shi, YY; Zhu, JD; Huang, H; Yao, XB			Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3	ONCOGENE			English	Article						acute promyelocytic leukemia; promyelocytic leukemia protein; nuclear body	ACUTE PROMYELOCYTIC LEUKEMIA; COVALENT MODIFICATION; CENP-E; UBIQUITIN; IDENTIFICATION; PATHOGENESIS; INTERACTS; COMPONENT; MODIFIER; RANGAP1	The PML gene of acute promyelocytic leukemia (APL) encodes a cell-growth and tumor suppressor. PML localizes to discrete nuclear bodies (NBs) that are disrupted in APL cells, resulting from a reciprocal chromosome translocation t (15;17). Here we show that the nuclear localization of PML is also regulated by SUMO-3, one of the three recently identified SUMO isoforms in human cells. SUMO-3 bears similar subcellular distribution to those of SUMO-1 and -2 in the interphase nuclear body, which is colocalized with PML protein. However, both SUMO-2 and -3 are also localized to nucleoli, a region lacking SUMO-1. Immunoprecipitated PML protein bears SUMO-3 moiety in a covalently modified form, supporting the notion that PML is conjugated by SUMO-3. To determine the functional relevance of SUMO-3 conjugation on PML molecular dynamics, we suppressed SUMO-3 protein expression using a siRNA-mediated approach. Depletion of SUMO-3 markedly reduced the number of PML-containing NBa and their integrity, which is rescued by exogenous expression of SUMO-3 but not SUMO-1 or SUMO-2. The specific requirement of SUMO-3 for PML nuclear localization is validated by expression of SUMO-3 conjugation defective mutant. Moreover, we demonstrate that oligomerization of SUMO-3 is required for PML retention in the nucleus. Taken together, our studies provide first line of evidence showing that SUMO-3 is essential for PML localization and offer novel insight into the pathobiochemistry of APL.	Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou 310003, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Peoples R China; Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA; Proteom Res Lab, Beijing 100086, Peoples R China	Zhejiang University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine	Huang, H (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou 310003, Peoples R China.	hehuang@mail.hz.zj.cn; yaoxb@ustc.edu.cn	MIAO, YONG/D-4244-2015; Fu, Chuanhai/G-8303-2016; Yao, Xuebiao/P-5771-2014; Shi, Yunyu/B-3240-2009; Ding, Husheng/K-9688-2013	Fu, Chuanhai/0000-0003-4354-3796; Shi, Yunyu/0000-0002-1348-4759; Ding, Husheng/0000-0003-1877-7961; huang, he/0000-0002-2723-1621	NCI NIH HHS [CA89019] Funding Source: Medline; NIDDK NIH HHS [DK56292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Eskiw CH, 2003, J CELL SCI, V116, P4455, DOI 10.1242/jcs.00758; Guo DH, 2004, NAT GENET, V36, P837, DOI 10.1038/ng1391; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mishra RK, 2004, J BIOL CHEM, V279, P31445, DOI 10.1074/jbc.M402911200; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Wang ZG, 1998, SCIENCE, V279, P1547; Yao JH, 2004, FEBS LETT, V575, P112, DOI 10.1016/j.febslet.2004.08.047; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887	31	90	91	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5401	5413		10.1038/sj.onc.1208714	http://dx.doi.org/10.1038/sj.onc.1208714			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15940266				2022-12-25	WOS:000231222300001
J	Shekar, SC; Wu, HY; Fu, Z; Yip, SC; Nagajyothi; Cahill, SM; Girvin, ME; Backer, JM				Shekar, SC; Wu, HY; Fu, Z; Yip, SC; Nagajyothi; Cahill, SM; Girvin, ME; Backer, JM			Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; SH2 DOMAINS; P85-ALPHA SUBUNIT; PROTEINS; PI-3-KINASE; 3'-KINASE; RAS; IDENTIFICATION	p85/p110 phosphoinositide 3-kinases regulate multiple cell functions and are frequently mutated in human cancer. The p85 regulatory subunit stabilizes and inhibits the p110 catalytic subunit. The minimal fragment of p85 capable of regulating p110 is the N-terminal SH2 domain linked to the coiled-coil iSH2 domain ( referred to as p85ni). We have previously proposed that the conformationally rigid iSH2 domain tethers p110 to p85, facilitating regulatory interactions between p110 and the p85 nSH2 domain. In an oncogenic mutant of murine p85, truncation at residue 571 leads to constitutively increased phosphoinositide 3-kinase activity, which has been proposed to result from either loss of an inhibitory Ser-608 autophosphorylation site or altered interactions with cellular regulatory factors. We have examined this mutant ( referred to as p65) in vitro and find that p65 binds but does not inhibit p110, leading to constitutive p110 activity. This activated phenotype is observed with recombinant proteins in the absence of cellular factors. Importantly, this effect is also produced by truncating p85ni at residue 571. Thus, the phenotype is not because of loss of the Ser-608 inhibitory autophosphorylation site, which is not present in p85ni. To determine the structural basis for the phenotype of p65, we used a broadly applicable spin label/NMR approach to define the positioning of the nSH2 domain relative to the iSH2 domain. We found that one face of the nSH2 domain packs against the 581-593 region of the iSH2 domain. The loss of this interaction in the truncated p65 would remove the orienting constraints on the nSH2 domain, leading to a loss of p110 regulation by the nSH2. Based on these findings, we propose a general model for oncogenic mutants of p85 and p110 in which disruption of nSH2-p110 regulatory contacts leads to constitutive p110 activity.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Backer, JM (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	Backer@aecom.yu.edu	Srinivasan, Chandrashekar/I-5553-2019	Srinivasan, Chandrashekar/0000-0003-2687-3056	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM066354] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK07513] Funding Source: Medline; NIGMS NIH HHS [GM66354, GM55692] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Battiste JL, 2000, BIOCHEMISTRY-US, V39, P5355, DOI 10.1021/bi000060h; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CANTLEY LC, 1991, CELL, V64, P231; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P32, DOI 10.1021/bi00052a006; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano WL, 2002, PYMOL USERS MANUAL; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Dwek RA., 1973, NUCL MAGNETIC RESONA; Fischer MWF, 1999, BIOCHEMISTRY-US, V38, P9013, DOI 10.1021/bi9905213; Foukas LC, 2004, MOL CELL BIOL, V24, P966, DOI 10.1128/MCB.24.3.966-975.2004; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fu Z, 2004, ARCH BIOCHEM BIOPHYS, V432, P244, DOI 10.1016/j.abb.2004.09.032; Fu Z, 2003, P NATL ACAD SCI USA, V100, P3275, DOI 10.1073/pnas.0535975100; Fushman D, 1999, BIOCHEMISTRY-US, V38, P10225, DOI 10.1021/bi990897g; Gunther UL, 1996, BIOCHEMISTRY-US, V35, P15570, DOI 10.1021/bi961783x; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Jimenez C, 2002, J BIOL CHEM, V277, P41556, DOI 10.1074/jbc.M205893200; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; O'Brien R, 2000, PROTEIN SCI, V9, P570; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Philp AJ, 2001, CANCER RES, V61, P7426; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Weber T, 2000, BIOCHEMISTRY-US, V39, P15860, DOI 10.1021/bi001474d; Yang DW, 1999, J BIOMOL NMR, V13, P3, DOI 10.1023/A:1008329230975; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	48	69	79	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27850	27855		10.1074/jbc.M506005200	http://dx.doi.org/10.1074/jbc.M506005200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15932879	hybrid			2022-12-25	WOS:000230678600046
J	Tate, JJ; Rai, R; Cooper, TG				Tate, JJ; Rai, R; Cooper, TG			Methionine sulfoximine treatment and carbon starvation elicit Snf1-independent phosphorylation of the transcription activator Gln3 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; SNF1 PROTEIN-KINASE; RETROGRADE GENE-EXPRESSION; TOR PROTEINS; CELL-GROWTH; NUCLEAR-LOCALIZATION; SIGNALING PATHWAYS; RAPAMYCIN; TAP42; PHOSPHATASE	Tor proteins are global regulators situated at the top of a signal transduction pathway conserved from yeast to humans. Specific inhibition of the two Saccharomyces cerevisiae Tor proteins by rapamycin alters many cellular processes and the expression of hundreds of genes. Among the regulated genes are those whose expression is activated by the GATA family transcription activator, Gln3. The extent of Gln3 phosphorylation has been thought to determine its intracellular localization, with phosphorylated and dephosphorylated forms accumulating in the cytoplasm and nucleus, respectively. Data presented here demonstrate that rapamycin and the glutamine synthetase inhibitor, methionine sulfoximine (MSX), although eliciting the same outcomes with respect to Gln3-Myc(13) nuclear accumulation and nitrogen catabolite repression-sensitive transcription, generate diametrically opposite effects on Gln3-Myc(13) phosphorylation. MSX increases Gln3-Myc(13) phosphorylation and rapamycin decreases it. Gln3-Myc(13) phosphorylation levels are regulated by at least three mechanisms as follows: (i) depends on Snf1 kinase as observed during carbon starvation, (ii) is Snf1-independent as observed during both carbon starvation and MSX treatment, and (iii) is rapamycin-induced dephosphorylation. MSX and rapamycin act additively on Gln3-Myc(13) phosphorylation, but MSX clearly predominates. These results suggest that MSX- and rapamycin-inhibited proteins are more likely to function in separate regulatory pathways than they are to function tandemly in a single pathway as thought previously. Furthermore, as we and others have detected thus far, Gln3 phosphorylation/dephosphorylation is not a demonstrably required step in achieving Gln3 nuclear localization and nitrogen catabolite repression-sensitive transcription in response to MSX or rapamycin treatment.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NIGMS NIH HHS [R01 GM035642-17, GM-35642, R01 GM035642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; Cooper TG, 1996, MYCOTA, V3, P139; Cox KH, 2004, J BIOL CHEM, V279, P19294, DOI 10.1074/jbc.M309240200; Cox KH, 2004, J BIOL CHEM, V279, P10270, DOI 10.1074/jbc.M312023200; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Das BK, 1999, MOL CELL BIOL, V19, P6796; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Duvel K, 2003, MOL CELL, V11, P1467, DOI 10.1016/S1097-2765(03)00228-4; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; Kuchin S, 2003, BIOCHEM SOC T, V31, P175, DOI 10.1042/bst0310175; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Luke MM, 1996, MOL CELL BIOL, V16, P2744; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Neuhaus P, 2001, LIVER TRANSPLANT, V7, P473, DOI 10.1053/jlts.2001.24645; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Santhanam A, 2004, EUKARYOT CELL, V3, P1261, DOI 10.1128/EC.3.5.1261-1271.2004; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shirra MK, 2005, GENETICS, V169, P1957, DOI 10.1534/genetics.104.038075; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Tate JJ, 2003, J BIOL CHEM, V278, P36924, DOI 10.1074/jbc.M301829200; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; THOMAS G, 2004, CURR TOP MICROBIOL I, V279; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Zheng Y, 2005, MOL BIOL CELL, V16, P2119, DOI 10.1091/mbc.e04-09-0797	46	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27195	27204		10.1074/jbc.M504052200	http://dx.doi.org/10.1074/jbc.M504052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911613	Green Accepted, hybrid			2022-12-25	WOS:000230589500067
J	Chen, HC; Chomyn, A; Chan, DC				Chen, HC; Chomyn, A; Chan, DC			Disruption of fusion results in mitochondrial heterogeneity and dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT OPTIC ATROPHY; DYNAMIN-RELATED GTPASE; MORPHOLOGY; OPA1; PROTEASE; CELLS; COMPLEMENTATION; MITOFUSIN-1; EXPRESSION; APOPTOSIS	Mitochondria undergo continual cycles of fusion and fission, and the balance of these opposing processes regulates mitochondrial morphology. Paradoxically, cells invest many resources to maintain tubular mitochondrial morphology, when reducing both fusion and fission simultaneously achieves the same end. This observation suggests a requirement for mitochondrial fusion, beyond maintenance of organelle morphology. Here, we show that cells with targeted null mutations in Mfn1 or Mfn2 retained low levels of mitochondrial fusion and escaped major cellular dysfunction. Analysis of these mutant cells showed that both homotypic and heterotypic interactions of Mfns are capable of fusion. In contrast, cells lacking both Mfn1 and Mfn2 completely lacked mitochondrial fusion and showed severe cellular defects, including poor cell growth, widespread heterogeneity of mitochondrial membrane potential, and decreased cellular respiration. Disruption of OPA1 by RNAi also blocked all mitochondrial fusion and resulted in similar cellular defects. These defects in Mfn-null or OPA1-RNAi mammalian cells were corrected upon restoration of mitochondrial fusion, unlike the irreversible defects found in fzo Delta yeast. In contrast, fragmentation of mitochondria, without severe loss of fusion, did not result in such cellular defects. Our results showed that key cellular functions decline as mitochondrial fusion is progressively abrogated.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Chan, DC (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	dchan@caltech.edu	Chan, Doris/O-1227-2014	Chan, Doris/0000-0002-4990-986X	NIGMS NIH HHS [1 R01 GM62967-01, GM11726] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; BAKEEVA LE, 1981, EUR J CELL BIOL, V25, P175; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen HC, 2004, CURR TOP DEV BIOL, V59, P119, DOI 10.1016/S0070-2153(04)59005-1; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Duan S, 2003, J BIOL CHEM, V278, P1346, DOI 10.1074/jbc.M209269200; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; Herlan M, 2004, J CELL BIOL, V165, P167, DOI 10.1083/jcb.200403022; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; McQuibban GA, 2003, NATURE, V423, P537, DOI 10.1038/nature01633; Misaka T, 2002, J BIOL CHEM, V277, P15834, DOI 10.1074/jbc.M109260200; Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116; Rojo M, 2002, J CELL SCI, V115, P1663; Santel A, 2001, J CELL SCI, V114, P867; Sesaki H, 2003, BIOCHEM BIOPH RES CO, V308, P276, DOI 10.1016/S0006-291X(03)01348-2; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; Villani G, 2001, METHOD CELL BIOL, V65, P119, DOI 10.1016/S0091-679X(01)65007-6; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	28	953	986	8	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26185	26192		10.1074/jbc.M503062200	http://dx.doi.org/10.1074/jbc.M503062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899901	hybrid, Green Accepted			2022-12-25	WOS:000230386800032
J	Nagaya, N; Tittle, RK; Saar, N; Dellal, SS; Hume, RI				Nagaya, N; Tittle, RK; Saar, N; Dellal, SS; Hume, RI			An intersubunit zinc binding site in rat P2X(2) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; GLYCINE RECEPTOR; ATP-BINDING; CRYSTAL-STRUCTURES; GABA(A) RECEPTORS; DEPENDENT CHANGES; AMINO-ACIDS; SUBUNIT; IDENTIFICATION; INHIBITION	P2X receptors are ATP-gated ion channels made up of three similar or identical subunits. It is unknown whether ligand binding is intersubunit or intrasubunit, either for agonists or for allosteric modulators. Zinc binds to rat P2X(2) receptors and acts as an allosteric modulator, potentiating channel opening. To probe the location of this zinc binding site, P2X(2) receptors bearing mutations of the histidines at positions 120 and 213 were expressed in Xenopus oocytes. Studies of H120C and H213C mutants produced five lines of evidence consistent with the hypothesis that the residues in these positions bind zinc. Mixing of subunits containing the H120A or H213A mutation generated receptors that showed zinc potentiation, even though neither of these mutant receptors showed zinc potentiation on its own. Furthermore, expression of trimeric concatamers with His 3 Ala mutations at some but not all six positions showed that zinc potentiation correlated with the number of intersubunit histidine pairs. These results indicate that zinc potentiation requires an interaction across a subunit interface. Expression of the H120C/H213C double mutant resulted in the formation of ectopic disulfide bonds that could be detected by changes in the physiological properties of the receptors after treatment with reducing and oxidizing agents. Immunoblot analysis of H120C/H213C protein separated under nonreducing conditions demonstrated that the ectopic bonds were between adjacent subunits. Taken together, these data indicate that His(120) and His(213) sit close to each other across the interface between subunits and are likely to be key components of the zinc binding site in P2X(2) receptors.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Hume, RI (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	rhume@umich.edu	, Richard/AAI-5000-2020	Hume, Richard/0000-0001-9807-112X	NINDS NIH HHS [R01-NS039196, R01 NS039196-01A2, R01 NS039196, T32 NS076401] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS076401, R01NS039196] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Cascio M, 2004, J BIOL CHEM, V279, P19383, DOI 10.1074/jbc.R300035200; Clyne JD, 2003, NEUROPHARMACOLOGY, V44, P403, DOI 10.1016/S0028-3908(02)00406-9; Clyne JD, 2002, J PHYSIOL-LONDON, V539, P347, DOI 10.1113/jphysiol.2001.013244; Egan TM, 1998, J NEUROSCI, V18, P2350; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Freist W, 1998, FEBS LETT, V434, P61, DOI 10.1016/S0014-5793(98)00958-2; Fujiwara Y, 2004, J PHYSIOL-LONDON, V558, P31, DOI 10.1113/jphysiol.2004.064568; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; Harvey RJ, 1999, J PHYSIOL-LONDON, V520, P53, DOI 10.1111/j.1469-7793.1999.00053.x; Hosie AM, 2003, NAT NEUROSCI, V6, P362, DOI 10.1038/nn1030; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Jiang LH, 2003, J NEUROSCI, V23, P8903; Kanjhan R, 1999, J COMP NEUROL, V407, P11; Miles E W, 1977, Methods Enzymol, V47, P431; Nevin ST, 2003, J BIOL CHEM, V278, P28985, DOI 10.1074/jbc.M300097200; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nicke A, 2003, MOL PHARMACOL, V63, P243, DOI 10.1124/mol.63.1.243; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Paoletti P, 2000, NEURON, V28, P911, DOI 10.1016/S0896-6273(00)00163-X; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Roberts JA, 2004, J BIOL CHEM, V279, P9043, DOI 10.1074/jbc.M308964200; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Vial C, 2004, TRENDS PHARMACOL SCI, V25, P487, DOI 10.1016/j.tips.2004.07.008; Wildman SS, 1998, BRIT J PHARMACOL, V123, P1214, DOI 10.1038/sj.bjp.0701717; Zhou Z, 1998, J PHYSIOL-LONDON, V507, P353, DOI 10.1111/j.1469-7793.1998.353bt.x; ZN, 2005, MOL PHARM, V67, P1078	32	77	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					25982	25993		10.1074/jbc.M504545200	http://dx.doi.org/10.1074/jbc.M504545200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899882	Green Accepted, hybrid			2022-12-25	WOS:000230386800006
J	Mingrone, G; Manco, M; Granato, L; Calvani, M; Scarfone, A; Mora, EV; Greco, AV; Vidal, H; Castagneto, M; Ferrannini, E				Mingrone, G; Manco, M; Granato, L; Calvani, M; Scarfone, A; Mora, EV; Greco, AV; Vidal, H; Castagneto, M; Ferrannini, E			Leptin pulsatility in formerly obese women	FASEB JOURNAL			English	Article						euglycemic-hyperinsulinemic clamp; calorimetric chamber; morbid obesity; biliopancreatic diversion; ACC2 mRNA expression	ACTIVATED PROTEIN-KINASE; ACETYL-COA CARBOXYLASE; HUMAN SKELETAL-MUSCLE; FATTY-ACID OXIDATION; PLASMA LEPTIN; GENE-EXPRESSION; INSULIN-RESISTANCE; BILIOPANCREATIC DIVERSION; ENERGY-EXPENDITURE; BODY-COMPOSITION	Plasma leptin and growth hormone (GH) profile and pulsatility have been studied in morbidly obese subjects before and 14 months after bilio-pancreatic diversion (BPD), a bariatric technique producing massive lipid malabsorption. The maximum leptin diurnal variation (acrophase) decreased (10.27 +/- 1.70 vs. 22.60 +/- 2.79 ng(.)ml(-1); P= 0.001), while its pulsatility index (PI) increased (1.084 +/- 0.005 vs. 1.050 +/- 0.004 ng(.)ml(-1.)min(- 1); P= 0.02) after BPD. Plasma GH acrophase increased ( P= 0.0001) from 0.91 +/- 0.20 to 4.58 +/- 0.80 mu g(.)l(-1.)min(-1) after BPD as well as GH PI (1.70 +/- 0.13 vs. 1.20 +/- 0.04 mu g.l(-1 .)min(-1); P= 0.024). Whole-body glucose uptake ( M), assessed by euglycemic-hyperinsulinemic clamp, almost doubled after BPD (from 0.274 +/- 0.022 to 0.573 +/- 0.027 mmol(.)kg(FFM) (1.)min(-1); P < 0.0001), while 24 h lipid oxidation was significantly (P < 0.0001) reduced (131.94 +/- 35.58 vs. 44.56 +/- 15.10 g). However, the average lipid oxidation was 97.2 +/- 3.1% (P < 0.01) of the metabolizable lipid intake after the bariatric operation, while it was 69.2 +/- 8.5% before. After the operation, skeletal muscle ACC2 mRNA decreased ( P < 0.0001) from 452.82 +/- 76.35 to 182.45 +/- 40.69% of cyclophilin mRNA as did the malonyl-CoA (from 0.28 +/- 0.02 to 0.16 +/- 0.01 nmol(.)g(-1); P < 0.0001). Leptin changes negatively correlated with M changes (R-2= 0.69, P < 0.001). In a stepwise regression (R-2= 0.87, P= 0.0055), only changes in 24 h free fatty acids (B=0.105 +/- 0.018, P= 0.002) and glucose/ insulin ratio (B= 0.247 +/- 0.081, P= 0.029) were the best predictors of leptin variations. In conclusion, the reversion of insulin resistance after BPD might allow reversal of leptin resistance, restoration of leptin pulsatility, and consequent inhibition of ACC2 mRNA expression, translating to a reduced synthesis of malonyl-CoA, which, in turn, results in increased fatty acid oxidation. Finally, since leptin inhibits GH secretion, a reduction of circulating leptin levels might have produced an increase in GH secretion, as observed in our series.	Catholic Univ, Dipartimento Med Interna, Sch Med, CNR Ctr Fisiopatol Shock, I-00168 Rome, Italy; Univ Roma La Sapienza, Dept Comp Sci & Syst, Rome, Italy; INSERM, Unite 449, Lyon, France; Catholic Univ, CNR Ctr Fisiopatol Shock, Dept Surg, Sch Med, Rome, Italy; Univ Pisa, Dept Internal Med, Pisa, Italy; Univ Pisa, CNR, Inst Clin Physiol, Pisa, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Sapienza University Rome; Institut National de la Sante et de la Recherche Medicale (Inserm); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Pisa	Mingrone, G (corresponding author), Catholic Univ, Dipartimento Med Interna, Sch Med, CNR Ctr Fisiopatol Shock, Largo A Gemelli 8, I-00168 Rome, Italy.	gmingrone@rm.unicatt.it	Mingrone, Geltrude/AAB-9681-2019; Manco, Melania/M-1058-2013; VIDAL, Hubert/M-6674-2017	Manco, Melania/0000-0002-6581-975X; VIDAL, Hubert/0000-0002-9467-0317; Mingrone, Geltrude/0000-0003-2021-528X				Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Auboeuf D, 1997, ANAL BIOCHEM, V245, P141, DOI 10.1006/abio.1996.9986; Barbe P, 2001, FASEB J, V15, P13; Boden G, 1997, J CLIN INVEST, V100, P1107, DOI 10.1172/JCI119621; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Calvani M, 2004, DIABETES, V53, P939, DOI 10.2337/diabetes.53.4.939; Casanueva FF, 1999, FRONT NEUROENDOCRIN, V20, P317, DOI 10.1006/frne.1999.0187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Marinis L, 2004, J CLIN ENDOCR METAB, V89, P174, DOI 10.1210/jc.2002-021308; De Marinis L, 1999, J CLIN ENDOCR METAB, V84, P2386, DOI 10.1210/jc.84.7.2386; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Dirlewanger M, 2000, INT J OBESITY, V24, P1413, DOI 10.1038/sj.ijo.0801395; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fabris R, 2004, J CLIN ENDOCR METAB, V89, P1753, DOI 10.1210/jc.2003-031343; Goodwin GW, 1999, AM J PHYSIOL-ENDOC M, V277, pE772, DOI 10.1152/ajpendo.1999.277.4.E772; Granato L, 2004, J APPL PHYSIOL, V96, P1045, DOI 10.1152/japplphysiol.00788.2003; Greco AV, 2002, DIABETES, V51, P144, DOI 10.2337/diabetes.51.1.144; Greco AV, 2002, J INVEST MED, V50, P207, DOI 10.2310/6650.2002.33435; Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064; Hauffa B P, 2001, Growth Horm IGF Res, V11 Suppl A, pS1, DOI 10.1016/S1096-6374(01)80002-2; Havel PJ, 2004, DIABETES, V53, pS143, DOI 10.2337/diabetes.53.2007.S143; Havel PJ, 1999, DIABETES, V48, P334, DOI 10.2337/diabetes.48.2.334; HEYMSFIELD SB, 1990, AM J CLIN NUTR, V52, P52, DOI 10.1093/ajcn/52.1.52; HILL JO, 1992, INT J OBESITY, V16, P321; HORTON TJ, 1995, AM J CLIN NUTR, V62, P19, DOI 10.1093/ajcn/62.1.19; Kaltenbach M, 1984, MANGER CORRECTEMENT; Klein S, 1996, DIABETES, V45, P984, DOI 10.2337/diabetes.45.7.984; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; Kolattukudy P E, 1981, Methods Enzymol, V71 Pt C, P150; Lee Y, 2001, J BIOL CHEM, V276, P5629, DOI 10.1074/jbc.M008553200; Levine JA, 2000, AM J CLIN NUTR, V72, P1451; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mizuno T, 1996, HORM METAB RES, V28, P679, DOI 10.1055/s-2007-979877; Mizuno TM, 1996, P NATL ACAD SCI USA, V93, P3434, DOI 10.1073/pnas.93.8.3434; Mueller WM, 1998, ENDOCRINOLOGY, V139, P551, DOI 10.1210/en.139.2.551; MUNSON PJ, 1989, P STAT COMP SECT AM, P295; Muscelli E, 2005, AM J MED, V118, P51, DOI 10.1016/j.amjmed.2004.08.017; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; PRESS WH, 1992, NUMERICAL RECIPES C, P537; Reseland JE, 2001, AM J CLIN NUTR, V73, P240; Rosa G, 2003, OBES RES, V11, P1306, DOI 10.1038/oby.2003.177; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; Saad MF, 1998, DIABETES, V47, P544, DOI 10.2337/diabetes.47.4.544; Schmitz O, 1997, DIABETES METAB, V23, P80; Schoeller DA, 1997, J CLIN INVEST, V100, P1882, DOI 10.1172/JCI119717; SCOPINARO N, 1979, BRIT J SURG, V66, P618, DOI 10.1002/bjs.1800660906; Sinha MK, 1996, BIOCHEM BIOPH RES CO, V228, P733, DOI 10.1006/bbrc.1996.1724; Steinberg GR, 2000, AM J PHYSIOL-ENDOC M, V279, pE1374, DOI 10.1152/ajpendo.2000.279.6.E1374; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V283, pE187, DOI 10.1152/ajpendo.00542.2001; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Storlien L, 2004, P NUTR SOC, V63, P363, DOI 10.1079/PNS2004349; Tataranni PA, 1997, ANN NY ACAD SCI, V819, P37, DOI 10.1111/j.1749-6632.1997.tb51797.x; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; TREMBLAY A, 1989, AM J CLIN NUTR, V49, P799, DOI 10.1093/ajcn/49.5.799; Ueno N, 2004, ENDOCRINOLOGY, V145, P4176, DOI 10.1210/en.2004-0262; Unger RH, 2002, BBA-MOL CELL BIOL L, V1585, P202, DOI 10.1016/S1388-1981(02)00342-6; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; Wellhoener P, 2000, J CLIN ENDOCR METAB, V85, P1267, DOI 10.1210/jc.85.3.1267; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Xu B, 1999, ENDOCRINOLOGY, V140, P2868, DOI 10.1210/en.140.6.2868; Yildiz BO, 2004, P NATL ACAD SCI USA, V101, P10434, DOI 10.1073/pnas.0403465101	64	14	14	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1380	+		10.1096/fj.04-3453fje	http://dx.doi.org/10.1096/fj.04-3453fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15955844				2022-12-25	WOS:000230207800019
J	Pajusola, K; Kunnapuu, J; Vuorikoski, S; Soronen, J; Andre, H; Pereira, T; Korpisalo, P; Yla-Herttuala, S; Poellinger, L; Alitalo, K				Pajusola, K; Kunnapuu, J; Vuorikoski, S; Soronen, J; Andre, H; Pereira, T; Korpisalo, P; Yla-Herttuala, S; Poellinger, L; Alitalo, K			Stabilized HIF-1 alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer	FASEB JOURNAL			English	Article						cardiovascular ischemic diseases; pro-angiogenic gene therapy; arteriogenic growth factor	GROWTH-FACTOR; HYPOXIA; EXPRESSION; INDUCTION; HYPERPERMEABILITY; ANGIOPOIETIN-1; PROLIFERATION; LETHALITY; THERAPY; HIF-1	Therapeutic angiogenesis provides a potential alternative for the treatment of cardiovascular ischemic diseases. Vascular endothelial growth factor ( VEGF) is an important component of the angiogenic response to ischemia. Here we used adeno-associated virus (AAV) gene delivery to skeletal muscle to examine the effects of VEGF vs. a stabilized form of hypoxia-inducible factor-1 alpha ( HIF-1 alpha). The recombinant AAVs were injected into mouse tibialis anterior muscle, and their effects were analyzed by immunohistochemistry and functional assays. These analyses showed that stabilized HIF-1 alpha markedly increase capillary sprouting and proliferation, whereas VEGF(164) or VEGF(120) induced only proliferation of endothelial cells without formation of proper capillary structures. The Evans Blue permeability assay indicated that, unlike VEGF, HIF-1 alpha overexpression did not increase vascular leakiness in the transduced muscle. Doppler ultrasound imaging showed that vascular perfusion in the HIF-1 alpha treated muscles was significantly enhanced when compared to the controls and not further improved by co-expression of the arteriogenic growth factors angiopoietin-1 or platelet-derived growth factor-B. Our results show that AAV-mediated transduction of a stabilized form of HIF-1 alpha can circumvent the problems associated with overexpression of individual angiogenic growth factors. HIF-1 alpha should thus offer a potent alternative for pro-angiogenic gene therapy.	Univ Helsinki, Mol Canc Biol Lab, Biomed Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Biomed Helsinki, Helsinki, Finland; Univ Kuopio, AI Virtanen Inst, Kuopio, Finland; Univ Kuopio, Dept Med, SF-70210 Kuopio, Finland; Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Eastern Finland; University of Eastern Finland; Karolinska Institutet	Alitalo, K (corresponding author), Univ Helsinki, Mol Canc Biol Lab, Biomed Helsinki, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	kari.alitalo@helsinki.fi	Andre, Helder/AAC-5220-2019; Vulli, Jaana/C-1085-2015; Alitalo, Kari K/J-5013-2014; Pereira, Teresa/AAP-8197-2020	Andre, Helder/0000-0002-2926-2376; Vulli, Jaana/0000-0001-9509-1862; Alitalo, Kari K/0000-0002-7331-0902; Pereira, Teresa/0000-0001-8654-2385; Yla-Herttuala, Seppo/0000-0001-7593-2708				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bekeredjian R, 2004, AM J MED SCI, V327, P139; Brown M. D., 2003, Angiogenesis, V6, P1, DOI 10.1023/A:1025809808697; Buning H, 2004, CELLS TISSUES ORGANS, V177, P139, DOI 10.1159/000079988; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chu Danny, 2004, Methods Mol Biol, V246, P213; Clauss M, 1998, TRENDS CARDIOVAS MED, V8, P241, DOI 10.1016/S1050-1738(98)00015-2; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dor Y, 2003, ANN NY ACAD SCI, V995, P208, DOI 10.1111/j.1749-6632.2003.tb03224.x; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745; Hauck B, 2004, J VIROL, V78, P13678, DOI 10.1128/JVI.78.24.13678-13686.2004; Hewitson KS, 2004, DRUG DISCOV TODAY, V9, P704, DOI 10.1016/S1359-6446(04)03202-7; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; MANALO DJ, 2004, BLOOD; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Paterna JC, 2000, GENE THER, V7, P1304, DOI 10.1038/sj.gt.3301221; Pereira T, 2003, J BIOL CHEM, V278, P6816, DOI 10.1074/jbc.M209297200; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Ritter T, 2002, BIODRUGS, V16, P3, DOI 10.2165/00063030-200216010-00001; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 2002, J ANAT, V200, P575, DOI 10.1046/j.1469-7580.2002.00061.x; Tuomisto TT, 2004, ATHEROSCLEROSIS, V174, P111, DOI 10.1016/j.atherosclerosis.2004.01.015; Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood-2004-04-1485; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694	40	101	109	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1365	+		10.1096/fj.05-3720fje	http://dx.doi.org/10.1096/fj.05-3720fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15958522				2022-12-25	WOS:000230207800014
J	Gurvich, N; Berman, MG; Wittner, BS; Gentleman, RC; Klein, PS; Green, JBA				Gurvich, N; Berman, MG; Wittner, BS; Gentleman, RC; Klein, PS; Green, JBA			Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo	FASEB JOURNAL			English	Article						valproic acid; HDAC; trichostatin A; Xenopus laevis; Danio rerio; spina bifida	NEURAL-TUBE DEFECTS; GENE-EXPRESSION; HDAC INHIBITORS; ACID; MOUSE; ACETYLATION; DIFFERENTIATION; ANTICONVULSANT; TARGET; MODEL	Chemically induced birth defects are an important public health and human problem. Here we use Xenopus and zebrafish as models to investigate the mechanism of action of a well-known teratogen, valproic acid (VPA). VPA is a drug used in treatment of epilepsy and bipolar disorder but causes spina bifida if taken during pregnancy. VPA has several biochemical activities, including inhibition of histone deacetylases (HDACs). To investigate the mechanism of action of VPA, we compared its effects in Xenopus and zebrafish embryos with those of known HDAC inhibitors and noninhibitory VPA analogs. We found that VPA and other HDAC inhibitors cause very similar and characteristic developmental defects whereas VPA analogs with poor inhibitory activity in vivo have little teratogenic effect. Unbiased microarray analysis revealed that the effects of VPA and trichostatin A (TSA), a structurally unrelated HDAC inhibitor, are strikingly concordant. The concordance is apparent both by en masse correlation of fold-changes and by detailed similarity of dose-response profiles of individual genes. Together, the results demonstrate that the teratogenic effects of VPA are very likely mediated specifically by inhibition of HDACs.	Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA	University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; University of Pennsylvania; Harvard University; Harvard Medical School	Green, JBA (corresponding author), Guys Hosp, Univ London Kings Coll, Dept Craniofacial Dev, Floor 28 Guys Tower, London SE1 9RT, England.	jeremy.green@kcl.ac.uk	Green, Jeremy/F-3630-2010	Green, Jeremy/0000-0002-6102-2620	NIEHS NIH HHS [R21ES11710] Funding Source: Medline; NIMH NIH HHS [R01MH64761] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES011710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064761] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blaheta RA, 2002, MED RES REV, V22, P492, DOI 10.1002/med.10017; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Briner W, 2000, NEUROTOXICOL TERATOL, V22, P761, DOI 10.1016/S0892-0362(00)00086-6; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; DAWSON DA, 1991, TERATOLOGY, V44, P531, DOI 10.1002/tera.1420440507; DAWSON DA, 1987, J APPL TOXICOL, V7, P237, DOI 10.1002/jat.2550070403; Finnell RH, 2002, ANNU REV PHARMACOL, V42, P181, DOI 10.1146/annurev.pharmtox.42.083001.110955; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Glaser KB, 2003, MOL CANCER THER, V2, P151; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; HERRMANN K, 1993, TOXICOL IN VITRO, V7, P41, DOI 10.1016/0887-2333(93)90111-H; Kook H, 2003, J CLIN INVEST, V112, P863, DOI 10.1172/JCI200319137; Kratke R, 1996, TERATOGEN CARCIN MUT, V16, P149; Kultima K, 2004, ENVIRON HEALTH PERSP, V112, P1225, DOI 10.1289/txg.7034; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; NARUSE I, 1988, TERATOLOGY, V38, P87, DOI 10.1002/tera.1420380113; *NAT AC SCI, 2000, SCI FRONT DEV TOX RI; NAU H, 1994, CIBA F SYMP, V181, P144; NAU H, 1991, PHARMACOL TOXICOL, V69, P310, DOI 10.1111/j.1600-0773.1991.tb01303.x; OBEREMM A, 1992, TERATOGEN CARCIN MUT, V12, P251, DOI 10.1002/tcm.1770120603; Pennati R, 2001, TERATOGEN CARCIN MUT, V21, P121, DOI 10.1002/1520-6866(2001)21:2<121::AID-TCM2>3.0.CO;2-N; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Svensson K, 1998, DEVELOPMENT, V125, P61; Tou LQ, 2004, MOL CELL BIOL, V24, P3132, DOI 10.1128/MCB.24.8.3132-3139.2004; Tremolizzo L, 2002, P NATL ACAD SCI USA, V99, P17095, DOI 10.1073/pnas.262658999; van Straaten HWM, 2001, ANAT EMBRYOL, V203, P225, DOI 10.1007/s004290100169; VANSTRAATEN HWM, 1993, DEVELOPMENT, V117, P1163; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yildirim E, 2003, NEUROSCI LETT, V345, P141, DOI 10.1016/S0304-3940(03)00490-7	35	146	150	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1166	+		10.1096/fj.04-3425fje	http://dx.doi.org/10.1096/fj.04-3425fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15901671				2022-12-25	WOS:000229602600011
J	Peng, J; Stevenson, FF; Doctrow, SR; Andersen, JK				Peng, J; Stevenson, FF; Doctrow, SR; Andersen, JK			Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra - Implications for Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVIRONMENTAL RISK-FACTORS; HERBICIDE PARAQUAT; OXIDATIVE STRESS; SIGNAL-TRANSDUCTION; WELL WATER; LIFE-SPAN; EXPOSURE; MICE; PESTICIDES; BRAIN	Exposure of mice to the herbicide paraquat has been demonstrated to result in the selective loss of dopaminergic neurons of the substantia nigra, pars compacta (SNpc) akin to what is observed in Parkinson disease (PD). In this study, we investigate the efficacy of two synthetic superoxide dismutase/catalase mimetics (EUK-134 and EUK-189) in protecting against paraquat-induced dopaminergic cell death in both the rat dopaminergic cell line 1RB(3)AN(27) (N27) and primary mesencephalic cultures in vitro and in adult mice in vivo. Our data demonstrate that pretreatment with either EUK-134 or EUK-189 significantly attenuates paraquat-induced neurotoxicity in vitro in a concentration-dependent manner. Furthermore, systemic administration of EUK-189 decreases paraquat-mediated SNpc dopaminergic neuronal cell death in vivo. These findings support a role for oxidative stress in paraquat-induced neurotoxicity and suggest novel therapeutic approaches for neurodegenerative disorders associated with oxidative stress such as PD.	Buck Inst Age Res, Novato, CA 94945 USA; Eukarion Inc, Bedford, MA 01730 USA	Buck Institute for Research on Aging	Andersen, JK (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	jandersen@buckinstitute.org		Doctrow, Susan/0000-0003-0628-9960; Andersen, Julie/0000-0003-1324-4875	NIEHS NIH HHS [U54 ES12077] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012077] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JD, 2001, CURR MED CHEM, V8, P809, DOI 10.2174/0929867013372995; Alam ZI, 1997, J NEUROCHEM, V69, P1326; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; BAUDRY M, 1993, BIOCHEM BIOPH RES CO, V192, P964, DOI 10.1006/bbrc.1993.1509; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; BURKITT MJ, 1993, MOL PHARMACOL, V43, P257; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; CLEJAN L, 1989, BIOCHEM PHARMACOL, V38, P1779, DOI 10.1016/0006-2952(89)90412-7; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; GONZALEZ PK, 1995, J PHARMACOL EXP THER, V275, P798; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; HERTZMAN C, 1990, AM J IND MED, V17, P349, DOI 10.1002/ajim.4700170307; JELLINGER KA, 1993, ADV NEUROL, V60, P267; JIMENEZJIMENEZ FJ, 1992, MOVEMENT DISORD, V7, P149, DOI 10.1002/mds.870070209; Jung CW, 2001, NEUROSCI LETT, V304, P157, DOI 10.1016/S0304-3940(01)01784-0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Malfroy B, 1997, CELL IMMUNOL, V177, P62, DOI 10.1006/cimm.1997.1091; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Melov S, 2001, J NEUROSCI, V21, P8348, DOI 10.1523/JNEUROSCI.21-21-08348.2001; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; Peng J, 2004, J BIOL CHEM, V279, P32626, DOI 10.1074/jbc.M404596200; Peng J, 2002, J BIOL CHEM, V277, P44285, DOI 10.1074/jbc.M207407200; PERRY TL, 1986, NEUROSCI LETT, V67, P269, DOI 10.1016/0304-3940(86)90320-4; PRASAD KN, 1994, IN VITRO CELL DEV-AN, V30A, P596; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; Shimura-Miura H, 1999, ANN NEUROL, V46, P920, DOI 10.1002/1531-8249(199912)46:6<920::AID-ANA17>3.0.CO;2-R; SOFIC E, 1991, J NEUROCHEM, V56, P978, DOI 10.1111/j.1471-4159.1991.tb02017.x; Stephenson J, 2000, JAMA-J AM MED ASSOC, V283, P3055, DOI 10.1001/jama.283.23.3055; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696	42	134	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29194	29198		10.1074/jbc.M500984200	http://dx.doi.org/10.1074/jbc.M500984200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15946937	hybrid			2022-12-25	WOS:000231021300047
J	Ertel, F; Mirus, O; Bredemeier, R; Moslavac, S; Becker, T; Schleiff, E				Ertel, F; Mirus, O; Bredemeier, R; Moslavac, S; Becker, T; Schleiff, E			The evolutionarily related beta-barrel polypeptide transporters from Pisum sativum and Nostoc PCC7120 contain two distinct functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; PROTEIN IMPORT CHANNEL; CONSERVED BACTERIAL PROTEIN; GRAM-NEGATIVE BACTERIA; SERRATIA-MARCESCENS; PHYSICAL-PROPERTIES; ASSEMBLY MACHINERY; ESCHERICHIA-COLI; ENVELOPE; BIOGENESIS	Several beta-barrel-type channels are involved in the translocation or assembly of outer membrane proteins of bacteria or endosymbiotically derived organelles. Here we analyzed the functional units of the beta-barrel polypeptide transporter Toc75 (translocon in outer envelope of chloroplasts) of the outer envelope of chloroplasts and of a protein, alr2269, from Nostoc PCC7120 with homology to Toc75, both proteins having a similar domain organization. We demonstrated that the N-terminal region functions as a recognition and complex assembly unit, whereas the C terminus forms the beta-barreltype pore. The pore region is, in turn, modulated by the N terminus of the proteins. The protein from Nostoc PCC7120, which shares a common ancestor with Toc75, is able to recognize precursor proteins destined for chloroplasts. In contrast, the recognition of peripheral translocon subunits by Toc75 is a novel feature acquired through evolution.	Univ Munich, Dept Biol 1, D-80638 Munich, Germany	University of Munich	Schleiff, E (corresponding author), Univ Munich, Dept Biol 1, Menzinger Str 67, D-80638 Munich, Germany.	schleiff@lrz.uni-muenchen.de	Becker, Thomas/AAS-9404-2020; Schleiff, Enrico/C-5105-2017	Schleiff, Enrico/0000-0002-0518-3489				ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; Becker T, 2004, EMBO J, V23, P520, DOI 10.1038/sj.emboj.7600089; Bevans CG, 1999, J BIOL CHEM, V274, P3711, DOI 10.1074/jbc.274.6.3711; Bolter B, 1998, P NATL ACAD SCI USA, V95, P15831, DOI 10.1073/pnas.95.26.15831; Genevrois S, 2003, EMBO J, V22, P1780, DOI 10.1093/emboj/cdg174; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hertle R, 1997, MOL MICROBIOL, V26, P853, DOI 10.1046/j.1365-2958.1997.6031978.x; Hincha DK, 2003, BBA-BIOMEMBRANES, V1611, P180, DOI 10.1016/S0005-2736(03)00053-1; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; Inoue K, 2004, PLANT J, V39, P354, DOI 10.1111/j.1365-313X.2004.02135.x; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; Jacob-Dubuisson F, 2001, MOL MICROBIOL, V40, P306, DOI 10.1046/j.1365-2958.2001.02278.x; Konninger UW, 1999, MOL MICROBIOL, V32, P1212, DOI 10.1046/j.1365-2958.1999.01433.x; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; Martin W, 2002, P NATL ACAD SCI USA, V99, P12246, DOI 10.1073/pnas.182432999; Milenkovic D, 2004, J BIOL CHEM, V279, P22781, DOI 10.1074/jbc.C400120200; Moslavac S, 2005, FEBS J, V272, P1367, DOI 10.1111/j.1742-4658.2005.04569.x; MOSLAVAC S, 2005, IN PRESS J PROTEOME; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Pencer J, 2001, BIOPHYS J, V81, P2716, DOI 10.1016/S0006-3495(01)75914-0; Reumann S, 1999, P NATL ACAD SCI USA, V96, P784, DOI 10.1073/pnas.96.2.784; Sanchez-Pulido L, 2003, TRENDS BIOCHEM SCI, V28, P523, DOI 10.1016/j.tibs.2003.08.003; SCHIEBEL E, 1989, J BIOL CHEM, V264, P16311; Schleiff E, 1998, BIOCHEMISTRY-US, V37, P13043, DOI 10.1021/bi9807456; Schleiff E, 2003, PROTEIN SCI, V12, P748, DOI 10.1110/ps.0237503; Schleiff E, 2002, PLANT MOL BIOL, V50, P177, DOI 10.1023/A:1016027020193; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; Shimizu T, 2004, J MOL BIOL, V339, P1, DOI 10.1016/j.jmb.2004.03.048; Smart OS, 1997, BIOPHYS J, V72, P1109, DOI 10.1016/S0006-3495(97)78760-5; Soll J, 2004, NAT REV MOL CELL BIO, V5, P198, DOI 10.1038/nrm1333; Surana NK, 2004, P NATL ACAD SCI USA, V101, P14497, DOI 10.1073/pnas.0404679101; Sveshnikova N, 2000, BIOL CHEM, V381, P687, DOI 10.1515/BC.2000.089; Timmis JN, 2004, NAT REV GENET, V5, P123, DOI 10.1038/nrg1271; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; Voulhoux R, 2004, RES MICROBIOL, V155, P129, DOI 10.1016/j.resmic.2003.11.007; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Waizenegger T, 2004, EMBO REP, V5, P704, DOI 10.1038/sj.embor.7400183; White GF, 2000, BBA-BIOMEMBRANES, V1468, P175, DOI 10.1016/S0005-2736(00)00255-8; Wimley WC, 2003, CURR OPIN STRUC BIOL, V13, P404, DOI 10.1016/S0959-440X(03)00099-X; Yen MR, 2002, BBA-BIOMEMBRANES, V1562, P6, DOI 10.1016/S0005-2736(02)00359-0	45	85	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28281	28289		10.1074/jbc.M503035200	http://dx.doi.org/10.1074/jbc.M503035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15951438	hybrid			2022-12-25	WOS:000230857300014
J	Miyamoto, S; Patel, P; Hershey, JWB				Miyamoto, S; Patel, P; Hershey, JWB			Changes in ribosomal binding activity of eIF3 correlate with increased translation rates during activation of T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; FACTOR 3 SUBUNITS; MESSENGER-RNA; GENE-EXPRESSION; PHORBOL ESTERS; COMPLEX; PHYTOHEMAGGLUTININ; STIMULATION; ASSOCIATION; INTERACTS	The rate of protein synthesis in quiescent peripheral blood T lymphocytes increases dramatically following mitogenic activation. The stimulation of translation is due to an increase in the rate of initiation caused by the regulation of initiation factor activities. Here, we focus on eIF3, a large multiprotein complex that plays a central role in the formation of the 40 S initiation complex. Using sucrose density gradient centrifugation to analyze ribosome complexes, we find that most eIF3 is not bound to 40 S ribosomal subunits in unactivated T lymphocytes but becomes ribosome-bound following activation. Immunoblot analyses of sucrose gradient fractions for individual eIF3 subunits show that the small eIF3j subunit is unassociated with the eIF3 complex in quiescent T lymphocytes, but upon activation joins the other eIF3 subunits and binds 40 S ribosomal subunits. Because eIF3j has been shown to be required for eIF3 binding to 40 S ribosomes in vitro, the results suggest that mitogenic stimulation of T lymphocytes leads to an activation of eIF3j, thereby enabling eIF3 to bind to the larger ribosome-free eIF3 subunit complex, and then to the 40 S ribosomes. The association of eIF3j with the other eIF3 subunits appears to be inhibited by rapamycin, suggesting a mechanism that lies downstream from the mammalian target of rapamycin kinase. This association requires ionomycin together with a phorbol ester, which also suggests that calcium signaling is involved. We conclude that the complex formation of eIF3 and its association with the ribosomes might contribute to increased translation rates during T lymphocyte activation.	Univ Calif Davis, Ctr Canc, Div Hematol Oncol, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Miyamoto, S (corresponding author), Univ Calif Davis, Ctr Canc, Div Hematol Oncol, 4501 X St,Rm 3016, Sacramento, CA 95817 USA.	smiyamot@ucdavis.edu			NIGMS NIH HHS [GM22135] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHERN T, 1973, BIOCHIM BIOPHYS ACTA, V331, P91, DOI 10.1016/0005-2787(73)90422-X; AHERN T, 1971, BIOCHEM J, V125, pP73; AHERN T, 1974, NATURE, V248, P519, DOI 10.1038/248519a0; AHERN T, 1975, EXP CELL RES, V92, P513, DOI 10.1016/0014-4827(75)90410-3; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; AYUSOPARILLA M, 1973, J BIOL CHEM, V248, P4386; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BOAL TR, 1993, BIOCHIM BIOPHYS ACTA, V1176, P257, DOI 10.1016/0167-4889(93)90053-R; Browning KS, 2001, TRENDS BIOCHEM SCI, V26, P284, DOI 10.1016/S0968-0004(01)01825-4; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; CARINI C, 1993, INT ARCH ALLERGY IMM, V101, P31, DOI 10.1159/000236495; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; COOPER HL, 1977, J CELL PHYSIOL, V93, P213, DOI 10.1002/jcp.1040930207; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dunand-Sauthier I, 2002, MOL BIOL CELL, V13, P1626, DOI 10.1091/mbc.01-06-0301; Fraser CS, 2004, J BIOL CHEM, V279, P8946, DOI 10.1074/jbc.M312745200; Grolleau A, 2000, J CLIN INVEST, V106, P1561, DOI 10.1172/JCI9352; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P637; Hui DJ, 2003, J BIOL CHEM, V278, P39477, DOI 10.1074/jbc.M305038200; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; JAGUS R, 1979, EUR J BIOCHEM, V100, P503, DOI 10.1111/j.1432-1033.1979.tb04195.x; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; KAY JE, 1983, IMMUNOL LETT, V7, P151, DOI 10.1016/0165-2478(83)90063-9; KAY JE, 1968, EUR J BIOCHEM, V4, P225, DOI 10.1111/j.1432-1033.1968.tb00198.x; KAY JE, 1967, NATURE, V215, P737, DOI 10.1038/215737a0; KAY JE, 1969, EXP CELL RES, V58, P185, DOI 10.1016/0014-4827(69)90134-7; KAY JE, 1975, BIOCHIM BIOPHYS ACTA, V378, P241, DOI 10.1016/0005-2787(75)90112-4; KAY JE, 1971, BIOCHIM BIOPHYS ACTA, V247, P322, DOI 10.1016/0005-2787(71)90680-0; KAY JE, 1979, CELL BIOL IMMUNOLOGY, P107; Kedersha N, 2002, MOL BIOL CELL, V13, P195, DOI 10.1091/mbc.01-05-0221; KUMAGAI N, 1987, J IMMUNOL, V139, P1393; KUMAGAI N, 1988, J CELL PHYSIOL, V137, P329, DOI 10.1002/jcp.1041370217; KUMAR RV, 1989, J CELL BIOL, V108, P2107, DOI 10.1083/jcb.108.6.2107; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Majumdar R, 2003, J BIOL CHEM, V278, P6580, DOI 10.1074/jbc.M210357200; MAO XH, 1992, J BIOL CHEM, V267, P20444; Methot N, 1996, MOL CELL BIOL, V16, P5328; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MEYER LJ, 1981, J BIOL CHEM, V256, P351; Miyamoto S, 1999, BIOCHEM J, V344, P803, DOI 10.1042/0264-6021:3440803; Miyamoto S, 1996, BIOCHEM J, V315, P791, DOI 10.1042/bj3150791; Miyamoto S, 2000, BBA-GENE STRUCT EXPR, V1494, P28, DOI 10.1016/S0167-4781(00)00208-6; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; Morley Simon J., 1993, Biochemical Society Transactions, V21, p397S; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; Nishida J, 2002, J BIOCHEM, V131, P485, DOI 10.1093/oxfordjournals.jbchem.a003125; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Shi JQ, 2003, J BIOL CHEM, V278, P5062, DOI 10.1074/jbc.M206427200; TAMORI S, 1989, ACTA HAEMATOL JAPON, V52, P996; TOLAN DR, 1983, BIOCHIMIE, V65, P427, DOI 10.1016/S0300-9084(83)80062-5; Valasek L, 2004, MOL CELL BIOL, V24, P9437, DOI 10.1128/MCB.24.21.9437-9455.2004; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; WALLACE DM, 1981, BIOSCIENCE REP, V1, P539, DOI 10.1007/BF01116302; WALLACE DM, 1979, BIOCHEM J, V184, P277, DOI 10.1042/bj1840277; WEISS A, 1984, J IMMUNOL, V133, P123; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410	69	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28251	28264		10.1074/jbc.M414129200	http://dx.doi.org/10.1074/jbc.M414129200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15946946	hybrid			2022-12-25	WOS:000230857300011
J	Wilson, S; Wilkinson, G; Milligan, G				Wilson, S; Wilkinson, G; Milligan, G			The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; RESONANCE ENERGY-TRANSFER; LIGAND-INDEPENDENT DIMERIZATION; BIOLUMINESCENCE-RESONANCE; LIVING CELLS; CHEMOKINE RECEPTORS; OLIGOMERIZATION; RHODOPSIN; SURFACE; DELTA	Both homo- and heterodimeric interactions between the CXCR1 and CXCR2 chemokine receptors were observed following co-expression of forms of these receptors in HEK293 cells using assays, including co-immuno-precipitation, single cell imaging of fluorescence resonance energy transfer, cell surface time-resolved fluorescence resonance energy transfer, and bioluminescence resonance energy transfer. These interactions were constitutive and unaffected by the presence of the agonist interleukin 8 and selective as no significant interactions were noted between either the CXCR1 or CXCR2 receptor and the alpha(1A)-adrenoreceptor. Saturation bioluminescence resonance energy transfer indicated that heteromeric interactions between CXCR1 and CXCR2 were of similar affinity as the corresponding homomeric interactions. A novel endoplasmic reticulum trapping strategy demonstrated that these interactions were initiated during protein synthesis and maturation and prior to cell surface delivery. These studies indicated that CXCR1-CXCR2 heterodimers are as likely to form in cells co- expressing these two chemokine receptors as the corresponding homodimers and stand in contrast to previous studies indicating an inability of the CXCR1 receptor to homodimerize or to interact with the CXCR2 receptor.	Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; AstraZeneca, Biol Chem, Macclesfield SK10 4TG, Cheshire, England	University of Glasgow; AstraZeneca	Milligan, G (corresponding author), Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Berglund MM, 2003, J PHARMACOL EXP THER, V307, P1120, DOI 10.1124/jpet.103.055673; Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; CAO T, 2004, MOL PHARMACOL, V67, P288; Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Eglen RM, 2002, ASSAY DRUG DEV TECHN, V1, P97, DOI 10.1089/154065802761001356; El-Asmar L, 2005, MOL PHARMACOL, V67, P460, DOI 10.1124/mol.104.003624; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Hall DA, 1999, BRIT J PHARMACOL, V126, P810, DOI 10.1038/sj.bjp.0702329; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Javitch JA, 2004, MOL PHARMACOL, V66, P1077, DOI 10.1124/mol.104.006320; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kostenis E, 2005, CIRCULATION, V111, P1806, DOI 10.1161/01.CIR.0000160867.23556.7D; Latif R, 2002, J BIOL CHEM, V277, P45059, DOI 10.1074/jbc.M206693200; Lee SP, 2004, J BIOL CHEM, V279, P35671, DOI 10.1074/jbc.M401923200; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Margeta-Mitrovic M, 2002, METHODS, V27, P311, DOI 10.1016/S1046-2023(02)00088-9; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.; Milligan G, 2004, EUR J PHARM SCI, V21, P397, DOI 10.1016/j.ejps.2003.11.010; Milligan G, 2003, LIFE SCI, V74, P181, DOI 10.1016/j.lfs.2003.09.005; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Ramsay D, 2004, MOL PHARMACOL, V66, P228, DOI 10.1124/mol.66.2.228; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Rodriguez-Frade JM, 2001, TRENDS IMMUNOL, V22, P612, DOI 10.1016/S1471-4906(01)02036-1; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Suzuki S, 2002, EXP CELL RES, V280, P192, DOI 10.1006/excr.2002.5638; Tao YX, 2004, J BIOL CHEM, V279, P5904, DOI 10.1074/jbc.M311162200; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Trettel F, 2003, J BIOL CHEM, V278, P40980, DOI 10.1074/jbc.M306815200; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; Wang DX, 2005, MOL PHARMACOL, V67, P2173, DOI 10.1124/mol.104.010272; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	57	103	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28663	28674		10.1074/jbc.M413475200	http://dx.doi.org/10.1074/jbc.M413475200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15946947	hybrid			2022-12-25	WOS:000230857300057
J	Andersson, MX; Larsson, KE; Tjellstrom, H; Liljenberg, C; Sandelius, AS				Andersson, MX; Larsson, KE; Tjellstrom, H; Liljenberg, C; Sandelius, AS			The plasma membrane and the tonoplast as major targets for phospholipid- to-glycolipid replacement and stimulation of phospholipases in the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE DEPRIVATION; GALACTOLIPID DIGALACTOSYLDIACYLGLYCEROL; LIPID-COMPOSITION; ARABIDOPSIS; PHOSPHATIDYLCHOLINE; LEAVES; CELLS; CHLOROPLAST; ACQUISITION; STRESS	We recently reported that cultivation of oat (Avena sativa L.) without phosphate resulted in plasma membrane phosphoglycerolipids being replaced to a large extent by digalactosyldiacylglycerol (DGDG) (Andersson, M. X., Stridh, M. H., Larsson, K. E., Liljenberg, C., and Sandelius, A. S. ( 2003) FEBS Lett. 537, 128-132). We report here that DGDG is not the only non-phosphorous-containing lipid that replaces phospholipids but that also the content of glucosylceramides and sterolglycosides increased in plasma membranes as a response to phosphate starvation. In addition, phosphate deficiency induced similar changes in lipid composition in the tonoplast. The phospholipid-to-glycolipid replacement apparently did not occur to any greater extent in endoplasmic reticulum, Golgi apparatus, or mitochondrial inner membranes. In contrast to the marked effects on lipid composition, the polypeptide patterns were largely similar between root plasma membranes from well-fertilized and phosphate-limited oat, although the latter condition induced at least four polypeptides, including a chaperone of the HSP80 or HSP90 family, a phosphate transporter, and a bacterial-type phosphoesterase. The latter polypeptide reacted with an antibody raised against a phosphate deficiency-induced phospholipase C from Arabidopsis thaliana (Nakamura, Y., Awai, K., Masuda, T., Yoshioka, Y., Takamiya, K., and Ohta, H. ( 2005) J. Biol. Chem. 280, 7469-7476). In plasma membranes from oat, however, a phospholipase D-type activity and a phosphatidic acid phosphatase were the dominant lipase activities induced by phosphate deficiency. Our results reflect a highly developed plasticity in the lipid composition of the plasma membrane and the tonoplast. In addition, phosphate deficiency-induced alterations in plasma membrane lipid composition may involve different sets of lipid-metabolizing enzymes in different plant tissues or species, at different stages of plant development and/or at different stages of stress adjustments.	Univ Gothenburg, Dept Bot, SE-40530 Gothenburg, Sweden	University of Gothenburg	Sandelius, AS (corresponding author), Univ Gothenburg, Dept Bot, POB 461, SE-40530 Gothenburg, Sweden.	annastina.sandelius@botany.gu.se	Andersson, Mats/E-7958-2010	Andersson, Mats/0000-0003-4279-6572				Andersson MX, 2004, BBA-MOL CELL BIOL L, V1684, P46, DOI 10.1016/j.bbalip.2004.06.003; Andersson MX, 2003, FEBS LETT, V537, P128, DOI 10.1016/S0014-5793(03)00109-1; BECART J, 1990, HRC-J HIGH RES CHROM, V13, P126; BENNING C, 1995, ARCH BIOCHEM BIOPHYS, V317, P103, DOI 10.1006/abbi.1995.1141; FREDRIKSON K, 1989, PHYSIOL PLANTARUM, V77, P196, DOI 10.1111/j.1399-3054.1989.tb04969.x; Gaude N, 2004, J BIOL CHEM, V279, P34624, DOI 10.1074/jbc.M404098200; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Hartel H, 2000, BIOCHEM SOC T, V28, P729, DOI 10.1042/BST0280729; Hartel H, 2001, J PHOTOCH PHOTOBIO B, V61, P46, DOI 10.1016/S1011-1344(01)00144-0; HOLM M, 1972, BIOCHIM BIOPHYS ACTA, V280, P356, DOI 10.1016/0005-2760(72)90104-X; Jouhet J, 2004, J CELL BIOL, V167, P863, DOI 10.1083/jcb.200407022; Jouhet J, 2003, FEBS LETT, V544, P63, DOI 10.1016/S0014-5793(03)00477-0; Kjellberg JM, 2000, BBA-MOL CELL BIOL L, V1485, P100, DOI 10.1016/S1388-1981(00)00040-8; LARSSON C, 1983, ISOLATION MEMBRANES, P277; LILJENBERG C, 1985, CAN J BIOCHEM CELL B, V63, P77, DOI 10.1139/o85-011; Lopez-Lara IM, 2003, MOL PLANT MICROBE IN, V16, P567, DOI 10.1094/MPMI.2003.16.7.567; Mileykovskaya E, 1997, J BACTERIOL, V179, P1029, DOI 10.1128/jb.179.4.1029-1034.1997; MINNIKIN DE, 1974, NATURE, V249, P268, DOI 10.1038/249268a0; Mueller-Roeber B, 2002, PLANT PHYSIOL, V130, P22, DOI 10.1104/pp.004770; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; Nakamura Y, 2005, J BIOL CHEM, V280, P7469, DOI 10.1074/jbc.M408799200; NORBERG P, 1991, PLANT PHYSIOL, V96, P1136, DOI 10.1104/pp.96.4.1136; Olsen JV, 2004, MOL CELL PROTEOMICS, V3, P608, DOI 10.1074/mcp.T400003-MCP200; Raghothama KG, 1999, ANNU REV PLANT PHYS, V50, P665, DOI 10.1146/annurev.arplant.50.1.665; ROCHESTER CP, 1987, PHYSIOL PLANTARUM, V71, P257, DOI 10.1111/j.1399-3054.1987.tb04339.x; Sandelius A. S., 1990, The plant plasma membrane., P44; SANDELIUS AS, 1990, PLANT LIPID BIOCHEMISTRY, STRUCTURE AND UTILIZATION, P257; SANDELIUS AS, 1986, PLANT PHYSIOL, V81, P177, DOI 10.1104/pp.81.1.177; Smith FW, 1997, PLANT J, V11, P83, DOI 10.1046/j.1365-313X.1997.11010083.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMMARIN M, 1988, BIOCHIM BIOPHYS ACTA, V958, P268, DOI 10.1016/0005-2760(88)90185-3; Vance CP, 2003, NEW PHYTOL, V157, P423, DOI 10.1046/j.1469-8137.2003.00695.x; VERHOEK B, 1983, Z NATURFORSCH C, V38, P770; Wang XM, 2002, CURR OPIN PLANT BIOL, V5, P408, DOI 10.1016/S1369-5266(02)00283-2; Widell S., 1990, The plant plasma membrane., P16	35	166	174	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27578	27586		10.1074/jbc.M503273200	http://dx.doi.org/10.1074/jbc.M503273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15927962	hybrid			2022-12-25	WOS:000230678600014
J	Kim, S; Lapham, AN; Freedman, CGK; Reed, TL; Schmidt, WK				Kim, S; Lapham, AN; Freedman, CGK; Reed, TL; Schmidt, WK			Yeast as a tractable genetic system for functional studies of the insulin-degrading enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; BUD-SITE-SELECTION; FACTOR MATING PHEROMONE; A-FACTOR; SACCHAROMYCES-CEREVISIAE; IN-VIVO; METALLOENDOPROTEASE INHIBITORS; ENDOPLASMIC-RETICULUM; INVASIVE GROWTH; CELL-FUSION	We have developed yeast as an expression and genetic system for functional studies of the insulin-degrading enzyme (IDE), which cleaves and inactivates certain small peptide molecules, including insulin and the neurotoxic A beta peptide. We show that heterologously expressed rat IDE is enzymatically active, as judged by the ability of IDE-containing yeast extracts to cleave insulin in vitro. We also show that IDE can promote the in vivo production of the yeast a-factor mating pheromone, a function normally attributed to the yeast enzymes Axl1p and Ste23p. However, IDE cannot substitute for the function of Axl1p in promoting haploid axial budding and repressing haploid invasive growth, activities that require an uncharacterized activity of Axl1p. Particulate fractions enriched for Axl1p or Ste23p are incapable of cleaving insulin, suggesting that the functional conservation of these enzymes may not be bidirectionally conserved. We have made practical use of our genetic system to confirm that residues composing the extended zinc metalloprotease motif of M16A family enzymes are required for the enzymatic activity of IDE, Ste23p, and Axl1p. We have determined that IDE and Axl1p both require an intact C terminus for optimal activity. We expect that the tractable genetic system that we have developed will be useful for investigating the enzymatic and structure/function properties of IDE and possibly for the identification of novel IDE alleles having altered substrate specificity.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Schmidt, WK (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, 120 Green St, Athens, GA 30602 USA.	wschmidt@bmb.uga.edu						ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; BECKER AB, 1995, METHOD ENZYMOL, V248, P693; Bracha K, 2002, J BIOL CHEM, V277, P29856, DOI 10.1074/jbc.M202916200; Brachat S, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r45; Brizzio V, 1996, J CELL BIOL, V135, P1727, DOI 10.1083/jcb.135.6.1727; Cadinanos J, 2003, J BIOL CHEM, V278, P42091, DOI 10.1074/jbc.M306700200; Cadinanos J, 2003, BIOCHEM J, V370, P1047, DOI 10.1042/BJ20021514; CALDWELL GA, 1994, J BIOL CHEM, V269, P19817; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Chen P, 1997, J CELL BIOL, V136, P251, DOI 10.1083/jcb.136.2.251; Cullen PJ, 2002, MOL BIOL CELL, V13, P2990, DOI 10.1091/mbc.E02-03-0151; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Elia L, 1998, J CELL BIOL, V142, P1473, DOI 10.1083/jcb.142.6.1473; Fakhrai-Rad H, 2000, HUM MOL GENET, V9, P2149, DOI 10.1093/hmg/9.14.2149; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Farris W, 2004, AM J PATHOL, V164, P1425, DOI 10.1016/S0002-9440(10)63229-4; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; Karamohamed S, 2003, DIABETES, V52, P1562, DOI 10.2337/diabetes.52.6.1562; KAYALAR C, 1989, J BIOL CHEM, V264, P8928; KAYALAR C, 1990, J CELL BIOCHEM, V44, P137, DOI 10.1002/jcb.240440303; Lazarow PB, 2003, CURR OPIN CELL BIOL, V15, P489, DOI 10.1016/S0955-0674(03)00082-6; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; LI D, 1992, J BIOL CHEM, V267, P2414; Lord M, 2002, CURR BIOL, V12, P1347, DOI 10.1016/S0960-9822(02)01042-4; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Morita M, 2000, CELL STRUCT FUNCT, V25, P309, DOI 10.1247/csf.25.309; Nijbroek GL, 1998, METHOD ENZYMOL, V292, P193; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Palecek SP, 2000, GENETICS, V156, P1005; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROTH RA, 2004, HDB PROTEOLYTIC ENZY, P868; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Schmidt WK, 2000, J BIOL CHEM, V275, P6227, DOI 10.1074/jbc.275.9.6227; Seta KA, 1997, BIOCHEM BIOPH RES CO, V231, P167, DOI 10.1006/bbrc.1997.6066; SIKORSKI RS, 1989, GENETICS, V122, P19; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; Yalovsky S, 1997, MOL CELL BIOL, V17, P1986, DOI 10.1128/MCB.17.4.1986	47	21	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27481	27490		10.1074/jbc.M414192200	http://dx.doi.org/10.1074/jbc.M414192200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15944156	hybrid			2022-12-25	WOS:000230678600003
J	Lleo, A; Waldron, E; von Arnim, CAF; Herl, L; Tangredi, MM; Peltan, ID; Strickland, DK; Koo, EH; Hyman, BT; Pietrzik, CU; Berezovska, O				Lleo, A; Waldron, E; von Arnim, CAF; Herl, L; Tangredi, MM; Peltan, ID; Strickland, DK; Koo, EH; Hyman, BT; Pietrzik, CU; Berezovska, O			Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; C-TERMINAL FRAGMENTS; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; DOCKING SITE; COMPLEX; NOTCH1; FE65	Presenilin 1 (PS1) is a critical component of the gamma-secretase complex, which is involved in the cleavage of several substrates including the amyloid precursor protein (APP) and the Notch receptor. Recently, the low density receptor-related protein (LRP) has been shown to be cleaved by a gamma-secretase-like activity. We postulated that LRP may interact with PS1 and tested its role as a competitive substrate for gamma-secretase. In this report we show that LRP colocalizes and interacts with endogenous PS1 using coimmunoprecipitation and fluorescence lifetime imaging microscopy. In addition, we found that gamma-secretase active site inhibitors do not disrupt the interaction between LRP and PS1, suggesting that the substrate associates with a gamma-secretase docking site located in close proximity to PS1. This is analogous to APP-gamma-secretase interactions. Finally, we show that LRP competes with APP for gamma-secretase activity. Overexpression of a truncated LRP construct consisting of the C terminus, the transmembrane domain, and a short extracellular portion leads to a reduction in the levels of the A beta(40), A beta(42), and p3 peptides without changing the total level of APP expression. In addition, transfection with the beta-chain of LRP causes an increase in uncleaved APP C-terminal fragments and a concomitant decrease in the signaling effects of the APP intracellular domain. In conclusion, LRP is a PS1 interactor and can compete with APP for gamma-secretase enzymatic activity.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, Dept Mol Neurodegenerat, D-55099 Mainz, Germany; Massachusetts Gen Hosp, Massachusetts Inst Neurodgenerat Disorders, Alzheimer Res Unit, Charlestown, MA 02129 USA; Univ Maryland, Sch Med, Dept Surg, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Physiol, Rockville, MD 20855 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Johannes Gutenberg University of Mainz; Harvard University; Massachusetts General Hospital; University of California System; University of California San Diego	Pietrzik, CU (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, Dept Mol Neurodegenerat, Rm 04-128, D-55099 Mainz, Germany.	Pietrzik@uni-mainz.de; oberezovska@partners.org	Lleó, Alberto/K-5783-2019; Peltan, Ithan/J-1853-2019	Peltan, Ithan/0000-0003-1730-234X	NHLBI NIH HHS [HL50784] Funding Source: Medline; NIA NIH HHS [AG12406, AG12376, AG15379] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012406, P01AG015379, R01AG012406, R01AG012376] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Berezovska O, 2003, J NEUROSCI, V23, P4560; Berezovska O, 2001, J BIOL CHEM, V276, P30018, DOI 10.1074/jbc.M008268200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Jack C, 2001, MOL BRAIN RES, V87, P166, DOI 10.1016/S0169-328X(01)00010-9; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lleo A, 2003, J BIOL CHEM, V278, P47370, DOI 10.1074/jbc.M308480200; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Narita M, 1997, J NEUROCHEM, V69, P1904; ORTH K, 1994, J BIOL CHEM, V269, P21117; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; Ramdya P, 2003, J NEUROCHEM, V87, P843, DOI 10.1046/j.1471-4159.2003.02030.x; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; SISODIA SS, 1993, J NEUROSCI, V13, P3136; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	55	57	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27303	27309		10.1074/jbc.M413969200	http://dx.doi.org/10.1074/jbc.M413969200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917251	hybrid			2022-12-25	WOS:000230589500080
J	Schnell, R; Sandalova, T; Hellman, U; Lindqvist, Y; Schneider, G				Schnell, R; Sandalova, T; Hellman, U; Lindqvist, Y; Schneider, G			Siroheme- and [Fe-4-S-4]-dependent NirA from Mycobacterium tuberculosis is a sulfite reductase with a covalent Cys-Tyr bond in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH NITRITE REDUCTASE; PROSTHETIC GROUPS; MESSENGER-RNA; EXPRESSION; MODEL; CRYSTALLOGRAPHY; CLASSIFICATION; PURIFICATION; HEMOPROTEIN; CATALYSIS	The nirA gene of Mycobacterium tuberculosis is upregulated in the persistent state of the bacteria, suggesting that it is a potential target for the development of antituberculosis agents particularly active against the pathogen in its dormant phase. This gene encodes a ferredoxin-dependent sulfite reductase, and the structure of the enzyme has been determined using x-ray crystallography. The enzyme is a monomer comprising 555 amino acids and contains a [Fe-4-S-4] cluster and a siroheme cofactor. The molecule is built up of three domains with an alpha/beta fold. The first domain consists of two ferredoxin-like subdomains, related by a pseudo-2-fold symmetry axis passing through the whole molecule. The other two domains, which provide much of the binding interactions with the cofactors, have a common fold that is unique to the sulfite/nitrite reductase family. The domains form a trilobal structure, with the cofactors and the active site located at the interface of all three domains in the center of the molecule. NirA contains an unusual covalent bond between the side chains of Tyr(69) and Cys(161) in the active site, in close proximity to the siroheme cofactor. Removal of this covalent bond by site-directed mutagenesis impairs catalytic activity, suggesting that it is important for the enzymatic reaction. These residues are part of a sequence fingerprint, able to distinguish between ferredoxin-dependent sulfite and nitrite reductases. Comparison of NirA with the structure of the truncated NADPH-dependent sulfite reductase from Escherichia coli suggests a binding site for the external electron donor ferredoxin close to the [Fe-4-S-4] cluster.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Karolinska Institutet; Ludwig Institute for Cancer Research	Schneider, G (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Scheeles Vag 2, S-17177 Stockholm, Sweden.	gunter.schneider@mbb.ki.se	Lindqvist, Ylva/F-9009-2010	Lindqvist, Ylva/0000-0003-3162-8661; Sandalova, Tatyana/0000-0002-7694-6420; SCHNELL, ROBERT/0000-0001-7530-3629; Schneider, Gunter/0000-0003-0622-5713				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASADA K, 1967, J BIOL CHEM, V242, P3646; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Bloom BR, 1999, NAT MED, V5, P872, DOI 10.1038/11309; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTNER JA, 1983, J BIOL CHEM, V258, P1147; CLINE JF, 1985, BIOCHEMISTRY-US, V24, P7942, DOI 10.1021/bi00348a015; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Crane BR, 1997, BIOCHEMISTRY-US, V36, P12120, DOI 10.1021/bi971066i; Crane BR, 1996, CURR OPIN STRUC BIOL, V6, P744, DOI 10.1016/S0959-440X(96)80003-0; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; Curdt I, 2000, BBA-PROTEIN STRUCT M, V1543, P60, DOI 10.1016/S0167-4838(00)00198-9; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; Hampshire T, 2004, TUBERCULOSIS, V84, P228, DOI 10.1016/j.tube.2003.12.010; Hellman U, 2000, EXS, V88, P43; Hu YM, 2000, J BACTERIOL, V182, P6358, DOI 10.1128/JB.182.22.6358-6365.2000; Hu YM, 2001, FEMS MICROBIOL LETT, V202, P59, DOI 10.1016/S0378-1097(01)00280-4; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JANICK PA, 1982, BIOCHEMISTRY-US, V21, P3538, DOI 10.1021/bi00258a003; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAUFMAN J, 1993, BIOCHEMISTRY-US, V32, P2853, DOI 10.1021/bi00062a017; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; KRUEGER RJ, 1982, BIOCHEMISTRY-US, V21, P2892, DOI 10.1021/bi00541a014; Kuznetsova S, 2004, BIOCHEMISTRY-US, V43, P10765, DOI 10.1021/bi048826r; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakayama M, 2000, J INORG BIOCHEM, V82, P27, DOI 10.1016/S0162-0134(00)00138-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; SIEGEL LM, 1974, J BIOL CHEM, V249, P1572; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; Snell FD, 1949, COLORIMETRIC METHODS, P804; Starck J, 2004, MICROBIOL-SGM, V150, P3821, DOI 10.1099/mic.0.27284-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VEGA JM, 1977, J BIOL CHEM, V252, P896; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; Wallis RS, 1999, ANTIMICROB AGENTS CH, V43, P2600, DOI 10.1128/AAC.43.11.2600; WAYNE LG, 1994, ANTIMICROB AGENTS CH, V38, P2054, DOI 10.1128/AAC.38.9.2054; Wayne LG, 1996, INFECT IMMUN, V64, P2062, DOI 10.1128/IAI.64.6.2062-2069.1996; Whittaker JW, 2003, CHEM REV, V103, P2347, DOI 10.1021/cr020425z; Whittaker MM, 2003, J BIOL CHEM, V278, P22090, DOI 10.1074/jbc.M300112200; WU JY, 1991, J BACTERIOL, V173, P325, DOI 10.1128/jb.173.1.325-333.1991; Zeghouf M, 2000, J BIOL CHEM, V275, P37651, DOI 10.1074/jbc.M005619200	53	84	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27319	27328		10.1074/jbc.M502560200	http://dx.doi.org/10.1074/jbc.M502560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917234	hybrid			2022-12-25	WOS:000230589500082
J	Misra, UK; Deedwania, R; Pizzo, SV				Misra, UK; Deedwania, R; Pizzo, SV			Binding of activated alpha(2)-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21-ACTIVATED PROTEIN-KINASE; SIGNALING RECEPTOR; RECOGNIZED FORMS; EXPRESSION; GROWTH; ALPHA-2-MACROGLOBULIN; TRANSDUCTION; MITOGENESIS; MECHANISM; ANTIGEN	Two characteristics of highly malignant cells are their increased motility and secretion of proteinases allowing these cells to penetrate surrounding basement membranes and metastasize. Activation of 21-kDa activated kinases (PAKs) is an important mechanism for increasing cell motility. Recently, we reported that binding of receptor-recognized forms of the proteinase inhibitor alpha(2)-macroglobulin (alpha M-2*) to GRP78 on the cell surface of 1-LN human prostate cancer cells induces mitogenic signaling and cellular proliferation. In the current study, we have examined the ability of alpha 2M* to activate PAK-1 and PAK-2. Exposure of 1-LN cells to alpha M-2* caused a 2- to 3-fold increase in phosphorylated PAK-2 and a similar increase in its kinase activity toward myelin basic protein. By contrast, the phosphorylation of PAK-1 was only negligibly affected. Silencing the expression of the GRP78 gene, using either of two different mRNA sequences, greatly attenuated the appearance of phosphorylated PAK-2 in alpha M-2*-stimulated cells. Treatment of 1-LN cells with alpha M-2* caused translocation of PAK-2 in association with NCK to the cell surface as evidenced by the coimmunoprecipitation of PAK-2 and NCK in the GRP78 immunoprecipitate from plasma membranes. alpha M-2*-induced activation of PAK-2 was inhibited by prior incubation of the cells with specific inhibitors of tyrosine kinases and phosphatidylinositol 3-kinase. PAK-2 activation was accompanied by significant increases in the levels of phosphorylated LIMK and phosphorylated cofilin. Silencing the expression of the PAK-2 gene greatly attenuated the phosphorylation of LIMK. In conclusion, we show for the first time the activation of PAK-2 in 1-LN prostate cancer cells by a proteinase inhibitor, alpha(2)-macroglobulin. These studies suggest a mechanism by which alpha M-2* enhances the metastatic potential of these cells.	Duke Univ, Ctr Med, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Ctr Med, Dept Pathol, Box 3712, Durham, NC 27710 USA.	Pizzo001@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL024066, R37 HL024066, HL-24066] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Asplin IR, 2000, ARCH BIOCHEM BIOPHYS, V383, P135, DOI 10.1006/abbi.2000.2052; Bhattacharjee G, 2001, J CELL BIOCHEM, V82, P260, DOI 10.1002/jcb.1152; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hart JP, 2004, J IMMUNOL, V172, P70, DOI 10.4049/jimmunol.172.1.70; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hendershot LM, 2004, MT SINAI J MED, V71, P289; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Misra UK, 1997, J BIOL CHEM, V272, P497; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; Misra UK, 2005, J IMMUNOL, V174, P2092, DOI 10.4049/jimmunol.174.4.2092; Misra UK, 2004, CELL SIGNAL, V16, P929, DOI 10.1016/j.cellsig.2004.01.003; Misra UK, 2004, CELL SIGNAL, V16, P487, DOI 10.1016/j.cellsig.2003.09.010; Misra UK, 2002, J BIOL CHEM, V277, P42082, DOI 10.1074/jbc.M206174200; Misra UK, 2002, J BIOL CHEM, V277, P4069, DOI 10.1074/jbc.M109764200; MISRA UK, 1994, J BIOL CHEM, V269, P18303; Montano X, 2004, FEBS LETT, V571, P1, DOI 10.1016/j.febslet.2004.06.088; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Otto A, 1998, J UROLOGY, V159, P297, DOI 10.1016/S0022-5347(01)64085-0; Pizzo S. V., 2000, HEMOSTASIS THROMBOSI, P367; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang WM, 1998, CLIN CHEM, V44, P2471	55	136	137	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26278	26286		10.1074/jbc.M414467200	http://dx.doi.org/10.1074/jbc.M414467200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15908432	hybrid, Green Accepted			2022-12-25	WOS:000230386800043
J	Ouellet, V; Provencher, DM; Maugard, CM; Le Page, C; Ren, FF; Lussier, C; Novak, J; Ge, B; Hudson, TJ; Tonin, PN; Mes-Masson, AM				Ouellet, V; Provencher, DM; Maugard, CM; Le Page, C; Ren, FF; Lussier, C; Novak, J; Ge, B; Hudson, TJ; Tonin, PN; Mes-Masson, AM			Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling	ONCOGENE			English	Review						borderline tumors; epithelial ovarian cancer; microarray	DIFFERENTIALLY EXPRESSED GENES; FLUID LACTATE-DEHYDROGENASE; RECEPTOR MESSENGER-RNA; CANCER CELL-LINES; CYCLIN-E; SURFACE EPITHELIUM; BORDERLINE TUMORS; POOR-PROGNOSIS; ALPHA-CATENIN; CDNA MICROARRAY	Tumors of low malignant potential (LMP) represent 20% of epithelial ovarian cancers (EOCs) and are associated with a better prognosis than the invasive tumors (TOV). De. ning the relationship between LMPs and TOVs remains an important goal towards understanding the molecular pathways that contribute to prognosis, as well as providing molecular markers, for these EOCs. To this end, DNA microarray analyses were performed either in a primary culture or a tumor tissue model system and selected candidate genes showing a distinctive expression pro. le between LMPs and TOVs were identified using a class prediction approach based on three statistical methods of analysis. Both model systems appear relevant as candidate genes identified by either model allowed the proper reclassification of samples as either LMPs or TOVs. Selected candidate genes (CAS, CCNE1, LGALS8, ITG beta 3, ATP1B1, FLIP, KRT7 and KRT19) were validated by real-time quantitative PCR analysis and show differential expression between LMPs and TOVs. Immunohistochemistry analyses showed that the two tumor classes were distinguishable by their expression of CAS, TNFR1A, FLIP, CKS1 and CCNE1. These results de. ne signature patterns for gene expression of LMPs and TOVs and identify gene candidates that warrant further study to deepen our understanding of the biology of EOC.	CHUM, ICM, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Div Gynecol Oncol, Montreal, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; CHUM, Dept Pathol, Montreal, PQ H2L 4M1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; Genome Quebec Innovat Ctr, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University; McGill University	Mes-Masson, AM (corresponding author), CHUM, ICM, Ctr Rech, 1560,Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.	anne-marie.mes-masson@umontreal.ca	Le Page, Cecile/B-3215-2010	Le Page, Cecile/0000-0002-8020-1544; Mes-Masson, Anne-Marie/0000-0002-6498-266X				Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603; Anttila M, 1998, J CLIN ONCOL, V16, P2591, DOI 10.1200/JCO.1998.16.8.2591; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bayani J, 2002, CANCER RES, V62, P3466; BLAUSTEIN A, 1982, CANCER, V49, P722, DOI 10.1002/1097-0142(19820215)49:4<722::AID-CNCR2820490421>3.0.CO;2-C; Boran N, 2000, GYNECOL OBSTET INVES, V49, P272, DOI 10.1159/000010258; BOSE CK, 1994, CANCER LETT, V77, P39, DOI 10.1016/0304-3835(94)90345-X; Boss EA, 2001, EUR J GYNAECOL ONCOL, V22, P427; Brinkmann U, 1998, AM J HUM GENET, V62, P509, DOI 10.1086/301773; Brustmann H, 2004, GYNECOL ONCOL, V92, P268, DOI 10.1016/j.ygyno.2003.10.029; Burger CW, 2000, INT J GYNECOL CANCER, V10, P181, DOI 10.1046/j.1525-1438.2000.010003181.x; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Casey RC, 2003, CLIN EXP METASTAS, V20, P143, DOI 10.1023/A:1022670501667; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; Courjal F, 1996, INT J CANCER, V69, P247; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Davidson B, 2003, CLIN CANCER RES, V9, P2248; Davidson B, 2000, J PATHOL, V192, P460; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; DESOUZA PL, 1992, HEMATOL ONCOL CLIN N, V6, P761; Dietel M, 2000, VIRCHOWS ARCH, V436, P403, DOI 10.1007/s004280050467; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Dore M, 1998, J HISTOCHEM CYTOCHEM, V46, P77, DOI 10.1177/002215549804600110; Farley J, 2003, CANCER RES, V63, P1235; Fujimoto J, 1997, CANCER LETT, V115, P207, DOI 10.1016/S0304-3835(97)04735-6; Garzetti GG, 1999, CANCER, V85, P2226, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2226::AID-CNCR18>3.0.CO;2-X; Gascoyne DM, 2003, CELL CYCLE, V2, P238, DOI 10.4161/cc.2.3.355; Giuntoli RL, 1998, CANCER RES, V58, P5546; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GOODMAN GE, 1990, J CLIN ONCOL, V8, P1083, DOI 10.1200/JCO.1990.8.6.1083; Gotlieb WH, 1998, CANCER-AM CANCER SOC, V82, P141, DOI 10.1002/(SICI)1097-0142(19980101)82:1<141::AID-CNCR17>3.0.CO;2-2; Gu J, 2001, JNCI-J NATL CANCER I, V93, P1147, DOI 10.1093/jnci/93.15.1147; Gupta RA, 2003, CANCER RES, V63, P906; Halperin R, 1999, EUR J GYNAECOL ONCOL, V20, P40; Halperin R, 2001, EUR J GYNAECOL ONCOL, V22, P292; HARLOZINSKASZMYRKA A, 1986, CANCER DETECT PREV, V9, P347; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hashiguchi Y, 2004, HUM PATHOL, V35, P165, DOI 10.1016/j.humpath.2003.07.018; Hefler L, 1999, BRIT J CANCER, V81, P855, DOI 10.1038/sj.bjc.6690776; Hough CD, 2000, CANCER RES, V60, P6281; Houle CD, 2002, GYNECOL ONCOL, V86, P69, DOI 10.1006/gyno.2002.6729; Huntsman D, 1999, AM J PATHOL, V155, P343, DOI 10.1016/S0002-9440(10)65130-9; Hutchinson S, 2003, CLIN CHEM, V49, P746, DOI 10.1373/49.5.746; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Ismail RS, 2000, CANCER RES, V60, P6744; Kamarainen M, 1996, AM J PATHOL, V148, P1435; KASTELIC L, 1994, CANCER LETT, V82, P81, DOI 10.1016/0304-3835(94)90149-X; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Kitakata H, 2002, CANCER RES, V62, P6682; Kohlberger P, 2002, ANTICANCER RES, V22, P3541; Korneeva I, 2002, INT J CANCER, V102, P483, DOI 10.1002/ijc.10747; KRUK PA, 1990, LAB INVEST, V63, P132; Kudoh K, 1999, GYNECOL OBSTET INVES, V47, P52, DOI 10.1159/000010062; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LAH TT, 1992, CANCER LETT, V61, P243, DOI 10.1016/0304-3835(92)90295-7; Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004; Lancaster JM, 2003, CLIN CANCER RES, V9, P762; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Le Page C, 2004, EXPERT REV MOL DIAGN, V4, P157, DOI 10.1586/14737159.4.2.157; Lee BC, 2004, INT J ONCOL, V24, P847; Li SF, 2004, GYNECOL ONCOL, V92, P622, DOI 10.1016/j.ygyno.2003.10.053; Lin CJ, 1996, GYNECOL ONCOL, V60, P347, DOI 10.1006/gyno.1996.0054; Link CJ, 1996, AM J MED, V101, P217, DOI 10.1016/S0002-9343(96)80079-9; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; Maggiora P, 2003, EXP CELL RES, V288, P382, DOI 10.1016/S0014-4827(03)00250-7; Mandelin E, 2003, CANCER RES, V63, P6258; Manderson EN, 2002, GENOME RES, V12, P112, DOI 10.1101/gr.174202; Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2; Martoglio AM, 2000, MOL MED, V6, P750, DOI 10.1007/BF03402191; Masuda T, 2003, CLIN CANCER RES, V9, P5693; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Milde-Langosch K, 2003, INT J GYNECOL PATHOL, V22, P168, DOI 10.1097/00004347-200304000-00009; MOGHUL A, 1994, ONCOGENE, V9, P2045; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Naora H, 2001, P NATL ACAD SCI USA, V98, P4060, DOI 10.1073/pnas.071594398; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Negus RPM, 1997, AM J PATHOL, V150, P1723; Negus RPM, 1998, J LEUKOCYTE BIOL, V63, P758, DOI 10.1002/jlb.63.6.758; NEGUS RPM, 1995, J CLIN INVEST, V95, P2391, DOI 10.1172/JCI117933; Nijman HW, 2001, EUR J OBSTET GYN R B, V94, P114, DOI 10.1016/S0301-2115(00)00294-3; Novak JP, 2002, GENOMICS, V79, P104, DOI 10.1006/geno.2001.6675; Ono K, 2000, CANCER RES, V60, P5007; Ortiz BH, 2001, CANCER RES, V61, P7264; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Peiro G, 2002, AM J CLIN PATHOL, V118, P922, DOI 10.1092/JU8YP7MJK2WDT1FY; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Presneau N, 2003, ONCOGENE, V22, P1568, DOI 10.1038/sj.onc.1206219; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Roberts D, 2002, DNA CELL BIOL, V21, P11, DOI 10.1089/10445490252810276; Rosenberg E, 2001, HUM PATHOL, V32, P808, DOI 10.1053/hupa.2001.26462; Sakamoto M, 2001, Hum Cell, V14, P305; Sasano H, 1996, MODERN PATHOL, V9, P386; Sawasaki T, 2001, J SOC GYNECOL INVEST, V8, P179, DOI 10.1016/S1071-5576(01)00102-2; Sawiris GP, 2002, CANCER RES, V62, P2923; Schneider D, 1997, GYNECOL ONCOL, V66, P399, DOI 10.1006/gyno.1997.4792; Schraml P, 2003, J PATHOL, V200, P375, DOI 10.1002/path.1356; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Seidman JD, 2000, HUM PATHOL, V31, P539, DOI 10.1053/hp.2000.8048; Seidman JD, 2002, CANCER, V95, P675, DOI 10.1002/cncr.10777; Shapira M, 2004, CANCER-AM CANCER SOC, V100, P1615, DOI 10.1002/cncr.20172; Shridhar V, 2001, CANCER RES, V61, P5895; Singer G, 2002, AM J PATHOL, V160, P1223, DOI 10.1016/S0002-9440(10)62549-7; Singer G, 2003, INT J GYNECOL PATHOL, V22, P37, DOI 10.1097/00004347-200301000-00009; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; SLOTMAN BJ, 1991, EUR J OBSTET GYN R B, V38, P221, DOI 10.1016/0028-2243(91)90296-W; SLOTMAN BJ, 1990, CANCER, V66, P740, DOI 10.1002/1097-0142(19900815)66:4<740::AID-CNCR2820660423>3.0.CO;2-H; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stone B, 2003, INT J CANCER, V104, P73, DOI 10.1002/ijc.10900; Sui L, 1999, GYNECOL ONCOL, V73, P202, DOI 10.1006/gyno.1999.5373; Sui L, 2001, GYNECOL ONCOL, V83, P56, DOI 10.1006/gyno.2001.6308; Sui L, 2001, CLIN CANCER RES, V7, P4130; Tamada Y, 1999, ONCOL RES, V11, P233; Tanaka Y, 2003, CANCER-AM CANCER SOC, V98, P424, DOI 10.1002/cncr.11506; Tapper J, 2001, CANCER GENET CYTOGEN, V128, P1, DOI 10.1016/S0165-4608(01)00386-7; TAVASSOLI FA, 1988, MODERN PATHOL, V1, P407; Tiniakos DG, 1998, HUM PATHOL, V29, P1250, DOI 10.1016/S0046-8177(98)90253-2; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; Trope C, 1998, SEMIN ONCOL, V25, P372; Troyanskaya OG, 2002, BIOINFORMATICS, V18, P1454, DOI 10.1093/bioinformatics/18.11.1454; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05; Yanagawa T, 2004, LAB INVEST, V84, P513, DOI 10.1038/labinvest.3700057; YU H, 1995, CANCER RES, V55, P1603; Yuce K, 2001, EUR J GYNAECOL ONCOL, V22, P228; ZHENG JP, 1993, CANCER RES, V53, P4138	130	68	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4672	4687		10.1038/sj.onc.1208214	http://dx.doi.org/10.1038/sj.onc.1208214			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15940270				2022-12-25	WOS:000230304500006
J	Shalli, K; Brown, I; Heys, SD; Schofield, AC				Shalli, K; Brown, I; Heys, SD; Schofield, AC			Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel	FASEB JOURNAL			English	Article						drug resistance; MCF-7 and MDA-MB-231 cells	EXPRESSION; TAXOL; MICROTUBULES; CHEMOTHERAPY; PREDICTION; DYNAMICS; TAXOTERE	Docetaxel is one of the most active drugs used to treat breast cancer. The cellular target of docetaxel is the microtubule, specifically the beta-tubulin subunit, that comprises a series of isotypes and that can modulate function. This study has examined the role of alteration in beta-tubulin isotypes in vitro and has sequenced the beta-tubulin gene to determine if there were mutations, both of which may represent important mechanisms of acquired resistance to docetaxel. Breast cancer cells, MCF-7 (oestrogen-receptor positive) and MDA-MB-231, (oestrogen-receptor negative) were made resistant to docetaxel in vitro. Expression of beta-tubulin isotypes ( class I, II, III, IVa, IVb, and VI) was determined at the RNA and protein level using RT-PCR and western analysis, respectively. DNA sequencing evaluated the beta-tubulin gene. At the mRNA level, class I, II, III, and IVa beta-tubulin mRNA isotypes were over-expressed in docetaxel-resistant MCF-7 cells when compared with the docetaxel-sensitive parental cells. However, class VI beta-tubulin mRNA isotype expression was decreased in resistant cells. In MDA-MB-231 cells, there was a decrease in expression of the class I and class IVa beta-tubulin mRNA. However, there were increased expressions in class II, IVb, and VI beta-tubulin mRNA isotypes in resistant cells. Western analysis has confirmed corresponding increases in beta-tubulin protein levels in MCF- 7 cells. However, in MDA-MB-231 cells, there were decreased protein levels for class II and class III beta-tubulin. This study demonstrates that altered expression of mRNA beta-tubulin isotypes and modulation of beta-tubulin protein levels are associated with acquired docetaxel resistance in breast cancer cells. This allows further understanding and elucidation of mechanisms involved in resistance to docetaxel.	Univ Aberdeen, Sch Med, Coll Life Sci & Med, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Sch Med Sci, Coll Life Sci & Med, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen	Schofield, AC (corresponding author), Univ Aberdeen, Sch Med, Coll Life Sci & Med, Aberdeen AB25 2ZD, Scotland.	a.schofield@abdn.ac.uk	Shalli, Kawan/CAE-9898-2022; Shalli, Kawan/K-3111-2019		Breast Cancer Now [2001:209] Funding Source: Medline	Breast Cancer Now		Banerjee A, 2002, BIOCHEM BIOPH RES CO, V293, P598, DOI 10.1016/S0006-291X(02)00269-3; Berrieman HK, 2004, LANCET ONCOL, V5, P158, DOI 10.1016/S1470-2045(04)01411-1; BISSETT D, 1993, EUR J CANCER, V29A, P1228, DOI 10.1016/0959-8049(93)90062-K; Bonneterre J, 1999, EUR J CANCER, V35, P1431, DOI 10.1016/S0959-8049(99)00174-4; Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918; Carles G, 1999, BRIT J CANCER, V80, P1162, DOI 10.1038/sj.bjc.6690481; Chan S, 1999, J CLIN ONCOL, V17, P2341, DOI 10.1200/JCO.1999.17.8.2341; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Derry WB, 1997, BIOCHEMISTRY-US, V36, P3554, DOI 10.1021/bi962724m; Dumontet C, 1996, CELL MOTIL CYTOSKEL, V35, P49, DOI 10.1002/(SICI)1097-0169(1996)35:1<49::AID-CM4>3.0.CO;2-D; Hasegawa S, 2003, CLIN CANCER RES, V9, P2992; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Katsetos CD, 2003, CELL MOTIL CYTOSKEL, V55, P77, DOI 10.1002/cm.10116; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; Liu B, 2001, J SURG RES, V99, P179, DOI 10.1006/jsre.2001.6126; Mason KA, 1997, CLIN CANCER RES, V3, P2431; MCDONALD SL, EUR J CANC, V41, P1086; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; O'Brien MER, 1999, ANN ONCOL, V10, P205, DOI 10.1023/A:1008370930599; Ogston KN, 2004, BREAST CANCER RES TR, V86, P181, DOI 10.1023/B:BREA.0000032986.00879.d7; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; Ranganathan S, 1998, BRIT J CANCER, V77, P562, DOI 10.1038/bjc.1998.91; RINGEL I, 1989, JNCI-J NATL CANCER I, V285, P197; SEIDMAN AD, 1993, P AN M AM SOC CLIN, V12, P52; Sjostrom J, 1999, EUR J CANCER, V35, P1194, DOI 10.1016/S0959-8049(99)00122-7; Smith IC, 2002, J CLIN ONCOL, V20, P1456, DOI 10.1200/JCO.20.6.1456; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503	32	93	99	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1299	+		10.1096/fj.04-3178fje	http://dx.doi.org/10.1096/fj.04-3178fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946994				2022-12-25	WOS:000230207800026
J	Hagman, DK; Hays, LB; Parazzoli, SD; Poitout, V				Hagman, DK; Hays, LB; Parazzoli, SD; Poitout, V			Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; LONG-TERM EXPOSURE; HOMEODOMAIN TRANSCRIPTION FACTOR; FREE FATTY-ACIDS; OXIDATIVE STRESS; DUODENAL HOMEOBOX-1; SIGNAL-TRANSDUCTION; METABOLIC SYNDROME; GLUCOSE; KINASE	Abnormalities in lipid metabolism have been proposed as contributing factors to both defective insulin secretion from the pancreatic beta cell and peripheral insulin resistance in type 2 diabetes. Previously, we have shown that prolonged exposure of isolated rat islets of Langerhans to excessive fatty acid levels impairs insulin gene transcription. This study was designed to assess whether palmitate alters the expression and binding activity of the key regulatory factors pancreas-duodenum homeobox-1 (PDX-1), MafA, and Beta2, which respectively bind to the A3, C1, and E1 elements in the proximal region of the insulin promoter. Nuclear extracts of isolated rat islets cultured with 0.5mM palmitate exhibited reduced binding activity to the A3 and C1 elements but not the E1 element. Palmitate did not affect the overall expression of PDX-1 but reduced its nuclear localization. In contrast, palmitate blocked the stimulation of MafA mRNA and protein expression by glucose. Combined adenovirus-mediated overexpression of PDX-1 and MafA in islets completely prevented the inhibition of insulin gene expression by palmitate. These results demonstrate that prolonged exposure of islets to palmitate inhibits insulin gene transcription by impairing nuclear localization of PDX-1 and cellular expression of MafA.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Poitout, V (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	vpoitout@pnri.org		Poitout, Vincent/0000-0002-6555-5053	NIDDK NIH HHS [R01DK58096, R56 DK058096, R01 DK058096] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK058096, R01DK058096] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Briaud I, 2001, DIABETES, V50, P315, DOI 10.2337/diabetes.50.2.315; Campbell SC, 2002, BIOCHEM BIOPH RES CO, V299, P277, DOI 10.1016/S0006-291X(02)02633-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Gerrish K, 2004, MOL ENDOCRINOL, V18, P533, DOI 10.1210/me.2003-0371; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Jacqueminet S, 2000, METABOLISM, V49, P532, DOI 10.1016/S0026-0495(00)80021-9; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; Kawamori D, 2003, DIABETES, V52, P2896, DOI 10.2337/diabetes.52.12.2896; Kelpe CL, 2003, J BIOL CHEM, V278, P30015, DOI 10.1074/jbc.M302548200; Kharroubi I, 2004, ENDOCRINOLOGY, V145, P5087, DOI 10.1210/en.2004-0478; Leibowitz G, 2002, ENDOCRINOLOGY, V143, P3214, DOI 10.1210/en.2002-220174; Macfarlane WM, 2000, DIABETES, V49, P418, DOI 10.2337/diabetes.49.3.418; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; Moore PC, 2004, DIABETES, V53, P2610, DOI 10.2337/diabetes.53.10.2610; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Rafiq I, 2000, J BIOL CHEM, V275, P15977, DOI 10.1074/jbc.275.21.15977; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; Ritz-Laser B, 1999, ENDOCRINOLOGY, V140, P4005, DOI 10.1210/en.140.9.4005; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; Samaras SE, 2003, J BIOL CHEM, V278, P12263, DOI 10.1074/jbc.M210801200; Sander M, 1998, P NATL ACAD SCI USA, V95, P11572, DOI 10.1073/pnas.95.20.11572; Seijffers R, 1999, ENDOCRINOLOGY, V140, P3311, DOI 10.1210/en.140.7.3311; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; STEIN R, 2001, HDB PHYSL 7, V2, P25; Summers SA, 2005, DIABETES, V54, P591, DOI 10.2337/diabetes.54.3.591; Tran POT, 2002, DIABETES, V51, P1772, DOI 10.2337/diabetes.51.6.1772; Unger RH, 2003, ENDOCRINOLOGY, V144, P5159, DOI 10.1210/en.2003-0870; Wang XL, 1999, ENDOCRINOLOGY, V140, P4904, DOI 10.1210/en.140.10.4904; Wang XL, 2001, ENDOCRINOLOGY, V142, P1820, DOI 10.1210/en.142.5.1820; Wrede CE, 2002, J BIOL CHEM, V277, P49676, DOI 10.1074/jbc.M208756200; Wu H, 1999, BIOCHEM J, V344, P813, DOI 10.1042/0264-6021:3440813; Yoshikawa H, 2001, METABOLISM, V50, P613, DOI 10.1053/meta.2001.22565; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; ZHOU YP, 1995, J CLIN ENDOCR METAB, V80, P1584, DOI 10.1210/jc.80.5.1584	49	161	174	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32413	32418		10.1074/jbc.M506000200	http://dx.doi.org/10.1074/jbc.M506000200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	15944145	Green Accepted, hybrid			2022-12-25	WOS:000231794800047
J	Osanai, T; Kanesaki, Y; Nakano, T; Takahashi, H; Asayama, M; Shirai, M; Kanehisa, M; Suzuki, I; Murata, N; Tanaka, K				Osanai, T; Kanesaki, Y; Nakano, T; Takahashi, H; Asayama, M; Shirai, M; Kanehisa, M; Suzuki, I; Murata, N; Tanaka, K			Positive regulation of sugar catabolic pathways in the cyanobacterium Synechocystis sp PCC 6803 by the group 2 sigma factor sigE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN PCC-6803; HISTIDINE KINASE; RNA-POLYMERASE; CIRCADIAN EXPRESSION; GENE-EXPRESSION; FACTOR HOMOLOGS; PCC 7002; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; IDENTIFICATION; EUBACTERIA	The sigE gene of Synechocystis sp. PCC 6803 encodes a group 2 sigma factor for RNA polymerase and has been proposed to function in transcriptional regulation of nitrogen metabolism. By using microarray and Northern analyses, we demonstrated that the abundance of transcripts derived from genes important for glycolysis, the oxidative pentose phosphate pathway, and glycogen catabolism is reduced in a sigE mutant of Synechocystis maintained under the normal growth condition. Furthermore, the activities of the two key enzymes of the oxidative pentose phosphate pathway, glucose- 6- phosphate dehydrogenase and 6- phophogluconate dehydrogenase, encoded by the zwf and gnd genes were also reduced in the sigE mutant. The dark enhancements in both enzyme activity and transcript abundance apparent in the wild type were eliminated by the mutation. In addition, the sigE mutant showed a reduced rate of glucose uptake and an increased intracellular level of glycogen. Moreover, it was unable to proliferate under the light- activated heterotrophic growth conditions. These results indicate that SigE functions in the transcriptional activation of sugar catabolic pathways in Synechocystis sp. PCC 6803.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Ibaraki Univ, Coll Agr, Inashiki, Ibaraki 3000393, Japan; Kyoto Univ, Inst Chem Res, Uji 6110011, Japan; Natl Inst Basic Biol, Dept Regulat Biol, Okazaki, Aichi 4448585, Japan	University of Tokyo; Ibaraki University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Tanaka, K (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	kntanaka@iam.u-tokyo.ac.jp	Kanesaki, Yu/J-3817-2017; Murata, Norio/O-7945-2019; Kanehisa, Minoru/R-3081-2018; Tanaka, Kan/E-3724-2015; Murata, Norio/E-6569-2010	Kanesaki, Yu/0000-0003-3537-9789; Murata, Norio/0000-0002-6605-5800; Tanaka, Kan/0000-0001-7560-7884; 				ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Asayama M, 2004, BIOSCI BIOTECH BIOCH, V68, P477, DOI 10.1271/bbb.68.477; Ball SG, 2003, ANNU REV PLANT BIOL, V54, P207, DOI 10.1146/annurev.arplant.54.031902.134927; BRAHAMSHA B, 1992, J BACTERIOL, V174, P7273, DOI 10.1128/jb.174.22.7273-7282.1992; Campbell EL, 1998, J BACTERIOL, V180, P4938, DOI 10.1128/JB.180.18.4938-4941.1998; Caslake LF, 1997, MICROBIOL-SGM, V143, P3807, DOI 10.1099/00221287-143-12-3807; FORCHHAMMER K, 1995, J BACTERIOL, V177, P2033, DOI 10.1128/jb.177.8.2033-2040.1995; Goto-Seki A, 1999, MOL MICROBIOL, V34, P473, DOI 10.1046/j.1365-2958.1999.01608.x; Gruber TM, 1998, ARCH MICROBIOL, V169, P211, DOI 10.1007/s002030050563; Imamura S, 2003, FEBS LETT, V554, P357, DOI 10.1016/S0014-5793(03)01188-8; Iwasaki H, 2000, CELL, V101, P223, DOI 10.1016/S0092-8674(00)80832-6; Kanamaru K, 2000, PLANT CELL PHYSIOL, V41, P1119, DOI 10.1093/pcp/pcd037; Kanamaru K, 2001, PLANT CELL PHYSIOL, V42, P1034, DOI 10.1093/pcp/pce155; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; Kanesaki Y, 2002, BIOCHEM BIOPH RES CO, V290, P339, DOI 10.1006/bbrc.2001.6201; Koksharova O, 1998, PLANT MOL BIOL, V36, P183, DOI 10.1023/A:1005925732743; Kucho K, 2005, J BACTERIOL, V187, P2190, DOI 10.1128/JB.187.6.2190-2199.2005; Los DA, 1997, MOL MICROBIOL, V25, P1167, DOI 10.1046/j.1365-2958.1997.5641912.x; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; Mrazek J, 2001, NUCLEIC ACIDS RES, V29, P1590, DOI 10.1093/nar/29.7.1590; Muro-Pastor AM, 2001, J BACTERIOL, V183, P1090, DOI 10.1128/JB.183.3.1090-1095.2001; Nair U, 2002, J BACTERIOL, V184, P3530, DOI 10.1128/JB.184.13.3530-3538.2002; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; SAKAMOTO T, 1993, INT J SYST BACTERIOL, V43, P844, DOI 10.1099/00207713-43-4-844; SCANLAN DJ, 1995, J BACTERIOL, V177, P2550, DOI 10.1128/jb.177.9.2550-2553.1995; Singh AK, 2005, J BACTERIOL, V187, P2368, DOI 10.1128/JB.187.7.2368-2376.2005; SUMMERS ML, 1995, J BACTERIOL, V177, P6184, DOI 10.1128/jb.177.21.6184-6194.1995; Summers ML, 1996, MOL MICROBIOL, V22, P473, DOI 10.1046/j.1365-2958.1996.1371502.x; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; TANAKA K, 1988, SCIENCE, V242, P1040, DOI 10.1126/science.3194753; Tsinoremas NF, 1996, EMBO J, V15, P2488, DOI 10.1002/j.1460-2075.1996.tb00606.x; Tuominen I, 2003, J BACTERIOL, V185, P1116, DOI 10.1128/JB.185.3.1116-1119.2003; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Wolk C.P., 1994, MOL BIOL CYANOBACTER, P769, DOI DOI 10.1007/978-94-011-0227-8_27; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; Yang C, 2002, APPL MICROBIOL BIOT, V58, P813, DOI 10.1007/s00253-002-0949-0	38	125	131	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30653	30659		10.1074/jbc.M505043200	http://dx.doi.org/10.1074/jbc.M505043200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15944148	hybrid			2022-12-25	WOS:000231487800003
J	Vanharanta, S; Wortham, NC; Laiho, P; Sjoberg, J; Aittomaki, K; Arola, J; Tomlinson, IP; Karhu, A; Arango, D; Aaltonen, LA				Vanharanta, S; Wortham, NC; Laiho, P; Sjoberg, J; Aittomaki, K; Arola, J; Tomlinson, IP; Karhu, A; Arango, D; Aaltonen, LA			7q deletion mapping and expression profiling in uterine fibroids	ONCOGENE			English	Article						fibroid; oligonucleotide microarray; gene expression; chromosome 7; loss of heterozygosity; tumour suppressor gene	GENE-EXPRESSION; MITOTIC RECOMBINATION; ADJACENT MYOMETRIUM; LEIOMYOMAS; TUMORS; HETEROZYGOSITY; CANCER; MICROARRAYS; ALLELOTYPE; ONTOLOGY	Uterine fibroids are some of the most common tumours of females, but relatively little is known about their molecular basis. Several studies have suggested that deletions on chromosome 7q could have a role in fibroid formation. We analysed 165 sporadic uterine fibroids to define a small 3.2 megabase (Mb) commonly deleted region on 7q22.3-q31.1, flanked by clones AC005070 and AC007567. We also used oligonucleotide microarrays to compare the expression profiles of 10 samples of normal myometrium and 15 fibroids, nine of which displayed 7q-deletions. Activating transcription factor 3, patched homolog ( Drosophila), homeo box A5, death-associated protein kinase 1, and retinoic acid receptor responder 3 were downregulated, and excision repair crosscomplementing 3, transcription factor AP-2 gamma and protein kinase C beta 1 were upregulated in fibroids. New pathways were discovered related to fibroid formation. The presence or absence of 7q-deletions did not dramatically affect the global expression pattern of the tumours; changes, however, were observed in genes related to vesicular transport and nucleic acid binding.	Univ Helsinki, Biomedicum, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Clin Genet, FIN-00029 Helsinki, Finland; Univ Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland	University of Helsinki; Cancer Research UK; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Aaltonen, LA (corresponding author), Univ Helsinki, Biomedicum, Haartman Inst, Dept Med Genet, Room B520A,POB 63,Haatmaninkatu 8, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Aaltonen, Lauri/A-5375-2010; Arango, Diego/M-5667-2016; Arango, Diego/AFW-0125-2022	Aaltonen, Lauri/0000-0001-6839-4286; Arango, Diego/0000-0003-2953-3284; Arango, Diego/0000-0003-2953-3284; Karhu, Auli/0000-0002-7927-0796				Ahn WS, 2003, INT J EXP PATHOL, V84, P267, DOI 10.1111/j.0959-9673.2003.00362.x; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Blackburn AC, 2004, CANCER RES, V64, P5140, DOI 10.1158/0008-5472.CAN-03-3435; CAIRNS P, 1994, CANCER RES, V54, P1422; Canzian F, 1996, CANCER RES, V56, P3331; Chegini N, 2003, J SOC GYNECOL INVEST, V10, P161, DOI 10.1016/S1071-5576(03)00004-2; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Gupta PK, 1997, CANCER RES, V57, P1188; Hall KL, 1997, GYNECOL ONCOL, V65, P330, DOI 10.1006/gyno.1997.4653; Herz DB, 2003, J UROLOGY, V170, P2072, DOI 10.1097/01.ju.0000091810.33953.13; Hoffman EP, 2004, NAT REV GENET, V5, P229, DOI 10.1038/nrg1297; Ishwad CS, 1997, GENE CHROMOSOME CANC, V19, P156, DOI 10.1002/(SICI)1098-2264(199707)19:3<156::AID-GCC4>3.0.CO;2-X; ISHWAD CS, 1995, GENE CHROMOSOME CANC, V14, P51, DOI 10.1002/gcc.2870140109; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kovacs KA, 2001, MOL HUM REPROD, V7, P1085, DOI 10.1093/molehr/7.11.1085; Lehtonen R, 2004, AM J PATHOL, V164, P17, DOI 10.1016/S0002-9440(10)63091-X; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Ligon AH, 2000, GENE CHROMOSOME CANC, V28, P235, DOI 10.1002/1098-2264(200007)28:3<235::AID-GCC1>3.3.CO;2-Z; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Mao X, 1999, CANCER GENET CYTOGEN, V114, P89, DOI 10.1016/S0165-4608(99)00053-9; Mori Y, 2003, CANCER RES, V63, P4577; NILBERT M, 1990, GENE CHROMOSOME CANC, V2, P3, DOI 10.1002/gcc.2870020103; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; PANDIS N, 1991, CANCER GENET CYTOGEN, V55, P11, DOI 10.1016/0165-4608(91)90229-N; Parameswaran K, 2004, EUR RESPIR J, V24, P545, DOI 10.1183/09031936.04.00113103; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; REIN MS, 1991, OBSTET GYNECOL, V77, P923; Stewart EA, 2001, LANCET, V357, P293, DOI 10.1016/S0140-6736(00)03622-9; Terashita Y, 2004, ONCOL REP, V12, P827; Tsibris JCM, 2002, FERTIL STERIL, V78, P114, DOI 10.1016/S0015-0282(02)03191-6; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van der Heijden O, 1998, MOL CARCINOGEN, V23, P243, DOI 10.1002/(SICI)1098-2744(199812)23:4<243::AID-MC7>3.0.CO;2-E; VANNI R, 1991, CANCER GENET CYTOGEN, V53, P247, DOI 10.1016/0165-4608(91)90101-Y; Wang HB, 2003, FERTIL STERIL, V80, P266, DOI 10.1016/S0015-0282(03)00730-1; Weston G, 2003, MOL HUM REPROD, V9, P541, DOI 10.1093/molehr/gag066; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	42	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6545	6554		10.1038/sj.onc.1208784	http://dx.doi.org/10.1038/sj.onc.1208784			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	15940248				2022-12-25	WOS:000232204100008
J	Manna, PP; Dimitry, J; Oldenborg, PA; Frazier, WA				Manna, PP; Dimitry, J; Oldenborg, PA; Frazier, WA			CD47 augments Fas/CD95-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; CELL-DEATH; INDEPENDENT APOPTOSIS; SIGNALING COMPLEX; HEMOLYTIC-ANEMIA; NOD MICE; KINASE-A; T-CELLS; FAS; LIGANDS	Fas (CD95) mediates apoptosis of many cell types, but the susceptibility of cells to killing by Fas ligand and anti-Fas antibodies is highly variable. Jurkat T cells lacking CD47 (integrin-associated protein) are relatively resistant to Fas-mediated death but are efficiently killed by Fas ligand or anti-Fas IgM (CH11) upon expression of CD47. Lack of CD47 impairs events downstream of Fas activation including caspase activation, poly(ADP-ribose) polymerase cleavage, cytochrome c release from mitochondria, loss of mitochondrial membrane potential, and DNA cleavage. Neither CD47 signaling nor raft association of CD47 is required to enable Fas apoptosis. CH11 induces association of Fas and CD47. Primary T cells from CD47-null mice are also protected from Fas-mediated killing relative to wild type T cells. Thus CD47 associates with Fas upon its activation and augments Fas-mediated apoptosis.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Umea Univ, Sect Histol & Cell Biol, Dept Integrat Med Biol, SE-90187 Umea, Sweden	Washington University (WUSTL); Umea University	Frazier, WA (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231,660 S Euclid Ave, St Louis, MO 63110 USA.	frazier@biochem.wustl.edu		Manna, Partha Pratim/0000-0003-2939-0818	NHLBI NIH HHS [HL54390] Funding Source: Medline; NIGMS NIH HHS [GM57573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL054390, R01HL054390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barazi HO, 2002, J BIOL CHEM, V277, P42859, DOI 10.1074/jbc.M206849200; BAXTER AG, 1991, EUR J IMMUNOL, V21, P2051, DOI 10.1002/eji.1830210912; Blazar BR, 2001, J EXP MED, V194, P541, DOI 10.1084/jem.194.4.541; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Graf R, 2003, APOPTOSIS, V8, P531, DOI 10.1023/A:1025598609965; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; HU YF, 1992, AM J PHYSIOL, V263, pE607, DOI 10.1152/ajpendo.1992.263.4.E607; Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877; Johansson U, 2004, SCAND J IMMUNOL, V59, P40, DOI 10.1111/j.0300-9475.2004.01355.x; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; Jung KC, 2003, FEBS LETT, V554, P478, DOI 10.1016/S0014-5793(03)01224-9; KOLALOVICH K, 2001, J BIOL CHEM, V276, P26605; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Manna PP, 2004, CANCER RES, V64, P1026, DOI 10.1158/0008-5472.CAN-03-1708; Manna PP, 2003, J IMMUNOL, V170, P3544, DOI 10.4049/jimmunol.170.7.3544; Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217; McDonald JF, 2004, J BIOL CHEM, V279, P17301, DOI 10.1074/jbc.M312782200; Moorman JP, 2003, VIROLOGY, V312, P320, DOI 10.1016/S0042-6822(03)00208-3; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Oldenborg PA, 2002, BLOOD, V99, P3500, DOI 10.1182/blood.V99.10.3500; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pettersen RD, 1999, J IMMUNOL, V162, P7031; RATHMELL JC, 2002, CELL S, V109, P97; Rebres RA, 2001, J BIOL CHEM, V276, P7672, DOI 10.1074/jbc.M008858200; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; REINHOLD MI, 1995, J CELL SCI, V108, P3419; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Ticchioni M, 2001, FASEB J, V15, P341, DOI 10.1096/fj.99-0833com	37	54	62	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29637	29644		10.1074/jbc.M500922200	http://dx.doi.org/10.1074/jbc.M500922200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15917238	hybrid			2022-12-25	WOS:000231176200032
J	Illarionov, B; Eisenreich, W; Schramek, N; Bacher, A; Fischer, M				Illarionov, B; Eisenreich, W; Schramek, N; Bacher, A; Fischer, M			Biosynthesis of vitamin B-2 - Diastereomeric reaction intermediates of archaeal and non-archaeal riboflavin synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; N-TERMINAL DOMAIN; LUMAZINE SYNTHASE; BACILLUS-SUBTILIS; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; ESCHERICHIA-COLI; 4-CARBON PRECURSOR; REACTION-MECHANISM; STRUCTURAL BASIS; LIGAND-BINDING	The dismutation of 6,7-dimethyl-8-ribityllumazine catalyzed by riboflavin synthase affords riboflavin and 5-amino-6-ribitylamino-2,4( 1H, 3H)-pyrimidinedione. A pentacyclic adduct of two 6,7-dimethyl-8-ribityllumazines has been identified earlier as a catalytically competent reaction intermediate of the Escherichia coli enzyme. Acid quenching of reaction mixtures of riboflavin synthase of Methanococcus jannaschii, a paralog of 6,7-dimethyl-8-ribityllumazine synthase devoid of similarity with riboflavin synthases of eubacteria and eukaryotes, afforded a compound whose optical absorption and NMR spectra resemble that of the pentacyclic E. coli riboflavin synthase intermediate, whereas the circular dichroism spectra of the two compounds have similar envelopes but opposite signs. Each of the compounds could serve as a catalytically competent intermediate for the enzyme by which it was produced, but not vice versa. All available data indicate that the respective pentacyclic intermediates of the M. jannaschii and E. coli enzymes are diastereomers.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Eisenreich, W (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	wolfgang.eisenreich@ch.tum.de; markus.fischer@ch.tum.de	Fischer, Markus/AFT-1856-2022; Fischer, Markus/H-2870-2012; Fischer, Markus J./G-9477-2012; Eisenreich, Wolfgang/A-1258-2013	Fischer, Markus/0000-0001-7243-4199; Eisenreich, Wolfgang/0000-0002-9832-8279				BACHER A, 1980, J BIOL CHEM, V255, P632; Bacher A, 1997, METHOD ENZYMOL, V280, P389; Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BEACH RL, 1970, J AM CHEM SOC, V92, P2913, DOI 10.1021/ja00712a052; BEACH RL, 1969, TETRAHEDRON LETT, V6, P3489; BOWN DH, 1986, J ORG CHEM, V51, P2461, DOI 10.1021/jo00363a011; Braden BC, 2000, J MOL BIOL, V297, P1031, DOI 10.1006/jmbi.2000.3640; Cushman M, 1999, J ORG CHEM, V64, P4635, DOI 10.1021/jo9821731; CUSHMAN M, 1991, J ORG CHEM, V56, P4603, DOI 10.1021/jo00015a009; CUSHMAN M, 1992, J ORG CHEM, V57, P5630, DOI 10.1021/jo00047a015; Eberhardt S, 1996, EUR J BIOCHEM, V242, P712, DOI 10.1111/j.1432-1033.1996.0712r.x; Eberhardt S, 1997, J BACTERIOL, V179, P2938, DOI 10.1128/jb.179.9.2938-2943.1997; Fischer M, 2004, J MOL BIOL, V343, P267, DOI 10.1016/j.jmb.2004.08.016; Fischer Markus, 2003, BMC Biochemistry, V4, P18, DOI 10.1186/1471-2091-4-18; Gerhardt S, 2002, J MOL BIOL, V318, P1317, DOI 10.1016/S0022-2836(02)00116-X; Gerhardt S, 2002, STRUCTURE, V10, P1371, DOI 10.1016/S0969-2126(02)00864-X; Haase I, 2003, EUR J BIOCHEM, V270, P1025, DOI 10.1046/j.1432-1033.2003.03478.x; HARDERS H, 1974, BIOCHEMISTRY-US, V13, P3360, DOI 10.1021/bi00713a028; HARVEY RA, 1966, J BIOL CHEM, V241, P2120; Illarionov B, 2004, J ORG CHEM, V69, P5588, DOI 10.1021/jo0493222; Illarionov B, 2001, P NATL ACAD SCI USA, V98, P7224, DOI 10.1073/pnas.131610698; Illarionov B, 2001, J BIOL CHEM, V276, P11524, DOI 10.1074/jbc.M008931200; KIS K, 1995, J BIOL CHEM, V270, P16788, DOI 10.1074/jbc.270.28.16788; KIS K, 1995, BIOCHEMISTRY-US, V34, P2883, DOI 10.1021/bi00009a019; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LADENSTEIN R, 1986, J MOL BIOL, V187, P87, DOI 10.1016/0022-2836(86)90408-0; Lee, 1991, CHEM BIOCH FLAVOENZY, V2, P109; Liao DI, 2001, STRUCTURE, V9, P11, DOI 10.1016/S0969-2126(00)00550-5; Meining W, 2000, J MOL BIOL, V299, P181, DOI 10.1006/jmbi.2000.3742; Meining W, 2003, J MOL BIOL, V331, P1053, DOI 10.1016/S0022-2836(03)00844-1; Mortl S, 1996, J BIOL CHEM, V271, P33201, DOI 10.1074/jbc.271.52.33201; PATERSON T, 1969, J CHEM SOC CHEM COMM, P290, DOI 10.1039/c29690000290; PATERSON T, 1972, J CHEM SOC P1, V1, P1051; Persson K, 1999, PROTEIN SCI, V8, P2355; Petushkov VN, 1997, EUR J BIOCHEM, V245, P790, DOI 10.1111/j.1432-1033.1997.00790.x; Plaut G. W., 1975, CHEM BIOL PTERIDINES, P101; Plaut G. W. E., 1976, FLAVINS FLAVOPROTEIN, P737; PLAUT GW, 1970, BIOCHEMISTRY-US, V17, P771; PLAUT GWE, 1963, J BIOL CHEM, V238, P2225; PLAUT GWE, 1974, ANNU REV BIOCHEM, V43, P899, DOI 10.1146/annurev.bi.43.070174.004343; PLAUT GWE, 1971, COMPREHENSIVE BIOCH, V21, P11; ROWAN T, 1963, P CHEM SOC LONDON, P21; ROWAN T, 1968, J CHEM SOC C, P452, DOI 10.1039/j39680000452; Scheuring J, 1996, BIOCHEMISTRY-US, V35, P9637, DOI 10.1021/bi9600916; SCHOTT K, 1990, J BIOL CHEM, V265, P4204; SCHOTT K, 1990, J BIOL CHEM, V265, P12686; Truffault V, 2001, J MOL BIOL, V309, P949, DOI 10.1006/jmbi.2001.4683; VOLK R, 1990, J BIOL CHEM, V265, P19479; VOLK R, 1988, J AM CHEM SOC, V110, P3651, DOI 10.1021/ja00219a047; WACKER H, 1964, J BIOL CHEM, V239, P3493; Zhang XF, 2003, J MOL BIOL, V328, P167, DOI 10.1016/S0022-2836(03)00186-4; Zheng YJ, 2003, BIOORG CHEM, V31, P278, DOI 10.1016/S0045-2068(03)00029-4	52	18	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28541	28546		10.1074/jbc.M503093200	http://dx.doi.org/10.1074/jbc.M503093200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15944152	hybrid			2022-12-25	WOS:000230857300044
J	Ishiki, M; Randhawa, VK; Poon, V; JeBailey, L; Klip, A				Ishiki, M; Randhawa, VK; Poon, V; JeBailey, L; Klip, A			Insulin regulates the membrane arrival, fusion, and C-terminal unmasking of glucose transporter-4 via distinct phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE-TRANSPORTER; STIMULATED GLUT4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; ADIPOSE-CELLS; FAT-CELLS; KINASE; ACTIN	Insulin increases glucose uptake into muscle via glucose transporter-4 ( GLUT4) translocation to the cell membrane, but the regulated events in GLUT4 traffic are unknown. Here we focus on the role of class IA phosphatidylinositol ( PI) 3-kinase and specific phosphoinositides in the steps of GLUT4 arrival and fusion with the membrane, using L6 muscle cells expressing GLUT4myc. To this end, we detected the availability of the myc epitope at the cell surface or intravesicular spaces and of the cytosol-facing C-terminal epitope, in cells and membrane lawns derived from them. We observed the following: ( a) Wortmannin and LY294002 at concentrations that inhibit class IA PI 3-kinase reduced but did not abate the C terminus gain, yet the myc epitope was unavailable for detection unless lawns or cells were permeabilized, suggesting the presence of GLUT4myc in docked, unfused vesicles. Accordingly, GLUT4myc-containing vesicles were detected by immunoelectron microscopy of membranes from cells pretreated with wortmannin and insulin, but not insulin or wortmannin alone. ( b) Insulin caused greater immunological availability of the C terminus than myc epitopes, suggesting that C terminus unmasking had occurred. Delivering phosphatidylinositol 3,4,5-trisphosphate ( PI( 3,4,5) P3) to intact cells significantly increased lawn-associated myc signal without C terminus gain. Conversely, phosphatidylinositol 3-phosphate ( PI3P) increased the detection of C terminus epitope without any myc gain. We propose that insulin regulates GLUT4 membrane arrival, fusion, and C terminus unmasking, through distinct phosphoinositides. PI( 3,4,5) P3 causes arrival and fusion without unmasking, whereas PI3P causes arrival and unmasking without fusion.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Klip, A (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	amira@sickkids.ca						BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Bogan JS, 2003, NATURE, V425, P727, DOI 10.1038/nature01989; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Chaussade C, 2003, MOL ENDOCRINOL, V17, P2448, DOI 10.1210/me.2003-0261; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; James DJ, 2004, J BIOL CHEM, V279, P20567, DOI 10.1074/jbc.C400096200; KAHN BB, 1988, J CLIN INVEST, V82, P691, DOI 10.1172/JCI113649; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; Karlsson M, 2001, FASEB J, V15, P249, DOI 10.1096/fj.01-0646fje; Khayat ZA, 2000, J CELL SCI, V113, P279; Kishi K, 1998, DIABETES, V47, P550, DOI 10.2337/diabetes.47.4.550; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; Lalioti VS, 2002, J BIOL CHEM, V277, P19783, DOI 10.1074/jbc.M110294200; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Malide D, 2000, J CELL SCI, V113, P4203; MIOZZARI GF, 1978, ANAL BIOCHEM, V90, P220, DOI 10.1016/0003-2697(78)90026-X; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Patel N, 2003, MOL CELL BIOL, V23, P4611, DOI 10.1128/MCB.23.13.4611-4626.2003; Randhawa VK, 2004, MOL BIOL CELL, V15, P5565, DOI 10.1091/mbc.E04-03-0266; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Rudich A, 2003, DIABETOLOGIA, V46, P649, DOI 10.1007/s00125-003-1080-1; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; SATOH S, 1993, J BIOL CHEM, V268, P17820; Shigematsu S, 2002, MOL ENDOCRINOL, V16, P1060, DOI 10.1210/me.16.5.1060; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Sweeney G, 2004, J BIOL CHEM, V279, P32233, DOI 10.1074/jbc.M402897200; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tengholm A, 2002, CURR BIOL, V12, P1871, DOI 10.1016/S0960-9822(02)01223-X; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; van Dam EM, 2005, MOL ENDOCRINOL, V19, P1067, DOI 10.1210/me.2004-0413; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zierath JR, 1998, MOL CELL BIOCHEM, V182, P153, DOI 10.1023/A:1006861628496; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504	53	49	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28792	28802		10.1074/jbc.M500501200	http://dx.doi.org/10.1074/jbc.M500501200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15955810	hybrid			2022-12-25	WOS:000230857300071
J	Lee, SH; Williams, MV; DuBois, RN; Blair, IA				Lee, SH; Williams, MV; DuBois, RN; Blair, IA			Cyclooxygenase-2-mediated DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2; ARACHIDONIC-ACID METABOLITES; LIPID-PEROXIDATION; EPITHELIAL-CELLS; H SYNTHASE-2; ACTIVE-SITE; 1,N-2-ETHENO-2'-DEOXYGUANOSINE ADDUCTS; COLORECTAL-CANCER; BREAST-CANCER	Rat intestinal epithelial cells that express the cyclooxygenase-2 (COX-2) gene permanently (RIES cells) were used as a model of in vivo oxidative stress. A targeted lipidomics approach showed that 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) was the major hydroxylated non-esterified lipid formed in unstimulated intact cells. The corresponding hydroperoxide, 15( S)hydroperoxyeicosatetraenoic acid (15(S)-HPETE) undergoes homolytic decomposition to the DNA-reactive bifunctional electrophile 4-oxo-2(E)-nonenal, a precursor of heptanone-etheno-2'-deoxyguanosine. This etheno adduct was identified in the DNA of RIES cells. A dose-dependent increase in adduct levels was observed in the presence of vitamin C. This suggested that vitamin C increased lipid hydroperoxide-mediated 4-oxo-2(E)-nonenal formation in the cells. The selective COX-2 inhibitor NS-398 was protective against cellular DNA damage but was less effective if vitamin C was present. Prostaglandin E-2 and 15(S)-HETE biosynthesis were completely inhibited by 110 mu M NS-398 in the intact RIES cells. No inhibition of COX-1 was detected in the wildtype RIE cells at this concentration of NS-398. Arachidonic acid treatment of RIES cell lysates and ionophore stimulation of intact RIES cells produced significantly more 15(R)-HETE than the untreated intact cells. These preparations also both produced 11(R)-HETE, which was not detected in the intact cells. Aspirin treatment of the intact unstimulated RIES cells resulted in the exclusive formation of 15(R)-HETE in amounts that were slightly higher than the original 15(S)-HETE observed in the absence of aspirin, implying that significant amounts of 15(R)-HPETE had also been formed. 15(R)HPETE should give exactly the same amount of heptanone-etheno-2'-deoxyguanosine as its 15(S)-enantiomer. However, no increase in heptanone-etheno adduct formation occurred in the aspirin-treated cells. The present study suggests a potential mechanism of tumorigenesis that involves DNA adduct formation from COX-2-mediated lipid peroxidation rather than prostaglandin formation. Therefore, inhibition of COX-2-mediated lipid hydroperoxide formation offers a potential therapeutic alternative to COX-2 inhibitors in chemoprevention strategies.	Univ Penn, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA	University of Pennsylvania; Pennsylvania Medicine; Vanderbilt University	Blair, IA (corresponding author), Univ Penn, Ctr Canc Pharmacol, 854 RBR 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	ian@spirit.gcrc.upenn.edu	Blair, Ian A/B-3320-2010; DuBois, Raymond N./AAX-8869-2020	Lee, Seon Hwa/0000-0003-1095-5516	NATIONAL CANCER INSTITUTE [R01CA095586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047297, R01DK047297] Funding Source: NIH RePORTER; NCI NIH HHS [CA95586] Funding Source: Medline; NIDDK NIH HHS [DK047297] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akasaka S, 1999, CHEM RES TOXICOL, V12, P501, DOI 10.1021/tx980259j; Boyle JE, 1999, AM J RESP CELL MOL, V20, P433, DOI 10.1165/ajrcmb.20.3.3284; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Davies GLS, 2003, J STEROID BIOCHEM, V86, P495, DOI 10.1016/j.jsbmb.2003.07.004; Douki T, 2004, FREE RADICAL BIO MED, V37, P62, DOI 10.1016/j.freeradbiomed.2004.04.013; DuBois RN, 1996, CANCER RES, V56, P733; Fernandez-Tome M, 2004, BIOCHEM PHARMACOL, V67, P245, DOI 10.1016/j.bcp.2003.08.028; Gallasch BAW, 2000, LIPIDS, V35, P953, DOI 10.1007/s11745-000-0605-z; Gros L, 2003, MUTAT RES-FUND MOL M, V531, P219, DOI 10.1016/j.mrfmmm.2003.07.008; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hamberg M, 1998, ARCH BIOCHEM BIOPHYS, V349, P376, DOI 10.1006/abbi.1997.0443; HECKER M, 1987, EUR J BIOCHEM, V169, P113, DOI 10.1111/j.1432-1033.1987.tb13587.x; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Ikawa H, 1999, CANCER RES, V59, P360; JIAN W, 2005, IN PRESS FREE RAD BI; Jian WY, 2005, CHEM RES TOXICOL, V18, P599, DOI 10.1021/tx049693d; Johnson JL, 1995, ARCH BIOCHEM BIOPHYS, V324, P26, DOI 10.1006/abbi.1995.9934; Kamitani H, 1999, ARCH BIOCHEM BIOPHYS, V368, P45, DOI 10.1006/abbi.1999.1284; Kawai Y, 2004, FREE RADICAL BIO MED, V36, P529, DOI 10.1016/j.freeradbiomed.2003.12.006; Kempen EC, 2001, ANAL BIOCHEM, V297, P183, DOI 10.1006/abio.2001.5325; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Kuhn H, 2002, FREE RADICAL BIO MED, V33, P154, DOI 10.1016/S0891-5849(02)00855-9; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Lee SH, 2000, CHEM RES TOXICOL, V13, P565, DOI 10.1021/tx000057z; Lee SH, 2005, CHEM RES TOXICOL, V18, P780, DOI 10.1021/tx0497088; Lee SH, 2005, CHEM RES TOXICOL, V18, P566, DOI 10.1021/tx049716o; Lee SH, 2003, RAPID COMMUN MASS SP, V17, P2168, DOI 10.1002/rcm.1170; Lee SH, 2002, CHEM RES TOXICOL, V15, P300, DOI 10.1021/tx010147j; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; Levine RL, 2000, CANCER RES, V60, P4098; Lippman SM, 1998, JNCI-J NATL CANCER I, V90, P1514, DOI 10.1093/jnci/90.20.1514; Liu ZF, 2003, CHEM RES TOXICOL, V16, P901, DOI 10.1021/tx0300030; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Oe T, 2003, CHEM RES TOXICOL, V16, P1598, DOI 10.1021/tx034178l; Oe T, 2003, J BIOL CHEM, V278, P42098, DOI 10.1074/jbc.M308167200; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; Pollack M, 2003, CHEM RES TOXICOL, V16, P893, DOI 10.1021/tx030009p; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; PRYOR WA, 1975, J ORG CHEM, V40, P3615, DOI 10.1021/jo00912a038; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; Rindgen D, 2000, CHEM RES TOXICOL, V13, P846, DOI 10.1021/tx0000771; Rowlinson SW, 2000, J BIOL CHEM, V275, P6586, DOI 10.1074/jbc.275.9.6586; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; Schneider C, 2002, J BIOL CHEM, V277, P478, DOI 10.1074/jbc.M107471200; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Singh G, 2000, ANAL CHEM, V72, P3007, DOI 10.1021/ac000374a; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Szewczuk LM, 2004, J BIOL CHEM, V279, P22727, DOI 10.1074/jbc.M314302200; Teather LA, 2003, NEUROSCI LETT, V340, P177, DOI 10.1016/S0304-3940(03)00129-0; THUN MJ, 1993, CANCER RES, V53, P1322; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; Tran POT, 1999, J BIOL CHEM, V274, P31245, DOI 10.1074/jbc.274.44.31245; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wang DZ, 2004, SEMIN ONCOL, V31, P64, DOI 10.1053/j.seminoncol.2004.01.008; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; Williams MV, 2005, RAPID COMMUN MASS SP, V19, P849, DOI 10.1002/rcm.1854; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; Yu ZY, 2003, P NATL ACAD SCI USA, V100, P9162, DOI 10.1073/pnas.1633612100; Zarini S, 2003, J BIOL CHEM, V278, P11190, DOI 10.1074/jbc.M208496200; Zhang WH, 2003, CHEM RES TOXICOL, V16, P512, DOI 10.1021/tx020105a	65	76	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28337	28346		10.1074/jbc.M504178200	http://dx.doi.org/10.1074/jbc.M504178200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15964853	hybrid			2022-12-25	WOS:000230857300021
J	Keese, M; Magdeburg, RJ; Herzog, T; Hasenberg, T; Offterdinger, M; Pepperkok, R; Sturm, RW; Bastiaens, PIH				Keese, M; Magdeburg, RJ; Herzog, T; Hasenberg, T; Offterdinger, M; Pepperkok, R; Sturm, RW; Bastiaens, PIH			Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHATASES; SIGNAL PROPAGATION; CARCINOMA-CELLS; GLOBAL ANALYSIS; MICROSCOPY DATA; EXPRESSION; ACTIVATION; LINES; EGFR; INHIBITION	In tumor cells, high phosphorylation levels of receptor tyrosine kinases may occur in the absence of exogenous ligands due to autocrine signaling or enhanced tyrosine kinase activity. Here we show that the phosphorylation state of the endogenous epidermal growth factor receptor ( EGFR) can be quantitatively imaged in tumor cells and tissues by detecting fluorescence resonance energy transfer between fluorophores conjugated to antibodies against the receptor and phosphotyrosine, respectively. Five different human colorectal cell lines were analyzed for activity and expression of EGFR. All cell lines exhibited basal EGFR phosphorylation under serum starvation conditions. Phosphorylation levels increased after stimulation with EGF or pervanadate, dependent on the level of basal EGFR phosphorylation in the respective cell lines. This basal activity correlated inversely with receptor expression. Using the acceptor photobleaching fluorescence resonance energy transfer imaging approach, a significantly higher phosphorylation state of EGFR was also found in resected human colorectal tumor samples as compared with adjacent healthy tissue. Imaging of EGFR phosphorylation may thus serve as a valuable tool to investigate the role of receptor tyrosine kinase activity in malignant cell growth.	European Mol Biol Lab, Cell Biol & Biophys Program, D-69117 Heidelberg, Germany; Univ Hosp Mannheim, Surg Clin, D-68167 Mannheim, Germany	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg	Bastiaens, PIH (corresponding author), European Mol Biol Lab, Cell Biol & Biophys Program, Meyerhofstr 1, D-69117 Heidelberg, Germany.	bastiaen@embl.de		Hasenberg, Till/0000-0003-2681-8006; Pepperkok, Rainer/0000-0002-9762-3583				Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; ANZANO MA, 1989, CANCER RES, V49, P2898; Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; CARLIN CR, 1988, MOL CELL BIOL, V8, P25, DOI 10.1128/MCB.8.1.25; Cohen Roger B, 2003, Clin Colorectal Cancer, V2, P246, DOI 10.3816/CCC.2003.n.006; Flint AJ, 1995, P NATL ACAD SCI USA, V95, P1680; Giralt J, 2002, INT J RADIAT ONCOL, V54, P1460, DOI 10.1016/S0360-3016(02)03752-5; Gradilone A, 2003, ONCOL REP, V10, P217; Grunwald V, 2003, SEMIN ONCOL, V30, P23, DOI 10.1016/S0093-7754(03)70022-0; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Ioachim EE, 1999, ANTICANCER RES, V19, P2147; Kedar D, 2002, CLIN CANCER RES, V8, P3592; Kopp R, 2003, RECENT RESULTS CANC, V162, P115; LAROCCA RV, 1992, ONCOLOGY, V49, P209; Layfield LJ, 2003, J SURG ONCOL, V83, P227, DOI 10.1002/jso.10272; McKay JA, 2002, EUR J CANCER, V38, P2258, DOI 10.1016/S0959-8049(02)00234-4; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Nicholson KM, 2003, BREAST CANCER RES TR, V81, P117, DOI 10.1023/A:1025765215765; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; O'Dwyer PJ, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.35643; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sasaki Hidefumi, 2003, Int J Clin Oncol, V8, P79, DOI 10.1007/s101470300014; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Thomas CY, 2003, INT J CANCER, V104, P19, DOI 10.1002/ijc.10880; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Tong WM, 1998, BRIT J CANCER, V77, P1792, DOI 10.1038/bjc.1998.298; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Verveer PJ, 2000, BIOPHYS J, V78, P2127, DOI 10.1016/S0006-3495(00)76759-2; Verveer PJ, 2001, J MICROSC-OXFORD, V202, P451, DOI 10.1046/j.1365-2818.2001.00917.x; Waksal HW, 1999, CANCER METAST REV, V18, P427, DOI 10.1023/A:1006302101468; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; XIE H, 1995, CLIN EXP METASTAS, V13, P407, DOI 10.1007/BF00118180; Yarden Y, 2001, EUR J CANCER, V37, pS3	41	31	32	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27826	27831		10.1074/jbc.M504485200	http://dx.doi.org/10.1074/jbc.M504485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15908435	hybrid			2022-12-25	WOS:000230678600043
J	Zeng, Y; Cullen, BR				Zeng, Y; Cullen, BR			Efficient processing of primary microRNA hairpins by drosha requires flanking nonstructured RNA sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DICER; MICROPROCESSOR COMPLEX; SUBSTRATE RECOGNITION; RIBONUCLEASE; CLEAVAGE; BINDING; BACTERIAL	Drosha is a member of the ribonuclease ( RNase) III family that selectively processes RNAs with prominent double-stranded features. Drosha plays a key role in the generation of precursor microRNAs from primary microRNA (pri-miRNA) transcripts in animal cells, yet how Drosha recognizes its RNA substrates remains incompletely understood. Previous studies have indicated that, within the context of a larger pri-miRNA, an similar to 80-nucleotide-long RNA hairpin structure is necessary for processing by Drosha. Here, by performing in vitro Drosha processing reactions with RNA substrates of various sizes and structures, we show that Drosha function also requires single-stranded RNA extensions located outside the pri-miRNA hairpin. The sequence of these RNA extensions was largely unimportant, but a strong secondary structure within the extension or a blunt-ended pri-miRNA hairpin blocked Drosha cleavage. The requirement for single-stranded extensions on the pri-miRNA hairpin substrate for Drosha processing is currently unique among the RNase III enzymes.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Virol, Durham, NC 27710 USA	Duke University; Duke University	Cullen, BR (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Box 3025, Durham, NC 27710 USA.	culle002@mc.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071408] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM071408] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Chanfreau C, 2000, P NATL ACAD SCI USA, V97, P3142, DOI 10.1073/pnas.070043997; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Lamontagne B, 2004, J BIOL CHEM, V279, P2231, DOI 10.1074/jbc.M309324200; Lamontagne B, 2003, J MOL BIOL, V327, P985, DOI 10.1016/S0022-2836(03)00231-6; Lamontagne B, 2001, Curr Issues Mol Biol, V3, P71; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Nagel R, 2000, RNA, V6, P1142, DOI 10.1017/S1355838200000431; Nicholson Allen W., 2003, P149; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zeng Y, 2005, EMBO J, V24, P138, DOI 10.1038/sj.emboj.7600491; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582; Zhang KJ, 1997, P NATL ACAD SCI USA, V94, P13437, DOI 10.1073/pnas.94.25.13437; ZNEG Y, 2002, MOL CELL, V9, P1327	22	214	249	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27595	27603		10.1074/jbc.M504714200	http://dx.doi.org/10.1074/jbc.M504714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15932881	hybrid			2022-12-25	WOS:000230678600016
J	Lee, WJ; Robinson, JA; Holman, NA; McCall, MN; Roberts-Thomson, SJ; Monteith, GR				Lee, WJ; Robinson, JA; Holman, NA; McCall, MN; Roberts-Thomson, SJ; Monteith, GR			Antisense-mediated inhibition of the plasma membrane Calcium-ATPase suppresses proliferation of MCF-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; BREAST-CANCER CELLS; NA+/CA2+ EXCHANGE; GENE-EXPRESSION; ENDOTHELIAL-CELLS; RAT-BRAIN; PUMP; CA2+-ATPASE; MODULATION; OVEREXPRESSION	Alterations in Ca2+ signaling may contribute to tumorigenesis and the mechanism of action of some anticancer drugs. The plasma membrane calcium-ATPase (PMCA) is a crucial controller of intracellular Ca2+ signaling. Altered PMCA expression occurs in the mammary gland during lactation and in breast cancer cell lines. Despite this, the consequences of PMCA inhibition in breast cancer cell lines have not been investigated. In this work, we used Tet-off PMCA antisense-expressing MCF-7 cells to assess the effects of PMCA inhibition in a human breast cancer cell line. At a level of PMCA inhibition that did not completely prevent PMCA-mediated Ca2+ efflux and did not induce cell death, a dramatic inhibition of cellular proliferation was observed. Fluorescence-activated cell sorting analysis indicated that PMCA antisense involves changes in cell cycle kinetics but not cell cycle arrest. We concluded that modulation of PMCA has important effects in regulating the proliferation of human breast cancer MCF-7 cells.	Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia; Acute Biotech Pty Ltd, Sydney, NSW 2052, Australia	University of Queensland	Monteith, GR (corresponding author), Univ Queensland, Sch Pharm, Steele Bldg, Brisbane, Qld 4072, Australia.	G.Monteith@pharmacy.uq.edu.au	Roberts-Thomson, Sarah/W-5676-2019; Monteith, Gregory/B-1626-2008; Roberts-Thomson, Sarah J/B-4282-2011	Roberts-Thomson, Sarah/0000-0001-8202-5786; Monteith, Gregory/0000-0002-4345-530X; Roberts-Thomson, Sarah J/0000-0001-8202-5786				Bautista DM, 2002, J PHYSIOL-LONDON, V541, P877, DOI 10.1113/jphysiol.2001.016154; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Brandt PC, 1996, P NATL ACAD SCI USA, V93, P13843, DOI 10.1073/pnas.93.24.13843; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Chene P, 2002, NAT REV DRUG DISCOV, V1, P665, DOI 10.1038/nrd894; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ferrington DA, 1997, BIOCHEM BIOPH RES CO, V237, P163, DOI 10.1006/bbrc.1997.7105; Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; GOODWIN CJ, 1995, J IMMUNOL METHODS, V179, P95, DOI 10.1016/0022-1759(94)00277-4; Haverstick DM, 2000, CANCER RES, V60, P1002; Hu QH, 2002, BIOCHEM BIOPH RES CO, V292, P325, DOI 10.1006/bbrc.2002.6675; Ichikawa J, 2000, CELL BIOCHEM FUNCT, V18, P215; Johnson PH, 2002, MOL CANCER THER, V1, P1293; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; Kamrava M.R., 2002, PHARM NEWS, V9, P435; Klishin A, 1998, AM J PHYSIOL-CELL PH, V274, pC1117, DOI 10.1152/ajpcell.1998.274.4.C1117; Kuo TH, 1997, CELL CALCIUM, V21, P399, DOI 10.1016/S0143-4160(97)90051-8; Laskey AD, 1998, CELL CALCIUM, V23, P423, DOI 10.1016/S0143-4160(98)90099-9; Lee WJ, 2002, CELL SIGNAL, V14, P1015, DOI 10.1016/S0898-6568(02)00049-9; Lipskaia L, 2004, BIOL CELL, V96, P55, DOI 10.1016/j.biolcel.2003.11.001; MONTEITH GR, 1995, CELL CALCIUM, V18, P459, DOI 10.1016/0143-4160(95)90009-8; Munster PN, 2001, CANCER RES, V61, P2945; Nie L, 1997, CELL CALCIUM, V22, P75, DOI 10.1016/S0143-4160(97)90107-X; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; Reinhardt TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1595, DOI 10.1152/ajpcell.2000.279.5.C1595; Reinhardt TA, 2004, J BIOL CHEM, V279, P42369, DOI 10.1074/jbc.M407788200; Reisner PD, 1997, CELL CALCIUM, V21, P53, DOI 10.1016/S0143-4160(97)90096-8; Rizzuto R, 2003, NAT GENET, V34, P135, DOI 10.1038/ng0603-135; Rosado JA, 2000, J BIOL CHEM, V275, P19529, DOI 10.1074/jbc.M001319200; Sazani P, 2002, CURR OPIN BIOTECH, V13, P468, DOI 10.1016/S0958-1669(02)00366-X; Sedova M, 1999, CELL CALCIUM, V25, P333, DOI 10.1054/ceca.1999.0036; Shimizu H, 1997, CELL CALCIUM, V21, P31, DOI 10.1016/S0143-4160(97)90094-4; Slodzinski MK, 1998, AM J PHYSIOL-CELL PH, V275, pC459, DOI 10.1152/ajpcell.1998.275.2.C459; Smith SA, 2003, J NEUROSCI RES, V72, P747, DOI 10.1002/jnr.10613; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Usachev YM, 2002, NEURON, V33, P113, DOI 10.1016/S0896-6273(01)00557-8; Vanden Abeele F, 2002, CANCER CELL, V1, P169; White PJ, 1999, J INVEST DERMATOL, V112, P699, DOI 10.1046/j.1523-1747.1999.00578.x; Williams SS, 2000, CANCER RES, V60, P4358; Zhang W, 2000, CANCER RES, V60, P5395	46	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27076	27084		10.1074/jbc.M414142200	http://dx.doi.org/10.1074/jbc.M414142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911623	hybrid			2022-12-25	WOS:000230589500054
J	Lu, KV; Jong, KA; Kim, GY; Singh, J; Dia, EQ; Yoshimoto, K; Wang, MY; Cloughesy, TF; Nelson, SF; Mischel, PS				Lu, KV; Jong, KA; Kim, GY; Singh, J; Dia, EQ; Yoshimoto, K; Wang, MY; Cloughesy, TF; Nelson, SF; Mischel, PS			Differential induction of glioblastoma migration and growth by two forms of pleiotrophin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ANAPLASTIC LYMPHOMA KINASE; AFFIN REGULATORY PEPTIDE; MOLECULE HB-GAM; BETA-CATENIN; SIGNALING PATHWAY; NERVOUS-SYSTEM; ZETA/RPTP-BETA; CELL MIGRATION; RECEPTOR	Glioblastoma is the most common malignant brain tumor of adults and one of the most lethal cancers. The secreted growth factor pleiotrophin (PTN) promotes glioblastoma migration and proliferation, initiating its oncogenic activities through two cell surface receptors, the protein tyrosine phosphatase receptor zeta (PTPRZ1) and the anaplastic lymphoma kinase (ALK), respectively. Here, we report on the presence and purification of two naturally occurring forms of PTN ( 18 and 15 kDa) that differentially promote glioblastoma migration and proliferation. Using a panel of glioblastoma cell lines, including low passage patient-derived cultures, we demonstrate that PTN15 promotes glioblastoma proliferation in an ALK-dependent fashion, whereas immobilized PTN18 promotes haptotactic migration of glioblastoma cells in a PTPRZ1-dependent fashion. Mass spectrometric analysis indicated that PTN15 differs from PTN18 by processing of 12 C-terminal amino acids. To demonstrate clinical relevance, we show that PTN15, PTN18, and PTPRZ1 are significantly overexpressed in glioblastoma relative to normal brain at both mRNA and protein levels using microarray, Western blot, and tissue microarray analyses on human tumors. These results indicate that the PTN18-PTPRZ1 and the PTN15-ALK signaling pathways represent potentially important therapeutic targets for glioblastoma invasion and growth.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Henry E Singleton Brain Tumor Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mischel, PS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	pmischel@mednet.ucla.edu	Nelson, Stanley F/D-4771-2009; Cloughesy, Timothy Francis/AGV-1013-2022	Nelson, Stanley F/0000-0002-2082-3114; 	NATIONAL CANCER INSTITUTE [T32CA009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS043147, R01NS050151] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09056] Funding Source: Medline; NINDS NIH HHS [NS43147, NS050151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bernard-Pierrot I, 2002, J BIOL CHEM, V277, P32071, DOI 10.1074/jbc.M202747200; Bernard-Pierrot I, 1999, BIOCHEM BIOPH RES CO, V266, P437, DOI 10.1006/bbrc.1999.1835; Bernard-Pierrot I, 2001, J BIOL CHEM, V276, P12228, DOI 10.1074/jbc.M010913200; BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Choe G, 2003, CANCER RES, V63, P2742; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jones MD, 1998, ANAL CHEM, V70, P136, DOI 10.1021/ac9707693; Klomp HJ, 2002, CLIN CANCER RES, V8, P823; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Lu KV, 2004, LAB INVEST, V84, P8, DOI 10.1038/labinvest.3700003; LU KV, 1995, BIOCHEM J, V309, P411, DOI 10.1042/bj3090411; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Malerczyk C, 2005, GENE THER, V12, P339, DOI 10.1038/sj.gt.3302398; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Mentlein R, 2002, J NEUROCHEM, V83, P747, DOI 10.1046/j.1471-4159.2002.01179.x; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; Mischel PS, 2003, BRAIN PATHOL, V13, P52; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Muller S, 2003, ONCOGENE, V22, P6661, DOI 10.1038/sj.onc.1206763; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAULO E, 1992, J BIOL CHEM, V267, P11408; SilosSantiago I, 1996, J NEUROBIOL, V31, P283, DOI 10.1002/(SICI)1097-4695(199611)31:3<283::AID-NEU2>3.0.CO;2-6; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Ulbricht U, 2003, J NEUROPATH EXP NEUR, V62, P1265, DOI 10.1093/jnen/62.12.1265; Vacherot F, 1999, PROSTATE, V38, P126, DOI 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wang YL, 2004, ONCOGENE, V23, P1283, DOI 10.1038/sj.onc.1207244; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Zhang N, 1999, J BIOL CHEM, V274, P12959, DOI 10.1074/jbc.274.19.12959	43	106	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26953	26964		10.1074/jbc.M502614200	http://dx.doi.org/10.1074/jbc.M502614200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15908427	hybrid			2022-12-25	WOS:000230589500039
J	Moh, MC; Zhang, CL; Luo, CL; Lee, LH; Shen, SL				Moh, MC; Zhang, CL; Luo, CL; Lee, LH; Shen, SL			Structural and functional analyses of a novel Ig-like cell adhesion molecule, hepaCAM, in the human breast carcinoma MCF7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION; EPITHELIAL-CELLS; DOMAIN; PHOSPHORYLATION; DIMERIZATION; RECEPTORS; REGULATOR; DIMER	We have recently identified a novel gene, hepaCAM, in liver that encodes a cell adhesion molecule of the immunoglobulin superfamily. In this study, we examined the characteristics of hepaCAM protein and the relationship between its structure and function, in particular its adhesive properties. The wild-type and the cytoplasmic domain-truncated mutants of hepaCAM were transfected into the human breast carcinoma MCF7 cells, and the physiological and biological properties were assessed. Biochemical analyses revealed that hepaCAM is an N-linked glycoprotein phosphorylated in the cytoplasmic domain and that it forms homodimers through cis-interaction on the cell surface. The subcellular localization of hepaCAM appears density-dependent; in well spread cells, hepaCAM is distributed to cell protrusions, whereas in confluent cells, hepaCAM is predominantly accumulated at the sites of cell-cell contacts on the cell membrane. In polarized cells, hepaCAM is recruited to the lateral and basal membranes, and lacking physical interaction, hepaCAM is shown to co-localize with E-cadherin at the lateral membrane. Cell adhesion and motility assays demonstrated that hepaCAM increased cell spreading on the matrices fibronectin and matrigel, delayed cell detachment, and enhanced wound healing. Furthermore, when the cytoplasmic domain was deleted, hepaCAM mutants did not affect cell surface localization and dimer formation. Cell-matrix adhesion, however, was less significantly increased, and cell motility was almost unchanged when compared with the effect of the wild-type hepaCAM. Taken together, the cytoplasmic domain of hepaCAM is essential to its function on cell-matrix interaction and cell motility.	Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117597, Singapore; Chongqing Med Univ, Dept Lab Diag, Chongqing 400016, Peoples R China	National University of Singapore; Chongqing Medical University	Shen, SL (corresponding author), Natl Univ Singapore, Fac Med, Dept Physiol, 2 Med Dr, Singapore 117597, Singapore.	phsssl@nus.edu.sg						BATES PA, 1992, FEBS LETT, V301, P207, DOI 10.1016/0014-5793(92)81249-L; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EDELMAN GM, 1984, P NATL ACAD SCI-BIOL, V81, P1460, DOI 10.1073/pnas.81.5.1460; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hunter I, 1996, BIOCHEM J, V320, P847, DOI 10.1042/bj3200847; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Moh MC, 2005, J HEPATOL, V42, P833, DOI 10.1016/j.jhep.2005.01.025; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Peck D, 1996, CURR BIOL, V6, P884, DOI 10.1016/S0960-9822(02)00612-7; REILLY PL, 1995, J IMMUNOL, V155, P529; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Sundberg U, 2004, J CELL SCI, V117, P1091, DOI 10.1242/jcs.00944; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Xie H, 1998, J CELL SCI, V111, P615	20	47	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27366	27374		10.1074/jbc.M500852200	http://dx.doi.org/10.1074/jbc.M500852200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917256	hybrid			2022-12-25	WOS:000230589500087
J	Pedram, A; Razandi, M; Aitkenhead, M; Levin, ER				Pedram, A; Razandi, M; Aitkenhead, M; Levin, ER			Estrogen inhibits cardiomyocyte hypertrophy in vitro - Antagonism of calcineurin-related hypertrophy through induction of MCIP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR HYPERTROPHY; ATRIAL-NATRIURETIC-PEPTIDE; PROTEIN-KINASE-C; HORMONE REPLACEMENT THERAPY; CARDIAC-HYPERTROPHY; ANGIOTENSIN-II; RECEPTOR; SIGNAL; ACTIVATION; EXPRESSION	Evidence from in vivo studies suggests that some inputs to cardiac hypertrophy are opposed by the actions of estrogen. However, the mechanisms of E-2 action in this respect are mainly unknown. An important pathway that is utilized by multiple hypertrophic stimuli involves the activation of the tyrosine phosphatase, calcineurin (PP2B). Here we show that 17 beta-estradiol ( E2) significantly prevents angiotensin II (AngII)- or endothelin-1 (ET-1)-induced new protein synthesis, skeletal muscle actin expression, and increased surface area in cultured rat cardiomyocytes. ET-1 stimulated calcineurin phosphatase activity, resulting in new protein synthesis, and both were prevented by E2. E2 induced the MCIP1 gene, an inhibitor of calcineurin activity, via phosphatidylinositol 3-kinase, transcriptional, and mRNA stability mechanisms. Small interfering RNA for MCIP1 significantly reversed both the E2 restraint of protein synthesis and the inhibition of AngII-induced calcineurin activity. AngII-induced the translocation of the hypertrophic transcription factor, NF-AT, to the nucleus of the cardiomyocyte and stimulated NF-AT transcriptional activity. Both were prevented by E2. AngII also stimulated the activation of ERK and protein kinase C, contributing to cardiac hypertrophy. E2 inhibited these pathways, related to the stimulation of atrial natriuretic peptide production and secretion. Thus, restraint of calcineurin and kinase signaling to the hypertrophic program underlie these important effects of E2.	Vet Affairs Med Ctr, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Calif State Univ Long Beach, Med Serv, Long Beach Vet Affairs Med Ctr, 111-1,5901 E 7th St, Long Beach, CA 90822 USA.	ellis.levin@med.va.gov	Levin, Ellis/J-5402-2013		NATIONAL CANCER INSTITUTE [R01CA100366] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059890] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100366, CA-100366] Funding Source: Medline; NHLBI NIH HHS [HL-59890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agabiti-Rosei E, 2002, J HYPERTENS, V20, pS34; Aoki H, 2000, BIOCHEM J, V347, P275, DOI 10.1042/0264-6021:3470275; Babiker FA, 2004, CIRCULATION, V109, P269, DOI 10.1161/01.CIR.0000105682.85732.BD; Bayer AL, 2003, J MOL CELL CARDIOL, V35, P1121, DOI 10.1016/S0022-2828(03)00228-1; Brede M, 2003, HYPERTENSION, V42, P1177, DOI 10.1161/01.HYP.0000100445.80029.8E; Bubikat A, 2005, J BIOL CHEM, V280, P21594, DOI 10.1074/jbc.m501103200; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Cavasin MA, 2003, AM J PHYSIOL-HEART C, V284, pH1560, DOI 10.1152/ajpheart.01087.2002; Dunn FG, 1999, NEW ENGL J MED, V340, P1279, DOI 10.1056/NEJM199904223401610; EskildsenHelmond YEG, 1997, J MOL CELL CARDIOL, V29, P2545, DOI 10.1006/jmcc.1997.0491; Forster C, 2004, P NATL ACAD SCI USA, V101, P14234, DOI 10.1073/pnas.0405571101; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Jankowski M, 2001, P NATL ACAD SCI USA, V98, P11765, DOI 10.1073/pnas.201394198; Klinger JR, 2002, AM J PHYSIOL-HEART C, V282, pH58, DOI 10.1152/ajpheart.2002.282.1.H58; Kumar R, 1997, BBA-MOL CELL RES, V1356, P221, DOI 10.1016/S0167-4889(96)00168-1; Kurisu S, 2003, HYPERTENSION, V41, P99, DOI 10.1161/01.HYP.0000050101.90932.14; LIGHT KC, 2001, J HYPERTENS, V104, P2300; Lim WK, 1999, AM J CARDIOL, V83, P1132, DOI 10.1016/S0002-9149(99)00029-6; Miya Y, 2002, HYPERTENS RES, V25, P153, DOI 10.1291/hypres.25.153; Murohara T, 1999, J CARDIOVASC PHARM, V34, P870, DOI 10.1097/00005344-199912000-00015; Nuedling S, 1999, CARDIOVASC RES, V43, P666, DOI 10.1016/S0008-6363(99)00093-0; Pedram A, 2002, J BIOL CHEM, V277, P50768, DOI 10.1074/jbc.M210106200; Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004-0115; Razandi M, 1996, AM J PHYSIOL-HEART C, V270, pH1342, DOI 10.1152/ajpheart.1996.270.4.H1342; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Sanna B, 2005, MOL CELL BIOL, V25, P865, DOI 10.1128/MCB.25.3.865-878.2005; Saxon Leslie A, 2002, Card Electrophysiol Rev, V6, P18, DOI 10.1023/A:1017914517113; Shlipak MG, 2001, CIRCULATION, V104, P2300, DOI 10.1161/hc4401.98414; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Turgeon JL, 2004, SCIENCE, V304, P1269, DOI 10.1126/science.1096725; van Eickels M, 2001, CIRCULATION, V104, P1419, DOI 10.1161/hc3601.095577; Vega RB, 2003, J BIOL CHEM, V278, P36981, DOI 10.1074/jbc.R300023200; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Wagenaar LJ, 2002, CAN J CARDIOL, V18, P1331; Wang LJ, 2002, CIRC RES, V91, P821, DOI 10.1161/01.RES.0000041029.97988.E9; Wehrens XHT, 2004, SCIENCE, V304, P292, DOI 10.1126/science.1094301; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Williams RS, 2002, CIRCULATION, V105, P2242, DOI 10.1161/01.CIR.0000017141.01845.FA; Xia Y, 2004, J PHARMACOL EXP THER, V310, P43, DOI 10.1124/jpet.104.065185; Xin HB, 2002, NATURE, V416, P334, DOI 10.1038/416334a; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Yue TL, 2000, J BIOL CHEM, V275, P37895, DOI 10.1074/jbc.M007037200	45	110	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26339	26348		10.1074/jbc.M414409200	http://dx.doi.org/10.1074/jbc.M414409200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899894	Green Accepted, hybrid			2022-12-25	WOS:000230386800050
J	Kerley-Hamilton, JS; Pike, AM; Li, N; DiRenzo, J; Spinella, MJ				Kerley-Hamilton, JS; Pike, AM; Li, N; DiRenzo, J; Spinella, MJ			A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma	ONCOGENE			English	Article						cisplatin; microarray; germ cell tumors; p53; teratocarcinoma	HUMAN EMBRYONAL CARCINOMA; TERATOCARCINOMA CELLS; DNA-DAMAGE; P53; APOPTOSIS; CANCER; DIFFERENTIATION; SENSITIVITY; ACTIVATION; GENES	Testicular germ cell cancers remain one of the few solid tumors routinely cured in advanced stages with conventional cisplatin-based chemotherapy. The mechanisms remain largely unknown. Through use of gene-expression array pro. ling we de. ne immediate transcriptional targets in response to cisplatin in testicular germ cell-derived human embryonal carcinoma cells. We report 46 genes upregulated and five genes repressed by cisplatin. Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation. Approximately 54% of the upregulated genes are established or suspected downstream targets of p53. Specific siRNA to p53 prevents cisplatin-mediated activation of p53 and p53 pathway genes and renders embryonal carcinoma cells relatively resistant to cisplatin cytotoxicity. Interestingly, in p53 knockdown cells nearly the entire set of identified cisplatin targets fail to respond or have a diminished response to cisplatin, suggesting that many are new direct or indirect targets of p53 including GPR87, STK17A, INPP5D, FLJ11259, and EPS8L2. The data indicate that robust transcriptional activation of p53 is linked to the known hypersensitivity of testicular germ cell tumors to chemotherapy. Many of the gene products may participate in the unique curability of this disease.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NCI NIH HHS [R01 CA104312, R01-CA104312] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; Einhorn Lawrence H, 2002, Chest Surg Clin N Am, V12, P695, DOI 10.1016/S1052-3359(02)00029-7; Fei PW, 2002, CANCER RES, V62, P7316; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Jakupec MA, 2003, REV PHYSIOL BIOCH P, V146, P1, DOI 10.1007/s10254-002-0001-x; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Lutzker SG, 2001, ONCOGENE, V20, P2982, DOI 10.1038/sj.onc.1204394; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Masters JRW, 2003, NAT REV CANCER, V3, P517, DOI 10.1038/nrc1120; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; PENG HQ, 1993, CANCER RES, V53, P3574; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Schrader M, 2001, REPROD TOXICOL, V15, P611, DOI 10.1016/S0890-6238(01)00182-4; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Spierings DCJ, 2003, CELL DEATH DIFFER, V10, P808, DOI 10.1038/sj.cdd.4401248; Spierings DCJ, 2003, J PATHOL, V200, P137, DOI 10.1002/path.1373; Spinella MJ, 2003, J NUTR, V133, p273S, DOI 10.1093/jn/133.1.273S; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; White KA, 2003, J BIOL CHEM, V278, P43889, DOI 10.1074/jbc.C300374200; Wright MM, 2002, BIOL RES, V35, P223, DOI 10.4067/S0716-97602002000200014; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	31	78	82	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6090	6100		10.1038/sj.onc.1208755	http://dx.doi.org/10.1038/sj.onc.1208755			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940259				2022-12-25	WOS:000231718100003
J	Carmelo, E; Barilla, D; Golovanov, AP; Lian, LY; Derome, A; Hayes, F				Carmelo, E; Barilla, D; Golovanov, AP; Lian, LY; Derome, A; Hayes, F			The unstructured N-terminal tail of ParG modulates assembly of a quaternary nucleoprotein complex in transcription repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTAPEPTIDE SCANNING MUTAGENESIS; CRYSTAL-STRUCTURE; PLASMID-PARTITION; OPERATOR COMPLEX; DNA RECOGNITION; MET REPRESSOR; P1 PLASMID; PROTEIN; SEGREGATION; SYSTEM	ParG is the prototype of a group of small (< 10 kDa) proteins involved in accurate plasmid segregation. The protein is a dimeric DNA binding factor, which consists of symmetric paired C-terminal domains that interleave into a ribbon-helix-helix fold that is crucial for the interaction with DNA, and unstructured N-terminal domains of previously unknown function. Here the ParG protein is shown to be a transcriptional repressor of the parFG genes. The protein assembles on its operator site initially as a tetramer ( dimer of dimers) and, at elevated protein concentrations, as a pair of tetramers. Progressive deletion of the mobile N-terminal tails concomitantly decreased transcriptional repression by ParG and perturbed the DNA binding kinetics of the protein. The flexible tails are not necessary for ParG dimerization but instead modulate the organization of a higher order nucleoprotein complex that is crucial for proper transcriptional repression. This is achieved by transient associations between the flexible and folded domains in complex with the target DNA. Numerous ParG homologs encoded by plasmids of Gram-negative bacteria similarly are predicted to possess N-terminal disordered tails, suggesting that this is a common feature of partition operon autoregulation. The results provide new insights into the role of natively unfolded domains in protein function, the molecular mechanisms of transcription regulation, and the control of plasmid segregation.	Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England	University of Manchester	Hayes, F (corresponding author), Univ Manchester, Fac Life Sci, POB 88,Sackville St, Manchester M60 1QD, Lancs, England.	finbarr.hayes@manchester.ac.uk	Golovanov, Alexander P./ABN-0572-2022; Carmelo, Emma/AAF-2357-2020	Golovanov, Alexander P./0000-0002-8592-3984; Carmelo, Emma/0000-0003-1126-993X; Barilla, Daniela/0000-0002-3486-7492	Biotechnology and Biological Sciences Research Council [G19857] Funding Source: Medline; Medical Research Council [G0400287] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0400287] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barilla D, 2003, MOL MICROBIOL, V49, P487, DOI 10.1046/j.1365-2958.2003.03564.x; BROWN BM, 1993, BIOCHEMISTRY-US, V32, P1354, DOI 10.1021/bi00056a022; Davis MA, 1996, MOL MICROBIOL, V21, P1029, DOI 10.1046/j.1365-2958.1996.721423.x; del Solar G, 2002, J BACTERIOL, V184, P4943, DOI 10.1128/JB.184.18.4943-4951.2002; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; Fothergill TJG, 2005, J BACTERIOL, V187, P2651, DOI 10.1128/JB.187.8.2651-2661.2005; FRIEDMAN SA, 1988, PLASMID, V19, P103, DOI 10.1016/0147-619X(88)90049-2; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; Golovanov AP, 2004, J AM CHEM SOC, V126, P8933, DOI 10.1021/ja049297h; Golovanov AP, 2003, MOL MICROBIOL, V50, P1141, DOI 10.1046/j.1365-2958.2003.03750.x; Gomis-Ruth FX, 1998, EMBO J, V17, P7404, DOI 10.1093/emboj/17.24.7404; Hallet B, 1997, NUCLEIC ACIDS RES, V25, P1866, DOI 10.1093/nar/25.9.1866; HAYES F, 1994, MOL MICROBIOL, V11, P249, DOI 10.1111/j.1365-2958.1994.tb00305.x; Hayes F, 2003, ANNU REV GENET, V37, P3, DOI 10.1146/annurev.genet.37.110801.142807; Hayes F, 2000, TRENDS MICROBIOL, V8, P571, DOI 10.1016/S0966-842X(00)01857-6; Hayes F, 2000, MOL MICROBIOL, V37, P528, DOI 10.1046/j.1365-2958.2000.02030.x; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; KNIGHT KL, 1989, P NATL ACAD SCI USA, V86, P797, DOI 10.1073/pnas.86.3.797; KUSUKAWA N, 1987, MOL GEN GENET, V208, P365, DOI 10.1007/BF00328125; Kwong SM, 2001, MOL MICROBIOL, V40, P621, DOI 10.1046/j.1365-2958.2001.02405.x; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Li YG, 2004, MOL MICROBIOL, V53, P93, DOI 10.1111/j.1365-2958.2004.04111.x; Love JJ, 2004, BIOCHEMISTRY-US, V43, P8725, DOI 10.1021/bi049591m; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Macartney DP, 1997, MICROBIOL-UK, V143, P2167, DOI 10.1099/00221287-143-7-2167; Oberer M, 2002, BIOCHEM J, V361, P41, DOI 10.1042/0264-6021:3610041; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; PHILLIPS K, 1994, STRUCTURE, V2, P309, DOI 10.1016/S0969-2126(00)00032-0; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; SALATREP.JM, 1971, EUR J BIOCHEM, V20, P400, DOI 10.1111/j.1432-1033.1971.tb01406.x; Sawitzke JA, 2002, J BACTERIOL, V184, P2447, DOI 10.1128/JB.184.9.2447-2454.2002; Schreiter ER, 2003, NAT STRUCT BIOL, V10, P794, DOI 10.1038/nsb985; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SHAH S, 1991, J BACTERIOL, V173, P3238, DOI 10.1128/JB.173.10.3238-3242.1991; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Surtees JA, 2003, CURR TOP DEV BIOL, V56, P145, DOI 10.1016/S0070-2153(03)01010-X; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Youngren B, 1997, MOL MICROBIOL, V25, P1023, DOI 10.1046/j.1365-2958.1997.4761842.x	47	24	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28683	28691		10.1074/jbc.M501173200	http://dx.doi.org/10.1074/jbc.M501173200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15951570	hybrid			2022-12-25	WOS:000230857300059
J	Fang, XH; Stachowiak, EK; Dunham-Ems, SM; Klejbor, I; Stachowiak, MK				Fang, XH; Stachowiak, EK; Dunham-Ems, SM; Klejbor, I; Stachowiak, MK			Control of CREB-binding protein signaling by nuclear fibroblast growth factor receptor-1 - A novel mechanism of gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES TRANSCRIPTIONAL ACTIVATION; CELL-GROWTH; ANGIOTENSIN-II; FGF RECEPTORS; KINASE; CBP; PROLIFERATION; TRANSLOCATION; EXPRESSION; DIFFERENTIATION	In integrative nuclear fibroblast growth factor receptor-1 ( FGFR1) signaling a newly synthesized FGFR1 translocates to the nucleus to stimulate cell differentiation and associated gene activities. The present study shows that FGFR1 accumulates and interacts with the transcriptional co-activator CREB-binding protein ( CBP) in nuclear speckle domains in the developing brain and in neural progenitor-like cells in vitro, which accompanies differentiation and postmitotic growth. Cell differentiation and gene activation by nuclear FGFR1 do not require tyrosine kinase activity. Instead, FGFR1 stimulates transcription in cooperation with CBP by increasing recruitment of RNA polymerase II and histone acetylation at the active gene promoter. FGFR1 is a multifactorial protein whose N terminus interacts with CBP and C terminus with ribosomal S6 kinase 1 ( RSK1). Nuclear FGFR1 augments CBP-mediated transcription by 1) releasing the CBP C-terminal domain from RSK1 inhibition and 2) activating the CBP N-terminal domain. The interaction of FGFR1 with CBP and RSK1 allows activation of gene transcription and may play a role in cell differentiation.	SUNY Buffalo, Dept Pathol & Anat Sci, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Chem, Buffalo, NY 14214 USA; Gdansk Med Univ, Dept Anat, PL-80211 Gdansk, Poland	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Fahrenheit Universities; Medical University Gdansk	Stachowiak, MK (corresponding author), SUNY Buffalo, Dept Pathol & Anat Sci, 206A Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	mks4@buffalo.edu		Klejbor, Ilona/0000-0002-5295-6974				BAKER J, 1982, BRAIN RES, V252, P151, DOI 10.1016/0006-8993(82)90989-1; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Bryant DM, 2005, MOL BIOL CELL, V16, P14, DOI 10.1091/mbc.E04-09-0845; Buzanska L, 2002, J CELL SCI, V115, P2131; Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548; Clarke WE, 2001, MOL CELL NEUROSCI, V17, P17, DOI 10.1006/mcne.2000.0920; Dunham SM, 2004, J PHYS CHEM B, V108, P10540, DOI 10.1021/jp0400972; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; GONZALEZ AM, 1995, BRAIN RES, V701, P201, DOI 10.1016/0006-8993(95)01002-X; Goodman RH, 2000, GENE DEV, V14, P1553; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hu YF, 2004, J BIOL CHEM, V279, P29325, DOI 10.1074/jbc.M311144200; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Myers JM, 2003, J CELL BIOCHEM, V88, P1273, DOI 10.1002/jcb.10476; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Peng H, 2003, J BIOL CHEM, V278, P38068, DOI 10.1074/jbc.M302259200; Peng H, 2002, J NEUROCHEM, V81, P506, DOI 10.1046/j.1471-4159.2002.00833.x; Peng H, 2001, MOL BIOL CELL, V12, P449, DOI 10.1091/mbc.12.2.449; Reilly JF, 2004, DNA CELL BIOL, V23, P538, DOI 10.1089/1044549041939223; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sabbieti MG, 2005, CELL TISSUE RES, V319, P267, DOI 10.1007/s00441-004-0981-8; Schmahl J, 2004, DEVELOPMENT, V131, P3627, DOI 10.1242/dev.01239; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Somanathan S, 2003, J CELL BIOCHEM, V90, P856, DOI 10.1002/jcb.10672; Stachowiak EK, 2003, J NEUROCHEM, V84, P1296, DOI 10.1046/j.1471-4159.2003.01624.x; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 2003, J CELL BIOCHEM, V90, P662, DOI 10.1002/jcb.10606; Stachowiak MK, 1997, MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02740663; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Waltner-Law M, 2000, J BIOL CHEM, V275, P31847, DOI 10.1074/jbc.M003656200; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	40	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28451	28462		10.1074/jbc.M504400200	http://dx.doi.org/10.1074/jbc.M504400200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15929978	hybrid			2022-12-25	WOS:000230857300034
J	Garau, G; Lemaire, D; Vernet, T; Dideberg, O; Di Guilmi, AM				Garau, G; Lemaire, D; Vernet, T; Dideberg, O; Di Guilmi, AM			Crystal structure of phosphorylcholine esterase domain of the virulence factor choline-binding protein E from Streptococcus pneumoniae - New structural features among the metallo-beta-lactamase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE ACID-PHOSPHATASE; MOLECULAR CHARACTERIZATION; GLYOXALASE-II; CELL-WALL; ENZYME; IDENTIFICATION; REVEALS; AMIDASE; GENOME; FAMILY	Streptococcus pneumoniae is the worldwide leading cause of deaths from invasive infections such as pneumoniae, sepsis, and meningitidis in children and the elderly. Nasopharyngeal colonization, which plays a key role in the development of pneumococcal disease, is highly dependent on a family of surface-exposed proteins, the choline-binding proteins ( CBPs). Here we report the crystal structure of phosphorylcholine esterase ( Pce), the catalytic domain of choline-binding protein E ( CBPE), which has been shown to be crucial for host/pathogen interaction processes. The unexpected features of the Pce active site reveal that this enzyme is unique among the large family of hydrolases harboring the metallo-beta-lactamase fold. The orientation and calcium stabilization features of an elongated loop, which lies on top of the active site, suggest that the cleft may be rearranged. Furthermore, the structure of Pce complexed with phosphorylcholine, together with the characterization of the enzymatic role played by two iron ions located in the active site allow us to propose a reaction mechanism reminiscent of that of purple acid phosphatase. This mechanism is supported by site-directed mutagenesis experiments. Finally, the interactions of the choline binding domain and the Pce region of CBPE with chains of teichoic acids have been modeled. The ensemble of our biochemical and structural results provide an initial understanding of the function of CBPE.	CEA, CNRS, URM 5075, UJF,Lab Ingn Macromol,Inst Biol Struct Jean Pierr, F-38027 Grenoble, France; CEA, CNRS, URM 5075, UJF,Lab Cristallog Macromol, F-38027 Grenoble, France; CEA, CNRS, URM 5075, UJF,Lab Spectrometrie Masse Prot, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Di Guilmi, AM (corresponding author), CEA, CNRS, URM 5075, UJF,Lab Ingn Macromol,Inst Biol Struct Jean Pierr, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	diguilmi@ibs.fr	Garau, Gianpiero/AAM-4234-2021; Garau, Gianpiero/A-2800-2012; Vernet, Thierry/G-1118-2012	Garau, Gianpiero/0000-0001-9473-5814; Garau, Gianpiero/0000-0001-9473-5814; Di Guilmi, Anne Marie/0000-0001-7335-3470; Lemaire, David/0000-0001-6874-3685				Anand K, 2002, ACTA CRYSTALLOGR D, V58, P1722, DOI 10.1107/S0907444902014610; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2003, TRENDS BIOCHEM SCI, V28, P234, DOI 10.1016/S0968-0004(03)00061-6; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Botzki A, 2004, J BIOL CHEM, V279, P45990, DOI 10.1074/jbc.M406146200; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; Dauter Z, 2002, ACTA CRYSTALLOGR D, V58, P494, DOI 10.1107/S090744490200118X; de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284; De las Rivas B, 2002, J BACTERIOL, V184, P4988, DOI 10.1128/JB.184.18.4988-5000.2002; de las Rivas B, 2001, MICROB DRUG RESIST, V7, P213, DOI 10.1089/10766290152652756; Di Guilmi AM, 2002, EMBO REP, V3, P728, DOI 10.1093/embo-reports/kvf152; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Ehinger S, 2004, J MOL BIOL, V343, P997, DOI 10.1016/j.jmb.2004.08.088; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fernandez-Tornero C, 2001, NAT STRUCT BIOL, V8, P1020, DOI 10.1038/nsb724; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Garau G, 2004, ANTIMICROB AGENTS CH, V48, P2347, DOI 10.1128/AAC.48.7.2347-2349.2004; Garcia P, 1999, MOL MICROBIOL, V33, P128, DOI 10.1046/j.1365-2958.1999.01455.x; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Gosink KK, 2000, INFECT IMMUN, V68, P5690, DOI 10.1128/IAI.68.10.5690-5695.2000; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; Hammerschmidt S, 2000, MOL MICROBIOL, V36, P726, DOI 10.1046/j.1365-2958.2000.01897.x; Hava D, 2002, MOL MICROBIOL, V45, P1389, DOI 10.1046/j.1365-2958.2002.t01-1-03106.x; Hava DL, 2003, MOL MICROBIOL, V50, P1103, DOI 10.1046/j.1365-2958.2003.03764.x; Hermoso JA, 2003, STRUCTURE, V11, P1239, DOI 10.1016/j.str.2003.09.005; HOLTJE JV, 1974, J BIOL CHEM, V249, P7032; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; Jackson MD, 2001, CHEM REV, V101, P2313, DOI 10.1021/cr000247e; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; Lagartera L, 2005, ACTA CRYSTALLOGR F, V61, P221, DOI 10.1107/S1744309105001636; Lau GW, 2001, MOL MICROBIOL, V40, P555, DOI 10.1046/j.1365-2958.2001.02335.x; Lawrence MC, 1998, STRUCTURE, V6, P1553, DOI 10.1016/S0969-2126(98)00153-1; LUO R, 2004, EMBO J; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitchell TJ, 2003, NAT REV MICROBIOL, V1, P219, DOI 10.1038/nrmicro771; MUELLER EG, 1993, J AM CHEM SOC, V115, P2974, DOI 10.1021/ja00060a055; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Polissi A, 1998, INFECT IMMUN, V66, P5620, DOI 10.1128/IAI.66.12.5620-5629.1998; Riboldi-Tunnicliffe A, 2004, ACTA CRYSTALLOGR D, V60, P926, DOI 10.1107/S0907444904004573; Rigden DJ, 2003, TRENDS BIOCHEM SCI, V28, P230, DOI 10.1016/S0968-0004(03)00062-8; Ring A, 1998, J CLIN INVEST, V102, P347, DOI 10.1172/JCI2406; RONDA C, 1987, EUR J BIOCHEM, V164, P621, DOI 10.1111/j.1432-1033.1987.tb11172.x; Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x; Sanchez-Beato AR, 1998, FEMS MICROBIOL LETT, V164, P207, DOI 10.1016/S0378-1097(98)00206-7; Schilling O, 2005, BIOCHEM J, V385, P145, DOI 10.1042/BJ20040773; Schilling O, 2003, BIOCHEMISTRY-US, V42, P11777, DOI 10.1021/bi034672o; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Vollmer W, 2001, MOL MICROBIOL, V39, P1610, DOI 10.1046/j.1365-2958.2001.02349.x; Weiser JN, 1998, J EXP MED, V187, P631, DOI 10.1084/jem.187.4.631; Weiser JN, 1998, INFECT IMMUN, V66, P4263; Wizemann TM, 2001, INFECT IMMUN, V69, P1593, DOI 10.1128/IAI.69.3.1593-1598.2001; Yang YJ, 1999, J BIOL CHEM, V274, P15706, DOI 10.1074/jbc.274.22.15706; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	59	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28591	28600		10.1074/jbc.M502744200	http://dx.doi.org/10.1074/jbc.M502744200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15908436	hybrid			2022-12-25	WOS:000230857300050
J	Jacobs, RL; Stead, LM; Devlin, C; Tabas, I; Brosnan, ME; Brosnan, JT; Vance, DE				Jacobs, RL; Stead, LM; Devlin, C; Tabas, I; Brosnan, ME; Brosnan, JT; Vance, DE			Physiological regulation of phospholipid methylation alters plasma homocysteine in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; CYSTATHIONINE-BETA-SYNTHASE; ENDOTHELIUM-DEPENDENT VASODILATION; CULTURED RAT HEPATOCYTES; LOW-DENSITY LIPOPROTEINS; LDL RECEPTOR-DEFICIENT; CHINESE-HAMSTER OVARY; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; CHOLINE DEFICIENCY	Biological methylation reactions and homocysteine (Hcy) metabolism are intimately linked. In previous work, we have shown that phosphatidylethanolamine N-methyltransferase, an enzyme that methylates phosphatidylethanolamine to form phosphatidylcholine, plays a significant role in the regulation of plasma Hcy levels through an effect on methylation demand (Noga, A. A., Stead, L. M., Zhao, Y., Brosnan, M. E., Brosnan, J. T., and Vance, D. E. ( 2003) J. Biol. Chem. 278, 5952 - 5955). We have further investigated methylation demand and Hcy metabolism in liver-specific CTP: phosphocholine cytidylyl-transferase-alpha( CT alpha) knockout mice, since flux through the phosphatidylethanolamine N-methyltransferase pathway is increased 2-fold to meet hepatic demand for phosphatidylcholine. Our data show that plasma Hcy is elevated by 20-40% in mice lacking hepatic CT alpha. CT alpha-deficient hepatocytes secrete 40% more Hcy into the medium than do control hepatocytes. Liver activity of betaine: homocysteine methyltransferase and methionine adenosyltransferase are elevated in the knockout mice as a mechanism for maintaining normal hepatic S-adenosylmethionine and S-adenosylhomocysteine levels. These data suggest that phospholipid methylation in the liver is a major consumer of AdoMet and a significant source of plasma Hcy.	Univ Alberta, Canadian Inst, Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Mem Univ Newfoundland, Dept Biochem, St John, NF, Canada; Columbia Univ, Dept Med, New York, NY 10032 USA	University of Alberta; University of Alberta; Memorial University Newfoundland; Columbia University	Vance, DE (corresponding author), Univ Alberta, Canadian Inst, Hlth Res Grp Mol & Cell Biol Lipids, 328 HMRC, Edmonton, AB T6G 2S2, Canada.	dennis.vance@ualberta.ca		Jacobs, Rene/0000-0002-5525-1355				BJORNSTAD P, 1966, J LIPID RES, V7, P38; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; Chao CL, 2000, CIRCULATION, V101, P485, DOI 10.1161/01.CIR.101.5.485; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FINKELSTEIN JD, 1971, ARCH BIOCHEM BIOPHYS, V146, P84, DOI 10.1016/S0003-9861(71)80044-9; FOLCH J, 1957, J BIOL CHEM, V226, P497; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; Jacobs RL, 2004, J BIOL CHEM, V279, P47402, DOI 10.1074/jbc.M404027200; Jacobs RL, 2001, J BIOL CHEM, V276, P43740, DOI 10.1074/jbc.M107553200; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; KOBLIN DD, 1981, ANESTHESIOLOGY, V54, P318, DOI 10.1097/00000542-198104000-00012; Lichtman AH, 1999, ARTERIOSCL THROM VAS, V19, P1938, DOI 10.1161/01.ATV.19.8.1938; LOO G, 1986, J NUTR, V116, P2403, DOI 10.1093/jn/116.12.2403; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; MUDD SH, 1965, J BIOL CHEM, V240, P4382; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; Noga AA, 2003, J BIOL CHEM, V278, P5952, DOI 10.1074/jbc.M212194200; Noga AA, 2003, J LIPID RES, V44, P1998, DOI 10.1194/jlr.M300226-JLR200; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; Olthof MR, 2003, J NUTR, V133, P4135, DOI 10.1093/jn/133.12.4135; PANI P, 1978, EXP MOL PATHOL, V28, P154, DOI 10.1016/0014-4800(78)90048-5; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P447, DOI 10.1016/0005-2760(84)90171-1; PELECH SL, 1983, BIOCHEM J, V216, P129, DOI 10.1042/bj2160129; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RIDGWAY ND, 1989, J BIOL CHEM, V264, P1203; Robinson Karyn-Siobhan, 2001, HOMOCYSTEINE HLTH DI, P10; SCHNEIDER WJ, 1978, EUR J BIOCHEM, V85, P181, DOI 10.1111/j.1432-1033.1978.tb12226.x; Schwahn BC, 2004, BIOCHEM J, V382, P831, DOI 10.1042/BJ20030822; Schwahn BC, 2004, METABOLISM, V53, P594, DOI 10.1016/j.metabol.2003.10.033; Schwahn BC, 2003, FASEB J, V17, P512, DOI 10.1096/fj.02-0456fje; Selhub J, 2000, AM J CLIN NUTR, V71, p614S; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; Stead LM, 2001, AM J PHYSIOL-ENDOC M, V281, pE1095, DOI 10.1152/ajpendo.2001.281.5.E1095; Sugiyama K, 1998, LIPIDS, V33, P235, DOI 10.1007/s11745-998-0201-2; Sugiyama K, 1997, J NUTR, V127, P600, DOI 10.1093/jn/127.4.600; SUGIYAMA K, 1989, J NUTR SCI VITAMINOL, V35, P613, DOI 10.3177/jnsv.35.613; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Tawakol A, 1997, CIRCULATION, V95, P1119; TESSITORE L, 1995, INT J EXP PATHOL, V76, P125; UTAL AK, 1991, J BIOL CHEM, V266, P24084; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; VANCE JE, 1986, FEBS LETT, V204, P243, DOI 10.1016/0014-5793(86)80820-1; VANCE JE, 1986, BIOCHIM BIOPHYS ACTA, V875, P501, DOI 10.1016/0005-2760(86)90070-6; Verhoef P, 1997, ATHEROSCLEROSIS, V132, P105, DOI 10.1016/S0021-9150(97)00084-1; VESTER B, 1991, EUR J CLIN CHEM CLIN, V29, P549; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; YAO ZM, 1990, J BIOL CHEM, V265, P4326; Zhou J, 2004, CIRCULATION, V110, P207, DOI 10.1161/01.CIR.0000134487.51510.97; Zhou J, 2003, ATHEROSCLEROSIS, V168, P255, DOI 10.1016/S0021-9150(03)00138-2; Zhou J, 2001, ARTERIOSCL THROM VAS, V21, P1470, DOI 10.1161/hq0901.096582	67	77	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28299	28305		10.1074/jbc.M501971200	http://dx.doi.org/10.1074/jbc.M501971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15958390	hybrid			2022-12-25	WOS:000230857300016
J	Sansom, OJ; Reed, KR; van de Wetering, M; Muncan, V; Winton, DJ; Clevers, H; Clarke, AR				Sansom, OJ; Reed, KR; van de Wetering, M; Muncan, V; Winton, DJ; Clevers, H; Clarke, AR			Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEOPLASIA MIN MICE; COLORECTAL-CANCER; EXPRESSION; PATHWAY; DIFFERENTIATION; PROLIFERATION; CELLS; GENE	Cyclin D1 is postulated to be a target of the canonical Wnt pathway and critical for intestinal adenoma development. We show here that, unlike cyclin D1 reporter assays, endogenous cyclin D1 levels are not affected following antagonism of the Wnt pathway in vitro, nor is cyclin D1 immediately up-regulated following conditional loss of Apc in vivo. Cyclin D1 levels do, however, increase in a delayed manner in a small subset of cells, suggesting such up-regulation occurs as a secondary event. We also analyzed the immediate consequences of Apc loss in a cyclin D1(-/-) background and failed to find any cyclin D1-dependent phenotypes. However, we did observe elevated cyclin D1 expression in lesions developing 20 days after Apc loss. In these circumstances, all adenomas ( but not smaller lesions) showed cyclin D1 up-regulation. Finally in a smaller study, we analyzed whether cyclin D1 deficiency affected adenoma formation 20 days following induced loss of Apc. Unlike Ah-Cre(+) Apc(fl/fl) mice ( which all developed adenomas), doubly mutant Ah-Cre(+) Apc(fl/fl) cyclin D1(-/-) mice only developed small lesions. Taken together, this argues that cyclin D1 up-regulation in intestinal neoplasia is important for tumor progression rather than initiation.	Univ Cardiff, Sch Biosci, Cardiff CF10 3US, Wales; Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Canc Res UK, Dept Oncol, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Beatson Inst Canc Res UK, Glasgow G61 1BD, Lanark, Scotland	Cardiff University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Beatson Institute	Sansom, OJ (corresponding author), Univ Cardiff, Sch Biosci, POB 911, Cardiff CF10 3US, Wales.	o.sansom@beatson.gla.ac.uk	Reed, Karen/B-8813-2011; Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Reed, Karen/0000-0002-7467-1718; Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Galceran J, 2001, P NATL ACAD SCI USA, V98, P8668, DOI 10.1073/pnas.151258098; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wilding J, 2002, CANCER RES, V62, P4562; Zhang T, 1997, CANCER RES, V57, P169	22	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28463	28467		10.1074/jbc.M500191200	http://dx.doi.org/10.1074/jbc.M500191200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15946945	hybrid			2022-12-25	WOS:000230857300035
J	Sarantos, MR; Raychaudhuri, S; Lum, AFH; Staunton, DE; Simon, SI				Sarantos, MR; Raychaudhuri, S; Lum, AFH; Staunton, DE; Simon, SI			Leukocyte function-associated antigen 1-mediated adhesion stability is dynamically regulated through affinity and valency during bond formation with intercellular adhesion molecule-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-LIKE DOMAIN; INTEGRIN ALPHA-L-BETA-2; NEUTROPHIL CAPTURE; STRUCTURAL BASIS; STABLE ADHESION; DISULFIDE BOND; BINDING-SITES; CELL-ADHESION; SHEAR-FLOW; L-SELECTIN	Neutrophil rolling and transition to arrest on inflamed endothelium are dynamically regulated by the affinity of the beta(2) integrin CD11a/CD18 ( leukocyte function associated antigen 1 (LFA-1)) for binding intercellular adhesion molecule (ICAM)-1. Conformational shifts are thought to regulate molecular affinity and adhesion stability. Also critical to adhesion efficiency is membrane redistribution of active LFA-1 into dense submicron clusters where multimeric interactions occur. We examined the influences of affinity and dimerization of LFA-1 on LFA-1/ICAM-1 binding by engineering a cell-free model in which two recombinant LFA-1 heterodimers are bound to respective Fab domains of an antibody attached to latex microspheres. Binding of monomeric and dimeric ICAM-1 to dimeric LFA-1 was measured in real time by fluorescence flow cytometry. ICAM-1 dissociation kinetics were measured while LFA-1 affinity was dynamically shifted by the addition of allosteric small molecules. High affinity LFA-1 dissociated 10-fold faster when bound to monomeric compared with dimeric ICAM-1, corresponding to bond lifetimes of 25 and 330 s, respectively. Downshifting LFA-1 into an intermediate affinity state with the small molecule I domain allosteric inhibitor IC487475 decreased the difference in dissociation rates between monomeric and dimeric ICAM-1 to 4-fold. When LFA-1 was shifted into the low affinity state by lovastatin, both monomeric and dimeric ICAM-1 dissociated in less than 1 s, and the dissociation rates were within 50% of each other. These data reveal the respective importance of LFA-1 affinity and proximity in tuning bond lifetime with ICAM-1 and demonstrate a nonlinear increase in the bond lifetime of the dimer versus the monomer at higher affinity.	Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; ICOS Corp, Bothell, WA 98021 USA	University of California System; University of California Davis; Icos Corporation	Simon, SI (corresponding author), Univ Calif Davis, Dept Biomed Engn, 451 E Hlth Sci Dr, Davis, CA 95616 USA.	sisimon@ucdavis.edu		Raychaudhuri, Subhadip/0000-0002-9873-6475; Raychaudhuri, Subhadip/0000-0003-3426-8382				Beals CR, 2001, J IMMUNOL, V167, P6113, DOI 10.4049/jimmunol.167.11.6113; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Chigaev A, 2003, J BIOL CHEM, V278, P38174, DOI 10.1074/jbc.M210472200; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Green CE, 2004, J IMMUNOL, V172, P7780, DOI 10.4049/jimmunol.172.12.7780; Hentzen ER, 2000, BLOOD, V95, P911, DOI 10.1182/blood.V95.3.911.003k36_911_920; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Jun CD, 2001, J BIOL CHEM, V276, P29019, DOI 10.1074/jbc.M103394200; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kelly TA, 1999, J IMMUNOL, V163, P5173; Kim M, 2004, J CELL BIOL, V167, P1241, DOI 10.1083/jcb.200404160; Labadia ME, 1998, J IMMUNOL, V161, P836; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Ley K, 2002, IMMUNOL REV, V186, P8, DOI 10.1034/j.1600-065X.2002.18602.x; Liu G, 2000, J MED CHEM, V43, P4025, DOI 10.1021/jm0002782; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; Lu CF, 2004, J IMMUNOL, V173, P3972, DOI 10.4049/jimmunol.173.6.3972; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Lum AFH, 2002, J BIOL CHEM, V277, P20660, DOI 10.1074/jbc.M202223200; Lupher ML, 2001, J IMMUNOL, V167, P1431, DOI 10.4049/jimmunol.167.3.1431; McDonough DB, 2004, ANN BIOMED ENG, V32, P1179, DOI 10.1114/B:ABME.0000039352.11428.9d; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; Shaw SK, 2004, J EXP MED, V200, P1571, DOI 10.1084/jem.20040965; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Sigal A, 2000, J IMMUNOL, V165, P442, DOI 10.4049/jimmunol.165.1.442; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Tominaga Y, 1998, J IMMUNOL, V161, P4016; Tsang YTM, 1997, J IMMUNOL, V159, P4566; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Welzenbach K, 2002, J BIOL CHEM, V277, P10590, DOI 10.1074/jbc.M110521200; Woska JR, 1996, J IMMUNOL, V156, P4680; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101; Yang YT, 2004, MOL CELL, V14, P269, DOI 10.1016/S1097-2765(04)00204-7	44	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28290	28298		10.1074/jbc.M501662200	http://dx.doi.org/10.1074/jbc.M501662200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15955822	hybrid			2022-12-25	WOS:000230857300015
J	Ahmad, Z; Senior, AE				Ahmad, Z; Senior, AE			Modulation of charge in the phosphate binding site of Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; CATALYTIC SITES; F1F0-ATP SYNTHASE; OXIDATIVE-PHOSPHORYLATION; NUCLEOTIDE-BINDING; MUTANT STRAINS; PROTON-ATPASE; PI BINDING; F-1 MOTOR; F-1-ATPASE	This paper presents a study of the role of positive charge in the P-i binding site of Escherichia coli ATP synthase, the enzyme responsible for ATP-driven proton extrusion and ATP synthesis by oxidative phosphorylation. Arginine residues are known to occur with high propensity in P-i binding sites of proteins generally and in the P-i binding site of the beta E catalytic site of ATP synthase specifically. Removal of natural beta Arg-246 (beta R246A mutant) abrogates P-i binding; restoration of P-i binding was achieved by mutagenesis of either residue beta Asn-243 or alpha Phe-291 to Arg. Both residues are located in the P-i binding site close to beta Arg-246 in x-ray structures. Insertion of one extra Arg at beta-243 or alpha-291 in presence of beta Arg-246 retained P-i binding, but insertion of two extra Arg, at both positions simultaneously, abrogated it. Transition state stabilization was measured using phosphate analogs fluoroaluminate and fluoroscandium. Removal of beta Arg-246 in beta R246A caused almost complete loss of transition state stabilization, but partial rescue was achieved in beta N243R/beta R246A and alpha F291R/beta R246A. beta Arg-243 or alpha Arg-291 in presence of beta Arg-246 was less effective; the combination of alpha F291R/beta N243R with natural beta Arg-246 was just as detrimental as beta R246A. The data demonstrate that electrostatic interaction is an important component of initial P-i binding in catalytic site beta E and later at the transition state complex. However, since none of the mutants showed significant function in growth tests, ATP-driven proton pumping, or ATPase activity assays, it is apparent that specific stereochemical interactions of catalytic site Arg residues are paramount.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu		Ahmad, Zulfiqar/0000-0001-7306-8151	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349, R15GM085771] Funding Source: NIH RePORTER; NIGMS NIH HHS [R15 GM085771, GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad Z, 2005, FEBS LETT, V579, P523, DOI 10.1016/j.febslet.2004.12.022; Ahmad Z, 2004, J BIOL CHEM, V279, P46057, DOI 10.1074/jbc.M407608200; Ahmad Z, 2004, J BIOL CHEM, V279, P31505, DOI 10.1074/jbc.M404621200; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P886, DOI 10.1021/bi00118a034; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12961, DOI 10.1021/bi971478r; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; COPLEY RR, 1994, J MOL BIOL, V242, P321; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P127, DOI 10.1111/j.1432-1033.1975.tb04121.x; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P117, DOI 10.1111/j.1432-1033.1975.tb04120.x; Hirono-Hara Y, 2005, P NATL ACAD SCI USA, V102, P4288, DOI 10.1073/pnas.0406486102; KASAHARA M, 1978, J BIOL CHEM, V253, P4180; Ketchum CJ, 1998, BIOCHEM J, V330, P707; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leslie AGW, 2000, PHILOS T ROY SOC B, V355, P465, DOI 10.1098/rstb.2000.0588; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; Masaike T, 2002, J BIOL CHEM, V277, P21643, DOI 10.1074/jbc.M110297200; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nishizaka T, 2004, NAT STRUCT MOL BIOL, V11, P142, DOI 10.1038/nsmb721; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; Penefsky HS, 2005, FEBS LETT, V579, P2250, DOI 10.1016/j.febslet.2005.02.072; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEREZ JA, 1986, FEBS LETT, V198, P113, DOI 10.1016/0014-5793(86)81195-4; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; RAO R, 1987, ARCH BIOCHEM BIOPHYS, V255, P309, DOI 10.1016/0003-9861(87)90398-5; ROSING J, 1977, J BIOL CHEM, V252, P2478; Senior AE, 2004, NAT STRUCT MOL BIOL, V11, P110, DOI 10.1038/nsmb0204-110; SENIOR AE, 1983, BIOCHEM J, V210, P395, DOI 10.1042/bj2100395; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; Shimabukuro K, 2003, P NATL ACAD SCI USA, V100, P14731, DOI 10.1073/pnas.2434983100; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER J, 1995, J BIOL CHEM, V270, P12653, DOI 10.1074/jbc.270.21.12653; Yasuda R, 2003, P NATL ACAD SCI USA, V100, P9314, DOI 10.1073/pnas.1637860100	39	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27981	27989		10.1074/jbc.M503955200	http://dx.doi.org/10.1074/jbc.M503955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15939739	hybrid			2022-12-25	WOS:000230678600060
J	Ikeno, Y; Konno, N; Cheon, SH; Bolchi, A; Ottonello, S; Kitamoto, K; Arioka, M				Ikeno, Y; Konno, N; Cheon, SH; Bolchi, A; Ottonello, S; Kitamoto, K; Arioka, M			Secretory phospholipases A(2) induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; GROUP-II PHOSPHOLIPASE-A2; SENSITIVE CA2+ CHANNELS; GROUP-IB; FUNGAL PROTEIN; GROUP-X; SPHINGOSYLPHOSPHORYLCHOLINE; IDENTIFICATION; EXPRESSION; APOPTOSIS	We previously demonstrated that secretory phospholipase A(2) (sPLA(2)) and lysophosphatidylcholine (LPC) exhibit neurotrophin-like neuritogenic activity in the rat pheochromocytoma cell line PC12. In this study, we further analyzed the mechanism whereby sPLA2 displays neurite-inducing activity. Exogenously added mammalian group X sPLA(2) (sPLA(2)-X), but not group IB and IIA sPLA(2)s, induced neuritogenesis, which correlated with the ability of sPLA(2)-X to liberate LPC into the culture media. In accordance, blocking the effect of LPC by supplementation of bovine serum albumin or phospholipase B attenuated neuritogenesis by sPLA(2) or LPC. Overproduction or suppression of G2A, a G-protein-coupled receptor involved in LPC signaling, resulted in the enhancement or reduction of neuritogenesis induced by sPLA(2) treatment. These results indicate that the neuritogenic effect of sPLA(2) is mediated by generation of LPC and subsequent activation of G2A.	Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Parma, Dipartmento Biochim & Biol Mol, I-43100 Parma, Italy	University of Tokyo; University of Parma	Arioka, M (corresponding author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	arioka@mail.ecc.u-tokyo.ac.jp	Bolchi, Angelo/GOJ-9730-2022					Bezzine S, 2002, J BIOL CHEM, V277, P48523, DOI 10.1074/jbc.M203137200; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; Foreman-Wykert AK, 2000, INFECT IMMUN, V68, P1259, DOI 10.1128/IAI.68.3.1259-1264.2000; Hanasaki K, 2004, BIOL PHARM BULL, V27, P1165, DOI 10.1248/bpb.27.1165; Hanasaki K, 2002, PROSTAG OTH LIPID M, V68-9, P71, DOI 10.1016/S0090-6980(02)00022-9; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Ishii S, 2005, J BIOL CHEM, V280, P9083, DOI 10.1074/jbc.M407832200; JALINK K, 1990, J BIOL CHEM, V265, P12232; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Murakami M, 2004, BIOL PHARM BULL, V27, P1158, DOI 10.1248/bpb.27.1158; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; NAKANO T, 1990, J BIOL CHEM, V265, P12745; Nakashima S, 2004, BRAIN RES, V1015, P207, DOI 10.1016/j.brainres.2004.04.069; Nakashima S, 2003, BIOCHEM J, V376, P655, DOI 10.1042/BJ20030830; Nakashima S, 2003, BIOSCI BIOTECH BIOCH, V67, P77, DOI 10.1271/bbb.67.77; OKA S, 1991, J BIOL CHEM, V266, P9956; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Soga T, 2005, BIOCHEM BIOPH RES CO, V326, P744, DOI 10.1016/j.bbrc.2004.11.120; Wakatsuki S, 1999, J BIOCHEM-TOKYO, V126, P1151, DOI 10.1093/oxfordjournals.jbchem.a022561; Wakatsuki S, 2001, BBA-GENE STRUCT EXPR, V1522, P74, DOI 10.1016/S0167-4781(01)00308-6; Wang JQ, 2004, J BIOL CHEM, V279, P45626, DOI 10.1074/jbc.M406966200; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Xu Y, 2002, BBA-MOL CELL BIOL L, V1582, P81, DOI 10.1016/S1388-1981(02)00140-3; Yagami T, 2003, J NEUROCHEM, V85, P749, DOI 10.1046/j.1471-4159.2003.01712.x; Yagami T, 2003, BRAIN RES, V960, P71, DOI 10.1016/S0006-8993(02)03775-7; Yagami T, 2002, J NEUROCHEM, V81, P449, DOI 10.1046/j.1471-4159.2002.00800.x; Yagami T, 2002, MOL PHARMACOL, V61, P114, DOI 10.1124/mol.61.1.114; Yan JJ, 2004, NAT MED, V10, P161, DOI 10.1038/nm989; Yang LV, 2005, BLOOD, V105, P1127, DOI 10.1182/blood-2004-05-1916; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	42	45	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28044	28052		10.1074/jbc.M503343200	http://dx.doi.org/10.1074/jbc.M503343200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15927955	hybrid			2022-12-25	WOS:000230678600067
J	Inoue, T; Forgac, M				Inoue, T; Forgac, M			Cysteine-mediated cross-linking indicates that subunit C of the V-ATPase is in close proximity to subunits E and G of the V-1 domain and subunit a of the V-0 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; MUTATIONAL ANALYSIS; 2ND STALK; G VMA10P; YEAST; ROTATION; SYNTHASE; BINDING; LOCALIZATION	The vacuolar (H+)- ATPases (V-ATPases) are multisubunit complexes responsible for ATP-dependent proton transport across both intracellular and plasma membranes. The V-ATPases are composed of a peripheral domain (V-1) that hydrolyzes ATP and an integral domain (V-0) that conducts protons. Dissociation of V1 and V0 is an important mechanism of controlling V-ATPase activity in vivo. The crystal structure of subunit C of the V-ATPase reveals two globular domains connected by a flexible linker (Drory, O., Frolow, F., and Nelson, N. ( 2004) EMBO Rep. 5, 1 - 5). Subunit C is unique in being released from both V1 and V0 upon in vivo dissociation. To localize subunit C within the V-ATPase complex, unique cysteine residues were introduced into 25 structurally defined sites within the yeast C subunit and used as sites of attachment of the photoactivated sulfhydryl reagent 4-(N-maleimido) benzophenone (MBP). Analysis of photocross-linked products by Western blot reveals that subunit E ( part of V1) is in close proximity to both the head domain ( residues 166 - 263) and foot domain ( residues 1 - 151 and 287 - 392) of subunit C. By contrast, subunit G ( also part of V1) shows cross-linking to only the head domain whereas subunit a ( part of V0) shows cross-linking to only the foot domain. The localization of subunit C to the interface of the V1 and V0 domains is consistent with a role for this subunit in controlling assembly of the V-ATPase complex.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 135 Harrison Ave, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34928] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, R37 GM034478, GM34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AMBRUSTER A, 2003, FEBS LETT, V546, P395; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; Brown D, 2000, J EXP BIOL, V203, P137; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; Drory O, 2004, EMBO REP, V5, P1148, DOI 10.1038/sj.embor.7400294; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Graham LA, 2003, J BIOENERG BIOMEMBR, V35, P301, DOI 10.1023/A:1025772730586; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; Hunt IE, 1997, J BIOENERG BIOMEMBR, V29, P533, DOI 10.1023/A:1022474816665; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; Inoue T, 2003, J BIOENERG BIOMEMBR, V35, P291, DOI 10.1023/A:1025720713747; Jones RPO, 2005, BIOCHEMISTRY-US, V44, P3933, DOI 10.1021/bi048402x; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Kluge C, 2003, J BIOENERG BIOMEMBR, V35, P377, DOI 10.1023/A:1025737117382; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; Nelson N, 2003, J BIOENERG BIOMEMBR, V35, P281, DOI 10.1023/A:1025768529677; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; Nishi T, 2001, J BIOL CHEM, V276, P34122, DOI 10.1074/jbc.M104682200; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambade M, 2004, J BIOL CHEM, V279, P17361, DOI 10.1074/jbc.M314104200; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Sun-Wada GH, 2003, J BIOENERG BIOMEMBR, V35, P347, DOI 10.1023/A:1025780932403; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Vasilyeva E, 2000, J BIOL CHEM, V275, P255, DOI 10.1074/jbc.275.1.255; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; Vitavska O, 2005, J BIOL CHEM, V280, P1070, DOI 10.1074/jbc.M406797200; Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200; Wagner CA, 2004, PHYSIOL REV, V84, P1263, DOI 10.1152/physrev.00045.2003; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; Wieczorek H, 2003, J BIOENERG BIOMEMBR, V35, P359, DOI 10.1023/A:1025733016473; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Xie XS, 1996, J BIOL CHEM, V271, P30980; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	75	79	83	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27896	27903		10.1074/jbc.M504890200	http://dx.doi.org/10.1074/jbc.M504890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15951435	hybrid			2022-12-25	WOS:000230678600052
J	Kobryn, K; Burgin, AB; Chaconas, G				Kobryn, K; Burgin, AB; Chaconas, G			Uncoupling the chemical steps of telomere resolution by ResT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; DNA TOPOISOMERASE; BIDIRECTIONAL REPLICATION; BORRELIA-BURGDORFERI; LAMBDA-INTEGRASE; TERMINAL DOMAINS; RESOLVASE REST; MECHANISM; MODEL; PROTELOMERASE	ResT is the telomere resolvase of the spirochete Borrelia burgdorferi, the causative agent of Lyme disease. ResT is an essential cellular function that processes replication intermediates to produce linear replicons terminated by covalently closed hairpin telomeres. ResT generates these hairpin telomeres in a reaction with mechanistic similarities to those catalyzed by type IB topoisomerases and tyrosine recombinases. We report here, that like most of the tyrosine recombinases, ResT requires interprotomer communication, likely in an in-line synapse, to activate reaction chemistry. Unlike the tyrosine recombinases, however, we infer that the cleavage and strand transfer reactions on the two sides of the replicated telomere occur nearly simultaneously. Nonetheless, the chemical steps of the forward and reverse reactions performed by ResT can occur in a non-concerted fashion (i.e. events on the two sides of the replicated telomere can occur independently). We propose that uncoupling of reaction completion on the two sides of the substrate is facilitated by an early commitment to hairpin formation that is imposed by the precleavage action of the hairpin binding module of the ResT active site.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; deCode BioStruct, Bainbridge Isl, WA 98110 USA	University of Calgary; University of Calgary	Chaconas, G (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	chaconas@ucalgary.ca						Allingham JS, 2001, EMBO J, V20, P2931, DOI 10.1093/emboj/20.11.2931; Ason B, 2002, J BIOL CHEM, V277, P11284, DOI 10.1074/jbc.M111119200; Bankhead T, 2004, P NATL ACAD SCI USA, V101, P13768, DOI 10.1073/pnas.0405762101; BANNWARTH W, 1988, HELV CHIM ACTA, V71, P1517, DOI 10.1002/hlca.19880710618; Barbour AG, 2001, EMERGING INFECTIONS 5, P153; Barre FX, 2000, GENE DEV, V14, P2976, DOI 10.1101/gad.188700; Bromberg KD, 2003, J BIOL CHEM, V278, P7406, DOI 10.1074/jbc.M212056200; Bromberg KD, 2004, BIOCHEMISTRY-US, V43, P13416, DOI 10.1021/bi049420h; Bromberg KD, 2003, BIOCHEMISTRY-US, V42, P3393, DOI 10.1021/bi027383t; BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Byram R, 2004, J BACTERIOL, V186, P3561, DOI 10.1128/JB.186.11.3561-3569.2004; Casjens S, 1999, CURR OPIN MICROBIOL, V2, P529, DOI 10.1016/S1369-5274(99)00012-0; Chaconas G, 2001, EMBO J, V20, P3229, DOI 10.1093/emboj/20.12.3229; Chaconas George, 2005, P525; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Conway AB, 2003, J MOL BIOL, V326, P425, DOI 10.1016/S0022-2836(02)01370-0; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; Deneke J, 2004, J BIOL CHEM, V279, P53699, DOI 10.1074/jbc.M409001200; Deneke J, 2000, P NATL ACAD SCI USA, V97, P7721, DOI 10.1073/pnas.97.14.7721; Dworkin MS, 2002, MED CLIN N AM, V86, P417, DOI 10.1016/S0025-7125(03)00095-6; Ferreira H, 2003, J MOL BIOL, V330, P15, DOI 10.1016/S0022-2836(03)00558-8; Grindley NDF, 2002, MOBILE DNA, P272; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Huang WM, 2004, J MOL BIOL, V337, P77, DOI 10.1016/j.jmb.2004.01.012; Kobryn K, 2005, MOL CELL, V17, P783, DOI 10.1016/j.molcel.2005.02.025; Kobryn K, 2002, MOL CELL, V9, P195, DOI 10.1016/S1097-2765(01)00433-6; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Lee J, 1997, GENE DEV, V11, P3061, DOI 10.1101/gad.11.22.3061; Lee J, 1999, EMBO J, V18, P784, DOI 10.1093/emboj/18.3.784; Lee SY, 2005, J MOL BIOL, V345, P475, DOI 10.1016/j.jmb.2004.10.068; Lee SY, 2004, J MOL BIOL, V342, P1647, DOI 10.1016/j.jmb.2004.08.008; LIM HM, 1992, J BIOL CHEM, V267, P11183; Mizuuchi Kiyoshi, 2002, P12; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; Picardeau M, 1999, MOL MICROBIOL, V32, P437, DOI 10.1046/j.1365-2958.1999.01368.x; Ravin NV, 2003, NUCLEIC ACIDS RES, V31, P6552, DOI 10.1093/nar/gkg856; Ravin NV, 2003, FEMS MICROBIOL LETT, V221, P1, DOI 10.1016/S0378-1097(03)00125-3; SCHWAN TG, 1999, MANUAL CLIN MICROBIO, P746; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; Stanek G, 2003, LANCET, V362, P1639, DOI 10.1016/S0140-6736(03)14798-8; Steere AC, 2004, J CLIN INVEST, V113, P1093, DOI [10.1172/JCI200421681, 10.1172/JCI21681]; Stewart PE, 2005, PLASMID, V53, P1, DOI 10.1016/j.plasmid.2004.10.006; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; Voziyanov Y, 1999, NUCLEIC ACIDS RES, V27, P930, DOI 10.1093/nar/27.4.930; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	50	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26788	26795		10.1074/jbc.M504530200	http://dx.doi.org/10.1074/jbc.M504530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917226	hybrid			2022-12-25	WOS:000230589500020
J	Olayioye, MA; Vehring, S; Muller, P; Herrmann, A; Schiller, J; Thiele, C; Lindeman, GJ; Visvader, JE; Pomorski, T				Olayioye, MA; Vehring, S; Muller, P; Herrmann, A; Schiller, J; Thiele, C; Lindeman, GJ; Visvader, JE; Pomorski, T			StarD10, a START domain protein overexpressed in breast cancer, functions as a phospholipid transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE TRANSFER PROTEIN; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; ASSISTED LASER-DESORPTION; MASS-SPECTROMETRY; INTRACELLULAR TRAFFICKING; BOVINE LIVER; CHOLESTEROL; MEMBRANES; BINDING; LIPIDS	We originally identified StarD10 as a protein overexpressed in breast cancer that cooperates with the ErbB family of receptor tyrosine kinases in cellular transformation. StarD10 contains a steroidogenic acute regulatory protein (StAR/StarD1)-related lipid transfer ( START) domain that is thought to mediate binding of lipids. We now provide evidence that StarD10 interacts with phosphatidylcholine ( PC) and phosphatidylethanolamine ( PE) by electron spin resonance measurement. Interaction with these phospholipids was verified in a fluorescence resonance energy transfer-based assay with 7-nitro-2,1,3-benzoxadiazol-4- yl-labeled lipids. Binding was not restricted to lipid analogs since StarD10 selectively extracted PC and PE from small unilamellar vesicles prepared with endogenous radiolabeled lipids from Vero monkey kidney cells. Mass spectrometry revealed that StarD10 preferentially selects lipid species containing a palmitoyl or stearoyl chain on the sn-1 and an unsaturated fatty acyl chain ( 18: 1 or 18: 2) on the sn-2 position. StarD10 was further shown to bind lipids in vivo by cross-linking of protein expressed in transfected HEK-293T cells with photoactivable phosphatidylcholine. In addition to a lipid binding function, StarD10 transferred PC and PE between membranes. Interestingly, these lipid binding and transfer specificities distinguish StarD10 from the related START domain proteins Pctp and CERT, suggesting a distinct biological function.	Humboldt Univ, Inst Biol, Dept Cell Biophys, D-10115 Berlin, Germany; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Leipzig, Fac Med, Inst Med Phys & Biophys, D-04103 Leipzig, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	Humboldt University of Berlin; Walter & Eliza Hall Institute; Leipzig University; Max Planck Society; University of Stuttgart	Pomorski, T (corresponding author), Humboldt Univ, Inst Biol, Dept Cell Biophys, Invalidenstr 42, D-10115 Berlin, Germany.	thomas.pomorski@rz.hu-berlin.de	Schiller, Jürgen/A-1500-2008; Pomorski, Thomas Günther/G-4804-2014	Schiller, Jürgen/0000-0002-4328-8652; Pomorski, Thomas Günther/0000-0002-4889-0829; Lindeman, Geoffrey/0000-0001-9386-2416				Allen-Baume V, 2002, FEBS LETT, V531, P74, DOI 10.1016/S0014-5793(02)03412-9; Angeletti S, 2004, BIOCHEM BIOPH RES CO, V314, P181, DOI 10.1016/j.bbrc.2003.12.076; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONNER WM, 1978, ANAL BIOCHEM, V89, P247, DOI 10.1016/0003-2697(78)90747-9; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; de Brouwer APM, 2001, CHEM PHYS LIPIDS, V112, P109, DOI 10.1016/S0009-3084(01)00171-2; Fellmann P, 1994, Methods Mol Biol, V27, P161; Geijtenbeek TBH, 1996, FEBS LETT, V391, P333, DOI 10.1016/0014-5793(96)00770-3; GORDESKY SE, 1973, J MEMBRANE BIOL, V14, P229, DOI 10.1007/BF01868080; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hurley JH, 2000, CURR OPIN STRUC BIOL, V10, P737; KAMP HH, 1977, BIOCHEMISTRY-US, V16, P1310, DOI 10.1021/bi00626a011; KISHIMOTO Y, 1975, CHEM PHYS LIPIDS, V15, P33, DOI 10.1016/0009-3084(75)90029-8; Levine T, 2004, TRENDS CELL BIOL, V14, P483, DOI 10.1016/j.tcb.2004.07.017; Malinina L, 2004, NATURE, V430, P1048, DOI 10.1038/nature02856; Marsh D, 1981, Mol Biol Biochem Biophys, V31, P51; MEIER EM, 1991, J BIOL CHEM, V266, P1879; Muller P, 2002, EUR BIOPHYS J BIOPHY, V31, P438, DOI 10.1007/s00249-002-0234-2; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Olayioye MA, 2004, CANCER RES, V64, P3538, DOI 10.1158/0008-5472.CAN-03-3731; Petkovic M, 2001, ANAL BIOCHEM, V289, P202, DOI 10.1006/abio.2000.4926; Pomorski T, 2001, SEMIN CELL DEV BIOL, V12, P139, DOI 10.1006/scdb.2000.0231; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Routt SM, 2004, BIOCHEM CELL BIOL, V82, P254, DOI 10.1139/o03-089; Schiller J, 1999, ANAL BIOCHEM, V267, P46, DOI 10.1006/abio.1998.3001; Schiller J, 2003, CHROMATOGRAPHIA, V57, pS297, DOI 10.1007/BF02492119; Schiller J, 2004, PROG LIPID RES, V43, P449, DOI 10.1016/j.plipres.2004.08.001; Schrick K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r41; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Snoek GT, 1999, J BIOL CHEM, V274, P35393, DOI 10.1074/jbc.274.50.35393; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; SOMERHARJU PJ, 1992, METHOD ENZYMOL, V209, P495; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Strauss JF, 2003, MOL CELL ENDOCRINOL, V202, P59, DOI 10.1016/S0303-7207(03)00063-7; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; van Helvoort A, 1999, P NATL ACAD SCI USA, V96, P11501, DOI 10.1073/pnas.96.20.11501; VANPARIDON PA, 1988, BIOCHEMISTRY-US, V27, P6208, DOI 10.1021/bi00417a003; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73	42	67	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27436	27442		10.1074/jbc.M413330200	http://dx.doi.org/10.1074/jbc.M413330200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911624	hybrid			2022-12-25	WOS:000230589500095
J	Starai, VJ; Gardner, JG; Escalante-Semerena, JC				Starai, VJ; Gardner, JG; Escalante-Semerena, JC			Residue Leu-641 of acetyl-CoA synthetase is critical for the acetylation of residue Lys-609 by the protein acetyltransferase enzyme of Salmonella enterica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; SIR2; DEACETYLASE; HISTONE; EXPRESSION; FAMILY	Posttranslational regulation of protein function by acetylation is present throughout nature. Regulation of protein function by Sir2 protein (sirtuin) deacetylases is conserved in all domains of life. In the prokaryote Salmonella enterica, the metabolic enzyme acetyl-coenzyme A synthetase (Acs) is regulated by a Sir2-dependent protein acetylation/deacetylation system (SDPADS). The recent identification of the acetyltransferase enzyme responsible for the acetylation of Acs defined the SDPADS in prokaryotes. This report identifies one residue in Acs, Leu-641, which is critical for the acetylation of Acs by the protein acetyltransferase enzyme. In vivo and in vitro evidence shows that mutations at Leu-641 prevent the acetylation of Acs by protein acetyltransferase, maintain the Acs enzyme in its active state, and bypass the need for sirtuin deacetylase activity during growth on acetate.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53726 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), 264 Enzyme Inst,1710 Univ Ave, Madison, WI 53726 USA.	escalante@bact.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062203] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62203, R01 GM062203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avalos JL, 2002, MOL CELL, V10, P523, DOI 10.1016/S1097-2765(02)00628-7; Bell SD, 2002, SCIENCE, V296, P148, DOI 10.1126/science.1070506; BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BROWN TDK, 1977, J GEN MICROBIOL, V102, P327, DOI 10.1099/00221287-102-2-327; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; Chang JH, 2002, J BIOL CHEM, V277, P34489, DOI 10.1074/jbc.M205460200; DAVIS RW, 1980, MANUAL GENETIC ENG A, P78; FOX DK, 1986, J BIOL CHEM, V261, P3487; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gulick AM, 2003, BIOCHEMISTRY-US, V42, P2866, DOI 10.1021/bi0271603; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Horswill AR, 2002, BIOCHEMISTRY-US, V41, P2379, DOI 10.1021/bi015647q; HUGHES KT, 1988, GENETICS, V119, P9; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Poux AN, 2003, BIOCHEMISTRY-US, V42, P14366, DOI 10.1021/bi035632n; RINE J, 1987, GENETICS, V116, P9; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; SASSE J, 1991, CURRENT PROTOCOLS MO, V1, DOI DOI 10.6.1-10.6.8; SCHMIEGER H, 1973, MOL GEN GENET, V120, P181, DOI 10.1007/BF00267246; SCHMIEGER H, 1971, MOL GEN GENET, V110, P378, DOI 10.1007/BF00438281; SEIDMAN CG, 1997, CURRENT PROTOCOLS MO, V1; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Starai VJ, 2004, CELL MOL LIFE SCI, V61, P2020, DOI 10.1007/s00018-004-3448-x; Starai VJ, 2004, J MOL BIOL, V340, P1005, DOI 10.1016/j.jmb.2004.05.010; Starai VJ, 2003, GENETICS, V163, P545; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tsang AW, 1998, J BIOL CHEM, V273, P31788, DOI 10.1074/jbc.273.48.31788; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; WILLIAMSON JR, 1969, METHOD ENZYMOL, V13, P494; WONG TK, 1982, BIOCHEM BIOPH RES CO, V107, P584, DOI 10.1016/0006-291X(82)91531-5; Wycuff DR, 2000, ANAL BIOCHEM, V277, P67, DOI 10.1006/abio.1999.4385; Zhao KH, 2004, J MOL BIOL, V337, P731, DOI 10.1016/j.jmb.2004.01.060; Zhao KH, 2003, J BIOL CHEM, V278, P26071, DOI 10.1074/jbc.M303666200; Zhao KH, 2004, P NATL ACAD SCI USA, V101, P8563, DOI 10.1073/pnas.0401057101	44	46	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26200	26205		10.1074/jbc.M504863200	http://dx.doi.org/10.1074/jbc.M504863200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899897	hybrid			2022-12-25	WOS:000230386800034
J	Zajicek, RS; Cheesman, MR; Gordon, EHJ; Ferguson, SJ				Zajicek, RS; Cheesman, MR; Gordon, EHJ; Ferguson, SJ			Y25S variant of Paracoccus pantotrophus cytochrome cd(1) provides insight into anion binding by d(1) heme and a rare example of a critical difference between solution and crystal structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AERUGINOSA NITRITE REDUCTASE; THIOSPHAERA-PANTOTROPHA; PSEUDOMONAS-AERUGINOSA; MAGNETIC-PROPERTIES; OXIDASE REACTION; PSEUDOAZURIN; CYANIDE; ENZYME; SPECTROSCOPY; IMIDAZOLE	Tyr(25) is a ligand to the active site d(1) heme in as isolated, oxidized cytochrome cd(1) nitrite reductase from Paracoccus pantotrophus. This form of the enzyme requires reductive activation, a process that involves not only displacement of Tyr(25) from the d(1) heme but also switching of the ligands at the c heme from bis-histidinyl to His/Met. A Y25S variant retains this bis-histidinyl coordination in the crystal of the oxidized state that has sulfate bound to the d(1) heme iron. This Y25S form of the enzyme does not require reductive activation, an observation previously interpreted as meaning that the presence of the phenolate oxygen of Tyr(25) is the critical determinant of the requirement for activation. This interpretation now needs re-evaluation because, unexpectedly, the oxidized as prepared Y25S protein, unlike the wild type, has different heme iron ligands in solution at room temperature, as judged by magnetic circular dichroism and electron spin resonance spectroscopies, than in the crystal. In addition, the binding of nitrite and cyanide to oxidized Y25S cytochrome cd(1) is markedly different from the wild type enzyme, thus providing insight into the affinity of the oxidized d(1) heme ring for anions in the absence of the steric barrier presented by Tyr(25).	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ E Anglia, Sch Chem Sci, Norwich NR4 7TJ, Norfolk, England; Chalmers Univ Technol, Dept Chem & Biosci, SE-41296 Gothenburg, Sweden	University of Oxford; University of East Anglia; Chalmers University of Technology	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	ferguson@bioch.ox.ac.uk			Biotechnology and Biological Sciences Research Council [C19430] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Allen JWA, 2000, NAT STRUCT BIOL, V7, P885; Allen JWA, 2002, BIOCHEM J, V366, P883, DOI 10.1042/BJ20020795; Allen JWA, 2000, BIOCHEM BIOPH RES CO, V279, P674, DOI 10.1006/bbrc.2000.4009; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; BRUNORI M, 1992, J BIOL CHEM, V267, P2258; CHEESMAN MR, 1991, ADV INORG CHEM, V36, P201, DOI 10.1016/S0898-8838(08)60040-9; Cheesman MR, 1997, BIOCHEMISTRY-US, V36, P16267, DOI 10.1021/bi971677a; Cutruzzola F, 2003, IUBMB LIFE, V55, P617, DOI 10.1080/15216540310001628672; DOI M, 1989, EUR J BIOCHEM, V184, P521, DOI 10.1111/j.1432-1033.1989.tb15045.x; Feinberg BA, 1998, BIOCHEMISTRY-US, V37, P13091, DOI 10.1021/bi981037n; Fulop V, 2001, ADV INORG CHEM, V51, P163; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; George SJ, 2000, J BIOL CHEM, V275, P33231, DOI 10.1074/jbc.M005033200; Gordon EHJ, 2003, J BIOL CHEM, V278, P11773, DOI 10.1074/jbc.M211886200; Jafferji A, 2000, J BIOL CHEM, V275, P25089, DOI 10.1074/jbc.M001377200; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; Leung YC, 1997, BIOCHEM J, V321, P699, DOI 10.1042/bj3210699; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; Nurizzo D, 1997, STRUCTURE, V5, P1157, DOI 10.1016/S0969-2126(97)00267-0; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Pearson IV, 2003, J BACTERIOL, V185, P6308, DOI 10.1128/JB.185.21.6308-6315.2003; Richter CD, 2002, J BIOL CHEM, V277, P3093, DOI 10.1074/jbc.M108944200; SILVESTRINI MC, 1994, BIOCHIMIE, V76, P641, DOI 10.1016/0300-9084(94)90141-4; Sjogren T, 2001, J BIOL CHEM, V276, P13072, DOI 10.1074/jbc.M011312200; STEUP MB, 1989, J INORG BIOCHEM, V37, P233, DOI 10.1016/0162-0134(89)80045-5; STOLZENBERG AM, 1981, J AM CHEM SOC, V103, P4763, DOI 10.1021/ja00406a018; SUTHERLAND J, 1986, BIOCHEM J, V233, P893, DOI 10.1042/bj2330893; Viola F, 1996, J INORG BIOCHEM, V62, P213, DOI 10.1016/0162-0134(95)00155-7; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WALSH TA, 1979, BIOCHEM J, V177, P29, DOI 10.1042/bj1770029; WALSH TA, 1981, J INORG BIOCHEM, V14, P1, DOI 10.1016/S0162-0134(00)80010-0; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775	34	4	5	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26073	26079		10.1074/jbc.M501890200	http://dx.doi.org/10.1074/jbc.M501890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901734	hybrid			2022-12-25	WOS:000230386800017
J	Asin-Cayuela, J; Schwend, T; Farge, G; Gustafsson, CM				Asin-Cayuela, J; Schwend, T; Farge, G; Gustafsson, CM			The human mitochondrial transcription termination factor (mTERF) is fully active in vitro in the non-phosphorylated form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; CELLS; EXPRESSION; PHOSPHORYLATION; IDENTIFICATION; REVEALS; MONOMER	The human mitochondrial transcription termination factor ( mTERF) is a 39- kDa protein that terminates transcription at the 3 ' end of the 16 S rRNA gene and thereby controls expression of the ribosomal transcription unit of mitochondrial DNA. The transcription termination activity of human mTERF has been notoriously difficult to study in vitro, and it has been suggested that the activity of the protein is regulated by posttranslational modifications or by protein polymerization. We here characterize the activity of recombinant human mTERF expressed in insect cells. We observed that mTERF efficiently promotes sequence- specific termination in a completely recombinant and highly purified in vitro system for mitochondrial transcription. The termination activity has a distinct polarity, and we observed complete transcription termination when the mTERF- binding site is oriented in a forward position relative the heavy strand promoter but only partial transcription termination when the binding site is in the reverse position. We analyzed the biochemical characteristics of the active mTERF protein and found that it is a stable monomer at physiological salt concentration. Structural analysis, including phosphostaining, two- dimensional electrophoresis, and electrospray mass spectrometry, detected no evidence of phosphorylation. We conclude that the monomeric human mTERF is fully active in its non- phosphorylated form and that the protein does not require additional cellular factors to terminate mitochondrial transcription in vitro.	Huddinge Hosp, Karolinska Inst, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet	Gustafsson, CM (corresponding author), Huddinge Hosp, Karolinska Inst, Dept Med Nutr, S-14186 Huddinge, Sweden.	claes.gustafsson@mednut.ki.se	farge, geraldine/M-2803-2018	farge, geraldine/0000-0003-1054-4274; Gustafsson, Claes/0000-0003-3531-8468				Asin-Cayuela J, 2004, J BIOL CHEM, V279, P15670, DOI 10.1074/jbc.M312537200; ATTARDI G, 1990, BIOCHEM SOC T, V18, P509, DOI 10.1042/bst0180509; DAGA A, 1993, J BIOL CHEM, V268, P8123; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P9811, DOI 10.1021/bi00105a001; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6165; DUHE RJ, 1995, J BIOL CHEM, V270, P23084, DOI 10.1074/jbc.270.39.23084; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; Goodman T, 2004, ELECTROPHORESIS, V25, P2533, DOI 10.1002/elps.200406008; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; KU NO, 1994, EXP CELL RES, V211, P24, DOI 10.1006/excr.1994.1054; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; Polosa PL, 1999, NUCLEIC ACIDS RES, V27, P1890, DOI 10.1093/nar/27.8.1890; Prieto-Martin A, 2004, NUCLEIC ACIDS RES, V32, P2059, DOI 10.1093/nar/gkh528; Roberti M, 2003, NUCLEIC ACIDS RES, V31, P1597, DOI 10.1093/nar/gkg272; SHANG J, 1994, J BIOL CHEM, V269, P29112; Spahr H, 2001, P NATL ACAD SCI USA, V98, P11985, DOI 10.1073/pnas.211253898	19	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25499	25505		10.1074/jbc.M501145200	http://dx.doi.org/10.1074/jbc.M501145200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15899902	hybrid			2022-12-25	WOS:000230207900025
J	Chiang, GG; Abraham, RT				Chiang, GG; Abraham, RT			Phosphorylation of mammalian target of rapamycin (mTOR) at ser-2448 is mediated by p70S6 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURVIVAL; S6 KINASE; SIGNALING PATHWAY; ACTIVATION; INSULIN; GROWTH; AKT; PROTEIN; TSC2; IDENTIFICATION	The mammalian target of rapamycin ( mTOR) coordinates cell growth with the growth factor and nutrient/ energy status of the cell. The phosphatidylinositol 3kinase- AKT pathway is centrally involved in the transmission of mitogenic signals to mTOR. Previous studies have shown that mTOR is a direct substrate for the AKT kinase and identified Ser- 2448 as the AKT target site in mTOR. In this study, we demonstrate that rapamycin, a specific inhibitor of mTOR function, blocks serum- stimulated Ser- 2448 phosphorylation and that this drug effect is not explained by the inhibition of AKT. Furthermore, the phosphorylation of Ser- 2448 was dependent on mTOR kinase activity, suggesting that mTOR itself or a protein kinase downstream from mTOR was responsible for the modification of Ser- 2448. Here we show that p70S6 kinase phosphorylates mTOR at Ser- 2448 in vitro and that ectopic expression of rapamycin- resistant p70S6 kinase restores Ser- 2448 phosphorylation in rapamycintreated cells. In addition, we show that cellular amino acid status, which modulates p70S6 kinase ( S6K1) activity via the TSC/ Rheb pathway, regulates Ser- 2448 phosphorylation. Finally, small interfering RNA- mediated depletion of p70S6 kinase reduces Ser- 2448 phosphorylation in cells. Taken together, these results suggest that p70S6 kinase is a major effector of mTOR phosphorylation at Ser- 2448 in response to both mitogenand nutrient- derived stimuli.	Burnham Inst, Program Signal Transduct Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Chiang, GG (corresponding author), Burnham Inst, Program Signal Transduct Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gchiang@burnham.org		Chiang, Gary/0000-0003-3004-7400	NCI NIH HHS [F32 CA099354, CA76193, CA52995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA099354, U19CA052995, R01CA076193, U01CA052995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2004, DNA REPAIR, V3, P919, DOI 10.1016/j.dnarep.2004.04.003; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Balsara BR, 2004, CARCINOGENESIS, V25, P2053, DOI 10.1093/carcin/bgh226; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; Chiang Gary G, 2004, Methods Mol Biol, V281, P125; Choe G, 2003, CANCER RES, V63, P2742; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Edinger AL, 2004, ONCOGENE, V23, P5654, DOI 10.1038/sj.onc.1207738; Edinger AL, 2003, CANCER RES, V63, P8451; ENG QP, 1995, P NATL ACAD SCI USA, V92, P5744; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hosoi H, 1999, CANCER RES, V59, P886; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mothe-Satney I, 2004, J BIOL CHEM, V279, P42628, DOI 10.1074/jbc.M405173200; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sekulic A, 2000, CANCER RES, V60, P3504; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112	42	427	443	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25485	25490		10.1074/jbc.M501707200	http://dx.doi.org/10.1074/jbc.M501707200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15899889	hybrid			2022-12-25	WOS:000230207900023
J	Dollins, DE; Immormino, RM; Gewirth, DT				Dollins, DE; Immormino, RM; Gewirth, DT			Structure of unliganded GRP94, the endoplasmic reticulum Hsp90 - Basis for nucleotide-induced conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; ATP BINDING; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; DIFFRACTION DATA; IN-VIVO; PROTEIN; GELDANAMYCIN; HYDROLYSIS; KINASE	GRP94, the endoplasmic reticulum paralog of Hsp90, is regulated by adenosine nucleotides that bind to its N-terminal regulatory domain. Because of its weak affinity for nucleotides, the functionally relevant transition in GRP94 is likely to be between the unliganded and nucleotide-bound states. We have determined the structure of the unliganded GRP94 N-domain. The helix 1-4-5 subdomain of the unliganded protein adopts the closed conformation seen in the structure of the protein in complex with inhibitors. This conformation is distinct from the open conformation of the subdomain seen when the protein is bound to ATP or ADP. ADP soaked into crystals of the unliganded protein reveals an intermediate conformation midway between the open and closed states and demonstrates that in GRP94 the conversion between the open and closed states is driven by ligand binding. The direction of the observed movement in GRP94 shows that nucleotides act to open the subdomain elements rather than close them, which is contrary to the motion proposed for Hsp90. These observations support a model where ATP binding dictates the conformation of the N-domain and regulates its ability to form quaternary structural interactions.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Gewirth, DT (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711 DUMC, Durham, NC 27710 USA.	gewirth@duke.edu						Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Descoteaux A, 2002, EMBO J, V21, P4458, DOI 10.1093/emboj/cdf447; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; Huai Q, 2005, STRUCTURE, V13, P579, DOI 10.1016/j.str.2004.12.018; Immormino RM, 2004, J BIOL CHEM, V279, P46162, DOI 10.1074/jbc.M405253200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McLaughlin SH, 2004, J MOL BIOL, V344, P813, DOI 10.1016/j.jmb.2004.09.055; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; Richardson JS, 2003, METHOD ENZYMOL, V374, P385, DOI 10.1016/S0076-6879(03)74018-X; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Rosser MFN, 2000, J BIOL CHEM, V275, P22798, DOI 10.1074/jbc.M001477200; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Soldano KL, 2003, J BIOL CHEM, V278, P48330, DOI 10.1074/jbc.M308661200; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	33	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30438	30447		10.1074/jbc.M503761200	http://dx.doi.org/10.1074/jbc.M503761200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15951571	hybrid			2022-12-25	WOS:000231362500057
J	Duran-Sandoval, D; Cariou, B; Percevault, F; Hennuyer, N; Grefhorst, A; van Dijk, TH; Gonzalez, FJ; Fruchart, JC; Kuipers, F; Staels, B				Duran-Sandoval, D; Cariou, B; Percevault, F; Hennuyer, N; Grefhorst, A; van Dijk, TH; Gonzalez, FJ; Fruchart, JC; Kuipers, F; Staels, B			The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; REQUIRES GLUCOSE-METABOLISM; BILE-ACIDS; NUCLEAR RECEPTOR; RESPONSE ELEMENT; TRANSCRIPTION FACTOR; EXPRESSION; INSULIN; BINDING; LIVER	The liver plays a central role in the control of blood glucose homeostasis by maintaining a balance between glucose production and utilization. The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor. Hepatic FXR expression is regulated by glucose and insulin. Here we identify a role for FXR in the control of hepatic carbohydrate metabolism. When submitted to a controlled fasting-refeeding schedule, FXR-/- mice displayed an accelerated response to high carbohydrate refeeding with an accelerated induction of glycolytic and lipogenic genes and a more pronounced repression of gluconeogenic genes. Plasma insulin and glucose levels were lower in FXR-/- mice upon refeeding the high-carbohydrate diet. These alterations were paralleled by decreased hepatic glycogen content. Hepatic insulin sensitivity was unchanged in FXR-/- mice. Treatment of isolated primary hepatocytes with a synthetic FXR agonist attenuated glucose-induced mRNA expression as well as promoter activity of L-type pyruvate kinase, acetyl-CoA carboxylase 1, and Spot14. Moreover, activated FXR interfered negatively with the carbohydrate response elements regions. These results identify a novel role for FXR as a modulator of hepatic carbohydrate metabolism.	Inst Pasteur, INSERM, UR 545, F-59019 Lille, France; Univ Lille, Fac Pharm, F-59019 Lille, France; Univ Groningen Hosp, Pediat Lab, Ctr Liver Digest & Metab Dis, Groningen, Netherlands; NCI, Lab Metab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; University of Groningen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Staels, B (corresponding author), Inst Pasteur, INSERM, UR 545, 1 Rue Prof Calmette-BP245, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Staels, Bart/N-9497-2016; percevault, frederic/K-1836-2015	Staels, Bart/0000-0002-3784-1503; Cariou, Bertrand/0000-0002-1580-8040; HENNUYER, Nathalie/0000-0003-0303-7258; Kuipers, Folkert/0000-0003-2518-737X	NATIONAL CANCER INSTITUTE [Z01BC005708, ZIABC005708] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Borgius LJ, 2002, J BIOL CHEM, V277, P49761, DOI 10.1074/jbc.M205641200; Claudel T, 2002, J CLIN INVEST, V109, P961; Cournarie F, 1999, FEBS LETT, V460, P527, DOI 10.1016/S0014-5793(99)01407-6; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Dentin R, 2004, J BIOL CHEM, V279, P20314, DOI 10.1074/jbc.M312475200; DUERDEN JM, 1988, BIOCHEM J, V255, P929, DOI 10.1042/bj2550929; Duran-Sandoval D, 2004, DIABETES, V53, P890, DOI 10.2337/diabetes.53.4.890; ELZINGA BM, 2004, ARTERIOSCLER THROMB, V24, pE80; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; GIBBONS GF, 1990, BIOCHEM J, V268, P1; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; Han SL, 2004, HEPATOLOGY, V39, P456, DOI 10.1002/hep.20043; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hellerstein MK, 1996, ANNU REV NUTR, V16, P523, DOI 10.1146/annurev.nu.16.070196.002515; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Stayrook KR, 2005, ENDOCRINOLOGY, V146, P984, DOI 10.1210/en.2004-0965; VADIJK TH, 2001, J BIOL CHEM, V276, P25727; van Dijk TH, 2003, ANAL BIOCHEM, V322, P1, DOI 10.1016/j.ab.2003.07.008; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Yamada K, 1999, BIOCHEM J, V337, P1, DOI 10.1042/0264-6021:3370001; Yamagata K, 2004, J BIOL CHEM, V279, P23158, DOI 10.1074/jbc.M314322200; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang YQ, 2004, GENE DEV, V18, P157, DOI 10.1101/gad.1138104	41	172	185	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29971	29979		10.1074/jbc.M501931200	http://dx.doi.org/10.1074/jbc.M501931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15899888	hybrid			2022-12-25	WOS:000231176200070
J	Chen, WG; Wang, N; Tall, AR				Chen, WG; Wang, N; Tall, AR			A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN DEFICIENCY; CASSETTE TRANSPORTER 1; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; APOA-I; BINDING; DEGRADATION; MUTATIONS; RECEPTOR; TRAFFICKING	ATP-binding cassette transporter A1 (ABCA1) promotes the efflux of cellular cholesterol and phospholipids to apoA-I. We described previously a cytoplasmic PEST sequence in ABCA1 and showed that deletion of the PEST sequence results in a prominent increase in the cell surface concentration of ABCA1. In the current study we evaluated the hypothesis that the PEST sequence-deleted ABCA1 might display defective internalization and trafficking to the late endosomes/lysosomes. As assessed by monensin treatment and cell surface bio-tinylation, the internalization rate of PEST sequence-deleted ABCA1 (ABCA1-dPEST) was markedly decreased compared with wild-type ABCA1 (ABCA1-wt). Immunofluorescence confocal microscopy of ABCA1-wt showed both plasma membrane localization and substantial co-localization with LAMP2 in late endosomes. In contrast, ABCA1-dPEST showed more prominent plasma membrane localization but little co-localization with LAMP2. To assess cholesterol efflux from late endosomes, HEK293 cells were transiently co-transfected with scavenger receptor A (SR-A) and incubated with [H-3] cholesterol/acetyl low density lipoprotein (acLDL). Although ABCA1-dPEST showed higher cholesterol efflux than did ABCA1-wt following cell surface labeling ([H-3] cholesterol/alpha LDL in the absence of SR-A co-transfection), it showed impaired cholesterol efflux after late endosomal labeling ([3H] cholesterol/acLDL in the presence of SR-A). Thus, deletion of the PEST sequence leads to a decrease in the internalization of ABCA1 and decreased cholesterol efflux from late endosomal cholesterol pools, providing evidence that the internalization and trafficking of ABCA1 is functionally important in mediating cholesterol efflux from intracellular cholesterol pools.	Columbia Univ, Div Mol Med, Dept Med, New York, NY 10032 USA	Columbia University	Tall, AR (corresponding author), Columbia Univ, Div Mol Med, Dept Med, P&S 8-401,630 W 168th St, New York, NY 10032 USA.	art1@columbia.edu	Tall, Alan/AAT-8528-2021		NHLBI NIH HHS [HL22682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Michaely P, 2004, J BIOL CHEM, V279, P34023, DOI 10.1074/jbc.M405242200; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808	19	91	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29277	29281		10.1074/jbc.M505566200	http://dx.doi.org/10.1074/jbc.M505566200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15951431	hybrid			2022-12-25	WOS:000231021300058
J	Bergo, VB; Spudich, EN; Rothschild, KJ; Spudich, JL				Bergo, VB; Spudich, EN; Rothschild, KJ; Spudich, JL			Photoactivation perturbs the membrane-embedded contacts between sensory rhodopsin II and its transducer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRONOBACTERIUM-PHARAONIS; CONFORMATIONAL-CHANGES; STRUCTURAL-CHANGES; PROTON TRANSPORT; RECEPTOR; BACTERIORHODOPSIN; FTIR; PHOBORHODOPSIN; PROTEORHODOPSIN; PHOTOCHEMISTRY	The photoactivation mechanism of the sensory rhodopsin II (SRII)-HtrII receptor-transducer complex of Natronomonas pharaonis was investigated by time-resolved Fourier transform infrared difference spectroscopy to identify structural changes associated with early events in the signal relay mechanism from the receptor to the transducer. Several prominent bands in the wild-type SRII-HtrII spectra are affected by amino acid substitutions at the receptor Tyr(199) and transducer Asn(74) residues, which form a hydrogen bond between the two proteins near the middle of the bilayer. Our results indicate disappearance of this hydrogen bond in the M and O photointermediates, the likely signaling states of the complex. This event represents one of the largest light-induced alterations in the binding contacts between the receptor and transducer. The vibrational frequency changes suggest that Asn(74) and Tyr(199) form other stronger hydrogen bonds in the M state. The light-induced disruption of the Tyr(199)-Asn(74) bond also occurs when the Schiff base counterion Asp(75) is replaced with a neutral asparagine. We compared the decrease in intensity of difference bands assigned to the Tyr(199)-Asn(74) pair and to chromophore and protein groups of the receptor at various time points during the recovery of the initial state. All difference bands exhibit similar decay kinetics indicating that reformation of the Tyr(199)-Asn(74) hydrogen bond occurs concomitantly with the decay of the M and O photointermediates. This work demonstrates that the signal relay from SRII to HtrII involves early structural alterations in the deeply membrane-embedded domain of the complex and provides a spectroscopic signal useful for correlation with the downstream events in signal transduction.	Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Boston Univ, Dept Phys, Mol Biophys Lab, Boston, MA 02215 USA	University of Texas System; Boston University	Spudich, JL (corresponding author), Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, MSB 6-130,6431 Fannin St, Houston, TX 77030 USA.	John.L.Spudich@uth.tmc.edu	Rothschild, Kenneth J/P-6177-2018	Rothschild, Kenneth J/0000-0002-2847-6671	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069969, R37GM027750] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; Beja O, 2001, NATURE, V411, P786, DOI 10.1038/35081051; Bellamy L.J., 1968, INFRARED SPECTRA COM; Bergo V, 2000, BIOCHEMISTRY-US, V39, P2823, DOI 10.1021/bi991676d; Bergo V, 2004, BIOCHEMISTRY-US, V43, P9075, DOI 10.1021/bi0361968; Bergo V, 2003, J BIOL CHEM, V278, P36556, DOI 10.1074/jbc.M303719200; Bergo V, 2003, BIOPHYS J, V84, P960, DOI 10.1016/S0006-3495(03)74912-1; Bieszke JA, 1999, BIOCHEMISTRY-US, V38, P14138, DOI 10.1021/bi9916170; BOUSCHE O, 1991, BIOCHEMISTRY-US, V30, P5395, DOI 10.1021/bi00236a010; Chizhov I, 1998, BIOPHYS J, V75, P999, DOI 10.1016/S0006-3495(98)77588-5; Engelhard M, 1996, FEBS LETT, V395, P195, DOI 10.1016/0014-5793(96)01041-1; Furutani Y, 2005, BIOCHEMISTRY-US, V44, P2909, DOI 10.1021/bi047893i; Furutani Y, 2002, BIOPHYS J, V83, P3482, DOI 10.1016/S0006-3495(02)75347-2; Gordeliy VI, 2002, NATURE, V419, P484, DOI 10.1038/nature01109; Hein M, 2004, BIOCHEMISTRY-US, V43, P995, DOI 10.1021/bi0354381; Hein M, 2003, BIOPHYS J, V84, P1208, DOI 10.1016/S0006-3495(03)74935-2; Hienerwadel R, 1997, BIOCHEMISTRY-US, V36, P14712, DOI 10.1021/bi971521a; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Kamo N, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1277, DOI 10.1023/A:1013187403599; Kandori H, 2001, BIOCHEMISTRY-US, V40, P9238, DOI 10.1021/bi0103819; Klare JP, 2004, PHOTOCH PHOTOBIO SCI, V3, P543, DOI 10.1039/b402656j; Krebs MP, 1995, PROTEIN EXPRES PURIF, V6, P780, DOI 10.1006/prep.1995.0009; PARKER FS, 1983, APPL INFRARED RAMAN; Pebay-Peyroula E, 2002, BBA-BIOMEMBRANES, V1565, P196, DOI 10.1016/S0005-2736(02)00569-2; PIMENTEL GC, 1956, J CHEM PHYS, V24, P639, DOI 10.1063/1.1742588; ROTHSCHILD KJ, 1981, BIOCHEM BIOPH RES CO, V103, P483, DOI 10.1016/0006-291X(81)90478-2; Sasaki J, 2000, BBA-BIOENERGETICS, V1460, P230, DOI 10.1016/S0005-2728(00)00142-0; Schmies G, 2000, BIOPHYS J, V78, P967, DOI 10.1016/S0006-3495(00)76654-9; SIEBERT F, 1983, EUR J BIOCHEM, V130, P565, DOI 10.1111/j.1432-1033.1983.tb07187.x; Sineshchekov OA, 2002, P NATL ACAD SCI USA, V99, P8689, DOI 10.1073/pnas.122243399; Spudich EN, 1997, P NATL ACAD SCI USA, V94, P4960, DOI 10.1073/pnas.94.10.4960; Spudich J, 2002, NAT STRUCT BIOL, V9, P797, DOI 10.1038/nsb1102-797; Spudich JL, 1998, MOL MICROBIOL, V28, P1051, DOI 10.1046/j.1365-2958.1998.00859.x; Sudo Y, 2002, BIOPHYS J, V83, P427, DOI 10.1016/S0006-3495(02)75180-1; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; Vogeley L, 2004, SCIENCE, V306, P1390, DOI 10.1126/science.1103943; Webre DJ, 2003, CURR BIOL, V13, pR47, DOI 10.1016/S0960-9822(02)01424-0; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Wegener AA, 2001, EMBO J, V20, P5312, DOI 10.1093/emboj/20.19.5312; YAN B, 1991, BIOCHEMISTRY-US, V30, P10686, DOI 10.1021/bi00108a012; Yang CS, 2004, J BIOL CHEM, V279, P42970, DOI 10.1074/jbc.M406504200; Zhang XN, 1999, P NATL ACAD SCI USA, V96, P857, DOI 10.1073/pnas.96.3.857	42	35	36	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28365	28369		10.1074/jbc.M505555200	http://dx.doi.org/10.1074/jbc.M505555200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15951432	hybrid			2022-12-25	WOS:000230857300024
J	Yin, GY; Zheng, QL; Yan, C; Berk, BC				Yin, GY; Zheng, QL; Yan, C; Berk, BC			GIT1 is a scaffold for ERK1/2 activation in focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; PHOSPHOLIPASE C-GAMMA; ANGIOTENSIN-II; PROTEIN-KINASE; LD4 MOTIF; PHOSPHORYLATION; PAXILLIN; SRC; MIGRATION	GIT1 (G protein-coupled receptor kinase-interacting protein 1) has been shown to regulate focal adhesion disassembly. We previously reported that GIT1 associates with MEK1 and acts as a scaffold to enhance ERK1/2 activation. Here, we show that GIT1 co-localizes with ERK1/2 in focal adhesions and regulates cell migration in vascular smooth muscle cells, HEK293 cells, and HeLa cells. Immunofluorescence showed that GIT1 co-localized with phospho-ERK1/2 in focal adhesions after epidermal growth factor stimulation. Because Src is required for both GIT1 tyrosine phosphorylation and focal adhesion disassembly, we studied the effects of Src on GIT1-ERK1/2 interactions. PP2 (4-amino-5-(4-chlorophenyl)7-( t-butyl) pyrazolo[3,4-d] pyrimidine) inhibited association of GIT1 with ERK1/2, and their co-localization in focal adhesions was dramatically decreased in SYF-/- cells. GIT1 small interfering RNA significantly inhibited ERK1/2 recruitment to and activation in focal adhesions. GIT1 small interfering RNA and mutated GIT1 lacking the MEK1 binding domain significantly decreased epidermal growth factor-stimulated cell spreading and migration, suggesting that GIT1-mediated events such as ERK1/2 activation are required for spreading and migration. In summary, the present study further supports a key role for GIT1 (a MEK1-binding protein) as a scaffold for signal transduction in focal adhesions.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, Box MED,601 Elmwood Ave, Rochester, NY 14642 USA.	Bradford_Berk@URMC.Rochester.edu		Yin, Guoyong/0000-0002-7268-5374; Yan, Chen/0000-0002-1397-6358; Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063462] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL63462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amerongen GPV, 2004, CIRC RES, V94, P1041, DOI 10.1161/01.RES.0000125627.77235.0C; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Haendeler J, 2003, J BIOL CHEM, V278, P49936, DOI 10.1074/jbc.M307317200; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Hunger-Glaser I, 2003, J BIOL CHEM, V278, P22631, DOI 10.1074/jbc.M210876200; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Ishida M, 1998, CIRC RES, V82, P7; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Manabe R, 2002, J CELL SCI, V115, P1497; Melaragno MG, 1998, CIRC RES, V83, P697, DOI 10.1161/01.RES.83.7.697; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schmitz U, 1997, CIRC RES, V81, P550, DOI 10.1161/01.RES.81.4.550; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; van Drogen F, 2002, CURR BIOL, V12, P1698, DOI 10.1016/S0960-9822(02)01186-7; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Xi XP, 1999, ARTERIOSCL THROM VAS, V19, P73, DOI 10.1161/01.ATV.19.1.73; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yin GY, 2004, MOL CELL BIOL, V24, P875, DOI 10.1128/MCB.24.2.875-885.2004; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	34	62	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27705	27712		10.1074/jbc.M502271200	http://dx.doi.org/10.1074/jbc.M502271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923189	hybrid			2022-12-25	WOS:000230678600029
J	Loiseau, L; Ollagnier-de Choudens, S; Lascoux, D; Forest, E; Fontecave, M; Barras, F				Loiseau, L; Ollagnier-de Choudens, S; Lascoux, D; Forest, E; Fontecave, M; Barras, F			Analysis of the heteromeric CsdA-CsdE cysteine desulfurase, assisting Fe-S cluster biogenesis in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; ASSEMBLY PROTEIN ISCU; NIFS-LIKE PROTEIN; SELENOCYSTEINE LYASE; SUF SYSTEM; BIOSYNTHESIS; SCAFFOLD; OPERON; GENE; REQUIREMENT	Biogenesis of iron-sulfur (Fe-S) cluster-containing proteins relies on assistance of complex machineries. To date three systems, NIF, ISC, and SUF, were reported to allow maturation of Fe-S proteins. Here we report that the csdA-csdE (formally ygdK) genes of Escherichia coli constitute a sulfur-generating system referred to as CSD which also contributes to Fe-S biogenesis in vivo. This conclusion was reached by applying a thorough combination of both in vivo and in vitro strategies and techniques. Yeast two-hybrid analysis allowed us to show that CsdA and CsdE interact. Enzymology analysis showed that CsdA cysteine desulfurase activity is increased 2-fold in the presence of CsdE. Mass spectrometry analysis and site-directed mutagenesis showed that residue Cys-61 from CsdE acted as an acceptor site for sulfur provided by cysteine desulfurase activity of CsdA. Genetic investigations revealed that the csdA-csdE genes could act as multicopy suppressors of iscS mutation. Moreover, both in vitro and in vivo investigations pointed to a specific connection between the CSD system and quinolinate synthetase NadA.	CNRS, UPR 9043, Chim Bacterienne Lab, Inst Biol Struct & Microbiol, F-13402 Marseille, France; Univ Grenoble 1, CNRS, CEA Saclay,UMR 5047, DRDC CB,Lab Chim & Biochim,Ctr Redox Biol, F-38054 Grenoble, France; Univ Grenoble 1, CNRS, CEA Saclay, Inst Biol Struct,Lab Spectrometrie Masse Prot, F-38027 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Universite Paris Saclay	Barras, F (corresponding author), CNRS, UPR 9043, Chim Bacterienne Lab, Inst Biol Struct & Microbiol, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.	barras@ibsm.cnrs-mrs.fr	Forest, Eric/E-9042-2012	Ollagnier de Choudens, Sandrine/0000-0002-0080-6659; Barras, Frederic/0000-0003-3458-2574				BARRAS F, 2005, IN PRESS ADV BACTERI, V50; Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; Cupp-Vickery JR, 2003, J MOL BIOL, V330, P1049, DOI 10.1016/S0022-2836(03)00690-9; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Ding H, 2004, J BIOL CHEM, V279, P37499, DOI 10.1074/jbc.M404533200; Djaman O, 2004, J BIOL CHEM, V279, P44590, DOI 10.1074/jbc.M406487200; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; Goldsmith-Fischman S, 2004, J MOL BIOL, V344, P549, DOI 10.1016/j.jmb.2004.08.074; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hjorth E, 2005, FEBS LETT, V579, P1129, DOI 10.1016/j.febslet.2004.12.084; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Kurihara T, 2003, BBA-PROTEINS PROTEOM, V1647, P303, DOI 10.1016/S1570-9639(03)00078-5; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lima CD, 2002, J MOL BIOL, V315, P1199, DOI 10.1006/jmbi.2001.5308; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 2002, J BIOCHEM, V131, P679, DOI 10.1093/oxfordjournals.jbchem.a003151; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Moller SG, 2001, GENE DEV, V15, P90, DOI 10.1101/gad.850101; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Nuth M, 2002, J AM CHEM SOC, V124, P8774, DOI 10.1021/ja0264596; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Ollagnier-de-Choudens S, 2004, J BIOL INORG CHEM, V9, P828, DOI 10.1007/s00775-004-0581-9; Ollagnier-De-Choudens S, 2003, FEBS LETT, V555, P263, DOI 10.1016/S0014-5793(03)01244-4; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Ramelot TA, 2004, J MOL BIOL, V344, P567, DOI 10.1016/j.jmb.2004.08.038; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tirupati B, 2004, BIOCHEMISTRY-US, V43, P12210, DOI 10.1021/bi0491447; Tokumoto U, 2004, J BIOCHEM, V136, P199, DOI 10.1093/jb/mvh104; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Wilson RJM, 2002, J MOL BIOL, V319, P257, DOI 10.1016/S0022-2836(02)00303-0; Xu XM, 2004, P NATL ACAD SCI USA, V101, P9143, DOI 10.1073/pnas.0400799101; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	57	86	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26760	26769		10.1074/jbc.M504067200	http://dx.doi.org/10.1074/jbc.M504067200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15901727	hybrid			2022-12-25	WOS:000230589500017
J	Mistrik, P; Mader, R; Michalakis, S; Weidinger, M; Pfeifer, A; Biel, M				Mistrik, P; Mader, R; Michalakis, S; Weidinger, M; Pfeifer, A; Biel, M			The murine HCN3 gene encodes a hyperpolarization-activated cation channel with slow kinetics and unique response to cyclic nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PACEMAKER CHANNELS; FUNCTIONAL-CHARACTERIZATION; ION CHANNELS; I-F; MODULATION; CELLS; HETEROMERIZATION; IDENTIFICATION; EXPRESSION; ARRHYTHMIA	Hyperpolarization-activated cation channels of the HCN gene family are crucial for the regulation of cell excitability. Importantly, these channels play a pivotal role in the control of cardiac and neuronal pacemaker activity. Dysfunction of HCN channels has been associated with human diseases, including cardiac arrhythmia, epilepsy, and neuropathic pain. The properties of three HCN channel isoforms (HCN1, HCN2, and HCN4) have been extensively investigated. By contrast, due to the lack of an efficient heterologous expression system, the functional characteristics of HCN3 were by and large unknown so far. Here, we have used lentiviral gene transfer to overexpress HCN3 in HEK293T cells. HCN3 currents revealed slow activation and deactivation kinetics and were effectively blocked by extracellular Cs+ and the bradycardic agent ivabradine. Cyclic AMP and cGMP had no significant impact on activation kinetics but induced a 5-mV shift of the half-maximal activation voltage (V-0.5) to more hyperpolarized potentials. A negative shift of V-0.5 induced by cyclic nucleotides is an unprecedented feature within the HCN channel family. The expression of HCN3 in mouse brain was examined by Western blot analysis using a specific antibody. High levels of protein were detected in olfactory bulb and hypothalamus. In contrast, only very low expression was found in cortex. Using reverse transcriptase PCR transcripts of HCN3 were also detected in heart ventricle. In conclusion, the distinct expression pattern in conjunction with the unusual biophysical properties implies that HCN3 may play an unique role in the body.	Univ Munich, Dept Pharm Pharmakol Nat Wissensch, D-81377 Munich, Germany	University of Munich	Biel, M (corresponding author), Univ Munich, Dept Pharm Pharmakol Nat Wissensch, Butenandtstr 7, D-81377 Munich, Germany.	mbiel@cup.uni-muenchen.de	Mistrik, Pavel/Q-3947-2019; Michalakis, Stylianos/M-4677-2019; Mistrik, Pavel/A-9999-2008; Biel, Martin/G-1175-2014; Michalakis, Stylianos/W-2094-2018	Mistrik, Pavel/0000-0002-0448-4730; Michalakis, Stylianos/0000-0001-5092-9238; Biel, Martin/0000-0002-9974-3052; Michalakis, Stylianos/0000-0001-5092-9238				Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; Bois P, 1996, BRIT J PHARMACOL, V118, P1051, DOI 10.1111/j.1476-5381.1996.tb15505.x; Bucchi A, 2002, J GEN PHYSIOL, V120, P1, DOI 10.1085/jgp.20028593; Cerbai E, 2001, J MOL CELL CARDIOL, V33, P441, DOI 10.1006/jmcc.2000.1316; Chaplan SR, 2003, J NEUROSCI, V23, P1169, DOI 10.1523/JNEUROSCI.23-04-01169.2003; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Craven KB, 2004, J GEN PHYSIOL, V124, P663, DOI 10.1085/jgp.200409178; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Hofmann F, 2003, PHARMACOL REV, V55, P587, DOI 10.1124/pr.55.4.10; KANDEL ER, 2000, PRINCIPLES NEURAL SC, P974; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Monteggia LM, 2000, MOL BRAIN RES, V81, P129, DOI 10.1016/S0169-328X(00)00155-8; Moosmang S, 1999, BIOL CHEM, V380, P975, DOI 10.1515/BC.1999.121; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Muller F, 2003, EUR J NEUROSCI, V17, P2084, DOI 10.1046/j.1460-9568.2003.02634.x; Nolan MF, 2003, CELL, V115, P551, DOI 10.1016/S0092-8674(03)00884-5; Notomi T, 2004, J COMP NEUROL, V471, P241, DOI 10.1002/cne.11039; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; Poolos Nicholas P., 2004, Epilepsy Curr, V4, P3, DOI 10.1111/j.1535-7597.2004.04101.x; Qu JH, 2004, J BIOL CHEM, V279, P43497, DOI 10.1074/jbc.M405018200; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Schulze-Bahr E, 2003, J CLIN INVEST, V111, P1537, DOI 10.1172/JCI200316387; Stieber J, 2004, TRENDS CARDIOVAS MED, V14, P23, DOI 10.1016/j.tcm.2003.09.006; Stieber J, 2003, P NATL ACAD SCI USA, V100, P15235, DOI 10.1073/pnas.2434235100; Stieber J, 2003, J BIOL CHEM, V278, P33672, DOI 10.1074/jbc.M305318200; Ueda K, 2004, J BIOL CHEM, V279, P27194, DOI 10.1074/jbc.M311953200; Ulens C, 2003, NEURON, V40, P959, DOI 10.1016/S0896-6273(03)00753-0; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Wang J, 2002, NEURON, V36, P451, DOI 10.1016/S0896-6273(02)00968-6; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; Zhou L, 2004, NEURON, V44, P823, DOI 10.1016/j.neuron.2004.11.012	39	82	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27056	27061		10.1074/jbc.M502696200	http://dx.doi.org/10.1074/jbc.M502696200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15923185	hybrid			2022-12-25	WOS:000230589500051
J	Mifune, M; Ohtsu, H; Suzuki, H; Nakashima, H; Brailoiu, E; Dun, NJ; Frank, GD; Inagami, T; Higashiyama, S; Thomas, WG; Eckhart, AD; Dempsey, PJ; Eguchi, S				Mifune, M; Ohtsu, H; Suzuki, H; Nakashima, H; Brailoiu, E; Dun, NJ; Frank, GD; Inagami, T; Higashiyama, S; Thomas, WG; Eckhart, AD; Dempsey, PJ; Eguchi, S			G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ALPHA-CONVERTING-ENZYME; TYROSINE KINASE ACTIVATION; SIGNAL-REGULATED KINASE; EGF RECEPTOR; POSSIBLE REQUIREMENT; TRANSACTIVATION; CALCIUM; CELLS; CLEAVAGE	A G protein-coupled receptor agonist, angiotensin II ( AngII), induces epidermal growth factor ( EGF) receptor ( EGFR) transactivation possibly through metalloprotease-dependent, heparin-binding EGF (HB-EGF) shedding. Here, we have investigated signal transduction of this process by using COS7 cells expressing an AngII receptor, AT(1). In these cells AngII-induced EGFR transactivation was completely inhibited by pretreatment with a selective HB-EGF inhibitor, or with a metalloprotease inhibitor. We also developed a COS7 cell line permanently expressing a HB-EGF construct tagged with alkaline phosphatase, which enabled us to measure HB-EGF shedding quantitatively. In the COS7 cell line AngII stimulated release of HB-EGF. This effect was mimicked by treatment either with a phospholipase C activator, a Ca2+ ionophore, a metalloprotease activator, or H2O2. Conversely, pretreatment with an intracellular Ca2+ antagonist or an antioxidant blocked AngII-induced HB-EGF shedding. Moreover, infection of an adenovirus encoding an inhibitor of G(q) markedly reduced EGFR transactivation and HB-EGF shedding through AT1. In this regard, AngII-stimulated HB-EGF shedding was abolished in an AT1 mutant that lacks Gq protein coupling. However, in cells expressing AT1 mutants that retain Gq protein coupling, AngII is still able to induce HB-EGF shedding. Finally, the AngII-induced EGFR transactivation was attenuated in COS7 cells overexpressing a catalytically inactive mutant of ADAM17. From these data we conclude that AngII stimulates a metalloprotease ADAM17-dependent HB-EGF shedding through AT1/Gq/phospholipase C-mediated elevation of intracellular Ca2+ and reactive oxygen species production, representing a key mechanism indispensable for EGFR transactivation.	Temple Univ, Cardiovasc Res Ctr, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Physiol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19140 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Baker Med Res Inst, Mol Endocrinol Lab, Melbourne, Vic 8008, Australia; Thomas Jefferson Univ, Ctr Translat Med, Philadelphia, PA 19107 USA; Pacific NW Res Inst, Seattle, WA 98122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Vanderbilt University; Baker Heart and Diabetes Institute; Jefferson University	Eguchi, S (corresponding author), Temple Univ, Cardiovasc Res Ctr, Sch Med, 3420 N Broad St, Philadelphia, PA 19140 USA.	seguchi@temple.edu	Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952	NHLBI NIH HHS [HL076770, HL058205, HL076575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL076575, R37HL058205, R01HL058205, R01HL076770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bae YS, 2003, MOL PHARMACOL, V63, P1043, DOI 10.1124/mol.63.5.1043; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Conchon S, 1999, J AM SOC NEPHROL, V10, pS8; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Doan TN, 2001, J BIOL CHEM, V276, P20954, DOI 10.1074/jbc.C100199200; Eguchi S, 2003, BIOCHEM SOC T, V31, P1198; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Filipeanu CM, 2002, J NEUROCHEM, V83, P879, DOI 10.1046/j.1471-4159.2002.01196.x; Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004; Frank GD, 2003, ANTIOXID REDOX SIGN, V5, P771, DOI 10.1089/152308603770380070; Frank GD, 2003, MOL CELL BIOL, V23, P1581, DOI 10.1128/MCB.23.5.1581-1589.2003; Frank GD, 2001, BIOCHEM BIOPH RES CO, V280, P1116, DOI 10.1006/bbrc.2001.4251; Fujiyama S, 2001, CIRC RES, V88, P22, DOI 10.1161/01.RES.88.1.22; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Gonzales PE, 2004, J BIOL CHEM, V279, P31638, DOI 10.1074/jbc.M401311200; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Ishida M, 1998, CIRC RES, V82, P7; Kim S, 2000, PHARMACOL REV, V52, P11; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Leonard JD, 2005, BIOCHEM J, V387, P797, DOI 10.1042/BJ20041727; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Mifune M, 2004, AM J PHYSIOL-CELL PH, V287, pC807, DOI 10.1152/ajpcell.00436.2003; Nanba D, 2004, CYTOKINE GROWTH F R, V15, P13, DOI 10.1016/j.cytogfr.2003.10.002; Ohyama K, 2002, BIOCHEM BIOPH RES CO, V292, P362, DOI 10.1006/bbrc.2002.6670; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Saito S, 2002, BIOCHEM BIOPH RES CO, V294, P1023, DOI 10.1016/S0006-291X(02)00595-8; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Sanderson MP, 2005, J BIOL CHEM, V280, P1826, DOI 10.1074/jbc.M408804200; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Schafer B, 2004, J BIOL CHEM, V279, P47929, DOI 10.1074/jbc.M400129200; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Seta K, 2003, J BIOL CHEM, V278, P9019, DOI 10.1074/jbc.M208017200; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; Shah BH, 2004, MOL ENDOCRINOL, V18, P2035, DOI 10.1210/me.2003-0476; Shin HS, 2003, CIRC RES, V93, P302, DOI 10.1161/01.RES.0000086803.64109.9E; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; SUZUKI H, 2005, IN PRESS CURR MED CH; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Tamura R, 2001, ATHEROSCLEROSIS, V155, P413, DOI 10.1016/S0021-9150(00)00576-1; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; Thomas WG, 2002, CIRC RES, V90, P135, DOI 10.1161/hh0202.104109; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Touyz RM, 2000, PHARMACOL REV, V52, P639; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yin GY, 2003, INT J BIOCHEM CELL B, V35, P780, DOI 10.1016/S1357-2725(02)00300-X; Zhang ZL, 2001, FASEB J, V15, P303; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	75	109	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26592	26599		10.1074/jbc.M502906200	http://dx.doi.org/10.1074/jbc.M502906200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15905175	hybrid			2022-12-25	WOS:000230386800076
J	Sun, LP; Li, L; Goldstein, JL; Brown, MS				Sun, LP; Li, L; Goldstein, JL; Brown, MS			Insig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; COMPETITIVE INHIBITOR; SCAP; CHOLESTEROL; SREBPS; ER; EXPORT; CELLS; MECHANISMS; EXPRESSION	When added to living cells, sterols such as cholesterol and 25-hydroxycholesterol block the lateral movement of sterol regulatory element-binding proteins (SREBPs) into COPII-coated vesicles on endoplasmic reticulum ( ER) membranes and thereby prevent the SREBPs from reaching the Golgi complex for processing to the mature forms that activate cholesterol synthesis. Sorting of SREBPs into COPII vesicles is mediated by Sar1 and the coat proteins Sec23 and Sec24. Here, we explore the mechanism of sterol inhibition in vitro through use of protein pull-down assays. We show that addition of cholesterol or 25-hydroxycholesterol to microsomal membranes in vitro blocks Sar1-dependent binding of the Sec23/24 complex to Scap, the SREBP escort protein. This in vitro inhibition is dependent on the presence of Insig-1, an ER resident protein that is necessary for sterol-mediated inhibition of Scap/SREBP transport in intact cells. Sec23/24 binding to Scap requires the hexapeptide sequence MELADL located in a cytoplasmic loop of Scap. This hexapeptide acts as a sterol-regulated ER sorting signal. These studies define the biochemical parameters responsible for regulated sorting of an ER membrane protein into COPII-coated vesicles.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joe.goldstein@utsouthwestern.edu; mike.brown@utsouthwestern.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1978, J BIOL CHEM, V253, P1121; Espenshade PJ, 2002, P NATL ACAD SCI USA, V99, P11694, DOI 10.1073/pnas.182412799; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13413, DOI 10.1073/pnas.212519199; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; ROWE T, 1995, METHOD ENZYMOL, V257, P49; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Sambrook J, 2001, MOL CLONING LAB MANU; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	28	165	173	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26483	26490		10.1074/jbc.M504041200	http://dx.doi.org/10.1074/jbc.M504041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15899885	hybrid			2022-12-25	WOS:000230386800064
J	Wang, GH; Silva, J; Krishnamurthy, K; Tran, E; Condie, BG; Bieberich, E				Wang, GH; Silva, J; Krishnamurthy, K; Tran, E; Condie, BG; Bieberich, E			Direct binding to ceramide activates protein kinase C zeta before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; NF-KAPPA-B; PKC-ZETA; CANCER-CELLS; SELECTIVE APOPTOSIS; ENDOGENOUS CERAMIDE; SIGNAL-TRANSDUCTION; MEMBRANE; DOMAIN; ALPHA	We have reported that ceramide mediates binding of atypical protein kinase C (PKC) zeta to its inhibitor protein, PAR-4 ( prostate apoptosis response-4), thereby inducing apoptosis in differentiating embryonic stem cells. Using a novel method of lipid vesicle-mediated affinity chromatography, we showed here that endogenous ceramide binds directly to the PKC zeta(.)PAR-4 complex. Ceramide and its analogs activated PKC zeta prior to binding to PAR-4, as determined by increased levels of phosphorylated PKC zeta and glycogen synthase kinase-3 beta and emergence of a PAR-4-to-phosphorylated PKC zeta fluorescence resonance energy transfer signal that co- localizes with ceramide. Elevated expression and activation of PKC zeta increased cell survival, whereas expression of PAR-4 promoted apoptosis. This suggests that PKC zeta counteracts apoptosis, unless its ceramide-induced activation is compromised by binding to PAR-4. A luciferase reporter assay showed that ceramide analogs activate nuclear factor (NF)-kappa B unless PAR-4-dependent inhibition of PKC zeta suppresses NF-kappa B activation. Taken together, our results show that direct physical association with ceramide and PAR-4 regulates the activity of PKC zeta. They also indicate that this interaction regulates the activity of glycogen synthase kinase-3 beta and NF-kappa B.	Med Coll Georgia, Inst Mol Med & Genet, Sch Med, Augusta, GA 30912 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA	University System of Georgia; Augusta University; University System of Georgia; University of Georgia	Bieberich, E (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Sch Med, 1120 15th St,Rm CB-2803, Augusta, GA 30912 USA.	ebieberich@mail.mcg.edu		Silva, PhD, MPA, EdS, EdD, MB(ASCP)CM, Jeane/0000-0003-3368-3963	NINDS NIH HHS [R01NS046835] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046835] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ballou LM, 2001, J BIOL CHEM, V276, P40910, DOI 10.1074/jbc.M103480200; Bezombes C, 2004, BLOOD, V104, P1166, DOI 10.1182/blood-2004-01-0277; Bieberich E, 2000, J BIOL CHEM, V275, P177, DOI 10.1074/jbc.275.1.177; Bieberich E, 2003, J CELL BIOL, V162, P469, DOI 10.1083/jcb.200212067; Bieberich E, 2004, J CELL BIOL, V167, P723, DOI 10.1083/jcb.200405144; Bieberich E, 2002, CANCER LETT, V181, P55, DOI 10.1016/S0304-3835(02)00049-6; Bieberich E, 2001, J BIOL CHEM, V276, P44396, DOI 10.1074/jbc.M107239200; Bionda C, 2004, BIOCHEM J, V382, P527, DOI 10.1042/BJ20031819; Bolsover SR, 2003, J BIOL CHEM, V278, P10282, DOI 10.1074/jbc.M212145200; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Buteau J, 2001, DIABETES, V50, P2237, DOI 10.2337/diabetes.50.10.2237; Camandola S, 2000, J NEUROSCI RES, V61, P134, DOI 10.1002/1097-4547(20000715)61:2<134::AID-JNR3>3.0.CO;2-P; Chalfant CE, 2004, J LIPID RES, V45, P496, DOI 10.1194/jlr.M300347-JLR200; Contreras FX, 2005, BIOPHYS J, V88, P348, DOI 10.1529/biophysj.104.050690; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Cowart LA, 2002, J LIPID RES, V43, P2042, DOI 10.1194/jlr.M200241-JLR200; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; DE BP, 1995, P NATL ACAD SCI USA, V92, P5204, DOI 10.1073/pnas.92.11.5204; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; El-Guendy N, 2003, MOL CELL BIOL, V23, P5516, DOI 10.1128/MCB.23.16.5516-5525.2003; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fanzo JC, 2003, CANCER BIOL THER, V2, P392, DOI 10.4161/cbt.2.4.442; Garcia-Cao I, 2003, EMBO REP, V4, P307, DOI 10.1038/sj.embor.embor769; GOODE N, 1992, J BIOL CHEM, V267, P16878; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Gulbins E, 2002, BBA-MOL CELL BIOL L, V1585, P139, DOI 10.1016/S1388-1981(02)00334-7; Hendrich AB, 2002, EUR J PHARM SCI, V16, P201, DOI 10.1016/S0928-0987(02)00106-9; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Hsueh YW, 2002, BIOPHYS J, V82, P3089, DOI 10.1016/S0006-3495(02)75650-6; Kumagai K, 2005, J BIOL CHEM, V280, P6488, DOI 10.1074/jbc.M409290200; Lafuente MJ, 2003, EMBO J, V22, P4689, DOI 10.1093/emboj/cdg460; Lange S, 1997, J BIOL CHEM, V272, P20884, DOI 10.1074/jbc.272.33.20884; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; Le Good JA, 2004, BIOCHEM J, V378, P83, DOI 10.1042/BJ20031194; LEE MH, 1986, J BIOL CHEM, V261, P4867; LEE MH, 1989, J BIOL CHEM, V264, P14797; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mora M, 2000, LIPIDS, V35, P513, DOI 10.1007/s11745-000-551-9; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Petrache I, 2005, NAT MED, V11, P491, DOI 10.1038/nm1238; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Simon CG, 1999, BIOCHEMISTRY-US, V38, P14676, DOI 10.1021/bi991537w; Sun RH, 2005, CANCER RES, V65, P1433, DOI 10.1158/0008-5472.CAN-04-1163; Suzuki A, 2003, J BIOCHEM, V133, P9, DOI 10.1093/jb/mvg018; Tang SH, 1998, DIABETES, V47, P905, DOI 10.2337/diabetes.47.6.905; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; van Blitterswijk WJ, 1998, BIOCHEM J, V331, P679; van der Hoeven PCJ, 2000, BIOCHEM J, V347, P781, DOI 10.1042/0264-6021:3470781; Vance JE, 2003, PROG NUCLEIC ACID RE, V75, P69, DOI 10.1016/S0079-6603(03)75003-X; Vielhaber G, 2001, GLYCOBIOLOGY, V11, P451, DOI 10.1093/glycob/11.6.451; WANG XJ, 1993, J CANCER RES CLIN, V119, P279, DOI 10.1007/BF01212726; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0	56	121	127	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26415	26424		10.1074/jbc.M501492200	http://dx.doi.org/10.1074/jbc.M501492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901738	hybrid			2022-12-25	WOS:000230386800057
J	Schild, S; Lamprecht, AK; Reidl, J				Schild, S; Lamprecht, AK; Reidl, J			Molecular and functional characterization of O antigen transfer in Vibrio cholerae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STRUCTURAL-ANALYSIS; OUTER-MEMBRANE; SALMONELLA-TYPHIMURIUM; POLYACRYLAMIDE GELS; INTESTINAL COLONIZATION; VIRULENCE DETERMINANTS; HELICOBACTER-PYLORI; DNA-SEQUENCE; CORE REGION	The majority of Gram-negative bacteria transfer O antigen polysaccharides ontothe lipid A-core oligosaccharide via the action of surface polymer: lipid A-core ligases (WaaL). Here, we characterize the WaaL proteins of Vibrio choleraewith emphasis on structural and functional characterization of O antigen transfer and core oligosaccharide recognition. We demonstrate that the activity oftwo distantly related O antigen ligases is dependent on the presence of N-acetylglucosamine, and substitution of an additional sugar, i. e. galactose, alters the site specificity of the core oligosaccharide necessitating discriminative WaaL types. Protein topology analysis and a conserved domain search identified two distinct conserved motifs in the periplasmic domains of WaaL proteins.Site-directed mutagenesis of the two motifs, shown for WaaLs of V. cholerae and Salmonella enterica, caused a loss of O antigen transfer activity. Moreover, analogy of topology and motifs between WaaLs and O polysaccharide polymerases (Wzy) reveals a relationship between the two protein families, suggesting that the catalyzed reactions are related to each other.	Univ Wurzburg, Inst Hyg & Mikrobiol, D-97080 Wurzburg, Germany	University of Wurzburg	Reidl, J (corresponding author), Univ Wurzburg, Inst Hyg & Mikrobiol, Josef Schneider Str 2,E1, D-97080 Wurzburg, Germany.	joachim.reidl@mail.uni-wuerzburg.de	Reidl, Joachim/O-2107-2016	Reidl, Joachim/0000-0001-5798-9524; Schild, Stefan/0000-0001-7842-0177				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; Amor K, 2000, INFECT IMMUN, V68, P1116, DOI 10.1128/IAI.68.3.1116-1124.2000; BARONDESS JJ, 1990, NATURE, V346, P871, DOI 10.1038/346871a0; BOCK K, 1994, EUR J BIOCHEM, V225, P1029, DOI 10.1111/j.1432-1033.1994.1029b.x; Boyd EF, 1996, APPL ENVIRON MICROB, V62, P804, DOI 10.1128/AEM.62.3.804-808.1996; Chiang SL, 1999, INFECT IMMUN, V67, P976, DOI 10.1128/IAI.67.2.976-980.1999; Correa NE, 2000, MOL MICROBIOL, V35, P743, DOI 10.1046/j.1365-2958.2000.01745.x; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Cox AD, 1996, CARBOHYD RES, V290, P59, DOI 10.1016/0008-6215(96)00131-0; Cox AD, 1997, CARBOHYD RES, V304, P191, DOI 10.1016/S0008-6215(97)00207-3; Cox AD, 1996, CARBOHYD RES, V290, P43, DOI 10.1016/0008-6215(96)00135-8; Daniels C, 1998, MOL MICROBIOL, V28, P1211, DOI 10.1046/j.1365-2958.1998.00884.x; Edwards NJ, 2000, MOL MICROBIOL, V35, P1530, DOI 10.1046/j.1365-2958.2000.01823.x; Faruque SM, 1998, MICROBIOL MOL BIOL R, V62, P1301, DOI 10.1128/MMBR.62.4.1301-1314.1998; GRIMBERG J, 1989, NUCLEIC ACIDS RES, V17, P8893, DOI 10.1093/nar/17.21.8893; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Harvey HA, 2001, J AUTOIMMUN, V16, P257, DOI 10.1006/jaut.2000.0477; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Heinrichs DE, 1998, J BIOL CHEM, V273, P8849, DOI 10.1074/jbc.273.15.8849; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Iredell JR, 1998, FEMS IMMUNOL MED MIC, V20, P45, DOI 10.1016/S0928-8244(97)00106-5; KAMIO Y, 1976, BIOCHEMISTRY-US, V15, P2561, DOI 10.1021/bi00657a012; KENNE L, 1982, CARBOHYD RES, V100, P341, DOI 10.1016/S0008-6215(00)81047-2; Knirel YA, 1997, EUR J BIOCHEM, V247, P402, DOI 10.1111/j.1432-1033.1997.00402.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLACHLAN PR, 1991, J BACTERIOL, V173, P7151, DOI 10.1128/jb.173.22.7151-7163.1991; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Moran AP, 1999, J PHYSIOL PHARMACOL, V50, P787; MULFORD CA, 1983, P NATL ACAD SCI-BIOL, V80, P1159, DOI 10.1073/pnas.80.5.1159; Nesper J, 2000, J BACTERIOL, V182, P5097, DOI 10.1128/JB.182.18.5097-5104.2000; Nesper J, 2002, INFECT IMMUN, V70, P5990, DOI 10.1128/IAI.70.11.5990-5996.2002; Nesper J, 2002, INFECT IMMUN, V70, P2419, DOI 10.1128/IAI.70.5.2419-2433.2002; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Paton AW, 1998, MICROB PATHOGENESIS, V24, P57, DOI 10.1006/mpat.1997.0172; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Reidl J, 2002, FEMS MICROBIOL REV, V26, P125, DOI 10.1111/j.1574-6976.2002.tb00605.x; RICHARDS FM, 1971, ENZYMES, V4, P647; SCHILD S, 2005, IN PRESS INT J MED M; SCHMIDT G, 1970, EUR J BIOCHEM, V16, P382, DOI 10.1111/j.1432-1033.1970.tb01092.x; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Terrak M, 1999, MOL MICROBIOL, V34, P350, DOI 10.1046/j.1365-2958.1999.01612.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VINOGRADOV EV, 1995, EUR J BIOCHEM, V233, P152, DOI 10.1111/j.1432-1033.1995.152_1.x; WALDOR MK, 1994, P NATL ACAD SCI USA, V91, P11388, DOI 10.1073/pnas.91.24.11388; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; Yethon J. A., 2001, Current Drug Targets - Infectious Disorders, V1, P91, DOI 10.2174/1568005014606143	53	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25936	25947		10.1074/jbc.M501259200	http://dx.doi.org/10.1074/jbc.M501259200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15908430	hybrid			2022-12-25	WOS:000230207900075
J	Ortega-Gutierrez, S; Molina-Holgado, E; Arevalo-Martin, A; Correa, F; Viso, A; Lopez-Rodriguez, ML; Di Marzo, V; Guaza, C				Ortega-Gutierrez, S; Molina-Holgado, E; Arevalo-Martin, A; Correa, F; Viso, A; Lopez-Rodriguez, ML; Di Marzo, V; Guaza, C			Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis	FASEB JOURNAL			English	Article						Theiler's virus; anandamide; microglia; MS; UCM707	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NITRIC-OXIDE SYNTHASE; CANNABINOID RECEPTORS; CONTROL SPASTICITY; ANIMAL-MODEL; VIRAL MODEL; EXPRESSION; ANANDAMIDE; INHIBITORS	Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) is a well-characterized murine model of human multiple sclerosis ( MS) that closely resembles the chronic and progressive clinical form of the disease. Recent studies have described the involvement of the cannabinoid system in the progression of the disease and the benefits associated with the administration of cannabinoid agonists. With the objective to study whether "indirect" agonists, that is, compounds able to reinforce the physiological endocannabinoid transmission and, therefore, devoid of the psychotropic effects of "direct" agonists, could be suitable agents for the amelioration of MS neurological deficits, we administered the potent and selective anandamide uptake inhibitor UCM707 to TMEV-infected mice. Our results indicate that treatment during established disease significantly improves the motor function of the diseased mice. At the histological level, UCM707 is able to reduce microglial activation, diminish major histocompatibility complex class II antigen expression, and decrease cellular infiltrates in the spinal cord. Additionally, in microglial cells, UCM707 decreases the production of the proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, and IL- 6; reduces nitric oxide levels and inducible nitric oxide synthase expression; and is able to potentiate the action of a subeffective dose of the endocannabinoid anandamide. Overall, these results suggest that agents able to activate the endocannabinoid system could constitute a new series of drugs for the treatment of MS.	CSIC, Inst Cajal, Neural Plastic Dept, Neuroimmunol Grp, E-28002 Madrid, Spain; Univ Complutense, Dept Quim Organ 1, E-28040 Madrid, Spain; Hosp Nacl Paraplej, Neuroinflammat Grp, Toledo, OH USA; CSIC, Inst Quim Organ Gen, E-28006 Madrid, Spain; CNR, Ist Chim Biomol, I-80078 Pozzuoli, NA, Italy	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Guaza, C (corresponding author), CSIC, Inst Cajal, Neural Plastic Dept, Neuroimmunol Grp, Plaza Murillo 2, E-28002 Madrid, Spain.	cgjb@cajal.csic.es	viso, alma/AAN-6044-2020; Arevalo-Martin, Angel/C-1597-2008; Molina-Holgado, Eduardo/C-2714-2008; Ortega-Gutierrez, Silvia/I-1935-2017; Viso, Alma/AAA-4971-2020; Ortega-Gutierrez, Silvia/ABC-7653-2021; Arevalo-Martin, Angel/A-5376-2011; Lopez-Rodriguez, Maria L/S-6342-2016; Di Marzo, Vincenzo/AAD-7742-2019	Molina-Holgado, Eduardo/0000-0001-6693-1682; Ortega-Gutierrez, Silvia/0000-0002-0257-6754; Viso, Alma/0000-0003-2622-4777; Lopez-Rodriguez, Maria L/0000-0001-8607-1085; Di Marzo, Vincenzo/0000-0002-1490-3070; Arevalo-Martin, Angel/0000-0002-0549-6098				Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Becher B, 2000, GLIA, V29, P293; Berrendero F, 2001, SYNAPSE, V41, P195, DOI 10.1002/syn.1075; Biswas KK, 2003, HEPATOLOGY, V38, P1167, DOI 10.1053/jhep.2003.50459; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; DALCANTO MC, 1977, AM J PATHOL, V88, P497; de Lago E, 2004, EUR J PHARMACOL, V484, P249, DOI 10.1016/j.ejphar.2003.11.027; de Lago E, 2002, EUR J PHARMACOL, V449, P99, DOI 10.1016/S0014-2999(02)01996-9; Di Marzo V, 2000, TRENDS PHARMACOL SCI, V21, P195, DOI 10.1016/S0165-6147(00)01487-5; Di Marzo V, 2001, TRENDS PHARMACOL SCI, V22, P346, DOI 10.1016/S0165-6147(00)01712-0; Goodin DS, 2002, NEUROLOGY, V58, P169, DOI 10.1212/WNL.58.2.169; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Iwahashi T, 1999, CELL IMMUNOL, V194, P186, DOI 10.1006/cimm.1999.1482; Katz-Levy Y, 1999, J CLIN INVEST, V104, P599, DOI 10.1172/JCI7292; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lopez-Rodriguez ML, 2003, J MED CHEM, V46, P1512, DOI 10.1021/jm0210818; LYMAN WD, 1989, J NEUROIMMUNOL, V23, P73, DOI 10.1016/0165-5728(89)90075-1; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; McGavern DB, 1999, EXP NEUROL, V158, P171, DOI 10.1006/exnr.1999.7082; McGavern DB, 2000, BRAIN, V123, P519, DOI 10.1093/brain/123.3.519; Mestre L, 2005, J NEUROCHEM, V92, P1327, DOI 10.1111/j.1471-4159.2004.02979.x; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Molina-Holgado E, 2001, EUR J NEUROSCI, V13, P493, DOI 10.1046/j.0953-816x.2000.01412.x; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; OKUDA Y, 1995, J NEUROIMMUNOL, V62, P103, DOI 10.1016/0165-5728(95)00114-H; Ortar G, 2003, BIOCHEM PHARMACOL, V65, P1473, DOI 10.1016/S0006-2952(03)00109-6; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224; Ruiz L, 1999, FEBS LETT, V458, P400, DOI 10.1016/S0014-5793(99)01073-X; Sato S, 1997, J NEUROIMMUNOL, V76, P213, DOI 10.1016/S0165-5728(97)00059-3; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; Wiendl H, 2002, BIODRUGS, V16, P183, DOI 10.2165/00063030-200216030-00003; WIRGUIN I, 1994, IMMUNOPHARMACOLOGY, V28, P209, DOI 10.1016/0162-3109(94)90056-6; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	37	110	113	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1338	+		10.1096/fj.04-2464fje	http://dx.doi.org/10.1096/fj.04-2464fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15941768				2022-12-25	WOS:000230207800028
J	Bonomi, F; Iametti, S; Ta, D; Vickery, LE				Bonomi, F; Iametti, S; Ta, D; Vickery, LE			Multiple turnover transfer of [2Fe2S] clusters by the iron-sulfur cluster assembly scaffold proteins IscU and IscA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOTOGA-MARITIMA ISCU; CRYSTAL-STRUCTURE; 2FE-2S CLUSTER; MOLYBDENUM COFACTOR; KINETIC-ANALYSIS; BIOSYNTHESIS; ADRENODOXIN; BIOGENESIS; SUBSTRATE; DYNAMICS	IscU/Isu and IscA/Isa (and related NifU and SufA proteins) have been proposed to serve as molecular scaffolds for preassembly of [FeS] clusters to be used in the biogenesis of iron-sulfur proteins. In vitro studies demonstrating transfer of preformed scaffold-[FeS] complexes to apoprotein acceptors have provided experimental support for this hypothesis, but investigations to date have yielded only single-cluster transfer events. We describe an in vitro assay system that allows for real-time monitoring of [ FeS] cluster formation using circular dichroism spectroscopy and use this to investigate de novo [FeS] cluster formation and transfer from Escherichia coli IscU and IscA to apo-ferredoxin. Both IscU and IscA were found to be capable of multiple cycles of [2Fe2S] cluster formation and transfer suggesting that these scaffold proteins are capable of acting "catalytically." Kinetic studies further showed that cluster transfer exhibits Michaelis-Menten behavior indicative of complex formation of holo-IscU and holo-IscA with apoferredoxin and consistent with a direct [FeS] cluster transfer mechanism. Analysis of the dependence of the rate of cluster transfer, however, revealed enhanced efficiency at low ratios of scaffold to acceptor protein suggesting participation of a transient, labile scaffold-[FeS] species in the transfer process.	Univ Milan, DISMA, Biochem Sect, I-20133 Milan, Italy; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of Milan; University of California System; University of California Irvine	Bonomi, F (corresponding author), Univ Milan, DISMA, Biochem Sect, Via Celoria 2, I-20133 Milan, Italy.	francesco.bonomi@unimi.it; lvickery@uci.edu	Iametti, Stefania/AGY-9694-2022	Iametti, Stefania/0000-0002-4159-3768; Bonomi, Francesco/0000-0003-4556-2640	NIGMS NIH HHS [GM54264] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Bertini I, 2003, J MOL BIOL, V331, P907, DOI 10.1016/S0022-2836(03)00768-X; Bilder PW, 2004, BIOCHEMISTRY-US, V43, P133, DOI 10.1021/bi035440s; Cupp-Vickery JR, 2004, J MOL BIOL, V338, P127, DOI 10.1016/j.jmb.2004.02.027; DEAN DR, 1985, P NATL ACAD SCI USA, V82, P5720, DOI 10.1073/pnas.82.17.5720; Ding H, 2004, J BIOL CHEM, V279, P37499, DOI 10.1074/jbc.M404533200; Ding HG, 2004, BIOCHEM J, V379, P433, DOI 10.1042/BJ20031702; Dos Santos PC, 2004, J BIOL CHEM, V279, P19705, DOI 10.1074/jbc.M400278200; Dutkiewicz R, 2004, J BIOL CHEM, V279, P29167, DOI 10.1074/jbc.M402947200; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Iametti S, 2001, EUR J BIOCHEM, V268, P2421, DOI 10.1046/j.1432-1327.2001.02130.x; Kakuta Y, 2001, BIOCHEMISTRY-US, V40, P11007, DOI 10.1021/bi010544t; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Mansy SS, 2004, ACCOUNTS CHEM RES, V37, P719, DOI 10.1021/ar0301781; Mansy SS, 2004, J BIOL CHEM, V279, P10469, DOI 10.1074/jbc.M312051200; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Ollagnier-de-Choudens S, 2004, J BIOL INORG CHEM, V9, P828, DOI 10.1007/s00775-004-0581-9; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Ramelot TA, 2004, J MOL BIOL, V344, P567, DOI 10.1016/j.jmb.2004.08.038; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; Silberg JJ, 2004, J BIOL CHEM, V279, P53924, DOI 10.1074/jbc.M410117200; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; TA DT, 1992, J BIOL CHEM, V267, P11120; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Wollenberg M, 2003, EUR J BIOCHEM, V270, P1662, DOI 10.1046/j.1432-1033.2003.03522.x; Wu G, 2002, BIOCHEMISTRY-US, V41, P5024, DOI 10.1021/bi016073s; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Wu SP, 2005, BIOCHEMISTRY-US, V44, P4284, DOI 10.1021/bi0483007; Wu SP, 2003, BIOCHEMISTRY-US, V42, P5784, DOI 10.1021/bi026939+; Wu SP, 2002, BIOCHEMISTRY-US, V41, P8876, DOI 10.1021/bi0256781; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599	38	57	59	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29513	29518		10.1074/jbc.M504344200	http://dx.doi.org/10.1074/jbc.M504344200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15964837	Green Published, hybrid			2022-12-25	WOS:000231176200017
J	Keen, JC; Zhou, Q; Park, BH; Pettit, C; Mack, KM; Blair, B; Brenner, K; Davidson, NE				Keen, JC; Zhou, Q; Park, BH; Pettit, C; Mack, KM; Blair, B; Brenner, K; Davidson, NE			Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; BREAST-CANCER CELLS; HISTONE DEACETYLASE INHIBITION; GENE-EXPRESSION; ACTIVATION; CARCINOMA; APOPTOSIS; PP2A; SP1; DEPHOSPHORYLATION	Protein phosphatase 2A (PP2A) is a ubiquitously expressed member of the serine-threonine phosphatase family that is involved in regulation of many cellular processes including transcription, translation, cellular metabolism, and apoptosis. Because of a correlation between PP2A and estrogen receptor alpha ( ER) expression in several human breast cancer cell lines, the effect of PP2A on regulation of ER expression in the human breast cancer cell line MCF-7 was studied. Inhibition of PP2A using the pharmacologic inhibitor okadaic acid at 250 nM for 16 h resulted in a 60% reduction in PP2A activity in MCF-7 cells concurrent with a 75% reduction in ER mRNA and protein expression. Similar results were obtained with a small interfering RNA probe that specifically inhibited PP2A expression. ER promoter studies showed that regulation of ER through the PP2A pathway did not occur through transcriptional activation. Rather, PP2A mediated ER expression through modulation of ER mRNA stability through degradation of ER mRNA, reversible with concomitant treatment with the proteasomal inhibitor MG 132. These data suggest a novel pathway controlling ER expression resulting from the activation of PP2A, potentially providing a novel therapeutic target.	Sidney Kimmel Comprehens Canc Ctr Johsn Hopkins, Baltimore, MD 21231 USA; Univ Maryland Eastern Shore, Dept Nat Sci, Princess Anne, MD 21853 USA	Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Eastern Shore	Davidson, NE (corresponding author), Sidney Kimmel Comprehens Canc Ctr Johsn Hopkins, 1650 Orleans St,CRB Rm 409, Baltimore, MD 21231 USA.	davidna@jhmi.edu		Keen, Judith/0000-0002-2894-130X	NCI NIH HHS [CA88843] Funding Source: Medline; NIGMS NIH HHS [GM63673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA088843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Cuisset L, 1998, BIOCHEM BIOPH RES CO, V246, P760, DOI 10.1006/bbrc.1998.8698; deGraffenried LA, 2004, BREAST CANCER RES TR, V85, P111, DOI 10.1023/B:BREA.0000025398.93829.78; deGraffenried LA, 2002, J STEROID BIOCHEM, V82, P7, DOI 10.1016/S0960-0760(02)00151-6; Farhana L, 2000, CELL GROWTH DIFFER, V11, P541; FERGUSON AT, 1995, CANCER RES, V55, P2279; Galasinski SC, 2002, J BIOL CHEM, V277, P2579, DOI 10.1074/jbc.M107894200; Gopalakrishna R, 1999, CANCER LETT, V136, P143, DOI 10.1016/S0304-3835(98)00315-2; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126; Keen JC, 2004, CANCER BIOL THER, V3, P1304, DOI 10.4161/cbt.3.12.1458; Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737; Keen JC, 2001, AM J RESP CELL MOL, V24, P58, DOI 10.1165/ajrcmb.24.1.3870; Kenealy MR, 1996, BIOCHEM SOC T, V24, pS107, DOI 10.1042/bst024107s; Kenealy MR, 2000, ENDOCRINOLOGY, V141, P2805, DOI 10.1210/en.141.8.2805; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; Lacroix I, 2002, J BIOL CHEM, V277, P9598, DOI 10.1074/jbc.M111444200; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Lee T, 2003, J CELL PHYSIOL, V194, P349, DOI 10.1002/jcp.10211; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; MARTIN MB, 1993, ADV EXP MED BIOL, V330, P143; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mishra SK, 2001, FEBS LETT, V507, P88, DOI 10.1016/S0014-5793(01)02951-9; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Sundaresan P, 2002, FEBS LETT, V528, P139, DOI 10.1016/S0014-5793(02)03277-5; Tamaki M, 2004, ONCOL REP, V11, P655; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	38	34	35	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29519	29524		10.1074/jbc.M505317200	http://dx.doi.org/10.1074/jbc.M505317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15965230	hybrid			2022-12-25	WOS:000231176200018
J	Mack, JA; Li, L; Sato, N; Hascall, VC; Maytin, EV				Mack, JA; Li, L; Sato, N; Hascall, VC; Maytin, EV			Hoxb13 up-regulates transglutaminase activity and drives terminal differentiation in an epidermal organotypic model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS C/EBP; CORNIFIED CELL ENVELOPES; PROSTATE-CANCER CELLS; HOMEODOMAIN PROTEIN; SKIN DEVELOPMENT; HOMEOBOX GENES; TUMOR-SUPPRESSOR; IN-VIVO; KERATINOCYTE; EXPRESSION	Hox genes act to differentiate and pattern embryonic structures by promoting the proliferation of specific cell types. An exception is Hoxb13, which functions as a proapoptotic and antiproliferative protein during development of the caudal spinal cord and tail vertebrae and has also been implicated in adult cutaneous wound repair. The adult epidermis, which expresses several Hox genes including Hoxb13, is continually renewed in a program of growth arrest, differentiation, and a specialized form of apoptosis ( cornification). Yet little is known about the function(s) of these genes in skin. Based on its role during embryogenesis, Hoxb13 is an attractive candidate to be involved in the regulation of epidermal differentiation. Here, we demonstrate that Hoxb13 overexpression in an adult organotypic epidermal model recapitulates actions of Hoxb13 reported in embryonic development. Epidermal cell proliferation is decreased, apoptosis increased, and excessive terminal differentiation observed, as characterized by enhanced transglutaminase activity and excessive cornified envelope formation. Overexpression of Hoxb13 also produces abnormal phenotypes in the epidermal tissue that resemble certain pathological features of dysplastic skin diseases. Our results suggest that Hoxb13 functions to promote epidermal differentiation, a critical process for skin regeneration and for the maintenance of normal barrier function.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Dermatol, Cleveland, OH 44195 USA; Nova SE Univ, Coll Dent Med, Ft Lauderdale, FL 33328 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Nova Southeastern University	Mack, JA (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave,ND-20, Cleveland, OH 44195 USA.	mackj@ccf.org			NATIONAL CANCER INSTITUTE [P01CA084203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049249, K01AR051076] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA84203-4] Funding Source: Medline; NIAMS NIH HHS [R01 AR049249-01, K01 AR51076-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDO Y, 1988, ARCH DERMATOL RES, V280, P380, DOI 10.1007/BF00426618; Chang PY, 1998, BIOCHEM BIOPH RES CO, V248, P749, DOI 10.1006/bbrc.1998.9076; Duboule D, 1998, GENE DEV, V12, P1, DOI 10.1101/gad.12.1.1; Duvic M, 2000, CLIN CANCER RES, V6, P3249; Eckert RL, 2005, J INVEST DERMATOL, V124, P481, DOI 10.1111/j.0022-202X.2005.23627.x; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Economides KD, 2003, DEVELOPMENT, V130, P2061, DOI 10.1242/dev.00432; Economides KD, 2003, DEV BIOL, V256, P317, DOI 10.1016/S0012-1606(02)00137-9; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; FUKUYAMA K, 1984, ANAT RECORD, V208, P357, DOI 10.1002/ar.1092080306; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; HENNINGS H, 1981, BIOCHEM BIOPH RES CO, V102, P739, DOI 10.1016/S0006-291X(81)80194-5; Jarnik M, 2002, J INVEST DERMATOL, V118, P102, DOI 10.1046/j.0022-202x.2001.01661.x; Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330; Jung CY, 2004, CANCER RES, V64, P3046, DOI 10.1158/0008-5472.CAN-03-2614; Kawashima K, 2004, J DERMATOL SCI, V35, P207, DOI 10.1016/j.jdermsci.2004.05.008; Kim SY, 1998, EXP MOL MED, V30, P257, DOI 10.1038/emm.1998.38; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; Kirkham Nigel, 1997, P685; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; Komuves LG, 2000, DEV DYNAM, V218, P636; Komuves LG, 2003, DEV DYNAM, V227, P192, DOI 10.1002/dvdy.10290; Komuves LG, 2002, DEV DYNAM, V224, P58, DOI 10.1002/dvdy.10085; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; La Celle PT, 2001, J BIOL CHEM, V276, P32844, DOI 10.1074/jbc.M104598200; LILLIE JH, 1980, EXP CELL RES, V125, P153, DOI 10.1016/0014-4827(80)90199-8; Mack JA, 2003, FASEB J, V17, P1352, DOI 10.1096/fj.02-0959fje; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; MANAK JR, 1994, DEVELOPMENT, P61; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Martinez P, 2002, COMP BIOCHEM PHYS B, V133, P571, DOI 10.1016/S1096-4959(02)00121-5; Maytin EV, 1999, DEV BIOL, V216, P164, DOI 10.1006/dbio.1999.9460; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Maytin EV, 2004, AM J PATHOL, V165, P1331, DOI 10.1016/S0002-9440(10)63391-3; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; OGAWA H, 1976, J BIOL CHEM, V251, P7281; Passi A, 2004, EXP CELL RES, V296, P123, DOI 10.1016/j.yexer.2004.01.031; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; SCOTT GA, 1993, J INVEST DERMATOL, V101, P3, DOI 10.1111/1523-1747.ep12358258; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sreenath T, 1999, PROSTATE, V41, P203, DOI 10.1002/(SICI)1097-0045(19991101)41:3<203::AID-PROS8>3.0.CO;2-J; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; Stelnicki EJ, 1998, J INVEST DERMATOL, V110, P110, DOI 10.1046/j.1523-1747.1998.00092.x; Stelnicki EJ, 1998, J INVEST DERMATOL, V111, P57, DOI 10.1046/j.1523-1747.1998.00238.x; STEVEN AC, 1994, J CELL SCI, V107, P693; Sturniolo MT, 2003, J BIOL CHEM, V278, P48066, DOI 10.1074/jbc.M307215200; Tammi RH, 2000, HISTOCHEM CELL BIOL, V113, P265, DOI 10.1007/s004180000128; Toussaint Sonia, 1997, P151; WIER KA, 1971, J ULTRA MOL STRUCT R, V37, P138, DOI 10.1016/S0022-5320(71)80046-1; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	53	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29904	29911		10.1074/jbc.M505262200	http://dx.doi.org/10.1074/jbc.M505262200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15964834	hybrid			2022-12-25	WOS:000231176200062
J	Knieszner, H; Schilke, B; Dutkiewicz, R; D'Silva, P; Cheng, S; Ohlson, M; Craig, EA; Marszalek, J				Knieszner, H; Schilke, B; Dutkiewicz, R; D'Silva, P; Cheng, S; Ohlson, M; Craig, EA; Marszalek, J			Compensation for a defective interaction of the Hsp70 Ssq1 with the mitochondrial Fe-S cluster scaffold Isu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE SYSTEM; ASSEMBLY PROTEIN ISCU; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; IRON-METABOLISM; DNAK CHAPERONE; MECHANISM; BIOGENESIS; BINDING	Ssq1, a specialized yeast mitochondrial Hsp70, plays a critical role in the biogenesis of proteins containing Fe-S clusters through its interaction with Isu, the scaffold on which clusters are built. Two substitutions within the Ssq1 substrate binding cleft, both of which severely reduced affinity for Isu, had very different effects in vivo. Cells expressing Ssq1(F462S), which had no detectable affinity for Isu, are indistinguishable from Delta ssq1 cells, underscoring the importance of the Ssq1Isu1 interaction in vivo. In contrast, cells expressing Ssq1(V472F), whose affinity for Isu is at least 10-fold lower than that of wild-type Ssq1, had only moderately reduced Fe-S enzyme activities and increased iron levels and grew similarly to wild-type cells. Consistent with the reduced affinity for Isu, the ATPase activity of Ssq1(V472F) was stimulated less well than that of Ssq1 upon addition of Isu and Jac1, the J-protein partner of Ssq1. However, higher concentrations of Jac1 or Isu1, which form a stable complex, could compensate for this defect in stimulation of Ssq1( V472F). Expression of Isu1 was up-regulated 10-fold in ssq1( V472F) compared with wild-type cells, suggesting that formation of a Jac1-Isu1 complex can overcome a lowered affinity of Ssq1 for Isu in vivo as well as in vitro.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	University of Wisconsin System; University of Wisconsin Madison; Fahrenheit Universities; University of Gdansk	Craig, EA (corresponding author), Univ Wisconsin, Dept Biochem, 441E Biochem Addict,433 Babcock Dr, Madison, WI 53706 USA.	ecraig@wisc.edu	D'Silva, Patrick/L-6653-2019; Marszalek, Jaroslaw/F-5824-2011; Dutkiewicz, Rafal/ABE-6979-2020; Dutkiewicz, Rafal/F-5956-2011	Dutkiewicz, Rafal/0000-0003-4150-0450; Marszalek, Jaroslaw/0000-0002-6978-1189; Ohlson, Maikke/0000-0002-1055-2269	NCRR NIH HHS [S10 RR13790] Funding Source: Medline; NIGMS NIH HHS [R01GM27870] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Craig EA, 1999, BIOL CHEM, V380, P1167, DOI 10.1515/BC.1999.148; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Dutkiewicz R, 2004, J BIOL CHEM, V279, P29167, DOI 10.1074/jbc.M402947200; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Mansy SS, 2004, ACCOUNTS CHEM RES, V37, P719, DOI 10.1021/ar0301781; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Ramelot TA, 2004, J MOL BIOL, V344, P567, DOI 10.1016/j.jmb.2004.08.038; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WATSON K, 1975, BIOCHEM J, V146, P401, DOI 10.1042/bj1460401; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0	33	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28966	28972		10.1074/jbc.M503031200	http://dx.doi.org/10.1074/jbc.M503031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15958384	hybrid			2022-12-25	WOS:000231021300018
J	Liu, YZ; Dvornyk, V; Lu, Y; Shen, H; Lappe, JM; Recker, RR; Deng, HW				Liu, YZ; Dvornyk, V; Lu, Y; Shen, H; Lappe, JM; Recker, RR; Deng, HW			A novel pathophysiological mechanism for osteoporosis suggested by an in vivo gene expression study of circulating monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOCLAST FORMATION; CHEMOATTRACTANT PROTEIN-1; BLOOD MONOCYTES; BONE LOSS; HISTAMINE; BIOLOGY; MONOCYTES/MACROPHAGES; DIFFERENTIATION; INFLAMMATION; POLYMORPHISM	Bone mineral density (BMD) is a major risk factor for osteoporosis. Circulating monocytes may serve as early progenitors of osteoclasts and produce a wide variety of factors important to bone metabolism. However, little is known about the roles of circulating monocytes in relation to the pathophysiology of osteoporosis. Using the Affymetrix HG-U133A GeneChip (R) array, we performed a comparative gene expression study of circulating monocytes in subjects with high and low BMD. We identified in total 66 differentially expressed genes including some novel as well as some already known to be relevant to bone metabolism. Three genes potentially contributing to bone metabolism, CCR3 (chemokine receptor 3), HDC ( histidine decarboxylase, i.e. the histamine synthesis enzyme), and GCR ( glucocorticoid receptor), were confirmed by quantitative real-time reverse transcriptase-PCR as up-regulated in subjects with lower BMD. In addition, significant negative correlation was observed between expression levels of the genes and BMD Z-scores. These three genes and/or their products mediate monocyte chemotaxis, histamine production, and/or sensitivity to glucocorticoids. Our results suggest a novel pathophysiological mechanism for osteoporosis that is characterized by increased recruitment of circulating monocyte into bone, enhanced monocyte differentiation into osteoclasts, as well as osteoclast stimulation via monocyte functional changes. This is the first in vivo microarray study of osteoporosis in humans. The results may contribute to identification of new genes and their functions for osteoporosis and suggest genetic markers to discern individuals at higher risk to osteoporosis with an aim for preventive intervention and treatment.	Creighton Univ, Med Ctr, Osteoporosis Res Ctr, Omaha, NE 68131 USA; Creighton Univ, Dept Biomed Sci, Omaha, NE 68131 USA; Xi An Jiao Tong Univ, Sch Life Sci & Technol, Inst Genet Mol, Xian 710049, Peoples R China; Minist Educ, Key Lab Biomed Informat & Engn, Xian 710049, Peoples R China; Hunan Normal Univ, Coll Life Sci, Lab Mol & Stat Genet, Changsha, Hunan, Peoples R China; Kent State Univ, Dept Biol Sci, Kent, OH 44242 USA	Creighton University; Creighton University; Xi'an Jiaotong University; Hunan Normal University; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem	Deng, HW (corresponding author), Creighton Univ, Med Ctr, Osteoporosis Res Ctr, 601 N 30th St,Ste 6787, Omaha, NE 68131 USA.	deng@creighton.edu	Dvornyk, Volodymyr/C-6031-2008; Liu, Yaozhong/ABD-5544-2020; Dvornyk, Volodymyr/X-6072-2019	Dvornyk, Volodymyr/0000-0002-2535-103X; Deng, Hong-Wen/0000-0002-0387-8818	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002170, R01AR045349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060402] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR45349-01, K01 AR02170-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM60402-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*AFF INC, 2002, GEN EXPR AN TECHN MA; *APPL BIOS, 2004, 127AP0502 APPL BIOS; Beaulieu S, 2002, J IMMUNOL, V169, P2925, DOI 10.4049/jimmunol.169.6.2925; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blair HC, 2004, HISTOL HISTOPATHOL, V19, P189, DOI 10.14670/HH-19.189; BLOOM W, 1975, TXB HIST, P153; Boyce BF, 1999, LAB INVEST, V79, P83; Campbell IA, 2004, THORAX, V59, P761, DOI 10.1136/thx.2003.013839; Cohen-Solal ME, 1998, J CLIN ENDOCR METAB, V83, P1687, DOI 10.1210/jc.83.5.1687; Day CJ, 2004, J CELL BIOCHEM, V91, P303, DOI 10.1002/jcb.10780; DEGENNES C, 1992, CLIN ORTHOP RELAT R, V279, P281; Delsignore J L, 1996, Iowa Orthop J, V16, P126; Dobigny C, 1997, J CELL PHYSIOL, V173, P10, DOI 10.1002/(SICI)1097-4652(199710)173:1<10::AID-JCP2>3.3.CO;2-A; DVORNYK V, 2004, 54 ANN M AM SOC HUM, P307; Etienne W, 2004, BIOTECHNIQUES, V36, P618, DOI 10.2144/04364ST02; FALUS A, 1993, IMMUNOLOGY, V78, P193; Fitzpatrick LA, 2003, P NATL ACAD SCI USA, V100, P6027, DOI 10.1073/pnas.0934373100; Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Graves DT, 1999, FRONT BIOSCI, V4, P571; GRAVES L, 1990, J BONE MINER RES, V5, P1113, DOI 10.1002/jbmr.5650051104; Higuchi S, 2001, FEBS LETT, V505, P217, DOI 10.1016/S0014-5793(01)02823-X; Hirayama T, 2002, J ENDOCRINOL, V175, P155, DOI 10.1677/joe.0.1750155; Hodge JM, 2004, J BONE MINER RES, V19, P190, DOI 10.1359/JBMR.0301232; HORTON MA, 1994, BONE, V15, P639, DOI 10.1016/8756-3282(94)90312-3; Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P144, DOI 10.1210/jc.83.1.144; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jevon M, 2003, SCAND J RHEUMATOL, V32, P95, DOI 10.1080/03009740310000102; Kimura S, 2004, PATHOL INT, V54, P465, DOI 10.1111/j.1440-1827.2004.01653.x; Ko YG, 2001, J BIOL CHEM, V276, P23028, DOI 10.1074/jbc.M101544200; Kraft S, 2002, J INVEST DERMATOL, V118, P830, DOI 10.1046/j.1523-1747.2002.01757.x; Laszlo V, 2001, INFLAMM RES, V50, P428, DOI 10.1007/PL00000266; Lean JM, 2002, J CELL BIOCHEM, V87, P386, DOI 10.1002/jcb.10319; Lesclous P, 2004, BONE, V34, P91, DOI 10.1016/j.bone.2003.08.007; Lisignoli G, 2002, CYTOKINE, V20, P231, DOI 10.1006/cyto.2002.2006; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MOR S, 1995, J LEUKOCYTE BIOL, V58, P445, DOI 10.1002/jlb.58.4.445; Murdoch C, 2000, BLOOD, V95, P3032; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; Parfitt AM, 1998, BONE, V23, P491, DOI 10.1016/S8756-3282(98)00140-9; PERKINS SL, 1994, BONE, V15, P65, DOI 10.1016/8756-3282(94)90893-1; Quinn JMW, 1998, CALCIFIED TISSUE INT, V62, P527, DOI 10.1007/s002239900473; RAHIMI P, 1995, ENDOCRINOLOGY, V136, P2752, DOI 10.1210/en.136.6.2752; Sasaguri Yasuyuki, 2004, J Atheroscler Thromb, V11, P122; Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200; Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128; Tomkinson A, 1998, J BONE MINER RES, V13, P1243, DOI 10.1359/jbmr.1998.13.8.1243; TYAN ML, 1993, J INTERN MED, V234, P143, DOI 10.1111/j.1365-2796.1993.tb00723.x; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Volejnikova S, 1997, AM J PATHOL, V150, P1711; Wang KY, 2000, FEBS LETT, V473, P345, DOI 10.1016/S0014-5793(00)01560-X; Yamada Y, 2002, GENOMICS, V80, P8, DOI 10.1006/geno.2002.6793; ZALLONE AZ, 1984, J CELL SCI, V66, P335; Zwadlo-Klarwasser G, 1998, INFLAMM RES, V47, P434, DOI 10.1007/s000110050357	60	103	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29011	29016		10.1074/jbc.M501164200	http://dx.doi.org/10.1074/jbc.M501164200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15965235	hybrid			2022-12-25	WOS:000231021300024
J	Barzik, M; Kotova, TI; Higgs, HN; Hazelwood, L; Hanein, D; Gertler, FB; Schafer, DA				Barzik, M; Kotova, TI; Higgs, HN; Hazelwood, L; Hanein, D; Gertler, FB; Schafer, DA			Ena/VASP proteins enhance actin polymerization in the presence of barbed end capping proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; INTACT HUMAN PLATELETS; LISTERIA-MONOCYTOGENES; FOCAL ADHESION; IN-VITRO; INTRACELLULAR MOTILITY; KINASE PHOSPHORYLATION; NUCLEOTIDE EXCHANGE; MONOMERIC ACTIN; PROFILIN-ACTIN	Ena/VASP proteins influence the organization of actin filament networks within lamellipodia and filopodia of migrating cells and in actin comet tails. The molecular mechanisms by which Ena/ VASP proteins control actin dynamics are unknown. We investigated how Ena/ VASP proteins regulate actin polymerization at actin filament barbed ends in vitro in the presence and absence of barbed end capping proteins. Recombinant His-tagged VASP increased the rate of actin polymerization in the presence of the barbed end cappers, heterodimeric capping protein (CP), CapG, and gelsolin-actin complex. Profilin enhanced the ability of VASP to protect barbed ends from capping by CP, and this required interactions of profilin with G-actin and VASP. The VASP EVH2 domain was sufficient to protect barbed ends from capping, and the F-actin and G-actin binding motifs within EVH2 were required. Phosphorylation by protein kinase A at sites within the VASP EVH2 domain regulated anticapping and F-actin bundling by VASP. We propose that Ena/ VASP proteins associate at or near actin filament barbed ends, promote actin assembly, and restrict the access of barbed end capping proteins.	Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Burnham Inst, Cell Adhesion Program, La Jolla, CA 92037 USA	University of Virginia; Massachusetts Institute of Technology (MIT); Dartmouth College; Sanford Burnham Prebys Medical Discovery Institute	Schafer, DA (corresponding author), Univ Virginia, Dept Biol, Gilmer Hall, Charlottesville, VA 22903 USA.	das9w@virginia.edu	Barzik, Melanie/AAJ-9269-2021	Barzik, Melanie/0000-0003-3003-1281; Higgs, Henry/0000-0002-2917-9644	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058801, R01GM067222] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058801, R01 GM067222, GM067222, U54 GM646346, GM055801] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auerbuch V, 2003, MOL MICROBIOL, V49, P1361, DOI 10.1046/j.1365-2958.2003.03639.x; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Bearer EL, 2000, CELL MOTIL CYTOSKEL, V47, P351, DOI 10.1002/1097-0169(200012)47:4<351::AID-CM8>3.0.CO;2-8; BJORKEGREN C, 1993, FEBS LETT, V333, P123, DOI 10.1016/0014-5793(93)80388-B; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; BUTT E, 1994, J BIOL CHEM, V269, P14509; DINUBILE MJ, 1995, MOL BIOL CELL, V6, P1659, DOI 10.1091/mbc.6.12.1659; Domanski M, 2004, J BIOL CHEM, V279, P23637, DOI 10.1074/jbc.M311413200; DRENCKHAHN D, 1986, J BIOL CHEM, V261, P2754; Geese M, 2000, J CELL SCI, V113, P1415; Geese M, 2002, MOL BIOL CELL, V13, P2383, DOI 10.1091/mbc.E02-01-0058; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Grenklo S, 2003, EMBO REP, V4, P523, DOI 10.1038/sj.embor.embor823; Gutsche-Perelroizen I, 1999, J BIOL CHEM, V274, P6234, DOI 10.1074/jbc.274.10.6234; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; Han YH, 2002, J BIOL CHEM, V277, P49877, DOI 10.1074/jbc.M209107200; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Hertzog M, 2004, CELL, V117, P611, DOI 10.1016/S0092-8674(04)00403-9; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Klenchin VA, 2003, NAT STRUCT BIOL, V10, P1058, DOI 10.1038/nsb1006; Korenbaum E, 1998, BIOCHEMISTRY-US, V37, P9274, DOI 10.1021/bi9803675; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Kuhnel K, 2004, P NATL ACAD SCI USA, V101, P17027, DOI 10.1073/pnas.0403069101; Lambrechts A, 2000, J BIOL CHEM, V275, P36143, DOI 10.1074/jbc.M006274200; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lebrand C, 2004, NEURON, V42, P37, DOI 10.1016/S0896-6273(04)00108-4; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Loureiro JJ, 2002, MOL BIOL CELL, V13, P2533, DOI 10.1091/mbc.E01-10-0102; Lu J, 2001, MOL BIOL CELL, V12, P1161, DOI 10.1091/mbc.12.4.1161; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Mejillano MR, 2004, CELL, V118, P363, DOI 10.1016/j.cell.2004.07.019; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Owen CH, 1996, J STRUCT BIOL, V116, P167, DOI 10.1006/jsbi.1996.0027; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; Skoble J, 2001, J CELL BIOL, V155, P89, DOI 10.1083/jcb.200106061; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Smith JM, 1999, J STRUCT BIOL, V125, P223, DOI 10.1006/jsbi.1998.4073; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Tanaka J, 2003, P NATL ACAD SCI USA, V100, P13851, DOI 10.1073/pnas.2233339100; Walders-Harbeck B, 2002, FEBS LETT, V529, P275, DOI 10.1016/S0014-5793(02)03356-2; WALDMANN R, 1987, EUR J BIOCHEM, V167, P441, DOI 10.1111/j.1432-1033.1987.tb13357.x; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057; Zimmermann J, 2002, BIOCHEMISTRY-US, V41, P11143, DOI 10.1021/bi020379x	58	236	245	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28653	28662		10.1074/jbc.M503957200	http://dx.doi.org/10.1074/jbc.M503957200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15939738	Green Accepted, hybrid			2022-12-25	WOS:000230857300056
J	Mariappan, MM; Senthil, D; Natarajan, KS; Choudhury, GG; Kasinath, BS				Mariappan, MM; Senthil, D; Natarajan, KS; Choudhury, GG; Kasinath, BS			Phospholipase C gamma-Erk axis in vascular endothelial growth factor-induced eukaryotic initiation factor 4E phosphorylation and protein synthesis in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II; DEPENDENT ACTIVATION; FACTOR EIF-4E; PLC-GAMMA; ANG-II; TRANSLATION; KINASE; EIF4E; RAF-1; MNK1	Vascular endothelial growth factor ( VEGF) increases protein synthesis and induces hypertrophy in renal tubular epithelial cells ( Senthil, D., Choudhury, G. G., McLaurin, C., and Kasinath, B. S. ( 2003) Kidney Int. 64, 468 - 479). We examined the role of Erk1/2 MAP kinase in protein synthesis induced by VEGF. VEGF stimulated Erk phosphorylation that was required for induction of protein synthesis. VEGF-induced Erk activation was not dependent on phosphoinositide ( PI) 3-kinase activation but required sequential phosphorylation of type 2 VEGF receptor, PLC gamma and c-Src, as demonstrated by inhibitors SU1498, U73122, and PP1, respectively. c-Src phosphorylation was inhibited by U73122, indicating it was downstream of phospholipase ( PL)C gamma. Studies with PP1/2 showed that phosphorylation of c-Src was required for tyrosine phosphorylation of Raf-1, an upstream regulator of Erk. VEGF also stimulated phosphorylation of Pyk-2; VEGF-induced phosphorylation of Pyk2, c-Src and Raf-1 could be abolished by BAPTA/AM, demonstrating requirement for induction of intracellular calcium currents. We examined the downstream events following the phosphorylation of Erk. VEGF stimulated phosphorylation of Mnk1 and eIF4E and induced Mnk1 to shift from the cytoplasm to the nucleus upon phosphorylation. VEGF-induced phosphorylation of Mnk1 and eIF4E required phosphorylation of PLC gamma, c-Src, and Erk. Expression of dominant negative Mnk1 abrogated eIF4E phosphorylation and protein synthesis induced by VEGF. VEGF-stimulated protein synthesis could be blocked by inhibition of PLC gamma by a chemical inhibitor or expression of a dominant negative construct. Our data demonstrate that VEGF-stimulated protein synthesis is Erk-dependent and requires the activation of VEGF receptor 2, PLC gamma, c-Src, Raf, and Erk pathway. VEGF also stimulates Erk-dependent phosphorylation of Mnk1 and eIF4E, crucial events in the initiation phase of protein translation.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; O Brien Kidney Res Ctr, San Antonio, TX 78229 USA; S Texas Vet Healthcare Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Kasinath, BS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr,Mail Code 7882, San Antonio, TX 78229 USA.	Kasinath@uthscsa.edu			NIDDK NIH HHS [P50-DK 061597, DK 50190, DK 55815] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050190, P50DK061597, R01DK055815, R29DK050190] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhandari BK, 2001, KIDNEY INT, V59, P866; Cha DR, 2004, J ENDOCRINOL, V183, P183, DOI 10.1677/joe.1.05647; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Feliers D, 2001, KIDNEY INT, V60, P495, DOI 10.1046/j.1523-1755.2001.060002495.x; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Flyvbjerg A, 2002, DIABETES, V51, P3090, DOI 10.2337/diabetes.51.10.3090; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; Hou M, 2000, ACTA PHYSIOL SCAND, V168, P301; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Kim YG, 2000, KIDNEY INT, V58, P2390, DOI 10.1046/j.1523-1755.2000.00422.x; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McLaughlin AP, 2001, AM J PHYSIOL-CELL PH, V281, pC1448, DOI 10.1152/ajpcell.2001.281.5.C1448; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Miron M, 2001, J NUTR, V131, p2988S, DOI 10.1093/jn/131.11.2988S; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Parra-Palau JL, 2003, J BIOL CHEM, V278, P44197, DOI 10.1074/jbc.M302398200; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rocic P, 2003, AM J PHYSIOL-CELL PH, V285, pC1437, DOI 10.1152/ajpcell.00075.2003; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Schrijvers BF, 2004, KIDNEY INT, V65, P2003, DOI 10.1111/j.1523-1755.2004.00621.x; Senthil D, 2003, KIDNEY INT, V64, P468, DOI 10.1046/j.1523-1755.2003.00135.x; Senthil D, 2002, AM J PHYSIOL-RENAL, V283, pF1226, DOI 10.1152/ajprenal.00109.2002; Senthil D, 2001, BIOCHEM J, V360, P87, DOI 10.1042/0264-6021:3600087; Singal T, 2004, BIOCHEM BIOPH RES CO, V320, P1015, DOI 10.1016/j.bbrc.2004.06.052; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Touyz RM, 2001, HYPERTENSION, V38, P56, DOI 10.1161/01.HYP.38.1.56; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Zuberek J, 2003, RNA, V9, P52, DOI 10.1261/rna.2133403	50	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28402	28411		10.1074/jbc.M504861200	http://dx.doi.org/10.1074/jbc.M504861200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15919658	hybrid			2022-12-25	WOS:000230857300029
J	Mirza, M; Marston, S; Willott, R; Ashley, C; Mogensen, J; McKenna, W; Robinson, P; Redwood, C; Watkins, H				Mirza, M; Marston, S; Willott, R; Ashley, C; Mogensen, J; McKenna, W; Robinson, P; Redwood, C; Watkins, H			Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC TROPONIN-T; VITRO MOTILITY ASSAY; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; ALPHA-TROPOMYOSIN; HEART-FAILURE; CA2+ SENSITIVITY; ACTIN-FILAMENTS; BINDING-SITE; MUTANT; DISEASE	Dilated cardiomyopathy ( DCM), characterized by cardiac dilatation and contractile dysfunction, is a major cause of heart failure. Inherited DCM can result from mutations in the genes encoding cardiac troponin T, troponin C, and alpha-tropomyosin; different mutations in the same genes cause hypertrophic cardiomyopathy. To understand how certain mutations lead specifically to DCM, we have investigated their effect on contractile function by comparing wild-type and mutant recombinant proteins. Because initial studies on two troponin T mutations have generated conflicting findings, we analyzed all eight published DCM mutations in troponin T, troponin C, and alpha-tropomyosin in a range of in vitro assays. Thin filaments, reconstituted with a 1: 1 ratio of mutant/wild-type proteins ( the likely in vivo ratio), all showed reduced Ca2+ sensitivity of activation in ATPase and motility assays, and except for one alpha-tropomyosin mutant showed lower maximum Ca2+ activation. Incorporation of either of two troponin T mutants in skinned cardiac trabeculae also decreased Ca2+ sensitivity of force generation. Structure/function considerations imply that the diverse thin filament DCM mutations affect different aspects of regulatory function yet change contractility in a consistent manner. The DCM mutations depress myofibrillar function, an effect fundamentally opposite to that of hypertrophic cardiomyopathy-causing thin filament mutations, suggesting that decreased contractility may trigger pathways that ultimately lead to the clinical phenotype.	Univ Oxford, Dept Cardiovasc Med, Oxford OX3 9DU, England; Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, London SW3 6LY, England; Univ Oxford, Dept Physiol, Oxford OX1 3PT, England; Skejby Univ Hosp, DK-8200 Aarhus, Denmark; UCL, Heart Hosp, London, England	University of Oxford; Imperial College London; University of Oxford; Aarhus University; University College London Hospitals NHS Foundation Trust; University of London; University College London	Watkins, H (corresponding author), John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England.	hugh.watkins@cardiov.ox.ac.uk	McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460; Watkins, Hugh/0000-0002-5287-9016; Mogensen, Jens/0000-0002-8813-573X				Alpert NR, 2002, CARDIOVASC RES, V54, P1, DOI 10.1016/S0008-6363(02)00248-1; Ashrafian H, 2003, TRENDS GENET, V19, P263, DOI 10.1016/S0168-9525(03)00081-7; Baig MK, 1998, J AM COLL CARDIOL, V31, P195, DOI 10.1016/S0735-1097(97)00433-6; Bing W, 2000, BIOCHEM J, V350, P693, DOI 10.1042/0264-6021:3500693; Bing W, 2000, J MOL CELL CARDIOL, V32, P1489, DOI 10.1006/jmcc.2000.1182; Bing W, 1997, BIOCHEM J, V327, P335, DOI 10.1042/bj3270335; Blumenschein TMA, 2001, J BIOL CHEM, V276, P36606, DOI 10.1074/jbc.M105130200; Bottinelli R, 1998, CIRC RES, V82, P106; Bowles NE, 2000, HERZ, V25, P168, DOI 10.1007/s000590050003; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Burton D, 2002, BIOCHEM J, V362, P443, DOI 10.1042/0264-6021:3620443; CabralLilly D, 1997, BIOPHYS J, V73, P1763, DOI 10.1016/S0006-3495(97)78206-7; Farah CS, 1999, BIOCHEMISTRY-US, V38, P10543, DOI 10.1021/bi982813u; Gerull B, 2002, NAT GENET, V30, P201, DOI 10.1038/ng815; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; Heller MJ, 2003, J BIOL CHEM, V278, P41742, DOI 10.1074/jbc.M303408200; Hinkle A, 2003, J BIOL CHEM, V278, P506, DOI 10.1074/jbc.M209194200; Holthauzen LMF, 2004, J BIOL CHEM, V279, P15204, DOI 10.1074/jbc.M308904200; Houser SR, 2003, CIRC RES, V92, P350, DOI 10.1161/01.RES.0000060027.40275.A6; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; Knollmann BC, 2001, TRENDS CARDIOVAS MED, V11, P206, DOI 10.1016/S1050-1738(01)00115-3; Knott A, 2002, J MOL CELL CARDIOL, V34, P469, DOI 10.1006/jmcc.2002.1528; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461; Li DX, 2001, CIRCULATION, V104, P2188, DOI 10.1161/hc4301.098285; Lu QW, 2003, J MOL CELL CARDIOL, V35, P1421, DOI 10.1016/j.yjmcc.2003.09.003; Malinchik S, 1997, J MOL CELL CARDIOL, V29, P667, DOI 10.1006/jmcc.1996.0309; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Marston S, 2003, J MUSCLE RES CELL M, V24, P149, DOI 10.1023/A:1026097313020; Marston SB, 1996, J MUSCLE RES CELL M, V17, P497, DOI 10.1007/BF00123365; Marston SB, 2001, J MUSCLE RES CELL M, V22, P1, DOI 10.1023/A:1010355716511; McConnell BK, 1999, J CLIN INVEST, V104, P1235, DOI 10.1172/JCI7377; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; Mogensen J, 2004, J AM COLL CARDIOL, V44, P2033, DOI 10.1016/j.jacc.2004.08.027; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Morimoto S, 2002, P NATL ACAD SCI USA, V99, P913, DOI 10.1073/pnas.022628899; Olson TM, 2001, J MOL CELL CARDIOL, V33, P723, DOI 10.1006/jmcc.2000.1339; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Palm T, 2001, BIOPHYS J, V81, P2827, DOI 10.1016/S0006-3495(01)75924-3; Purcell IF, 1999, CARDIOVASC RES, V43, P884, DOI 10.1016/S0008-6363(99)00123-6; Redwood C, 2000, CIRC RES, V86, P1146; Robinson P, 2002, J BIOL CHEM, V277, P40710, DOI 10.1074/jbc.M203446200; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Schonberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; She MD, 2000, J MUSCLE RES CELL M, V21, P737, DOI 10.1023/A:1010300802980; Solaro RJ, 2002, J MOL CELL CARDIOL, V34, P689, DOI 10.1006/jmcc.2002.2028; Sumandea MP, 2003, J BIOL CHEM, V278, P35135, DOI 10.1074/jbc.M306325200; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; van der Velden J, 2001, CIRCULATION, V104, P1140, DOI 10.1161/hc3501.095485; Venkatraman G, 2005, J BIOL CHEM, V280, P17584, DOI 10.1074/jbc.M409337200; Venkatraman G, 2003, J BIOL CHEM, V278, P41670, DOI 10.1074/jbc.M302148200; Vinogradova MV, 2005, P NATL ACAD SCI USA, V102, P5038, DOI 10.1073/pnas.0408882102	54	128	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28498	28506		10.1074/jbc.M412281200	http://dx.doi.org/10.1074/jbc.M412281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15923195	hybrid			2022-12-25	WOS:000230857300040
J	Liu, GT; Akasaki, Y; Khong, HT; Wheeler, CJ; Das, A; Black, KL; Yu, JS				Liu, GT; Akasaki, Y; Khong, HT; Wheeler, CJ; Das, A; Black, KL; Yu, JS			Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy	ONCOGENE			English	Article						glioma; TRP-2; drug resistance; cancer vaccine; cytotoxic T lymphocyte	TYROSINASE-RELATED PROTEIN-2; RADIATION-RESISTANCE; FUNCTIONAL-ANALYSIS; INDUCED APOPTOSIS; MELANOMA-CELLS; TUMOR ESCAPE; IMMUNOTHERAPY; VACCINATION; CANCER; DRUG	Tyrosinase-related protein (TRP)-2 is not only expressed on glioma cells, but is naturally processed and presented by their surface MHC molecules and is recognized by TRP-2-specific cytotoxic T cells. After active immunotherapy, we detected TRP-2-specific cytotoxic T lymphocyte (CTL) activity in patients' peripheral blood mononuclear cells (PBMC). Tumor cells from postvaccination resections showed significantly lower TRP-2 expression and higher sensitivity to carboplatin and temozolomide than those autologous cell lines from prevaccination resections in two patients who demonstrated CTL response to TRP-2. One of two patients underwent treatment with temozolomide after recurrence and responded dramatically. TRP-2-transfected cell line (TRP-2-U373) resulted in significant drug resistance to carboplatin and temozolomide compared to wild-type U-373 (W-U373). There was no significant difference, however, in the mRNA expression of other common drug resistance related proteins, such as BCRP-1, MGMT, MDR-1, MRP-1 and MRP-3, after TRP-2 transfection. TRP-2-U373 tumor cells were immunoselected by a TRP-2-specific CTL line. The immunoselected cells (IS-TRP-2-U373) demonstrated significantly increased sensitivity to carboplatin and temozolomide compared to TRP-2-U373. For the first time, we provide evidence that immunological targeting of tumor-associated antigen TRP-2 significantly increases sensitivity to chemotherapy.	Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA; Univ S Alabama, Canc Res Inst, Mobile, AL 36688 USA	Cedars Sinai Medical Center; University of South Alabama	Yu, JS (corresponding author), 8631 W Third St,Suit 800E, Los Angeles, CA 90048 USA.	yuj@cshs.org		Yu, John/0000-0003-1230-8494; Black, Keith/0000-0002-0546-4934	NINDS NIH HHS [K23 NS02232] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS002232] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bodey B, 2000, ANTICANCER RES, V20, P2665; Bredel M, 2002, LANCET ONCOL, V3, P397, DOI 10.1016/S1470-2045(02)00786-6; Chi DDJ, 1997, AM J PATHOL, V150, P2143; Chu W, 2000, ONCOGENE, V19, P395, DOI 10.1038/sj.onc.1203315; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; DENNY BJ, 1994, BIOCHEMISTRY-US, V33, P9045, DOI 10.1021/bi00197a003; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Fang D, 2001, PIGM CELL RES, V14, P132, DOI 10.1034/j.1600-0749.2001.140209.x; Fisk B, 1998, CANCER RES, V58, P4790; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Khong HT, 2002, J IMMUNOL, V168, P951, DOI 10.4049/jimmunol.168.2.951; Lee KH, 1999, J IMMUNOL, V163, P6292; Liu G, 2004, CANCER RES, V64, P4980, DOI 10.1158/0008-5472.CAN-03-3504; Liu GT, 2003, J IMMUNOTHER, V26, P301, DOI 10.1097/00002371-200307000-00002; Liu GT, 2004, EUR J IMMUNOL, V34, P1680, DOI 10.1002/eji.200425081; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Nair S, 2003, BLOOD, V102, P964, DOI 10.1182/blood-2002-12-3738; Nishioka E, 1999, MELANOMA RES, V9, P433, DOI 10.1097/00008390-199910000-00002; Nowak AK, 2003, CANCER RES, V63, P4490; Pak BJ, 2000, MELANOMA RES, V10, P499, DOI 10.1097/00008390-200010000-00013; Pak BJ, 2004, ONCOGENE, V23, P30, DOI 10.1038/sj.onc.1207007; Pak BJ, 2001, CANCER METAST REV, V20, P27, DOI 10.1023/A:1013175516793; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Wang RF, 1999, IMMUNOL REV, V170, P85, DOI 10.1111/j.1600-065X.1999.tb01331.x; Wheeler CJ, 2004, CLIN CANCER RES, V10, P5316, DOI 10.1158/1078-0432.CCR-04-0497; Yamada A, 2001, CANCER RES, V61, P6459; YOKOYAMA K, 1994, BBA-GENE STRUCT EXPR, V1217, P317, DOI 10.1016/0167-4781(94)90292-5; Yu JS, 2001, CANCER RES, V61, P842; Yu JS, 2004, CANCER RES, V64, P4973, DOI 10.1158/0008-5472.CAN-03-3505; Yung WKA, 2001, SEMIN ONCOL, V28, P43	32	56	64	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5226	5234		10.1038/sj.onc.1208519	http://dx.doi.org/10.1038/sj.onc.1208519			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897911				2022-12-25	WOS:000230964600009
J	Ben-Ami, HC; Yassin, L; Farah, H; Michaeli, A; Eshel, M; Treinin, M				Ben-Ami, HC; Yassin, L; Farah, H; Michaeli, A; Eshel, M; Treinin, M			RIC-3 affects properties and quantity of nicotinic acetylcholine receptors via a mechanism that does not require the coiled-coil domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; IDENTIFICATION; PERSPECTIVE; SUBUNIT; GENE	Members of the RIC-3 gene family are effectors of nicotinic acetylcholine receptor ( nAChR) expression in vertebrates and invertebrates. In Caenorhabditis elegans RIC-3 is needed for functional expression of multiple nAChRs, including the DEG-3/DES-2 nAChR. Effects of RIC-3 on DEG-3/DES-2 functional expression are found in vivo and following heterologous expression in Xenopus leavis oocytes. We now show that in X. leavis oocytes RIC-3 also affects the kinetics and agonist affinity properties of the DEG-3/DES-2 receptor. Because these effects are mimicked by increasing the ratio of DEG-3 subunits within DEG-3/DES-2 receptors, this suggests that RIC-3 may preferentially promote maturation of DEG-3-rich receptors. Indeed, effects of RIC-3 on functional expression of DEG-3/DES-2 positively correlate with the DEG-3 to DES-2 ratio. All RIC-3 family members have two transmembrane domains followed by one or two coiled-coil domains. Here we show that the effects of RIC-3 on functional expression and on receptor properties are mediated by the transmembrane domains and do not require the coiled-coil domains. In agreement with this, mammals express a RIC-3 transcript lacking the coiled-coil domain that is capable of promoting DEG-3/DES-2 functional expression. Last, we show that RIC-3 affects DEG-3 quantity, suggesting stabilization of receptors or receptor intermediates by RIC-3. Together our results suggest that subunit-specific interactions of RIC-3 with nAChR subunits, mediated by the transmembrane domains, are sufficient for the effects of RIC-3 on nAChR quantity and quality.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Treinin, M (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel.	millet_t@cc.huji.ac.il		Michaeli, Avner/0000-0001-9087-9706				Bernier V, 2004, TRENDS ENDOCRIN MET, V15, P222, DOI 10.1016/j.tem.2004.05.003; Cheng AX, 2005, J BIOL CHEM, V280, P22502, DOI 10.1074/jbc.M414341200; Green WN, 1999, J GEN PHYSIOL, V113, P163, DOI 10.1085/jgp.113.2.163; Halevi S, 2003, J BIOL CHEM, V278, P34411, DOI 10.1074/jbc.M300170200; Halevi S, 2002, EMBO J, V21, P1012, DOI 10.1093/emboj/21.5.1012; Keller SH, 1999, J GEN PHYSIOL, V113, P171, DOI 10.1085/jgp.113.2.171; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; Nelson ME, 2003, MOL PHARMACOL, V63, P332, DOI 10.1124/mol.63.2.332; NUMA S, 1983, COLD SPRING HARB SYM, V48, P57, DOI 10.1101/SQB.1983.048.01.008; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; Treinin M, 1998, P NATL ACAD SCI USA, V95, P15492, DOI 10.1073/pnas.95.26.15492; Williams ME, 2005, J BIOL CHEM, V280, P1257, DOI 10.1074/jbc.M410039200; Yassin L, 2001, MOL CELL NEUROSCI, V17, P589, DOI 10.1006/mcne.2000.0944; Zwart R, 1998, MOL PHARMACOL, V54, P1124, DOI 10.1124/mol.54.6.1124	14	34	42	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28053	28060		10.1074/jbc.M504369200	http://dx.doi.org/10.1074/jbc.M504369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15932871	hybrid			2022-12-25	WOS:000230678600068
J	Langlet, C; Langer, I; Vertongen, P; Gaspard, N; Vanderwinden, JM; Robberecht, P				Langlet, C; Langer, I; Vertongen, P; Gaspard, N; Vanderwinden, JM; Robberecht, P			Contribution of the carboxyl terminus of the VPAC(1) receptor to agonist-induced receptor phosphorylation, internalization, and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; PROTEIN-COUPLED RECEPTORS; 3RD INTRACELLULAR LOOP; BETA(2)-ADRENERGIC RECEPTOR; SECRETIN RECEPTOR; CHO-CELLS; WILD-TYPE; KINASE; DESENSITIZATION; CYCLASE	When exposed to vasoactive intestinal peptide ( VIP), the human wild type VPAC(1) receptor expressed in Chinese hamster ovary (CHO) cells is rapidly phosphorylated, desensitized, and internalized in the endosomal compartment and is not re-expressed at the cell membrane within 2 h after agonist removal. The aims of the present work were first to correlate receptor phosphorylation level to internalization and recycling, measured by flow cytometry and in some cases by confocal microscopy using a monoclonal antibody that did not interfere with ligand binding, and second to identify the phosphorylated Ser/Thr residues. Combining receptor mutations and truncations allowed identification of Ser(250) ( in the second intracellular loop), Thr(429), Ser(435), Ser(448) or Ser(449), and Ser(455) ( all in the distal part of the C terminus) as candidates for VIP-stimulated phosphorylation. The effects of single mutations were not additive, suggesting alternative phosphorylation sites in mutated receptors. Replacement of all of the Ser/Thr residues in the carboxyl-terminal tail and truncation of the domain containing these residues completely inhibited VIP-stimulated phosphorylation and receptor internalization. There was, however, no direct correlation between receptor phosphorylation and internalization; in some truncated and mutated receptors, a 70% reduction in phosphorylation had little effect on internalization. In contrast to results obtained on the wild type and all of the mutated or truncated receptors that still underwent phosphorylation, internalization of the severely truncated receptor was reversed within 2 h of incubation in the absence of the agonist. Receptor recovery was blocked by monensin, an endosome inhibitor.	Univ Libre Bruxelles, Sch Med, Dept Biochem & Nutr, Lab Chim Biol & Nutr, B-1070 Brussels, Belgium; Univ Libre Bruxelles, Neurophysiol Lab, Fac Med, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles	Robberecht, P (corresponding author), Univ Libre Bruxelles, Sch Med, Dept Biochem & Nutr, Lab Chim Biol & Nutr, Bat G-E,CP 611,808 Route Lennik, B-1070 Brussels, Belgium.	probbe@ulb.ac.be						BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Busto R, 1999, CELL SIGNAL, V11, P691, DOI 10.1016/S0898-6568(99)00041-8; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Costagliola S, 1998, J IMMUNOL, V160, P1458; Couvineau A, 2003, J BIOL CHEM, V278, P24759, DOI 10.1074/jbc.M301916200; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Gray JA, 2003, BIOCHEMISTRY-US, V42, P10853, DOI 10.1021/bi035061z; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; INAGAKI M, 1986, MOL PHARMACOL, V29, P577; Juarranz MG, 1999, EUR J BIOCHEM, V265, P449, DOI 10.1046/j.1432-1327.1999.00769.x; Langer I, 2005, CELL SIGNAL, V17, P17, DOI 10.1016/j.cellsig.2004.05.009; Langer I, 2002, MOL ENDOCRINOL, V16, P1089, DOI 10.1210/me.16.5.1089; Langer I, 2001, CELL CALCIUM, V30, P229, DOI 10.1054/ceca.2001.0230; Langlet C, 2004, PEPTIDES, V25, P2079, DOI 10.1016/j.peptides.2004.08.017; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Marie JC, 2003, MOL PHARMACOL, V64, P1565, DOI 10.1124/mol.64.6.1565; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Rao RV, 1997, MOL PHARMACOL, V51, P185, DOI 10.1124/mol.51.2.185; Rao RV, 2000, AM J PHYSIOL-CELL PH, V279, pC1986, DOI 10.1152/ajpcell.2000.279.6.C1986; ROBBERECHT P, 1989, PEPTIDES, V10, P1027, DOI 10.1016/0196-9781(89)90186-1; ROBBERECHT P, 1989, PEPTIDES, V10, P441, DOI 10.1016/0196-9781(89)90056-9; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Schulz S, 2004, CLIN CANCER RES, V10, P8235, DOI 10.1158/1078-0432.CCR-04-0939; Shetzline MA, 2002, J BIOL CHEM, V277, P25519, DOI 10.1074/jbc.M201815200; SHICHI H, 1978, J BIOL CHEM, V253, P7040; Tobin AB, 2002, TRENDS PHARMACOL SCI, V23, P337, DOI 10.1016/S0165-6147(02)02043-6; Vertongen P, 2004, PEPTIDES, V25, P1943, DOI 10.1016/j.peptides.2004.06.001; Vilardaga JP, 2002, J BIOL CHEM, V277, P8121, DOI 10.1074/jbc.M110433200; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	39	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28034	28043		10.1074/jbc.M500449200	http://dx.doi.org/10.1074/jbc.M500449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15932876	hybrid			2022-12-25	WOS:000230678600066
J	Schmidt, AE; Chand, HS; Cascio, D; Kisiel, W; Bajaj, SP				Schmidt, AE; Chand, HS; Cascio, D; Kisiel, W; Bajaj, SP			Crystal structure of Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in complex with trypsin - Implications for KD1 specificity of inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; MOLECULAR REPLACEMENT; PROTEASE INHIBITOR; MESSENGER-RNA; HUMAN SKIN; FACTOR-IX; EXPRESSION; BPTI; MATRIX; DOMAIN	Kunitz domain 1 (KD1) of tissue factor pathway inhibtor-2 inhibits trypsin, plasmin, and factor VIIa ( FVIIa)/ tissue factor with K-i values of 13, 3, and 1640 nM, respectively. To investigate the molecular specificity of KD1, crystals of the complex of KD1 with bovine beta-trypsin were obtained that diffracted to 1.8 angstrom. The P-1 residue Arg-15 ( bovine pancreatic trypsin inhibitor numbering) in KD1 interacts with Asp-189 ( chymotrypsin numbering) and with the carbonyl oxygens of Gly-219 and O gamma of Ser-190. Leu-17, Leu-18, Leu-19, and Leu-34 in KD1 make van der Waals contacts with Tyr-39, Phe-41, and Tyr-151 in trypsin, forming a hydrophobic interface. Molecular modeling indicates that this complementary hydrophobic patch is composed of Phe-37, Met-39, and Phe-41 in plasmin, whereas in FVIIa/tissue factor, it is essentially absent. Arg-20, Tyr-46, and Glu-39 in KD1 interact with trypsin through ordered water molecules. In contrast, insertions in the 60-loop in plasmin and FVIIa allow Arg-20 of KD1 to directly interact with Glu-60 in plasmin and Asp-60 in FVIIa. Moreover, Tyr-46 in KD1 electrostatically interacts with Lys-60A and Arg-60D in plasmin and Lys-60A in FVIIa. Glu-39 in KD1 interacts directly with Arg- 175 of the basic patch in plasmin, whereas in FVIIa, such interactions are not possible. Thus, the specificity of KD1 for plasmin is attributable to hydrophobic and direct electrostatic interactions. For trypsin, hydrophobic interactions are intact, and electrostatic interactions are weak, whereas for FVIIa, hydrophobic interactions are missing, and electrostatic interactions are partially intact. These findings provide insight into the protease selectivity of KD1.	Univ Calif Los Angeles, Orthoped Hosp, Inst Mol Biol, Dept Orthoped Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Saint Louis University; University of New Mexico; University of New Mexico's Health Sciences Center	Bajaj, SP (corresponding author), Univ Calif Los Angeles, Orthoped Hosp, Inst Mol Biol, Dept Orthoped Surg, Box 951795,Rehab 22-53, Los Angeles, CA 90095 USA.	pbajaj@mednet.ucla.edu	Chand, Hitendra/AAE-7975-2020	Chand, Hitendra/0000-0002-0574-9307	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070369, R56HL036365, R01HL064119, R01HL036365, R55HL036365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031299] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70369, HL64119, HL36365] Funding Source: Medline; NIGMS NIH HHS [GM31299-22] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bajaj MS, 2001, THROMB HAEMOSTASIS, V86, P959; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Busuttil SJ, 2004, J THROMB HAEMOST, V2, P1798, DOI 10.1111/j.1538-7836.2004.00916.x; Chand HS, 2004, J BIOL CHEM, V279, P17500, DOI 10.1074/jbc.M400802200; Chand HS, 2004, BLOOD, V103, P1069, DOI 10.1182/blood-2003-06-1930; Chun TH, 2004, J CELL BIOL, V167, P757, DOI 10.1083/jcb.200405001; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Crawley JTB, 2002, ARTERIOSCL THROM VAS, V22, P218, DOI 10.1161/hq0102.101842; Daci E, 1999, J BONE MINER RES, V14, P946, DOI 10.1359/jbmr.1999.14.6.946; Grzesiak A, 2000, J MOL BIOL, V301, P205, DOI 10.1006/jmbi.2000.3935; Helland R, 1999, J MOL BIOL, V287, P923, DOI 10.1006/jmbi.1999.2654; Herman MP, 2001, J CLIN INVEST, V107, P1117, DOI 10.1172/JCI10403; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; Kamei S, 1999, THROMB RES, V94, P147, DOI 10.1016/S0049-3848(98)00205-9; KISIEL W, 1985, BLOOD, V66, P1302; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kissinger CR, 2001, ACTA CRYSTALLOGR D, V57, P1474, DOI 10.1107/S0907444901012458; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; OBATA R, 2004, EYE, V18, P1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Rao CN, 1999, BIOCHEM BIOPH RES CO, V255, P94, DOI 10.1006/bbrc.1999.0153; RAO CN, 1995, J INVEST DERMATOL, V104, P379, DOI 10.1111/1523-1747.ep12665851; Rao CN, 2001, CLIN CANCER RES, V7, P570; RAO CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P45; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; Sugiyama T, 2002, FEBS LETT, V517, P121, DOI 10.1016/S0014-5793(02)02588-7; Udagawa K, 1998, PLACENTA, V19, P217, DOI 10.1016/S0143-4004(98)90011-X; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452	40	33	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27832	27838		10.1074/jbc.M504105200	http://dx.doi.org/10.1074/jbc.M504105200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15932872	hybrid			2022-12-25	WOS:000230678600044
J	Deleault, NR; Geoghegan, JC; Nishina, K; Kascsak, R; Williamson, RA; Supattapone, S				Deleault, NR; Geoghegan, JC; Nishina, K; Kascsak, R; Williamson, RA; Supattapone, S			Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE FORMATION; NUCLEOCAPSID PROTEIN; SCRAPIE PRION; ALZHEIMERS-DISEASE; NUCLEIC-ACID; IN-VITRO; CYCLIC AMPLIFICATION; SENILE PLAQUES; CONVERSION; PRP	Little is currently known about the biochemical mechanism by which induced prion protein (PrP) conformational change occurs during mammalian prion propagation. In this study, we describe the reconstitution of PrPres amplification in vitro using partially purified and synthetic components. Overnight incubation of purified PrP27 - 30 and PrPC molecules at a molar ratio of 1: 250 yielded similar to 2-fold baseline PrPres amplification. Addition of various polyanionic molecules increased the level of PrPres amplification to similar to 10-fold overall. Polyanionic compounds that stimulated purified PrPres amplification to varying degrees included synthetic, homopolymeric nucleic acids such as poly( A) and poly(dT), as well as non-nucleic acid polyanions, such as heparan sulfate proteoglycan. Size fractionation experiments showed that synthetic poly( A) polymers must be > 0.2 kb in length to stimulate purified PrPres amplification. Thus, one possible set of minimal components for efficient conversion of PrP molecules in vitro may be surprisingly simple, consisting of PrP27 - 30, PrPC, and a stimulatory polyanionic compound.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Supattapone, S (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	supattapone@dartmouth.edu			NIAID NIH HHS [AI058979] Funding Source: Medline; NINDS NIH HHS [NS046478] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI058979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adjou KT, 2003, J GEN VIROL, V84, P2595, DOI 10.1099/vir.0.19073-0; Adler V, 2003, J MOL BIOL, V332, P47, DOI 10.1016/S0022-2836(03)00919-7; ANSEVIN AT, 1975, J BIOL CHEM, V250, P281; Appel TR, 1999, BIOL CHEM, V380, P1295, DOI 10.1515/BC.1999.165; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Caughey B, 2003, NATURE, V425, P673, DOI 10.1038/425673a; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Derrington E, 2002, CR BIOL, V325, P17, DOI 10.1016/S1631-0691(02)01388-4; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; Ginsberg SD, 1999, ANN NEUROL, V45, P174, DOI 10.1002/1531-8249(199902)45:2<174::AID-ANA7>3.0.CO;2-E; Ginsberg SD, 1997, ANN NEUROL, V41, P200, DOI 10.1002/ana.410410211; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lucassen R, 2003, BIOCHEMISTRY-US, V42, P4127, DOI 10.1021/bi027218d; Moscardini M, 2002, J MOL BIOL, V318, P149, DOI 10.1016/S0022-2836(02)00092-X; Nandi PK, 2004, J MOL BIOL, V344, P827, DOI 10.1016/j.jmb.2004.09.080; Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7; Nishina K, 2004, BIOCHEMISTRY-US, V43, P2613, DOI 10.1021/bi035889l; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Saborio GP, 1999, BIOCHEM BIOPH RES CO, V258, P470, DOI 10.1006/bbrc.1999.0660; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Schonberger O, 2003, BIOCHEM BIOPH RES CO, V312, P473, DOI 10.1016/j.bbrc.2003.10.150; Shaked GM, 2001, J BIOL CHEM, V276, P14324, DOI 10.1074/jbc.M007815200; Soto C, 2005, FEBS LETT, V579, P638, DOI 10.1016/j.febslet.2004.12.035; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; van Horssen J, 2003, LANCET NEUROL, V2, P482, DOI 10.1016/S1474-4422(03)00484-8; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Zeiler B, 2003, BIOTECHNOL APPL BIOC, V37, P173, DOI 10.1042/BA20020087	47	147	155	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26873	26879		10.1074/jbc.M503973200	http://dx.doi.org/10.1074/jbc.M503973200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917229	hybrid			2022-12-25	WOS:000230589500029
J	Mengwasser, KE; Bush, LA; Shih, P; Cantwell, AM; Di Cera, E				Mengwasser, KE; Bush, LA; Shih, P; Cantwell, AM; Di Cera, E			Hirudin binding reveals key determinants of thrombin allostery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; N-TERMINAL REGION; NA+ BINDING; SLOW->FAST TRANSITION; IONIC INTERACTIONS; CRYSTAL-STRUCTURE; SERINE PROTEASES; FAST FORMS; HOT-SPOT; SITE	Thrombin exists in two allosteric forms, slow ( S) and fast ( F), that recognize natural substrates and inhibitors with significantly different affinities. Because under physiologic conditions the two forms are almost equally populated, investigation of thrombin function must address the contribution from the S and F forms and the molecular origin of their differential recognition of ligands. Using a panel of 79 Ala mutants, we have mapped for the first time the epitopes of thrombin recognizing a macromolecular ligand, hirudin, in the S and F forms. Hirudin binding is a relevant model for the interaction of thrombin with fibrinogen and PAR1 and is likewise influenced by the allosteric S-->F transition. The epitopes are nearly identical and encompass two hot spots, one in exosite I and the other in the Na+ site at the opposite end of the protein. The higher affinity of the F form is due to the preferential interaction of hirudin with Lys-36, Leu-65, Thr-74, and Arg-75 in exosite I; Gly-193 in the oxyanion hole; and Asp-221 and Asp-222 in the Na+ site. Remarkably, no correlation is found between the energetic and structural involvements of thrombin residues in hirudin recognition, which invites caution in the analysis of protein-protein interactions in general.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	enrico@wustl.edu						AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; AYALA YM, 1995, J MOL BIOL, V253, P787, DOI 10.1006/jmbi.1995.0591; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BETZ A, 1992, BIOCHEMISTRY-US, V31, P4557, DOI 10.1021/bi00134a004; BETZ A, 1991, BIOCHEMISTRY-US, V30, P9848, DOI 10.1021/bi00105a006; BETZ A, 1991, BIOCHEM J, V275, P801, DOI 10.1042/bj2750801; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; BODE W, 1992, PROTEIN SCI, V1, P426; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHA S, 1976, BIOCHEM PHARMACOL, V25, P2695, DOI 10.1016/0006-2952(76)90259-8; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DANG QD, 1994, J PROTEIN CHEM, V13, P367, DOI 10.1007/BF01901692; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 2004, CR BIOL, V327, P1065, DOI 10.1016/j.crvi.2004.07.011; Di Cera E, 1998, ADV PROTEIN CHEM, V51, P59; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Di Cera E., 1995, THERMODYNAMIC THEORY; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Greenspan NS, 1999, NAT BIOTECHNOL, V17, P936, DOI 10.1038/13590; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; He XH, 1999, J BIOL CHEM, V274, P4970, DOI 10.1074/jbc.274.8.4970; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; Krem MM, 2003, BIOPHYS CHEM, V100, P315, DOI 10.1016/S0301-4622(02)00289-2; Krem MM, 2002, J BIOL CHEM, V277, P40260, DOI 10.1074/jbc.M206173200; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; Nogami K, 2005, J BIOL CHEM, V280, P18476, DOI 10.1074/jbc.M412778200; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; Pineda AO, 2004, J BIOL CHEM, V279, P39824, DOI 10.1074/jbc.M407272200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Richieri GV, 1998, J BIOL CHEM, V273, P7397, DOI 10.1074/jbc.273.13.7397; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Schmidt AE, 2002, J BIOL CHEM, V277, P28987, DOI 10.1074/jbc.M201892200; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; STONE SR, 1989, BIOCHEMISTRY-US, V28, P6857, DOI 10.1021/bi00443a012; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Sun WY, 2001, THROMB HAEMOSTASIS, V85, P651, DOI 10.1055/s-0037-1615648; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WALLACE A, 1989, BIOCHEMISTRY-US, V28, P10079, DOI 10.1021/bi00452a030; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; Xu H, 2005, J BIOL CHEM, V280, P7956, DOI 10.1074/jbc.M412869200; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	46	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26997	27003		10.1074/jbc.M502678200	http://dx.doi.org/10.1074/jbc.M502678200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15923186	hybrid			2022-12-25	WOS:000230589500044
J	Norstrom, EM; Mastrianni, JA				Norstrom, EM; Mastrianni, JA			The AGAAAAGA palindrome in PrP is required to generate a productive PrPSc-PrPC complex that leads to prion propagation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVING CELLS; PROTEIN ISOFORMS; SCRAPIE ISOFORM; INHIBITION; CONVERSION; CONFORMATION; PEPTIDES; FRAGMENT; SEQUENCE; FEATURES	The molecular hallmark of prion disease is the conversion of normal prion protein (PrPC) to an insoluble, proteinase K-resistant, pathogenic isoform (PrPSc). Once generated, PrPSc propagates by complexing with, and transferring its pathogenic conformation onto, PrPC. Defining the specific nature of this PrPSc-PrPC interaction is critical to understanding prion genesis. To begin to approach this question, we employed a prion-infected neuroblastoma cell line (ScN2a) combined with a heterologous yeast expression system to independently model PrPSc generation and propagation. We additionally applied fluorescence resonance energy transfer analysis to the latter to specifically study PrP-PrP interactions. In this report we focus on an N-terminal hydrophobic palindrome of PrP (112-AGAAAAGA-119) thought to feature intimately in prion generation via an unclear mechanism. We found that, in contrast to wild type (wt) PrP, PrP lacking the palindrome (PrP Delta 112-119) neither converted to PrPSc when expressed in ScN2a cells nor generated proteinase K-resistant PrP when expressed in yeast. Furthermore, PrP Delta 112-119 was a dominant-negative inhibitor of wtPrP in ScN2a cells. Both wtPrP and PrP Delta 112-119 were highly insoluble when expressed in yeast and produced distinct cytosolic aggregates when expressed as fluorescent fusion proteins (PrP::YFP). Although self-aggregation was evident, fluorescence resonance energy transfer studies in live yeast co-expressing PrPSc-like protein and PrP Delta 112-119 indicated altered interaction properites. These results suggest that the palindrome is required, not only for the attainment of the PrPSc conformation but also to facilitate the proper association of PrPSc with PrPC to effect prion propagation.	Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Mastrianni, JA (corresponding author), Univ Chicago, Dept Neurol, MC2030,5841 S Maryland Ave, Chicago, IL 60637 USA.	jmastria@uchicago.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046037] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS046037] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Holscher C, 1998, J VIROL, V72, P1153; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Majoul I, 2001, DEV CELL, V1, P139, DOI 10.1016/S1534-5807(01)00004-1; Mastrianni JA, 2000, SEMIN NEUROL, V20, P337, DOI 10.1055/s-2000-9396; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Zulianello L, 2000, J VIROL, V74, P4351, DOI 10.1128/JVI.74.9.4351-4360.2000	29	71	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27236	27243		10.1074/jbc.M413441200	http://dx.doi.org/10.1074/jbc.M413441200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917252	hybrid			2022-12-25	WOS:000230589500072
J	Song, JJ; Lee, YJ				Song, JJ; Lee, YJ			Cross-talk between JIP3 and JIP1 during glucose deprivation - SEK1-JNK2 and Akt1 act as mediators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; SYNERGISTIC ACTIVATION; SCAFFOLD PROTEINS; CELL-SURVIVAL; JNK; PHOSPHORYLATION; MODULE; SEK1	We have previously observed that glucose deprivation activates the ASK1-MEK-MAPK signal transduction pathway. In the present study, we reveal that two scaffolding proteins, JIP1 and JIP3, have a cross-talk that leads to the regulation of the ASK1-SEK1-JNK signal during glucose deprivation. Glucose deprivation rapidly increases the interaction between ASK1 and JIP3, and the consequently activated ASK1 phosphorylates SEK1 on the Thr-261 residue. The activated SEK1 dissociates from JIP3 and phosphorylates JNK2 on the Tyr-185 residue. Phosphorylated JNK2 binds to JIP1, and the phosphorylation of the Thr-183 residue of JNK2 occurs. JNK2 phosphorylates JIP1 on the Thr-103 residue and leads to dissociation of Akt1 from JIP1. Dissociated Akt1 binds to SEK1 and ASK1 and inhibits their enzyme activity by phosphorylating SEK1 on the Ser-80 residue and ASK1 on the Ser-83 residue. Taken together, our data demonstrate that cross-talk between JIP3 and JIP1 is mediated through SEK1-JNK2 and Akt1.	Univ Pittsburgh, Dept Surg & Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, 5117 Ctr Ave, Pittsburgh, PA 15213 USA.	leeyj@msx.upmc.edu		Song, Jae/0000-0001-8183-9550	NCI NIH HHS [CA96989, CA95191] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095191, R01CA096989] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aikin R, 2004, ENDOCRINOLOGY, V145, P4522, DOI 10.1210/en.2004-0488; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hetman M, 2000, J NEUROSCI, V20, P2567; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kim AH, 2003, J BIOL CHEM, V278, P29830, DOI 10.1074/jbc.M305349200; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leinninger GM, 2004, FASEB J, V18, P1544, DOI 10.1096/fj.04-1581fje; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Levresse V, 2000, J NEUROSCI RES, V62, P799; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nihalani D, 2003, J BIOL CHEM, V278, P28694, DOI 10.1074/jbc.M304212200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Suzuki A, 2004, ONCOGENE, V23, P7067, DOI 10.1038/sj.onc.1207963; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	44	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26845	26855		10.1074/jbc.M502318200	http://dx.doi.org/10.1074/jbc.M502318200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911620	hybrid			2022-12-25	WOS:000230589500026
J	Yu, WX; Ko, MH; Yanagisawa, K; Michikawa, M				Yu, WX; Ko, MH; Yanagisawa, K; Michikawa, M			Neurodegeneration in heterozygous Niemann-Pick type C1 (NPC1) mouse - Implication of heterozygous NPC1 mutations being a risk for tauopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NEUROFIBRILLARY TANGLES; TAU-PHOSPHORYLATION; PLASMA-MEMBRANE; LIPID EFFLUX; ATP LEVELS; CHOLESTEROL; DISEASE; TRANSPORT; PROTEIN	Niemann-Pick type C1 (NPC1) disease is an autosomal recessive, fatal disorder characterized by a defect in cholesterol trafficking and progressive neurodegeneration. The disease is predominantly caused by mutations in the NPC1 gene; however, it has been assumed that heterozygous NPC1 mutations do not cause any symptoms. Here we demonstrate that cholesterol accumulation does not occur in young mouse brains; however, it does in aged ( 104 - 106-week-old) NPC1 +/- mouse brains. In addition, Purkinje cell loss was observed in aged NPC1 +/- mouse cerebellums. Immunoblot analysis using anti-phospho-tau antibodies (AT-8, AT-100, AT-180, AT-270, PHF-1, and SMI-31) demonstrates the site-specific phosphorylation of tau at Ser-199, Ser-202, Ser-212, and Thr-214 in the brains of aged NPC1 +/- mice. Mitogen-activated protein kinase, a potential serine kinase known to phosphorylate tau, was activated, whereas other serine kinases, including glycogen synthase kinase 3 beta, cyclin-dependent kinase 5, or stress-activated protein kinase/c-Jun N-terminal kinase were not activated. Cholesterol level in the lipid raft isolated from the cerebral cortices, ATP level, and ATP synthase activity in the cerebral cortices significantly decreased in the aged NPC1 +/- brains compared with those in the NPC1 +/+ brains. All of these changes observed in NPC1 +/- brains were determined to be associated with aging and were not observed in the age-matched NPC1 +/+ brains. These results clearly demonstrate that heterozygous NPC1 impairs neuronal functions and causes neurodegeneration in aged mouse brains, suggesting that human heterozygous NPC1 mutations may be a risk factor for neurodegenerative disorders, such as tauopathy, in the aged population.	Natl Inst Longev Sci, Dept Alzheimers Dis Res, Aichi 4748522, Japan		Michikawa, M (corresponding author), Natl Inst Longev Sci, Dept Alzheimers Dis Res, 36-3 Gengo, Aichi 4748522, Japan.	michi@nils.go.jp						AUER IA, 1995, ACTA NEUROPATHOL, V90, P547; Bu BT, 2002, J NEUROSCI, V22, P6515; BUSH ML, 1995, P NATL ACAD SCI USA, V92, P1861, DOI 10.1073/pnas.92.6.1861; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; Fan QW, 2001, J NEUROCHEM, V76, P391, DOI 10.1046/j.1471-4159.2001.00063.x; Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100; Garver WS, 2000, J LIPID RES, V41, P673; Garver WS, 2002, J LIPID RES, V43, P579; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Karten B, 2003, J BIOL CHEM, V278, P4168, DOI 10.1074/jbc.M205406200; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; Lang-Rollin ICJ, 2003, J NEUROSCI, V23, P11015; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOVE S, 1995, BRAIN, V118, P119, DOI 10.1093/brain/118.1.119; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; Mizukami Y, 2004, J BIOL CHEM, V279, P50120, DOI 10.1074/jbc.M402299200; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Sawamura N, 2001, J BIOL CHEM, V276, P10314, DOI 10.1074/jbc.M009733200; Sawamura N, 2003, J NEUROCHEM, V84, P1086, DOI 10.1046/j.1471-4159.2003.01596.x; SUZUKI K, 1995, ACTA NEUROPATHOL, V89, P227; VANIER MT, 1988, CLIN GENET, V33, P331; VANIER MT, 1991, BIOCHIM BIOPHYS ACTA, V1096, P328, DOI 10.1016/0925-4439(91)90069-L; Walkley SU, 1998, ANN NY ACAD SCI, V845, P188, DOI 10.1111/j.1749-6632.1998.tb09671.x; Wang PY, 2003, EMBO J, V22, P2658, DOI 10.1093/emboj/cdg255; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200; YU W, 2005, J BIOL CHEM	38	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27296	27302		10.1074/jbc.M503922200	http://dx.doi.org/10.1074/jbc.M503922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15919659	hybrid			2022-12-25	WOS:000230589500079
J	Osenkowski, P; Meroueh, SO; Pavel, D; Mobashery, S; Fridman, R				Osenkowski, P; Meroueh, SO; Pavel, D; Mobashery, S; Fridman, R			Mutational and structural analyses of the hinge region of membrane type 1-matrix metalloproteinase and enzyme processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE; CELL-SURFACE; TISSUE-INHIBITOR; GELATINASE-A; I COLLAGEN; EXTRACELLULAR-MATRIX; RAPID TRAFFICKING; MT1-MMP MMP-14; UP-REGULATION; ACTIVATION	Membrane type 1 (MT1)-matrix metalloproteinase (MMP) is a major mediator of collagen degradation in the pericellular space in both physiological and pathological conditions. Previous evidence has shown that on the cell surface, active MT1-MMP undergoes autocatalytic processing to a major membrane-tethered 44-kDa product lacking the catalytic domain and displaying Gly(285) at its N terminus, which is at the beginning of the hinge domain. However, the importance of this site and the hinge region in MT1-MMP processing is unknown. In the current study, we generated mutations and deletions in the hinge of MT1-MMP and followed their effect on processing. These studies established Gly(284)-Gly(285) as the main cleavage site involved in the formation of the 44-kDa species. However, alterations at this site did not prevent processing. Instead, they forced downstream cleavages within the stretch of residues flanked by Gln(296) and Ser(304) in the hinge region, as determined by the processing profile of various hinge deletion mutants. Also, replacement of the hinge of MT1-MMP with the longer MT3-MMP hinge did not prevent processing of MT1-MMP. Molecular dynamic studies using a computational model of MT1-MMP revealed that the hinge region is a highly motile element that undergoes significant motion in the highly exposed loop formed by Pro(295)-Arg(302) consistent with being a prime target for proteolysis, in agreement with the mutational data. These studies suggest that the hinge of MT1-MMP evolved to facilitate processing, a promiscuous but compulsory event in the destiny of MT1-MMP, which may play a key role in the control of pericellular proteolysis.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	Wayne State University; University of Notre Dame	Fridman, R (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	rfridman@med.wayne.edu			NATIONAL CANCER INSTITUTE [T32CA009531] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09531] Funding Source: Medline; NCPDCID CDC HHS [NCI-CA61986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCPDCID CDC HHS		Annabi B, 2001, BIOCHEM J, V359, P325, DOI 10.1042/0264-6021:3590325; Aznavoorian S, 2001, CANCER RES, V61, P6264; Bashford D, 2000, ANNU REV PHYS CHEM, V51, P129, DOI 10.1146/annurev.physchem.51.1.129; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Case DA, 2002, AMBER VERSION 7; Collen A, 2003, BLOOD, V101, P1810, DOI 10.1182/blood-2002-05-1593; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; Deryugina EI, 2004, TRAFFIC, V5, P627, DOI 10.1111/j.1600-0854.2004.00206.x; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRIDMAN R, 1995, CANCER RES, V55, P2548; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Guo C, 2005, J CELL BIOCHEM, V94, P446, DOI 10.1002/jcb.20272; Guo P, 2005, AM J PATHOL, V166, P877, DOI 10.1016/S0002-9440(10)62308-5; Harayama T, 1999, JPN J CANCER RES, V90, P942, DOI 10.1111/j.1349-7006.1999.tb00839.x; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 2004, TRENDS BIOCHEM SCI, V29, P285, DOI 10.1016/j.tibs.2004.04.001; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Karsdal MA, 2002, J BIOL CHEM, V277, P44061, DOI 10.1074/jbc.M207205200; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Konttinen YT, 1998, MATRIX BIOL, V17, P585, DOI 10.1016/S0945-053X(98)90110-X; Koo HM, 2002, MOL CELLS, V13, P118; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Li H, 1998, MOL CARCINOGEN, V22, P84; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; Maquoi E, 2003, BIOCHEM J, V373, P19, DOI 10.1042/BJ20030170; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Munshi HG, 2004, J BIOL CHEM, V279, P39042, DOI 10.1074/jbc.M404958200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OHARE MC, 1995, BIOCHEM BIOPH RES CO, V216, P329, DOI 10.1006/bbrc.1995.2628; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Pap T, 2000, ARTHRITIS RHEUM, V43, P1226, DOI 10.1002/1529-0131(200006)43:6<1226::AID-ANR5>3.0.CO;2-4; Preaux AM, 1999, HEPATOLOGY, V30, P944, DOI 10.1002/hep.510300432; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Robinet A, 2005, J CELL SCI, V118, P343, DOI 10.1242/jcs.01613; Roux B, 1999, BIOPHYS CHEM, V78, P1, DOI 10.1016/S0301-4622(98)00226-9; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Stanton H, 1998, J CELL SCI, V111, P2789; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Takino T, 2004, CANCER RES, V64, P1044, DOI 10.1158/0008-5472.CAN-03-1843; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; Toth M, 2005, BIOCHEM J, V387, P497, DOI 10.1042/BJ20041324; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Toth M, 1997, CANCER RES, V57, P3159; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Yu M, 1997, FEBS LETT, V412, P568, DOI 10.1016/S0014-5793(97)00849-1; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200; Zucker S, 2004, EXP CELL RES, V293, P164, DOI 10.1016/j.yexcr.2003.10.007; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A	84	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26160	26168		10.1074/jbc.M414379200	http://dx.doi.org/10.1074/jbc.M414379200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901740	hybrid			2022-12-25	WOS:000230386800029
J	Su, D; Novoselov, SV; Sun, QA; Moustafa, ME; Zhou, Y; Oko, R; Hatfield, DL; Gladyshev, VN				Su, D; Novoselov, SV; Sun, QA; Moustafa, ME; Zhou, Y; Oko, R; Hatfield, DL; Gladyshev, VN			Mammalian selenoprotein thioredoxin-glutathione reductase - Roles in disulfide bond formation and sperm maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION PATTERN; ESCHERICHIA-COLI; REDOX REGULATION; MESSENGER-RNA; PEROXIDASE; PROTEIN; CELLS; GENE; IDENTIFICATION; SELENOCYSTEINE	Thioredoxin reductases (TRs) are important redox regulatory enzymes, which control the redox state of thioredoxins. Mammals have cytosolic and mitochondrial TRs, which contain an essential selenocysteine residue and reduce cytosolic and mitochondrial thioredoxins. In addition, thioredoxin/glutathione reductase (TGR) was identified, which is a fusion of an N-terminal glutaredoxin domain and the TR module. Here we show that TGR is expressed at low levels in various tissues but accumulates in testes after puberty. The protein is particularly abundant in elongating spermatids at the site of mitochondrial sheath formation but is absent in mature sperm. We found that TGR can catalyze isomerization of protein and interprotein disulfide bonds and localized this function to its thiol domain. TGR targets include proteins that form structural components of the sperm, including glutathione peroxidase GPx4/PHGPx. Together, TGR and GPx4 can serve as a novel disulfide bond formation system. Both enzymes contain a catalytic selenocysteine consistent with the role of selenium in male reproduction.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Nebraska, Ctr Biotechnol, Lincoln, NE 68588 USA; NCI, NIH, Bethesda, MD 20892 USA; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Queens University - Canada	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Moustafa, Mohamed E/E-9002-2018; Gladyshev, Vadim N/A-9894-2013; Gladyshev, Vadim N/J-6187-2013; Moustafa, Mohamed/AAM-2211-2021; Su, Dan/B-1972-2010	Moustafa, Mohamed/0000-0003-1308-6221; Gladyshev, Vadim/0000-0002-0372-7016; Novoselov, Sergey/0000-0003-0104-6492	NATIONAL CANCER INSTITUTE [Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065204, R37GM065204] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM065204] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bardwell JCA, 2002, DEV CELL, V3, P758, DOI 10.1016/S1534-5807(02)00370-2; Bessette PH, 1999, P NATL ACAD SCI USA, V96, P13703, DOI 10.1073/pnas.96.24.13703; Borchert A, 2003, J BIOL CHEM, V278, P2571, DOI 10.1074/jbc.M209064200; Burmester S, 1996, MOL REPROD DEV, V45, P10, DOI 10.1002/(SICI)1098-2795(199609)45:1&lt;10::AID-MRD2&gt;3.0.CO;2-V; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Fassio A, 2002, HISTOCHEM CELL BIOL, V117, P151, DOI 10.1007/s00418-001-0364-0; Foresta C, 2002, BIOL REPROD, V67, P967, DOI 10.1095/biolreprod.102.003822; FULCHER KD, 1995, BIOL REPROD, V52, P41, DOI 10.1095/biolreprod52.1.41; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Holmgren A, 1980, Experientia Suppl, V36, P149; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Lei XG, 1997, BIOL TRACE ELEM RES, V59, P195, DOI 10.1007/BF02783245; Maiorino M, 2002, BIOL CHEM, V383, P591, DOI 10.1515/BC.2002.061; Miranda-Vizuete A, 2001, J BIOL CHEM, V276, P31567, DOI 10.1074/jbc.M101760200; MORALES CR, 1994, MOL REPROD DEV, V37, P229, DOI 10.1002/mrd.1080370215; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; Nalvarte I, 2004, J BIOL CHEM, V279, P54510, DOI 10.1074/jbc.M408494200; Nam SY, 1997, J VET MED SCI, V59, P983, DOI 10.1292/jvms.59.983; Pfeifer H, 2001, FASEB J, V15, P1236, DOI 10.1096/fj.00-0655fje; Qiu J, 1998, APPL ENVIRON MICROB, V64, P4891; ROVERI A, 1992, J BIOL CHEM, V267, P6142; Rundlof AK, 2004, FREE RADICAL BIO MED, V36, P641, DOI 10.1016/j.freeradbiomed.2003.12.004; Sadek CM, 2001, GENES CELLS, V6, P1077, DOI 10.1046/j.1365-2443.2001.00484.x; Senkevich TG, 2002, P NATL ACAD SCI USA, V99, P6667, DOI 10.1073/pnas.062163799; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Strauss E, 1999, SCIENCE, V285, P1339; Su D, 2004, BIOCHEMISTRY-US, V43, P12177, DOI 10.1021/bi048478t; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun QA, 2002, METHOD ENZYMOL, V347, P451; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; Sutovsky P, 1997, MOL REPROD DEV, V47, P79, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;79::AID-MRD11&gt;3.0.CO;2-V; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Ursini F, 1997, BIOMED ENVIRON SCI, V10, P327	39	147	154	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26491	26498		10.1074/jbc.M503638200	http://dx.doi.org/10.1074/jbc.M503638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901730	Green Submitted, hybrid			2022-12-25	WOS:000230386800065
J	Demidenko, ZN; Rapisarda, A; Garayoa, M; Giannakakou, P; Melillo, G; Blagosklonny, MV				Demidenko, ZN; Rapisarda, A; Garayoa, M; Giannakakou, P; Melillo, G; Blagosklonny, MV			Accumulation of hypoxia-inducible factor-1 alpha is limited by transcription-dependent depletion	ONCOGENE			English	Article						HIF-1; hypoxia; p53; the proteasome; degradation	TUMOR-SUPPRESSOR PROTEIN; HIPPEL-LINDAU PROTEIN; PROLYL HYDROXYLASES; TOPOISOMERASE-I; HIF-ALPHA; HIF-1-ALPHA; OXYGEN; P53; INHIBITION; PATHWAY	In the presence of oxygen and iron, hypoxia- inducible factor (HIF-1 alpha) is rapidly degraded via the prolyl hydroxylases (PHD)/VHL pathways. Given striking similarities between p53 and HIF-1 alpha regulation, we previously suggested that HIF-1 transcriptionally initiates its own degradation and therefore inhibitors of transcription must induce HIF-1 alpha. Under normoxia, while inducing p53, inhibitors of transcription did not induce HIF-1 alpha. Under hypoxia or low iron (DFX), inhibitors of transcription dramatically super- induced HIF-1 alpha. Removal of inhibitors resulted in outburst of the HIF-1-dependent transcription followed by depletion of HIF-1 alpha. Although hypoxia/ DFX induced PHD3, we excluded the PHD/VHL pathway in the regulation of HIF-1 alpha under hypoxia/DFX. The transcription-dependent degradation of HIF-1 alpha under hypoxia occurs via the proteasome and is accelerated by protein acetylation. Thus, HIF-1 alpha is regulated by two distinct mechanisms. Under normoxia, HIF-1 alpha is degraded via the classic PHD/VHL pathway, is expressed at low levels and therefore does not activate the feedback loop. But under hypoxia, HIF-1 alpha accumulates and transcriptionally activates its own degradation that is independent from the PHD/VHL pathway.	New York Med Coll, Brander Canc Res Inst, Valhalla, NY USA; SAID Frederick Inc, NCI, Tumor Hypoxia Lab, Frederick, MD USA; Univ Navarra, Fac Med & Ciencias, Dept Histol & Anat Patol, Navarra, Spain; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	New York Medical College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Navarra; Emory University	Blagosklonny, MV (corresponding author), Ordway Res Inst, Ctr Canc, 150 New Scotland Ave, Albany, NY 12208 USA.	Blagosklonny@hotmail.com	Garayoa, Mercedes/O-6039-2017	Garayoa, Mercedes/0000-0003-2194-2841; Giannakakou, Paraskevi/0000-0001-7378-262X				Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Blagosklonny MV, 2001, ONCOGENE, V20, P395, DOI 10.1038/sj.onc.1204055; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; de Azevedo WF, 2002, BIOCHEM BIOPH RES CO, V293, P566; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304; Haupt Y, 2004, CELL CYCLE, V3, P884; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lin SK, 2004, MOL PHARMACOL, V66, P612; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Rapisarda A, 2004, CELL CYCLE, V3, P172; Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139; Rapisarda A, 2002, CANCER RES, V62, P4316; Salnikow K, 2000, CANCER RES, V60, P5630; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Turcotte S, 2004, AM J PHYSIOL-RENAL, V286, pF338, DOI 10.1152/ajprenal.00254.2003; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	42	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4829	4838		10.1038/sj.onc.1208636	http://dx.doi.org/10.1038/sj.onc.1208636			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897903				2022-12-25	WOS:000230477900010
J	Liedtke, CM; Wang, XY; Smallwood, ND				Liedtke, CM; Wang, XY; Smallwood, ND			Role for protein phosphatase 2A in the regulation of Calu-3 epithelial Na+-K+-2Cl(-), type 1 co-transport function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; PKC-DELTA; NA-K-2CL COTRANSPORT; OKADAIC ACID; KINASE-C; PHOSPHORYLATION; MODULATION; ACTIVATION; BINDING; STRESS	Activity of Na (+)- K (+)- 2Cl(-) co- transport ( NKCC1) in epithelia is thought to be highly regulated through phosphorylation and dephosphorylation of the transporter. Previous functional studies from this laboratory suggested a role for protein phosphatase 2A ( PP2A) as a serine/ threonine protein phosphatase involved in the regulation of mammalian tracheal epithelial NKCC1. We expand on these studies to characterize serine/ threonine protein phosphatase( s) necessary for regulation of NKCC1 function and the interaction of the phosphatase( s) with proteins associated with NKCC1. NKCC1 activity was measured as bumetanide- sensitive Rb-86 uptake or basolateral to apical 86Rb flux in primary cultures of human tracheal epithelial cells or in Calu- 3 airway epithelial cells grown on Transwell filter inserts. Preincubation with 0.1 n(M) okadaic acid, a PP2A >> phosphatase 1 ( PP1) inhibitor, increased NKCC1 activity 3.5- fold in human tracheal epithelial cells and 4.1- fold in Calu- 3 cells. Calyculin, a PP1 >> PP2A inhibitor, did not alter NKCC1 activity or percent bumetanide- sensitive flux. The effect of OA was dose- dependent with an IC50 of 0.4 nM. The alpha(1)- adrenergic agonist methoxamine increased NKCC1 activity and transiently increased PP2A activity 3.8- fold but did not alter PP1 activity. OA augmented methoxaminedependent stimulation of NKCC1 activity. PP1, PP2A, and PP2C but not PP2B were detected in lysates from Calu- 3 cells by immunoblot analysis. PP1 was not detected in immunoprecipitates of NKCC1 and vice versa. PP2A co- immunoprecipitated with NKCC1 and protein kinase C-delta ( PKC-delta) and was pulled down by a recombinant N terminus of NKCC1 consisting of amino acids 1 - 286. One novel finding is co- precipitation of STE20related proline- alanine- rich kinase, a regulatory kinase for NKCC1, with PP2A and PKC-delta. The results suggest a model of actin serving as a scaffold for binding and association of PKC-delta, PP2A, and STE20- related proline- alanine- rich kinase. The role of the complex of serine/ threonine protein kinases and a protein phosphatase is probably the maintenance of optimal phosphorylation of NKCC1 coincident with its physiological function in epithelial absorption and secretion.	Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Willard Alan Bernbaum Ctr Cyst Fibrosis Res, Cleveland, OH 44106 USA; Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Physiol & Biophys, Willard Alan Bernbaum Ctr Cyst Fibrosis Res, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Liedtke, CM (corresponding author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Willard Alan Bernbaum Ctr Cyst Fibrosis Res, Biomed Res Bldg,Rm 824,2109 Adelbert Rd, Cleveland, OH 44106 USA.	carole.liedtke@case.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058598] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58598] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTAMIRANO AA, 1995, AM J PHYSIOL-CELL PH, V269, pC878, DOI 10.1152/ajpcell.1995.269.4.C878; Andersen GO, 2004, AM J PHYSIOL-HEART C, V286, pH1354, DOI 10.1152/ajpheart.00549.2003; Cohen PTW, 2002, J CELL SCI, V115, P241; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; GAGNON KB, 2005, FASEB J, V19, pA1155; Kurihara K, 2002, AM J PHYSIOL-CELL PH, V282, pC817, DOI 10.1152/ajpcell.00352.2001; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; LIEDTKE CM, 1992, AM J PHYSIOL, V262, pL621, DOI 10.1152/ajplung.1992.262.5.L621; LIEDTKE CM, 1995, AM J PHYSIOL-LUNG C, V268, pL414, DOI 10.1152/ajplung.1995.268.3.L414; Liedtke CM, 2003, AM J PHYSIOL-CELL PH, V284, pC487, DOI 10.1152/ajpcell.00357.2002; Liedtke CM, 2002, BBA-MOL CELL RES, V1589, P77, DOI 10.1016/S0167-4889(01)00189-6; Liedtke CM, 2002, AM J PHYSIOL-LUNG C, V282, pL1151, DOI 10.1152/ajplung.00143.2001; Liedtke CM, 2001, AM J PHYSIOL-LUNG C, V280, pL739, DOI 10.1152/ajplung.2001.280.4.L739; Liedtke CM, 1996, AM J PHYSIOL-CELL PH, V271, pC338, DOI 10.1152/ajpcell.1996.271.1.C338; Lytle C, 1998, AM J PHYSIOL-CELL PH, V274, pC1002, DOI 10.1152/ajpcell.1998.274.4.C1002; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 2002, AM J PHYSIOL-CELL PH, V283, pC1422, DOI 10.1152/ajpcell.00130.2002; ODONNELL ME, 1995, AM J PHYSIOL, V269, pC1512; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; Piechotta K, 2003, J BIOL CHEM, V278, P52848, DOI 10.1074/jbc.M309436200; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Smallwood ND, 2005, AM J PHYSIOL-CELL PH, V288, pC906, DOI 10.1152/ajpcell.00484.2004; Srivastava J, 2002, FEBS LETT, V516, P265, DOI 10.1016/S0014-5793(02)02500-0	29	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25491	25498		10.1074/jbc.M504473200	http://dx.doi.org/10.1074/jbc.M504473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15899883	hybrid			2022-12-25	WOS:000230207900024
J	Farmer, P; Bonnefoi, H; Becette, V; Tubiana-Hulin, M; Fumoleau, P; Larsimont, D; MacGrogan, G; Bergh, J; Cameron, D; Goldstein, D; Duss, S; Nicoulaz, AL; Brisken, C; Fiche, M; Delorenzi, M; Iggo, R				Farmer, P; Bonnefoi, H; Becette, V; Tubiana-Hulin, M; Fumoleau, P; Larsimont, D; MacGrogan, G; Bergh, J; Cameron, D; Goldstein, D; Duss, S; Nicoulaz, AL; Brisken, C; Fiche, M; Delorenzi, M; Iggo, R			Identification of molecular apocrine breast tumours by microarray analysis	ONCOGENE			English	Article						breast cancer; microarrays; apocrine carcinoma	GENE-EXPRESSION PATTERNS; ANDROGEN RECEPTOR; GROWTH-HORMONE; CANCER; ENDOCRINE; PROLIFERATION; VALIDATION; CARCINOMAS; EPITHELIUM; PROLACTIN	Previous microarray studies on breast cancer identified multiple tumour classes, of which the most prominent, named luminal and basal, differ in expression of the oestrogen receptor a gene ( ER). We report here the identification of a group of breast tumours with increased androgen signalling and a 'molecular apocrine' gene expression pro. le. Tumour samples from 49 patients with large operable or locally advanced breast cancers were tested on Affymetrix U133A gene expression microarrays. Principal components analysis and hierarchical clustering split the tumours into three groups: basal, luminal and a group we call molecular apocrine. All of the molecular apocrine tumours have strong apocrine features on histological examination (P = 0.0002). The molecular apocrine group is androgen receptor (AR) positive and contains all of the ER-negative tumours outside the basal group. Kolmogorov-Smirnov testing indicates that oestrogen signalling is most active in the luminal group, and androgen signalling is most active in the molecular apocrine group. ERBB2 amplification is commoner in the molecular apocrine than the other groups. Genes that best split the three groups were identified by Wilcoxon test. Correlation of the average expression pro. le of these genes in our data with the expression pro. le of individual tumours in four published breast cancer studies suggest that molecular apocrine tumours represent 8-14% of tumours in these studies. Our data show that it is possible with microarray data to divide mammary tumour cells into three groups based on steroid receptor activity: luminal (ER+AR+), basal (ER+AR+) and molecular apocrine (ER+AR+).	Swiss Inst Bioinformat, Lausanne, Switzerland; Swiss Inst Expt Canc Res, Natl Ctr Competence Res Mol Oncol, CH-1066 Epalinges, Switzerland; Hop Univ Geneve, Geneva, Switzerland; Swiss Grp Clin Canc Res, Bern, Switzerland; Eortc Data Ctr, European Org Res Treatment Canc, Brussels, Belgium; Ctr Rene Gauducheau, F-44035 Nantes, France; Ctr Rene Huguenin, St Cloud, France; Inst Jules Bordet, B-1000 Brussels, Belgium; Inst Bergonie, Bordeaux, France; Karolinska Inst, Swedish Breast Canc Grp, Stockholm, Sweden; Univ Edinburgh, ACCOG, Edinburgh, Midlothian, Scotland; CHU Vaudois, CH-1011 Lausanne, Switzerland	Swiss Institute of Bioinformatics; Swiss Institute Experimental Cancer Research; University of Geneva; Swiss Group for Clinical Cancer Research (SAKK); European Organisation for Research & Treatment of Cancer; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Rene Huguenin Hospital; Institut Jules Bordet; UNICANCER; Institut Bergonie; Karolinska Institutet; University of Edinburgh; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Iggo, R (corresponding author), Swiss Inst Bioinformat, Lausanne, Switzerland.	richard.iggo@isrec.ch	Iggo, Richard/G-3546-2014; Cameron, David A/C-7781-2013	Cameron, David A/0000-0002-2717-7979; MacGrogan, Gaetan/0000-0002-3483-9758; Brisken, Cathrin/0000-0002-6857-3230; Bergh, Jonas/0000-0001-5526-1847; Duss, Stephan/0000-0002-0521-162X				Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Birrell SN, 1998, J MAMMARY GLAND BIOL, V3, P95, DOI 10.1023/A:1018730519839; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Chen WY, 1999, CLIN CANCER RES, V5, P3583; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; ELLIS I, 2003, PATHOLOGY GENETICS T, V5, P13; FRABLE WJ, 1968, CANCER, V21, P756, DOI 10.1002/1097-0142(196804)21:4<756::AID-CNCR2820210428>3.0.CO;2-Y; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Jain AN, 2001, P NATL ACAD SCI USA, V98, P7952, DOI 10.1073/pnas.151241198; Jones C, 2001, AM J PATHOL, V158, P207, DOI 10.1016/S0002-9440(10)63959-4; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Levesque E, 2001, BIOCHEMISTRY-US, V40, P3869, DOI 10.1021/bi002607y; Liao DJ, 2002, J STEROID BIOCHEM, V80, P175, DOI 10.1016/S0960-0760(01)00185-6; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; MILLER WR, 1985, BREAST CANCER RES TR, V5, P67, DOI 10.1007/BF01807652; MILLWARD MJ, 1991, BRIT J CANCER, V63, P763, DOI 10.1038/bjc.1991.170; Moinfar F, 2003, CANCER-AM CANCER SOC, V98, P703, DOI 10.1002/cncr.11532; Molist R, 2004, ONCOGENE, V23, P5986, DOI 10.1038/sj.onc.1207799; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; ROSEN PP, 1996, DIS BREAST, P413; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221; Schmitt FC, 2002, BREAST, V11, P463, DOI 10.1054/brst.2002.0480; Selim AGA, 2000, J PATHOL, V191, P138, DOI 10.1002/(SICI)1096-9896(200006)191:2<138::AID-PATH611>3.0.CO;2-J; Selim AGA, 1999, J CLIN PATHOL, V52, P838, DOI 10.1136/jcp.52.11.838; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Viacava P, 1997, VIRCHOWS ARCH, V431, P205, DOI 10.1007/s004280050089; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; WU L, 1993, J BIOL CHEM, V268, P12964; Yu H, 2000, BREAST CANCER RES TR, V59, P153, DOI 10.1023/A:1006356502820	49	561	584	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4660	4671		10.1038/sj.onc.1208561	http://dx.doi.org/10.1038/sj.onc.1208561			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897907				2022-12-25	WOS:000230304500005
J	Furst, J; Schedlbauer, A; Gandini, R; Garavaglia, ML; Saino, S; Gschwentner, M; Sarg, B; Lindner, H; Jakab, M; Ritter, M; Bazzini, C; Botta, G; Meyer, G; Kontaxis, G; Tilly, BC; Konrat, R; Paulmichl, M				Furst, J; Schedlbauer, A; Gandini, R; Garavaglia, ML; Saino, S; Gschwentner, M; Sarg, B; Lindner, H; Jakab, M; Ritter, M; Bazzini, C; Botta, G; Meyer, G; Kontaxis, G; Tilly, BC; Konrat, R; Paulmichl, M			ICln(159) folds into a pleckstrin homology domain-like structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SM PROTEINS; CHLORIDE CHANNELS; VOLUME REGULATION; PH DOMAIN; PI(CLN); ICLN; COMPLEX; CELLS; PICLN	ICln is a multifunctional protein involved in regulatory mechanisms as different as membrane ion transport and RNA splicing. The protein is water-soluble, and during regulatory volume decrease after cell swelling, it is able to migrate from the cytosol to the cell membrane. Purified, water-soluble ICln is able to insert into lipid bilayers to form ion channels. Here, we show that ICln(159), a truncated ICln mutant, which is also able to form ion channels in lipid bilayers, belongs to the pleckstrin homology (PH) domain superfold family of proteins. The ICln PH domain shows unusual properties as it lacks the electrostatic surface polarization seen in classical PH domains. However, similar to many classical PH domain-containing proteins, ICln interacts with protein kinase C, and in addition, interacts with cAMP-dependent protein kinase and cGMP-dependent protein kinase type II but not cGMP-dependent protein kinase type I beta. A major phosphorylation site for all three kinases is Ser-45 within the ICln PH domain. Furthermore, ICln159 interacts with LSm4, a protein involved in splicing and mRNA degradation, suggesting that the ICln159 PH domain may serve as a protein-protein interaction platform.	Innsbruck Med Univ, Dept Physiol & Med Phys, A-6020 Innsbruck, Austria; Univ Vienna, Inst Theoret Chem & Mol Struct Biol, A-1030 Vienna, Austria; Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy; Innsbruck Med Univ, Div Clin Biochem, Biozentrum, A-6020 Innsbruck, Austria; Paracelsus Private Med Univ, Inst Physiol, A-5020 Salzburg, Austria; Erasmus Univ, Med Ctr, Dept Biochem, NL-3015 GE Rotterdam, Netherlands	Medical University of Innsbruck; University of Vienna; University of Milan; Medical University of Innsbruck; Paracelsus Private Medical University; Erasmus University Rotterdam; Erasmus MC	Paulmichl, M (corresponding author), Innsbruck Med Univ, Dept Physiol & Med Phys, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	markus.paulmichl@uibk.ac.at	Garavaglia, Maria Lisa/AFV-3214-2022; Meyer, Giuliano/G-8062-2011; Bazzini, Claudia/G-8214-2011; Ritter, Markus/AAG-4987-2020	Ritter, Markus/0000-0001-7346-7750; Gandini, Rosaria/0000-0003-4171-0693				Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; CAVANAGH J, 1996, MEASUREMENTS 3 BOND; Chen LX, 1999, AM J PHYSIOL-CELL PH, V276, pC182, DOI 10.1152/ajpcell.1999.276.1.C182; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Emma F, 1998, BBA-MOL CELL RES, V1404, P321, DOI 10.1016/S0167-4889(98)00073-1; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Furst J, 2002, PFLUG ARCH EUR J PHY, V444, P1, DOI 10.1007/s00424-002-0805-1; Furst J, 2000, CELL PHYSIOL BIOCHEM, V10, P329, DOI 10.1159/000016374; Furst J, 2000, PFLUG ARCH EUR J PHY, V440, P100; Garavaglia M, 2004, CELL PHYSIOL BIOCHEM, V14, P231, DOI 10.1159/000080332; Garavaglia ML, 2002, PFLUG ARCH EUR J PHY, V443, P748, DOI 10.1007/s00424-001-0772-y; Grimmler M, 2005, EMBO REP, V6, P70, DOI 10.1038/sj.embor.7400301; GRZESIEK S, 1993, J BIOMOL NMR, V3, P487; GSCHWENTNER M, 1995, MOL MED, V1, P407, DOI 10.1007/BF03401578; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; Guimera R, 2005, NATURE, V433, P895, DOI 10.1038/nature03288; Hubert MD, 2000, BBA-BIOMEMBRANES, V1466, P105, DOI 10.1016/S0005-2736(00)00177-2; Jakab M, 2002, CELL PHYSIOL BIOCHEM, V12, P235, DOI 10.1159/000067895; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; Jobin CM, 2003, BIOCHEMISTRY-US, V42, P11716, DOI 10.1021/bi035066w; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; Larkin D, 2004, J BIOL CHEM, V279, P27286, DOI 10.1074/jbc.M402159200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lemmon MA, 2004, BIOCHEM SOC T, V32, P707, DOI 10.1042/BST0320707; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Li CH, 1998, J GEN PHYSIOL, V112, P727, DOI 10.1085/jgp.112.6.727; Li YY, 1999, J BIOCHEM-TOKYO, V126, P643, DOI 10.1093/oxfordjournals.jbchem.a022497; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OKADA Y, 1997, AM J PHYSIOL, V273, P755; Ott HW, 2003, CANCER RES, V63, P7507; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; Pu WT, 1999, MOL CELL BIOL, V19, P4113; Pu WT, 2000, J BIOL CHEM, V275, P12363, DOI 10.1074/jbc.275.17.12363; Ritter M, 2003, J BIOL CHEM, V278, P50163, DOI 10.1074/jbc.M300374200; Ruth P, 1999, PHARMACOL THERAPEUT, V82, P355, DOI 10.1016/S0163-7258(98)00067-9; Sanchez-Olea R, 1998, BBA-GEN SUBJECTS, V1381, P49, DOI 10.1016/S0304-4165(98)00009-9; Schedlbauer A, 2003, J BIOMOL NMR, V27, P399, DOI 10.1023/A:1025809828637; Schmarda A, 2001, CELL PHYSIOL BIOCHEM, V11, P55, DOI 10.1159/000047792; Schwartz RS, 1997, BIOCHEM J, V327, P609; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Sugimoto K, 2003, J AM CHEM SOC, V125, P5000, DOI 10.1021/ja029477w; Tang CJC, 1998, BLOOD, V92, P1442, DOI 10.1182/blood.V92.4.1442.416k14_1442_1447; Tao GZ, 1998, BIOCHEM BIOPH RES CO, V247, P668, DOI 10.1006/bbrc.1998.8837; Tao GZ, 2000, PEPTIDES, V21, P485, DOI 10.1016/S0196-9781(00)00176-5; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071	53	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31276	31282		10.1074/jbc.M500541200	http://dx.doi.org/10.1074/jbc.M500541200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15905169	hybrid			2022-12-25	WOS:000231487800075
J	Wenzel, A; Oberhauser, V; Pugh, EN; Lamb, TD; Grimm, C; Samardzija, M; Fahl, E; Seeliger, MW; Reme, CE; von Lintig, J				Wenzel, A; Oberhauser, V; Pugh, EN; Lamb, TD; Grimm, C; Samardzija, M; Fahl, E; Seeliger, MW; Reme, CE; von Lintig, J			The retinal G protein-coupled receptor (RGR) enhances isomerohydrolase activity independent of light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL CYCLE; 11-CIS-RETINOL DEHYDROGENASE; BINDING-PROTEIN; RPE65; VERTEBRATE; RHODOPSIN; METARHODOPSIN; CHROMOPHORE; ESTERS; DAMAGE	Rod and cone visual pigments use 11-cis-retinal, a vitamin A derivative, as their chromophore. Light isomerizes 11-cis-intoall-trans-retinal, triggering a conformational transition of the opsin molecule that initiates phototransduction. After bleaching all-trans-retinal leaves the opsin, and light sensitivity must be restored by regeneration of 11-cis-retinal. Under bright light conditions the retinal G protein-coupled receptor (RGR) was reported to support this regeneration by acting as a photoisomerase in a proposed photic visual cycle. We analyzed the contribution of RGR to rhodopsin regeneration under different light regimes and show that regeneration, during light exposure and in darkness, is slowed about 3-fold in Rgr(-/-) mice. These findings are not in line with the proposed function of RGR as a photoisomerase. Instead, RGR, independent of light, accelerates the conversion of retinyl esters to 11-cis-retinal by positively modulating isomerohydrolase activity, a key step in the "classical" visual cycle. Furthermore, we find that light accelerates rhodopsin regeneration, independent of RGR.	Univ Zurich Hosp, Lab Retinal Cell Biol, ONO EM, CH-8091 Zurich, Switzerland; Univ Freiburg, Inst Biol 1, D-79104 Freiburg, Germany; FM Kirby Ctr, Dept Ophthalmol, Philadelphia, PA 19104 USA; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; Univ Eye Hosp Tuebingen, Retinal Electrodiagnost Res Grp, Dept Pathophysiol Vis & Neuroophthalmol, D-72076 Tubingen, Germany	University of Zurich; University Zurich Hospital; University of Freiburg; University of Pennsylvania; Pennsylvania Medicine; Australian National University; John Curtin School of Medical Research; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Wenzel, A (corresponding author), Univ Zurich Hosp, Lab Retinal Cell Biol, ONO EM, H-Lab-13,Sternwartstr 14, CH-8091 Zurich, Switzerland.	awenzel@opht.unizh.ch	Samardzija, Marijana/B-9245-2008; Lamb, Trevor/C-9755-2009	Samardzija, Marijana/0000-0003-0991-4653; von Lintig, Johannes/0000-0002-2079-2143; Grimm, Christian/0000-0001-9318-4352	NATIONAL EYE INSTITUTE [R01EY002660] Funding Source: NIH RePORTER; NEI NIH HHS [EY02660] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bartl FJ, 2001, J BIOL CHEM, V276, P30161, DOI 10.1074/jbc.M101506200; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; BERNSTEIN PS, 1987, J BIOL CHEM, V262, P16848; Bhattacharya S.K., 2002, INVEST OPHTH VIS SCI, V43, pU1301; BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Chen P, 2001, NAT GENET, V28, P256, DOI 10.1038/90089; Chen P, 2001, J BIOL CHEM, V276, P21098, DOI 10.1074/jbc.M010441200; CHEN P, 2005, INVESTIG OPHTHALMOL, V46, P5127; Danciger M, 2004, MAMM GENOME, V15, P277, DOI 10.1007/s00335-003-2336-2; Danciger M, 2000, MAMM GENOME, V11, P422, DOI 10.1007/s003350010081; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Fedorov LM, 1997, TRANSGENIC RES, V6, P223, DOI 10.1023/A:1018446325492; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P11824, DOI 10.1021/bi035227w; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; Grimm C, 2000, INVEST OPHTH VIS SCI, V41, P3984; Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004; HAMEL CP, 1994, GENOMICS, V20, P509, DOI 10.1006/geno.1994.1212; Hao WS, 2000, METHOD ENZYMOL, V316, P413; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; Hao WS, 1999, J BIOL CHEM, V274, P6085, DOI 10.1074/jbc.274.10.6085; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; JANSSEN JJM, 1994, INVEST OPHTH VIS SCI, V35, P189; Kolesnikov AV, 2003, VISUAL NEUROSCI, V20, P249, DOI 10.1017/S0952523803203047; Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001; Lampert JM, 2003, DEVELOPMENT, V130, P2173, DOI 10.1242/dev.00437; Lyubarsky AL, 2004, INVEST OPHTH VIS SCI, V45, pU525; Lyubarsky AL, 2005, BIOCHEMISTRY-US, V44, P9880, DOI 10.1021/bi0505363; MA JX, 2005, INVESTIG OPHTHALMOL, V46, P1057; Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x; Mahroo OAR, 2004, J PHYSIOL-LONDON, V554, P417, DOI 10.1113/jphysiol.2003.051250; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y; Nikonov SS, 2005, J GEN PHYSIOL, V125, P287, DOI 10.1085/jgp.200409208; Nusinowitz S, 2003, EXP EYE RES, V77, P627, DOI 10.1016/S0014-4835(03)00217-3; Pepperberg DR, 2001, LANCET, V358, P2098, DOI 10.1016/S0140-6736(01)07231-2; Qtaishat NM, 2003, INVEST OPHTH VIS SCI, V44, P1435, DOI 10.1167/iovs.02-0679; RANDO RR, 1992, PHOTOCHEM PHOTOBIOL, V56, P1145, DOI 10.1111/j.1751-1097.1992.tb09739.x; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2000, METHOD ENZYMOL, V316, P705; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; Simon A, 1999, J CELL SCI, V112, P549; Tao L, 1998, Mol Vis, V4, P25; Tsilou E, 1997, ARCH BIOCHEM BIOPHYS, V346, P21, DOI 10.1006/abbi.1997.0276; Wenzel A, 2003, INVEST OPHTH VIS SCI, V44, P2798, DOI 10.1167/iovs.02-1134; Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001; WILLIAMS TP, 1968, VISION RES, V8, P1457, DOI 10.1016/0042-6989(68)90120-X; WILLIAMS TP, 1964, J GEN PHYSIOL, V47, P679, DOI 10.1085/jgp.47.4.679; Wolf G, 2002, NUTR REV, V60, P62, DOI 10.1301/00296640260085976; Wu BX, 2004, INVEST OPHTH VIS SCI, V45, P3857, DOI 10.1167/iovs.03-1302; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016	53	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29874	29884		10.1074/jbc.M503603200	http://dx.doi.org/10.1074/jbc.M503603200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15961402	hybrid			2022-12-25	WOS:000231176200059
J	Vazquez-Novelle, MD; Esteban, VN; Bueno, A; Sacristan, MP				Vazquez-Novelle, MD; Esteban, VN; Bueno, A; Sacristan, MP			Functional homology among human and fission yeast Cdc14 phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 PROTEIN PHOSPHATASES; CELL-CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; MITOTIC EXIT; SCHIZOSACCHAROMYCES-POMBE; BUDDING YEAST; AURORA-B; ANAPHASE; KINASE	Budding and fission yeast Cdc14 homologues, a conserved family of serine-threonine phosphatases, play a role in the inactivation of mitotic cyclin-dependent kinases (CDKs) by molecularly distinct mechanisms. Saccharomyces cerevisiae Cdc14 protein phosphatase inactivates CDKs by promoting mitotic cyclin degradation and the accumulation of a CDK inhibitor to allow budding yeast cells to exit from mitosis. Schizosaccharomyces pombe Flp1 phosphatase down-regulates CDK/cyclin activity, controlling the degradation of the Cdc25 tyrosine phosphatase for fission yeast cells to undergo cytokinesis. In the present work, we show that human Cdc14 homologues (hCdc14A and hCdc14B) rescued flp1-deficient fission yeast strains, indicating functional homology. We also show that hCdc14A and B interacted in vivo with S. pombe Cdc25 and that hCdc14A dephosphorylated this mitotic inducer both in vitro and in vivo. Our results support a Cdc14 conserved inhibitory mechanism acting on S. pombe Cdc25 protein and suggest that human cells may regulate Cdc25 in a similar manner to inactivate Cdk1-mitotic cyclin complexes.	Univ Salamanca, CSIC, Ctr Invest Canc, Salamanca 37007, Spain; Univ Salamanca, CSIC, Dept Microbiol & Genet, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca	Sacristan, MP (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Miguel Unamuno, Salamanca 37007, Spain.	msacristan@usal.es	Sacristan, Maria/Y-4923-2019; Bueno, Avelino/A-9505-2016; Sacristán, María P/A-9587-2016	Sacristan, Maria/0000-0003-2314-8430; Bueno, Avelino/0000-0002-0362-4391; Sacristán, María P/0000-0003-2314-8430				AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Bahler J, 1998, GENE DEV, V12, P1356, DOI 10.1101/gad.12.9.1356; Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Calzada A, 2000, J BIOL CHEM, V275, P9734, DOI 10.1074/jbc.275.13.9734; Creanor J, 1996, J CELL SCI, V109, P1647; Cueille N, 2001, J CELL SCI, V114, P2649; D'Amours D, 2004, CELL, V117, P455, DOI 10.1016/S0092-8674(04)00413-1; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; Ekwall K, 1996, J CELL SCI, V109, P2637; Esteban V, 2004, J CELL SCI, V117, P2461, DOI 10.1242/jcs.01107; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Gray CH, 2003, EMBO J, V22, P3524, DOI 10.1093/emboj/cdg348; Gruneberg U, 2004, J CELL BIOL, V166, P167, DOI 10.1083/jcb.200403084; Jaspersen SL, 2000, CURR BIOL, V10, P615, DOI 10.1016/S0960-9822(00)00491-7; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; Menssen R, 2001, CURR BIOL, V11, P345, DOI 10.1016/S0960-9822(01)00095-1; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Norbury C, 1997, METHOD ENZYMOL, V283, P44; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Sangrador A, 1998, MOL GEN GENET, V259, P449, DOI 10.1007/s004380050835; Shiozaki K, 1997, METHOD ENZYMOL, V283, P506; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Sullivan M, 2004, CELL, V117, P471, DOI 10.1016/S0092-8674(04)00415-5; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Trautmann S, 2001, CURR BIOL, V11, P931, DOI 10.1016/S0960-9822(01)00268-8; Traverso EE, 2001, J BIOL CHEM, V276, P21924, DOI 10.1074/jbc.M011689200; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Wang BD, 2004, CELL CYCLE, V3, P960; Wolfe BA, 2004, EMBO J, V23, P919, DOI 10.1038/sj.emboj.7600103; Yoo EJ, 2000, NUCLEIC ACIDS RES, V28, P2004, DOI 10.1093/nar/28.9.2004	45	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29144	29150		10.1074/jbc.M413328200	http://dx.doi.org/10.1074/jbc.M413328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15911625	hybrid			2022-12-25	WOS:000231021300041
J	Albert, MA; Haanstra, JR; Hannaert, V; Van Roy, J; Opperdoes, FR; Bakker, BM; Michels, PAM				Albert, MA; Haanstra, JR; Hannaert, V; Van Roy, J; Opperdoes, FR; Bakker, BM; Michels, PAM			Experimental and in silico analyses of glycolytic flux control in bloodstream form Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PHOSPHOGLYCERATE MUTASE; STEADY-STATE TREATMENT; DOUBLE-STRANDED-RNA; TRIOSEPHOSPHATE ISOMERASE; SIMULTANEOUS PURIFICATION; CARBOHYDRATE-METABOLISM; GLUCOSE-TRANSPORT; ENZYMATIC CHAINS; ENZYMES; PHOSPHOFRUCTOKINASE	A mathematical model of glycolysis in bloodstream form Trypanosoma brucei was developed previously on the basis of all available enzyme kinetic data (Bakker, B. M., Michels, P. A. M., Opperdoes, F. R., and Westerhoff, H. V. (1997) J. Biol. Chem. 272, 3207 - 3215). The model predicted correctly the fluxes and cellular metabolite concentrations as measured in non-growing trypanosomes and the major contribution to the flux control exerted by the plasma membrane glucose transporter. Surprisingly, a large overcapacity was predicted for hexokinase (HXK), phosphofructokinase (PFK), and pyruvate kinase (PYK). Here, we present our further analysis of the control of glycolytic flux in bloodstream form T. brucei. First, the model was optimized and extended with recent information about the kinetics of enzymes and their activities as measured in lysates of in vitro cultured growing trypanosomes. Second, the concentrations of five glycolytic enzymes (HXK, PFK, phosphoglycerate mutase, enolase, and PYK) in trypanosomes were changed by RNA interference. The effects of the knockdown of these enzymes on the growth, activities, and levels of various enzymes and glycolytic flux were studied and compared with model predictions. Data thus obtained support the conclusion from the in silico analysis that HXK, PFK, and PYK are in excess, albeit less than predicted. Interestingly, depletion of PFK and enolase had an effect on the activity ( but not, or to a lesser extent, expression) of some other glycolytic enzymes. Enzymes located both in the glycosomes ( the peroxisome-like organelles harboring the first seven enzymes of the glycolytic pathway of trypanosomes) and in the cytosol were affected. These data suggest the existence of novel regulatory mechanisms operating in trypanosome glycolysis.	Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, Trop Dis Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, Biochem Lab, B-1200 Brussels, Belgium; Free Univ Amsterdam, Fac Earth & Life Sci, Dept Mol Cell Physiol, NL-1081 HV Amsterdam, Netherlands	Universite Catholique Louvain; Universite Catholique Louvain; Vrije Universiteit Amsterdam	Michels, PAM (corresponding author), Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, Trop Dis Res Unit, ICP-TROP 74-39,Ave Hippocrate 74, B-1200 Brussels, Belgium.	michels@bchm.ucl.ac.be	Opperdoes, Fred/N-9922-2019; Opperdoes, Frederik R/C-8897-2018; Michels, Paul A/A-5637-2009	Opperdoes, Fred/0000-0003-1984-3764; Opperdoes, Frederik R/0000-0003-1984-3764; Michels, Paul A/0000-0003-3726-6104; Haanstra, Jurgen/0000-0001-9652-0219; Bakker, Barbara/0000-0001-6274-3633				Bakker BM, 1995, J BIOENERG BIOMEMBR, V27, P513, DOI 10.1007/BF02110191; Bakker BM, 2000, MOL BIOCHEM PARASIT, V106, P1, DOI 10.1016/S0166-6851(99)00197-8; Bakker BM, 1999, J BIOL CHEM, V274, P14551, DOI 10.1074/jbc.274.21.14551; Bakker BM, 1997, J BIOL CHEM, V272, P3207, DOI 10.1074/jbc.272.6.3207; Bakker BM, 2000, P NATL ACAD SCI USA, V97, P2087, DOI 10.1073/pnas.030539197; Bakker BM, 1999, P NATL ACAD SCI USA, V96, P10098, DOI 10.1073/pnas.96.18.10098; Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; BOITEUX A, 1981, PHILOS T ROY SOC B, V293, P5, DOI 10.1098/rstb.1981.0056; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; CALLENS M, 1991, MOL BIOCHEM PARASIT, V47, P19, DOI 10.1016/0166-6851(91)90144-U; Chen YL, 2003, MOL BIOCHEM PARASIT, V126, P275, DOI 10.1016/S0166-6851(02)00276-1; Chevalier N, 2000, EUR J BIOCHEM, V267, P1464, DOI 10.1046/j.1432-1327.2000.01145.x; CRONIN CN, 1985, BIOCHEM J, V227, P113, DOI 10.1042/bj2270113; de Walque S, 1999, MOL BIOCHEM PARASIT, V104, P107, DOI 10.1016/S0166-6851(99)00144-9; Durand-Dubief M, 2003, MOL BIOCHEM PARASIT, V129, P11, DOI 10.1016/S0166-6851(03)00071-9; EISENTHAL R, 1985, FEBS LETT, V181, P23, DOI 10.1016/0014-5793(85)81106-6; EISENTHAL R, 1989, BIOCHIM BIOPHYS ACTA, V985, P81, DOI 10.1016/0005-2736(89)90107-7; FAIRLAMB AH, 1977, NATURE, V265, P270, DOI 10.1038/265270a0; Fell D., 1997, FRONTIERS METABOLISM, V2; GRUENBERG J, 1978, EUR J BIOCHEM, V89, P461, DOI 10.1111/j.1432-1033.1978.tb12549.x; Guerra DG, 2004, EUR J BIOCHEM, V271, P1798, DOI 10.1111/j.1432-1033.2004.04097.x; Hannaert V, 2003, EUR J BIOCHEM, V270, P3205, DOI 10.1046/j.1432-1033.2003.03692.x; HANNAERT V, 2003, KINETOPLASTID BIOL D; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; Helfert S, 2001, BIOCHEM J, V357, P117, DOI 10.1042/0264-6021:3570117; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; Kralova I, 2000, EUR J BIOCHEM, V267, P2323, DOI 10.1046/j.1432-1327.2000.01238.x; Lopez C, 2002, EUR J BIOCHEM, V269, P3978, DOI 10.1046/j.1432-1033.2002.03086.x; McCulloch Richard, 2004, Methods Mol Biol, V262, P53; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; MISSET O, 1984, EUR J BIOCHEM, V144, P475, DOI 10.1111/j.1432-1033.1984.tb08490.x; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; NWAGWU M, 1982, ACTA TROP, V39, P61; ODURO KK, 1980, EXP PARASITOL, V50, P123, DOI 10.1016/0014-4894(80)90014-4; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; Opperdoes FR, 2001, INT J PARASITOL, V31, P482, DOI 10.1016/S0020-7519(01)00155-2; RAPOPORT TA, 1974, EUR J BIOCHEM, V42, P107, DOI 10.1111/j.1432-1033.1974.tb03320.x; Sambrook J, 2001, MOL CLONING LAB MANU; Sauro Herbert M., 2003, OMICS A Journal of Integrative Biology, V7, P355, DOI 10.1089/153623103322637670; SAURO HM, 2000, P 9 INT M BIOTH JARN; SEYFANG A, 1991, EUR J BIOCHEM, V202, P191, DOI 10.1111/j.1432-1033.1991.tb16362.x; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; TERKUILE BH, 1991, J BIOL CHEM, V266, P857; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Verlinde CLM, 2001, DRUG RESIST UPDATE, V4, P50, DOI 10.1054/drup.2000.0177; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835	47	125	128	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28306	28315		10.1074/jbc.M502403200	http://dx.doi.org/10.1074/jbc.M502403200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15955817	hybrid			2022-12-25	WOS:000230857300017
J	Li, WG; Jain, MR; Chen, C; Yue, X; Hebbar, V; Zhou, RP; Kong, ANT				Li, WG; Jain, MR; Chen, C; Yue, X; Hebbar, V; Zhou, RP; Kong, ANT			Nrf2 possesses a redox-insensitive nuclear export signal overlapping with the leucine zipper motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; HEME OXYGENASE-1 GENE; TRANSCRIPTION FACTOR NRF2; YA-SUBUNIT GENE; INDUCIBLE EXPRESSION; OXIDATIVE STRESS; PROTEASOMAL DEGRADATION; MEDIATED EXPRESSION; SULFHYDRYL-GROUPS; PHASE-2 ENZYMES	Basic leucine zipper ( bZIP) protein Nrf2 is a key transcription factor mediating the antioxidant response. Under homeostatic conditions Nrf2 is anchored to cysteine-rich Keap1 and sequestered in the cytoplasm. When challenged with oxidative stress, Keap1 functions as a redox-sensitive switch and releases Nrf2. Subsequently, Nrf2 translocates into the cell nucleus and binds to a cis-acting enhancer called the antioxidant response element located in the promoters of a battery of cytoprotective genes and initiates their transcription. In this study we identify a canonical nuclear export signal ( NES) ( (537w)LKKQLST-LYL546) located in the leucine zipper ( ZIP) domain of the Nrf2 protein. The enhanced green fluorescent protein-tagged ZIP domain of Nrf2 ( amino acids 503 - 589) exhibited a CRM1-dependent cytosolic distribution that could be abrogated by site-directed mutations or treatment with the nuclear export inhibitor, leptomycin B. Ectotopic expression of the Nrf2-NES could also exclude the GAL4 DNA binding domain into the cytoplasm. This NES overlapped with the ZIP motif in Nrf2, suggesting that the formation of heterodimers between Nrf2 and other bZIP proteins may simultaneously mask the NES and attenuate Nrf2 nuclear export. The Nrf2-NES appeared to be redox-insensitive. Neither oxidants ( sulforaphane and diethyl maleate) nor reducing compounds ( N-acetyl-L-cysteine and reducing glutathione) could disrupt the cytosolic distribution of Nrf2 zip. Because Nrf2 activation is generally redox-sensitive, the redox insensitivity of this Nrf2-NES indicates the importance of Keap1 retention as a key rate-limiting step in Nrf2 activation. The characterization of the Nrf2 NES may help decipher the mechanisms governing nuclear localization and subsequent transcriptional activation of Nrf2-mediated cytoprotective genes.	Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Biol Chem, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Kong, ANT (corresponding author), Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	KongT@rci.rutgers.edu	Chen, Chi/AAF-5343-2020; JAIN, MOHIT/E-8230-2012; Kong, Ah-Ng Tony/AAX-2828-2020	Chen, Chi/0000-0001-9703-604X; 	NCI NIH HHS [R01 CA94828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094828] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Husberg C, 2003, BBA-MOL CELL RES, V1640, P143, DOI 10.1016/S0167-4889(03)00041-7; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kim BR, 2003, CANCER RES, V63, P7520; Kitamuro T, 2003, J BIOL CHEM, V278, P9125, DOI 10.1074/jbc.M209939200; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2004, METHOD ENZYMOL, V378, P273; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; NISHI K, 1994, J BIOL CHEM, V269, P6320; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Suzuki H, 2004, EMBO J, V23, P2544, DOI 10.1038/sj.emboj.7600248; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; Thimmulappa RK, 2002, CANCER RES, V62, P5196; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	60	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28430	28438		10.1074/jbc.M410601200	http://dx.doi.org/10.1074/jbc.M410601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15917227	hybrid			2022-12-25	WOS:000230857300032
J	Simmons, RA; Suponitsky-Kroyter, I; Selak, MA				Simmons, RA; Suponitsky-Kroyter, I; Selak, MA			Progressive accumulation of mitochondrial DNA mutations and decline in mitochondrial function lead to beta-cell failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPAIRED OXIDATIVE-PHOSPHORYLATION; ENZYME GENE-EXPRESSION; INSULIN-SECRETION; BIRTH-WEIGHT; SUPEROXIDE-PRODUCTION; MEDIATED SUPPRESSION; GLUCOSE-METABOLISM; DIABETES-MELLITUS; PANCREATIC-ISLETS; SKELETAL-MUSCLE	A key adaptation enabling the fetus to survive in a limited energy environment may be the reprogramming of mitochondrial function, which can have deleterious effects. Critical questions are whether mitochondrial dysfunction progressively declines after birth, and if so, what mechanism might underlie this process. To address this, we developed a model of intrauterine growth retardation ( IUGR) in the rat that leads to diabetes in adulthood. Reactive oxygen species ( ROS) production and oxidative stress gradually increased in IUGR islets. ATP production was impaired and continued to deteriorate with age. The activities of complex I and III of the electron transport chain progressively declined in IUGR islets. Mitochondrial DNA point mutations accumulated with age and were associated with decreased mitochondrial DNA content and reduced expression of mitochondria-encoded genes in IUGR islets. Mitochondrial dysfunction resulted in impaired insulin secretion. These results demonstrate that IUGR induces mitochondrial dysfunction in the fetal beta-cell, leading to increased production of ROS, which in turn damage mitochondrial DNA. A self-reinforcing cycle of progressive deterioration in mitochondrial function leads to a corresponding decline in beta-cell function. Finally, a threshold in mitochondrial dysfunction and ROS production is reached, and diabetes ensues.	Univ Penn, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Simmons, RA (corresponding author), Univ Penn, BRB 2-3,Rm 1308,421 Curie Blvd, Philadelphia, PA 19104 USA.	rsimmons@mail.med.upenn.edu		Simmons, Rebecca/0000-0002-2901-8904	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK055704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020898] Funding Source: NIH RePORTER; NIA NIH HHS [AG20898] Funding Source: Medline; NIDDK NIH HHS [DK19525, DK55704] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antinozzi PA, 2002, J BIOL CHEM, V277, P11746, DOI 10.1074/jbc.M108462200; Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1986, LANCET, V1, P1077; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Barros F, 1997, ELECTROPHORESIS, V18, P52, DOI 10.1002/elps.1150180110; Bindokas VP, 2003, J BIOL CHEM, V278, P9796, DOI 10.1074/jbc.M206913200; Bowen RS, 2001, ACTA OBSTET GYN SCAN, V80, P719, DOI 10.1034/j.1600-0412.2001.080008719.x; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; Crowther NJ, 2000, DIABETOLOGIA, V43, P978, DOI 10.1007/s001250051479; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; Ejima K, 1999, PLACENTA, V20, P95, DOI 10.1053/plac.1998.0338; Englander EW, 1999, J NEUROSCI RES, V58, P262, DOI 10.1002/(SICI)1097-4547(19991015)58:2<262::AID-JNR6>3.0.CO;2-W; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Gauthier BR, 2004, J BIOL CHEM, V279, P31121, DOI 10.1074/jbc.M405030200; Gorgias N, 1996, BRAIN RES, V714, P215, DOI 10.1016/0006-8993(95)01548-5; Hagar H, 1996, AM J PHYSIOL-RENAL, V271, pF209, DOI 10.1152/ajprenal.1996.271.1.F209; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HEUNGMAN L, 2002, J NEUROCHEM, V80, P928; Hilsdorf AW, 1999, BRAZ J MED BIOL RES, V32, P267, DOI 10.1590/S0100-879X1999000300003; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; Jaquet D, 2000, J CLIN ENDOCR METAB, V85, P1401, DOI 10.1210/jc.85.4.1401; Jensen CB, 2002, DIABETES, V51, P1271, DOI 10.2337/diabetes.51.4.1271; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Jonas JC, 2001, J BIOL CHEM, V276, P35375, DOI 10.1074/jbc.M105020200; Kaneto H, 1999, DIABETOLOGIA, V42, P1093, DOI 10.1007/s001250051276; Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855; Kaneto H, 2002, J BIOL CHEM, V277, P3680, DOI 10.1074/jbc.M109647200; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Karowicz-Bilinska Agata, 2002, Med Sci Monit, V8, pCR211; Kato H, 1997, GYNECOL OBSTET INVES, V43, P158, DOI 10.1159/000291845; KIM YL, 1995, ANAL BIOCHEM, V224, P608, DOI 10.1006/abio.1995.1096; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; Lane RH, 1996, BIOCHEM MOL MED, V59, P192, DOI 10.1006/bmme.1996.0087; Leger J, 1997, BRIT MED J, V315, P341; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; LENZEN S, 1986, BIOSCIENCE REP, V6, P163, DOI 10.1007/BF01115002; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Lynn S, 2003, DIABETOLOGIA, V46, P296, DOI 10.1007/s00125-002-1018-z; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; MALAISSE WJ, 1980, DIABETES, V29, P431, DOI 10.2337/diabetes.29.6.431; Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126; Mertz RJ, 1996, J BIOL CHEM, V271, P4838, DOI 10.1074/jbc.271.9.4838; Moran A, 1997, J CLIN INVEST, V99, P534, DOI 10.1172/JCI119190; Myatt L, 1997, J HISTOCHEM CYTOCHEM, V45, P1433, DOI 10.1177/002215549704501012; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Noda M, 2002, J BIOL CHEM, V277, P41817, DOI 10.1074/jbc.M207690200; OGATA ES, 1986, METABOLISM, V35, P970, DOI 10.1016/0026-0495(86)90064-8; Ortsater H, 2002, PFLUG ARCH EUR J PHY, V444, P506, DOI 10.1007/s00424-002-0842-9; PANTEN U, 1984, BIOCHEM J, V219, P189, DOI 10.1042/bj2190189; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Peterside IE, 2003, AM J PHYSIOL-ENDOC M, V285, pE1258, DOI 10.1152/ajpendo.00437.2002; RAVELLI G, 1995, NEW ENGL J MED, V295, P349; Rich-Edwards JW, 1999, ANN INTERN MED, V130, P278, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00005; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Sakai K, 2003, BIOCHEM BIOPH RES CO, V300, P216, DOI 10.1016/S0006-291X(02)02832-2; Sakuraba H, 2002, DIABETOLOGIA, V45, P85, DOI 10.1007/s125-002-8248-z; SCHARP DW, 1973, TRANSPLANTATION, V16, P686, DOI 10.1097/00007890-197312000-00028; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Selak MA, 2003, AM J PHYSIOL-ENDOC M, V285, pE130, DOI 10.1152/ajpendo.00322.2002; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; SIMMONS RA, 1992, PEDIATR RES, V31, P59, DOI 10.1203/00006450-199201000-00011; Simmons RA, 2001, DIABETES, V50, P2279, DOI 10.2337/diabetes.50.10.2279; Stoffers DA, 2003, DIABETES, V52, P734, DOI 10.2337/diabetes.52.3.734; SUGIOKA K, 1988, BIOCHIM BIOPHYS ACTA, V936, P377, DOI 10.1016/0005-2728(88)90014-X; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; UNTERMAN T, 1990, ENDOCRINOLOGY, V127, P2035, DOI 10.1210/endo-127-4-2035; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Wang Y, 1998, PLACENTA, V19, P581, DOI 10.1016/S0143-4004(98)90018-2; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510	86	161	168	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28785	28791		10.1074/jbc.M505695200	http://dx.doi.org/10.1074/jbc.M505695200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15946949	hybrid			2022-12-25	WOS:000230857300070
J	Kostlanova, N; Mitchell, EP; Lortat-Jacob, H; Oscarson, S; Lahmann, M; Gilboa-Garber, N; Chambat, G; Wimmerova, M; Imberty, A				Kostlanova, N; Mitchell, EP; Lortat-Jacob, H; Oscarson, S; Lahmann, M; Gilboa-Garber, N; Chambat, G; Wimmerova, M; Imberty, A			The fucose-binding lectin from Ralstonia solanacearum - A new type of beta-propeller architecture formed by oligomerization and interacting with fucoside, fucosyllactose, and plant xyloglucan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; PRIMARY-CELL WALLS; OLIGOSACCHARIDES; PROTEINS; REFINEMENT; LIGANDS; PROGRAM; DEFENSE; BIOLOGY; MODELS	Plant pathogens, like animal ones, use protein-carbohydrate interactions in their strategy for host recognition, attachment, and invasion. The bacterium Ralstonia solanacearum, which is distributed worldwide and causes lethal wilt in many agricultural crops, was shown to produce a potent L-fucose-binding lectin, R. solanacearum lectin, a small protein of 90 amino acids with a tandem repeat in its amino acid sequence. In the present study, surface plasmon resonance experiments conducted on a series of oligosaccharides show a preference for binding to alpha Fuc1-2Gal and alpha Fuc1-6Gal epitopes. Titration microcalorimetry demonstrates the presence of two binding sites per monomer and an unusually high affinity of the lectin for alpha Fuc1-2Gal-containing oligosaccharides (K-D = 2.5 x 10(-7) M for 2-fucosyllactose). R. solanacearum lectin has been crystallized with a methyl derivative of fucose and with the highest affinity ligand, 2-fucosyllactose. X-ray crystal structures, the one with alpha-methyl-fucoside being at ultrahigh resolution, reveal that each monomer consists of two small four-stranded anti-parallel beta-sheets. Trimerization through a 3-fold or pseudo-3-fold axis generates a six-bladed beta-propeller architecture, very similar to that previously described for the fungal lectin of Aleuria aurantia. This is the first report of a beta-propeller formed by oligomerization and not by sequential domains. Each monomer presents two fucose binding sites, resulting in six symmetrically arranged sugar binding sites for the beta-propeller. Crystals were also obtained for a mutated lectin complexed with a fragment of xyloglucan, a fucosylated polysaccharide from the primary cell wall of plants, which may be the biological target of the lectin.	Masaryk Univ, Dept Biochem, CS-61137 Brno, Czech Republic; Masaryk Univ, Natl Ctr Biomol Res, CS-61137 Brno, Czech Republic; European Synchrotron Radiat Facil, Facil Expt Div, F-38043 Grenoble, France; CNRS, CEA, UJF, UMR 5075,Inst Biol Struct, F-38027 Grenoble, France; Stockholm Univ, Arrhenius Lab, Dept Organ Chem, S-10691 Stockholm, Sweden; Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France	Masaryk University Brno; Masaryk University Brno; European Synchrotron Radiation Facility (ESRF); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Stockholm University; Bar Ilan University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Imberty, A (corresponding author), Masaryk Univ, Dept Biochem, Kotlarska 2, CS-61137 Brno, Czech Republic.	imberty@cermav.cnrs.fr	Lahmann, Martina/A-3090-2010; Wimmerova, Michaela/A-4114-2010; Imberty, Anne/P-6451-2018	Lahmann, Martina/0000-0002-8513-1952; Wimmerova, Michaela/0000-0002-7108-4198; Imberty, Anne/0000-0001-6825-9527; Oscarson, Stefan/0000-0002-8273-4918				Aldon D, 2000, EMBO J, V19, P2304, DOI 10.1093/emboj/19.10.2304; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; Bock K, 1988, Adv Exp Med Biol, V228, P153; Buts L, 2003, ACTA CRYSTALLOGR D, V59, P1012, DOI 10.1107/S0907444903007170; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Chambat G, 2005, CELLULOSE, V12, P117, DOI 10.1007/s10570-004-1040-z; Chambat G, 1997, PLANT PHYSIOL BIOCH, V35, P655; Dam TK, 2002, CHEM REV, V102, P387, DOI 10.1021/cr000401x; DARVILL A, 1992, GLYCOBIOLOGY, V2, P181, DOI 10.1093/glycob/2.3.181; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Fan EK, 2004, INT J MED MICROBIOL, V294, P217, DOI 10.1016/j.ijmm.2004.07.002; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; Fujihashi M, 2003, BIOCHEMISTRY-US, V42, P11093, DOI 10.1021/bi034983z; Fulop V, 1999, CURR OPIN STRUC BIOL, V9, P715, DOI 10.1016/S0959-440X(99)00035-4; GILBOAGARBER N, 1982, METHOD ENZYMOL, V83, P378; HAYWARD AC, 1991, ANNU REV PHYTOPATHOL, V29, P65, DOI 10.1146/annurev.py.29.090191.000433; Hooper LV, 2001, GLYCOBIOLOGY, V11, p1R, DOI 10.1093/glycob/11.2.1R; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; Imberty A, 2004, MICROBES INFECT, V6, P221, DOI 10.1016/j.micinf.2003.10.016; Ishida H, 2002, BIOSCI BIOTECH BIOCH, V66, P1002, DOI 10.1271/bbb.66.1002; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSELEAU JP, 1992, BIOCHIMIE, V74, P81, DOI 10.1016/0300-9084(92)90187-J; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; MCNEIL M, 1984, ANNU REV BIOCHEM, V53, P625, DOI 10.1146/annurev.bi.53.070184.003205; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otter A, 1999, EUR J BIOCHEM, V259, P295, DOI 10.1046/j.1432-1327.1999.00036.x; Paoli M, 2001, PROG BIOPHYS MOL BIO, V76, P103, DOI 10.1016/S0079-6107(01)00007-4; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PERRET S, 2005, IN PRESS BIOCH J; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; Sauer FG, 2000, CURR OPIN STRUC BIOL, V10, P548, DOI 10.1016/S0959-440X(00)00129-9; Schell MA, 2000, ANNU REV PHYTOPATHOL, V38, P263, DOI 10.1146/annurev.phyto.38.1.263; Sims IM, 1996, CARBOHYD RES, V293, P147, DOI 10.1016/0008-6215(96)00142-5; Sudakevitz D, 2004, MOL MICROBIOL, V52, P691, DOI 10.1111/j.1365-2958.2004.04020.x; Sudakevitz D, 2002, J BIOCHEM, V132, P353, DOI 10.1093/oxfordjournals.jbchem.a003230; Turton K, 2002, TRENDS BIOCHEM SCI, V27, P552, DOI 10.1016/S0968-0004(02)02177-1; Vincken JP, 1996, CARBOHYD RES, V288, P219, DOI 10.1016/0008-6215(96)00096-1; Waldherr-Teschner M., 1992, Advances in Scientific Visualization, P58; Watt DK, 1996, CARBOHYD RES, V285, P1; Watt DK, 2000, CARBOHYD RES, V325, P300, DOI 10.1016/S0008-6215(00)00017-3; Wilson IBH, 2002, CURR OPIN STRUC BIOL, V12, P569, DOI 10.1016/S0959-440X(02)00367-6; Wimmerova M, 2003, J BIOL CHEM, V278, P27059, DOI 10.1074/jbc.M302642200; York WS, 1996, CARBOHYD RES, V285, P99, DOI 10.1016/0008-6215(96)00029-8	48	134	136	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27839	27849		10.1074/jbc.M505184200	http://dx.doi.org/10.1074/jbc.M505184200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923179	hybrid			2022-12-25	WOS:000230678600045
J	Moseley, JB; Goode, BL				Moseley, JB; Goode, BL			Differential activities and regulation of Saccharomyces cerevisiae formin proteins Bni1 and Bnr1 by Bud6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN NUCLEOTIDE EXCHANGE; CAPPING PROTEIN; MOUSE FORMIN; NUCLEATION; PROFILIN; LOCALIZATION; CYTOSKELETON; CYTOKINESIS; ELONGATION; MECHANISM	Formins are conserved proteins that nucleate actin assembly and tightly associate with the fast growing barbed ends of actin filaments to allow insertional growth. Most organisms express multiple formins, but it has been unclear whether they have similar or distinct activities and how they may be regulated differentially. We isolated and compared the activities of carboxyl-terminal fragments of the only two formins expressed in Saccharomyces cerevisiae, Bni1 and Bnr1. Bnr1 was an order of magnitude more potent than Bni1 in actin nucleation and processive capping, and unlike Bni1, Bnr1 bundled actin filaments. Profilin bound directly to Bni1 and Bnr1 and regulated their activities similarly. However, the cell polarity factor Bud6/Aip3 specifically bound to and stimulated Bni1, but not Bnr1. This was unexpected, since previous two-hybrid studies suggested Bud6 interacts with both formins. We mapped Bud6 binding activity to specific residues in the carboxyl terminus of Bni1 that are adjacent to its diaphanous autoregulatory domain ( DAD). Fusion of the carboxyl terminus of Bni1 to Bnr1 conferred Bud6 stimulation to a Bnr1-Bni1 chimera. Thus, Bud6 differentially stimulates Bni1 and not Bnr1. We found that Bud6 is up-regulated during bud growth, when it is delivered to the bud tip on Bni1-nucleated actin cables. We propose that Bud6 stimulation of Bni1 promotes robust cable formation, which in turn delivers more Bud6 to the bud tip, reinforcing polarized cell growth through a positive feedback loop.	Brandeis Univ, Rosenstiel Ctr, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Brandeis University; Brandeis University	Goode, BL (corresponding author), Brandeis Univ, Rosenstiel Ctr, Dept Biol, 415 South St, Waltham, MA 02454 USA.	goode@brandeis.edu			NIGMS NIH HHS [GM63691] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063691] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; AMATRUDA JF, 1992, J CELL BIOL, V117, P1067, DOI 10.1083/jcb.117.5.1067; Amberg DC, 1997, MOL BIOL CELL, V8, P729, DOI 10.1091/mbc.8.4.729; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Dong YQ, 2003, J CELL BIOL, V161, P1081, DOI 10.1083/jcb.200212040; Eads JC, 1998, BIOCHEMISTRY-US, V37, P11171, DOI 10.1021/bi9720033; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Goehring AS, 2003, MOL BIOL CELL, V14, P1501, DOI 10.1091/mbc.E02-06-0348; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Jin H, 2000, MOL BIOL CELL, V11, P647, DOI 10.1091/mbc.11.2.647; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Kamei T, 1998, J BIOL CHEM, V273, P28341, DOI 10.1074/jbc.273.43.28341; Kikyo M, 1999, ONCOGENE, V18, P7046, DOI 10.1038/sj.onc.1203184; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Lu J, 2001, MOL BIOL CELL, V12, P1161, DOI 10.1091/mbc.12.4.1161; Matheos D, 2004, J CELL BIOL, V165, P99, DOI 10.1083/jcb.200309089; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Ozaki-Kuroda K, 2001, MOL CELL BIOL, V21, P827, DOI 10.1128/MCB.21.3.827-839.2001; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Pruyne D, 2004, MOL BIOL CELL, V15, P4971, DOI 10.1091/mbc.E04-04-0296; Pruyne D, 2004, ANNU REV CELL DEV BI, V20, P559, DOI 10.1146/annurev.cellbio.20.010403.103108; Rodal AA, 2003, CURR BIOL, V13, P1000, DOI 10.1016/S0960-9822(03)00383-X; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Schott D, 2002, CURR OPIN MICROBIOL, V5, P564, DOI 10.1016/S1369-5274(02)00369-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Umikawa M, 1998, ONCOGENE, V16, P2011, DOI 10.1038/sj.onc.1201724; Vallen EA, 2000, MOL BIOL CELL, V11, P593, DOI 10.1091/mbc.11.2.593; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wolven AK, 2000, J CELL BIOL, V150, P895, DOI 10.1083/jcb.150.4.895; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Zahner JE, 1996, MOL CELL BIOL, V16, P1857; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057; [No title captured]	47	121	124	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28023	28033		10.1074/jbc.M503094200	http://dx.doi.org/10.1074/jbc.M503094200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923184	hybrid			2022-12-25	WOS:000230678600065
J	Pece-Barbara, N; Vera, S; Kathirkamathamby, K; Liebner, S; Di Guglielmo, GM; Dejana, E; Wrana, JL; Letarte, M				Pece-Barbara, N; Vera, S; Kathirkamathamby, K; Liebner, S; Di Guglielmo, GM; Dejana, E; Wrana, JL; Letarte, M			Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta 1 with higher affinity receptors and an activated Alk1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-RECEPTOR; GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; SMOOTH-MUSCLE-CELLS; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSES; MESSENGER-RNA; UP-REGULATION; I RECEPTORS; PROTEIN	Endoglin is an accessory receptor for transforming growth factor beta(TGF beta) in endothelial cells, essential for vascular development. Its pivotal role in angiogenesis is underscored in Endoglin null (Eng(-/-)) murine embryos, which die at mid-gestation (E10.5) from impaired yolk sac vessel formation. Moreover, mutations in endoglin and the endothelial-specific TGF beta type I receptor, ALK1, are linked to hereditary hemorrhagic telangiectasia. To determine the role of endoglin in TGF beta pathways, we derived murine endothelial cell lines from Eng(-/-) and Eng(-/-) embryos (E9.0). Whereas Eng(+/ +) cells were only partially growth inhibited by TGF beta, Eng(-/-) cells displayed a potent anti-proliferative response. TGF beta-dependent Smad2 phosphorylation and Smad2/3 translocation were unchanged in the Eng(-/-) cells. In contrast, TGF beta treatment led to a more rapid activation of the Smad1/5 pathway in Eng null cells that was apparent at lower TGF beta concentrations. Enhanced activity of the Smad1 pathway in Eng(-/-) cells was reflected in higher expression of ALK1-dependent genes such as Id1, Smad6, and Smad7. Analysis of cell surface receptors revealed that the TGF beta type I receptor, ALK5, which is required for ALK1 function, was increased in Eng(-/-) cells. TGF beta receptor complexes were less numerous but displayed a higher binding affinity. These results suggest that endoglin modulates TGF beta signaling in endothelial cells by regulating surface TGF beta receptors and suppressing Smad1 activation. Thus an altered balance in TGF beta receptors and downstream Smad pathways may underlie defects in vascular development and homeostasis.	Univ Toronto, Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Heart & Stroke Lewar Ctr Excellence, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada; Univ Milan, Inst Mol Oncol, Italian Fdn Canc Res, I-20146 Milan, Italy; Univ Milan, Dept Biomol & Biotechnol Sci, I-20146 Milan, Italy	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; IFOM - FIRC Institute of Molecular Oncology; University of Milan; University of Milan	Letarte, M (corresponding author), Univ Toronto, Hosp Sick Children, Canc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mablab@sickkids.ca	Wrana, Jeffrey/F-8857-2013	DEJANA, ELISABETTA/0000-0002-0007-0426				Abdalla SA, 2000, HUM MOL GENET, V9, P1227, DOI 10.1093/hmg/9.8.1227; Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; Balconi G, 2000, ARTERIOSCL THROM VAS, V20, P1443, DOI 10.1161/01.ATV.20.6.1443; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bodey B, 1998, ANTICANCER RES, V18, P1485; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Carvalho RLC, 2004, DEVELOPMENT, V131, P6237, DOI 10.1242/dev.01529; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fonsatti E, 2003, CURR DRUG TARGETS, V4, P291, DOI 10.2174/1389450033491073; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; LETARTE M, 2005, IN PRESS CARDIOV RES; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Ma XL, 2000, ARTERIOSCL THROM VAS, V20, P2546, DOI 10.1161/01.ATV.20.12.2546; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MASSAGUE J, 1985, PROG MED VIROL, V32, P142; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Pece N, 1997, J CLIN INVEST, V100, P2568, DOI 10.1172/JCI119800; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; ROBERTS AB, 1989, AM REV RESPIR DIS, V140, P1126, DOI 10.1164/ajrccm/140.4.1126; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	50	98	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27800	27808		10.1074/jbc.M503471200	http://dx.doi.org/10.1074/jbc.M503471200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923183	hybrid			2022-12-25	WOS:000230678600040
J	Bali, P; Pranpat, M; Bradner, J; Balasis, M; Fiskus, W; Guo, F; Rocha, K; Kumaraswamy, S; Boyapalle, S; Atadja, P; Seto, E; Bhalla, K				Bali, P; Pranpat, M; Bradner, J; Balasis, M; Fiskus, W; Guo, F; Rocha, K; Kumaraswamy, S; Boyapalle, S; Atadja, P; Seto, E; Bhalla, K			Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOGENOUS LEUKEMIA-CELLS; BCR-ABL; MOLECULAR CHAPERONES; BREAST-CANCER; MUTANT FLT-3; IN-VIVO; PROTEIN; HSP90; APOPTOSIS; LAQ824	The hydroxamic acid (HAA) analogue pan-histone deacetylase (HDAC) inhibitors (HDIs) LAQ824 and LBH589 have been shown to induce acetylation and inhibit the ATP binding and chaperone function of heat shock protein (HSP) 90. This promotes the polyubiquitylation and degradation of the pro-growth and pro-survival client proteins Bcr-Abl, mutant FLT-3, c-Raf, and AKT in human leukemia cells. HDAC6 is a member of the class IIB HDACs. It is predominantly cytosolic, microtubule-associated alpha-tubulin deacetylase that is also known to promote aggresome inclusion of the misfolded polyubiquitylated proteins. Here we demonstrate that in the Bcr-abl oncogene expressing human leukemia K562 cells, HDAC6 can be co-immunoprecipitated with HSP90, and the knock-down of HDAC6 by its siRNA induced the acetylation of HSP90 and alpha-tubulin. Depletion of HDAC6 levels also inhibited the binding of HSP90 to ATP, reduced the chaperone association of HSP90 with its client proteins, e.g. Bcr-Abl, and induced polyubiquitylation and partial depletion of Bcr-Abl. Conversely, the ectopic overexpression of HDAC6 inhibited LAQ824-induced acetylation of HSP90 and alpha-tubulin and reduced LAQ824-mediated depletion of Bcr-Abl, AKT, and c-Raf. Collectively, these findings indicate that HDAC6 is also an HSP90 deacetylase. Targeted inhibition of HDAC6 leads to acetylation of HSP90 and disruption of its chaperone function, resulting in polyubiquitylation and depletion of pro-growth and pro-survival HSP90 client proteins including Bcr-Abl. Depletion of HDAC6 sensitized human leukemia cells to HAA-HDIs and proteasome inhibitors.	Univ S Florida, H Lee Moffitt Canc Ctr, Interdisciplinary Oncol Program, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Novartis Pharmaceut Inc, Cambridge, MA 02139 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Harvard University; Dana-Farber Cancer Institute; Novartis	Bhalla, K (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Interdisciplinary Oncol Program, Dept Interdisciplinary Oncol, 12902 Magnolia Dr,MRC 3 E,Rm 3056, Tampa, FL 33612 USA.	bhallakn@moffitt.usf.edu		Bhalla, Kapil/0000-0001-5209-5126				Bagatell R, 2004, MOL CANCER THER, V3, P1021; Bagatell R, 2000, CLIN CANCER RES, V6, P3312; Bali P, 2004, CLIN CANCER RES, V10, P4991, DOI 10.1158/1078-0432.CCR-04-0210; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fuino L, 2003, MOL CANCER THER, V2, P971; George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413; George P, 2004, CANCER RES, V64, P3645, DOI 10.1158/0008-5472.CAN-04-0006; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Guo F, 2004, CANCER RES, V64, P2580, DOI 10.1158/0008-5472.CAN-03-2629; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; Minnnaugh EG, 2004, MOL CANCER THER, V3, P551; Nimmanapalli R, 2003, CANCER RES, V63, P5126; Nimmanapalli R, 2002, CANCER RES, V62, P5761; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Wegele H, 2003, J BIOL CHEM, V278, P39303, DOI 10.1074/jbc.M305751200; Yu XD, 2002, J NATL CANCER I, V94, P504; Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455	40	660	697	4	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26729	26734		10.1074/jbc.C500186200	http://dx.doi.org/10.1074/jbc.C500186200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15937340	hybrid			2022-12-25	WOS:000230589500013
J	Pu, YM; Perry, NA; Yang, DZ; Lewin, NE; Kedei, N; Braun, DC; Choi, SH; Blumberg, PM; Garfield, SH; Stone, JC; Duan, DH; Marquez, VE				Pu, YM; Perry, NA; Yang, DZ; Lewin, NE; Kedei, N; Braun, DC; Choi, SH; Blumberg, PM; Garfield, SH; Stone, JC; Duan, DH; Marquez, VE			A novel diacylglycerol-lactone shows marked selectivity in vitro among C1 domains of protein kinase C (PKC) isoforms alpha and delta as well as selectivity for RasGRP compared with PKC alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY CONSTRAINED ANALOGS; PHORBOL 12-MYRISTATE 13-ACETATE; ESTER RECEPTORS; DOWN-REGULATION; BINDING ASSAY; BRYOSTATIN 1; PHOSPHORYLATION; ACTIVATION; ISOZYMES; DAG	Although multiple natural products are potent ligands for the diacylglycerol binding C1 domain of protein kinase C (PKC), RasGRP, and related targets, the high conservation of C1 domains has impeded the development of selective ligands. We characterized here a diacylglycerol-lactone, 130C037, emerging from a combinatorial chemical synthetic strategy, which showed substantial selectivity. 130C037 gave shallow binding curves for PKC isoforms alpha, beta, gamma, delta, and epsilon, with apparent K-i values ranging from 340 nM for PKC alpha to 29 nM for PKC epsilon. When binding to isolated C1 domains of PKC alpha and -delta, 130C037 showed good affinity (K-i = 1.78 nM) only for delta C1b, whereas phorbol 12,13-dibutyrate showed affinities within 10-fold for all. In LNCaP cells, 130C037 likewise selectively induced membrane translocation of delta C1b. 130C037 bound intact RasGRP1 and RasGRP3 with K-i values of 3.5 and 3.8 nM, respectively, reflecting 8- and 90-fold selectivity relative to PKC epsilon and PKC alpha. By Western blot of Chinese hamster ovary cells, 130C037 selectively induced loss from the cytosol of RasGRP3 (ED50 = 286 nM), partial reduction of PKC epsilon (ED50 > 10 mu M), and no effect on PKC alpha. As determined by confocal microscopy in LNCaP cells, 130C037 caused rapid translocation of RasGRP3, limited slow translocation of PKC epsilon, and no translocation of PKC alpha. Finally, 130C037 induced Erk phosphorylation in HEK-293 cells ectopically expressing RasGRP3 but not in control cells, whereas phorbol ester induced phosphorylation in both. The properties of 130C037 provide strong proof of principle for the feasibility of developing ligands with selectivity among C1 domain-containing therapeutic targets.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; NCI Frederick, Med Chem Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alberta; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Blumberg, PM (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, NIH, Bldg 37,Rm 4048,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	blumberp@dc37a.nci.nih.gov	Marquez, Victor/AAP-3549-2021		NATIONAL CANCER INSTITUTE [ZIABC005270, Z01BC005270, Z01BC006176] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiba Y, 2004, P NATL ACAD SCI USA, V101, P16612, DOI 10.1073/pnas.0407468101; Brodie C, 2004, MOL PHARMACOL, V66, P76, DOI 10.1124/mol.66.1.76; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Duan DH, 2004, J MED CHEM, V47, P3248, DOI 10.1021/jm030610k; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; FURSTENBERGER G, 1972, PLANTA MED, V22, P241; Geiger M, 2003, CURR OPIN MOL THER, V5, P631; Giorgione J, 2003, BIOCHEMISTRY-US, V42, P11194, DOI 10.1021/bi0350046; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; Irie K, 2004, BIOORGAN MED CHEM, V12, P4575, DOI 10.1016/j.bmc.2004.07.008; Irie K, 2002, PHARMACOL THERAPEUT, V93, P271, DOI 10.1016/S0163-7258(02)00196-1; Lewin Nancy E, 2003, Methods Mol Biol, V233, P129; Lorenzo PS, 1999, CANCER RES, V59, P6137; Lorenzo PS, 2001, CANCER RES, V61, P943; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marquez VE, 2003, ACCOUNTS CHEM RES, V36, P434, DOI 10.1021/ar020124b; Nacro K, 2000, J MED CHEM, V43, P921, DOI 10.1021/jm9904607; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Pellecchia M, 2004, CURR PHARM DESIGN, V10, P1371, DOI 10.2174/1381612043384907; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Shao L, 2001, J MED CHEM, V44, P3872, DOI 10.1021/jm010258f; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; SZALLASI Z, 1993, CANCER RES, V53, P2507; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	36	49	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27329	27338		10.1074/jbc.M414132200	http://dx.doi.org/10.1074/jbc.M414132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15923197	hybrid			2022-12-25	WOS:000230589500083
J	Wilson, MC; Meredith, D; Fox, JEM; Manoharan, C; Davies, AJ; Halestrap, AP				Wilson, MC; Meredith, D; Fox, JEM; Manoharan, C; Davies, AJ; Halestrap, AP			Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4 - The ancillary protein for the insensitive MCT2 is embigin (gp70)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-PIGMENT EPITHELIUM; XENOPUS-LAEVIS OOCYTES; LACTIC-ACID EFFLUX; LACTATE TRANSPORTER; IMMUNOGLOBULIN SUPERFAMILY; SKELETAL-MUSCLE; ESCHERICHIA-COLI; TUMOR-CELLS; EXPRESSION; RAT	Translocation of monocarboxylate transporters MCT1 and MCT4 to the plasma membrane requires CD147 (basigin) with which they remain tightly associated. However, the importance of CD147 for MCT activity is unclear. MCT1 and MCT4 are both inhibited by the cell-impermeant organomercurial reagent p-chloromercuribenzene sulfonate (pCMBS). Here we demonstrate by site-directed mutagenesis that removal of all accessible cysteine residues on MCT4 does not prevent this inhibition. pCMBS treatment of cells abolished co-immunoprecipitation of MCT1 and MCT4 with CD147 and enhanced labeling of CD147 with a biotinylated-thiol reagent. This suggested that CD147 might be the target of pCMBS, and further evidence for this was obtained by treatment of cells with the bifunctional organomercurial reagent fluorescein dimercury acetate that caused oligomerization of CD147. Site-directed mutagenesis of CD147 implicated the disulfide bridge in the Ig-like C2 domain of CD147 as the target of pCMBS attack. MCT2, which is pCMBS-insensitive, was found to co-immunoprecipitate with gp70 rather than CD147. The interaction between gp70 and MCT2 was confirmed using fluorescence resonance energy transfer between the cyan fluorescent protein- and yellow fluorescent protein-tagged MCT2 and gp70. pCMBS strongly inhibited lactate transport into rabbit erythrocytes, where MCT1 interacts with CD147, but not into rat erythrocytes where it interacts with gp70. These data imply that inhibition of MCT1 and MCT4 activity by pCMBS is mediated through its binding to CD147, whereas MCT2, which associates with gp70, is insensitive to pCMBS. We conclude that ancillary proteins are required to maintain the catalytic activity of MCTs as well as for their translocation to the plasma membrane.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halestrap, AP (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	a.halestrap@bristol.ac.uk	Halestrap, Andrew P/G-7275-2011; Meredith, David/F-3664-2010	Wilson, Marieangela/0000-0001-6218-3533; Halestrap, Andrew/0000-0001-5374-2778				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bergersen L, 2001, EXP BRAIN RES, V136, P523, DOI 10.1007/s002210000600; Broer S, 1999, BIOCHEM J, V341, P529, DOI 10.1042/0264-6021:3410529; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; DEUTICKE B, 1982, J MEMBRANE BIOL, V70, P89, DOI 10.1007/BF01870219; DEUTICKE B, 1978, BIOCHIM BIOPHYS ACTA, V507, P137, DOI 10.1016/0005-2736(78)90381-4; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Finnemann SC, 1997, INVEST OPHTH VIS SCI, V38, P2366; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Friesema ECH, 2003, J BIOL CHEM, V278, P40128, DOI 10.1074/jbc.M300909200; Galic S, 2003, BIOCHEM J, V376, P413, DOI 10.1042/BJ20030799; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Grollman EF, 2000, BIOCHEMISTRY-US, V39, P9351, DOI 10.1021/bi000464+; Guenette RS, 1997, DEV GENET, V21, P268, DOI 10.1002/(SICI)1520-6408(1997)21:4<268::AID-DVG4>3.0.CO;2-5; HALESTRAP AP, 1976, BIOCHEM J, V156, P193, DOI 10.1042/bj1560193; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; Juel C, 1999, J PHYSIOL-LONDON, V517, P633, DOI 10.1111/j.1469-7793.1999.0633s.x; KARUSH F, 1964, ANAL BIOCHEM, V9, P100, DOI 10.1016/0003-2697(64)90088-0; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; KIMGARCIA C, 1994, CELL, V76, P865; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Leeks DR, 1978, BIOCHEM SOC T, V6, P1363, DOI 10.1042/bst0061363; Lynch GW, 1999, EUR J IMMUNOL, V29, P2590, DOI 10.1002/(SICI)1521-4141(199908)29:08<2590::AID-IMMU2590>3.0.CO;2-R; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; Meredith D, 2000, J PHYSIOL-LONDON, V526, p23P; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; PAPAYANNOPOULOU T, 1992, BLOOD, V79, P1686; Pellerin L, 2005, J NEUROSCI RES, V79, P55, DOI 10.1002/jnr.20307; POOLE RC, 1991, BIOCHEM J, V275, P307, DOI 10.1042/bj2750307; POOLE RC, 1992, BIOCHEM J, V283, P855, DOI 10.1042/bj2830855; POOLE RC, 1988, BIOCHEM J, V254, P385, DOI 10.1042/bj2540385; Poole RC, 1996, BIOCHEM J, V320, P817, DOI 10.1042/bj3200817; Poole RC, 1997, J BIOL CHEM, V272, P14624, DOI 10.1074/jbc.272.23.14624; Rahman B, 1999, BIOCHEMISTRY-US, V38, P11577, DOI 10.1021/bi990973f; Schuster VL, 1996, BBA-MOL CELL RES, V1311, P13, DOI 10.1016/0167-4889(95)00186-7; SPENCER TL, 1976, BIOCHEM J, V154, P405, DOI 10.1042/bj1540405; Telen MJ, 2000, SEMIN HEMATOL, V37, P130, DOI 10.1016/S0037-1963(00)90038-6; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Wilson MC, 1998, J BIOL CHEM, V273, P15920, DOI 10.1074/jbc.273.26.15920	42	217	227	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27213	27221		10.1074/jbc.M411950200	http://dx.doi.org/10.1074/jbc.M411950200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917240	hybrid			2022-12-25	WOS:000230589500069
J	Fischer, BM; Cuellar, JG; Byrd, AS; Rice, AB; Bonner, JC; Martin, LD; Voynow, JA				Fischer, BM; Cuellar, JG; Byrd, AS; Rice, AB; Bonner, JC; Martin, LD; Voynow, JA			ErbB2 activity is required for airway epithelial repair following neutrophil elastase exposure	FASEB JOURNAL			English	Article; Proceedings Paper	17th Annual North American Cystic Fibrosis Conference	OCT 16-19, 2003	Anaheim, CA			DNA synthesis; protease	EPIDERMAL-GROWTH-FACTOR; CELLS IN-VITRO; TYROSINE KINASE; CYSTIC-FIBROSIS; FACTOR RECEPTOR; BREAST-CANCER; LEUKOCYTE ELASTASE; GENE-EXPRESSION; CARCINOMA-CELLS; MESSENGER-RNA	In cystic fibrosis and chronic bronchitis, airways are chronically injured by exposure to neutrophil elastase ( NE). We sought to identify factors required for epithelial repair following NE exposure. Normal human bronchial epithelial cells were treated with NE ( 50 nM, 22 h) or control vehicle. Following NE treatment, we found a marked and sustained decrease in epithelial proliferation as detected by Ki67 immunostaining. H-3-thymidine incorporation was also initially depressed but increased over 72 h in NE-treated cells, which suggests that DNA synthesis constitutes an early repair process following NE exposure. We hypothesized that ErbB2 receptor tyrosine kinase, a regulator of cancer cell proliferation, was required for epithelial DNA synthesis following NE exposure. Immediately following NE treatment, by flow cytometry analysis, we found a decrease in ErbB2 surface expression. Protein levels of the full-length 185 kD ErbB2 receptor significantly decreased following NE treatment and smaller ErbB2-positive bands, ranging in size from 23 to 40 kD, appeared, which suggests that NE caused ErbB2 degradation. By real-time RT-PCR analysis, we found no change in ErbB2 mRNA expression following NE treatment, which suggests that changes in ErbB2 protein levels were regulated at the post-translational level. Following NE treatment, full-length 185 kD ErbB2 levels increased to pretreatment levels, correlating with the increase in thymidine incorporation during the same time period. Importantly, inhibition of ErbB2 activity with AG825 ( 5 mu M) or Herceptin (3.1 mu M), an ErbB2-neutralizing antibody, blocked thymidine incorporation only in NE-treated cells. These results suggest ErbB2 is a critical factor for epithelial recovery following NE exposure.	Duke Univ, Med Ctr, Div Pediat Pulm Med, Dept Pediat, Durham, NC 27710 USA; NIEHS, Lab Resp Biol, Res Triangle Pk, NC 27709 USA; N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; North Carolina State University	Voynow, JA (corresponding author), Duke Univ, Med Ctr, Div Pediat Pulm Med, Dept Pediat, Box 2994, Durham, NC 27710 USA.	voyno001@mc.duke.edu		Byrd, Angela/0000-0002-6743-4343	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073174, R01HL066236] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL073174, HL66236] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMITANI R, 1991, AM J RESP CELL MOL, V4, P26, DOI 10.1165/ajrcmb/4.1.26; Aoshiba K, 2001, AM J PHYSIOL-LUNG C, V281, pL556; BURNETT D, 1995, ARCH BIOCHEM BIOPHYS, V317, P305, DOI 10.1006/abbi.1995.1167; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Chitano P, 2004, PEDIATR PULM, V38, P456, DOI 10.1002/ppul.20118; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Dammann CEL, 2003, AM J RESP CRIT CARE, V167, P1711, DOI 10.1164/rccm.200205-468OC; Davies DE, 1999, ALLERGY, V54, P771; Devaney JM, 2003, FEBS LETT, V544, P129, DOI 10.1016/S0014-5793(03)00482-4; El-Metwally TH, 1999, BIOCHEM BIOPH RES CO, V257, P596, DOI 10.1006/bbrc.1999.0502; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Fischer BM, 1999, AM J RESP CELL MOL, V20, P413, DOI 10.1165/ajrcmb.20.3.3393; Fischer BM, 2003, AM J PHYSIOL-LUNG C, V284, pL671, DOI 10.1152/ajplung.00220.2002; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447, DOI 10.1165/ajrcmb.26.4.4473; Ginzberg HH, 2001, AM J PHYSIOL-GASTR L, V281, pG705, DOI 10.1152/ajpgi.2001.281.3.G705; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; KERCSMAR CM, 1993, AM J RESP CELL MOL, V8, P56, DOI 10.1165/ajrcmb/8.1.56; KIM KC, 1987, P NATL ACAD SCI USA, V84, P9304, DOI 10.1073/pnas.84.24.9304; Kohri K, 2002, AM J PHYSIOL-LUNG C, V283, pL531, DOI 10.1152/ajplung.00455.2001; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; Le-Barillec K, 1999, J CLIN INVEST, V103, P1039, DOI 10.1172/JCI5779; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu JB, 2002, AM J RESP CELL MOL, V27, P306, DOI 10.1165/rcmb.4850; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; ORiordan TG, 1997, AM J RESP CRIT CARE, V155, P1522, DOI 10.1164/ajrccm.155.5.9154852; Patel NV, 2000, AM J RESP CELL MOL, V22, P432, DOI 10.1165/ajrcmb.22.4.3854; Perkett Elizabeth Ann, 1995, Current Opinion in Pediatrics, V7, P242, DOI 10.1097/00008480-199506000-00002; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; Ramsauer VP, 2003, J BIOL CHEM, V278, P30142, DOI 10.1074/jbc.M303220200; Roh H, 2000, CANCER RES, V60, P560; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Snedecor GW, 1980, STAT METHODS, V7th; STAL O, 1994, CYTOMETRY, V16, P160, DOI 10.1002/cyto.990160210; STOCKLEY RA, 1979, AM REV RESPIR DIS, V120, P1081; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; Vandivier RW, 2002, J CLIN INVEST, V109, P661, DOI 10.1172/JCI200213572; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; von Bredow C, 2001, EUR RESPIR J, V17, P716, DOI 10.1183/09031936.01.17407160; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; You XL, 1998, ONCOGENE, V17, P3177, DOI 10.1038/sj.onc.1202246	47	16	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					1374	+		10.1096/fj.04-2675fje	http://dx.doi.org/10.1096/fj.04-2675fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15923396				2022-12-25	WOS:000229602600006
J	Becker, KA; Lu, SL; Dickinson, ES; Dunphy, KA; Mathews, L; Schneider, SS; Jerry, DJ				Becker, KA; Lu, SL; Dickinson, ES; Dunphy, KA; Mathews, L; Schneider, SS; Jerry, DJ			Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-beta-dependent pathways	ONCOGENE			English	Article						p53; estrogen; progesterone; TGF-beta; chemoprevention; mammary	GROWTH-FACTOR-BETA; CELL-CYCLE; BREAST-CANCER; CROSS-TALK; IN-VIVO; RECEPTOR; ASSOCIATION; ACTIVATION; PROLIFERATION; INSTABILITY	DNA damage normally induces p53 activity, but responses to ionizing radiation in the mammary epithelium vary among developmental stages. The following studies examined the hormones and growth factors that regulate radiation-responsiveness of p53 in mouse mammary epithelium. Immunoreactive p21/WAF1 and TUNEL staining were used as indicators of p53 activity following exposure to ionizing radiation. In ovariectomized mice, radiation-induced accumulation of p21/WAF1 was minimal in the mammary epithelial cells ( < 1%). Systemic injections of estrogen and progesterone (E + P) for 72 h were necessary to recover maximal expression of p21/WAF1 following ionizing radiation (55%). The effects of E + P on radiation-induced p21/WAF1 were p53-dependent as responses were absent in Trp53(-/-) mice. Though hormonal treatments stimulated increases in the proportion of cycling cells (PCNA-positive), this was not directly correlated with p53 activity. Whole organ cultures were used to determine whether E + P act directly upon the mammary gland. Treatment with E + P was sufficient to render p53 responsive to radiation, but TGF-beta-neutralizing antibodies blocked responsiveness. In the absence of E + P, TGF-beta 1 alone did not alter p53 activity. These results demonstrate that estrogen and progesterone together with TGF-beta signaling are necessary for maintenance of p53 activity in the mammary epithelium.	Univ Massachusetts, Mol & Cellular Biol Program, Amherst, MA 01003 USA; Univ Massachusetts, Dept Vet & Anim Sci, Paige Lab, Amherst, MA 01003 USA; Baystate Med Ctr, UMass Biomed Res Inst, Springfield, MA 01099 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center	Jerry, DJ (corresponding author), Univ Massachusetts, Mol & Cellular Biol Program, Amherst, MA 01003 USA.	jjerry@vasci.umass.edu		Lu, Shaolei/0000-0003-2870-5793	NATIONAL CANCER INSTITUTE [R21CA087531, R01CA095164] Funding Source: NIH RePORTER; NCI NIH HHS [CA87531, CA095164] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson E, 2004, J MAMMARY GLAND BIOL, V9, P3, DOI 10.1023/B:JOMG.0000023584.01750.16; BARCELLOSHOFF MH, 2003, BREAST CANC RES S1, V5, P33; Bedford JS, 2002, RADIAT RES, V158, P251, DOI 10.1667/0033-7587(2002)158[0251:HACHIR]2.0.CO;2; Blackburn AC, 2002, BREAST CANCER RES, V4, P98; Bode AM, 2004, MUTAT RES-FUND MOL M, V555, P33, DOI 10.1016/j.mrfmmm.2004.05.018; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke RB, 1997, BREAST CANCER RES TR, V45, P121, DOI 10.1023/A:1005805831460; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; DIBBS KI, 1995, AM J OBSTET GYNECOL, V173, P134, DOI 10.1016/0002-9378(95)90181-7; Ewan KB, 2002, CANCER RES, V62, P5627; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Iatropoulos MJ, 1996, EXP TOXICOL PATHOL, V48, P175, DOI 10.1016/S0940-2993(96)80039-X; JENG MH, 1993, ENDOCRINOLOGY, V132, P2622, DOI 10.1210/en.132.6.2622; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kuperwasser C, 2000, CANCER RES, V60, P2723; Lanari C, 2001, CANCER RES, V61, P293; Liu GZ, 2000, CANCER RES, V60, P1810; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Medina D, 2003, CANCER RES, V63, P6140; Medina D, 2003, CANCER RES, V63, P1067; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Minter LM, 2002, DEVELOPMENT, V129, P2997; Pati D, 2004, CANCER RES, V64, P5608, DOI 10.1158/0008-5472.CAN-03-0629; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; RUSSO IH, 1990, J NATL CANCER I, V82, P1286, DOI 10.1093/jnci/82.15.1286; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Said TK, 1997, ENDOCRINOLOGY, V138, P3933, DOI 10.1210/en.138.9.3933; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Stavridi ES, 2001, CANCER RES, V61, P7030; Thorstenson YR, 2003, CANCER RES, V63, P3325; THURSTON SJ, 1989, ANAL BIOCHEM, V178, P41, DOI 10.1016/0003-2697(89)90353-9; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Yamamoto T, 2002, ENDOCRINOLOGY, V143, P2635, DOI 10.1210/en.143.7.2635	46	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6345	6353		10.1038/sj.onc.1208787	http://dx.doi.org/10.1038/sj.onc.1208787			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	15940247				2022-12-25	WOS:000232038200002
J	Bjorling-Poulsen, M; Siehler, S; Wiesmuller, L; Meek, D; Niefind, K; Issinger, OG				Bjorling-Poulsen, M; Siehler, S; Wiesmuller, L; Meek, D; Niefind, K; Issinger, OG			The 'regulatory' beta-subunit of protein kinase CK2 negatively influences p53-mediated allosteric effects on Chk2 activation	ONCOGENE			English	Article						Chk2; p53; CK2; protein kinase; phosphorylation	TOPOISOMERASE-II-ALPHA; CELL-CYCLE; MITOTIC PHOSPHORYLATION; SUPPRESSOR PROTEIN; CK2-BETA SUBUNIT; DOCKING-SITE; DNA-BINDING; P53; DOMAIN; CHECKPOINT	The 'regulatory' beta-subunit of protein kinase CK2 has previously been shown to interact with protein kinases such as A-Raf, c-Mos, Lyn and Chk1 in addition to the catalytic subunit of CK2. Sequence alignments suggest that these interactions have a structural basis, and hence other protein kinases harboring corresponding sequences may be potential interaction partners for CK2 beta. We show here that Chk2 specifically interacts with CK2 beta in vitro and in cultured cells, and that activation of Chk2 leads to a reduction of this interaction. Additionally, we show that the presence of the CK2 beta subunit significantly reduces the Chk2-catalysed phosphorylation of p53 in vitro. These findings support the notion that CK2 beta can act as a general modulator of remote docking sites in protein kinase substrate interactions.	Syddansk Univ, Inst Biokem Mol Biol, Odense, Denmark; Univ Ulm, Univ Frauenklin, Ulm, Germany; Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 4HN, Scotland; Univ Cologne, Inst Biochem, D-5000 Cologne, Germany	University of Southern Denmark; Ulm University; University of Dundee; University of Cologne	Issinger, OG (corresponding author), Univ So Denmark, BMB, Campusvej 55, DK-5230 Odense, Denmark.	ogi@bmb.sdu.dk	Niefind, Karsten/F-8726-2019	Niefind, Karsten/0000-0002-0183-6315				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; APPEL K, 1995, ONCOGENE, V11, P1971; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bell S, 2002, BIOPHYS CHEM, V96, P243, DOI 10.1016/S0301-4622(02)00011-X; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Boehden GS, 2004, CARCINOGENESIS, V25, P1305, DOI 10.1093/carcin/bgh092; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Gotz C, 1999, MOL CELL BIOCHEM, V191, P111, DOI 10.1023/A:1006886727248; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Korn I, 1999, MOL CELL BIOCHEM, V191, P75, DOI 10.1023/A:1006818513560; Kusk M, 1999, MOL CELL BIOCHEM, V191, P51, DOI 10.1023/A:1006840613986; Lehner B, 2004, GENOMICS, V83, P153, DOI 10.1016/S0888-7543(03)00235-0; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LORENZ P, 1994, CELL MOL BIOL RES, V40, P519; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Prowald A, 1997, FEBS LETT, V408, P99, DOI 10.1016/S0014-5793(97)00399-2; Schuster N, 2001, J CELL BIOCHEM, V81, P172, DOI 10.1002/1097-4644(20010401)81:1<172::AID-JCB1033>3.0.CO;2-O; Schwindling SL, 2004, ONCOGENE, V23, P4155, DOI 10.1038/sj.onc.1207566; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X	47	14	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6194	6200		10.1038/sj.onc.1208762	http://dx.doi.org/10.1038/sj.onc.1208762			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940255				2022-12-25	WOS:000231718100013
J	Head, BP; Patel, HH; Roth, DM; Lai, NC; Niesman, IR; Farquhar, MG; Insel, PA				Head, BP; Patel, HH; Roth, DM; Lai, NC; Niesman, IR; Farquhar, MG; Insel, PA			G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING T-TUBULES; SMOOTH-MUSCLE-CELLS; ADENYLYL-CYCLASE; LIPID RAFTS; CAVEOLAE MICRODOMAINS; VENTRICULAR MYOCYTES; PLASMA-MEMBRANE; RAT; COLOCALIZATION; EXPRESSION	This study tests the hypothesis that G- protein- coupled receptor ( GPCR) signaling components involved in the regulation of adenylyl cyclase ( AC) localize with caveolin ( Cav), a protein marker for caveolae, in both cellsurface and intracellular membrane regions. Using sucrose density fractionation of adult cardiac myocytes, we detected Cav- 3 in both buoyant membrane fractions ( BF) and heavy/ non- buoyant fractions ( HF); beta (2)- adrenergic receptors ( AR) in BF; and AC5/ 6, beta(1)- AR, M-4- muscarinic acetylcholine receptors ( mAChR), mu- opioid receptors, and G alpha(s) in both BF and HF. In contrast, M-2- mAChR, G alpha(i3), and G alpha(i2) were found only in HF. Immunofluorescence microscopy showed co- localization of Cav- 3 with AC5/ 6, G alpha s, beta(2)- AR, and mu- opioid receptors in both sarcolemmal and intracellular membranes, whereas M-2-mAChR were detected only intracellularly. Immunofluorescence of adult heart revealed a distribution of Cav- 3 identical to that in isolated adult cardiac myocytes. Upon immunoelectron microscopy, Cav- 3 co- localized with AC5/ 6 and G alpha(s) in sarcolemmal and intracellular vesicles, the latter closely allied with T- tubules. Cav- 3 immunoprecipitates possessed components that were necessary and sufficient for GPCR agonist- promoted stimulation and inhibition of cAMP formation. The distribution of GPCR, G- proteins, and AC with Cav- 3 in both sarcolemmal and intracellular T- tubule- associated regions indicates the existence of multiple Cav- 3- localized cellular microdomains for signaling by hormones and drugs in the heart.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,BSB 3076, La Jolla, CA 92093 USA.	pinsel@ucsd.edu	Patel, Hemal/C-7325-2019	Patel, Hemal/0000-0001-6722-9625; Niesman, Ingrid/0000-0001-9767-6629	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063885, P50HL053773, P01HL066941, F32HL074625] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL074625, HL63885, HL66941, HL53773] Funding Source: Medline; CSR NIH HHS [RGS CA1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CSR NIH HHS		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Brette F, 2003, CIRC RES, V92, P1182, DOI 10.1161/01.RES.0000074908.17214.FD; Carozzi AJ, 2000, TRAFFIC, V1, P326, DOI 10.1034/j.1600-0854.2000.010406.x; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; COSTANTIN LL, 1970, J GEN PHYSIOL, V55, P703, DOI 10.1085/jgp.55.6.703; Dessy C, 2000, EMBO J, V19, P4272, DOI 10.1093/emboj/19.16.4272; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Fryer RM, 2000, J PHARMACOL EXP THER, V294, P451; Fujita T, 2001, CARDIOVASC RES, V51, P709, DOI 10.1016/S0008-6363(01)00348-0; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; GONZALEZ.H, 1971, J PHYSIOL-LONDON, V212, P777, DOI 10.1113/jphysiol.1971.sp009356; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Mitcheson JS, 1998, CARDIOVASC RES, V39, P280, DOI 10.1016/S0008-6363(98)00128-X; NAKAJIMA S, 1980, J GEN PHYSIOL, V76, P751, DOI 10.1085/jgp.76.6.751; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Page E, 1998, AM J PHYSIOL-HEART C, V274, pH1988, DOI 10.1152/ajpheart.1998.274.6.H1988; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Ralston E, 1999, EXP CELL RES, V246, P510, DOI 10.1006/excr.1998.4305; ROTH DA, 1992, FEBS LETT, V296, P46, DOI 10.1016/0014-5793(92)80400-B; Rybin VO, 2003, MOL PHARMACOL, V63, P1338, DOI 10.1124/mol.63.6.1338; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; SCHULTZ JEJ, 1995, AM J PHYSIOL-HEART C, V268, pH2157, DOI 10.1152/ajpheart.1995.268.5.H2157; Scriven DRL, 2000, BIOPHYS J, V79, P2682, DOI 10.1016/S0006-3495(00)76506-4; Sedarat F, 2000, AM J PHYSIOL-HEART C, V279, pH202, DOI 10.1152/ajpheart.2000.279.1.H202; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Soeller C, 1999, CIRC RES, V84, P266, DOI 10.1161/01.RES.84.3.266; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; VENTURA C, 1989, BIOCHIM BIOPHYS ACTA, V987, P69, DOI 10.1016/0005-2736(89)90456-2; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Wittert G, 1996, BIOCHEM BIOPH RES CO, V218, P877, DOI 10.1006/bbrc.1996.0156; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yu XC, 1999, J MOL CELL CARDIOL, V31, P1809, DOI 10.1006/jmcc.1999.1014	46	180	186	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31036	31044		10.1074/jbc.M502540200	http://dx.doi.org/10.1074/jbc.M502540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15961389	hybrid			2022-12-25	WOS:000231487800047
J	Lewandowicz, A; Ringia, EAT; Ting, LM; Kim, K; Tyler, PC; Evans, GB; Zubkova, OV; Mee, S; Painter, GF; Lenz, DH; Furneaux, RH; Schramm, VL				Lewandowicz, A; Ringia, EAT; Ting, LM; Kim, K; Tyler, PC; Evans, GB; Zubkova, OV; Mee, S; Painter, GF; Lenz, DH; Furneaux, RH; Schramm, VL			Energetic mapping of transition state analogue interactions with human and Plasmodium falciparum purine nucleoside phosphorylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUCILLIN-H; ATOMIC MOTION; INHIBITORS; BINDING	Human purine nucleoside phosphorylase ( huPNP) is essential for human T-cell division by removing deoxyguanosine and preventing dGTP imbalance. Plasmodium falciparum expresses a distinct PNP ( PfPNP) with a unique substrate specificity that includes 5'-methylthioinosine. The PfPNP functions both in purine salvage and in recycling purine groups from the polyamine synthetic pathway. Immucillin-H is an inhibitor of both huPNP and PfPNPs. It kills activated human T-cells and induces purine-less death in P. falciparum. Immucillin-H is a transition state analogue designed to mimic the early transition state of bovine PNP. The DADMe-Immucillins are second generation transition state analogues designed to match the fully dissociated transition states of huPNP and PfPNP. Immucillins, DADMe-Immucillins and related analogues are compared for their energetic interactions with human and P. falciparum PNPs. Immucillin-H and DADMe-Immucillin-H are 860 and 500 pM inhibitors against P. falciparum PNP but bind human PNP 15 - 35 times more tightly. This common pattern is a result of k(cat) for huPNP being 18-fold greater than k(cat) for PfPNP. This energetic binding difference between huPNP and PfPNP supports the k(chem)/k(cat) binding argument for transition state analogues. Preferential PfPNP inhibition is gained in the Immucillins by 5'-methylthio substitution which exploits the unique substrate specificity of PfPNP. Human PNP achieves part of its catalytic potential from 5'-OH neighboring group participation. When PfPNP acts on 5'-methylthioinosine, this interaction is not possible. Compensation for the 5'-OH effect in the P. falciparum enzyme is provided by improved leaving group interactions with Asp(206) as a general acid compared with Asn at this position in huPNP. Specific atomic modifications in the transition state analogues cause disproportionate binding differences between huPNP and PfPNPs and pinpoint energetic binding differences despite similar transition states.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Schramm, VL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	vern@aecom.yu.edu	Evans, Gary/B-8343-2011; Taylor, Erika A./F-5635-2015; Evans, Gary/I-4123-2019; Furneaux, Richard Hubert/B-4157-2015	Evans, Gary/0000-0002-6973-2002; Taylor, Erika A./0000-0001-5598-640X; Evans, Gary/0000-0002-6973-2002; Furneaux, Richard Hubert/0000-0003-0973-2606; Kim, Kami/0000-0003-3384-152X; Lewandowicz, Andrzej/0000-0002-4207-9023	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049512, R21AI052469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041916, R37GM041916] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49512, AI52469] Funding Source: Medline; NIGMS NIH HHS [GM41916] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bantia S, 2004, CURR OPIN DRUG DISC, V7, P243; Bols M, 1996, TETRAHEDRON LETT, V37, P2097, DOI 10.1016/0040-4039(96)00202-X; Deng H, 2004, BIOCHEMISTRY-US, V43, P1980, DOI 10.1021/bi0358115; Evans GB, 2004, J MED CHEM, V47, P3275, DOI 10.1021/jm0306475; Evans GB, 2004, J ORG CHEM, V69, P2217, DOI 10.1021/jo035744k; Evans GB, 2003, J MED CHEM, V46, P5271, DOI 10.1021/jm030305z; Evans GB, 2003, ORG LETT, V5, P3639, DOI 10.1021/ol035293q; Evans GB, 2003, J MED CHEM, V46, P3412, DOI 10.1021/jm030145r; Evans GB, 2003, J MED CHEM, V46, P155, DOI 10.1021/jm0203332; EVANS GB, 2005, IN PRESS J MED CHEM, V48; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; Furman RR, 2004, BLOOD, V104, p750A, DOI 10.1182/blood.V104.11.2743.2743; Kicska GA, 2002, BIOCHEMISTRY-US, V41, P14489, DOI 10.1021/bi026636f; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; Kicska GA, 2002, J BIOL CHEM, V277, P3219, DOI 10.1074/jbc.M105905200; Kicska GA, 2001, P NATL ACAD SCI USA, V98, P4593, DOI 10.1073/pnas.071050798; Kilpatrick JM, 2003, INT IMMUNOPHARMACOL, V3, P541, DOI 10.1016/S1567-5769(03)00044-4; KLINE PC, 1993, BIOCHEMISTRY-US, V32, P13212, DOI 10.1021/bi00211a033; Lewandowicz A, 2004, BIOCHEMISTRY-US, V43, P1458, DOI 10.1021/bi0359123; Lewandowicz A, 2003, J BIOL CHEM, V278, P31465, DOI 10.1074/jbc.C300259200; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Nunez S, 2004, J AM CHEM SOC, V126, P15720, DOI 10.1021/ja0457563; Pugmire MJ, 2002, BIOCHEM J, V361, P1, DOI 10.1042/0264-6021:3610001; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P5694, DOI 10.1021/bi034003a; Schramm VL, 1998, ANNU REV BIOCHEM, V67, P693, DOI 10.1146/annurev.biochem.67.1.693; Schramm VL, 2001, CURR OPIN STRUC BIOL, V11, P657, DOI 10.1016/S0959-440X(01)00269-X; Shi WX, 2004, J BIOL CHEM, V279, P18103, DOI 10.1074/jbc.C400068200; Ting LM, 2005, J BIOL CHEM, V280, P9547, DOI 10.1074/jbc.M412693200	29	51	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30320	30328		10.1074/jbc.M505033200	http://dx.doi.org/10.1074/jbc.M505033200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15961383	hybrid			2022-12-25	WOS:000231362500041
J	Diederich, S; Moll, M; Klenk, HD; Maisner, A				Diederich, S; Moll, M; Klenk, HD; Maisner, A			The nipah virus fusion protein is cleaved within the endosomal compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; HENDRA-VIRUS; CATHEPSIN-B; AMINO-ACID; PROTEOLYSIS; ACTIVATION; IDENTIFICATION; GLYCOPROTEINS; ENCEPHALITIS; ENDOCYTOSIS	Nipah virus (NiV) is a recently emerged and highly pathogenic paramyxovirus that causes a systemic infection in animals and humans and can infect a wide range of cultured cells. Interestingly, the NiV fusion ( F) protein has a single arginine at the cleavage site similar to paramyxoviruses that are activated by exogenous trypsin-like enzymes only present in specific cells and tissues and therefore only cause localized infections. We show here that NiV F activation is not mediated by an exogenous serum protease but by an endogenous ubiquitous cellular protease after endocytosis of the protein. In addition to endocytosis, acidification of the endosome is a prerequisite for F cleavage. These results show that activation of the NiV F protein depends on a type of proteolytic cleavage that is clearly different from what is known for other paramyxoviral and orthomyxoviral fusion proteins. To our knowledge, this is the first example of a viral class I fusion protein whose activation depends on clathrin-mediated constitutive endocytosis.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg	Maisner, A (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.	maisner@staff.uni-marburg.de		Moll, Markus/0000-0003-4592-3063				AUTHIER F, 1995, J BIOL CHEM, V270, P15798, DOI 10.1074/jbc.270.26.15798; Authier F, 2002, J BIOL CHEM, V277, P9437, DOI 10.1074/jbc.M110188200; Authier F, 1996, FEBS LETT, V389, P55, DOI 10.1016/0014-5793(96)00368-7; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bossart KN, 2002, J VIROL, V76, P11186, DOI 10.1128/JVI.76.22.11186-11198.2002; Chapman HA, 1998, CURR OPIN IMMUNOL, V10, P93, DOI 10.1016/S0952-7915(98)80038-1; Choi C, 2004, SCI AM, V291, p21A; Chua KB, 2002, MICROBES INFECT, V4, P145, DOI 10.1016/S1286-4579(01)01522-2; Chua KB, 1999, LANCET, V354, P1257, DOI 10.1016/S0140-6736(99)04299-3; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; Harcourt BH, 2000, VIROLOGY, V271, P334, DOI 10.1006/viro.2000.0340; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hsu VP, 2004, EMERG INFECT DIS, V10, P2082, DOI 10.3201/eid1012.040701; HUANG RTC, 1981, VIROLOGY, V110, P243, DOI 10.1016/0042-6822(81)90030-1; Jutras I, 1999, FEBS LETT, V443, P48, DOI 10.1016/S0014-5793(98)01672-X; KLENK HD, 1994, COLD SPRING HARBOR M, P241; Maisner A, 2000, J GEN VIROL, V81, P441, DOI 10.1099/0022-1317-81-2-441; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; Moll M, 2004, J VIROL, V78, P9705, DOI 10.1128/JVI.78.18.9705-9712.2004; Moll M, 2004, J VIROL, V78, P7274, DOI 10.1128/JVI.78.13.7274-7278.2004; Moll M, 2002, J VIROL, V76, P7174, DOI 10.1128/JVI.76.14.7174-7186.2002; Moll M, 2001, J BIOL CHEM, V276, P17887, DOI 10.1074/jbc.M010183200; Murakami M, 2001, EUR J BIOCHEM, V268, P2847, DOI 10.1046/j.1432-1327.2001.02166.x; ODA K, 1985, EUR J BIOCHEM, V152, P605, DOI 10.1111/j.1432-1033.1985.tb09238.x; Pager CT, 2004, J VIROL, V78, P9154, DOI 10.1128/JVI.78.17.9154-9163.2004; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Schlondorff J, 1999, J CELL SCI, V112, P3603; Tamin A, 2002, VIROLOGY, V296, P190, DOI 10.1006/viro.2002.1418; TASHIRO M, 1992, J VIROL, V66, P7211, DOI 10.1128/JVI.66.12.7211-7216.1992; Vogt C, 2005, J VIROL, V79, P3865, DOI 10.1128/JVI.79.6.3865-3872.2005; Wang LF, 2000, J VIROL, V74, P9972, DOI 10.1128/JVI.74.21.9972-9979.2000; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; WATANABE M, 1995, J VIROL, V69, P3206, DOI 10.1128/JVI.69.5.3206-3210.1995; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095	40	74	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29899	29903		10.1074/jbc.M504598200	http://dx.doi.org/10.1074/jbc.M504598200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15961384	hybrid			2022-12-25	WOS:000231176200061
J	Schiefner, A; Gerber, K; Seitz, S; Welte, W; Diederichs, K; Boos, W				Schiefner, A; Gerber, K; Seitz, S; Welte, W; Diederichs, K; Boos, W			The crystal structure of Mlc, a global regulator of sugar metabolism in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT GLUCOKINASE; PHOSPHOTRANSFERASE SYSTEM; GLUCOSE-TRANSPORTER; DIFFRACTION DATA; GENE-EXPRESSION; DNA RECOGNITION; MAJOR GLUCOSE; LAC REPRESSOR; PTS; BINDING	Mlc from Escherichia coli is a transcriptional repressor controlling the expression of a number of genes encoding enzymes of the phosphotransferase system (PTS), including ptsG and manXYZ, the specific enzyme II for glucose and mannose PTS transporters. In addition, Mlc controls the transcription of malT, the gene of the global activator of the mal regulon. The inactivation of Mlc as a repressor is mediated by binding to an actively transporting PtsG ( EIICBGlc). Here we report the crystal structure of Mlc at 2.7 angstrom resolution representing the first described structure of an ROK (repressors, open reading frames, and kinases) family protein. Mlc forms stable dimers thus explaining its binding affinity to palindromic operator sites. The N-terminal helix-turn-helix domain of Mlc is stabilized by the amphipathic C-terminal helix implicated earlier in EIICBGlc binding. Furthermore, the structure revealed a metal-binding site within the cysteine-rich ROK consensus motif that coordinates a structurally important zinc ion. A strongly reduced repressor activity was observed when two of the zinc-coordinating cysteine residues were exchanged against serine or alanine, demonstrating the role of zinc in Mlc-mediated repressor function. The structures of a putative fructokinase from Bacillus subtilis, the glucokinase from Escherichia coli, and a glucomannokinase from Arthrobacter sp. showed high structural homology to the ROK family part of Mlc.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Schiefner, A (corresponding author), Univ Konstanz, Dept Biol, Univ Str 10, D-78457 Constance, Germany.	andre.schiefner@uni-konstanz.de		Schiefner, Andre/0000-0001-5215-4122				Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; Decker K, 1998, MOL MICROBIOL, V27, P381, DOI 10.1046/j.1365-2958.1998.00694.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gerber K, 2005, ACTA CRYSTALLOGR F, V61, P183, DOI 10.1107/S1744309104033640; Hansen T, 2002, J BACTERIOL, V184, P5955, DOI 10.1128/JB.184.21.5955-5965.2002; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOSONO K, 1995, BIOSCI BIOTECH BIOCH, V59, P256, DOI 10.1271/bbb.59.256; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Janin J, 1997, NAT STRUCT BIOL, V4, P973, DOI 10.1038/nsb1297-973; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kalodimos CG, 2002, EMBO J, V21, P2866, DOI 10.1093/emboj/cdf318; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Lunin VV, 2004, J BACTERIOL, V186, P6915, DOI 10.1128/JB.186.20.6915-6927.2004; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miller JH., 1972, EXPT MOL GENETICS; Mukai T, 2004, J BIOL CHEM, V279, P50591, DOI 10.1074/jbc.M408126200; Mukai T, 2003, APPL ENVIRON MICROB, V69, P3849, DOI 10.1128/AEM.69.7.3849-3857.2003; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Plumbridge J, 1998, MOL MICROBIOL, V27, P369, DOI 10.1046/j.1365-2958.1998.00685.x; Plumbridge J, 2002, CURR OPIN MICROBIOL, V5, P187, DOI 10.1016/S1369-5274(02)00296-5; PLUMBRIDGE J, 1993, MOL MICROBIOL, V10, P973, DOI 10.1111/j.1365-2958.1993.tb00969.x; Plumbridge J, 2001, J MOL MICROB BIOTECH, V3, P371; RICHARME G, 1983, BIOCHIM BIOPHYS ACTA, V742, P16, DOI 10.1016/0167-4838(83)90353-9; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Seitz S, 2003, J BIOL CHEM, V278, P10744, DOI 10.1074/jbc.M212066200; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; Tanaka Y, 1999, GENES CELLS, V4, P391, DOI 10.1046/j.1365-2443.1999.00268.x; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TITGEMEYER F, 1994, MICROBIOL-UK, V140, P2349, DOI 10.1099/13500872-140-9-2349; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514	45	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29073	29079		10.1074/jbc.M504215200	http://dx.doi.org/10.1074/jbc.M504215200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15929984	hybrid, Green Published			2022-12-25	WOS:000231021300033
J	Williams, DC; Lee, JY; Cai, ML; Bewley, CA; Clore, GM				Williams, DC; Lee, JY; Cai, ML; Bewley, CA; Clore, GM			Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man(3)GlcNAc(2) - Structural basis for specificity and high-affinity binding to the core pentasaccharide from N-linked oligomannoside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE GLYCOPROTEIN GP120; CYANOVIRIN-N; NMR; ALIGNMENT; CRYSTALLOGRAPHY; MAN(8); SITES; PHASE	The cyanobacterial protein MVL inhibits HIV-1 envelope-mediated cell fusion at nanomolar concentrations by binding to high mannose N-linked carbohydrate on the surface of the envelope glycoprotein gp120. Although a number of other carbohydrate-binding proteins have been shown to inhibit HIV-1 envelope-mediated cell fusion, the specificity of MVL is unique in that its minimal target comprises the Man alpha(136)Man beta(1 -> 4)GlcNAc beta(1 -> 4) GlcNAc tetrasaccharide core of oligomannosides. We have solved the crystal structures of MVL free and bound to the pentasaccharide Man(3)GlcNAc(2) at 1.9- and 1.8-angstrom resolution, respectively. MVL is a homodimer stabilized by an extensive intermolecular interface between monomers. Each monomer contains two structurally homologous domains with high sequence similarity connected by a short five-amino acid residue linker. Intriguingly, a water-filled channel is observed between the two monomers. Residual dipolar coupling measurements indicate that the structure of the MVL dimer in solution is identical to that in the crystal. Man(3)GlcNAc(2) binds to a preformed cleft at the distal end of each domain such that a total of four independent carbohydrate molecules associate with each homodimer. The binding cleft provides shape complementarity, including the presence of a deep hydrophobic hole that accommodates the N-acetyl methyl at the reducing end of the carbohydrate, and specificity arises from 7-8 intermolecular hydrogen bonds. The structures of MVL and the MVL-Man(3)GlcNAc(2) complex further our understanding of the molecular basis of high affinity and specificity in protein-carbohydrate recognition.	NIDDK, Phys Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Phys Chem Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.	mariusc@intra.niddk.nih.gov	Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Bewley, Carole/0000-0003-2203-0852	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK029023, Z01DK032103, Z01DK029023, ZIADK032103] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; Bewley CA, 2004, J MOL BIOL, V339, P901, DOI 10.1016/j.jmb.2004.04.019; Bewley CA, 2001, STRUCTURE, V9, P931, DOI 10.1016/S0969-2126(01)00653-0; Bewley CA, 2002, J MOL BIOL, V322, P881, DOI 10.1016/S0022-2836(02)00842-2; Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828; Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e; Botos I, 2005, PROG BIOPHYS MOL BIO, V88, P233, DOI 10.1016/j.pbiomolbio.2004.05.001; Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLORE BM, 1999, J AM CHEM SOC, V126, P2923; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; NAVAZA J, 1990, ACTA CRYSTALLOGR A, V46, P619, DOI 10.1107/S0108767390000290; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Taylor G, 2003, ACTA CRYSTALLOGR D, V59, P1881, DOI 10.1107/S0907444903017815; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; Wormald MR, 2002, CHEM REV, V102, P371, DOI 10.1021/cr990368i; Yamaguchi M, 1999, BIOCHEM BIOPH RES CO, V265, P703, DOI 10.1006/bbrc.1999.1749; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	36	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29269	29276		10.1074/jbc.M504642200	http://dx.doi.org/10.1074/jbc.M504642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15937331	hybrid			2022-12-25	WOS:000231021300057
J	Elkin, SK; Ivanov, D; Ewalt, M; Ferguson, CG; Hyberts, SG; Sun, ZYJ; Prestwich, GD; Yuan, JY; Wagner, G; Oettinger, MA; Gozani, OP				Elkin, SK; Ivanov, D; Ewalt, M; Ferguson, CG; Hyberts, SG; Sun, ZYJ; Prestwich, GD; Yuan, JY; Wagner, G; Oettinger, MA; Gozani, OP			A PHD finger motif in the C terminus of RAG2 modulates recombination activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASES; HUMAN V(D)J RECOMBINATION; FYVE DOMAIN; B-CELL; MEDIATED TRANSPOSITION; NUCLEAR-LOCALIZATION; JOINT FORMATION; BINDING; MUTATIONS; IDENTIFICATION	The RAG1 and RAG2 proteins catalyze V( D) J recombination and are essential for generation of the diverse repertoire of antigen receptor genes and effective immune responses. RAG2 is composed of a "core" domain that is required for the recombination reaction and a C-terminal nonessential or "non-core" region. Recent evidence has emerged arguing that the non-core region plays a critical regulatory role in the recombination reaction, and mutations in this region have been identified in patients with immunodeficiencies. Here we present the first structural data for the RAG2 protein, using NMR spectroscopy to demonstrate that the C terminus of RAG2 contains a noncanonical PHD finger. All of the non-core mutations of RAG2 that are implicated in the development of immunodeficiencies are located within the PHD finger, at either zinc-coordinating residues or residues adjacent to an alpha-helix on the surface of the domain that participates in binding to the signaling molecules, phosphoinositides. Functional analysis of disease and phosphoinositide-binding mutations reveals novel intramolecular interactions within the noncore region and suggests that the PHD finger adopts two distinct states. We propose a model in which the equilibrium between these states modulates recombination activity. Together, these data identify the PHD finger as a novel and functionally important domain of RAG2.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84108 USA; Echelon Biosci Inc, Salt Lake City, UT 84108 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Stanford University; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Wagner, G (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	wagner@hms.harvard.edu; oettinger@frodo.mgh.harvard.edu; ogozani@stanford.edu	Ewalt, Mark D/Y-4878-2019; Gozani, Or P/I-6157-2013; Ferguson, Colin/AAY-2524-2021; Ivanov, Dmitri/B-4600-2011	Ewalt, Mark D/0000-0003-4245-752X; Ferguson, Colin/0000-0002-9021-4533; Gozani, Or/0000-0002-1365-4463	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R44GM065683, R01GM048026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016674, K08AG019245] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI37587] Funding Source: Medline; NIA NIH HHS [KO8AG19245, R01 AG16674] Funding Source: Medline; NIGMS NIH HHS [R01 GM48026, R44 GM065683] Funding Source: Medline; NINDS NIH HHS [R01 NS29632] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P1209, DOI 10.1073/pnas.0237043100; Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Callebaut I, 1998, CELL MOL LIFE SCI, V54, P880, DOI 10.1007/s000180050216; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Clatworthy AE, 2003, MOL CELL, V12, P489, DOI 10.1016/S1097-2765(03)00305-8; Cocco L, 2004, EUR J HISTOCHEM, V48, P83; Corneo B, 2002, EUR J IMMUNOL, V32, P2068, DOI 10.1002/1521-4141(200207)32:7<2068::AID-IMMU2068>3.0.CO;2-6; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DINITTO JP, 2003, SCI STKE, pRE16, DOI DOI 10.1126/STKE.2132003RE16; Eberharter A, 2004, EMBO J, V23, P4029, DOI 10.1038/sj.emboj.7600382; Elkin SK, 2003, EMBO J, V22, P1931, DOI 10.1093/emboj/cdg184; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; Gauss GH, 1996, MOL CELL BIOL, V16, P258; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Gomez CA, 2000, MOL CELL BIOL, V20, P5653, DOI 10.1128/MCB.20.15.5653-5664.2000; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hama Hiroko, 2004, Methods Mol Biol, V284, P243; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Hyberts SG, 2003, J BIOMOL NMR, V26, P335, DOI 10.1023/A:1024078926886; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jiang H, 2004, J BIOL CHEM, V279, P8478, DOI 10.1074/jbc.M311219200; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Kwan AHY, 2003, STRUCTURE, V11, P803, DOI 10.1016/S0969-2126(03)00122-9; Liang HE, 2002, IMMUNITY, V17, P639, DOI 10.1016/S1074-7613(02)00448-X; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; Martelli AM, 2004, PHARMACOL THERAPEUT, V101, P47, DOI 10.1016/j.pharmthera.2003.10.003; Matthews AGW, 2004, EMBO J, V23, P1198, DOI 10.1038/sj.emboj.7600131; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Noordzij JG, 2002, BLOOD, V100, P2145; O'Driscoll M, 2002, MUTAT RES-FUND MOL M, V509, P109, DOI 10.1016/S0027-5107(02)00221-X; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Papayannopoulos V, 2005, MOL CELL, V17, P181, DOI 10.1016/j.molcel.2004.11.054; Pascual J, 2000, J MOL BIOL, V304, P723, DOI 10.1006/jmbi.2000.4308; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Prestwich GD, 2004, CHEM BIOL, V11, P619, DOI 10.1016/j.chembiol.2004.03.025; Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051; Ross AE, 2003, MOL CELL BIOL, V23, P5308, DOI 10.1128/MCB.23.15.5308-5319.2003; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; Saugier-Veber P, 2001, EUR J ENDOCRINOL, V144, P347, DOI 10.1530/eje.0.1440347; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Scheel H, 2003, TRENDS CELL BIOL, V13, P285, DOI 10.1016/S0962-8924(03)00102-8; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Sekiguchi J, 2001, MOL CELL, V8, P1383, DOI 10.1016/S1097-2765(01)00423-3; Steen SB, 1999, MOL CELL BIOL, V19, P3010; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Sutherland HGE, 2001, HUM MOL GENET, V10, P1995, DOI 10.1093/hmg/10.18.1995; Swanson PC, 2004, J BIOL CHEM, V279, P4034, DOI 10.1074/jbc.M311100200; Tsai CL, 2003, EMBO J, V22, P1922, DOI 10.1093/emboj/cdg185; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	64	56	57	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28701	28710		10.1074/jbc.M504731200	http://dx.doi.org/10.1074/jbc.M504731200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15964836	Green Published, hybrid			2022-12-25	WOS:000230857300061
J	Kim, SJ; Choi, WS; Han, JSM; Warnock, G; Fedida, D; McIntosh, CHS				Kim, SJ; Choi, WS; Han, JSM; Warnock, G; Fedida, D; McIntosh, CHS			Novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide - Protein kinase A-dependent endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; SURFACE EXPRESSION; ALPHA-SUBUNITS; ION CHANNELS; INACTIVATION; DYNAMIN; CELLS; MODULATION; MEMBRANE; FISSION	The mechanisms involved in glucose regulation of insulin secretion by ATP-sensitive ( K-ATP) and calcium-activated ( K-CA) potassium channels have been extensively studied, but less is known about the role of voltage-gated ( K-V) potassium channels in pancreatic beta-cells. The incretin hormone, glucose-dependent insulinotropic polypeptide ( GIP) stimulates insulin secretion by potentiating events underlying membrane depolarization and exerting direct effects on exocytosis. In the present study, we identified a novel role for GIP in regulating K(V)1.4 channel endocytosis. In GIP receptor-expressing HEK293 cells, GIP reduced A-type peak ionic current amplitude of KV1.4 via activation of protein kinase A (PKA). Using mutant forms of KV1.4 with Ala-Ser/Thr substitutions in a potential PKA phosphorylation site, C-terminal phosphorylation was shown to be linked to GIP-mediated current amplitude decreases. Proteinase K digestion and immunocytochemical studies on mutant KV1.4 localization following GIP stimulation demonstrated phosphorylation-dependent rapid endocytosis of KV1.4. Expression of KV1.4 protein was also demonstrated in human beta-cells; GIP treatment resulting in similar decreases in A-type potassium current peak amplitude to those in HEK293 cells. Transient overexpression in INS-1 beta-cells ( clone 832/13) of wild-type ( WT) KV1.4, or a T601A mutant form resistant to PKA phosphorylation, resulted in reduced glucose- stimulated insulin secretion; WT KV1.4 overexpression potentiated GIP-induced insulin secretion, whereas this response was absent in T601A cells. These results strongly support an important novel role for GIP in regulating KV1.4 cell surface expression and modulation of A-type potassium currents, which is likely to be critically important for its insulinotropic action.	Univ British Columbia, Fac Med, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Surg, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	McIntosh, CHS (corresponding author), Univ British Columbia, Fac Med, Dept Cellular & Physiol Sci, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintoch@interchange.ubc.ca						Brahmajothi MV, 1999, J GEN PHYSIOL, V113, P581, DOI 10.1085/jgp.113.4.581; Campomanes CR, 2002, J BIOL CHEM, V277, P8298, DOI 10.1074/jbc.M110276200; Davis MJ, 2001, AM J PHYSIOL-HEART C, V281, pH1835, DOI 10.1152/ajpheart.2001.281.5.H1835; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; Delisle BP, 2004, CIRC RES, V94, P1418, DOI 10.1161/01.RES.0000128561.28701.ea; Deutsch C, 2003, NEURON, V40, P265, DOI 10.1016/S0896-6273(03)00506-3; Dockray JH., 1994, GUT PEPTIDES BIOCH P, P217; Ehses JA, 2002, J BIOL CHEM, V277, P37088, DOI 10.1074/jbc.M205055200; Ehses JA, 2001, J BIOL CHEM, V276, P23667, DOI 10.1074/jbc.M103023200; FERRER J, 1995, J BIOL CHEM, V270, P26086, DOI 10.1074/jbc.270.44.26086; HABENER JF, 1993, ENDOCRIN METAB CLIN, V22, P775, DOI 10.1016/S0889-8529(18)30135-X; Hille B., 2001, ION CHANNELS EXCITAB, P131; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; Judge SIV, 1999, BRAIN RES, V831, P43, DOI 10.1016/S0006-8993(99)01391-8; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kurata HT, 2004, J GEN PHYSIOL, V123, P505, DOI 10.1085/jgp.200308956; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; MacDonald PE, 2003, DIABETOLOGIA, V46, P1046, DOI 10.1007/s00125-003-1159-8; MacDonald PE, 2002, DIABETES, V51, pS434, DOI 10.2337/diabetes.51.2007.S434; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; Miki T, 2005, DIABETES, V54, P1056, DOI 10.2337/diabetes.54.4.1056; MURRAY KT, 1994, CIRC RES, V75, P999, DOI 10.1161/01.RES.75.6.999; Nesti E, 2004, MOL BIOL CELL, V15, P4073, DOI 10.1091/mbc.E03-11-0788; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Ottschytsch N, 2002, P NATL ACAD SCI USA, V99, P7986, DOI 10.1073/pnas.122617999; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; ROBERDS SL, 1993, J CARDIOVASC ELECTR, V4, P68, DOI 10.1111/j.1540-8167.1993.tb01214.x; Roeper J, 1997, J NEUROSCI, V17, P3379; SAH PAJ, 1992, J NEUROPHYSIOL, V68, P1834, DOI 10.1152/jn.1992.68.5.1834; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Strock J, 2004, MOL PHARMACOL, V66, P1071, DOI 10.1124/mol.104.002261; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; WARNOCK GL, 2004, IN PRESS ARCH SURG, V140; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Yan LZ, 2004, DIABETES, V53, P597, DOI 10.2337/diabetes.53.3.597	42	26	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28692	28700		10.1074/jbc.M504913200	http://dx.doi.org/10.1074/jbc.M504913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15955806	hybrid			2022-12-25	WOS:000230857300060
J	Ljusberg, J; Wang, YL; Lang, P; Norgard, M; Dodds, R; Hultenby, K; Ek-Rylander, B; Andersson, G				Ljusberg, J; Wang, YL; Lang, P; Norgard, M; Dodds, R; Hultenby, K; Ek-Rylander, B; Andersson, G			Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL IRON TRANSPORT; BONE-RESORPTION; MATRIX METALLOPROTEINASES; CYSTEINE PROTEINASES; CRYSTAL-STRUCTURE; GROWTH-FACTOR; ACP 5; SEQUENCE HOMOLOGY; DEFICIENT MICE; EXPRESSION	Tartrate-resistant acid phosphatase ( TRAP) is a metal-lophosphoesterase participating in osteoclast-mediated bone turnover. Activation of TRAP is associated with the redox state of the di-iron metal center as well as with limited proteolytic cleavage in an exposed loop domain. The cysteine proteinases cathepsin B, L, K, and S as well as the matrix metalloproteinase-2, -9, -13, and -14 are expressed by osteoclasts and/or other bone cells and have been implicated in the turnover of bone and cartilage. To identify proteases that could act as activators of TRAP in bone, we report here that cathepsins K and L, in contrast to the matrix metalloproteinases, efficiently cleaved and activated recombinant TRAP in vitro. Activation of TRAP by cathepsin K/L was because of increases in catalytic activity, substrate affinity, and sensitivity to reductants. Processing by cathepsin K occurred sequentially by an initial excision of the loop peptide Gly(143)-Gly(160) followed by the removal of a Val(161)-Ala(162) dipeptide at the N terminus of the C-terminal 16-kDa TRAP subunit. Cathepsin L initially released a shorter Gln(151)-Gly(160) peptide and completed processing at Ser(145) or Gly(143) at the C terminus of the N-terminal 23-kDa TRAP subunit and at Arg(163) at the N terminus of the C-terminal 16-kDa TRAP subunit. Mutation of Ser145 to Ala partly mimicked the effect of proteolysis on catalytic activity, identifying Ser145 as well as Asp(146) (Funhoff, E. G., Ljusberg, J., Wang, Y., Andersson, G., and Averill, B. A. ( 2001) Biochemistry 40, 11614 11622) as repressive amino acids of the loop region to maintain the TRAP enzyme in a catalytically latent state. The C-terminal sequence of TRAP isolated from rat bone was consistent with cathepsin K-mediated processing in vivo. Moreover, cathepsin K, but not cathepsin L, co-localized with TRAP in osteoclast-resorptive compartments, supporting a role for cathepsin K in the extracellular processing of monomeric TRAP in the resorption lacuna.	Karolinska Univ Hosp, Karolinska Inst, Div Pathol, Dept Lab Med, S-14186 Huddinge, Sweden; Karolinska Univ Hosp, Karolinska Inst, Clin Res Ctr, S-14186 Huddinge, Sweden; Johnson & Johnson Pharmaceut Res & Dev, Growth Factors Drug Discovery, Raritan, NJ 08869 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Johnson & Johnson; Johnson & Johnson USA	Andersson, G (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Div Pathol, Dept Lab Med, S-14186 Huddinge, Sweden.	Goran.Andersson@labmed.ki.se	Lång, Pernilla/AAA-6660-2019	Lång, Pernilla/0000-0002-3605-4014				Almeida PC, 2001, J BIOL CHEM, V276, P944, DOI 10.1074/jbc.M003820200; Alves MFM, 2003, BIOCHEM J, V373, P981, DOI 10.1042/BJ20030438; Andersson G, 2003, J BONE MINER RES, V18, P1912, DOI 10.1359/jbmr.2003.18.10.1912; Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103; Atley LM, 2000, BONE, V26, P241, DOI 10.1016/S8756-3282(99)00270-7; BAZER FW, 1991, EXP HEMATOL, V19, P910; BLAVIER L, 1995, J CELL SCI, V108, P3649; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BUHI WC, 1982, J BIOL CHEM, V257, P1712; CASSADY AI, 1993, GENE, V130, P201, DOI 10.1016/0378-1119(93)90420-8; DAVIS JC, 1981, BIOCHEMISTRY-US, V20, P4062, DOI 10.1021/bi00517a018; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; Delaisse JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374; Dodds RA, 2001, J BONE MINER RES, V16, P478, DOI 10.1359/jbmr.2001.16.3.478; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; DUCSAY CA, 1984, J ANIM SCI, V59, P1303, DOI 10.2527/jas1984.5951303x; EKRYLANDER B, 1991, J BIOL CHEM, V266, P24684; EkRylander B, 1997, BIOCHEM J, V321, P305, DOI 10.1042/bj3210305; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Everts V, 1998, J BONE MINER RES, V13, P1420, DOI 10.1359/jbmr.1998.13.9.1420; Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Funhoff EG, 2001, CHEMBIOCHEM, V2, P355, DOI 10.1002/1439-7633(20010504)2:5<355::AID-CBIC355>3.0.CO;2-Q; Funhoff EG, 2001, BIOCHEMISTRY-US, V40, P11614, DOI 10.1021/bi010766r; Furuyama N, 2000, BIOCHEM BIOPH RES CO, V272, P116, DOI 10.1006/bbrc.2000.2698; Goto A, 2003, CALCIFIED TISSUE INT, V73, P180, DOI 10.1007/s00223-002-2040-3; Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Halleen JM, 1999, J BIOL CHEM, V274, P22907, DOI 10.1074/jbc.274.33.22907; Hayman AR, 2000, J HISTOCHEM CYTOCHEM, V48, P219, DOI 10.1177/002215540004800207; Hayman AR, 2001, J HISTOCHEM CYTOCHEM, V49, P675, DOI 10.1177/002215540104900601; Hayman AR, 1996, DEVELOPMENT, V122, P3151; HAYMAN AR, 1994, J BIOL CHEM, V269, P1294; HAYMAN AR, 1991, BIOCHEM J, V277, P631, DOI 10.1042/bj2770631; Hollberg K, 2002, EXP CELL RES, V279, P227, DOI 10.1006/excr.2002.5612; Hou WS, 2003, BIOL CHEM, V384, P891, DOI 10.1515/BC.2003.100; HULTENBY K, 1991, MATRIX, V11, P206, DOI 10.1016/S0934-8832(11)80160-5; HUNT DF, 1987, BIOCHEM BIOPH RES CO, V144, P1154, DOI 10.1016/0006-291X(87)91432-X; Igarashi Y, 2001, J CHROMATOGR B, V757, P269, DOI 10.1016/S0378-4347(01)00157-8; Ishibashi O, 2001, CALCIFIED TISSUE INT, V68, P109, DOI 10.1007/BF02678149; Janckila AJ, 2005, J LEUKOCYTE BIOL, V77, P209, DOI 10.1189/jlb.0504287; Kaija H, 2002, BIOCHEM BIOPH RES CO, V292, P128, DOI 10.1006/bbrc.2002.6615; Kamiya T, 1998, J BIOCHEM-TOKYO, V123, P752; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020; Kiviranta R, 2001, J BONE MINER RES, V16, P1444, DOI 10.1359/jbmr.2001.16.8.1444; Lang P, 2005, CELL MOL LIFE SCI, V62, P905, DOI 10.1007/s00018-005-4550-4; Lecaille F, 2002, BIOCHEMISTRY-US, V41, P8447, DOI 10.1021/bi025638x; Lindqvist Y, 1999, J MOL BIOL, V291, P135, DOI 10.1006/jmbi.1999.2962; LittlewoodEvans A, 1997, BONE, V20, P81, DOI 10.1016/S8756-3282(96)00351-1; Ljusberg J, 1999, BIOCHEM J, V343, P63, DOI 10.1042/0264-6021:3430063; LORD DK, 1990, EUR J BIOCHEM, V189, P287, DOI 10.1111/j.1432-1033.1990.tb15488.x; Naseri JI, 2004, ARCH BIOCHEM BIOPHYS, V432, P25, DOI 10.1016/j.abb.2004.08.008; ORLANDO JL, 1993, BIOCHEMISTRY-US, V32, P8120, DOI 10.1021/bi00083a010; Potts W, 2004, INT J EXP PATHOL, V85, P85, DOI 10.1111/j.0959-9673.2004.00373.x; Reinholt FP, 1999, EXP CELL RES, V251, P477, DOI 10.1006/excr.1999.4585; REINHOLT FP, 1990, J BONE MINER RES, V5, P1055; Rieman DJ, 2001, BONE, V28, P282, DOI 10.1016/S8756-3282(00)00445-2; ROBERTS RM, 1986, FED PROC, V45, P2513; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Sato T, 1998, J BONE MINER RES, V13, P59, DOI 10.1359/jbmr.1998.13.1.59; SAUNDERS PTK, 1985, J BIOL CHEM, V260, P3658; Schenk G, 1999, ARCH BIOCHEM BIOPHYS, V370, P183, DOI 10.1006/abbi.1999.1407; Sheu TJ, 2003, J BIOL CHEM, V278, P438, DOI 10.1074/jbc.M208292200; SIBILLE JC, 1987, J BIOL CHEM, V262, P59; Soderstrom M, 1999, BBA-GENE STRUCT EXPR, V1446, P35, DOI 10.1016/S0167-4781(99)00068-8; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; Suter A, 2001, DEVELOPMENT, V128, P4899; Twitchett MB, 1999, EUR J INORG CHEM, P2105; Uppenberg J, 1999, J MOL BIOL, V290, P201, DOI 10.1006/jmbi.1999.2896; VINCENT JB, 1990, FEBS LETT, V263, P265, DOI 10.1016/0014-5793(90)81389-6; VOGEL A, 2001, HDB METALLOPROTEINS, P752; Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang YL, 2005, ARCH BIOCHEM BIOPHYS, V435, P147, DOI 10.1016/j.abb.2004.11.029; Yamaza T, 1998, BONE, V23, P499, DOI 10.1016/S8756-3282(98)00138-0	78	100	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28370	28381		10.1074/jbc.M502469200	http://dx.doi.org/10.1074/jbc.M502469200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15929988	hybrid			2022-12-25	WOS:000230857300025
J	Pereira, CM; Sattlegger, E; Jiang, HY; Longo, BM; Jaqueta, CB; Hinnebusch, AG; Wek, RC; Mello, LEAM; Castilho, BA				Pereira, CM; Sattlegger, E; Jiang, HY; Longo, BM; Jaqueta, CB; Hinnebusch, AG; Wek, RC; Mello, LEAM; Castilho, BA			IMPACT, a protein preferentially expressed in the mouse brain, binds GCN1 and inhibits GCN2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCHARGED TRANSFER-RNA; AMINO-ACID DEFICIENCY; FACTOR 2-ALPHA KINASE; TRANSLATIONAL CONTROL; GENE-EXPRESSION; INITIATION; PHOSPHORYLATION; REINITIATION; ASSOCIATION; DEPRIVATION	Translational control directed by the eukaryotic translation initiation factor 2 alpha-subunit (eIF2 alpha) kinase GCN2 is important for coordinating gene expression programs in response to nutritional deprivation. The GCN2 stress response, conserved from yeast to mammals, is critical for resistance to nutritional deficiencies and for the control of feeding behaviors in rodents. The mouse protein IMPACT has sequence similarities to the yeast YIH1 protein, an inhibitor of GCN2. YIH1 competes with GCN2 for binding to a positive regulator, GCN1. Here, we present evidence that IMPACT is the functional counterpart of YIH1. Overexpression of IMPACT in yeast lowered both basal and amino acid starvation-induced levels of phosphorylated eIF2 alpha, as described for YIH1 (31). Overexpression of IMPACT in mouse embryonic fibroblasts inhibited phosphorylation of eIF2 alpha by GCN2 under leucine starvation conditions, abolishing expression of its downstream target genes, ATF4 (CREB-2) and CHOP (GADD153). IMPACT bound to the minimal yeast GCN1 segment required for interaction with yeast GCN2 and YIH1 and to native mouse GCN1. At the protein level, IMPACT was detected mainly in the brain. IMPACT was found to be abundant in the majority of hypothalamic neurons. Scattered neurons expressing this protein at higher levels were detected in other regions such as the hippocampus and piriform cortex. The abundance of IMPACT correlated inversely with phosphorylated eIF2 alpha levels in different brain areas. These results suggest that IMPACT ensures constant high levels of translation and low levels of ATF4 and CHOP in specific neuronal cells under amino acid starvation conditions.	Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, BR-04023062 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Fisiol, BR-04023062 Sao Paulo, Brazil; NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Indiana University System; Indiana University-Purdue University Indianapolis	Castilho, BA (corresponding author), Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Rua Botucatu 862, BR-04023062 Sao Paulo, Brazil.	bac@ecb.epm.br	Mello, Luiz E/B-4177-2009; Checchinato, Catia/AAK-8775-2021; Castilho, Beatriz A/C-2503-2012; Monteiro Longo, Beatriz/D-2216-2012	Mello, Luiz E/0000-0002-6969-1108; Castilho, Beatriz A/0000-0003-4509-5237; Monteiro Longo, Beatriz/0000-0002-2638-8061	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abbott CM, 2004, TRENDS BIOCHEM SCI, V29, P25, DOI 10.1016/j.tibs.2003.11.006; Anthony TG, 2004, J BIOL CHEM, V279, P36553, DOI 10.1074/jbc.M404559200; Carnevalli LS, 2004, NEUROSCI LETT, V357, P191, DOI 10.1016/j.neulet.2003.12.093; Chen A, 2003, NEURON, V39, P655, DOI 10.1016/S0896-6273(03)00501-4; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; Gietzen DW, 2004, J NUTR, V134, P717, DOI 10.1093/jn/134.4.717; Hagiwara Y, 1997, P NATL ACAD SCI USA, V94, P9249, DOI 10.1073/pnas.94.17.9249; Hao SZ, 2005, SCIENCE, V307, P1776, DOI 10.1126/science.1104882; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Klann E, 2004, NAT REV NEUROSCI, V5, P931, DOI 10.1038/nrn1557; Kubota H, 2000, J BIOL CHEM, V275, P20243, DOI 10.1074/jbc.C000262200; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; Maurin AC, 2005, CELL METAB, V1, P273, DOI 10.1016/j.cmet.2005.03.004; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Qiu H, 2001, EMBO J, V20, P1425, DOI 10.1093/emboj/20.6.1425; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; Sattlegger E, 2004, J BIOL CHEM, V279, P29952, DOI 10.1074/jbc.M404009200; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Si K, 2003, CELL, V115, P893, DOI 10.1016/S0092-8674(03)01021-3; Sood R, 2000, GENETICS, V154, P787; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002	37	54	58	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28316	28323		10.1074/jbc.M408571200	http://dx.doi.org/10.1074/jbc.M408571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15937339	hybrid			2022-12-25	WOS:000230857300018
J	Herbert, BS; Gellert, GC; Hochreiter, A; Pongracz, K; Wright, WE; Zielinska, D; Chin, AC; Harley, CB; Shay, JW; Gryaznov, SM				Herbert, BS; Gellert, GC; Hochreiter, A; Pongracz, K; Wright, WE; Zielinska, D; Chin, AC; Harley, CB; Shay, JW; Gryaznov, SM			Lipid modification of GRN163, an N3 ' -> P5 ' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition	ONCOGENE			English	Article						telomerase inhibitors; oligonucleotide; thio-phosphoramidates; lipid conjugates	CHOLESTERYL-CONJUGATED OLIGONUCLEOTIDES; HUMAN IMMUNODEFICIENCY VIRUS; AMPLIFICATION PROTOCOL TRAP; ANTISENSE OLIGONUCLEOTIDES; TEMPLATE ANTAGONIST; MULTIPLE-MYELOMA; IN-VITRO; CELLS; CANCER; OLIGODEOXYNUCLEOTIDES	The vast majority of human cancers express telomerase activity, while most human somatic cells do not have detectable telomerase activity. Since telomerase plays a critical role in cell immortality, it is an attractive target for a selective cancer therapy. Oligonucleotides complementary to the RNA template region of human telomerase (hTR) have been shown to be effective inhibitors of telomerase and, subsequently, cancer cell growth in vitro. We show here that a lipid-modified N3'-> P5' thio-phosphoramidate oligonucleotide (GRN163L) inhibits telomerase more potently than its parental nonconjugated thio-phosphoramidate sequence (GRN163). Cells were treated with both the first- (GRN163) and second-generation (GRN163L) oligonucleotides, including a mismatch control, with or without a transfection enhancer reagent. GRN163L inhibited telomerase activity effectively in a dose-dependent manner, even without the use of a transfection reagent. The IC50 values for GRN163 in various cell lines were on average sevenfold higher than for GRN163L. GRN163L inhibition of telomerase activity resulted in a more rapid loss of telomeres and cell growth than GRN163. This report is the first to show that lipid modi. cation enhanced the potency of the novel GRN163 telomerase inhibitor. These results suggest that the lipid-conjugated thio-phosphoramidates could be important for improved pharmacodynamics of telomerase inhibitors in cancer therapy.	Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA; Geron Corp, Menlo Pk, CA 94025 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University-Purdue University Indianapolis; Geron Corporation	Herbert, BS (corresponding author), Indiana Univ, Sch Med, Dept Med & Mol Genet, 975 W Walnut St,IB242, Indianapolis, IN 46202 USA.	brherber@iupui.edu	Shay, Jerry W/F-7878-2011		NCPDCID CDC HHS [NCI CA85363, NCI CA70907] Funding Source: Medline	NCPDCID CDC HHS		AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; Akiyama M, 2003, CANCER RES, V63, P6187; Asai A, 2003, CANCER RES, V63, P3931; BOUTORIN AS, 1989, FEBS LETT, V254, P129, DOI 10.1016/0014-5793(89)81023-3; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; FAROOQUI F, 1991, BIOCONJUGATE CHEM, V2, P422, DOI 10.1021/bc00012a007; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553; MACKELLAR C, 1992, NUCLEIC ACIDS RES, V20, P3411, DOI 10.1093/nar/20.13.3411; MISHRA RK, 1995, BBA-GENE STRUCT EXPR, V1264, P229, DOI 10.1016/0167-4781(95)00145-7; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; OBERHAUSER B, 1992, NUCLEIC ACIDS RES, V20, P533, DOI 10.1093/nar/20.3.533; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Ozawa T, 2004, NEURO-ONCOLOGY, V6, P218, DOI 10.1215/S1152851704000055; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; POLUSHIN NN, 1994, NUCLEIC ACIDS RES, V22, P5492, DOI 10.1093/nar/22.24.5492; REED MW, 1991, BIOCONJUGATE CHEM, V2, P217, DOI 10.1021/bc00010a005; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHEA RG, 1990, NUCLEIC ACIDS RES, V18, P3777, DOI 10.1093/nar/18.13.3777; Shea-Herbert B, 2002, ONCOGENE, V21, P638, DOI 10.1038/sj.onc.1205064; STEIN CA, 1991, BIOCHEMISTRY-US, V30, P2439, DOI 10.1021/bi00223a020; Wang ES, 2004, BLOOD, V103, P258, DOI 10.1182/blood-2003-02-0546; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	31	170	209	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5262	5268		10.1038/sj.onc.1208760	http://dx.doi.org/10.1038/sj.onc.1208760			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15940257				2022-12-25	WOS:000230964600014
J	Deng, L; Sugiura, R; Ohta, K; Tada, K; Suzuki, M; Hirata, M; Nakamura, S; Shuntoh, H; Kuno, T				Deng, L; Sugiura, R; Ohta, K; Tada, K; Suzuki, M; Hirata, M; Nakamura, S; Shuntoh, H; Kuno, T			Phosphatidylinositol-4-phosphate 5-kinase regulates fission yeast cell integrity through a phospholipase C-mediated protein kinase C-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; ACTIN CYTOSKELETON; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; WALL FORMATION; SHAPE CONTROL; GENE; CALCINEURIN; PHOSPHOINOSITIDES; HOMOLOG	Fission yeast its3-1 mutant is an allele of the essential gene its3(+) that encodes a phosphatidylinositol-4-phosphate 5-kinase (PIP5K) that produces phosphatidylinositol 4,5-bisphosphate. We found that the its3-1 mutant is sensitive to micafungin, a (1,3)-beta-D-glucan synthase inhibitor, suggesting a cell wall integrity defect. Consistently, its3-1 mutation caused synthetic lethality with a (1,3)-beta-D-glucan synthase mutant, bgs1-i2, and its3-1 mutant cells showed aberrant localization of green fluorescent protein-Bgs1. Similar aberrant localization of green fluorescent protein-tagged Rgf1, a putative phosphatidylinositol 4,5-bisphosphate-binding guanine nucleotide exchange factor for Rho protein, in its3-1 mutants was observed, suggesting a defective Rgf1/Rho pathway. To unravel the molecular mechanism(s), putative downstream components of PIP5K signaling were analyzed. Unexpectedly, overexpression of phospholipase C (Plc1), but not that of protein kinase C (PKC; Pck1 and Pck2), suppressed the phenotypes of the its3-1 mutant. These findings indicate that PKCs are not involved in the suppression, and further analysis revealed that PKCs are not downstream of Plc1 in fission yeast. Also, the enzymatic activity of Plc1 is essential for the suppression of the phenotypes and for the viability of the its3-1 mutant. These findings suggest that Its3 PIP5K regulates cell integrity through a Plc1-mediated PKC-independent pathway, in addition to the Rho/PKC pathway.	Kobe Univ, Grad Sch Med, Div Mol Pharmacol & Pharmacogenom, Dept Genome Sci,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Div Biochem, Dept Mol & Cellular Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kinki Univ, Sch Pharmaceut Sci, Lab Mol Pharmacogenom, Higashiosaka, Osaka 5778502, Japan; Kyushu Univ, Mol & Cellular Biochem Lab, Fac Med Sci, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Stn Collaborat Res, Higashi Ku, Fukuoka 8128582, Japan; Kobe Univ, Sch Med, Fac Hlth Sci, Suma Ku, Kobe, Hyogo 6540142, Japan	Kobe University; Kobe University; Kindai University (Kinki University); Kyushu University; Kyushu University; Kobe University	Kuno, T (corresponding author), Kobe Univ, Grad Sch Med, Div Mol Pharmacol & Pharmacogenom, Dept Genome Sci,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tkuno@med.kobe-u.ac.jp						Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Andoh T, 1998, MOL GEN GENET, V258, P139, DOI 10.1007/s004380050716; ANDOH T, 1995, YEAST, V11, P179, DOI 10.1002/yea.320110209; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Calonge TM, 2000, MOL BIOL CELL, V11, P4393, DOI 10.1091/mbc.11.12.4393; Carver PL, 2004, ANN PHARMACOTHER, V38, P1707, DOI 10.1345/aph.1D301; Cortes JCG, 2002, J CELL SCI, V115, P4081, DOI 10.1242/jcs.00085; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hermosura MC, 2000, NATURE, V408, P735, DOI 10.1038/35047115; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Jun Y, 2004, J BIOL CHEM, V279, P53186, DOI 10.1074/jbc.M411363200; Kita A, 2004, MOL BIOL CELL, V15, P2920, DOI 10.1091/mbc.E03-09-0659; KOBORI H, 1994, J CELL SCI, V107, P1131; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAZZEI GJ, 1993, J BIOL CHEM, V268, P7401; Mitra P, 2004, J CELL BIOL, V166, P205, DOI 10.1083/jcb.200404150; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NISHIZUKA Y, 1992, NEUROSCI RES, V15, P3, DOI 10.1016/0168-0102(92)90013-3; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Sayers LG, 2000, GENES CELLS, V5, P17, DOI 10.1046/j.1365-2443.2000.00301.x; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Takeuchi H, 2000, BIOCHEM J, V349, P357, DOI 10.1042/0264-6021:3490357; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; Toda T, 1996, MOL CELL BIOL, V16, P6752; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Yada T, 2001, J BIOL CHEM, V276, P13579, DOI 10.1074/jbc.M009260200; YAMAGUCHI H, 1985, MICROBIOL IMMUNOL, V29, P609, DOI 10.1111/j.1348-0421.1985.tb00865.x; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Zhang YJ, 2000, J BIOL CHEM, V275, P35600, DOI 10.1074/jbc.M005575200	45	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27561	27568		10.1074/jbc.M502660200	http://dx.doi.org/10.1074/jbc.M502660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923187	hybrid			2022-12-25	WOS:000230678600012
J	Lefevre, P; Lacroix, C; Tagoh, H; Hoogenkamp, M; Melnik, S; Ingram, R; Bonifer, C				Lefevre, P; Lacroix, C; Tagoh, H; Hoogenkamp, M; Melnik, S; Ingram, R; Bonifer, C			Differentiation-dependent alterations in histone methylation and chromatin architecture at the inducible chicken lysozyme gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; COMPLEX-FORMATION; EUKARYOTIC GENES; PHO5 PROMOTER; CELLS; LOCUS; H3; REORGANIZATION; RECRUITMENT; NUCLEOSOME	It is now well established that locus-wide chromatin remodeling and dynamic alterations of histone modifications are required for the developmentally regulated activation of tissue-specific genes. However, little is known about the dynamics of these events during cell differentiation and how chromatin of an entire gene locus responds to signal transduction processes. To address this issue we investigated chromatin accessibility, linker histone distribution, and the histone methylation status at the macrophage-specific chicken lysozyme locus and the ubiquitously expressed gas41 locus in multipotent precursor cell lines and BM2 monoblast cells. The latter can be induced to go through macrophage maturation by treatment with phorbol-12-myristate acetate and can be further stimulated with bacterial lipopolysaccharide. We show that expression of the lysozyme gene in undifferentiated monoblasts is low and that a high level of gene expression requires both cell differentiation and lipopolysaccharide stimulation. However, depletion of the linker histone H1 is observed already in lysozyme non-expressing multipotent precursor cells. In undifferentiated monoblasts, the lysozyme regulatory regions are marked by the presence of monomethylated histone H3 lysine 4, which becomes increasingly converted into trimethylated H3 lysine K4 during cell differentiation. We also present evidence for extensive, differentiation-dependent alterations in nuclease accessibility at the lysozyme promoter without alterations of nucleosome and transcription factor occupancy.	Univ Leeds, St Jamess Univ Hosp, Div Expt Hematol, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Bonifer, C (corresponding author), Univ Leeds, St Jamess Univ Hosp, Div Expt Hematol, Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.	c.bonifer@leeds.ac.uk	Bonifer, Constanze/B-3000-2009; Tagoh, Hiromi/B-2954-2009	Tagoh, Hiromi/0000-0001-9905-6992; Hoogenkamp, Maarten/0000-0003-2429-1271; Bonifer, Constanze/0000-0002-4267-0825; Melnik, Svitlana/0000-0001-7227-3321	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAGNIS C, 1993, ONCOGENE, V8, P737; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Bonifer C, 1997, J BIOL CHEM, V272, P26075, DOI 10.1074/jbc.272.42.26075; Chong SY, 2002, NUCLEIC ACIDS RES, V30, P463, DOI 10.1093/nar/30.2.463; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Flavin M, 2004, MOL CELL BIOL, V24, P7891, DOI 10.1128/MCB.24.18.7891-7901.2004; Fragoso G, 1997, METHODS, V11, P246, DOI 10.1006/meth.1996.0411; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GREZ M, 1981, CELL, V25, P743, DOI 10.1016/0092-8674(81)90182-3; Huber MC, 1996, NUCLEIC ACIDS RES, V24, P1443, DOI 10.1093/nar/24.8.1443; Ingram R, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni001; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; Kontaraki J, 2000, GENE DEV, V14, P2106; Korber P, 2004, MOL CELL BIOL, V24, P10965, DOI 10.1128/MCB.24.24.10965-10974.2004; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Lefevre P, 2003, MOL CELL BIOL, V23, P4386, DOI 10.1128/MCB.23.12.4386-4400.2003; LEFEVRE P, 2005, IN PRESS METHODS MOL; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; MODAK SP, 1980, NUCLEIC ACIDS RES, V8, P2665, DOI 10.1093/nar/8.12.2665; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Santos-Rosa H, 2004, J BIOL CHEM, V279, P47506, DOI 10.1074/jbc.M407949200; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; SIPPEL AE, 1993, COLD SPRING HARB SYM, V58, P37, DOI 10.1101/SQB.1993.058.01.007; Stadler S, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-44; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Tagoh H, 2004, BLOOD, V103, P2950, DOI 10.1182/blood-2003-09-3323; Vicent GP, 2004, MOL CELL, V16, P439, DOI 10.1016/j.molcel.2004.10.025	36	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27552	27560		10.1074/jbc.M502422200	http://dx.doi.org/10.1074/jbc.M502422200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923188	hybrid			2022-12-25	WOS:000230678600011
J	Mizuhara, E; Nakatani, T; Minaki, Y; Sakamoto, Y; Ono, Y; Takai, Y				Mizuhara, E; Nakatani, T; Minaki, Y; Sakamoto, Y; Ono, Y; Takai, Y			MAGI1 recruits Dll1 to cadherin-based adherens junctions and stabilizes it on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOTCH LIGAND DELTA1; MAMMALIAN NEUROEPITHELIAL CELLS; UBIQUITIN LIGASE; BETA-CATENIN; GUANYLATE KINASE; EPITHELIAL-CELLS; TIGHT JUNCTIONS; GAMMA-SECRETASE; NERVOUS-SYSTEM; DROSOPHILA	Delta-Notch signaling plays an essential role in cell fate determination in many tissue types, including the central nervous system. Although the signaling mechanism of Notch has been extensively studied, the behaviors of its ligands are not well understood. In the present study, we found that, in the developing neural tube, Dll1( Delta-like 1) was mainly localized on the processes extending from nascent neurons toward both the pia and the ventricle and accumulated at apical termini, where adherens junctions (AJs) were formed. To understand the mechanism of Dll1 localization, we searched for binding proteins for Dll1 and identified a scaffolding molecule, MAGI1. In the developing spinal cord, MAGI1 mRNA was highly expressed in the ventricular zone, where Dll1 mRNA was expressed. MAGI1 protein accumulated at the AJs formed around the termini of apically extending processes and was partially colocalized with Dll1. MAGI1 bound not only to Dll1 but also to N-cadherin-beta-catenin complexes. In cultured AJ-forming fibroblasts, MAGI1 was localized at AJs, and Dll1 was recruited to these AJs through binding to MAGI1. In addition, Dll1 was stabilized on the cell surface by MAGI1. Taken together, these results suggest that Dll1 is presented on the surface of AJs formed at the apical termini of processes through interaction with MAGI1 to activate Notch on neighboring cells in the developing central nervous system.	KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan; Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan	KAN Research Institute; Osaka University	Ono, Y (corresponding author), KAN Res Inst Inc, Shimogyo Ku, 93 Chudoji Awata Cho, Kyoto 6008815, Japan.	y-ono@kan.gr.jp		Minaki, Yasuko/0000-0001-5926-4746				AakuSaraste E, 1996, DEV BIOL, V180, P664, DOI 10.1006/dbio.1996.0336; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Chae TH, 2004, NAT GENET, V36, P264, DOI 10.1038/ng1302; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Chenn A, 1998, MOL CELL NEUROSCI, V11, P183, DOI 10.1006/mcne.1998.0680; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; de Joussineau C, 2003, NATURE, V426, P555, DOI 10.1038/nature02157; Deblandre GA, 2001, DEV CELL, V1, P795, DOI 10.1016/S1534-5807(01)00091-0; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Fishell G, 2003, CURR OPIN NEUROBIOL, V13, P34, DOI 10.1016/S0959-4388(03)00013-8; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; Hukriede NA, 1997, DEVELOPMENT, V124, P3427; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Kageyama R, 1999, CELL RES, V9, P179, DOI 10.1038/sj.cr.7290016; Klueg KM, 1999, J CELL SCI, V112, P3289; Kosodo Y, 2004, EMBO J, V23, P2314, DOI 10.1038/sj.emboj.7600223; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; Lai EC, 2001, DEV CELL, V1, P783, DOI 10.1016/S1534-5807(01)00092-2; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Laura RP, 2002, EXP CELL RES, V275, P155, DOI 10.1006/excr.2002.5475; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Le Borgne R, 2003, CURR BIOL, V13, pR273, DOI 10.1016/S0960-9822(03)00199-4; Lewis J, 1998, SEMIN CELL DEV BIOL, V9, P583, DOI 10.1006/scdb.1998.0266; Minaki Y, 2005, NEUROSCI RES, V52, P250, DOI 10.1016/j.neures.2005.03.014; Myat A, 1996, DEV BIOL, V174, P233, DOI 10.1006/dbio.1996.0069; Nadarajah B, 2002, NAT REV NEUROSCI, V3, P423, DOI 10.1038/nrn845; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nakatani T, 2004, J BIOL CHEM, V279, P16356, DOI 10.1074/jbc.M311740200; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Parks AL, 2000, DEVELOPMENT, V127, P1373; Pavlopoulos E, 2001, DEV CELL, V1, P807, DOI 10.1016/S1534-5807(01)00093-4; Pfister S, 2003, J MOL BIOL, V333, P229, DOI 10.1016/j.jmb.2003.08.043; Seugnet L, 1997, DEV BIOL, V192, P585, DOI 10.1006/dbio.1997.8723; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; Six EM, 2004, J BIOL CHEM, V279, P55818, DOI 10.1074/jbc.M408022200; Sun X, 1996, DEVELOPMENT, V122, P2465; Sun X, 1997, DEVELOPMENT, V124, P3439; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Wang SL, 2000, NEURON, V27, P197, DOI 10.1016/S0896-6273(00)00028-3; Wright GJ, 2004, DEVELOPMENT, V131, P5659, DOI 10.1242/dev.01417; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yeh E, 2001, CURR BIOL, V11, P1675, DOI 10.1016/S0960-9822(01)00527-9; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4	56	56	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26499	26507		10.1074/jbc.M500375200	http://dx.doi.org/10.1074/jbc.M500375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15908431	hybrid			2022-12-25	WOS:000230386800066
J	Umetani, N; Mori, T; Koyanagi, K; Shinozaki, M; Kim, J; Giuliano, AE; Hoon, DSB				Umetani, N; Mori, T; Koyanagi, K; Shinozaki, M; Kim, J; Giuliano, AE; Hoon, DSB			Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer	ONCOGENE			English	Article						ID4; breast cancer; hypermethylation; lymph node metastasis	EPIGENETIC INACTIVATION; DNA METHYLATION; CUTANEOUS MELANOMA; EXPRESSION; PROTEINS; CELLS; DIFFERENTIATION; CARCINOMA; DISEASE; ID-1	ID4 gene is a member of the inhibitor of DNA-binding ( ID) family, which inhibits DNA binding of basic helix loop-helix transcription factors. Certain human primary breast cancers reportedly have low or no expression of ID4 protein, but its role in carcinogenesis and cancer progression is unknown. To determine its possible role, we examined epigenetic inactivation of ID4 gene by promoter hypermethylation in human breast cell lines and T1 breast cancer tissues. Methylation status of ID4 promoter CpG island was assessed by methylation-specific PCR (MSP); ID4 mRNA level was assessed by quantitative real-time RT-PCR. Of eight cell lines, two were fully methylated, four were partially methylated, and two were not methylated. ID4 mRNA level was suppressed in fully methylated cell lines. ID4 hypermethylation was observed in 16 of 24 (67%) node- positive and seven of 36 (19%) node- negative T1 primary breast cancers matched by patient age and tumor diameter. It was a significant risk factor for nodal metastasis (OR 13.1, P = 0.0004). ID4 mRNA level was suppressed in hypermethylated cancer specimens (P = 0.014). ID4 may play an important suppressive role in tumor progression, and its silencing by hypermethylation may increase the risk of regional lymph node metastasis.	John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; John Wayne Canc Inst, Joyce Eisenberg Keefer Breast Ctr, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; John Wayne Cancer Institute	Hoon, DSB (corresponding author), John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Hoon, Dave SB/C-7146-2018	Hoon, Dave SB/0000-0003-1915-3683				Barth A, 1997, CANCER-AM CANCER SOC, V79, P1918, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1918::AID-CNCR12>3.0.CO;2-Y; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Brenin DR, 2001, ANN SURG ONCOL, V8, P432, DOI 10.1245/aso.2001.8.5.432; Carter BA, 2000, AM J CLIN PATHOL, V113, P259, DOI 10.1309/7EF8-F1W7-YVNT-H8H5; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; FISHER ER, 1984, CANCER-AM CANCER SOC, V54, P3002, DOI 10.1002/1097-0142(19841215)54:12<3002::AID-CNCR2820541231>3.0.CO;2-V; FISHER ER, 1993, CANCER, V71, P2507, DOI 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0; Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holland PA, 1996, BRIT J CANCER, V74, P1643, DOI 10.1038/bjc.1996.602; Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505; Itahana Y, 2003, CANCER RES, V63, P7098; Jen Y, 1996, DEV DYNAM, V207, P235; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kee Y, 2001, MECH DEVELOP, V109, P341, DOI 10.1016/S0925-4773(01)00576-7; Lin CQ, 2000, CANCER RES, V60, P1332; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Moore KH, 2004, CANCER-AM CANCER SOC, V100, P929, DOI 10.1002/cncr.20035; PAGLIUCA A, 1995, GENOMICS, V27, P200, DOI 10.1006/geno.1995.1026; Rivera R, 2001, ONCOGENE, V20, P8308, DOI 10.1038/sj.onc.1205091; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; Shan L, 2003, AM J PATHOL, V163, P2495, DOI 10.1016/S0002-9440(10)63604-8; Singh J, 2002, ONCOGENE, V21, P1812, DOI 10.1038/sj.onc.1205252; Spugnardi M, 2003, CANCER RES, V63, P1639; Takeuchi H, 2003, CANCER RES, V63, P441; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689; Umetani N, 2004, ONCOGENE, V23, P8292, DOI 10.1038/sj.onc.1208022; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	36	80	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4721	4727		10.1038/sj.onc.1208538	http://dx.doi.org/10.1038/sj.onc.1208538			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897910				2022-12-25	WOS:000230304500010
J	Anilkumar, N; Uekita, T; Couchman, JR; Nagase, H; Seiki, M; Itoh, Y				Anilkumar, N; Uekita, T; Couchman, JR; Nagase, H; Seiki, M; Itoh, Y			Palmitoylation at Cys(574) is essential for MT1-MMP to promote cell migration	FASEB JOURNAL			English	Article						cell motility; internalization	TYPE-1 MATRIX-METALLOPROTEINASE; GELATINASE-A; SACCHAROMYCES-CEREVISIAE; TUMOR-CELLS; ACTIVATION; SURFACE; PROTEOLYSIS; RECEPTOR; MMP; OLIGOMERIZATION	MT1-MMP is a type I transmembrane proteinase that promotes cell migration and invasion. Here, we report that MT1-MMP is palmitoylated at Cys(574) in the cytoplasmic domain, and this lipid modification is critical for its promotion of cell migration and clathrin-mediated internalization. The palmitoylation-defective mutant (C574A) failed to promote cell migration and was not internalized through clathrin pathway like wild-type, but it was internalized through the caveolae pathway. Reintroducing a cysteine at different positions in the cytoplasmic tail of the C574A mutant revealed that the position of the palmitoylated cysteine relative to LLY573, a motif that interacts with mu 2 subunit of adaptor protein 2, is critical for the cell motility-promoting activity of MT1-MMP and its clathrin-mediated internalization. Taken together, palmitoylation of MT1-MMP is one of the key posttranslational modifications that determines MT1-MMP-dependent cell migration.	Univ London Imperial Coll Sci & Technol, Kennedy Inst, Div Rheumatol, Dept Matrix Biol,Fac Med, London W6 7LH, England; Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo, Japan; Univ London Imperial Coll Sci & Technol, Fac Med, Div Biomed Sci, London, England	Imperial College London; University of Oxford; University of Tokyo; Imperial College London	Itoh, Y (corresponding author), Univ London Imperial Coll Sci & Technol, Kennedy Inst, Div Rheumatol, Dept Matrix Biol,Fac Med, 1 Aspenlea Rd, London W6 7LH, England.	y.itoh@imperial.ac.uk	Seiki, Motoharu/K-9443-2015	Itoh, Yoshifumi/0000-0002-2128-2823	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Linder ME, 2004, J CELL SCI, V117, P521, DOI 10.1242/jcs.00989; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Mazzone M, 2004, J CELL SCI, V117, P6275, DOI 10.1242/jcs.01563; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Stanton H, 1998, J CELL SCI, V111, P2789; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Yik JHN, 2002, J BIOL CHEM, V277, P47305, DOI 10.1074/jbc.M208751200; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	44	51	51	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1326	+		10.1096/fj.04-3651fje	http://dx.doi.org/10.1096/fj.04-3651fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946988				2022-12-25	WOS:000230207800020
J	Hepple, RT; Baker, DJ; Kaczor, JJ; Krause, DJ				Hepple, RT; Baker, DJ; Kaczor, JJ; Krause, DJ			Long-term caloric restriction abrogates the age-related decline in skeletal muscle aerobic function	FASEB JOURNAL			English	Article						aging; oxygen uptake; mitochondria; rats; sarcopenia	MITOCHONDRIAL PROTON LEAK; DIETARY RESTRICTION; BLOOD-FLOW; F344BNF1-HYBRID RATS; OXIDATIVE CAPACITY; FOOD RESTRICTION; GENE-EXPRESSION; EXERCISE; FISCHER-344; RESPONSES	The purpose of this study was to determine the effect of long-term caloric restriction (CR) on the age-associated decline of skeletal muscle aerobic function. Skeletal muscle maximal aerobic performance (VO(2)max) was assessed in ad libitum (AL) and CR rats aged 8-10 months and 35 months using a pump-perfused hindlimb model to match oxygen delivery to muscle mass between groups. Whereas there was a 46% decline in muscle mass- specific VO2max between 8 10 mo (524 +/- 13 mu mol center dot min(-1)similar to 100 g(-1); mean SE) and 35 mo (281 +/- 54 mu mol(.)min(-1)center dot 100 g(- 1)) in AL rats, not only did CR rats begin at the same point in 8-10 mo old rats (490 +/- 42 mu mol center dot min(-1)center dot 100 g(-1)), we found no decline in 35 mo old CR animals (484 +/- 49 mu mol center dot min(-1)center dot 100g(-1)). Interestingly, although most markers of oxidative capacity began at a lower point in young adult CR animals, CR rats exhibited a higher in situ activity of complex IV at VO2max. This activity allows the young adult CR animals to exhibit normal aerobic capacity despite the lower oxidative enzyme activities. In stark contrast to the 19-41% decline in activities of citrate synthase, complexes I-III, and complex IV in homogenates prepared from the plantaris muscle and mixed region of gastrocnemius muscle with aging in AL rats, no age-related decline was found in CR animals. Thus, our results showed that CR preserves aerobic function in aged skeletal muscles by facilitating a higher in situ function of complex IV and by preventing the age-related decline in mitochondrial oxidative capacity.	Univ Calgary, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Fac Med, Calgary, AB, Canada; McMaster Univ, Dept Pediat, Hamilton, ON, Canada	University of Calgary; University of Calgary; McMaster University	Hepple, RT (corresponding author), Univ Calgary, Fac Kinesiol, 2500 Univ Dr,NW, Calgary, AB T2N 1N4, Canada.	hepple@ucalgary.ca	Kaczor, Jan/A-1990-2008; Kaczor, Jan/AAH-5078-2021; Kaczor, Jan/ABC-6283-2021	Kaczor, Jan/0000-0002-6370-2160; Hepple, Russell/0000-0003-3640-486X				ARMSTRONG RB, 1985, J APPL PHYSIOL, V59, P1322, DOI 10.1152/jappl.1985.59.4.1322; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Bevilacqua L, 2004, AM J PHYSIOL-ENDOC M, V286, pE852, DOI 10.1152/ajpendo.00367.2003; BOREHAM CAG, 1988, J ANAT, V157, P111; Bota DA, 2002, FEBS LETT, V532, P103, DOI 10.1016/S0014-5793(02)03638-4; Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212; Bronikowski AM, 2003, PHYSIOL GENOMICS, V12, P129, DOI 10.1152/physiolgenomics.00082.2002; Brown M, 1996, J GERONTOL A-BIOL, V51, pB117, DOI 10.1093/gerona/51A.2.B117; BUA EA, 2004, FASEB J; DAVIES KJA, 1981, ARCH BIOCHEM BIOPHYS, V209, P539, DOI 10.1016/0003-9861(81)90312-X; Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Glantz S.A., 2002, PRIMER BIOSTATISTICS; GOODRICK CL, 1980, GERONTOLOGY, V26, P22, DOI 10.1159/000212390; GORSKI J, 1986, AM J PHYSIOL, V250, pE441, DOI 10.1152/ajpendo.1986.250.4.E441; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; HAGBERG JM, 1985, J APPL PHYSIOL, V58, P2041, DOI 10.1152/jappl.1985.58.6.2041; Hagen JL, 2004, J GERONTOL A-BIOL, V59, P1099, DOI 10.1093/gerona/59.11.1099; Hepple RT, 2004, J GERONTOL A-BIOL, V59, P1111, DOI 10.1093/gerona/59.11.1111; Hepple RT, 2004, J APPL PHYSIOL, V96, P2257, DOI 10.1152/japplphysiol.01309.2003; Hepple RT, 2003, J APPL PHYSIOL, V95, P705, DOI 10.1152/japplphysiol.00058.2003; Hepple RT, 2003, J APPL PHYSIOL, V94, P744, DOI 10.1152/japplphysiol.00737.2002; Hepple RT, 2002, J PHYSIOL-LONDON, V541, P1003, DOI 10.1113/jphysiol.2001.013649; Holloszy JO, 1997, J APPL PHYSIOL, V82, P399, DOI 10.1152/jappl.1997.82.2.399; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Kanda K, 2002, MICROSC RES TECHNIQ, V59, P301, DOI 10.1002/jemt.10208; Kent-Braun JA, 2002, J APPL PHYSIOL, V93, P1813, DOI 10.1152/japplphysiol.00091.2002; Lal SB, 2001, J GERONTOL A-BIOL, V56, pB116, DOI 10.1093/gerona/56.3.B116; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CM, 1998, ANN NY ACAD SCI, V854, P182, DOI 10.1111/j.1749-6632.1998.tb09901.x; Lipman RD, 1996, J GERONTOL A-BIOL, V51, pB54, DOI 10.1093/gerona/51A.1.B54; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MASORO EJ, 2003, SCI AGING KNOWLEDGE, pRE2; Mathieu-Costello O, 2003, FASEB J, V17, pA1279; Mayhew M, 1998, BIOCHEM BIOPH RES CO, V251, P95, DOI 10.1006/bbrc.1998.9438; MCCARTER R, 1987, J GERONTOL, V42, P432, DOI 10.1093/geronj/42.4.432; McCarter RJM, 1997, AGING-CLIN EXP RES, V9, P73, DOI 10.1007/BF03340130; MCKIERNAN S, 2004, FASEB J; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Miller RA, 2000, J GERONTOL A-BIOL, V55, pB117, DOI 10.1093/gerona/55.3.B117; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; Musch TI, 2004, J APPL PHYSIOL, V96, P81, DOI 10.1152/japplphysiol.00729.2003; OGAWA T, 1992, CIRCULATION, V86, P494, DOI 10.1161/01.CIR.86.2.494; Osborne TB, 1917, SCIENCE, V45, P294, DOI 10.1126/science.45.1160.294; Paterson DH, 2004, J AM GERIATR SOC, V52, P1632, DOI 10.1111/j.1532-5415.2004.52454.x; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Poole JG, 2003, AM J PHYSIOL-HEART C, V284, pH1251, DOI 10.1152/ajpheart.00790.2002; Proctor DN, 1998, J APPL PHYSIOL, V85, P68, DOI 10.1152/jappl.1998.85.1.68; Russell JA, 2003, AM J PHYSIOL-HEART C, V285, pH251, DOI 10.1152/ajpheart.01086.2002; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492	53	57	58	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1320	+		10.1096/fj.04-3535fje	http://dx.doi.org/10.1096/fj.04-3535fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15955841				2022-12-25	WOS:000230207800016
J	Meshorer, E; Biton, IE; Ben-Shaul, Y; Ben-Ari, S; Assaf, Y; Soreq, H; Cohen, Y				Meshorer, E; Biton, IE; Ben-Shaul, Y; Ben-Ari, S; Assaf, Y; Soreq, H; Cohen, Y			Chronic cholinergic imbalances promote brain diffusion and transport abnormalities	FASEB JOURNAL			English	Article						cholinergic neurotransmission; acetylcholinesterase; blood-brain barrier; aquaporin 4	ACETYLCHOLINESTERASE-TRANSGENIC MICE; POSTTRAUMATIC-STRESS-DISORDER; AQUAPORIN-4 WATER CHANNEL; CEREBRAL-ISCHEMIA; HEAD-INJURY; READTHROUGH ACETYLCHOLINESTERASE; BARRIER PERMEABILITY; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; UP-REGULATION	Cholinergic imbalances occur after traumatic effects and in the initial stages of neurodegenerative diseases, but their long-lasting effects remained largely unexplained. To address this, we used TgS transgenic mice constitutively overexpressing synaptic acetylcholinesterase (AChE-S) and presenting a complex phenotype of progressive neuro-deterioration. T-1- and T-2- weighted magnetic resonance (MR) brain images appeared similar. However, diffusion-weighted MRI showed decreased baseline water apparent diffusion coefficient in the brains of TgS animals. Furthermore, contrast-enhanced MRI after gadolinium diethylenetriaminepentaacetic acid (Gd- DTPA) injection demonstrated slower recovery of normal signals in the TgS brains than with controls. Perfusion MR imaging and difference T-1 maps calculated from pre- postcontrast T1- weighted MR images indicated accumulation of more Gd- DTPA molecules in the TgS brains than in the parent strain, reflecting impaired blood-brain barrier (BBB) functioning in these transgenic mice. To explore the molecular mechanism(s) underlying these global phenotypes, we performed microarray analysis in the stress-controlling prefrontal cortex of TgS vs. strain-matched wild-type animals. Profound overexpression of numerous ion channels, transporters, and adhesion genes was confirmed by real time RT-PCR tests. Immunohistochemical and immuno-blot analyses revealed corresponding increases in the level and cellular distributions of the chloride channel CLCN3 and the water channel AQP4, both of which contribute to BBB maintenance. Our study attributes to balanced cholinergic neurotransmission, a central role in the brain's maintenance of water diffusion and ion transport, and indicates that chronic impairments in this maintenance facilitate neurodeterioration through interference with BBB function.	Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Israel Ctr Neuronal Computat, IL-91904 Jerusalem, Israel; Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Chem, Ramat Aviv, Israel; Wohl Inst Adv Imaging, Tel Aviv Sourasky Med Ctr, Human Brain Imaging Unit, Tel Aviv, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@cc.huji.ac.il		Assaf, Yaniv/0000-0001-6828-7595; Soreq, Hermona/0000-0002-0955-526X; Meshorer, Eran/0000-0003-4777-986X				Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Andres C, 1997, P NATL ACAD SCI USA, V94, P8173, DOI 10.1073/pnas.94.15.8173; Arreola J, 2002, J PHYSIOL-LONDON, V545, P207, DOI 10.1113/jphysiol.2002.021980; BADAUT J, 2002, J CEREB BLOOD FLOW M, V22, P367, DOI DOI 10.1097/00004647-200204000-00001; Beeri R, 1997, J NEUROCHEM, V69, P2441; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; Benveniste H, 2002, PROG NEUROBIOL, V67, P393, DOI 10.1016/S0301-0082(02)00020-5; Birikh KR, 2003, P NATL ACAD SCI USA, V100, P283, DOI 10.1073/pnas.0135647100; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Cao H, 1996, BIOCHEM BIOPH RES CO, V227, P266, DOI 10.1006/bbrc.1996.1499; CHEN Y, 2003, P NATL ACAD SCI US; Cho H, 1998, EXP BRAIN RES, V122, P227, DOI 10.1007/s002210050510; Cohen O, 2002, MOL PSYCHIATR, V7, P874, DOI 10.1038/sj.mp.4001103; Darboux I, 1996, EMBO J, V15, P4835, DOI 10.1002/j.1460-2075.1996.tb00864.x; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; Erb C, 2001, J NEUROCHEM, V77, P638, DOI 10.1046/j.1471-4159.2001.00287.x; Esposito P, 2001, BRAIN RES, V888, P117, DOI 10.1016/S0006-8993(00)03026-2; Farchi N, 2003, J PHYSIOL-LONDON, V546, P165, DOI 10.1113/jphysiol.2002.030841; Forch P, 2001, APOPTOSIS, V6, P463, DOI 10.1023/A:1012441824719; Franklin KBJ, 2001, MOUSE BRAIN STEROTAX; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Grauer E, 2001, LIFE SCI, V68, P985, DOI 10.1016/S0024-3205(00)01000-6; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HOSSMANN KA, 1995, CEREBROVAS BRAIN MET, V7, P187; Johnson MD, 2002, J BIOL CHEM, V277, P23000, DOI 10.1074/jbc.M201907200; Le Bihan D, 2002, NMR BIOMED, V15, P431, DOI 10.1002/nbm.798; Lu H, 2003, CHINESE MED J-PEKING, V116, P1063; Lupien SJ, 2001, BEHAV BRAIN RES, V127, P137, DOI 10.1016/S0166-4328(01)00361-8; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; McDaniel B, 2001, NEUROIMAGE, V14, P1244, DOI 10.1006/nimg.2001.0934; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Moghaddam B, 2002, BIOL PSYCHIAT, V51, P775, DOI 10.1016/S0006-3223(01)01362-2; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nico B, 2001, J CELL SCI, V114, P1297; Omori N, 2002, BRAIN RES, V954, P317, DOI 10.1016/S0006-8993(02)03366-8; Ovadia H, 2001, BRAIN RES, V905, P21, DOI 10.1016/S0006-8993(01)02361-7; Park SE, 2004, CANCER RES, V64, P2652, DOI 10.1158/0008-5472.CAN-04-0649; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; SCHAEFFER E, 1994, P NATL ACAD SCI USA, V91, P3882, DOI 10.1073/pnas.91.9.3882; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SHARMA HS, 1988, NEUROSCI RES, V5, P224, DOI 10.1016/0168-0102(88)90051-X; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Stark D, 1999, MAGNETIC RESONANCE I, V1; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Tomkins O, 2001, CELL MOL NEUROBIOL, V21, P675, DOI 10.1023/A:1015147920283; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; van Eden CG, 2000, PROG BRAIN RES, V126, P49; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang GX, 2003, AM J PHYSIOL-HEART C, V285, pH1453, DOI 10.1152/ajpheart.00244.2003; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; Wilson JTL, 2003, J NEUROL NEUROSUR PS, V74, P841, DOI 10.1136/jnnp.74.7.841; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Yongbi MN, 1997, NMR BIOMED, V10, P79, DOI 10.1002/(SICI)1099-1492(199704)10:2<79::AID-NBM449>3.0.CO;2-K; Zhang ZG, 2001, J CEREBR BLOOD F MET, V21, P541, DOI 10.1097/00004647-200105000-00008	62	29	30	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					910	922		10.1096/fj.04-2957com	http://dx.doi.org/10.1096/fj.04-2957com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923401				2022-12-25	WOS:000230207800038
J	Groten, T; Pierce, AA; Huen, AC; Schnaper, HW				Groten, T; Pierce, AA; Huen, AC; Schnaper, HW			17 beta-estradiol transiently disrupts adherens junctions in endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; vascular endothelial cadherin; vascular endothelial growth factor; Src-family kinases	ESTROGEN-RECEPTOR-ALPHA; NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; VE-CADHERIN; VASCULAR-PERMEABILITY; MICROVASCULAR PERMEABILITY; BETA-CATENIN; PARACELLULAR PERMEABILITY; MOLECULAR-ORGANIZATION	Interendothelial junctions are important regulators of endothelial cell functions such as migration and proliferation, major features in angiogenesis, and endothelial cell monolayer wound healing. 17 beta-estradiol regulates these functions in vivo and in vitro and also increases endothelial monolayer permeability as it results from impaired monolayer integrity and intercellular adhesion. We hypothesized that 17 beta-estradiol affects these cell adhesion-dependent functions in endothelial cells by targeting the adherens junction complex. Here, we show that 17 beta-estradiol increases uterine microvascular endothelial cell monolayer permeability and transiently redistributes interendothelial junction-forming proteins in endothelial cells. Concomitantly, adherens junction proteins are disconnected from the cytoskeleton and alpha-catenin, which links VE-cadherin to the cytoskeleton, is redistributed from the membrane and the adherens junction complex. Furthermore, 17 beta-estradiol increased tyrosine phosphorylation of the adherens junction complex. These effects were inhibited by the estrogen receptor antagonist ICI 182,780 but could be provoked using non-cell membrane-permeable 17 beta-estradiol-BSA in all cells tested, including EA.hy 926 cells, which have been shown unable to stimulate 17 beta-estradiol- dependent gene transcription. Additionally, 17 beta-estradiol treatment enhanced the angiogenic effect of vascular endothelial growth factor in an in vitro angiogenesis model, as a potential implication of the adherens junction disruption. Cotreatment with the Src-family kinase inhibitor PP2 prevented the redistribution and phosphorylation of the adherens junction proteins. Taken together, our data show that adherens junctions in endothelial cells are a downstream target of membrane-associated 17 beta-estradiol signaling, possibly through Src-family kinases.	Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA; Northwestern Univ, Childrens Mem Inst Educ & Res, Chicago, IL 60611 USA; Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University	Groten, T (corresponding author), Univ Ulm, Dept Obstet & Gynecol, Prittwitzstr 43, D-89075 Ulm, Germany.	tanja.groten@web.de	Groten, Tanja/G-7339-2018		NHLBI NIH HHS [HL-53918] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053918] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Andriopoulou P, 1999, ARTERIOSCL THROM VAS, V19, P2286, DOI 10.1161/01.ATV.19.10.2286; Baldwin AL, 2001, CRIT REV BIOMED ENG, V29, P247, DOI 10.1615/CritRevBiomedEng.v29.i2.20; Bates DO, 2002, J ANAT, V200, P581, DOI 10.1046/j.1469-7580.2002.00066.x; Bausero P, 2000, AM J PHYSIOL-HEART C, V279, pH2033, DOI 10.1152/ajpheart.2000.279.5.H2033; Bazzoni G, 2001, MICROCIRCULATION, V8, P143, DOI 10.1038/sj.mn.7800084; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; Chew TL, 2002, J CELL BIOL, V156, P543, DOI 10.1083/jcb.200110161; Cho MM, 1999, AM J PHYSIOL-CELL PH, V276, pC337; Cid MC, 2002, ANN NY ACAD SCI, V966, P143, DOI 10.1111/j.1749-6632.2002.tb04211.x; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Dejana E, 2000, INT J DEV BIOL, V44, P743; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Esser S, 1998, J CELL SCI, V111, P1853; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Figtree GA, 2003, CIRCULATION, V107, P120, DOI 10.1161/01.CIR.0000043805.11780.F5; Fujimoto J, 1998, HORM RES, V50, P30, DOI 10.1159/000053121; Gotsch U, 1997, J CELL SCI, V110, P583; Groten T, 2000, MOL HUM REPROD, V6, P1027, DOI 10.1093/molehr/6.11.1027; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Haynes MP, 2002, VASC PHARMACOL, V38, P99, DOI 10.1016/S0306-3623(02)00133-7; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Ho KJ, 2002, ARTERIOSCL THROM VAS, V22, P1952, DOI 10.1161/01.ATV.0000041200.85946.4A; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Johns A, 1996, ENDOCRINOLOGY, V137, P4511, DOI 10.1210/en.137.10.4511; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Korff T, 1999, J CELL SCI, V112, P3249; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Lampugnani MG, 1997, J CELL SCI, V110, P2065; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Martin TA, 2001, CLIN CANCER RES, V7, P734; McIlhenny C, 2002, BRIT J CANCER, V86, P1786, DOI 10.1038/sj.bjc.6600322; MORALES DE, 1995, CIRCULATION, V91, P755, DOI 10.1161/01.CIR.91.3.755; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; Nwariaku FE, 2002, SURGERY, V132, P180, DOI 10.1067/msy.2002.125305; Petzelbauer P, 2000, J INVEST DERM SYMP P, V5, P10, DOI 10.1046/j.1087-0024.2000.00002.x; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; Sorby M, 1996, J BIOL CHEM, V271, P10963; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Suzuki T, 2003, MICROSC RES TECHNIQ, V60, P76, DOI 10.1002/jemt.10246; Vestweber D, 2000, J PATHOL, V190, P281; Vinals F, 1999, MOL CELL BIOL, V19, P2763; Watson CS, 2002, STEROIDS, V67, P429, DOI 10.1016/S0039-128X(01)00172-6; Wong RK, 1999, AM J PHYSIOL-HEART C, V276, pH736; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7	66	41	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					1368	+		10.1096/fj.04-2558fje	http://dx.doi.org/10.1096/fj.04-2558fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15928195				2022-12-25	WOS:000229602600003
J	Niu, Z; Yu, W; Zhang, SX; Barron, M; Belaguli, NS; Schneider, MD; Parmacek, M; Nordheim, A; Schwartz, RJ				Niu, Z; Yu, W; Zhang, SX; Barron, M; Belaguli, NS; Schneider, MD; Parmacek, M; Nordheim, A; Schwartz, RJ			Conditional mutagenesis of the murine serum response factor gene blocks cardiogenesis and the transcription of downstream gene targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; TERNARY COMPLEX FACTORS; MYOCARDIAL DEFECTS; EXPRESSION; SRF; ACTIVATION; CLEAVAGE; DIFFERENTIATION; INACTIVATION; ORGANIZATION	Serum response factor (SRF) homozygous-null embryos from our backcross of SRFLacZ/+ "knock-in" mice failed to gastrulate and form mesoderm, similar to the findings of an earlier study (Arsenian, S., Weinhold, B., Oelgeschlager, M., Ruther, U., and Nordheim, A. ( 1998) EMBO J. 17, 6289 - 6299). Our use of embryonic stem cells provided amodel system that could be used to investigate the specification of multiple embryonic lineages, including cardiac myocytes. We observed the absence of myogenic alpha-actins, SM22 alpha, and myocardin expression and the failure to form beating cardiac myocytes in aggregated SRF null embryonic stem cells, whereas the appearance of transcription factors Nkx2 - 5 and GATA4 were unaffected. To study the role of SRF during heart organogenesis, we then performed cardiac-specific ablation of SRF by crossing the transgenic alpha-myosin heavy chain Cre recombinase line with SRF LoxP-engineered mice. Cardiac-specific ablation of SRF resulted in embryonic lethality due to cardiac insufficiency during chamber maturation. Conditional ablation of SRF also reduced cell survival concomitant with increased apoptosis and reduced cellularity. Significant reductions in SRF (>= 95%), atrial naturetic factor (>= 80%), and cardiac (>= 60%), skeletal (>= 90%), and smooth muscle (>= 75%) alpha-actin transcripts were also observed in the cardiac-conditional knock-out heart. This was consistent with the idea that SRF directs de novo cardiac and smooth muscle gene activities. Finally, quantitation of the knock-in LacZ reporter gene transcripts in the hearts of cardiac-conditional knock-out embryos revealed an similar to 30% reduction in gene activity, indicating SRF gene autoregulation during cardiogenesis.	Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cardiovasc Dev, Div Cardiovasc Sci, Dept Mol & Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Univ Penn, Hlth Syst, Div Cardiovasc Med, Philadelphia, PA 19104 USA; Univ Tubingen, Dept Mol Biol, Inst Cell Biol, D-72704 Tubingen, Germany	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Pennsylvania; Eberhard Karls University of Tubingen	Schwartz, RJ (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rschwartz@ibt.tamhsc.edu	niu, zhiyv/A-6558-2009	Schneider, Michael/0000-0001-9645-1938	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953, R01HL079628] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL79628-01, P01 HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Barron MR, 2005, J BIOL CHEM, V280, P11816, DOI 10.1074/jbc.M412408200; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chang J, 2003, CIRCULATION, V108, P407, DOI 10.1161/01.CIR.0000084502.02147.83; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CHOW KL, 1991, P NATL ACAD SCI USA, V88, P1301, DOI 10.1073/pnas.88.4.1301; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Drewett V, 2001, J BIOL CHEM, V276, P33444, DOI 10.1074/jbc.M103877200; Gaussin V, 2002, P NATL ACAD SCI USA, V99, P2878, DOI 10.1073/pnas.042390499; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; Hogan B, 1994, MANIPULATING MOUSE E, P497; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Miano JM, 2004, P NATL ACAD SCI USA, V101, P17132, DOI 10.1073/pnas.0406041101; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; Ng WA, 1997, PEDIATR RES, V41, P285, DOI 10.1203/00006450-199702000-00021; Parlakian A, 2004, MOL CELL BIOL, V24, P5281, DOI 10.1128/MCB.24.12.5281-5289.2004; REECY JM, 1999, HEART DEV, P273; Schratt G, 2004, EMBO J, V23, P1834, DOI 10.1038/sj.emboj.7600188; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Tanaka M, 1999, DEVELOPMENT, V126, P1439; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Wei L, 2001, DEVELOPMENT, V128, P2953; Wiebel FF, 2002, GENESIS, V32, P124, DOI 10.1002/gene.10049; Yamada M, 2000, DEV BIOL, V228, P95, DOI 10.1006/dbio.2000.9927	37	99	102	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32531	32538		10.1074/jbc.M501372200	http://dx.doi.org/10.1074/jbc.M501372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	15929941	hybrid			2022-12-25	WOS:000231794800062
J	Ishitsuka, K; Hideshima, T; Hamasaki, M; Raje, N; Kumar, S; Podar, K; Le Gouill, S; Shiraishi, N; Yasui, H; Roccaro, AM; Tai, YZ; Chauhan, D; Fram, R; Tamura, K; Jain, J; Anderson, KC				Ishitsuka, K; Hideshima, T; Hamasaki, M; Raje, N; Kumar, S; Podar, K; Le Gouill, S; Shiraishi, N; Yasui, H; Roccaro, AM; Tai, YZ; Chauhan, D; Fram, R; Tamura, K; Jain, J; Anderson, KC			Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway	ONCOGENE			English	Article						multiple myeloma; IMPDH inhibitor; VX-944; apoptosis; AIF/Endo G pathway	GUANINE-NUCLEOTIDE DEPLETION; MYCOPHENOLIC-ACID; BENZAMIDE RIBOSIDE; DRUG-RESISTANCE; IMPDH INHIBITOR; CLINICAL-TRIAL; T-LYMPHOCYTES; GROWTH-FACTOR; DEATH; EXPRESSION	Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme required for the de novo synthesis of guanine nucleotides from IMP. VX-944 (Vertex Pharmaceuticals, Cambridge, MA, USA) is a small-molecule, selective, noncompetitive inhibitor directed against human IMPDH. In this report, we show that VX-944 inhibits in vitro growth of human multiple myeloma (MM) cell lines via induction of apoptosis. Interleukin-6, insulin-like growth factor-1, or co-culture with bone marrow stromal cells (BMSCs) do not protect against VX-944-induced MM cell growth inhibition. VX-944 induced apoptosis in MM cell lines with only modest activation of caspases 3, 8, and 9. Furthermore, the pan-caspase inhibitor z-VAD-fmk did not inhibit VX-944-induced apoptosis and cell death. During VX-944-induced apoptosis, expressions of Bax and Bak were enhanced, and both apoptosis-inducing factor (AIF) and endonuclease G (Endo G) were released from the mitochondria to cytosol, suggesting that VX-944 triggers apoptosis in MM cells primarily via a caspase-independent, Bax/AIF/Endo G pathway. Importantly, VX-944 augments the cytotoxicity of doxorubicin and melphalan even in the presence of BMSCs. Taken together, our data demonstrate a primarily non-caspase-dependent apoptotic pathway triggered by VX-944, thereby providing a rationale to enhance MM cell cytotoxicity by combining this agent with conventional agents which trigger caspase activation.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA; Fukuoka Univ, Dept Internal Med 1, Fukuoka 8140180, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Vertex Pharmaceuticals; Fukuoka University	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Hamasaki, Makoto/AAO-2229-2020; Roccaro, Aldo/AAA-8957-2022; Ishitsuka, Kenji/O-9296-2019; Podar, Klaus/ABD-1112-2020	Roccaro, Aldo/0000-0002-1872-5128; Ishitsuka, Kenji/0000-0002-7030-497X; Podar, Klaus/0000-0002-7414-3632; le gouill, steven/0000-0001-9840-2128; Yasui, Hiroshi/0000-0003-0905-6855	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [1P50 CA10070-01, R01- CA50947] Funding Source: Medline; PHS HHS [P0-1 78378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; AHLUWALIA GS, 1984, BIOCHEM PHARMACOL, V33, P1195, DOI 10.1016/0006-2952(84)90170-9; Ahn HJ, 2004, J CELL BIOCHEM, V91, P1043, DOI 10.1002/jcb.20006; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; EUGUI EM, 1990, P NATL ACAD SCI USA, V87, P1305, DOI 10.1073/pnas.87.4.1305; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P161, DOI 10.1111/j.1365-3083.1991.tb03746.x; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Ge NL, 2000, BLOOD, V96, P2856; Gu JJ, 2003, BLOOD, V101, P4958, DOI 10.1182/blood-2002-08-2547; Hayashi T, 2002, MOL CANCER THER, V1, P851; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hunakova L, 2000, NEOPLASMA, V47, P274; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jain J, 2001, J PHARM SCI-US, V90, P625, DOI 10.1002/1520-6017(200105)90:5<625::AID-JPS1019>3.0.CO;2-1; Jelinek DF, 1997, J IMMUNOL, V159, P487; Kagawa S, 2001, CLIN CANCER RES, V7, P1474; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KNUDTZON S, 1972, CANCER CHEMOTH REP 1, V56, P221; Laliberte J, 1998, BLOOD, V91, P2896, DOI 10.1182/blood.V91.8.2896.2896_2896_2904; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; McCafferty-Grad J, 2003, MOL CANCER THER, V2, P1155; McLean JE, 2004, BIOCHEM J, V379, P243, DOI 10.1042/BJ20031585; Messina E, 2004, INT J CANCER, V108, P812, DOI 10.1002/ijc.11642; Miyashita T, 1998, CELL DEATH DIFFER, V5, P1034, DOI 10.1038/sj.cdd.4400442; NAGAI M, 1991, CANCER RES, V51, P3886; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Richardson P, 2004, MAYO CLIN PROC, V79, P875, DOI 10.4065/79.7.875; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; SENDA M, 1994, LIFE SCI, V54, P1917, DOI 10.1016/0024-3205(94)90150-3; SWEENEY MJ, 1972, CANCER RES, V32, P1795; Szekeres T, 2002, CURR MED CHEM, V9, P759, DOI 10.2174/0929867024606911; Takebe N, 2004, CLIN CANCER RES, V10, P8301, DOI 10.1158/1078-0432.CCR-04-0747; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; UCHIYAMA H, 1993, BLOOD, V82, P3712; Wright DG, 1996, ANTICANCER RES, V16, P3349; Yalowitz JA, 2002, CURR MED CHEM, V9, P749, DOI 10.2174/0929867024606867; Yalowitz JA, 2002, CANCER LETT, V181, P31, DOI 10.1016/S0304-3835(02)00045-9; Zimmermann AG, 1998, PROG NUCLEIC ACID RE, V61, P181, DOI 10.1016/S0079-6603(08)60827-2	45	58	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5888	5896		10.1038/sj.onc.1208739	http://dx.doi.org/10.1038/sj.onc.1208739			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15940263				2022-12-25	WOS:000231590400011
J	Anderson, JL; Henriksen, BS; Gibbs, RA; Hrycyna, CA				Anderson, JL; Henriksen, BS; Gibbs, RA; Hrycyna, CA			The isoprenoid substrate specificity of isoprenylcysteine carboxylmethyltransferase - Development of novel inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; FARNESYL DIPHOSPHATE ANALOGS; C-TERMINAL METHYLATION; SACCHAROMYCES-CEREVISIAE; BIOLOGICAL EVALUATION; A-FACTOR; STE14 GENE; IN-VITRO; K-RAS; PRENYLATION	Isoprenylcysteine carboxylmethyltransferase (Icmt) is an integral membrane protein localized to the endoplasmic reticulum of eukaryotic cells that catalyzes the post-translational alpha-carboxylmethylesterification of CAAX motif proteins, including the oncoprotein Ras. Prior to methylation, these protein substrates all contain an isoprenylcysteine residue at the C terminus. In this study, we developed a variety of substrates and inhibitors of Icmt that vary in the isoprene moiety in order to gain information about the nature of the lipophilic substrate binding site. These isoprenoid-modified analogs of the minimal Icmt substrate N-acetyl-S-farnesyl-L-cysteine (AFC) were synthesized from newly and previously prepared farnesol analogs. Using both yeast and human Icmt enzymes, these compounds were found to vary widely in their ability to act as substrates, supporting the isoprenoid moiety as a key substrate recognition element for Icmt. Compound 3 is a competitive inhibitor of overexpressed yeast Icmt (K-I = 17.1 +/- 1.7 mu M). Compound 4 shows a mix of competitive and uncompetitive inhibition for both the yeast and the human Icmt proteins (yeast K-IC = 35.4 +/- 3.4 mu M, K-IU = 614.4 +/- 148 mu M; human K-IC = 119.3 +/- 18.1 mu M, K-IU = 377.2 +/- 42.5 mu M). These data further suggest that differences in substrate specificity exist between the human and yeast enzymes. Biological studies suggest that inhibition of Icmt results in Ras mislocalization and loss of cellular transformation ability, making Icmt an attractive and novel anticancer target. Further elaboration of the lead compounds synthesized and assayed here may lead to clinically useful higher potency inhibitors.	Purdue Univ, Purdue Canc Ctr, Dept Chem, W Lafayette, IN 47907 USA; Purdue Univ, Purdue Canc Ctr, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Gibbs, RA (corresponding author), Purdue Univ, Purdue Canc Ctr, Dept Chem, W Lafayette, IN 47907 USA.	rag@pharmacy.purdue.edu; hrycyna@purdue.edu	Kelts, Jessica L./B-3946-2014	Kelts, Jessica L./0000-0002-1084-0498	NCI NIH HHS [P30 CA023168, P30 CA21368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Ambroziak P., 2001, ENZYMES, P155; Anderson JL, 2005, J BIOL CHEM, V280, P7336, DOI 10.1074/jbc.M410292200; ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; BROWN MJ, 1991, J AM CHEM SOC, V113, P3176, DOI 10.1021/ja00008a058; Chiu VK, 2004, J BIOL CHEM, V279, P7346, DOI 10.1074/jbc.M311602200; Clarke S, 2004, J CLIN INVEST, V113, P513, DOI 10.1072/JCI200421059; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; DING JB, 1994, J BIOL CHEM, V269, P16837; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Gibbs BS, 1999, J MED CHEM, V42, P3800, DOI 10.1021/jm9902786; Gibbs RA, 2001, CURR MED CHEM, V8, P1437, DOI 10.2174/0929867013372111; GIBBS RA, 1995, J ORG CHEM, V60, P7821, DOI 10.1021/jo00129a023; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1995, METHOD ENZYMOL, V250, P251; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; Michaelson D, 2005, MOL BIOL CELL, V16, P1606, DOI 10.1091/mbc.e04-11-0960; Mu YQ, 2002, BIOORGAN MED CHEM, V10, P1207, DOI 10.1016/S0968-0896(01)00390-X; OTA IM, 1989, J BIOL CHEM, V264, P12879; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; Rawat DS, 2002, ORG LETT, V4, P3027, DOI 10.1021/ol026176i; REIGARD SA, 2005, IN PRESS BIOCHEMISTR, V44; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Shao Y, 1999, ORG LETT, V1, P627, DOI 10.1021/ol990714i; SHI YQ, 1992, J BIOL CHEM, V267, P9547; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102; Winter-Vann AM, 2003, P NATL ACAD SCI USA, V100, P6529, DOI 10.1073/pnas.1135239100; Xie HB, 2000, J ORG CHEM, V65, P8552, DOI 10.1021/jo000942m; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhou CM, 2002, BIOORG MED CHEM LETT, V12, P1417, DOI 10.1016/S0960-894X(02)00187-7	44	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29454	29461		10.1074/jbc.M504982200	http://dx.doi.org/10.1074/jbc.M504982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15946942	hybrid, Green Accepted			2022-12-25	WOS:000231176200010
J	Hait, NC; Sarkar, S; Le Stunff, H; Mikami, A; Maceyka, M; Milstien, S; Spiegel, S				Hait, NC; Sarkar, S; Le Stunff, H; Mikami, A; Maceyka, M; Milstien, S; Spiegel, S			Role of sphingosine kinase 2 in cell migration toward epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; SPHINGOSINE-1-PHOSPHATE RECEPTORS; LYMPHOCYTE RECIRCULATION; DEPENDENT ACTIVATION; VASCULAR MATURATION; PLASMA-MEMBRANE; KINASE TYPE-2; 1-PHOSPHATE	Sphingosine 1-phosphate (S1P), produced by two sphingosine kinase isoenzymes, denoted SphK1 and SphK2, is the ligand for a family of five specific G protein-coupled receptors that regulate cytoskeletal rearrangements and cell motility. Whereas many growth factors stimulate SphK1, much less is known of the regulation of SphK2. Here we report that epidermal growth factor (EGF) stimulated SphK2 in HEK 293 cells. This is the first example of an agonist-dependent regulation of SphK2. Chemotaxis of HEK 293 cells toward EGF was inhibited by N,N-dimethylsphingosine, a competitive inhibitor of both SphKs, implicating S1P generation in this process. Down-regulating expression of SphK1 in HEK 293 cells with a specific siRNA abrogated migration toward EGF, whereas decreasing SphK2 expression had no effect. EGF contributes to the invasiveness of human breast cancer cells, and EGF receptor expression is associated with poor prognosis. EGF also stimulated SphK2 in MDA-MB-453 breast cancer cells. Surprisingly, however, down-regulation of SphK2 in these cells completely eliminated migration toward EGF without affecting fibronectin-induced haptotaxis. Our results suggest that SphK2 plays an important role in migration of MDA-MB-453 cells toward EGF.	Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA 23298 USA; NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.	sspiegel@vcu.edu	Maceyka, Michael/B-9277-2008; LE STUNFF, Hervé/AAA-6882-2019		NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH001039, Z01MH001039] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA61774] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; Dolezalova H, 2003, J CELL BIOCHEM, V88, P732, DOI 10.1002/jcb.10394; Duan HF, 2004, EXP CELL RES, V298, P593, DOI 10.1016/j.yexcr.2004.04.049; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; ENDO K, 1991, CANCER RES, V51, P1613; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; French KJ, 2003, CANCER RES, V63, P5962; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GOPARAJU K, 2005, IN PRESS MOL CELL BI; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Jendiroba DB, 2002, LEUKEMIA RES, V26, P301, DOI 10.1016/S0145-2126(01)00129-1; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kaneider NC, 2003, J VIROL, V77, P5535, DOI 10.1128/JVI.77.9.5535-5539.2003; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Le Stunff H, 2004, J BIOL CHEM, V279, P34290, DOI 10.1074/jbc.M404907200; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Price JT, 1999, CANCER RES, V59, P5475; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Rosenfeldt HM, 2001, BIOCHEM SOC T, V29, P836, DOI 10.1042/0300-5127:0290836; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Sawyer C, 2003, CANCER RES, V63, P1667; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Toman RE, 2004, J CELL BIOL, V166, P381, DOI 10.1083/jcb.200402016; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1999, CANCER RES, V59, P6185; Wu WC, 2003, ONCOGENE, V22, P3361, DOI 10.1038/sj.onc.1206285; Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074/jbc.M410144200; Yoshimoto T, 2003, J IMMUNOL, V171, P1352, DOI 10.4049/jimmunol.171.3.1352	59	123	134	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29462	29469		10.1074/jbc.M502922200	http://dx.doi.org/10.1074/jbc.M502922200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15951439	hybrid			2022-12-25	WOS:000231176200011
J	Tiwari, A; Xu, ZS; Hayward, LJ				Tiwari, A; Xu, ZS; Hayward, LJ			Aberrantly increased hydrophobicity shared by mutants of Cu,Zn-superoxide dismutase in familial amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU/ZN-SUPEROXIDE-DISMUTASE; MOLECULAR-WEIGHT COMPLEXES; MOTOR-NEURON DEGENERATION; PROTEIN AGGREGATION; INTERMEMBRANE SPACE; TRANSGENIC MICE; SOD1; MUTATIONS; ZINC; ALS	More than 100 different mutations in the gene encoding Cu, Zn-superoxide dismutase (SOD1) cause preferential motor neuron degeneration in familial amyotrophic lateral sclerosis (ALS). Although the cellular target(s) of mutant SOD1 toxicity have not been precisely specified, evidence to date supports the hypothesis that ALS-related mutations may increase the burden of partially unfolded SOD1 species. Influences that may destabilize SOD1 in vivo include impaired metal ion binding, reduction of the intrasubunit disulfide bond, or oxidative modification. In this study, we observed that metal-deficient as-isolated SOD1 mutants (H46R, G85R, D124V, D125H, and S134N) with disordered electrostatic and zinc-binding loops exhibited aberrant binding to hydrophobic beads in the absence of other destabilizing agents. Other purified ALS-related mutants that can biologically incorporate nearly normal amounts of stabilizing zinc ions (A4V, L38V, G41S, D90A, and G93A) exhibited maximal hydrophobic behavior after exposure to both a disulfide reducing agent and a metal chelator, while normal SOD1 was more resistant to these agents. Moreover, we detected hydrophobic SOD1 species in lysates from affected tissues in G85R and G93A mutant but not wildtype SOD1 transgenic mice. These findings suggest that a susceptibility to the cellular disulfide reducing environment and zinc loss may convert otherwise stable SOD1 mutants into metal-deficient forms with locally destabilized electrostatic and zinc-binding loops. These abnormally hydrophobic SOD1 species may promote aberrant interactions of the enzyme with itself or with other cellular constituents to produce toxicity in familial ALS.	Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Program Neurosci, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Hayward, LJ (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol, 55 Lake Ave N, Worcester, MA 01655 USA.	Lawrence.Hayward@umassmed.edu	Tiwari, Ashutosh/A-7458-2008	Tiwari, Ashutosh/0000-0001-7373-349X; Hayward, Lawrence/0000-0003-0579-0358	NINDS NIH HHS [R01 NS41739, R01 NS44170, R01 NS044170] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044170, R01NS041739] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen PM, 2003, AMYOTROPH LATERAL SC, V4, P62, DOI 10.1080/14660820310011700; Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Batulan Z, 2003, J NEUROSCI, V23, P5789; Berggren K, 1999, ANAL BIOCHEM, V276, P129, DOI 10.1006/abio.1999.4364; Betts S, 1999, METHOD ENZYMOL, V309, P333; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Calloni G, 2005, J BIOL CHEM, V280, P10607, DOI 10.1074/jbc.M412951200; Cardoso RMF, 2002, J MOL BIOL, V324, P247, DOI 10.1016/S0022-2836(02)01090-2; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Crow JP, 1997, J NEUROCHEM, V69, P1936; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Goto JJ, 2000, J BIOL CHEM, V275, P1007, DOI 10.1074/jbc.275.2.1007; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hart PJ, 1998, PROTEIN SCI, V7, P545; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Higgins CMJ, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-16; Higgins CMJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-06-j0001.2002; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Jonsson PA, 2004, BRAIN, V127, P73, DOI 10.1093/brain/awh005; Koide T, 1998, NEUROSCI LETT, V257, P29, DOI 10.1016/S0304-3940(98)00800-3; Kong JM, 1998, J NEUROSCI, V18, P3241; Leinweber B, 2004, FREE RADICAL BIO MED, V36, P911, DOI 10.1016/j.freeradbiomed.2003.12.021; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; Liu HB, 2000, BIOCHEMISTRY-US, V39, P8125, DOI 10.1021/bi000846f; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; MARKLUND S, 1980, ACTA PHYSIOL SCAND, P19; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; PANTOLIANO MW, 1982, J INORG BIOCHEM, V17, P325, DOI 10.1016/S0162-0134(00)80093-8; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; PRAMATAROVA A, 1994, HUM MOL GENET, V3, P2061; Queiroz JA, 2001, J BIOTECHNOL, V87, P143, DOI 10.1016/S0168-1656(01)00237-1; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Ray SS, 2004, BIOCHEMISTRY-US, V43, P4899, DOI 10.1021/bi030246r; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Shipp EL, 2003, BIOCHEMISTRY-US, V42, P1890, DOI 10.1021/bi026704y; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Strange RW, 2003, J MOL BIOL, V328, P877, DOI 10.1016/S0022-2836(03)00355-3; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Tummala H, 2005, J BIOL CHEM, V280, P17725, DOI 10.1074/jbc.M501705200; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Vijayvergiya C, 2005, J NEUROSCI, V25, P2463, DOI 10.1523/JNEUROSCI.4385-04.2005; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Watanabe Y, 1997, FEBS LETT, V400, P108, DOI 10.1016/S0014-5793(96)01362-2; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zu JS, 1997, NEUROGENETICS, V1, P65, DOI 10.1007/s100480050010	69	84	88	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29771	29779		10.1074/jbc.M504039200	http://dx.doi.org/10.1074/jbc.M504039200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15958382	hybrid			2022-12-25	WOS:000231176200047
J	Wu, XJ; Ahn, EY; McKenna, MA; Yeo, H; McDonald, JM				Wu, XJ; Ahn, EY; McKenna, MA; Yeo, H; McDonald, JM			Fas binding to calmodulin regulates apoptosis in osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLANGIOCARCINOMA CELLS; MEDIATED APOPTOSIS; KINASE ACTIVATION; CALCIUM-CHANNELS; BONE-RESORPTION; BREAST-CANCER; IN-VITRO; T-CELLS; TAMOXIFEN; ANTAGONISTS	Promotion of osteoclast apoptosis is one therapeutic approach to osteoporosis. Calmodulin, the major intracellular Ca2+ receptor, modulates both osteoclastogenesis and bone resorption. The calmodulin antagonist, trifluoperazine, rescues bone loss in ovariectomized mice (Zhang, L., Feng, X., and McDonald, J. M. ( 2003) Endocrinology 144, 4536 - 4543). We show here that a 3-h treatment of mouse osteoclasts with either of the calmodulin antagonists, tamoxifen or trifluoperazine, induces osteoclast apoptosis dose- dependently. Tamoxifen, 10 mu M, and trifluoperazine, 10 mu M, induce 7.3 +/- 1.8-fold and 5.3 +/- 0.9-fold increases in osteoclast apoptosis, respectively. In Jurkat cells, calmodulin binds to Fas, the death receptor, and this binding is regulated during Fas-mediated apoptosis (Ahn, E. Y., Lim, S. T., Cook, W. J., and McDonald, J. M. ( 2004) J. Biol. Chem. 279, 5661 - 5666). In osteoclasts, calmodulin also binds Fas. When osteoclasts are treated with 10 mu M trifluoperazine, the binding between Fas and calmodulin is dramatically decreased at 15 min and gradually recovers by 60 min. A point mutation of the Fas death domain in the Lpr-(cg) mouse renders Fas inactive. Using glutathione S-transferase fusion proteins, the human Fas cytoplasmic domain is shown to bind calmodulin, whereas a point mutation ( V254N) comparable with the Lpr-cg mutation in mice has markedly reduced calmodulin binding. Osteoclasts derived from Lpr-(cg) mice have diminished calmodulin/ Fas binding and are more sensitive to calmodulin antagonist-induced apoptosis than those from wild-type mice. Both tamoxifen-and twrifluoperazine-induced apoptosis are increased 1.6 +/- 0.2-fold in Lpr(-cg)-derived osteoclasts compared with osteoclasts derived from wild-type mice. In summary, calmodulin antagonists induce apoptosis in osteoclasts by a mechanism involving interference with calmodulin binding to Fas. The effects of calmodulin/ Fas binding on calmodulin antagonist-induced apoptosis may open a new avenue for therapy for osteoporosis.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McDonald, JM (corresponding author), Univ Alabama, Dept Pathol, 509 LHRB,1530 3rd Ave,Sd, Birmingham, AL 35294 USA.	mcdonald@uab.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046031, R01AR043225] Funding Source: NIH RePORTER; NIAMS NIH HHS [P30AR46031, R01 AR 43225, P30 AR046031, R01 AR043225] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; Ahn EY, 2004, J BIOL CHEM, V279, P5661, DOI 10.1074/jbc.M311040200; Ahn EY, 2003, AM J PATHOL, V163, P2053, DOI 10.1016/S0002-9440(10)63563-8; CHINNAIYAN AM, 1995, CELL, V81, P512; Cohen P, 1988, CALMODULIN; Evans J.S., 1988, CALMODULIN, P57; FRANKFURT OS, 1995, CANCER LETT, V97, P149, DOI 10.1016/0304-3835(95)03970-8; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; ITOH N, 1993, J BIOL CHEM, V268, P10932; KAMEDA T, 1995, BIOCHEM BIOPH RES CO, V207, P753, DOI 10.1006/bbrc.1995.1251; Kimura M, 1994, Int Rev Immunol, V11, P193, DOI 10.3109/08830189409061727; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Liao BR, 1999, P NATL ACAD SCI USA, V96, P6217, DOI 10.1073/pnas.96.11.6217; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MAMARBACHI A, 1987, CELL CALCIUM, V8, P473, DOI 10.1016/0143-4160(87)90030-3; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Micoli KJ, 2000, J BIOL CHEM, V275, P1233, DOI 10.1074/jbc.275.2.1233; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Pan G, 1999, AM J PATHOL, V155, P193, DOI 10.1016/S0002-9440(10)65113-9; Pan G, 1998, IMMUNOPHARMACOLOGY, V40, P91, DOI 10.1016/S0162-3109(98)00018-6; Radding W, 2000, AIDS RES HUM RETROV, V16, P1519, DOI 10.1089/088922200750006047; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; VANELDIK LJ, 1998, CALMODULIN SIGNAL T; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538; Williams JP, 1996, J BIOL CHEM, V271, P12488, DOI 10.1074/jbc.271.21.12488; Williams JP, 2000, BIOCHEM CELL BIOL, V78, P715, DOI 10.1139/bcb-78-6-715; Wu XJ, 2005, J BONE MINER RES, V20, P107, DOI 10.1359/JBMR.041022; Wu XJ, 2003, ENDOCRINOLOGY, V144, P5545, DOI 10.1210/en.2003-0296; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhang L, 2003, ENDOCRINOLOGY, V144, P4536, DOI 10.1210/en.2003-0147; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	39	42	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29964	29970		10.1074/jbc.M500710200	http://dx.doi.org/10.1074/jbc.M500710200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15965236	Green Accepted, hybrid			2022-12-25	WOS:000231176200069
J	Matsuoka, H; Obama, H; Kelly, ML; Matsui, T; Nakamoto, M				Matsuoka, H; Obama, H; Kelly, ML; Matsui, T; Nakamoto, M			Biphasic functions of the kinase-defective Ephb6 receptor in cell adhesion and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES INTEGRIN ACTIVITY; NEURAL CREST MIGRATION; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; AUTOPHOSPHORYLATION SITE; BRANCH EXTENSION; CROSS-LINKING; FAMILY; PROTEIN; LIGAND	EphB6 is a unique member in the Eph family of receptor tyrosine kinases in that its kinase domain contains several alterations in conserved amino acids and is catalytically inactive. Although EphB6 is expressed both in a variety of embryonic and adult tissues, biological functions of this receptor are largely unknown. In the present study, we examined the function of EphB6 in cell adhesion and migration. We demonstrated that EphB6 exerted biphasic effects in response to different concentrations of the ephrin-B2 ligand; EphB6 promoted cell adhesion and migration when stimulated with low concentrations of ephrin-B2, whereas it induced repulsion and inhibited migration upon stimulation with high concentrations of ephrin-B2. A truncated EphB6 receptor lacking the cytoplasmic domain showed monophasic-positive effects on cell adhesion and migration, indicating that the cytoplasmic domain is essential for the negative effects. EphB6 is constitutively associated with the Src family kinase Fyn. High concentrations of ephrin-B2 induced tyrosine phosphorylation of EphB6 through an Src family kinase activity. These results indicate that EphB6 can both positively and negatively regulate cell adhesion and migration, and suggest that tyrosine phosphorylation of the receptor by an Src family kinase acts as the molecular switch for the functional transition.	Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Cleveland Clin Lerner Coll Med, Dept Mol Med, Cleveland, OH 44195 USA; Kobe Univ, Grad Sch Med, Dept Med, Div Hematol Oncol, Kobe, Hyogo 6500017, Japan	Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Kobe University	Nakamoto, M (corresponding author), Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	nakamom@ccf.org	Matsui, Toshimitsu/E-8065-2010	Nakamoto, Masaru/0000-0001-9356-1189; Matsui, Toshimitsu/0000-0002-2536-7584	NICHD NIH HHS [HD042191, HD039886] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042191, R01HD039886] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; Bonkowsky JL, 1999, NATURE, V402, P540, DOI 10.1038/990122; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Choi S, 1999, ONCOGENE, V18, P5413, DOI 10.1038/sj.onc.1202917; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Ellis C, 1996, ONCOGENE, V12, P1727; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Freywald A, 2002, J BIOL CHEM, V277, P3823, DOI 10.1074/jbc.M108011200; Freywald A, 2003, J BIOL CHEM, V278, P10150, DOI 10.1074/jbc.M208179200; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Gao PP, 1999, P NATL ACAD SCI USA, V96, P4073, DOI 10.1073/pnas.96.7.4073; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Gurniak CB, 1996, ONCOGENE, V13, P777; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Halford MM, 2000, NAT GENET, V25, P414, DOI 10.1038/78099; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hansen MJ, 2004, NEURON, V42, P717, DOI 10.1016/j.neuron.2004.05.009; Hindges R, 2002, NEURON, V35, P475, DOI 10.1016/S0896-6273(02)00799-7; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; KIM GJ, 1991, J NEUROBIOL, V22, P629, DOI 10.1002/neu.480220608; Knoll B, 2004, J NEUROSCI, V24, P6248, DOI 10.1523/JNEUROSCI.0985-04.2004; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; Luo HY, 2002, J CLIN INVEST, V110, P1141, DOI 10.1172/JCI200215883; Luo HY, 2004, J CLIN INVEST, V114, P1762, DOI 10.1172/JCI200421846; Mann F, 2002, NEURON, V35, P461, DOI 10.1016/S0896-6273(02)00786-9; Matsuoka H, 1997, BIOCHEM BIOPH RES CO, V235, P487, DOI 10.1006/bbrc.1997.6812; McLaughlin T, 2003, DEVELOPMENT, V130, P2407, DOI 10.1242/dev.00467; Menzel P, 2001, DEV BIOL, V230, P74, DOI 10.1006/dbio.2000.0109; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miller MA, 2000, DEV BIOL, V224, P286, DOI 10.1006/dbio.2000.9786; MOSSIE K, 1995, ONCOGENE, V11, P2179; Munthe E, 2000, FEBS LETT, V466, P169, DOI 10.1016/S0014-5793(99)01793-7; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Park SK, 1996, J BIOCHEM, V119, P235; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Santiago A, 2002, DEVELOPMENT, V129, P3621; Savant-Bhonsale S, 1999, GENE, V231, P155, DOI 10.1016/S0378-1119(99)00061-X; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shimoyama M, 2000, GROWTH FACTORS, V18, P63, DOI 10.3109/08977190009003234; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Trivier E, 2002, J BIOL CHEM, V277, P23037, DOI 10.1074/jbc.M202486200; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; Yoshikawa S, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-01-j0002.2001; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	67	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29355	29363		10.1074/jbc.M500010200	http://dx.doi.org/10.1074/jbc.M500010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15955811	hybrid, Green Published			2022-12-25	WOS:000231021300067
J	Orsomando, G; de la Garza, RD; Green, BJ; Peng, MS; Rea, PA; Ryan, TJ; Gregory, JF; Hanson, AD				Orsomando, G; de la Garza, RD; Green, BJ; Peng, MS; Rea, PA; Ryan, TJ; Gregory, JF; Hanson, AD			Plant gamma-glutamyl hydrolases and folate polyglutamates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; ARABIDOPSIS-THALIANA; MEMBRANE-TRANSPORT; BETA-VULGARIS; PEA LEAVES; IN-VITRO; CELLS; PROTEINS; VACUOLES; CLONING	gamma-Glutamyl hydrolase ( GGH, EC 3.4.19.9) catalyzes removal of the polyglutamyl tail from folyl and p-aminobenzoyl polyglutamates. Plants typically have one or a few GGH genes; Arabidopsis has three, tandemly arranged on chromosome 1, which encode proteins with predicted secretory pathway signal peptides. Two representative Arabidopsis GGH proteins, AtGGH1 and AtGGH2 ( the At1g78660 and At1g78680 gene products, respectively) were expressed in truncated form in Escherichia coli and purified. Both enzymes were active as dimers, had low Km values (0.5-2 mu M) for folyl and p-aminobenzoyl pentaglutamates, and acted as endopeptidases. However, despite 80% sequence identity, they differed in that AtGGH1 cleaved pentaglutamates, mainly to di-and triglutamates, whereas AtGGH2 yielded mainly monoglutamates. Analysis of subcellular fractions of pea leaves and red beet roots established that GGH activity is confined to the vacuole and that this activity, if not so sequestered, would deglutamylate all cellular folylpolyglutamates within minutes. Purified pea leaf vacuoles contained an average of 20% of the total cellular folate compared with similar to 50 and similar to 10%, respectively, in mitochondria and chloroplasts. The main vacuolar folate was 5-methyltetrahydrofolate, of which 51% was polyglutamylated. In contrast, the principal mitochondrial and chloroplastic forms were 5-formyl-and 5,10-methenyltetrahydrofolate polyglutamates, respectively. In beet roots, 16-60% of the folate was vacuolar and was again mainly 5-methyltetrahydrofolate, of which 76% was polyglutamylated. These data point to a hitherto unsuspected role for vacuoles in folate storage. Furthermore, the paradoxical co-occurrence of GGH and folylpolyglutamates in vacuoles implies that the polyglutamates are somehow protected from GGH attack.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA; Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Pennsylvania; State University of New York (SUNY) System; Wadsworth Center	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.	adha@mail.ifas.ufl.edu	Orsomando, Giuseppe/L-2120-2015; de la Garza, Rocío Isabel Diaz/B-7449-2011	de la Garza, Rocío Isabel Diaz/0000-0002-0006-5694; Gregory, Jesse/0000-0002-9976-2085; Orsomando, Giuseppe/0000-0001-6640-097X	NIGMS NIH HHS [R01 GM071382-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071382] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed SU, 2000, J CELL BIOL, V149, P1335, DOI 10.1083/jcb.149.7.1335; Bagley PJ, 2000, CLIN CHEM, V46, P404; BALDET P, 1993, ARCH BIOCHEM BIOPHYS, V303, P67, DOI 10.1006/abbi.1993.1256; BARRUECO JR, 1992, J BIOL CHEM, V267, P15356; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BESSON V, 1993, BIOCHEM J, V292, P425, DOI 10.1042/bj2920425; BHANDARI SD, 1990, J NUTR, V120, P467, DOI 10.1093/jn/120.5.467; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brzezinska A, 2000, ACTA BIOCHIM POL, V47, P735; Carter C, 2004, PLANT CELL, V16, P3285, DOI 10.1105/tpc.104.027078; Chan SY, 2003, PTERIDINES, V14, P67; Chave KJ, 2000, J BIOL CHEM, V275, P40365, DOI 10.1074/jbc.M007908200; Chen LF, 1997, PLANT PHYSIOL, V115, P299, DOI 10.1104/pp.115.1.299; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cossins E, 2000, CAN J BOT, V78, P691, DOI 10.1139/cjb-78-6-691; de la Garza RD, 2004, P NATL ACAD SCI USA, V101, P13720, DOI 10.1073/pnas.0404208101; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; Farre EM, 2001, PLANT PHYSIOL, V127, P685, DOI 10.1104/pp.127.2.685; Galivan J, 2000, PHARMACOL THERAPEUT, V85, P207, DOI 10.1016/S0163-7258(99)00063-7; Gambonnet B, 2001, J SCI FOOD AGR, V81, P835, DOI 10.1002/jsfa.870; GREGORY JF, 1988, ANAL BIOCHEM, V170, P94, DOI 10.1016/0003-2697(88)90094-2; Hanson AD, 2002, CURR OPIN PLANT BIOL, V5, P244, DOI 10.1016/S1369-5266(02)00249-2; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; Hossain T, 2004, P NATL ACAD SCI USA, V101, P5158, DOI 10.1073/pnas.0401342101; Huangpu J, 1996, BIOCHEM BIOPH RES CO, V228, P1, DOI 10.1006/bbrc.1996.1608; HUANGPU J, 1996, PLANT PHYSIOL, V112, P862; Jabrin S, 2003, PLANT PHYSIOL, V131, P1431, DOI 10.1104/pp.016915; Konings EJM, 2001, AM J CLIN NUTR, V73, P765; Kuriyama H, 2002, CURR OPIN PLANT BIOL, V5, P568, DOI 10.1016/S1369-5266(02)00305-9; LEICHTER J, 1979, AM J CLIN NUTR, V32, P92, DOI 10.1093/ajcn/32.1.92; LEIGH RA, 1979, BIOCHEM J, V178, P539, DOI 10.1042/bj1780539; LEIGH RA, 1976, PLANT PHYSIOL, V58, P656, DOI 10.1104/pp.58.5.656; Li HM, 2002, J BIOL CHEM, V277, P24522, DOI 10.1074/jbc.M202020200; LIN S, 1993, PHYTOCHEMISTRY, V32, P1109, DOI 10.1016/S0031-9422(00)95074-X; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; Melse-Boonstra A, 2002, J AGR FOOD CHEM, V50, P3473, DOI 10.1021/jf0112318; Nok AJ, 2000, PARASITOL RES, V86, P923, DOI 10.1007/s004360000274; Ravanel S, 2004, J BIOL CHEM, V279, P22548, DOI 10.1074/jbc.M313250200; Ravanel S, 2001, P NATL ACAD SCI USA, V98, P15360, DOI 10.1073/pnas.261585098; Rhee MS, 1998, MOL PHARMACOL, V53, P1040; RICKLE SA, 1998, PLANT PHYSIOL, V117, P1526; Roje S, 2002, J BIOL CHEM, V277, P42748, DOI 10.1074/jbc.M205632200; Roje S, 1999, J BIOL CHEM, V274, P36089, DOI 10.1074/jbc.274.51.36089; *ROYAL SOC CHEM MA, 1991, MCCANC WIDD COMP FOO; Schirch V, 1997, METHOD ENZYMOL, V281, P81; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Scott J, 2000, J SCI FOOD AGR, V80, P795, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;795::AID-JSFA599&gt;3.0.CO;2-K, 10.1002/(SICI)1097-0010(20000515)80:7<795::AID-JSFA599>3.0.CO;2-K]; SHANE B, 1989, VITAM HORM, V45, P263; Shimaoka T, 2004, PLANT CELL PHYSIOL, V45, P672, DOI 10.1093/pcp/pch099; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Trossat C, 1996, PLANT PHYSIOL, V111, P965, DOI 10.1104/pp.111.4.965; VITALE A, 1992, BIOESSAYS, V14, P151, DOI 10.1002/bies.950140303; WANG Y, 1993, BIOCHIM BIOPHYS ACTA, V1164, P227, DOI 10.1016/0167-4838(93)90253-N; WINTER H, 1994, PLANTA, V193, P530, DOI 10.1007/BF02411558; WU KQ, 1994, PLANT PHYSIOL, V104, P373, DOI 10.1104/pp.104.2.373; Yao R, 1996, P NATL ACAD SCI USA, V93, P10134, DOI 10.1073/pnas.93.19.10134; Yao R, 1996, J BIOL CHEM, V271, P8525, DOI 10.1074/jbc.271.15.8525; ZHENG LL, 1992, PHYTOCHEMISTRY, V31, P2277, DOI 10.1016/0031-9422(92)83264-Y	60	80	85	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28877	28884		10.1074/jbc.M504306200	http://dx.doi.org/10.1074/jbc.M504306200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15961386	hybrid, Green Submitted			2022-12-25	WOS:000231021300007
J	Braun, HA; Umbreen, S; Groll, M; Kuckelkorn, U; Mlynarczuk, I; Wigand, ME; Drung, I; Kloetzel, PM; Schmidt, B				Braun, HA; Umbreen, S; Groll, M; Kuckelkorn, U; Mlynarczuk, I; Wigand, ME; Drung, I; Kloetzel, PM; Schmidt, B			Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; 20S PROTEASOME; KAPPA-B; APOPTOSIS; PS-341; GROWTH; EXPRESSION; PEPTIDASE; CELLS	Proteasomes play an important role in protein turnover in living cells. The inhibition of proteasomes affects cell cycle processes and induces apoptosis. Thus, 20 S proteasomal inhibitors are potential tools for the modulation of neoplastic growth. Based on MG132, a potent but nonspecific 20 S proteasome inhibitor, we designed and synthesized 22 compounds and evaluated them for the inhibition of proteasomes. The majority of the synthesized compounds reduced the hydrolysis of LLVY-7-aminomethyl-coumarin peptide substrate in cell lysates, some of them drastically. Several compounds displayed inhibitory effects when tested in vitro on isolated 20 S proteasomes, with lowest IC50 values of 58 nM ( chymotrypsin-like activity), 53 nM ( trypsin-like activity), and 100 nM ( caspase-like activity). Compounds 16, 21, 22, and 28 affected the chymotrypsin-like activity of the beta 5 subunit exclusively, whereas compounds 7 and 8 inhibited the beta 2 trypsin-like active site selectively. Compounds 13 and 15 inhibited all three proteolytic activities. Compound 15 was shown to interact with the active site by x-ray crystallography. The potential of these novel inhibitors was assessed by cellular tolerance and biological response. HeLa cells tolerated up to 1 mu M concentrations of all substances. Intracellular reduction of proteasomal activity and accumulation of polyubiquitinated proteins were observed for compounds 7, 13, 15, 22, 25, 26, 27, and 28 on HeLa cells. Four of these compounds ( 7, 15, 26, and 28) induced apoptosis in HeLa cells and thus are considered as promising leads for antitumor drug development.	Tech Univ Darmstadt, Clemens Schopf Inst Organ Chem & Biochem, D-64287 Darmstadt, Germany; Univ Munich, Inst Phys Chem, D-81377 Munich, Germany; Charite Univ Med Berlin, Inst Biochem, D-10117 Berlin, Germany; Med Univ Warsaw, Dept Histol & Embryol, Ctr Biostruct Res, PL-02004 Warsaw, Poland	Technical University of Darmstadt; University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Medical University of Warsaw	Schmidt, B (corresponding author), Tech Univ Darmstadt, Clemens Schopf Inst Organ Chem & Biochem, Petersenstr 22, D-64287 Darmstadt, Germany.	schmibo@oc.chemie.tu-darmstadt.de	Groll, Michael/F-5572-2015; Groll, Michael/C-1174-2010; Schmidt, Boris/D-3293-2009; Schmidt, Boris/M-7886-2019; Mlynarczuk-Bialy, Izabela/AAA-2064-2022	Schmidt, Boris/0000-0003-1662-2392; Schmidt, Boris/0000-0003-1662-2392; Mlynarczuk-Bialy, Izabela/0000-0002-5192-6415; Kuckelkorn, Ulrike/0000-0002-3085-9161				Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; ADAMS J, 2004, PROTEASOME INHIBITOR; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cusack JC, 2001, CANCER RES, V61, P3535; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Garcia-Echeverria C, 2001, BIOORG MED CHEM LETT, V11, P1317, DOI 10.1016/S0960-894X(01)00205-0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Golab J, 2004, CLIN CHIM ACTA, V340, P27, DOI 10.1016/j.cccn.2003.10.025; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Groll M, 2002, CHEM BIOL, V9, P655, DOI 10.1016/S1074-5521(02)00144-8; Groll M, 2004, BBA-MOL CELL RES, V1695, P33, DOI 10.1016/j.bbamcr.2004.09.025; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Hideshima T, 2001, CANCER RES, V61, P3071; John V, 2003, J MED CHEM, V46, P4625, DOI 10.1021/jm030247h; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; LESLIE A, 1994, MOSFLM USER GUIDE MO; Ling YH, 2002, MOL CANCER THER, V1, P841; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Orlowski RZ, 1998, CANCER RES, V58, P4342; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Schmidt B, 2004, TETRAHEDRON LETT, V45, P1751, DOI 10.1016/j.tetlet.2003.12.088; Schmidt B, 2003, CHEMBIOCHEM, V4, P366, DOI 10.1002/cbic.200200532; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Stoklosa T, 2004, APOPTOSIS, V9, P193, DOI 10.1023/B:APPT.0000018801.59062.1d; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TURK D, 1992, THESIS TU MUNCHEN MU; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015	37	58	60	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28394	28401		10.1074/jbc.M502453200	http://dx.doi.org/10.1074/jbc.M502453200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15919666	hybrid			2022-12-25	WOS:000230857300028
J	Goyal, P; Pandey, D; Behring, A; Siess, W				Goyal, P; Pandey, D; Behring, A; Siess, W			Inhibition of nuclear import of LIMK2 in endothelial cells by protein kinase C-dependent phosphorylation at Ser-283	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN D1; COFILIN PHOSPHORYLATION; STRESS FIBERS; LEPTOMYCIN B; PDZ DOMAIN; ACTIVATION; LOCALIZATION; GENE; IDENTIFICATION; ANGIOGENESIS	LIM kinases (LIMKs) are mainly in the cytoplasm and regulate actin dynamics through cofilin phosphorylation. Recently, it has been reported that nuclear localization of LIMKs can mediate suppression of cyclin D1 expression. Using immunofluorescence monitoring of enhanced green fluorescent protein-tagged LIMK2 in combination with photobleaching techniques and leptomycin B treatment, we demonstrate that LIMK2 shuttles between the cytoplasm and the nucleus in endothelial cells. Sequence analysis predicted two PKC phosphorylation sites in LIMK2 but not in LIMK1. One site at Ser-283 is present between the PDZ and the kinase domain, and the other site at Thr-494 is within the kinase domain. Activation of PKC by phorbol ester treatment of endothelial cells stimulated LIMK2 phosphorylation at Ser-283 and inhibited nuclear import of LIMK2 and the PDZ kinase construct of LIMK2 (amino acids 142-638) but not of LIMK1. The PKC-delta isoform phosphorylated LIMK2 at Ser-283 in vitro. Mutational analysis indicated that LIMK2 phosphorylation at Ser-283 but not Thr-494 was functional. Serum stimulation of endothelial cells also inhibited nuclear import of PDZK-LIMK2 by protein kinase C-dependent phosphorylation of Ser-283. Our study shows that phorbol ester and serum stimulation of endothelial cells inhibit nuclear import of LIMK2 but not LIMK1. This effect was dependent on PKC-delta-mediated phosphorylation of Ser-283. Since phorbol ester enhanced cyclin D1 expression and subsequent G(1)-to-S-phase transition of endothelial cells, we suggest that the PKC-mediated exclusion of LIMK2 from the nucleus might be a mechanism to relieve suppression of cyclin D1 expression by LIMK2.	Univ Munich, Inst Prevent Cardiovasc Dis, D-80336 Munich, Germany	University of Munich	Siess, W (corresponding author), Univ Munich, Klinikum Innenstadt, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, Pettenkoferstr 9, D-80336 Munich, Germany.	wsiess@med.uni-muenchen.de	Siess, Wolfgang/A-6430-2009; Pandey, Dharmendra/O-9158-2017; Goyal, Pankaj/C-3567-2012	Siess, Wolfgang/0000-0003-0698-6416; Pandey, Dharmendra/0000-0002-3172-5923; Pandey, Dharmendra/0000-0003-4871-964X				Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Ear T, 2001, J IMMUNOL METHODS, V257, P41, DOI 10.1016/S0022-1759(01)00445-8; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; ELLENBERG J, 1998, CELLS LAB MANUAL, P24; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; Hiraoka J, 1996, FEBS LETT, V399, P117, DOI 10.1016/S0014-5793(96)01303-8; Ikebe C, 1998, BIOCHEM BIOPH RES CO, V246, P307, DOI 10.1006/bbrc.1998.8609; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JIANG W, 1993, ONCOGENE, V8, P3447; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Nagata K, 1999, BIOCHEM J, V343, P99, DOI 10.1042/0264-6021:3430099; NUNOUE K, 1995, ONCOGENE, V11, P701; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Osada H, 1996, BIOCHEM BIOPH RES CO, V229, P582, DOI 10.1006/bbrc.1996.1847; Peterman EE, 2004, J CARDIOVASC PHARM, V43, P645, DOI 10.1097/00005344-200405000-00006; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Roovers K, 2003, DEV CELL, V5, P273, DOI 10.1016/S1534-5807(03)00206-5; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Sumi T, 2002, BIOCHEM BIOPH RES CO, V290, P1315, DOI 10.1006/bbrc.2002.6346; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Takahashi H, 2002, DEV BIOL, V241, P259, DOI 10.1006/dbio.2001.0512; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zhang SS, 1999, J BIOL CHEM, V274, P24865, DOI 10.1074/jbc.274.35.24865	42	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27569	27577		10.1074/jbc.M504448200	http://dx.doi.org/10.1074/jbc.M504448200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15923181	hybrid			2022-12-25	WOS:000230678600013
J	Gregory, KE; Ono, RN; Charbonneau, NL; Kuo, CL; Keene, DR; Bachinger, HP; Sakai, LY				Gregory, KE; Ono, RN; Charbonneau, NL; Kuo, CL; Keene, DR; Bachinger, HP; Sakai, LY			The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BOVINE OSTEOGENIC PROTEIN; HAMSTER OVARY CELLS; LATENT TGF-BETA; BINDING-PROTEIN; EXPRESSION; FIBRILLIN; MICROFIBRILS; SEQUENCE; REPEAT	Biochemical and biophysical methods are used to show that BMP-7 is secreted as a stable complex consisting of the processed growth factor dimer noncovalently associated with its two prodomain propeptide chains and that the BMP-7 complex is structurally similar to the small transforming growth factor beta (TGF beta) complex. Because the prodomain of TGF beta interacts with latent TGF beta-binding proteins, a family of molecules homologous to the fibrillins, the prodomain of BMP-7 was tested for binding to fibrillin-1 or to LTBP-1. The BMP-7 prodomain and BMP-7 complex, but not the separated growth factor dimer, interact with N-terminal regions of fibrillin-1. This interaction may target the BMP-7 complex to fibrillin microfibrils in the extracellular matrix. Immunolocalization of BMP-7 in tissues like the kidney capsule and skin reveals co-localization with fibrillin. However, BMP-7 immunolocalization in other tissues known to be active sites for BMP-7 signaling is not apparent, suggesting that immunolocalization of BMP-7 in certain tissues represents specific extracellular storage sites. These studies suggest that the prodomains of TGF beta-like growth factors are important for positioning and concentrating growth factors in the extracellular matrix. In addition, they raise the possibility that prodomains of other TGF beta-like growth factors interact with fibrillins and/or LTBPs and are also targeted to the extracellular matrix.	Shriners Hosp Children, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Sakai, LY (corresponding author), Shriners Hosp Children, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	lys@shcc.org		Keller, Kate/0000-0002-1616-972X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046811, P01AR049698] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR46811, P01AR049698] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arteaga-Solis E, 2001, J CELL BIOL, V154, P275, DOI 10.1083/jcb.200105046; Charbonneau NL, 2003, J BIOL CHEM, V278, P2740, DOI 10.1074/jbc.M209201200; Charbonneau Noe L, 2004, Birth Defects Res C Embryo Today, V72, P37, DOI 10.1002/bdrc.20000; Collod-Beroud G, 2003, HUM MUTAT, V22, P199, DOI 10.1002/humu.10249; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; De Crescenzo G, 2001, J BIOL CHEM, V276, P29632, DOI 10.1074/jbc.M009765200; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; Gleizes PE, 1996, J BIOL CHEM, V271, P29891, DOI 10.1074/jbc.271.47.29891; Godin RE, 1998, DEVELOPMENT, V125, P3473; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Israel DI, 1992, GROWTH FACTORS, V7, P139, DOI 10.3109/08977199209046403; JONES WK, 1994, GROWTH FACTORS, V11, P215, DOI 10.3109/08977199409046919; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; McMahon GA, 1996, BIOCHEM J, V313, P343, DOI 10.1042/bj3130343; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; Pereira L, 1999, P NATL ACAD SCI USA, V96, P3819, DOI 10.1073/pnas.96.7.3819; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; Saharinen J, 2000, MOL BIOL CELL, V11, P2691, DOI 10.1091/mbc.11.8.2691; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Vallejo LF, 2004, BIOTECHNOL BIOENG, V85, P601, DOI 10.1002/bit.10906; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997	35	146	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27970	27980		10.1074/jbc.M504270200	http://dx.doi.org/10.1074/jbc.M504270200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15929982	hybrid			2022-12-25	WOS:000230678600059
J	Lallemand, F; Seo, SR; Ferrand, N; Pessah, M; L'Hoste, S; Rawadi, G; Roman-Roman, S; Camonis, J; Atfi, A				Lallemand, F; Seo, SR; Ferrand, N; Pessah, M; L'Hoste, S; Rawadi, G; Roman-Roman, S; Camonis, J; Atfi, A			AIP4 restricts transforming growth factor-beta signaling through a ubiquitination-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SMAD PROTEINS; DEGRADATION; RECEPTOR; LIGASE; APOPTOSIS; MEMBRANE; PATHWAY; SMURF2; ANTAGONIST	Smad7 functions as an intracellular antagonist in transforming growth factor-beta (TGF-beta) signaling. In addition to interacting stably with the activated TGF-beta type I receptor (T beta RI) to prevent phosphorylation of the receptor-regulated Smads (Smad2 and Smad3), Smad7 also induces degradation of the activated T beta RI through association with different E3 ubiquitin ligases. Using the two-hybrid screen, we identified atrophin 1-interacting protein 4 (AIP4) as an E3 ubiquitin ligase that specifically targets Smad7 for ubiquitin-dependent degradation without affecting the turnover of the activated T beta RI. Surprisingly, we found that despite the ability to degrade Smad7, AIP4 can inhibit TGF-beta signaling, presumably by enhancing the association of Smad7 with the activated T beta RI. Consistent with this notion, expression of a catalytic mutant of AIP4, which is unable to induce ubiquitination and degradation of Smad7, also stabilizes the T beta RI(.)Smad7 complex, resulting in inhibition of TGF-beta signaling. The ability of AIP4 to enhance the inhibitory function of Smad7 independent of its ubiquitin ligase activity reveals a new mechanism by which E3 ubiquitin ligases may function to turn off TGF-beta signaling.	Hop St Antoine, INSERM, U482, F-75571 Paris, France; Inst Curie, INSERM, U528, F-75248 Paris, France; ProSkelia Pharma, F-93230 Romainville, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Atfi, A (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris, France.	atfi@st-antoine.inserm.fr	Roman-Roman, Sergio/K-9993-2014	Roman-Roman, Sergio/0000-0001-6459-2613; Rawadi, Georges/0000-0003-4735-2188				Bitzer M, 2000, GENE DEV, V14, P187; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 2000, J CELL BIOCHEM, P40; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Massague J, 2000, GENE DEV, V14, P627; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Schwartz AL, 1999, ANNU REV MED, V50, P57; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; SUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	33	46	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27645	27653		10.1074/jbc.M500188200	http://dx.doi.org/10.1074/jbc.M500188200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15946939	hybrid			2022-12-25	WOS:000230678600022
J	Machida, YJ; Teer, JK; Dutta, A				Machida, YJ; Teer, JK; Dutta, A			Acute reduction of an origin recognition complex (ORC) subunit in human cells reveals a requirement of ORC for Cdk2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; S-PHASE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; GENOMIC INSTABILITY; PHOSPHORYLATION; UBIQUITINATION; DEGRADATION; EXPRESSION	The origin recognition complex (ORC) is involved in formation of prereplicative complexes (pre-RCs) on replication origins in the G(1) phase. At the G(1)/S transition, elevated cyclin E-CDK2 activity triggers DNA replication to enter S phase. The CDK cycle works as an engine that drives progression of cell cycle events by successive activation of different types of cyclin-CDK. However, how the CDK cycle is coordinated with replication initiation remains elusive. Here we report that acute depletion of ORC2 by RNA interference (RNAi) arrests cells with low cyclin E-CDK2 activity. This result suggests that loss of a replication initiation protein prevents progression of the CDK cycle in G(1). p27 and p21 proteins accumulate following ORC2 RNAi and are required for the CDK2 inhibition. Restoration of CDK activity by co-depletion of p27 and p21 allows many ORC2-depleted cells to enter S phase and go on to mitosis. However, in some cells the release of the CDK2 block caused catastrophic events like apoptosis. Therefore, the CDK2 inhibition observed following ORC2 RNAi seems to protect cells from premature S phase entry and crisis in DNA replication. These results demonstrate an unexpected role of ORC2 in CDK2 activation, a linkage that could be important for maintaining genomic stability.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016; Machida, Yuichi/AAO-3533-2021	Machida, Yuichi/0000-0003-1414-0568; Dutta, Anindya/0000-0002-4319-0073	NATIONAL CANCER INSTITUTE [R01CA089406, R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA089406, R01 CA089406-07A2, R01 CA060499-12, R01 CA60499, R01 CA060499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chesnokov IN, 2003, P NATL ACAD SCI USA, V100, P9150, DOI 10.1073/pnas.1633580100; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Detweiler CS, 1998, P NATL ACAD SCI USA, V95, P2384, DOI 10.1073/pnas.95.5.2384; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lemoine FJ, 2005, CELL, V120, P587, DOI 10.1016/j.cell.2004.12.039; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Schraml P, 2003, J PATHOL, V200, P375, DOI 10.1002/path.1356; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; You ZS, 2002, GENE DEV, V16, P1182, DOI 10.1101/gad.985302; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	52	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27624	27630		10.1074/jbc.M502615200	http://dx.doi.org/10.1074/jbc.M502615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15944161	hybrid			2022-12-25	WOS:000230678600019
J	Shetty, S; Gyetko, MR; Mazar, AP				Shetty, S; Gyetko, MR; Mazar, AP			Induction of p53 by urokinase in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; TUMOR-SUPPRESSOR GENE; DNA-DAMAGE; IN-VITRO; POSTTRANSCRIPTIONAL REGULATION; IONIZING-RADIATION; BOUND UROKINASE; TERMINAL DOMAIN; HUMAN-MONOCYTES; GROWTH-FACTOR	Urokinase plasminogen activator (uPA) is a serine protease that catalyzes the conversion of plasminogen to plasmin. The plasminogen/plasmin system includes the uPA, its receptor, and its inhibitor (plasminogen activator inhibitor-1). Interactions between these molecules regulate cellular proteolysis as well as adhesion, cellular proliferation, and migration, processes germane to the pathogenesis of lung injury and neoplasia. In previous studies, we found that uPA regulates cell surface fibrinolysis by regulating its own expression as well as that of the uPA receptor and plasminogen activator inhibitor-1. In this study, we found that uPA alters expression of the tumor suppressor protein p53 in Beas2B airway epithelial cells in both a time- and concentration-dependent manner. These effects do not require uPA catalytic activity because the amino-terminal fragment of uPA lacking catalytic activity was as potent as two chain active uPA. Single chain uPA also enhanced p53 expression to the same extent as intact two chain active uPA and the amino-terminal fragment. Pretreatment of cells with anti-beta 1 integrin antibody blocked uPA-induced p53 expression. uPA-induced p53 expression occurs without increased p53 mRNA expression. However, uPA induced oncoprotein MDM2 in a concentration-dependent manner. uPA-induced p53 expression does not require activation of tyrosine kinases. Inactivation of protein-tyrosine phosphatase SHP-2 inhibits both basal and uPA-induced p53 expression. Plasmin did not alter uPA-mediated p53 expression. The induction of p53 expression by exposure of lung epithelial cells to uPA is a newly recognized pathway by which urokinase may influence the proliferation of lung epithelial cells. This pathway could regulate pathophysiologic alterations of p53 expression in the setting of lung inflammation or neoplasia.	Univ Texas Hlth Ctr, Dept Specialty Care Serv, Tyler, TX 75708 USA; Ann Arbor Vet Affairs Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA; Attenuon LLC, San Diego, CA 92121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	Shetty, S (corresponding author), Univ Texas Hlth Ctr, Dept Specialty Care Serv, 11937 US Highway 271, Tyler, TX 75708 USA.	sreerama.shetty@uthct.edu			NHLBI NIH HHS [R01-HL-62453, HL071147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071147, R01HL062453] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHBAROU A, 1994, CANCER RES, V54, P2372; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOYD D, 1988, CANCER RES, V48, P3112; Broet P, 1999, BRIT J CANCER, V80, P536, DOI 10.1038/sj.bjc.6690389; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; DULMER I, 1993, FEBS LETT, V322, P37; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; IDELL S, 1995, LUNG BIOL HEALTH DIS, V80, P743; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KIRCHHEIMER JC, 1989, EUR J BIOCHEM, V181, P103, DOI 10.1111/j.1432-1033.1989.tb14699.x; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; KUEBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Lane D, 2004, NEW ENGL J MED, V350, P2711, DOI 10.1056/NEJMcibr041288; LIOTTA LA, 1991, CANCER INVEST, V9, P543, DOI 10.3109/07357909109018952; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Nakanishi Y, 2000, AM J RESP CELL MOL, V22, P747, DOI 10.1165/ajrcmb.22.6.3877; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; Parra M, 2001, J BIOL CHEM, V276, P36303, DOI 10.1074/jbc.M103735200; PEDERSEN H, 1994, CANCER RES, V54, P4671; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; Shetty S, 2003, J BIOL CHEM, V278, P18124, DOI 10.1074/jbc.M207445200; Shetty S, 2000, AM J PHYSIOL-LUNG C, V278, pL148, DOI 10.1152/ajplung.2000.278.1.L148; Shetty S, 2001, J BIOL CHEM, V276, P24549, DOI 10.1074/jbc.M101605200; SHETTY S, 1995, ANTISENSE RES DEV, V5, P307, DOI 10.1089/ard.1995.5.307; Shetty S, 2000, J BIOL CHEM, V275, P13771, DOI 10.1074/jbc.275.18.13771; SHETTY S, 1995, AM J PHYSIOL-LUNG C, V268, pL972, DOI 10.1152/ajplung.1995.268.6.L972; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; SPRENGERS ED, 1987, BLOOD, V69, P381; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WANG SW, 1995, INT J ONCOL, V7, P143; Xu J, 1999, MOL CELL BIOL, V19, P12; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	58	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28133	28141		10.1074/jbc.M413190200	http://dx.doi.org/10.1074/jbc.M413190200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15937335	hybrid			2022-12-25	WOS:000230678600077
J	Tsujimoto, K; Ono, T; Sato, M; Nishida, T; Oguma, T; Tadakuma, T				Tsujimoto, K; Ono, T; Sato, M; Nishida, T; Oguma, T; Tadakuma, T			Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD95 FAS/APO-1 GENE; RAT HEPATOMA-CELLS; FACTOR AP-4; PROMOTER REGION; LYMPHOID-CELLS; CYTOCHROME-C; CD3 COMPLEX; IN-VITRO; DEATH; INHIBITION	Caspase-9 (Casp-9) induces death signals by triggering other types of caspase activation, and its expression greatly influences the onset of apoptosis. During the isolation of apoptosis-related genes involved in glucocorticoid (GC)-induced cell death in murine thymic lymphomas, we found that the antisense gene of the transcription factor activator protein-4 (AP-4) inhibited dexamethasone-induced apoptosis. Western blot analysis revealed that the expression of Bcl-x(L), Bax, and Apaf-1 was not affected in cells transfected with sense or antisense AP-4 genes. In contrast, both the expression and activation of Casp-9 were inhibited in the antisense AP-4 transfectants. We isolated the 2.4-kb 5'-flanking region of Casp-9, and the promoter activity was investigated. We found the AP-4-binding sites at -1.55 and -1.38 kb to be responsible for the promoter activity. Furthermore, a negative cis-element was expected to exist between bases -1140 and -944. When the cells were treated with dexamethasone, a rapid down-regulation of AP-4 and Casp-9 was observed whether the cells were GC-sensitive lymphomas or GC-insensitive L929 fibroblast cells. In addition, L929 cells pretreated with dexamethasone were found to be resistant to subsequent treatment with etoposide, an apoptosis-inducing reagent. GC has a two-sided effect on apoptosis, i.e. a pro-apoptotic effect on certain cell types and a prosurvival effect on other cell types. Our findings will explain, at least in part, this effect.	Natl Def Med Coll, Dept Parasitol & Immunol, Tokorozawa, Saitama 3598513, Japan	National Defense Medical College - Japan	Tadakuma, T (corresponding author), Natl Def Med Coll, Dept Parasitol & Immunol, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	tadakuma@ndmc.ac.jp						Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Amsterdam A, 2002, BIOCHEM PHARMACOL, V64, P843, DOI 10.1016/S0006-2952(02)01147-4; Aranburu A, 2001, BIOCHEM J, V354, P431, DOI 10.1042/0264-6021:3540431; Badinga L, 1998, ENDOCRINE, V8, P281, DOI 10.1385/ENDO:8:3:281; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Evans-Storms RB, 2000, ENDOCRINOLOGY, V141, P1854, DOI 10.1210/en.141.5.1854; FODOR E, 1991, BIOCHEMISTRY-US, V30, P8102, DOI 10.1021/bi00247a002; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; GRUBER J, 1994, EUR J IMMUNOL, V24, P1115, DOI 10.1002/eji.1830240516; Herr I, 2003, CANCER RES, V63, P3112; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Iida N, 1998, CARCINOGENESIS, V19, P1191, DOI 10.1093/carcin/19.7.1191; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; King-Jones K, 1999, J MOL BIOL, V291, P71, DOI 10.1006/jmbi.1999.2963; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MOORE NC, 1994, IMMUNOLOGY, V81, P115; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; PAGLIACCI MC, 1993, J ENDOCRINOL INVEST, V16, P591, DOI 10.1007/BF03347677; RUDERT F, 1995, DNA CELL BIOL, V14, P931, DOI 10.1089/dna.1995.14.931; Rudert F, 1998, DNA CELL BIOL, V17, P991, DOI 10.1089/dna.1998.17.991; Sato M, 2000, FEBS LETT, V478, P34, DOI 10.1016/S0014-5793(00)01816-0; SCHWARTZMAN RA, 1994, INT ARCH ALLERGY IMM, V105, P347, DOI 10.1159/000236781; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; TAKAI T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P105, DOI 10.1016/0167-4781(90)90029-2; UNK I, 1994, NUCLEIC ACIDS RES, V22, P4872; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020; Xiu Y, 2002, J IMMUNOL, V169, P4340, DOI 10.4049/jimmunol.169.8.4340; Yamamoto M, 1998, HEPATOLOGY, V27, P959, DOI 10.1002/hep.510270410; YASUTOMI D, 1992, IMMUNOLOGY, V77, P68; ZACHARCHUK CM, 1991, J IMMUNOL, V147, P460; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	41	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27638	27644		10.1074/jbc.M501304200	http://dx.doi.org/10.1074/jbc.M501304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15944155	hybrid			2022-12-25	WOS:000230678600021
J	Fredriksson, L; Ehnman, M; Fieber, C; Eriksson, U				Fredriksson, L; Ehnman, M; Fieber, C; Eriksson, U			Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL RECEPTOR; PDGF-BETA-RECEPTOR; ALPHA-RECEPTOR; EXPRESSION; FAMILY; DOMAIN; GENE; INHIBITION; SEIZURE; PROTEIN	Platelet-derived growth factor C (PDGF-C) is one of four members in the PDGF family of growth factors, which are known mitogens and survival factors for cells of mesenchymal origin. PDGF-C has a unique two-domain structure consisting of an N-terminal CUB and a conserved C-terminal growth factor domain that are separated by a hinge region. PDGF-C is secreted as a latent dimeric factor (PDGF-CC), which undergoes extracellular removal of the CUB domains to become a PDGF receptor alpha agonist. Recently, the multidomain serine protease tissue plasminogen activator (tPA), a thrombolytic agent used for treatment of acute ischemic stroke, was shown to cleave and activate PDGF-CC. In this study we determine the molecular mechanism of tPA-mediated activation of PDGF-CC. Using various PDGF-CC and tPA mutants, we were able to demonstrate that both the CUB and the growth factor domains of PDGF-C, as well as the kringle-2 domain of tPA, are required for the interaction and cleavage to occur. We also show that Arg(231) in PDGF-C is essential for tPA-mediated proteolysis and that the released "free" CUB domain of PDGF-C can act as a competitive inhibitor of the cleavage reaction. Furthermore, we studied how the PDGF-C/tPA axis is regulated in primary fibroblasts and found that PDGF-C expression is downregulated by hypoxia but induced by transforming growth factor (TGF)-beta(1) treatment. Elucidating the regulation and the mechanism of tPA-mediated activation of PDGF-CC will advance our knowledge of the physiological function of PDGF-CC and tPA and may provide new therapeutic opportunities for thrombolytic and cardiovascular therapies.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research	Eriksson, U (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.	ulf.eriksson@licr.ki.se	; Ehnman, Monika/R-3687-2016	Fredriksson, Linda/0000-0003-4952-2742; Ehnman, Monika/0000-0003-0468-2531				BEEBE DP, 1989, BLOOD, V74, P2034; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; Cameron NE, 2001, DIABETOLOGIA, V44, P1973, DOI 10.1007/s001250100001; Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; Carroll VA, 2005, ARTERIOSCL THROM VAS, V25, P736, DOI 10.1161/01.ATV.0000157980.15710.2b; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; Collen D, 2001, Hematology Am Soc Hematol Educ Program, P1; Ding H, 2004, NAT GENET, V36, P1111, DOI 10.1038/ng1415; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; Docagne F, 1999, FASEB J, V13, P1315, DOI 10.1096/fasebj.13.11.1315; Eitner F, 2003, J AM SOC NEPHROL, V14, P1145, DOI 10.1097/01.ASN.0000062964.75006.A8; Eliasson MCE, 2003, CARDIOVASC DIABETOL, V2, DOI 10.1186/1475-2840-2-19; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Fernandez-Monreal M, 2004, J BIOL CHEM, V279, P50850, DOI 10.1074/jbc.M407069200; Fredriksson L, 2004, EMBO J, V23, P3793, DOI 10.1038/sj.emboj.7600397; Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hehenberger K, 1998, J DERMATOL SCI, V16, P144, DOI 10.1016/S0923-1811(97)00042-X; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Kalani M, 2002, J DIABETES COMPLICAT, V16, P153, DOI 10.1016/S1056-8727(01)00182-9; Kazlauskas A, 2000, NAT CELL BIOL, V2, pE78, DOI 10.1038/35010508; Kim HK, 2003, BIOCHEM BIOPH RES CO, V304, P740, DOI 10.1016/S0006-291X(03)00656-9; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Li XR, 2005, J CLIN INVEST, V115, P118, DOI 10.1172/JCI200519189; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Li XR, 2003, CYTOKINE GROWTH F R, V14, P91, DOI 10.1016/S1359-6101(02)00090-4; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Midgley VC, 2004, J BIOL CHEM, V279, P40289, DOI 10.1074/jbc.M406063200; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; Ponten A, 2003, AM J PATHOL, V163, P673, DOI 10.1016/S0002-9440(10)63694-2; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Saed GM, 2003, FERTIL STERIL, V79, P164, DOI 10.1016/S0015-0282(02)04557-0; Schacke W, 2002, INVEST OPHTH VIS SCI, V43, P2799; Seeland U, 2002, EUR J CLIN INVEST, V32, P295, DOI 10.1046/j.1365-2362.2002.00985.x; Siegfried G, 2003, CANCER RES, V63, P1458; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; Yepes M, 2004, TRENDS CARDIOVAS MED, V14, P173, DOI 10.1016/j.tcm.2004.03.004; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308	47	40	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26856	26862		10.1074/jbc.M503388200	http://dx.doi.org/10.1074/jbc.M503388200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911618	hybrid			2022-12-25	WOS:000230589500027
J	Hosoya, T; Maruyama, A; Kang, MI; Kawatani, Y; Shibata, T; Uchida, K; Itoh, K; Yamamoto, M				Hosoya, T; Maruyama, A; Kang, MI; Kawatani, Y; Shibata, T; Uchida, K; Itoh, K; Yamamoto, M			Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRF2; ELEMENT-MEDIATED EXPRESSION; ACTIVATED RECEPTOR-GAMMA; HEME OXYGENASE-1 GENE; NAD(P)H-QUINONE OXIDOREDUCTASE1; VASCULAR ENDOTHELIUM; MOLECULAR-MECHANISM; OXIDATIVE STRESS; LESION FORMATION; INDUCIBLE GENES	The Nrf2-Keap1 system coordinately regulates cytoprotective gene expression via the antioxidant responsive element (ARE). The expression of several ARE-regulated genes was found to be up-regulated in endothelial cells by laminar shear stress, suggesting that Nrf2 contributes to the anti-atherosclerosis response via the ARE. To gain further insight into the roles that Nrf2 plays in the development of atherosclerosis, we examined how Nrf2 regulates gene expression in response to anti-atherogenic laminar flow (L-flow) or pro-atherogenic oscillatory flow (O-flow). Exposure of human aortic endothelial cells (HAECs) to L-flow, but not to O-flow, induced the expression of cytoprotective genes, such as NAD(P)H quinone oxidoreductase 1 (NQO1) by 5-fold and heme oxygenase-1 by 8-fold. The critical contribution of Nrf2 to the expression induced by L-flow was ascertained in siRNA-mediated knockdown experiments. Two cyclooxygenase-2 (COX-2) specific inhibitors attenuated Nrf2 nuclear accumulation in the acute phase of L-flow exposure. A downstream product of COX-2, 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), activated the Nrf2 regulatory pathway in HAECs through binding to the cysteines of Keap1. These results demonstrate that 15d-PGJ(2) is essential for L-flow to activate Nrf2 and induce anti-atherosclerotic gene expression. Whereas both L-flow and O-flow induced the nuclear accumulation of Nrf2 to comparable levels, chromatin immunoprecipitation analysis revealed that Nrf2 binding to the NQO1 ARE was significantly diminished in the case of O-flow compared with that of L-flow. These results suggest that O-flow inhibits Nrf2 activity at the DNA binding step, thereby suppressing atheroprotective gene expression and hence predisposing the blood vessels to the formation of atherosclerosis.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Environm Response Project ERATO Japan Sci & Techn, Tsukuba, Ibaraki 3058575, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan	University of Tsukuba; University of Tsukuba; Nagoya University	Yamamoto, M (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	masi@tara.tsukuba.ac.jp	Yamamoto, Masayuki/A-4873-2010; Itoh, Ken/B-9506-2013; Shibata, Takahiro/I-6872-2014	Yamamoto, Masayuki/0000-0002-9073-9436; Itoh, Ken/0000-0002-5518-0729; Uchida, Koji/0000-0003-3894-5299; Shibata, Takahiro/0000-0003-3194-607X				Aird WC, 2004, CRIT CARE MED, V32, pS271, DOI 10.1097/01.CCM.0000129669.21649.40; Bakin AV, 2005, FREE RADICAL BIO MED, V38, P375, DOI 10.1016/j.freeradbiomed.2004.10.033; Bao XP, 1999, ARTERIOSCL THROM VAS, V19, P996, DOI 10.1161/01.ATV.19.4.996; Barakat AI, 2003, CELL BIOCHEM BIOPHYS, V38, P323, DOI 10.1385/CBB:38:3:323; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Brooks AR, 2002, PHYSIOL GENOMICS, V9, P27, DOI 10.1152/physiolgenomics.00075.2001; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Chen BPC, 2001, PHYSIOL GENOMICS, V7, P55, DOI 10.1152/physiolgenomics.2001.7.1.55; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Chen XL, 2003, J BIOL CHEM, V278, P703, DOI 10.1074/jbc.M203161200; Cheng C, 2004, CELL BIOCHEM BIOPHYS, V41, P279, DOI 10.1385/CBB:41:2:279; Cooke JP, 2003, P NATL ACAD SCI USA, V100, P768, DOI 10.1073/pnas.0430082100; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Forman HJ, 2004, FREE RADICAL BIO MED, V36, P1197, DOI 10.1016/j.freeradbiomed.2004.03.004; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; Frangos JA, 1996, BIOCHEM BIOPH RES CO, V224, P660, DOI 10.1006/bbrc.1996.1081; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Gong PF, 2002, ANTIOXID REDOX SIGN, V4, P249, DOI 10.1089/152308602753666307; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Iiyama K, 1999, CIRC RES, V85, P199, DOI 10.1161/01.RES.85.2.199; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Ishikawa K, 2001, CIRC RES, V88, P506, DOI 10.1161/01.RES.88.5.506; Itoh K, 2004, MOL CELL BIOL, V24, P36, DOI 10.1128/MCB.24.1.36-45.2004; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jardine H, 2002, J BIOL CHEM, V277, P21158, DOI 10.1074/jbc.M112145200; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Kobayashi A, 2004, METHOD ENZYMOL, V378, P273; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Lin T, 2003, CIRC RES, V92, P1296, DOI 10.1161/01.RES.0000078780.65824.8B; Liu Y, 2004, CIRCULATION, V110, P1128, DOI 10.1161/01.CIR.0000139850.08365.EC; Lu X, 2004, J PHYSIOL-LONDON, V561, P575, DOI 10.1113/jphysiol.2004.075218; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Pearce MJ, 1996, BIOCHEM BIOPH RES CO, V218, P500, DOI 10.1006/bbrc.1996.0089; Primiano T, 1997, Adv Pharmacol, V38, P293; Resnick N, 2003, PROG BIOPHYS MOL BIO, V81, P177, DOI 10.1016/S0079-6107(02)00052-4; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Taba Y, 2000, CIRC RES, V86, P967, DOI 10.1161/01.RES.86.9.967; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Warabi E, 2004, FREE RADICAL BIO MED, V37, P682, DOI 10.1016/j.freeradbiomed.2004.05.020; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Wilkinson J, 1998, BIOCHEM BIOPH RES CO, V253, P855, DOI 10.1006/bbrc.1998.9804; Yet SF, 2003, FASEB J, V17, P1759, DOI 10.1096/fj.03-0187fje; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003	58	185	191	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27244	27250		10.1074/jbc.M502551200	http://dx.doi.org/10.1074/jbc.M502551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15917255	hybrid			2022-12-25	WOS:000230589500073
J	Messiha, HL; Bruce, NC; Sattelle, BM; Sutcliffe, MJ; Munro, AW; Scrutton, NS				Messiha, HL; Bruce, NC; Sattelle, BM; Sutcliffe, MJ; Munro, AW; Scrutton, NS			Role of active site residues and solvent in proton transfer and the modulation of flavin reduction potential in bacterial morphinone reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLD YELLOW ENZYME; PENTAERYTHRITOL TETRANITRATE REDUCTASE; ENTEROBACTER-CLOACAE PB2; MOLECULAR-DYNAMICS SIMULATIONS; PSEUDOMONAS-PUTIDA M10; X-RAY-STRUCTURE; TRIMETHYLAMINE DEHYDROGENASE; 12-OXOPHYTODIENOATE REDUCTASE; CRYSTAL-STRUCTURE; HALF-REACTION	The reactions of several active site mutant forms of bacterial morphinone reductase (MR) with NADH and 2-cyclohexen-1-one as substrates have been studied by stopped-flow and steady-state kinetic methods and redox potentiometry. The enzymes were designed to (i) probe a role for potential proton donors (Tyr-72 and Tyr-356) in the oxidative half-reaction of MR; (ii) assess the function of a highly conserved tryptophan residue (Trp-106) in catalysis; (iii) investigate the role of Thr-32 in modulating the FMN reduction potential and catalysis. The Y72F and Y356F enzymes retained activity in both steady-state and stopped-flow kinetic studies, indicating they do not serve as key proton donors in the oxidative reaction of MR. Taken together with our recently published data (Messiha, H. L., Munro, A. W., Bruce, N. C., Barsukov, I., and Scrutton, N. S. (2005) J. Biol. Chem. 280, 4627-4631) that rule out roles for Cys-191 (corresponding with the proton donor, Tyr-196, in the structurally related OYE1 enzyme) and His-186 as proton donors, we infer solvent is the source of the proton in the oxidative half-reaction of MR. We demonstrate a key role for Thr-32 in modulating the reduction potential of the FMN, which is decreased similar to 50 mV in the T32A mutant MR. This effects a change in rate-limiting step in the catalytic cycle of the T32A enzyme with the oxidizing substrate 2-cyclohexenone. Despite the conservation of Trp-106 throughout the OYE family, we show this residue does not play a major role in catalysis, although affects on substrate and coenzyme binding are observed in a W106F enzyme. Our studies show some similarities, but also major differences, in the catalytic mechanism of MR and OYE1, and emphasize the need for caution in inferring mechanism by structural comparison of highly related enzymes in the absence of solution studies.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ York, Dept Biol, Ctr Novel Agr Prod, York YO10 5YW, N Yorkshire, England	University of Leicester; University of York - UK	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	nss4@le.ac.uk	Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X; Sutcliffe, Mike/0000-0003-0414-1700; Bruce, Neil Charles/0000-0003-0398-2997	Biotechnology and Biological Sciences Research Council [BBS/B/03572/2] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Barna T, 2002, J BIOL CHEM, V277, P30976, DOI 10.1074/jbc.M202846200; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Basran J, 2003, J BIOL CHEM, V278, P43973, DOI 10.1074/jbc.M305983200; Blehert DS, 1999, J BACTERIOL, V181, P6254, DOI 10.1128/JB.181.20.6254-6263.1999; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; Breithaupt C, 2001, STRUCTURE, V9, P419, DOI 10.1016/S0969-2126(01)00602-5; Brown BJ, 1998, J BIOL CHEM, V273, P32753, DOI 10.1074/jbc.273.49.32753; Craig DH, 1998, BIOCHEMISTRY-US, V37, P7598, DOI 10.1021/bi980345i; Craig DH, 2001, BIOCHEM J, V359, P315, DOI 10.1042/0264-6021:3590315; Dutton P L, 1978, Methods Enzymol, V54, P411; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; French CE, 1995, BIOCHEM J, V312, P671, DOI 10.1042/bj3120671; FRENCH CE, 1994, BIOCHEM J, V301, P97, DOI 10.1042/bj3010097; French CE, 1998, APPL ENVIRON MICROB, V64, P2864; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; Fujieda N, 2004, BIOCHEMISTRY-US, V43, P10800, DOI 10.1021/bi049061q; Hasford JJ, 1998, J AM CHEM SOC, V120, P2251, DOI 10.1021/ja972992n; Khan H, 2004, J BIOL CHEM, V279, P30563, DOI 10.1074/jbc.M403541200; Kohli RM, 1998, J BIOL CHEM, V273, P32763, DOI 10.1074/jbc.273.49.32763; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; LIU XL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P187, DOI 10.1016/0167-4781(93)90113-R; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; Malone TE, 2005, PROTEINS, V58, P243, DOI 10.1002/prot.20162; MESSIHA HL, 2005, J BIOL CHEM, V280, P4627; Miura K, 1997, BIOL PHARM BULL, V20, P110; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; NIINO YS, 1995, J BIOL CHEM, V270, P1983, DOI 10.1074/jbc.270.5.1983; RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040; RAPPE AK, 1991, J PHYS CHEM-US, V95, P3358, DOI 10.1021/j100161a070; SAITO K, 1991, J BIOL CHEM, V266, P20720; Schaller F, 1997, J BIOL CHEM, V272, P28066, DOI 10.1074/jbc.272.44.28066; SCRUTTON NS, 1994, BIOESSAYS, V16, P115, DOI 10.1002/bies.950160208; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; STOTT K, 1993, J BIOL CHEM, V268, P6097; Strassner J, 1999, J BIOL CHEM, V274, P35067, DOI 10.1074/jbc.274.49.35067; STRASSNER J, 1999, FLAVINS FLAVOPROTEIN, P655; Tipton K.F., 1996, ENZYMOLOGY LABFAX, P115; Trickey P, 2000, BIOCHEMISTRY-US, V39, P7678, DOI 10.1021/bi9927181; Vreven T, 2000, J COMPUT CHEM, V21, P1419, DOI 10.1002/1096-987X(200012)21:16<1419::AID-JCC1>3.0.CO;2-C; Williams RE, 2004, APPL ENVIRON MICROB, V70, P3566, DOI 10.1128/AEM.70.6.3566-3574.2004; Xu D, 1999, P NATL ACAD SCI USA, V96, P3556, DOI 10.1073/pnas.96.7.3556; YANG CC, 1995, EUR J BIOCHEM, V232, P264, DOI 10.1111/j.1432-1033.1995.tb20808.x	43	21	22	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27103	27110		10.1074/jbc.M502293200	http://dx.doi.org/10.1074/jbc.M502293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15905167	hybrid			2022-12-25	WOS:000230589500057
J	Hashimoto, A; Hirose, K; Iino, M				Hashimoto, A; Hirose, K; Iino, M			BAD detects coincidence of G(2)/M phase and growth factor deprivation to regulate apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH AGONIST BAD; PROTEIN-KINASE; CELL-SURVIVAL; DEPENDENT PHOSPHORYLATION; SIGNALING PATHWAY; MYC EXPRESSION; C-MYC; ACTIVATION; CYCLE; INACTIVATION	BAD, a member of the Bcl-2 protein family, promotes mitochondria-dependent apoptosis. Here, we report that BAD dissociates from 14-3-3 zeta at each G(2)/M phase of proliferating lymphoid cells. The cell cycle-dependent dissociation of BAD was associated with phosphorylation at Ser-128, whereas mutant S128A-BAD, in which Ser-128 was converted to alanine, remained associated with 14-3-3 zeta throughout the cell cycle. Although the cell cycle-dependent dissociation of BAD per se did not induce apoptosis, growth factor deprivation induced prompt apoptosis at the G(2)/M phase but not at the G(1) phase. In cells expressing S128A-BAD, growth factor deprivation-induced apoptosis was markedly delayed and was accompanied by a delayed dephosphorylation of growth factor-dependent regulatory serine residues. These results indicate that BAD induces apoptosis upon detecting the coincidence of G(2)/M phase and growth factor deprivation.	Univ Tokyo, Grad Sch Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Iino, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1130033, Japan.	iino@m.u-tokyo.ac.jp		Hashimoto-Tane, Akiko/0000-0001-8519-266X				ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; SPACEY GD, 1990, CELL SIGNAL, V2, P329, DOI 10.1016/0898-6568(90)90062-F; Strobel T, 1998, ONCOGENE, V17, P2419, DOI 10.1038/sj.onc.1202180; Subramanian RR, 2001, EXP CELL RES, V271, P142, DOI 10.1006/excr.2001.5376; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Yang HZ, 2001, BBA-PROTEIN STRUCT M, V1547, P313, DOI 10.1016/S0167-4838(01)00202-3; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	39	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26225	26232		10.1074/jbc.M409363200	http://dx.doi.org/10.1074/jbc.M409363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901741	hybrid			2022-12-25	WOS:000230386800037
J	Nho, RS; Xia, H; Kahm, J; Kleidon, J; Diebold, D; Henke, CA				Nho, RS; Xia, H; Kahm, J; Kleidon, J; Diebold, D; Henke, CA			Role of integrin-linked kinase in regulating phosphorylation of akt and fibroblast survival in type I collagen matrices through a beta 1 integrin viability signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; PROTEIN-KINASE; TYROSINE KINASES; CELL-ADHESION; EXTRACELLULAR-MATRIX; GRANULATION-TISSUE; ENDOTHELIAL-CELLS; BETA-CATENIN; SHEAR-STRESS; APOPTOSIS	A beta 1 integrin phosphatidylinositol 3-kinase/Akt pathway regulates fibroblast survival in collagen matrices. When fibroblasts attach to collagen, Akt becomes phosphorylated, providing a survival signal. In contrast, in response to mechanical forces generated during collagen contraction, Akt is dephosphorylated and fibroblasts undergo apoptosis. The kinase(s) responsible for regulating Akt phosphorylation in response to matrix-derived mechanical signals are unclear. Integrin-linked kinase ( ILK) is associated with the beta 1 integrin in the focal adhesion complex and as such is a candidate kinase that may regulate Akt phosphorylation and fibroblast viability. Nevertheless, there is no direct evidence that matrix-derived mechanical forces regulate cell viability by modulating ILK activity. Here, we show that ILK activity decreased in response to collagen matrix contraction, which correlated with Akt dephosphorylation and induction of fibroblast apoptosis. In contrast, enforced activation of beta 1 integrin by activating antibody preserved ILK and Akt activity during collagen matrix contraction, and this is associated with protection from collagen contraction-induced apoptosis. Knock-down of ILK by small, interfering RNA ( siRNA) attenuated Akt phosphorylation in response to ligation of beta 1 integrin by collagen or activating antibody and enhanced fibroblast apoptosis in response to collagen contraction. Kinase dead ILK attenuated Akt phosphorylation and enhanced fibroblast apoptosis, whereas hyperactive and wild type ILK augmented Akt phosphorylation and protected fibroblasts from apoptosis. Constitutively active Akt preserved Akt activity and rescued ILK siRNA-treated fibroblasts from collagen contraction-induced apoptosis. These data establish that matrix-derived mechanical forces sensed by beta 1 integrin are capable of modulating ILK activity which regulates fibroblast viability via an Akt-dependent mechanism.	Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Henke, CA (corresponding author), Univ Minnesota, Dept Med, Box 276,420 Delaware St SE, Minneapolis, MN 55455 USA.	henke002@umn.edu						Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Cordes N, 2004, CANCER RES, V64, P5683, DOI 10.1158/0008-5472.CAN-04-1056; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Fluck J, 1998, J INVEST DERMATOL, V110, P153, DOI 10.1046/j.1523-1747.1998.00095.x; Friedrich EB, 2004, MOL CELL BIOL, V24, P8134, DOI 10.1128/MCB.24.18.8134-8144.2004; Friedrich EB, 2002, J BIOL CHEM, V277, P16371, DOI 10.1074/jbc.M201240200; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Zhang XW, 2003, CLIN CANCER RES, V9, P1155; Zhang XW, 2001, CIRCULATION, V104, P2762, DOI 10.1161/hc4801.100792; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	39	84	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26630	26639		10.1074/jbc.M411798200	http://dx.doi.org/10.1074/jbc.M411798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15905178	hybrid			2022-12-25	WOS:000230386800080
J	Zhang, YL; Zhu, L; Zhang, JJ; Inouye, M				Zhang, YL; Zhu, L; Zhang, JJ; Inouye, M			Characterization of ChpBK, an mRNA interferase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADDICTION ANTIDOTE MAZE; BACTERIAL-CELL DEATH; CRYSTAL-STRUCTURE; STABLE MAINTENANCE; PLASMID R100; PROTEIN; CLEAVAGE; RECOGNITION; ANTITOXINS; EXPRESSION	Escherichia coli contains a number of antitoxin-toxin modules on its chromosome, which are responsible for cell growth arrest and possible cell death. ChpBK is a toxin encoded by the ChpBIK antitoxin-toxin module. This module consists of a pair of genes, chpBI and chpBK encoding antitoxin ChpBI and toxin ChpBK, respectively. ChpBK consists of 116 amino acid residues, and its sequence shows 35% identity and 52% similarity to MazF, another E. coli toxin. MazF has been shown to be a sequence-specific (ACA) endoribonuclease that cleaves cellular mRNAs and effectively blocks protein synthesis and is thus termed as an mRNA interferase. Here we demonstrate that ChpBK is another mRNA interferase in E. coli whose induction effectively blocks cell growth in a manner similar to that of MazF. The protein synthesis as judged by incorporation of [S-35] methionine was, however, reduced by only 60% upon ChpBK induction. We demonstrate that ChpBK is a new sequence-specific endoribonuclease that cleaves mRNAs both in vivo and in vitro at the 5'-or 3'- side of the A residue in ACY sequences (Y is U, A, or G). The ChpBK cleavage of a synthetic RNA substrate generated a 2', 3'-cyclic phosphate group at the 3'-end of the 5'-end product and a 5'-OH group at the 5'-end of the 3'-end product in a manner identical to that of MazF.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	inouye@umdnj.edu	Zhu, Ling/M-3887-2013	Zhu, Ling/0000-0003-0776-1630; Zhang, Junjie/0000-0001-8809-1485				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Amitai S, 2004, J BACTERIOL, V186, P8295, DOI 10.1128/JB.186.24.8295-8300.2004; Christensen SK, 2004, MOL MICROBIOL, V51, P1705, DOI 10.1046/j.1365-2958.2003.03941.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Engelberg-Kulka H, 2004, TRENDS MICROBIOL, V12, P66, DOI 10.1016/j.tim.2003.12.008; Gerdes K, 2005, NAT REV MICROBIOL, V3, P371, DOI 10.1038/nrmicro1147; Gotfredsen M, 1998, MOL MICROBIOL, V29, P1065, DOI 10.1046/j.1365-2958.1998.00993.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hargreaves D, 2002, STRUCTURE, V10, P1425, DOI 10.1016/S0969-2126(02)00856-0; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; HIRASHIMA A, 1973, NATURE, V242, P405, DOI 10.1038/242405a0; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; Lah J, 2005, J BIOL CHEM, V280, P17397, DOI 10.1074/jbc.M501128200; Lah J, 2003, J BIOL CHEM, V278, P14101, DOI 10.1074/jbc.M209855200; Loris R, 2003, J BIOL CHEM, V278, P28252, DOI 10.1074/jbc.M302336200; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; Pedersen K, 2002, MOL MICROBIOL, V45, P501, DOI 10.1046/j.1365-2958.2002.03027.x; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Suzuki M, 2005, MOL CELL, V18, P253, DOI 10.1016/j.molcel.2005.03.011; Takagi H, 2005, NAT STRUCT MOL BIOL, V12, P327, DOI 10.1038/nsmb911; TSUCHIMOTO S, 1989, MOL GEN GENET, V215, P463, DOI 10.1007/BF00427044; Zhang JJ, 2004, J BIOL CHEM, V279, P20678, DOI 10.1074/jbc.M314284200; Zhang JJ, 2002, J BACTERIOL, V184, P5323, DOI 10.1128/JB.184.19.5323-5329.2002; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7; Zhang YL, 2005, J BIOL CHEM, V280, P3143, DOI 10.1074/jbc.M411811200	25	91	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26080	26088		10.1074/jbc.M502050200	http://dx.doi.org/10.1074/jbc.M502050200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15901733	hybrid			2022-12-25	WOS:000230386800018
J	Hirsila, M; Koivunen, P; Xu, L; Seeley, T; Kivirikko, KI; Myllyharju, J				Hirsila, M; Koivunen, P; Xu, L; Seeley, T; Kivirikko, KI; Myllyharju, J			Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway	FASEB JOURNAL			English	Article						hypoxia-inducible transciption factor; prolyl 4-hydroxylase; asparaginyl hydroxylase	DISULFIDE-ISOMERASE SUBUNIT; INDUCIBLE FACTOR-ALPHA; PROLYL 4-HYDROXYLASES; ERYTHROPOIETIN GENE; FACTOR HIF; HYPOXIA; PROTEIN; COLLAGEN; HIF-1-ALPHA; BINDING	/ Hypoxia-inducible transcription factor (HIF) is regulated by two oxygen-dependent events that are catalyzed by the HIF prolyl 4-hydroxylases (HIF-P4Hs) and HIF asparaginyl hydroxylase (FIH). We have purified the three recombinant human HIF-P4Hs to near homogeneity and characterized their catalytic properties and inhibition and those of FIH. The specific activities of the HIF-P4Hs were at least 40-50 mol/ mol/ min, and they and FIH catalyzed an uncoupled decarboxylation of 2-oxoglutarate in the absence of any peptide substrate. The purified HIF-P4Hs showed considerable activities even without added Fe2+, their apparent Km values for iron being markedly lower than that of FIH. Desferrioxamine and several metals were effective inhibitors of FIH, but surprisingly, ineffective inhibitors of the HIF-P4Hs in vitro, especially of HIF-P4H-2. Desferrioxamine and cobalt were more effective in cultured insect cells synthesizing recombinant HIF-P4H-2, but complete inhibition was not achieved and most of the enzyme was inactivated irreversibly. Cobalt also rapidly inactivated HIF-P4Hs during storage at 4 degrees C. The well-known stabilization of HIF-alpha by cobalt and nickel is thus not due to a simple competitive inhibition of HIF-P4Hs. The effective inhibition of FIH by these metals and zinc probably leads to full transcriptional activity of HIF-alpha even in concentrations that produce no stabilization of HIF-alpha.	Oulu Univ, Bioctr, Collagen Res Unit, FIN-90014 Oulu, Finland; Oulu Univ, Dept Med Bichem & Mol Biol, FIN-90014 Oulu, Finland; FibroGen Inc, San Francisco, CA 94080 USA	University of Oulu; University of Oulu; FibroGen	Myllyharju, J (corresponding author), Oulu Univ, Bioctr, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chun YS, 2001, J CELL SCI, V114, P4051; Chun YS, 2000, BIOCHEM BIOPH RES CO, V268, P652, DOI 10.1006/bbrc.2000.2180; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esposito BP, 2002, ANAL BIOCHEM, V304, P1, DOI 10.1006/abio.2002.5611; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kanaya K, 2003, BIOCHEM BIOPH RES CO, V306, P750, DOI 10.1016/S0006-291X(03)01041-6; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Li DX, 2004, J BIOL CHEM, V279, P55051, DOI 10.1074/jbc.M410287200; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Rautavuoma K, 2002, J BIOL CHEM, V277, P23084, DOI 10.1074/jbc.M112077200; Salnikow K, 2004, J BIOL CHEM, V279, P40337, DOI 10.1074/jbc.M403057200; Salnikow K, 1999, CARCINOGENESIS, V20, P1819, DOI 10.1093/carcin/20.9.1819; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Stolze IP, 2004, J BIOL CHEM, V279, P42719, DOI 10.1074/jbc.M406713200; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; WANG GL, 1993, BLOOD, V82, P3610; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Yuan Y, 2001, BIOCHEM BIOPH RES CO, V288, P849, DOI 10.1006/bbrc.2001.5835	43	166	170	1	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1308	+		10.1096/fj.04-3399fje	http://dx.doi.org/10.1096/fj.04-3399fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15941769				2022-12-25	WOS:000230207800027
J	Godbout, JP; Chen, J; Abraham, J; Richwine, AF; Berg, BM; Kelley, KW; Johnson, RW				Godbout, JP; Chen, J; Abraham, J; Richwine, AF; Berg, BM; Kelley, KW; Johnson, RW			Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune system	FASEB JOURNAL			English	Article						aging; cytokines; behavior; brain; inflammation	LONG-TERM POTENTIATION; GENE-EXPRESSION; TRANSGENIC MICE; VITAMIN-E; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; MOUSE MODEL; TNF-ALPHA; BRAIN	Acute cognitive impairment (i.e., delirium) is common in elderly emergency department patients and frequently results from infections that are unrelated to the central nervous system. Since activation of the peripheral innate immune system induces brain microglia to produce inflammatory cytokines that are responsible for behavioral deficits, we investigated if aging exacerbated neuroinflammation and sickness behavior after peripheral injection of lipopolysaccharide (LPS). Microarray analysis revealed a transcriptional profile indicating the presence of primed or activated microglia and increased inflammation in the aged brain. Furthermore, aged mice had a unique gene expression profile in the brain after an intraperitoneal injection of LPS,and the LPS-induced elevation in the brain inflammatory cytokines and oxidative stress was both exaggerated and prolonged compared with adults. Aged mice were anorectic longer and lost more weight than adults after peripheral LPS administration. Moreover, reductions in both locomotor and social behavior remained 24 h later in aged mice, when adults had fully recovered, and the exaggerated neuroinflammatory response in aged mice was not reliably paralleled by increased circulating cytokines in the periphery. Taken together, these data establish that activation of the peripheral innate immune system leads to exacerbated neuroinflammation in the aged as compared with adult mice. This dysregulated link between the peripheral and central innate immune system is likely to be involved in the severe behavioral deficits that frequently occur in older adults with systemic infections.	Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Johnson, RW (corresponding author), Univ Illinois, Anim Sci Lab 390, 1207 W Gregory Dr, Urbana, IL 61801 USA.	rwjohn@uiuc.edu		Kelley, Keith W./0000-0002-6837-8793; Johnson, Rodney/0000-0002-2376-1852	NIA NIH HHS [AG-16710] Funding Source: Medline; NIMH NIH HHS [MH-069148] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016710] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berg BM, 2004, BRAIN BEHAV IMMUN, V18, P149, DOI 10.1016/S0889-1591(03)00113-2; Blalock EM, 2003, J NEUROSCI, V23, P3807; Blasko I, 2004, AGING CELL, V3, P169, DOI 10.1111/j.1474-9728.2004.00101.x; BLUTHE RM, 1991, EUR J PHARMACOL, V209, P281, DOI 10.1016/0014-2999(91)90184-R; Bluthe RM, 2000, PHYSIOL BEHAV, V70, P367, DOI 10.1016/S0031-9384(00)00269-9; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BRUGG B, 1995, P NATL ACAD SCI USA, V92, P3032, DOI 10.1073/pnas.92.7.3032; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Capuron L, 2003, BIOL PSYCHIAT, V54, P906, DOI 10.1016/S0006-3223(03)00173-2; Castle SC, 2000, CLIN INFECT DIS, V31, P578, DOI 10.1086/313947; Chorinchath BB, 1996, J IMMUNOL, V156, P1525; Combrinck MI, 2002, NEUROSCIENCE, V112, P7, DOI 10.1016/S0306-4522(02)00030-1; Cunningham C, 2003, EUR J NEUROSCI, V17, P2147, DOI 10.1046/j.1460-9568.2003.02662.x; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Ginaldi L, 2001, MICROBES INFECT, V3, P851, DOI 10.1016/S1286-4579(01)01443-5; Godbout JP, 2004, J NEUROIMMUNOL, V149, P101, DOI 10.1016/j.jneuroim.2003.12.017; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Holmes C, 2003, J NEUROL NEUROSUR PS, V74, P788, DOI 10.1136/jnnp.74.6.788; JOHNSTON M, 1987, BRIT J MED PSYCHOL, V60, P133, DOI 10.1111/j.2044-8341.1987.tb02723.x; Kalehua AN, 2000, GERONTOLOGY, V46, P115, DOI 10.1159/000022146; Kelley KW, 2003, BRAIN BEHAV IMMUN, V17, pS112; Kheir-Eldin AA, 2001, INT J BIOCHEM CELL B, V33, P475, DOI 10.1016/S1357-2725(01)00032-2; Kiecolt-Glaser JK, 2003, P NATL ACAD SCI USA, V100, P9090, DOI 10.1073/pnas.1531903100; Konsman JP, 2002, TRENDS NEUROSCI, V25, P154, DOI 10.1016/S0166-2236(00)02088-9; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Li AJ, 1997, BRAIN RES, V748, P30, DOI 10.1016/S0006-8993(96)01283-8; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; Morgan TE, 1999, NEUROSCIENCE, V89, P687, DOI 10.1016/S0306-4522(98)00334-0; Morley AA, 2001, BIOGERONTOLOGY, V2, P109, DOI 10.1023/A:1011589218219; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Musselman DL, 2001, NEW ENGL J MED, V344, P961, DOI 10.1056/NEJM200103293441303; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Nicolle MM, 2001, NEUROSCIENCE, V107, P415, DOI 10.1016/S0306-4522(01)00374-8; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004; PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Pollmacher T, 2002, BRAIN BEHAV IMMUN, V16, P525, DOI 10.1016/S0889-1591(02)00004-1; RICHWINE AF, IN PRESS BRAIN BEHAV; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; ROBERTS SB, 1994, JAMA-J AM MED ASSOC, V272, P1601, DOI 10.1001/jama.272.20.1601; ROGERS J, 1988, NEUROBIOL AGING, V9, P339, DOI 10.1016/S0197-4580(88)80079-4; Sheffield LG, 1998, NEUROBIOL AGING, V19, P47, DOI 10.1016/S0197-4580(97)00168-1; SIBLEY WA, 1985, LANCET, V1, P1313; Sly LM, 2001, BRAIN RES BULL, V56, P581, DOI 10.1016/S0361-9230(01)00730-4; Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319; Streit WJ, 1997, J MOL MED-JMM, V75, P130, DOI 10.1007/s001090050097; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Wilson CJ, 2002, J AM GERIATR SOC, V50, P2041, DOI 10.1046/j.1532-5415.2002.50619.x; Wofford JL, 1996, AM J EMERG MED, V14, P649, DOI 10.1016/S0735-6757(96)90080-7; Xie Z, 2003, EXP NEUROL, V182, P135, DOI 10.1016/S0014-4886(03)00057-8; Ye SM, 2001, J NEUROIMMUNOL, V117, P87, DOI 10.1016/S0165-5728(01)00316-2; Ye SM, 2001, NEUROIMMUNOMODULAT, V9, P183, DOI 10.1159/000049025; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3; Yirmiya R, 1997, BRAIN RES, V749, P71, DOI 10.1016/S0006-8993(96)01295-4	57	583	596	3	57	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1329	+		10.1096/fj.05-3776fje	http://dx.doi.org/10.1096/fj.05-3776fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15919760				2022-12-25	WOS:000229602600008
J	An, LX; Tang, W; Ranalli, TA; Kim, HJ; Wytiaz, J; Kong, HM				An, LX; Tang, W; Ranalli, TA; Kim, HJ; Wytiaz, J; Kong, HM			Characterization of a thermostable UvrD helicase and its participation in helicase-dependent amplification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROTHERMOPHILUS PCRA HELICASE; DNA MISMATCH CORRECTION; ESCHERICHIA-COLI UVRD; GENE-PRODUCT; ACTIVE FORM; PROTEIN; MUTL; MECHANISM; SEQUENCE; STEP	Helicase-dependent amplification (HDA) is an isothermal in vitro DNA amplification method based upon the coordinated actions of helicases to separate double-stranded DNA and DNA polymerases to synthesize DNA. Previously, a mesophilic form of HDA (mHDA) utilizing the Escherichia coli UvrD helicase, DNA polymerase I Klenow fragment, two accessory proteins, MutL and single-stranded DNA-binding protein (SSB), was developed ( 1). In an effort to improve the specificity and performance of HDA, we have cloned and purified a thermostable UvrD helicase (Tte-UvrD) and the mutL homolog (Tte-MutL) from Thermoanaerobacter tengcongensis. Characterization of the Tte-UvrD helicase shows that it is stable and active from 45 to 65 degrees C. We have found that the Tte-UvrD helicase unwinds blunt-ended DNA duplexes as well as substrates possessing 3'- or 5'- ssDNA tails. Tte-UvrD was used to develop athermophilichelicase-dependent amplification ( tHDA) system to selectively amplify target sequences at 60 - 65 degrees C. The tHDA system is more efficient than mHDA, displaying heightened amplification sensitivity without the need for the MutL and SSB accessory proteins. Amplification independent of MutL corresponds with studies demonstrating that maximal Tte-UvrD helicase activity does not require the mutL homolog. The tHDA system allows for rapid amplification and detection of targets present in genomic DNA. The expeditious nature and simplistic design of the tHDA platform makes the technology ideal for use in diagnostic applications requiring rapid identification of organisms at the point-of-need.	New England Biolabs Inc, Beverly, MA 01915 USA; BioHelix, Beverly, MA 01915 USA		Kong, HM (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	kong@biohelix.com			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI066487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM073402, R44GM071155] Funding Source: NIH RePORTER; NIAID NIH HHS [R43 AI066487] Funding Source: Medline; NIGMS NIH HHS [R44 GM071155, R43 GM073402] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Bao QY, 2002, GENOME RES, V12, P689, DOI 10.1101/gr.219302; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; Carrick CS, 1998, GENE, V220, P21, DOI 10.1016/S0378-1119(98)00424-7; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; Collins R, 2003, EXTREMOPHILES, V7, P35, DOI 10.1007/s00792-002-0293-4; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hiramatsu Y, 1997, GENE, V199, P77, DOI 10.1016/S0378-1119(97)00349-1; KORNBERG A, 1992, DNA REPLICATION, V2, P355; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MATSON SW, 1986, J BIOL CHEM, V261, P169; McGlynn P, 2000, NUCLEIC ACIDS RES, V28, P2324, DOI 10.1093/nar/28.12.2324; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; MODRICH P, 1989, J BIOL CHEM, V264, P6597; PUTNAM BF, 1981, BIOPHYS J, V35, P271, DOI 10.1016/S0006-3495(81)84789-3; ROYCHOUDHURY R, 1979, NUCLEIC ACIDS RES, V6, P1323, DOI 10.1093/nar/6.4.1323; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; Soultanas P, 1998, NUCLEIC ACIDS RES, V26, P2374, DOI 10.1093/nar/26.10.2374; Soultanas P, 1999, NUCLEIC ACIDS RES, V27, P1421, DOI 10.1093/nar/27.6.1421; Vincent M, 2004, EMBO REP, V5, P795, DOI 10.1038/sj.embor.7400200; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	26	112	146	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28952	28958		10.1074/jbc.M503096200	http://dx.doi.org/10.1074/jbc.M503096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15955821	Green Accepted, hybrid			2022-12-25	WOS:000231021300016
J	Homma, K; Ikebe, M				Homma, K; Ikebe, M			Myosin X is a high duty ratio motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC MECHANISM; LIGHT-CHAIN; DOMAIN DETERMINES; FLUORESCENT-PROBE; ACTIN-FILAMENTS; MOLECULAR MOTOR; LARGE STEP; TRANSPORT; VI; SUPERFAMILY	Myosin X is expressed in a variety of cell types and plays a role in cargo movement and filopodia extension, but its mechanoenzymatic characteristics are not fully understood. Here we analyzed the kinetic mechanism of the ATP hydrolysis cycle of acto-myosin X using a single-headed construct (M10IQ1). Myosin X was unique for the weak "strong actin binding state" (AMD) with a K-d of 1.6 mu M attributed to the large dissociation rate constant (2.1 s(-1)). V-max and K-ATPase of the actin-activated ATPase activity of M10IQ1 were 13.5 s(-1) and 17.4 mu M, respectively. The ATP hydrolysis rate (> 100 s(-1)) and the phosphate release rate from acto-myosin X (> 100 s(-1)) were much faster than the entire ATPase cycle rate and, thus, not rate-limiting. The ADP off-rate from acto-myosin X was 23 s(-1), which was two times larger than the V-max. The P-i-burst size was low (0.46 mol/ mol), indicating that the equilibrium is significantly shifted toward the prehydrolysis intermediate. The steady-state ATPase rate can be explained by a combination of the unfavorable equilibrium constant of the hydrolysis step and the relatively slow ADP off-rate. The duty ratio calculated from our kinetic model, 0.6, was consistent with the duty ratio, 0.7, obtained from comparison of K-m ATPase and K-m motility. Our results suggest that myosin X is a high duty ratio motor.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA.	Mitsuo.Ikebe@umassmed.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048898, R01AR048526, R01AR041653] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 048526, AR 41653, AR 048898] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Berg JS, 2000, J CELL SCI, V113, P3439; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Brown JR, 2004, J NEUROBIOL, V58, P175, DOI 10.1002/neu.10317; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; deCastro MJ, 1999, BIOCHEMISTRY-US, V38, P5076, DOI 10.1021/bi9829175; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; Evans LL, 1998, J CELL SCI, V111, P2055; Hodge T, 2000, J CELL SCI, V113, P3353; Homma K, 2001, J BIOL CHEM, V276, P34348, DOI 10.1074/jbc.M104785200; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; Kambara T, 1999, J BIOL CHEM, V274, P16400, DOI 10.1074/jbc.274.23.16400; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovacs M, 2005, J BIOL CHEM, V280, P15071, DOI 10.1074/jbc.M500616200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; Ostap EM, 1996, J CELL BIOL, V133, P221, DOI 10.1083/jcb.133.2.221; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Rogers SL, 1999, J CELL BIOL, V146, P1265, DOI 10.1083/jcb.146.6.1265; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tabb JS, 1998, J CELL SCI, V111, P3221; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Thompson RF, 2002, ANAT RECORD, V268, P276, DOI 10.1002/ar.10160; Tokuo H, 2004, BIOCHEM BIOPH RES CO, V319, P214, DOI 10.1016/j.bbrc.2004.04.167; Tominaga M, 2003, EMBO J, V22, P1263, DOI 10.1093/emboj/cdg130; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Yonezawa S, 2000, BIOCHEM BIOPH RES CO, V271, P526, DOI 10.1006/bbrc.2000.2669; Zhang HQ, 2004, NAT CELL BIOL, V6, P523, DOI 10.1038/ncb1136	41	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29381	29391		10.1074/jbc.M504779200	http://dx.doi.org/10.1074/jbc.M504779200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15961399	hybrid			2022-12-25	WOS:000231021300070
J	Kushnareva, YE; Wiley, SE; Ward, MW; Andreyev, AY; Murphy, AN				Kushnareva, YE; Wiley, SE; Ward, MW; Andreyev, AY; Murphy, AN			Excitotoxic injury to mitochondria isolated from cultured neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ACUTE GLUTAMATE EXCITOTOXICITY; PERMEABILITY TRANSITION; BRAIN MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; HIPPOCAMPAL-NEURONS; CEREBELLAR NEURONS; FOREBRAIN ISCHEMIA; CALCIUM CONTENT; CELL-DEATH	Neuronal death in response to excitotoxic levels of glutamate is dependent upon mitochondrial Ca2+ accumulation and is associated with a drop in ATP levels and a loss in ionic homeostasis. Yet the mapping of temporal events in mitochondria subsequent to Ca2+ sequestration is incomplete. By isolating mitochondria from primary cultures, we discovered that glutamate treatment of cortical neurons for 10 min caused 44% inhibition of ADP-stimulated respiration, whereas the maximal rate of electron transport (uncoupler-stimulated respiration) was inhibited by similar to 10%. The Ca2+ load in mitochondria from glutamate-treated neurons was estimated to be 167 +/- 19 nmol/mg protein. The glutamate-induced Ca2+ load was less than the maximal Ca2+ uptake capacity of the mitochondria determined in vitro (363 +/- 35 nmol/mg protein). Comparatively, mitochondria isolated from cerebellar granule cells demonstrated a higher Ca2+ uptake capacity (686 +/- 71 nmol/mg protein) than the cortical mitochondria, and the glutamate- induced load of Ca2+ was a smaller percentage of the maximal Ca2(+) uptake capacity. Thus, this study indicated that Ca2+-induced impairment of mitochondrial ATP production is an early event in the excitotoxic cascade that may contribute to decreased cellular ATP and loss of ionic homeostasis that precede commitment to neuronal death.	MitoKor, San Diego, CA 92121 USA		Murphy, AN (corresponding author), BioEnergetix LLC, 310 Cole Ranch Rd, Encinitas, CA 92024 USA.	anmurphy@cox.net	; Murphy, Anne N/H-3217-2016	Wiley, Sandra/0000-0003-3979-2474; Andreyev, Alexander Y./0000-0002-9246-9943; Ward, Manus/0000-0002-7085-9668; Murphy, Anne N/0000-0002-5222-9902				Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Almeida A, 1998, BRAIN RES, V790, P209, DOI 10.1016/S0006-8993(98)00064-X; Almeida A, 1998, BRAIN RES PROTOC, V2, P209, DOI 10.1016/S1385-299X(97)00044-5; ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; Anderson MF, 1999, J NEUROCHEM, V73, P1189, DOI 10.1046/j.1471-4159.1999.0731189.x; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Atlante A, 1996, NEUROREPORT, V7, P2519, DOI 10.1097/00001756-199611040-00023; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Baron KT, 2003, BRAIN RES, V993, P124, DOI 10.1016/j.brainres.2003.09.022; Bezprozvanny I, 2004, BIOCHEM BIOPH RES CO, V322, P1310, DOI 10.1016/j.bbrc.2004.08.035; Brocard JB, 2001, J PHYSIOL-LONDON, V531, P793, DOI 10.1111/j.1469-7793.2001.0793h.x; Brustovetsky N, 2002, NEUROSCI LETT, V332, P91, DOI 10.1016/S0304-3940(02)00948-5; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Budd SL, 1996, J NEUROCHEM, V67, P2282; Castilho RF, 1998, J NEUROSCI, V18, P10277; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; COURTNEY MJ, 1990, J NEUROSCI, V10, P3873, DOI 10.1523/JNEUROSCI.10-12-03873.1990; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; Holmuhamedov EL, 2001, MOL CELL BIOCHEM, V220, P135, DOI 10.1023/A:1010894427373; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; Isaev NK, 1996, FEBS LETT, V392, P143, DOI 10.1016/0014-5793(96)00804-6; Jekabsons MB, 2004, J BIOL CHEM, V279, P32989, DOI 10.1074/jbc.M401540200; JURKOWITZ MS, 1983, ARCH BIOCHEM BIOPHYS, V223, P120, DOI 10.1016/0003-9861(83)90577-5; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Khodorov B I, 2000, Membr Cell Biol, V14, P149; Krieger C, 2002, EUR J PHARMACOL, V447, P177, DOI 10.1016/S0014-2999(02)01842-3; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Lai J C, 1979, Methods Enzymol, V55, P51; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Luetjens CM, 2000, J NEUROSCI, V20, P5715; MEDRANO CJ, 1989, NEUROTOXICOLOGY, V10, P249; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nicholls David, 1994, PROTEINS TRANSMITTER, p[3, 46]; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; Peng TI, 1998, MOL PHARMACOL, V53, P974; Pivovarova NB, 2004, J NEUROSCI, V24, P5611, DOI 10.1523/JNEUROSCI.0531-04.2004; Pivovarova NB, 2002, J NEUROSCI, V22, P10653; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; ROMAN I, 1981, MEMBRANE BIOCHEM, V4, P1, DOI 10.3109/09687688109065419; ROSENTHAL RE, 1987, J CEREBR BLOOD F MET, V7, P752, DOI 10.1038/jcbfm.1987.130; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1016, P77, DOI 10.1016/0005-2728(90)90009-S; Ruiz F, 2000, EUR J PHARMACOL, V404, P29, DOI 10.1016/S0014-2999(00)00584-7; Schild L, 2003, J BIOL CHEM, V278, P25454, DOI 10.1074/jbc.M302743200; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; Scorziello A, 2001, J NEUROSCI RES, V63, P20, DOI 10.1002/1097-4547(20010101)63:1<20::AID-JNR3>3.0.CO;2-N; SIMS NR, 1991, J NEUROCHEM, V56, P1836, DOI 10.1111/j.1471-4159.1991.tb03438.x; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Syroeshkin A. V., 1999, Biochemistry (Moscow), V64, P1337; Tang TS, 2005, P NATL ACAD SCI USA, V102, P2602, DOI 10.1073/pnas.0409402102; THORNE RFW, 1974, FEBS LETT, V41, P118, DOI 10.1016/0014-5793(74)80968-3; TSUJI K, 1994, BRAIN RES, V662, P289, DOI 10.1016/0006-8993(94)90828-1; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Urushitani M, 2001, J NEUROSCI RES, V63, P377, DOI 10.1002/1097-4547(20010301)63:5<377::AID-JNR1032>3.0.CO;2-#; VASINGTON FD, 1962, J BIOL CHEM, V237, P2670; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; Vergun O, 2001, J PHYSIOL-LONDON, V531, P147, DOI 10.1111/j.1469-7793.2001.0147j.x; VILLALOBO A, 1980, J BIOL CHEM, V255, P2457; Wang GJ, 2002, J NEUROPHYSIOL, V87, P740, DOI 10.1152/jn.00345.2001; Ward MW, 2005, J NEUROCHEM, V92, P1081, DOI 10.1111/j.1471-4159.2004.02928.x; Ward MW, 2000, J NEUROSCI, V20, P7208; WEINBACH EC, 1965, BIOCHEM BIOPH RES CO, V19, P133, DOI 10.1016/0006-291X(65)90131-2; White RJ, 1996, J NEUROSCI, V16, P5688; ZAIDAN E, 1994, J NEUROCHEM, V63, P1812; ZOCCARATO F, 1982, EUR J BIOCHEM, V127, P333, DOI 10.1111/j.1432-1033.1982.tb06875.x	77	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					28894	28902		10.1074/jbc.M503090200	http://dx.doi.org/10.1074/jbc.M503090200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15932874	hybrid			2022-12-25	WOS:000231021300009
J	Poliakov, E; Gentleman, S; Cunningham, FX; Miller-Ihli, NJ; Redmond, TM				Poliakov, E; Gentleman, S; Cunningham, FX; Miller-Ihli, NJ; Redmond, TM			Key role of conserved histidines in recombinant mouse beta-carotene 15,15 '-monooxygenase-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PAUCIMOBILIS TMY1009; LIGNOSTILBENE-ALPHA,BETA-DIOXYGENASE GENE; SUBSTRATE-SPECIFICITY; ENZYMATIC CLEAVAGE; OXIDATIVE CLEAVAGE; ENZYMES; EXPRESSION; CLONING; 15,15'-DIOXYGENASE; IDENTIFICATION	Alignment of sequences of vertebrate beta-carotene 15,15'-monooxygenase-1 (BCMO1) and related oxygenases revealed four perfectly conserved histidines and five acidic residues (His(172), His(237), His(308), His(514), Asp(52), Glu(140), Glu(314), Glu(405), and Glu(457) in mouse BCMO1). Because BCMO1 activity is iron-dependent, we propose that these residues participate in iron coordination and therefore are essential for catalytic activity. To test this hypothesis, we produced mutant forms of mouse BCMO1 by replacing the conserved histidines and acidic residues as well as four histidines and one glutamate nonconserved in the overall family with alanines by site-directed mutagenesis. Our in vitro and in vivo data showed that mutation of any of the four conserved histidines and Glu405 caused total loss of activity. However, mutations of non-conserved histidines or any of the other conserved acidic residues produced impaired although enzymatically active proteins, with a decrease in activity mostly due to changes in V-max. The iron bound to protein was determined by inductively coupled plasma atomic emission spectrometry. Bound iron was much lower in preparations of inactive mutants than in the wild-type protein. Therefore, the conserved histidines and Glu405 are absolutely required for the catalytic mechanism of BCMO1. Because the mutant proteins are impaired in iron binding, these residues are concluded to coordinate iron required for catalytic activity. These data are discussed in the context of the predicted structure for the related eubacterial apocarotenal oxygenase.	NEI, LRCMB, NIH, Bethesda, MD 20892 USA; Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; USDA ARS, Food Composit Lab, Beltsville, MD 20705 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University System of Maryland; University of Maryland College Park; United States Department of Agriculture (USDA)	Redmond, TM (corresponding author), NEI, LRCMB, NIH, Bldg 7,Rm 303,7 Mem Dr,MSC 0706, Bethesda, MD 20892 USA.	Redmond@helix.nih.gov		Redmond, T. Michael/0000-0002-1813-5291	NATIONAL EYE INSTITUTE [Z01EY000260, ZIAEY000260] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arora D, 1996, J BIOTECHNOL, V52, P127, DOI 10.1016/S0168-1656(96)01636-7; BAKER SA, 2000, ENCY ANAL CHEM APPL, P3888; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Cunningham FX, 1996, PLANT CELL, V8, P1613, DOI 10.2307/3870254; DEVERY J, 1994, BRIT J NUTR, V72, P397, DOI 10.1079/BJN19940042; During A, 1996, ANAL BIOCHEM, V241, P199, DOI 10.1006/abio.1996.0400; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; Hogan DA, 2000, J BIOL CHEM, V275, P12400, DOI 10.1074/jbc.275.17.12400; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P926, DOI 10.1271/bbb.57.926; KAMODA S, 1991, AGR BIOL CHEM TOKYO, V55, P1411, DOI 10.1080/00021369.1991.10870789; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P931, DOI 10.1271/bbb.57.931; Katona G, 2003, J MOL BIOL, V331, P681, DOI 10.1016/S0022-2836(03)00751-4; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Lancaster CRD, 1999, J MOL BIOL, V286, P883, DOI 10.1006/jmbi.1998.2532; Lange SJ, 1998, CURR OPIN CHEM BIOL, V2, P159, DOI 10.1016/S1367-5931(98)80057-4; Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200; MillerIhli NJ, 1996, J AGR FOOD CHEM, V44, P2675, DOI 10.1021/jf950616l; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Ruch S, 2005, MOL MICROBIOL, V55, P1015, DOI 10.1111/j.1365-2958.2004.04460.x; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Shanklin J, 1997, P NATL ACAD SCI USA, V94, P2981, DOI 10.1073/pnas.94.7.2981; Simovich M J, 2001, Hum Mutat, V18, P164, DOI 10.1002/humu.1168; SINGH H, 1974, BIOCHIM BIOPHYS ACTA, V370, P49, DOI 10.1016/0005-2744(74)90030-8; Tan BC, 1997, P NATL ACAD SCI USA, V94, P12235, DOI 10.1073/pnas.94.22.12235; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476; ZHANG YY, 1993, J BIOL CHEM, V268, P2535	37	68	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29217	29223		10.1074/jbc.M500409200	http://dx.doi.org/10.1074/jbc.M500409200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15951442	hybrid			2022-12-25	WOS:000231021300050
J	Moon, JC; Hah, YS; Kim, WY; Jung, BG; Jang, HH; Lee, JR; Kim, SY; Lee, YM; Jeon, MG; Kim, CW; Cho, MJ; Lee, SY				Moon, JC; Hah, YS; Kim, WY; Jung, BG; Jang, HH; Lee, JR; Kim, SY; Lee, YM; Jeon, MG; Kim, CW; Cho, MJ; Lee, SY			Oxidative stress-dependent structural and functional switching of a human 2-Cys peroxiredoxin Isotype II that enhances HeLa cell resistance to H2O2-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SULFINIC ACID; HYDROGEN-PEROXIDE; THIOREDOXIN PEROXIDASE; ALZHEIMERS-DISEASE; CHAPERONE FUNCTION; CRYSTAL-STRUCTURE; SITE CYSTEINE; ACTIVE-SITE; LIFE-SPAN; EXPRESSION	Although biochemical properties of 2-Cys peroxire-doxins ( Prxs) have been extensively studied, their real physiological functions in higher eukaryotic cells remain obscure and certainly warrant further study. Here we demonstrated that human ( h) PrxII, a cytosolic isotype of human 2-Cys Prx, has dual functions as a peroxidase and a molecular chaperone, and that these different functions are closely associated with its adoption of distinct protein structures. Upon exposure to oxidative stress, hPrxII assumes a high molecular weight complex structure that has a highly efficient chaperone function. However, the subsequent removal of stressors induces the dissociation of this protein structure into low molecular weight proteins and triggers a chaperone-to-peroxidase functional switch. The formation of a high molecular weight hPrxII complex depends on the hyperoxidation of its N-terminal peroxidatic Cys residue as well as on its C-terminal domain, which contains a "YF motif" that is exclusively found in eukaryotic 2-Cys Prxs. A C-terminally truncated hPrxII exists as low and oligomeric protein species and does not respond to oxidative stress. Moreover, this C-terminal deletion of hPrxII converted it from an oxidation-sensitive to a hyperoxidation-resistant form of peroxidase. When functioning as a chaperone, hPrxII protects HeLa cells from H2O2-induced cell death, as measured by a terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling assay and fluorescence-activated cell sorting analysis.	Gyeongsang Natl Univ, Environm Biotechnol Natl Core Res Ctr, Jinju 660701, South Korea; Gyeongsang Natl Univ, Div Appl Life Sci, BK21 Program, Jinju 660701, South Korea; Gyeongsang Natl Univ, Dept Biochem, Coll Med, Jinju 660701, South Korea; Gyeongsang Natl Univ, Inst Hlth Sci, Jinju 660701, South Korea	Gyeongsang National University; Gyeongsang National University; Gyeongsang National University; Gyeongsang National University	Lee, SY (corresponding author), Gyeongsang Natl Univ, Environm Biotechnol Natl Core Res Ctr, Jinju 660701, South Korea.	sylee@gsnu.ac.kr	Cho, Moo Je/F-1649-2010	LEE, JUNG RO/0000-0002-9596-3330				Akhtar MW, 2004, J BIOL CHEM, V279, P55760, DOI 10.1074/jbc.M406333200; Barford D, 2004, CURR OPIN STRUC BIOL, V14, P679, DOI 10.1016/j.sbi.2004.09.012; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chang JW, 2001, BIOCHEM BIOPH RES CO, V289, P507, DOI 10.1006/bbrc.2001.5989; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Chang TS, 2004, J BIOL CHEM, V279, P50994, DOI 10.1074/jbc.M409482200; Chen WC, 2002, J NEUROSCI RES, V70, P794, DOI 10.1002/jnr.10435; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Echalier A, 2005, BIOCHEMISTRY-US, V44, P1755, DOI 10.1021/bi048226s; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Haslbeck M, 2004, J MOL BIOL, V343, P445, DOI 10.1016/j.jmb.2004.08.048; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Kang SW, 2004, J BIOL CHEM, V279, P2535, DOI 10.1074/jbc.M307698200; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; Kim KS, 2002, FREE RADICAL BIO MED, V32, P544, DOI 10.1016/S0891-5849(02)00741-4; Kinnula VL, 2002, J PATHOL, V196, P316, DOI 10.1002/path.1042; Koo KH, 2002, ARCH BIOCHEM BIOPHYS, V397, P312, DOI 10.1006/abbi.2001.2700; Krapfenbauer K, 2003, BRAIN RES, V967, P152, DOI 10.1016/S0006-8993(02)04243-9; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Matsuzaki M, 2004, BRAIN RES, V1004, P83, DOI 10.1016/j.brainres.2004.01.017; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Morrow G, 2004, FASEB J, V18, P598, DOI 10.1096/fj.03-0860fje; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Multhaup G, 1997, BIOCHEM PHARMACOL, V54, P533, DOI 10.1016/S0006-2952(97)00062-2; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Noh DY, 2001, ANTICANCER RES, V21, P2085; Nonn L, 2003, MOL CANCER RES, V1, P682; Papp E, 2003, BIOFACTORS, V17, P249, DOI 10.1002/biof.5520170124; Pratico D, 2002, BIOCHEM PHARMACOL, V63, P563, DOI 10.1016/S0006-2952(01)00919-4; Ritz D, 2001, SCIENCE, V294, P158, DOI 10.1126/science.1063143; Sayed AA, 2004, J BIOL CHEM, V279, P26159, DOI 10.1074/jbc.M401748200; Schroder E, 1998, BBA-PROTEIN STRUCT M, V1383, P279, DOI 10.1016/S0167-4838(97)00217-3; Veal EA, 2004, MOL CELL, V15, P129, DOI 10.1016/j.molcel.2004.06.021; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yanagawa T, 2000, CANCER LETT, V156, P27, DOI 10.1016/S0304-3835(00)00434-1; Yanagawa T, 1999, CANCER LETT, V145, P127, DOI 10.1016/S0304-3835(99)00243-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	50	240	249	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28775	28784		10.1074/jbc.M505362200	http://dx.doi.org/10.1074/jbc.M505362200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15941719	hybrid			2022-12-25	WOS:000230857300069
J	Pham, V; Dong, MQ; Wade, JD; Miller, LJ; Morton, CJ; Ng, H; Parker, MW; Sexton, PM				Pham, V; Dong, MQ; Wade, JD; Miller, LJ; Morton, CJ; Ng, H; Parker, MW; Sexton, PM			Insights into interactions between the alpha-helical region of the salmon calcitonin antagonists and the human calcitonin receptor using photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DODECYL-SULFATE MICELLES; GASTRIC-ACID SECRETION; PARATHYROID-HORMONE; AMINO-TERMINUS; LIGAND-BINDING; CROSS-LINKING; DIRECT IDENTIFICATION; CLINICAL RESISTANCE; SIGNAL-TRANSDUCTION	Fish-like calcitonins ( CTs), such as salmon CT (sCT), are widely used clinically in the treatment of bone-related disorders; however, the molecular basis for CT binding to its receptor, a class II G protein-coupled receptor, is not well defined. In this study we have used photoaffinity labeling to identify proximity sites between CT and its receptor. Two analogues of the antagonist sCT( 8-32) containing a single photolabile p-benzo-yl-L- phenylalanine (Bpa) residue in position 8 or 19 were used. Both analogues retained high affinity for the CT receptor and potently inhibited agonist-induced cAMP production. The [Bpa(19)] sCT( 8-32) analogue cross-linked to the receptor at or near the equivalent cross-linking site of the full-length peptide, within the fragment Cys(134)-Lys(141) ( within the amino terminus of the receptor, adjacent to transmembrane 1) ( Pham, V., Wade, J. D., Purdue, B. W., and Sexton, P. M. ( 2004) J. Biol. Chem. 279, 6720-6729). In contrast, proteolytic mapping and mutational analysis identified Met(49) as the crosslinking site for [ Bpa(8)] sCT( 8-32). This site differed from the previously identified cross-linking site of the agonist [ Bpa(8)] human CT ( Dong, M., Pinon, D. I., Cox, R. F., and Miller, L. J. ( 2004) J. Biol. Chem. 279, 31177-31182) and may provide evidence for conformational differences between interaction with active and inactive state receptors. Molecular modeling suggests that the difference in cross-linking between the two Bpa8 analogues can be accounted for by a relatively small change in peptide orientation. The model was also consistent with cooperative interaction between the receptor amino terminus and the receptor core.	Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; Mayo Clinic; Mayo Clinic Phoenix; St. Vincent's Institute of Medical Research	Sexton, PM (corresponding author), Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia.	p.sexton@hfi.unimelb.edu.au	Morton, Craig/GON-8638-2022; Parker, Michael W/F-9069-2013; Sexton, Patrick M/B-1319-2008	Morton, Craig/0000-0001-5452-5193; Parker, Michael W/0000-0002-3101-1138; Sexton, Patrick M/0000-0001-8902-2473; Wade, John/0000-0002-1352-6568	NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adeya-Osiguwa SA, 2003, MOL REPROD DEV, V65, P228, DOI 10.1002/mrd.10273; ALBRANDT K, 1995, ENDOCRINOLOGY, V136, P5377, DOI 10.1210/en.136.12.5377; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Behar V, 1999, ENDOCRINOLOGY, V140, P4251, DOI 10.1210/en.140.9.4251; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1999, J PEPT RES, V54, P120, DOI 10.1034/j.1399-3011.1999.00096.x; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Boucard AA, 2003, BIOCHEM J, V370, P829, DOI 10.1042/BJ20021566; CARNEY SL, 1992, CLIN EXP PHARMACOL P, V19, P433, DOI 10.1111/j.1440-1681.1992.tb00486.x; CHAIT A, 1995, BRAIN RES BULL, V36, P467, DOI 10.1016/0361-9230(94)00223-N; Chen WJ, 1997, MOL PHARMACOL, V52, P1164, DOI 10.1124/mol.52.6.1164; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DEMOL P, 1986, ARCH INT PHYSIOL BIO, V94, P331, DOI 10.3109/13813458609071433; DEROUFFIGNAC C, 1991, PFLUG ARCH EUR J PHY, V419, P472, DOI 10.1007/BF00370791; DOI M, 1990, 11 AM PEPT S ESCOM L, P165; Dong MQ, 2004, J BIOL CHEM, V279, P31177, DOI 10.1074/jbc.M404113200; Dong MQ, 2004, J BIOL CHEM, V279, P2894, DOI 10.1074/jbc.M310407200; Dong MQ, 2004, J BIOL CHEM, V279, P1167, DOI 10.1074/jbc.M305719200; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DSANTOS CS, 1988, ENDOCRINOLOGY, V123, P1483, DOI 10.1210/endo-123-3-1483; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; FINDLAY DM, 1980, CANCER RES, V40, P1311; Fraser LR, 2001, VITAM HORM, V63, P1, DOI 10.1016/S0083-6729(01)63001-2; FRENDO JL, 1994, FEBS LETT, V342, P214, DOI 10.1016/0014-5793(94)80503-2; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 2002, PHARMACOL TOXICOL, V91, P304, DOI 10.1034/j.1600-0773.2002.910607.x; GONZALEZ D, 1986, CALCIFIED TISSUE INT, V38, P71, DOI 10.1007/BF02556832; GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046; GORN AH, 1995, J CLIN INVEST, V95, P2680, DOI 10.1172/JCI117970; Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101; Grauer A, 1995, EXP CLIN ENDOCR DIAB, V103, P345, DOI 10.1055/s-0029-1211376; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUIDOBONO F, 1991, FARMACO, V46, P555; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hashimoto Y, 1999, BIOCHEMISTRY-US, V38, P8377, DOI 10.1021/bi983018j; Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOSKING DJ, 1984, Q J MED, V53, P359; IKEGAME M, 1994, J BONE MINER RES, V9, P25; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kumar S, 2003, BIOL REPROD, V68, P1318, DOI 10.1095/biolreprod.102.007708; LENZ HJ, 1986, GASTROENTEROLOGY, V91, P905, DOI 10.1016/0016-5085(86)90693-1; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MEADOWS RP, 1991, BIOCHEMISTRY-US, V30, P1247, DOI 10.1021/bi00219a012; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; MORELLI MAC, 1992, J BIOMOL NMR, V2, P335, DOI 10.1007/BF01874812; MOTTA A, 1991, BIOCHEMISTRY-US, V30, P10444, DOI 10.1021/bi00107a012; Motta A, 1998, PROTEINS, V32, P314, DOI 10.1002/(SICI)1097-0134(19980815)32:3<314::AID-PROT7>3.3.CO;2-J; Motulsky H. A., 2003, FITTING MODELS BIOLO; MUFF R, 1994, ENDOCRINOLOGY, V134, P1593, DOI 10.1210/en.134.3.1593; NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V209, P744, DOI 10.1006/bbrc.1995.1562; NIALL HD, 1969, P NATL ACAD SCI USA, V64, P771, DOI 10.1073/pnas.64.2.771; NICHOLSON GC, 1988, BIOCHEM J, V253, P505, DOI 10.1042/bj2530505; NICHOLSON GC, 1988, BIOCHEM J, V250, P877, DOI 10.1042/bj2500877; NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584; NUSSENZVEIG DR, 1995, ENDOCRINOLOGY, V136, P2047, DOI 10.1210/en.136.5.2047; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Perodin J, 2002, BIOCHEMISTRY-US, V41, P14348, DOI 10.1021/bi0258602; Pham V, 2004, J BIOL CHEM, V279, P6720, DOI 10.1074/jbc.M307214200; Pham VI, 2004, J PEPT SCI, V10, P179, DOI 10.1002/psc.541; PLEHWE WE, 1977, MED J AUSTRALIA, V1, P577, DOI 10.5694/j.1326-5377.1977.tb130922.x; Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365-2613.2000.00176.x; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Pozvek G, 1997, MOL PHARMACOL, V51, P658, DOI 10.1124/mol.51.4.658; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; Sexton PM, 1999, CURR MED CHEM, V6, P1067; SINGER FR, 1972, J CLIN INVEST, V51, P2331, DOI 10.1172/JCI107044; SINGER FR, 1980, ARTHRITIS RHEUM, V23, P1148, DOI 10.1002/art.1780231012; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; TAGLIARO F, 1995, HORM METAB RES, V27, P31, DOI 10.1055/s-2007-979902; WADA S, 1995, ENDOCRINOLOGY, V136, P2611, DOI 10.1210/en.136.6.2611; ZAIDI M, 2002, PRINCIPLES BONE BIOL, V2, P1423	80	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28610	28622		10.1074/jbc.M503272200	http://dx.doi.org/10.1074/jbc.M503272200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15929987	hybrid			2022-12-25	WOS:000230857300052
J	Butler, MP; Hanly, JA; Moynagh, PN				Butler, MP; Hanly, JA; Moynagh, PN			Pellino3 is a novel upstream regulator of p38 MAPK and activates CREB in a p38-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; IL-1 RECEPTOR; KINASE CASCADE; ADAPTER MOLECULE; NUCLEAR EXPORT; CUTTING EDGE; KAPPA-B; PROTEIN; PATHWAY; PHOSPHORYLATION	Engagement of the interleukin-1 (IL-1) and Toll-like receptors triggers mitogen- activated protein kinase ( MAPK) pathways and activation of transcription factors such as NF kappa B and AP-1. Recent studies have identified members of the Pellino protein family as novel mediators in mediating activation of these pathways. However, no evidence has been presented to date to suggest a role for the Pellino proteins in activation of the p38 MAPK pathway. We demonstrate herein that Pellino3 is a strong activator of p38 MAPK. RNA interference was used to reveal a physiological role for Pellino3 in the IL-1 pathway leading to activation of p38 MAPK. A series of N- terminal truncation and point mutants of Pellino3 were generated and tested for their ability to activate p38 MAPK in an effort to map sites of protein interaction important for p38 MAPK activation. In this way we show that the binding of Pellino3 to IL-1 receptor- associated kinase 1 coincides with its ability to promote p38 MAPK activation. TRAF-6 and transforming growth factor-beta-activating kinase 1 are shown to act as downstream mediators of the activation of p38 MAPK by Pellino3. Finally we confirm the functional consequences of the activation of p38 MAPK by Pellino3 by demonstrating that Pellino3 promotes translocation of the p38 substrate, MAPK-activated protein kinase2, from the nucleus to the cytoplasm and activates the transcription factor CREB in a p38 MAPK-dependent manner. Our study not only identifies Pellino3 as a novel upstream regulator of the p38 MAPK pathway but also probes the mechanistic basis underlying the ability of Pellino3 to promote activation of this pathway.	Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Pharmacol, Dublin 4, Ireland	University College Dublin	Moynagh, PN (corresponding author), Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Pharmacol, Dublin 4, Ireland.	P.Moynagh@ucd.ie		Hanly, Jennifer/0000-0002-1553-7228; Moynagh, Paul/0000-0002-4139-3061				Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Grosshans J, 1999, MECH DEVELOP, V81, P127, DOI 10.1016/S0925-4773(98)00236-6; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Jensen LE, 2003, FEBS LETT, V545, P199, DOI 10.1016/S0014-5793(03)00533-7; Jensen LE, 2003, J IMMUNOL, V171, P1500, DOI 10.4049/jimmunol.171.3.1500; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Resch K, 2001, CYTOGENET CELL GENET, V92, P172, DOI 10.1159/000056895; Rich T, 2000, IMMUNOGENETICS, V52, P145, DOI 10.1007/s002510000249; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Strelow A, 2003, FEBS LETT, V547, P157, DOI 10.1016/S0014-5793(03)00697-5; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yu KY, 2002, J IMMUNOL, V169, P4075, DOI 10.4049/jimmunol.169.8.4075	40	41	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27759	27768		10.1074/jbc.M500756200	http://dx.doi.org/10.1074/jbc.M500756200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15917247	hybrid, Green Accepted			2022-12-25	WOS:000230678600035
J	Pushkarsky, T; Yurchenko, V; Vanpouille, C; Brichacek, B; Vaisman, I; Hatakeyama, S; Nakayama, KI; Sherry, B; Bukrinsky, MI				Pushkarsky, T; Yurchenko, V; Vanpouille, C; Brichacek, B; Vaisman, I; Hatakeyama, S; Nakayama, KI; Sherry, B; Bukrinsky, MI			Cell surface expression of CD147/EMMPRIN is regulated by cyclophilin 60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE INDUCER; COLLAGENASE-STIMULATORY FACTOR; A-BINDING-PROTEIN; CYCLOSPORINE-A; HOMOLOG NINAA; CD147; RECEPTOR; EMMPRIN; CHAPERONE; ENCODES	CD147, also known as extracellular matrix metalloproteinase inducer, is a regulator of matrix metalloproteinase production and also serves as a signaling receptor for extracellular cyclophilins. Previously, we demonstrated that cell surface expression of CD147 is sensitive to cyclophilin-binding drug cyclosporin A, suggesting involvement of a cyclophilin in the regulation of intracellular transport of CD147. In this report, we identify this cyclophilin as cyclophilin 60 (Cyp60), a distinct member of the cyclophilin family of proteins. CD147 co-immunoprecipitated with Cyp60, and confocal immunofluorescent microscopy revealed intracellular colocalization of Cyp60 and CD147. This interaction with Cyp60 involved proline 211 of CD147, which was shown previously to be critical for interaction between CD147 and another cyclophilin, cyclophilin A, in solution. Mutation of this proline residue abrogated co-immunoprecipitation of CD147 and Cyp60 and reduced surface expression of CD147 on the plasma membrane. Suppression of Cyp60 expression using RNA interference had an effect similar to that of cyclosporin A: reduction of cell surface expression of CD147. These results suggest that Cyp60 plays an important role in the translocation of CD147 to the cell surface. Therefore, Cyp60 may present a novel target for therapeutic interventions in diseases where CD147 functions as a pathogenic factor, such as cancer, human immunodeficiency virus infection, or rheumatoid arthritis.	George Washington Univ, Med Ctr, Washington, DC 20037 USA; Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY 10461 USA; George Mason Univ, Fairfax, VA 22030 USA; Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan; N Shore Long Isl Jewish Res Inst, Manhasset, NY 11030 USA	George Washington University; Yeshiva University; Albert Einstein College of Medicine; George Mason University; Kyushu University; Northwell Health	Bukrinsky, MI (corresponding author), George Washington Univ, Med Ctr, Ross Hall,Rm 734,2300 Eye St NW, Washington, DC 20037 USA.	mtmmib@gwumc.edu	Sherry, Barbara/GSD-7179-2022; Yurchenko, Vyacheslav/E-4532-2013; Hatakeyama, Shigetsugu/C-8333-2012; Vaisman, Iosif/K-5268-2012	Sherry, Barbara/0000-0003-3119-1463; Yurchenko, Vyacheslav/0000-0003-4765-3263; Hatakeyama, Shigetsugu/0000-0002-2150-9979; Vaisman, Iosif/0000-0001-6858-1516; Molodiuc, Veaceslav/0000-0002-3014-4203	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029110] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI029110] Funding Source: Medline; PHS HHS [R03 A1057018, R21 A1060720] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BISWAS C, 1995, CANCER RES, V55, P434; Bukrinsky MI, 2002, TRENDS IMMUNOL, V23, P323, DOI 10.1016/S1471-4906(02)02237-8; Chklovskaia E, 2001, BLOOD, V97, P1027, DOI 10.1182/blood.V97.4.1027; Deora AA, 2004, MOL BIOL CELL, V15, P4148, DOI 10.1091/mbc.E04-01-0058; ELLIS SM, 1989, CANCER RES, V49, P3385; FERREIRA PA, 1995, J BIOL CHEM, V270, P23179, DOI 10.1074/jbc.270.39.23179; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Huang TM, 2002, J BIOL CHEM, V277, P37798, DOI 10.1074/jbc.M204786200; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; Kasinrerk W, 1999, IMMUNOLOGY, V96, P184; Klein CA, 2002, NAT BIOTECHNOL, V20, P387, DOI 10.1038/nbt0402-387; Konttinen YT, 2000, ARTHRITIS RHEUM, V43, P275, DOI 10.1002/1529-0131(200002)43:2<275::AID-ANR6>3.0.CO;2-#; ONDEK B, 1992, J BIOL CHEM, V267, P16460; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; Pushkarsky T, 2001, P NATL ACAD SCI USA, V98, P6360, DOI 10.1073/pnas.111583198; Sameshima T, 2000, INT J CANCER, V88, P21, DOI 10.1002/1097-0215(20001001)88:1<21::AID-IJC4>3.0.CO;2-S; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; Shiraishi S, 2000, NEUROSCI LETT, V293, P211, DOI 10.1016/S0304-3940(00)01513-5; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; Sun JX, 2001, CANCER RES, V61, P2276; Tang W, 2004, J BIOL CHEM, V279, P11112, DOI 10.1074/jbc.M312947200; Wang BB, 1996, BIOCHEM J, V314, P313, DOI 10.1042/bj3140313; Wilson MC, 2002, J BIOL CHEM, V277, P3666, DOI 10.1074/jbc.M109658200; Yurchenko V, 2005, J BIOL CHEM, V280, P17013, DOI 10.1074/jbc.M412851200; Yurchenko V, 2002, J BIOL CHEM, V277, P22959, DOI 10.1074/jbc.M201593200; Yurchenko V, 2001, BIOCHEM BIOPH RES CO, V288, P786, DOI 10.1006/bbrc.2001.5847	29	63	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27866	27871		10.1074/jbc.M503770200	http://dx.doi.org/10.1074/jbc.M503770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15946952	hybrid			2022-12-25	WOS:000230678600048
J	Huber, PAJ; Birdsey, GM; Lumb, MJ; Prowse, DTR; Perkins, TJ; Knight, DR; Danpure, CJ				Huber, PAJ; Birdsey, GM; Lumb, MJ; Prowse, DTR; Perkins, TJ; Knight, DR; Danpure, CJ			Peroxisomal import of human alanine : glyoxylate aminotransferase requires ancillary targeting information remote from its C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY HYPEROXALURIA TYPE-1; SACCHAROMYCES-CEREVISIAE; PYRUVATE AMINOTRANSFERASE; SUBCELLULAR-DISTRIBUTION; MOLECULAR EVOLUTION; HEPATIC ALANINE; POINT MUTATION; PTS1 MOTIF; RAT-LIVER; IN-VITRO	Although human alanine: glyoxylate aminotransferase (AGT) is imported into peroxisomes by a Pex5p-dependent pathway, the properties of its C-terminal tripeptide (KKL) are unlike those of any other type 1 peroxisomal targeting sequence (PTS1). We have previously suggested that AGT might possess ancillary targeting information that enables its unusual PTS1 to work. In this study, we have attempted to locate this information and to determine whether or not it is a characteristic of all vertebrate AGTs. Using the two-hybrid system, we show that human AGT interacts with human Pex5p in mammalian cells, but not yeast cells. Using (immuno) fluorescence microscopic analysis of the distribution of various constructs expressed in COS cells, we show the following. 1) The putative ancillary peroxisomal targeting information (PTS1A) in human AGT is located entirely within the smaller C-terminal structural domain of 110 amino acids, with the sequence between Val-324 and Ile-345 being the most likely candidate region. 2) The PTS1A is present in all mammalian AGTs studied (human, rat, guinea pig, rabbit, and cat), but not amphibian AGT (Xenopus). 3) The PTS1A is necessary for peroxisomal import of human, rabbit, and cat AGTs, but not rat and guinea pig AGTs. We speculate that the internal PTS1A of human AGT works in concert with the C-terminal PTS1 by interacting with Pex5p indirectly with the aid of a yet-to-be-identified mammal-specific adaptor molecule. This interaction might reshape the tetratricopeptide repeat domain allosterically, enabling it to accept KKL as a functional PTS1.	UCL, Dept Biol, London WC1E 6BT, England	University of London; University College London	Danpure, CJ (corresponding author), UCL, Dept Biol, Gower St, London WC1E 6BT, England.	c.danpure@ucl.ac.uk	Knight, Daniel R./F-2522-2014	Knight, Daniel R./0000-0002-9480-4733; Huber, Pia AJ/0000-0001-9823-7863; Birdsey, Graeme M./0000-0002-0981-8672	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Birdsey GM, 2004, MOL BIOL EVOL, V21, P632, DOI 10.1093/molbev/msh054; Birdsey GM, 1998, BIOCHEM J, V331, P49, DOI 10.1042/bj3310049; Birdsey GM, 2005, P ROY SOC B-BIOL SCI, V272, P833, DOI 10.1098/rspb.2004.3011; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Caldwell EF, 2004, HUM GENET, V115, P504, DOI 10.1007/s00439-004-1191-x; Coulter-Mackie MB, 2004, MOL GENET METAB, V83, P38, DOI 10.1016/j.ymgme.2004.08.009; Coulter-Mackie MB, 2003, MOL GENET METAB, V78, P44, DOI 10.1016/S1096-7192(02)00204-4; Danpure C. J., 2001, METABOLIC MOL BASES, V2, P3323; DANPURE CJ, 1994, EUR J CELL BIOL, V64, P295; DANPURE CJ, 1994, J INHERIT METAB DIS, V17, P27, DOI 10.1007/BF00735393; DANPURE CJ, 1990, J CELL SCI, V97, P669; DANPURE CJ, 1989, J CELL BIOL, V108, P1345, DOI 10.1083/jcb.108.4.1345; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Gatto GJ, 2003, BIOCHEMISTRY-US, V42, P1660, DOI 10.1021/bi027034z; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Holbrook JD, 2002, J BIOL CHEM, V277, P2336, DOI 10.1074/jbc.M107047200; Holbrook JD, 2000, MOL BIOL EVOL, V17, P387, DOI 10.1093/oxfordjournals.molbev.a026318; Knott TG, 2000, BIOCHEM J, V352, P409, DOI 10.1042/0264-6021:3520409; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; Leiper JM, 1996, J CELL BIOL, V135, P939, DOI 10.1083/jcb.135.4.939; Li XM, 1999, SOMAT CELL MOLEC GEN, V25, P67, DOI 10.1023/B:SCAM.0000007142.36524.58; Lumb MJ, 1999, J BIOL CHEM, V274, P20587, DOI 10.1074/jbc.274.29.20587; Lumb MJ, 2000, J BIOL CHEM, V275, P36415, DOI 10.1074/jbc.M006693200; LUMB MJ, 1994, EUR J BIOCHEM, V221, P53, DOI 10.1111/j.1432-1033.1994.tb18714.x; Maynard EL, 2004, PROTEINS, V55, P856, DOI 10.1002/prot.20112; MIURA S, 1992, J BIOL CHEM, V267, P14405; Mizuno T, 2002, HISTOCHEM CELL BIOL, V118, P321, DOI 10.1007/s00418-002-0455-6; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; Neuberger G, 2003, J MOL BIOL, V328, P581, DOI 10.1016/S0022-2836(03)00319-X; Neuberger G, 2003, J MOL BIOL, V328, P567, DOI 10.1016/S0022-2836(03)00318-8; Oatey PB, 1996, ANN NY ACAD SCI, V804, P652, DOI 10.1111/j.1749-6632.1996.tb18653.x; ODA T, 1987, EUR J BIOCHEM, V168, P537, DOI 10.1111/j.1432-1033.1987.tb13451.x; PURDUE PE, 1991, P NATL ACAD SCI USA, V88, P10900, DOI 10.1073/pnas.88.23.10900; PURDUE PE, 1990, J CELL BIOL, V111, P2341, DOI 10.1083/jcb.111.6.2341; PURDUE PE, 1992, EUR J BIOCHEM, V207, P757, DOI 10.1111/j.1432-1033.1992.tb17106.x; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; Sambrook J, 2001, MOL CLONING LAB MANU; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; TAKADA Y, 1990, BIOCHEM J, V268, P517, DOI 10.1042/bj2680517; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WANDERS RJA, 1987, CLIN CHIM ACTA, V165, P311, DOI 10.1016/0009-8981(87)90176-8; Zhang XX, 2003, J MOL BIOL, V331, P643, DOI 10.1016/S0022-2836(03)00791-5	44	30	30	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27111	27120		10.1074/jbc.M502719200	http://dx.doi.org/10.1074/jbc.M502719200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15911627	Green Published, hybrid			2022-12-25	WOS:000230589500058
J	Sakuraba, H; Tsuge, H; Yoneda, K; Katunuma, N; Ohshima, T				Sakuraba, H; Tsuge, H; Yoneda, K; Katunuma, N; Ohshima, T			Crystal structure of the NAD biosynthetic enzyme quinolinate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							L-ASPARTATE OXIDASE; PYROCOCCUS-HORIKOSHII OT-3; DE-NOVO BIOSYNTHESIS; ESCHERICHIA-COLI; HYPERTHERMOPHILIC ARCHAEON; PROTEIN; SYNTHETASE; SPECIFICITY; PROGRAM; DENSITY	A gene encoding a quinolinate synthase has been identified in the hyperthermophilic archaeon Pyrococcus horikoshii via genome sequencing. The gene was overexpressed in Escherichia coli, and the crystal structure of the produced enzyme was determined to 2.0 angstrom resolution in the presence of malate, a substrate analogue. The overall structure exhibits a unique triangular architecture composed of a 3-fold repeat of three-layer (alpha beta alpha) sandwich folding. Although some aspects of the fold homologous to the each domain have been observed previously, the overall structure of quinolinate synthase shows no similarity to any known protein structure. The three analogous domains are related to a pseudo-3-fold symmetry. The active site is located at the interface of the three domains and is centered on the pseudo-3-fold axis. The malate molecule is tightly held near the bottom of the active site cavity. The model of the catalytic state during the first condensation step of the quinolinate synthase reaction indicates that the elimination of inorganic phosphate from dihydroxyacetone phosphate may precede the condensation reaction.	Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan; Tokushima Bunri Univ, Inst Hlth Sci, Tokushima 7708514, Japan	Tokushima University; Tokushima Bunri University	Ohshima, T (corresponding author), Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, 2-1 Minamijosanjima Cho, Tokushima 7708506, Japan.	ohshima@bio.tokushima-u.ac.jp	Tsuge, Hideaki/ABF-6424-2021	Tsuge, Hideaki/0000-0003-0166-9163; Yoneda, Kazunari/0000-0001-9152-8772				Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Begley TP, 2001, VITAM HORM, V61, P103; Bossi RT, 2002, BIOCHEMISTRY-US, V41, P3018, DOI 10.1021/bi015939r; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceciliani F, 2000, PROTEIN EXPRES PURIF, V18, P64, DOI 10.1006/prep.1999.1153; FOSTER JW, 1980, MICROBIOL REV, V44, P83, DOI 10.1128/MMBR.44.1.83-105.1980; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; GROSS D, 1965, Z NATURFORSCH PT B, VB 20, P1116, DOI 10.1515/znb-1965-1114; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; Mathews II, 1999, STRUCTURE, V7, P1395, DOI 10.1016/S0969-2126(00)80029-5; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NASU S, 1982, J BIOL CHEM, V257, P626; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Rizzi M, 2002, CURR OPIN STRUC BIOL, V12, P709, DOI 10.1016/S0959-440X(02)00385-8; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sakuraba H, 2003, J MOL CATAL B-ENZYM, V23, P273, DOI 10.1016/S1381-1177(03)00090-0; Sakuraba H, 2003, J BIOL CHEM, V278, P10799, DOI 10.1074/jbc.M212449200; Sakuraba H, 2002, EXTREMOPHILES, V6, P275, DOI 10.1007/s00792-001-0254-3; SAMBROOK J, 1989, MOL CLONING, V2, P9; Spallarossa A, 2001, STRUCTURE, V9, P1117, DOI 10.1016/S0969-2126(01)00666-9; SUZUKI N, 1973, BIOCHIM BIOPHYS ACTA, V304, P309, DOI 10.1016/0304-4165(73)90249-3; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; WICKS FD, 1977, BIOCHIM BIOPHYS ACTA, V500, P213, DOI 10.1016/0304-4165(77)90061-7; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	29	29	30	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26645	26648		10.1074/jbc.C500192200	http://dx.doi.org/10.1074/jbc.C500192200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15937336	hybrid			2022-12-25	WOS:000230589500003
J	Semenov, M; Tamai, K; Xi, H				Semenov, M; Tamai, K; Xi, H			SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAN-BUCHEM-DISEASE; RECEPTOR-RELATED PROTEIN-5; INCREASED BONE-DENSITY; BMP ANTAGONIST; BETA-CATENIN; GENE FAMILY; SCLEROSTIN; LRP5; IDENTIFICATION; MUTATION	Sclerosteosis is an autosomal recessive disease that is characterized by overgrowth of bone tissue and is linked to mutations in the gene encoding the secreted protein SOST. Sclerosteosis shares remarkable similarities with "high bone mass" diseases caused by "gain-of-function" mutations in the LRP5 gene, which encodes a coreceptor for Wnt signaling proteins. We show here that SOST antagonizes Wnt signaling in Xenopus embryos and mammalian cells by binding to the extracellular domain of the Wnt coreceptors LRP5 and LRP6 and disrupting Wnt-induced Frizzled-LRP complex formation. Our findings suggest that SOST is an antagonist for Wnt signaling and that the loss of SOST function likely leads to the hyperactivation of Wnt signaling that underlies bone overgrowth seen in sclerosteosis patients.	Harvard Univ, Childrens Hosp, Sch Med, Div Neurosci, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Semenov, M (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.	mikhail.semenov@childrens.harvard.edu; xi.he@childrens.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057603, R55GM057603] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM057603] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91; Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; BEIGHTON P, 1976, ANN INTERN MED, V84, P393, DOI 10.7326/0003-4819-84-4-393; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399-0004.2003.00036.x; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378-1119(98)00311-4; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Laurikkala J, 2003, DEV BIOL, V264, P91, DOI 10.1016/j.ydbio.2003.08.011; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; O'Shaughnessy RFL, 2004, J INVEST DERMATOL, V123, P613, DOI 10.1111/j.0022-202X.2004.23410.x; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Staehling-Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401; Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; VANBUCHEM FSP, 1955, ACTA RADIOL, V44, P109, DOI 10.3109/00016925509170789; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wergedal JE, 2003, J CLIN ENDOCR METAB, V88, P5778, DOI 10.1210/jc.2003-030201; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	42	568	640	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26770	26775		10.1074/jbc.M504308200	http://dx.doi.org/10.1074/jbc.M504308200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15908424	hybrid			2022-12-25	WOS:000230589500018
J	Wang, L; Piserchio, A; Mierke, DF				Wang, L; Piserchio, A; Mierke, DF			Structural characterization of the intermolecular interactions of synapse-associated protein-97 with the NR2B subunit of N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PDZ DOMAINS; POSTSYNAPTIC DENSITY; GUANYLATE KINASES; NMR-SPECTROSCOPY; CHEMICAL-SHIFT; SAP97; PSD-95; RECOGNITION; DYNAMICS	The synapse-associated protein-97 (SAP97) is important in the proper trafficking and cell surface maintenance of the N-methyl-D-aspartate ionotropic glutamate receptor. The molecular scaffold/receptor interaction is mediated by the association of the C terminus of the NR2B subunit of the N-methyl-D-aspartate receptor with the PDZ domains of SAP97. Here, we characterize the binding of the C terminus of NR2B with the PDZ domains of SAP97 and determine the structure of the PDZ1-NR2B complex employing high-resolution NMR. Based on fluorescence anisotropy, the NR2B subunit binds to the first and second PDZ domains of SAP97, with higher affinity for PDZ2; no appreciable binding to PDZ3 could be measured. The structural features of the NR2B bound to PDZ1 is consistent with the canonical PDZ-binding motif with the glutamic acid at the - 3 position of the C terminus (i.e. - E-S-D-V) interacting with the beta 2/beta 3 loop. Two sites within the loop of PDZ1 were replaced with the corresponding residue from PDZ2, D243G and P245Q. The former mutation, designed to remove a possible Coulombic repulsion between E-3 (NR2B) and Asp-243 ( PDZ1) has only a minimal effect on binding. The P245Q mutation leads to a 2-fold increase in binding affinity of NR2B, approaching that observed for wild-type PDZ2. These results indicate that modification of the beta 2/beta 3 loop provides an avenue for regulating the ligand specificity of PDZ domains.	Brown Univ, Dept Mol Pharmacol, Div Biol & Med, Providence, RI 02912 USA; Brown Univ, Dept Phys, Providence, RI 02912 USA	Brown University; Brown University	Mierke, DF (corresponding author), Brown Univ, Dept Mol Pharmacol, Div Biol & Med, Box G-B4, Providence, RI 02912 USA.	dale_mierke@brown.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054082, R29GM054082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA018428] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-18428] Funding Source: Medline; NIGMS NIH HHS [GM-54082] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bassand P, 1999, EUR J NEUROSCI, V11, P2031, DOI 10.1046/j.1460-9568.1999.00611.x; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fujita A, 2000, BIOCHEM BIOPH RES CO, V269, P1, DOI 10.1006/bbrc.1999.1893; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Klocker N, 2002, EUR J NEUROSCI, V16, P1517, DOI 10.1046/j.1460-9568.2002.02228.x; LARSSON M, 2003, BIOCHEM J, V15, P381; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Lynch DR, 2001, CURR DRUG TARGETS, V2, P215, DOI 10.2174/1389450013348434; Mehta S, 2001, J BIOL CHEM, V276, P16092, DOI 10.1074/jbc.M100643200; Mori H, 1998, NEURON, V21, P571, DOI 10.1016/S0896-6273(00)80567-X; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; OTTING G, 1989, J MAGN RESON, V85, P586, DOI 10.1016/0022-2364(89)90249-7; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Piserchio A, 2002, J BIOL CHEM, V277, P6967, DOI 10.1074/jbc.M109453200; Piserchio A, 2004, CHEM BIOL, V11, P469, DOI 10.1016/j.chembiol.2004.03.013; Reina J, 2002, NAT STRUCT BIOL, V9, P621, DOI 10.1038/nsb815; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Suzuki T, 2005, EUR J NEUROSCI, V21, P339, DOI 10.1111/j.1460-9568.2005.03856.x; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Yu J, 2002, J CELL BIOCHEM, V85, P809, DOI 10.1002/jcb.10171; Ziv NE, 2001, CURR OPIN NEUROBIOL, V11, P536, DOI 10.1016/S0959-4388(00)00246-4	35	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26992	26996		10.1074/jbc.M503555200	http://dx.doi.org/10.1074/jbc.M503555200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15929985	hybrid			2022-12-25	WOS:000230589500043
J	Alder-Baerens, N; Muller, P; Pohl, A; Korte, T; Hamon, Y; Chimini, G; Pomorski, T; Herrmann, A				Alder-Baerens, N; Muller, P; Pohl, A; Korte, T; Hamon, Y; Chimini, G; Pomorski, T; Herrmann, A			Headgroup-specific exposure of phospholipids in ABCA1-expressing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN-LABELED PHOSPHOLIPIDS; TANGIER-DISEASE PATIENTS; MDR1 P-GLYCOPROTEIN; PLASMA-MEMBRANE; TRANSBILAYER MOVEMENT; CHOLESTEROL EFFLUX; HUMAN FIBROBLASTS; LIPID ASYMMETRY; PHOSPHATIDYLCHOLINE; TRANSPORT	ABCA1 has been established to be required for the efflux of cholesterol and phospholipids to apolipoproteins such as apoA-I. At present, it is unclear whether ABCA1-mediated lipid exposure is specific with regard to lipid headgroups and whether it requires calcium activation and the presence of a lipid acceptor. In the present work, we found exofacial exposure of endogenous phosphatidylserine in the absence of apoA-I to be enhanced in ABCA1-GFP expressing MDCKII and HeLa cells compared with control cells. By using C6-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) (NBD)-labeled phospholipid analogues, we observed elevated redistribution of phosphatidylserine and phosphatidylethanolamine but not of phosphatidylcholine analogues from the cytoplasmic to the exoplasmic leaflet of the plasma membrane of ABCA1-GFP expressing cells. Whereas glyburide affected neither the level of exofacial endogenous PS nor the outward movement of the amino phospholipid analogues, the latter was sensitive to intracellular Ca2+ in ABCA1-GFP expressing cells, further enhancing outward analogue redistribution with respect to control cells. Both receptor-mediated endocytosis and fluid-phase endocytosis were reduced in MDCKII cells expressing ABCA1-GFP. Glyburide raised the level of receptor-mediated endocytosis in the ABCA1-GFP expressing cell to the level of control cells in the absence of glyburide. In control cells, however, fluid-phase endocytosis but not receptor-mediated endocytosis was significantly reduced upon glyburide treatment.	Humboldt Univ, Inst Biol, Ctr Biophys & Bioinformat, D-10115 Berlin, Germany; Ctr Immunol Marseille Luminy, F-13288 Marseille, France	Humboldt University of Berlin; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Herrmann, A (corresponding author), Humboldt Univ, Inst Biol, Ctr Biophys & Bioinformat, Invalidenstr 42, D-10115 Berlin, Germany.	andreas.herrmann@rz.hu-berlin.de	Pomorski, Thomas Günther/G-4804-2014; HAMON, Yannick YH/N-5372-2016; HAMON, Yannick/S-3118-2019	Pomorski, Thomas Günther/0000-0002-4889-0829; HAMON, Yannick YH/0000-0002-7636-2310; HAMON, Yannick/0000-0002-7636-2310				Abulrob ANG, 1999, BIOCHEM BIOPH RES CO, V262, P121, DOI 10.1006/bbrc.1999.1120; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bosch I, 1997, BIOCHEMISTRY-US, V36, P5685, DOI 10.1021/bi962728r; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; DACHARYPRIGENT J, 1993, BLOOD, V81, P2554; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Devaux PF, 2002, CHEM PHYS LIPIDS, V116, P115, DOI 10.1016/S0009-3084(02)00023-3; Devaux PF, 2000, BIOCHIMIE, V82, P497, DOI 10.1016/S0300-9084(00)00209-1; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Ernest S, 1999, J AM SOC NEPHROL, V10, P2306; FARGE E, 1999, AM J PHYSIOL, V76, pC725; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Gillotte-Taylor K, 2002, J BIOL CHEM, V277, P11811, DOI 10.1074/jbc.M108268200; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Kalin N, 2004, J BIOL CHEM, V279, P33228, DOI 10.1074/jbc.M401751200; Kamp D, 1998, BBA-BIOMEMBRANES, V1372, P91, DOI 10.1016/S0005-2736(98)00049-2; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Kozerski C, 2000, J VIROL, V74, P7529, DOI 10.1128/JVI.74.16.7529-7537.2000; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MULLER P, 1994, BIOCHEM BIOPH RES CO, V199, P881, DOI 10.1006/bbrc.1994.1311; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1999, J LIPID RES, V40, P1769; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Pohl A, 2005, BBA-MOL CELL BIOL L, V1733, P29, DOI 10.1016/j.bbalip.2004.12.007; Pohl A, 2002, BIOCHEM J, V365, P259, DOI 10.1042/BJ20011880; Pomorski T, 1996, J CELL SCI, V109, P687; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; Raggers RJ, 2000, TRAFFIC, V1, P226, DOI 10.1034/j.1600-0854.2000.010305.x; Raggers RJ, 1999, J CELL SCI, V112, P415; Rigot W, 2002, J LIPID RES, V43, P2077, DOI 10.1194/jlr.M200279-JLR200; Rothnie A, 2001, EUR BIOPHYS J BIOPHY, V30, P430, DOI 10.1007/s002490100156; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Small DM, 2003, P NATL ACAD SCI USA, V100, P4, DOI 10.1073/pnas.0237205100; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; VAN GENDEREN I, 1995, J CELL BIOL, V131, P645, DOI 10.1083/jcb.131.3.645; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; von Eckardstein A, 1998, J LIPID RES, V39, P987; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Zegers MMP, 1997, J CELL BIOL, V138, P307, DOI 10.1083/jcb.138.2.307; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200	50	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26321	26329		10.1074/jbc.M413993200	http://dx.doi.org/10.1074/jbc.M413993200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15905177	hybrid			2022-12-25	WOS:000230386800048
J	Zhang, XP; Lee, KI; Solinger, JA; Kiianitsa, K; Heyer, WD				Zhang, XP; Lee, KI; Solinger, JA; Kiianitsa, K; Heyer, WD			Gly-103 in the N-terminal domain of Saccharomyces cerevisiae Rad51 protein is critical for DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; RECA PROTEIN; YEAST RAD51; HOMOLOGOUS RECOMBINATION; HELICAL FILAMENTS; CRYSTAL-STRUCTURE; REPAIR; ATP; EXCHANGE; SURFACE	Rad51 is a homolog of the bacterial RecA protein and is central for recombination in eukaryotes performing homology search and DNA strand exchange. Rad51 and RecA share a core ATPase domain that is structurally similar to the ATPase domains of helicases and the F1 ATPase. Rad51 has an additional N-terminal domain, whereas RecA protein has an additional C-terminal domain. Here we show that glycine 103 in the N-terminal domain of Saccharomyces cerevisiae Rad51 is important for binding to single-stranded and duplex DNA. The Rad51-G103E mutant protein is deficient in DNA strand exchange and ATPase activity due to a primary DNA binding defect. The N-terminal domain of Rad51 is connected to the ATPase core through an extended elbow linker that ensures flexibility of the N-terminal domain. Molecular modeling of the Rad51-G103E mutant protein shows that the negatively charged glutamate residue lies on the surface of the N-terminal domain facing a positively charged patch composed of Arg-260, His-302, and Lys-305 on the ATPase core domain. A possible structural explanation for the DNA binding defect is that a charge interaction between Glu-103 and the positive patch restricts the flexibility of the N-terminal domain. Rad51-G103E was identified in a screen for Rad51 interaction-deficient mutants and was shown to ablate the Rad54 interaction in two-hybrid assays ( Krejci, L., Damborsky, J., Thomsen, B., Duno, M., and Bendixen, C. ( 2001) Mol. Cell. Biol. 21, 966 - 976). Surprisingly, we found that the physical interaction of Rad51-G103E with Rad54 was not affected. Our data suggest that the two-hybrid interaction defect was an indirect consequence of the DNA binding defect.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Heyer, WD (corresponding author), Univ Calif Davis, Microbiol Sect, 1 Shields Ave, Davis, CA 95616 USA.	wdheyer@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058015] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58015] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aihara H, 1999, J MOL BIOL, V290, P495, DOI 10.1006/jmbi.1999.2904; Aihara H, 1997, J MOL BIOL, V274, P213, DOI 10.1006/jmbi.1997.1403; Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Ariza A, 2005, NUCLEIC ACIDS RES, V33, P1465, DOI 10.1093/nar/gki288; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Brendel V, 1997, J MOL EVOL, V44, P528, DOI 10.1007/PL00006177; CARDOZO T, 1995, PROTEINS, V23, P403, DOI 10.1002/prot.340230314; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; DeLano W, 2002, PYMOL 0 99; ELLOUZE C, 1995, EUR J BIOCHEM, V233, P579, DOI 10.1111/j.1432-1033.1995.579_2.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hosfield DJ, 2001, PROG NUCLEIC ACID RE, V68, P315; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Jaskelioff M, 2003, J BIOL CHEM, V278, P9212, DOI 10.1074/jbc.M211545200; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kiianitsa K, 2002, J BIOL CHEM, V277, P46205, DOI 10.1074/jbc.M207967200; Kinebuchi T, 2004, MOL CELL, V14, P363, DOI 10.1016/S1097-2765(04)00218-7; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; Krejci L, 2001, MOL CELL BIOL, V21, P966, DOI 10.1128/MCB.21.3.966-976.2001; Kurumizaka H, 1996, J BIOL CHEM, V271, P33515, DOI 10.1074/jbc.271.52.33515; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; McGrew DA, 2003, CRIT REV BIOCHEM MOL, V38, P385, DOI 10.1080/10409230390242489; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Morimatsu K, 2002, P NATL ACAD SCI USA, V99, P11688, DOI 10.1073/pnas.142404499; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Passy SI, 1999, P NATL ACAD SCI USA, V96, P10684, DOI 10.1073/pnas.96.19.10684; Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Raschle M, 2004, J BIOL CHEM, V279, P51973, DOI 10.1074/jbc.M410101200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; Shin DS, 2004, DNA REPAIR, V3, P863, DOI 10.1016/j.dnarep.2004.03.022; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tan TLR, 2003, DNA REPAIR, V2, P787, DOI 10.1016/S1568-7864(03)00070-3; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Wu Y, 2004, MOL CELL, V15, P423, DOI 10.1016/j.molcel.2004.07.014; Yang SX, 2001, J MOL BIOL, V314, P1077, DOI 10.1006/jmbi.2000.5213; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	74	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26303	26311		10.1074/jbc.M503244200	http://dx.doi.org/10.1074/jbc.M503244200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15908697	hybrid			2022-12-25	WOS:000230386800046
J	Bu, DX; Erl, W; de Martin, R; Hansson, GK; Yan, ZQ				Bu, DX; Erl, W; de Martin, R; Hansson, GK; Yan, ZQ			IKK beta-dependent NF-kappa B pathway controls vascular inflammation and intimal hyperplasia	FASEB JOURNAL			English	Article						nuclear factor-kappa B; angioplastic injury; intima; vascular repair	SMOOTH-MUSCLE-CELLS; KINASE COMPLEX; SYSTEMIC INFLAMMATION; GENE-EXPRESSION; BINDING-SITE; ACTIVATION; ALPHA; INJURY; INHIBITION; CYTOKINE	Nuclear factor-kappaB (NF-kappaB)-mediated vascular inflammation is a prominent characteristic of atherogenesis and restenosis. We noted that angioplastic injury to carotid artery elicited two phases of NF-kappaB activation characterized by an early activation in the arterial media and a late activation coupled with high levels of inhibitor of IkappaB kinase (IKK) activity in intima. These findings prompted us to elucidate the role for the different phases of NF-kappaB activation and IKK in the progress of vascular repair. Our results show that blockade of the early NF-kappaB activation by perivascular administration of pyrrolidine dithiocarbamate transiently attenuates the expression of proinflammatory genes in the injured vessels but does not affect intimal formation. Interruption of IKKbeta by overexpressing a dominant-negative IKKbeta in the injured artery effectively inhibited the late phase of NF-kappaB activation, resulting in down-regulation of inducible nitric oxide synthase, tumor necrosis factor alpha, and monocyte chemoattractant protein-1 expression in conjunction with a 36% reduction in intima size, albeit with a lack of inhibitory effect on the early NF-kappaB activation. Collectively, these findings show that the IKKbeta-mediated late-phase NF-kappaB activation contributes to intimal hyperplasia and the accompanied vascular inflammatory responses.	Karolinska Hosp, Ctr Mol Med, Cardiovasc Res Unit, S-17176 Stockholm, Sweden; Dalian Med Univ, Dalian, Peoples R China; Univ Munich, Inst Prophylaxe Kreislaufrkankheiten, Munich, Germany; Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, Vienna, Austria	Karolinska Institutet; Karolinska University Hospital; Dalian Medical University; University of Munich; Medical University of Vienna	Yan, ZQ (corresponding author), Karolinska Hosp, Ctr Mol Med, Cardiovasc Res Unit, S-17176 Stockholm, Sweden.	zhong-qun.yan@cmm.ki.se	Hansson, Goran K/B-7423-2012	Hansson, Goran/0000-0003-4148-5190				Andreakos E, 2003, ARTHRITIS RHEUM, V48, P1901, DOI 10.1002/art.11044; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Breuss JM, 2002, CIRCULATION, V105, P633, DOI 10.1161/hc0502.102966; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Danenberg HD, 2002, CIRCULATION, V105, P2917, DOI 10.1161/01.CIR.0000018168.15904.BB; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hawiger J, 1999, BLOOD, V94, P1711, DOI 10.1182/blood.V94.5.1711.417k20_1711_1716; Ialenti A, 2001, N-S ARCH PHARMACOL, V364, P343, DOI 10.1007/s002100100467; Kanters E, 2003, J CLIN INVEST, V112, P1176, DOI 10.1172/JCI18580; Landry DB, 1997, AM J PATHOL, V151, P1085; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lindner V, 1998, PATHOBIOLOGY, V66, P311, DOI 10.1159/000028039; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Oitzinger W, 2001, BLOOD, V97, P1611, DOI 10.1182/blood.V97.6.1611; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shintani T, 2002, ANN THORAC SURG, V74, P1132, DOI 10.1016/S0003-4975(02)03921-8; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yan ZQ, 1999, ARTERIOSCL THROM VAS, V19, P2854, DOI 10.1161/01.ATV.19.12.2854; Yan ZQ, 1996, CIRC RES, V79, P38, DOI 10.1161/01.RES.79.1.38; Yoshimura S, 2001, GENE THER, V8, P1635, DOI 10.1038/sj.gt.3301566; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zuckerbraun BS, 2003, J VASC SURG, V38, P812, DOI 10.1016/S0741-5214(03)00427-0	36	40	43	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1293	+		10.1096/fj.04-2645fje	http://dx.doi.org/10.1096/fj.04-2645fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15939736				2022-12-25	WOS:000230207800032
J	Curfs, DMJ; Knaapen, AM; Pachen, DMFA; Gijbels, MJJ; Lutgens, E; Smook, MLF; Kockx, MM; Daemen, MJAP; van Schooten, FJ				Curfs, DMJ; Knaapen, AM; Pachen, DMFA; Gijbels, MJJ; Lutgens, E; Smook, MLF; Kockx, MM; Daemen, MJAP; van Schooten, FJ			Polycyclic aromatic hydrocarbons induce an inflammatory atherosclerotic plaque phenotype irrespective of their DNA binding properties	FASEB JOURNAL			English	Article						atherosclerosis; chemical carcinogens; DNA adduct formation; inflammation; apoE-KO mice	B6C3F1 MICE; KNOCKOUT MICE; DIOL-EPOXIDES; EXPOSURE; IMMUNOSUPPRESSION; SUPPRESSION; INHIBITION; INVITRO; SPLEEN; CELLS	Although it has been demonstrated that carcinogenic environmental polycyclic aromatic hydrocarbons (PAHs) cause progression of atherosclerosis, the underlying mechanism remains unclear. In the present study, we aimed to investigate whether DNA binding events are critically involved in the progression of PAH-mediated atherogenesis. Apolipoprotein E knockout mice were orally (24 wk, once/wk) exposed to 5 mg/kg benzo[a] pyrene ( B[a] P), or its nonmutagenic, noncarcinogenic structural isoform benzo[e] pyrene ( B[e] P). P-32-postlabeling of lung tissue confirmed the presence of promutagenic PAH-DNA adducts in B[a] P-exposed animals, whereas in B[e] P-exposed and vehicle control animals, these adducts were undetectable. Morphometrical analysis showed that both B[a] P and B[e] P caused an increase in plaque size, whereas location or number of plaques was unaffected. Immunohistochemistry revealed no differences in oxidative DNA damage (8-OHdG) or apoptosis in the plaques. Also plasma lipoprotein levels remained unchanged after PAH-exposure. However, T lymphocytes were increased >= 2-fold in the plaques of B[a]P- and B[e] P- exposed animals. Additionally, B[a] P and to a lesser extent B[e] P exposure resulted in increased TGF beta protein levels in the plaques, that was mainly localized in the plaque macrophages. In vitro studies using the murine macrophage like RAW264.7 cells showed that inhibition of TGF beta resulted in decreased tumor necrosis factor (TNF) alpha release, suggesting that enhanced TGF beta expression in the plaque macrophages contributes to the proinflammatory effects in the vessel wall. In general, this inflammatory reaction in the plaques appeared to be a local response since peripheral blood cell composition ( T cells, B cells, granulocytes, and macrophages) was not changed upon PAH exposure. In conclusion, we showed that both B[a] P and B[e] P cause progression of atherosclerosis, irrespective of their DNA binding properties. Moreover, our data revealed a possible novel mechanism of PAH-mediated atherogenesis, which likely involves a TGF-mediated local inflammatory reaction in the vessel wall.	Univ Maastricht, Dept Hlth Risk Anal & Toxicol, Maastricht, Netherlands; Univ Maastricht, Dept Mol Genet, Maastricht, Netherlands; Univ Maastricht, Dept Pathol, Maastricht, Netherlands; Univ Maastricht, Dept Immunol, Maastricht, Netherlands; Univ Antwerp, Dept Pathol, B-2020 Antwerp, Belgium	Maastricht University; Maastricht University; Maastricht University; Maastricht University; University of Antwerp	van Schooten, FJ (corresponding author), Univ Maastricht, Dept Hlth Risk Anal & Toxicol, Maastricht, Netherlands.	f.vanschooten@grat.unimaas.nl	Lutgens, Esther/E-2919-2010	Lutgens, Esther/0000-0002-2609-5744; Daemen, Mat/0000-0003-1076-199X				ADAMS DH, 1991, J IMMUNOL, V147, P609; BENDITT EP, 1974, CIRCULATION, V50, P650, DOI 10.1161/01.CIR.50.4.650; Binkova B, 2001, INT J HYG ENVIR HEAL, V204, P49, DOI 10.1078/1438-4639-00072; Branen L, 2004, ARTERIOSCL THROM VAS, V24, P2137, DOI 10.1161/01.ATV.0000143933.20616.1b; BURCHIEL SW, 1988, INT J IMMUNOPHARMACO, V10, P369, DOI 10.1016/0192-0561(88)90123-3; Curfs DMJ, 2003, ENVIRON MOL MUTAGEN, V42, P243, DOI 10.1002/em.10200; Curfs DMJ, 2004, AM J PATHOL, V164, P101, DOI 10.1016/S0002-9440(10)63101-X; De Jong WH, 1999, TOXICOL SCI, V50, P214, DOI 10.1093/toxsci/50.2.214; DEAN JH, 1983, CLIN EXP IMMUNOL, V52, P199; DeFlora S, 1997, FASEB J, V11, P1021, DOI 10.1096/fasebj.11.12.9337155; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; Godschalk RWL, 1998, CARCINOGENESIS, V19, P819, DOI 10.1093/carcin/19.5.819; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; HOLLADAY SD, 1995, VET HUM TOXICOL, V37, P99; *INT AG RES CANC, 1983, IARC MON EV CARC RIS, V32, P1; Izzotti A, 2001, FASEB J, V15, P752, DOI 10.1096/fj.00-0312com; Johnson CD, 2003, PHYSIOL GENOMICS, V13, P263, DOI 10.1152/physiolgenomics.00006.2003; LADICS GS, 1991, TOXICOL APPL PHARM, V110, P31, DOI 10.1016/0041-008X(91)90287-O; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; Ross JS, 2001, ANN NY ACAD SCI, V947, P271; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schulick AH, 1998, P NATL ACAD SCI USA, V95, P6983, DOI 10.1073/pnas.95.12.6983; SHERMAN JH, 1993, MOL CARCINOGEN, V8, P264, DOI 10.1002/mc.2940080409; STARY H, 1995, ARTERIOSCLER THROMB, V15, P1513; Stary HC, 1989, ARTERIOSCLER, V99, pI19; THAKKER DR, 1981, CANCER RES, V41, P1389; VAN SF, 1998, FASEB J, V12, P1409; WAKABAYASHI K, 1990, MUTAT RES, V239, P181, DOI 10.1016/0165-1110(90)90005-V; WHITE KL, 1984, CANCER RES, V44, P3388; WHITE KL, 1985, IMMUNOPHARMACOLOGY, V9, P155, DOI 10.1016/0162-3109(85)90011-6; WOOD AW, 1979, J BIOL CHEM, V254, P4408; WOOD AW, 1980, CANCER RES, V40, P1985	36	77	79	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1290	+		10.1096/fj.04-2269fje	http://dx.doi.org/10.1096/fj.04-2269fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15939734				2022-12-25	WOS:000230207800030
J	Hanlon, PR; Fu, P; Wright, GL; Steenbergen, C; Arcasoy, MO; Murphy, E				Hanlon, PR; Fu, P; Wright, GL; Steenbergen, C; Arcasoy, MO; Murphy, E			Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling	FASEB JOURNAL			English	Article						cardiac; erythropoietin receptor; signal transduction; myocardial infarction	HYPOXIA-INDUCED APOPTOSIS; PKC-EPSILON; ATP CHANNELS; RAT HEARTS; ACTIVATION; PROTECTION; INHIBITOR; TRANSLOCATION; MYOCARDIUM; PATHWAY	Langendorff-perfused rat hearts treated with EPO exhibited significantly improved postischemic recovery of left ventricular developed pressure (LVDP) and reduced infarct size compared with control hearts. Perfusion with the mitogen/extracellular signal- regulated kinase (MEK) inhibitor U0126 just before and concomitant with EPO treatment abolished EPO-induced phosphorylation of the MEK substrate extracellular signal-regulated kinase (ERK) but had no effect of EPO-mediated cardioprotection. EPO treatment of the perfused hearts induced translocation of protein kinase C (PKC) epsilon isoform to the membrane fraction of the hearts and the protective effect of EPO was significantly inhibited by the PKC catalytic inhibitor chelerythrine added before and concomitant with EPO. These data demonstrate that EPO- mediated activation of the PKC signaling pathway before or during ischemia is required for the cardioprotective effect of EPO during ischemia-reperfusion injury. Perfusion with the phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 or wortmannin just before and concomitant with EPO treatment attenuated EPO-induced phosphorylation of the PI3K substrate Akt but had no effect on EPO-mediated cardioprotection. However, when wortmannin was added during EPO treatment and continued during reperfusion, EPO-mediated cardioprotection was significantly inhibited. We also show that postischemia EPO treatment at the onset of reperfusion significantly improved recovery of LVDP and reduced infarct size. Postischemia cardioprotection by EPO required the PI3K pathway but was not affected by inhibition of PKC at the time of EPO treatment.	Duke Univ, Sch Med, Dept Med, Div Hematol,Med Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University	Arcasoy, MO (corresponding author), Duke Univ, Sch Med, Dept Med, Div Hematol,Med Ctr, DUMC Box 3912, Durham, NC 27710 USA.	arcas001@mc.duke.edu			NHLBI NIH HHS [R01 HL039752, HL-39752] Funding Source: Medline; NIDDK NIH HHS [R21 DK-065065] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039752, R01HL039752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010004] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Bianchi R, 2004, P NATL ACAD SCI USA, V101, P823, DOI 10.1073/pnas.0307823100; Cai ZQ, 2004, CIRCULATION, V109, P2050, DOI 10.1161/01.CIR.0000127954.98131.23; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Cross HR, 2002, J MOL CELL CARDIOL, V34, P361, DOI 10.1006/jmcc.2001.1518; de Ruijter W, 2003, ANESTH ANALG, V97, P1370, DOI 10.1213/01.ANE.0000081786.74722.DA; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Fryer RM, 2001, J PHARMACOL EXP THER, V296, P642; GANOTE CE, 1985, AM J PATHOL, V120, P129; Hassouna A, 2004, AM J PHYSIOL-CELL PH, V287, pC1418, DOI 10.1152/ajpcell.00144.2004; Hausenloy DJ, 2005, AM J PHYSIOL-HEART C, V288, pH971, DOI 10.1152/ajpheart.00374.2004; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kim MH, 2003, BIOCHEM BIOPH RES CO, V309, P1, DOI 10.1016/S0006-291X(03)01525-0; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lipsic E, 2004, J CARDIOVASC PHARM, V44, P473, DOI 10.1097/01.fjc.0000140209.04675.c3; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Liu HP, 2002, AM J PHYSIOL-HEART C, V282, pH1380, DOI 10.1152/ajpheart.00348.2001; LIU YG, 1994, J MOL CELL CARDIOL, V26, P661, DOI 10.1006/jmcc.1994.1078; Matsui T, 2001, CIRCULATION, V104, P330; Moon C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/pnas.1930406100; Ooie T, 2003, CIRC J, V67, P955, DOI 10.1253/circj.67.955; Parsa CJ, 2004, J BIOL CHEM, V279, P20655, DOI 10.1074/jbc.M314099200; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Schaffer SW, 2000, AM J PHYSIOL-HEART C, V278, pH1948; Shi Y, 2004, BASIC RES CARDIOL, V99, P173, DOI 10.1007/s00395-004-0455-x; Sun Y, 2004, J CEREBR BLOOD F MET, V24, P259, DOI 10.1097/01.WCB.0000110049.43905.AC; Tong HY, 2000, J BIOL CHEM, V275, P11981, DOI 10.1074/jbc.275.16.11981; Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; van der Meer P, 2004, EUR J HEART FAIL, V6, P853, DOI 10.1016/j.ejheart.2004.03.012; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vondriska TM, 2001, CIRC RES, V88, P1306, DOI 10.1161/hh1201.092994; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wright GL, 2004, FASEB J, V18, P1031, DOI 10.1096/fj.03-1289fje; Xu PC, 2004, ANESTH ANALG, V99, P993, DOI 10.1213/01.ane.0000131506.38512.7c; Yang CW, 2003, FASEB J, V17, P1754, DOI 10.1096/fj.02-1191fje; Yang XM, 2004, J AM COLL CARDIOL, V44, P1103, DOI 10.1016/j.jacc.2004.05.060	42	98	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1323	+		10.1096/fj.04-3545fje	http://dx.doi.org/10.1096/fj.04-3545fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946993				2022-12-25	WOS:000230207800025
